<?xml version="1.0" encoding="utf-8"?>
<documents>
  <document>
    <id>262775</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.bmj.com/cgi/content/full/334/7606/1273]]&gt;</url>
    <title>10-minute consultation: Chronic kidney disease</title>
    <publicationDate>2007-06-16T00:00:00</publicationDate>
    <publisher>BMJ 2007;334(7606):1273 (16 June)</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ BLOOD PRESSURE,PREDISPOSING FACTORS,COMPLICATIONS OF KIDNEY DISEASE,CARDIOVASCULAR DISEASE,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Article in BMJ</description>
    <body>&lt;![CDATA[ &lt;P&gt;Extract from National Library for Medicines website &lt;/P&gt;
&lt;P&gt;This article forms part of a series of occasional articles in the BMJ on common problems in primary care. Here the authors present a case study relating to a patient with hypertension who has been called in for an appointment as blood tests carried out over the year indicate he has chronic kidney disease. They discuss the issues which should be covered during a practice consultation and how the condition should be managed.&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>27/05/2010 10:00:44</lastReviewDate>
    <expiryDate>27/05/2011 10:00:44</expiryDate>
  </document>
  <document>
    <id>305545</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.18weeks.nhs.uk/Content.aspx?path=/achieve-and-sustain/Specialty-focussed-areas/Renal/chronic-kidney-disease]]&gt;</url>
    <title>18 Week CKD Pathways</title>
    <publicationDate>2009-01-26T00:00:00</publicationDate>
    <publisher>18 Weeks</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The information and links below have been developed to support the implementation of the 18 weeks commissioning pathway for chronic kidney disease (CKD).</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Extract:&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;The information and links below have been developed to support the implementation of the 18 weeks commissioning pathway for chronic kidney disease (CKD).&lt;/P&gt;
&lt;P&gt;These links will also be helpful for other pathways/specialties and can be read in conjunction with the commissioning pathways or on their own. They are specifically aimed at supporting local implementation of good practice, to improve efficiency, reduce delays, and improve quality of service provision in a safe and effective way.&lt;/P&gt;
&lt;P&gt;This pathway is from the second tranche of 18 weeks commissioning pathways. We are still gathering examples of good practice and will add these on to the pathway and this page as they become available. If you have an example of good practice you would like to share, please use the submission form.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>11/01/2011 10:22:35</lastReviewDate>
    <expiryDate>11/01/2012 10:22:35</expiryDate>
  </document>
  <document>
    <id>287959</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=287959]]&gt;</url>
    <title>2008 National Knowledge Week on Proteinuria and eGFR - Annual Evidence Update for year ending 30 April 2008</title>
    <publicationDate>2008-06-05T00:00:00</publicationDate>
    <publisher>NLH Kidney Diseases Specialist Library</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2008 National Knowledge Week on Proteinuria and eGFR - Annual Evidence Update for year ending 30 April 2008&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;This Annual Evidence Update was prepared for the 2008 National Knowledge Week on Proteinuria and use of eGFR&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;This Annual Evidence Update has been prepared by the Information Specialist for the Kidney Diseases Specialist Library, and is based on a search of the literature for guidelines, systematic reviews, RCTs and other papers published between April 2006 and April 2008. April 2006 was chosen as the starting point, as this was when eGFR was first introduced to UK clinical practice. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Resources searched:&lt;BR&gt;&lt;/STRONG&gt;&lt;BR&gt;PubMed&lt;BR&gt;Embase via Dialog DataStar interface&lt;BR&gt;Cochrane Database of Systematic Reviews&lt;BR&gt;Database of Abstracts of Reviews of Effects &lt;BR&gt;Cochrane CENTRAL register of controlled trials&lt;BR&gt;NLH Specialist Libraries&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Methodology:&lt;BR&gt;&lt;/STRONG&gt;&lt;BR&gt;Search results were limited to publications written in English and mainly concerning humans. The results were limited further to include papers published in journals that have an impact factor higher than 2. Following this, abstracts were reviewed by the Clinical Lead and Information Specialist and those that were not deemed relevant were rejected. Included papers are listed below. Their inclusion does not imply endorsement and the Kidney Diseases Specialist Library does not accept responsibility for the content or quality of included studies.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Results:&lt;BR&gt;&lt;/STRONG&gt;&lt;BR&gt;•&amp;nbsp;Guidance/Evidence-based management (14)&lt;BR&gt;•&amp;nbsp;Section 1, Basic Science (57)&lt;BR&gt;•&amp;nbsp;Section 2, Clinical Aspects (106)&lt;BR&gt;•&amp;nbsp;Section 3, Management (77)&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Guidance/Evidence-based management:&lt;BR&gt;&lt;/STRONG&gt;&lt;BR&gt;NICE: Early identification and management of adults with chronic kidney disease in primary and secondary care consultation documents (full guideline due in September 2008) [&lt;A href="http://www.nice.org.uk/nicemedia/pdf/CKDConsFullGuideline.pdf" target="_blank"&gt;link&lt;/A&gt;] &lt;/P&gt;
&lt;P&gt;NICE: Management of type 2 diabetes: renal disease, prevention and early management (2002) [&lt;A href="http://www.nice.org.uk/nicemedia/pdf/diabetesrenalguideline.pdf" target="_blank"&gt;link&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Royal College of Physicians of London/Renal Association: Identification, management and referral of adults with chronic kidney disease - guidelines for general physicians and general practitioners (2006) [&lt;A href="http://www.rcplondon.ac.uk/pubs/contents/57f485dc-4730-4b2d-be90-fa6937cc15af.pdf" target="_blank"&gt;link&lt;/A&gt;] &lt;/P&gt;
&lt;P&gt;UK Renal Association: Chronic Kidney Disease in Adults - UK Guidelines for Identification, Management and Referral of Adults (2005) [&lt;A href="http://www.renal.org/CKDguide/full/Contents.htm" target="_blank"&gt;link&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;UK Renal Association: The short CKD eGuide, derived from the UK CKD Guidelines (2005) [&lt;A href="http://www.renal.org/eGFR/eguide.html" target="_blank"&gt;link&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;UK Renal Association: Clinical practice guidelines for the care of patients with chronic kidney disease (2007) [&lt;A href="http://www.renal.org/guidelines/print/CKDfinalMar07.pdf" target="_blank"&gt;link&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;UK Renal Association: Complications of Chronic Kidney Disease (2007) [&lt;A href="http://www.renal.org/guidelines/print/ComplicationsfinalDec07.pdf" target="_blank"&gt;link&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;UK Renal Association/Scottish Renal Association/The Royal College of Physicians of Edinburgh: Consensus statement on management of early CKD (2007) [&lt;A href="http://www.renal.org/CKDguide/consensus.html" target="_blank"&gt;link&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;US National Kidney Foundation: Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification (2002) [&lt;A href="http://www.kidney.org/professionals/KDOQI/guidelines_ckd/toc.htm" target="_blank"&gt;link&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Clinical Knowledge Summaries topic: Diabetes Type 1 and 2 - screening/managing renal disease (2006) [&lt;A href="http://cks.library.nhs.uk/diabetes_renal_disease" target="_blank"&gt;link&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Department of Health: National Service Framework for renal services part two: chronic kidney disease, acute renal failure and end of life care (2005) [&lt;A href="http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4102680.pdf" target="_blank"&gt;link&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;NLH Palliative &amp;amp; Supportive Care Specialist Library topic review: Epidemiology and prognosis in advanced chronic kidney disease: Implications for palliative care (2005) [&lt;A href="http://www.library.nhs.uk/palliative/viewResource.aspx?resID=271071" target="_blank"&gt;link]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Renal Unit of the Royal Infirmary of Edinburgh EdRen Handbook: Kidney tests (2006) [&lt;A href="http://renux.dmed.ed.ac.uk/edren/EdRenINFObits/kidneytests.html" target="_blank"&gt;link&lt;/A&gt;] &lt;/P&gt;
&lt;P&gt;Renal Unit of the Royal Infirmary of Edinburgh EdRen Handbook: Proteinuria in renal disease (2006) [&lt;A href="http://renux.dmed.ed.ac.uk/edren/Handbookbits/HDBKProteinuria.html" target="_blank"&gt;link&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Section 1, Basic science:&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;(1) &amp;nbsp;Abbate M, Zoja C, Remuzzi G. How does proteinuria cause progressive renal damage? Journal of the American Society of Nephrology 2006;17(11):2974-84.&lt;/P&gt;
&lt;P&gt;(2) &amp;nbsp;Adachi J, Kumar C, Zhang Y, Olsen J, V, Mann M. The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins. Genome Biology 2006;7(9, 2006 Article Number):R80Date.&lt;/P&gt;
&lt;P&gt;(3) &amp;nbsp;Amer H, Fidler ME, Myslak M, Morales P, Kremers WK, Larson TS, et al. Proteinuria after kidney transplantation, relationship to allograft histology and survival. Am J Transplant 2007 Dec;7(12):2748-56.&lt;/P&gt;
&lt;P&gt;(4) &amp;nbsp;Atthobari J, Brantsma AH, Gansevoort RT, Visser ST, Asselbergs FW, van Gilst WH, et al. The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study. Nephrol Dial Transplant 2006 Nov;21(11):3106-14.&lt;/P&gt;
&lt;P&gt;(5) &amp;nbsp;Barratt J, Topham P. Urine proteomics: the present and future of measuring urinary protein components in disease. CMAJ 2007 Aug 14;177(4):361-8.&lt;/P&gt;
&lt;P&gt;(6) &amp;nbsp;Bello AK, de ZD, El NM, Brantsma AH, Bakker SJ, de Jong PE, et al. Impact of weight change on albuminuria in the general population. Nephrol Dial Transplant 2007 Jun;22(6):1619-27.&lt;/P&gt;
&lt;P&gt;(7) &amp;nbsp;Biemesderfer D. Regulated intramembrane proteolysis of megalin: linking urinary protein and gene regulation in proximal tubule? Kidney Int 2006 May;69(10):1717-21.&lt;/P&gt;
&lt;P&gt;(8) &amp;nbsp;Brantsma AH, Atthobari J, Bakker SJ, de ZD, de Jong PE, Gansevoort RT. What predicts progression and regression of urinary albumin excretion in the nondiabetic population? J Am Soc Nephrol 2007 Feb;18(2):637-45.&lt;/P&gt;
&lt;P&gt;(9) &amp;nbsp;Celie JW, Reijmers RM, Slot EM, Beelen RH, Spaargaren M, Ter Wee PM, et al. Tubulointerstitial heparan sulfate proteoglycan changes in human renal diseases correlate with leukocyte influx and proteinuria. Am J Physiol Renal Physiol 2008 Jan;294(1):F253-F263&lt;/P&gt;
&lt;P&gt;(10) &amp;nbsp;Cowan ML, Vera J. Proteomics: advances in biomarker discovery. Expert Rev Proteomics 2008 Feb;5(1):21-3.&lt;/P&gt;
&lt;P&gt;(11) &amp;nbsp;Devarajan P. Proteomics for biomarker discovery in acute kidney injury. Semin Nephrol 2007 Nov;27(6):637-51.&lt;/P&gt;
&lt;P&gt;(12) &amp;nbsp;Dihazi H. Clinical proteomics: An insight into the urinary proteome. Expert Review of Proteomics 2006;3(5):481-2.&lt;/P&gt;
&lt;P&gt;(13) &amp;nbsp;Dihazi H, Muller GA. Urinary proteomics: a tool to discover biomarkers of kidney diseases. Expert Rev Proteomics 2007 Feb;4(1):39-50.&lt;/P&gt;
&lt;P&gt;(14) &amp;nbsp;Dihazi H, Muller GA, Lindner S, Meyer M, Asif AR, Oellerich M, et al. Characterization of diabetic nephropathy by urinary proteomic analysis: identification of a processed ubiquitin form as a differentially excreted protein in diabetic nephropathy patients. Clin Chem 2007 Sep;53(9):1636-45.&lt;/P&gt;
&lt;P&gt;(15) &amp;nbsp;Eknoyan G. Looking at the urine: the renaissance of an unbroken tradition. Am J Kidney Dis 2007 Jun;49(6):865-72.&lt;/P&gt;
&lt;P&gt;(16) &amp;nbsp;Erkan E, Devarajan P, Schwartz G, J. Mitochondria are the major targets in albumin-induced apoptosis in proximal tubule cells. Journal of the American Society of Nephrology 2007;18(4):1199-208.&lt;/P&gt;
&lt;P&gt;(17) &amp;nbsp;Fliser D, Novak J, Thongboonkerd V, Argiles A, Jankowski V, Girolami MA, et al. Advances in urinary proteome analysis and biomarker discovery. J Am Soc Nephrol 2007 Apr;18(4):1057-71.&lt;/P&gt;
&lt;P&gt;(18) &amp;nbsp;Goligorsky MS, Addabbo F, O'Riordan E. Diagnostic potential of urine proteome: a broken mirror of renal diseases. J Am Soc Nephrol 2007 Aug;18(8):2233-9.&lt;/P&gt;
&lt;P&gt;(19) &amp;nbsp;Gonzalez-Buitrago JM, Ferreira L, Lorenzo I. Urinary proteomics. Clin Chim Acta 2007 Jan;375(1-2):49-56.&lt;/P&gt;
&lt;P&gt;(20) &amp;nbsp;Halimi JM, Buchler M, Al-Najjar A, Laouad I, Chatelet V, Marliere JF, et al. Urinary albumin excretion and the risk of graft loss and death in proteinuric and non-proteinuric renal transplant recipients. Am J Transplant 2007 Mar;7(3):618-25.&lt;/P&gt;
&lt;P&gt;(21) &amp;nbsp;Hortin G, L, Sviridov D. Diagnostic potential for urinary proteomics. Pharmacogenomics 2007;8(3):237-55.&lt;/P&gt;
&lt;P&gt;(22) &amp;nbsp;Hryciw D, H, Ekberg J, Pollock C, A, Poronnik P. ClC-5: A chloride channel with multiple roles in renal tubular albumin uptake. International Journal of Biochemistry and Cell Biology 2006;38(7):1036-42.&lt;/P&gt;
&lt;P&gt;(23) &amp;nbsp;Janech MG, Raymond JR, Arthur JM. Proteomics in renal research. Am J Physiol Renal Physiol 2007 Feb;292(2):F501-F512.&lt;/P&gt;
&lt;P&gt;(24) &amp;nbsp;Khan A, Packer NH. Simple urinary sample preparation for proteomic analysis. J Proteome Res 2006 Oct;5(10):2824-38.&lt;/P&gt;
&lt;P&gt;(25) &amp;nbsp;Kohn E, C, Azad N, Annunziata C, Dhamoon A, S, et al. Proteomics as a tool for biomarker discovery. Disease Markers 2007;23(5-6):411-7.&lt;/P&gt;
&lt;P&gt;(26) &amp;nbsp;Lai K, N, Leung J, C, K, Chan L, et al. Interaction between proximal tubular epithelial cells and infiltrating monocytes/T cells in the proteinuric state. Kidney International 2007;71(6):526-38.&lt;/P&gt;
&lt;P&gt;(27) &amp;nbsp;Lazzara MJ, Deen WM. Model of albumin reabsorption in the proximal tubule. Am J Physiol Renal Physiol 2007 Jan;292(1):F430-F439.&lt;/P&gt;
&lt;P&gt;(28) &amp;nbsp;Magliano D, J, Polkinghorne K, R, Barr E, L, et al. HPLC-detected albuminuria predicts mortality. Journal of the American Society of Nephrology 2007;18(12):3171-6.&lt;/P&gt;
&lt;P&gt;(29) &amp;nbsp;Merchant ML, Klein JB. Proteomics and diabetic nephropathy. Semin Nephrol 2007 Nov;27(6):627-36.&lt;/P&gt;
&lt;P&gt;(30) &amp;nbsp;Murussi M, Campagnolo N, Beck MO, Gross JL, Silveiro SP. High-normal levels of albuminuria predict the development of micro- and macroalbuminuria and increased mortality in Brazilian Type 2 diabetic patients: an 8-year follow-up study. Diabet Med 2007 Oct;24(10):1136-42.&lt;/P&gt;
&lt;P&gt;(31) &amp;nbsp;Ngai HH, Sit WH, Jiang PP, Xu RJ, Wan JM, Thongboonkerd V. Serial changes in urinary proteome profile of membranous nephropathy: implications for pathophysiology and biomarker discovery. J Proteome Res 2006 Nov;5(11):3038-47.&lt;/P&gt;
&lt;P&gt;(32) &amp;nbsp;Otu HH, Can H, Spentzos D, Nelson RG, Hanson RL, Looker HC, et al. Prediction of diabetic nephropathy using urine proteomic profiling 10 years prior to development of nephropathy. Diabetes Care 2007 Mar;30(3):638-43.&lt;/P&gt;
&lt;P&gt;(33) &amp;nbsp;Palmas W, Moran A, Pickering T, Eimicke JP, Teresi J, Schwartz JE, et al. Ambulatory pulse pressure and progression of urinary albumin excretion in older patients with type 2 diabetes mellitus. Hypertension 2006 Aug;48(2):301-8.&lt;/P&gt;
&lt;P&gt;(34) &amp;nbsp;Papale M, Pedicillo MC, Thatcher BJ, Di PS, Lo ML, Bufo P, et al. Urine profiling by SELDI-TOF/MS: monitoring of the critical steps in sample collection, handling and analysis. J Chromatogr B Analyt Technol Biomed Life Sci 2007 Sep 1;856(1-2):205-13.&lt;/P&gt;
&lt;P&gt;(35) &amp;nbsp;Parving HH, Lewis JB, Ravid M, Remuzzi G, Hunsicker LG. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int 2006 Jun;69(11):2057-63.&lt;/P&gt;
&lt;P&gt;(36) &amp;nbsp;Pollock CA, Poronnik P. Albumin transport and processing by the proximal tubule: physiology and pathophysiology. Curr Opin Nephrol Hypertens 2007 Jul;16(4):359-64.&lt;/P&gt;
&lt;P&gt;(37) &amp;nbsp;Rao F, Wessel J, Wen G, Zhang L, Rana BK, Kennedy BP, et al. Renal albumin excretion: twin studies identify influences of heredity, environment, and adrenergic pathway polymorphism. Hypertension 2007 May;49(5):1015-31.&lt;/P&gt;
&lt;P&gt;(38) &amp;nbsp;Rao P, V, Lu X, Standley M, Pattee P, Neelima G, et al. Proteomic identification of urinary biomarkers of diabetic nephropathy. Diabetes Care 2007;30(3):629-37.&lt;/P&gt;
&lt;P&gt;(39) &amp;nbsp;Rocchetti M, T, Centra M, Papale M, Bortone G, Palermo C, et al. Urine protein profile of IgA nephropathy patients may predict the response to ACE-inhibitor therapy. Proteomics 2008;8(1):206-16.&lt;/P&gt;
&lt;P&gt;(40) &amp;nbsp;Russo LM, Sandoval RM, McKee M, Osicka TM, Collins AB, Brown D, et al. The normal kidney filters nephrotic levels of albumin retrieved by proximal tubule cells: retrieval is disrupted in nephrotic states. Kidney Int 2007 Mar;71(6):504-13.&lt;/P&gt;
&lt;P&gt;(41) &amp;nbsp;Shalamanova L, McArdle F, Amara A, B, Jackson M, J, et al. Albumin overload induces adaptive responses in human proximal tubular cells through oxidative stress but not via angiotensin II type 1 receptor. American Journal of Physiology - Renal Physiology 2007;292(6):F1846-F1857.&lt;/P&gt;
&lt;P&gt;(42) &amp;nbsp;Theilig F, Kriz W, Jerichow T, Schrade P, Hahnel B, Willnow T, et al. Abrogation of protein uptake through megalin-deficient proximal tubules does not safeguard against tubulointerstitial injury. J Am Soc Nephrol 2007 Jun;18(6):1824-34.&lt;/P&gt;
&lt;P&gt;(43) &amp;nbsp;Thompson J, Reid M, Hambleton I, Serjeant GR. Albuminuria and renal function in homozygous sickle cell disease: observations from a cohort study. Arch Intern Med 2007 Apr 9;167(7):701-8.&lt;/P&gt;
&lt;P&gt;(44) &amp;nbsp;Thongboonkerd V, Chutipongtanate S, Kanlaya R. Systematic evaluation of sample preparation methods for gel-based human urinary proteomics: Quantity, quality, and variability. Journal of Proteome Research 2006;5(1):183-91.&lt;/P&gt;
&lt;P&gt;(45) &amp;nbsp;Thongboonkerd V. Practical points in urinary proteomics. Journal of Proteome Research 2007;6(10):3881-90.&lt;/P&gt;
&lt;P&gt;(46) &amp;nbsp;Thongboonkerd V, Saetun P. Bacterial overgrowth affects urinary proteome analysis: recommendation for centrifugation, temperature, duration, and the use of preservatives during sample collection. J Proteome Res 2007 Nov;6(11):4173-81.&lt;/P&gt;
&lt;P&gt;(47) &amp;nbsp;Thongboonkerd V, Songtawee N, Sritippayawan S. Urinary proteome profiling using microfluidic technology on a chip. J Proteome Res 2007 May;6(5):2011-8.&lt;/P&gt;
&lt;P&gt;(48) &amp;nbsp;Thongboonkerd V, Semangoen T, Chutipongtanate S. Enrichment of the basic/cationic urinary proteome using ion exchange chromatography and batch adsorption. J Proteome Res 2007 Mar;6(3):1209-14.&lt;/P&gt;
&lt;P&gt;(49) &amp;nbsp;Tyan Y, -C, Guo H, -R, Liu C, -Y, et al. Proteomic profiling of human urinary proteome using nano-high performance liquid chromatography/electrospray ionization tandem mass spectrometry. Analytica Chimica Acta 2006;579(2):158-76.&lt;/P&gt;
&lt;P&gt;(50) &amp;nbsp;van Timmeren MM, Bakker SJ, Vaidya VS, Bailly V, Schuurs TA, Damman J, et al. Tubular kidney injury molecule-1 in protein-overload nephropathy. Am J Physiol Renal Physiol 2006 Aug;291(2):F456-F464.&lt;/P&gt;
&lt;P&gt;(51) &amp;nbsp;van TM, M, van den HM, C, Bailly V, Bakker S, et al. Tubular kidney injury molecule-1 (KIM-1) in human renal disease. Journal of Pathology 2007;212(2):209-17.&lt;/P&gt;
&lt;P&gt;(52) &amp;nbsp;Varghese SA, Powell TB, Budisavljevic MN, Oates JC, Raymond JR, Almeida JS, et al. Urine biomarkers predict the cause of glomerular disease. J Am Soc Nephrol 2007 Mar;18(3):913-22.&lt;/P&gt;
&lt;P&gt;(53) &amp;nbsp;Wilkey DW, Merchant ML. Proteomic methods for biomarker discovery in urine. Semin Nephrol 2007 Nov;27(6):584-96.&lt;/P&gt;
&lt;P&gt;(54) &amp;nbsp;Williams SM. Lumping, splitting and mapping: assessing linkage in different ethnic groups for albuminuria and glomerular filtration rate in the HyperGen study. Nephrol Dial Transplant 2007 Mar;22(3):687-9.&lt;/P&gt;
&lt;P&gt;(55) &amp;nbsp;Wong MG, Suzuki Y, Tanifuji C, Akiba H, Okumura K, Sugaya T, et al. Peritubular ischemia contributes more to tubular damage than proteinuria in immune-mediated glomerulonephritis. J Am Soc Nephrol 2008 Feb;19(2):290-7.&lt;/P&gt;
&lt;P&gt;(56) &amp;nbsp;Zhang L, Zhang P, Wang F, Zuo L, Zhou Y, Shi Y, et al. Prevalence and Factors Associated With CKD: A Population Study From Beijing. American Journal of Kidney Diseases 2008;51(3):373-84.&lt;/P&gt;
&lt;P&gt;(57) &amp;nbsp;Zimmerli L, U, Schiffer E, Zurbig P, Good D, M, et al. Urinary proteomic biomarkers in coronary artery disease. Molecular and Cellular Proteomics 2008;7(2):290-8.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Section 2, Clinical aspects:&lt;/STRONG&gt;&lt;BR&gt;&lt;BR&gt;(1) &amp;nbsp;Agarwal R. Reproducibility of renal function measurements in adult men with diabetic nephropathy: research and clinical implications. American journal of nephrology 2007;27(1):92-100.&lt;/P&gt;
&lt;P&gt;(2) &amp;nbsp;Atthobari J, Gansevoort RT, Visser ST, De Jong PE, de Jong-van den Berg LT. The effect of screening for cardio-renal risk factors on drug use in the general population. Br J Clin Pharmacol 2007 Dec;64(6):810-8.&lt;/P&gt;
&lt;P&gt;(3) &amp;nbsp;Azizi M, Menard J, Peyrard S, Lievre M, Marre M, Chatellier G. Assessment of patients' and physicians' compliance to an ACE inhibitor treatment based on urinary N-acetyl Ser-Asp-Lys-Pro determination in the Noninsulin-Dependent Diabetes, Hypertension, Microalbuminuria, Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR) study. Diabetes Care 2006 Jun;29(6):1331-6.&lt;/P&gt;
&lt;P&gt;(4) &amp;nbsp;Babic N, Larson TS, Grebe SK, Turner ST, Kumar R, Singh RJ. Application of liquid chromatography-mass spectrometry technology for early detection of microalbuminuria in patients with kidney disease. Clin Chem 2006 Nov;52(11):2155-7.&lt;/P&gt;
&lt;P&gt;(5) &amp;nbsp;Bakoush O, Segelmark M, Torffvit O, Ohlsson S, Tencer J. Urine IgM excretion predicts outcome in ANCA-associated renal vasculitis. Nephrol Dial Transplant 2006 May;21(5):1263-9.&lt;/P&gt;
&lt;P&gt;(6) &amp;nbsp;Bang H, Vupputuri S, Shoham D, A, Klemmer P, J, et al. SCreening for Occult REnal Disease (SCORED): A simple prediction model for chronic kidney disease. Archives of Internal Medicine 2007;167(4):374-81.&lt;/P&gt;
&lt;P&gt;(7) &amp;nbsp;Beullens M, Delanghe JR, Bollen M. False-positive detection of recombinant human erythropoietin in urine following strenuous physical exercise. Blood 2006 Jun 15;107(12):4711-3.&lt;/P&gt;
&lt;P&gt;(8) &amp;nbsp;Birn H, Christensen E, I. Renal albumin absorption in physiology and pathology. Kidney International 2006;69(3):440-9.&lt;/P&gt;
&lt;P&gt;(9) &amp;nbsp;Bohm M, Reil J, -C, Danchin N, Thoenes M, Bramlage P, et al. Association of heart rate with microalbuminuria in cardiovascular risk patients: Data from I-SEARCH. Journal of Hypertension 2008;26(1):18-25.&lt;/P&gt;
&lt;P&gt;(10) &amp;nbsp;Caglar K, Yilmaz MI, Sonmez A, Cakir E, Kaya A, Acikel C, et al. ADMA, proteinuria, and insulin resistance in non-diabetic stage I chronic kidney disease. Kidney Int 2006 Aug;70(4):781-7.&lt;/P&gt;
&lt;P&gt;(11) &amp;nbsp;Chan O, T, M, Herold D, A. Chip Electrophoresis as a method for quantifying total microalbuminuria. Clinical Chemistry 2006;52(11):2141-6.&lt;/P&gt;
&lt;P&gt;(12) &amp;nbsp;Chien TI, Lu JY, Kao JT, Lee TF, Ho SY, Chang CY, et al. Comparison of three automated urinalysis systems--Bayer Clinitek Atlas, Roche Urisys 2400 and Arkray Aution Max for testing urine chemistry and detection of bacteriuria. Clin Chim Acta 2007 Feb;377(1-2):98-102.&lt;/P&gt;
&lt;P&gt;(13) &amp;nbsp;Cholongitas E, Shusang V, Marelli L, Nair D, Thomas M, Patch D, et al. Review article: renal function assessment in cirrhosis - difficulties and alternative measurements. Aliment Pharmacol Ther 2007 Oct 1;26(7):969-78.&lt;/P&gt;
&lt;P&gt;(14) &amp;nbsp;Cirillo M, Laurenzi M, Mancini M, Zanchetti A, De SN, G. Low muscular mass and overestimation of microalbuminuria by urinary albumin/creatinine ratio. Hypertension 2006;47(1):56-61.&lt;/P&gt;
&lt;P&gt;(15) &amp;nbsp;de B, I, H, Ioannou G, N, Kestenbaum B, Brunzell J, et al. 25-Hydroxyvitamin D Levels and Albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III). American Journal of Kidney Diseases 2007;50(1):69-77.&lt;/P&gt;
&lt;P&gt;(16) &amp;nbsp;de JP, E, Halbesma N, Gansevoort R, T. Screening for early chronic kidney disease - What method fits best? Nephrology Dialysis Transplantation 2006;21(9):2358-61.&lt;/P&gt;
&lt;P&gt;(17) &amp;nbsp;de ZD, Parving H, -H, Henning R, H. Microalbuminuria as an early marker for cardiovascular disease. Journal of the American Society of Nephrology 2006;17(8):2100-5.&lt;/P&gt;
&lt;P&gt;(18) &amp;nbsp;Di AE, Danesh J, Eiriksdottir G, Gudnason V. Renal function and risk of coronary heart disease in general populations: new prospective study and systematic review. PLoS Med 2007 Sep;4(9):e270.&lt;/P&gt;
&lt;P&gt;(19) &amp;nbsp;Dong X, He M, Song X, Lu B, Yang Y, Zhang S, et al. Performance and comparison of the Cockcroft-Gault and simplified Modification of Diet in Renal Disease formulae in estimating glomerular filtration rate in a Chinese Type 2 diabetic population. Diabet Med 2007 Dec;24(12):1482-6.&lt;/P&gt;
&lt;P&gt;(20) &amp;nbsp;Erdmann E. Microalbuminuria as a marker of cardiovascular risk in patients with type 2 diabetes. International Journal of Cardiology 2006;107(2):152-8.&lt;/P&gt;
&lt;P&gt;(21) &amp;nbsp;Fernandez-Llama P, Bover J. Is albuminuria a marker of arterial remodeling? Journal of Hypertension 2008;26(4):633-5.&lt;/P&gt;
&lt;P&gt;(22) &amp;nbsp;Gansevoort R, T, Lambers H, Witte E, C. Methodology of screening for albuminuria. Nephrology Dialysis Transplantation 2007;22(8):2109-11.&lt;/P&gt;
&lt;P&gt;(23) &amp;nbsp;Gansevoort RT, Brinkman J, Bakker SJ, De Jong PE, de ZD. Evaluation of measures of urinary albumin excretion. Am J Epidemiol 2006 Oct 15;164(8):725-7.&lt;/P&gt;
&lt;P&gt;(24) &amp;nbsp;Gerber L, M, Schwartz J, E, Pickering T, G. Albumin-to-creatinine ratio predicts change in ambulatory blood pressure in normotensive persons: A 7. American Journal of Hypertension 2006;19(2):220-6.&lt;/P&gt;
&lt;P&gt;(25) &amp;nbsp;Halbesma N, Kuiken D, -S, Brantsma A, H, Bakker S, et al. Macroalbuminuria is a better risk marker than low estimated GFR to identify individuals at risk for accelerated GFR loss in population screening. Journal of the American Society of Nephrology 2006;17(9):2582-90.&lt;/P&gt;
&lt;P&gt;(26) &amp;nbsp;Hallan SI, Dahl K, Oien CM, Grootendorst DC, Aasberg A, Holmen J, et al. Screening strategies for chronic kidney disease in the general population: follow-up of cross sectional health survey. BMJ 2006 Nov 18;333(7577):1047.&lt;/P&gt;
&lt;P&gt;(27) &amp;nbsp;Hayden MR, Kolb L, Chowdbury N, Karuparthi PR, Khanna R, Sowers JR. Detecting microalbuminuria and taking action in the cardiometabolic syndrome and type 2 diabetes mellitus. Mo Med 2006 Sep;103(5):533-8.&lt;/P&gt;
&lt;P&gt;(28) &amp;nbsp;Herget-Rosenthal S, Bokenkamp A, Hofmann W. How to estimate GFR-serum creatinine, serum cystatin C or equations? Clin Biochem 2007 Feb;40(3-4):153-61.&lt;/P&gt;
&lt;P&gt;(29) &amp;nbsp;Ibrahim HN, Rogers T, Tello A, Matas A. The performance of three serum creatinine-based formulas in estimating GFR in former kidney donors. Am J Transplant 2006 Jun;6(6):1479-85.&lt;/P&gt;
&lt;P&gt;(30) &amp;nbsp;Ingelsson E, Sundstrom J, Lind L, Riserus U, Larsson A, Basu S, et al. Low-grade albuminuria and the incidence of heart failure in a community-based cohort of elderly men. European Heart Journal 2007;28(14):1739-45.&lt;/P&gt;
&lt;P&gt;(31) &amp;nbsp;Iseki K. Screening for renal disease - What can be learned from the Okinawa experience. Nephrology Dialysis Transplantation 2006;21(4):839-43.&lt;/P&gt;
&lt;P&gt;(32) &amp;nbsp;Iseki K, Iseki C, Ikemiya Y, Kinjo K, Takishita S. Risk of developing low glomerular filtration rate or elevated serum creatinine in a screened cohort in Okinawa, Japan. Hypertens Res 2007 Feb;30(2):167-74.&lt;/P&gt;
&lt;P&gt;(33) &amp;nbsp;Iseki K, Kohagura K, Sakima A, Iseki C, Kinjo K, Ikemiya Y, et al. Changes in the demographics and prevalence of chronic kidney disease in Okinawa, Japan (1993 to 2003). Hypertens Res 2007 Jan;30(1):55-62.&lt;/P&gt;
&lt;P&gt;(34) &amp;nbsp;Ishani A, Grandits GA, Grimm RH, Svendsen KH, Collins AJ, Prineas RJ, et al. Association of single measurements of dipstick proteinuria, estimated glomerular filtration rate, and hematocrit with 25-year incidence of end-stage renal disease in the multiple risk factor intervention trial. Journal of the American Society of Nephrology : JASN 2006;17(5):1444-52.&lt;/P&gt;
&lt;P&gt;(35) &amp;nbsp;Ishizaka N, Ishizaka Y, Toda E, Koike K, Seki G, Nagai R, et al. Association between obesity and chronic kidney disease in Japanese: differences in gender and hypertensive status? Hypertens Res 2007 Nov;30(11):1059-64.&lt;/P&gt;
&lt;P&gt;(36) &amp;nbsp;Ito H, Fujita H, Takahashi T. Diagnostic biomarkers of diabetic nephropathy. Expert Opinion on Medical Diagnostics 2008;2(2):161-9.&lt;/P&gt;
&lt;P&gt;(37) &amp;nbsp;Jafar T, H, Chaturvedi N, Hatcher J, Levey A, S. Use of albumin creatinine ratio and urine albumin concentration as a screening test for albuminuria in an Indo-Asian population. Nephrology Dialysis Transplantation 2007;22(8):2194-200.&lt;/P&gt;
&lt;P&gt;(38) &amp;nbsp;Johnson S, L, Tierney E, F, Onyemere K, U, et al. Who is tested for diabetic kidney disease and who initiates treatment? The Translating Research Into Action for Diabetes (TRIAD) study. Diabetes Care 2006;29(8):1733-8.&lt;/P&gt;
&lt;P&gt;(39) &amp;nbsp;Jorgensen L, Jenssen T, Johnsen SH, Mathiesen EB, Heuch I, Joakimsen O, et al. Albuminuria as risk factor for initiation and progression of carotid atherosclerosis in non-diabetic persons: the Tromso Study. Eur Heart J 2007 Feb;28(3):363-9.&lt;/P&gt;
&lt;P&gt;(40) &amp;nbsp;Julian BA, Wittke S, Novak J, Good DM, Coon JJ, Kellmann M, et al. Electrophoretic methods for analysis of urinary polypeptides in IgA-associated renal diseases. Electrophoresis 2007 Dec;28(23):4469-83.&lt;/P&gt;
&lt;P&gt;(41) &amp;nbsp;Katzmann J, A, Dispenzieri A, Kyle R, A, Snyder M, et al. Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays. Mayo Clinic Proceedings 2006;81(12):1575-8.&lt;/P&gt;
&lt;P&gt;(42) &amp;nbsp;Kong A, P, S, So W, Y, Szeto C, et al. Assessment of glomerular filtration rate in addition to albuminuria is important in managing type II diabetes. Kidney International 2006;69(2):383-7.&lt;/P&gt;
&lt;P&gt;(43) &amp;nbsp;Kshirsagar AV, Bomback AS, Bang H, Gerber LM, Vupputuri S, Shoham DA, et al. Association of C-reactive protein and microalbuminuria (from the National Health and Nutrition Examination Surveys, 1999 to 2004). Am J Cardiol 2008 Feb 1;101(3):401-6.&lt;/P&gt;
&lt;P&gt;(44) &amp;nbsp;Kyle PM, Fielder JN, Pullar B, Horwood LJ, Moore MP. Comparison of methods to identify significant proteinuria in pregnancy in the outpatient setting. BJOG 2008 Mar;115(4):523-7.&lt;/P&gt;
&lt;P&gt;(45) &amp;nbsp;Lambers HH, J, Brinkman J, W, Bakker S, J, et al. Update on microalbuminuria as a biomarker in renal and cardiovascular disease. Current Opinion in Nephrology and Hypertension 2006;15(6):631-6.&lt;/P&gt;
&lt;P&gt;(46) &amp;nbsp;Lameire N, Adam A, Becker CR, Davidson C, McCullough PA, Stacul F, et al. Baseline renal function screening. Am J Cardiol 2006 Sep 18;98(6A):21K-6K.&lt;/P&gt;
&lt;P&gt;(47) &amp;nbsp;Leanos-Miranda A, Marquez-Acosta J, Romero-Arauz F, Cardenas-Mondragon G, M, Rivera-Leanos R, et al. Protein:creatinine ratio in random urine samples is a reliable marker of increased 24-hour protein excretion in hospitalized women with hypertensive disorders of pregnancy. Clinical Chemistry 2007;53(9):1623-8.&lt;/P&gt;
&lt;P&gt;(48) &amp;nbsp;Leon JM, Freedman BI, Miller MB, North KE, Hunt SC, Eckfeldt JH, et al. Genome scan of glomerular filtration rate and albuminuria: the HyperGEN study. Nephrol Dial Transplant 2007 Mar;22(3):763-71.&lt;/P&gt;
&lt;P&gt;(49) &amp;nbsp;Levey AS, Stevens LA, Hostetter T. Automatic reporting of estimated glomerular filtration rate--just what the doctor ordered. Clin Chem 2006 Dec;52(12):2188-93.&lt;/P&gt;
&lt;P&gt;(50) &amp;nbsp;Lo JC, Go AS, Chandra M, Fan D, Kaysen GA. GFR, body mass index, and low high-density lipoprotein concentration in adults with and without CKD. Am J Kidney Dis 2007 Oct;50(4):552-8.&lt;/P&gt;
&lt;P&gt;(51) &amp;nbsp;Luo Y, Chen M, Wen Q, Zhao M, Zhang B, Li X, et al. Rapid and simultaneous quantification of 4 urinary proteins by piezoelectric quartz crystal microbalance immunosensor array. Clinical Chemistry 2006;52(12):2273-80.&lt;/P&gt;
&lt;P&gt;(52) &amp;nbsp;Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y, et al. Improved GFR estimation by combined creatinine and cystatin C measurements. Kidney Int 2007 Dec;72(12):1535-42.&lt;/P&gt;
&lt;P&gt;(53) &amp;nbsp;Macdonald J, Marcora S, Jibani M, Roberts G, Kumwenda M, Glover R, et al. GFR Estimation Using Cystatin C Is Not Independent of Body Composition. American Journal of Kidney Diseases 2006;48(5):712-9.&lt;/P&gt;
&lt;P&gt;(54) &amp;nbsp;MacIsaac R, J, Tsalamandris C, Thomas M, C, Premaratne E, et al. Estimating glomerular filtration rate in diabetes: A comparison of cystatin-C- and creatinine-based methods. Diabetologia 2006;49(7):1686-9.&lt;/P&gt;
&lt;P&gt;(55) &amp;nbsp;Magliano D, J, Polkinghorne K, R, Barr E, L, et al. HPLC-detected albuminuria predicts mortality. Journal of the American Society of Nephrology 2007;18(12):3171-6.&lt;/P&gt;
&lt;P&gt;(56) &amp;nbsp;Marouf R, Mojiminiyi O, Abdella N, Kortom M, Al WH. Comparison of renal function markers in Kuwaiti patients with sickle cell disease. Journal of Clinical Pathology 2006;59(4):345-51.&lt;/P&gt;
&lt;P&gt;(57) &amp;nbsp;Marsik C, Endler G, Gulesserian T, Wagner O, F, Sunder-Plassmann G. Classification of chronic kidney disease by estimated glomerular filtration rate. European Journal of Clinical Investigation 2008;38(4):253-9.&lt;/P&gt;
&lt;P&gt;(58) &amp;nbsp;May A, Wang T, J. Evaluating the role of biomarkers for cardiovascular risk prediction: Focus on CRP, BNP and urinary microalbumin. Expert Review of Molecular Diagnostics 2007;7(6):793-804.&lt;/P&gt;
&lt;P&gt;(59) &amp;nbsp;McCullough PA, Jurkovitz CT, Pergola PE, McGill JB, Brown WW, Collins AJ, et al. Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP). Arch Intern Med 2007 Jun 11;167(11):1122-9.&lt;/P&gt;
&lt;P&gt;(60) &amp;nbsp;Middleton R, J, Foley R, N, Hegarty J, Cheung C, et al. The unrecognized prevalence of chronic kidney disease in diabetes. Nephrology Dialysis Transplantation 2006;21(1):88-92.&lt;/P&gt;
&lt;P&gt;(61) &amp;nbsp;Narva A. Screening is part of kidney disease education. Clin J Am Soc Nephrol 2007 Nov;2(6):1352-4.&lt;/P&gt;
&lt;P&gt;(62) &amp;nbsp;Navarro J, F, Mora C, Muros M, Garcia J. Urinary tumour necrosis factor-alpha excretion independently correlates with clinical markers of glomerular and tubulointerstitial injury in type 2 diabetic patients. Nephrology Dialysis Transplantation 2006;21(12):3428-34.&lt;/P&gt;
&lt;P&gt;(63) &amp;nbsp;New J, P, O'Donoghue D, J, Middleton R, J, et al. Time to move from serum creatinine to eGFR. Diabetic Medicine 2006;23(10):1047-9.&lt;/P&gt;
&lt;P&gt;(64) &amp;nbsp;New J, P, Middleton R, J, Klebe B, Farmer C, et al. Assessing the prevalence, monitoring and management of chronic kidney disease in patients with diabetes compared with those without diabetes in general practice. Diabetic Medicine 2007;24(4):364-9.&lt;/P&gt;
&lt;P&gt;(65) &amp;nbsp;Nguyen T, Q, Tarnow L, Andersen S, Hovind P, Parving H, et al. Urinary connective tissue growth factor excretion correlates with clinical markers of renal disease in a large population of type 1 diabetic patients with diabetic nephropathy. Diabetes Care 2006;29(1):83-8.&lt;/P&gt;
&lt;P&gt;(66) &amp;nbsp;Palmer BF. Proteinuria as a therapeutic target in patients with chronic kidney disease. Am J Nephrol 2007;27(3):287-93.&lt;/P&gt;
&lt;P&gt;(67) &amp;nbsp;Poggio E, D, Rule A, D. Can we do better than a single estimated GFR threshold when screening for chronic kidney disease? Kidney International 2007;72(5):534-6.&lt;/P&gt;
&lt;P&gt;(68) &amp;nbsp;Polkinghorne K, R. Detection and measurement of urinary protein. Current Opinion in Nephrology and Hypertension 2006;15(6):625-30.&lt;/P&gt;
&lt;P&gt;(69) &amp;nbsp;Pollak J, Sypniewska G. Microalbuminuria and risk of cardiovascular diseases in patients with diabetes and hypertension. Biochemia Medica 2008;18(1):25-34.&lt;/P&gt;
&lt;P&gt;(70) &amp;nbsp;Prigent A. Monitoring renal function and limitations of renal function tests. Semin Nucl Med 2008 Jan;38(1):32-46.&lt;/P&gt;
&lt;P&gt;(71) &amp;nbsp;Rao PV, Lu X, Standley M, Pattee P, Neelima G, Girisesh G, et al. Proteomic identification of urinary biomarkers of diabetic nephropathy. Diabetes Care 2007 Mar;30(3):629-37.&lt;/P&gt;
&lt;P&gt;(72) &amp;nbsp;Ratto E, Leoncini G, Viazzi F, Bezante G, P, Falqui V, et al. Inappropriate left ventricular mass is associated with microalbuminuria independently of left ventricular hypertrophy in primary hypertension. Journal of Hypertension 2008;26(2):345-50.&lt;/P&gt;
&lt;P&gt;(73) &amp;nbsp;Redon J. New insights into urinary proteins as markers of cardiovascular risk in hypertension. Journal of Hypertension 2006;24(3):447-9.&lt;/P&gt;
&lt;P&gt;(74) &amp;nbsp;Rodondi N, Yerly P, Gabriel A, Riesen WF, Burnier M, Paccaud F, et al. Microalbuminuria, but not cystatin C, is associated with carotid atherosclerosis in middle-aged adults. Nephrol Dial Transplant 2007 Apr;22(4):1107-14.&lt;/P&gt;
&lt;P&gt;(75) &amp;nbsp;Rodriguez-Yanez M, Castellanos M, Blanco M, Millan M, Nombela F, Sobrino T, et al. Micro- and macroalbuminuria predict hemorrhagic transformation in acute ischemic stroke. Neurology 2006 Oct 10;67(7):1172-7.&lt;/P&gt;
&lt;P&gt;(76) &amp;nbsp;Ruggenenti P, Remuzzi G. Time to abandon microalbuminuria? Kidney Int 2006 Oct;70(7):1214-22.&lt;/P&gt;
&lt;P&gt;(77) &amp;nbsp;Rule A, D. Understanding estimated glomerular filtration rate: Implications for identifying chronic kidney disease. Current Opinion in Nephrology and Hypertension 2007;16(3):242-9.&lt;/P&gt;
&lt;P&gt;(78) &amp;nbsp;Saenger AK, Laha TJ, Edenfield MJ, Sadrzadeh SM. Quantification of urinary 8-iso-PGF2alpha using liquid chromatography-tandem mass spectrometry and association with elevated troponin levels. Clin Biochem 2007 Nov;40(16-17):1297-304.&lt;/P&gt;
&lt;P&gt;(79) &amp;nbsp;Sarafidis P, A, Riehle J, Bogojevic Z, Basta E, Chugh A, et al. A comparative evaluation of various methods for microalbuminuria screening. American journal of nephrology 2008;28(2):324-9.&lt;/P&gt;
&lt;P&gt;(80) &amp;nbsp;Schelling JR, Abboud HE, Nicholas SB, Pahl MV, Sedor JR, Adler SG, et al. Genome-wide scan for estimated glomerular filtration rate in multi-ethnic diabetic populations: the Family Investigation of Nephropathy and Diabetes (FIND). Diabetes 2008 Jan;57(1):235-43.&lt;/P&gt;
&lt;P&gt;(81) &amp;nbsp;Schonberg L, Grobosch T, Lampe D, Kloft C. New screening method for basic compounds in urine by on-line extraction-high-performance liquid chromatography with photodiode-array detection. J Chromatogr A 2006 Nov 17;1134(1-2):177-85.&lt;/P&gt;
&lt;P&gt;(82) &amp;nbsp;Sciarretta S, Ferrucci A, Ciavarella GM, De PP, Venturelli V, Tocci G, et al. Markers of inflammation and fibrosis are related to cardiovascular damage in hypertensive patients with metabolic syndrome. Am J Hypertens 2007 Jul;20(7):784-91.&lt;/P&gt;
&lt;P&gt;(83) &amp;nbsp;Shlipak MG, Ix JH, Bibbins-Domingo K, Lin F, Whooley MA. Biomarkers to predict recurrent cardiovascular disease: the Heart and Soul Study. Am J Med 2008 Jan;121(1):50-7.&lt;/P&gt;
&lt;P&gt;(84) &amp;nbsp;Siedner MJ, Atta MG, Lucas GM, Perazella MA, Fine DM. Poor validity of urine dipstick as a screening tool for proteinuria in HIV-positive patients. J Acquir Immune Defic Syndr 2008 Feb 1;47(2):261-3.&lt;/P&gt;
&lt;P&gt;(85) &amp;nbsp;Singh D, Whooley MA, Ix JH, Ali S, Shlipak MG. Association of cystatin C and estimated GFR with inflammatory biomarkers: the Heart and Soul Study. Nephrol Dial Transplant 2007 Apr;22(4):1087-92.&lt;/P&gt;
&lt;P&gt;(86) &amp;nbsp;Smilde T, D, J, Van VD, J, Navis G, et al. Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction. Circulation 2006;114(15):1572-80.&lt;/P&gt;
&lt;P&gt;(87) &amp;nbsp;Smith M, C, Moran P, Ward M, K, Davison J, et al. Assessment of glomerular filtration rate during pregnancy using the MDRD formula. BJOG: An International Journal of Obstetrics and Gynaecology 2008;115(1):109-12.&lt;/P&gt;
&lt;P&gt;(88) &amp;nbsp;Sonmez K, Eskisar A, O, Demir D, Yazicioglu M, V, et al. Increased urinary albumin excretion rates can be a marker of coexisting coronary artery disease in patients with peripheral arterial disease. Angiology 2006;57(1):15-20.&lt;/P&gt;
&lt;P&gt;(89) &amp;nbsp;Steffes M, W. Estimating GFR From Cystatin C in Serum: Seeking to Enhance Its Clinical Application. American Journal of Kidney Diseases 2006;48(5):842-3.&lt;/P&gt;
&lt;P&gt;(90) &amp;nbsp;Stehouwer CD, Smulders YM. Microalbuminuria and risk for cardiovascular disease: Analysis of potential mechanisms. J Am Soc Nephrol 2006 Aug;17(8):2106-11.&lt;/P&gt;
&lt;P&gt;(91) &amp;nbsp;Stevens LA, Coresh J, Schmid CH, Feldman HI, Froissart M, Kusek J, et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis 2008 Mar;51(3):395-406.&lt;/P&gt;
&lt;P&gt;(92) &amp;nbsp;Stevens P, E, O'Donoghue D, J, De LS, Van VJ, et al. Chronic kidney disease management in the United Kingdom: NEOERICA project results. Kidney International 2007;72(1):92-9.&lt;/P&gt;
&lt;P&gt;(93) &amp;nbsp;Sung KC, Kim BJ, Ryu S. An association of a variety of cardiovascular risk factors with low grade albuminuria in Korean men. Atherosclerosis 2008 Jan;196(1):320-6.&lt;/P&gt;
&lt;P&gt;(94) &amp;nbsp;Szeto C, -C, Chow K, -M, Lai K, -B, et al. MRNA expression of target genes in the urinary sediment as a noninvasive prognostic indicator of CKD. American Journal of Kidney Diseases 2006;47(4):578-86.&lt;/P&gt;
&lt;P&gt;(95) &amp;nbsp;Trachtenberg F, Barregard L. The effect of age, sex, and race on urinary markers of kidney damage in children. Am J Kidney Dis 2007 Dec;50(6):938-45.&lt;/P&gt;
&lt;P&gt;(96) &amp;nbsp;Traynor J, Mactier R, Geddes CC, Fox JG. How to measure renal function in clinical practice. BMJ 2006 Oct 7;333(7571):733-7.&lt;/P&gt;
&lt;P&gt;(97) &amp;nbsp;Tsai WC, Lin CC, Huang YY, Chen JY, Chen JH. Association of increased arterial stiffness and inflammation with proteinuria and left ventricular hypertrophy in non-diabetic hypertensive patients. Blood Press 2007;16(4):270-5.&lt;/P&gt;
&lt;P&gt;(98) &amp;nbsp;Tsioufis C, Dimitriadis K, Taxiarchou E, Vasiliadou C, Chartzoulakis G, Tousoulis D, et al. Diverse associations of microalbuminuria with C-reactive protein, interleukin-18 and soluble CD 40 ligand in male essential hypertensive subjects. Am J Hypertens 2006 May;19(5):462-6.&lt;/P&gt;
&lt;P&gt;(99) &amp;nbsp;Twomey PJ, Pledger DR. Comparison of estimated glomerular filtration rate with routine creatinine clearance using a kinetic alkaline picrate assay from Olympus Diagnostica. J Clin Pathol 2007 Jun;60(6):732-3.&lt;/P&gt;
&lt;P&gt;(100) &amp;nbsp;Valappil N, I, Jacobs J, D, R, Duprez D, et al. Association between endothelial biomarkers and arterial elasticity in young adults: the CARDIA Study. Journal of the American Society of Hypertension 2008;2(2):70-9.&lt;/P&gt;
&lt;P&gt;(101) &amp;nbsp;Voskaridou E, Terpos E, Michail S, Hantzi E, Anagnostopoulos A, Margeli A, et al. Early markers of renal dysfunction in patients with sickle cell/beta-thalassemia. Kidney Int 2006 Jun;69(11):2037-42.&lt;/P&gt;
&lt;P&gt;(102) &amp;nbsp;Wang T, J, Gona P, Larson M, G, Levy D, et al. Multiple biomarkers and the risk of incident hypertension. Hypertension 2007;49(3):432-8.&lt;/P&gt;
&lt;P&gt;(103) &amp;nbsp;Wannamethee S, G, Shaper A, G, Lowe G, D, et al. Renal function and cardiovascular mortality in elderly men: The role of inflammatory, procoagulant, and endothelial biomarkers. European Heart Journal 2006;27(24):2975-81.&lt;/P&gt;
&lt;P&gt;(104) &amp;nbsp;Wolff F, Willems D. Immunonephelometric quantification of specific urinary proteins versus a simple electrophoretic method for characterizing proteinuria. Clinical Biochemistry 2008;41(6):418-22.&lt;/P&gt;
&lt;P&gt;(105) &amp;nbsp;Yamamoto T, Nakagawa T, Suzuki H, Ohashi N, Fukasawa H, Fujigaki Y, et al. Urinary angiotensinogen as a marker of intrarenal angiotensin II activity associated with deterioration of renal function in patients with chronic kidney disease. Journal of the American Society of Nephrology 2007;18(5):1558-65.&lt;/P&gt;
&lt;P&gt;(106) &amp;nbsp;Zhang L, Zuo L, Xu G, Wang F, Wang M, Wang S, et al. Community-based screening for chronic kidney disease among populations older than 40 years in Beijing. Nephrol Dial Transplant 2007 Apr;22(4):1093-9.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Section 3, Management:&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;(1) &amp;nbsp;Agarwal R. Antihypertensive agents and arterial stiffness: Relevance to reducing cardiovascular risk in the chronic kidney disease patient. Current Opinion in Nephrology and Hypertension 2007;16(5):409-15.&lt;/P&gt;
&lt;P&gt;(2) &amp;nbsp;Agarwal R. Effects of statins on renal function. Mayo Clin Proc 2007 Nov;82(11):1381-90.&lt;/P&gt;
&lt;P&gt;(3) &amp;nbsp;Appel L, Agodoa L, Bakris G, Gabbai F, Gassman J, Greene T, et al. Relentless progression of hypertensive chronic kidney disease (CKD) despite excellent blood pressure (BP) control and use of angiotensin converting enzyme inhibitor (ACEI) therapy: results from the African-American Study of Kidney disease and hypertension (AASK) cohort study [abstract no: F-FC085]. Journal of the American Society of Nephrology 2006;17(Abstracts):54A-5A.&lt;/P&gt;
&lt;P&gt;(4) &amp;nbsp;Aslam S, Santha T, Leone A, Wilcox C. Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis. Kidney Int 2006 Dec;70(12):2109-15.&lt;/P&gt;
&lt;P&gt;(5) &amp;nbsp;Bakris GL, Ruilope LM, Mcmorn SO, Weston WM, Heise MA, Freed MI, et al. Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. Journal of hypertension 2006;24(10):2047-55.&lt;/P&gt;
&lt;P&gt;(6) &amp;nbsp;Bakris GL, Ruilope L, Locatelli F, Ptaszynska A, Pieske B, de CJ, et al. Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial. Kidney international 2007;72(7):879-85.&lt;/P&gt;
&lt;P&gt;(7) &amp;nbsp;Barnett A. Preventing renal complications in type 2 diabetes: results of the diabetics exposed to telmisartan and enalapril trial. Journal of the American Society of Nephrology : JASN 2006;17(4 Suppl 2):S132-S135.&lt;/P&gt;
&lt;P&gt;(8) &amp;nbsp;Basi S, Lewis J, B. Microalbuminuria as a target to improve cardiovascular and renal outcomes in diabetic patients. Current Diabetes Reports 2007;7(6):439-42.&lt;/P&gt;
&lt;P&gt;(9) &amp;nbsp;Bellizzi V, Di Iorio BR, De NL, Minutolo R, Zamboli P, Trucillo P, et al. Very low protein diet supplemented with ketoanalogs improves blood pressure control in chronic kidney disease. Kidney international 2007;71(3):245-51.&lt;/P&gt;
&lt;P&gt;(10) &amp;nbsp;Bhatnagar V, O'Connor DT, Schork NJ, Salem RM, Nievergelt CM, Rana BK, et al. Angiotensin-converting enzyme gene polymorphism predicts the time-course of blood pressure response to angiotensin converting enzyme inhibition in the AASK trial. Journal of hypertension 2007;25(10):2082-92.&lt;/P&gt;
&lt;P&gt;(11) &amp;nbsp;Bianchi S, Bigazzi R, Campese V, M. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney international 2006;70(12):2116-23.&lt;/P&gt;
&lt;P&gt;(12) &amp;nbsp;Blake R, Raij L, Schulman I, H. Renal protection: Are all antihypertensive drugs comparable? Current Hypertension Reports 2007;9(5):373-9.&lt;/P&gt;
&lt;P&gt;(13) &amp;nbsp;Bostom A, G, Carpenter M, A, Kusek J, W, et al. Rationale and design of the Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT) trial. American heart journal 2006;152(3):448-53.&lt;/P&gt;
&lt;P&gt;(14) &amp;nbsp;Burnier M, Zanchi A. Blockade of the renin-angiotensin-aldosterone system: A key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. Journal of hypertension 2006;24(1):11-25.&lt;/P&gt;
&lt;P&gt;(15) &amp;nbsp;Cooper CJ, Murphy TP, Matsumoto A, Steffes M, Cohen DJ, Jaff M, et al. Stent revascularization for the prevention of cardiovascular and renal events among patients with renal artery stenosis and systolic hypertension: Rationale and design of the CORAL trial. American heart journal 2006;152(1):59-66.&lt;/P&gt;
&lt;P&gt;(16) &amp;nbsp;Coyle D, Rodby R, Soroka S, Levin A, Muirhead N, de Cotret PR, et al. Cost-effectiveness of irbesartan 300 mg given early versus late in patients with hypertension and a history of type 2 diabetes and renal disease: a Canadian perspective. Clinical Therapeutics 2007;29(7):1508-23.&lt;/P&gt;
&lt;P&gt;(17) &amp;nbsp;Cravedi P, Ruggenenti P, Remuzzi G. Intensified inhibition of renin-angiotensin system: A way to improve renal protection? Current Hypertension Reports 2007;9(5):430-6.&lt;/P&gt;
&lt;P&gt;(18) &amp;nbsp;Deyneli O, Yavuz D, Velioglu A, Cacina H, Aksoy N, Haklar G, et al. Effects of ACE inhibition and angiotensin II receptor blockade on glomerular basement membrane protein excretion and charge selectivity in type 2 diabetic patients. Journal of the renin angiotensin aldosterone system : JRAAS 2006;7(2):98-103.&lt;/P&gt;
&lt;P&gt;(19) &amp;nbsp;Douglas K, O'Malley PG, Jackson JL. Meta-analysis: the effect of statins on albuminuria. Ann Intern Med 2006 Jul 18;145(2):117-24.&lt;/P&gt;
&lt;P&gt;(20) &amp;nbsp;Drueke T, B, Locatelli F, Clyne N, Eckardt K, -U, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. New England Journal of Medicine 2006;355(20):2071-84.&lt;/P&gt;
&lt;P&gt;(21) &amp;nbsp;Eijkelkamp W, B, A, Zhang Z, Remuzzi G, Parving H, et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: Post hoc analysis from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) trial. Journal of the American Society of Nephrology 2007;18(5):1540-6.&lt;/P&gt;
&lt;P&gt;(22) &amp;nbsp;Epstein M. Aldosterone blockade: an emerging strategy for abrogating progressive renal disease. Am J Med 2006 Nov;119(11):912-9.&lt;/P&gt;
&lt;P&gt;(23) &amp;nbsp;Estacio RO, Coll JR, Tran ZV, Schrier RW. Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes. American journal of hypertension : journal of the American Society of Hypertension 2006;19(12):1241-8.&lt;/P&gt;
&lt;P&gt;(24) &amp;nbsp;Fernandez-Juarez G, Barrio V, de Vinuesa SG, Goicoechea M, Praga M, Luno J. Dual blockade of the renin-angiotensin system in the progression of renal disease: the need for more clinical trials. J Am Soc Nephrol 2006 Dec;17(12 Suppl 3):S250-S254.&lt;/P&gt;
&lt;P&gt;(25) &amp;nbsp;Fogari R, Corradi L, Zoppi A, Lazzari P, Mugellini A, Preti P, et al. Addition of manidipine improves the antiproteinuric effect of candesartan in hypertensive patients with type II diabetes and microalbuminuria. American journal of hypertension : journal of the American Society of Hypertension 2007;20(10):1092-6.&lt;/P&gt;
&lt;P&gt;(26) &amp;nbsp;Fogari R, Derosa G, Zoppi A, Preti P, Lazzari P, Destro M, et al. Effect of telmisartan-amlodipine combination at different doses on urinary albumin excretion in hypertensive diabetic patients with microalbuminuria. American journal of hypertension : journal of the American Society of Hypertension 2007;20(4):417-22.&lt;/P&gt;
&lt;P&gt;(27) &amp;nbsp;Formica J, R, N, Friedman A, L, Lorber M, et al. A randomized trial comparing losartan with amlodipine as initial therapy for hypertension in the early post-transplant period. Nephrology Dialysis Transplantation 2006;21(5):1389-94.&lt;/P&gt;
&lt;P&gt;(28) &amp;nbsp;Fujita T, Ando K, Nishimura H, Ideura T, Yasuda G, Isshiki M, et al. Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease. Kidney international 2007;72(12):1543-9.&lt;/P&gt;
&lt;P&gt;(29) &amp;nbsp;Furumatsu Y, Nagasawa Y, Tomida K, Mikami S, Kaneko T, Okada N, et al. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker. Hypertens Res 2008 Jan;31(1):59-67.&lt;/P&gt;
&lt;P&gt;(30) &amp;nbsp;Gradman A, H, Pinto R, Kad R. Current concepts: renin inhibition in the treatment of hypertension. Current Opinion in Pharmacology 2008;8(2):120-6.&lt;/P&gt;
&lt;P&gt;(31) &amp;nbsp;Haller H, Viberti GC, Mimran A, Remuzzi G, Rabelink AJ, Ritz E, et al. Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. Journal of hypertension 2006;24(2):403-8.&lt;/P&gt;
&lt;P&gt;(32) &amp;nbsp;Hart P, D, Bakris G, L. Should beta-Blockers Be Used to Control Hypertension in People With Chronic Kidney Disease? Seminars in Nephrology 2007;27(5):555-64.&lt;/P&gt;
&lt;P&gt;(33) &amp;nbsp;Hollenberg N, K, Parving H, -H, Viberti G, Remuzzi G, et al. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. Journal of hypertension 2007;25(9):1921-6.&lt;/P&gt;
&lt;P&gt;(34) &amp;nbsp;Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. The New England journal of medicine 2006;354(2):131-40.&lt;/P&gt;
&lt;P&gt;(35) &amp;nbsp;Hou FF, Xie D, Zhang X, Chen PY, Zhang WR, Liang M, et al. Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency. Journal of the American Society of Nephrology : JASN 2007;18(6):1889-98.&lt;/P&gt;
&lt;P&gt;(36) &amp;nbsp;Isbel N, M, Haluska B, Johnson D, W, Beller E, et al. Increased targeting of cardiovascular risk factors in patients with chronic kidney disease does not improve atheroma burden or cardiovascular function. American heart journal 2006;151(3):745-53.&lt;/P&gt;
&lt;P&gt;(37) &amp;nbsp;Katayama S, Yagi S, Yamamoto H, Yamaguchi M, Izumida T, Noguchi Y, et al. Is renoprotection by angiotensin receptor blocker dependent on blood pressure?: the Saitama Medical School, Albuminuria Reduction in Diabetics with Valsartan (STAR) study. Hypertens Res 2007 Jun;30(6):529-33.&lt;/P&gt;
&lt;P&gt;(38) &amp;nbsp;Kent D, M, Jafar T, H, Hayward R, A, et al. Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. Journal of the American Society of Nephrology 2007;18(6):1959-64.&lt;/P&gt;
&lt;P&gt;(39) &amp;nbsp;Klinger M, Arias M, Vargemezis V, Besarab A, Sulowicz W, Gerntholtz T, et al. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial. American journal of kidney diseases : the official journal of the National Kidney Foundation 2007;50(6):989-1000.&lt;/P&gt;
&lt;P&gt;(40) &amp;nbsp;Lambers Heerspink HJ, Fowler MJ, Volgi J, Reutens AT, Klein I, Herskovits TA, et al. Rationale for and study design of the sulodexide trials in Type 2 diabetic, hypertensive patients with microalbuminuria or overt nephropathy. Diabet Med 2007 Nov;24(11):1290-5.&lt;/P&gt;
&lt;P&gt;(41) &amp;nbsp;Lash JP, Wang X, Greene T, Gadegbeku CA, Hall Y, Jones K, et al. Quality of life in the African American Study of Kidney Disease and Hypertension: effects of blood pressure management. American journal of kidney diseases : the official journal of the National Kidney Foundation 2006;47(6):956-64.&lt;/P&gt;
&lt;P&gt;(42) &amp;nbsp;Levey A, S, Uhlig K. Which antihypertensive agents in chronic kidney disease? Annals of Internal Medicine 2006;144(3):213-5.&lt;/P&gt;
&lt;P&gt;(43) &amp;nbsp;Matsumoto N, Ishimitsu T, Okamura A, Seta H, Takahashi M, Matsuoka H. Effects of imidapril on left ventricular mass in chronic hemodialysis patients. Hypertension research : official journal of the Japanese Society of Hypertension 2006;29(4):253-60.&lt;/P&gt;
&lt;P&gt;(44) &amp;nbsp;Mimura T, Takenaka T, Kanno Y, Moriwaki K, Okada H, Suzuki H. Vascular compliance is secured under angiotensin inhibition in non-diabetic chronic kidney diseases. J Hum Hypertens 2008 Jan;22(1):38-47.&lt;/P&gt;
&lt;P&gt;(45) &amp;nbsp;Nakamura T, Sugaya T, Kawagoe Y, Suzuki T, Inoue T, Node K. Effect of pitavastatin on urinary liver-type fatty-acid-binding protein in patients with nondiabetic mild chronic kidney disease. American Journal of Nephrology 2006;26(1):82-6.&lt;/P&gt;
&lt;P&gt;(46) &amp;nbsp;Nanayakkara P, W, B, Van GC, Ter WP, M, et al. Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on carotid intima-media thickness, endothelial function, and renal function in patients with mild to moderate chronic kidney disease: Results from the anti-oxidant therapy in chronic renal insufficiency (ATIC) study. Archives of Internal Medicine 2007;167(12):1262-70.&lt;/P&gt;
&lt;P&gt;(47) &amp;nbsp;Norris K, Bourgoigne J, Gassman J, Hebert L, Middleton J, Phillips RA, et al. Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial. American journal of kidney diseases : the official journal of the National Kidney Foundation 2006;48(5):739-51.&lt;/P&gt;
&lt;P&gt;(48) &amp;nbsp;Ogawa S, Mori T, Nako K, Kato T, Takeuchi K, Ito S. Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy. Hypertension 2006;47(4):699-705.&lt;/P&gt;
&lt;P&gt;(49) &amp;nbsp;Osawa H, Nakamura N, Shirato K, Nakamura M, Shimada M, Kumasaka R, et al. Losartan, an angiotensin-II receptor antagonist, retards the progression of advanced renal insufficiency. Tohoku J Exp Med 2006 May;209(1):7-13.&lt;/P&gt;
&lt;P&gt;(50) &amp;nbsp;Pi-Sunyer X, Blackburn G, Brancati FL, Bray GA, Bright R, Clark JM, et al. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes care 2007 Jun;30(6):1374-83.&lt;/P&gt;
&lt;P&gt;(51) &amp;nbsp;Pozzi C, Del VL, Casartelli D, Pozzoni P, Andrulli S, Amore A, et al. ACE inhibitors and angiotensin II receptor blockers in IgA nephropathy with mild proteinuria: the ACEARB study. Journal of nephrology 2006;19(4):508-14.&lt;/P&gt;
&lt;P&gt;(52) &amp;nbsp;Puig JG, Marre M, Kokot F, Fernandez M, Jermendy G, Opie L, et al. Efficacy of indapamide SR compared with enalapril in elderly hypertensive patients with type 2 diabetes. American journal of hypertension : journal of the American Society of Hypertension 2007;20(1):90-7.&lt;/P&gt;
&lt;P&gt;(53) &amp;nbsp;Rahman M, Pressel S, Davis B, R, Nwachuku C, Wright J, et al. Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. Annals of Internal Medicine 2006;144(3):172-80.&lt;/P&gt;
&lt;P&gt;(54) &amp;nbsp;Rakhit DJ, Marwick TH, Armstrong KA, Johnson DW, Leano R, Isbel NM. Effect of aggressive risk factor modification on cardiac events and myocardial ischaemia in patients with chronic kidney disease. Heart 2006 Oct;92(10):1402-8.&lt;/P&gt;
&lt;P&gt;(55) &amp;nbsp;Remuzzi G, Macia M, Ruggenenti P. Prevention and treatment of diabetic renal disease in type 2 diabetes: The BENEDICT study. Journal of the American Society of Nephrology 2006;17(SUPPL 2):S90-S97.&lt;/P&gt;
&lt;P&gt;(56) &amp;nbsp;Remuzzi G. Clinical perspectives in the prevention and treatment of chronic nephropathy, including an overview of the DEMAND Study. Clinical Therapeutics 2007;29(SUPPL B):S64-S72.&lt;/P&gt;
&lt;P&gt;(57) &amp;nbsp;Ruggenenti P, Perna A, Ganeva M, Ene-Iordache B, Remuzzi G. Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial. J Am Soc Nephrol 2006 Dec;17(12):3472-81.&lt;/P&gt;
&lt;P&gt;(58) &amp;nbsp;Ruilope LM, Segura J. Renal protection in diabetic patients: benefits of a first-line combination of perindopril-indapamide (Preterax). J Hypertens Suppl 2006 May;24(3):S9-12.&lt;/P&gt;
&lt;P&gt;(59) &amp;nbsp;Saito F, Fujita H, Takahashi A, Ichiyama I, Harasawa S, Oiwa K, et al. Renoprotective effect and cost-effectiveness of using benidipine, a calcium channel blocker, to lower the dose of angiotensin receptor blocker in hypertensive patients with albuminuria. Hypertens Res 2007 Jan;30(1):39-47.&lt;/P&gt;
&lt;P&gt;(60) &amp;nbsp;Sajja LR, Mannam G, Chakravarthi RM, Sompalli S, Naidu SK, Somaraju B, et al. Coronary artery bypass grafting with or without cardiopulmonary bypass in patients with preoperative non-dialysis dependent renal insufficiency: a randomized study. The Journal of thoracic and cardiovascular surgery 2007;133(2):378-88.&lt;/P&gt;
&lt;P&gt;(61) &amp;nbsp;Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 2006 Jul;17(7):2006-16.&lt;/P&gt;
&lt;P&gt;(62) &amp;nbsp;Schmieder RE, Delles C, Mimran A, Fauvel JP, Ruilope LM. Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes care 2007 Jun;30(6):1351-6.&lt;/P&gt;
&lt;P&gt;(63) &amp;nbsp;Segura J, Garcia-Donaire J, A, Ruilope L, M. Are differences in calcium antagonists relevant across all stages of nephropathy or only proteinuric nephropathy? Current Opinion in Nephrology and Hypertension 2007;16(5):422-6.&lt;/P&gt;
&lt;P&gt;(64) &amp;nbsp;Senior PA, MacNair L, Jindal K. Delivery of multifactorial interventions by nurse and dietitian teams in a community setting to prevent diabetic complications: a quality-improvement report. Am J Kidney Dis 2008 Mar;51(3):425-34.&lt;/P&gt;
&lt;P&gt;(65) &amp;nbsp;Shurraw S, Tonelli M. Statins for treatment of dyslipidemia in chronic kidney disease. Perit Dial Int 2006 Sep;26(5):523-39.&lt;/P&gt;
&lt;P&gt;(66) &amp;nbsp;Sika M, Lewis J, Douglas J, Erlinger T, Dowie D, Lipkowitz M, et al. Baseline characteristics of participants in the African American Study of Kidney Disease and Hypertension (AASK) Clinical Trial and Cohort Study. Am J Kidney Dis 2007 Jul;50(1):78-89, 89.&lt;/P&gt;
&lt;P&gt;(67) &amp;nbsp;Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. American journal of kidney diseases : the official journal of the National Kidney Foundation 2006;47(1):51-9.&lt;/P&gt;
&lt;P&gt;(68) &amp;nbsp;Song JH, Cha SH, Lee HJ, Lee SW, Park GH, Lee SW, et al. Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association European Renal Association 2006;21(3):683-9.&lt;/P&gt;
&lt;P&gt;(69) &amp;nbsp;Steinmetz O, M, Panzer U, Stahl R, A, K, et al. Statin therapy in patients with chronic kidney disease: To use or not to use. European Journal of Clinical Investigation 2006;36(8):519-27.&lt;/P&gt;
&lt;P&gt;(70) &amp;nbsp;Strippoli GF, Navaneethan SD, Johnson DW, Perkovic V, Pellegrini F, Nicolucci A, et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ 2008 Mar 22;336(7645):645-51.&lt;/P&gt;
&lt;P&gt;(71) &amp;nbsp;Tahir H, Jackson LL, Warnock DG. Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta. J Am Soc Nephrol 2007 Sep;18(9):2609-17.&lt;/P&gt;
&lt;P&gt;(72) &amp;nbsp;Tuttle KR. Albuminuria reduction: the holy grail for kidney protection. Kidney Int 2007 Oct;72(7):785-6.&lt;/P&gt;
&lt;P&gt;(73) &amp;nbsp;Uchida H, Nakamura Y, Kaihara M, Norii H, Hanayama Y, Makino H. The MUSCAT study: a Multicenter PROBE Study Comparing the Effects of Angiotensin II Type-1 Receptor Blockers on Self-Monitored Home Blood Pressure in Patients with Morning Hypertension: study design and background characteristics. Hypertens Res 2008 Jan;31(1):51-8.&lt;/P&gt;
&lt;P&gt;(74) &amp;nbsp;Vidt DG, Harris S, McTaggart F, Ditmarsch M, Sager PT, Sorof JM. Effect of short-term rosuvastatin treatment on estimated glomerular filtration rate. The American journal of cardiology 2006;97(11):1602-6.&lt;/P&gt;
&lt;P&gt;(75) &amp;nbsp;Wheeler D, C. Cardiovascular complications of chronic kidney disease. Medicine 2007;35(8):453-6.&lt;/P&gt;
&lt;P&gt;(76) &amp;nbsp;Zannad F, Kessler M, Lehert P, Grünfeld JP, Thuilliez C, Leizorovicz A, et al. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney international 2006;70(7):1318-24.&lt;/P&gt;
&lt;P&gt;(77) &amp;nbsp;Zheng F, Guan Y. Thiazolidinediones: A novel class of drugs for the prevention of diabetic nephropathy? Kidney international 2007;72(11):1301-3.&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>27/05/2010 09:53:21</lastReviewDate>
    <expiryDate>27/05/2011 09:53:21</expiryDate>
  </document>
  <document>
    <id>287721</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=287721]]&gt;</url>
    <title>2008 National Knowledge Week on Proteinuria and eGFR - Characterisation and description of urinary protein excretion in health and in disease</title>
    <publicationDate>2008-06-03T00:00:00</publicationDate>
    <publisher>NLH Kidney Diseases Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ PROTEINURIA/ NEPHROTIC SYNDROME,PRESENTATION OF CKD,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2008 National Knowledge Week on Proteinuria and eGFR - Characterisation and description of urinary protein excretion in health and in disease&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;1 a) Characterisation and description of urinary protein excretion in health and in disease&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;The presence of protein in the urine (lardaceous urine) was first recognized as a marker of disease in the first half of the nineteenth century. Now, in 2008, this “simple” test reveals a useful marker of future propensity to adverse renal and cardiac outcomes. Put simply, the presence of protein in the urine is a bad prognostic marker for patients. Given the fact that this test is relatively easy and cheap to do, and is reliable (in the absence of urinary tract infection, menstruation and acute intercurrent illness) it is remarkable how it is not routinely offered in situations of increased renal or cardiac risk, such as older age, diabetes, hypertension and strong family history of renal diseases.&lt;BR&gt;&lt;BR&gt;For screening purposes the use of (preferably) an early morning urine sample for albumin:creatinine ratio (or alternatively a protein:creatinine ratio) is recommended. The use of full 24 hours collections of urine for protein rarely adds, more often loses, accuracy, but is much less convenient for patients and healthcare professionals.&lt;BR&gt;&lt;BR&gt;The prevalence of proteinuria in the general population is around 4-8% but this rises steeply if hypertension, obesity and diabetes are over-represented in the study population, to around 10-20%.&lt;BR&gt;&lt;BR&gt;The latest NICE guidance gives indications for the use of urine testing for (blood and) protein (NICE, 2008).&lt;BR&gt;1.1.3 Detection of blood and protein in the urine&lt;BR&gt;1.1.3.1 When testing for the presence of haematuria, reagent strips rather than urine microscopy are recommended: A result of 1+ or more requires further evaluation; Urine microscopy should not be used to confirm a positive reagent strip test.&lt;BR&gt;1.1.3.2 For the initial detection of proteinuria, if the ACR is &amp;gt;30 mg/mmol and &amp;lt;70 mg/mmol this should be confirmed by a subsequent early morning (first pass) sample. If the initial ACR is &amp;gt;70 mg/mmol the sample need not be repeated.&lt;BR&gt;1.1.4 Urinary albumin:creatinine and protein: creatinine ratios, and their relationship to 24 hour urinary protein&lt;BR&gt;1.1.4.1 In people without diabetes therapeutically significant proteinuria should be considered to be present when the ACR exceeds 30 mg/mmol (this is approximately equivalent to 0.5 g total protein/24hrs). In people with diabetes microalbuminuria is considered significant, and is defined as ACR = 2.5 mg/mmol in men and ACR = 3.5 mg/mmol in women.&lt;BR&gt;1.1.4.2 An albumin:creatinine ratio (ACR) should normally be used to quantify proteinuria.&lt;BR&gt;1.1.4.3 All people with diabetes, and people without diabetes with a GFR&amp;lt;60 ml/min/1.73m2, should have their urinary albumin excretion quantified by an ACR. The first abnormal result should be confirmed on an early morning sample (if not previously obtained).&lt;BR&gt;1.1.4.4 Those with a GFR greater than or equal to 60 ml/min/1.73m2 should have their urinary albumin/protein excretion quantified by laboratory testing if there is a strong suspicion of CKD.&lt;BR&gt;&lt;BR&gt;In a recent review (Pollock et al, 2007), it was stated that significant epidemiological and clinical trial evidence supports the association between increased urinary albumin excretion, cardiovascular events and renal failure. An increase in albumin excretion has traditionally been considered to reflect a 'glomerular' leak of protein; however, it is now recognized that significant tubular reabsorption of albumin occurs under physiological conditions that may be modified by genetic determinants, systemic disease and drug therapies: The endocytosis of albumin by the proximal tubule is a highly regulated process depending on protein-protein interactions between several membrane proteins and scaffolding and regulatory molecules. There is also mounting evidence for a transcytotic pathway for retrieval of albumin from the tubular filtrate. The clinical implications of albuminuria due to a glomerular leak vs. reduced tubular reabsorption of albumin are, however, now under consideration. In particular, the prognostic implication of microalbuminuria induced by the more potent 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors is under study.&lt;BR&gt;&lt;BR&gt;The utility of detecting the presence of protein in the urine can be seen well from a recent study (Murussi et al, 2007) concentrating on type II diabetic patients in Brazil. 193 Type 2 DM patients with urinary albumin excretion (UAE) &amp;lt; 20 microg/min, 96 men (50%), aged 56.5 +/- 9 years, were followed for a mean period of 8 +/- 3 years. UAE and estimated glomerular filtration rate (eGFR; Modification of Diet in Renal Disease) were measured. The outcomes were development of persistent micro- and macroalbuminuria and mortality. Twenty patients were lost to follow-up. Of the 173 remaining patients, 33 (19%) died. The Cox analysis [hazard ratio (HR), 95% confidence interval] revealed that the baseline significant predictors of mortality were higher UAE [above median (5 microg/min); HR 2.7, 1.2-6.1; P = 0.02], male sex (HR 3.9, 1.7-9.2; P = 0.002), age (HR 1.6, 1.3-1.9; P = 0.0001), and fasting plasma glucose (HR 1.2, 1.1-1.3; P = 0.004). Smoking and eGFR were not significant in this model. Follow-up renal data were available for 158 patients: 34 (22%) progressed to microalbuminuria and seven (4%) to macroalbuminuria, and the baseline predictors were a higher UAE (&amp;gt; 5 microg/min, HR 2.5, 1.2-5.1; P = 0.02), presence of diabetic retinopathy (HR 2.5, 1.3-5.0; P = 0.009), fasting glucose (HR 1.1, 1.0-1.2; P = 0.015), and male sex (HR 2.2, 1.1-4.7; P = 0.04), independently of smoking and hypertension. Lower GFR (HR 0.98, 0.97-1.00; P = 0.07) was of borderline significance. In normoalbuminuric Type 2 DM patients, the development of micro- or macroalbuminuria and mortality rates was independently and positively associated with higher levels of albuminuria, although still in the traditionally established normal range. This study re-inforces data from the older studies which suggest that the arbitrary division between normal urinary albumin excretion, and early low-grade microalbuminuria as the first stage of proteinuria does not equate with a suddent change from no risk to increased risk. The association between cardiovascular risk and urinary albumin excretion is linear and extends down into the so-called normal range.&lt;BR&gt;&lt;BR&gt;Further information about type II diabetes and urinary protein comes from Parving and co-workers (Parving et al, 2006). They described the characteristics in a referred cohort of type II diabetic patients in the Developing Education on Microalbuminuria for Awareness of renal and cardiovascular risk in Diabetes study evaluating the global prevalence and determinants of microalbuminuria. A cross-sectional study evaluating 32,208 type II diabetic patients without known albuminuria from 33 countries was performed. One single random urinary albumin/creatinine ratio was obtained in 24,151 patients (75%). The overall global prevalence of normo-, micro-, and macroalbuminuria was 51, 39, and 10%, respectively. The Asian and Hispanic patients had the highest prevalence of a raised urinary albumin/creatinine ratio (55%) and Caucasians the lowest (40.6), P&amp;lt;0.0001. HbA1c, systolic blood pressure (BP), ethnicity, retinopathy, duration of diabetes, kidney function, body height, and smoking were all independent risk factors of MA, P&amp;lt;0.0001. Estimated glomerular filtration rate was below 60 ml/min/1.73 m(2) in 22% of the 11,573 patients with available data. Systolic BP below 130 mmHg was found in 33 and 43% had an HbA1c below 7%. The frequency of patients receiving aspirin was 32%, statins 29%, and BP-lowering therapy 63%. A high prevalence globally of MA and reduced kidney function, both conditions associated with enhanced renal and cardiovascular risk, was detected in type II diabetic patients without prior known nephropathy. Early detection, monitoring of vascular complications, and more aggressive multifactorial treatment aiming at renal and vascular protection are urgently needed.&lt;BR&gt;&lt;BR&gt;In non-diabetic renal disease there are similar findings. Brantsma et al (2007) looked at how an increase or decrease in urinary albumin excretion&amp;nbsp; is associated with, respectively, a higher or lower risk for renal and cardiovascular disease, independent of widely known cardiovascular risk factors. Their study aimed to identify factors that are associated with changes in UAE in the nondiabetic population using data of the Prevention of Renal and Vascular End stage Disease (PREVEND) Study, a community-based prospective cohort study. Data of the 6647 nondiabetic participants who completed the first (1997 through 2001) and second (2001 through 2003) screening were used. Change in UAE was categorized as regression (n = 650), stable (n = 5240), or progression (n = 757) on the basis of change in class during follow-up, with classes being a UAE &amp;lt;15, 15 to 30, 30 to 300, and &amp;gt;300 mg/24 h. With the use of stepwise forward multinomial regression analysis changes in BP, fasting glucose concentration, and start of antihypertensive drugs were found to be the most important modifiable variables associated with the risk for progression and regression (P &amp;lt; 0.01 for likelihood ratio test). The odds ratios to develop regression or progression of UAE during follow-up were 0.64 (95% confidence interval [CI] 0.57 to 0.73) and 1.91 (95% CI 1.72 to 2.12), respectively, per 10-mmHg increase in BP during follow-up, 0.89 (95% CI 0.80 to 0.98) and 1.09 (95% CI 1.01 to 1.17), respectively, per 1-mmol/L increase of fasting glucose levels during follow-up, and 1.57 (95% CI 1.21 to 2.06) and 0.70 (95% CI 0.51 to 0.95), respectively, for start of antihypertensive drugs during follow-up. These associations were independent of baseline BP, glucose, body mass index, estimated GFR, and UAE and changes in high-sensitivity C-reactive protein during follow-up. They concluded that changes in glucose concentration and BP and start of antihypertensive drugs (angiotensin-converting enzyme inhibitors/angiotensin receptor blockers in &amp;gt;50% of cases) are associated with progression and regression of urinary albumin in the nondiabetic population. Although associations do not necessarily suggest causality, it is hypothesized that in the general population, the most important ways to reduce urinary albumin are by lowering glucose concentration and BP (including start of antihypertensive medication), even in normotensive, nondiabetic individuals.&lt;BR&gt;&lt;BR&gt;Overweight is strongly linked to increased prevalence and progression of proteinuria. A total of 6894 participants of the Prevention of Renal and Vascular Endstage Disease (PREVEND) study were evaluated from baseline to a mean period of follow-up of 4.2 years for weight change (gain/loss), and its impact on albuminuria, renal function and cardiovascular risk factors (Bello et al, 2007). Participants were categorized into three groups based on absolute change in weight from baseline to follow-up: significant weight loss (&amp;gt;10 kg reduction in weight), stable weight, or significant weight gain (&amp;gt;10 kg increase). Multivariate regression analysis was used to evaluate the effect of baseline characteristics and time-dependent changes in these characteristics on the relationship of weight change with urine albumin excretion (UAE). At follow-up 101 subjects experienced significant weight loss (mean change = -14.2 kg), 348 had significant weight gain (mean change = +13.4 kg) and the remaining were defined stable in weight (mean change = +1.4 kg). Weight loss was associated with significant improvement in systolic blood pressure (-11 +/- 15 mmHg), diastolic blood pressure (-5 +/- 8 mmHg), and cholesterol (-0.7 +/- 1.3 mmol/l), even after adjustment for the use of medications (P &amp;lt; 0.001). These parameters worsened significantly in those who substantially gained weight (P &amp;lt; 0.001). Similarly, weight loss was significantly associated with a reduction in UAE (mean -2.2 +/- 1.1 mg/24 h), whereas weight gain was associated with a rise in UAE (mean +0.42 +/- 2.0 mg/24 h). Notably, no changes were observed in GFR (assessed as 24 h urinary creatinine clearance) in subjects with weight loss or weight gain. Multivariate regression modelling with changes in UAE as dependent variable-correcting for factors that might explain the association-showed that only part of the relationship between weight changes and changes in UAE was explained by effect of weight change on blood pressure and cholesterol, whereas the association disappeared with changes in CRP in the model (P = 0.50). The importance of this first population-based longitudinal study to show that changes in weight are associated with parallel changes in albuminuria cannot be over-estimated. This relationship cannot be fully explained by the association between weight and classical cardiovascular risk factors and renal function. &lt;BR&gt;&lt;BR&gt;Even after renal transplantation it is clear from two recent studies (Halimi et al, 2007; Amer et al, 2007) that the development of, or increase in, micro-albuminuria is an adverse prognostic factor for renal allograft function and cardiovascular outcomes in renal transplant patients. This should be part of good quality medical management of long-term renal transplant outcomes; one of the significant reasons for return to dialysis after renal transplantation is chronic allograft nephropathy – while this has many potential aetiologies and promoters, it is clear that good control of blood pressure, and the selective early use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in these patients, may help to slow down otherwise inexorable progress towards allograft failure.&lt;BR&gt;&lt;BR&gt;One relatively unknown feature of albuminuria-proteinuria is the extent to which this is under genetic control. There is no doubt that the propensity to develop kidney disease does run strongly in families, even if the precise histopathological type of disease may vary from one member to another. Rao and colleagues conducted a study to investigate heritability of albumin excretion in twin pairs and its genetic determination by adrenergic pathway polymorphism (Rao et al, 2007). Genetic associations used single nucleotide polymorphisms at adrenergic pathway loci spanning catecholamine biosynthesis, storage, catabolism, receptor action, and postreceptor signal transduction. We studied 134 single nucleotide polymorphisms at 46 loci for a total of &amp;gt;51,000 genotypes. Albumin excretion heritability was 45.2+/-7.4% (P=2x10(-7)), and the phenotype aggregated significantly with adrenergic, renal, metabolic, and hemodynamic traits. In the adrenergic system, excretions of both norepinephrine and epinephrine correlated with albumin. In the kidney, albumin excretion correlated with glomerular and tubular traits (Na(+) and K(+) excretion; fractional excretion of Na(+) and Li(+)). Albumin excretion shared genetic determination (genetic covariance) with epinephrine excretion, and environmental determination with glomerular filtration rate and electrolyte intake/excretion. Albumin excretion associated with polymorphisms at multiple points in the adrenergic pathway: catecholamine biosynthesis (tyrosine hydroxylase), catabolism (monoamine oxidase A), storage/release (chromogranin A), receptor target (dopamine D1 receptor), and postreceptor signal transduction (sorting nexin 13 and rho kinase). Epistasis (gene-by-gene interaction) occurred between alleles at rho kinase, tyrosine hydroxylase, chromogranin A, and sorting nexin 13. Dopamine D1 receptor polymorphism showed pleiotropic effects on both albumin and dopamine excretion. These studies establish new roles for heredity and environment in albumin excretion. Urinary excretions of albumin and catecholamines are highly heritable, and their parallel suggests adrenergic mediation of early glomerular permeability alterations. Albumin excretion is influenced by multiple adrenergic pathway genes and is, thus, polygenic. Such functional links between adrenergic activity and glomerular injury suggest novel approaches to its prediction, prevention, diagnosis, and treatment.&lt;BR&gt;&lt;BR&gt;It is clear that there is a complex interplay between some modifiable, non-modifiable environmental phenotypic, and genetic, factors in the development and progression of protein loss in the kidney.&amp;nbsp; Much rests on the early detection and rapid intervention of specific targeted therapies to reverse the underlying exacerbating factors and to prevent proteinuria progression and nephron loss.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;References&lt;BR&gt;&lt;BR&gt;1.&lt;/STRONG&gt; &lt;STRONG&gt;NICE Consultation Document&lt;/STRONG&gt; (March 2008): Chronic kidney disease: early identification and management of chronic kidney disease in adults in primary and secondary care. [&lt;A href="http://www.nice.org.uk/nicemedia/pdf/CKDConsNICEGuidance.pdf" target="_blank"&gt;Guideline&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;2. Pollock CA&lt;/STRONG&gt;, Poronnik P. Albumin transport and processing by the proximal tubule: physiology and pathophysiology. Curr Opin Nephrol Hypertens 2007 Jul;16(4):359-64. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=%22Current%20opinion%20in%20nephrology%20and%20hypertension%22%5bJour%5d%20AND%202007%5bpdat%5d%20AND%20Pollock%5bauthor%5d%20AND%20albumin%20transport" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;3. Murussi M&lt;/STRONG&gt;, Campagnolo N, Beck MO, Gross JL, Silveiro SP. High-normal levels of albuminuria predict the development of micro- and macroalbuminuria and increased mortality in Brazilian Type 2 diabetic patients: an 8-year follow-up study. Diabet Med 2007 Oct;24(10):1136-42. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=2007%5bpdat%5d%20AND%20Murussi%5bauthor%5d%20AND%20albuminuria" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;4. Parving HH&lt;/STRONG&gt;, Lewis JB, Ravid M, Remuzzi G, Hunsicker LG. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int 2006 Jun;69(11):2057-63. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=%22Kidney%20international%22%5bJour%5d%20AND%202006%5bpdat%5d%20AND%20Parving%5bauthor%5d%20AND%20prevalence" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;5. Brantsma AH&lt;/STRONG&gt;, Atthobari J, Bakker SJ, de ZD, de Jong PE, Gansevoort RT. What predicts progression and regression of urinary albumin excretion in the nondiabetic population? J Am Soc Nephrol 2007 Feb;18(2):637-45. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=%22Journal%20of%20the%20American%20Society%20of%20Nephrology%20:%20JASN%22%5bJour%5d%20AND%202007%5bpdat%5d%20AND%20Brantsma%5bauthor%5d%20AND%20what%20predicts%20progression" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;6. Bello AK&lt;/STRONG&gt;, de ZD, El NM, Brantsma AH, Bakker SJ, de Jong PE, et al. Impact of weight change on albuminuria in the general population. Nephrol Dial Transplant 2007 Jun;22(6):1619-27. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=%22Nephrology%2C%20dialysis%2C%20transplantation%20%3A%20official%20publication%20of%20the%20European%20Dialysis%20and%20Transplant%20Association%20-%20European%20Renal%20Association%22%5BJour%5D%20AND%202007%5Bpdat%5D%20AND%20Bello%5Bauthor%5D%20AND%20impact" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;7. Halimi JM&lt;/STRONG&gt;, Buchler M, Al-Najjar A, Laouad I, Chatelet V, Marliere JF, et al. Urinary albumin excretion and the risk of graft loss and death in proteinuric and non-proteinuric renal transplant recipients. Am J Transplant 2007 Mar;7(3):618-25. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17217438?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;8. Amer H&lt;/STRONG&gt;, Fidler ME, Myslak M, Morales P, Kremers WK, Larson TS, et al. Proteinuria after kidney transplantation, relationship to allograft histology and survival. Am J Transplant 2007 Dec;7(12):2748-56. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=%22American%20journal%20of%20transplantation%20%3A%20official%20journal%20of%20the%20American%20Society%20of%20Transplantation%20and%20the%20American%20Society%20of%20Transplant%20Surgeons%22%5BJour%5D%20AND%202007%5Bpdat%5D%20AND%20Amer%5Bauthor%5D%20AND%20proteinuria" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;9. Rao F&lt;/STRONG&gt;, Wessel J, Wen G, Zhang L, Rana BK, Kennedy BP, et al. Renal albumin excretion: twin studies identify influences of heredity, environment, and adrenergic pathway polymorphism. Hypertension 2007 May;49(5):1015-31. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=%22Hypertension%22%5bJour%5d%20AND%202007%5bpdat%5d%20AND%20Rao%5bauthor%5d%20AND%20renal%20albumin" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;A href="http://www.nice.org.uk/guidance/index.jsp?action=byID&amp;amp;o=11647" target="_blank"&gt;Link to 2008 NICE Chronic Kidney Disease guideline&lt;/A&gt;&lt;/STRONG&gt;&lt;STRONG&gt;&lt;BR&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=PGFNKWCONT" target="_blank"&gt;Link to National Knowledge Week contents page&lt;/A&gt;&lt;BR&gt;&lt;/STRONG&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>27/05/2010 09:53:27</lastReviewDate>
    <expiryDate>27/05/2011 09:53:27</expiryDate>
  </document>
  <document>
    <id>287855</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=287855]]&gt;</url>
    <title>2008 National Knowledge Week on Proteinuria and eGFR - eGFR as a marker of renal function</title>
    <publicationDate>2008-06-03T00:00:00</publicationDate>
    <publisher>NLH Kidney Diseases Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ ASSESSMENT TESTS,ASSESSMENT OF RENAL FUNCTION,GFR AND EGFR,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2008 National Knowledge Week on Proteinuria and eGFR - eGFR as a marker of renal function&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;2 e) eGFR as a marker of renal function&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;The gold standard for measurement of renal function is the glomerular filtration rate (GFR). Its precise measurement using isotopic clearances is expensive and inconvenient. Serum creatinine concentration is easy to measure and related to the GFR but cannot be used in isolation to determine renal function because it is also influenced by muscle mass. The relationship with GFR is exponential reducing diagnostic sensitivity at less severe levels of renal impairment.&lt;BR&gt;&lt;BR&gt;Several mathematical formulae have been developed to estimate GFR (eGFR) from the creatinine concentration and parameters such as the patient’s age and sex. The most widely used are the Cockcroft Gault (CG) (Cockcroft &amp;amp; Gault, 1976) and the Modification of Diet in Renal Disease (MDRD) (Levey et al, 2000) formulae though many others exist. CG was originally validated against creatinine clearance as the gold standard whereas MDRD was developed using iothalamate determined GFR. Creatinine clearance is inevitably higher than true GFR because creatinine is cleared by tubular secretion as well as filtration. Subsequent studies have shown that CG tends to overestimate renal function especially at lower levels (Lin et al, 2003) whilst MDRD underestimates GFR particularly at near normal levels of function.&lt;BR&gt;&lt;BR&gt;Several studies (Dong et al, 2007; Ibrahim et al, 2006) have demonstrated the superiority of MDRD for&amp;nbsp; screening in a variety of different populations and it is now advocated as the method of choice in the UK (Department of Health, 2005). &lt;BR&gt;&lt;BR&gt;eGFR is inaccurate in situations where the renal function is changing such as developing or recovering acute renal failure. The formulae have not been shown to be accurate in children, pregnancy, liver disease, heart failure and after transplantation. &lt;BR&gt;&lt;BR&gt;The tendency of MDRD to underestimate GFR at near normal levels of renal function has raised concerns about its routine use as a screening tool. Rule (2007) suggested that estimation of GFR differs between healthy individuals and those with CKD because of differences in creatinine production between these two populations. He proposed that serum creatinine alone should be used for screening for renal disease eGFR be reserved for patients with known CKD. Nevertheless the National Service Framework for Renal Services (Department of Health, 2005) mandated use of the MDRD to estimate a GFR for all creatinine measurements reported in the UK.&lt;BR&gt;&lt;BR&gt;Ethnicity may influence eGFR. The MDRD requires adjustment in African Caribbean populations because it underestimates GFR by 20%. It appears to be accurate in Chinese populations (Dong et al, 2007). &lt;BR&gt;&lt;BR&gt;Serum creatinine results are subject to systematic error dependent upon the method of analysis used. These differences although slight in absolute terms are amplified when the result is used for eGFR calculation and make a dramatic difference to the results, particularly at near normal levels of renal function. Laboratories calculating eGFR must normalise or “harmonise” the creatinine value before including it in the equation. For this reason use of web based eGFR calculators (and some GP computer systems) using unharmonised creatinine results is liable to give misleading results.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;References&lt;BR&gt;&lt;/STRONG&gt;&lt;BR&gt;&lt;STRONG&gt;1. Cockcroft DW&lt;/STRONG&gt;, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31–41. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=%22Nephron%22%5BJour%5D%20AND%201976%5Bpdat%5D%20AND%20Cockcroft%5Bauthor%5D" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;2. Levey AS&lt;/STRONG&gt;, Greene T, Kusek JW, Beck GJ. Simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 2000; 11: 155A. [Abstract not available online]&lt;BR&gt;&lt;STRONG&gt;3. Lin J&lt;/STRONG&gt;, Knight EL, Hogan ML, Singh AK. A comparison of prediction equations for estimating glomerular filtration rate in adults without kidney disease. J Am Soc Nephrol 2003; 14: 2573–2580. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Journal%20of%20the%20American%20Society%20of%20Nephrology%5BJour%5D%20AND%20Lin%5Bauthor%5D%20AND%20prediction" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;4. Dong X&lt;/STRONG&gt;, He M, Song X, Lu B, Yang Y, Zhang S, et al. Performance and comparison of the Cockcroft-Gault and simplified Modification of Diet in Renal Disease formulae in estimating glomerular filtration rate in a Chinese Type 2 diabetic population. Diabetic Medicine 2007;24(12):1482-6. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17971183?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;5. Ibrahim HN&lt;/STRONG&gt;, Rogers T, Tello A, Matas A. The performance of three serum creatinine-based formulas in estimating GFR in former kidney donors. Am J Transplant 2006 Jun;6(6):1479-85. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16686774?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;6. Department of Health&lt;/STRONG&gt; (2005): National Service Framework for renal services part two: chronic kidney disease, acute renal failure and end of life care [&lt;A href="http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4113505.pdf" target="_blank"&gt;link to NSF&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;7. Rule AD&lt;/STRONG&gt;. Understanding estimated glomerular filtration rate: implications for identifying chronic kidney disease. Curr Opin Nephrol Hypertens 2007 May;16(3):242-9. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=%22Current%20opinion%20in%20nephrology%20and%20hypertension%22%5BJour%5D%20AND%202007%5Bpdat%5D%20AND%20Rule%5Bauthor%5D" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;A href="http://www.nice.org.uk/guidance/index.jsp?action=byID&amp;amp;o=11647" target="_blank"&gt;Link to 2008 NICE Chronic Kidney Disease guideline&lt;/A&gt;&lt;/STRONG&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=PGFNKWCONT" target="_blank"&gt;Link to National Knowledge Week contents page&lt;/A&gt;&lt;/STRONG&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>27/05/2010 09:53:30</lastReviewDate>
    <expiryDate>27/05/2011 09:53:30</expiryDate>
  </document>
  <document>
    <id>287856</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=287856]]&gt;</url>
    <title>2008 National Knowledge Week on Proteinuria and eGFR - eGFR as a screening tool</title>
    <publicationDate>2008-06-03T00:00:00</publicationDate>
    <publisher>NLH Kidney Diseases Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ EGFR,SCREENING OPTIONS,SCREENING TESTS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2008 National Knowledge Week on Proteinuria and eGFR - eGFR as a screening tool&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;2 f) eGFR as a screening tool&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Detection of asymptomatic renal disease is important because it is associated with an increased incidence of cardiovascular disease (Halbesma et al, 2006; Stevens et al, 2007). Attention to cardiovascular risk factors in this population may reduce the risk of vascular events and allow interventions to slow the rate of progression of renal failure.&lt;BR&gt;&lt;BR&gt;A reduction in glomerular filtration rate (GFR) is a sensitive indicator or renal disease though it is difficult and expensive to measure. The creatinine clearance determined from 24 hour urine and blood measurements approximates to GFR but is prone to error and inconvenient as it involves 24 hour urine collections (Smith, 1988). Creatinine concentration alone is a poor predictor of renal function because of its dependence upon an individuals muscle mass as well as renal function. Development of estimated GFR (eGFR) calculations based upon the creatinine and patient characteristics such as age and sex have allowed more accurate identification and classification of CKD from a single creatinine measurement. Two formulae have been widely used (de Jong et al, 2006). The earlier Cockcroft Gault formula tends to overestimate eGFR especially in individuals with renal impairment and the MDRD generally underestimates eGFR particularly in individuals with near normal renal function. Use of eGFR allows early detection of renal disease and categorisation into stages of chronic kidney disease. Te ease of calculation of eGFR raises the possibility of population screening renal disease.&amp;nbsp; &lt;BR&gt;&lt;BR&gt;Population studies show a prevalence of significantly reduced eGFR (&amp;lt; 60 ml/min/1.73m2) in about 5% of the population (Stevens et al, 2007; Zhang et al, 2007; NICE, 2008). As long as 20 years ago (Smith, 1988) it was proposed that the laboratory computers could be used to calculate eGFR from serum creatinine measurements using the age and sex information contained on the request form. More recently the National Service Framework for renal services recommended use of the MDRD formula for calculation of eGFR routinely when creatinine was reported (Department of Health, 2005). &lt;BR&gt;The cost effectiveness of population screening is not established. Draft guidance from the National Institute of Clinical Excellence (NICE, 2008) suggests that eGFR should be measured in high risk patients including all people with diabetes, hypertension, cardiovascular disease, family history of CKD stage 5, known structural renal tract disease such as stones, incidental urine sediment abnormality or know use of nephrotoxic drugs. Hallan et al (2006) suggested screening of people with hypertension, diabetes or aged over 55 was most effective. The NEOERICA study (Stevens et al, 2007) showed that many patients at risk already had creatinine estimate on file and that reduced eGFR is easily detected in existing computerised records.&lt;BR&gt;&lt;BR&gt;Patients with reduced GFR are at risk of acute renal failure following radiological contrast eGFR and screening for patients prior to contrast studies has been advocated (Lameire et al, 2006). &lt;BR&gt;&lt;BR&gt;eGFR does not work in a variety of well defined circumstances including, in children, during pregnancy, following transplantation and when renal function is changing (Smith, 1988; Leanos et al, 2007). A fixed eGFR cut off point has been advocated to diagnose chronic kidney disease but Poggio and Rule (2007) have noted the decline in eGFR with age and female sex in otherwise healthy individuals and have proposed that age and gender specific reference values be developed.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;1. Halbesma N&lt;/STRONG&gt;, Kuiken DS, Brantsma AH, Bakker SJ, Wetzels JF, De ZD, et al. Macroalbuminuria is a better risk marker than low estimated GFR to identify individuals at risk for accelerated GFR loss in population screening. J Am Soc Nephrol 2006;17(9):2582-90. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=%22Journal%20of%20the%20American%20Society%20of%20Nephrology%20%3A%20JASN%22%5BJour%5D%20AND%202006%5Bpdat%5D%20AND%20Halbesma%5Bauthor%5D" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;2. Stevens PE&lt;/STRONG&gt;, O'Donoghue D, J, de LS, Van VJ, et al. Chronic kidney disease management in the United Kingdom: NEOERICA project results. Kidney International 2007;72(1):92-9. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17440495?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;3. Smith SA&lt;/STRONG&gt;. Estimation of glomerular filtration rate from the serum creatinine concentration. Postgrad Med J 1988; 64: 204 208. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/3174538?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;4. de Jong PE&lt;/STRONG&gt;, Halbesma N, Gansevoort R, T. Screening for early chronic kidney disease - What method fits best? Nephrology Dialysis Transplantation 2006;21(9):2358-61. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16887849?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;5. Zhang L&lt;/STRONG&gt;, Zuo L, Xu G, Wang F, Wang M, Wang S, et al. Community-based screening for chronic kidney disease among populations older than 40 years in Beijing. Nephrol Dial Transplant 2007 Apr;22(4):1093-9. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17210584?ordinalpos=7&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;6. Iseki K&lt;/STRONG&gt;, Kohagura K, Sakima A, Iseki C, Kinjo K, Ikemiya Y, et al. Changes in the demographics and prevalence of chronic kidney disease in Okinawa, Japan (1993 to 2003). Hypertens Res 2007 Jan;30(1):55-62. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17460372?ordinalpos=3&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;7. Department of Health&lt;/STRONG&gt; (2005): National Service Framework for renal services part two: chronic kidney disease, acute renal failure and end of life care [&lt;A href="http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4113505.pdf" target="_blank"&gt;link to NSF&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;8. NICE&lt;/STRONG&gt; (full guideline due in September 2008): Early identification and management of adults with chronic kidney disease in primary and secondary care. [&lt;A href="http://www.nice.org.uk/guidance/index.jsp?action=byID&amp;amp;o=11647" target="_blank"&gt;consultation documents&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;9. Hallan SI&lt;/STRONG&gt;, Dahl K, Oien CM, Grootendorst DC, Aasberg A, Holmen J, et al. Screening strategies for chronic kidney disease in the general population: follow-up of cross sectional health survey. BMJ 2006 Nov 18;333(7577):1047. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=BMJ%5BJour%5D%20AND%202006%5Bpdat%5D%20AND%20Hallan%5Bauthor%5D" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;10. Lameire N&lt;/STRONG&gt;, Adam A, Becker CR, Davidson C, McCullough PA, Stacul F, et al. Baseline renal function screening. Am J Cardiol 2006 Sep 18;98(6A):21K-6K. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16949377?ordinalpos=5&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;11. Leanos-Miranda A&lt;/STRONG&gt;, Marquez-Acosta J, Romero-Arauz F, Cardenas-Mondragon GM, Rivera-Leanos R, et al. Protein:creatinine ratio in random urine samples is a reliable marker of increased 24-hour protein excretion in hospitalized women with hypertensive disorders of pregnancy. Clinical Chemistry 2007;53(9):1623-8. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=%22Clinical%20chemistry%22%5BJour%5D%20AND%202007%5Bpdat%5D%20AND%20protein%20excretion" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;12. Poggio ED &amp;amp; Rule AD&lt;/STRONG&gt;. Can we do better than a single estimated GFR threshold when screening for chronic kidney disease? Kidney International 2007;72(5):534-6. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=%22Kidney%20international%22%5BJour%5D%20AND%202007%5Bpdat%5D%20AND%20Poggio%5Bauthor%5D" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;A href="http://www.nice.org.uk/guidance/index.jsp?action=byID&amp;amp;o=11647" target="_blank"&gt;Link to 2008 NICE Chronic Kidney Disease guideline&lt;/A&gt;&lt;/STRONG&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=PGFNKWCONT" target="_blank"&gt;Link to National Knowledge Week contents page&lt;/A&gt;&lt;/STRONG&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>27/05/2010 09:53:34</lastReviewDate>
    <expiryDate>27/05/2011 09:53:34</expiryDate>
  </document>
  <document>
    <id>287857</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=287857]]&gt;</url>
    <title>2008 National Knowledge Week on Proteinuria and eGFR - How early should active management of proteinuria or eGFR be started?</title>
    <publicationDate>2008-06-03T00:00:00</publicationDate>
    <publisher>NLH Kidney Diseases Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ OTHERS,INTERVENTIONS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2008 National Knowledge Week on Proteinuria and eGFR - How early should active management of proteinuria or eGFR be started?&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;3 a) How early should active management of proteinuria or reduced eGFR be started?&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;In the UK, the staging of CKD is based on the US National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF-KDOQI) (2002) classification of CKD.&lt;BR&gt;&lt;BR&gt;The National Service Framework (NSF) for Renal Services (Department of Health, 2005) recommended that kidney function should be assessed and monitored using an estimated glomerular filtration rate (eGFR), rather than serum creatinine concentration alone.&amp;nbsp; &lt;BR&gt;&lt;BR&gt;Proteinuria can be measured with either a protein:creatinine ratio or albumin:creatinine ratio. Presence of proteinuria is an independent marker of progression of renal disease (Halbesma et al, 2006). &lt;BR&gt;&lt;BR&gt;The presence of proteinuria and progressive reduction of eGFR have been shown to be reliable markers of kidney disease progression. The question is how early should active management of proteinuria and reduced eGFR commence? Both guidance from the Royal College of Physicians (2006) and NICE draft guidance for CKD (2008) give recommendations for when to commence active management, although it has been suggested that there is a shortfall in the research evidence base to underpin robust recommendations in many areas of disease management for patients with early CKD (Royal College of Physicians of Edinburgh, 2007).&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Proteinuria&lt;BR&gt;&lt;/STRONG&gt;&lt;BR&gt;The NICE draft guideline on the early identification and management of adults with CKD in primary and secondary care has been published in draft form for stakeholder comments (2008). NICE draft guidance recommends that people with non-diabetic CKD and ACR = 30 mg/mmol (equivalent to proteinuria of =0.5g/day) should be treated with ACEI/ARBs irrespective of the presence of hypertension or cardio-vascular disease. For those with diabetes, the use of ACEIs or ARBs are recommended once microalbuminuria is found (NICE, 2008). Early use of irbesartan for those with hypertension and Type 2 diabetes and microalbuminuria, has been shown to be both more effective and less costly that delaying irbesartan use until overt nephropathy is present (Coyle et al, 2007).&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Reduced eGFR&lt;/STRONG&gt;&lt;BR&gt;&lt;BR&gt;Staging of CKD is based on eGFR, and the majority of local clinical practice guidelines for CKD, based on national guidance (Royal College of Physicians, 2006) focus their recommendations on stages three-five CKD (eGFR&amp;lt;60). In summary the recommendations for active management of CKD stages 3-5 are:&lt;BR&gt;&lt;STRONG&gt;Carry out medication review&lt;/STRONG&gt; for any potentially nephrotoxic drugs, or drugs that need dose alterations when GFR reduced &lt;BR&gt;&lt;STRONG&gt;Manage blood pressure&lt;/STRONG&gt; as there is strong evidence that blood pressure lowering reduces cardiovascular disease risk and the progression of CKD. Treatment should be offered to those with blood pressure equal to or greater than 140/90 mmHg; with prescription of ACE inhibitor for initial therapy for those less than 55 yrs; and for those older than 55 yrs, calcium channel blockers or diuretic. &lt;BR&gt;There is limited evidence that a target of less than 130/80 is recommended for those with stage 3-5 CKD. An ACE inhibitor or ARB is recommended.&lt;BR&gt;&lt;STRONG&gt;Give lifestyle advice:&lt;/STRONG&gt; smoking cessation, weight reduction, regular exercise and dietary salt restriction. Encourage self-management, and purchase of BP machine.&lt;BR&gt;&lt;STRONG&gt;Manage anaemia:&lt;/STRONG&gt; Anaemia due to kidney disease is uncommon in early CKD except in those with diabetes or an eGFR of &amp;lt;45. All patients with anaemia should be investigated for alternative causes before ascribing it to CKD. The use of erythropoiesis stimulating agents should be initiated if the haemoglobin level falls below 11g/dL.&lt;BR&gt;&lt;STRONG&gt;Carry out Imaging&lt;/STRONG&gt; to exclude obstruction in patients with significant urinary symptoms; declining GFR, or intractable hypertension.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;1. National Kidney Foundation&lt;/STRONG&gt;. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. American Journal of Kidney Diseases. 2002; 39(2:Suppl 1):S1-S266. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11904577?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;2 Department of Health&lt;/STRONG&gt; National Service Framework for renal services Part Two: chronic kidney disease, acute renal failure and end of life care 2005. [&lt;A href="https://rmsadmin.library.nhs.uk/admin/wizards/articles/www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4102680.pdf" target="_blank"&gt;link to NSF&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;3. Halbesma N&lt;/STRONG&gt;, Kuiken D, Brantsma A, H, Bakker S, et al. Macroalbuminuria is a better risk marker than low estimated GFR to identify individuals at risk for accelerated GFR loss in population screening. Journal of the American Society of Nephrology 2006;17 (9):2582-90. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=%22Journal%20of%20the%20American%20Society%20of%20Nephrology%20%3A%20JASN%22%5BJour%5D%20AND%202006%5Bpdat%5D%20AND%20Halbesma%5Bauthor%5D" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;4. Royal College of Physicians&lt;/STRONG&gt;. Chronic kidney diseases in adults: UK guidelines for identification, management and referral. London: UK: 2006 [&lt;A href="https://rmsadmin.library.nhs.uk/admin/wizards/articles/www.rcplondon.ac.uk/pubs/contents/57f485dc-4730-4b2d-be90-fa6937cc15af.pdf" target="_blank"&gt;link to guidelines&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;5. NICE draft guidance&lt;/STRONG&gt;: Early identification and management of adults with chronic kidney disease in primary and secondary care. 2008 [&lt;A href="http://www.nice.org.uk/guidance/index.jsp?action=byID&amp;amp;o=11647" target="_blank"&gt;link to consultation document&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;6. Royal College of Physicians of Edinburgh&lt;/STRONG&gt;. Consensus statement on management of early CKD, February 2007. [&lt;A href="https://rmsadmin.library.nhs.uk/admin/wizards/articles/www.renal.org/CKDguide/consensus.html" target="_blank"&gt;link to Consensus Statement&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;7. NICE guidance&lt;/STRONG&gt;: Type 2 diabetes: the management of type 2 diabetes (update). 2008. [&lt;A href="http://www.nice.org.uk/guidance/index.jsp?action=byID&amp;amp;o=11983" target="_blank"&gt;Link to guideline&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;8. Coyle D&lt;/STRONG&gt;, Rodby R, Soroka S, Levin A, Muirhead N, de CP, et al. Cost-Effectiveness of Irbesartan 300 mg Given Early Versus Late in Patients with Hypertension and a History of Type 2 Diabetes and Renal Disease: A Canadian Perspective. Clinical Therapeutics 2007;29(7):1508-23. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=%22Clinical%20therapeutics%22%5BJour%5D%20AND%202007%5Bpdat%5D%20AND%20Coyle%5Bauthor%5D" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;A href="http://www.nice.org.uk/guidance/index.jsp?action=byID&amp;amp;o=11647" target="_blank"&gt;Link to 2008 Chronic Kidney Disease guideline&lt;/A&gt;&lt;/STRONG&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=PGFNKWCONT" target="_blank"&gt;Link to National Knowledge Week contents page&lt;/A&gt;&lt;/STRONG&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>27/05/2010 09:53:38</lastReviewDate>
    <expiryDate>27/05/2011 09:53:38</expiryDate>
  </document>
  <document>
    <id>287763</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=287763]]&gt;</url>
    <title>2008 National Knowledge Week on Proteinuria and eGFR - How to detect and quantify urinary albumin and proteinuria</title>
    <publicationDate>2008-06-03T00:00:00</publicationDate>
    <publisher>NLH Kidney Diseases Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ PRESENTATION OF CKD,PROTEINURIA/ NEPHROTIC SYNDROME,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2008 National Knowledge Week on Proteinuria and eGFR - How to detect and quantify urinary albumin and proteinuria&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;2 a) How to detect and quantify urinary albumin and proteinuria&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;How best to detect and quantify proteinuria in the setting of chronic kidney disease is an important issue. A recent review (Gansevoort et al, 2006) considered the several different ways in which we can analyse and present albuminuria / proteinuria. Albuminuria can be measured and expressed in several ways: 1) in a spot morning urine sample as urinary albumin concentration (mg/liter) or albumin:creatinine ratio (mg/mmol) and 2) in a 24-hour urine collection as urinary albumin excretion (mg/24 hours). It has not yet been clarified which measure for albuminuria is preferable in clinical practice. One of the points on which a choice should be made is which measure shows the least within-person coefficient of variation. It is argued that fresh urine should be used, since freezing at -20 degrees C results in considerable extra variability in the albumin concentration. Furthermore, it is important to use specifically collected urine samples and not portions of a 24-hour urine sample as a surrogate for a spot morning urine sample. Albuminuria follows a circadian rhythm. Consequently, values for the within-person coefficient of variation will therefore be different when they are measured in a portion of a 24-hour urine collection in comparison with a spot morning urine sample. These important practical points are a challenge when we try to “upscale” utiltisation of albuminuria screening for large populations. In diabetes however, over many years, the use of albumin:creatinine ratios have become familiar now, and are recommended by the latest NICE guidance on chronic kidney disease (see Section 1 a)).&lt;BR&gt;&lt;BR&gt;However, it has to be conceded, as we discussed in Section 1 c), that there is more than one way to detect urine albumin (eg using HPLC). In addition, we have many more proteins which we might detect (short of the full-blown proteome). The quantification of urinary proteins presenting different molecular sizes is useful in characterizing a proteinuria. Wolff and Willems (2008) assessed the performance of an electrophoretic system, the Hydragel Urine Profile, which allows firstly the identification of proteinuria and secondly a qualitative detection of monoclonal free light chains (FLC). Initially, the proteinuria was characterized on 127 pathological urines by quantifying albumin, a1microglobulin, immunoglobulins G by immunonephelometric quantification technique and the results were compared with the protein pattern obtained by the electrophoretic method. They also assessed the sensitivity and specificity of this electrophoretic test for the detection and characterization of Bence Jones proteins. FLC were analyzed quantitatively by an immunonephelometric assay and qualitatively by the electrophoretic test in 150 urines. The agreement between the two methods was good with a percentage of homology for characterizing the proteinuria of 89%. For detecting a monoclonal FLC, the electrophoretic method demonstrated a lesser sensitivity but a higher specificity compared to the immunoassay.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;References&lt;/STRONG&gt; &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;1. Gansevoort RT&lt;/STRONG&gt;, Brinkman J, Bakker SJ, De Jong PE, de ZD. Evaluation of measures of urinary albumin excretion. Am J Epidemiol 2006 Oct 15;164(8):725-7. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=%22American%20journal%20of%20epidemiology%22%5BJour%5D%20AND%202006%5Bpdat%5D%20AND%20Gansevoort%5Bauthor%5D" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;2. Wolff F &amp;amp; Willems D&lt;/STRONG&gt;. Immunonephelometric quantification of specific urinary proteins versus a simple electrophoretic method for characterizing proteinuria. Clinical Biochemistry 2008;41(6):418-22. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=%22Clinical%20biochemistry%22%5BJour%5D%20AND%202008%5Bpdat%5D%20AND%20Wolff%5Bauthor%5D" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;A href="http://www.nice.org.uk/guidance/index.jsp?action=byID&amp;amp;o=11647" target="_blank"&gt;Link to 2008 NICE Chronic Kidney Disease guideline&lt;/A&gt;&lt;/STRONG&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=PGFNKWCONT" target="_blank"&gt;Link to National Knowledge Week contents page&lt;/A&gt;&lt;BR&gt;&lt;/STRONG&gt;&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>27/05/2010 09:53:42</lastReviewDate>
    <expiryDate>27/05/2011 09:53:42</expiryDate>
  </document>
  <document>
    <id>287858</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=287858]]&gt;</url>
    <title>2008 National Knowledge Week on Proteinuria and eGFR - Managing cardiovascular risk factors in chronic kidney disease</title>
    <publicationDate>2008-06-03T00:00:00</publicationDate>
    <publisher>NLH Kidney Diseases Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ COMPLICATIONS OF KIDNEY DISEASE,CARDIOVASCULAR DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2008 National Knowledge Week on Proteinuria and eGFR - Managing cardiovascular risk factors in chronic kidney disease&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;3 b) Managing cardiovascular risk factors in chronic kidney disease&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;There are a number of guidelines on the management of CKD, which discuss the ways in which CV risk in CKD can be managed. These include guidelines from the&amp;nbsp; Royal College of Physicians/Renal Association (2006) and NICE guidance (2008) on the early identification and management of adults with CKD in primary care which is due to be published in September, but has been published in draft form for stakeholder comments six months earlier.&lt;BR&gt;&lt;BR&gt;Twenty-nine papers have been identified for this evidence review, although a small number of papers found that early interventions, such as correction of anaemia (Drueke et al, 2006) did not reduce cardio-vascular risk. Norris et al (2006) reporting on the AASK trial, identified that neither class of antihypertensive therapy nor BP level had a significant effect on the occurrence of CV events, but this might have been due to limited power of the study. However, they hypothesised that their analysis did identify unique and potentially modifiable CV risk factors, such as urine PCR, in this high-risk cohort. &lt;BR&gt;In a review of CV complications of CKD (Wheeler, 2007) it was suggested that current guidelines for cardiovascular risk reduction in CKD patients are based on knowledge of the benefits of such strategies in the general population. These strategies include targeting hypertension and hypercholesterolaemia.&amp;nbsp; Current opinion is that controlling blood pressure is the most important intervention to reduce cardiovascular disease risk in all CKD patients (Wheeler, 2007). &lt;BR&gt;&lt;BR&gt;While there are some data to support this approach in patients with stages 1-3 CKD, randomized controlled trials in stage 5 CKD patients receiving dialysis have failed to confirm that well-established cardioprotective therapies (such as statins and angiotensin II converting enzyme inhibitors) are necessarily beneficial. Draft NICE guidance (2) recommends that the use of statin therapy for primary prevention of CVD in people with CKD should not differ from its use in people without CKD, and should be based on existing risk tables recommended for people with and without diabetes. However it should be noted that Framingham risk tables significantly underestimate risk in people with early CKD. &lt;BR&gt;&lt;BR&gt;Statin therapy should be offered in secondary prevention of CVD in people with CKD irrespective of baseline lipid values (NICE, 2008).&lt;BR&gt;&lt;BR&gt;With respect to lifestyle modification and CV risk, draft NICE guidance (2008) concluded that although the evidence on the effects of smoking on the risk of progression of CKD was not conclusive it was sufficiently suggestive to merit highlighting within a recommendation. The guideline development group agreed however that the evidence on the effects of obesity on the risk of progression was unconvincing.&lt;BR&gt;&lt;BR&gt;In summary, health care professionals should pay attention to controlling blood pressure and cholesterol, whilst people with CKD should be encouraged to take exercise, achieve a healthy weight and stop smoking. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;References &lt;/STRONG&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;1. Royal College of Physicians&lt;/STRONG&gt;. Chronic kidney diseases in adults: UK guidelines for identification, management and referral. London: UK: 2006. [&lt;A href="https://rmsadmin.library.nhs.uk/admin/wizards/articles/www.rcplondon.ac.uk/pubs/contents/57f485dc-4730-4b2d-be90-fa6937cc15af.pdf" target="_blank"&gt;link to guidelines&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;2. NICE draft guidance&lt;/STRONG&gt;: Early identification and management of adults with chronic kidney disease in primary and secondary care. 2008 [&lt;A href="http://www.nice.org.uk/guidance/index.jsp?action=byID&amp;amp;o=11647" target="_blank"&gt;link to consultation document&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;3. Drueke TB&lt;/STRONG&gt;, Locatelli F, Clyne N, Eckardt KU, et al. Normalization of haemoglobin level in patients with chronic kidney disease and anemia. New England Journal of Medicine 2006;355(20):2071-84. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=%22The%20New%20England%20journal%20of%20medicine%22%5BJour%5D%20AND%202006%5Bpdat%5D%20AND%20Drueke%5Bauthor%5D" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;4. Norris K&lt;/STRONG&gt;, Bourgoigne J, Gassman J, Hebert L, Middleton J, Phillips RA, et al. Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial. American Journal of Kidney Diseases : the official journal of the National Kidney Foundation 2006;48(5):739-51. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17059993?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;5. Wheeler DC&lt;/STRONG&gt;. Cardiovascular complications of chronic kidney disease. Medicine 2007;35(8):453-6. [&lt;A href="http://linkinghub.elsevier.com/retrieve/pii/S135730390600497X" target="_blank"&gt;Elsevier&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;A href="http://www.nice.org.uk/guidance/index.jsp?action=byID&amp;amp;o=11647" target="_blank"&gt;Link to 2008 NICE Chronic Kidney Disease guideline&lt;/A&gt;&lt;/STRONG&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=PGFNKWCONT" target="_blank"&gt;Link to National Knowledge Week contents page&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>27/05/2010 09:53:46</lastReviewDate>
    <expiryDate>27/05/2011 09:53:46</expiryDate>
  </document>
  <document>
    <id>288225</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=288225]]&gt;</url>
    <title>2008 National Knowledge Week on Proteinuria and eGFR - PDF version</title>
    <publicationDate>2008-06-11T00:00:00</publicationDate>
    <publisher>NLH Kidney Diseases Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2008 National Knowledge Week on Proteinuria and eGFR - PDF version&lt;/pageTitle&gt;&lt;pageBody&gt;A PDF version of the Proteinuria and use of eGFR National Knowledge Week has been produced for anyone who would prefer to download and/or print the contents in one document.&lt;BR&gt;&lt;BR&gt;Click on the link under &lt;STRONG&gt;Related Files&lt;/STRONG&gt;&amp;nbsp;open the PDF version.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=PGFNKWCONT" target="_blank"&gt;Link back to National Knowledge Week contents page&lt;/A&gt;&lt;/STRONG&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>27/05/2010 09:53:50</lastReviewDate>
    <expiryDate>27/05/2011 09:53:50</expiryDate>
  </document>
  <document>
    <id>287860</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=287860]]&gt;</url>
    <title>2008 National Knowledge Week on Proteinuria and eGFR - Preventing new onset development of proteinuria in people with CKD</title>
    <publicationDate>2008-06-03T00:00:00</publicationDate>
    <publisher>NLH Kidney Diseases Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ PROTEINURIA/ NEPHROTIC SYNDROME,PRESENTATION OF CKD,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2008 National Knowledge Week on Proteinuria and eGFR - Preventing new onset development of proteinuria in people with CKD&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;3 d) Preventing new onset development of proteinuria in people with CKD&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;There are a number of guidelines on the management of CKD, which discuss the prevention of new onset proteinuria. These include guidelines from the Renal Association (2005). The NICE guideline on the early identification and management of adults with CKD in primary and secondary care which is likely to be the definitive evidence review and&amp;nbsp; is due to be published in September 2008; it has been published in draft form for stakeholder comments. (NICE, 2008).&lt;BR&gt;&lt;BR&gt;Twenty four new papers have been highlighted for this evidence review.&amp;nbsp; A review of progression risk, urinary protein excretion and the effects of ACE inhibition in nondiabetic renal disease utilizing data from 1860 people from 11 RCTs&amp;nbsp; is included. This review concludes that&amp;nbsp; patients with nondiabetic renal disease vay considerably in their risk of disease progression, but the treatment effect of&amp;nbsp; ACE inhibitors does not vary across risk strata. Patients with proteinuria of less than 500mg/d do not seem to benefit, even when at relatively high risk for progression.&lt;BR&gt;&lt;BR&gt;Seven papers are concerned with the effects of statin therapy on renal outcomes. Three of these are reviews with meta-analysis. (Douglas et al, 2006; Sandhu et al, 2006; Strippoli et al, 2008). The two reviews from 2006 conclude that statins have a beneficial effect on pathological albuminuria. The meta-analysis published in 2008 (Strippoli, 2008) is of 30144 patients from 50 trials. It concludes that statins significantly reduce lipid concentrations and cardiovascular endpoints in patients with CKD, irrespective of stage of disease. However no benefit on all cause mortality or the role of statins in primary prevention has been established. The renoprotective effects of statins are uncertain because of the relatively sparse data and possible outcomes reporting bias.&lt;BR&gt;&lt;BR&gt;The other 17 papers are mainly reports of&amp;nbsp; blood pressure lowering therapies in CKD and their effects on proteinuria. Three&amp;nbsp; (Bianchi et al, 2006; Epstein et al, 2006, Furumatsu et al, 2008) refer to the efficacy of triple blockade using an ACE inhibitor plus a ARB2 agent plus the aldosterone blocker spironolactone. These papers report the possible additional benefits of this triple regime.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;References&lt;BR&gt;&lt;BR&gt;1. UK Renal Association&lt;/STRONG&gt;: Chronic Kidney Disease in Adults - UK Guidelines for Identification, Management and Referral of Adults; 2005. [&lt;A href="https://rmsadmin.library.nhs.uk/admin/wizards/articles/www.renal.org/CKDguide/full/Contents.htm" target="_blank"&gt;link to guidelines&lt;/A&gt;]&lt;BR&gt;2&lt;STRONG&gt;. NICE Guideline&lt;/STRONG&gt;. Early identification and management of adults with chronic kidney disease in primary and secondary care; Due for publication in Sept 2008. [&lt;A href="http://www.nice.org.uk/guidance/index.jsp?action=byID&amp;amp;o=11647" target="_blank"&gt;link to consultation document&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;3. Douglas K&lt;/STRONG&gt;, O'Malley PG, Jackson JL. Meta-analysis: the effect of statins on albuminuria. Ann Intern Med 2006 Jul 18;145(2):117-24. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16847294?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;4. Sandhu S&lt;/STRONG&gt;, Wiebe N, Fried L, F, Tonelli M. Statins for improving renal outcomes: A meta-Analysis. Journal of the American Society of Nephrology 2006;17(7):2006-16. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=%22Journal%20of%20the%20American%20Society%20of%20Nephrology%20%3A%20JASN%22%5BJour%5D%20AND%202006%5Bpdat%5D%20AND%20Sandhu%5Bauthor%5D" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;5. Strippoli GF&lt;/STRONG&gt;, Navaneethan SD, Johnson DW, Perkovic V, Pellegrini F, Nicolucci A, et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ 2008 Mar 22;336(7645):645-51. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=BMJ%20%5BJour%5D%20AND%202008%5Bpdat%5D%20AND%20Strippoli%5Bauthor%5D" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;6. Bianchi S&lt;/STRONG&gt;, Bigazzi R, Campese V, M. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney international 2006;70(12):2116-23. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=%22Kidney%20international%22%5BJour%5D%20AND%202006%5Bpdat%5D%20AND%20Bianchi%5Bauthor%5D" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;7. Epstein M&lt;/STRONG&gt;. Aldosterone blockade: an emerging strategy for abrogating progressive renal disease. Am J Med 2006 Nov;119(11):912-9. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17071154?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;8. Furumatsu Y&lt;/STRONG&gt;, Nagasawa Y, Tomida K, Mikami S, Kaneko T, Okada N, et al. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker. Hypertens Res 2008 Jan;31(1):59-67. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=%22Hypertension%20research%20%3A%20official%20journal%20of%20the%20Japanese%20Society%20of%20Hypertension%22%5BJour%5D%20AND%202008%5Bpdat%5D%20AND%20Furumatsu%5Bauthor%5D" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=PGFNKWCONT" target="_blank"&gt;&lt;STRONG&gt;Link to 2008 NICE Chronic Kidney Disease guideline&lt;/STRONG&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Link to National Knowledge Week contents page&lt;/STRONG&gt;&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>27/05/2010 09:53:54</lastReviewDate>
    <expiryDate>27/05/2011 09:53:54</expiryDate>
  </document>
  <document>
    <id>287859</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=287859]]&gt;</url>
    <title>2008 National Knowledge Week on Proteinuria and eGFR - Preventing new onset development of proteinuria in people with diabetes or hypertension</title>
    <publicationDate>2008-06-03T00:00:00</publicationDate>
    <publisher>NLH Kidney Diseases Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ PRESENTATION OF CKD,PROTEINURIA/ NEPHROTIC SYNDROME,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2008 National Knowledge Week on Proteinuria and eGFR - Preventing new onset development of proteinuria in people with diabetes or hypertension&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;3 c) Preventing new onset development of proteinuria in people with diabetes or hypertension&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;All the evidence relating to proteinuria, hypertension and diabetes has recently been reviewed by the guideline development group for the NICE type 2 diabetes guideline which was published at the end of May 2008. (1)&amp;nbsp; They conclude that the prevention and management of diabetic nephropathy has not changed significantly from the NICE guideline of 2002 (2) and is similar in type 2 diabetes as in type 1 diabetes as outlined in the NICE guideline for type 1 diabetes in adults (2004). The management centres around tight blood pressure control and renin-angiotensin system blockade. The new guideline recommends maintaining blood pressure at or below 140/80 for everyone with type 2 diabetes and 130/80 for those with microalbuminuria or proteinuria. An ACE inhibitor (or ARB2 agent if ACE is not tolerated) should be the first line therapy for blood pressure control in someone with type 2 diabetes. Yearly screening for evidence for nephropathy using a first pass urine specimen for estimation of albumin: creatinine ratio, with repeat if positive is recommended, along with measuring serum creatinine&amp;nbsp; and calculated eGFR . The group recognized some problems with reporting of eGFR using the MDRD (4-variable) equation in people with diabetes but could see no better alternative.&lt;BR&gt;&lt;BR&gt;Of the 27 new articles relating to this question found in this annual evidence update the majority are concerned with the effects of ACE or ARB2 on blood pressure and proteinuria, and confirm the benefits described in guideline and reviews. There is a review and meta-analysis&amp;nbsp; of the effects of statin therapy on improving renal outcomes, which concludes that statin therapy seems to reduce proteinuria modestly and results in a small reduction in the rate of kidney loss. (Sandhu et al, 2006)&amp;nbsp; There are two papers that discuss the possible benefits that the glitazone drugs may have on proteinuria (Bakris et al, 2006; Zheng &amp;amp; Guan, 2007), and one that discusses the role that aliskiren (Gradman et al, 2008), the first orally active renin inhibitor might have on proteinuria&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;References&lt;BR&gt;&lt;/STRONG&gt;&lt;BR&gt;&lt;STRONG&gt;1. NICE&lt;/STRONG&gt;: Type 2 Diabetes Guideline; NICE London 2008 [&lt;A href="http://www.nice.org.uk/guidance/index.jsp?action=byID&amp;amp;o=11983" target="_blank"&gt;link to guideline&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;2.&amp;nbsp; NICE&lt;/STRONG&gt;: Management of Type 2 diabetes. Renal disease- prevention and early management; NICE London 2002 [&lt;A href="http://www.nice.org.uk/guidance/index.jsp?action=byID&amp;amp;o=10914" target="_blank"&gt;link to guideline&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;3. NICE&lt;/STRONG&gt;: Diagnosis and management of type 1 diabetes in children, young people and adults CG15; NICE London 2004 [&lt;A href="http://www.nice.org.uk/guidance/index.jsp?action=byID&amp;amp;o=10944" target="_blank"&gt;link to guideline&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;4. Sandhu S&lt;/STRONG&gt;, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 2006 Jul;17(7):2006-16. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=%22Journal%20of%20the%20American%20Society%20of%20Nephrology%20%3A%20JASN%22%5BJour%5D%20AND%202006%5Bpdat%5D%20AND%20Sandhu%5Bauthor%5D" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;5. Bakris GL&lt;/STRONG&gt;, Ruilope LM, Mcmorn SO, Weston WM, Heise MA, Freed MI, et al. Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. Journal of Hypertension 2006;24(10):2047-55. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=%22Journal%20of%20hypertension%22%5BJour%5D%20AND%202006%5Bpdat%5D%20AND%20Bakris%5Bauthor%5D" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;6. Zheng F&lt;/STRONG&gt;, Guan Y. Thiazolidinediones: A novel class of drugs for the prevention of diabetic nephropathy? Kidney International 2007;72(11):1301-3. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18004308?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;7. Gradman AH&lt;/STRONG&gt;, Pinto R, Kad R. Current concepts: renin inhibition in the treatment of hypertension. Current Opinion in Pharmacology 2008;8(2):120-6. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=%22Current%20opinion%20in%20pharmacology%22%5BJour%5D%20AND%202008%5Bpdat%5D%20AND%20Gradman%5Bauthor%5D" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;A href="http://www.nice.org.uk/guidance/index.jsp?action=byID&amp;amp;o=11647" target="_blank"&gt;Link to 2008 NICE Chronic Kidney Disease guideline&lt;/A&gt;&lt;/STRONG&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=PGFNKWCONT" target="_blank"&gt;Link to National Knowledge Week contents page&lt;/A&gt;&lt;/STRONG&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>27/05/2010 09:53:59</lastReviewDate>
    <expiryDate>27/05/2011 09:53:59</expiryDate>
  </document>
  <document>
    <id>287772</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=287772]]&gt;</url>
    <title>2008 National Knowledge Week on Proteinuria and eGFR - Proteinuria as a marker of chronic kidney damage</title>
    <publicationDate>2008-06-03T00:00:00</publicationDate>
    <publisher>NLH Kidney Diseases Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ PROTEINURIA/ NEPHROTIC SYNDROME,PRESENTATION OF CKD,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2008 National Knowledge Week on Proteinuria and eGFR - Proteinuria as a marker of chronic kidney damage&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;2 b) Proteinuria as a marker of chronic kidney damage&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Whatever technique we employ to detect our urinary protein or proteins of choice, we need to know about the reproducibility and reliability of the technique, its strengths and weaknesses, and of course a cost sensitivity analysis as a screening tool.&lt;BR&gt;&lt;BR&gt;Agarwal (2007) attempted to look at the reproducibility and reliability of renal function and albuminuria testing in a cohort of type II diabetic patients. They studied 44 elderly men with diabetic nephropathy who participated in a clinical trial. Glomerular filtration rate and renal plasma flow were measured by continuous infusion technique with five urine collection periods on two occasions 4 months apart. Protein and creatinine excretion rates were measured in the same specimens. In addition, two consecutive 24-hour specimens every month for 4 months were collected to analyze urine protein, creatinine, urea nitrogen, and electrolytes. A hierarchical random effects model was used to analyze the reproducibility from hour to hour, from day to day, and from month to month. A total of 824 urine specimens were analyzed, of which 412 constituted specimens collected in the short term and 412 were 24-hour urine collections. Hour-to-hour variation accounted for 45% for urinary clearance of iothalamate, but for only 0.5% of the variability in plasma clearance of iothalamate. Day-to-day variability in 24-hour urinary excretion rates for creatinine was 46% and for protein 10%. Month-to-month variability in 24-hour excretion rates for creatinine was 11% and for protein 19%. The urine protein/creatinine ratio had a day-to-day variability of 2% and a month-to-month variability of 19%. Sample size requirements can be reduced by correcting for urine creatinine for some but not all urinary analytes. In nephrotic men with diabetic nephropathy, the coefficient of variation in the month-to-month protein excretion rate is 36%. Approximately 28 patients in each arm of two groups are needed to detect a difference in protein excretion rate of 28% (1 g/day in this study). The coefficient of variation in plasma iothalamate clearance over 4 months is 16%. To detect a 10% change in glomerular filtration rate between two groups, 44 patients per group are needed. To be deemed statistically significant, a change in daily protein excretion rate of at least 72% over month(s) is needed in individual patients. These findings illustrate the challenges of not only screening for the presence of something, but then following on with repeated quantifications over time.&lt;BR&gt;&lt;BR&gt;The power of a single point in time estimate of urinary protein using urine dipsticks (at best semi-quantitative) was nicely shown by Ishani et al (2006). This study aimed to determine over 25 yr the risk for ESRD associated with proteinuria, estimated GFR (eGFR), and hematocrit in men who did not have identified kidney disease and were randomly assigned into the Multiple Risk Factor Intervention Study (MRFIT). A total of 12,866 men who were at high risk for heart disease were enrolled (1973 to 1975) and followed through 1999. Renal replacement therapy was ascertained by matching identifiers with the United States Renal Data System's data; vital status was from the National Death Index. Men who initiated renal replacement therapy or died as a result of kidney disease were deemed to have developed ESRD. Dipstick urine for proteinuria, eGFR, and hematocrit were related to development of ESRD. During 25 yr, 213 (1.7%) men developed ESRD. Predictors of ESRD were dipstick proteinuria of 1+ or &amp;gt; or =2+ (hazard ratio [HR] 3.1 [95% confidence interval (CI) 1.8 to 5.4] and 15.7 [95% CI 10.3 to 23.9] respectively) and an eGFR of &amp;lt;60 ml/min per 1.73 m(2) (HR 2.4; 95% CI 1.5 to 3.8). Correlation between eGFR and serum creatinine was 0.9; the risk for ESRD with a 1-SD difference of each was identical (HR 1.21). Bivariate analysis demonstrated a 41-fold increase in ESRD risk in those with an eGFR &amp;lt;60 ml/min per 1.73 m(2) and &amp;gt; or =2+ proteinuria (95% CI 15.2 to 71.1). There was no association between hematocrit and ESRD. Other baseline measures that independently predicted ESRD included age, cigarette smoking, BP, low HDL cholesterol, and fasting glucose. Among middle-aged men who were at high risk for cardiovascular disease but had no clinical evidence of cardiovascular disease or significant kidney disease, dipstick proteinuria and an eGFR value &amp;lt;60 ml/min per 1.73 m(2) were strong predictors of long-term development of ESRD. It remains unknown whether intervention for proteinuria or early identification of those with chronic kidney disease reduces the risk for subsequent manifestation of renal or cardiovascular diseases.&lt;BR&gt;&lt;BR&gt;Other associations between albuminuria and markers of disease states abound in the literature. This can be a confusing area, as everything in time seems to be linked to everything else. Thus, de B and colleagues used samples derived from the Third National Health and Nutrition Examination Survey from 15,068 adults participating (de Boer et al, 2007). A stepwise increase in the prevalence of albuminuria was observed with decreasing quartiles of vitamin D concentration: 8.9%, 11.5%, 13.7%, and 15.8% (P &amp;lt; 0.001). Adjusting for age, sex, race/ethnicity, region and season of measurement, smoking status, body mass index, and estimated glomerular filtration rate, relative risks for albuminuria by decreasing quartile of vitamin D concentration were 1.00 (reference group), 1.14 (95% confidence interval, 0.95 to 1.37), 1.22 (95% confidence interval, 1.03 to 1.45), and 1.37 (95% confidence interval, 1.10 to 1.71; P = 0.006). Additionally adjusting for blood pressure and diabetes mellitus, these risks were somewhat attenuated and retained statistical significance. This was a cross-sectional survey, so additional studies are needed to clarify the relationship of vitamin D with albuminuria and determine whether vitamin D therapy prevents or improves markers of kidney and cardiovascular disease.&lt;BR&gt;&lt;BR&gt;From the same NHANES study, Kshirsagar et al (2008) examined the association between CRP and microalbuminuria. They conducted a cross-sectional analysis of a nationally representative, population-based survey. Weighted multiple logistic regression was used to study the association between CRP and microalbuminuria, adjusting for well-known risk factors. CRP was analyzed by a continuous variable and two categorized variables using quartiles and clinically recommended cutpoints. CRP concentration was positively associated with microalbuminuria. In the multivariate model, a one unit (in milligrams per liter) increase in CRP concentration was associated with a 2% increased odds of microalbuminuria (odds ratio 1.02, 95% confidence interval [CI] 1.01 to 1.02, p=0.0003). When CRP concentrations were stratified by clinically recommended cutpoints, compared with persons with CRP concentrations&amp;lt;1 mg/dl, persons with CRP concentrations between 1 and 3 mg/L and &amp;gt;3 mg/L were 1.15 times (95% CI 0.94 to 1.42) and 1.33 times (95% CI 1.08 to 1.65) more likely to have microalbuminuria, respectively. In subgroup analyses, the strength of association was comparable or stronger. In conclusion, elevated CRP levels were associated with microalbuminuria in a large, nationally representative data set. Vascular inflammation, as measured by CRP, may be a common contributor to early heart and kidney disease.&lt;BR&gt;Although having a “normal” range of course is essential for the concept of screening for elevation in urinary albumin excretion, Ruggenenti and Remuzzi provocatively but remorselessly point out that any distinction between the normal and elevated is both arbitrary and spurious. There is a linear graded relationship between adverse outcome and urinary albumin excretion rates which extends well down into the normal range of urinary albumin levels (Ruggenenti &amp;amp; Remuzzi, 2006).&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;1. Agarwal R&lt;/STRONG&gt;. Reproducibility of renal function measurements in adult men with diabetic nephropathy: research and clinical implications. American journal of nephrology 2007;27(1):92-100. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=%22American%20journal%20of%20nephrology%22%5BJour%5D%20AND%202007%5Bpdat%5D%20AND%20Agarwal%5Bauthor%5D%20AND%20renal%20function" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;2. Ishani A&lt;/STRONG&gt;, Grandits GA, Grimm RH, Svendsen KH, Collins AJ, Prineas RJ, et al. Association of single measurements of dipstick proteinuria, estimated glomerular filtration rate, and hematocrit with 25-year incidence of end-stage renal disease in the multiple risk factor intervention trial. Journal of the American Society of Nephrology : JASN 2006;17(5):1444-52. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=%22Journal%20of%20the%20American%20Society%20of%20Nephrology%20%3A%20JASN%22%5BJour%5D%20AND%202006%5Bpdat%5D%20AND%20Ishani%5Bauthor%5D" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;3. de Boer IH&lt;/STRONG&gt;, Ioannou G, N, Kestenbaum B, Brunzell J, et al. 25-Hydroxyvitamin D Levels and Albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III). American Journal of Kidney Diseases 2007;50(1):69-77. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17591526?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;4. Kshirsagar AV&lt;/STRONG&gt;, Bomback AS, Bang H, Gerber LM, Vupputuri S, Shoham DA, et al. Association of C-reactive protein and microalbuminuria (from the National Health and Nutrition Examination Surveys, 1999 to 2004). Am J Cardiol 2008 Feb 1;101(3):401-6. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=%22The%20American%20journal%20of%20cardiology%22%5BJour%5D%20AND%202008%5Bpdat%5D%20AND%20Kshirsagar%5Bauthor%5D" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;5. Ruggenenti P &amp;amp; Remuzzi G&lt;/STRONG&gt;. Time to abandon microalbuminuria? Kidney Int 2006 Oct;70(7):1214-22. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=%22Kidney%20international%22%5BJour%5D%20AND%202006%5Bpdat%5D%20AND%20Ruggenenti%5Bauthor%5D" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;A href="http://www.nice.org.uk/guidance/index.jsp?action=byID&amp;amp;o=11647" target="_blank"&gt;Link to 2008 NICE Chronic Kidney Disease guideline&lt;/A&gt;&lt;/STRONG&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=PGFNKWCONT" target="_blank"&gt;Link to National Knowledge Week contents page&lt;/A&gt;&lt;/STRONG&gt;&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>27/05/2010 09:54:03</lastReviewDate>
    <expiryDate>27/05/2011 09:54:03</expiryDate>
  </document>
  <document>
    <id>287781</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=287781]]&gt;</url>
    <title>2008 National Knowledge Week on Proteinuria and eGFR - Proteinuria as a marker of CVD</title>
    <publicationDate>2008-06-03T00:00:00</publicationDate>
    <publisher>NLH Kidney Diseases Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ PRESENTATION OF CKD,PROTEINURIA/ NEPHROTIC SYNDROME,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2008 National Knowledge Week on Proteinuria and eGFR - Proteinuria as a marker of CVD&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;2 c) Proteinuria as a marker of CVD&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;The strength of the link between the presence of urinary protein and other important biological risk factors for cardiovascular disease can be high-lighted by the examination of several large trial databases.&lt;BR&gt;&lt;BR&gt;Thus, Ingelsson and colleagues (Ingelson et al, 2007) looked at a cohort of “healthy” elderly men (&amp;gt; 70 years of age) and quantified urinary albumin, then they correlated de novo onset of heart failure against baseline urinary protein losses. UAER (from timed overnight samples) was analysed with established risk factors for HF [acute MI before baseline, acute MI during follow-up (modelled as a time-dependent covariate), hypertension, diabetes, left ventricular hypertrophy, smoking, body mass index, and glomerular filtration rate] and more recently described risk factors [high-sensitive C-reactive protein and insulin sensitivity (clamp glucose disposal rate)] as predictors of HF incidence. Ninety-eight participants developed HF during a median follow-up of 9.0 years. In Cox proportional hazards models adjusted for established and novel risk factors for HF, a 1 SD increase in log UAER increased the risk of HF in individuals without anti-hypertensive treatment (hazard ratio 1.49; 95% CI 1.13-1.98; P = 0.005). Furthermore, UAER remained an independent predictor of HF, also in participants without diabetes at baseline or myocardial infarction at baseline or during follow-up. There were no significant associations between UAER and HF incidence in individuals with anti-hypertensive treatment. These observations support the notion that low-grade albuminuria is a marker for subclinical cardiovascular damage that predisposes to future HF in the community.&lt;BR&gt;&lt;BR&gt;In another interesting study, carotid ultrasonography and measurements of ACR, fibrinogen, monocytes, white cell count, and well-established cardiovascular risk factors were performed in 4037 non-diabetic subjects, 2203 without, and 1834 with pre-existing plaques at baseline (Jorgensen et al, 2007). After 7 years new ultrasound measurements were performed. In subjects without pre-existing plaques, 884 had developed at least one plaque during follow-up. Baseline ACR was significantly related to the area of the novel plaques (P for linear trend = 0.009 over the baseline ACR quartiles, after multiple adjustments). The relationship with ACR was clearly modified by fibrinogen (P = 0.001, for the interaction ACR x fibrinogen). Subjects with high levels of both ACR and fibrinogen developed plaques with the largest area. In subjects with pre-existing plaques, ACR was related to plaque-progression (P for linear trend = 0.026, after multiple adjustments). In these individuals, the interaction between fibrinogen and ACR on plaque-growth appeared only in those with minimal atherosclerosis at baseline. ACR is positively related to plaque-initiation and plaque-growth. This relationship is substantially modified by fibrinogen in previously plaque-free subjects.&lt;BR&gt;&lt;BR&gt;Tsai et al (2007) argued that as both arterial stiffness and proteinuria are important markers for organ damage in hypertension they needed to investigate the association between arterial stiffness and inflammation and to define the influences of proteinuria on arterial stiffness and inflammation in non-diabetic hypertension. They enrolled 205 patients (mean age 41 +/- 8 years, 66 women) with essential hypertension noted for less than 5 years in this study. They did not have diabetes mellitus or any overt cardiac, vascular, or renal complications. Stiffness index (SI) derived from digital volume pulse was used for assessment of arterial stiffness. High-sensitivity C-reactive protein (hsCRP) was measured in each patient during enrollment. Left ventricular hypertrophy (LVH) was documented by electrocardiography and proteinuria was assessed by measuring 24-h urine protein. SI was significantly correlated with hsCRP (r = 0.166, p = 0.017). LVH was noted in 34 patients (17%). SI was significantly higher in patients with LVH (8.03 +/- 1.74 vs 7.19 +/- 1.19 m/s, p = 0.001). Proteinuria was noted in three patients with LVH. SI was gradually increased among patients without LVH, with LVH but not proteinuria, and with LVH and proteinuria (7.19 +/- 1.19, 7.68 +/- 1.21, 11.75 +/- 2.51 m/s respectively; p&amp;lt;0.001). HsCRP was also gradually increased among patients without LVH, with LVH but not proteinuria, and with LVH and proteinuria (0.20 +/- 0.24, 0.30 +/- 0.59, 1.56 +/- 1.58 mg/dl respectively; p&amp;lt;0.001). SI was significantly correlated with hsCRP. Arterial stiffness and inflammation were increased in association with proteinuria in non-diabetic essential hypertension&lt;BR&gt;&lt;BR&gt;Valappil did a similar study in young adults for the same reasons (Valappil et al, 2008). Reduced arterial elasticity and endothelial dysfunction both may indicate early cardiovascular (CV) disease in young adults. Pulse waveform analysis estimates large (LAE) and small (SAE) artery elasticity noninvasively. They assessed the associations between LAE and SAE and markers of endothelial dysfunction and CV risk factors. The Coronary Artery Risk Development in Young Adults (CARDIA) assessed arterial elasticity and other characteristics cross-sectionally in 389 men and 381 women age 27 to 42 years in 1995 (CARDIA year 10) and circulating levels of P-selectin and soluble intercellular adhesion molecule 1 (sICAM1) in 2000. Adjustment for variables included in the estimation of arterial elasticity (year 10 height, body mass index, age, heart rate, and blood pressure) and other year 10 characteristics. Mean adjusted SAE was 8.5 vs. 7.6 mL/mm Hg x 100 in those with urine albumin/creatinine ratio &amp;lt; 4 vs. microalbuminuria (ratio &amp;gt;25; P = .008). Mean LAE was 25.6 vs. 24.2 mL/mm Hg x 10 in the lowest vs. highest quintile of P-selectin (P = .004). sICAM1 was unrelated to either LAE or SAE. Plasma triglycerides were inversely related to LAE (P&amp;lt;sub&amp;gt;trend&amp;lt;/sub&amp;gt; = .029). Cigarette smokers had lower SAE than nonsmokers (P = .009). In addition to smoking and triglycerides, biomarkers for endothelial dysfunction were associated with impaired LAE and SAE in young adults.&lt;BR&gt;&lt;BR&gt;Of course, as we have seen, microalbuminuria is but one cardiovascularly-relevant biomarker we have at our disposal. It is intimately linked to several of the other key cardiovascular biomarkers. Shlipak et al (2008) examined the association of N-terminal prohormone brain natriuretic peptide (Nt-proBNP), cystatin C, albuminuria, C-reactive protein (CRP), interleukin-6, and fibrinogen with cardiovascular events in 979 Heart and Soul Study participants with coronary artery disease after adjusting for demographic, lifestyle, and behavior variables; cardiovascular risk factors; cardiovascular disease severity; medication use; and left ventricular ejection fraction. The outcome was a composite of stroke, myocardial infarction, and coronary heart disease death during an average of 3.5 years of follow-up.: During follow-up, 142 participants (15%) developed cardiovascular events. The highest quartiles (vs lower 3 quartiles) of 5 biomarkers were individually associated with cardiovascular risk after multivariate analysis: Nt-proBNP hazard ratio (HR)=2.13 (95% confidence interval [CI], 1.43-3.18); cystatin C HR=1.72 (95% CI, 1.10-2.70); albuminuria HR=1.71 (95% CI, 1.15-2.54); CRP HR=2.00 (95% CI, 1.40-2.85); and interleukin-6 HR=1.76 (95% CI, 1.22-2.53). When all biomarkers were included in the multivariable analysis, only Nt-proBNP, albuminuria, and CRP remained significant predictors of events: HR=1.88 (95% CI, 1.23-2.85), HR=1.63 (95% CI, 1.09-2.43), and HR=1.82 (95% CI, 1.24-2.67), respectively. The area under the receiver operator curve for clinical predictors alone was 0.73 (95% CI, 0.68-0.78); adding Nt-proBNP, albuminuria, and CRP significantly increased the area under the receiver operator curve to 0.77 (95% CI, 0.73-0.82, P&amp;lt;.005). Among persons with prevalent coronary artery disease, biomarkers reflecting hemodynamic stress, kidney damage, and inflammation added significant risk discrimination for cardiovascular events.&lt;BR&gt;&lt;BR&gt;It may well be, in time, that we are able to augment the priceless information we can so simply and relatively cheaply obtain from urine analysis, by using bespoke biomarkers to compile a “score” for future cardio-renal events. All of this optimism, as with proteomics of blood or urine, needs rigorously to be tested / nested in large population databases with appropriate follow-up. A better understanding of the genetic predisposition to disease, and the use of more sophisticated biomarkers, promises to be a new way to predict cardio-renal events, and, if coupled with affordable but efficacious interventions (life-style as well as pharmacological), to permit a more successful organized approach to disease prevention.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;1. Ingelsson E&lt;/STRONG&gt;, Sundstrom J, Lind L, Riserus U, Larsson A, Basu S, et al. Low-grade albuminuria and the incidence of heart failure in a community-based cohort of elderly men. European Heart Journal 2007;28(14):1739-45. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17495987?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;2. Jorgensen L&lt;/STRONG&gt;, Jenssen T, Johnsen SH, Mathiesen EB, Heuch I, Joakimsen O, et al. Albuminuria as risk factor for initiation and progression of carotid atherosclerosis in non-diabetic persons: the Tromso Study. Eur Heart J 2007 Feb;28(3):363-9. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17132646?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;3. Tsai WC&lt;/STRONG&gt;, Lin CC, Huang YY, Chen JY, Chen JH. Association of increased arterial stiffness and inflammation with proteinuria and left ventricular hypertrophy in non-diabetic hypertensive patients. Blood Press 2007;16(4):270-5. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=%22Blood%20pressure%22%5BJour%5D%20AND%202007%5Bpdat%5D%20AND%20Tsai%5Bauthor%5D" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;4. Valappil NI&lt;/STRONG&gt;, Jacobs JDR, Duprez D, et al. Association between endothelial biomarkers and arterial elasticity in young adults: the CARDIA Study. Journal of the American Society of Hypertension 2008;2(2):70-9. [&lt;A href="http://linkinghub.elsevier.com/retrieve/pii/S193317110700201X" target="_blank"&gt;Elsevier&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;5. Shlipak MG&lt;/STRONG&gt;, Ix JH, Bibbins-Domingo K, Lin F, Whooley MA. Biomarkers to predict recurrent cardiovascular disease: the Heart and Soul Study. Am J Med 2008 Jan;121(1):50-7. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=%22The%20American%20journal%20of%20medicine%22%5BJour%5D%20AND%202008%5Bpdat%5D%20AND%20Shlipak%5Bauthor%5D" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;A href="http://www.nice.org.uk/guidance/index.jsp?action=byID&amp;amp;o=11647" target="_blank"&gt;Link to 2008 NICE Chronic Kidney Disease guideline&lt;/A&gt;&lt;/STRONG&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=PGFNKWCONT" target="_blank"&gt;Link to National Knowledge Week contents page&lt;/A&gt;&lt;/STRONG&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>27/05/2010 09:54:07</lastReviewDate>
    <expiryDate>27/05/2011 09:54:07</expiryDate>
  </document>
  <document>
    <id>287854</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=287854]]&gt;</url>
    <title>2008 National Knowledge Week on Proteinuria and eGFR - Proteinuria as a screening tool</title>
    <publicationDate>2008-06-03T00:00:00</publicationDate>
    <publisher>NLH Kidney Diseases Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ ALBUMIN,SCREENING TESTS,SCREENING OPTIONS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2008 National Knowledge Week on Proteinuria and eGFR - Proteinuria as a screening tool&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;2 d) Proteinuria as a screening tool&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Proteinuria and impaired renal function are both strong predictors for progressive renal failure and perhaps more importantly for cardiovascular disease (Halbesma et al, 2006). Screening for renal disease may make sense as interventions such ACE inhibition and control of cardiovascular risk factors in at risk subjects is effective in prevention or retardation of progressive renal impairment and avoidance of cardiovascular complications. Nevertheless there is ongoing debate on the cost effectiveness of population based screening for renal disease (de Jong et al, 2006). &lt;BR&gt;&lt;BR&gt;Detection of chronic kidney disease (CKD) requires quantitative evaluation of both renal function (for stages 2 to 5) and proteinuria (for stages 1 and 2). Presence of proteinuria is an independent marker of progression of renal failure at all levels of renal function (Halbesma et al, 2006). Cost effectiveness may be improved by confining screening to high risk populations identified as having predisposition for CKD or individuals having abnormal results using cheaper “pre-screening” tests such as dip stick urinalysis. &lt;BR&gt;&lt;BR&gt;Bang et al. (2007) have developed a simple model for prediction of occult CKD based upon demographic parameters and the presence of various health conditions such as hypertension, diabetes and peripheral vascular disease. Iseki (2006) and Iseki et al (2007, 2007) have examined mass screening data from Okinawa&amp;nbsp; and have shown changes in the demographic characteristics of Japanese patients with CKD between 1993 and 2003. Dipstick positive proteinuria and both high systolic and diastolic blood pressure were useful to identify individuals at risk of developing progressive CKD. Another study (Ishizaka et al, 2007) demonstrated that overweight and obesity were strong independent predictors of increased risk of CKD in Japanese individuals.&lt;BR&gt;&lt;BR&gt;Albuminuria of greater than 30 mg/day is one of the criteria for CKD but this requires collection of a 24 hour urine sample which is expensive, inconvenient and may lead to inaccuracy due to incomplete collection. Two studies have examined the effectiveness of pre screening using spot urine sample for albumin concentration or albumin creatinine ratios (Jafar et al, 2007; Gansevoort et al, 2005). Of note, both studies found the diagnostic performance of assessment of the albumin concentration and the albumin:creatinine ratio comparable. From an economic perspective this is an important observation. In order to keep costs involved in mass screening for micro-albuminuria as low as possible, it was therefore proposed that pre-screening should take place by measuring only albumin concentration in a spot morning urine sample.&amp;nbsp; &lt;BR&gt;&lt;BR&gt;Best practice for screening for renal disease in the UK is under discussion. The National Institute for Clinical Excellence have produced draft guidance (NICE, 2008) which is published for consultation on their web site. Current recommendations include the use of an albumin creatinine ratio to quantify proteinuria and screening for CKD using the MDRD formula in all people with diabetes, hypertension, cardiovascular disease, family history of CKD stage 5, known structural renal tract disease such as stones, incidental urine sediment abnormality or know use of nephrotoxic drugs.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;References&lt;BR&gt;&lt;/STRONG&gt;&lt;BR&gt;&lt;STRONG&gt;1. Halbesma N&lt;/STRONG&gt;, Kuiken DS, Brantsma AH, Bakker S, et al. Macroalbuminuria is a better risk marker than low estimated GFR to identify individuals at risk for accelerated GFR loss in population screening. Journal of the American Society of Nephrology 2006;17(9):2582-90. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=%22Journal%20of%20the%20American%20Society%20of%20Nephrology%20%3A%20JASN%22%5BJour%5D%20AND%202006%5Bpdat%5D%20AND%20Halbesma%5Bauthor%5D" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;2. de Jong PE&lt;/STRONG&gt;, Halbesma N, Gansevoort RT. Screening for early chronic kidney disease - What method fits best? Nephrology Dialysis Transplantation 2006;21(9):2358-61. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16887849?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;3. Bang H&lt;/STRONG&gt;, Vupputuri S, Shoham D, A, Klemmer P, J, et al. SCreening for Occult REnal Disease (SCORED): A simple prediction model for chronic kidney disease. Archives of Internal Medicine 2007;167(4):374-81. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=%22Archives%20of%20internal%20medicine%22%5BJour%5D%20AND%202007%5Bpdat%5D%20AND%20Bang%5Bauthor%5D" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;4. Iseki K&lt;/STRONG&gt;. Screening for renal disease - What can be learned from the Okinawa experience. Nephrology Dialysis Transplantation 2006;21(4):839-43. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=%22Nephrology%2C%20dialysis%2C%20transplantation%20%3A%20official%20publication%20of%20the%20European%20Dialysis%20and%20Transplant%20Association%20-%20European%20Renal%20Association%22%5BJour%5D%20AND%202006%5Bpdat%5D%20AND%20Iseki%5Bauthor%5D" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;5. Iseki K&lt;/STRONG&gt;, Kohagura K, Sakima A, Iseki C, Kinjo K, Ikemiya Y, et al. Changes in the demographics and prevalence of chronic kidney disease in Okinawa, Japan (1993 to 2003). Hypertens Res 2007 Jan;30(1):55-62. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17460372?ordinalpos=3&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;6. Iseki K&lt;/STRONG&gt;, Iseki C, Ikemiya Y, Kinjo K, Takishita S. Risk of developing low glomerular filtration rate or elevated serum creatinine in a screened cohort in Okinawa, Japan. Hypertens Res 2007 Feb;30(2):167-74. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17460387?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;7. Ishizaka N&lt;/STRONG&gt;, Ishizaka Y, Toda E, Koike K, Seki G, Nagai R, et al. Association between obesity and chronic kidney disease in Japanese: differences in gender and hypertensive status? Hypertens Res 2007 Nov;30(11):1059-64. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18250555?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;8. Jafar TH&lt;/STRONG&gt;, Chaturvedi N, Hatcher J, Levey AS. Use of albumin creatinine ratio and urine albumin concentration as a screening test for albuminuria in an Indo-Asian population. Nephrology Dialysis Transplantation 2007;22(8):2194-200. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=%22Nephrology%2C%20dialysis%2C%20transplantation%20%3A%20official%20publication%20of%20the%20European%20Dialysis%20and%20Transplant%20Association%20-%20European%20Renal%20Association%22%5BJour%5D%20AND%202007%5Bpdat%5D%20AND%20Jafar%5Bauthor%5D" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;9. Gansevoort RT&lt;/STRONG&gt;, Verhave JC, Hillege HL, et al. for the PREVEND Study Group. The validity of screening based on spot morning urine samples to detect subjects with microalbuminuria in the general population. Kidney Int Suppl (2005) 94:S28–S35. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Kidney%20international%5BJour%5D%20AND%20Gansevoort%5Bauthor%5D%20AND%20validity" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;10. NICE&lt;/STRONG&gt; (full guideline due in September 2008): Early identification and management of adults with chronic kidney disease in primary and secondary care. [&lt;A href="http://www.nice.org.uk/guidance/index.jsp?action=byID&amp;amp;o=11647" target="_blank"&gt;Consultation documents&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;A href="http://www.nice.org.uk/guidance/index.jsp?action=byID&amp;amp;o=11647" target="_blank"&gt;Link to 2008 NICE Chronic Kidney Disease guideline&lt;/A&gt;&lt;/STRONG&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=PGFNKWCONT" target="_blank"&gt;Link to National Knowledge Week contents page&lt;/A&gt;&lt;/STRONG&gt;&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>27/05/2010 09:54:11</lastReviewDate>
    <expiryDate>27/05/2011 09:54:11</expiryDate>
  </document>
  <document>
    <id>288027</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=288027]]&gt;</url>
    <title>2008 National Knowledge Week on Proteinuria and eGFR - Proteinuria foreword</title>
    <publicationDate>2008-06-06T00:00:00</publicationDate>
    <publisher>NLH Kidney Diseases Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ PRESENTATION OF CKD,PROTEINURIA/ NEPHROTIC SYNDROME,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2008 National Knowledge Week on Proteinuria and eGFR - Proteinuria foreword&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=PGFNKWCONT" target="_blank"&gt;Link back to National Knowledge Week contents page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Proteinuria is the hallmark of Glomerular disease.&amp;nbsp; It is a risk factor for progression of kidney disease and an independent cardiovascular risk factor.&amp;nbsp; The level of proteinuria should be determined in any person considered at risk of, or with, kidney disease.&amp;nbsp; In the early stages of kidney disease, before there is evidence of reduced kidney function as measured by Glomerular filtration rate, proteinuria may be the only marker of kidney damage.&amp;nbsp; &lt;BR&gt;&lt;BR&gt;There has been much debate recently about the question – what is proteinuria? And what should we measure?&amp;nbsp; The answer may well be – it depends on the context!&amp;nbsp; Our evidence base is incomplete – previously kidney researchers have tended to measure proteinuria and diabetes researchers albuminuria.&amp;nbsp; They have studied different populations.&amp;nbsp; Community based epidemiological and intervention studies in the general population are relatively few.&amp;nbsp; It is not possible to precisely equate one level of albuminuria with an exact counterpart level of proteinuria. Does that matter?&amp;nbsp; Yes.&amp;nbsp; Is there anything we can do about it? Yes, research.&amp;nbsp; What should we do now – well, not stand still.&amp;nbsp; We do need a practical and usable definition.&amp;nbsp; Albuminuria because it is much more easy to define and standardise may offer advantages over proteinuria.&amp;nbsp; The National Institute for Clinical Excellence is considering this issue at the moment.&amp;nbsp; &lt;BR&gt;&lt;BR&gt;There is good evidence that whatever the disease, if there is a response to treatment, whatever that may be, in terms of proteinuria reduction then this confers benefit in terms of both cardiovascular and renal end points.&amp;nbsp; In diabetes there is a wealth of data and understanding of the implications of different levels of albuminuria and the relationship to the natural history of diabetic kidney disease.&amp;nbsp; The care and outcomes of people with diabetic nephropathy is now, as a result of that understanding and the systematic approach to chronic disease management, much better than in the 20th century.&lt;BR&gt;&lt;BR&gt;The lessons from diabetes tell us that not all individuals respond equally to rennin-angiotensin system blockade, or other interventions, thus response in terms of proteinuria reduction implies a modifiable disease or stage in a disease process.&amp;nbsp; Responsiveness identifies individuals that can obtain benefits.&amp;nbsp; We also need to study those that do not respond to see if we can isolate other factors that determine responsiveness and explore new “progression promoters” which might be amenable to other interventions or modifications.&amp;nbsp; Thus proteinuria reduction per se may not have a direct impact on disease progression but merely be a marker of underlying potential for reduction of end stage renal failure.&amp;nbsp; The possibility that proteinuria itself accelerates progression remains but is unproven in man.&amp;nbsp; This might explain the minimal change conundrum where heavy proteinuria does not seem to lead to kidney damage.&amp;nbsp; So the case for proteinuria as a bio marker is secure.&amp;nbsp; For practical and scientific reasons the case for it as a surrogate is also strong but perhaps more as a marker of a modifiable underlying disease or stage in a disease than as a definite cause of progression in its own right.&amp;nbsp; &lt;BR&gt;&lt;BR&gt;In the nephrotic syndrome where there is heavy proteinuria (greater than 3.5 grams for 24 hours), it assumes an even greater significance.&amp;nbsp; In these circumstances, whatever the underlying Glomerular lesion and pathology, proteinuria can be regarded as a disease surrogate.&amp;nbsp; Cure the proteinuria and the disease can be considered to be in remission.&amp;nbsp; Although individually primary Glomerular diseases are often considered rare, together they are responsible for over 35% cases of end stage renal failure accepted onto renal replacement therapy programmes in the United Kingdom and if we add in Diabetic Kidney Disease it is apparent that over 55% of people who need dialysis or kidney transplantation have proteinuric kidney disease as the cause of their kidney failure.&amp;nbsp; &lt;BR&gt;The growing understanding of the molecular biology of the glomerulus with the re-interpretation of the physiology and patho physiology of macromolecular handling via the kidney offers the prospect of new and innovative treatments targeted to the underlying molecular disturbance.&lt;BR&gt;&lt;BR&gt;I am delighted that the National Library is majoring on proteinuria for the first National Knowledge Week on Kidney Disease.&amp;nbsp; It is very fitting because proteinuria is the hallmark and major prognostic factor in kidney disease – and it’s modifiable!&amp;nbsp; This series is also very timely given the inclusion of proteinuria in the Quality and Outcomes Framework of the General Medical Services Contract with primary care.&amp;nbsp; Marker 5 in the Chronic Kidney Disease domain now reads “The percentage of patients on the CKD register with hypertension and proteinuria who are treated with an angiotensin converting enzyme inhibitor (ACE-I) or angiotensin receptor blocker (ARB) (unless a contraindication or side effects are recorded)”.&amp;nbsp; Marker 4, that previously required the use of rennin – angiotensin blockers didn’t specify the importance of proteinuria and has therefore been dropped from 1 April 2008.&amp;nbsp; The guidance is quite clear – have a look at the BMA website for all the details, it states “people with none diabetic Stage 3-5 CKD should have an annual test of proteinuria unless they have a previous diagnosis of proteinuria.&amp;nbsp; People with diabetes already have an annual – micro albuminuria test”.&amp;nbsp; This is preceded by a statement that a laboratory test is required for the diagnosis of proteinuria.&amp;nbsp; &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Please incorporate measurements of proteinuria into your systems of care for people at risk of or with kidney disease.&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>27/05/2010 09:54:15</lastReviewDate>
    <expiryDate>27/05/2011 09:54:15</expiryDate>
  </document>
  <document>
    <id>287747</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=287747]]&gt;</url>
    <title>2008 National Knowledge Week on Proteinuria and eGFR - Tubular toxicity of urinary protein</title>
    <publicationDate>2008-06-03T00:00:00</publicationDate>
    <publisher>NLH Kidney Diseases Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ PRESENTATION OF CKD,PROTEINURIA/ NEPHROTIC SYNDROME,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2008 National Knowledge Week on Proteinuria and eGFR - Tubular toxicity of urinary protein&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;1 b) Tubular toxicity of urinary protein&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;A really early and important question to try to answer is why is the presence of urinary protein harmful / injurious to the kidneys, at least under some circumstances? Celie and co-workers (Celie et al, 2008) postulated that as heparan sulfate proteoglycans (HSPGs) are well known for their proposed role in glomerular filtration, and that HSPGs can bind the leukocyte adhesion molecule l-selectin and chemokines, there may be a role for inflammation in proteinuria. They examined a panel of biopsies representing different human primary kidney diseases for l-selectin and monocyte chemoattractant protein-1 (MCP-1) binding. In various renal diseases, l-selectin and MCP-1 binding to interstitial perivascular matrix HSPGs is increased, which is significantly associated with leukocyte influx. In proteinuric diseases, including membranous glomerulopathy, minimal change disease, but also IgA nephropathy and lupus nephritis, increased binding of l-selectin and MCP-1 to tubular epithelial cell (TEC) HSPGs is observed, which colocalizes with increased basolateral syndecan-1 and anti-heparan sulfate 10E4 staining. Short-hairpin RNA-mediated silencing demonstrates that syndecan-1 on TECs indeed mediates l-Selectin binding. Increased TEC expression of IL-8 in biopsies of proteinuric patients suggests that the increase in luminal protein may activate TECs to increase expression of l-selectin and MCP-1 binding syndecan-1. Strikingly, urinary syndecan-1 from proteinuric patients is less capable of binding l-selectin compared with urinary syndecan-1 from healthy controls, although syndecan-1 concentrations are similar in both groups. Together, the data show pronounced tubulointerstitial HSPG alterations in primary kidney disease, which may affect the inflammatory response.&lt;BR&gt;&lt;BR&gt;Shalamanova et al (2007) determined the effects of human serum albumin (HSA) overload on the changes in gene and protein expression stimulated by oxidative stress in proximal tubular cells (PTC) and any interaction with ANG II that is pivotal in disease pathogenesis. Markers of oxidative stress, antioxidant defences, transcription factor activation, and the expression of stress-related genes were measured in human PTC (HK-2 cells) overloaded with either globulin-free fatty acid free (GF/FAF) HSA or globulin-free (GF) HSA. The effects of ANG II were also determined. HSA overload in HK-2 cells caused PTC hyperfunction, increased oxidative stress, and an upregulation of adaptive responses and stress-related genes. Some responses were common to both HSAs but others were unique to either HSA and unaffected by addition of ANG II or candesartan (a specific ANG II type 1 receptor blocker). ANG II also independently induced oxidative stress and upregulated other stress-related genes. HSA overload in HK-2 cells stimulated increased oxidative stress and upregulated changes in stress-related gene expression indicating new pathways of PTC injury that are not mediated via ANG II type 1 receptors.&lt;BR&gt;&lt;BR&gt;Abbate et al (2006) reviewed the many potential mechanisms that might link urinary protein to kidney damage – they cited evidence indicating that this process occurs through multiple pathways, including induction of tubular chemokine expression and complement activation that lead to inflammatory cell infiltration in the interstitium and sustained fibrogenesis, is reviewed. Macrophages are prominent in the interstitial inflammatory infiltrate. This cell type mediates progression of renal injury to the extent that macrophage numbers in renal biopsy predict renal survival in patients with chronic renal disease. Chemoattractants and adhesive molecules for inflammatory cells are upregulated by excess ultrafiltered protein load of proximal tubular cells via activation of NF-kappaB-dependent and NF-kappaB-independent pathways. This mechanism is a potential target for therapeutic approaches, as shown by beneficial effects of manipulations with inhibitory molecules of NF-kappaB activation or of chemokine receptors in experimental studies. Targeting complement synthesis or activation in proximal tubule might offer novel therapeutic opportunities. Finally, proximal tubular cell receptors for uptake of plasma proteins that are under investigation may provide activation signals on excess tubular protein handling&lt;BR&gt;&lt;BR&gt;Finally, Lai and co-workers (Lai et al, 2007) hypothesized an interaction between T cells/monocytes and the tubules in the development of tubulointerstitial injury in chronic proteinuric nephropathy. They established in vitro co-culture systems of proximal tubular epithelial cells (PTEC) and T cells/monocytes to study the contribution of soluble factors and cell-to-cell contact in the development of tubulointerstitial injury. The release of monocyte chemoattractant protein-1 (MCP1 or CCL2), Regulated upon Activation, normal T cell Expressed and Secreted (RANTES or CCL5), soluble intracellular adhesion molecules-1 (sICAM-1), or interleukin-6 (IL-6) was increased in PTEC following apical exposure to human serum albumin (HSA). The release of CCL2, CCL5, or sICAM-1 from PTEC was enhanced by contact of monocytes/T cells on the basolateral surface. Tumor necrosis factor-alpha (TNF-alpha) and IL-1beta are important soluble factors as suggested by the blocking effect of antibodies (Abs) against TNF-alpha or IL-1beta but not against other cytokines. The percentage of CD4+ T cells expressing both chemokine receptors, CCR2 and CCR5, was increased after culturing with supernatant from the apical or basolateral surface of PTEC following apical exposure to HSA. However, only CCR2 was upregulated in CD8+ T cells, whereas CCR5 expression was increased in monocytes. The chemotaxis of CD4+ or CD8+ T cells to supernatant from PTEC upon apical exposure to HSA was reduced with neutralizing Abs against CCL5 and/or CCL2, whereas the chemotaxis of monocytes was only reduced by anti-CCL5 but not by anti-CCL2. In summary, chemokines released by HSA-activated PTEC are amplified by monocytes/T cells. Mediators released by HSA-activated PTEC can differentially modulate the expression of chemokine receptors in monocytes/T cells and hence, alter their chemotaxis towards activated PTEC. These interactions are pivotal in the development of tubulointerstitial injury.&lt;BR&gt;&lt;BR&gt;This is an exciting and rapidly-developing area of kidney science; with luck and in time there may be new therapies for proteinuria and the downstream pathomechanisms which may significant retard progressive proteinuria-induced kidney fibrosis.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;1. Celie JW&lt;/STRONG&gt;, Reijmers RM, Slot EM, Beelen RH, Spaargaren M, Ter Wee PM, et al. Tubulointerstitial heparan sulfate proteoglycan changes in human renal diseases correlate with leukocyte influx and proteinuria. Am J Physiol Renal Physiol 2008 Jan;294(1):F253-F263. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=american%20journal%20of%20physiology%20renal%20physiology%5BJour%5D%20AND%202008%5Bpdat%5D%20AND%20Celie%5Bauthor%5D" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;2. Shalamanova L&lt;/STRONG&gt;, McArdle F, Amara A, B, Jackson M, J, et al. Albumin overload induces adaptive responses in human proximal tubular cells through oxidative stress but not via angiotensin II type 1 receptor. American Journal of Physiology - Renal Physiology 2007;292(6):F1846-F1857. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=american%20journal%20of%20physiology%20renal%20physiology%5BJour%5D%20AND%202007%5Bpdat%5D%20AND%20Shalamanova%5Bauthor%5D" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;3. Abbate M&lt;/STRONG&gt;, Zoja C, Remuzzi G. How does proteinuria cause progressive renal damage? Journal of the American Society of Nephrology 2006;17(11):2974-84. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=%22Journal%20of%20the%20American%20Society%20of%20Nephrology%20%3A%20JASN%22%5BJour%5D%20AND%202006%5Bpdat%5D%20AND%20Abbate%5Bauthor%5D%20AND%20proteinuria" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;4. Lai KN&lt;/STRONG&gt;, Leung JCK, Chan L, et al. Interaction between proximal tubular epithelial cells and infiltrating monocytes/T cells in the proteinuric state. Kidney International 2007;71(6):526-38. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Kidney%20international%5BJour%5D%20AND%202007%5Bpdat%5D%20AND%20Lai%5Bauthor%5D%20AND%20proximal%20tubular" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;A href="http://www.nice.org.uk/guidance/index.jsp?action=byID&amp;amp;o=11647" target="_blank"&gt;Link to 2008 NICE Chronic Kidney Disease guideline&lt;/A&gt;&lt;/STRONG&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=PGFNKWCONT" target="_blank"&gt;Link to National Knowledge Week contents page&lt;/A&gt;&lt;/STRONG&gt;&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>27/05/2010 09:54:20</lastReviewDate>
    <expiryDate>27/05/2011 09:54:20</expiryDate>
  </document>
  <document>
    <id>287757</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=287757]]&gt;</url>
    <title>2008 National Knowledge Week on Proteinuria and eGFR - Urinary proteomics</title>
    <publicationDate>2008-06-03T00:00:00</publicationDate>
    <publisher>NLH Kidney Diseases Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ PROTEINURIA/ NEPHROTIC SYNDROME,PRESENTATION OF CKD,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2008 National Knowledge Week on Proteinuria and eGFR - Urinary proteomics&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;1 c) Urinary proteomics&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Given the importance of urinary albumin excretion it may come as a shock and a surprise that urinary albumin is but one of a myriad urinary proteins, seen in both health and disease states. Are there novel or remarkable proteins, or patterns of protein excretion, which we could detect in urine, and by so doing, refine our diagnostic and predictive yields?&lt;BR&gt;&lt;BR&gt;Garabad Eknoyan (2007) has eloquently said that science of looking at the urine for diagnostic purposes, uroscopy, is as ancient as disease. Throughout history, urine, the first bodily fluid to be examined, has continuously and persistently provided medicine with an increasing body of knowledge about the workings of the inner body. For most of its history, uroscopy was a visual science; this focus peaked in the Middle Ages, when the vessel used to examine urine, the matula, became a symbol of the medical profession. Over time, the practice of uroscopy spread into the hands of quacks and apothecaries, who prescribed and sold their potions by merely looking at the urine. The consequent reformation measures of the 16th and 17th centuries coincided with the first attempts at analyzing the contents of urine. As a result, many of the chemical components now reported in metabolic profiles were first analyzed and identified in urine during the first half of the 18th century. In the process, what started as a science that bordered on divination laid the foundations of chemical analysis and spawned the disciplines of urology, endocrinology, and, after the use of urine in clearance studies, nephrology. The analytical methods and remarkable achievements of each of these disciplines have increased the value of examining urine. A renaissance of this oldest diagnostic tool of medicine is now under way in the proteomic profiling and detection of biomarkers in the urine, an approach which promises to further extend the merits of the unbroken tradition of looking at the urine.&lt;BR&gt;&lt;BR&gt;Urine represents a modified ultrafiltrate of plasma, with protein concentrations typically approximately 1000-fold lower than plasma. Urine's low protein concentration might suggest it to be a less promising diagnostic specimen than plasma. However, urine can be obtained noninvasively and tests of many urinary proteins are well-established in clinical practice. Proteomic technologies expand opportunities to analyze urinary proteins, identifying more than 1000 proteins and peptides in urine. Urine offers a sampling of most plasma proteins, with increased proportions of low-molecular-weight protein and peptide components. Urine also offers enriched sampling of proteins released along the urinary tract. Although urine presents some challenges as a diagnostic specimen, its diverse range of potential markers offers great potential for diagnosis of both systemic and kidney diseases. Examples of clinical situations where this may be of value are for more sensitive detection of kidney transplant rejection or of renal toxicity of medication.&lt;BR&gt;&lt;BR&gt;The majority of urine proteins appear as cleavage products that are found not only as free solutes but also in secreted membrane vesicles called exosomes. Several recent examples of important diagnostic findings using urine proteomics along with the idea that signature profiles of injury to individual nephron segments can be measured by this technology. Integration of seemingly unrelated findings of various protein fragments into a rational pathogenetic pathway(s) remains the most challenging step. The future chance that the centuries-old technique of uroscopy will reveal its secrets using modern proteomic approaches makes gradual improvement (Goligorsky et al, 2007)&lt;BR&gt;&lt;BR&gt;Rocchetti et al (2008) studied the urinary proteome of 18 IgAN patients (and 20 healthy controls) who had been chronically treated with ACEi by using 2-D PAGE coupled to nano-HPLC-ESI-MS/MS analysis. We identified 3 proteins, kininogen (p = 0.02), inter-alpha-trypsin- inhibitor heavy chain 4 (35 kDa fragment) (p = 0.02) and transthyretin (p&amp;lt;0.0001), whose urinary excretion was different in IgAN patients' responders when compared to those who had not responded to ACEi. A reduction of daily proteinuria &amp;gt;50% and a stable renal function over time were used to classify patients as responders. Then, we adopted immunoblotting to confirm the predictive power of one of the above proteins, kininogen, in 20 patients with biopsy-proven IgAN, before starting any therapy. Thus, we confirmed that very low levels of Kininogen urine excretion were indeed predictive of an inadequate or absent clinical response to ACEi therapy of IgAN patients, after 6-month follow-up.&lt;BR&gt;&lt;BR&gt;Urinary proteomics has been used in the detection of acute kidney injury (AKI) represents a common and devastating problem in clinical medicine. Despite significant improvements in therapeutics, the mortality and morbidity associated with AKI remain high. A major reason for this is the lack of early markers for AKI, and hence an unacceptable delay in initiating therapy. Fortunately, the application of&amp;nbsp; innovative technologies such as functional genomics and proteomics to human and animal models of&amp;nbsp; AKI has uncovered several novel biomarkers and therapeutic targets (Devarajan, 2007).These include the identification of biomarker panels in plasma (neutrophil gelatinase-associated lipocalin and cystatin C) and urine&amp;nbsp; (neutrophil gelatinase-associated lipocalin, kidney injury molecule-1, interleukin-18, cystatin C, alpha1-microglobulin, Fetuin-A, Gro-alpha, and meprin). It is likely that the AKI panels will be useful for timing the initial insult, and assessing the duration and severity of AKI. It is also probable that the AKI panels will distinguish between the various etiologies of AKI and predict clinical outcomes. It will be important in future studies to validate the sensitivity and specificity of these biomarker panels in clinical samples from large cohorts and from multiple clinical situations. Such studies will be facilitated markedly by the development of commercial tools for the reproducible measurement of biomarkers across different laboratories.&lt;BR&gt;&lt;BR&gt;In Diabetic nephropathy microalbuminuria is of course the conventional marker of the start of overt renal damage. However, newer evidence from urinary proteomics suggests that other urinary markers may complement this traditional approach and in time surpass it. Thus, Dihazi et al (5) reported on the identification of markers for prediction of the clinical course of diabetic nephropathy which remains a major challenge in disease management. They used SELDI-TOF mass spectrometry and SAX2 protein arrays to compare protein profiles from urine of 4 defined patient groups. Samples from patients with type 2 diabetes (DM; n = 45) without nephropathy and without microalbuminuria (DM-WNP), patients with DM with macro- or microalbuminuria (DM-NP; n = 38), patients with proteinuria due to nondiabetic renal disease (n = 34), and healthy controls (n = 45) were analyzed. Anionic exchange, reversed-phase fractionation, gel electrophoresis, and mass spectrometry were used to isolate and identify proteins with high discriminatory power. A protein with m/z 6188 (P &amp;lt;0.0000004) was strongly released in the urine of healthy controls, patients with proteinuria due to nondiabetic disease, and DM-WNP in contrast to DM-NP patients. An m/z 14 766 protein (P &amp;lt;0.00008) was selectively excreted in the urine of DM-NP patients, whereas the protein with m/z 11 774 (P &amp;lt;0.000004) was significantly excreted by patients with proteinuria and DM-NP. The m/z 11 774 and m/z 14 766 mass peaks were identified as beta(2)-microglobulin and UbA52, a ubiquitin ribosomal fusion protein, respectively. The protein with m/z 6188 was identified as a processed form of ubiquitin. The release of high amounts of UbA52 in urine of DM-NP patients could serve as a diagnostic marker, whereas the lack of the short form of ubiquitin raises interesting questions about the pathophysiology. &lt;BR&gt;&lt;BR&gt;Rao et al (2007) used proteomic analyses to identify novel biomarkers of nephropathy in urine from type 2 diabetic patients with demonstrated normo-, micro-, or macroalbuminuria. Samples were analyzed by fluorescence two-dimensional (2-D) differential in-gel electrophoresis (DIGE), and protein identification was performed by liquid chromatography-tandem mass spectrometry. 2-D DIGE analysis of the urinary proteome in diabetes with nephropathy identified 195 protein spots representing 62 unique proteins. These proteins belonged to several functional groups, i.e., cell development, cell organization, defense response, metabolism, and signal transduction. Comparisons between control and diabetic subjects with different stages of renal dysfunction revealed the differential expression of several proteins. Spot volume quantification identified 7 proteins that were progressively upregulated with increasing albuminuria and 4 proteins that exhibited progressive downregulation. The majority of these potential candidate biomarkers were glycoproteins. These data demonstrate the ability of proteomic analyses to reveal potential biomarkers for diabetic nephropathy in urine, an important step forward in advancing accurate diagnosis and our understanding of disease mechanisms.&lt;BR&gt;&lt;BR&gt;This is a revolutionary and exciting new field of scientific endeavour (see the accompanying editorial by Eddie O’Riordan. It is however at a very early stage technically, and many more large scale population based studies will be needed to understand just how well, at what stages, and in what disease states urinary proteomics will help us detect, diagnose and target therapies for patients with chronic kidney disease.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;1. Eknoyan G&lt;/STRONG&gt;. Looking at the urine: the renaissance of an unbroken tradition. Am J Kidney Dis 2007 Jun;49(6):865-72. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=%22American%20journal%20of%20kidney%20diseases%20%3A%20the%20official%20journal%20of%20the%20National%20Kidney%20Foundation%22%5BJour%5D%20AND%202007%5Bpdat%5D%20AND%20Eknoyan%5Bauthor%5D%20AND%20urine" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;2. Goligorsky MS&lt;/STRONG&gt;, Addabbo F, O'Riordan E. Diagnostic potential of urine proteome: a broken mirror of renal diseases. J Am Soc Nephrol 2007 Aug;18(8):2233-9. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=%22Journal%20of%20the%20American%20Society%20of%20Nephrology%20%3A%20JASN%22%5BJour%5D%20AND%202007%5Bpdat%5D%20AND%20Goligorsky%5Bauthor%5D%20AND%20urine%20proteome" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;3. Rocchetti MT&lt;/STRONG&gt;, Centra M, Papale M, Bortone G, Palermo C, et al. Urine protein profile of IgA nephropathy patients may predict the response to ACE-inhibitor therapy. Proteomics 2008;8(1):206-16. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=%22Proteomics%22%5BJour%5D%20AND%202008%5Bpdat%5D%20AND%20Rocchetti%5Bauthor%5D%20AND%20urine%20protein" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;4. Devarajan P&lt;/STRONG&gt;. Proteomics for biomarker discovery in acute kidney injury. Semin Nephrol 2007 Nov;27(6):637-51. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=%22Seminars%20in%20nephrology%22%5BJour%5D%20AND%202007%5Bpdat%5D%20AND%20Devarajan%5Bauthor%5D" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;5. Dihazi H&lt;/STRONG&gt;, Muller GA, Lindner S, Meyer M, Asif AR, Oellerich M, et al. Characterization of diabetic nephropathy by urinary proteomic analysis: identification of a processed ubiquitin form as a differentially excreted protein in diabetic nephropathy patients. Clin Chem 2007; 53(9):1636-45. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Dihazi%5Bauthor%5D%20AND%20diabetic%20nephropathy" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;6. Rao P&lt;/STRONG&gt;, V, Lu X, Standley M, Pattee P, Neelima G, et al. Proteomic identification of urinary biomarkers of diabetic nephropathy. Diabetes Care 2007;30(3):629-37. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=%22Diabetes%20care%22%5BJour%5D%20AND%202007%5Bpdat%5D%20AND%20Rao%5Bauthor%5D%20AND%20Proteomic%20identification" target="_blank"&gt;PubMed&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;A href="http://www.nice.org.uk/guidance/index.jsp?action=byID&amp;amp;o=11647" target="_blank"&gt;Link to 2008 NICE Chronic Kidney Disease guideline&lt;/A&gt;&lt;/STRONG&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=PGFNKWCONT" target="_blank"&gt;Link to National Knowledge Week contents page&lt;/A&gt;&lt;/STRONG&gt;&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>27/05/2010 09:54:25</lastReviewDate>
    <expiryDate>27/05/2011 09:54:25</expiryDate>
  </document>
  <document>
    <id>329860</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=329860]]&gt;</url>
    <title>2009 Annual Evidence Update on Post Transplant Lymphoproliferative Disorders in Renal Transplant patients - 1. Science</title>
    <publicationDate>2009-12-07T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ TRANSPLANTATION,PREVENTION OF COMPLICATIONS,IMMUNOSUPPRESSIVE DRUGS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;2&lt;/pageSequence&gt;&lt;pageTitle&gt;Science: Commentary by Ed Sharples&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A href="nelh:329868:0" name=internalLink&gt;&lt;STRONG&gt;Link to 2009 Annual Evidence Update on PTLD in Renal Transplant patients Contents page&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentary by Ed Sharples, Consultant in Nephrology and Transplant Medicine, Churchill Hospital, Oxford.&amp;nbsp; &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Science&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Biology of Post-Transplant Lymphoproliferative Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Although post-transplant lymphoproliferative disorders (PTLD) are histologically and clinically heterogeneous, there is strong evidence that Epstein-Barr virus (EBV) plays a critical role on the biology of the condition for the majority of cases (1). A revised classification was published in 2008 by the WHO and recommends classifications into 4 categories: [1] early lesions, [2] polymorphic PTLD, [3] monomorphic PTLD and [4] classic Hodgkin lymphoma-type PTLD (2). Despite this and earlier efforts to standardize the pathological classification of PTLD, neither histology nor clonality consistently predict outcome.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;EBV&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;EBV is a member of the gamma herpesvirus family. In vitro, all herpesviruses replicate in lymphoid cells and some are capable of lytic replication in epithelial cells and fibroblasts. Human herpesvirus-8 (HHV-8) is associated with Kaposi’s sarcoma. &lt;/P&gt;
&lt;P&gt;EBV infects the majority of the world’s population. Infection typically occurs in childhood, but if exposure is delayed until adolescence, infection can result in symptomatic infectious mononucleosis. Latent infection affecting primate B lymphocytes is characterised by the persistence of the viral genome, with expression of a restricted set of latent gene products which drive transformation and proliferation. The EBV genome consists of a linear, 172-kilobase pair, double-stranded DNA molecule. The characteristic features of the EBV genome include variable tandem repeats (3). When EBV infects a B lymphocyte, the linear viral genome becomes circular, and the virus persists within the cell as a epistome.&lt;/P&gt;
&lt;P&gt;The majority of people carry latent EBV without symptoms, but in a minority, latent infection is associated with Burkitt’s lymphoma, B-cell lymphoproliferative diseases, Hodgkin’s lymphoma and T-cell lymphomas. In latent infection, a set of nine viral genes known as “latency” genes are expressed (4). These include the Epstein-Barr nuclear antigens (EBNA1 to 6) and latent membrane proteins (LMP1, LMP2A, and LMP2B). These genes act to produce a “growth programme” that result in infected B cells escaping normal control mechanisms and proliferating in an autonomous fashion. Infected cells produce two polymerase III RNA transcripts known as EBER-1 and EBER-2, which can be used for detection of infected cells because of their large copy number. &lt;/P&gt;
&lt;P&gt;LMP1 is the major transforming protein of EBV; the expression of LMP1 affects B cell activation, with change in expression of CD23, CD39, CD40 and cell adhesion molecules. LMP1 also upregulates expression of anti-apoptotic proteins Bcl-2 and A20, and stimulates cytokine production (3).&lt;/P&gt;
&lt;P&gt;The EBV growth programme-driven B cell proliferation is polyclonal in nature. Immunocompetent individuals develop a cellular immune response to the virus-infected cells which are targeted by EBV-specific cytotoxic T-cells (CTLs). In solid organ recipients, the PTLD is derived from recipient cells, suggesting EBV reactivation. In the immunosuppressed transplant patient, where there is reduced cytotoxic T cell function, the EBV-proliferation can exceed the rate of clearance by the immune system. The risk of PTLD is associated with the degree of immunsuppression, so there is a higher incidence after lung or small bowel transplantation, as well as in EBV-naïve paediatric patients receiving an organ from an EBV-positive donor (5). Reduction in immunosuppression can lead to regression of PTLD due to restoration of cytotoxic T-cell function, and treatment with autologous EBV-specific CTLs can result in reduced viral counts and decreased tumour burden (6).&lt;/P&gt;
&lt;P&gt;PTLD lesions can be polyclonal, oligoclonal or monoclonal. Progression of initially polyclonal PTLD lesions to frank lymphoma is a complex process, and is not fully elucidated. In contrast to lymphomas presenting in immuncompetent individuals, stable cytogenetic abnormalities are rare in PTLD, although proliferating B cells can be identified by their molecular signature, with microsatellite instability due to DNA mismatcxh repair defects, C-myc, BCL-6 and p53 mutations, and DNA hypermethylation. Aberrent somatic mutations may also play a role, and have been identified in 30% monomorphic PTLD, mainly of diffuse large B-cell lymphoma type (7). &lt;/P&gt;
&lt;P&gt;The histogenesis of rare T-cell PTLD cases in which EBV infection leads to a T-cell proliferation and PTLD is unknown.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL dir=ltr style="MARGIN-RIGHT: 0px"&gt;
&lt;OL&gt;
&lt;LI&gt;Dolcetti R. B lymphocytes and Epstein-Barr virus: The lesson of post-transplant lymphoproliferative disorders. Autoimmun Rev. 2007;7(2):96-101. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18035317" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Swerdlow SH, Webber SA, Chadburn A, Ferry J. Post transplant lymphoproliferative disorders. In: Classification of Tumours of Haematopoieitc and lymphoid Tissues (4th Ed) Lyon, France: international agency for Research on Cancer; 2008.&amp;nbsp;pp342-349&lt;/LI&gt;
&lt;LI&gt;Cohen JI, Bollard C, Khanna R, Pittaluga S. Current understanding of the role of Epstein-Barr virus in lymphomagenesis and therapeutic approaches to EBV-associated lyphomas. Leuk Lymphoma 2008; &amp;nbsp;49 Suppl 1: 27- 34&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18821430" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Carbone A, Gloghini A, Dotti G. EBV-associated lymphoproliferative disorders: classification and treatment. Oncologist 2008; 13(5):577-85 [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/15877793" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Smith JM, Corey L, Headley PJ, Davis CL, McDonald Ra. Adolescents are more likely to develop post-transplant lymphoproliferative disorder after primary EBV infection than younger renal transplant patients. Transplantation 2007; 83(11):1423-1428&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17565314" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Comoli P, Maccario R, Locatelli F et al. Treatment of EBV-Related Post-Renal Transplant Lymphoproliferative Disease with a Tailored Regimen Including EBV-Specific T Cells. Am J Transplant 2005; 5: 1415-1422&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/15888049" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Capello D, Berra E, Cerri M, Gaidano G. Post-transplant lymphoproliferative disorders. Molecular analysis of histogenesis and pathogenesis. Minerva Med. 2004; 95(1):53-64. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15041926" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;&lt;/OL&gt;
&lt;P dir=ltr&gt;&lt;STRONG&gt;Additional reference&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Capello D, Berra E. ; Cerri M. ; Gaidano G. Post-transplant lymphoproliferative disorders: Molecular analysis of histogenesis and pathogenesis. Minerva Med. 2004; 95(1):53-64. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/15041926" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Monitoring of EBV viral load&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;There is a direct correlation between EBV proliferation and progression to PTLD. Several techniques including EBV seroconversion and limiting dilution assays have been used to try to determine the presence of EBV proliferation. Quantitative PCR is now used commonly to monitor EBV viral load. It is difficult to compare studies from different laboratories, which may use samples from different tissues, different processing of samples and the lack of a defined standard viral load measurement. The principle of routine monitoring is that it may allow early detection, and, potentially, lead to pre-emptive reduction in immunosuppression, or other management strategies. The strongest evidence for the use of routine monitoring comes from haemopoietic stem cell transplantation, and solid organ transplantation in children. Sato et al&amp;nbsp; quantified EBV loads every 1-3 months in 22 renal transplant recipients (1). The maximal DNA load was noted in patients whom developed PTLD, and this also correlated with a reduced anti-viral CTL response (1). Lee et al monitored EBV viral load in 73 paediatric liver transplant recipients, and noted a reduction in PTLD from 16 to 2% following pre-emptive reduction in immunosuppression in patients with high EBV viral load (&amp;gt;4000 copies/µg blood) (2). &lt;/P&gt;
&lt;P&gt;In adults, there is little published evidence. Whelass et al reported a retrospective study of 296 lung transplant patients (3). Of 13 patients who developed PTLD, 5 had positive EBV viral load, and no patient who has EBV DNA negative developed PTLD (3). Bakker et al reported 75 patients who received lung transplants and correlated rapid reduction in EBV DNA load with reduction in immunosuppression in patients with positive monitoring (4). Tsai et al performed EBV PCR panel measuring LMP-1, EBER-1 and EBNA-1 in both plasma and whole blood (5). The panel had high specificity (72%), sensitivivty (92%) and negative predictive value (93%) doe diagnosing EBV-positive PTLD.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Sato T, Fujieda M, Maeda A, Tanaka E, Miyamura M, Chikamoto H, Hisano M, Akioka Y, Ishiura Y, Dohno S, Hattori M, Wakiguchi H. Monitoring of Epstein-Barr virus load and killer T cells in pediatric renal transplant recipients. Clin Nephrol. 2008 ; 70(5):393-403.&amp;nbsp;&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19000539" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lee TC, Savoldo B, Barshes NR, Rooney CM, Heslop HE, Gee AP, Caldwell Y, Scott JD, Goss JA. Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients. Clin Transplant. 2006; 20(3):389-93.&amp;nbsp;&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16824159" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Wheless SA, Gulley ML, Raab-Traub N, McNeillie P, Neuringer IP, Ford HJ, Aris&amp;nbsp; RM. Post-transplantation lymphoproliferative disease: Epstein-Barr virus DNA levels, HLA-A3, and survival. Am J Respir Crit Care Med. 2008; 178(10):1060-5.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18755927" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Bakker, N. A., G. W. van Imhoff, et al. "Early onset post-transplant lymphoproliferative disease is associated with allograft localization." Clinical Transplantation 2005;&amp;nbsp;19(3): 327-334. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/15877793" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Tsai DE, Douglas L, Andreasdis C et al. EBV PCR in the diagnosis and monitoring of PTLD : results of a two arm prospective trial. Am J Transplant 2008, 8:1016&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18312608" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Additional references&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Bingler MA, Feingold B, Miller SA, Quivers E, Michaels MG, Green M, Wadowsky RM, Rowe DT, Webber SA. Chronic high Epstein-Barr viral load state and risk for late-onset posttransplant lymphoproliferative disease/lymphoma in children. Am J Transplant. 2008; 8(2):442-445&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18211510" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Holmes MV, Caplin B, Atkinson C, Smith C, Harber M, Sweny P, Haque T. Prospective monitoring of Epstein-Barr virus DNA in adult renal transplant recipients during the early posttransplant period: role of mycophenolate mofetil. Transplantation. 2009; 87(6):852-856.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19300188" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;EBV - Negative PTLD&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;In approximately 20% of PTLD cases the cells are EBV negative. The origin of these lesions is unclear, but there are marked clinical differences between EBV-positive and EBV-negative PTLD – the latter tend to present late after transplantation and are more likely to be monomorphic in nature. Whether these represent co-incidental development of a non-hogdkins lymphoma in an indivial is uncertain, and some EBV-negative PTLD may respond to a reduction in immunosuppression. PTLD has also been observed in association with other viral infections including hepatitis C (1).&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Zignego AL, Giannini C, et al. “Hepatitis C virus-related lymphoproliferative disorders: an overview”. World Journal of Gastroenterology 2007; 13 (17): 2467-2478.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17552031" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/OL&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;2&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Evidence&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;&lt;STRONG&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A href="nelh:329868:0" name=internalLink&gt;&lt;STRONG&gt;Link to 2009 Annual Evidence Update on PTLD in Renal Transplant patients Contents page&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Science references&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2004 &lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Capello D, Berra E, Cerri M, Gaidano G. Post-transplant lymphoproliferative disorders. Molecular analysis of histogenesis and pathogenesis. Minerva Med. 2004; 95(1):53-64. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/15041926" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Vossen, M. T. M., M. R. Gent, et al.&amp;nbsp; "Spontaneous outgrowth of EBV-transformed B-cells reflects EBV-specific immunity in vivo; a useful tool in the follow-up of EBV-driven immunoproliferative disorders in allograft recipients." Transplant International 2004; 17(2): 89-96. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/14652716" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;2005&lt;/STRONG&gt; &lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Baiocchi, O. C. G., G. W. B. Colleoni, et al. "Epstein-Barr viral load, interleukin-6 and interleukin-10 levels in post-transplant lymphoproliferative disease: A nested case-control study in a renal transplant cohort." Leukemia and Lymphoma 2005; 46(4): 533-539. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16019481" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;2006 &lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Okudaira, T., K. Yamamoto, et al. "Transactivation of CCL20 gene by Epstein-Barr virus latent membrane protein 1." British Journal of Haematology 2006;&amp;nbsp;132(3): 293-302. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16409294" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt; &lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Bergallo, M., C. Costa, et al. "Multiplex-nested RT-PCR to evaluate latent and lytic Epstein Barr virus gene expression." Journal of Biotechnology 2007;&amp;nbsp;128(3): 462-76. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17147963" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Dolcetti R. B lymphocytes and Epstein-Barr virus: The lesson of post-transplant lymphoproliferative disorders. Autoimmun Rev. 2007; 7(2):96-101. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18035317" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Zignego, A. L., C. Giannini, et al. "Hepatitis C virus-related lymphoproliferative disorders: an overview." World Journal of Gastroenterology 2007;&amp;nbsp;13(17): 2467-78. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17552031" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;2008 &lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Cohen JI, Bollard CM, Khanna R, Pittaluga S. Current understanding of the role of Epstein-Barr virus in lymphomagenesis and therapeutic approaches to EBV-associated lymphomas. Leuk Lymphoma. 2008; 49 Suppl 1:27-34.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18821430" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Sato, T., M. Fujieda, et al. "Monitoring of Epstein-Barr virus load and killer T cells in pediatric renal transplant recipients." Clinical Nephrology 2008; 70(5): 393-403. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19000539" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;&lt;EM&gt;No relevant references published.&lt;/EM&gt; &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>25/10/2010 13:46:42</lastReviewDate>
    <expiryDate>25/10/2011 13:46:42</expiryDate>
  </document>
  <document>
    <id>329863</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=329863]]&gt;</url>
    <title>2009 Annual Evidence Update on Post Transplant Lymphoproliferative Disorders in Renal Transplant patients - 2. Diagnosis and Surveillance</title>
    <publicationDate>2009-12-07T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ IMMUNOSUPPRESSIVE DRUGS,PREVENTION OF COMPLICATIONS,TRANSPLANTATION,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;2&lt;/pageSequence&gt;&lt;pageTitle&gt;Commentary&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;STRONG&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A href="nelh:329868:0" name=internalLink&gt;&lt;STRONG&gt;Link to 2009 Annual Evidence Update on PTLD in Renal Transplant patients Contents page&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;&lt;/STRONG&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Diagnosis and Surveillance - by Dr David Goldsmith, Consultant Nephrologist and Deputy Director of Research and Development, Member of the Faculty of Translational Medicine, Guy's and St Thomas' NHS Foundation Trust&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Clearly, accurate and timely diagnosis of PTLD is at a premium. Given the diverse clinical spectrum of patients receiving organ transplants, their often different immunosuppressive burdens, and clinical courses, it is difficult to generalise about diagnosis and surveillance. However, in the special situation of paediatric organ receipients, where EBV seronegativity is more common (as most adults by age 20 are seropositive), and therefore the norm is for EBV seropositive organs to be transplanted into seronegative recipients, there has always been the view that EBV surveillance would allow for accurate early PTLD detection.&lt;/P&gt;
&lt;P&gt;This is indeed what is often tried, but success is more variable. First, not all EBV leads to PTLD. Depending on many factors, EBV seroconversion illness can be transient and minor, or of moderate severity, or in rarer cases, a fulminant illness with a significant morbidity and mortality. Viral load alone is not a good predictor. This is what Baiocchi (1) points out. The type of host immune response, the extent of immunosuppression, and the development of virally targeted clones of cytotoxic T-cells (2), all play a crucial role in determining what happens. Vossen et al’s paper (3) demonstated a reciprocity between cytotoxic anti EBV effector T-cells and virally clonally expaneded B-lymphoctes. Kopf et al (4) also point out the importance of not over-reading the presence of EBV lest immunosuppression become too lightweight and rejection ensues. This is exactly what we see, and fear, in responding to other virally-driven challenges to transplantation such as BK nephropathy, and CMV. Lee’s paper from 2005 reports, with historical controls (and all the imbalances and biases that this type of approach brings) a marked drop in PTLD cases using EBV viral load monitoring (5). Guppy et al developed a quantitative assay for Epstein-Barr Virus-specific immunity and showed that interferon-gamma producing CD8+ T cells increased during immunosuppression reduction to treat posttransplant lymphoproliferative disease (6). Papers by Mendes (7), Sato (8), Toyoda (9), Tsai (10) and Holmes (11), and others, are in a similar vein. All of this sounds splendid news, but, quantifying the nature and degree of immunosuppression remains the holy grail of clinical organ transplantation, and it remains disappointing that we are as ever tantalisingly close to this much-needed advance.&lt;/P&gt;
&lt;P&gt;Because detecting the integration of EBV into the lymphocyte genome (evidenced by production of neo / viral antigens) is not as straightforward as it might seem, a lot of effort has been expended in attempting more precisely to characterise the host cell response. Bergallo et al (12) described the development of two multiplex-nested RT-PCR devised to evaluate latent/immortalizing (EBNA1, EBNA2, LMP1 and LMP2) and lytic [immediate early (Zebra), early, and late (VCA), respectively] Epstein Barr virus (EBV) transcripts. This needs prospective testing in a suitable population.&lt;/P&gt;
&lt;P&gt;Presentations of PTLD can be clinically very diverse indeed. Most PTLD is B-cell driven, and mostly arises from the small bowel (as so many B-lymphocytes reside there). Transplant organ-specific presentations are seen in liver, and kidney, disease, and Halkos et al (13) report that this can happen for thoracic transplantation too. CNS lymphoma, primary or generalised, always presents special diagnostic and therapeutic challenges, as described by Castellano-Sanchez et al (14), Brennan (15) and Buell (16).&lt;/P&gt;
&lt;P&gt;One of the many problems with this challenging area is the small case numbers, and small clinical series. The lack of evidence slows the development in therapy. It is good therefore to report the series by Caillard et al (17) where they report 230 cases from the French Registry. All adult kidney recipients developing PTLD between January 1, 1998, and December 31, 2003 were prospectively enrolled. 230 cases of PTLD were referred to the French Registry. Cumulative incidence was 1.18% after 5 years. Older age (per year, AHR = 2.19, CI = 1.22-3.94) and recipient Epstein-Barr virus seronegativity (AHR = 3.01, CI = 1.57-5.08) were associated with an increased risk of PTLD. Patients with PTLD had a reduced survival rate (61% at 5 years). Graft PTLD had the best prognosis with an 81% survival rate after 5 years. Infection with hepatitis C or B virus (HCV or HBV), late-onset PTLD, multiple sites involvement and high Ann Arbor staging were risk factors for patient death. Use of azathioprine was associated with a poorer survival rate.&lt;/P&gt;
&lt;P&gt;One challenging question with PTLD patients who might have survived, but perhaps in the context of their illness, or later, lost their allograft – and then, should the patient be retransplanted becomes the critical problem to debate. Johnson et al (18) have examined this area, using the OPTN/UNOS database. Sixty-nine retransplants were identified - 27 kidney, 22 liver, 9 lung, 6 heart, 4 intestine and 1 pancreas. At first transplant, most subjects (63.8%) were &amp;lt;17 years of age and was similar at retransplant with 50.7% less than 17 years. Time from transplant to PTLD was &amp;lt;1 year in 33.3%, 1-3 years in 21.7%, 3-5 years in 21.7%, 5-10 years in 21.7% and &amp;gt;10 years in 1.4%. Time from PTLD to retransplant was &amp;lt;1 year in 24.6%, 1-3 years in 37.7%, 3-5 years in 17.4% and 5-10 years in 20.3%. Induction agents were used in 21.7% of first and 47.8% of retransplants. Immunosuppression for first transplant was cyclosporine (CSA) in 55.1%, tacrolimus (TAC) in 27.5% versus CSA in 26.1%, TAC in 66.7% of retransplants. At last follow-up, patient and graft survival are 85.5% and 73.9%, respectively. Most subjects retransplanted after PTLD are &amp;lt;17 years on TAC-based immunosuppression. Patient/graft survival was excellent and retransplantation in PTLD subjects should be considered acceptable, and surely is preferable to be attempted, than a lingering death on dialysis.&lt;/P&gt;
&lt;P&gt;FDG-PET scanning is a tremendous advance both for diagnosis, tumour burden quantification, evaluating the response to therapy, and prognosis, and O’Conner (19) and Juweid (20) provide good evidence of the utility of a PET-CT based PTLD therapy approach.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Baiocchi, O. C. G., G. W. B. Colleoni, et al. "Quantification of Epstein-Barr viral load and determination of a cut-off value to predict the risk of post-transplant lymphoproliferative disease in a renal transplant cohort." Haematologica 2004;&amp;nbsp;89(3): 366-368. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/15020282" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Baudouin, V., A. Dehee, et al. "Relationship between CD8+ T-cell phenotype and function, Epstein-Barr virus load, and clinical outcome in pediatric renal transplant recipients: A prospective study." Transplantation 2004; 77(11): 1706-1713. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/15201670" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Vossen, M. T. M., M. R. Gent, et al. "Spontaneous outgrowth of EBV-transformed B-cells reflects EBV-specific immunity in vivo; a useful tool in the follow-up of EBV-driven immunoproliferative disorders in allograft recipients." Transplant International 2004; 17(2): 89-96. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/14652716" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kopf, S. and B. Tonshoff "Surveillance of Epstein-Barr virus infection as a risk factor for post-transplant lymphoproliferative disorder in pediatric renal transplant recipients." Pediatric Nephrology 2004; &amp;nbsp;19(4): 365-8. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/14963763" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lee TC, Savoldo B, Rooney CM, Heslop HE, Gee AP, Caldwell Y. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant.&amp;nbsp;2005;5(9):2222-8. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16095501" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Guppy, A. E., E. Rawlings, et al. "A quantitative assay for Epstein-Barr Virus-specific immunity shows interferon-gamma producing CD8+ T cells increase during immunosuppression reduction to treat posttransplant lymphoproliferative disease." Transplantation 2007;&amp;nbsp;84(11): 1534-9. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18091531" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mendes, T. M., L. C. Oliveira, et al. "Epstein-Barr virus nuclear antigen-2 detection and typing in immunocompromised children correlated with lymphoproliferative disorder biopsy findings." Brazilian Journal of Infectious Diseases 2008; 12(3): 186-91. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18833401" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Sato, T., M. Fujieda, et al. "Monitoring of Epstein-Barr virus load and killer T cells in pediatric renal transplant recipients." Clinical Nephrology 2008; 70(5): 393-403. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19000539" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Toyoda, M., A. Moudgil, et al.&amp;nbsp; "Clinical significance of peripheral blood Epstein-Barr viral load monitoring using polymerase chain reaction in renal transplant recipients." Pediatric Transplantation 2008; 12(7): 778-84. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18331541" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Tsai, DE, Douglas, L, Andreadis, C, et al. EBV PCR in the diagnosis and monitoring of posttransplant lymphoproliferative disorder: results of a two-arm prospective trial. Am J Transplant 2008; 8:1016. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18312608" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Holmes, M. V., B. Caplin, et al. "Prospective monitoring of Epstein-Barr virus DNA in adult renal transplant recipients during the early posttransplant period: role of mycophenolate mofetil." Transplantation 2009; 87(6): 852-6. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19300188" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Bergallo, M., C. Costa, et al. "Multiplex-nested RT-PCR to evaluate latent and lytic Epstein Barr virus gene expression." Journal of Biotechnology 2007;&amp;nbsp;128(3): 462-76. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17147963" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Halkos, M. E., J. I. Miller, et al. "Thoracic presentations of posttransplant lymphoproliferative disorders." Chest 2004;&amp;nbsp;126(6): 2013-2020. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/15596707" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Castellano-Sanchez, A. A., S. Li, et al. "Primary Central Nervous System Posttransplant Lymphoproliferative Disorders." American Journal of Clinical Pathology 2004; 121(2): 246-253. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/14983939" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Brennan, K. C., L. H. Lowe, et al. "Pediatric central nervous system posttransplant lymphoproliferative disorder." American Journal of Neuroradiology 2005; 26(7): 1695-1697. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16091516" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Buell, J. F., T. G. Gross, et al. "Posttransplant lymphoproliferative disorder: Significance of central nervous system involvement." Transplantation Proceedings 2005; 37(2): 954-955. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/15848587" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Caillard, S., C. Lelong, et al. "Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: report of 230 cases from the French Registry." American Journal of Transplantation 2006; 6(11): 2735-42. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17049061" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Johnson, S. R., W. S. Cherikh, et al. "Retransplantation after post-transplant lymphoproliferative disorders: an OPTN/UNOS database analysis." American Journal of Transplantation 2006; 6(11): 2743-9. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17049062" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;O'Conner, A. R. and B. L. Franc&amp;nbsp;"FDG PET imaging in the evaluation of post-transplant lymphoproliferative disorder following renal transplantation." Nuclear Medicine Communications 2005; 26(12): 1107-1111. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16264358" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Juweid, M.E., Stroobants, S., Hoekstra, O.S., Mottaghy, F.M., Dietlein, M., Guermazi, A., Wiseman, G.A., Kostakoglu, L., Scheidhauer, K., Buck, A., Naumann, R., Spaepen, K., Hicks, R.J., Weber, W.A., Reske, S.N., Schwaiger, M., Schwartz, L.H., Zijlstra, J.M., Siegel, B.A. &amp;amp; Cheson, B.D.&amp;nbsp;Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007; 25, 571-578. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17242397" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;2&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Evidence&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:329868:0" name=internalLink&gt;&lt;STRONG&gt;Link to 2009 Annual Evidence Update on PTLD in Renal Transplant patients Contents page&lt;/STRONG&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;&lt;/STRONG&gt;
&lt;P&gt;&lt;STRONG&gt;2004&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Babel, N., F. Schwarzmann, et al.&amp;nbsp;"Monoclonal gammopathy of undetermined significance (MGUS) is associated with an increased frequency of Epstein-Barr Virus (EBV) latently infected B lymphocytes in long-term renal transplant patients." Transplantation Proceedings 2004; 36(9): 2679-2682.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/15621122" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Baiocchi, O. C. G., G. W. B. Colleoni, et al.&amp;nbsp;"Quantification of Epstein-Barr viral load and determination of a cut-off value to predict the risk of post-transplant lymphoproliferative disease in a renal transplant cohort." Haematologica 2004;&amp;nbsp;89(3): 366-368.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/15020282" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Baudouin, V., A. Dehee, et al.&amp;nbsp;"Relationship between CD8+ T-cell phenotype and function, Epstein-Barr virus load, and clinical outcome in pediatric renal transplant recipients: A prospective study." Transplantation 2004;&amp;nbsp;77(11): 1706-1713.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/15201670" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Castellano-Sanchez, A. A., S. Li, et al.&amp;nbsp;"Primary Central Nervous System Posttransplant Lymphoproliferative Disorders." American Journal of Clinical Pathology 2004; 121(2): 246-253.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/14983939" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Cosio, F. G., M. Nuovo, et al.&amp;nbsp;"EBV Kidney Allograft Infection: Possible Relationship with a Peri-Graft Localization of PTLD." American Journal of Transplantation 2004; 4(1): 116-123.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/14678042" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Coyne, J. D., S. S. Banerjee, et al.&amp;nbsp;"Post-transplant T-cell lymphoproliferative disorder/T-cell lymphoma: A report of three cases of T-anaplastic large-cell lymphoma with cutaneous presentation and a review of the literature." Histopathology 2004; 44(4): 387-393.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/15049906" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Halkos, M. E., J. I. Miller, et al.&amp;nbsp;"Thoracic presentations of posttransplant lymphoproliferative disorders." Chest 2004; 126(6): 2013-2020.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/15596707" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kopf, S. and B. Tonshoff&amp;nbsp;"Surveillance of Epstein-Barr virus infection as a risk factor for post-transplant lymphoproliferative disorder in pediatric renal transplant recipients." Pediatric Nephrology 2004; 19(4): 365-8. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/14963763" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Leung, E., B. K. Shenton, et al.&amp;nbsp;"Dynamic EBV gene loads in renal, hepatic, and cardiothoracic transplant recipients as determined by real-time PCR light cycler." Transplant Infectious Disease 2004; 6(4): 156-164. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/15762933" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Shroff, R. and L. Rees&amp;nbsp;"The post-transplant lymphoproliferative disorder - A literature review." Pediatric Nephrology 2004; 19(4): 369-377.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/14986084" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Vossen, M. T. M., M. R. Gent, et al.&amp;nbsp;"Spontaneous outgrowth of EBV-transformed B-cells reflects EBV-specific immunity in vivo; a useful tool in the follow-up of EBV-driven immunoproliferative disorders in allograft recipients." Transplant International 2004; 17(2): 89-96. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/14652716" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;2005&lt;/STRONG&gt; &lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Babel, N., L. Gabdrakhmanova, et al.&amp;nbsp;"Induction of pre-transplant Epstein-Barr virus (EBV) infection by donor blood transfusion in EBV-seronegative recipients may reduce risk of post-transplant lymphoproliferative disease in adolescent renal transplant patients: Report of two cases." Transplant Infectious Disease 2005; 7(3-4): 133-136.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16390402" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Baiocchi, O. C. G., G. W. B. Colleoni, et al.&amp;nbsp;"Epstein-Barr viral load, interleukin-6 and interleukin-10 levels in post-transplant lymphoproliferative disease: A nested case-control study in a renal transplant cohort." Leukemia and Lymphoma 2005; 46(4): 533-539. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16019481" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Bakker, N. A., G. W. van Imhoff, et al.&amp;nbsp;"Early onset post-transplant lymphoproliferative disease is associated with allograft localization." Clinical Transplantation 2005; 19(3): 327-334.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/15877793" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Bakker, N. A., G. W. Van Imhoff, et al.&amp;nbsp;"HLA antigens and post renal transplant lymphoproliferative disease: HLA-B matching is critical." Transplantation 2005; 80(5): 595-599.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16177631" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Brennan, K. C., L. H. Lowe, et al.&amp;nbsp;"Pediatric central nervous system posttransplant lymphoproliferative disorder." American Journal of Neuroradiology 2005; 26(7): 1695-1697.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16091516" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Buell, J. F., T. G. Gross, et al.&amp;nbsp;"Posttransplant lymphoproliferative disorder: Significance of central nervous system involvement." Transplantation Proceedings 2005; 37(2): 954-955.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/15848587" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Caillard, S., V. Dharnidharka, et al.&amp;nbsp;"Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression." Transplantation 2005; 80(9): 1233-1243.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16314791" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Caillard, S., E. Pencreach, et al.&amp;nbsp;"Simultaneous development of lymphoma in recipients of renal transplants from a single donor: Donor origin confirmed by human leukocyte antigen staining and microsatellite analysis." Transplantation 2005; 79(1): 79-84.&amp;nbsp;&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/15714173" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Funch, D. P., H. H. Ko, et al.&amp;nbsp;"Posttransplant lymphoproliferative disorder among renal transplant patients in relation to the use of mycophenolate mofetil." Transplantation 2005; 80(9): 1174-80.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16314782" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lee TC, Savoldo B, Rooney CM, Heslop HE, Gee AP, Caldwell Y. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant.&amp;nbsp;2005;5(9):2222-8. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16095501" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;O'Conner, A. R. and B. L. Franc "FDG PET imaging in the evaluation of post-transplant lymphoproliferative disorder following renal transplantation." Nuclear Medicine Communications 2005; 26(12): 1107-1111.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16264358" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Paraskevas, S., J. E. Coad, et al.&amp;nbsp;"Posttransplant lymphoproliferative disorder in pancreas transplantation: A single-center experience." Transplantation 2005; 80(5): 613-622.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16177635" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Wilde, G. E., D. J. Moore, et al. "Posttransplantation lymphoproliferative disorder in pediatric recipients of solid organ transplants: Timing and location of disease." American Journal of Roentgenology 2005; 185(5): 1335-1341.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16247159" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2006 &lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Burra, P., A. Buda, et al.&amp;nbsp; "Occurrence of post-transplant lymphoproliferative disorders among over thousand adult recipients: Any role for hepatitis C infection?" European Journal of Gastroenterology and Hepatology 2006; 18(10): 1065-1070.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16957512" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Caillard, S., C. Lelong, et al.&amp;nbsp;"Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: report of 230 cases from the French Registry." American Journal of Transplantation 2006; 6(11): 2735-42.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17049061" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Johnson, S. R., W. S. Cherikh, et al. "Retransplantation after post-transplant lymphoproliferative disorders: an OPTN/UNOS database analysis." American Journal of Transplantation 2006;&amp;nbsp;6(11): 2743-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17049062" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mourad, W. A., A. Tulabah, et al.&amp;nbsp;"The impact of the World Health Organization classification and clonality assessment of posttransplant lymphoproliferative disorders on disease management." Archives of Pathology &amp;amp; Laboratory Medicine 2006;&amp;nbsp;130(11): 1649-53.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17076526" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Ravat, F. E., M. F. Spittle, et al.&amp;nbsp;"Primary cutaneous T-cell lymphoma occurring after organ transplantation." Journal of the American Academy of Dermatology 2006; 54(4): 668-75.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16546591" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Smith, JM, Rudser, K, Gillen, D, et al. Risk of lymphoma after renal transplantation varies with time: an analysis of the United States Renal Data System. Transplantation 2006; 81:175.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16436959" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Trappe, R., S. Oertel, et al. "HIV associated and post-transplantation lymphomas." Onkologe 2006; 12(7): 641-650.&amp;nbsp;[No PubMed abstract]&lt;/LI&gt;
&lt;LI&gt;Traum, A. Z., N. M. Rodig, et al.&amp;nbsp;"Central nervous system lymphoproliferative disorder in pediatric kidney transplant recipients." Pediatric Transplantation 2006; 10(4): 505-512.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16712612" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2007 &lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Bergallo, M., C. Costa, et al.&amp;nbsp;"Multiplex-nested RT-PCR to evaluate latent and lytic Epstein Barr virus gene expression." Journal of Biotechnology 2007; 128(3): 462-76. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17147963" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Dolcetti R. B lymphocytes and Epstein-Barr virus: The lesson of post-transplant lymphoproliferative disorders. Autoimmun Rev.&amp;nbsp;2007; 7(2):96-101. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18035317" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Guppy, A. E., E. Rawlings, et al.&amp;nbsp;"A quantitative assay for Epstein-Barr Virus-specific immunity shows interferon-gamma producing CD8+ T cells increase during immunosuppression reduction to treat posttransplant lymphoproliferative disease." Transplantation 2007; 84(11): 1534-9. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18091531" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Li, L., A. Chaudhuri, et al.&amp;nbsp;"Subclinical cytomegalovirus and Epstein-Barr virus viremia are associated with adverse outcomes in pediatric renal transplantation." Pediatric Transplantation 2007; 11(2): 187-195.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17300499" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Juweid, M.E., Stroobants, S., Hoekstra, O.S., Mottaghy, F.M., Dietlein, M., Guermazi, A., Wiseman, G.A., Kostakoglu, L., Scheidhauer, K., Buck, A., Naumann, R., Spaepen, K., Hicks, R.J., Weber, W.A., Reske, S.N., Schwaiger, M., Schwartz, L.H., Zijlstra, J.M., Siegel, B.A. &amp;amp; Cheson, B.D.&amp;nbsp;"Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma." 2007;&amp;nbsp;J Clin Oncol, 25, 571-578. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17242397" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kirk, A. D., W. S. Cherikh, et al.&amp;nbsp;"Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab." American Journal of Transplantation 2007; 7(11): 2619-25.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17868060" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Maecker, B., T. Jack, et al. "CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation." Journal of Clinical Oncology 2007; 25(31): 4902-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17971586" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Opelz, G., V. Daniel, et al. "Effect of cytomegalovirus prophylaxis with immunoglobulin or with antiviral drugs on post-transplant non-Hodgkin lymphoma: a multicentre retrospective analysis." Lancet Oncology 2007;&amp;nbsp;8(3): 212-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17329191" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;
&lt;P&gt;Saadat, A., B. Einollahi, et al. "Posttransplantation lymphoproliferative disorders in renal transplant recipients: report of over 20 years of experience." Transplantation Proceedings 2007; 39(4): 1071-3.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17524894" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/P&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008 &lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Abderrahim, E., A. Harzallah, et al.&amp;nbsp;"[Lymphoproliferative disorders in kidney transplant recipients: incidence, clinical characteristics and outcome]. [French] Syndromes lymphoproliferatifs apres transplantation renale: incidence et particularites cliniques et evolutives." Revue de Medecine Interne 2008; 29(7): 535-40. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18262684" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Aversa, S. M. L., S. Stragliotto, et al.&amp;nbsp;"Post-Transplant Lymphoproliferative Disorders after Heart or Kidney Transplantation at a Single Centre: Presentation and Response to Treatment." Acta Haematologica 2008; 120(1): 36-46. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18797163" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mendes, T. M., L. C. Oliveira, et al.&amp;nbsp;"Epstein-Barr virus nuclear antigen-2 detection and typing in immunocompromised children correlated with lymphoproliferative disorder biopsy findings." Brazilian Journal of Infectious Diseases 2008; 12(3): 186-91. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18833401" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Sato, T., M. Fujieda, et al.&amp;nbsp;"Monitoring of Epstein-Barr virus load and killer T cells in pediatric renal transplant recipients." Clinical Nephrology 2008; 70(5): 393-403. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19000539" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Toyoda, M., A. Moudgil, et al.&amp;nbsp;"Clinical significance of peripheral blood Epstein-Barr viral load monitoring using polymerase chain reaction in renal transplant recipients." Pediatric Transplantation 2008; 12(7): 778-84. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18331541" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Tsai, DE, Douglas, L, Andreadis, C, et al. "EBV PCR in the diagnosis and monitoring of posttransplant lymphoproliferative disorder: results of a two-arm prospective trial." Am J Transplant 2008; 8:1016. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18312608" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;2009 &lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Holmes, M. V., B. Caplin, et al. "Prospective monitoring of Epstein-Barr virus DNA in adult renal transplant recipients during the early posttransplant period: role of mycophenolate mofetil." Transplantation 2009; 87(6): 852-6. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19300188" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Issa, N., H. Amer, et al. "Posttransplant lymphoproliferative disorder following pancreas transplantation." American Journal of Transplantation 2009; 9(8): 1894-1902. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19519812" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Nabors, L. B., C. A. Palmer, et al.&amp;nbsp;"Isolated central nervous system posttransplant lymphoproliferative disorder treated with high-dose intravenous methotrexate." American Journal of Transplantation 2009; 9(5): 1243-8. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19422350" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>25/10/2010 13:46:46</lastReviewDate>
    <expiryDate>25/10/2011 13:46:46</expiryDate>
  </document>
  <document>
    <id>329866</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=329866]]&gt;</url>
    <title>2009 Annual Evidence Update on Post Transplant Lymphoproliferative Disorders in Renal Transplant patients - 3. Treatment and Management</title>
    <publicationDate>2009-12-07T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ TRANSPLANTATION,PREVENTION OF COMPLICATIONS,IMMUNOSUPPRESSIVE DRUGS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;2&lt;/pageSequence&gt;&lt;pageTitle&gt;Commentary&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;STRONG&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A href="nelh:329868:0" name=internalLink&gt;&lt;STRONG&gt;Link to 2009 Annual Evidence Update on PTLD in Renal Transplant patients Contents page&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;&lt;/STRONG&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentary by Ed Sharples, Consultant in Nephrology and Transplant Medicine, Churchill Hospital, Oxford. &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Treatment and Management&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The optimal treatment of post-transplant lymphoproliferative disease (PTLD) is not clearly defined due to the heterogenity of the condition, and a lack of randomised controlled trials. The majority of published data on treatment options is in the form of moderately sized case series, which should be interpreted with caution due to risks of selection bias and publication bias. &lt;/P&gt;
&lt;P&gt;The recently published guidelines from the British Transplant Society and the Committee for Haematological malignancies (1) identify the goal of treatment to be a complete and durable remission, with retention of the transplanted organ function with minimal toxicity. This will represent a clinical challenge that can only be met with a combined approach from transplant physicians, haemato-oncologists and surgeons.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Reference&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;British Committee for Standards in Haematology "Guidelines on the Surveillance, Diagnosis and Management of Post-Transplant Lymphoproliferative Disorders in Adult Solid Organ Transplant Recipients." British Journal of Haematology 2008; 147, 22–42. &lt;A href="nelh:322242:0" name=internalLink&gt;Link to guidelines&lt;/A&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Manipulation of Immunosuppression&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;Immunosuppression reduction is an essential step in the management of PTLD, allowing restoration of the EBV-specific CTL response. In some patients, stepwise reduction in the level of immunosuppression will be effective and adequate to induce complete and sustained clinical remission. Tsai et al reported a 63 % response to IS reduction alone in 30 patients, with a median time to response 3.4 weeks (1). The study identified risk factors that were associated with poor response, including multiorgan involvement, raised serum lactate dehydrogenase (LDH) and organ dysfunction. Patients without these risk factors had a 90% response rate to IS reduction alone. In comparison, Swinnen et al used a management algorithm commencing with IS reduction, with progression to interferon therapy and then chemotherapy in non-responders (2). Of 16 patients, only 1 had a partial response to IS reduction alone, and the majority progressed through the protocol to chemotherapy.&lt;/P&gt;
&lt;P&gt;There are European guidelines for the reduction of immunosuppression in first line PTLD management (3). The recent BTS guidelines recommend cessation of myelosuppressive agents such as azathioprine and mycophenolate mofetil, with stepwise reduction of dose of Calcineurin inhibitors (4). Patients require close monitoring of organ dysfunction, and response to therapy. A response to IS reduction is usually seen within 2-4 weeks. &lt;/P&gt;
&lt;P&gt;In addition, the development of an appropriate cytotoxic T-cell response to EBV can be measured by assessing T-cell activation antigens (MHC Class II expression on cytotoxic T cells) or EBV-specific CTL (5).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Tsai DE, Hardy CL, Tomaszewski JE, Kotloff RM, Oltoff KM, Somer BG, Schuster SJ, Porter DL, Montone KT, Stadtmauer EA. "Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients." Transplantation 2001; 71(8):1076-88. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/11374406" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Swinnen, L. J., M. LeBlanc, et al.&amp;nbsp;"Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder." Transplantation 2008;&amp;nbsp;86(2): 215-22.[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18645482" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;EBPG Expert Group on Renal Transplantation. "European Best Practice Guidelines for Renal Transplantation (Part 1)." Nephrol Dialysis Transplantation 2000; 15 Suppl 7:1-85. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11286185" target="_blank"&gt;Link to PubMed&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;British Committee for Standards in Haematology. "Guidelines on the Surveillance, Diagnosis and Management of Post-Transplant Lymphoproliferative Disorders in Adult Solid Organ Transplant Recipients." British Journal of Haematology 2008; 147, 22–42. [&lt;A href="nelh:322242:0" name=internalLink&gt;Link to guidelines&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Guppy AE, Rawlings E, Madigral JA, Amlot P, Barber L. "A quantitative assay for Epstein-Barr Virus-specific immunity shows interferon gamma producing CD8+ T cells increase during immunosuppression reduction to treat posttransplant lymphoproliferative disease." Transplantation 2007; 77, 431-437 [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18091531" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Rituximab&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Rituximab is a monoclonal antibody directed against CD20, an antigen expressed on the surface of mature and developing B lymphocytes, but not plasma cells. Rituxiamb has been shown to have a significant response and survival benefit in large RCTs setting in Large B cell lypmphomas, and in other types of NHL, when combined with standard chemotherapy.&lt;/P&gt;
&lt;P&gt;Several case series and phase 2 trials have shown response in patients with PTLD (1, 2, 3). As in the case of NHL, monotherapy with rituximab is not associated with a sustained response, and patients required further chemotherapy. Blaes et al treated eleven patients with PTLD, who were CD20 positive, received an intravenous dose of rituximab, 375 mg/m2, weekly for 4 doses, repeated every 6 months for 2 years in responding patients (1). The overall response rate was 64%, with 6 complete responses (CR), 1 partial response, 2 cases of progressive disease, and 2 deaths. Treatment with rituximab has been associated with bowel perforation in patients with gastrointestinal PTLD – although this may represent worsening of the underlying malignant process, or loss in integrity of the bowel wall after rapid response to intensive therapy (4)&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Blaes, A. H., B. A. Peterson, et al.&amp;nbsp;"Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: Results of a phase II trial." Cancer 2005; 104(8): 1661-1667.[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16149091" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Choquet, S, Leblond, V, Herbrecht, R, et al. "Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study." Blood 2006; 107:3053. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16254143" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Oertel SH, Verschuuren E, Reinke P, Zeidler K, Papp-Vary M, Babel N et al. "Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD)." Am J Transplant. 2005; 5(12):2901-6. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16303003" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hsu YC, Liao WC, Wang HP, Yao M, Lin JT. "Catastrophic gastrointestinal manifestations of post-transplant lymphoproliferative disorder." Dig Liver Dis. 2007 [Epub ahead of print] [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18083078" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Additional references&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Trappe, RU, Choquet, S, Reinke, P, et al. "Salvage Therapy for Relapsed Posttransplant Lymphoproliferative Disorders (PTLD) With a Second Progression of PTLD After Upfront Chemotherapy: The Role of Single-Agent Rituximab." Transplantation 2007; 84:1708.[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18165786" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Ghobrial I, Habermann T, Ristow K, et al. "Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era." Leuk Lymphoma.&amp;nbsp;2005; 46(2):191-6.[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/15621801" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;González-Barca E, Domingo-Domenech E, Capote FJ, Gómez-Codina J, Salar A, Bailen A. "Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease." Haematologica.&amp;nbsp;2007; 92(11):1489-94. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18024397" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Elstrom, RL, Andreadis, C, Aqui, NA, et al. "Treatment of PTLD with rituximab or chemotherapy." Am J Transplant 2006; 6:569.[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16468968" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Gross, T.G., Bucuvalas, J.C., Park, J.R., Greiner, T.C., Hinrich, S.H., Kaufman, S.S., Langnas, A.N., McDonald, R.A., Ryckman, F.C., Shaw, B.W., Sudan, D.L. &amp;amp; Lynch, J.C. "Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation." J Clin Oncol. 2005;&amp;nbsp;23, 6481-6488. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16170157?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&amp;amp;ordinalpos=1" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Chemotherapy&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Increasing intensity of treatment with higher response rates with chemotherapy is hampered by an increase in toxicity. Anthracycline based chemotherapy in combination with rituximab is generally considered the standard in non-transplant B cell lymphomas. Similar treatment strategies have been shown to induce remission in patients with PTLD (1, 2). Responses rate ranges from 65-100% in these studies. Taylor et al showed 59% complete response rate and 5 year disease free survival in patients managed with combination IS reduction and anthracycline-based chemotherapy (3). These regimes may be suitable for patients with initial poor response to IS reduction, or with evidence of disease progression. Non-EBV related PTLDs are less likely to respond to IS reduction, and early consideration should be given to chemotherapeutic options.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Buadi FK, Heyman MR, Gocke CD, et al. "Treatment and outcomes of post-transplant lymphoproliferative disease: a single institution study." Am J Hematol.&amp;nbsp;2007; 82(3):208-14. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17022049" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Elstrom, RL, Andreadis, C, Aqui, NA, et al. "Treatment of PTLD with rituximab or chemotherapy." Am J Transplant 2006; 6:569. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16468968" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Taylor, AL.; Bowles, KM.; Callaghan, CJ.; Wimperis, JZ.; Grant, JW.; Marcus, RE.; Bradley, JA. "Anthracycline-based Chemotherapy as First-line Treatment in Adults with Malignant Posttransplant Lymphoproliferative Disorder after Solid Organ Transplantation." Transplantation 2006; 82(3) 375-381 [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16906036" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Additional references&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Trappe R, Oertel SH, Choquet S, LeBlond V, Papp-Vary M, Riess H. "Sequential treatment with the anti-CD 20 antibody rituximab and CHOP+GCSF chemotherapy in patients with post-transplant lymphoproliferative disorder (PTLD): first results of a multicenter phase II study." Blood 2005; 106:932.&amp;nbsp;[No PubMed abstract]&lt;/LI&gt;
&lt;LI&gt;Gross, T.G., Bucuvalas, J.C., Park, J.R., Greiner, T.C., Hinrich, S.H., Kaufman, S.S., Langnas, A.N., McDonald, R.A., Ryckman, F.C., Shaw, B.W., Sudan, D.L. &amp;amp; Lynch,&amp;nbsp;J.C. "Low-dose chemotherapy for Epstein-Barr virus-positive posttransplantation lymphoproliferative disease in children after solid organ transplantation." &amp;nbsp;J Clin Oncol 2005; 23, 6481-6488. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16170157" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Wagner HJ, Cheng YC, Huls MH, et al. "Prompt versus preemptive intervention for EBV lymphoproliferative disease." Blood 2004; 103(10):3979-81.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/14751931" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Buell JF, Gross TG, Hanaway MJ, Trofe J, Muthiak C, First MR, et al. "Chemotherapy for posttransplant lymphoproliferative disorder: the Israel Penn International Transplant Tumor Registry experience.2 Transplant Proc 2005; 37:956-7 [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/15848588" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Immunotherapy&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Manipulation of the immune system to reduce the risk of EBV-related PTLD, and to improve the response to therapy has been explored. Guppy et al demonstrated an increase in EBV-specific CD8+ T cells during IS reduction, which may be used to guide whether further reductions in IS are required (1).&lt;/P&gt;
&lt;P&gt;The recipient’s own cells can be used to generate an autologous EBV-specific cytotoxic T-cell (CTLs) line. Comoli et al treated seven paediatric PTLD patients with CTL infusions, and in five there was a log reduction in EBV viral load (2). Savoldo et al showed response in 2 patients treated with CTL infusions, and none the patients treated developed de novo disease (3). The development of a patient specific autologous CTL line is slow and expensive, and at present remains an experimental therapy only. The alternative – a development of a cell bank&amp;nbsp; of EBV-specific CTLs harvested from healthy EBV-seropositive donors which are HLA-typed and preserved, has been reported in one small study (4).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Guppy, A. E., E. Rawlings, et al.&amp;nbsp;"A quantitative assay for Epstein-Barr Virus-specific immunity shows interferon-gamma producing CD8+ T cells increase during immunosuppression reduction to treat posttransplant lymphoproliferative disease." Transplantation 2007; 84(11): 1534-9. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18091531" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Comoli, P., R. Maccario, et al.&amp;nbsp;"Treatment of EBV-related post-renal transplant lymphoproliferative disease with a tailored regimen including EBV-specific T cells." American Journal of Transplantation 2005; 5(6): 1415-1422. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/15888049" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Savoldo, B, Goss, JA, Hammer, MM, et al." Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs)." Blood 2006; 108:2942. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16835376" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Haque T, Wilkie G, Taylor C, Amlot P, Murad P et al. "Treatment of Epstein-Barr-virus-positive PTLD with partly HLA-matched allogeneic cytotoxic T cells." The Lancet 2002; 360: 436-442 [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/12241714" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;2&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Evidence&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:329868:0" name=internalLink&gt;&lt;STRONG&gt;Link to 2009 Annual Evidence Update on PTLD in Renal Transplant patients Contents page&lt;/STRONG&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;&lt;/STRONG&gt;
&lt;P&gt;&lt;STRONG&gt;Treatment references&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2004 &lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Jimenez-Rivera, C., Y. Avitzur, et al.&amp;nbsp;"Sirolimus for pediatric liver transplant recipients with post-transplant lymphoproliferative disease and hepatoblastoma." Pediatric Transplantation 2004; 8(3): 243-248. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/15176961" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Karras, A., E. Thervet, et al.&amp;nbsp;"Successful renal retransplantation after post-transplant lymphoproliferative disease." American Journal of Transplantation 2004; 4(11): 1904-1909. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/15476493" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Ryu, H. J., J. S. Hahn, et al.&amp;nbsp;"Complete resolution of posttransplant lymphoproliferative disorder (diffuse large B-cell lymphoma) with reduction of immunosuppressive therapy." Yonsei Medical Journal 2004; 45(3): 527-532. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/15227742" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Shroff, R. and L. Rees&amp;nbsp;"The post-transplant lymphoproliferative disorder - A literature review." Pediatric Nephrology 2004; 19(4): 369-377. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/14986084" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Wagner HJ, Cheng YC, Huls MH, et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood.&amp;nbsp;2004;103(10):3979-81.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/14751931" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2005 &lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Aikawa, A. and A. Hasegawa&amp;nbsp;"[Pediatric kidney transplantation]." Nippon Rinsho - Japanese Journal of Clinical Medicine 2005; 63(11): 1993-9. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16277265" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Babel, N., L. Gabdrakhmanova, et al.&amp;nbsp;"Induction of pre-transplant Epstein-Barr virus (EBV) infection by donor blood transfusion in EBV-seronegative recipients may reduce risk of post-transplant lymphoproliferative disease in adolescent renal transplant patients: Report of two cases." Transplant Infectious Disease 2005; 7(3-4): 133-136.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16390402" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Blaes, A. H., B. A. Peterson, et al.&amp;nbsp;"Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: Results of a phase II trial." Cancer 2005; 104(8): 1661-1667.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16149091" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Buell, J. F., T. G. Gross, et al.&amp;nbsp;"Chemotherapy for posttransplant lymphoproliferative disorder: The Israel Penn International Transplant Tumor Registry Experience." Transplantation Proceedings 2005; 37(2): 956-957.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/15848588" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Buell, J. F., T. G. Gross, et al.&amp;nbsp;"Posttransplant lymphoproliferative disorder: Significance of central nervous system involvement." 2005; Transplantation Proceedings 37(2): 954-955.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/15848587" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Caillard, S., V. Dharnidharka, et al.&amp;nbsp;"Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression." Transplantation 2005; 80(9): 1233-1243.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16314791" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Comoli, P., R. Maccario, et al.&amp;nbsp;"Treatment of EBV-related post-renal transplant lymphoproliferative disease with a tailored regimen including EBV-specific T cells." American Journal of Transplantation 2005; 5(6): 1415-1422.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/15888049" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Funch, D. P., A. M. Walker, et al.&amp;nbsp;"Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients." American Journal of Transplantation 2005; 5(12): 2894-2900.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16303002" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Ghobrial I, Habermann T, Ristow K, et al. "Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era." Leuk Lymphoma.&amp;nbsp;2005; 46(2):191-6.&amp;nbsp;&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/15621801" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Gross, T.G., Bucuvalas, J.C., Park, J.R., Greiner, T.C., Hinrich, S.H., Kaufman, S.S., Langnas, A.N., McDonald, R.A., Ryckman, F.C., Shaw, B.W., Sudan, D.L. &amp;amp; Lynch, J.C.&amp;nbsp;"Low-dose chemotherapy for Epstein-Barr virus-positive posttransplantation lymphoproliferative disease in children after solid organ transplantation." &amp;nbsp;J Clin Oncol. 2005; 23, 6481-6488.&amp;nbsp;[No PubMed abstract]&lt;/LI&gt;
&lt;LI&gt;Kahan, B. D., Y. K. Yakupoglu, et al.&amp;nbsp;"Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients." Transplantation 2005; 80(6): 749-758.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16210961" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Oertel, S. H. K., E. Verschuuren, et al.&amp;nbsp;"Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD)." American Journal of Transplantation 2005; 5(12): 2901-2906.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16303003" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Trofe, J., J. F. Buell, et al.&amp;nbsp;"Analysis of factors that influence survival with post-transplant lymphoproliferative disorder in renal transplant recipients: The Israel Penn International Transplant Tumor Registry experience." American Journal of Transplantation 2005; 5(4 I): 775-780.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/15760401" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2006 &lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Choquet, S, Leblond, V, Herbrecht, R, et al. "Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study." Blood 2006; 107:3053.&amp;nbsp;&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16254143" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Elstrom, RL, Andreadis, C, Aqui, NA, et al. "Treatment of PTLD with rituximab or chemotherapy." Am J Transplant 2006; 6:569.&amp;nbsp;&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16468968" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Fohrer, C., S. Caillard, et al.&amp;nbsp;"Long-term survival in post-transplant lymphoproliferative disorders with a dose-adjusted ACVBP regimen." British Journal of Haematology 2006;134(6): 602-612.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16889621" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Humar, A, Hebert, D, Davies, HD, et al. "A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder." Transplantation 2006; 81:856.&amp;nbsp;&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16570008" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Johnson, S. R., W. S. Cherikh, et al.&amp;nbsp;"Retransplantation after post-transplant lymphoproliferative disorders: an OPTN/UNOS database analysis." American Journal of Transplantation 2006; 6(11): 2743-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17049062" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Messahel, B., M. M. Taj, et al.&amp;nbsp;"Single agent efficacy of rituximab in childhood immunosuppression related lymphoproliferative disease: a United Kingdom Children's Cancer Study Group (UKCCSG) retrospective review." Leukemia &amp;amp; Lymphoma 2006; 47(12): 2584-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17169802" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Savoldo, B, Goss, JA, Hammer, MM, et al. "Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs)." Blood 2006; 108:2942.&amp;nbsp;&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16835376" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Taylor, A. L., K. M. Bowles, et al.&amp;nbsp;"Anthracycline-based chemotherapy as first-line treatment in adults with malignant posttransplant lymphoproliferative disorder after solid organ transplantation." Transplantation 2006; 82(3): 375-81.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16906036" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2007 &lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Buadi FK, Heyman MR, Gocke CD, et al. "Treatment and outcomes of post-transplant lymphoproliferative disease: a single institution study." Am J Hematol.&amp;nbsp;2007; 82(3):208-14.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17022049" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Boratynska, M., E. Watorek, et al.&amp;nbsp;"Anticancer effect of sirolimus in renal allograft recipients with de novo malignancies." Transplantation Proceedings 2007; 39(9): 2736-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18021973" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;González-Barca E, Domingo-Domenech E, Capote FJ, Gómez-Codina J, Salar A, Bailen A. "Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease." Haematologica.&amp;nbsp;2007; 92(11):1489-94.&amp;nbsp;&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18024397" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Guppy, A. E., E. Rawlings, et al.&amp;nbsp;"A quantitative assay for Epstein-Barr Virus-specific immunity shows interferon-gamma producing CD8+ T cells increase during immunosuppression reduction to treat posttransplant lymphoproliferative disease." Transplantation 2007; 84(11): 1534-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18091531" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Opelz, G., V. Daniel, et al.&amp;nbsp;"Effect of cytomegalovirus prophylaxis with immunoglobulin or with antiviral drugs on post-transplant non-Hodgkin lymphoma: a multicentre retrospective analysis." Lancet Oncology 2007; 8(3): 212-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17329191" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Pascual, J.&amp;nbsp;"Post-transplant lymphoproliferative disorder--the potential of proliferation signal inhibitors." Nephrology Dialysis Transplantation 2007; 22 Suppl 1: i27-35.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17456616" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Schuster, I. G., D. H. Busch, et al. "Allorestricted T cells with specificity for the FMNL1-derived peptide PP2 have potent antitumor activity against hematologic and other malignancies." Blood 2007; 110(8): 2931-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17626842" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Trappe, RU, Choquet, S, Reinke, P, et al. "Salvage Therapy for Relapsed Posttransplant Lymphoproliferative Disorders (PTLD) With a Second Progression of PTLD After Upfront Chemotherapy: The Role of Single-Agent Rituximab." Transplantation 2007; 84:1708.&amp;nbsp;&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18165786" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;2008 &lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Aversa, S. M. L., S. Stragliotto, et al.&amp;nbsp;"Post-Transplant Lymphoproliferative Disorders after Heart or Kidney Transplantation at a Single Centre: Presentation and Response to Treatment." Acta Haematologica 2008; 120(1): 36-46.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18797163" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kordelas, L., R. Trenschel, et al.&amp;nbsp;"Successful treatment of EBV PTLD with CNS lymphomas with the monoclonal anti-CD20 antibody rituximab." Onkologie 2008; 31(12): 691-3.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19060508" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Sampson, V. B., S. P. Dunn, et al.&amp;nbsp;"Failure of immunosuppressive drug levels to predict T-cell reactivity in pediatric transplant patients." Journal of Pediatric Surgery 2008; 43(6): 1134-41.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18558196" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Sato, T., M. Fujieda, et al.&amp;nbsp;"Monitoring of Epstein-Barr virus load and killer T cells in pediatric renal transplant recipients." Clinical Nephrology 2008; 70(5): 393-403.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19000539" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Swinnen, L. J., M. LeBlanc, et al.&amp;nbsp;"Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder." Transplantation 2008; 86(2): 215-22.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18645482" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Teachey, D. T., A. E. Seif, et al.&amp;nbsp;"Targeting Notch signaling in autoimmune and lymphoproliferative disease." Blood 2008; 111(2): 705-14.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17925488" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Toyoda, M., A. Moudgil, et al.&amp;nbsp;"Clinical significance of peripheral blood Epstein-Barr viral load monitoring using polymerase chain reaction in renal transplant recipients." Pediatric Transplantation 2008; 12(7): 778-84.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18331541" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Tsai, DE, Douglas, L, Andreadis, C, et al. "EBV PCR in the diagnosis and monitoring of posttransplant lymphoproliferative disorder: results of a two-arm prospective trial." Am J Transplant 2008; 8:1016.&amp;nbsp;&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18312608" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;&lt;EM&gt;No relevant references published. &lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>25/10/2010 13:46:50</lastReviewDate>
    <expiryDate>25/10/2011 13:46:50</expiryDate>
  </document>
  <document>
    <id>329868</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=329868]]&gt;</url>
    <title>2009 Annual Evidence Update on Post Transplant Lymphoproliferative Disorders in Renal Transplant patients - Contents</title>
    <publicationDate>2009-12-07T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ TRANSPLANTATION,PREVENTION OF COMPLICATIONS,IMMUNOSUPPRESSIVE DRUGS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Post Transplant Lymphoproliferative Disorders in Renal Transplant patients - Contents&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;This Annual Evidence Update is being launched on Monday 7th December 2009 to link to and raise awareness of the Guidelines on the surveillance, diagnosis and management of post transplant lymphoproliferative disorders in adult solid organ transplant recipients, recently published by the British Transplant Society. [&lt;A href="nelh:322242:0" name=internalLink&gt;Link to Guidelines&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=center&gt;&lt;IMG id=nelh_tempImage1 height=185 alt="Post Transplant Lymphoproliferative Disorder illustration" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID329868/nelhImp_0000_PTLDillust1_ES_03dec09.JPG" width=303 border=0 name=nelh_tempImage1&gt;&lt;/P&gt;
&lt;P align=center&gt;&amp;nbsp;&lt;EM&gt;Image (above) supplied with thanks by Dr Edward Sharples&lt;/EM&gt;&lt;/P&gt;
&lt;P align=center&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BIG&gt;Contents&lt;/BIG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BIG&gt;&lt;/BIG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:330086:0" name=internalLink&gt;Introduction&lt;/A&gt; - by Dr David Goldsmith&lt;A href="nelh:330086:0" name=internalLink&gt;&lt;/A&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;&lt;A href="nelh:329860:0" name=internalLink&gt;Science&lt;/A&gt;&amp;nbsp;- with a commentary by Dr Edward Sharples&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:329863:0" name=internalLink&gt;Diagnosis&amp;nbsp;and Surveillance&lt;/A&gt;&amp;nbsp;- with a commentary by Dr David Goldsmith&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:329866:0" name=internalLink&gt;Treatment and Management&lt;/A&gt; - with a commentary by Dr&amp;nbsp;Edward Sharples&amp;nbsp;&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;A href="nelh:329867:0" name=internalLink&gt;Methodology&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:331540:0" name=internalLink&gt;UK Database of Uncertainties about the Effects of Treatments (DUETs) on post transplant lymphoproliferative disorders&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Key PTLD references: Guidelines&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;National Institute for Clinical Excellence. Immunosuppressive therapy for renal transplantation in adults. Technology Appraisal 85 September 2004. [&lt;A href="nelh:60828:0" name=internalLink&gt;Link to Guideline&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Guidelines on the Surveillance, Diagnosis and Management of Post-Transplant Lymphoproliferative Disorders in Adult Solid Organ Transplant Recipients. British Committee for Standards in Haematology. British Journal of Haematology 2008; 147, 22–42. [&lt;A href="nelh:322242:0" name=internalLink&gt;Link to guidelines&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;We welcome feedback about resources that we identify. Please&amp;nbsp;contact us if you would like to comment.&lt;/STRONG&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>25/10/2010 13:46:55</lastReviewDate>
    <expiryDate>25/10/2011 13:46:55</expiryDate>
  </document>
  <document>
    <id>330086</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=330086]]&gt;</url>
    <title>2009 Annual Evidence Update on Post Transplant Lymphoproliferative Disorders in Renal Transplant patients - Introduction</title>
    <publicationDate>2009-12-07T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ IMMUNOSUPPRESSIVE DRUGS,PREVENTION OF COMPLICATIONS,TRANSPLANTATION,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Post Transplant Lymphoproliferative Disorders in Renal Transplant patients - Introduction&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;A href="nelh:329868:0" name=internalLink&gt;&lt;STRONG&gt;Link to 2009 Annual Evidence Update on PTLD in Renal Transplant patients Contents page&lt;/STRONG&gt;&lt;/A&gt; 
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Introduction by Dr David Goldsmith, Consultant Nephrologist and Deputy Director of Research and Development, Member of the Faculty of Translational Medicine, Guy's and St Thomas' NHS Foundation Trust&lt;BR&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;POST-TRANSPLATATION LYMPHOPROLIFERATIVE DISEASE (PTLD)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Lymphoproliferative disorders are among the most serious and potentially fatal complications of chronic immunosuppression in organ transplant recipients – this is by far the commonest situation in which they are seen, though very rarely they occur with chronic immunosuppression given for other reasons eg auto-immune diseases (1, 2). Lymphoproliferative disorders are the most common malignancies complicating organ transplantation (excluding nonmelanomatous skin cancer and in situ cervical cancer), accounting for 21 percent&amp;nbsp;of all malignancies versus 5 percent&amp;nbsp;of malignancies in the general population (1, 3, 4). &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The lymphoproliferative disorders occurring after transplantation have different characteristics from those that occur in the general population. Non-Hodgkin lymphoma (NHL) accounts for 65 percent of lymphomas in the general population, compared to 93 percent in transplant recipients. These tumors are mostly large-cell lymphomas, the great majority of which are of the B-cell type. Extranodal involvement is common, occurring in approximately 30 to 70 percent of cases. Although uncommon, posttransplant lymphoproliferative disorders (PTLD) may also originate from T cells, and extremely rarely from natural killer cells. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The pathogenesis of posttransplant NHL in most patients appears to be related to B cell proliferation induced by infection with Epstein-Barr virus (EBV) in the setting of chronic immunosuppression. However, EBV-negative disease can occur. The cellular events underlying EBV-induced B cell proliferation include production of EBV-associated protein (LMP-1) which engages signaling host proteins from the tumor necrosis factor (TNF) receptor family that may then lead to cell growth and transformation.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Most PTLD cells observed in patients with solid organ allografts are of host origin. PTLD of donor origin is an uncommon occurrence; however, at least in renal transplantation, PTLD of donor origin occurs can occur in the allograft.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Three types of EBV-related lymphoproliferative disease occur in transplant recipients: Benign polyclonal lymphoproliferation is an infectious mononucleosis-type acute illness that develops two to eight weeks after immunosuppressive therapy begins. This disorder is characterized by polyclonal B cell proliferation with normal cytogenetics and no evidence of immunoglobulin gene rearrangements to suggest malignant transformation. It accounts for approximately 55 percent of cases. The second EBV-induced disorder is similar to the first in its clinical presentation, but is characterized by polyclonal B cell proliferation with evidence of early malignant transformation, such as clonal cytogenetic abnormalities and immunoglobulin gene rearrangements. This form accounts for approximately 30 percent of cases. The last disorder, accounting for about 15 percent of cases, is usually an extranodal condition presenting with localized solid tumors characterized by monoclonal B cell proliferation with malignant cytogenetic abnormalities and immunoglobulin gene rearrangements. More than 50 percent of patients with PTLD present with extranodal masses. Involved organs include the gastrointestinal tract (stomach, intestine), lungs, skin, liver, central nervous system, and the allograft itself. More specifically, 20 to 25 percent have central nervous system disease (which is rare in the general population), and a similar proportion have infiltrative lesions in the allograft. Involvement of the allograft can lead to allograft dysfunction, including renal failure, heart failure, and respiratory dysfunction.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;An accurate diagnosis of PTLD requires a high index of suspicion, since the disorder may present subtly and/or extranodally. Radiologic evidence of a mass or the presence of elevated serum markers (such as increased LDH levels) are suggestive of PTLD, with positive positron emission tomography (PET) scanning enhancing information from CT scans (indicating metabolically active areas) also favoring the diagnosis. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Management of PTLD varies significantly according to the type of lymphoproliferative disease present, as well as from institution to institution (4, 5). Multi-centre trials are rare and this has severely hindered progress to everyone's detriment. In the Spanish PTLD Study Group report (6), dealing with 108 patients treated between 1996 and 2004, rituximab was used relatively commonly, while antiviral drugs were given less often: Reduction in immunosuppression - 91 percent. Chemotherapy - 59 percent. Rituximab - 33 percent. Antiviral agents - 13 percent. The majority of polyclonal lymphoproliferative disease lesions either resolve completely or improve significantly with reductions in immunosuppression. EBV-related plasmacytomas also may disappear after reduction of immunosuppression. This is why this historically, and now, remains an integral part of successful management. (See (7) as well).&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Reducing immunosuppressive therapy however increases the risk of allograft rejection, which may result in death among those with heart, lung, and liver allografts. However, a careful decrease in immunosuppressive therapy based upon the individual's clinical features and type of allograft can result in both a high response rate and a low rate of rejection and allograft loss. The administration of a number of anti-B-cell antibodies has been evaluated in patients with PTLD. The anti-CD20 monoclonal antibody rituximab has induced complete remissions in some patients with PTLD following either solid organ transplantation or hematopoietic cell transplantation. Although much of the reported information is anecdotal, early treatment with rituximab, along with reduction of immunosuppression, appears to be the evolving standard of care for CD20+ PTLD (8, 9). &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Patients with monoclonal malignancies can be treated with chemotherapy, such as cyclophosphamide plus prednisone, CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), dose adjusted ACVBP (doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisolone). For patients with localized disease and those with central nervous system involvement, local field radiation therapy may be beneficial. Other modalities that have been used in severe cases of polyclonal PTLD, and in some cases of monoclonal B cell lymphoma, or relapsing disease, are infusions of donor leukocytes or EBV-specific cytotoxic T cell lines. The rationale for donor leukocyte infusion is that the infection is, as noted above, usually acquired from the donor who presumably has cytotoxic T cells sensitized to EBV. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Although the prognosis varies with clonality and extent of disease, published series suggest overall survival rates ranging between 25 to 35 percent. Mortality with monoclonal malignancies has been reported to be as high as 80 percent, though there is much more optimism now than a decade ago. The aspiration should be to achieve response rates and remission rates that are similar to those seen in NHL in the general population. T-cell lymphomas by contrast have a significantly worse prognosis (10).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The publication of the National Guidelines for Management of this rare condition (between the British Haematological Society and the British Transplantation Society) is an important moment (11). The joint care between haemoncologists and organ transplant surgeons and physicians is pivotal to their implementation and also, to the organisation and undertaking of large scale interventional trials.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Penn, Penn, I. Cancers complicating organ transplantation. N Engl J Med 1990; 323:1767.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/2247108" target="_blank"&gt;Link to PubMed&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Adami, J, Gabel, H, Lindelof, B, et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer 2003; 89:1221. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/14520450" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Caillard, S, Agodoa, LY, Bohen, EM, Abbott, KC. Myeloma, Hodgkin disease, and lymphoid leukemia after renal transplantation: characteristics, risk factors and prognosis. Transplantation 2006; 81:888.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16570013" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Leblond, V, Sutton, L, Dorent, R, et al. Lymphoproliferative disorders after organ transplantation: A report of 24 cases observed in a single center. J Clin Oncol 1995; 13:961.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/7707124" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Nalesnik, MA, Makowka, L, Starzl, TE. The diagnosis and treatment of posttransplant lymphoproliferative disorders. Curr Probl Surg 1988; 25:367.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/3063441" target="_blank"&gt;Link to PubMed&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Gonzalez-Barca, E, Domingo-Domenech, E, Gomez-Codina, J, et al. First-line treatment with rituximab improves survival of patients with post-transplant lymphoproliferative disease (PTLD). Blood 2004; 104:39a. (No abstract)&lt;/LI&gt;
&lt;LI&gt;Caillard S, Lelong C, Pessione F, Moulin B; French PTLD Working Group.Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: report of 230 cases from the French Registry.Am J Transplant. 2006; 6(11):2735-42. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17049061" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Abu-Elmagd KM, Mazariegos G, Costa G, Soltys K, Bond G, Sindhi R, Green M, Jaffe R, Wu T, Koritsky D, Matarese L, Schuster B, Martin L, Dvorchik I, Nalesnik MA. Lymphoproliferative disorders and de novo malignancies in intestinal and multivisceral recipients: improved outcomes with new outlooks. Transplantation. 2009; 88(7):926-34. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19935465" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Muzaffar M, Taj A, Ratnam S. Aggressive Posttransplant Lymphoproliferative Disease in a Renal Transplant Patient Treated With Alemtuzumab. Am J Ther. 2009&amp;nbsp;[Epub ahead of print] [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19918163" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Hanson, MN, Morrison, VA, Peterson, BA, et al. Posttransplant T-cell lymphoproliferative disorders - An aggressive, late complication of solid-organ transplantation. Blood 1996; 88: 3626.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/8896433" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;British Committee for Standards in Haematology. Guidelines on the Surveillance, Diagnosis and Management of Post-Transplant Lymphoproliferative Disorders in Adult Solid Organ Transplant Recipients.&amp;nbsp; British Journal of Haematology 2008; 147, 22–42. &lt;A href="nelh:322242:0" name=internalLink&gt;Link to guidelines&lt;/A&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>25/10/2010 13:46:59</lastReviewDate>
    <expiryDate>25/10/2011 13:46:59</expiryDate>
  </document>
  <document>
    <id>329867</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=329867]]&gt;</url>
    <title>2009 Annual Evidence Update on Post Transplant Lymphoproliferative Disorders in Renal Transplant patients - Methodology</title>
    <publicationDate>2009-12-07T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ IMMUNOSUPPRESSIVE DRUGS,PREVENTION OF COMPLICATIONS,TRANSPLANTATION,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Post Transplant Lymphoproliferative Disorders in Renal Transplant patients - Methodology&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;&lt;A href="nelh:329868:0" name=internalLink&gt;&lt;STRONG&gt;Link to 2009 Annual Evidence Update on PTLD in Renal Transplant patients Contents page&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methodology in brief&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;We have retrieved the references on the presentation, diagnosis and treatment of PTLD for the 2009 Annual Evidence Update by searching Medline, Embase and the Transplant Library, and cross-referencing using the recent BTS Guidelines on the surveillance, diagnosis and management of PTLD in adult solid organ transplant recipients, and the eMedicine and UpToDate articles on PTLD. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Databases searched:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Medline&lt;/LI&gt;
&lt;LI&gt;Embase&lt;/LI&gt;
&lt;LI&gt;The Transplant Library&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Period of Search:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;2004 - 2009&amp;nbsp;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Search Strategy:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;(ptld.ti,ab OR "post transplant lymphoproliferative disorder*" OR exp *LYMPHOPROLIFERATIVE DISORDERS/ OR exp *EPSTEIN-BARR VIRUS INFECTIONS/ OR exp *HERPESVIRUS 4, HUMAN/)&lt;/P&gt;
&lt;P&gt;AND&lt;/P&gt;
&lt;P&gt;((renal OR kidney OR nephr*) OR (exp *KIDNEY TRANSPLANTATION/)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Inclusion Criteria:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Included articles had to meet the following criteria:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Publication types other than letters, commentaries or case reports.&lt;/LI&gt;
&lt;LI&gt;Relevancy to topics included in the 2009 AEU.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Drs David Goldsmith and Edward Sharples sifted the references independently, including references from the following sources where relevant:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Guidelines on the Surveillance, Diagnosis and Management of Post-Transplant Lymphoproliferative Disorders in Adult Solid Organ Transplant Recipients. British Committee for Standards in Haematology. British Journal of Haematology 2008; 147, 22–42. [&lt;A href="nelh:322242:0" name=internalLink&gt;Link to guidelines&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Friedberg JW, Jessup M, Brennan DC. Lymphoproliferative disorders following solid organ transplantation. UpToDate. (March 2007 2009).&lt;/LI&gt;
&lt;LI&gt;Mukherjee S, Prendergast M.&amp;nbsp;Posttransplant Lymphoproliferative Disease. eMedicine 2008. Available at: &lt;A href="http://emedicine.medscape.com/article/431364-overview" target="_blank"&gt;http://emedicine.medscape.com/article/431364-overview&lt;/A&gt;&amp;nbsp;[Accessed 01/12/09].&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>25/10/2010 13:47:03</lastReviewDate>
    <expiryDate>25/10/2011 13:47:03</expiryDate>
  </document>
  <document>
    <id>331540</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=331540]]&gt;</url>
    <title>2009 Annual Evidence Update on Post Transplant Lymphoproliferative Disorders in Renal Transplant patients - Treatment Uncertainties</title>
    <publicationDate>2009-12-07T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ PREVENTION OF COMPLICATIONS,IMMUNOSUPPRESSIVE DRUGS,TRANSPLANTATION,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Post Transplant Lymphoproliferative Disorders in Renal Transplant patients - Treatment Uncertainties&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A href="nelh:329868:0" name=internalLink&gt;&lt;STRONG&gt;Link to 2009 Annual Evidence Update on PTLD in Renal Transplant patients Contents page&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;What clinical questions would you like answered on PTLD and renal transplant patients?&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders is collaborating in the development of UK DUETs - the UK Database of Uncertainties about the Effects of Treatments.&lt;/P&gt;
&lt;P&gt;DUETs has been established to publish uncertainties that cannot currently be answered reliably by referring to up-to-date systematic reviews of existing research evidence.&amp;nbsp;&amp;nbsp; It is being developed to help those prioritising research in the UK to take account of the information needs of patients, carers and clinicians.&lt;/P&gt;
&lt;P&gt;DUETs draws on three main sources to identify uncertainties about the effects of treatments:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;patients', carers' and clinicians' questions about the effects of&amp;nbsp;&amp;nbsp; treatments&lt;/LI&gt;
&lt;LI&gt;research recommendations in reports of systematic reviews and clinical guidelines&lt;/LI&gt;
&lt;LI&gt;ongoing research, both systematic reviews in preparation and new 'primary' studies &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;DUETs does not include unanswered questions about the frequency, causes and diagnosis of health problems.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Uncertainties identified from the evidence included in this AEU:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:331587:0" name=internalLink&gt;How and when should immunosuppression in kidney transplant patients be reduced?&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:331603:0" name=internalLink&gt;Is rituximab therapy associated with a higher rate of relapse in kidney transplant patients with post-transplant lymphoproliferative disorder?&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:332109:0" name=internalLink&gt;Are novel immunotherapy treatments such as banked HLA-matched (human leucocyte antigen) cytotoxic T lymphocytes (CTLs) effective in kidney transplant patients with Post Transplant Lymphoproliferative Disorders?&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:332108:0" name=internalLink&gt;Is bortezomib an effective therapy for Post Transplant Lymphoproliferative Disorders?&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:331615:0" name=internalLink&gt;What is the role of immunosuppression reduction versus chemotherapy in non-EBV&amp;nbsp;related PTLD?&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:332118:0" name=internalLink&gt;How effective is radiotherapy in localised versus widespread PTLD?&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:332119:0" name=internalLink&gt;What is the role of anti-viral agents in conjunction with chemotherapy in patients with Post Transplant Lymphoproliferative Disorders?&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:332209:0" name=internalLink&gt;What is the optimum timing and&amp;nbsp;best immunosuppressive treatment&amp;nbsp;for re-transplantation in patients with Post Transplant Lymphoproliferative Disorders?&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:332322:0" name=internalLink&gt;Can EBV monitoring, such as measuring viral loads and responses such as cytotoxic T-cell counts, be effective in patients with Post Transplant Lymphoproliferative Disorders?&lt;/A&gt;&lt;A href="nelh:332323:0" name=internalLink&gt;&lt;/LI&gt;
&lt;LI&gt;What is the role of PET scanning in detecting and monitoring Post Transplant Lymphoproliferative Disorders?&lt;/LI&gt;&lt;/A&gt;&lt;/UL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>03/11/2010 15:38:18</lastReviewDate>
    <expiryDate>03/11/2011 15:38:18</expiryDate>
  </document>
  <document>
    <id>314688</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=314688]]&gt;</url>
    <title>2009 Annual Evidence Update on Proteinuria and eGFR: 1. Systematic Reviews</title>
    <publicationDate>2009-05-26T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ PRESENTATION OF CKD,PROTEINURIA/ NEPHROTIC SYNDROME,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Proteinuria and eGFR: 1. Systematic Reviews&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;&lt;BIG&gt;Systematic Reviews&lt;/BIG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Commentary written by Dr David Goldsmith, NHS Evidence - kidney diseases clinical lead.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A href="nelh:315169:0" name=internalLink&gt;&lt;STRONG&gt;Link back&amp;nbsp;to 2009 AEU on Proteinuria and eGFR Contents page&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Proteinuria, rather than reduced kidney function, rightly takes centre stage in this first AEU "renewal" (our first comprehensive foray into this domain was last year (&lt;A href="http://www.library.nhs.uk/KIDNEY/Page.aspx?pagename=PGFNKWCONT" target="_blank"&gt;click here to link to the 2008 National Knowledge Week on Proteinuria and eGFR&lt;/A&gt;) in which we co-featured reduced GFR and proteinuria. Since the introduction of mandatory MDRD eGFR reporting in about 1PD (pre-Donal) in April 2006, there has been a much greater emphasis on accurately and reliably "counting" renal patients by reduced renal function.&amp;nbsp;But, this is a relatively crude way to screen for the presence of renal disease, especially likely to over-represent the effect of age, and female gender by reliance on the MDRD formula to manipulate plasma creatinine values. The way to "individualise" renal and cardiovascular risk more successfully is to find out about whether a patient has microalbuminuria, or proteinuria. The latest NICE guidelines on CKD (published in Sept 2008 in final form (&lt;A href="http://www.nice.org.uk/nicemedia/pdf/CG073NICEGuideline.pdf" target="_blank"&gt;click here to link to the full NICE guideline&lt;/A&gt;) lay out in detail the importance of measuring and interpreting urinary protein in a wide range of patients with chronic illnesses, from diabetes, through heart and other cerebrovascular diseases.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Both reduced eGFR, and especially microalbuminuria, should be regarded as important "vascular" risk factors - as important as a prior heart attack, stroke, or having LVH or diabetes, in terms of cardiovascular outcomes.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The evidence we feature in the update here is of necessity much more limited than the more comprehensive data-set we assembled before. We have deliberately restricted ourselves to RCTs this time around, which in nephrology are rare beasts. But we have had both AVOID and also ONTARGET studies in patient groups at increased renal risk, and these are rightly&amp;nbsp; discussed in some detail. These articles should be read in conjunction with our earlier work to gain a proper perspective.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Magee et al's paper published in Diabetologia in April 2009 takes an intelligent view of asking what is the import of hyperfiltration - in other words, increased GFR. Even if you believe that MDRD eGFR is a robust and reliable guide to reduced kidney function (CKD), no-one will claim that MDRD eGFR values &amp;gt; 90 mls/min have validity (many would use a pragmatic cut off of 60 mls/min). So, we are now talking about creatinine clearances, iothalamate, or Cr51 EDTA derived datasets. This paper gathered information about type 1 diabetics with hyperfiltration, and showed that greater hyperfiltration was associated with a greater tendency to progression of CKD (start higher, end up lower). How we can measure hyperfiltration in clinical practice remains difficult however. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Ninomiya's paper in AJKD in March 2009 examined the consistency of the association between proteinuria and adverse CV outcomes. This was done mainly by meta-analysis of observational cohort studies. Data from 10 published studies involving 140,231 participants showed 3,266 strokes. There was a robust association between proteinuria and the risk of stroke, weakened slightly by different approaches to&amp;nbsp;the classification of&amp;nbsp;proteinuria.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;In a similar vein (and artery) Perkovic et al published a study in 2008 using a meta-analysis of cohort derived information examining the relation between proteinuria and coronary artery disease. They found a strong and graded relationship between degree of proteinuria (normal, microalbuminuria and macro-proteinuria) and likelyhood of CAD.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Esnault et al (2008) report on a randomised comparison study between the effects of amlodipine and enalapril on renal function in NON diabetic subjects with raised BP and chronic renal disease. This was a three years ramdomised double-blinded multicentre study, using Cr51-EDTA renal clearances to chart the outcome variable, renal function. The BP at outset in this study, around 165/100 mm Hg was fierce, and the control achieved, around 138/85, moderate not optimal, but was the same across both groups. Interestingly, no difference in GFR decline between the two agents was observed over 3 years, irrespective of proteinuria - even in a the smaller number of people with protein losses of &amp;gt; 1 gram / day. This is food for thought, and it is a truism that if our crown jewel evidence for nephroprotection remains the MDRD study, we need a great deal more evidence in the modern era of good BP control and efficient&lt;BR&gt;proteinuria reduction.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Esnault VL, Brown EA, Apetrei E, Bagon J, Calvo C, DeChatel R, Holdaas H, Krcmery S, Kobalava Z, Amlodipine Versus Enalapril in Renal Failure (AVER) Study Group. (2008) The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebo-controlled study. &lt;EM&gt;Clinical Therapeutics.&lt;/EM&gt; March 2008, 30 (3); 482-98. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18405787" target="_blank"&gt;Link to Pubmed abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Magee GM, Bilous RW, Cardwell CR, Hunter SJ, Kee F, Fogarty DG. (2009) Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis. &lt;EM&gt;Diabetologia.&lt;/EM&gt; April 2009, 52 (4); 691-697. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19198800" target="_blank"&gt;Link to Pubmed abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Ninomiya T, Perkovic V, Verdon C, Barzi F, Cass A, Gallagher M, Jardine M, Anderson C, Chalmers J, Craig JC, Huxley R. (2009) Proteinuria and stroke: a meta-analysis of cohort studies. &lt;EM&gt;Am J Kidney Dis. &lt;/EM&gt;2009 Mar; 53 (3); 417-25. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19070947" target="_blank"&gt;Link to Pubmed abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Perkovic V, Verdon C, Ninomiya T, Barzi F, Cass A, Patel A, Jardine M, Gallagher M, Turnbull F, Chalmers&amp;nbsp;J, Craig J, Huxley F. (2008) The relationship between proteinuria and coronary risk: A systematic review and meta-analysis. &lt;EM&gt;PLoS Medicine,&lt;/EM&gt; October 2008, 5 (10); 1486-1495.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18942886" target="_blank"&gt;Link to Pubmed abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;STRONG&gt;&lt;A href="nelh:315169:0" name=internalLink&gt;
&lt;P&gt;&lt;STRONG&gt;Link back to 2009 AEU on Proteinuria and eGFR Contents page&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>27/05/2010 09:54:30</lastReviewDate>
    <expiryDate>27/05/2011 09:54:30</expiryDate>
  </document>
  <document>
    <id>314925</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=314925]]&gt;</url>
    <title>2009 Annual Evidence Update on Proteinuria and eGFR: 2. Randomised Controlled Trials and Management of Proteinuria and CKD 2009</title>
    <publicationDate>2009-05-26T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ PRESENTATION OF CKD,PROTEINURIA/ NEPHROTIC SYNDROME,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Proteinuria and eGFR: 2. Randomised Controlled Trials and Management of Proteinuria and CKD 2009&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;&lt;BIG&gt;Randomised Controlled Trials and Management of Proteinuria and CKD 2009&lt;/BIG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Commentary written by Dr Edward Sharples, Consultant in Nephrology and Transplant Medicine, Oxford Renal Unit, Churchill Hospital, Old Road, Headington, Oxford OX3 7LJ&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A href="nelh:315169:0" name=internalLink&gt;&lt;STRONG&gt;Link back to 2009 AEU on Proteinuria and eGFR Contents page&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;There are common pathogenic mechanisms that contribute to progression of established CKD, independent of the original cause. The common stems of these pathways include hypertension, glomerular hypertension, altered glomerular permeability, proteinuria and the development of interstitial inflammation and atrophy. Proteinuria may act as an independent factor in tubular atrophy. In both diabetic and non-diabetic CKD, there is a strong correlation between macroproteinuria and rate of progression of CKD. The MDRD study showed an inverse relationship between proteinuria and increased progression. The REIN study in non-diabetic CKD showed that despite similar blood pressures achieved in the different treatment groups, there was additional benefit of ACE inhibitors in those patients with &amp;gt;3g/24 hr proteinuria [Ruggenenti P, 1998]. In this group, reduction of proteinuria was associated with a 50% reduction in relative risk of renal end points (dialysis or doubling of creatinine). A meta-analysis by Chiurchiu et al in 2005 confirmed the link between proteinuria and progression of CKD, and that treatments that reduce proteinuria (ACE inhibitors and Angiotensin receptor antagonists) slow progression [Chiurchiu C, 2005].&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Combining ACE inhibition with ARB has shown increased reductions of proteinuria (25% greater than with single agent) in a number of studies, although these early small studies were generally short-term (2-4 months). The COOPERATE study of 263 patients showed improvement in proteinuria reduction without excess complications [Nakao N, 2003]. This study has been criticised for the design and potential bias in randomisation due to the patient stratification used. In the last year the large ONTARGET study has led to 2 reports. This was a large, randomised, double-blind, non-inferiority comparison of 3 treatment groups: telmisartan (80mg daily) alone, ramipril (10 mg dialy) alone or combination of telmisartan and ramipril. The study enrolled patients 55 years of age or older who had atherosclerotic cardiovascular disease, or diabetes with associated end-organ damage. After the initial run-in screening phase with telmisartan alone therapy, 25620 patients were randomised to the three treatment groups. The study reported in 2008 with no significant difference between the groups in the primary outcome, a composite of death from cardiovascular disease, myocardial infarction, stroke or hospitalisation for heart failure [The ONTARGET investigators, 2008].&amp;nbsp; The mean blood pressure throughout the study was slightly lower in the combination groups. There was concern that the combination therapy was associated with the secondary outcome of "renal impairment", with reported higher side effects, in particular hypotension. The renal outcomes were not pre-defined in the study protocol, and an in-depth report on the renal outcomes was published in the Lancet [Mann JF, 2008]. Initiation of dialysis was more common with combination therapy (0.8% vs. 0.6% for each monotherapy), although this did not reach significance, and the main difference was seen in the need for "acute dialysis" which was not clearly defined. The renal outcomes have to be assessed with regard to the fact that the trial was designed as a cardiovascular intervention trial, and the renal outcomes was only a secondary outcome measure. Most patients had relatively low levels of proteinuria, and were not at very high risk of CKD progression. Assessment of proteinuria and GFR were infrequent in the study period, and the kidney disease outcomes, particularly dialysis requirement, were not rigorously and consistently defined. However, this large study contradicts the outcome of the COOPERATE study, and should lead to caution in the use of combination therapy in CKD patients, particularly in the elderly and those with cardiac dysfunction or widespread vascular disease. It is uncertain whether the additional reduction in proteinuria observed is associated with a reduction in progression in those patients able to tolerate dual therapy, for example the young patient with proteinuric IgA nephropathy.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Treatments that block the renin-angiotensin system such as ACE inhibitors or ARBs are associated with a rise in plasma renin activity. Renin appears to exert additional actions through the renin receptor, distinct from its actions that lead to the production of angiotensin and aldosterone. The introduction of the first oral renin inhibitor, aliskiren, and the success of combination therapy with valsartan in short-term hypertension trials [Oparil, 2007], opens the possibility for combined therapy as a renoprotective strategy. The results of the Aliskiren in the Evaluation of Proteinuria in Diabetes (AVOID) trial were published in 2008 in the New England Journal of Medicine [Parving HH, 2008]. 599 patients with type 2 diabetes mellitus and hypertension were entered in a randomised, double-blind, placebo controlled trial were assigned randomly to receive aliskiren or placebo in addition to their losartan over a six month period. The primary outcome was the reduction in urinary albumin/creatinine ratio (ACR). There was a 20% reduction in ACR in the aliskiren group, associated with a small fall in both systolic and diastolic BP (2mmHg/ 1 mm Hg). Aliskiren therapy was not associated with any excess side effects or hyperkalaemia. Direct renin inhibition may be a useful addition in the management of CKD and renoprotection. Further studies are needed to answer the uncertainty of the role of these newer agents in renoprotection.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Chiurchiu C, Remuzzi G, Ruggententi P. Angiotensin-Converting enzyme inhibtion and Renal protection in nondiabetic patients: The data of the Meta-Analyses. J Am Soc Nephrol 16; S58-62 (2005) [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/15938036" target="_blank"&gt;Link to Pubmed abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsärinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S; ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 372(9638):547-53 (2008) [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18707986" target="_blank"&gt;Link to Pubmed abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;The ONTARGET investigators. Telimsartan, Ramipril, or both in patients at high risk for vascular events. NEJM 358; 1547-1559. (2008) [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18378520" target="_blank"&gt;Link to Pubmed abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren Combined with Losartan in Type 2 diabetes and Nephropathy. NEJM 358; 2433-2447. (2008). [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18525041" target="_blank"&gt;Link to Pubmed abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Oparil S, Yarows S, Patel S, Fang H, Zhang J, Satlin A. Efficiacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 370; 211-229 (2007). [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17658393" target="_blank"&gt;Link to Pubmed abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Nakao N, Yoshimura A, Moriha H et al. Combination treatment of angiotensin II receptor blocker and angiotensin-converting enzyme inhibtitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial. Lancet 361; 117-124 (2003) [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/12531578?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Link to Pubmed abstract&lt;/A&gt;] [**N.B. This&amp;nbsp;article has been withdrawn** - 03/02/10 specialist collection team]&lt;/P&gt;
&lt;P&gt;Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet. 352; 1252-6 (1998). [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/9788454" target="_blank"&gt;Link to Pubmed abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Uncertainties&amp;nbsp;from these studies - UK DUETs&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/duets/ViewResource.aspx?resID=315292&amp;amp;tabID=297&amp;amp;catID=14530" target="_blank"&gt;Best therapy for renoprotection - ACEi or ARBs and role of combination therapy&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/DUETS/ViewResource.aspx?resID=315293&amp;amp;tabID=297" target="_blank"&gt;Role of aliskiren in proteinuria reduction&lt;/A&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;STRONG&gt;&lt;STRONG&gt;&lt;A href="nelh:315169:0" name=internalLink&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;STRONG&gt;Link back to 2009 AEU on Proteinuria and eGFR Contents page&lt;/STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>27/05/2010 09:54:37</lastReviewDate>
    <expiryDate>27/05/2011 09:54:37</expiryDate>
  </document>
  <document>
    <id>315010</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=315010]]&gt;</url>
    <title>2009 Annual Evidence Update on Proteinuria and eGFR: 3. Early identification and management of CKD: Review of NICE guidelines</title>
    <publicationDate>2009-05-26T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ PROTEINURIA/ NEPHROTIC SYNDROME,PRESENTATION OF CKD,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Proteinuria and eGFR: 3. Early identification and management of CKD: Review of NICE guidelines&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;&lt;BIG&gt;Early identification and management of CKD: Review of NICE guidelines&lt;/BIG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Commentary written by Dr Edward Sharples, Consultant in Nephrology and Transplant Medicine, Oxford Renal Unit, Churchill Hospital, Old Road, Headington, Oxford OX3 7LJ&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;STRONG&gt;&lt;A href="nelh:315169:0" name=internalLink&gt;&lt;STRONG&gt;&lt;STRONG&gt;Link back to 2009 AEU on Proteinuria and eGFR Contents page&lt;/STRONG&gt;&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Following on from the publication of the renal diseases National Service Framework, and a change of focus from treatment to the early detection and prevention of CKD, the NICE guidelines for the early detection and management of CKD in primary and secondary care were published in 2008. Their recommendations are the result of a thorough review of all current published evidence. CKD is associated with substantial co-morbidity including hypertension, cardiovascular disease, anaemia and mineral bone disease [Crowe 2008, Landray 2008].&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The guidelines are based on the KDOQI classification for CKD, with the five stages of CKD defined on the basis of calculated GFR, and the presence or absence of urinary markers of kidney disease (haematuria and proteinuria). Kidney function should be calculated by the estimation of glomerular filtration rate (eGFR) from the serum creatinine using the IDMS traceable simplified MDRD equation. There has been a great deal of opinion and debate in 2008 regarding the near-universal uptake of eGFR and the KDOQI CKD classification, with some calls to re-define the classification [Glassock R, 2008, Winearls C, 2008]. The staging system based on eGFR largely ignores the other measures of kidney damage, in particular proteinuria, although the NICE guidelines have recommended two adaptations to the KDOQI system, with the suffix “p” for proteinuria if present, and the introduction of 3A (60-45 ml/min eGFR) and 3B (45-30 ml/min eGFR). These adaptations of the classification should help to identify those at highest risk of renal progression and its complications. The classification assumes preservation of eGFR with age, whereas the large population study from Belgium [Wetzels J, 2008], and more recent studies demonstrating that actual muscle mass is lower in some populations than the demographic approximations used to generate the MDRD formula [Rule A, 2009].&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;An albumin/ creatinine ratio &amp;gt; 30 mg/mmol has been recommended as the measure of proteinuria, rather than a protein/ creatinine ratio. This recommendation is based on the strong evidence for microalbuminuria as a marker of early nephropathy in diabetes mellitus and the 1a level evidence of response to intervention.&amp;nbsp; The role for microalbuminuria as a risk factor for CKD progression in non-diabetic kidney disease is uncertain, and the intervention trials (for example GISEN/ REIN) showed the greatest association with proteinuria &amp;gt;1-3 g/24hrs. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The guideline defines which groups of patients with CKD and its complications should be referred for specialist assessment and management. The definitions for progression of CKD (&amp;gt;5 ml/min/1.73m2 with one year or &amp;gt;10 ml/min/1.73m2 within 5 years) are recommendations based on the best observational studies available. Control of blood pressure is recommended with targets for systolic BP &amp;lt; 140 mmHg and diastolic BP &amp;lt;90 mmHg, with lower targets in patients with diabetes or proteinuria (below 130/80). These targets are similar to the target blood pressures for the large ACE inhibitor renoprotection trials, although the achieved BP within the studies is usually higher than that targeted.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The early identification of CKD has been linked to the observed increased risk of cardiovascular mortality and morbidity in this population, although a causal link is not established. The guidelines suggest use of statins for secondary prevention, and primary prevention in those patients in whom they would be used as defined by their score on existing risk tables. The recent Cochrane review of statins in CKD patients has concluded that the indications for use should be similar to those in the general population, although the SHARP trial will not report until 2010.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The guidelines are a successful and concise review of the current best practice in the management of early detection of CKD in high risk groups.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;National Institute for Health and Clinical Effectiveness. Chronic kidney disease: Early identification and management of chronic kidney disease in adults in primary and secondary care.&amp;nbsp;September 2008. [&lt;A href="http://www.nice.org.uk/nicemedia/pdf/CG073NICEGuideline.pdf" target="_blank"&gt;Link to full-text PDF&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Glassock RJ, Winearls CG. eGFR: Readjusting its rating. Clin J Am Soc Nephrol. 4:867-869(2009) [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19414566" target="_blank"&gt;Link to Pubmed abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Winearls CG, Glassock RJ. Dissecting and refining the staging of chronic kidney disease. Kidney Int.75:1009-1014 (2009) [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19242501" target="_blank"&gt;Link to Pubmed abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Roderick PJ, Atkins RJ, Smeeth L, Mylne A, Nitsch DD, Hubbard RB, Bulpitt CJ, Fletcher AE. CKD and Mortality Risk in Older People: A Community-Based Population Study in the United Kingdom. Am J Kidney Dis 2009 [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19394727" target="_blank"&gt;Link to Pubmed abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Crowe E, Halpin D, Stevens P. Early identification and management of chronic kidney disease: summary of NICE guidance. BMJ 2008; 337: 1530-1533 [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18824486" target="_blank"&gt;Link to Pubmed abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Landray MJ, Haynes RJ. Commentary: Controversies in NICE guidance on chronic kidney disease BMJ 2008; 337: 815-818 [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18824482?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Link to Pubmed abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Andrew D Rule, Kent R Bailey, Gary L Schwartz, Sundeep Khosla, John C Lieske and L Joseph Melton III.&amp;nbsp; For estimating creatinine clearance measuring muscle mass gives better results than those based on demographics Kidney Int 75: 1071-1078 (2009). [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19177154" target="_blank"&gt;Link to Pubmed abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;J F M Wetzels, H L Willems and M den Heijer, Age- and gender-specific reference values of estimated glomerular filtration rate in a Caucasian population: Results of the Nijmegen Biomedical Study. Kidney Int 73:657-658 (2008) [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18274547" target="_blank"&gt;Link to Pubmed abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;STRONG&gt;&lt;A href="nelh:315169:0" name=internalLink&gt;
&lt;P&gt;&lt;STRONG&gt;Link back to 2009 AEU on Proteinuria and eGFR Contents page&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>27/05/2010 09:54:41</lastReviewDate>
    <expiryDate>27/05/2011 09:54:41</expiryDate>
  </document>
  <document>
    <id>315167</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=315167]]&gt;</url>
    <title>2009 Annual Evidence Update on Proteinuria and eGFR: 4. Evidence</title>
    <publicationDate>2009-05-26T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ PRESENTATION OF CKD,PROTEINURIA/ NEPHROTIC SYNDROME,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Proteinuria and eGFR: 4. Evidence&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;&lt;STRONG&gt;&lt;A href="nelh:315169:0" name=internalLink&gt;&lt;STRONG&gt;&lt;STRONG&gt;Link back to 2009 AEU on Proteinuria and eGFR Contents page&lt;/STRONG&gt;&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;SYSTEMATIC REVIEWS AND META-ANALYSES&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;We searched Embase and MEDLINE for systematic reviews and meta-analyses published between April 2008 and April 2009 to supplement the evidence retrieved and presented during the 2008 National Knowledge Week on Proteinuria and eGFR. [&lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=PGFNKWCONT" target="_blank"&gt;Link to 2008 NKW Contents page&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;1a) Basic Science: Characterisation and description of urinary protein excretion in health and in disease.&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;Ninomiya T, Perkovic V, Verdon C, Barzi F, Cass A, Gallagher M, Jardine M, Anderson C, Chalmers J, Craig JC, Huxley R. (2009) Proteinuria and stroke: a meta-analysis of cohort studies. American Journal of Kidney Diseases, March 2009, 53 (3); 417-25. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19070947" target="_blank"&gt;Link to Pubmed abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Perkovic V, Verdon C, Ninomiya T, Barzi F, Cass A, Patel A, Jardine M, Gallagher M, Turnbull F, Chalmers J, Craig J, Huxley R. (2008) The relationship between proteinuria and coronary risk: A systematic review and meta-analysis. PLoS Medicine, October 2008, 5 (1); 1486-1495. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18942886/" target="_blank"&gt;Link to Pubmed abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Treatment Uncertainty (UK DUETs):&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Magee GM, Bilous RW, Cardwell CR, Hunter SJ, Kee F, Fogarty DG. (2009) Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis. &lt;EM&gt;Diabetologia&lt;/EM&gt;, April 2009, 52 (4); 691-697.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19198800" target="_blank"&gt;Link to Pubmed abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2a) Clinical aspects: How to detect and quantify urinary albumin and proteinuria&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Cote AM, Brown MA, Lam E, von Dadelszen P, Firoz T, Liston RM, Magee LA. (2008) Diagnostic accuracy of urinary spot protein:creatinine ratio for proteinuria in hypertensive&amp;nbsp;pregnant women: systematic review. BMJ, May 2008, 336 (7651); 1003-6. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18403498" target="_blank"&gt;Link to Pubmed abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;3a) Management: How early should active management of proteinuria or reduced eGFR be started?&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Magee GM, Bilous RW, Cardwell CR, Hunter SJ, Kee F, Fogarty DG. (2009) Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis. &lt;EM&gt;Diabetologia&lt;/EM&gt;, April 2009, 52 (4); 691-697.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19198800" target="_blank"&gt;Link to Pubmed abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;3b) Management: Managing cardiovascular risk factors in chronic kidney disease&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Balamuthusamy S, Srinivasan L, Verma M, Adigopula S, Jalandara N, Hathiwala S, Smith E. (2008) Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: A meta-analysis. American Heart Journal, May 2008, 155 (5); 791-805. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18440325" target="_blank"&gt;Link to Pubmed abstract&lt;/A&gt;] &lt;/P&gt;
&lt;P&gt;Sarafidis PA, Stafylas PC, Kanaki AI, Lasaridis AN. (2008) Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: An updated meta-analysis. American Journal of Hypertension. August 2008, 21 (8); 922-929. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18535536" target="_blank"&gt;Link to Pubmed abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Treatment Uncertainty (UK DUETs) (non-systematic review):&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Arici M, Erdem Y. (2009) Dual blockade of the renin-angiotensin system for cardiorenal protection: an update. American Journal of Kidney Diseases, February 2009, 53 (2); 332-45. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19166800" target="_blank"&gt;Link to Pubmed abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;3c) Management: Preventing new onset development of proteinuria in people with diabetes and hypertension&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Balamuthusamy S, Srinivasan L, Verma M, Adigopula S, Jalandara N, Hathiwala S, Smith E. (2008) Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: A meta-analysis. American Heart Journal, May 2008, 155 (5); 791-805. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18440325" target="_blank"&gt;Link to Pubmed abstract&lt;/A&gt;] &lt;/P&gt;
&lt;P&gt;Khan NA, Hammelgarn B, Herman RJ, Rabkin SW, McAlister FA, Bell CM, Touyz RM, et al. (2008) The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. Canadian Journal of Cardiology, June 2008, 24 (6); 465-75. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18548143" target="_blank"&gt;Link to Pubmed abstract&lt;/A&gt;]&amp;nbsp; &lt;/P&gt;
&lt;P&gt;Lang CD, Arora RR, Saha SA, Molnar J. (2008) Bayesian meta-analysis of tissue angiotensin-converting enzyme inhibitors for reduction of adverse cardiovascular events in patients with diabetes mellitus and preserved left ventricular function. Journal of CardioMetabolic Syndrome, 2008, 3 (1); 45-52. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18326970" target="_blank"&gt;Link to Pubmed abstract&lt;/A&gt;] &lt;/P&gt;
&lt;P&gt;McCormick BB, Sydor A, Akbari A, Fergusson D, Doucette S, Knoll G. (2008) The Effect of Pentoxifylline on Proteinuria in Diabetic Kidney Disease: A Meta-analysis. American Journal of Kidney Diseases, September 2008, 52 (3); 454-463. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18433957" target="_blank"&gt;Link to Pubmed abstract&lt;/A&gt;] &lt;/P&gt;
&lt;P&gt;Pan Y, Guo LL, Jin HM. (2008) Low-protein diet for diabetic nephropathy: a meta-analysis of randomized controlled trials. American Journal of Clinical Nutrition, September 2008, 88 (3); 660-6. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18779281" target="_blank"&gt;Link to Pubmed abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Papanna R, Mann LK, Kouides RW, Glantz JC. (2008) Protein/ creatinine ratio in preeclampsia: a systematic review. Obstetrics &amp;amp; Gynecology, July 2008, 112 (1); 135-44.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18591319" target="_blank"&gt;Link to Pubmed abstract&lt;/A&gt;] &lt;/P&gt;
&lt;P&gt;Wang F, Wu H-M. (2009) Xuezhikang for diabetic kidney disease: A systematic review of randomized controlled trials. Chinese Journal of Evidence-Based Medicine, 2009, 9 (1); 63-70. &lt;/P&gt;
&lt;P&gt;Wang H, Zhang G-L, Zhang Q-B, Deng J-L. (2009) Spironolactone for diabetic nephropathy: A systematic review. Chinese Journal of Evidence-Based Medicine. 2009 9 (1); 71-75. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;3d) Management: Preventing new onset development of proteinuria in people with CKD&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Catapano F, Chiodini P, De Nicola L, Minutolo R, Zamboli P, Gallo C, Conte G. (2008) Antiproteinuric Response to Dual Blockade of the Renin-Angiotensin System in Primary Glomerulonephritis: Meta-analysis and Metaregression. American Journal of Kidney Diseases, September 2008, 52 (3); 475-485. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18468748" target="_blank"&gt;Link to Pubmed abstract&lt;/A&gt;] &lt;/P&gt;
&lt;P&gt;Chartapisak W, Opastiraku SL, Willis NS, Craig JC, Hodson EM. (2009) Prevention and treatment of renal disease in Henoch-Schonlein purpura: A systematic review. Archives of Disease in Childhood, February 2009, 94 (2); 132-137. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18701559" target="_blank"&gt;Link to Pubmed abstract&lt;/A&gt;] &lt;/P&gt;
&lt;P&gt;Navaneethan SD, Nigwekar SU,&amp;nbsp;Sehgal AR, Strippoli GF. (2009) Aldosterone antagonists for preventing the progression of chronic kidney disease: a&amp;nbsp;systematic review and meta-analysis. Clinical Journal of the American Society for Nephrology,&amp;nbsp;March 2009, 4 (3); 542-51. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19261819" target="_blank"&gt;Link to Pubmed abstract&lt;/A&gt;] &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;OTHER EVIDENCE PUBLISHED 2008-9&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Guidance&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/KIDNEY/ViewResource.aspx?resID=59818" target="_blank"&gt;British National Formulary: Diabetic Nephropathy (01 Mar 2009)&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/KIDNEY/ViewResource.aspx?resID=312475" target="_blank"&gt;British National Formulary: Urinalysis (01 Mar 2009)&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=60996" target="_blank"&gt;National Screening Committee UK - Kidney (renal) disease screening (01 Dec 2008)&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=294680" target="_blank"&gt;NICE - Chronic Kidney Disease (24 Sept 2008)&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/KIDNEY/ViewResource.aspx?resID=155511" target="_blank"&gt;Renal Association - CKD eGuide (31 Jan 2009)&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=289369" target="_blank"&gt;SIGN - Diagnosis and management of chronic kidney disease (01 June 2008)&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Evidence&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Braun N, Schmutzler F, Lange C, Perna A, Remuzzi G, Willis NS. &lt;A href="http://www.library.nhs.uk/KIDNEY/ViewResource.aspx?resID=293690&amp;amp;tabID=289" target="_blank"&gt;Immunosuppressive treatment for focal segmental glomerulosclerosis in adults&lt;/A&gt;. Cochrane Database of Systematic Reviews 2008, Issue 3. Art. No.: CD003233. DOI: 10.1002/14651858.CD003233.pub2.&lt;/LI&gt;
&lt;LI&gt;Michael M, Elliott EJ, Ridley GF, Hodson EM, Craig JC. &lt;A href="http://www.library.nhs.uk/KIDNEY/ViewResource.aspx?resID=304876" target="_blank"&gt;Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura&lt;/A&gt;. Cochrane Database of Systematic Reviews 2009, Issue 1. Art. No.: CD003595. DOI: 10.1002/14651858.CD003595.pub2.&lt;/LI&gt;
&lt;LI&gt;Navaneethan SD, Pansini F, Perkovic V, Manno C, Pellegrini F, Johnson DW, Craig JC, Strippoli GFM. &lt;A href="http://www.library.nhs.uk/KIDNEY/ViewResource.aspx?resID=312247" target="_blank"&gt;HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis&lt;/A&gt;. Cochrane Database of Systematic Reviews 2009, Issue 2. Art. No.: CD007784. DOI: 10.1002/14651858.CD007784.&lt;/LI&gt;
&lt;LI&gt;Walters G, Willis NS, Craig JC. &lt;A href="http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=293689&amp;amp;tabID=289" target="_blank"&gt;Interventions for renal vasculitis in adults&lt;/A&gt;. Cochrane Database of Systematic Reviews 2008, Issue 3. Art. No.: CD003232. DOI: 10.1002/14651858.CD003232.pub2.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Reference&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=308755" target="_blank"&gt;Department of Health: Proteinuria: detection and quantitation in adults using ACR: information for GPs&lt;/A&gt; &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=308754" target="_blank"&gt;Department of Health: Proteinuria: detection and quantitation in adults using ACR: information for laboratories&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=301383" target="_blank"&gt;Map of Medicine: Proteinuria in adults&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Education/ CPD&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/KIDNEY/ViewResource.aspx?resID=308757" target="_blank"&gt;Department of Health: chronic kidney disease -&amp;nbsp; a guide for primary care&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;STRONG&gt;&lt;STRONG&gt;&lt;A href="nelh:315169:0" name=internalLink&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;STRONG&gt;Link back to 2009 AEU on Proteinuria and eGFR Contents page&lt;/STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>27/05/2010 09:54:45</lastReviewDate>
    <expiryDate>27/05/2011 09:54:45</expiryDate>
  </document>
  <document>
    <id>315193</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=315193]]&gt;</url>
    <title>2009 Annual Evidence Update on Proteinuria and eGFR: 5. Methodology</title>
    <publicationDate>2009-05-26T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ PRESENTATION OF CKD,PROTEINURIA/ NEPHROTIC SYNDROME,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Proteinuria and eGFR: 5. Methodology&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;&lt;A href="nelh:315169:0" name=internalLink&gt;&lt;STRONG&gt;Link back to 2009 AEU on Proteinuria and eGFR Contents page&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methodology:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;MEDLINE and Embase were searched for systematic reviews and meta-analyses published between April 2008 and April 2009, using the Clinical Evidence systematic review search filter and the search strategies employed by the kidney diseases team in 2008 (l&lt;A href="http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=287959&amp;amp;tabID=290" target="_blank"&gt;ink to 2008 Methodology&lt;/A&gt;).&lt;/P&gt;
&lt;P&gt;Additional references, such as the RCTs, were retrieved using the subject search strategy without the systematic review search filter. &lt;/P&gt;
&lt;P&gt;The following search terms were used for &lt;STRONG&gt;Proteinuria&lt;/STRONG&gt;:&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;"urinary protein".ti,ab&lt;/LI&gt;
&lt;LI&gt;"urine protein".ti,ab&lt;/LI&gt;
&lt;LI&gt;"urinary albumin excretion".ti,ab&lt;/LI&gt;
&lt;LI&gt;"urine albulmin excretion".ti,ab&lt;/LI&gt;
&lt;LI&gt;exp ALBUMINURIA/&lt;/LI&gt;
&lt;LI&gt;microalbuminuria.ti,ab&lt;/LI&gt;
&lt;LI&gt;macroalbuminuria.ti,ab&lt;/LI&gt;
&lt;LI&gt;*PROTEINURIA/&lt;/LI&gt;
&lt;LI&gt;proteinuria.ti,ab&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The following search terms were used for &lt;STRONG&gt;eGFR&lt;/STRONG&gt;:&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;"estimated glomerular filtration rate".ti,ab&lt;/LI&gt;
&lt;LI&gt;*GLOMERULUS FILTRATION RATE/&lt;/LI&gt;
&lt;LI&gt;"estimating glomerular filtration rate".ti,ab&lt;/LI&gt;
&lt;LI&gt;"estimated gfr".ti,ab&lt;/LI&gt;
&lt;LI&gt;"estimating gfr".ti,ab&lt;/LI&gt;
&lt;LI&gt;egfr.ti,ab&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Numbers of systematic reviews/ meta-analyses published April 2008- April 2009:&lt;/P&gt;
&lt;P&gt;1. Basic science&lt;/P&gt;
&lt;P&gt;1 a) Characterisation and description of urinary protein excretion in health and in disease [10 systematic reviews]&lt;BR&gt;1 b) Tubular toxicity of urinary protein [1 SR]&lt;BR&gt;1 c) Urinary proteomics [1 SR]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;2. Clinical aspects&lt;/P&gt;
&lt;P&gt;2 a) How to detect and quantify urinary albumin and proteinuria [0 SRs]&lt;BR&gt;2 b) Proteinuria as a marker of chronic kidney damage [4 SRs]&lt;BR&gt;2 c) Proteinuria as a marker of CVD [4 SRs]&lt;BR&gt;2 d) Proteinuria as a screening tool [8 SRs]&lt;BR&gt;2 e) eGFR as a marker of renal function [1 SR]&lt;BR&gt;2 f) eGFR as a screening tool [1 SR]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;3. Management&lt;/P&gt;
&lt;P&gt;3 a) How early should active management of proteinuria or reduced eGFR be started? [4 SRs]&lt;BR&gt;3 b) Managing cardiovascular risk factors in chronic kidney disease [22 SRs]&lt;BR&gt;3 c) Preventing new onset development of proteinuria in people with diabetes and hypertension [9 SRs]&lt;BR&gt;3 d) Preventing new onset development of proteinuria in people with CKD [27 SRs]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=center&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage0 style="WIDTH: 306px; HEIGHT: 200px" height=265 src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID315193/nelhImp_0000_Kidneys_istock_vsmall_08jan09.jpg" width=306 name=nelh_tempImage0&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;STRONG&gt;&lt;A href="nelh:315169:0" name=internalLink&gt;
&lt;P&gt;&lt;STRONG&gt;Link back to 2009 AEU on Proteinuria and eGFR Contents page&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>27/05/2010 09:54:48</lastReviewDate>
    <expiryDate>27/05/2011 09:54:48</expiryDate>
  </document>
  <document>
    <id>315169</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=315169]]&gt;</url>
    <title>2009 Annual Evidence Update on Proteinuria and eGFR: Contents and Introduction</title>
    <publicationDate>2009-05-26T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ PROTEINURIA/ NEPHROTIC SYNDROME,PRESENTATION OF CKD,CAUSES,CHRONIC COMPLICATIONS,CONDITION MANAGEMENT,DIAGNOSIS,DIABETES,NEPHROPATHY,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Proteinuria and eGFR: Contents and Introduction&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=center&gt;&lt;IMG id=nelh_tempImage1 style="WIDTH: 131px; HEIGHT: 199px" height=184 alt="kidney crosssection" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID315169/nelhImp_0000_Kidneydiagram_istock_compressed.jpg" width=141 border=0 name=nelh_tempImage1&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;IMG id=nelh_tempImage2 style="WIDTH: 229px; HEIGHT: 198px" height=184 alt="pair of kidneys" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID315169/nelhImp_0001_Kidneys_istock_compressed.jpg" width=211 border=0 name=nelh_tempImage2&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BIG&gt;Introduction&lt;/BIG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;This Annual Evidence Update has been created to update the evidence presented last year for the 2008 National Knowledge Week on Proteinuria and eGFR. You can read commentaries on the latest systematic reviews, randomised controlled trials and the 2008 NICE guideline on Chronic Kidney Disease, as well as see what evidence has been produced in the last 12 months for the different topics presented last year. Drs David Goldsmith and Edward Sharples have also picked out the Treatment Uncertainties from the evidence, which have been added to the UK DUETs database. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BIG&gt;Contents&lt;/BIG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;&lt;A href="nelh:314688:0" name=internalLink&gt;Systematic Reviews&lt;/A&gt; - Evidence and commentary by Dr David Goldsmith&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:314925:0" name=internalLink&gt;Randomised Controlled Trials and Management of Proteinuria and CKD 2009&lt;/A&gt; - Evidence and commentary by Dr Edward Sharples&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:315010:0" name=internalLink&gt;Early identification and management of CKD: Review of NICE guidelines&lt;/A&gt; - Evidence and commentary by Dr Edward Sharples&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:315167:0" name=internalLink&gt;References&lt;/A&gt; - Evidence&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:315193:0" name=internalLink&gt;Methodology&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Related Treatment Uncertainties:&lt;/LI&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=315292&amp;amp;tabID=289" target="_blank"&gt;What is the best therapy for renoprotection - ACEi or ARBs - and what is the role of combination therapy?&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=315293&amp;amp;tabID=289" target="_blank"&gt;What is the therapeutic role of aliskiren in proteinuria reduction?&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=315378&amp;amp;tabID=289" target="_blank"&gt;Spironolactone in diabetic nephropathy&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=315386&amp;amp;tabID=289" target="_blank"&gt;The use of mycophenolate mofetil (MMF) in the treatment of IgA nephropathy&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=315421&amp;amp;tabID=289" target="_blank"&gt;Pentoxyfilline as a treatment for proteinuria&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/KIDNEY/Page.aspx?pagename=PGFNKWCONT" target="_blank"&gt;&lt;STRONG&gt;Link to 2008 National Knowledge Week on Proteinuria and eGFR: Contents page&lt;/STRONG&gt;&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>27/05/2010 09:54:52</lastReviewDate>
    <expiryDate>27/05/2011 09:54:52</expiryDate>
  </document>
  <document>
    <id>303594</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=303594]]&gt;</url>
    <title>2009 Annual Evidence Update on Urinary Incontinence - Botulinum Toxin A and Male Urinary Incontinence</title>
    <publicationDate>2009-01-19T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE URINARY INCONTINENCE,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Urinary Incontinence - Botulinum Toxin A and Male Urinary Incontinence&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;H2&gt;&lt;A href="nelh:301849:0" name=internalLink&gt;Link back to Contents page&lt;/A&gt;&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Evidence&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Kalsi V, Apostolidis A, Gonzales G, Elneil S, Dasgupta P, Fowler CJ. Early effect on the overactive bladder symptoms following botulinum neurotoxin type A injections for detrusor overactivity. European Urology 2008;54(1):181-7.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18191323?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lim SK, Quek PL. Intraprostatic and bladder-neck injection of botulinum A toxin in treatment of males with bladder-neck dyssynergia: a pilot study. European Urology 2008;53(3):620-5.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17950522?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Sahai A, Khan MS, Le GN, Dasgupta P, GKT Botulinum Study Group. Urodynamic assessment of poor responders after botulinum toxin-A treatment for overactive bladder. Urology 2008;71(3):455-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18342186?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Dmochowski R, Sand PK. Botulinum toxin A in the overactive bladder: current status and future directions. BJU International 2007;99(2):247-62.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17313422?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Duthie J, Wilson DI, Herbison GP, Wilson D. Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database of Systematic Reviews 2007, Issue 3. Art. No.: CD005493. DOI: 10.1002/14651858.CD005493.pub2. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17636801?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Ghalayini IF, Al-Ghazo MA. Intradetrusor injection of botulinum-A toxin in patients with idiopathic and neurogenic detrusor overactivity: urodynamic outcome and patient satisfaction. Neurourology &amp;amp; Urodynamics 2007;26(4):531-6.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17330289?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hirst GR, Watkins AJ, Guerrero K, Wareham K, Emery SJ, Jones DR, et al. Botulinum toxin B is not an effective treatment of refractory overactive bladder. Urology 2007;69(1):69-73.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17270619?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Jeffery S, Fynes M, Lee F, Wang K, Williams L, Morley R. Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity. BJU International 2007;100(6):1302-6.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17979928?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kuo HC. Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin a for idiopathic detrusor overactivity. Journal of Urology 2007;178(4 Pt 1):1359-63.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17706718?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Sahai A, Khan MS, Dasgupta P. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. Journal of Urology 2007;177(6):2231-6.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17509328?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Pubmed link&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Unwala DJ, Barboglio P, Gousse AE. Repeated botulinum toxin injection for idiopathic overactive bladder: will chemodenervation become a long-term solution? Current Urology Reports 2007;8(5):419-24.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17880843?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2006&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Kalsi V, Apostolidis A, Popat R, Gonzales G, Fowler CJ, Dasgupta P. Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes. European Urology 2006;49(3):528-35.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16426735?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kalsi V, Popat RB, Apostolidis A, Kavia R, Odeyemi IA, Dakin HA, et al. Cost-consequence analysis evaluating the use of botulinum neurotoxin-A in patients with detrusor overactivity based on clinical outcomes observed at a single UK centre. European Urology 2006;49(3):519-27.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16413656?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kuo HC. Will suburothelial injection of small dose of botulinum A toxin have similar therapeutic effects and less adverse events for refractory detrusor overactivity? Urology 2006;68(5):993-7.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17113890?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lucioni A, Rapp DE, Gong EM, Fedunok P, Bales GT. Intravesical botulinum type A toxin injection in patients with overactive bladder: Trigone versus trigone-sparing injection. Canadian Journal of Urology 2006;13(5):3291-5.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17076955?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Schmid DM, Sauermann P, Werner M, Schuessler B, Blick N, Muentener M, et al. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. Journal of Urology 2006;176(1):177-85.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16753396?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;2005&lt;/H2&gt;
&lt;OL&gt;
&lt;LI&gt;Apostolidis A, Popat R, Yiangou Y, Cockayne D, Ford AP, Davis JB, et al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. Journal of Urology 2005;174(3):977-82. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16094018?ordinalpos=15&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Ghei M, Maraj BH, Miller R, Nathan S, O'Sullivan C, Fowler CJ, et al. Effects of botulinum toxin B on refractory detrusor overactivity: a randomized, double-blind, placebo controlled, crossover trial. Journal of Urology 2005;174(5):1873-7.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16217327?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kuo HC. Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics. Urology 2005;66(1):94-8. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15992869?ordinalpos=15&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Schulte-Baukloh H, Weiss C, Stolze T, Herholz J, Sturzebecher B, Miller K, et al. Botulinum-A toxin detrusor and sphincter injection in treatment of overactive bladder syndrome: objective outcome and patient satisfaction. European Urology 2005;48(6):984-90.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16126328?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;STRONG&gt;&lt;A href="nelh:304187:0" name=internalLink&gt;
&lt;P&gt;&lt;STRONG&gt;Link to Women's Health SL page on Intravesical Botulinum toxin injections in the management of Overactive Bladder (OAB) syndrome&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>06/12/2010 12:27:14</lastReviewDate>
    <expiryDate>06/12/2011 12:27:14</expiryDate>
  </document>
  <document>
    <id>303725</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=303725]]&gt;</url>
    <title>2009 Annual Evidence Update on Urinary Incontinence - Conservative Management of Urinary Incontinence</title>
    <publicationDate>2009-01-19T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE URINARY INCONTINENCE,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;2&lt;/pageSequence&gt;&lt;pageTitle&gt;Commentary&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;&lt;A href="nelh:301849:0" name=internalLink&gt;Link back to Contents page&lt;/A&gt;&lt;/H2&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;&lt;STRONG&gt;Conservative management of urinary incontinence in men&lt;/STRONG&gt;&lt;/H2&gt;
&lt;H3&gt;Author: &amp;nbsp;Jane Newman&lt;BR&gt;Clinical Specialist Physiotherapist in Women’s and Men’s Health, Oxford Radcliffe NHS Trust, OX3 9DU&lt;/H3&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;There is increasing evidence that conservative management is useful in the treatment of men pre and post radical prostatectomy, with post micturition dribbling and in some cases of erectile dysfunction. More studies need to be done and much more evidence is available when searching in relation to the treatment of female pelvic floor dysfunction.&amp;nbsp; Early indications are encouraging particularly if exercises are continued for at least a year after surgery. This is useful given the complication rate of some other forms of treatment of post surgical incontinence.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;As with the treatment of women the only data available has been done by specialist physiotherapists rather than general physiotherapists, and includes wider assessment than just that of the pelvic floor itself. Assessment of bowel function and lifestyle is particularly relevant with these men as obstructive defaecation seems to link with affected pelvic floor function. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Increasing numbers of members of the Association of Chartered Physiotherapists in Women’s Health are developing an interest in the treatment of male pelvic floor problems and these members can be found using the ACPWH links below.&lt;/P&gt;
&lt;P&gt;Treatment regimes pursued so far have followed the broad outline of those in the attached document for women but as yet there is very little research evidence to support specific regimes.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Useful links:&lt;BR&gt;&lt;A href="http://www.acpwh.org.uk/" target="_blank"&gt;www.acpwh.org.uk&lt;/A&gt;&lt;BR&gt;&lt;A href="http://www.csp.org.uk/" target="_blank"&gt;www.csp.org.uk&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;See also:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Dorey G, Speakman MJ, Feneley RCL, Swinkels A, Dunn CDR. Pelvic floor exercises for erectile dysfunction. BJUI 2005;96(4):595-597 [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16104916?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Dorey, Grace. Pelvic Floor Exercises for Erectile Dysfunction. Whurr Publishers ISBN 1-86156-365-5&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A href="nelh:304322:0" name=internalLink&gt;&lt;STRONG&gt;Link to article in the Women's Health Specialist Library on the Conservative&amp;nbsp;Management of Stress Urinary Incontinence in Women&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;2&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Evidence&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A href="nelh:301849:0" name=internalLink&gt;&lt;STRONG&gt;Link back to Contents page&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Hurtado EA, McCrery RJ, Appell RA. Complications of Ethylene Vinyl Alcohol Copolymer as an Intraurethral Bulking Agent in Men with Stress Urinary Incontinence. Urology 2008;71(4):662-5.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18279931" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Overgard M, Angelsen A, Lydersen S, Morkved S. Does Physiotherapist-Guided Pelvic Floor Muscle Training Reduce Urinary Incontinence After Radical Prostatectomy?. A Randomised Controlled Trial. European Urology 2008;54(2):438-48.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18448233?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;anonymous. NIH state-of-the-science conference statement on prevention of fecal and urinary incontinence in adults. NIH Consensus &amp;amp; State-of-the-Science Statements 2007;24(1):1-37.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18183046?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hunter KF , Moore KN, Glazener CMA Conservative management for postprostatectomy urinary incontinence Cochrane Database of Systematic Reviews: Reviews 2007 Issue 2 John Wiley &amp;amp; Sons , Ltd Chichester, UK DOI : 10 1002 /14651858 CD001843 pub3 2007.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17443512?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;MacDonald R, Fink HA, Huckabay C, Monga M, Wilt TJ. Pelvic floor muscle training to improve urinary incontinence after radical prostatectomy: a systematic review of effectiveness. BJU International 2007;100(1):76-81.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17433028?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Manassero F, Traversi C, Ales V, Pistolesi D, Panicucci E, Valent F, et al. Contribution of early intensive prolonged pelvic floor exercises on urinary continence recovery after bladder neck-sparing radical prostatectomy: Results of a prospective controlled randomized trial. Neurourology and Urodynamics 2007;26(7):985-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17487874" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;2006&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Burgio KL, Goode PS, Urban DA, Umlauf MG, Locher JL, Bueschen A, et al. Preoperative biofeedback assisted behavioral training to decrease post-prostatectomy incontinence: a randomized, controlled trial. Journal of Urology 2006;175(1):196-201.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16406909" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Madjar S, Sharma AK, Waltzer WC, Frischer Z, Secrest CL. Periurethral mass formations following bulking agent injection for the treatment of urinary incontinence. Journal of Urology 2006;175(4):1408-10.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16516009" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;2005&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Cornel EB, de WR, Witjes JA. Evaluation of early pelvic floor physiotherapy on the duration and degree of urinary incontinence after radical retropubic prostatectomy in a non-teaching hospital. World Journal of Urology 2005;23(5):353-5. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16211421" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Filocamo MT, Li M, V, Del PG, Cecconi F, Marzocco M, Tosto A, et al. Effectiveness of early pelvic floor rehabilitation treatment for post-prostatectomy incontinence. European Urology 2005;48(5):734-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16002204" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Schneider T, Sperling H, Rossi R, Schmidt S, Rubben H. Do early injections of bulking agents following radical prostatectomy improve early continence? World Journal of Urology 2005;23(5):338-42.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16261366" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>06/12/2010 12:27:19</lastReviewDate>
    <expiryDate>06/12/2011 12:27:19</expiryDate>
  </document>
  <document>
    <id>301849</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=301849]]&gt;</url>
    <title>2009 Annual Evidence Update on Urinary Incontinence - Contents</title>
    <publicationDate>2009-01-19T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE URINARY INCONTINENCE,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Urinary Incontinence - Contents&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;H1 align=center&gt;&amp;nbsp;&lt;/H1&gt;
&lt;P align=center&gt;&lt;IMG id=nelh_tempImage0 style="WIDTH: 165px; HEIGHT: 129px" height=153 alt="Urine sample" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID301849/nelhImp_0002_Anotherurinesample_istock_vsmall_08jan09.jpg" width=165 border=0 name=nelh_tempImage0&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;IMG id=nelh_tempImage2 style="WIDTH: 161px; HEIGHT: 129px" height=153 alt="Male toilet sign " src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID301849/nelhImp_0003_Maletoiletabstract_istock_vsmall_08jan09.jpg" width=161 border=0 name=nelh_tempImage2&gt;&lt;/P&gt;
&lt;P style="FONT-SIZE: 110%; COLOR: red; FONT-FAMILY: verdana" align=center&gt;&lt;BIG&gt;&lt;B&gt;19th - 23rd January 2009&amp;nbsp;Annual Evidence&amp;nbsp;Update&amp;nbsp;on Urinary Incontinence&lt;/B&gt;&lt;/BIG&gt; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Introduction:&amp;nbsp; &lt;STRONG&gt;Urinary Incontinence&lt;/STRONG&gt;&lt;/H2&gt;
&lt;P&gt;&lt;BR&gt;By Alison Brading, Emeritus professor of Pharmacology, University Department of Pharmacology, Mansfield Road, Oxford OX1 3QT&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Urinary incontinence is normally not life-threatening, and yet may have a greater detrimental effect on the quality of life of those suffering from it than many more serious conditions. A great deal of literature is published yearly, and the aim of this annual evidence update is to direct attention to the relevant information gleaned from papers published about male and female urinary incontinence in recent years.&lt;/P&gt;
&lt;P&gt;We have considered the more traditional pharmacological and surgical treatment of adult male and female stress and urge incontinence, including post-prostatectomy incontinence in men, and, as well as more conservative approaches now cover the rapidly growing use of botulinum toxin injected into the bladder wall as a treatment for urge incontinence.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;We hope that this will provide a useful source for busy clinicians, and will help to improve treatment of this devastating condition.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A href="nelh:304503:0" name=internalLink&gt;&lt;STRONG&gt;Download the 2009 AEU poster from this page&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Topics:&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;&lt;A href="nelh:302108:0" name=internalLink&gt;&lt;A href="nelh:302108:0" name=internalLink&gt;Post-prostatectomy and Urinary Incontinence&lt;/A&gt;&amp;nbsp;This page contains a &lt;STRONG&gt;Commentary&lt;/STRONG&gt; by Mr Alastair Henderson and Mr Jonathon Olsburgh, and links to the Evidence.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:303594:0" name=internalLink&gt;Botulinum Toxin A and Male Urinary Incontinence&lt;/A&gt;&amp;nbsp;This page contains Evidence only &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:303725:0" name=internalLink&gt;Conservative Management of Male Urinary Incontinence&lt;/A&gt;&amp;nbsp;This page contains a &lt;STRONG&gt;Commentary&lt;/STRONG&gt; by Jane Newman, and links to the&amp;nbsp;Evidence&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:303722:0" name=internalLink&gt;Male and Female Quality of Life Studies&lt;/A&gt;&amp;nbsp;This page contains a &lt;STRONG&gt;Commentary&lt;/STRONG&gt; by Mrs Alison Bardsley, and links to the Evidence.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:302233:0" name=internalLink&gt;Validated and Disease-Specific Questionnaires&lt;/A&gt;&amp;nbsp;This page contains a &lt;STRONG&gt;list of Questionnaires&lt;/STRONG&gt; and other Evidence&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:303708:0" name=internalLink&gt;Male Stress Urinary Incontinence and Surgery&lt;/A&gt;&amp;nbsp;This page contains Evidence only&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:303709:0" name=internalLink&gt;Male Stress Urinary Incontinence&amp;nbsp;and Drug treatment&lt;/A&gt;&amp;nbsp;This page contains Evidence only&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:303710:0" name=internalLink&gt;Male Urgency Urinary Incontinence&amp;nbsp;and Surgery&lt;/A&gt;&amp;nbsp;This page contains Evidence only &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:303711:0" name=internalLink&gt;Male Urgency Urinary Incontinence&amp;nbsp;and Drug treatment&lt;/A&gt;&amp;nbsp;This page contains Evidence only&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;A href="nelh:302108:0" name=internalLink&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/womenshealth/page.aspx?pagename=09UIAEUCON" target="_blank"&gt;&lt;STRONG&gt;Link to Women's Health Specialist Library Annual Evidence Update on Urinary Incontinence&lt;/STRONG&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;&lt;A href="nelh:303707:0" name=internalLink&gt;Link to Methodology&lt;/A&gt;&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A href="nelh:303728:0" name=internalLink&gt;&lt;STRONG&gt;Link to page about our Contributors&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Key Publications:&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Abrams, P et al. (2005) Incontinence: 3rd international consultation on incontinence June 26-29, 2004. Vol. 2: Management.&amp;nbsp;Paris: Health Publication Ltd., 2005. ISBN: 0954695623. &lt;/LI&gt;
&lt;LI&gt;SIGN (2004) Management of urinary incontinence in primary care. [&lt;A href="http://www.sign.ac.uk/pdf/sign79.pdf" target="_blank"&gt;Link to guideline in full-text PDF&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Thuroff J, Abrams P, Andersson KE, Artibani W, Chartier-Kastler E, Hampel C, van Kerrebroeck Ph. (2005) Guidelines on Urinary Incontinence. European Association of Urology. March 2005. [&lt;A href="http://www.uroweb.org/fileadmin/tx_eauguidelines/16%20Urinary%20Incontinence.pdf" target="_blank"&gt;Link to guideline in full-text PDF&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The NICE guideline on Male lower urinary tract symptoms (LUTS) is due to be issued in&amp;nbsp; February 2010. [&lt;A href="http://www.nice.org.uk/Guidance/CG/Wave14/23" target="_blank"&gt;Link to NICE webpage on LUTS guideline&lt;/A&gt;].&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;We welcome your &lt;A href="http://www.library.nhs.uk/kidney/ContactUs.aspx" target="_blank"&gt;feedback&lt;/A&gt;&lt;/P&gt;&lt;/B&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>03/11/2010 15:38:23</lastReviewDate>
    <expiryDate>03/11/2011 15:38:23</expiryDate>
  </document>
  <document>
    <id>303728</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=303728]]&gt;</url>
    <title>2009 Annual Evidence Update on Urinary Incontinence - Contributors</title>
    <publicationDate>2009-01-19T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE URINARY INCONTINENCE,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Urinary Incontinence - Contributors&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;&lt;A href="nelh:301849:0" name=internalLink&gt;&lt;STRONG&gt;Link back to Contents page&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Alison Bardsley:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Oxfordshire Continence Services Manager&lt;BR&gt;Oxfordshire PCT&lt;BR&gt;Oxfordshire Continence Advisory Service&lt;BR&gt;Witney Community Hospital&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Alison Brading:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Emeritus professor of Pharmacology, &lt;BR&gt;University Department of Pharmacology,&lt;BR&gt;Mansfield Road,&lt;BR&gt;Oxford&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Dr David J A Goldsmith MA FRCP (UK):&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage0 height=200 alt="David Goldsmith" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID303728/nelhImp_0001_DG2008Headshot1.jpg" width=175 border=0 name=nelh_tempImage0&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Consultant Nephrologist&lt;BR&gt;Deputy Director of Research and Development&lt;BR&gt;Guy's and St Thomas' NHS Foundation Trust &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Mr Alastair Henderson PhD FRCS(Urol)&lt;/STRONG&gt;&lt;/P&gt;&lt;IMG id=nelh_tempImage0 height=150 alt="Alastair Henderson" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID303728/nelhImp_0003_AliHendersonphotoforNELHupdate.jpg" width=135 border=0 name=nelh_tempImage0&gt;&lt;BR&gt;Urology Specialist Registrar&lt;BR&gt;Guy's and St Thomas' NHS Foundation Trust 
&lt;P&gt;&lt;STRONG&gt;Jane Newman&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;Clinical Specialist Physiotherapist in Women’s and Men’s Health, &lt;BR&gt;Oxford Radcliffe NHS Trust, OX3 9DU&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Mr Jonathon Olsburgh PhD FRCS(Urol)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage1 height=150 alt="Jonathon Oldsburgh" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID303728/nelhImp_0002_MrJonathonOlsburgh.jpg" width=200 border=0 name=nelh_tempImage1&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Consultant Urologist and Transplant Surgeon &lt;BR&gt;Department of Urology, Guy's and St Thomas' NHS Foundation Trust, London &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Jo Turner:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Clinical Nurse Manager&lt;BR&gt;Urology Department&lt;BR&gt;Churchill Hospital&lt;BR&gt;Oxford&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>06/12/2010 12:27:23</lastReviewDate>
    <expiryDate>06/12/2011 12:27:23</expiryDate>
  </document>
  <document>
    <id>303722</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=303722]]&gt;</url>
    <title>2009 Annual Evidence Update on Urinary Incontinence - Male and Female Quality of Life Studies</title>
    <publicationDate>2009-01-19T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE URINARY INCONTINENCE,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;2&lt;/pageSequence&gt;&lt;pageTitle&gt;Commentary&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;&lt;A href="nelh:301849:0" name=internalLink&gt;Link back to Contents page&lt;/A&gt;&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Commentary on Urinary Incontinence and Quality of Life Scores&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This commentary was written by Mrs Alison Bardsley MSc, RGN, DN and Mrs Jo Turner BSc,RGN.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Urinary Incontinence&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Symptoms of urinary incontinence are common particularly in the older population. The estimated prevalence of urinary incontinence varies considerably between studies, mainly due to methodological issues and under-reporting due to embarrassment. Urinary symptoms can include frequency and urgency with or without incontinence, stress incontinence, urinary retention (complete and partial) and reflex incontinence. Urinary incontinence can have a severe impact on employment, social interactions and emotional well-being (1). High levels of depression and low quality of life have been reported in men and women with overactive bladder symptoms (2). The treatments currently available for incontinence are aimed at reducing the number of incontinent episodes and limit the impact on everyday life.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;From a review of the evidence in the literature over the last 5 years the use of patient completed methods (including voiding diaries and questionnaires) for measuring the impact of incontinence on quality of life are becoming increasingly common both clinically and within research (3-12) . &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The International Consultation on Incontinence (ICI) uses a grading system for recommendation of symptom scoring and quality of life scales based on validity, reliability and responsive to support their use and recommends the following validated tools for use in clinical practice and research:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;ICIQ, BFLUTS, I-QOL, SUIQQ, UISS, SEAPI-QMM, ISS, ICS male (ISCmale SF) and KHQ.&amp;nbsp; &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Quality of Life&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;The term quality of life is widely used in research. The World Health Organisation offers a definition which is includes physical, emotional and social well-being, not just the absence of disease (13) “Health related quality if life” (HRQL) refers to attributes valued by patients to have a sense of well-being: the extent to which they were able to maintain physical, emotional and intellectual function and ability to participate in valued activities within a community such as family and work. This highlights the multidimensional nature of quality of life and the individual’s perception in the context of their circumstances (14). &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Measurement of Quality of Life and Symptom Scores&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;The symptoms of incontinence and their impact on an individual’s quality of life can be assessed in a number of ways. However the only valid way to measure the patient’s personal perspective is by using self completion questionnaires (15). Quality of life and symptom scoring tools are useful in clinical settings to standardise the measurement of severity of incontinence which can help to determine required care and to evaluate the effectiveness of care provided. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Patient completed questionnaires are used to record the presence and severity of urinary symptoms including incontinence as well as the impact on quality of life and everyday activities. Although questionnaires used in clinical research can be long and detailed, those used for clinical practice need to be short and easy to complete.&lt;/P&gt;
&lt;P&gt;&amp;nbsp; &lt;BR&gt;&lt;STRONG&gt;Conclusion&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;The experience for people of the symptoms of incontinence, its impact on their quality of life and the outcomes of healthcare desired by patients is uniquely individual and multifaceted. Measuring quality of life and symptoms in a way that reflects the patient’s voice presents a challenge to healthcare professionals. However, identifying patient outcomes is the most credible method of assessment and can be achieved in a number of ways. The scoring of symptoms and quality of life in urinary incontinence provides a method of quantifying the impact of urinary symptoms for patients and can be used as a measure to assess outcomes of treatment at various stages. Evaluation and outcome measures should be built into all clinical assessment and research projects.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Irwin D, Milsom I, Reilly K, Hunskaar S, Coyne K S, Kopp Z, Herschom S, Kelleher C, Hampel C, Artibani W, Arams P. Impact of overactive bladder symtoms on employment, social interactions and emotional well-being in six European countries. British Journal of Urology International (2005) 97, 96-100. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16336336" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Irwin D, Milsom I, Reilly K, Hunskaar S, Coyne K S, Kopp Z, Herschom S, Kelleher C, Hampel C, Artibani W, Arams P. Men and Women with Overactive bladder symptoms report higher prevalence of depression and lower quality of life: results from the EPIC study. European Urology (2006) Volume 50, Issue 6, Pages 1306-1315. [No Pubmed link]&lt;/LI&gt;
&lt;LI&gt;Avery K, Donovan J, Peters TJ, Shaw C, Gotoh M, Abrams P. ICIQ: a brief and robust measure for evaluating the symptoms and impact of urinary incontinence.[see comment]. Neurourology &amp;amp; Urodynamics 2004;23(4):322-30.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15227649?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Brookes ST, Donovan JL, Wright M, Jackson S, Abrams P. A scored form of the Bristol Female Lower Urinary Tract Symptoms questionnaire: data from a randomized controlled trial of surgery for women with stress incontinence. Am J Obstet Gynecol 2004 Jul;191(1):73-82.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/15295345" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Bushnell DM, Martin ML, Summers KH, Svihra J, Lionis C, Patrick DL. Quality of life of women with urinary incontinence: cross-cultural performance of 15 language versions of the I-QOL. Quality of Life Research 2005 Oct;14(8):1901-13.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16155777" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Farage MA, Miller KW, Berardesca E, Maibach HI. Psychosocial and societal burden of incontinence in the aged population: a review. Archives of Gynecology &amp;amp; Obstetrics 2008 Apr;277(4):285-90.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18026973" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Haywood KL, Garratt AM, Lall R, Smith JF, Lamb SE. EuroQol EQ-5D and condition-specific measures of health outcome in women with urinary incontinence: reliability, validity and responsiveness. Quality of Life Research 2008 Apr;17(3):475-83.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18274881" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Homma Y, Uemura S. Use of the short form of King's Health Questionnaire to measure quality of life in patients with an overactive bladder. BJU International 2004&amp;nbsp;&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/15142153" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lagro-Janssen TAL, Hilkens CJM, Klaasen RI, Teunissen D. Greater emotional and social effect of urinary incontinence in men than women. J Am Geriatr Soc 2008 Sep;56(9):1779-81&amp;nbsp;&amp;nbsp;[No Pubmed link]&lt;/LI&gt;
&lt;LI&gt;Matza LS, Thompson CL, Krasnow J, Brewster-Jordan J, Zyczynski T, Coyne KS. Test-retest reliability of four questionnaires for patients with overactive bladder: the overactive bladder questionnaire (OAB-q), patient perception of bladder condition (PPBC), urgency questionnaire (UQ), and the primary OAB symptom questionnaire (POSQ). Neurourology &amp;amp; Urodynamics 2005;24(3):215-25.&amp;nbsp;&amp;nbsp;[&lt;A href="https://rmsadmin.library.nhs.uk/admin/wizards/articles/.%20http://www.ncbi.nlm.nih.gov/sites/entrez/15747340" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Oh SJ, Ku JH. Comparison of three disease-specific quality-of-life questionnaires (Bristol Female Lower Urinary Tract Symptoms, Incontinence Quality of Life and King's Health Questionnaire) in women with stress urinary incontinence. Scandinavian Journal of Urology &amp;amp; Nephrology 2007;41(1):66-71.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17366105" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Subak LL, Brown JS, Kraus SR, Brubaker L, Lin F, Richter HE, et al. The "costs" of urinary incontinence for women. OBSTET GYNECOL 2006 Apr;107(4):908-16.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16582131?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Donovan J, Bosch R, Gotoh M, Jackson S, Naughton M, Radley S, Valiquette L, Bastista J E, Avery K. Symptom and Quality of life Assessment. In: Incontinence, 3rd International Consultation on Incontinence. Abrams P, Cardozo L, Khoury S and Wein A. Eds. (2005)Internal Continence Society and Societe Internationale d’Urologie.&amp;nbsp;[No Pubmed link]&lt;/LI&gt;
&lt;LI&gt;World Health Organisation. Definition of Health. Geneva: WHO, 1978&lt;/LI&gt;
&lt;LI&gt;Naughton MJ, Shumaker SA. Assessment of health-related quality of life. In: Furberg CD, ed. Fundamentals of Clinical Trials. St Louis: Mosby Press, (1996); 185 &lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;2&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Evidence&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A href="nelh:301849:0" name=internalLink&gt;&lt;STRONG&gt;Link back to Contents page&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008 &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Azuma R, Murakami K, Iwamoto M, Tanaka M, Saita N, Abe Y. Prevalence and risk factors of urinary incontinence and its influence on the quality of life of Japanese women. Nurs Health Sci. 2008 Jun;10(2):151-8.&amp;nbsp;&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18466389" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Espuna PM, Puig CM. Coital urinary incontinence: impact on quality of life as measured by the King's Health Questionnaire. International Urogynecology. Journal 2008 May;19(5):621-5.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17973067" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Farage MA, Miller KW, Berardesca E, Maibach HI. Psychosocial and societal burden of incontinence in the aged population: a review. Archives of Gynecology &amp;amp; Obstetrics. 2008 Apr;277(4):285-90.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18026973" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Haywood KL, Garratt AM, Lall R, Smith JF, Lamb SE. EuroQol EQ-5D and condition-specific measures of health outcome in women with urinary incontinence: reliability, validity and responsiveness. Quality of Life Research. 2008 Apr;17(3):475-83.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18274881" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Innerkofler PC, Guenther V, Rehder P, Kopp M, Nguyen-Van-Tam DP, Giesinger JM, et al. Improvement of quality of life, anxiety and depression after surgery in patients with stress urinary incontinence: Results of a longitudinal short-term follow-up. Health and Quality of Life Outcomes. BioMed Central Ltd 6, 2008 Article Number: 72 Date of Publication: 29 Sep 2008 2008.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18823552" target="_blank"&gt;Pubmed link]&lt;/A&gt; &lt;/LI&gt;
&lt;LI&gt;Kelleher CJ, Tubaro A, Wang JT, Kopp Z. Impact of fesoterodine on quality of life: Pooled data from two randomized trials. BJU International. 2008;(1):56-61.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18564231" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Langford CF, Elmissiry MM, Ghoniem GM. Do women have realistic expectations of treatment for stress urinary incontinence? Neurourology &amp;amp; Urodynamics. 2008;27(6):480-4.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18551570?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Lowenstein L, Kenton K, FitzGerald MP, Brubaker L. Clinically useful measures in women with mixed urinary incontinence. Am J Obstet Gynecol. 2008 Jun;198(6):664.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18538148?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Lowenstein L, Kenton K, Dooley Y, Mueller R, Brubaker L. Women who experience detrusor overactive at lower bladder volumes report greater bother. Neurourology &amp;amp; Urodynamics. 2008;27(1):45-7.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17600369" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Murphy M, van RH, Mercurio E, Haff R, Wiseman B, Lucente VR. Incontinence-related quality of life and sexual function following the tension-free vaginal tape versus the "inside-out" tension-free vaginal tape obturator. International Urogynecology Journal. 2008 Apr;19(4):481-7.&amp;nbsp;&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17940718" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;O'Dell KK, Jacelon C, Morse AN. 'I'd rather just go on as I am' -- pelvic floor care preferences of frail, elderly women in residential care. Urol nurs. 2008 Feb;28(1):36-47.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18335696" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Oh SJ, Ku JH, Choo MS, Yun JM, Kim DY, Park WH. Health-related quality of life and sexual function in women with stress urinary incontinence and overactive bladder. International Journal of Urology. 2008 Jan;15(1):62-7.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18184175" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Ragins AI, Shan J, Thom DH, Subak LL, Brown JS, Van Den Eeden SK. Effects of urinary incontinence, comorbidity and race on quality of life outcomes in women. Journal of Urology. 2008;179(2):651-5.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18082212?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Staskin DR, Rosenberg MT, Dahl NV, Polishuk PV, Zinner NR. Effects of oxybutynin transdermal system on health-related quality of life and safety in men with overactive bladder and prostate conditions. International journal of clinical practice. 2008;62:27-38.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17983434" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Abdel-Fattah M, Ramsay I, Barrington JW. A simple visual analogue scale to assess the quality of life in women with urinary incontinence. European Journal of Obstetrics, Gynecology, &amp;amp; Reproductive Biology. 2007 Jul;133(1):86-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16797114?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Cam C, Sakalli M, Ay P, Cam M, Karateke A. Validation of the short forms of the incontinence impact questionnaire (IIQ-7) and the urogenital distress inventory (UDI-6) in a Turkish population. Neurourology &amp;amp; Urodynamics. 2007;26(1):129-33.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17083117?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Ehren I, Volz D, Farrelly E, Berglund L, Brundin L, Hultling C, et al. Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomised, placebo-controlled, double-blind study. Scandinavian journal of urology and nephrology. 2007;41:335-40.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17763227?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Ellis J. A literature review and critical appraisal of questionnaires designed to assess the symptoms and quality-of-life impact of urinary incontinence and lower urinary tract symptoms. Journal of the Association of Chartered Physiotherapists in Women's Health. 2007 Sep;(101):25-9.&amp;nbsp;[No Pubmed link] &lt;/LI&gt;
&lt;LI&gt;Gallagher BL, Dwyer NT, Gaynor-Krupnick DM, Latini JM, Kreder KJ. Objective and quality-of-life outcomes with bone-anchored male bulbourethral sling. Urology. 2007 Jun;69(6):1090-4.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17572193?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Geller EJ, Barbee ER, Wu JM, Loomis MJ, Visco AG. Validation of telephone administration of 2 condition-specific quality-of-life questionnaires. Am J Obstet Gynecol. 2007 Dec;197(6):632-4.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18060958?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Handa VL, Zyczynski HM, Burgio KL, FitzGerald MP, Borello-France D, Janz NK, et al. The impact of fecal and urinary incontinence on quality of life 6 months after childbirth. Am J Obstet Gynecol. 2007 Dec;197(6):636.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18060960?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Kim JC, Chung BS, Choi JB, Lee JY, Lee KS, Park WH, et al. A safety and quality of life analysis of intravaginal slingplasty in female stress incontinence: a prospective, open label, multicenter, and observational study. International Urogynecology. Journal 2007 Nov;18(11):1331-5.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17333435?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Lowenstein L, Dooley Y, Kenton K, Rickey L, FitzGerald MP, Mueller E, et al. The volume at which women leak first on urodynamic testing is not associated with quality of life, measures of urethral integrity or surgical failure. Journal of Urology. 2007 Jul;178(1):193-6.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17499809?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Matsuyama H, Shimizu Y, Kamiryo Y, Joko K, Shimabukuro T, Suga A, et al. [Does alpha1-blocker provide additional improvement of quality-of-life in patients with overactive bladder?--a multi-center prospective randomized trial between anti-cholinergic (propiverine chloride) with and without alpha1-blocker (urapidil)]. The japanese journal of urology 2007;98:604-13.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17564103?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Oh SJ, Ku JH. Comparison of three disease-specific quality-of-life questionnaires (Bristol Female Lower Urinary Tract Symptoms, Incontinence Quality of Life and King's Health Questionnaire) in women with stress urinary incontinence. Scandinavian Journal of Urology &amp;amp; Nephrology. 2007;41(1):66-71.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17366105?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Oliveira JMS, Salgado LBG, Schmitt ACB, Rosa LCL. Correlation between urinary symptoms and quality of life among women with urinary incontinence [Portuguese]. Fisioterapia e Pesquisa. 2007 Sep;14(3):12-7.&amp;nbsp;[No Pubmed link] &lt;/LI&gt;
&lt;LI&gt;Paick JS, Cho MC, Oh SJ, Kim SW, Ku JH. Influence of self-perceived incontinence severity on quality of life and sexual function in women with urinary incontinence. Neurourology &amp;amp; Urodynamics. 2007;26(6):828-35.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17335053?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Pozowski J, Sobanski A, Dudkiewicz D, Michalski B, Ulman-Wlodarz I. Quality of life in women with urinary stress incontinence and evaluation of tension-free vaginal tape treatment. Gynecologic &amp;amp; Obstetric Investigation. 2007;64(1):55-60.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17287606?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Robinson JP, vi-Itzhak T, McCorkle R. Psychometric properties of the Male Urogenital Distress Inventory (MUDI) and Male Urinary Symptom Impact Questionnaire (MUSIQ) in patients following radical prostatectomy. Urol Nurs. 2007 Dec;27(6):512-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18217534?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Sand P, Zinner N, Newman D, Lucente V, Dmochowski R, Kelleher C, et al. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study. BJU International. 2007 Apr;99(4):836-44.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17187655" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Seckiner I, Yesilli C, Mungan NA, Aykanat A, Akduman B. Correlations between the ICIQ-SF score and urodynamic findings. Neurourology &amp;amp; Urodynamics. 2007;26(4):492-4.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17304520" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Sung VW, Glasgow MA, Wohlrab KJ, Myers DL. Impact of age on preoperative and postoperative urinary incontinence quality of life. Am J Obstet Gynecol. 2007 Dec;197(6):680-5.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18060981?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Tennstedt SL, FitzGerald MP, Nager CW, Xu Y, Zimmern P, Kraus S, et al. Quality of life in women with stress urinary incontinence. International Urogynecology. Journal 2007 May;18(5):543-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17036169?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Zhang AY, Strauss GJ, Siminoff LA. Effects of combined pelvic floor muscle exercise and a support group on urinary incontinence and quality of life of postprostatectomy patients. Oncol Nurse Forum. 2007 Jan;Online.(1):47-53.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17562632" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;2006&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Bjelic-Radisic V, Dorfer M, Greimel E, Frudinger A, Tamussino K, Winter R. Quality of life and continence 1 year after the tension-free vaginal tape operation. Am J Obstet Gynecol. 2006 Dec;195(6):1784-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17132481?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Borello-France DF, Zyczynski HM, Downey PA, Rause CR, Wister JA. Effect of pelvic-floor muscle exercise position on continence and quality-of-life outcomes in women with stress urinary incontinence. Phys Ther 2006 Jul;86(7):974-86.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16813477?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Coyne KS, Matza LS, Thompson CL, Kopp ZS, Khullar V. Determining the importance of change in the overactive bladder questionnaire. Journal of Urology 2006;176(2):627-32.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16813906?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Dubeau CE, Simon SE, Morris JN. The effect of urinary incontinence on quality of life in older nursing home residents. J Am Geriatr Soc. 2006 Sep;54(9):1325-33.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16970638?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Edwards DF, Hahn M, Dromerick A. Post stroke urinary loss, incontinence and life satisfaction: when does post-stroke urinary loss become incontinence? Neurourology &amp;amp; Urodynamics 2006;25(1):39-45.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16299814?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Holmgren C, Hellberg D, Lanner L, Nilsson S. Quality of life after tension-free vaginal tape surgery for female stress incontinence. Scandinavian Journal of Urology &amp;amp; Nephrology 2006;40(2):131-7.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16608811?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Homma Y, Koyama N. Minimal clinically important change in urinary incontinence detected by a quality of life assessment tool in overactive bladder syndrome with urge incontinence. Neurourology &amp;amp; Urodynamics 2006;25(3):228-35.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16532466?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Huang AJ, Brown JS, Kanaya AM, Creasman JM, Ragins AI, Van Den Eeden SK, et al. Quality-of-life impact and treatment of urinary incontinence in ethnically diverse older women. Arch Intern Med. 2006 Oct 9;166(18):2000-6.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17030834?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Kalsi V, Apostolidis A, Popat R, Gonzales G, Fowler CJ, Dasgupta P. Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes. European Urology 2006 Mar;49(3):528-35.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16426735?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Koops SES, Bisseling TM, Heintz APM, Vervest HAM. Quality of life before and after TVT, a prospective multicentre cohort study, results from the Netherlands TVT database. BJOG 2006;113(1):26-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16398767?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Koops SES, Bisseling TM, Heintz APM, Vervest HAM. The effectiveness of tension-free vaginal tape (TVT) and quality of life measured in women with previous urogynecologic surgery: analysis from the Netherlands TVT database. Am J Obstet Gynecol. 2006 Aug;195(2):439-44.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16635472?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Lemelle JL, Guillemin F, Aubert D, Guys JM, Lottmann H, Lortat-Jacob S, et al. Quality of life and continence in patients with spina bifida. Quality of Life Research 2006 Nov;15(9):1481-92.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17033913?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Lim J, Cornish A, Carey MP. Clinical and quality-of-life outcomes in women treated by the TVT-O procedure. BJOG 2006 Nov;113(11):1315-20.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17059393?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Oh SJ, Ku JH. Is a generic quality of life instrument helpful for evaluating women with urinary incontinence? Quality of Life Research 2006 Apr;15(3):493-501.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16547788?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Saadoun K, Ringa V, Fritel X, Varnoux N, Zins M, Breart G. Negative impact of urinary incontinence on quality of life, a cross-sectional study among women aged 49-61 years enrolled in the GAZEL cohort. Neurourology &amp;amp; Urodynamics 2006;25(7):696-702.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16917934?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Schraffordt Koops SE, Bisseling TM, Heintz AP, Vervest HA. Quality of life before and after TVT, a prospective multicentre cohort study, results from the Netherlands TVT database. BJOG 2006 Jan;113(1):26-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16398767?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Subak LL, Brown JS, Kraus SR, Brubaker L, Lin F, Richter HE, et al. The "costs" of urinary incontinence for women. Obstet Gynecol. 2006 Apr;107(4):908-16.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16582131?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Teunissen D, Van Den BW, Van WC, Lagro-Janssen T. "It can always happen": the impact of urinary incontinence on elderly men and women. Scand J Prim Health Care. 2006 Sep;24(3):166-73.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16923626?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Van Brummen HJ, Bruinse HW, Van de PG, Heintz AP, Van d, V. What is the effect of overactive bladder symptoms on woman's quality of life during and after first pregnancy? BJU International 2006 Feb;97(2):296-300.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16430633?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Yalcin I, Patrick DL, Summers K, Kinchen K, Bump RC. Minimal clinically important differences in Incontinence Quality-of-Life scores in stress urinary incontinence. Urology 2006 Jun;67(6):1304-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16750246?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Zhang AY, Strauss GJ, Siminoff LA. Intervention of urinary incontinence and quality of life outcome in prostate cancer patients. J Psychosoc Oncol. 2006;24(2):17-30.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17046804?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2005&lt;/STRONG&gt; &lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Bunyavejchevin S. Urinary symptoms and quality of life changes in Thai women with overactive bladder after tolterodine treatment. Journal of the Medical Association of Thailand 2005 Nov;88(11):1497-501. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16471092?ordinalpos=3&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Bunyavejchevin S, Veeranarapanich S. Quality of life assessment in Thai postmenopausal women with an overactive bladder. Journal of the Medical Association of Thailand 2005 Aug;88(8):1023-7. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16404827?ordinalpos=3&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Bushnell DM, Martin ML, Summers KH, Svihra J, Lionis C, Patrick DL. Quality of life of women with urinary incontinence: cross-cultural performance of 15 language versions of the I-QOL. Quality of Life Research 2005 Oct;14(8):1901-13.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16155777?ordinalpos=3&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Epstein LB, Goldberg RP. The overactive bladder and quality of life. [Review] [52 refs]. International Journal of Fertility &amp;amp; Womens Medicine 2005 Jan;50(1):30-6.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15971719?ordinalpos=3&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Goldberg RP, Kwon C, Gandhi S, Atkuru LV, Sand PK. Urinary incontinence after multiple gestation and delivery: impact on quality of life. International Urogynecology Journal 2005 Sep;16(5):334-6.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15700106?ordinalpos=3&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Helstrom L, Nilsson B. Impact of vaginal surgery on sexuality and quality of life in women with urinary incontinence or genital descensus. Acta Obstetricia et Gynecologica Scandinavica 2005 Jan;84(1):79-84.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15603572?ordinalpos=9&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Hoffmann W, Liedke S, Dombo O, Otto U. [Electrostimulation in therapy of postoperative urinary incontinence. Therapeutic value for quality of life]. Der Urologe Ausg A 2005;44:33-40.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15580472?ordinalpos=9&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Kelleher CJ, Cardozo L, Chapple CR, Haab F, Ridder AM. Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU International 2005 Jan;95(1):81-5.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15638900?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link]&lt;/A&gt; &lt;/LI&gt;
&lt;LI&gt;Kinchen KS, Obenchain R, Swindle R. Impact of duloxetine on quality of life for women with symptoms of urinary incontinence. International Urogynecology Journal 2005 Sep;16(5):337-44.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15662490?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Ko Y, Lin S-J, Salmon JW, Bron MS. The impact of urinary incontinence on quality of life of the elderly. American Journal of Managed Care.&amp;nbsp; 2005;(SUPPL. 4):S103-S111.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16161383?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Lenihan JP, Jr. Comparison of the quality of life after nonsurgical radiofrequency energy tissue micro-remodeling in premenopausal and postmenopausal women with moderate-to-severe stress urinary incontinence... includes discussion. Am J Obstet Gynecol. 2005 Jun;192(6):1995-2001.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15970873?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Lukban JC. Suburethral sling using the transobturator approach: a quality-of-life analysis. Am J Obstet Gynecol.&amp;nbsp; 2005 Dec;193(6):2138-43.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16325630?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Matza LS, Thompson CL, Krasnow J, Brewster-Jordan J, Zyczynski T, Coyne KS. Test-retest reliability of four questionnaires for patients with overactive bladder: the overactive bladder questionnaire (OAB-q), patient perception of bladder condition (PPBC), urgency questionnaire (UQ), and the primary OAB symptom questionnaire (POSQ). Neurourology &amp;amp; Urodynamics 2005;24(3):215-25.&amp;nbsp;&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15747340?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Monz B, Pons ME, Hampel C, Hunskaar S, Quail D, Samsioe G, et al. Patient-reported impact of urinary incontinence--results from treatment seeking women in 14 European countries. Maturitas 2005 Nov 30;52:Suppl-34.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16297579?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Oh SJ, Hong SK, Son H, Paick JS, Ku JH. Quality of life and disease severity in Korean women with stress urinary incontinence. Urology 2005 Jul;66(1):69-73.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15992875?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Park SH, Davila GW. Overactive bladder: treatment options for the aging woman.&amp;nbsp; International Journal of Fertility &amp;amp; Womens Medicine 2005 Jan;50(1):37-44.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15971720?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Wren PA, Janz NK, Brubaker L, FitzGerald MP, Weber AM, LaPorte FB, et al. Reliability of health-related quality-of-life measures 1 year after surgical procedures for pelvic floor disorders. Am J Obstet Gynecol. 2005 Mar;192(3):780-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15746672?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2004&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Avery K, Donovan J, Peters TJ, Shaw C, Gotoh M, Abrams P. ICIQ: a brief and robust measure for evaluating the symptoms and impact of urinary incontinence.[see comment]. Neurourology &amp;amp; Urodynamics. 2004;23(4):322-30. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15227649?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;Brookes ST, Donovan JL, Wright M, Jackson S, Abrams P. A scored form of the Bristol Female Lower Urinary Tract Symptoms questionnaire: data from a randomized controlled trial of surgery for women with stress incontinence. Am J Obstet Gynecol. 2004 Jul;191(1):73-82. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15295345?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;Das AK, Carlson AM, Hull M, U.S.MDT-. Improvement in depression and health-related quality of life after sacral nerve stimulation therapy for treatment of voiding dysfunction. Urology. 2004 Jul;64(1):62-8. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15245937?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;Davis TL, Lukacz ES, Luber KM, Nager CW. Determinants of patient satisfaction after the tension-free vaginal tape procedure. Am J Obstet Gynecol. 2004 Jul;191(1):176-81. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15295361?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;Hagglund D, Walker-Engstrom ML, Larsson G, Leppert J. Changes in urinary incontinence and quality of life after four years. A population-based study of women aged 22-50 years. Scand J Prim Health Care. 2004 Jun;22(2):112-7. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15255492?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;Hajebrahimi S, Corcos J, Lemieux MC. International consultation on incontinence questionnaire short form: comparison of physician versus patient completion and immediate and delayed self-administration. Urology 2004 Jun;63(6):1076-8. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15183953?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;Hajjar RR. Psychosocial impact of urinary incontinence in the elderly population. Clinics in Geriatric Medicine. 2004;20(3):553-64. Review rather than research [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15341815?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&amp;nbsp;&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;Hashim H, Abrams P. Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations. Drugs. 2004 Aug;64(15):1643-56. [No Pubmed link] &lt;/LI&gt;
&lt;LI&gt;Homma Y, Kawabe K. Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial. World Journal of Urology. 2004 Oct;22(4):251-6. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15455256?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;Homma Y, Uemura S. Use of the short form of King's Health Questionnaire to measure quality of life in patients with an overactive bladder. BJU International. 2004 May;93(7):1009-13. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15142153?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;Nieto Blanco E, Camacho Perez J, Dívila +ülvarez V, Ledo Garc¡a MP, Moriano Bejar P, Perez Lorente M, et al. Effect of urinary incontinence on quality of life in women aged 40 to 65 years old in a health area of Madrid (Spain) [Spanish]. Enfermeria Clinica. 2004 May;14(3):129-35. [No Pubmed link]&lt;/LI&gt;
&lt;LI&gt;Stach-Lempinen B, Kirkinen P, Laippala P, Metsanoja R, Kujansuu E. Do objective urodynamic or clinical findings determine impact of urinary incontinence or its treatment on quality of life? Urology. 2004 Feb;63(1):67-71. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/14751350?ordinalpos=3&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Pubmed link&lt;/A&gt;]&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;van KP, ter MF, Larsson G, Farrelly E, Edwall L, Fianu-Jonasson A. Treatment of stress urinary incontinence using a copolymer system: Impact on quality of life. BJU International. 2004;(7):1040-3. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15541124?ordinalpos=3&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Pubmed link&lt;/A&gt;]&amp;nbsp;&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;Walsh K, Generao SE, White MJ, Katz D, Stone AR. The influence of age on quality of life outcome in women following a tension-free vaginal tape procedure. Journal of Urology 2004 Mar;171(3):1185-8. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/14767297?ordinalpos=3&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Pubmed link&lt;/A&gt;]&amp;nbsp; &lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>06/12/2010 12:27:27</lastReviewDate>
    <expiryDate>06/12/2011 12:27:27</expiryDate>
  </document>
  <document>
    <id>303709</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=303709]]&gt;</url>
    <title>2009 Annual Evidence Update on Urinary Incontinence - Male Stress Urinary Incontinence and Drug treatment</title>
    <publicationDate>2009-01-19T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE URINARY INCONTINENCE,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Urinary Incontinence - Male Stress Urinary Incontinence and Drug treatment&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;H2&gt;&lt;A href="nelh:301849:0" name=internalLink&gt;Link back to Contents page&lt;/A&gt;&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;&lt;BIG&gt;Evidence&lt;/BIG&gt;&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Systematic Review&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Tsakiris P, de la Rosette JJ, Michel MC, Oelke M. Pharmacologic treatment of male stress urinary incontinence: systematic review of the literature and levels of evidence. European Urology 2008 Jan;53(1):53-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17920183" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Other&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Fink KG, Huber J, Wurnschimmel E, Schmeller NT. The use of Duloxetine in the treatment of male stress urinary incontinence. Wiener Medizinische Wochenschrift&amp;nbsp; 2008;(3-4):116-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18330528?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Filocamo MT, Li M, V, Del PG, Cecconi F, Villari D, Marzocco M, et al. Pharmacologic treatment in postprostatectomy stress urinary incontinence. European Urology 2007 Jun;51(6):1559-64.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16942833?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Other&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;2006&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Schlenker B, Gratzke C, Reich O, Schorsch I, Seitz M, Stief CG. Preliminary results on the off-label use of duloxetine for the treatment of stress incontinence after radical prostatectomy or cystectomy.[see comment]. European Urology 2006 Jun;49(6):1075-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16481094" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;&amp;nbsp;van Leeuwen JHS, Castro R, Busse M, Bemelmans BLH. The Placebo Effect in the Pharmacologic Treatment of Patients with Lower Urinary Tract Symptoms. European Urology 2006; 50(3):440-53.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16753253?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Zahariou A, Papaioannou P, Kalogirou G. Is HCl duloxetine effective in the management of urinary stress incontinence after radical prostatectomy? Urologia Internationalis 2006;77(1):9-12.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16825808" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;2005&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Systematic Review&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Mariappan P, Alhasso AA, Grant A, N'Dow JMO Serotonin and noradrenaline reuptake inhibitors for stress urinary incontinence in adults Cochrane Database of Systematic Reviews: Reviews 2005 Issue 3 John Wiley &amp;amp; Sons , Ltd Chichester, UK DOI : 10 1002 /14 2005. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16034945?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>06/12/2010 12:27:31</lastReviewDate>
    <expiryDate>06/12/2011 12:27:31</expiryDate>
  </document>
  <document>
    <id>303708</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=303708]]&gt;</url>
    <title>2009 Annual Evidence Update on Urinary Incontinence - Male Stress Urinary Incontinence and Surgery</title>
    <publicationDate>2009-01-19T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ BLADDER,URINARY TRACT,SURGERY,SURGERY,URINARY INCONTINENCE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE URINARY INCONTINENCE,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Urinary Incontinence - Male Stress Urinary Incontinence and Surgery&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;H2&gt;&lt;A href="nelh:301849:0" name=internalLink&gt;Link back to Contents page&lt;/A&gt;&lt;/H2&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;&lt;BIG&gt;Evidence&lt;/BIG&gt;&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Diagnosis and Assessment&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Kneist W, Junginger T. Intraoperative electrostimulation objectifies the assessment of functional nerve preservation after mesorectal excision. International Journal of Colorectal Disease. 2007;(6):675-82.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17036224" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Twiss CO, Fischer MC, Nitti VW. Comparison between reduction in 24-hour pad weight, International Consultation on Incontinence-Short Form (ICIQ-SF) score, International Prostate Symptom Score (IPSS), and Post-Operative Patient Global Impression of Improvement (PGI-I) score in patient evaluation after male perineal sling. Neurourology &amp;amp; Urodynamics 2007;26(1):8-13.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17016797" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Morbid obesity and bariatric surgery&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Kuruba R, Almahmeed T, Martinez F, Torrella TA, Haines K, Nelson LG, et al. Bariatric surgery improves urinary incontinence in morbidly obese individuals. Surgery for Obesity &amp;amp; Related Diseases 2007 Nov-Dec;3(6):586-90; discussion 590-1&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17950043" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Benign prostate surgery&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Aho TF, Gilling PJ, Kennett KM, Westenberg AM, Fraundorfer MR, Frampton CM. Holmium laser bladder neck incision versus holmium enucleation of the prostate as outpatient procedures for prostates less than 40 grams: a randomized trial. Journal of Urology 2005 Jul;174(1):210-4.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/15947629" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Montorsi F, Naspro R, Salonia A, Suardi N, Briganti A, Zanoni M, et al. Holmium Laser Enucleation Versus Transurethral Resection of the Prostate: Results From a 2-Center Prospective Randomized Trial in Patients With Obstructive Benign Prostatic Hyperplasia. Journal of Urology. &amp;nbsp;Date of Publication: May 2008 2008;(5 SUPPL.):S87-S90.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18405765?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Cystectomy &amp;amp; ileal neo-bladder&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Hautmann RE, Volkmer BG, Schumacher MC, Gschwend JE, Studer UE. Long-term results of standard procedures in urology: the ileal neobladder. World Journal of Urology 2006 Aug;24(3):305-14.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16830152?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Slings, artificial sphincters, bulking agents and stem cells&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Comiter CV, Rhee EY. The 'ventral urethral elevation plus' sling: A novel approach to treating stress urinary incontinence in men. BJU International. 2008;(2):187-91.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17970788" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Henry GD, Graham SM, Cleves MA, Simmons CJ, Flynn B. Perineal approach for artificial urinary sphincter implantation appears to control male stress incontinence better than the transscrotal approach. Journal of Urology, 2008, 179(4):1475-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18295275?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kim SP, Sarmast Z, Daignault S, Faerber GJ, McGuire EJ, Latini JM. Long-term durability and functional outcomes among patients with artificial urinary sphincters: a 10-year retrospective review from the University of Michigan. Journal of Urology 2008&amp;nbsp;&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18353376" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Fassi-Fehri H, Badet L, Cherass A, Murat FJ, Colombel M, Martin X, et al. Efficacy of the InVance male sling in men with stress urinary incontinence.European Urology 2007 Feb;51(2):498-503.&amp;nbsp;&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16996679" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Fischer MC, Huckabay C, Nitti VW. The male perineal sling: assessment and prediction of outcome. Journal of Urology 2007 Apr;177(4):1414-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17382743?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Gallagher BL, Dwyer NT, Gaynor-Krupnick DM, Latini JM, Kreder KJ. Objective and quality-of-life outcomes with bone-anchored male bulbourethral sling. Urology 2007 Jun;69(6):1090-4.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17572193" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lai HH, Hsu EI, Teh BS, Butler EB, Boone TB. 13 years of experience with artificial urinary sphincter implantation at Baylor College of Medicine. Journal of Urology 2007 Mar;177(3):1021-5.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17296403" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Magera JS, Jr., Elliott DS. Tandem transcorporal artificial urinary sphincter cuff salvage technique: surgical description and results. Journal of&amp;nbsp; Urology. 2007 Mar;177(3):1015-9; discussion 1019-20.&amp;nbsp;&amp;nbsp;&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17296400" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;O'Connor RC, Nanigian DK, Patel BN, Guralnick ML, Ellision LM, Stone AR. Artificial Urinary Sphincter Placement in Elderly Men. Urology 69(1)()(pp 126-128), 2007 Date of Publication: Jan 2007 2007;(1):126-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17270633?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Rehder, P, Gozzi, C.&amp;nbsp; Transobturator sling suspension for male urinary incontinence including post-radical prostatectomy. European Urology 2007 52(3) 860-867&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17316969?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Strasser H, Marksteiner R, Margreiter E, Mitterberger M, Pinggera GM, Frauscher F, et al. Transurethral ultrasonography-guided injection of adult autologous stem cells versus transurethral endoscopic injection of collagen in treatment of urinary incontinence. World Journal of Urology 2007 Aug;25(4):385-92.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17701044?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;2006&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Montague DK, Angermeier KW. Treatment of postprostatectomy urinary incontinence: the case against the male sling. Nature Clinical Practice Urology 2006 Jun;3(6):290-1.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16763622" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Petero VG, Jr., Diokno AC. Comparison of the long-term outcomes between incontinent men and women treated with artificial urinary sphincter , Journal of Urology 2006 Feb;175(2):605-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16407005" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Romano SV, Metrebian SE, Vaz F, Muller V, D'Ancona CA, Costa-DE-Souza EA, et al. An adjustable male sling for treating urinary incontinence after prostatectomy: a phase III multicentre trial. BJU International 2006;97:533-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16469021" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;2005&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Castle EP, Andrews PE, Itano N, Novicki DE, Swanson SK, Ferrigni RG. The male sling for post-prostatectomy incontinence: mean followup of 18 months.[see comment]. Journal of Urology 2005 May;173(5):1657-60. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15821530?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Webster GD, Sherman ND. Management of male incontinence following artificial urinary sphincter failure. Current Opinion in Urology 2005 Nov;15(6):386-90.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16205488?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>06/12/2010 12:27:35</lastReviewDate>
    <expiryDate>06/12/2011 12:27:35</expiryDate>
  </document>
  <document>
    <id>303711</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=303711]]&gt;</url>
    <title>2009 Annual Evidence Update on Urinary Incontinence - Male Urgency Urinary Incontinence and Drug treatment</title>
    <publicationDate>2009-01-19T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE URINARY INCONTINENCE,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Urinary Incontinence - Male Urgency Urinary Incontinence and Drug treatment&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;H2&gt;&lt;A href="nelh:301849:0" name=internalLink&gt;Link back to Contents page&lt;/A&gt;&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;&lt;BIG&gt;Evidence&lt;/BIG&gt;&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp;&lt;BR&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Abrams P, Kelleher C, Huels J, Quebe FE, Omar MA, Steel M. Clinical relevance of health-related quality of life outcomes with darifenacin. BJU International 2008;102:208-13.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18325056" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Chancellor MB, Kianifard F, Beamer E, Mongay L, Ebinger U, Hicks G, et al. A comparison of the efficacy of darifenacin alone vs. darifenacin plus a Behavioural Modification Programme upon the symptoms of overactive bladder. International Journal of Clinical Practice. 2008;(4):606-13.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18324952" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Coyne KS, Elinoff V, Gordon DA, Deng DY, Brodsky M, Glasser DB, et al. Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine. Int J Clin&amp;nbsp;Pract. 2008 Jun;62(6):925-31.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18479285" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Dmochowski RR, Sand PK, Zinner NR, Staskin DR. Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study. Urology 2008;71:449-54.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18342185" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Dwyer P, Kelleher C, Young J, Haab F, Lheritier K, Ariely R, et al. Long-term benefits of darifenacin treatment for patient quality of life: results from a 2-year extension study. Neurourology &amp;amp; Urodynamics 2008;27(6):540-7.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18663723" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Homma Y, Yamaguchi T, Yamaguchi O. A randomized, double-blind, placebo-controlled phase II dose-finding study of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder. International Journal of Urology.&amp;nbsp; 2008;(9):809-15.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18637156" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Khullar V, Rovner ES, Dmochowski R, Nitti V, Wang J, Guan Z. Fesoterodine dose response in subjects with overactive bladder syndrome. Urology 2008;71:839-43.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18342923?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Salvatore S, Serati M, Bolis P. Tolterodine for the treatment of overactive bladder. Expert Opinion on Pharmacotherapy 2008 May;9(7):1249-55.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18422481?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Staskin DR, Rosenberg MT, Dahl NV, Polishuk PV, Zinner NR. Effects of oxybutynin transdermal system on health-related quality of life and safety in men with overactive bladder and prostate conditions. Int J Clin Pract 2008 Jan;62(1):27-38.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17983434" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Systematic Review&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Roxburgh C , Cook J, Dublin N Anticholinergic drugs versus other medications for overactive bladder syndrome in adults Cochrane Database of Systematic Reviews: Reviews 2007 Issue 4 John Wiley &amp;amp; Sons , Ltd Chichester, UK DOI : 10 1002 /14651858 CD003190 2007.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17943782?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Other evidence&lt;/STRONG&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Chapple C, DuBeau C, Ebinger U, Rekeda L, Viegas A. Darifenacin treatment of patients &amp;gt;or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial. Current medical research and opinion 2007;23:2347-58.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17706004?ordinalpos=16&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Chapple C, Van KP, Tubaro A, Haag MC, Forst HT, Massow U, et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. European Urology 2007;52:1204-12.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17651893?ordinalpos=20&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Chapple CR, Fianu JA, Indig M, Khullar V, Rosa J, Scarpa RM, et al. Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg. European Urology 2007;52(4):1195-203.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17574730?ordinalpos=28&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Dmochowski R, Abrams P, Marschall-Kehrel D, Wang JT, Guan Z. Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder. European Urology&amp;nbsp; 2007;51(4):1054-64.&amp;nbsp;&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17097217?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Dmochowski R, Kreder K, MacDiarmid S, Carlsson M, Guan Z. The clinical efficacy of tolterodine extended-release is maintained for 24 h in patients with overactive bladder. BJU International 2007;100:107-10.&amp;nbsp;&amp;nbsp;&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17552957" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hofner K, Burkart M, Jacob G, Jonas U. Safety and efficacy of tolterodine extended release in men with overactive bladder symptoms and presumed non-obstructive benign prostatic hyperplasia. World Journal of Urology 2007 Dec;25(6):627-33.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17906864" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kaplan SA. New Data on Tolterodine: Do Recent Findings Dispel Questions About Treating Overactive Bladder in Men? European Urology, Supplements 6(1). 2007;(1):10-6.&amp;nbsp;[No Pubmed link]&lt;/LI&gt;
&lt;LI&gt;Nitti VW, Dmochowski R, Sand PK, Forst HT, Haag MC, Massow U, et al. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. The Journal of urology 2007;178:2488-94.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17937959?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Sand P, Zinner N, Newman D, Lucente V, Dmochowski R, Kelleher C, et al. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study. BJU International 2007;99:836-44.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17187655" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Staskin D, Sand P, Zinner N, Dmochowski R, Trospium-Study-Group. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial. The Journal of urology 2007;178:978-83.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17632131" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Wein AJ, Khullar V, Wang JT, Guan Z. Achieving continence with antimuscarinic therapy for overactive bladder: effects of baseline incontinence severity and bladder diary duration. BJU International 2007;99:360-3.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17155987" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Yamaguchi O, Marui E, Kakizaki H, Itoh N, Yokota T, Okada H, et al. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. BJU International 2007 Sep;100(3):579-87.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17669143" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;2006&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Systematic Reviews&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Alhasso AA, McKinlay J, Patrick K , Stewart L. Anticholinergic drugs versus non drug active therapies for overactive bladder syndrome in adults. Cochrane Database of Systematic Reviews: Reviews 2006 Issue 4 John Wiley &amp;amp; Sons , Ltd Chichester, UK DOI : 10 2006.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17054163" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Nabi G , Cody JD, Ellis G , Herbison P, Hay Smith J Anticholinergic drugs versus placebo for overactive bladder syndrome in adults Cochrane Database of Systematic Reviews: Reviews 2006 Issue 4 John Wiley &amp;amp; Sons , Ltd Chichester, UK DOI : 10 1002 /146518 2006.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17054185?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Other evidence&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Chapple CR, Cardozo L, Steers WD, Govier FE. Solifenacin significantly improves all symptoms of overactive bladder syndrome. Int J Clin Pract 2006 Aug;60(8):959-66.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16893438" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Corcos J, Casey R, Patrick A, Andreou C, Miceli PC, Reiz JL, et al. A double-blind randomized dose-response study comparing daily doses of 5, 10 and 15 mg controlled-release oxybutynin: balancing efficacy with severity of dry mouth. BJU International 2006;97:520-7.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16469019" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Elinoff V, Bavendam T, Glasser DB, Carlsson M, Eyland N, Roberts R. Symptom-specific efficacy of tolterodine extended release in patients with overactive bladder: the IMPACT trial. Int J Clin Pract 2006 Jun;60(6):745-51.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16805763" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Garely AD, Kaufman JM, Sand PK, Smith N, Andoh M. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT). Clin Ther. 2006 Nov;28(11):1935-46.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17213014?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Haab F, Corcos J, Siami P, Glavind K, Dwyer P, Steel M, et al. Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study. BJU International 2006;98:1025-32.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16879437?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Jünemann KP, Hessdörfer E, Unamba O, I, Berse M, Brünjes R, Madersbacher H, et al. Propiverine hydrochloride immediate and extended release: comparison of efficacy and tolerability in patients with overactive bladder. Urologia internationalis 2006;77:334-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17135784?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.[see comment][erratum appears in JAMA. 2007 Mar 21:297(11):1195]. JAMA 2006 Nov 15;296(19):2319-28.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17105794?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kaplan SA, Roehrborn CG, Dmochowski R, Rovner ES, Wang JT, Guan Z. Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia. Urology 2006 Aug;68(2):328-32.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16904446" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kelleher C, Cardozo L, Kobashi K, Lucente V. Solifenacin: as effective in mixed urinary incontinence as in urge urinary incontinence. International urogynecology journal and pelvic floor dysfunction 2006;17:382-8. (This is a male and female paper)&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16283422" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mitropoulos D, Papadoukakis S, Zervas A, Alamanis C, Giannopoulos A. Efficacy of tolterodine in preventing urge incontinence immediately after prostatectomy. International urology and nephrology 2006;38:263-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16868694" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Roberts R, Bavendam T, Glasser DB, Carlsson M, Eyland N, Elinoff V. Tolterodine extended release improves patient-reported outcomes in overactive bladder: results from the IMPACT trial. Int J Clin Pract 2006 Jun;60(6):752-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16805764" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Roehrborn CG, Abrams P, Rovner ES, Kaplan SA, Herschorn S, Guan Z. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. BJU International 2006 May;97(5):1003-6.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16643482?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Zinner N, Susset J, Gittelman M, Arguinzoniz M, Rekeda L, Haab F. Efficacy, tolerability and safety of darifenacin, an M3 selective receptor antagonist: an investigation of warning time in patients with OAB. Int J Clin Pract 2006;60(1):119-26.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16409440" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;2005&lt;/STRONG&gt; &lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Cardozo L, Dixon A. Increased warning time with darifenacin: a new concept in the management of urinary urgency. The Journal of urology 2005;173:1214-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/15758755" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Takei M, Homma Y, The-Japanese-Tolterodine-Study-Group. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder in Japanese patients. International journal of urology : official journal of the Japanese Urological Association 2005;12:456-64.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/15948744" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Elderly&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Johnson II TM, Miller M, Tang T, Pillion DJ, Ouslander JG. Oral ddAVP for night time urinary incontinence in characterized nursing home residents: A pilot study. Journal of the American Medical Directors Association. 2006;(1):6-11.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16413428/16413428" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Wagg A, Wyndaele JJ, Sieber P. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.[see comment]. American Journal Geriatric Pharmacotherapy 2006 Mar;4(1):14-24.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16730617?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Asplund R. Pharmacotherapy for nocturia in the elderly patient.&amp;nbsp; Drugs &amp;amp; Aging 2007;24(4):325-43.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17432926?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>06/12/2010 12:27:39</lastReviewDate>
    <expiryDate>06/12/2011 12:27:39</expiryDate>
  </document>
  <document>
    <id>303710</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=303710]]&gt;</url>
    <title>2009 Annual Evidence Update on Urinary Incontinence - Male Urgency Urinary Incontinence and Surgery</title>
    <publicationDate>2009-01-19T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ URINARY TRACT,BLADDER,SURGERY,SURGERY,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,URINARY INCONTINENCE,MALE URINARY INCONTINENCE,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Urinary Incontinence - Male Urgency Urinary Incontinence and Surgery&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;H2&gt;&lt;A href="nelh:301849:0" name=internalLink&gt;Link back to Contents page&lt;/A&gt;&lt;/H2&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;&lt;BIG&gt;Evidence&lt;/BIG&gt;&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Recommended references on Nerve Stimulation and Urinary Incontinence: &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Groenendijk PM, et al. Urodynamic evaluation of sacral neuromodulation for urge urinary incontinence. BJU International, Feb 2008, vol./is. 101/3(325-9). [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18070199?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&amp;nbsp; &lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Sherman ND, Amundsen CL. Current and future techniques of neuromodulation for bladder dysfunction. Current Urology Reports 2007;8(6):448-54.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18042323?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Sutherland SE, Lavers A, Carlson A, Holtz C, Kesha J, Siegel SW. Sacral nerve stimulation for voiding dysfunction: One institution's 11-year experience. Neurourology and Urodynamics 2007;26(1):19-28.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17078071" target="_blank"&gt;Pubmed link&lt;/A&gt;]&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;Foster RT Sr, Anoia EJ, Webster GD, Amundsen CL. In patients undergoing neuromodulation for intractable urge incontinence a reduction in 24-hr pad weight after the initial test stimulation best predicts long-term patient satisfaction.Neurourology &amp;amp; Urodynamics, 2007, vol./is. 26/2(213-7).&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17009252" target="_blank"&gt;Pubmed link&lt;/A&gt;]&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;Van Kerrebroeck PE, et al. Results of Sacral Neuromodulation Therapy for Urinary Voiding Dysfunction: Outcomes of a Prospective, Worldwide Clinical StudyJournal of Urology, Nov 2007, vol./is. 178/5(2029-2034).&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17869298?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;2006&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Brazzelli M, Murray A, Fraser C. Efficacy and safety of sacral nerve stimulation for urinary urge incontinence: a systematic review. Journal of Urology 2006;175(3 Pt 1):835-41.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16469561" target="_blank"&gt;Pubmed link&lt;/A&gt;]&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;Cohen BL, Tunuguntla HS, Gousse A. Predictors of success for first stage neuromodulation: motor versus sensory response. Journal of Urology 2006;175(6):2178-80.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16697833" target="_blank"&gt;Pubmed link&lt;/A&gt;]&amp;nbsp;&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;van der PF, van Balken MR, Heesakkers JP, Debruyne FM, Bemelmans BL. Percutaneous tibial nerve stimulation in the treatment of refractory overactive bladder syndrome: is maintenance treatment necessary? BJU International 2006;97(3):547-50.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16469023" target="_blank"&gt;Pubmed link&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;van der PF, van Balken MR, Heesakkers JP, Debruyne FM, Kiemeney LA, Bemelmans BL. Correlation between quality of life and voiding variables in patients treated with percutaneous tibial nerve stimulation. BJU International 2006;97(1):113-6.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16336339" target="_blank"&gt;Pubmed link&lt;/A&gt;]&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;van Voskuilen AC, Oerlemans DJ, Weil EH, de Bie RA, van Kerrebroeck PE. Long term results of neuromodulation by sacral nerve stimulation for lower urinary tract symptoms: a retrospective single center study. European Urology 2006;49(2):366-72.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16413105" target="_blank"&gt;Pubmed link&lt;/A&gt;]&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;Efficacy of sacral neuromodulation for symptomatic treatment of refractory urinary urge incontinence. Urology, Mar 2006, vol./is. 67/3(550-3; discussion 553-4), 1527-9995.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16527577" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Other evidence:&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Mancini JG, Kizer WS, Jones LA, Mora RV, Morey AF. Patient satisfaction after dual implantation of inflatable penile and artificial urinary sphincter prostheses. Urology 2008 May;71(5):893-6.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18374398" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;2007&amp;nbsp; &lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Lai HH, Hsu EI, Teh BS, Butler EB, Boone TB. 13 years of experience with artificial urinary sphincter implantation at Baylor College of Medicine. Journal of Urology 2007 Mar;177(3):1021-5.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17296403" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Matoka DJ, Averch TD. Predictability of irritative voiding symptoms following photoselective laser vaporization of the prostate. Canadian Journal of Urology 2007 Oct;14(5):3710-4.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17949529" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Magera JS, Jr., Inman BA, Elliott DS. Does preoperative topical antimicrobial scrub reduce positive surgical site culture rates in men undergoing artificial urinary sphincter placement?&amp;nbsp; J Urol. 2007 Oct;178(4 Pt 1):1328-32; discussion 1332&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17698144" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;2006&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Van Dijk MM, Mochtar CA, Wijkstra H, Laguna MP, De La Rosette JJMC. The bell-shaped nitinol prostatic stent in the treatment of lower urinary tract symptoms: Experience in 108 patients. European Urology. 2006;(2):353-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16426738" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A href="nelh:304165:0" name=internalLink&gt;&lt;STRONG&gt;Link to Women's Health SL page on Sacral nerve stimulation in the management of overactive bladder syndrome&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;. &lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>06/12/2010 12:27:44</lastReviewDate>
    <expiryDate>06/12/2011 12:27:44</expiryDate>
  </document>
  <document>
    <id>303707</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=303707]]&gt;</url>
    <title>2009 Annual Evidence Update on Urinary Incontinence - Methodology</title>
    <publicationDate>2009-01-19T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE URINARY INCONTINENCE,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Urinary Incontinence - Methodology&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;H2&gt;&lt;A href="nelh:301849:0" name=internalLink&gt;Link back to Contents page&lt;/A&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;General methodology:&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2 class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto"&gt;1.&amp;nbsp;Starting point&lt;/H2&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto"&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto"&gt;The information team&amp;nbsp;identified a National document as a starting date for the searches and as a basis for the scope of the searches. &lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto"&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Key Publications:&lt;/STRONG&gt;&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;OL type=1&gt;
&lt;LI class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; mso-list: l0 level1 lfo2; tab-stops: list 36.0pt"&gt;Abrams, P et al. (2005) Incontinence: 3rd international consultation on incontinence June 26-29, 2004. Vol. 2: Management.&amp;nbsp;&lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;Paris&lt;/st1:place&gt;&lt;/st1:City&gt;: Health Publication Ltd., 2005. ISBN: 0954695623. &lt;o:p&gt;&lt;/o:p&gt;&lt;/LI&gt;
&lt;LI class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; mso-list: l0 level1 lfo2; tab-stops: list 36.0pt"&gt;SIGN (2004) Management of urinary incontinence in primary care. [&lt;A href="http://www.sign.ac.uk/pdf/sign79.pdf" target="_blank"&gt;Link to guideline in full-text PDF&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/LI&gt;
&lt;LI class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; mso-list: l0 level1 lfo2; tab-stops: list 36.0pt"&gt;Thuroff J, Abrams P, Andersson KE, Artibani W, Chartier-Kastler E, Hampel C, van Kerrebroeck Ph. (2005) Guidelines on Urinary Incontinence. European Association of Urology. March 2005. [&lt;A href="http://www.uroweb.org/fileadmin/tx_eauguidelines/16%20Urinary%20Incontinence.pdf" target="_blank"&gt;Link to guideline in full-text PDF&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;H2&gt;2. Date of last search&lt;/H2&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; mso-list: l2 level1 lfo1; tab-stops: list 36.0pt"&gt;The team searched from 2005 because of the dates of the last searches in the key publications. &lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; mso-list: l2 level1 lfo1; tab-stops: list 36.0pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;3. Scope&lt;/H2&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto"&gt;There is more evidence of a higher quality about urinary incontinence in women than in men, therefore the searches included evidence of all levels in order to capture relevant research about urinary incontinence in men. &lt;/P&gt;
&lt;UL type=disc&gt;
&lt;LI class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; mso-list: l1 level1 lfo3; tab-stops: list 36.0pt"&gt;The team&amp;nbsp;searched for 'urinary incontinence' or 'urine incontinence' on 4 databases.&lt;/LI&gt;
&lt;LI class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; mso-list: l1 level1 lfo3; tab-stops: list 36.0pt"&gt;With subheadings for 'stress', 'urge', and 'overactive bladder'&amp;nbsp;where possible and text words where not.&lt;/LI&gt;
&lt;LI class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; mso-list: l1 level1 lfo3; tab-stops: list 36.0pt"&gt;Appropriate&amp;nbsp;subheadings for drug therapy and surgery were applied.&lt;/LI&gt;
&lt;LI class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; mso-list: l1 level1 lfo3; tab-stops: list 36.0pt"&gt;Publication type not restricted to systematic reviews and meta-analyses due to the nature of the evidence on urinary incontinence in males.&lt;/LI&gt;
&lt;LI class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; mso-list: l1 level1 lfo3; tab-stops: list 36.0pt"&gt;Searched for evidence on adults only.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2 class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; mso-list: l1 level1 lfo3; tab-stops: list 36.0pt"&gt;&amp;nbsp;&lt;BR&gt;4. Filters&lt;/H2&gt;
&lt;P&gt;No standard filters were used. The search was restricted to clinical trials and well organised studies, eg. multicentre studies or randomised trials. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;5. Databases searched&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Medline&lt;/LI&gt;
&lt;LI&gt;Embase &lt;/LI&gt;
&lt;LI&gt;Cinahl &lt;/LI&gt;
&lt;LI&gt;Cochrane&lt;/LI&gt;&lt;/UL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>06/12/2010 12:27:51</lastReviewDate>
    <expiryDate>06/12/2011 12:27:51</expiryDate>
  </document>
  <document>
    <id>304503</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=304503]]&gt;</url>
    <title>2009 Annual Evidence Update on Urinary Incontinence - Poster</title>
    <publicationDate>2009-01-19T00:00:00</publicationDate>
    <publisher>NLH Kidney Diseases Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE URINARY INCONTINENCE,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Urinary Incontinence - Poster&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Download the poster from the link below.&lt;/P&gt;&lt;STRONG&gt;&lt;A href="nelh:301849:0" name=internalLink&gt;
&lt;P&gt;&lt;STRONG&gt;Link back to Contents page&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>06/12/2010 12:27:55</lastReviewDate>
    <expiryDate>06/12/2011 12:27:55</expiryDate>
  </document>
  <document>
    <id>302108</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=302108]]&gt;</url>
    <title>2009 Annual Evidence Update on Urinary Incontinence - Post-prostatectomy and Urinary Incontinence</title>
    <publicationDate>2009-01-19T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ BLADDER,URINARY TRACT,SURGERY,SURGERY,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,URINARY INCONTINENCE,MALE URINARY INCONTINENCE,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;4&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;4&lt;/pageID&gt;&lt;pageSequence&gt;2&lt;/pageSequence&gt;&lt;pageTitle&gt;Commentary&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A href="nelh:301849:0" name=internalLink&gt;&lt;STRONG&gt;Link back to Contents page&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Management of urinary incontinence in men after radical prostatectomy&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Mr Alastair Henderson, Specialist Registrar in Urology&lt;BR&gt;Mr Jonathon Olsburgh, Consultant Urologist and Transplant Surgeon&lt;BR&gt;Department of Urology, Guy’s and St Thomas’ NHS Foundation Trust, London&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Urinary incontinence is possible after most treatments for prostate cancer but in the short term is most common after radical prostatectomy and persists in 4-10% of patients managed conservatively with long term (5-8 year) follow up[1, 2].&amp;nbsp; Older medicare data which includes community hospitals as well as centres of excellence in the USA estimates that 31% of men following radical prostatectomy wore pads or clamps long-term[3].&amp;nbsp; Urinary incontinence is a bothersome symptom often necessitating pad use for the initial postoperative period.&amp;nbsp; New data has shown that 69% of men who did not regularly use pads in the long term after radical prostatectomy had occasional urinary leakage[4].&lt;/P&gt;
&lt;P&gt;Stress urinary incontinence after radical prostatectomy is usually treated with pelvic floor exercises.&amp;nbsp; The type of pelvic floor exercises and the surgical adjuncts for the occasions when they are not adequate to control the problem are the subject of current research.&amp;nbsp; Artificial urinary sphincters are established as an effective method of controlling severe urinary stress leakage in severe incontinence.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;NICE guideline 2008 on diagnosis and management of prostate cancer&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;The 2008 review of treatment for early prostate cancer by the National Institute for health and Clinical Excellence (NICE)[5] identified urinary incontinence after radical prostatectomy as an issue and gave the following summary:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Men experiencing troublesome urinary symptoms before treatment should be offered a urological assessment.&lt;/LI&gt;
&lt;LI&gt;Men undergoing treatment for prostate cancer should be warned of the likely effects of the treatment on their urinary function.&lt;/LI&gt;
&lt;LI&gt;Healthcare professionals should ensure that men with troublesome urinary symptoms after treatment should have access to specialist continence services for assessment, diagnosis and conservative treatment. This may include coping strategies, along with pelvic floor muscle re-education, bladder retraining and pharmacotherapy.&lt;/LI&gt;
&lt;LI&gt;Healthcare professionals should refer men with intractable stress incontinence to a specialist surgeon for consideration of an artificial urinary sphincter.&lt;/LI&gt;
&lt;LI&gt;The injection of bulking agents into the distal urinary sphincter is not recommended to treat stress incontinence.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;BR&gt;&lt;STRONG&gt;New evidence&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;A number of areas of research have since been explored which include:&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods of performing radical prostatectomy in order to improve continence&lt;/STRONG&gt;&lt;BR&gt;Much of the literature has centred on the possible advantages of laparoscopic and robotic surgery though no randomised controlled trials were performed in this area.&amp;nbsp;&amp;nbsp; Recent studies relating to cavernous nerve sparing and interposition nerve grafting are outlined in the accompanying abstracts.&amp;nbsp; A recent review concluded that the evidence of a comparative reduction in morbidity was poor for any specific technique[6].&amp;nbsp; Patients with good pre-operative erectile function on questionnaire assessment had better continence outcomes[7] than those with poor pre-operative erectile function.&lt;/P&gt;
&lt;P&gt;Recent randomised studies have included:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Assessment of the merits of robot assisted peri-prostatic reconstruction to assist early continence - no benefit was reported[8]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Pelvic floor muscle exercises (PFME) for post radical prostatectomy incontinence&lt;BR&gt;&lt;/STRONG&gt;The 2007 Cochrane review[9] considered the safety and efficacy of conservative therapy for post prostatectomy incontinence.&amp;nbsp; They concluded that whilst heterogeneity of results in randomised studies of PFME existed there were too few studies to confirm definite benefit to PFME.&amp;nbsp; A separate systematic review of randomised trials[10] including PFME concluded that these exercises improve continence after radical prostatectomy compared with no treatment whilst biofeedback offered no definite advantages over written or verbal instruction and extracorporeal magnetic innervation and electrical stimulation techniques lacked long term results.&amp;nbsp; Both reviews recommended further studies with better reporting and large numbers of subjects.&lt;/P&gt;
&lt;P&gt;Further studies have been published since these systemic reviews and are detailed in the abstract summary.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Pharmacotherapy for post radical prostatectomy incontinence&lt;/STRONG&gt;&lt;BR&gt;Duloxetine is a selective serotonin reuptake inhibitor which has been investigated in a randomised study after radical prostatectomy.&amp;nbsp; Whilst improvements in early continence were shown on patients treated with the drug and PFME there was no long term positive effect after the 12 week course of treatment was ceased[11] and post cessation incontinence initially worsened in the duloxetine treated group.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods of treating patients with problematic urinary incontinence post radical prostatectomy&lt;/STRONG&gt;&lt;BR&gt;A randomised study has shown that in patients with minimal urinary leakage there was no difference between injectable macroplastique and artificial urinary sphincter whereas in more marked incontinence the artificial sphincter was more effective[12].&lt;/P&gt;
&lt;P&gt;Assessment of a number of new devices have been developed to help men with continence problems after radical prostatectomy including the use of sub-urethral sling devices as an alternative to artificial urinary sphincter.&lt;/P&gt;
&lt;P&gt;These include:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;STRONG&gt;Synthetic slings&lt;/STRONG&gt; including the male bone anchored sling (e.g. InVance Sling)[13, 14], Male trans-obturator sling,&amp;nbsp; Argus Sling[15], and ProAct Sling[16-18].&amp;nbsp; As the area of male slings has generated a number of articles but little comparative (and no randomised) data the single centre series are further detailed in the attached abstract summary.&lt;/LI&gt;
&lt;LI&gt;&lt;STRONG&gt;Absorbable slings&lt;/STRONG&gt;[19]&lt;/LI&gt;
&lt;LI&gt;&lt;STRONG&gt;Ectopic placement&lt;/STRONG&gt; of standard artificial sphincters[20], and &lt;STRONG&gt;technical modifications to artificial sphincter design&lt;/STRONG&gt; have also been reported[21] &lt;/LI&gt;
&lt;LI&gt;The selection of &lt;STRONG&gt;high risk patients for proactive interventions&lt;/STRONG&gt; such as placement of a sub-urethral sling at radical prostatectomy.&amp;nbsp; This has not yet been proven to improve outcome[22].&lt;/LI&gt;
&lt;LI&gt;A non-randomised comparative study suggested that the InValance sling may be superior to collagen injections in mild-moderate stress incontinence after radical retropubic prostatectomy but this needs to be confirmed with a randomised study[23].&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusion&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;The NICE guidance from 2008 is still current though new studies suggest that there may be a role for male slings in moderate urinary incontinence after radical prostatectomy.&amp;nbsp; The efficacy of these devices in comparison to pelvic floor exercises or injectables in mild-moderate incontinence or compared with the artificial urinary sphincter in severe incontinence needs to be assessed in appropriately powered randomized studies.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Penson DF, McLerran D, Feng Z, et al. 5-year urinary and sexual outcomes after radical prostatectomy: results from the Prostate Cancer Outcomes Study. J Urol 2008;179(5 Suppl):S40-4. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15821561?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Karakiewicz PI, Tanguay S, Kattan MW, Elhilali MM, Aprikian AG. Erectile and urinary dysfunction after radical prostatectomy for prostate cancer in Quebec: a population-based study of 2415 men. Eur Urol 2004;46(2):188-94.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/15245812" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Fowler FJ, Jr., Barry MJ, Lu-Yao G, et al. Patient-reported complications and follow-up treatment after radical prostatectomy. The National Medicare Experience: 1988-1990 (updated June 1993). Urology 1993;42(6):622-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/8256394?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Rodriguez E, Jr., Skarecky DW, Ahlering TE. Post-robotic prostatectomy urinary continence: characterization of perfect continence versus occasional dribbling in pad-free men. Urology 2006;67(4):785-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16566988?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;NICE. Prostate Cancer: Diagnosis and Treatment. Cardiff: Velindre NHS Trust, Cardiff, Wales.; 2008. [&lt;A href="http://www.nice.org.uk/Guidance/CG58" target="_blank"&gt;Link to NICE webpage and links&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Cambio AJ, Evans CP. Minimising postoperative incontinence following radical prostatectomy: considerations and evidence. Eur Urol 2006;50(5):903-13; discussion 13.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16956715?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Wille S, Heidenreich A, Hofmann R, Engelmann U. Preoperative erectile function is one predictor for post prostatectomy incontinence. Neurourol Urodyn 2007;26(1):140-3; discussion 4.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16998858?ordinalpos=3&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Menon M, Muhletaler F, Campos M, Peabody JO. Assessment of early continence after reconstruction of the periprostatic tissues in patients undergoing computer assisted (robotic) prostatectomy: results of a 2 group parallel randomized controlled trial. J Urol 2008;180(3):1018-23.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18639300?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hunter KF, Glazener CM, Moore KN. Conservative management for postprostatectomy urinary incontinence. Cochrane Database Syst Rev 2007(2):CD001843.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17443512?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;MacDonald R, Fink HA, Huckabay C, Monga M, Wilt TJ. Pelvic floor muscle training to improve urinary incontinence after radical prostatectomy: a systematic review of effectiveness. BJU Int 2007;100(1):76-81.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17433028?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Filocamo MT, Li Marzi V, Del Popolo G, et al. Pharmacologic treatment in postprostatectomy stress urinary incontinence. Eur Urol 2007;51(6):1559-64.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16942833?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Imamoglu MA, Tuygun C, Bakirtas H, Yigitbasi O, Kiper A. The comparison of artificial urinary sphincter implantation and endourethral macroplastique injection for the treatment of postprostatectomy incontinence. Eur Urol 2005;47(2):209-13.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15661416?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Guimaraes M, Oliveira R, Pinto R, et al. Intermediate-term results, up to 4 years, of a bone-anchored male perineal sling for treating male stress urinary incontinence after prostate surgery. BJU Int 2008.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18782301" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Castle EP, Andrews PE, Itano N, et al. The male sling for post-prostatectomy incontinence: mean followup of 18 months. J Urol 2005;173(5):1657-60.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15821530?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Romano SV, Metrebian SE, Vaz F, et al. An adjustable male sling for treating urinary incontinence after prostatectomy: a phase III multicentre trial. BJU Int 2006;97(3):533-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16469021?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Crivellaro S, Singla A, Aggarwal N, Frea B, Kocjancic E. Adjustable continence therapy (ProACT) and bone anchored male sling: Comparison of two new treatments of post prostatectomy incontinence. Int J Urol 2008.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18761534?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Gregori A, Simonato A, Lissiani A, et al. Transrectal ultrasound guided implantation of the ProACT adjustable continence therapy system in patients with post-radical prostatectomy stress urinary incontinence: a pilot study. J Urol 2006;176(5):2109-13; discussion 13.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17070270?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Gregori A, Galli S, Kartalas IG, et al. Implantation of an adjustable continence therapy system using local anesthesia in patients with post-radical prostatectomy stress urinary incontinence: a pilot study. J Urol 2008;179(5):1902-6.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18353380" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Jones JS, Vasavada SP, Abdelmalak JB, et al. Sling may hasten return of continence after radical prostatectomy. Urology 2005;65(6):1163-7.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15922423?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Wilson SK, Delk JR, 2nd. Ectopic placement of AMS 800 urinary control system pressure-regulating balloon. Urology 2005;65(1):167-70.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15667886?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Knight SL, Susser J, Greenwell T, Mundy AR, Craggs MD. A new artificial urinary sphincter with conditional occlusion for stress urinary incontinence: preliminary clinical results. Eur Urol 2006;50(3):574-80.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16720077?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Westney OL, Scott S, Wood C, et al. Suburethral sling at the time of radical prostatectomy in patients at high risk of postoperative incontinence. BJU Int 2006;98(2):308-13.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16879670?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Onur R, Singla A. Comparison of bone-anchored male sling and collagen implant for the treatment of male incontinence. Int J Urol 2006;13(9):1207-11.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16984554?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;3&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Evidence&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;&lt;A href="nelh:301849:0" name=internalLink&gt;Link back to Contents page&lt;/A&gt;&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;General / Incidence&lt;/H2&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Systematic review&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Cambio AJ, Evans CP. (2006) Minimising Postoperative Incontinence Following Radical Prostatectomy: Considerations and Evidence. European Urology. 2006;(5):903-13. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16956715?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mochtar CA, Kauer PC, Laguna MP, de la Rosette JJ. (2007) Urinary leakage after laparoscopic radical prostatectomy: a systematic review. Journal of Endourology. 2007 Nov;21(11):1371-9. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18042033?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Others&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Montiglio C, Cespedes RD. (2007) Postprostatectomy incontinence: prevention and therapy. Contemporary Urology. 2007 Dec;19(12):16. [No Pubmed link]&lt;/LI&gt;
&lt;LI&gt;Namiki S, Saito S, Ishidoya S, Tochigi T, Ioritani N, Yoshimura K, et al. (2005) Adverse effect of radical prostatectomy on nocturia and voiding frequency symptoms. Urology. 2005;(1):147-51. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15992905?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Penson DF, McLerran D, Feng Z, Li L, Albertsen PC, Gilliland FD, et al. (2005) 5-Year urinary and sexual outcomes after radical prostatectomy: Results from the prostate cancer outcomes study. Journal of Urology. 2005;(5):1701-5. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15821561?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Rogers CG, Su L-M, Link RE, Sullivan W, Wagner A, Pavlovich CP. (2006) Age Stratified Functional Outcomes After Laparoscopic Radical Prostatectomy. Journal of Urology. 2006;(6):2448-52. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17085126?ordinalpos=3&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Wille S, Heidenreich A, Hofmann R, Engelmann U. (2007) Preoperative erectile function is one predictor for post prostatectomy incontinence. Neurourology and Urodynamics. 2007;(1):140-3. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16998858?ordinalpos=3&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;DIAGNOSIS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Systematic review&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Porena M, Mearini E, Mearini L, Vianello A, Giannantoni A. (2007) Voiding Dysfunction after Radical Retropubic Prostatectomy: More than External Urethral Sphincter Deficiency. European Urology. 2007;(1):38-45. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17403565?ordinalpos=3&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Other&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Kielb SJ, Clemens JQ. (2005) Comprehensive urodynamics evaluation of 146 men with incontinence after radical prostatectomy. Urology. 2005;(2):392-6. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16040102?ordinalpos=3&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Majoros A, Bach D, Keszthelyi A, Hamvas A, Romics I. (2006) Urinary incontinence and voiding dysfunction after radical retropubic prostatectomy (prospective urodynamic study). Neurourology and Urodynamics. 2006;(1):2-7. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16224797?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Rodriguez E Jr, Skarecky DW, Ahlering TE. (2006) Post-robotic prostatectomy urinary continence: characterization of perfect continence versus occasional dribbling in pad-free men. Urology. 2006 Apr;67(4):785-8. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16566988?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Radical Prostatectomy (RP)&amp;nbsp;and Surgical technique&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Systematic Reviews&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Ficarra V, Cavalleri S, Novara G, Aragona M, Artibani W. (2007) Evidence from Robot-Assisted Laparoscopic Radical Prostatectomy: A Systematic Review. European Urology. 2007;51(1):45-56. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16854519?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Parsons JK, Bennett JL. (2008) Outcomes of Retropubic, Laparoscopic, and Robotic-Assisted Prostatectomy. Urology. 2008;72(2):412-416. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18267330?ordinalpos=4&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Randomised Controlled Trial (RCT)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Menon M, Muhletaler F, Campos M, Peabody JO. (2008) Assessment of Early Continence After Reconstruction of the Periprostatic Tissues in Patients Undergoing Computer Assisted (Robotic) Prostatectomy: Results of a 2 Group Parallel Randomized Controlled Trial. Journal of Urology. 2008;(3):1018-23. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18639300?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Other&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Anger JT, Raj GV, Delvecchio FC, Webster GD. (2005) Anastomotic contracture and incontinence after radical prostatectomy: A graded approach to management. Journal of Urology. 2005;(4):1143-6. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15758723?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Jacobsen N-E, Moore KN, Estey E, Voaklander D. (2007) Open Versus Laparoscopic Radical Prostatectomy: A Prospective Comparison of Postoperative Urinary Incontinence Rates. Journal of Urology. 2007;(2):615-9. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17222646?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kordan Y, Alkibay T, Sozen S, Bozkurt Y, Acar C, Talu T, et al. (2007) Is there an impact of postoperative urethral and periurethral anatomical features in post-radical retropubic prostatectomy incontinence? Urologia Internationalis. 2007;(3):208-13. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17406128?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lee SE, Byun SS, Lee HJ, Song SH, Chang IH, Kim YJ, et al. (2006) Impact of variations in prostatic apex shape on early recovery of urinary continence after radical retropubic prostatectomy. Urology. 2006 Jul;68(1):137-41. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16777192?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Namiki S, Saito S, Nakagawa H, Sanada T, Yamada A, Arai Y. (2007) &amp;nbsp;Impact of Unilateral Sural Nerve Graft on Recovery of Potency and Continence Following Radical Prostatectomy: 3-Year Longitudinal Study. Journal of Urology. 2007;(1):212-6. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17499797?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Nandipati KC, Raina R, Agarwal A, Zippe CD. (2007) Nerve-Sparing Surgery Significantly Affects Long-Term Continence After Radical Prostatectomy. Urology. 2007;(6):1127-30. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18158032?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Rocco F, Carmignani L, Acquati P, Gadda F, Dell'Orto P, Rocco B, et al. (2006) Restoration of Posterior Aspect of Rhabdosphincter Shortens Continence Time After Radical Retropubic Prostatectomy. Journal of Urology. 2006;(6):2201-6. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16697841?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Surgical Treatment options including Slings, Artificial Sphincter &amp;amp; Bulking Agents&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;RCT&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Imamoglu MA, Tuygun C, Bakirtas H, Yigitbasi O, Kiper A. (2005) The comparison of artificial urinary sphincter implantation and endourethral macroplastique injection for the treatment of postprostatectomy incontinence. European Urology. 2005;(2):209-13. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15661416?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Others&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Crivellaro S, Singla A, Aggarwal N, Frea B, Kocjancic E. (2008)Adjustable continence therapy (ProACT) and bone anchored male sling: Comparison of two new treatments of post prostatectomy incontinence. International Journal of Urology. 2008;(10):910-4. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18761534?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lebret T, Cour F, Benchetrit J, Grise P, Bernstein J, Delaporte V, et al. (2008) Treatment of Postprostatectomy Stress Urinary Incontinence Using a Minimally Invasive Adjustable Continence Balloon Device, ProACT: Results of a Preliminary, Multicenter, Pilot Study. Urology. 2008;(2):256-60. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18308096?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;O'Connor RC, Lyon MB, Guralnick ML, Bales GT. (2008) Long-term Follow-up of Single Versus Double Cuff Artificial Urinary Sphincter Insertion for the Treatment of Severe Postprostatectomy Stress Urinary Incontinence. Urology. 2008;(1):90-3. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18242372?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Trigo RF, Gomes CM, Mitre AI, Arap S, Srougi M. (2008) A Prospective Study Evaluating the Efficacy of the Artificial Sphincter AMS 800 for the Treatment of Postradical Prostatectomy Urinary Incontinence and the Correlation Between Preoperative Urodynamic and Surgical Outcomes. Urology. 2008;(1):85-9. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18242371?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Comiter CV. (2007) Surgery Insight: Surgical management of postprostatectomy incontinence - The artificial urinary sphincter and male sling. Nature Clinical Practice Urology. 2007;(11):615-24. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17982438?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Fassi-Fehri H, Badet L, Cherass A, Murat F-J, Colombel M, Martin X, et al. (2007) Efficacy of the InVance[trademark] Male Sling in Men with Stress Urinary Incontinence. European Urology. 2007;(2):498-503. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16996679?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Fischer MC, Huckabay C, Nitti VW. (2007) The Male Perineal Sling: Assessment and Prediction of Outcome. Journal of Urology. 2007;(4):1414-8. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17382743?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kumar R, Nehra A. (2007) Dual implantation of penile and sphincter implants in the post-prostatectomy patient. Current Urology Reports. 2007;(6):477-81. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18042328?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Sousa-Escandon A, Cabrera J, Mantovani F, Moretti M, Ioanidis E, Kondelidis N, et al. (2007) Adjustable Suburethral Sling (Male Remeex System) in the Treatment of Male Stress Urinary Incontinence: A Multicentric European Study. European Urology. 2007;(5):1473-80. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17560016?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Wadie BS. (2007) A novel technique of bulbourethral sling for post-prostatectomy incontinence. Scandinavian Journal of Urology and Nephrology. 2007;(5):398-402. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17853033?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2006&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Comiter CV. (2006) The male perineal sling - A viable alternative to the artificial urinary sphincter. Nature Clinical Practice Urology. 2006;(3):118-9. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16528266?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Gregori A, Simonato A, Lissiani A, Scieri F, Rossi R, Gaboardi F. (2006) Transrectal Ultrasound Guided Implantation of the ProACT Adjustable Continence Therapy System in Patients With Post-Radical Prostatectomy Stress Urinary Incontinence: A Pilot Study. Journal of Urology. 2006;(5):2109-13. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17070270?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Klingler HC, Marberger M. (2006) Incontinence after radical prostatectomy: Surgical treatment options. Current Opinion in Urology. 2006;(2):60-4. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16479205?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Knight SL, Susser J, Greenwell T, Mundy AR, Craggs MD. (2006) A New Artificial Urinary Sphincter with Conditional Occlusion for Stress Urinary Incontinence: Preliminary Clinical Results. European Urology. &amp;nbsp;2006;(3):574-80. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16720077?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Montague DK, Angermeier KW. (2006) Treatment of postprostatectomy urinary incontinence: The case against the male sling. Nature Clinical Practice Urology. 2006;(6):290-1. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16763622?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Onur R, Singla A. (2006) Comparison of bone-anchored male sling and collagen implant for the treatment of male incontinence. International Journal of Urology. 2006;(9):1207-11. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16984554?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Romano SV, Metrebian SE, Vaz F, Muller V, D'Ancona CA, Costa De Souza EA, et al. (2006) An adjustable male sling for treating urinary incontinence after prostatectomy: A phase III multicentre trial. BJU International. 2006;(3):533-9. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16469021?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Trigo-Rocha F, Mendes GC, Lima Pompeo AC, Marmo LA, Arap S. (2006) Prospective study evaluating efficacy and safety of Adjustable Continence Therapy (ProACT) for post radical prostatectomy urinary incontinence. Urology. 2006;(5):965-9. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16698356?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Westney OL, Scott S, Wood C, Eddings T, Johnson MM, Taylor JM, et al. (2006) Suburethral sling at the time of radical prostatectomy in patients at high risk of postoperative incontinence. BJU International. 2006;98:308-13. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16879670?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2005&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Castle EP, Andrews PE, Itano N, Novicki DE, Swanson SK, Ferrigni RG. (2005) The male sling for post-prostatectomy incontinence: Mean followup of 18 months. Journal of Urology. 2005;(5):1657-60. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15821530?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Elliott DS. (2005) Is an artificial urinary sphincter more effective than a urethral bulking agent for postprostatectomy incontinence? Nature Clinical Practice Urology. &amp;nbsp;2005;(5):220-1. [No Pubmed link]&lt;/LI&gt;
&lt;LI&gt;Gousse AE, Tunuguntla HS, Leboeuf L. (2008) Two-stage management of severe postprostatectomy bladder neck contracture associated with stress incontinence. Urology. 2005 [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15708045?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Pubmed link&lt;/A&gt;]&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Jones JS, Vasavada SP, Abdelmalak JB, Liou L, Ahmed ES, Zippe CD, et al. (2005) Sling may hasten return of continence after radical prostatectomy. Urology. 2005;(6):1163-7. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15922423?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Stern JA, Clemens JQ, Tiplitsky SI, Matschke HM, Jain PM, Schaeffer AJ. (2005) Long-term results of the bulbourethral sling procedure. Journal of Urology. 2005;(5):1654-6. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15821529?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Vasavada SP, Comiter CV. (2005) The male sling for postprostatectomy SUI: indications, technique, and outcomes. Contemporary Urology. 2005 Dec;17(12):30. [No Pubmed link]&lt;/LI&gt;
&lt;LI&gt;Webster GD, Sherman ND. (2005) Management of male incontinence following artificial urinary sphincter failure. Current Opinion in Urology. 2005 Nov;15(6):386-90. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16205488?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Westney OL, Bevan-Thomas R, Palmer JL, Cespedes RD, McGuire EJ. (2005) Transurethral collagen injections for male intrinsic sphincter deficiency: The University of Texas-Houston experience. Journal of Urology.&amp;nbsp;2005;(3):994-7. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16094021?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Wilson SK, Delk JR. (2005) Ectopic placement of AMS 800 urinary control system pressure-regulating balloon. Urology. 2005 Jan;65(1):167-70. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15667886?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Pelvic Floor Exercises (PFEs)&amp;nbsp;/ Biofeedback /Conservative management&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Systematic reviews&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Glazer HI, Laine CD. (2006) Pelvic floor muscle biofeedback in the treatment of urinary incontinence: A literature review. Applied Psychophysiology Biofeedback. 2006;(3):187-201 [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16983505?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Nahon I, Dorey G, Waddington G, Adams R. Systematic review of the treatment of post-prostatectomy incontinence.&amp;nbsp;Urol&amp;nbsp;Nurs.&amp;nbsp;2006, 26(6):461-75, 482.[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17253081?ordinalpos=3&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Viola D, Comerci F, Martorana G. (2006) Rehabilitation therapy and urinary incontinence after radical retropubic prostatectomy: A critical review of the literature. Urologia Internationalis. 2006;(3):193-8. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16601377?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hunter KF, Moore KN, Glazener CMA. (2007) Conservative management for postprostatectomy urinary incontinence. Cochrane Database of Systematic Reviews (2), 2007 Article Number: CD001843 Date of Publication: 2007 2007;(2). [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17443512?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;MacDonald R, Fink HA, Huckabay C, Monga M, Wilt TJ. (2007) Pelvic floor muscle training to improve urinary incontinence after radical prostatectomy: A systematic review of effectiveness. BJU International. 2007;(1):76-81. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17433028?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;RCTS&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Manassero F, Traversi C, Ales V, Pistolesi D, Panicucci E, Valent F, et al. Contribution of early intensive prolonged pelvic floor exercises on urinary continence recovery after bladder neck-sparing radical prostatectomy: Results of a prospective controlled randomized trial. Neurourology and Urodynamics. &amp;nbsp;2007;(7):985-9. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17487874?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Overgard M, Angelsen A, Lydersen S, Morkved S. Does Physiotherapist-Guided Pelvic Floor Muscle Training Reduce Urinary Incontinence After Radical Prostatectomy?. A Randomised Controlled Trial. European Urology. 2008;(2):438-48. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18448233?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Filocamo MT, Li M, V, Del PG, Cecconi F, Marzocco M, Tosto A, et al. Effectiveness of early pelvic floor rehabilitation treatment for post-prostatectomy incontinence. European Urology. 2005; 48 (5):734-8. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16002204?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Burgio KL, Goode PS, Urban DA, Umlauf MG, Locher JL, Bueschen A, et al. Preoperative biofeedback assisted behavioral training to decrease post-prostatectomy incontinence: a randomized, controlled trial. The Journal of Urology. 2006;175:196-201. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16406909?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Others&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Miles BJ, Khera M. Can preoperative behavioral training reduce postprostatectomy incontinence? Nature clinical practice. Urology. 2006;3:302-3. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16763638?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Zhang AY, Strauss GJ, Siminoff LA. Intervention of urinary incontinence and quality of life outcome in prostate cancer patients. Journal of Psychosocial Oncology. 2006;(2):17-30. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17046804?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hunter KF, Moore KN, Glazener CM. Pelvic floor muscle training to improve urinary incontinence after radical prostatectomy: A systematic review of effectiveness. BJU International. 2007;(5):1191. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17922792?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Pharmacological&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;RCT&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Filocamo MT, Li M, V, Del PG, Cecconi F, Villari D, Marzocco M, et al. Pharmacologic Treatment in Postprostatectomy Stress Urinary Incontinence. European Urology. &amp;nbsp;2007;(6):1559-64. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16942833?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Others&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Hotston MR, Hurley K, Patel S, Persad R. The use of duloxetine for stress incontinence after prostatectomy [3]. BJU International. 2006;(4):916-7. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16978296?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Schlenker B, Gratzke C, Reich O, Schorsch I, Seitz M, Stief CG. Preliminary Results on the Off-Label Use of Duloxetine for the Treatment of Stress Incontinence after Radical Prostatectomy or Cystectomy. European Urology. 2006;(6):1075-8. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16481094?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>06/12/2010 12:28:00</lastReviewDate>
    <expiryDate>06/12/2011 12:28:00</expiryDate>
  </document>
  <document>
    <id>302233</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=302233]]&gt;</url>
    <title>2009 Annual Evidence Update on Urinary Incontinence - Validated and Disease-Specific Questionnaires</title>
    <publicationDate>2009-01-19T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE URINARY INCONTINENCE,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;2&lt;/pageSequence&gt;&lt;pageTitle&gt;Patient-Reported Outcome and Quality of Life Instruments Database&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;&lt;A href="nelh:301849:0" name=internalLink&gt;Link back to Contents page&lt;/A&gt;&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The main resource for validated questionnaires and disease-specific questionnaires about urinary incontinence is the ProQolid Patient-Reported Outcome and Quality of Life Instruments Database [&lt;A href="http://www.proqolid.org/proqolid/search__1/pathology_disease?pty=1928" target="_blank"&gt;link&lt;/A&gt;], which lists the following questionnaires:&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Lower urinary tract symptoms (LUTS)&lt;/STRONG&gt; &amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;DAN-PSS-1: Danish Prostatic Symptom Score. Andersen J T, Bilde T,&amp;nbsp;Hald T, et al.&lt;/LI&gt;
&lt;LI&gt;ICIQ-FLUTS: International Consultation on Incontinence Questionnaire-Female Lower Urinary Tract Symptoms. Abrams P. &lt;/LI&gt;
&lt;LI&gt;ICSmale: ICSmale. Donovan J L.&lt;/LI&gt;
&lt;LI&gt;ICSQoL: International Continence Society-Benign Prostatic Hyperplasia study quality-of-life. Donovan J L.&lt;/LI&gt;
&lt;LI&gt;MSHQ: Male Sexual Health Questionnaire. Althof S E, Catania J, O'Leary M et al.&lt;/LI&gt;
&lt;LI&gt;UROLIFETM/BPHQoL9: Benign Prostatic Hypertrophy Health-Related Quality of Life Questionnaire. Lukacs B, Sanofi A.&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Urinary Bladder, Overactive&lt;/STRONG&gt; &amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;OAB-q: Overactive Bladder symptom and health-related quality of life questionnaire. Coyne K, Hunt T, Revicki D A.&lt;BR&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Urinary incontinence&lt;/STRONG&gt; &amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Contilife®: Quality of Life Assessment Questionnaire Concerning Urinary Incontinence. Amarenco G, Haab F, Labat JJ, et al.&lt;/LI&gt;
&lt;LI&gt;DIS: Detrusor Instability Score. Kauppila A, Kujansuu E.&lt;/LI&gt;
&lt;LI&gt;I-QOL: Urinary Incontinence-Specific Quality of Life Instrument. Bushnell D M, Martin M L, Patrick D L, PhD, MSPH.&lt;/LI&gt;
&lt;LI&gt;ICIQ-FLUTS: International Consultation on Incontinence Questionnaire-Female Lower Urinary Tract Symptoms. Abrams P. &lt;/LI&gt;
&lt;LI&gt;ICIQ-UI Short Form: International Consultation on Incontinence Questionnaire - Urinary Incontinence Short Form. Avery K, ICIQ Group.&lt;/LI&gt;
&lt;LI&gt;ISI: Incontinence Stress Index. Yu L C.&lt;/LI&gt;
&lt;LI&gt;KHQ: King's Health Questionnaire. Cardozo L, Kelleher C J, Khullar V, et al.&lt;/LI&gt;
&lt;LI&gt;MUDI: Male Urogenital Distress Inventory. Robinson J P, Shea J A.&lt;/LI&gt;
&lt;LI&gt;MUSIQ: Male Urinary Symptom Impact Questionnaire. Robinson J P, Shea J A. &lt;/LI&gt;
&lt;LI&gt;N-QoL: Nocturia Quality of Life Questionnaire. Abraham L,&amp;nbsp; Abrams P, Hareendran A, et al.&lt;/LI&gt;
&lt;LI&gt;PMSES: Broome Pelvic Muscle Exercise Self-Efficacy Scale. Broome B S. &lt;/LI&gt;
&lt;LI&gt;SSI and SII: Symptom Severity Index and Symptom Impact Index for stress incontinence in women. Black N.&lt;/LI&gt;
&lt;LI&gt;UIHI: Urinary Incontinence Handicap Inventory. Rai GS.&lt;/LI&gt;
&lt;LI&gt;YIPS: York Incontinence Perceptions Scale. Lee P S, MA, Linton L, RN, MHA, Reid D W, PhD, et al.&lt;BR&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Urination disorders&lt;/STRONG&gt; &amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;SF-QUALIVEEN: QUALIVEEN Short Form. Bonniaud V.&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;2&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Systematic Reviews&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A href="nelh:301849:0" name=internalLink&gt;&lt;STRONG&gt;Link back to Contents page&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt; - No systematic reviews&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Avery KN, Bosch JL, Gotoh M, Naughton M, Jackson S, Radley SC, et al. Questionnaires to assess urinary and anal incontinence: review and recommendations. Journal of Urology 2007;177(1):39-49. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17161997?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;2006&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Martin JL, Williams KS, Abrams KR, Turner DA, Sutton AJ, Chapple C, et al. Systematic review and evaluation of methods of assessing urinary incontinence. Health Technology Assessment 2006;10(6):iii-87. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16487456?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Ross S, Soroka D, Karahalios A, Glazener CM, Hay-Smith EJ, Drutz HP. Incontinence-specific quality of life measures used in trials of treatments for female urinary incontinence: a systematic review. International Urogynecology Journal 2006;17(3):272-85. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16025188?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Pubmed link&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;2005&lt;/STRONG&gt; - No systematic reviews&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>06/12/2010 12:28:04</lastReviewDate>
    <expiryDate>06/12/2011 12:28:04</expiryDate>
  </document>
  <document>
    <id>333392</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=333392]]&gt;</url>
    <title>2010 Annual Evidence Update on Male Urinary Incontinence - Botulinum Toxin A and Male Urinary Incontinence</title>
    <publicationDate>2010-02-01T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE URINARY INCONTINENCE,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;2&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Male Urinary Incontinence - Botulinum Toxin A and Male Urinary Incontinence&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;&lt;A href="nelh:333390:0" name=internalLink&gt;Link to 2010 Annual Evidence Update on Male Urinary Incontinence contents page&lt;/A&gt;&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Systematic Reviews and Meta-analyses: Evidence&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Karsenty, G., P. Denys, et al.&amp;nbsp; "Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review." European Urology 2008; 53(2): 275-87.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17988791" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;MacDonald, R., M. Monga, et al. "Neurotoxin treatments for urinary incontinence in subjects with spinal cord injury or multiple sclerosis: a systematic review of effectiveness and adverse effects." Journal of Spinal Cord Medicine 2008; 31(2): 157-65.&amp;nbsp;[&lt;A href="nelh:316783:0" name=internalLink&gt;Link to&amp;nbsp;DARE abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;STRONG&gt;&lt;A href="nelh:301849:0" name=internalLink&gt;
&lt;P&gt;&lt;STRONG&gt;Link to 2009 Annual Evidence Update on Male Urinary Incontinence contents page&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;&lt;STRONG&gt;&lt;A href="nelh:303594:0" name=internalLink&gt;
&lt;P&gt;&lt;STRONG&gt;Link to 2009 evidence on Botulinum Toxin A and Male Urinary Incontinence&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;2&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Additional evidence&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A href="nelh:333390:0" name=internalLink&gt;&lt;STRONG&gt;Link to 2010 Annual Evidence Update on Male Urinary Incontinence contents page&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Other evidence&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;A href="nelh:333390:0" name=internalLink&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Apostolidis, A., P. Dasgupta, et al. "Recommendations on the Use of Botulinum Toxin in the Treatment of Lower Urinary Tract Disorders and Pelvic Floor Dysfunctions: A European Consensus Report." European Urology 2009; 55(1): 100-120. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18823697" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Campigotto, M.&amp;nbsp; "Using Botox to treat refractory voiding dysfunction in children: two case studies." Urol Nurs 2009; 29(1): 20-5, 46.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19331271" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Chapple, C. and D. De Ridder. "The second-line management of idiopathic overactive bladder: What is the place of sacral neuromodulation and botulinum toxin-A in contemporary practice?" BJU International 2009; 104(9): 1188-1190.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19681899" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Cohen, B. L., P. Barboglio, et al. "Preliminary results of a dose-finding study for botulinum toxin-a in patients with idiopathic overactive bladder: 100 versus 150 units." Neurourology and Urodynamics 2009; 28(3): 205-208.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19058190" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Da Silva, C. M. and F. Cruz. "Has botulinum toxin therapy come of age: What do we know, what do we need to know, and should we use it?" Current Opinion in Urology 2009; 19(4): 347-352.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19444121" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;DasGupta, R. and F. L. Murphy. "Botulinum toxin in paediatric urology: A systematic literature review." Pediatric Surgery International 2009; 25(1): 19-23.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18953547" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Flynn, M. K., C. L. Amundsen, et al. "Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder." J Urol 2009; 181(6): 2608-15.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19375091" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Giannantoni, A., E. Mearini, et al. "Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results." Eur Urol 2009; 55(3): 705-11.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18814955" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Giannantoni, A., A. Rossi, et al. "Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy." J Urol 2009; 182(4): 1453-7.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19683298" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Grosse, J., G. Kramer, et al. "Comparing two types of botulinum-A toxin detrusor injections in patients with severe neurogenic detrusor overactivity: a case-control study." BJU Int 2009; 104(5): 651-6.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19281462" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hori, S., P. Patki, et al. "Patients' perspective of botulinum toxin-A as a long-term treatment option for neurogenic detrusor overactivity secondary to spinal cord injury." BJU International 2009; 104(2): 216-220.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19220255" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kajbafzadeh, A., A. H. Mahboubi, et al. "Concomitant repeated intravesical injections of botulinum toxin-type A and laparoscopic antegrade continence enema; A new solution for an old problem." BJU International 2009; 103(9): 1248-1254.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19154454" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Khan, S., T. M. Kessler, et al. "What a patient with refractory idiopathic detrusor overactivity should know about botulinum neurotoxin type a injection." J Urol 2009; 181(4): 1773-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19233414" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Liu, H. T., M. B. Chancellor, et al. "Urinary Nerve Growth Factor Levels are Elevated in Patients with Detrusor Overactivity and Decreased in Responders to Detrusor Botulinum Toxin-A Injection." European Urology 2009; 56(4): 700-707.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18472208" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Roosen, A., S. N. Datta, et al. "Suburothelial myofibroblasts in the human overactive bladder and the effect of botulinum neurotoxin type A treatment." Eur Urol 2009; 55(6): 1440-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19054608" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Sahai, A., C. Dowson, et al. "Improvement in quality of life after botulinum toxin - A injections for idiopathic detrusor overactivity: Results from a randomized double-blind placebo-controlled trial." BJU International 2009; 103(11): 1509-1515.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19389019" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Sahai, A., P. Sangster, et al. "Assessment of urodynamic and detrusor contractility variables in patients with overactive bladder syndrome treated with botulinum toxin-A: Is incomplete bladder emptying predictable?" BJU International 2009; 103(5): 630-634.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18990156" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Wu, J. M., N. Y. Siddiqui, et al. "Cost-Effectiveness of Botulinum Toxin A Versus Anticholinergic Medications for Idiopathic Urge Incontinence." Journal of Urology 2009; 181(5): 2181-2186.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19296983" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Chancellor, M. B., C. J. Fowler, et al. "Drug insight: Biological effects of botulinum toxin A in the lower urinary tract." Nature Clinical Practice Urology 2008; 5(6): 319-328.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18461049" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Del Popolo, G., M. T. Filocamo, et al. "Neurogenic Detrusor Overactivity Treated with English Botulinum Toxin A: 8-Year Experience of One Single Centre." European Urology 2008; 53(5): 1013-1020.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17950989" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Drake, M. J. "Mechanisms of action of intravesical botulinum treatment in refractory detrusor overactivity." BJU International 2008; 102(SUPPL. 1): 11-16.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18665973" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kalsi, V., A. Apostolidis, et al. "Early Effect on the Overactive Bladder Symptoms following Botulinum Neurotoxin Type A Injections for Detrusor Overactivity." European Urology 2008; 54(1): 181-187.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18191323" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Karsenty, G., P. Denys, et al. Botulinum toxin A (Botox®) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. European Urology 2008; Feb;53(2): 275-287&amp;nbsp;&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17988791" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kuschel, S., M. Werner, et al. "Botulinum toxin-A for idiopathic overactivity of the vesical detrusor: A 2-year follow-up." International Urogynecology Journal and Pelvic Floor Dysfunction 2008; 19(7): 905-909.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18204796" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Manecksha, R. P., P. Redmond, et al. "Experience with intradetrusor injection of botulinum-a toxin for the treatment of idiopathic detrusor overactivity in a single irish institution." Current Urology 2008; 2(2): 62-66.&amp;nbsp;[&lt;A href="http://content.karger.com/ProdukteDB/produkte.asp?Aktion=ShowAbstract&amp;amp;ArtikelNr=115409&amp;amp;Ausgabe=243480&amp;amp;ProduktNr=231997" target="_blank"&gt;Link to abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mascarenhas, F., M. Cocuzza, et al. "Trigonal injection of botulinum toxin-A does not cause vesicoureteral reflux in neurogenic patients." Neurourology and Urodynamics 2008; 27(4): 311-314.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17914742" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mohseni, M. G. H., S. M. K. Aghamir, et al. "Botulinum-A toxin in the treatment of urinary incontinence due to overactive bladder following spinal cord injury." Tehran University Medical Journal 2008; 65(10): 55-60.&amp;nbsp;[&lt;A href="http://tumj.tums.ac.ir/archive/vol65/no10/issue.html" target="_blank"&gt;Link to&amp;nbsp;Journal issue webpage for&amp;nbsp;abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Sahai, A., M. S. Khan, et al. "Urodynamic Assessment of Poor Responders After Botulinum Toxin-A Treatment for Overactive Bladder." Urology 2008; 71(3): 455-459.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18342186" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Sangster, P. and V. Kalsi. "Health economics and intradetrusor injections of botulinum for the treatment of detrusor overactivity." BJU International 2008; 102(SUPPL. 1): 17-19.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18665974" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Schmid, D. M., S. Roy, et al. "Prospects and limitations of treatment with botulinum neurotoxin type A for patients with refractory idiopathic detrusor overactivity." BJU International 2008; 102(SUPPL. 1): 7-10.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18665972" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Schulte-Baukloh, H., H. Bigalke, et al. "Botulinum neurotoxin type A in urology: Antibodies as a cause of therapy failure." International Journal of Urology 2008; 15(5): 407-415.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18452456" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Shaban, A. M. and M. J. Drake. "Botulinum toxin treatment for overactive bladder: Risk of urinary retention." Current Urology Reports 2008; 9(6): 445-451.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18947508" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;White, W. M., R. B. Pickens, et al. "Short-term efficacy of botulinum toxin a for refractory overactive bladder in the elderly population." J Urol 2008; 180(6): 2522-6.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18930481" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>26/11/2010 15:24:31</lastReviewDate>
    <expiryDate>26/11/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>333393</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=333393]]&gt;</url>
    <title>2010 Annual Evidence Update on Male Urinary Incontinence - Conservative Management of Male Urinary Incontinence</title>
    <publicationDate>2010-02-01T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE URINARY INCONTINENCE,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Male Urinary Incontinence - Conservative Management of Male Urinary Incontinence&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;H2&gt;&lt;A href="nelh:333390:0" name=internalLink&gt;&lt;FONT size=2&gt;Link to 2010 Annual Evidence Update on Male Urinary Incontinence contents page&lt;/FONT&gt;&lt;/A&gt;&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;STRONG&gt;Systematic Reviews and Meta-analyses: &lt;/STRONG&gt;Evidence&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Offermans, M. P. W., M. F. M. T. Du Moulin, et al. "Prevalence of urinary incontinence and associated risk factors in nursing home residents: A systematic review." Neurourology and Urodynamics 2009; 28(4): 288-294. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19191259" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Fader, M., A. M. Cottenden, et al. "Absorbent products for moderate-heavy urinary and/or faecal incontinence in women and men." Cochrane Database of Systematic Reviews 2008; (4).&amp;nbsp;[&lt;A href="nelh:295760:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Fink, H. A., B. C. Taylor, et al. "Treatment interventions in nursing home residents with urinary incontinence: a systematic review of randomized trials." Mayo Clinic Proceedings 2008; 83(12): 1332-43.&amp;nbsp;[&lt;A href="nelh:329034:0" name=internalLink&gt;Link to&amp;nbsp;DARE abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Marshall, L. L. and W. Baliey. "Urinary incontinence management in geriatric patients." Consultant Pharmacist 2008; 23(9): 681-94.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19032011" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Rotzoll, S. "[Pelvic floor muscle training for urinary incontinence. Which training method is the most effective for people over 60 years?]. [German] Beckenbodentraining bei Harninkontinenz. Welche Trainingsmethode ist fur Menschen uber 60 Jahren am effektivsten?" Pflege Zeitschrift 2008; 61(11): 610-5.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19013924" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Thomas Lois, H., S. Cross, et al. Treatment of urinary incontinence after stroke in adults. Cochrane Database of Systematic Reviews&amp;nbsp; 2008; DOI: 10.1002/14651858.CD004462.pub3&amp;nbsp;[&lt;A href="nelh:238685:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;STRONG&gt;&lt;STRONG&gt;&lt;A href="nelh:301849:0" name=internalLink&gt;
&lt;P&gt;&lt;STRONG&gt;Link to 2009 Annual Evidence Update on Male Urinary Incontinence contents page&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;&lt;STRONG&gt;&lt;A href="nelh:303725:0" name=internalLink&gt;
&lt;P&gt;&lt;STRONG&gt;Link to 2009 evidence on Conservative Management of Male Urinary Incontinence&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>26/11/2010 15:24:35</lastReviewDate>
    <expiryDate>26/11/2011 15:24:35</expiryDate>
  </document>
  <document>
    <id>333390</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=333390]]&gt;</url>
    <title>2010 Annual Evidence Update on Male Urinary Incontinence - Contents</title>
    <publicationDate>2010-02-01T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE URINARY INCONTINENCE,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Male Urinary Incontinence - Contents&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;This Annual Evidence Update is being launched on 1st February 2010 in advance of the publication of the NICE guidelines on The Management of Lower Urinary Tract Symptoms in Men later this year. [&lt;/STRONG&gt;&lt;A href="http://www.nice.org.uk/guidance/index.jsp?action=folder&amp;amp;o=45292" target="_blank"&gt;&lt;STRONG&gt;Link to NICE guideline consultation webpage&lt;/STRONG&gt;&lt;/A&gt;&lt;STRONG&gt;]&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=center&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage0 style="WIDTH: 160px; HEIGHT: 261px" height=300 alt="Dripping tap" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID333390/nelhImp_0001_UIAEUdrippingtap.JPG" width=190 border=0 name=nelh_tempImage0&gt;&lt;/P&gt;
&lt;P align=center&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Introduction to the 2010 AEU from Prof. C. Chapple:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Dear Colleagues,&lt;/P&gt;
&lt;P&gt;I hope you will find the 2010 Annual Evidence Update on Male Urinary Incontinence provided by the Kidney Disease and Male Urogenital subgroup of NHS Evidence helpful.&amp;nbsp; This update reviews all of the latest data&amp;nbsp;relating to the management of incontinence in the male with preliminary&amp;nbsp;data on new aspects of treatment including male slings and botulinum toxin A injection therapy. &lt;/P&gt;
&lt;P&gt;I would encourage you to review the NICE guideline on male lower urinary&amp;nbsp;tract symptoms which is being released in April 2010 (the web page can be found here: &lt;A href="http://tinyurl.com/yenjo6a" target="_blank"&gt;http://tinyurl.com/yenjo6a&lt;/A&gt;).&amp;nbsp; The group have worked very hard on producing this update and I&amp;nbsp;hope that you will find it useful.&amp;nbsp; Please note that whilst this NHS Evidence update reviews the latest ideas, the NICE guideline cautions against some aspects of treatment based on the lack of a robust evidence base.&amp;nbsp; In particular, you will find in the NICE guideline that some treatments aren't recommended as first line, but this doesn't mean that they're not effective, but rather that we should evaluate them first in the context of research projects to accrue an appropriate evidence base to guide our practice in the future. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Prof Christopher Chapple, BSc, MD, FRCS (Urol), FEBU&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P align=center&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010 Annual Evidence Update on Male Urinary Incontinence: Contents&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;&lt;A href="nelh:333008:0" name=internalLink&gt;Post-prostatectomy and Urinary Incontinence&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:333392:0" name=internalLink&gt;Botulinum Toxin A and Male Urinary Incontinence&lt;/A&gt;&amp;nbsp;- includes RCTs and lower-level evidence published in 2009&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:333393:0" name=internalLink&gt;Conservative Management of Male Urinary Incontinence&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:333394:0" name=internalLink&gt;Male and Female Quality of Life Studies&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:333408:0" name=internalLink&gt;Male Stress Urinary Incontinence and Surgery&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:333409:0" name=internalLink&gt;Male Stress Urinary Incontinence and Drug Treatment&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:333410:0" name=internalLink&gt;Male Urgency Urinary Incontinence and Surgery&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:333412:0" name=internalLink&gt;Male Urgency&amp;nbsp;Urinary Incontinence and Drug Treatment&lt;/A&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;A href="nelh:334876:0" name=internalLink&gt;Link to 2010 AEU on Female Urinary Incontinence&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:333411:0" name=internalLink&gt;Click here to see the Methodology used for this AEU&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/DUETS/SearchResults.aspx?catID=14531" target="_blank"&gt;Click here to see the Treatment Uncertainties for urinary incontinence&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Please help us! - Fill in this &lt;/STRONG&gt;&lt;A href="http://www.surveymonkey.com/s/GGMQ5T8" target="_blank"&gt;&lt;STRONG&gt;quick&amp;nbsp;survey&lt;/STRONG&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:301849:0" name=internalLink&gt;Link to 2009 Annual Evidence Update on Male Urinary Incontinence contents page&lt;/A&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>26/11/2010 15:24:40</lastReviewDate>
    <expiryDate>26/11/2011 15:24:40</expiryDate>
  </document>
  <document>
    <id>333394</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=333394]]&gt;</url>
    <title>2010 Annual Evidence Update on Male Urinary Incontinence - Male and Female Quality of Life Studies</title>
    <publicationDate>2010-02-01T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE URINARY INCONTINENCE,MALE BLADDER DISORDERS,OTHER INCONTINENCE,MALE UROGENITAL DISORDERS,OVERACTIVE BLADDER]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Male Urinary Incontinence - Male and Female Quality of Life Studies&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;H2&gt;&lt;A href="nelh:333390:0" name=internalLink&gt;&lt;FONT size=2&gt;Link to 2010 Annual Evidence Update on Male Urinary Incontinence contents page&lt;/FONT&gt;&lt;/A&gt;&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;STRONG&gt;Systematic Reviews and Meta-analyses: &lt;/STRONG&gt;Evidence&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Bartoli S, Aguzzi G, Tarricone R. Impact on Quality of Life of Urinary Incontinence and Overactive Bladder: A Systematic Literature Review. Urology 2009; Dec 3 [Epub ahead of print]. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19962738" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;STRONG&gt;&lt;A href="nelh:301849:0" name=internalLink&gt;
&lt;P&gt;&lt;STRONG&gt;Link to 2009 Annual Evidence Update on Male Urinary Incontinence contents page&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;&lt;STRONG&gt;&lt;A href="nelh:303722:0" name=internalLink&gt;
&lt;P&gt;&lt;STRONG&gt;Link to 2009 evidence on Male and Female Quality of Life Studies&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>26/11/2010 15:24:43</lastReviewDate>
    <expiryDate>26/11/2011 15:24:43</expiryDate>
  </document>
  <document>
    <id>333409</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=333409]]&gt;</url>
    <title>2010 Annual Evidence Update on Male Urinary Incontinence - Male Stress Urinary Incontinence and Drug Treatment</title>
    <publicationDate>2010-02-01T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE URINARY INCONTINENCE,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Male Urinary Incontinence - Male Stress Urinary Incontinence and Drug Treatment&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;H2&gt;&lt;A href="nelh:333390:0" name=internalLink&gt;&lt;FONT size=2&gt;Link to 2010 Annual Evidence Update on Male Urinary Incontinence contents page&lt;/FONT&gt;&lt;/A&gt;&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Systematic Reviews and Meta-analyses: Evidence&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Athanasopoulos, A. and P. Perimenis. "Pharmacotherapy of urinary incontinence." International Urogynecology Journal 2009; 20(4): 475-82. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19002644" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lobo, E. D., T. Quinlan, et al.&amp;nbsp; "Population pharmacokinetics of orally administered duloxetine in patients: implications for dosing recommendation." Clinical Pharmacokinetics 2009; 48(3): 189-97.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19385712" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lunn Michael, P. T., A. C. Hughes Richard, et al. Duloxetine for treating painful neuropathy or chronic pain. Cochrane Database of Systematic Reviews&amp;nbsp; 2009; DOI: 10.1002/14651858.CD007115.pub2&amp;nbsp;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD007115/frame.html" target="_blank"&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Shamliyan, T.A, Wyman, J.F, Ping, R., Wilt, T.J., Kane, R.L. "Male urinary incontinence: prevalence, risk factors, and preventive interventions." Rev Urol. 2009 Summer;11(3):145-65. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19918340" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Marshall, L. L. and W. Baliey. "Urinary incontinence management in geriatric patients." Consultant Pharmacist 2008; 23(9): 681-94.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19032011" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Thomas Lois, H., S. Cross, et al. Treatment of urinary incontinence after stroke in adults. Cochrane Database of Systematic Reviews&amp;nbsp; 2008; DOI: 10.1002/14651858.CD004462.pub3&amp;nbsp;[&lt;A href="nelh:238685:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Other evidence&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Du Moulin, M.F., Hamers, J.P., Ambergen, A.W., Halfens, R.J. "Urinary incontinence in older adults receiving home care diagnosis and strategies." Scand J Caring Sci. 2009 Jun;23(2):222-30. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19645801" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;STRONG&gt;&lt;A href="nelh:301849:0" name=internalLink&gt;
&lt;P&gt;&lt;STRONG&gt;Link to 2009 Annual Evidence Update on Male Urinary Incontinence contents page&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&lt;A href="nelh:303709:0" name=internalLink&gt;&lt;/P&gt;
&lt;P&gt;Link to 2009 evidence on Male Stress Urinary Incontinence and Drug treatment&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>26/11/2010 15:24:51</lastReviewDate>
    <expiryDate>26/11/2011 15:24:51</expiryDate>
  </document>
  <document>
    <id>333408</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=333408]]&gt;</url>
    <title>2010 Annual Evidence Update on Male Urinary Incontinence - Male Stress Urinary Incontinence and Surgery</title>
    <publicationDate>2010-02-01T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE URINARY INCONTINENCE,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Male Urinary Incontinence - Male Stress Urinary Incontinence and Surgery&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;H2&gt;&lt;A href="nelh:333390:0" name=internalLink&gt;&lt;FONT size=2&gt;Link to 2010 Annual Evidence Update on Male Urinary Incontinence contents page&lt;/FONT&gt;&lt;/A&gt;&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;STRONG&gt;Systematic Reviews and Meta-analyses: &lt;/STRONG&gt;Evidence&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Latthe P.M., Singh P., Foon R., Toozs-Hobson P. Two routes of transobturator tape procedures in stress urinary incontinence: a meta-analysis with direct and indirect comparison of randomized trials. BJU Int. 2009; Nov 12. [Epub ahead of print]. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19912182" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mathis, S., B. Guba, et al.&amp;nbsp; "[Stress urinary incontinence. Evidence for 4 minimally invasive methods of treating - systematic overview]. [German] Belastungsinkontinenz. Evidenz zu 4 minimal-invasiven Behandlungsmethoden mit fragwurdigem Nutzen - systematische Ubersichtsarbeit." Urologe (Ausg. A) 2009; 48(11): 1330, 1332-8. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19690828" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Shamliyan, T.A, Wyman, J.F, Ping, R., Wilt, T.J., Kane, R.L. "Male urinary incontinence: prevalence, risk factors, and preventive interventions." Rev Urol. 2009 Summer;11(3):145-65. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19918340" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;STRONG&gt;&lt;A href="nelh:301849:0" name=internalLink&gt;
&lt;P&gt;&lt;STRONG&gt;Link to 2009 Annual Evidence Update on Male Urinary Incontinence contents page&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;&lt;A href="nelh:303708:0" name=internalLink&gt;
&lt;P&gt;Link to 2009 evidence on Stress Urinary Incontinence and Surgery&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>26/11/2010 15:25:02</lastReviewDate>
    <expiryDate>26/11/2011 15:25:02</expiryDate>
  </document>
  <document>
    <id>333412</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=333412]]&gt;</url>
    <title>2010 Annual Evidence Update on Male Urinary Incontinence - Male Urgency Urinary Incontinence and Drug Treatment</title>
    <publicationDate>2010-02-01T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE URINARY INCONTINENCE,MALE BLADDER DISORDERS,MALE UROGENITAL DISORDERS,OVERACTIVE BLADDER]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Male Urinary Incontinence - Male Urgency Urinary Incontinence and Drug Treatment&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;H2&gt;&lt;A href="nelh:333390:0" name=internalLink&gt;&lt;FONT size=2&gt;Link to 2010 Annual Evidence Update on Male Urinary Incontinence contents page&lt;/FONT&gt;&lt;/A&gt;&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;STRONG&gt;Systematic Reviews and Meta-analyses: &lt;/STRONG&gt;Evidence&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Athanasopoulos, A. and P. Perimenis. "Pharmacotherapy of urinary incontinence." International Urogynecology Journal 2009; 20(4): 475-82. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19002644" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Biastre, K. and T. Burnakis. "Trospium chloride treatment of overactive bladder." Annals of Pharmacotherapy 2009; 43(2): 283-95.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19193592" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Nicholas Richard, S., T. Friede, et al. Anticholinergics for urinary symptoms in multiple sclerosis. Cochrane Database of Systematic Reviews&amp;nbsp;2009; DOI: 10.1002/14651858.CD004193.pub2&amp;nbsp;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD004193/frame.html" target="_blank"&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Shamliyan, T.A, Wyman, J.F, Ping, R., Wilt, T.J., Kane, R.L. "Male urinary incontinence: prevalence, risk factors, and preventive interventions." Rev Urol. 2009 Summer;11(3):145-65. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19918340" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Tzefos M., Dolder C., et al. Fesoterodine for the treatment of overactive bladder. Ann Pharmacother 2009; 43(12): 1992-2000. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19920160" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Fink, H. A., B. C. Taylor, et al. "Treatment interventions in nursing home residents with urinary incontinence: a systematic review of randomized trials." Mayo Clinic Proceedings 2008; 83(12): 1332-43.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19046552" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kelleher, C. J., A. Tubaro, et al. "Impact of fesoterodine on quality of life: pooled data from two randomized trials." BJU International 2008; 102(1): 56-61.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18564231" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Marshall, L. L. and W. Baliey. "Urinary incontinence management in geriatric patients." Consultant Pharmacist 2008; 23(9): 681-94.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19032011" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Novara, G., A. Galfano, et al. "A Systematic Review and Meta-Analysis of Randomized Controlled Trials with Antimuscarinic Drugs for Overactive Bladder." European Urology 2008; 54(4): 740-764.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18632201" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Thomas Lois, H., S. Cross, et al. Treatment of urinary incontinence after stroke in adults. Cochrane Database of Systematic Reviews&amp;nbsp; 2008; DOI: 10.1002/14651858.CD004462.pub3&amp;nbsp;[&lt;A href="nelh:238685:0" name=internalLink&gt;Link to Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Other evidence&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Du Moulin, M.F., Hamers, J.P., Ambergen, A.W., Halfens, R.J. "Urinary incontinence in older adults receiving home care diagnosis and strategies." Scand J Caring Sci. 2009 Jun;23(2):222-30. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19645801" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;STRONG&gt;&lt;A href="nelh:301849:0" name=internalLink&gt;
&lt;P&gt;&lt;STRONG&gt;Link to 2009 Annual Evidence Update on Male Urinary Incontinence contents page&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;&lt;A href="nelh:303711:0" name=internalLink&gt;
&lt;P&gt;&lt;STRONG&gt;Link to 2009 evidence on Male Urgency Urinary Incontinence and Drug treatment&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>26/11/2010 15:25:11</lastReviewDate>
    <expiryDate>26/11/2011 15:25:11</expiryDate>
  </document>
  <document>
    <id>333410</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=333410]]&gt;</url>
    <title>2010 Annual Evidence Update on Male Urinary Incontinence - Male Urgency Urinary Incontinence and Surgery</title>
    <publicationDate>2010-02-01T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE URINARY INCONTINENCE,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Male Urinary Incontinence - Male Urgency Urinary Incontinence and Surgery&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;H2&gt;&lt;A href="nelh:333390:0" name=internalLink&gt;&lt;FONT size=2&gt;Link to 2010 Annual Evidence Update on Male Urinary Incontinence contents page&lt;/FONT&gt;&lt;/A&gt;&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;STRONG&gt;Systematic Reviews and Meta-analyses: &lt;/STRONG&gt;Evidence&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Herbison, G. P. and E. P. Arnold. "Sacral neuromodulation with implanted devices for urinary storage and voiding dysfunction in adults." Cochrane Database of Systematic Reviews 2009; (2). [&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD004202/frame.html" target="_blank"&gt;Link to Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Shamliyan, T.A, Wyman, J.F, Ping, R., Wilt, T.J., Kane, R.L. "Male urinary incontinence: prevalence, risk factors, and preventive interventions." Rev Urol. 2009 Summer;11(3):145-65. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19918340" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Fitzpatrick, M. "Sacral nerve stimulation for treatment of refractory urinary urge incontinence: a review." British Journal of Neuroscience Nursing 2008;&amp;nbsp;4(7): 322-326. [&lt;A href="http://www.internurse.com/cgi-bin/go.pl/library/article.cgi?uid=30668;article=BJNN_4_7_322_325" target="_blank"&gt;Link to abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;STRONG&gt;&lt;A href="nelh:301849:0" name=internalLink&gt;
&lt;P&gt;&lt;STRONG&gt;Link to 2009 Annual Evidence Update on Male Urinary Incontinence contents page&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;&lt;A href="nelh:303710:0" name=internalLink&gt;
&lt;P&gt;Link to 2009 evidence on Male Urgency urinary incontinence and Surgery&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>26/11/2010 15:25:15</lastReviewDate>
    <expiryDate>26/11/2011 15:25:15</expiryDate>
  </document>
  <document>
    <id>333411</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=333411]]&gt;</url>
    <title>2010 Annual Evidence Update on Male Urinary Incontinence - Methodology</title>
    <publicationDate>2010-02-01T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE URINARY INCONTINENCE,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Male Urinary Incontinence - Methodology&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;H2&gt;&lt;A href="nelh:333390:0" name=internalLink&gt;&lt;FONT size=2&gt;Link to 2010 Annual Evidence Update on Male Urinary Incontinence contents page&lt;/FONT&gt;&lt;/A&gt;&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010 UI AEU methodology&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Searching for systematic reviews and meta analyses on male urinary incontinence published 2008-2009:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;The&amp;nbsp;SIGN SR search filter for Cinahl, and the Clinical Evidence SR search filters&amp;nbsp;were used to search&amp;nbsp;Embase and Medline for systematic reviews and meta-analyses. &lt;/LI&gt;
&lt;LI&gt;In Cinahl, Embase, Medline and the Cochrane Library, “urinary incontinence” was used as a MeSH or thesaurus term, OR “urin* incontin*”.&lt;/LI&gt;
&lt;LI&gt;In Cinahl, Embase and Medline, the urinary incontinence terms were combined with (AND) the search filters, and limited by publication date 2008-2009.&lt;/LI&gt;
&lt;LI&gt;In Cochrane, the urinary incontinence terms were limited by publication date 2008-2009.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Search results:&lt;/P&gt;
&lt;P&gt;Medline: 98&lt;BR&gt;Embase: 64&lt;BR&gt;Cinahl: 30&lt;BR&gt;Cochrane: 52&lt;BR&gt;= 244 results&lt;/P&gt;
&lt;P&gt;After deduplication = 155.&lt;/P&gt;
&lt;P&gt;SIFTING&lt;BR&gt;1.&amp;nbsp;exclude irrelevant references&lt;BR&gt;2.&amp;nbsp;exclude references about women only&lt;BR&gt;3.&amp;nbsp;exclude references which are definitely not systematic reviews&lt;/P&gt;
&lt;P&gt;=&amp;nbsp;27 references&lt;/P&gt;
&lt;P&gt;GROUPING&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Systematic reviews and meta-analyses grouped by topic:&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Post-prostatectomy and Urinary Incontinence =&amp;nbsp;6 references&lt;/LI&gt;
&lt;LI&gt;Botulinum Toxin A and Male Urinary Incontinence&amp;nbsp; =&amp;nbsp;3 references&lt;/LI&gt;
&lt;LI&gt;Conservative Management of Male Urinary Incontinence&amp;nbsp;&amp;nbsp; =&amp;nbsp;6 references&lt;/LI&gt;
&lt;LI&gt;Male and Female Quality of Life Studies =&amp;nbsp;1 reference&lt;/LI&gt;
&lt;LI&gt;Male Stress Urinary Incontinence and Surgery&amp;nbsp; =&amp;nbsp;1 references&lt;/LI&gt;
&lt;LI&gt;Male Stress Urinary Incontinence and Drug treatment&amp;nbsp;&amp;nbsp;&amp;nbsp; =&amp;nbsp;6 references&lt;/LI&gt;
&lt;LI&gt;Male Urgency Urinary Incontinence and Surgery&amp;nbsp; =&amp;nbsp;2 references&lt;/LI&gt;
&lt;LI&gt;Male Urgency Urinary Incontinence and Drug treatment&amp;nbsp; =&amp;nbsp;9 references&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Some additional references were&amp;nbsp;added&amp;nbsp;afterwards which&amp;nbsp;were&amp;nbsp;recommended by &lt;A href="http://www.guysandstthomas.nhs.uk/services/managednetworks/urology/staff/consultants/jonathanolsburgh.aspx" target="_blank"&gt;Mr Jonathon Olsburgh&lt;/A&gt;. &amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;STRONG&gt;&lt;A href="nelh:301849:0" name=internalLink&gt;
&lt;P&gt;&lt;STRONG&gt;Link to 2009 Annual Evidence Update on Male Urinary Incontinence contents page&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>26/11/2010 15:25:19</lastReviewDate>
    <expiryDate>26/11/2011 15:25:19</expiryDate>
  </document>
  <document>
    <id>333008</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=333008]]&gt;</url>
    <title>2010 Annual Evidence Update on Male Urinary Incontinence - Post-prostatectomy and Urinary Incontinence</title>
    <publicationDate>2010-02-01T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE URINARY INCONTINENCE,OTHER INCONTINENCE,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Male Urinary Incontinence - Post-prostatectomy and Urinary Incontinence&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;H2&gt;&lt;A href="nelh:333390:0" name=internalLink&gt;Link to 2010 Annual Evidence Update on Male Urinary Incontinence contents page&lt;/A&gt;&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Systematic Reviews and Meta-analyses: Evidence&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Bauer, R. M., P. J. Bastian, et al. "Postprostatectomy incontinence: all about diagnosis and management." European Urology 2009; 55(2): 322-33. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18963418" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Ficarra, V., G. Novara, et al. "Retropubic, Laparoscopic, and Robot-Assisted Radical Prostatectomy: A Systematic Review and Cumulative Analysis of Comparative Studies." European Urology 2009; 55(5): 1037-1063.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19185977" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hamashima, C., T. Nakayama, et al. "The Japanese guideline for prostate cancer screening." Japanese Journal of Clinical Oncology 2009; 39(6): 339-351.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19346535" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lourenco, T., Shaw M., et al. "The clinical effectiveness of transurethral incision of the prostate: a systematic review of randomised controlled trials." World J Urol 2009; Dec 24 (Epub ahead of print). [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20033744" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Fritzsche, K., D. Diederich, et al. "[Psychooncology of prostate carcinoma - psychosocial distress and treatment approaches: a systematic review]. [German] Psychosoziale Belastungen und Behandlungsansatze: eine systematische Literaturubersicht." Zeitschrift Fuer Psychosomatische Medizin und Psychotherapie 2008; 54(4): 329-53.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19049684" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lourenco, T., R. Pickard, et al. "Minimally invasive treatments for benign prostatic enlargement: systematic review of randomised controlled trials." BMJ 2008; 337.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18845591" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Parsons, J. K. and J. L. Bennett. "Outcomes of retropubic, laparoscopic, and robotic-assisted prostatectomy." Urology 2008; 72(2): 412-6.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18267330" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Other evidence&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Bauer, R.M., Mayer, M.E., Gratzke, C., Soljanik, I., et al. "Prospective Evaluation of the Functional Sling Suspension for Male Postprostatectomy Stress Urinary Incontinence: Results after 1 Year." Eur Urol. 2009 Jul 29 (Epub ahead of print). [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19671227" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Gacci, M., Simonato, A., Masieri, L, Gore, J.L., et al. "Urinary and sexual outcomes in long-term (5+ years) prostate cancer disease free survivors after radical prostatectomy." Health Qual Life Outcomes. 2009 Nov 13;7:94. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19912640" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Smith, D.P., King, M.T., Egger, S., et al. "Quality of life three years after diagnosis of localised prostate cancer: population based cohort study." BMJ. 2009 Nov 27;339:b4817. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19945997" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Zorn, K.C., Wille, M.A., Thong, A.E., Katz, M.H., et al. "Continued improvement of perioperative, pathological and continence outcomes during 700 robot-assisted radical prostatectomies." Can J Urol. 2009 Aug;16(4):4742-9. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19671227" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;STRONG&gt;&lt;A href="nelh:301849:0" name=internalLink&gt;
&lt;P&gt;&lt;STRONG&gt;Link to 2009 Annual Evidence Update on Male Urinary Incontinence contents page&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;&lt;STRONG&gt;&lt;A href="nelh:302108:0" name=internalLink&gt;
&lt;P&gt;&lt;STRONG&gt;Link to 2009 evidence on Post-prostatectomy and Urinary Incontinence&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>26/11/2010 15:25:25</lastReviewDate>
    <expiryDate>26/11/2011 15:25:25</expiryDate>
  </document>
  <document>
    <id>396475</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=396475]]&gt;</url>
    <title>2010 Annual Evidence Update on Post Transplant Lymphoproliferative Disorders in Renal Transplant patients - Clinical Trials</title>
    <publicationDate>2010-12-06T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ IMMUNOSUPPRESSIVE DRUGS,PREVENTION OF COMPLICATIONS,TRANSPLANTATION,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Post Transplant Lymphoproliferative Disorders in Renal Transplant patients - Clinical Trials&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;H3&gt;&lt;A href="nelh:394440:0" name=internalLink&gt;Link back to 2010 Annual Evidence Update: Post Transplant Lymphoproliferative Disorders -&amp;nbsp;Contents page&lt;BR&gt;&lt;/A&gt;&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=center&gt;&amp;nbsp;&lt;IMG style="WIDTH: 143px; HEIGHT: 217px" id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="Post transplant lymphoproliferative disorders image" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID394440/nelhImp_0000_ptld1.JPG" width=167 height=318&gt;&amp;nbsp;&amp;nbsp; &lt;IMG style="WIDTH: 179px; HEIGHT: 217px" id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="Post transplant lymphoproliferative disorders body image" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID394440/nelhImp_0001_PTLDimage.JPG" width=179 height=215&gt;&lt;/P&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;&lt;BR&gt;Novel Immunosuppression Agents and risk of PTLD in Clinical Trials&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Belatacept is a first in class co-stimulation blocker in development for primary maintenance immunosuppresion. PTLD had been observed in a higher incidence with belatacept versus cyclosporin in the original study, published in 2005, and the results of phase 3 studies have been published in the last year. The five year extension to the original study has also been published. In this extension study, no belatacept patients developed PTLD, and the overall risk of PTLD was similar with standard and belatacept-based immunosuppression. Reviewing the data from all phase 3 studies, it has been suggested to avoid belatacept use in EBV-negative recipients.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;BLOCKQUOTE style="MARGIN-RIGHT: 0px" dir=ltr&gt;
&lt;P&gt;(1) Vincenti F, Blancho G et al (2010). Five-Year safety and Efficacy of Belatacept in Renal Transplantation. J AM Soc Nephrol 21:1587-1596. [&lt;A href="http://www.dovepress.com/the-pharmacokinetics-of-valganciclovir-prophylaxis-in-pediatric-solid--peer-reviewed-article-CPAA" target="_blank"&gt;Link to Journal website for abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;(2) Durrbach, A., S. Florman, et al. (2010). "Primary outcomes from a randomized, phase III study of belatacept versus cyclosporine in ECD kidney transplants (BENEFIT-EXT study)." American Journal of Transplantation 10. [No abstract available].&lt;/P&gt;
&lt;P&gt;(3) Durrbach, A., J. M. Pestana, et al. (2010). "A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT Study)." American Journal of Transplantation 10(3): 547-557. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20415898" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/P&gt;&lt;/BLOCKQUOTE&gt;
&lt;P&gt;&lt;BR&gt;From the same BENEFIT-EXT study, function outcomes were reported. The mean measured glomerular filtration rate was 4-7 mL/min higher on belatacept versus cyclosporine (p = 0.008 MI vs. cyclosporine; p = 0.1039 LI vs. cyclosporine), and the overall cardiovascular/metabolic profile was better on belatacept versus cyclosporine. The incidence of acute rejection was similar across groups (18% MI; 18% LI; 14% cyclosporine). Overall rates of infection and malignancy were similar between groups; however, more cases of posttransplant lymphoproliferative disorder (PTLD) occurred in the CNS on belatacept.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;BLOCKQUOTE style="MARGIN-RIGHT: 0px" dir=ltr&gt;
&lt;P&gt;(4) Pearson, T., F. Vincenti, et al. (2010). "Primary outcomes from a randomized, phase III study of belatacept versus cyclosporine in kidney transplant recipients (BENEFIT study)." American Journal of Transplantation 10. [No abstract available]&lt;/P&gt;&lt;/BLOCKQUOTE&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;BENEFIT is a 3-year, randomized, phase 3 study in adults receiving a kidney transplant from a living or deceased donor (LD, DD) with an anticipated CIT&amp;lt; 24 hrs. Patients were randomized 1:1:1 to a more intensive (MI) or less intensive (LI) regimen of belatacept or CsA; all patients received basiliximab induction, MMF, and corticosteroids. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;666 patients were randomized and transplanted. PTLD was observed in 1(0.5%), 2(0.9%), and 1(0.5%) patients in the MI, LI, and CsA groups in the first year. Conclusions: At 1 year, belatacept regimens demonstrated superior renal function and similar patient/graft survival vs CsA, despite an increase in AR in the early post-tx period. Belatacept represents a promising, non-nephrotoxic therapy option in kidney tx patients.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <expiryDate>05/12/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>394440</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=394440]]&gt;</url>
    <title>2010 Annual Evidence Update on Post Transplant Lymphoproliferative Disorders in Renal Transplant patients - Contents</title>
    <publicationDate>2010-12-06T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ PREVENTION OF COMPLICATIONS,IMMUNOSUPPRESSIVE DRUGS,TRANSPLANTATION,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Post Transplant Lymphoproliferative Disorders in Renal Transplant patients - Contents&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;6 - 10 December 2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Annual Evidence Update on Post Transplant Lymphoproliferative Disorders in Renal Transplant Patients&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=center&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;IMG style="WIDTH: 143px; HEIGHT: 217px" id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="Post transplant lymphoproliferative disorders image" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID394440/nelhImp_0000_ptld1.JPG" width=167 height=318&gt;&amp;nbsp;&amp;nbsp; &lt;IMG style="WIDTH: 179px; HEIGHT: 217px" id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="Post transplant lymphoproliferative disorders body image" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID394440/nelhImp_0001_PTLDimage.JPG" width=179 height=215&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;H2&gt;&lt;A href="nelh:394480:0" name=internalLink&gt;Introduction&lt;/A&gt; - commentary by Dr Edward Sharples&lt;/H2&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;H2&gt;&lt;A href="nelh:396475:0" name=internalLink&gt;Clinical Trials&lt;/A&gt; - commentary by Dr Edward Sharples&lt;/H2&gt;&lt;/LI&gt;&lt;A href="nelh:395030:0" name=internalLink&gt;
&lt;LI&gt;
&lt;H2&gt;Evidence&lt;/H2&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;H2&gt;&lt;/A&gt;&lt;A href="nelh:395029:0" name=internalLink&gt;Methodology&lt;/A&gt;&lt;/H2&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;H2&gt;&lt;A href="nelh:331540:0" name=internalLink&gt;UK Database of Uncertainties about the Effects of Treatments (DUETs) on post transplant lymphoproliferative disorders&lt;/A&gt;&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;We welcome feedback about resources that&amp;nbsp;we identify. Please &lt;A href="http://www.library.nhs.uk/kidney/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;A href="nelh:329868:0" name=internalLink&gt;
&lt;P&gt;Link to 2009 Annual Evidence Update on Post Transplant Lymphoproliferative Disorders in Renal Transplant patients - Contents&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <expiryDate>18/11/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>395030</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=395030]]&gt;</url>
    <title>2010 Annual Evidence Update on Post Transplant Lymphoproliferative Disorders in Renal Transplant patients - Evidence</title>
    <publicationDate>2010-12-06T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ TRANSPLANTATION,IMMUNOSUPPRESSIVE DRUGS,PREVENTION OF COMPLICATIONS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Post Transplant Lymphoproliferative Disorders in Renal Transplant patients - Evidence&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;H3&gt;&lt;A href="nelh:394440:0" name=internalLink&gt;Link back to 2010 Annual Evidence Update: Post Transplant Lymphoproliferative Disorders -&amp;nbsp;Contents page&lt;BR&gt;&lt;/A&gt;&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Evidence: 2010&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;BLOCKQUOTE style="MARGIN-RIGHT: 0px" dir=ltr&gt;
&lt;UL&gt;
&lt;LI&gt;Brewin J, Mancao C et al (2009). Generation of EBV-specific cytotoxic T Cells that are resistant to calcineurin inhibitors for the treatment of post-transplant lymphoproliferative disease. Blood 114: 4792-4803. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19770360" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Capello, D., Rasi, S., et al (2009) Molecular characterization of post-transplant lymphoproliferative disorders of donor origin occurring in liver transplant recipients. Journal of Pathology, 218, 478–486. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19391128" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Durrbach, A., &amp;nbsp;Florman, S. et al. (2010). "Primary outcomes from a randomized, phase III study of belatacept versus cyclosporine in ECD kidney transplants (BENEFIT-EXT study)." American Journal of Transplantation 10. [No abstract available].&lt;/LI&gt;
&lt;LI&gt;Durrbach, A., Pestana, J.M.&amp;nbsp;et al. (2010). "A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT Study)." American Journal of Transplantation 10(3): 547-557. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20415898" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evens AM, David KA et al (2010). Multicenter analysis of 80 solid organ transplant recipients with post-transplant lymphoproliferative disease: outcome and prognostic factors in the modern age. J Clin Oncol 28: 1038-1046. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20085936" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;].&lt;/LI&gt;
&lt;LI&gt;Fox CP, Haigh TA et al. (2010) A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK and T cell lymphoproliferative disease encodes a target for cellular immunotherapy. Blood&amp;nbsp;&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20671118" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Ison, M.G. &amp;amp; Nalesnik, M. (2009) OPTN/UNOS Ad Hoc Disease Transmission Advisory Committee Report to the Board of Directors. November 16-17, 2009, Orlando, Florida. pages 12–15. &lt;A href="http://optn.transplant.hrsa.gov/CommitteeReports/board_main_AdHocDiseaseTransmissionAdvisoryCommittee_11_20_2009_11_12.pdf" target="_blank"&gt;Link to full-text PDF (20 pages&lt;/A&gt;)&lt;/LI&gt;
&lt;LI&gt;Jones K, Nourse J at el. (2010) Expansion of EBNA-1 specific effector-T cells in posttransplant lymphoproliferative disorders. Blood 116:2245-2252. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20562330" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lu J, Tang Y (2010). Epstein-Barr virus facilitates the malignant potential of immortalised epithelial cells: from latent genome to viral production and maintenance. Laboratory investigation 90: 196-209. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19997065" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;McAulay KA, Haque T, Crawford D (2009). Tumour necrosis factor polymorphism: a predictive factor for the development of post-transplant lymphoproliferative disease. Br J Cancer 101: 1019-1027. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Tumour+necrosis+factor+polymorphism%3A+a+predictive+factor+for+the+development+of+post-transplant+lymphoproliferative+disease&amp;amp;TransSchema=title&amp;amp;cmd=detailssearch" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mucha K Foroncewicz B. (2010) Post-transplant lymphoproliferative disorder in view of the new WHO classification: a more rational approach to a protean disease? Nephrol Dial Transplant 25: 2089-2098. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20576725" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Parker, A., Bowles, K., Bradley, J. A., Emery, V., Featherstone, C., Gupte, G., Marcus, R., Parameshwar, J., Ramsay, A., Newstead, C. and On behalf of the Haemato-oncology Task Force of the British Committee for Standards in Haematology and British Transplantation Society (2010). Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients – BCSH and BTS Guidelines. British Jounal of Haematology 149: 675-692. [&lt;A href="nelh:387727:0" name=internalLink&gt;Link to abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Parker, A., Bowles, K., Bradley, J. A., Emery, V., Featherstone, C., Gupte, G., Marcus, R., Parameshwar, J., Ramsay, A., Newstead, C. and On behalf of the Haemato-oncology Task Force of the British Committee for Standards in Haematology and British Transplantation Society (2010), Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients – BCSH and BTS Guidelines. British Journal of Haematology, 149: 693–705. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20408848" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Pearson, T., F. Vincenti, et al. (2010). "Primary outcomes from a randomized, phase III study of belatacept versus cyclosporine in kidney transplant recipients (BENEFIT study)." American Journal of Transplantation 10.&amp;nbsp;&amp;nbsp;[No abstract available]&lt;/LI&gt;
&lt;LI&gt;Tisher J, Moosmann A. (2010) Transfer of EBV-specific T cells: A treatment option for patients with EBV-associated lymphoproliferative disease after allogeneic stem cell transplantation. Bone Marrow Transplantation 45:&amp;nbsp;&amp;nbsp;[No abstract available]&lt;/LI&gt;
&lt;LI&gt;Trappe R, Hinrichs C (2009). Treatment of PTLD with Rituximab and CHOP reduces the risk of renal graft impairment after reduction in Immunosuppression. American Journal of Transplantation 9: 2331-2337.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19663889" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Vezina H, Brundage R et al (2010) The pharmocokinetics of valganciclovir prophylaxis in paediatric solid organ transplant patients at risk for Ebstein-Barr virus disease. Clinical Pharmacology: Advances and Applications 2 (1) 1-7.&amp;nbsp;[&lt;A href="http://www.dovepress.com/the-pharmacokinetics-of-valganciclovir-prophylaxis-in-pediatric-solid--peer-reviewed-article-CPAA" target="_blank"&gt;Link to Journal website for abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;&lt;/BLOCKQUOTE&gt;
&lt;P&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <expiryDate>26/11/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>394480</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=394480]]&gt;</url>
    <title>2010 Annual Evidence Update on Post Transplant Lymphoproliferative Disorders in Renal Transplant patients - Introduction</title>
    <publicationDate>2010-12-06T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ TRANSPLANTATION,IMMUNOSUPPRESSIVE DRUGS,PREVENTION OF COMPLICATIONS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Post Transplant Lymphoproliferative Disorders in Renal Transplant patients - Introduction&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;H3&gt;&lt;A href="nelh:394440:0" name=internalLink&gt;Link back to 2010 Annual Evidence Update: Post Transplant Lymphoproliferative Disorders -&amp;nbsp;Contents page&lt;BR&gt;&lt;/A&gt;&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=center&gt;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P align=center&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;IMG style="WIDTH: 143px; HEIGHT: 217px" id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="Post transplant lymphoproliferative disorders image" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID394440/nelhImp_0000_ptld1.JPG" width=167 height=318&gt;&amp;nbsp;&amp;nbsp; &lt;IMG style="WIDTH: 179px; HEIGHT: 216px" id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="Post transplant lymphoproliferative disorders body image" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID394440/nelhImp_0001_PTLDimage.JPG" width=179 height=215&gt;&lt;/P&gt;
&lt;P align=center&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=center&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Introduction to the 2010 Update&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;In June 2010,&amp;nbsp;a joint working group established by the Haemato-oncology subgroup of the British Committee for Standards in Haematology (BCSH) and the British Transplantation Society (BTS) published their clinical guidelines for the diagnosis and management of post-transplant lymphoproliferative disorder (PTLD) in adult recipients of solid organ transplants [1].&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;PTLD is a relatively common malignancy post-transplantation, and an incidence as high as 10% in solid organ transplant recipients has been reported. In adult transplant recipients, it is the second most common malignancy after skin cancer, and in children the most common post-transplant malignancy. The USA United Network for Organ Sharing (UNOS) Ad Hoc Disease Transmission Advisory Committee recently reported a 5-year cumulative incidence of PTLD for paediatric recipients of 3.26% as against adult recipients of 0.91% for the 5 years 2003–2007 [3]. The overall mortality reported in the literature, which may not be representative of current clinical experience, is approximately 50%. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Management of PTLD varies significantly according to the type of lymphoproliferative disease present, as well as from institution to institution. Multi-centre trials are rare, and the evidence collated for this 2010 update shows that this trend continues. The published evidence consists of case reports, case series and small clinical trials. Evidence from large RCTs of novel therapeutic agents in transplantation do lead to valuable insights, and the results of the Belatacept trials will be discussed below.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;BLOCKQUOTE style="MARGIN-RIGHT: 0px" dir=ltr&gt;
&lt;P&gt;(1) Parker, A., Bowles, K., Bradley, J. A., Emery, V., Featherstone, C., Gupte, G., Marcus, R., Parameshwar, J., Ramsay, A., Newstead, C. and On behalf of the Haemato-oncology Task Force of the British Committee for Standards in Haematology and British Transplantation Society (2010). Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients – BCSH and BTS Guidelines. British Jounal of Haematology 149: 675-692. [&lt;A href="nelh:387727:0" name=internalLink&gt;Link to abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;(2) Parker, A., Bowles, K., Bradley, J. A., Emery, V., Featherstone, C., Gupte, G., Marcus, R., Parameshwar, J., Ramsay, A., Newstead, C. and On behalf of the Haemato-oncology Task Force of the British Committee for Standards in Haematology and British Transplantation Society (2010), Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients – BCSH and BTS Guidelines. British Journal of Haematology, 149: 693–705. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20408848" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;(3) Ison, M.G. &amp;amp; Nalesnik, M. (2009) OPTN/UNOS Ad Hoc Disease Transmission Advisory Committee Report to the Board of Directors. November 16-17, 2009, Orlando, Florida. pages 12–15. Link:&lt;BR&gt;&lt;A href="http://optn.transplant.hrsa.gov/CommitteeReports/board_main_AdHocDiseaseTransmissionAdvisoryCommittee_11_20_2009_11_12.pdf" target="_blank"&gt;http://optn.transplant.hrsa.gov/CommitteeReports/board_main_AdHocDiseaseTransmissionAdvisoryCommittee_11_20_2009_11_12.pdf&lt;/A&gt;&lt;/P&gt;&lt;/BLOCKQUOTE&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Science&lt;/STRONG&gt;&lt;/P&gt;
&lt;BLOCKQUOTE style="MARGIN-RIGHT: 0px" dir=ltr&gt;
&lt;P&gt;(4) McAulay KA, Haque T, Crawford D (2009). Tumour necrosis factor polymorphism: a predictive factor for the development of post-transplant lymphoproliferative disease. Br J Cancer 101: 1019-1027. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Tumour+necrosis+factor+polymorphism%3A+a+predictive+factor+for+the+development+of+post-transplant+lymphoproliferative+disease&amp;amp;TransSchema=title&amp;amp;cmd=detailssearch" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/P&gt;&lt;/BLOCKQUOTE&gt;
&lt;BLOCKQUOTE style="MARGIN-RIGHT: 0px" dir=ltr&gt;
&lt;P&gt;(5) Jones K, Nourse J at el. (2010) Expansion of EBNA-1 specific effector-T cells in posttransplant lymphoproliferative disorders. Blood 116:2245-2252. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20562330" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;(6) Lu J, Tang Y (2010). Epstein-Barr virus facilitates the malignant potential of immortalised epithelial cells: from latent genome to viral production and maintenance. Laboratory investigation 90: 196-209. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19997065" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;(7) Capello, D., Rasi, S., et al (2009) Molecular characterization of post-transplant lymphoproliferative disorders of donor origin occurring in liver transplant recipients. Journal of Pathology, 218, 478–486. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19391128" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;(8) Mucha K Foroncewicz B. (2010) Post-transplant lymphoproliferative disorder in view of the new WHO classification: a more rational approach to a protean disease? Nephrol Dial Transplant 25: 2089-2098. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20576725" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/P&gt;&lt;/BLOCKQUOTE&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Management&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Current strategies with first immunosuppression reduction and sequential chemotherapy risk immune recognition of the renal allograft with subsequent dysfunction or failure. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;BLOCKQUOTE style="MARGIN-RIGHT: 0px" dir=ltr&gt;
&lt;P&gt;(9) Trappe R, Hinrichs C (2009). Treatment of PTLD with Rituximab and CHOP reduces the risk of renal graft impairment after reduction in Immunosuppression. American Journal of Transplantation 9: 2331-2337.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19663889" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/P&gt;&lt;/BLOCKQUOTE&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;This retrospective study used the pooled data from two prospective, international multicentre trials of first line treatment of PTLD in patients who did not respond to immunosuppression reduction [Trappe R, 2007; Oertel SH, 2003], and data from the German PTLD registry. Renal function was reported in both studies and additional data was obtained from the trial patient databases. Fifty-eight patients with PTLD were included in this analysis. All patients underwent immunosuppression reduction on diagnosis with PTLD. 18 then received montherapy with rituximab, and 40 received CHOP or a CHOP-like chemotherapy regime. The complete remission rate was 69%. Treatment related mortality, mainly due to increased infection, was 12%. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Overall, this study showed that immunosuppression reduction followed by single agent rituximab or CHOP-based chemotherapies is not associated with an increased risk of graft impairment when compared to immunosuppresion reduction alone. When compared to a control group of stable renal transplant patients, PTLD patients receiving chemotherapy had a non-inferior graft function at follow up, using a linear mixed effects analysis model.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;BLOCKQUOTE style="MARGIN-RIGHT: 0px" dir=ltr&gt;
&lt;P&gt;(10) Evens AM, David KA et al (2010). Multicenter analysis of 80 solid organ transplant recipients with post-transplant lymphoproliferative disease: outcome and prognostic factors in the modern age. J Clin Oncol 28: 1038-1046. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20085936" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;].&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/BLOCKQUOTE&gt;
&lt;P dir=ltr&gt;This is a large case series from a&amp;nbsp; large cohort of solid organ transplant recipients. All patients had reduction of immunosuppression, with 74% have concurrent therapy with rituximab, with or without chemotherapy. There was a significant increase in 3 year progression-free survival associated with rituximab therapy. Adverse prognostic factors at diagnosis were CNS involvement, bone marrow involvement and hypoalbuminaemia.&lt;/P&gt;
&lt;P dir=ltr&gt;&amp;nbsp;&lt;/P&gt;
&lt;BLOCKQUOTE style="MARGIN-RIGHT: 0px" dir=ltr&gt;
&lt;P&gt;&lt;BR&gt;(11) Vezina H, Brundage R et al (2010) The pharmocokinetics of valganciclovir prophylaxis in paediatric solid organ transplant patients at risk for Ebstein-Barr virus disease. Clinical Pharmacology:Advances and Applications 2 (1) 1-7. [&lt;A href="http://www.dovepress.com/the-pharmacokinetics-of-valganciclovir-prophylaxis-in-pediatric-solid--peer-reviewed-article-CPAA" target="_blank"&gt;Link to Journal website for abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;(12) Brewin J, Mancao C et al (2009). Generation of EBV-specific cytotoxic T Cells that are resistant to calcineurin inhibitors for the treatment of post-transplant lymphoproliferative disease. Blood 114: 4792-4803. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19770360" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/BLOCKQUOTE&gt;
&lt;P dir=ltr&gt;Adoptive transfer of EBV-specific cytotoxic T cells has been considered as a novel therapy in EBV-related PTLD. The development of CNI-resistent EBV-specific T cells as a therapeutic agent would allow the continuation of low-dose immunosuppression and potentially reduce the risk of graft loss.&lt;/P&gt;
&lt;P dir=ltr&gt;&amp;nbsp;&lt;/P&gt;
&lt;BLOCKQUOTE style="MARGIN-RIGHT: 0px" dir=ltr&gt;
&lt;P&gt;&lt;BR&gt;(13) Fox CP, Haigh TA et al. (2010) A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK and T cell lymphoproliferative disease encodes a target for cellular immunotherapy. Blood. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20671118" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;(14) Tisher J, Moosmann A. (2010) Transfer of EBV-specific T cells: A treatment option for patients with EBV-associated lymphoproliferative disease after allogeneic stem cell transplantation. Bone Marrow Transplantation 45: [No abstract available]&lt;/P&gt;&lt;/BLOCKQUOTE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <expiryDate>19/11/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>395029</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=395029]]&gt;</url>
    <title>2010 Annual Evidence Update on Post Transplant Lymphoproliferative Disorders in Renal Transplant patients - Methodology</title>
    <publicationDate>2010-12-06T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ PREVENTION OF COMPLICATIONS,IMMUNOSUPPRESSIVE DRUGS,TRANSPLANTATION,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Post Transplant Lymphoproliferative Disorders in Renal Transplant patients - Methodology&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;H2&gt;&lt;A href="nelh:394440:0" name=internalLink&gt;Link back to 2010 Annual Evidence Update: Post Transplant Lymphoproliferative Disorders -&amp;nbsp;Contents page&lt;BR&gt;&lt;/A&gt;&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;&lt;STRONG&gt;Methodology&lt;/STRONG&gt;&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H3&gt;Databases searched:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Medline&lt;/LI&gt;
&lt;LI&gt;Embase&lt;/LI&gt;
&lt;LI&gt;The Transplant Library&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Period of Search:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;2009- 2010&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Search Strategy:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;(ptld.ti,ab OR "post transplant lymphoproliferative disorder*" OR exp *LYMPHOPROLIFERATIVE DISORDERS/ OR exp *EPSTEIN-BARR VIRUS INFECTIONS/ OR exp *HERPESVIRUS 4, HUMAN/)&lt;/P&gt;
&lt;P&gt;AND&lt;/P&gt;
&lt;P&gt;((renal OR kidney OR nephr*) OR (exp *KIDNEY TRANSPLANTATION/)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Inclusion Criteria:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Included articles had to meet the following criteria:&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Publication types other than letters, commentaries or case reports.&lt;/LI&gt;
&lt;LI&gt;Relevancy to topics included in the 2009 AEU [see below for link]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;We welcome feedback about resources that we identify. Please &lt;A href="http://www.library.nhs.uk/kidney/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;A href="nelh:329868:0" name=internalLink&gt;
&lt;P&gt;Link to 2009 Annual Evidence Update on Post Transplant Lymphoproliferative Disorders in Renal Transplant patients - Contents&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <expiryDate>26/11/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>373944</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=373944]]&gt;</url>
    <title>2010 Annual Evidence Update on Proteinuria and eGFR: 1 a. Controversies in eGFR and CKD</title>
    <publicationDate>2010-05-24T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ ASSESSMENT TESTS,ASSESSMENT OF RENAL FUNCTION,PROTEINURIA/ NEPHROTIC SYNDROME,PRESENTATION OF CKD,GFR AND EGFR,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Proteinuria and eGFR: 1 a. Controversies in eGFR and CKD&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;&lt;A href="nelh:372689:0" name=internalLink&gt;&lt;STRONG&gt;Link back to 2010 AEU on Proteinuria and eGFR: contents page&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentary by Ed Sharples, Consultant in Nephrology and Transplant Medicine, Churchill Hospital, Oxford, and specialist collection clinical lead.&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Glomerular filtration rate (GFR)&amp;nbsp;is the accepted measurement for evaluating renal function but measuring it directly is rarely done as it is expensive, time-consuming and cumbersome. The development of an estimated GFR equation from the study population in the Modification of Diet in Renal Disease (MDRD) study (1), and its general acceptance as the standard metric for estimation of renal function has led to near universal eGFR reporting. It is accepted that the MDRD formula does not function with similar sensitivity and accuracy across the full range of GFRs, performing with less accuracy with normal levels of kidney function. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;In parallel with the development of estimated GFR formulae, the KDOQI classification of chronic kidney disease (CKD) in 5 stages (2), with arbitrary cut-off values of eGFR separating these stages, has led to a great deal of controversy around the population prevalence of CKD, whether a large proportion of elderly patients are being labelled as having CKD stage 3 without evidence of a progressive renal pathology, and what constitutes normal aging and decline in kidney function (3, 4). Population studies of GFR have by and large been cross-sectional and have shown a slow but steady decline in eGFR with age, particularly in women, even in the apparently healthy. The question that remains unanswered is whether a low eGFR in these groups really represents a disease, particularly in the absence of proteinuria, a structural lesion in the kidney and normal or well treated hypertension. Epidemiological studies have shown an association between eGFR and mortality, and the recent evidence for this association is discussed in &lt;STRONG&gt;&lt;A href="nelh:374027:1" name=internalLink&gt;&lt;STRONG&gt;section 3c&lt;/STRONG&gt;&lt;/A&gt;.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The Baltimore Longitudinal Study of Aging (5) suggests that a proportion of the elderly do not have changes in kidney function, with mean creatinine clearance of 97 mls/min/1.72 m&lt;SUP&gt;2&lt;/SUP&gt; at age 80, with an average decline in creatinine clearance of -0.75 ml/min/year [reviewed in Glassock, 2010] (6, 7).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;El-Ghoul &lt;EM&gt;et al&lt;/EM&gt;. (8) have demonstrated that elderly patients without markers for progressive CKD may represent a group of patients with non-progressive CKD not associated with increased mortality or ERSD. Between January 1998 and December 2004, 177 consecutive patients aged 80 and older were referred for the first time to nephrology for CKD. The characteristics of patients with nonprogressive or progressive CKD (estimated glomerular filtration rate (eGFR) decline of &amp;lt; and &amp;gt; or =1 mL/min per 1.73 m&lt;SUP&gt;2&lt;/SUP&gt; per year, respectively) were observed and analyzed, and their risk of dying or requiring dialysis was determined. After exclusion of subjects requiring immediate dialysis or followed up for less than 6 months, 138 patients remained eligible for analysis. In the study cohort (initial mean eGFR 31.8 mL/min per 1.73 m&lt;SUP&gt;2&lt;/SUP&gt;, median follow-up 47 months), patients were more likely to require dialysis than to die; 36% of patients had nonprogressive CKD. This characteristic, predicted by low proteinuria, lack of hypertension, and low cardiovascular comorbidity, was the strongest predictor of global survival. In progressors, two independent covariates (eGFR &amp;lt;30 mL/min per 1.73 m&lt;SUP&gt;2&lt;/SUP&gt; and hemoglobin &amp;lt; or =11 g/dL at inclusion) predicted the risk of requiring dialysis. The authors conclude that more than one-third of subjects aged 80 and older referred to a nephrology center had severe but nonprogressive kidney dysfunction. This subgroup had a lower mortality rate than those with progressive kidney dysfunction. Simple covariates (low proteinuria, lack of hypertension, low cardiovascular comorbidity) predicted nonprogression of CKD.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Chronic kidney disease is common with older age and is characterized on renal biopsy by global glomerulosclerosis, tubular atrophy, interstitial fibrosis, and arteriosclerosis. Rule &lt;EM&gt;et al.&lt;/EM&gt; (9) studied biopsies from living kidney transplant donations and reviewed the changes of aging and associated histological changes. These patients are a self-selected group with normal kidney function, so it may not be possible to generalise to a larger age-matched population. They recruited 1203 adult living kidney donors, who underwent core-needle biopsy of the renal cortex during surgical implantation of the kidney, and medical record data of kidney function and risk factors obtained before donation. The prevalence of nephrosclerosis (&amp;gt; or =2 chronic histologic abnormalities) was 2.7% (95% CI, 1.1% to 6.7%) for patients aged 18 to 29 years, 16% (CI, 12% to 20%) for patients aged 30 to 39 years, 28% (CI, 24% to 32%) for patients aged 40 to 49 years, 44% (CI, 38% to 50%) for patients aged 50 to 59 years, 58% (CI, 47% to 67%) for patients aged 60 to 69 years, and 73% (CI, 43% to 90%) for patients aged 70 to 77 years. Adjustment for kidney function and risk factor covariates did not explain the age-related increase in the prevalence of nephrosclerosis. Occult vascular disease and subsequent glomerulosclerosis may account for some of the observed reduction in GFR in large observational cohorts used for population eGFR screening. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;There is evidence that the estimation equations used in common medical practice may also not be accurate in patients with non-average muscle mass, particularly elderly women where the MDRD eGFR shows wide variation. Estimation of creatinine clearance requires knowledge of creatinine generation which can vary in different groups of patients. Since the main source of creatinine is muscle, Rule &lt;EM&gt;et al.&lt;/EM&gt; (10) used dual-energy X-ray absorptiometry to measure the mass of muscle in a cohort of adult men and women in Rochester, Minnesota. Serum and 24 h urinary creatinines were measured directly. The urinary creatinine was estimated using equations based on age and gender and muscle mass in order to calculate creatinine clearance. Among 664 subjects with a mean age of 55 +/- 20 years, 51% of whom were women, the model fit for urinary creatinine estimated with age and gender (R2=0.359) was similar to that estimated with measured muscle mass (R2=0.359). The likelihood of chronic kidney disease (creatinine clearance of less than 60 ml/min per 1.73 m&lt;SUP&gt;2&lt;/SUP&gt;) in older subjects was highest with equations that used age, and likelihood of CKD in women was highest with equations that used gender. The outcomes of mortality and cardiovascular disease had stronger associations with decreased creatinine clearance calculated with age and gender than by the clearance calculated with muscle mass. This could be explained by age being a potent predictor of mortality and cardiovascular disease independent of urinary creatinine, muscle mass, and gender. The study shows that the likelihood of chronic kidney disease in the elderly and in women and the risk of adverse outcomes may be inflated by equations that use patient demographics to estimate creatinine generation.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The KDIGO group have had a controversial meeting to discuss all the issues around the K/DOQI classification of CKD, staging, the role of assessment of albuminuria to improve the classification, and a working party has been set up to report in 2010-2011 and will hopefully answer these controversies.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;OL&gt;
&lt;LI&gt;Levey AS, Greene T, Kusek JW, Beck GJ. "Simplified equation to predict glomerular filtration rate from serum creatinine." J Am Soc Nephrol 2000; 11: 155A. [Abstract not available online]&lt;/LI&gt;
&lt;LI&gt;KDOQI. "KDOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification." Available at: &lt;A href="http://www.kidney.org/professionals/kdoqi/guidelines_ckd/toc.htm" target="_blank"&gt;http://www.kidney.org/professionals/kdoqi/guidelines_ckd/toc.htm&lt;/A&gt;&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Winearls CG, Glassock RJ. "Dissecting and refining the staging of chronic kidney disease." Kidney Int. 2009 May;75(10):1009-14.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19242501" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Winearls CG. "Chronic kidney disease: definition and staging--an orthodox view." Clin Med. 2009 Dec;9(6):563-4. Review. PubMed PMID: 20095300.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20095300" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lindeman RD, Tobin J, Shock NW. "Longitudinal studies on the rate of decline in renal function with age." J Am Geriatr Soc. 1985;33: 278–85. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Longitudinal%20studies%20on%20the%20rate%20of%20decline%20in%20renal%20function%20with%20age" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Glassock RJ. "Referrals for chronic kidney disease: real problem or nuisance?" JAMA 2010&amp;nbsp;Mar 24;303(12):1201-3. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=2010[pdat]%20AND%20Glassock%20RJ[author]%20AND%20Referrals%20for%20Chronic%20Kidney%20Disease" target="_blank"&gt;Link to PubMed&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Glassock RJ, Winearls C. "Ageing and the glomerular filtration rate: truths and consequences." Trans Am Clin Climatol Assoc. 2009;120:419-28.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19768194" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;El-Ghoul B, Elie C, Sqalli T, Jungers P, Daudon M, Grünfeld JP, Lesavre P, Joly D. "Nonprogressive kidney dysfunction and outcomes in older adults with chronic kidney disease." J Am Geriatr Soc. 2009 Dec; 57(12):2217-23. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20121987" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Rule AD, Amer H, Cornell LD, Taler SJ, Cosio FG, Kremers WK, Textor SC, Stegall MD. "The association between age and nephrosclerosis on renal biopsy among healthy adults." Ann Intern Med. 2010 May 4;152(9):561-7.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20439574" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Rule AD, Bailey KR, Schwartz GL, Khosla S, Lieske JC, Melton LJ 3rd. "For estimating creatinine clearance measuring muscle mass gives better results than those based on demographics." Kidney Int. 2009 May;75(10):1071-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19177154" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Additional Useful References&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Glassock RJ, Winearls C. "CKD in the elderly." Am J Kidney Dis. 2008 Oct;52(4):803. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18805350" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Glassock RJ, Winearls C. "The global burden of chronic kidney disease: how valid are the estimates?" Nephron Clin Pract. 2008;110(1):c39-46; discussion c47.&amp;nbsp;&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18689986" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Glassock RJ, Winearls C. "Screening for CKD with eGFR: doubts and dangers." Clin J Am Soc Nephrol. 2008 Sep;3(5):1563-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18667744" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Glassock RJ, Winearls C. "An epidemic of chronic kidney disease: fact or fiction?" Nephrol Dial Transplant. 2008 Apr;23(4):1117-21.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18359870" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Glassock RJ, Winearls CG. "eGFR: Readjusting its rating." Clin J Am Soc Nephrol. 2009 May;4(5):867-869.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19414566" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Poggio ED, Rule AD. "A critical evaluation of chronic kidney disease—should isolated reduced estimated glomerular filtration rate be considered a 'disease'?"&amp;nbsp; Nephrol Dial Transplant. 2009 Mar;24(3):698-700.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19103736" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Rule AD. "The CKD-EPI Equation for Estimating GFR from Serum Creatinine: Real Improvement or More of the Same?" Clin J Am Soc Nephrol. 2010 May 6.&amp;nbsp;&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20448068" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Rule AD, Turner ST. "Prevalence of CKD in the United States: GFR-estimating equations matter." Am J Kidney Dis. 2009 Jul;54(1):184-5; author reply 185.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19559341" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Stevens LA, Schmid CH, Zhang YL, Coresh J, Manzi J, Landis R, Bakoush O, Contreras G, Genuth S, Klintmalm GB, Poggio E, Rossing P, Rule AD, Weir MR, Kusek J, Greene T, Levey AS. "Development and validation of GFR-estimating equations using diabetes, transplant and weight." Nephrol Dial Transplant. 2010 Feb;25(2):449-57.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19793928" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;] &lt;/LI&gt;&lt;/UL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <expiryDate>14/05/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>373996</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=373996]]&gt;</url>
    <title>2010 Annual Evidence Update on Proteinuria and eGFR: 1 b. Commentary on Pre-Eclampsia, microalbuminuria and risk of CKD</title>
    <publicationDate>2010-05-24T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ PROTEINURIA/ NEPHROTIC SYNDROME,PREDISPOSING FACTORS,ASSESSMENT OF RENAL FUNCTION,ASSESSMENT TESTS,PRESENTATION OF CKD,GFR AND EGFR,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Proteinuria and eGFR: 1 b. Commentary on Pre-Eclampsia, microalbuminuria and risk of CKD&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;&lt;A href="nelh:372689:0" name=internalLink&gt;&lt;STRONG&gt;Link back to 2010 AEU on Proteinuria and eGFR: contents page&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentary by Ed Sharples, Consultant in Nephrology and Transplant Medicine, Churchill Hospital, Oxford, and specialist collection clinical lead.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Pre-eclampsia was first described in 1843 when John Lever discovered proteinuria in women with puerperal convulsions. Pre-eclampsia is defined by the development of hypertension and proteinuria during the last trimester of pregnancy, and is reported to affect 3-5% of all pregnancies. The pathophysiological changes in pre-eclampsia are now more understood, with disturbance of the vascular development of the placenta resulting in placental hypoperfusion and ischaemia. The damaged placenta secretes a range of anti-angiogenic factors (1) into the maternal circulation that may led to endothelial dysfunction, and a microangiopathy. In the kidney, these effects are mainly observed in the glomerular endothelium, in which a milieu of pro- and anti-angiogenic factors including VEGF normally control vascular integrity. These changes led to proteinuria, and histological changes of glomerular endotheliosis, and podocyte injury (2). These changes were thought to resolve after delivery, but recent evidence, discussed here, have shown that pre-eclampsia is a significant cause of microalbuminuria, hypertension and possibly CKD.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Previous studies (3)&amp;nbsp;have shown an association with pre-eclampsia and the later development of cardiovascular disease. Risk factors for cardiovascular disease and CKD are similar, and recent studies have shown a relative risk of renal disease (4). The authors reviewed outcomes in a large cohort of mothers (n=570 344) in Norway, of whom 477 had developed ESRD. Among women who had been pregnant one or more times, preeclampsia during the first pregnancy was associated with a relative risk of ESRD of 4.7 (95% confidence interval [CI], 3.6 to 6.1). There was additional risk for multiple pregnancies, so that among women who had been pregnant two or more times, preeclampsia during the first pregnancy was associated with a relative risk of ESRD of 3.2 (95% CI, 2.2 to 4.9), preeclampsia during the second pregnancy with a relative risk of 6.7 (95% CI, 4.3 to 10.6), and preeclampsia during both pregnancies with a relative risk of 6.4 (95% CI, 3.0 to 13.5).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;A systematic review and meta-analysis has been published this year to review the evidence for this association (5). Seven cohort studies, totalling 273 patients with pre-eclampsia and 333 control patients with normal pregnancies were included. At a weighted mean of 7.1 years post-partum, 31% of women had microalbuminuria compared to 7% of uncomplicated patients, with a higher relative risk in those patients with more severe pre-eclampsia. At this time point, there was no difference in serum creatinine or estimated GFR.&amp;nbsp; The relative risk of microalbuminuria was higher in patients with pre-eclampsia than in women with a history of pregnancy induced hypertension (RR 2.2, 95% CI 1.17-4.13]. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Stepan H, Ebert T, Schrey S, Reisenbüchler C, Stein S, Lossner U, Bluher M, Stumvoll M, Kratzsch J, Faber R, Fasshauer M. "Serum levels of angiopoietin-related growth factor are increased in preeclampsia." Am J Hypertens. 2009 Mar;22(3):314-8. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19057519" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Aita K, Etoh M, Hamada H, Yokoyama C, Takahashi A, Suzuki T, Hara M, Nagata M. "Acute and transient podocyte loss and proteinuria in preeclampsia." Nephron Clin Pract. 2009;112(2):c65-70. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/%2019390204" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Smith GC, Pell JP, Walsh D. "Pregnancy complications and maternal risk of ischaemic heart disease: a retrospective cohort study of 129,290 births." Lancet. 2001 Jun 23;357(9273): 2002-6. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/11438131" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Vikse BE, Irgens LM, Leivestad T, Skjaerven R, Iversen BM. "Preeclampsia and the risk of end-stage renal disease." N Engl J Med. 2008 Aug 21;359(8):800-9. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18716297" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;McDonald SD, Han Z, Walsh MW, Gerstein HC, Devereaux PJ. "Kidney Disease After Preeclampsia: A Systematic Review and Meta-analysis." Am J Kidney Dis. 2010 Mar24. [Epub ahead of print]&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20346562" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Additional References&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Foster RR. "The importance of cellular VEGF bioactivity in the development of glomerular disease." Nephron Exp Nephrol. 2009;113(1):e8-e15 [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19590237" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Liu X, Zhou Z, Cao Y, Wang B, Xu G. "Contributions of blood pressure to proteinuria and renal function in the puerperium." Blood Press. 2009;18(6):362-6. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19929283" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mann JF. "What's new in hypertension 2009?" Nephrol Dial Transplant. 2010 Jan;25(1):37-41. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20028836" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Munkhaugen J, Vikse BE. "New aspects of pre-eclampsia: lessons for the nephrologist." Nephrol Dial Transplant. 2009 Oct;24(10):2964-7. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19605602" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Vikse BE, Hallan S, Bostad L, Leivestad T, Iversen BM. "Previous preeclampsia and risk for progression of biopsy-verified kidney disease to end-stage renal disease." Nephrol Dial Transplant. 2010 Mar 26. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/%2020348149" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <expiryDate>14/05/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>373973</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=373973]]&gt;</url>
    <title>2010 Annual Evidence Update on Proteinuria and eGFR: 2 a. Characterisation and description of urinary protein excretion in health and in disease</title>
    <publicationDate>2010-05-24T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ PRESENTATION OF CKD,PROTEINURIA/ NEPHROTIC SYNDROME,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Proteinuria and eGFR: 2 a. Characterisation and description of urinary protein excretion in health and in disease&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;&lt;A href="nelh:372689:0" name=internalLink&gt;&lt;STRONG&gt;Link back to 2010 AEU on Proteinuria and eGFR: contents page&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;The original commentary, written for the 2008 National Knowledge Week on Proteinuria and eGFR, has been updated for the 2010 AEU&amp;nbsp;by Ed Sharples, Consultant in Nephrology and Transplant Medicine, Churchill Hospital, Oxford, and specialist collection clinical lead. &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;BR&gt;The presence of protein in the urine (lardaceous urine) was first recognized as a marker of disease in the first half of the nineteenth century. Now, in 2010, this “simple” test reveals a useful marker of future propensity to adverse renal and cardiac outcomes. Put simply, the presence of protein in the urine is a bad prognostic marker for patients. Given the fact that this test is relatively easy and cheap to do, and is reliable (in the absence of urinary tract infection, menstruation and acute intercurrent illness) it is remarkable how it is not routinely offered in situations of increased renal or cardiac risk, such as older age, diabetes, hypertension and strong family history of renal diseases, and the issues regarding screening are discussed in &lt;STRONG&gt;&lt;A href="nelh:374198:0" name=internalLink&gt;&lt;STRONG&gt;section 3d&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;For screening purposes the use of (preferably) an early morning urine sample for albumin:creatinine ratio (or alternatively a protein:creatinine ratio) is recommended. The use of full 24 hours collections of urine for protein rarely adds, more often loses, accuracy, but is much less convenient for patients and healthcare professionals.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The 2008 NICE guidelines for the identification and diagnosis of CKD (1)&amp;nbsp;recommended:&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;"1.1.1&amp;nbsp;Do not use reagent strips to identify proteinuria unless they are capable of specifically measuring albumin at low concentrations and expressing the result as an ACR. &lt;BR&gt;"1.1.2&amp;nbsp;To detect and identify proteinuria, use urine ACR in preference, as it has greater sensitivity than PCR for low levels of proteinuria. For quantification and monitoring of proteinuria, PCR can be used as an alternative. ACR is the recommended method for people with diabetes. &lt;BR&gt;"1.1.3&amp;nbsp;For the initial detection of proteinuria, if the ACR is 30 mg/mmol or more (this is approximately equivalent to PCR 50 mg/mmol or more, or a urinary protein excretion 0.5 g/24 h or more) and less than 70 mg/mmol (approximately equivalent to PCR less than 100 mg/mmol, or urinary protein excretion less than 1 g/24 h) this should be confirmed by a subsequent early morning sample. If the initial ACR is 70 mg/mmol or more, or the PCR 100 mg/mmol or more, a repeat sample need not be tested. &lt;BR&gt;"1.1.4&amp;nbsp;In people without diabetes consider clinically significant proteinuria to be present when the ACR is 30 mg/mmol or more (this is approximately equivalent to PCR 50 mg/mmol or more, or a urinary protein excretion 0.5 g/24 h or more).&lt;BR&gt;"1.1.5&amp;nbsp;In people with diabetes consider microalbuminuria (ACR more than 2.5 mg/mmol in men and ACR more than 3.5 mg/mmol in women) to be clinically significant.&lt;BR&gt;"1.1.6&amp;nbsp;All people with diabetes, and people without diabetes with a GFR less than 60 ml/min/1.73 m2, should have their urinary albumin/protein excretion quantified. The first abnormal result should be confirmed on an early morning sample (if not previously obtained).&lt;BR&gt;"1.1.7&amp;nbsp;Quantify by laboratory testing the urinary albumin/protein excretion of people with an eGFR 60 ml/min/1.73 m2 or more if there is a strong suspicion of CKD (see also recommendation 1.1.22)."&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The prevalence of proteinuria in the general population is around 4-8% but this rises steeply if hypertension, obesity and diabetes are over-represented in the study population, to around 10-20%.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;In a recent review by Pollock &lt;EM&gt;et al.&lt;/EM&gt; (2), it was stated that significant epidemiological and clinical trial evidence supports the association between increased urinary albumin excretion, cardiovascular events and renal failure. An increase in albumin excretion has traditionally been considered to reflect a 'glomerular' leak of protein; however, it is now recognized that significant tubular reabsorption of albumin occurs under physiological conditions that may be modified by genetic determinants, systemic disease and drug therapies: The endocytosis of albumin by the proximal tubule is a highly regulated process depending on protein-protein interactions between several membrane proteins and scaffolding and regulatory molecules. There is also mounting evidence for a transcytotic pathway for retrieval of albumin from the tubular filtrate. The clinical implications of albuminuria due to a glomerular leak vs. reduced tubular reabsorption of albumin are, however, now under consideration. In particular, the prognostic implication of microalbuminuria induced by the more potent 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors is under study.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The utility of detecting the presence of protein in the urine can be seen well from a recent study (3) concentrating on type II diabetic patients in Brazil. 193 Type 2 DM patients with urinary albumin excretion (UAE) &amp;lt; 20 microg/min, 96 men (50%), aged 56.5 +/- 9 years, were followed for a mean period of 8 +/- 3 years. UAE and estimated glomerular filtration rate (eGFR; Modification of Diet in Renal Disease) were measured. The outcomes were development of persistent micro- and macroalbuminuria and mortality. Twenty patients were lost to follow-up. Of the 173 remaining patients, 33 (19%) died. The Cox analysis [hazard ratio (HR), 95% confidence interval] revealed that the baseline significant predictors of mortality were higher UAE [above median (5 microg/min); HR 2.7, 1.2-6.1; P = 0.02], male sex (HR 3.9, 1.7-9.2; P = 0.002), age (HR 1.6, 1.3-1.9; P = 0.0001), and fasting plasma glucose (HR 1.2, 1.1-1.3; P = 0.004). Smoking and eGFR were not significant in this model. Follow-up renal data were available for 158 patients: 34 (22%) progressed to microalbuminuria and seven (4%) to macroalbuminuria, and the baseline predictors were a higher UAE (&amp;gt; 5 microg/min, HR 2.5, 1.2-5.1; P = 0.02), presence of diabetic retinopathy (HR 2.5, 1.3-5.0; P = 0.009), fasting glucose (HR 1.1, 1.0-1.2; P = 0.015), and male sex (HR 2.2, 1.1-4.7; P = 0.04), independently of smoking and hypertension. Lower GFR (HR 0.98, 0.97-1.00; P = 0.07) was of borderline significance. In normoalbuminuric Type 2 DM patients, the development of micro- or macroalbuminuria and mortality rates was independently and positively associated with higher levels of albuminuria, although still in the traditionally established normal range. This study re-inforces data from the older studies which suggest that the arbitrary division between normal urinary albumin excretion, and early low-grade microalbuminuria as the first stage of proteinuria does not equate with a suddent change from no risk to increased risk. The association between cardiovascular risk and urinary albumin excretion is linear and extends down into the so-called normal range.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Further information about type II diabetes and urinary protein comes from Parving and co-workers (4). They described the characteristics in a referred cohort of type II diabetic patients in the Developing Education on Microalbuminuria for Awareness of renal and cardiovascular risk in Diabetes study evaluating the global prevalence and determinants of microalbuminuria. A cross-sectional study evaluating 32,208 type II diabetic patients without known albuminuria from 33 countries was performed. One single random urinary albumin/creatinine ratio was obtained in 24,151 patients (75%). The overall global prevalence of normo-, micro-, and macroalbuminuria was 51, 39, and 10%, respectively. The Asian and Hispanic patients had the highest prevalence of a raised urinary albumin/creatinine ratio (55%) and Caucasians the lowest (40.6), P&amp;lt;0.0001. HbA1c, systolic blood pressure (BP), ethnicity, retinopathy, duration of diabetes, kidney function, body height, and smoking were all independent risk factors of MA, P&amp;lt;0.0001. Estimated glomerular filtration rate was below 60 ml/min/1.73 m(2) in 22% of the 11,573 patients with available data. Systolic BP below 130 mmHg was found in 33 and 43% had an HbA1c below 7%. The frequency of patients receiving aspirin was 32%, statins 29%, and BP-lowering therapy 63%. A high prevalence globally of MA and reduced kidney function, both conditions associated with enhanced renal and cardiovascular risk, was detected in type II diabetic patients without prior known nephropathy. Early detection, monitoring of vascular complications, and more aggressive multifactorial treatment aiming at renal and vascular protection are urgently needed.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;In non-diabetic renal disease there are similar findings. Brantsma et al (5) looked at how an increase or decrease in urinary albumin excretion is associated with, respectively, a higher or lower risk for renal and cardiovascular disease, independent of widely known cardiovascular risk factors. Their study aimed to identify factors that are associated with changes in UAE in the nondiabetic population using data of the Prevention of Renal and Vascular End stage Disease (PREVEND) Study, a community-based prospective cohort study. Data of the 6647 nondiabetic participants who completed the first (1997 through 2001) and second (2001 through 2003) screening were used. Change in UAE was categorized as regression (n = 650), stable (n = 5240), or progression (n = 757) on the basis of change in class during follow-up, with classes being a UAE &amp;lt;15, 15 to 30, 30 to 300, and &amp;gt;300 mg/24 h. With the use of stepwise forward multinomial regression analysis changes in BP, fasting glucose concentration, and start of antihypertensive drugs were found to be the most important modifiable variables associated with the risk for progression and regression (P &amp;lt; 0.01 for likelihood ratio test). The odds ratios to develop regression or progression of UAE during follow-up were 0.64 (95% confidence interval [CI] 0.57 to 0.73) and 1.91 (95% CI 1.72 to 2.12), respectively, per 10-mmHg increase in BP during follow-up, 0.89 (95% CI 0.80 to 0.98) and 1.09 (95% CI 1.01 to 1.17), respectively, per 1-mmol/L increase of fasting glucose levels during follow-up, and 1.57 (95% CI 1.21 to 2.06) and 0.70 (95% CI 0.51 to 0.95), respectively, for start of antihypertensive drugs during follow-up. These associations were independent of baseline BP, glucose, body mass index, estimated GFR, and UAE and changes in high-sensitivity C-reactive protein during follow-up. They concluded that changes in glucose concentration and BP and start of antihypertensive drugs (angiotensin-converting enzyme inhibitors/angiotensin receptor blockers in &amp;gt;50% of cases) are associated with progression and regression of urinary albumin in the nondiabetic population. Although associations do not necessarily suggest causality, it is hypothesized that in the general population, the most important ways to reduce urinary albumin are by lowering glucose concentration and BP (including start of antihypertensive medication), even in normotensive, nondiabetic individuals.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Obesity is strongly linked to increased prevalence and progression of proteinuria. A total of 6894 participants of the Prevention of Renal and Vascular Endstage Disease (PREVEND) study were evaluated from baseline to a mean period of follow-up of 4.2 years for weight change (gain/loss), and its impact on albuminuria, renal function and cardiovascular risk factors (6). Participants were categorized into three groups based on absolute change in weight from baseline to follow-up: significant weight loss (&amp;gt;10 kg reduction in weight), stable weight, or significant weight gain (&amp;gt;10 kg increase). Multivariate regression analysis was used to evaluate the effect of baseline characteristics and time-dependent changes in these characteristics on the relationship of weight change with urine albumin excretion (UAE). At follow-up 101 subjects experienced significant weight loss (mean change = -14.2 kg), 348 had significant weight gain (mean change = +13.4 kg) and the remaining were defined stable in weight (mean change = +1.4 kg). Weight loss was associated with significant improvement in systolic blood pressure (-11 +/- 15 mmHg), diastolic blood pressure (-5 +/- 8 mmHg), and cholesterol (-0.7 +/- 1.3 mmol/l), even after adjustment for the use of medications (P &amp;lt; 0.001). These parameters worsened significantly in those who substantially gained weight (P &amp;lt; 0.001). Similarly, weight loss was significantly associated with a reduction in UAE (mean -2.2 +/- 1.1 mg/24 h), whereas weight gain was associated with a rise in UAE (mean +0.42 +/- 2.0 mg/24 h). Notably, no changes were observed in GFR (assessed as 24 h urinary creatinine clearance) in subjects with weight loss or weight gain. Multivariate regression modelling with changes in UAE as dependent variable-correcting for factors that might explain the association-showed that only part of the relationship between weight changes and changes in UAE was explained by effect of weight change on blood pressure and cholesterol, whereas the association disappeared with changes in CRP in the model (P = 0.50). The importance of this first population-based longitudinal study to show that changes in weight are associated with parallel changes in albuminuria cannot be over-estimated. This relationship cannot be fully explained by the association between weight and classical cardiovascular risk factors and renal function. Afshinnia et al (7) have performed a meta-analysis of the evidence that weight loss is an effective therapy in obesity-related proteinuric CKD. Three bibliographic databases including Medline, Cochrane and SCOPUS as well as reference list of articles were searched. Both randomized and non-randomized controlled trials were included, as well as single-arm trials published in English through May 2009 which examined urinary protein among obese or overweight adults before and after weight loss interventions including dietary restriction, exercise, anti-obesity medications and bariatric surgery. Study characteristics and methodological quality of trials were assessed. Five hundred twenty-two subjects from five controlled and eight uncontrolled trials were included. Weight loss interventions were associated with decreased proteinuria and microalbuminuria by 1.7 g [95% confidence interval (95% CI), 0.7 to 2.6 g] and 14 mg (95% CI, 11 to 17 mg), respectively (P &amp;lt; 0.05). Meta-regression showed that, independent of decline in mean arterial pressure, each 1 kg weight loss was associated with 110 mg (95% CI, 60 to 160 mg, P &amp;lt; 0.001) decrease in proteinuria and 1.1 mg (95% CI, 0.5 to 2.4 mg, P = 0.011) decrease in microalbuminuria, respectively. The decrease was observed across different designs and methods of weight loss. Only bariatric surgery resulted in a significant decrease in creatinine clearance.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Even after renal transplantation it is clear from two recent studies (8, 9) that the development of, or increase in, micro-albuminuria is an adverse prognostic factor for renal allograft function and cardiovascular outcomes in renal transplant patients. This should be part of good quality medical management of long-term renal transplant outcomes; one of the significant reasons for return to dialysis after renal transplantation is chronic allograft nephropathy – while this has many potential aetiologies and promoters, it is clear that good control of blood pressure, and the selective early use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in these patients, may help to slow down otherwise inexorable progress towards allograft failure.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;One relatively unknown feature of albuminuria-proteinuria is the extent to which this is under genetic control. There is no doubt that the propensity to develop kidney disease does run strongly in families, even if the precise histopathological type of disease may vary from one member to another. Rao and colleagues (10) conducted a study to investigate heritability of albumin excretion in twin pairs and its genetic determination by adrenergic pathway polymorphism. Genetic associations used single nucleotide polymorphisms at adrenergic pathway loci spanning catecholamine biosynthesis, storage, catabolism, receptor action, and postreceptor signal transduction.&amp;nbsp;They studied 134 single nucleotide polymorphisms at 46 loci for a total of &amp;gt;51,000 genotypes. Albumin excretion heritability was 45.2+/-7.4% (P=2x10(-7)), and the phenotype aggregated significantly with adrenergic, renal, metabolic, and hemodynamic traits. In the adrenergic system, excretions of both norepinephrine and epinephrine correlated with albumin. In the kidney, albumin excretion correlated with glomerular and tubular traits (Na(+) and K(+) excretion; fractional excretion of Na(+) and Li(+)). Albumin excretion shared genetic determination (genetic covariance) with epinephrine excretion, and environmental determination with glomerular filtration rate and electrolyte intake/excretion. Albumin excretion associated with polymorphisms at multiple points in the adrenergic pathway: catecholamine biosynthesis (tyrosine hydroxylase), catabolism (monoamine oxidase A), storage/release (chromogranin A), receptor target (dopamine D1 receptor), and postreceptor signal transduction (sorting nexin 13 and rho kinase). Epistasis (gene-by-gene interaction) occurred between alleles at rho kinase, tyrosine hydroxylase, chromogranin A, and sorting nexin 13. Dopamine D1 receptor polymorphism showed pleiotropic effects on both albumin and dopamine excretion. These studies establish new roles for heredity and environment in albumin excretion. Urinary excretions of albumin and catecholamines are highly heritable, and their parallel suggests adrenergic mediation of early glomerular permeability alterations. Albumin excretion is influenced by multiple adrenergic pathway genes and is, thus, polygenic. Such functional links between adrenergic activity and glomerular injury suggest novel approaches to its prediction, prevention, diagnosis, and treatment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;It is clear that there is a complex interplay between some modifiable, non-modifiable environmental phenotypic, and genetic, factors in the development and progression of protein loss in the kidney.&amp;nbsp; Much rests on the early detection and rapid intervention of specific targeted therapies to reverse the underlying exacerbating factors and to prevent proteinuria progression and nephron loss.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Original References&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;NICE CKD: Guideline (September 2008): Chronic kidney disease: early identification and management of chronic kidney disease in adults in primary and secondary care.&amp;nbsp;[&lt;A href="nelh:294680:0" name=internalLink&gt;Link to NICE guideline&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Pollock CA, Poronnik P. "Albumin transport and processing by the proximal tubule: physiology and pathophysiology." Curr Opin Nephrol Hypertens 2007 Jul;16(4):359-64.&amp;nbsp;&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17565279" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Murussi M, Campagnolo N, Beck MO, Gross JL, Silveiro SP. "High-normal levels of albuminuria predict the development of micro- and macroalbuminuria and increased mortality in Brazilian Type 2 diabetic patients: an 8-year follow-up study." Diabet Med 2007 Oct;24(10):1136-42.&amp;nbsp;&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17561963" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Parving HH, Lewis JB, Ravid M, Remuzzi G, Hunsicker LG. "Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective." Kidney Int 2006 Jun;69(11):2057-63.&amp;nbsp;&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16612330" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Brantsma AH, Atthobari J, Bakker SJ, de ZD, de Jong PE, Gansevoort RT. "What predicts progression and regression of urinary albumin excretion in the nondiabetic population?" J Am Soc Nephrol 2007 Feb;18(2):637-45.&amp;nbsp;&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17215442" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Bello AK, de ZD, El NM, Brantsma AH, Bakker SJ, de Jong PE, et al. "Impact of weight change on albuminuria in the general population." Nephrol Dial Transplant 2007 Jun;22(6):1619-27.&amp;nbsp;&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17360767" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Afshinnia F, Wilt TJ, Duval S, Esmaeili A, Ibrahim HN. "Weight loss and proteinuria: systematic review of clinical trials and comparative cohorts." Nephrol Dial Transplant. 2010 Apr;25(4):1173-83.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19945950" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Halimi JM, Buchler M, Al-Najjar A, Laouad I, Chatelet V, Marliere JF, et al. "Urinary albumin excretion and the risk of graft loss and death in proteinuric and non-proteinuric renal transplant recipients." Am J Transplant 2007 Mar;7(3):618-25.&amp;nbsp;&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17217438" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Amer H, Fidler ME, Myslak M, Morales P, Kremers WK, Larson TS, et al. "Proteinuria after kidney transplantation, relationship to allograft histology and survival." Am J Transplant 2007 Dec;7(12):2748-56. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17941956" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Rao F, Wessel J, Wen G, Zhang L, Rana BK, Kennedy BP, et al. "Renal albumin excretion: twin studies identify influences of heredity, environment, and adrenergic pathway polymorphism." Hypertension 2007 May;49(5):1015-31. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17353515" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Additional useful reference:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Wang Y, Chen X, Song Y, et al. Association between obesity and kidney disease: a systematic review and meta-analysis. Kidney Int (2008) 73:19–33.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17928825" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <expiryDate>14/05/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>374021</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=374021]]&gt;</url>
    <title>2010 Annual Evidence Update on Proteinuria and eGFR: 2 b. Tubular toxicity of urinary protein</title>
    <publicationDate>2010-05-24T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ PRESENTATION OF CKD,PROTEINURIA/ NEPHROTIC SYNDROME,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Proteinuria and eGFR: 2 b. Tubular toxicity of urinary protein&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;&lt;A href="nelh:372689:0" name=internalLink&gt;&lt;STRONG&gt;Link back to 2010 AEU on Proteinuria and eGFR: contents page&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;The original commentary, written for the 2008 National Knowledge Week on Proteinuria and eGFR, has been updated for the 2010 AEU by Ed Sharples, Consultant in Nephrology and Transplant Medicine, Churchill Hospital, Oxford, and specialist collection clinical lead.&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;A really early and important question to try to answer is why is the presence of urinary protein injurious to the kidneys, at least under some circumstances? In health it has been recognised that the glomerulus filters a significant amount of proteinuria that is then re-absorbed in the tubules without harm, and total daily urinary albumin is less than 20 mg. Proteinuria usually reflects an increase in glomerular permability for albumin and other plasma macromolecules. The glomerulus is a highly specialized vascular bed that ensure the selective ultrafiltration of plasma so that essential proteins are retained in the blood. The podocyte is the major cell that makes up the kidney filtration barrier, and mutations in a number of podocyte proteins that make up the slit-barrier, such as nephrin, podocin, PLCE1 are associated with hereditary proteinuric states.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;A number of different mechanisms has been postulated, which are discussed below:&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Celie and co-workers (1) postulated that as heparan sulfate proteoglycans (HSPGs) are well known for their proposed role in glomerular filtration, and that HSPGs can bind the leukocyte adhesion molecule l-selectin and chemokines, there may be a role for inflammation in proteinuria. They examined a panel of biopsies representing different human primary kidney diseases for l-selectin and monocyte chemoattractant protein-1 (MCP-1) binding. In various renal diseases, l-selectin and MCP-1 binding to interstitial perivascular matrix HSPGs is increased, which is significantly associated with leukocyte influx. In proteinuric diseases, including membranous glomerulopathy, minimal change disease, but also IgA nephropathy and lupus nephritis, increased binding of l-selectin and MCP-1 to tubular epithelial cell (TEC) HSPGs is observed, which colocalizes with increased basolateral syndecan-1 and anti-heparan sulfate 10E4 staining. Short-hairpin RNA-mediated silencing demonstrates that syndecan-1 on TECs indeed mediates l-Selectin binding. Increased TEC expression of IL-8 in biopsies of proteinuric patients suggests that the increase in luminal protein may activate TECs to increase expression of l-selectin and MCP-1 binding syndecan-1. Strikingly, urinary syndecan-1 from proteinuric patients is less capable of binding l-selectin compared with urinary syndecan-1 from healthy controls, although syndecan-1 concentrations are similar in both groups. Together, the data show pronounced tubulointerstitial HSPG alterations in primary kidney disease, which may affect the inflammatory response.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Shalamanova et al (2) determined the effects of human serum albumin (HSA) overload on the changes in gene and protein expression stimulated by oxidative stress in proximal tubular cells (PTC) and any interaction with ANG II that is pivotal in disease pathogenesis. Markers of oxidative stress, antioxidant defences, transcription factor activation, and the expression of stress-related genes were measured in human PTC (HK-2 cells) overloaded with either globulin-free fatty acid free (GF/FAF) HSA or globulin-free (GF) HSA. The effects of ANG II were also determined. HSA overload in HK-2 cells caused PTC hyperfunction, increased oxidative stress, and an upregulation of adaptive responses and stress-related genes. Some responses were common to both HSAs but others were unique to either HSA and unaffected by addition of ANG II or candesartan (a specific ANG II type 1 receptor blocker). ANG II also independently induced oxidative stress and upregulated other stress-related genes. HSA overload in HK-2 cells stimulated increased oxidative stress and upregulated changes in stress-related gene expression indicating new pathways of PTC injury that are not mediated via ANG II type 1 receptors.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Abbate et al (3) reviewed the many potential mechanisms that might link urinary protein to kidney damage – they cited evidence indicating that this process occurs through multiple pathways, including induction of tubular chemokine expression and complement activation that lead to inflammatory cell infiltration in the interstitium and sustained fibrogenesis, is reviewed. Macrophages are prominent in the interstitial inflammatory infiltrate. This cell type mediates progression of renal injury to the extent that macrophage numbers in renal biopsy predict renal survival in patients with chronic renal disease. Chemoattractants and adhesive molecules for inflammatory cells are upregulated by excess ultrafiltered protein load of proximal tubular cells via activation of NF-kappaB-dependent and NF-kappaB-independent pathways. This mechanism is a potential target for therapeutic approaches, as shown by beneficial effects of manipulations with inhibitory molecules of NF-kappaB activation or of chemokine receptors in experimental studies. Targeting complement synthesis or activation in proximal tubule might offer novel therapeutic opportunities. Finally, proximal tubular cell receptors for uptake of plasma proteins that are under investigation may provide activation signals on excess tubular protein handling.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Finally, Lai and co-workers (4) hypothesized an interaction between T cells/monocytes and the tubules in the development of tubulointerstitial injury in chronic proteinuric nephropathy. They established in vitro co-culture systems of proximal tubular epithelial cells (PTEC) and T cells/monocytes to study the contribution of soluble factors and cell-to-cell contact in the development of tubulointerstitial injury. The release of monocyte chemoattractant protein-1 (MCP1 or CCL2), Regulated upon Activation, normal T cell Expressed and Secreted (RANTES or CCL5), soluble intracellular adhesion molecules-1 (sICAM-1), or interleukin-6 (IL-6) was increased in PTEC following apical exposure to human serum albumin (HSA). The release of CCL2, CCL5, or sICAM-1 from PTEC was enhanced by contact of monocytes/T cells on the basolateral surface. Tumor necrosis factor-alpha (TNF-alpha) and IL-1beta are important soluble factors as suggested by the blocking effect of antibodies (Abs) against TNF-alpha or IL-1beta but not against other cytokines. The percentage of CD4+ T cells expressing both chemokine receptors, CCR2 and CCR5, was increased after culturing with supernatant from the apical or basolateral surface of PTEC following apical exposure to HSA. However, only CCR2 was upregulated in CD8+ T cells, whereas CCR5 expression was increased in monocytes. The chemotaxis of CD4+ or CD8+ T cells to supernatant from PTEC upon apical exposure to HSA was reduced with neutralizing Abs against CCL5 and/or CCL2, whereas the chemotaxis of monocytes was only reduced by anti-CCL5 but not by anti-CCL2. In summary, chemokines released by HSA-activated PTEC are amplified by monocytes/T cells. Mediators released by HSA-activated PTEC can differentially modulate the expression of chemokine receptors in monocytes/T cells and hence, alter their chemotaxis towards activated PTEC. These interactions are pivotal in the development of tubulointerstitial injury.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;In addition, tubular epithelial cells respond to exposure to filtered serum proteins, as to other forms of injury, by undergoing epithelial-to-mesenchymal transition (EMT), with reduction of epithelial phenotype and functions and induction of increased cell motility and matrix production. Transition toward a mesenchymal phenotype has been demonstrated in epithelial and endothelial cells by in vitro as well as in vivo studies and is recognized as an important contributor to the development of fibrosis. Tang et al elegantly studied the effect of proteins on complement activation and the upregulation of markers of EMT. Tubular epithelial cells exposed to serum proteins adopted phenotypic and functional characteristics of mesenchymal cells. Expression of E-cadherin protein decreased and expression of both&amp;nbsp; -smooth muscle actin protein and collagen I mRNA increased. Exposure of the cells to the complement anaphylotoxin C3a induced similar features. Treating with a C3a receptor (C3aR) antagonist prevented both C3a- and serum-induced epithelial-to-mesenchymal transition. In the adriamycin-induced proteinuria model, C3aR-deficient mice demonstrated less injury, preserved renal function, and improved survival compared with wild-type mice. Furthermore, the kidneys of C3aR-deficient mice had significantly less interstitial collagen I and&amp;nbsp; -smooth muscle actin. In summary, the complement anaphylotoxin C3a is an important mediator of glomerular and tubulointerstitial injury and can induce tubular epithelial-to-mesenchymal transition.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Complement activation is regulated by a series of inhibitors and soluble factors. Buelli et al studies whether albumin affected this regulation, which may exacerbate the toxic effect of albumin on proximal tubular cells. Addition of albumin or transferrin to HK-2 cells, a human epithelial cell line, incubated with diluted human serum as a source of complement caused increased apical C3 deposition. Soluble complement receptor-1 (an inhibitor of all 3 activation pathways) blocked complement deposition while the classical and lectin pathway inhibitor, magnesium chloride-EGTA, was, ineffective. Media containing albumin as well as complement had additive proinflammatory effects as shown by increased fractalkine and transforming growth factor-beta mRNA expression. This paralleled active C3 and C5b-9 generations, effects not shared by transferrin. Factor H, one of the main natural inhibitors of the alternative pathway, binds to heparan sulfate proteoglycans. Both the density of heparan sulfate and factor H binding were reduced with protein loading, thereby enhancing the albumin- and serum-dependent complement activation potential. Thus, protein overload reduces the ability of the tubule cell to bind factor H and counteract complement activation, effects instrumental to renal disease progression.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;This is an exciting and rapidly-developing area of kidney science; with luck and in time there may be new therapies for proteinuria and the downstream pathomechanisms which may significant retard progressive proteinuria-induced kidney fibrosis.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References&lt;/STRONG&gt; &lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Celie JW, Reijmers RM, Slot EM, Beelen RH, Spaargaren M, Ter Wee PM, et al. Tubulointerstitial heparan sulfate proteoglycan changes in human renal diseases correlate with leukocyte influx and proteinuria. Am J Physiol Renal Physiol 2008 Jan;294(1):F253-F263. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18032547" target="_blank"&gt;Link to PubMed&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Shalamanova L, McArdle F, Amara A, B, Jackson M, J, et al. Albumin overload induces adaptive responses in human proximal tubular cells through oxidative stress but not via angiotensin II type 1 receptor. American Journal of Physiology - Renal Physiology 2007;292(6):F1846-F1857. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17327499" target="_blank"&gt;Link to PubMed&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Abbate M, Zoja C, Remuzzi G. How does proteinuria cause progressive renal damage? Journal of the American Society of Nephrology 2006;17(11):2974-84. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17035611" target="_blank"&gt;Link to PubMed&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lai KN, Leung JCK, Chan L, et al. Interaction between proximal tubular epithelial cells and infiltrating monocytes/T cells in the proteinuric state. Kidney International 2007;71(6):526-38. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17245394" target="_blank"&gt;Link to PubMed&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Useful References 2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Mundel P, Reiser J. Proteinuria: an enzymatic disease of the podocyte. Kidney Int 2010 Apr;77(7):571-80 &lt;SPAN lang=EN style="FONT-SIZE: 9pt; COLOR: black; FONT-FAMILY: Arial; mso-ansi-language: EN"&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19924101" target="_blank"&gt;&lt;FONT color=#0066cc&gt;Link to PubMed abstract&lt;/FONT&gt;&lt;/A&gt;]&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/LI&gt;
&lt;LI&gt;Tang Z, Bao L, Hatch E, Sacks SH, Sheerin NS: C3a mediates epithelial- to-mesenchymal transition in proteinuric nephropathy. J Am Soc Nephrol 20: 593–603, 2009 &lt;SPAN lang=EN style="FONT-SIZE: 9pt; COLOR: black; FONT-FAMILY: Arial; mso-ansi-language: EN"&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19158354" target="_blank"&gt;&lt;FONT color=#0066cc&gt;Link to PubMed abstract&lt;/FONT&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/LI&gt;
&lt;LI&gt;Buelli S, Abbate M, Morigi M, Moioli D, Zanchi C, Noris M, Zoja C, Pusey CD, Zipfel PF, Remuzzi G. Protein load impairs factor H binding promoting complement-dependent dysfunction of proximal tubular cells. Kidney Int. 2009 May;75(10):1050-9 &lt;SPAN lang=EN style="FONT-SIZE: 9pt; COLOR: black; FONT-FAMILY: Arial; mso-ansi-language: EN"&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19242507" target="_blank"&gt;&lt;FONT color=#0066cc&gt;Link to PubMed abstract&lt;/FONT&gt;&lt;/A&gt;]&lt;/SPAN&gt;&lt;/LI&gt;&lt;/UL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <expiryDate>14/05/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>374024</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=374024]]&gt;</url>
    <title>2010 Annual Evidence Update on Proteinuria and eGFR: 3 a. How to detect and quantify urinary albumin and proteinuria</title>
    <publicationDate>2010-05-24T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ PROTEINURIA/ NEPHROTIC SYNDROME,PRESENTATION OF CKD,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Proteinuria and eGFR: 3 a. How to detect and quantify urinary albumin and proteinuria&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;&lt;A href="nelh:372689:0" name=internalLink&gt;&lt;STRONG&gt;Link back to 2010 AEU on Proteinuria and eGFR: contents page&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;The original commentary, written for the 2008 National Knowledge Week on Proteinuria and eGFR, has been updated for the 2010 AEU by Ed Sharples, Consultant in Nephrology and Transplant Medicine, Churchill Hospital, Oxford, and specialist collection clinical lead.&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;How best to detect and quantify proteinuria in the setting of chronic kidney disease is an important issue. In a recent review, Gansevoort et al (2006) (1) considered the several different ways in which we can analyse and present albuminuria / proteinuria. Albuminuria can be measured and expressed in several ways: 1) in a spot morning urine sample as urinary albumin concentration (mg/liter) or albumin:creatinine ratio (mg/mmol) and 2) in a 24-hour urine collection as urinary albumin excretion (mg/24 hours). It has not yet been clarified which measure for albuminuria is preferable in clinical practice. One of the points on which a choice should be made is which measure shows the least within-person coefficient of variation. It is argued that fresh urine should be used, since freezing at -20 degrees C results in considerable extra variability in the albumin concentration. Furthermore, it is important to use specifically collected urine samples and not portions of a 24-hour urine sample as a surrogate for a spot morning urine sample. Albuminuria follows a circadian rhythm. Consequently, values for the within-person coefficient of variation will therefore be different when they are measured in a portion of a 24-hour urine collection in comparison with a spot morning urine sample. These important practical points are a challenge when we try to “upscale” utiltisation of albuminuria screening for large populations. In diabetes however, over many years, the use of albumin:creatinine ratios have become familiar now, and are recommended by the new 2009 NICE guidance on chronic kidney disease (2) (&lt;STRONG&gt;&lt;STRONG&gt;&lt;A href="nelh:373973:0" name=internalLink&gt;&lt;STRONG&gt;&lt;STRONG&gt;see Section&amp;nbsp;2 a.&lt;/STRONG&gt;&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;).&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;However, it has to be conceded, as we discussed in Section&amp;nbsp;2 a., that there is more than one way to detect urine albumin (eg using HPLC). In addition, we have many more proteins which we might detect (short of the full-blown proteome). The quantification of urinary proteins presenting different molecular sizes is useful in characterizing a proteinuria. Wolff and Willems (2008) (3) assessed the performance of an electrophoretic system, the Hydragel Urine Profile, which allows firstly the identification of proteinuria and secondly a qualitative detection of monoclonal free light chains (FLC). Initially, the proteinuria was characterized on 127 pathological urines by quantifying albumin, a1microglobulin, immunoglobulins G by immunonephelometric quantification technique and the results were compared with the protein pattern obtained by the electrophoretic method. They also assessed the sensitivity and specificity of this electrophoretic test for the detection and characterization of Bence Jones proteins. FLC were analyzed quantitatively by an immunonephelometric assay and qualitatively by the electrophoretic test in 150 urines. The agreement between the two methods was good with a percentage of homology for characterizing the proteinuria of 89%. For detecting a monoclonal FLC, the electrophoretic method demonstrated a lesser sensitivity but a higher specificity compared to the immunoassay.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Mass population screening requires a simple and reproducible test for assessment of albuminuria. Screening studies have used both reagent strips and laboratory measurements of ACR. Graziani et al (4) compared the accuracy of reagent strips with ACR. Urine samples were obtained from 201 consecutive subjects enrolled in an epidemiological study and from 259 type 2 diabetic patients. Urine was tested for albumin and creatinine using the strip (Clinitek Microalbumin) and laboratory methods. A hundred samples were stored under various conditions to assess analyte stability. In the general population, the strip test reached a 90% sensitivity and 91% specificity, considering the laboratory method as the ‘gold standard’, sparing &amp;gt;80% of subjects the laboratory tests at the expense of a 1% false negative rate and an 8% false positive rate. Regarding sensitivity and specificity, the ACR test performs very similarly in the general population and in the diabetics. The stability study showed that storage at –20°C induced a significant decrease in the albumin concentration with both methods, such that 5% of the samples were re-classified in the lower ACR class. Storage at –80°C for up to 12 months did not affect the measurement with both methods. Clinitek Microalbumin strips can be used for screening purposes in the general population since they correctly classify a significant percentage of subjects, particularly those with a normal albuminuria.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Agarwal et al (2007) (5) attempted to look at the reproducibility and reliability of renal function and albuminuria testing in a cohort of type II diabetic patients. They studied 44 elderly men with diabetic nephropathy who participated in a clinical trial. Glomerular filtration rate and renal plasma flow were measured by continuous infusion technique with five urine collection periods on two occasions 4 months apart. Protein and creatinine excretion rates were measured in the same specimens. In addition, two consecutive 24-hour specimens every month for 4 months were collected to analyze urine protein, creatinine, urea nitrogen, and electrolytes. A hierarchical random effects model was used to analyze the reproducibility from hour to hour, from day to day, and from month to month. A total of 824 urine specimens were analyzed, of which 412 constituted specimens collected in the short term and 412 were 24-hour urine collections. Hour-to-hour variation accounted for 45% for urinary clearance of iothalamate, but for only 0.5% of the variability in plasma clearance of iothalamate. Day-to-day variability in 24-hour urinary excretion rates for creatinine was 46% and for protein 10%. Month-to-month variability in 24-hour excretion rates for creatinine was 11% and for protein 19%. The urine protein/creatinine ratio had a day-to-day variability of 2% and a month-to-month variability of 19%. Sample size requirements can be reduced by correcting for urine creatinine for some but not all urinary analytes. In nephrotic men with diabetic nephropathy, the coefficient of variation in the month-to-month protein excretion rate is 36%. Approximately 28 patients in each arm of two groups are needed to detect a difference in protein excretion rate of 28% (1 g/day in this study). The coefficient of variation in plasma iothalamate clearance over 4 months is 16%. To detect a 10% change in glomerular filtration rate between two groups, 44 patients per group are needed. To be deemed statistically significant, a change in daily protein excretion rate of at least 72% over month(s) is needed in individual patients. These findings illustrate the challenges of not only screening for the presence of something, but then following on with repeated quantifications over time.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Gansevoort RT, Brinkman J, Bakker SJ, De Jong PE, de ZD. “Evaluation of measures of urinary albumin excretion.” Am J Epidemiol 2006 Oct 15;164(8):725-7. &lt;SPAN lang=EN style="FONT-SIZE: 9pt; COLOR: black; FONT-FAMILY: Arial; mso-ansi-language: EN"&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16936069" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/SPAN&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;SPAN lang=EN style="FONT-SIZE: 9pt; COLOR: black; FONT-FAMILY: Arial; mso-ansi-language: EN"&gt;NICE CKD: Guideline (September 2008): Chronic kidney disease: early identification and management of chronic kidney disease in adults in primary and secondary care.&amp;nbsp;[&lt;A href="http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=294680" target="_blank"&gt;&lt;FONT color=#0066cc&gt;Link to NICE guideline&lt;/FONT&gt;&lt;/A&gt;]&lt;/SPAN&gt;&lt;/P&gt;&lt;/LI&gt;
&lt;LI&gt;Wolff F &amp;amp; Willems D. Immunonephelometric quantification of specific urinary proteins versus a simple electrophoretic method for characterizing proteinuria. Clinical Biochemistry 2008;41(6):418-22. &lt;SPAN lang=EN style="FONT-SIZE: 9pt; COLOR: black; FONT-FAMILY: Arial; mso-ansi-language: EN"&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18206114" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/SPAN&gt;&lt;/LI&gt;
&lt;LI&gt;Graziani MS, Gambaro G, Mantovani L, Sorio A, Yabarek T, Abaterusso C, Lupo A, Rizzotti P. “Diagnostic accuracy of a reagent strip for assessing urinary albumin excretion in the general population.” Nephrol Dial Transplant. 2009 May;24(5):1490-4. Epub 2008 Nov 26. &lt;SPAN lang=EN style="FONT-SIZE: 9pt; COLOR: black; FONT-FAMILY: Arial; mso-ansi-language: EN"&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19037085" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/SPAN&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;SPAN lang=EN style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: Arial; mso-ansi-language: EN"&gt;Agarwal R. Reproducibility of renal function measurements in adult men with diabetic nephropathy: research and clinical implications. American journal of nephrology 2007;27(1):92-100.[&lt;FONT face=Arial size=2&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17284896" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/FONT&gt;&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Useful References 2009-2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Kania K, Byrnes EA, Beilby JP, Webb SA, Strong KJ. “Urinary proteases degrade albumin: implications for measurement of albuminuria in stored samples.” Ann Clin&amp;nbsp; Biochem. 2010 Mar;47(Pt 2):151-7. Epub 2010 Feb 11. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20150213" target="_blank"&gt;Link to Pubmed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hellin JL, Bech-Serra JJ, Moctezuma EL, Chocron S, Santin S, Madrid A, Vilalta R, Canals F, Torra R, Meseguer A, Nieto JL. “Very low-molecular-mass fragments of albumin in the plasma of patients with focal segmental glomerulosclerosis.” Am J Kidney Dis. 2009 Nov;54(5):871-80. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19781833" target="_blank"&gt;Link to Pubmed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Seegmiller JC, Sviridov D, Larson TS, Borland TM, Hortin GL, Lieske JC. “Comparison of urinary albumin quantification by immunoturbidimetry, competitive immunoassay, and protein-cleavage liquid chromatography-tandem mass spectrometry.”&lt;BR&gt;Clin Chem. 2009 Nov;55(11):1991-4. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19745060" target="_blank"&gt;Link to Pubmed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Markó L, Molnár GA, Wagner Z, Böddi K, Koszegi T, Szabó Z, Matus Z, Szijártó I, Mérei A, Nagy G, Wittmann I. “Measurement of the modification and interference rate of urinary albumin detected by size-exclusion HPLC.” Physiol Meas. 2009 Oct;30(10):1137-50. Epub 2009 Sep 16. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19759403" target="_blank"&gt;Link to Pubmed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Markó L, Cseh J, Kószegi T, Szabó Z, Molnár GA, Mohás M, Szigeti N, Wittmann I. “Storage at -80 degrees C decreases the concentration of HPLC-detected urinary albumin: possible mechanisms and implications. J Nephrol. 2009 May-Jun;22(3):397-402.” [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19557717" target="_blank"&gt;Link to Pubmed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Graziani MS, Gambaro G, Mantovani L, Sorio A, Yabarek T, Abaterusso C, Lupo A, Rizzotti P. “Diagnostic accuracy of a reagent strip for assessing urinary albumin excretion in the general population.” Nephrol Dial Transplant. 2009 May;24(5):1490-4. Epub 2008 Nov 6. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19037085" target="_blank"&gt;Link to Pubmed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Bakker SJ, Gansevoort RT, de Zeeuw D. “Albuminuria: what can we expect from the determination of nonimmunoreactive albumin?” Curr Hypertens Rep. 2009 Apr;11(2):111-7. Review. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19278600" target="_blank"&gt;Link to Pubmed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Useful References from the 2008 National Knowledge Week&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Gansevoort RT, Brinkman J, Bakker SJ, De Jong PE, de ZD. “Evaluation of measures of urinary albumin excretion.” Am J Epidemiol 2006 Oct 15;164(8):725-7. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16936069" target="_blank"&gt;Link to Pubmed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Wolff F &amp;amp; Willems D. “Immunonephelometric quantification of specific urinary proteins versus a simple electrophoretic method for characterizing proteinuria.” Clinical Biochemistry 2008;41(6):418-22. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18206114" target="_blank"&gt;Link to Pubmed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <expiryDate>14/05/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>374026</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=374026]]&gt;</url>
    <title>2010 Annual Evidence Update on Proteinuria and eGFR: 3 b. Proteinuria as a marker of chronic kidney damage</title>
    <publicationDate>2010-05-24T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ PRESENTATION OF CKD,PROTEINURIA/ NEPHROTIC SYNDROME,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Proteinuria and eGFR: 3 b. Proteinuria as a marker of chronic kidney damage&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;&lt;A href="nelh:372689:0" name=internalLink&gt;&lt;STRONG&gt;Link back to 2010 AEU on Proteinuria and eGFR: contents page&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;The original commentary, written for the 2008 National Knowledge Week on Proteinuria and eGFR, has been updated for the 2010 AEU by Ed Sharples, Consultant in Nephrology and Transplant Medicine, Churchill Hospital, Oxford, and specialist collection clinical lead.&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The role and mechanism of proteinuria in the development of progressive CKD has been reviewed in &lt;STRONG&gt;&lt;A href="nelh:372689:0" name=internalLink&gt;&lt;STRONG&gt;section 2&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;. There is a body of evidence from RCTs that have shown a reduction in urinary protein is associated with significant reductions in the incidence of ESRD or doubling of creatinine, both in diabetes mellitus and some types of non-diabetic proteinuric CKD. It is also important to review the evidence of the association between the presence, and amount of proteinuria, and the progression to ESRD. This is often outside the scope of these RCTs, and cohort studies with very long follow-up times , i.e. 25 years, are important to show further evidence of this association.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The power of a single point in time estimate of urinary protein using urine dipsticks (at best semi-quantitative) was nicely shown by Ishani &lt;EM&gt;et al.&lt;/EM&gt; (2006) (1). This study aimed to determine over 25 yr the risk for ESRD associated with proteinuria, estimated GFR (eGFR), and hematocrit in men who did not have identified kidney disease and were randomly assigned into the Multiple Risk Factor Intervention Study (MRFIT). A total of 12,866 men who were at high risk for heart disease were enrolled (1973 to 1975) and followed through 1999. Renal replacement therapy was ascertained by matching identifiers with the United States Renal Data System's data; vital status was from the National Death Index. Men who initiated renal replacement therapy or died as a result of kidney disease were deemed to have developed ESRD. Dipstick urine for proteinuria, eGFR, and hematocrit were related to development of ESRD. During 25 yr, 213 (1.7%) men developed ESRD. Predictors of ESRD were dipstick proteinuria of 1+ or &amp;gt; or =2+ (hazard ratio [HR] 3.1 [95% confidence interval (CI) 1.8 to 5.4] and 15.7 [95% CI 10.3 to 23.9] respectively) and an eGFR of &amp;lt;60 ml/min per 1.73 m(2) (HR 2.4; 95% CI 1.5 to 3.8). Correlation between eGFR and serum creatinine was 0.9; the risk for ESRD with a 1-SD difference of each was identical (HR 1.21). Bivariate analysis demonstrated a 41-fold increase in ESRD risk in those with an eGFR &amp;lt;60 ml/min per 1.73 m(2) and &amp;gt; or =2+ proteinuria (95% CI 15.2 to 71.1). There was no association between hematocrit and ESRD. Other baseline measures that independently predicted ESRD included age, cigarette smoking, BP, low HDL cholesterol, and fasting glucose. Among middle-aged men who were at high risk for cardiovascular disease but had no clinical evidence of cardiovascular disease or significant kidney disease, dipstick proteinuria and an eGFR value &amp;lt;60 ml/min per 1.73 m&lt;SUP&gt;2&lt;/SUP&gt; were strong predictors of long-term development of ESRD. It remains unknown whether intervention for proteinuria or early identification of those with chronic kidney disease reduces the risk for subsequent manifestation of renal or cardiovascular diseases.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Hsu &lt;EM&gt;et al.&lt;/EM&gt; (2) studied 177 570 individuals from a large integrated health care delivery system in northern California, who volunteered for health checkups between June 1, 1964, and August 31, 1973. Initiation of ESRD treatment was ascertained using US Renal Data System registry data through December 31, 2000. RESULTS: A total of 842 cases of ESRD were observed during 5 275 957 person-years of follow-up. This comprehensive evaluation confirmed the importance of established risk factors, including the following: male sex, older age, proteinuria, diabetes mellitus, lower educational attainment, and African American race, as well as higher blood pressure, body mass index, and serum creatinine level. The 2 most potent risk factors were proteinuria and excess weight. For proteinuria, the adjusted hazard ratios (HRs) were 7.90 (95% confidence interval [CI], 5.35-11.67) for 3 to 4+ on urine dipstick, 3.59 (2.82-4.57) for 1 to 2+ on urine dipstick, and 2.37 (1.79-3.14) for trace vs negative on urine dipstick. For excess weight, the HRs were 4.39 (95% CI, 3.38-5.70) for class 2 to class 3 obesity, 3.11 (2.51-3.84) for class 1 obesity, and 1.65 (1.39-1.97) for overweight vs normal weight. Furthermore, several independent novel risk factors for ESRD were identified, including higher serum uric acid level (2.14 [1.65-2.77] for highest vs lowest quartile), self-reported history of nocturia (1.36 [1.17-1.58]), and family history of kidney disease (HR, 1.40 [95% CI, 1.02-1.90]). This large cohort study confirms the association between degree of proteinuria and risk of progression to ESRF, and also confirms the importance of established ESRD risk factors in this large cohort with broad sex and racial/ethnic representation. Lower hemoglobin level, higher serum uric acid level, self-reported history of nocturia, and family history of kidney disease are independent risk factors for ESRD.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Babazono &lt;EM&gt;et al.&lt;/EM&gt; (3)&amp;nbsp;examined whether ACR values within the normal range might also predict progression of nephropathy in patients with diabetes. A total of 5,449 Japanese diabetic patients were categorized according to sex and urinary albumin-to-creatinine ratio (ACR; &amp;lt;5, 5–9, 10–29, 30–99, 100–299, 300–999, 1,000–2,999, and =3,000 mg/g) and followed for at least 5 years. The rate of change in estimated GFR (eGFR) adjusted for age and baseline eGFR was compared among ACR categories. A higher baseline ACR predicted a faster decline in eGFR for both sexes. Even within the normal range (&amp;lt;30 mg/g), ACR =10 mg/g in women and =5 mg/g in men was associated with a significantly greater rate of decline in eGFR relative to subjects with ACR &amp;lt;5 mg/g. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Other associations between albuminuria and markers of disease states abound in the literature. This can be a confusing area, as everything in time seems to be linked to everything else. Thus, de Boer and colleagues used samples derived from the Third National Health and Nutrition Examination Survey from 15,068 adults participating (de Boer et al, 2007) (4). A stepwise increase in the prevalence of albuminuria was observed with decreasing quartiles of vitamin D concentration: 8.9%, 11.5%, 13.7%, and 15.8% (P &amp;lt; 0.001). Adjusting for age, sex, race/ethnicity, region and season of measurement, smoking status, body mass index, and estimated glomerular filtration rate, relative risks for albuminuria by decreasing quartile of vitamin D concentration were 1.00 (reference group), 1.14 (95% confidence interval, 0.95 to 1.37), 1.22 (95% confidence interval, 1.03 to 1.45), and 1.37 (95% confidence interval, 1.10 to 1.71; P = 0.006). Additionally adjusting for blood pressure and diabetes mellitus, these risks were somewhat attenuated and retained statistical significance. This was a cross-sectional survey, so additional studies are needed to clarify the relationship of vitamin D with albuminuria and determine whether vitamin D therapy prevents or improves markers of kidney and cardiovascular disease.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;From the same NHANES study, Kshirsagar et al (2008) (5) examined the association between CRP and microalbuminuria. They conducted a cross-sectional analysis of a nationally representative, population-based survey. Weighted multiple logistic regression was used to study the association between CRP and microalbuminuria, adjusting for well-known risk factors. CRP was analyzed by a continuous variable and two categorized variables using quartiles and clinically recommended cutpoints. CRP concentration was positively associated with microalbuminuria. In the multivariate model, a one unit (in milligrams per liter) increase in CRP concentration was associated with a 2% increased odds of microalbuminuria (odds ratio 1.02, 95% confidence interval [CI] 1.01 to 1.02, p=0.0003). When CRP concentrations were stratified by clinically recommended cutpoints, compared with persons with CRP concentrations&amp;lt;1 mg/dl, persons with CRP concentrations between 1 and 3 mg/L and &amp;gt;3 mg/L were 1.15 times (95% CI 0.94 to 1.42) and 1.33 times (95% CI 1.08 to 1.65) more likely to have microalbuminuria, respectively. In subgroup analyses, the strength of association was comparable or stronger. In conclusion, elevated CRP levels were associated with microalbuminuria in a large, nationally representative data set. Vascular inflammation, as measured by CRP, may be a common contributor to early heart and kidney disease.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Although having a “normal” range of course is essential for the concept of screening for elevation in urinary albumin excretion, Ruggenenti and Remuzzi provocatively but remorselessly point out that any distinction between the normal and elevated is both arbitrary and spurious. There is a linear graded relationship between adverse outcome and urinary albumin excretion rates which extends well down into the normal range of urinary albumin &lt;BR&gt;levels (6).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Ishani A, Grandits GA, Grimm RH, Svendsen KH, Collins AJ, Prineas RJ, et al. "Association of single measurements of dipstick proteinuria, estimated glomerular filtration rate, and hematocrit with 25-year incidence of end-stage renal disease in the multiple risk factor intervention trial." Journal of the American Society of Nephrology : JASN 2006;17(5):1444-52. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16611715" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hsu CY, Iribarren C, McCulloch CE, Darbinian J, Go AS. "Risk factors for end-stage renal disease: 25-year follow-up." Arch Intern Med. 2009 Feb 23;169(4):342-50. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19237717" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Babazono T, Nyumura I, Toya K, Hayashi T, Ohta M, Suzuki K, Kiuchi Y, Iwamoto Y. "Higher levels of urinary albumin excretion within the normal range predict faster decline in glomerular filtration rate in diabetic patients." Diabetes Care. 2009 Aug;32(8):1518-20. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Higher%20levels%20of%20urinary%20albumin%20excretion%20within%20the%20normal%20range%20predict%20faster%20decline%20in%20glomerular%20filtration%20rate%20in%20diabetic%20patients" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;de Boer IH, Ioannou G, N, Kestenbaum B, Brunzell J, et al. "25-Hydroxyvitamin D Levels and Albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III)." American Journal of Kidney Diseases 2007;50(1):69-77. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=25-Hydroxyvitamin%20D%20Levels%20and%20Albuminuria%20in%20the%20Third%20National%20Health%20and%20Nutrition%20Examination%20Survey%20%28NHANES%20III%29" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kshirsagar AV, Bomback AS, Bang H, Gerber LM, Vupputuri S, Shoham DA, et al. "Association of C-reactive protein and microalbuminuria (from the National Health and Nutrition Examination Surveys, 1999 to 2004)." Am J Cardiol 2008 Feb 1;101(3):401-6. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Association%20of%20C-reactive%20protein%20and%20microalbuminuria%20%28from%20the%20National%20Health%20and%20Nutrition%20Examination%20Surveys%2C%201999%20to%202004%29" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Ruggenenti P &amp;amp; Remuzzi G. "Time to abandon microalbuminuria?" Kidney Int 2006 Oct;70(7):1214-22. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Time%20to%20abandon%20microalbuminuria%3F" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <expiryDate>14/05/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>374027</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=374027]]&gt;</url>
    <title>2010 Annual Evidence Update on Proteinuria and eGFR: 3 c. Proteinuria, and CKD and Cardiovascular risk</title>
    <publicationDate>2010-05-24T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ PROTEINURIA/ NEPHROTIC SYNDROME,PRESENTATION OF CKD,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Proteinuria and eGFR: 3 c. Proteinuria, and CKD and Cardiovascular risk&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;&lt;A href="nelh:372689:0" name=internalLink&gt;&lt;STRONG&gt;Link back to 2010 AEU on Proteinuria and eGFR: contents page&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;The original commentary, written for the 2008 National Knowledge Week on Proteinuria and eGFR, has been updated for the 2010 AEU by Ed Sharples, Consultant in Nephrology and Transplant Medicine, Churchill Hospital, Oxford, and specialist collection clinical lead.&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Microalbuminuria has been associated with cardiovascular in a large number of studies, independent of the presence of recognised CKD. The strength of this link between the presence of urinary protein and other important biological risk factors for cardiovascular disease has been further studied in a number of important areas of cardiovascular disease. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;A large collaborative meta-analysis of the association between albuminuria, eGFR and mortalty, organized by KDIGO, has just been published in the Lancet [18th May 2010 online] (1). Standardized data for all-cause mortality and cardiovascular mortality was pooled from 21 studies (all &amp;gt;1000 individuals) reporting before July 2009. It included ARIC, AusDiab, Framingham, NHANES III with ACR measurements, and 7 studies with dipstick measurement of proteinuria. 105872 participants were included from ACR studies and 1128310 from dipstick studies. In studies with ACR measurement, risk of mortality was unrelated to eGFR between 75 – 105 ml/min/1.73 m&lt;SUP&gt;2&lt;/SUP&gt;, and increased at lower eGFRs. Adjusted HRs (hazard ratios) for all cause mortality increased at eGFR 60 (1.18, 95% CI 1.05-1.32). ACR was also independently associated with increased all cause and CV mortality, with rise in HR for near-normal ACR 1.1 mg/mmol (1.20, 95% CI 1-15-1.26). There were similar findings for dipstick proteinuria. The association with albuminuria was on the log-log scale, with a 2-fold increase in adverse outcome associated with ACR 11.3 mg/mmol when compared to normal values. The finding of microalbuminuria or a positive dipstick for albuminuria is associated with increased mortality, and suggest that either test is a useful screening tool. The association of eGFR with HR for mortality was less strong in the elderly when compared to younger patients, who are more likely to have significant renal disease. As with previous studies and meta-analysis, this data does not alter the uncertainly over whether there is a causal relationship or whether impaired eGFR and the presence of microalbuminuria are useful markers for significant vascular risk.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Perkovic &lt;EM&gt;et al.&lt;/EM&gt; (2)&amp;nbsp;performed a systematic review and meta-analysis of 26 studies identified from 297 studies published before 2007. 16 estimates from ten studies including 124, 997 patients reported in the relationship between total proteinuria and the risk of subsequent cardiovascular disease. The mean-weighted estimates from these studies indicated that individuals with macro-proteinuria (&amp;gt;300 mg/l) have significantly greater risk compared to those patients without proteinuria (RR 2.17, 95% CI 1.87-2.52), although there was considerable heterogenicity between studies. Seven studies (n=31591) for which information was available showed a similar relative risk associated with the presence of microalbuminuria (RR 1.47, 95% CI 1.3-1.66). Those studies that compared micro- with macro-proteinuria and CV outcome showed a correlation between amount of proteinuria and relative risk of CV disease [Perkovic V, 2008].&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Khan, Hemmelgarn&amp;nbsp;&lt;EM&gt;et al.&lt;/EM&gt; (3) &amp;nbsp;reviewed the outcomes of 920885 patients in primary care who had at least one measurement of eGFR. All patients had proteinuria screening by either urine dipstick or urinary ACR. 60% of patients had normal kidney function with eGFR &amp;gt; 60 ml/min at the beginning of the study. Over a seven year period, 3% of the study population died, or had a CV event. There was a significant relationship between proteinuria and CV disease and mortality that was independent of eGFR.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Ingelsson and colleagues (Ingelson &lt;EM&gt;et al&lt;/EM&gt;., 2007) (4) looked at a cohort of “healthy” elderly men (&amp;gt; 70 years of age) and quantified urinary albumin, then they correlated de novo onset of heart failure against baseline urinary protein losses. UAER (from timed overnight samples) was analysed with established risk factors for HF [acute MI before baseline, acute MI during follow-up (modelled as a time-dependent covariate), hypertension, diabetes, left ventricular hypertrophy, smoking, body mass index, and glomerular filtration rate] and more recently described risk factors [high-sensitive C-reactive protein and insulin sensitivity (clamp glucose disposal rate)] as predictors of HF incidence. Ninety-eight participants developed HF during a median follow-up of 9.0 years. In Cox proportional hazards models adjusted for established and novel risk factors for HF, a 1 SD increase in log UAER increased the risk of HF in individuals without anti-hypertensive treatment (hazard ratio 1.49; 95% CI 1.13-1.98; P = 0.005). Furthermore, UAER remained an independent predictor of HF, also in participants without diabetes at baseline or myocardial infarction at baseline or during follow-up. There were no significant associations between UAER and HF incidence in individuals with anti-hypertensive treatment. These observations support the notion that low-grade albuminuria is a marker for subclinical cardiovascular damage that predisposes to future HF in the community.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;In another interesting study, carotid ultrasonography and measurements of ACR, fibrinogen, monocytes, white cell count, and well-established cardiovascular risk factors were performed in 4037 non-diabetic subjects, 2203 without, and 1834 with pre-existing plaques at baseline (Jorgensen &lt;EM&gt;et al&lt;/EM&gt;., 2007) (5). After 7 years new ultrasound measurements were performed. In subjects without pre-existing plaques, 884 had developed at least one plaque during follow-up. Baseline ACR was significantly related to the area of the novel plaques (P for linear trend = 0.009 over the baseline ACR quartiles, after multiple adjustments). The relationship with ACR was clearly modified by fibrinogen (P = 0.001, for the interaction ACR x fibrinogen). Subjects with high levels of both ACR and fibrinogen developed plaques with the largest area. In subjects with pre-existing plaques, ACR was related to plaque-progression (P for linear trend = 0.026, after multiple adjustments). In these individuals, the interaction between fibrinogen and ACR on plaque-growth appeared only in those with minimal atherosclerosis at baseline. ACR is positively related to plaque-initiation and plaque-growth. This relationship is substantially modified by fibrinogen in previously plaque-free subjects.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Tsai &lt;EM&gt;et al.&lt;/EM&gt; (2007) (6) argued that as both arterial stiffness and proteinuria are important markers for organ damage in hypertension they needed to investigate the association between arterial stiffness and inflammation and to define the influences of proteinuria on arterial stiffness and inflammation in non-diabetic hypertension. They enrolled 205 patients (mean age 41 +/- 8 years, 66 women) with essential hypertension noted for less than 5 years in this study. They did not have diabetes mellitus or any overt cardiac, vascular, or renal complications. Stiffness index (SI) derived from digital volume pulse was used for assessment of arterial stiffness. High-sensitivity C-reactive protein (hsCRP) was measured in each patient during enrollment. Left ventricular hypertrophy (LVH) was documented by electrocardiography and proteinuria was assessed by measuring 24-h urine protein. SI was significantly correlated with hsCRP (r = 0.166, p = 0.017). LVH was noted in 34 patients (17%). SI was significantly higher in patients with LVH (8.03 +/- 1.74 vs 7.19 +/- 1.19 m/s, p = 0.001). Proteinuria was noted in three patients with LVH. SI was gradually increased among patients without LVH, with LVH but not proteinuria, and with LVH and proteinuria (7.19 +/- 1.19, 7.68 +/- 1.21, 11.75 +/- 2.51 m/s respectively; p&amp;lt;0.001). HsCRP was also gradually increased among patients without LVH, with LVH but not proteinuria, and with LVH and proteinuria (0.20 +/- 0.24, 0.30 +/- 0.59, 1.56 +/- 1.58 mg/dl respectively; p&amp;lt;0.001). SI was significantly correlated with hsCRP. Arterial stiffness and inflammation were increased in association with proteinuria in non-diabetic essential hypertension.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Masson &lt;EM&gt;et al.&lt;/EM&gt; (7)&amp;nbsp;examined the association between albuminuria and cardiac failure in a post-hoc analysis of patient data from the GISSI- heart failure trial, which randomised 2131 patients to treatment with rosuvastatin and n-3 polyunsaturated fats. Proteinuria was measured with ACR. 19.9% of patients had microalbuminuria, and 5.4% have macroscopic proteinuria (&amp;gt;300 mg/dl). There was a significant increase in the relative risk of mortality for every 1U increase in log-transformed ACR ratio (1.12, 95% CI 1.05-1.55). There was no effect of the randomised therapies on the degree of albuminuria.&lt;BR&gt;The role of proteinuria in the prognosis and outcomes of treatment in cardiovascular disease has also been shown in a RCT of an angiotensin-receptor anagonist in cardiac failure. In the Valsartan in Heart Failure Trial (Val-HeFT) (8), 5010 patients with class II, III, or IV heart failure were randomly assigned to receive valsartan or placebo. The 2 primary outcomes were death and first morbid event, defined as death, sudden death with resuscitation, hospitalization for HF, or administration of intravenous inotropic or vasodilator drugs for 4 hours or more without hospitalization. The study cohort was divided into subgroups according to the presence of CKD (estimated glomerular filtration rate &amp;lt;60 mL x min(-1) x 1.73 m(-2)) and proteinuria (positive dipstick). Multivariable Cox proportional hazards regression models were used to examine the relationships between study outcomes and proteinuria, including its interaction with CKD. The interaction between valsartan and CKD was also tested. The effect of valsartan on estimated glomerular filtration rate was estimated by generalized linear models, including tests of interactions between treatment and CKD. At baseline, CKD was found in 58% and dipstick-positive proteinuria in 8% of patients. Dipstick-positive proteinuria was independently associated with mortality (hazard ratio [HR] 1.28, 95% confidence interval [CI] 1.01 to 1.62, P=0.05) and first morbid event (HR 1.28, 95% CI 1.06 to 1.55, P=0.01). The increased risk of death associated with dipstick-positive proteinuria was similar for those with and without CKD (HR 1.26, 95% CI 0.96 to 1.66 versus HR 1.37, 95% CI 0.83 to 2.26; P=0.94), as was the hazard for first morbid event (HR 1.26, 95% CI 1.01 to 1.57 versus HR 1.42, 95% CI 0.98 to 2.07; P=0.71). Valsartan reduced estimated glomerular filtration rate compared with placebo to a similar extent (P=0.52) in the subgroups with CKD (mean reduction -3.6 mL x min(-1) x 1.73 m(-2)) and without CKD (mean reduction -4.0 mL x min(-1) x 1.73 m(-2)) and by -3.8 mL x min(-1) x 1.73 m(-2) in both groups combined. The beneficial effect of valsartan on first morbid events was similar in those with and without CKD (HR 0.86, 95% CI 0.74 to 0.99 versus HR 0.91, 95% CI 0.73 to 1.12; P=0.23) and was significant in the subgroup with CKD. The effect of valsartan on mortality did not differ in patients with and without CKD (HR 1.01, 95% CI 0.85 to 1.20 versus HR 0.91, 95% CI 0.69 to 1.25; P=0.08). CONCLUSIONS: CKD was common and dipstick-positive proteinuria was infrequent in this sample of patients with HF. After controlling for other risk factors, including CKD, the relatively small subgroup with dipstick-positive proteinuria did have worse outcomes. Valsartan reduced the estimated glomerular filtration rate by the same amount in patients with and without CKD and reduced the risk of the first morbid event in patients with CKD, which suggests its beneficial effects in patients with HF and CKD.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Valappil &lt;EM&gt;et al. &lt;/EM&gt;(9) did a study in young adults to determine whether reduced arterial elasticity and endothelial dysfunction both may indicate early cardiovascular (CV) disease in young adults. Pulse waveform analysis estimates large (LAE) and small (SAE) artery elasticity noninvasively. They assessed the associations between LAE and SAE and markers of endothelial dysfunction and CV risk factors. The Coronary Artery Risk Development in Young Adults (CARDIA) assessed arterial elasticity and other characteristics cross-sectionally in 389 men and 381 women age 27 to 42 years in 1995 (CARDIA year 10) and circulating levels of P-selectin and soluble intercellular adhesion molecule 1 (sICAM1) in 2000. Adjustment for variables included in the estimation of arterial elasticity (year 10 height, body mass index, age, heart rate, and blood pressure) and other year 10 characteristics. Mean adjusted SAE was 8.5 vs. 7.6 mL/mm Hg x 100 in those with urine albumin/creatinine ratio &amp;lt; 4 vs. microalbuminuria (ratio &amp;gt;25; P = .008). Mean LAE was 25.6 vs. 24.2 mL/mm Hg x 10 in the lowest vs. highest quintile of P-selectin (P = .004). sICAM1 was unrelated to either LAE or SAE. Plasma triglycerides were inversely related to LAE (P&amp;lt;sub&amp;gt;trend&amp;lt;/sub&amp;gt; = .029). Cigarette smokers had lower SAE than nonsmokers (P = .009). In addition to smoking and triglycerides, biomarkers for endothelial dysfunction were associated with impaired LAE and SAE in young adults.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Of course, as we have seen, microalbuminuria is but one cardiovascularly-relevant biomarker we have at our disposal. It is intimately linked to several of the other key cardiovascular biomarkers. Shlipak&lt;EM&gt; et al.&lt;/EM&gt; (2008) (10) examined the association of N-terminal prohormone brain natriuretic peptide (Nt-proBNP), cystatin C, albuminuria, C-reactive protein (CRP), interleukin-6, and fibrinogen with cardiovascular events in 979 Heart and Soul Study participants with coronary artery disease after adjusting for demographic, lifestyle, and behavior variables; cardiovascular risk factors; cardiovascular disease severity; medication use; and left ventricular ejection fraction. The outcome was a composite of stroke, myocardial infarction, and coronary heart disease death during an average of 3.5 years of follow-up.: During follow-up, 142 participants (15%) developed cardiovascular events. The highest quartiles (vs lower 3 quartiles) of 5 biomarkers were individually associated with cardiovascular risk after multivariate analysis: Nt-proBNP hazard ratio (HR)=2.13 (95% confidence interval [CI], 1.43-3.18); cystatin C HR=1.72 (95% CI, 1.10-2.70); albuminuria HR=1.71 (95% CI, 1.15-2.54); CRP HR=2.00 (95% CI, 1.40-2.85); and interleukin-6 HR=1.76 (95% CI, 1.22-2.53). When all biomarkers were included in the multivariable analysis, only Nt-proBNP, albuminuria, and CRP remained significant predictors of events: HR=1.88 (95% CI, 1.23-2.85), HR=1.63 (95% CI, 1.09-2.43), and HR=1.82 (95% CI, 1.24-2.67), respectively. The area under the receiver operator curve for clinical predictors alone was 0.73 (95% CI, 0.68-0.78); adding Nt-proBNP, albuminuria, and CRP significantly increased the area under the receiver operator curve to 0.77 (95% CI, 0.73-0.82, P&amp;lt;.005). Among persons with prevalent coronary artery disease, biomarkers reflecting hemodynamic stress, kidney damage, and inflammation added significant risk discrimination for cardiovascular events.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;It may well be, in time, that we are able to augment the priceless information we can so simply and relatively cheaply obtain from urine analysis, by using bespoke biomarkers to compile a “score” for future cardio-renal events. All of this optimism, as with proteomics of blood or urine, needs rigorously to be tested / nested in large population databases with appropriate follow-up. A better understanding of the genetic predisposition to disease, and the use of more sophisticated biomarkers, promises to be a new way to predict cardio-renal events, and, if coupled with affordable but efficacious interventions (life-style as well as pharmacological), to permit a more successful organized approach to disease prevention.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Chronic Kidney Disease Prognosis Consortium. "Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis." Lancet.&amp;nbsp;Available online 17 May 2010. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Association%20of%20estimated%20glomerular%20filtration%20rate%20and%20albuminuria%20with%20all-cause%20and%20cardiovascular%20mortality%20in%20general%20population%20cohorts%3A%20a%20collaborative%20meta-analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Perkovic, V., C. Verdon, et al. (2008). "The relationship between proteinuria and coronary risk: a systematic review and meta-analysis." PLoS Med 5(10): e207. [&lt;A href="http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.0050207" target="_blank"&gt;Link to PLoS Med full text&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Khan NA, Hammelgarn B, Herman RJ, Rabkin SW, McAlister FA, Bell CM, Touyz RM, et al. (2008) "The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy." Canadian Journal of Cardiology, June 2008, 24 (6); 465-75. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18548143" target="_blank"&gt;Link to Pubmed abstract&lt;/A&gt;]&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;Ingelsson E, Sundstrom J, Lind L, Riserus U, Larsson A, Basu S, et al. "Low-grade albuminuria and the incidence of heart failure in a community-based cohort of elderly men." European Heart Journal 2007;28(14):1739-45. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Low-grade%20albuminuria%20and%20the%20incidence%20of%20heart%20failure%20in%20a%20community-based%20cohort%20of%20elderly%20men" target="_blank"&gt;Link to PubMed&amp;nbsp;abstract&lt;/A&gt;]&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Jorgensen L, Jenssen T, Johnsen SH, Mathiesen EB, Heuch I, Joakimsen O, et al. "Albuminuria as risk factor for initiation and progression of carotid atherosclerosis in non-diabetic persons: the Tromso Study." Eur Heart J 2007 Feb;28(3):363-9. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Albuminuria%20as%20risk%20factor%20for%20initiation%20and%20progression%20of%20carotid%20atherosclerosis%20in%20non-diabetic%20persons%3A%20the%20Tromso%20Study" target="_blank"&gt;Link to PubMed&amp;nbsp;abstract&lt;/A&gt;]&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Tsai WC, Lin CC, Huang YY, Chen JY, Chen JH. "Association of increased arterial stiffness and inflammation with proteinuria and left ventricular hypertrophy in non-diabetic hypertensive patients." Blood Press 2007;16(4):270-5. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Association%20of%20increased%20arterial%20stiffness%20and%20inflammation%20with%20proteinuria%20and%20left%20ventricular%20hypertrophy%20in%20non-diabetic%20hypertensive%20patients" target="_blank"&gt;Link to PubMed&amp;nbsp;abstract&lt;/A&gt;]&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Masson S, Latini R, Milani V, Moretti L, et al. "Prevalence and prognostic value of elevated urinary albumin excretion in patients with chronic heart failure: data from the GISSI-Heart Failure trial." Circ Heart Fail. 2010 Jan;3(1):65-72. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Prevalence%20and%20prognostic%20value%20of%20elevated%20urinary%20albumin%20excretion%20in%20patients%20with%20chronic%20heart%20failure%3A%20data%20from%20the%20GISSI-Heart%20Failure%20trial" target="_blank"&gt;Link to PubMed&amp;nbsp;abstract&lt;/A&gt;]&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Anand IS, Bishu K, Rector TS, Ishani A, Kuskowski MA, Cohn JN. "Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure." Circulation. 2009 Oct 20;120(16):1577-84. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Proteinuria%2C%20chronic%20kidney%20disease%2C%20and%20the%20effect%20of%20an%20angiotensin%20receptor%20blocker%20in%20addition%20to%20an%20angiotensin-converting%20enzyme%20inhibitor%20in%20patients%20with%20moderate%20to%20severe%20heart%20failure" target="_blank"&gt;Link to PubMed&amp;nbsp;abstract&lt;/A&gt;]&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Valappil NI, Jacobs JDR, Duprez D, et al. "Association between endothelial biomarkers and arterial elasticity in young adults: the CARDIA Study." Journal of the American Society of Hypertension 2008;2(2):70-9. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Association%20between%20endothelial%20biomarkers%20and%20arterial%20elasticity%20in%20young%20adults%3A%20the%20CARDIA%20Study" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Shlipak MG, Ix JH, Bibbins-Domingo K, Lin F, Whooley MA. "Biomarkers to predict recurrent cardiovascular disease: the Heart and Soul Study." Am J Med 2008 Jan;121(1):50-7. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Biomarkers%20to%20predict%20recurrent%20cardiovascular%20disease%3A%20the%20Heart%20and%20Soul%20Study" target="_blank"&gt;Link to PubMed&amp;nbsp;abstract&lt;/A&gt;]&amp;nbsp;&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <expiryDate>14/05/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>374198</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=374198]]&gt;</url>
    <title>2010 Annual Evidence Update on Proteinuria and eGFR: 3 d. Proteinuria as a screening tool</title>
    <publicationDate>2010-05-24T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ SCREENING OPTIONS,PROTEINURIA/ NEPHROTIC SYNDROME,PRESENTATION OF CKD,SCREENING TESTS,OTHER,SCREENING,ADULT,NOT ROUTINELY OFFERED,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Proteinuria and eGFR: 3 d. Proteinuria as a screening tool&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;&lt;A href="nelh:372689:0" name=internalLink&gt;&lt;STRONG&gt;Link back to 2010 AEU on Proteinuria and eGFR: contents page&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;The original commentary, written for the 2008 National Knowledge Week on Proteinuria and eGFR, has been updated for the 2010 AEU by Ed Sharples, Consultant in Nephrology and Transplant Medicine, Churchill Hospital, Oxford, and specialist collection clinical lead.&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Proteinuria and impaired renal function are both strong predictors for progressive renal failure and perhaps more importantly for cardiovascular disease (1). Screening for renal disease may make sense as interventions such ACE inhibition and control of cardiovascular risk factors in at-risk subjects is effective in prevention or retardation of progressive renal impairment and avoidance of cardiovascular complications. Using ACR as a marker for prevalence of CKD, Plantinga reviewed the NHANES population to determine the prevalence of CKD in non-diabetic or pre-diabetic patients (2). A high proportion of patients with laboratory investigations consistent with pre-diabetes also had CKD, with 14% CKD stage 3 with positive ACR in pre-diabetes compared to 5% in patients without DM.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Nevertheless there is ongoing debate on the cost effectiveness of the general population based screening for renal disease (3). A cost-effectiveness analysis of screening for CKD by ACR has been performed by Hoerger TJ et al (4). Universal annual screening starting at age 50 years has a cost-effectiveness ratio of $73,000/QALY relative to no screening and $145,000/QALY relative to usual care. Cost-effectiveness ratios improved with longer screening intervals. Relative to no screening, targeted annual screening has cost-effectiveness ratios of $21,000/QALY, $55,000/QALY, and $155,000/QALY for persons with diabetes, those with hypertension, and those with neither current diabetes nor current hypertension, respectively. Screening the population in the absence of known risk factors such as diabetes or hypertension is not cost effective, unless it can be done within usual care practice (4).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Detection of chronic kidney disease (CKD) requires quantitative evaluation of both renal function (for stages 2 to 5) and proteinuria (for stages 1 and 2). Presence of proteinuria is an independent marker of progression of renal failure at all levels of renal function (5). Cost effectiveness may be improved by confining screening to high risk populations identified as having predisposition for CKD or individuals having abnormal results using cheaper “pre-screening” tests such as dip stick urinalysis. Van der Velde has examined three difference approaches to screening, to determine whether the use of urinary albumin measurement would be be efficient than screening according to known risk factors for CKD. They reviewed the sensitivity and number needed to screen for different strategies using the same population data (3398 patients with 7 year follow-up). During this period, only screening for urinary albumin concentration, similar to an ACR, was able to detect patients with CKD who had both significantly accelerated renal function loss and increased cardiovascular risk compared to subjects without CKD (6).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Bang et al. (2007) (7) have developed a simple model for prediction of occult CKD based upon demographic parameters and the presence of various health conditions such as hypertension, diabetes and peripheral vascular disease. Iseki (2006) (8) and Iseki et al (9, 10)&amp;nbsp;have examined mass screening data from Okinawa&amp;nbsp; and have shown changes in the demographic characteristics of Japanese patients with CKD between 1993 and 2003. Dipstick positive proteinuria and both high systolic and diastolic blood pressure were useful to identify individuals at risk of developing progressive CKD. Another study demonstrated that overweight and obesity were strong independent predictors of increased risk of CKD in Japanese individuals (11).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Albuminuria of greater than 30 mg/day is one of the criteria for CKD but this requires collection of a 24 hour urine sample which is expensive, inconvenient and may lead to inaccuracy due to incomplete collection. Two studies have examined the effectiveness of pre screening using spot urine sample for albumin concentration or albumin creatinine ratios (12,13). Of note, both studies found the diagnostic performance of assessment of the albumin concentration and the albumin:creatinine ratio comparable. From an economic perspective this is an important observation. In order to keep costs involved in mass screening for micro-albuminuria as low as possible, it was therefore proposed that pre-screening should take place by measuring only albumin concentration in a spot morning urine sample.&amp;nbsp; Based on this finding, the 2008 NICE guidelines (14) on the early identification, diagnosis and management of CKD recommended the use of ACR for identification of non-diabetic renal disease, based on the hypothesis that CKD would behave like diabetic nephropathy, such that overt proteinuria is almost always preceeded by microalbuminuria, and thus an abnormal ACR would identify non-diabetic CKD. The evidence of lowering of proteinuria with ACEi and ARBs is strongest with levels of proteinuria &amp;gt;1g/24 hrs. Methven &lt;EM&gt;et al.&lt;/EM&gt; (15)&lt;EM&gt; &lt;/EM&gt;&amp;nbsp;examined a cohort of 6842 patients by measuring ACR, PCR and a 24 hr timed urine collection. PCR correlated with total 24 hour proteinuria, with a higher sensitivity (94%) with threshold 100 mg/mmol but lower specificity (88%) than ACR of 70 mg/mmol to predict total protein loss &amp;gt;1g/24 hrs. The diagnostic performance of both tests varied with age and gender, which should be taken into account when interpreting results. Total proteinuria cannot be adequately predicted by ACR in non-diabetic renal disease [NDT, 2010].&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The approach that may fit best with the potential changes to the CKD classification is to use the combination of both eGFR and urinary albumin clearance to determine risk of progressive CKD. Hallen &lt;EM&gt;et al.&lt;/EM&gt; (16)&amp;nbsp;analyzed data from 65,589 adults who participated in the Nord-Trøndelag Health (HUNT 2) Study (1995 to 1997) and found 124 patients who progressed to ESRD after 10.3 yr of follow-up. In multivariable survival analysis, estimated GFR (eGFR) and albuminuria were independently and strongly associated with progression to ESRD: Hazard ratios for eGFR 45 to 59, 30 to 44, and 15 to 29 ml/min per 1.73 m2 were 6.7, 18.8, and 65.7, respectively (P &amp;lt; 0.001 for all), and for micro- and macroalbuminuria were 13.0 and 47.2 (P &amp;lt; 0.001 for both).&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Halbesma N, Kuiken DS, Brantsma AH, Bakker S, et al. "Macroalbuminuria is a better risk marker than low estimated GFR to identify individuals at risk for accelerated GFR loss in population screening." Journal of the American Society of Nephrology 2006;17(9):2582-90. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Macroalbuminuria%20is%20a%20better%20risk%20marker%20than%20low%20estimated%20GFR%20to%20identify%20individuals%20at%20risk%20for%20accelerated%20GFR%20loss%20in%20population%20screening" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Plantinga LC, Crews DC, Coresh J et al. "Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes." Clin J Am Soc Nephrol 2010; 5: 673-682. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20338960" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;de Jong PE, Halbesma N, Gansevoort RT. "Screening for early chronic kidney disease - What method fits best?" Nephrology Dialysis Transplantation 2006;21(9):2358-61. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Screening%20for%20early%20chronic%20kidney%20disease%20-%20What%20method%20fits%20best%3F" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hoerger TJ, Wittenborn JS, Segel JE, Burrows NR, Imai K, Eggers P, Pavkov ME, Jordan R, Hailpern SM, Schoolwerth AC, Williams DE; Centers for Disease Control and Prevention CKD Initiative. "A health policy model of CKD: 2. The cost-effectiveness of microalbuminuria screening." Am J Kidney Dis. 2010 Mar;55(3):463-73. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=A%20health%20policy%20model%20of%20CKD%3A%202.%20The%20cost-effectiveness%20of%20microalbuminuria%20screening" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Halbesma N, Kuiken DS, Brantsma AH, Bakker S, et al. "Macroalbuminuria is a better risk marker than low estimated GFR to identify individuals at risk for accelerated GFR loss in population screening." Journal of the American Society of Nephrology 2006;17(9):2582-90. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Macroalbuminuria%20is%20a%20better%20risk%20marker%20than%20low%20estimated%20GFR%20to%20identify%20individuals%20at%20risk%20for%20accelerated%20GFR%20loss%20in%20population%20screening" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Van der Velde M, De Jong P, Gansevoort RT. "Comparision of the yield of different screening approaches to detect chronic kidney disease." Nephrol Dial Transplant 2010&amp;nbsp;Mar 24 (Epub ahead of print)&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Comparision%20of%20the%20yield%20of%20different%20screening%20approaches%20to%20detect%20chronic%20kidney%20disease" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Bang H, Vupputuri S, Shoham D, A, Klemmer P, J, et al. "SCreening for Occult REnal Disease (SCORED): A simple prediction model for chronic kidney disease." Archives of Internal Medicine 2007;167(4):374-81. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=SCreening%20for%20Occult%20REnal%20Disease%20%28SCORED%29%3A%20A%20simple%20prediction%20model%20for%20chronic%20kidney%20disease" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Iseki K. "Screening for renal disease - What can be learned from the Okinawa experience." Nephrology Dialysis Transplantation 2006;21(4):839-43. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Screening%20for%20renal%20disease%20-%20What%20can%20be%20learned%20from%20the%20Okinawa%20experience" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Iseki K, Kohagura K, Sakima A, Iseki C, Kinjo K, Ikemiya Y, et al. "Changes in the demographics and prevalence of chronic kidney disease in Okinawa, Japan (1993 to 2003). "Hypertens Res 2007 Jan;30(1):55-62. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Changes%20in%20the%20demographics%20and%20prevalence%20of%20chronic%20kidney%20disease%20in%20Okinawa%2C%20Japan%20%281993%20to%202003%29" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Iseki K, Iseki C, Ikemiya Y, Kinjo K, Takishita S. "Risk of developing low glomerular filtration rate or elevated serum creatinine in a screened cohort in Okinawa, Japan." Hypertens Res 2007 Feb;30(2):167-74. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Risk%20of%20developing%20low%20glomerular%20filtration%20rate%20or%20elevated%20serum%20creatinine%20in%20a%20screened%20cohort%20in%20Okinawa%2C%20Japan" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Ishizaka N, Ishizaka Y, Toda E, Koike K, Seki G, Nagai R, et al. "Association between obesity and chronic kidney disease in Japanese: differences in gender and hypertensive status?" Hypertens Res 2007 Nov;30(11):1059-64. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Association%20between%20obesity%20and%20chronic%20kidney%20disease%20in%20Japanese%3A%20differences%20in%20gender%20and%20hypertensive%20status%3F" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Jafar TH, Chaturvedi N, Hatcher J, Levey AS. "Use of albumin creatinine ratio and urine albumin concentration as a screening test for albuminuria in an Indo-Asian population." Nephrology Dialysis Transplantation 2007;22(8):2194-200. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=%22Use%20of%20albumin%20creatinine%20ratio%20and%20urine%20albumin%20concentration%20as%20a%20screening%20test%20for%20albuminuria%20in%20an%20Indo-Asian%20population" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Gansevoort RT, Verhave JC, Hillege HL, et al. for the PREVEND Study Group. "The validity of screening based on spot morning urine samples to detect subjects with microalbuminuria in the general population." Kidney Int Suppl (2005) 94:S28–S35. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=The%20validity%20of%20screening%20based%20on%20spot%20morning%20urine%20samples%20to%20detect%20subjects%20with%20microalbuminuria%20in%20the%20general%20population" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;NICE CKD: Guideline (September 2008): Chronic kidney disease: early identification and management of chronic kidney disease in adults in primary and secondary care. [&lt;A href="http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=294680" target="_blank"&gt;Link to NICE guideline&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Methven S, Macgregor MS, Traynor JP, O'Reilly DS, Deighan CJ. "Assessing proteinuria in chronic kidney disease: protein-creatinine ratio versus albumin-creatinine ratio." Nephrol Dial Transplant. 2010 Mar 17. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Assessing%20proteinuria%20in%20chronic%20kidney%20disease%3A%20protein-creatinine%20ratio%20versus%20albumin-creatinine%20ratio" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hallen SI, Ritz E, Lydersen S, Romundstad S, Kvenild K, Orth SR. "Combining GFR and albuminuria to classify CKD improves prediction of ESRD." J Am Soc Nephrol. 2009 May;20(5):1069-77. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19357254" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <expiryDate>18/05/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>375012</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=375012]]&gt;</url>
    <title>2010 Annual Evidence Update on Proteinuria and eGFR: 3 e. eGFR as a marker of renal function</title>
    <publicationDate>2010-05-24T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EGFR,CREATININE,CREATININE CLEARANCE,GFR AND EGFR,SCREENING OPTIONS,SCREENING TESTS,ASSESSMENT TESTS,ASSESSMENT OF RENAL FUNCTION,PROTEINURIA/ NEPHROTIC SYNDROME,PRESENTATION OF CKD,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Proteinuria and eGFR: 3 e. eGFR as a marker of renal function&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;&lt;A href="nelh:372689:0" name=internalLink&gt;&lt;STRONG&gt;Link back to 2010 AEU on Proteinuria and eGFR: contents page&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;The original commentary, written for the 2008 National Knowledge Week on Proteinuria and eGFR, has been updated for the 2010 AEU by Ed Sharples, Consultant in Nephrology and Transplant Medicine, Churchill Hospital, Oxford, and specialist collection clinical lead. &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The gold standard for measurement of renal function is the glomerular filtration rate (GFR). Its precise measurement using isotopic clearances is expensive and inconvenient. Serum creatinine concentration is easy to measure and related to the GFR but cannot be used in isolation to determine renal function because it is also influenced by muscle mass. The relationship with GFR is exponential reducing diagnostic sensitivity at less severe levels of renal impairment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Several mathematical formulae have been developed to estimate GFR (eGFR) from the creatinine concentration and parameters such as the patient’s age and sex. The most widely used are the Cockcroft Gault (CG) (1) and the Modification of Diet in Renal Disease (MDRD) (2) formulae though many others exist. CG was originally validated against creatinine clearance as the gold standard whereas MDRD was developed using iothalamate determined GFR. Creatinine clearance is inevitably higher than true GFR because creatinine is cleared by tubular secretion as well as filtration. Subsequent studies have shown that CG tends to overestimate renal function especially at lower levels (3) whilst MDRD underestimates GFR particularly at near normal levels of function.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;eGFR is inaccurate in situations where the renal function is changing such as developing or recovering acute renal failure. The formulae have not been shown to be accurate in children, pregnancy, liver disease, heart failure and after transplantation.&amp;nbsp; The tendency of MDRD to underestimate GFR at near normal levels of renal function has raised concerns about its routine use as a screening tool.&amp;nbsp; Ethnicity may influence eGFR. The MDRD requires adjustment in African Caribbean populations because it underestimates GFR by 20%. It appears to be accurate in Chinese populations (4). &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Despite these inaccuracies, the MDRD formula was recommended by the DOH to be reported alongside all hospital and primary care serum creatinine measurements. The 2008 NICE guidelines on the early recognition, diagnosis and management of CKD uses the eGFR for screening and classification of CKD (5). This approach has led to a great deal of discussion, and the recent KDIGO controversies meeting has set up a working group to review the classification system for CKD.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Botev &lt;EM&gt;et al.&lt;/EM&gt; (6)&amp;nbsp;utilized patient data from 10 previous studies on calculated GFR to determine bias, accuracy and sensitivity of both creatinine clearance by Cockcroft-Gault, estimated GFR using the MDRD equation and measured GFR by inulin clearance in 2208 European adults (46% women, 1.4% Caribbean blacks), with and without CKD, and mean mGFR 72.4 ± 39.0 (range 2.2 to 177.2) ml/min/1.73 m2. Overall, the CG and MDRD formulas showed bias (mean difference) –3.5 ml/min/1.73 m2 (5.3%), P &amp;lt; 0.001, and –9.8 ml/min/1.73 m2 (–6.4%), P &amp;lt; 0.001; precision (SD of bias) 21.5 ml/min/1.73 m2 (43.1%) and 20.0 ml/min/1.73 m2 (33.0%); limits of agreement (2 SD by Bland–Altman method) 39.5 to –46.5 (range 86.0) ml/min/1.73 m2 and 30.2 to –49.8 (range 80.0) ml/min/1.73 m2; and accuracy within ±30% of mGFR 70.8 and 69.0%, respectively. Both formulas showed a trend for decreasing accuracy with lower mGFR levels. According to the Kidney Disease Outcomes Quality Initiative (K/DOQI)-CKD classification's five GFR groups, the CG and MDRD formulas properly assigned 61.6 and 57.1% of the entire population and had a range of positive predictive values 42.6 to 81.8% and 39.6 to 85.2% and of negative predictive values 81.7 to 96.6% and 76.4 to 97.5%, respectively (6).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Andrew Levey has continued to develop formulae for estimated GFR aiming for greater accuracy and specificity. The CKD-EPI equation performed better than the Modification of Diet in Renal Disease Study equation, especially at higher GFR (P &amp;lt; 0.001 for all subsequent comparisons), with less bias (median difference between measured and estimated GFR, 2.5 vs. 5.5 mL/min per 1.73 m2), improved precision (interquartile range [IQR] of the differences, 16.6 vs. 18.3 mL/min per 1.73 m2), and greater accuracy (percentage of estimated GFR within 30% of measured GFR, 84.1% vs. 80.6%). In NHANES, the median estimated GFR was 94.5 mL/min per 1.73 m2 (IQR, 79.7 to 108.1) vs. 85.0 (IQR, 72.9 to 98.5) mL/min per 1.73 m2, and the prevalence of chronic kidney disease was 11.5% (95% CI, 10.6% to 12.4%) versus 13.1% (CI, 12.1% to 14.0%) (7).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;References 2010&lt;/STRONG&gt; &lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Cockcroft DW, Gault MH. "Prediction of creatinine clearance from serum creatinine." Nephron 1976; 16: 31–41. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Cockcroft%20DW[author]%20AND%20Prediction%20of%20creatinine%20clearance%20from%20serum%20creatinine" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Levey AS, Greene T, Kusek JW, Beck GJ. "Simplified equation to predict glomerular filtration rate from serum creatinine." J Am Soc Nephrol 2000; 11: 155A.&amp;nbsp; [No abstract available]&lt;/LI&gt;
&lt;LI&gt;Lin J, Knight EL, Hogan ML, Singh AK. "A comparison of prediction equations for estimating glomerular filtration rate in adults without kidney disease." J Am Soc Nephrol 2003; 14: 2573–2580. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=A%20comparison%20of%20prediction%20equations%20for%20estimating%20glomerular%20filtration%20rate%20in%20adults%20without%20kidney%20disease" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Dong X, He M, Song X, Lu B, Yang Y, Zhang S, et al. "Performance and comparison of the Cockcroft-Gault and simplified Modification of Diet in Renal Disease formulae in estimating glomerular filtration rate in a Chinese Type 2 diabetic population." Diabetic Medicine 2007;24(12):1482-6. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Performance%20and%20comparison%20of%20the%20Cockcroft-Gault%20and%20simplified%20Modification%20of%20Diet%20in%20Renal%20Disease%20formulae%20in%20estimating%20glomerular%20filtration%20rate%20in%20a%20Chinese%20Type%202%20diabetic%20population" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;NICE CKD: Guideline (September 2008): Chronic kidney disease: early identification and management of chronic kidney disease in adults in primary and secondary care. [&lt;A href="http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=294680" target="_blank"&gt;Link to NICE guideline&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Botev R, Mallie JP, Couchoud C, Schuck O, Fauvel JP, Wetzels JF, Lee N, De Santo NG, Cirillo M. "Estimating glomerular filtration rate: Cockcroft-Gault and Modification of Diet in Renal Disease formulas compared to renal inulin clearance." Clin J Am Soc Nephrol. 2009 May;4(5):899-906. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19406960" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. "A new equation to estimate glomerular filtration rate." Ann Intern. Med. 2009 May5;150(9):604-12. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=%22Annals%20of%20internal%20medicine%22[Jour]%20AND%202009[pdat]%20AND%20Levey[author]" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Additional useful references&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Ibrahim HN, Rogers T, Tello A, Matas A. "The performance of three serum creatinine-based formulas in estimating GFR in former kidney donors." Am J Transplant 2006 Jun;6(6):1479-85. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=The%20performance%20of%20three%20serum%20creatinine-based%20formulas%20in%20estimating%20GFR%20in%20former%20kidney%20donors" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Rule AD. "Understanding estimated glomerular filtration rate: implications for identifying chronic kidney disease." Curr Opin Nephrol Hypertens 2007 May;16(3):242-9. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Understanding%20estimated%20glomerular%20filtration%20rate%3A%20implications%20for%20identifying%20chronic%20kidney%20disease" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <expiryDate>21/05/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>375014</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=375014]]&gt;</url>
    <title>2010 Annual Evidence Update on Proteinuria and eGFR: 3 f. eGFR as a screening tool</title>
    <publicationDate>2010-05-24T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ PRESENTATION OF CKD,PROTEINURIA/ NEPHROTIC SYNDROME,ASSESSMENT OF RENAL FUNCTION,ASSESSMENT TESTS,SCREENING TESTS,SCREENING OPTIONS,GFR AND EGFR,CREATININE CLEARANCE,CREATININE,EGFR,ADULT,SCREENING,NOT ROUTINELY OFFERED,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Proteinuria and eGFR: 3 f. eGFR as a screening tool&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;STRONG&gt;&lt;A href="nelh:372689:0" name=internalLink&gt;
&lt;P&gt;&lt;STRONG&gt;Link back to 2010 AEU on Proteinuria and eGFR: contents page&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;The original commentary, written for the 2008 National Knowledge Week on Proteinuria and eGFR, has been updated for the 2010 AEU by Ed Sharples, Consultant in Nephrology and Transplant Medicine, Churchill Hospital, Oxford, and specialist collection clinical lead. &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Detection of asymptomatic renal disease is important because it is associated with an increased incidence of cardiovascular disease (1, 2). Attention to cardiovascular risk factors in this population may reduce the risk of vascular events and allow interventions to slow the rate of progression of renal failure.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;A reduction in glomerular filtration rate (GFR) is a sensitive indicator or renal disease though it is difficult and expensive to measure. The creatinine clearance determined from 24 hour urine and blood measurements approximates to GFR but is prone to error and inconvenient as it involves 24 hour urine collections (3). Creatinine concentration alone is a poor predictor of renal function because of its dependence upon an individuals muscle mass as well as renal function. Development of estimated GFR (eGFR) calculations based upon the creatinine and patient characteristics such as age and sex have allowed more accurate identification and classification of CKD from a single creatinine measurement. Two formulae have been widely used (4). The earlier Cockcroft Gault formula tends to overestimate eGFR especially in individuals with renal impairment and the MDRD generally underestimates eGFR particularly in individuals with near normal renal function. Use of eGFR allows early detection of renal disease and categorisation into stages of chronic kidney disease. The ease of calculation of eGFR raises the possibility of population screening renal disease.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Population studies show a prevalence of significantly reduced eGFR (&amp;lt; 60 ml/min/1.73m&lt;SUP&gt;2&lt;/SUP&gt;) in about 5% of the population (2, 5, 6). As long as 20 years ago (3) it was proposed that the laboratory computers could be used to calculate eGFR from serum creatinine measurements using the age and sex information contained on the request form. More recently the National Service Framework for renal services recommended use of the MDRD formula for calculation of eGFR routinely when creatinine was reported (7).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The cost effectiveness of population screening is not established. Black &lt;EM&gt;et al. &lt;/EM&gt;(8)&amp;nbsp;have performed a systematic review focusing on cost effectiveness and clinical effectiveness of early management strategies after identification of reduced eGFR on screening. From 36 relevant natural history studies, CKD was found to be, despite marked heterogeneity between studies, a marker of increased risk of mortality, renal progression and end-stage renal disease. Mortality was generally high and increased with stage of CKD. After adjustment for comorbidities, the relative risk of mortality among those with CKD identified from the general population increased with stage. For clinical populations, the relative risk was higher. All three outcomes increased as eGFR fell. Only seven studies, and no randomised controlled trials, were identified as relevant to assessing the clinical effectiveness of early referral strategies for CKD. In the five retrospective studies constructed from cohorts starting on renal replacement therapy (RRT), mortality was reduced in the early referral group (more than 12 months prior to RRT) even as late as 5 years after initiation of RRT. Only two studies included predialysis participants. One study, in people screened for diabetic nephropathy, reported a reduction in the decline in renal function associated with early referral to nephrology specialists (eGFR decline 3.4 ml/min/1.73 m&lt;SUP&gt;2&lt;/SUP&gt;) when compared with a similar group that had no access to nephrology services until dialysis was required (eGFR decline 12.0 ml/min/1.73 m&lt;SUP&gt;2&lt;/SUP&gt;). The second study, among a group of veterans with two creatinine levels of at least 140 mg/dl, reported that a composite end point of death or progression was lower in the group receiving nephrology follow-up than in those receiving only primary care follow-up. The greatest effect was observed in those with stage 3 or worse disease after adjustment for comorbidities, age, race, smoking and proteinuria {stage 3: hazard ratio (HR) 0.8 [95% confidence interval (CI) 0.61 to 0.9)]; stage 4: HR 0.75 (95% CI 0.45 to 0.89)}. In the base-case analysis, all early referral strategies produced more quality-adjusted life-years (QALYs) than referral upon transit to stage 5 CKD (eGFR 15 ml/min/1.73 m&lt;SUP&gt;2&lt;/SUP&gt;). Referral for everyone with an eGFR below 60 ml/min/1.73 m&lt;SUP&gt;2&lt;/SUP&gt; (stage 3a CKD) generated the most QALYs and, compared with referral for stage 4 CKD (eGFR &amp;lt; 30 ml/min/1.73 m&lt;SUP&gt;2&lt;/SUP&gt;), had an incremental cost-effectiveness ratio of approximately 3806 pounds per QALY.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Guidance&amp;nbsp;from the National Institute of Clinical Excellence (6) suggests that eGFR should be measured in high risk patients including all people with diabetes, hypertension, cardiovascular disease, family history of CKD stage 5, known structural renal tract disease such as stones, incidental urine sediment abnormality or know use of nephrotoxic drugs. Hallan et al (9) suggested screening of people with hypertension, diabetes or aged over 55 was most effective. The NEOERICA study (2) showed that many patients at risk already had creatinine estimate on file and that reduced eGFR is easily detected in existing computerised records. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The impact of screening primary care populations with eGFR reporting on nephrology services has been reviewed by Hemmelgarn &lt;EM&gt;et al &lt;/EM&gt;(10). In a community-based cohort study (N = 1,135,968) with time-series analysis. Participants were identified from a laboratory registry in Alberta, Canada, and followed up from May 15, 2003, to March 14, 2007 (with estimated GFR reporting implemented October 15, 2004). Following estimated GFR reporting, the rate of first outpatient visits to a nephrologist for patients with chronic kidney disease (CKD; estimated GFR &amp;lt;60 mL/min/1.73 m(2)) increased by 17.5 (95% confidence interval [CI], 16.5-18.6) visits per 10,000 CKD patients per month, corresponding to a relative increase from baseline of 68.4% (95% CI, 65.7%-71.2%). There was no association between estimated GFR reporting and rate of first nephrologist visit among patients without CKD. Among patients with an estimated GFR of less than 30 mL/min/1.73 m&lt;SUP&gt;2&lt;/SUP&gt;, the rate of first nephrologist visits increased by 134.4 (95% CI, 60.0-208.7) visits per 10,000 patients per month. This increase was predominantly seen in women, patients aged 46 to 65 years as well as those aged 86 years or older, and those with hypertension, diabetes, and comorbidity. Reporting of estimated GFR was not associated with increased rates of internal medicine or general practitioner visits or increased use of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers among patients with CKD and proteinuria or the subgroup limited to patients with diabetes. Reporting of estimated GFR was associated with an increase in first nephrologist visits, particularly among patients with more severe kidney dysfunction, women, middle-aged and very elderly patients, and those with comorbidities. Any effect on outcomes remains to be shown.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Patients with reduced GFR are at risk of acute renal failure following radiological contrast eGFR and screening for patients prior to contrast studies has been advocated (11). &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;eGFR does not work in a variety of well defined circumstances including, in children, during pregnancy, following transplantation and when renal function is changing (3, 12). A fixed eGFR cut off point has been advocated to diagnose chronic kidney disease but Poggio and Rule (13) have noted the decline in eGFR with age and female sex in otherwise healthy individuals and have proposed that age and gender specific reference values be developed.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Halbesma N, Kuiken DS, Brantsma AH, Bakker SJ, Wetzels JF, De ZD, et al. "Macroalbuminuria is a better risk marker than low estimated GFR to identify individuals at risk for accelerated GFR loss in population screening." J Am Soc Nephrol 2006;17(9):2582-90. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Macroalbuminuria%20is%20a%20better%20risk%20marker%20than%20low%20estimated%20GFR%20to%20identify%20individuals%20at%20risk%20for%20accelerated%20GFR%20loss%20in%20population%20screening" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Stevens PE, O'Donoghue D, J, de LS, Van VJ, et al. "Chronic kidney disease management in the United Kingdom: NEOERICA project results." Kidney International 2007;72(1):92-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Chronic%20kidney%20disease%20management%20in%20the%20United%20Kingdom%3A%20NEOERICA%20project%20results" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Smith SA. "Estimation of glomerular filtration rate from the serum creatinine concentration." Postgrad Med J 1988; 64: 204 208.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/3174538" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;de Jong PE, Halbesma N, Gansevoort R, T. "Screening for early chronic kidney disease - What method fits best?" Nephrology Dialysis Transplantation 2006;21(9):2358-61.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Screening%20for%20early%20chronic%20kidney%20disease%20-%20What%20method%20fits%20best%3F" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Zhang L, Zuo L, Xu G, Wang F, Wang M, Wang S, et al. "Community-based screening for chronic kidney disease among populations older than 40 years in Beijing."&amp;nbsp;Nephrol Dial Transplant 2007 Apr;22(4):1093-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Community-based%20screening%20for%20chronic%20kidney%20disease%20among%20populations%20older%20than%2040%20years%20in%20Beijing" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;NICE CKD: Guideline (September 2008): Chronic kidney disease: early identification and management of chronic kidney disease in adults in primary and secondary care. [&lt;A href="http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=294680" target="_blank"&gt;Link to NICE guideline&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Department of Health (2005): National Service Framework for renal services part two: chronic kidney disease, acute renal failure and end of life care [&lt;A href="http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4113505.pdf" target="_blank"&gt;link to NSF&lt;/A&gt;&amp;nbsp;- dpwnload the document as a PDF]&lt;/LI&gt;
&lt;LI&gt;Black C, Sharma P, Scotland G, McCullough K, McGurn D, Robertson L, Fluck N, MacLeod A, McNamee P, Prescott G, Smith C. "Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis." Health Technol Assess. 2010 Apr;14(21):1-184.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Early%20referral%20strategies%20for%20management%20of%20people%20with%20markers%20of%20renal%20disease%3A%20a%20systematic%20review%20of%20the%20evidence%20of%20clinical%20effectiveness%2C%20cost-effectiveness%20and%20economic%20analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hallan SI, Dahl K, Oien CM, Grootendorst DC, Aasberg A, Holmen J, et al. "Screening strategies for chronic kidney disease in the general population: follow-up of cross sectional health survey." BMJ 2006 Nov 18;333(7577):1047.&amp;nbsp;&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Screening%20strategies%20for%20chronic%20kidney%20disease%20in%20the%20general%20population%3A%20follow-up%20of%20cross%20sectional%20health%20survey" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hemmelgarn BR, Zhang J, Manns BJ, James MT, Quinn RR, Ravani P, Klarenbach SW, Culleton BF, Krause R, Thorlacius L, Jain AK, Tonelli M; Alberta Kidney Disease Network. "Nephrology visits and health care resource use before and after reporting estimated glomerular filtration rate." JAMA. 2010 Mar 24;303(12):1151-8&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Nephrology%20visits%20and%20health%20care%20resource%20use%20before%20and%20after%20reporting%20estimated%20glomerular%20filtration%20rate" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lameire N, Adam A, Becker CR, Davidson C, McCullough PA, Stacul F, et al. "Baseline renal function screening." Am J Cardiol 2006 Sep 18;98(6A):21K-6K.&amp;nbsp;&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Baseline%20renal%20function%20screening" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Leanos-Miranda A, Marquez-Acosta J, Romero-Arauz F, Cardenas-Mondragon GM, Rivera-Leanos R, et al. "Protein:creatinine ratio in random urine samples is a reliable marker of increased 24-hour protein excretion in hospitalized women with hypertensive disorders of pregnancy." Clinical Chemistry 2007;53(9):1623-8.&amp;nbsp;&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Protein%3Acreatinine%20ratio%20in%20random%20urine%20samples%20is%20a%20reliable%20marker%20of%20increased%2024-hour%20protein%20excretion%20in%20hospitalized%20women%20with%20hypertensive%20disorders%20of%20pregnancy" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Poggio ED &amp;amp; Rule AD. "Can we do better than a single estimated GFR threshold when screening for chronic kidney disease?" Kidney International 2007;72(5):534-6.&amp;nbsp;&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Can%20we%20do%20better%20than%20a%20single%20estimated%20GFR%20threshold%20when%20screening%20for%20chronic%20kidney%20disease%3F" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <expiryDate>21/05/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>375023</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=375023]]&gt;</url>
    <title>2010 Annual Evidence Update on Proteinuria and eGFR: 4 a. Managing cardiovascular risk factors in chronic kidney disease</title>
    <publicationDate>2010-05-24T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ INTERVENTIONS,BLOOD PRESSURE,OTHERS,PROTEINURIA/ NEPHROTIC SYNDROME,BLOOD PRESSURE,PREDISPOSING FACTORS,PRESENTATION OF CKD,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Proteinuria and eGFR: 4 a. Managing cardiovascular risk factors in chronic kidney disease&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;&lt;A href="nelh:372689:0" name=internalLink&gt;&lt;STRONG&gt;Link back to 2010 AEU on Proteinuria and eGFR: contents page&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;The original commentary, written for the 2008 National Knowledge Week on Proteinuria and eGFR, has been updated for the 2010 AEU by Ed Sharples, Consultant in Nephrology and Transplant Medicine, Churchill Hospital, Oxford, and specialist collection clinical lead. &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;There are a number of guidelines on the management of CKD, which discuss the ways in which CV risk in CKD can be managed. These include guidelines from the Royal College of Physicians/Renal Association (2006) (1) and NICE guidance (2008) (2) on the early identification and management of adults with CKD in primary and secondary care.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Twenty-nine papers have been identified for this evidence review, although a small number of papers found that early interventions, such as correction of anaemia (3) did not reduce cardio-vascular risk. The TREAT study was a placebo controlled study with erythropoietin in patients with type 2 diabetes, CKD and anaemia (4). There was no significant benefit in cardiovascular outcomes, and a higher incidence of CVA in the ESA treated group. A recent meta-analysis systematically reviewed the randomized controlled trial (RCT) data on HQOL for patients treated with low to intermediate (9.0-12.0 g/dL) and high hemoglobin target levels (&amp;gt;12.0 g/dL) and performed a meta-analysis of all available 36-item short-form (SF-36) RCT data. METHODS: We conducted a search to identify all RCTs of ESA therapy in patients with anemia associated with CKD (1966-December 2006). Inclusion criteria were [1] 30 or more participants, [2] anemic adults with CKD, [3] epoetin (alfa and beta) or darbepoetin used, [4] a control arm, and [5] reported HQOL using a validated measure. All available SF-36 data underwent meta-analysis using the weighted mean difference. RESULTS: Of 231 full texts screened, 11 eligible studies were identified. The SF-36 was used in 9 trials. Reporting of these data was generally incomplete. Data from each domain of the SF-36 were summarized. Statistically significant changes were noted in the physical function (weighted mean difference [WMD], 2.9; 95% confidence interval [CI], 1.3 to 4.5), general health (WMD, 2.7; 95% CI, 1.3 to 4.2), social function (WMD, 1.3; 95% CI, -0.8 to 3.4), and mental health (WMD, 0.4; 95% CI, 0.1 to 0.8) domains. None of the changes would be considered clinically significant.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Norris et al (5) reporting on the AASK trial, identified that neither class of antihypertensive therapy nor BP level had a significant effect on the occurrence of CV events, but this might have been due to limited power of the study. However, they hypothesised that their analysis did identify unique and potentially modifiable CV risk factors, such as urine PCR, in this high-risk cohort. In a review of CV complications of CKD (6) it was suggested that current guidelines for cardiovascular risk reduction in CKD patients are based on knowledge of the benefits of such strategies in the general population. These strategies include targeting hypertension and hypercholesterolaemia.&amp;nbsp; Current opinion is that controlling blood pressure is the most important intervention to reduce cardiovascular disease risk in all CKD patients (6).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;While there are some data to support this approach in patients with stages 1-3 CKD, randomized controlled trials in stage 5 CKD patients receiving dialysis have failed to confirm that well-established cardioprotective therapies (such as statins and angiotensin II converting enzyme inhibitors) are necessarily beneficial. Draft NICE guidance (2) recommends that the use of statin therapy for primary prevention of CVD in people with CKD should not differ from its use in people without CKD, and should be based on existing risk tables recommended for people with and without diabetes. However it should be noted that Framingham risk tables significantly underestimate risk in people with early CKD.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;A Cochrane review of the use of statins in patients with CKD has now been published (7).Twenty six studies (25,017 participants) comparing statins with placebo were identified. Total cholesterol decreased significantly with statins (18 studies, 1677 patients: MD -41.48 mg/dL, 95% CI -49.97 to -33.99). Similarly, LDL cholesterol decreased significantly with statins (16 studies, 1605 patients: MD -42.38 mg/dL, 95% CI -50.71 to -34.05). Statins decreased both the risk of all-cause (21 RCTs, 18,781 patients, RR 0.81, 95% CI 0.74, 0.89) and cardiovascular deaths (20 studies, 18,746 patients: RR 0.80, 95% CI 0.70 to 0.90). Statins decreased 24-hour urinary protein excretion (6 studies, 311 patients: MD -0.73 g/24 h, 95% CI -0.95 to -0.52), but there was no significant improvement in creatinine clearance - a surrogate marker of renal function (11 studies, 548 patients: MD 1.48 mL/min, 95% CI -2.32 to 5.28).The incidence of rhabdomyolysis, elevated liver enzymes and withdrawal rates due to adverse events (well known complications of statins use), were not significantly different between patients receiving statins and placebo. AUTHORS' CONCLUSIONS: Statins significantly reduced the risk of all-cause and cardiovascular mortality in CKD patients who are not receiving renal replacement therapy. They do not impact on the decline in renal function as measured by creatinine clearance, but may reduce protein excretion in urine. Statins appear to be safe in this population. Guidelines recommendations on hyperlipidaemia management in CKD patients could therefore be followed targeting higher proportions of patients receiving a statin, with appropriate monitoring of adverse events.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;With respect to lifestyle modification and CV risk, NICE guidance (2008) concluded that although the evidence on the effects of smoking on the risk of progression of CKD was not conclusive it was sufficiently suggestive to merit highlighting within a recommendation. The guideline development group agreed however that the evidence on the effects of obesity on the risk of progression was unconvincing.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;In summary, health care professionals should pay attention to controlling blood pressure and cholesterol, whilst people with CKD should be encouraged to take exercise, achieve a healthy weight and stop smoking.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Royal College of Physicians. Chronic kidney diseases in adults: UK guidelines for identification, management and referral. London: UK: 2006. [&lt;A href="https://rmsadmin.library.nhs.uk/admin/wizards/articles/www.rcplondon.ac.uk/pubs/contents/57f485dc-4730-4b2d-be90-fa6937cc15af.pdf" target="_blank"&gt;link to guidelines&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;NICE CKD guidance: Early identification and management of adults with chronic kidney disease in primary and secondary care. 2008 [&lt;A href="http://guidance.nice.org.uk/CG73" target="_blank"&gt;link to guidelines&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Drueke TB, Locatelli F, Clyne N, Eckardt KU, et al. "Normalization of haemoglobin level in patients with chronic kidney disease and anemia." New England Journal of Medicine 2006;355(20):2071-84. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17108342" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R; TREAT Investigators. "A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease." N Engl J Med. 2009 Nov 19;361(21):2019-32. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=A%20trial%20of%20darbepoetin%20alfa%20in%20type%202%20diabetes%20and%20chronic%20kidney%20disease" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Norris K, Bourgoigne J, Gassman J, Hebert L, Middleton J, Phillips RA, et al. "Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial." American Journal of Kidney Diseases : the official journal of the National Kidney Foundation 2006;48(5):739-51. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Cardiovascular%20outcomes%20in%20the%20African%20American%20Study%20of%20Kidney%20Disease%20and%20Hypertension%20%28AASK%29%20Trial" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Wheeler DC. "Cardiovascular complications of chronic kidney disease." Medicine 2007;35(8):453-6. [&lt;A href="http://www.sciencedirect.com/science?_ob=ArticleURL&amp;amp;_udi=B82YB-4KY3VSX-5&amp;amp;_user=126524&amp;amp;_coverDate=06%2F01%2F2003&amp;amp;_rdoc=1&amp;amp;_fmt=high&amp;amp;_orig=search&amp;amp;_sort=d&amp;amp;_docanchor=&amp;amp;view=c&amp;amp;_searchStrId=1343807508&amp;amp;_rerunOrigin=google&amp;amp;_acct=C000010360&amp;amp;_version=1&amp;amp;_urlVersion=0&amp;amp;_userid=126524&amp;amp;md5=6c3d1a8c5874ee2f4bb6e748f034d2fd" target="_blank"&gt;Link to abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Navaneethan SD, Pansini F, Perkovic V, Manno C, Pellegrini F, Johnson DW, Craig JC, Strippoli GF. "HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis." Cochrane Database Syst Rev. 2009 Apr 15;(2):CD007784. [&lt;A href="nelh:312247:0" name=internalLink&gt;Link to Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <expiryDate>21/05/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>375024</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=375024]]&gt;</url>
    <title>2010 Annual Evidence Update on Proteinuria and eGFR: 4 b. Preventing new onset development of proteinuria in people with diabetes or hypertension</title>
    <publicationDate>2010-05-24T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ PRESENTATION OF CKD,PREDISPOSING FACTORS,DIABETES,BLOOD PRESSURE,PROTEINURIA/ NEPHROTIC SYNDROME,DIABETIC METABOLIC CONTROL,BLOOD PRESSURE,INTERVENTIONS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Proteinuria and eGFR: 4 b. Preventing new onset development of proteinuria in people with diabetes or hypertension&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;&lt;A href="nelh:372689:0" name=internalLink&gt;&lt;STRONG&gt;Link back to 2010 AEU on Proteinuria and eGFR: contents page&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;The original commentary, written for the 2008 National Knowledge Week on Proteinuria and eGFR, has been updated for the 2010 AEU by Ed Sharples, Consultant in Nephrology and Transplant Medicine, Churchill Hospital, Oxford, and specialist collection clinical lead. &lt;BR&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;All the evidence relating to proteinuria, hypertension and diabetes has recently been reviewed by the guideline development group for the NICE type 2 diabetes guideline which was published at the end of May 2008. (1)&amp;nbsp; They conclude that the prevention and management of diabetic nephropathy has not changed significantly from the NICE guideline of 2002 (2) and is similar in type 2 diabetes as in type 1 diabetes as outlined in the NICE guideline for type 1 diabetes in adults (2004) (3). The management centres around tight blood pressure control and renin-angiotensin system blockade. The new guideline (1) recommends maintaining blood pressure at or below 140/80 for everyone with type 2 diabetes and 130/80 for those with microalbuminuria or proteinuria. An ACE inhibitor (or ARB2 agent if ACE is not tolerated) should be the first line therapy for blood pressure control in someone with type 2 diabetes. Yearly screening for evidence for nephropathy using a first pass urine specimen for estimation of albumin: creatinine ratio, with repeat if positive is recommended, along with measuring serum creatinine and calculated eGFR. The group recognized some problems with reporting of eGFR using the MDRD (4-variable) equation in people with diabetes but could see no better alternative.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;In 2008,&amp;nbsp; 27 new articles relating to this question found in this annual evidence update the majority are concerned with the effects of ACE or ARB2 on blood pressure and proteinuria, and confirm the benefits described in guideline and reviews. There is a review and meta-analysis of the effects of statin therapy on improving renal outcomes, which concludes that statin therapy seems to reduce proteinuria modestly and results in a small reduction in the rate of kidney loss (4).&amp;nbsp;There are two papers that discuss the possible benefits that the glitazone drugs may have on proteinuria&amp;nbsp;(5, 6), &amp;nbsp;and one that discusses the role that aliskiren (7), the first orally active renin inhibitor might have on proteinuria.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;A study by Tu &lt;EM&gt;et al&lt;/EM&gt; (8) evaluated the effect of tightly controlling multiple factors, according to the recommendations of the American Diabetes Association (ADA), on the development and prevention of diabetic nephropathy in Chinese patients with type 2 diabetes mellitus and normoalbuminuria during a 4(1/2)-year period. This longitudinal cohort study enrolled 1290 patients with type 2 diabetes and normoalbuminuria who received intensified treatment to meet the following ADA recommended goals: hemoglobin A(1c )(HbA(1c)), less than 7%; systolic blood pressure, less than 130 mm Hg; diastolic blood pressure, less than 80 mm Hg; low-density lipoprotein cholesterol, less than 100 mg/dL; triglycerides, less than 150 mg/dL; and high-density lipoprotein cholesterol, greater than 40 mg/dL for men and greater than 50 mg/dL for women. During the study period, 211 patients (16.4%) developed new-onset microalbuminuria. A significant association was found between the achievement of ADA goals, including HbA(1c) level less than 7% (hazard ratio [HR], 0.729; 95% confidence interval [CI], 0.553-0.906; P = .03), systolic blood pressure less than 130 mm Hg (0.645; 0.491-0.848; P = .002), and high-density lipoprotein cholesterol level greater than 50 mg/dL for women and greater than 40 mg/dL for men (0.715; 0.537-0.951; P = .02) and the prevention of the development of new-onset microalbuminuria. Diabetic nephropathy can be delayed by tight simultaneous achievement of multiple ADA-recommended targets. This multifactorial intervention should be started in patients with diabetes and normoalbuminuria. Similar results of a primary care multiple target driven management of patients with diabetes and early proteinuria has been shown in the study by Hotu &lt;EM&gt;et al&lt;/EM&gt; (9).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The Randomised Olmesartan And Diabetes MicroAlbuminuria Prevention (ROADMAP) study is a placebo-controlled, multicentre, double-blind, parallel group study investigating the effect of the ARB, olmesartan, on the incidence of microalbuminuria (10). At the time of screening for the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) Study, the urinary albumin/creatinine ratio (UACR) was 0.44 mg/mmol in 4,449 type 2 diabetic patients. The independent correlates of UACR were analysed. RESULTS: Independent correlates of UACR during baseline were (in descending order): night-time systolic BP (r(s) = 0.19); HbA(1c) (r(s) = 0.18); mean 24 h systolic BP (r(s) = 0.16); fasting blood glucose (r(s) = 0.16); night-time diastolic BP (r(s) = 0.12); office systolic BP, sitting (r(s) = 0.11), standing (r(s) = 0.10); estimated GFR (r(s) = 0.10); heart rate, sitting (r(s) = 0.10); haemoglobin (r(s) = -0.10); triacylglycerol (r(s) = 0.09); and uric acid (r(s) = -0.08; all p &amp;lt;or= 0.001). Significantly higher albumin excretion rates were found for the following categorical variables: higher waist circumference (more marked in men); presence&amp;nbsp; of the metabolic syndrome; smoking (difference more marked in males); female sex; antihypertensive treatment; use of amlodipine; insulin treatment; family history&amp;nbsp; of diabetes; and family history of cardiovascular disease (more marked in women). The results of the study may be available later in 2010.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;NICE: Type 2 Diabetes Guideline; NICE London 2008 [&lt;A href="http://www.nice.org.uk/guidance/index.jsp?action=byID&amp;amp;o=11983" target="_blank"&gt;link to guideline&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;NICE: Management of Type 2 diabetes. Renal disease- prevention and early management; NICE London 2002 [&lt;A href="http://www.nice.org.uk/guidance/index.jsp?action=byID&amp;amp;o=10914" target="_blank"&gt;link to guideline&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;NICE: Diagnosis and management of type 1 diabetes in children, young people and adults CG15; NICE London 2004 [&lt;A href="http://www.nice.org.uk/guidance/index.jsp?action=byID&amp;amp;o=10944" target="_blank"&gt;link to guideline&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Sandhu S, Wiebe N, Fried LF, Tonelli M. "Statins for improving renal outcomes: a meta-analysis."&amp;nbsp;J Am Soc Nephrol 2006 Jul;17(7):2006-16. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Sandhu[author]%20AND%20Statins%20for%20improving%20renal%20outcomes%3A%20a%20meta-analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;(Bakris et al, 2006; Bakris GL, Ruilope LM, Mcmorn SO, Weston WM, Heise MA, Freed MI, et al. "Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria." Journal of Hypertension 2006;24(10):2047-55. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Rosiglitazone%20reduces%20microalbuminuria%20and%20blood%20pressure%20independently%20of%20glycemia%20in%20type%202%20diabetes%20patients%20with%20microalbuminuria" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Zheng F, Guan Y. "Thiazolidinediones: A novel class of drugs for the prevention of diabetic nephropathy?" Kidney International 2007;72(11):1301-3. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Thiazolidinediones%3A%20A%20novel%20class%20of%20drugs%20for%20the%20prevention%20of%20diabetic%20nephropathy%3F" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Gradman AH, Pinto R, Kad R. "Current concepts: renin inhibition in the treatment of hypertension." Current Opinion in Pharmacology 2008;8(2):120-6. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Current%20concepts%3A%20renin%20inhibition%20in%20the%20treatment%20of%20hypertension" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Tu ST, Chang SJ, Chen JF, Tien KJ, Hsiao JY, Chen HC, Hsieh MC. "Prevention of diabetic nephropathy by tight target control in an asian population with type 2 diabetes mellitus: a 4-year prospective analysis." Arch Intern Med. 2010 Jan 25;170(2):155-61. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Prevention%20of%20diabetic%20nephropathy%20by%20tight%20target%20control%20in%20an%20asian%20population%20with%20type%202%20diabetes%20mellitus%3A%20a%204-year%20prospective%20analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hotu C, Bagg W, Collins J, Harwood L, Whalley G, Doughty R, Gamble G, Braatvedt G; on behalf of the DEFEND investigators. "A community-based model of care improves blood pressure control and delays progression of proteinuria, left ventricular hypertrophy and diastolic dysfunction in Maori and Pacific patients with type 2 diabetes and chronic kidney disease: a randomized controlled trial." Nephrol Dial Transplant. 2010 Apr 6. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=A%20community-based%20model%20of%20care%20improves%20blood%20pressure%20control%20and%20delays%20progression%20of%20proteinuria%2C%20left%20ventricular%20hypertrophy%20and%20diastolic%20dysfunction%20in%20Maori%20and%20Pacific%20patients%20with%20type%202%20diabetes%20and%20chronic%20kidney%20disease%3A%20a%20randomized%20controlled%20trial" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Ritz E, Viberti GC, Ruilope LM, Rabelink AJ, Izzo JL Jr, Katayama S, Ito S, Mimran A, Menne J, Rump LC, Januszewicz A, Haller H. "Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study." Diabetologia. 2010 Jan;53(1):49-57. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Determinants%20of%20urinary%20albumin%20excretion%20within%20the%20normal%20range%20in%20patients%20with%20type%202%20diabetes%3A%20the%20Randomised%20Olmesartan%20and%20Diabetes%20Microalbuminuria%20Prevention%20%28ROADMAP%29%20study" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <expiryDate>21/05/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>375025</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=375025]]&gt;</url>
    <title>2010 Annual Evidence Update on Proteinuria and eGFR: 4 c. Preventing new onset development of proteinuria in people with CKD</title>
    <publicationDate>2010-05-24T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ INTERVENTIONS,OTHERS,SCREENING OPTIONS,SCREENING TESTS,PROTEINURIA/ NEPHROTIC SYNDROME,PREDISPOSING FACTORS,ASSESSMENT OF RENAL FUNCTION,PRESENTATION OF CKD,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Proteinuria and eGFR: 4 c. Preventing new onset development of proteinuria in people with CKD&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;&lt;A href="nelh:372689:0" name=internalLink&gt;&lt;STRONG&gt;Link back to 2010 AEU on Proteinuria and eGFR: contents page&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;The original commentary, written for the 2008 National Knowledge Week on Proteinuria and eGFR, has been updated for the 2010 AEU by Ed Sharples, Consultant in Nephrology and Transplant Medicine, Churchill Hospital, Oxford, and specialist collection clinical lead. &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;There are a number of guidelines on the management of CKD, which discuss the prevention of new onset proteinuria. These include guidelines from the Renal Association (2005) (1). The NICE guideline on the early identification and management of adults with CKD in primary and secondary care which is likely to be the definitive evidence review was published in September 2008 (2). &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Twenty four papers have been highlighted for this evidence review.&amp;nbsp; A review of progression risk, urinary protein excretion and the effects of ACE inhibition in nondiabetic renal disease utilizing data from 1860 people from 11 RCTs is included. This review concludes that patients with nondiabetic renal disease may considerably in their risk of disease progression, but the treatment effect of ACE inhibitors does not vary across risk strata. Patients with proteinuria of less than 500mg/d do not seem to benefit, even when at relatively high risk for progression.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Seven papers are concerned with the effects of statin therapy on renal outcomes. Three of these are reviews with meta-analysis (3, 4, 5). The two reviews from 2006 conclude that statins have a beneficial effect on pathological albuminuria. The meta-analysis published in 2008 (5) is of 30144 patients from 50 trials. It concludes that statins significantly reduce lipid concentrations and cardiovascular endpoints in patients with CKD, irrespective of stage of disease. However no benefit on all cause mortality or the role of statins in primary prevention has been established. The renoprotective effects of statins are uncertain because of the relatively sparse data and possible outcomes reporting bias.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The other 17 papers are mainly reports of&amp;nbsp; blood pressure lowering therapies in CKD and their effects on proteinuria. Three (6, 7 ,8) refer to the efficacy of triple blockade using an ACE inhibitor plus a ARB2 agent plus the aldosterone blocker spironolactone. These papers report the possible additional benefits of this triple regime.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;UK Renal Association: Chronic Kidney Disease in Adults - UK Guidelines for Identification, Management and Referral of Adults; 2005. [link to guidelines]&lt;/LI&gt;
&lt;LI&gt;NICE CKD: Guideline (September 2008): Chronic kidney disease: early identification and management of chronic kidney disease in adults in primary and secondary care.&amp;nbsp;&amp;nbsp;[&lt;A href="http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=294680" target="_blank"&gt;Link to NICE guideline&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Douglas K, O'Malley PG, Jackson JL. Meta-analysis: the effect of statins on albuminuria. Ann Intern Med 2006 Jul 18;145(2):117-24. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16847294?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Sandhu S, Wiebe N, Fried L, F, Tonelli M. Statins for improving renal outcomes: A meta-Analysis. Journal of the American Society of Nephrology 2006;17(7):2006-16.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=%22Journal%20of%20the%20American%20Society%20of%20Nephrology%20%3A%20JASN%22%5BJour%5D%20AND%202006%5Bpdat%5D%20AND%20Sandhu%5Bauthor%5D" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Strippoli GF, Navaneethan SD, Johnson DW, Perkovic V, Pellegrini F, Nicolucci A, et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ 2008 Mar 22;336(7645):645-51.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=BMJ%20%5BJour%5D%20AND%202008%5Bpdat%5D%20AND%20Strippoli%5Bauthor%5D" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Bianchi S, Bigazzi R, Campese V, M. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney international 2006;70(12):2116-23.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=%22Kidney%20international%22%5BJour%5D%20AND%202006%5Bpdat%5D%20AND%20Bianchi%5Bauthor%5D" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Epstein M. Aldosterone blockade: an emerging strategy for abrogating progressive renal disease. Am J Med 2006 Nov;119(11):912-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17071154?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Furumatsu Y, Nagasawa Y, Tomida K, Mikami S, Kaneko T, Okada N, et al. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker. Hypertens Res 2008 Jan;31(1):59-67. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=%22Hypertension%20research%20%3A%20official%20journal%20of%20the%20Japanese%20Society%20of%20Hypertension%22%5BJour%5D%20AND%202008%5Bpdat%5D%20AND%20Furumatsu%5Bauthor%5D" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <expiryDate>21/05/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>346395</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=346395]]&gt;</url>
    <title>2010 Annual Evidence Update on Proteinuria and eGFR: 5. New Systematic reviews and patient information</title>
    <publicationDate>2010-05-24T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ ASSESSMENT TESTS,ASSESSMENT OF RENAL FUNCTION,HAEMATURIA/ PROTEINURIA,PROTEINURIA/ NEPHROTIC SYNDROME,PREDISPOSING FACTORS,PRESENTATION OF CKD,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Proteinuria and eGFR: 5. New Systematic reviews and patient information&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;&lt;A href="nelh:372689:0" name=internalLink&gt;&lt;STRONG&gt;Link to 2010 AEU on Proteinuria and eGFR: Contents page&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;New Meta-analysis and Systematic Reviews: Proteinuria and CKD&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Arici M, Erdem Y. "Dual blockade of the renin-angiotensin system for cardiorenal protection: an update". Am J Kidney Dis. 2009 Feb;53(2):332-45. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Dual%20blockade%20of%20the%20renin-angiotensin%20system%20for%20cardiorenal%20protection%3A%20an%20update" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Cheng J, Zhang W, Zhang XH, He Q, Tao XJ, Chen JH. "ACEI/ARB therapy for IgA nephropathy: a meta analysis of randomised controlled trials." Int J Clin Pract. 2009 Jun;63(6):880-8. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=ACEI%2FARB%20therapy%20for%20IgA%20nephropathy%3A%20a%20meta%20analysis%20of%20randomised%20controlled%20trials" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Magee GM, Bilous RW, Cardwell CR, Hunter SJ, Kee F, Fogarty DG. "Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis." Diabetologia. 2009 Apr;52(4):691-7. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Is%20hyperfiltration%20associated%20with%20the%20future%20risk%20of%20developing%20diabetic%20nephropathy%3F%20A%20meta-analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;McDonald SD, Han Z, Walsh MW, Gerstein HC, Devereaux PJ. "Kidney Disease After Preeclampsia: A Systematic Review and Meta-analysis." Am J Kidney Dis. 2010 [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Kidney%20Disease%20After%20Preeclampsia%3A%20A%20Systematic%20Review%20and%20Meta-analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Navaneethan SD, Yehnert H, Moustarah F, Schreiber MJ, Schauer PR, Beddhu S. "Weight loss interventions in chronic kidney disease: a systematic review and meta-analysis." Clin J Am Soc Nephrol. 2009 Oct;4(10):1565-74. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Weight%20loss%20interventions%20in%20chronic%20kidney%20disease%3A%20a%20systematic%20review%20and%20meta-analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF. "Aldosterone antagonists for preventing the progression of chronic kidney disease." Cochrane Database Syst Rev. 2009 Jul 8;(3):CD007004. [&lt;A href="nelh:320802:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Navaneethan SD, Pansini F, Perkovic V, Manno C, Pellegrini F, Johnson DW, Craig JC, Strippoli GF. "HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis." Cochrane Database Syst Rev. 2009 Apr 15;(2):CD007784.&amp;nbsp;[&lt;A href="nelh:312247:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF. "Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis." Clin J Am Soc Nephrol. 2009 Mar;4(3):542-51. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Aldosterone%20antagonists%20for%20preventing%20the%20progression%20of%20chronic%20kidney%20disease%3A%20a%20systematic%20review%20and%20meta-analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Ninomiya T, Perkovic V, Verdon C, Barzi F, Cass A, Gallagher M, Jardine M, Anderson C, Chalmers J, Craig JC, Huxley R. "Proteinuria and stroke: a meta-analysis of cohort studies." Am J Kidney Dis. 2009 Mar;53(3):417-23 [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Proteinuria%20and%20stroke%3A%20a%20meta-analysis%20of%20cohort%20studies" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Ravid M. "Dual blockade of the renin-angiotensin system in diabetic nephropathy." Diabetes Care. 2009 Nov;32 Suppl 2:S410-3. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19875590" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Sarafidis PA, Stafylas PC, Georgianos PI, Saratzis AN, Lasaridis AN. "Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis." Am J Kidney Dis. 2010 May;55(5):835-47.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Effect%20of%20thiazolidinediones%20on%20albuminuria%20and%20proteinuria%20in%20diabetes%3A%20a%20meta-analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Schmieder RE, Martin S, Lang GE, Bramlage P, Böhm M. "Angiotensin blockade to reduce microvascular damage in diabetes mellitus." Dtsch Arztebl Int. 2009 Aug;106(34-35):556-62. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Angiotensin%20blockade%20to%20reduce%20microvascular%20damage%20in%20diabetes%20mellitus" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Other new&lt;/STRONG&gt; &lt;STRONG&gt;Systematic Reviews&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Afshinnia, F., T. J. Wilt, et al. (2009). "Weight loss and proteinuria: systematic review of clinical trials and comparative cohorts." Nephrol Dial Transplant. Nov 27 [Epub ahead of print] [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19945950" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Cheng J, Zhang X, Zhang W, He Q, Tao X, Chen J.&amp;nbsp;(2009). "Efficacy and safety of glucocorticoids therapy for IgA nephropathy: a meta-analysis of randomized controlled trials." American Journal of Nephrology. 30(4): 315-322 [&lt;A href="nelh:360824:0" name=internalLink&gt;Link to DARE abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Gonzalez Rodriguez, J. D., D. Canalejo, et al. (2009). "[Proteinuria in urinary infection and acute pyelonephritis in paediatric patients: can it replace scintigraphic studies in diagnostic localisation?]." Nefrologia 29(2): 163-9. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19396323" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Izzedine H, Massard C, Spano JP, et al. (2010). "VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management." European Journal of Cancer. 46(2): 439-48. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20006922" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Justus Hofmeyr, G. and M. Belfort (2009). "Proteinuria as a predictor of complications of pre-eclampsia." BMC Medicine 7. [&lt;A href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2667402/" target="_blank"&gt;Link to full text on BMC Medicine&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Miller ER, Juraschek SP, Appel LJ et al. (2009). "The effect of n-3 long-chain polyunsaturated fatty acid supplementation on urine protein excretion and kidney function: meta-analysis of clinical trials." American Journal of Clinical Nutrition, 89(6); 1937-45. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19403630" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Regeniter, A., H. Freidank, et al. (2009). "Evaluation of proteinuria and GFR to diagnose and classify kidney disease: systematic review and proof of concept." Eur J Intern Med 20(6): 556-61. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19782913" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Sarafidis, P. A., P. C. Stafylas, et al. (2010).&amp;nbsp;"Effect of Thiazolidinediones on Albuminuria and Proteinuria in Diabetes: A Meta-analysis." Am J Kidney Dis. 55(5); 835-47. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20110146" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;] &lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;A href="nelh:341852:0" name=internalLink&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;New Patient information on proteinuria:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:323588:0" name=internalLink&gt;Identifying unhealthy kidneys: what do I need to know about proteinuria?&lt;/A&gt; Information for patients from the Department of Health. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Treatment Uncertainties:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:346930:0" name=internalLink&gt;What are the long-term effects of aldosterone antagonists for preventing the progression of chronic kidney disease?&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>21/02/2011 11:26:53</lastReviewDate>
    <expiryDate>21/02/2012 11:26:53</expiryDate>
  </document>
  <document>
    <id>372689</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=372689]]&gt;</url>
    <title>2010 Annual Evidence Update on Proteinuria and eGFR: Contents</title>
    <publicationDate>2010-05-24T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ PRESENTATION OF CKD,PROTEINURIA/ NEPHROTIC SYNDROME,PREVENTION,CAUSES,CHRONIC COMPLICATIONS,CONDITION MANAGEMENT,DIAGNOSIS,DIABETES,NEPHROPATHY,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Proteinuria and eGFR: Contents&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;24th May 2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;NHS Evidence - kidney diseases and male urogenital disorders 2010 Annual Evidence Update on eGFR and Proteinuria&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The 2010 update on the topics of eGFR and proteinuria focuses on the new evidence underpinning the importance of microalbuminuria and proteinuria as a marker of renal and cardiovascular disease and progression. Two commentaries highlight the new evidence for pre-eclampsia as a risk factor for CKD, and the ongoing debates around eGFR, old age and CKD classifications.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Contents&lt;/H2&gt;
&lt;P&gt;1. Commentaries by Dr Edward Sharples, clinical lead:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:373944:0" name=internalLink&gt;Commentary: Controversies in eGFR and CKD&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:373996:0" name=internalLink&gt;Commentary: Pre-Eclampsia, microalbuminuria and risk of CKD&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;2. Basic science&lt;/P&gt;
&lt;P&gt;a) &lt;A href="nelh:373973:0" name=internalLink&gt;Characterisation and description of urinary protein excretion in health and in disease&lt;/A&gt;&lt;BR&gt;b) &lt;A href="nelh:374021:0" name=internalLink&gt;Tubular toxicity of urinary protein&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;3. Clinical aspects&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;a) &lt;A href="nelh:374024:0" name=internalLink&gt;How to detect and quantify urinary albumin and proteinuria&lt;/A&gt; &lt;BR&gt;b) &lt;A href="nelh:374026:0" name=internalLink&gt;Proteinuria as a marker of chronic kidney damage&lt;/A&gt;&lt;BR&gt;c) &lt;A href="nelh:374027:0" name=internalLink&gt;Proteinuria, CKD and cardiovascular risk&lt;BR&gt;&lt;/A&gt;d) &lt;A href="nelh:374198:0" name=internalLink&gt;Proteinuria as a screening tool&lt;/A&gt; &lt;BR&gt;e) &lt;A href="nelh:375012:0" name=internalLink&gt;eGFR as a marker of renal function&lt;/A&gt; &lt;BR&gt;f) &lt;A href="nelh:375014:0" name=internalLink&gt;eGFR as a screening tool&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;4. Management&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;a) &lt;A href="nelh:375023:0" name=internalLink&gt;Managing cardiovascular risk factors in chronic kidney disease&lt;/A&gt;&lt;BR&gt;b) &lt;A href="nelh:375024:0" name=internalLink&gt;Preventing new onset development of proteinuria in people with diabetes and hypertension&lt;/A&gt;&lt;BR&gt;c) &lt;A href="nelh:375025:0" name=internalLink&gt;Preventing new onset development of proteinuria in people with CKD&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;5. &lt;A href="nelh:346395:0" name=internalLink&gt;New systematic reviews and patient information&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:373626:0" name=internalLink&gt;Link to 2010 AEU on Proteinuria and eGFR Methodology&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/KIDNEY/Page.aspx?pagename=PGFNKWCONT" target="_blank"&gt;Link to 2008 National Knowledge Week on Proteinuria and eGFR contents&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=315169" target="_blank"&gt;Link to 2009 Annual Evidence Update on Proteinuria and eGFR contents&lt;BR&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <expiryDate>27/04/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>373626</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=373626]]&gt;</url>
    <title>2010 Annual Evidence Update on Proteinuria and eGFR: Methodology</title>
    <publicationDate>2010-05-24T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ PRESENTATION OF CKD,PROTEINURIA/ NEPHROTIC SYNDROME,HAEMATURIA/ PROTEINURIA,PREDISPOSING FACTORS,ASSESSMENT OF RENAL FUNCTION,ASSESSMENT TESTS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Proteinuria and eGFR: Methodology&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;&lt;A href="nelh:372689:0" name=internalLink&gt;&lt;STRONG&gt;Link back to 2010 AEU on Proteinuria and eGFR: contents page&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methodology:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;MEDLINE and Embase were searched for systematic reviews and meta-analyses published between April 2009 and April 2010, using the Clinical Evidence systematic review search filter and the search strategies employed by the kidney diseases team in 2008 (l&lt;A href="http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=287959&amp;amp;tabID=290" target="_blank"&gt;ink to 2008 Methodology&lt;/A&gt;).&lt;/P&gt;
&lt;P&gt;The following search terms were used for &lt;STRONG&gt;Proteinuria&lt;/STRONG&gt;:&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;*PROTEINURIA/&lt;/LI&gt;
&lt;LI&gt;exp ALBUMINURIA/&lt;/LI&gt;
&lt;LI&gt;"urinary protein".ti,ab&lt;/LI&gt;
&lt;LI&gt;"urine protein".ti,ab&lt;/LI&gt;
&lt;LI&gt;"urinary albumin excretion".ti,ab&lt;/LI&gt;
&lt;LI&gt;"urine albulmin excretion".ti,ab&lt;/LI&gt;
&lt;LI&gt;microalbuminuria.ti,ab&lt;/LI&gt;
&lt;LI&gt;macroalbuminuria.ti,ab&lt;/LI&gt;
&lt;LI&gt;proteinuria.ti,ab&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The following search terms were used for &lt;STRONG&gt;eGFR&lt;/STRONG&gt;:&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;*GLOMERULUS FILTRATION RATE/&lt;/LI&gt;
&lt;LI&gt;"estimated glomerular filtration rate".ti,ab&lt;/LI&gt;
&lt;LI&gt;"estimating glomerular filtration rate".ti,ab&lt;/LI&gt;
&lt;LI&gt;"estimated gfr".ti,ab&lt;/LI&gt;
&lt;LI&gt;"estimating gfr".ti,ab&lt;/LI&gt;
&lt;LI&gt;egfr.ti,ab&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Numbers of systematic reviews/ meta-analyses published April 2009- April 2010: 8&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <expiryDate>11/05/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>401031</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=401031]]&gt;</url>
    <title>2011 Annual Evidence Update on Male Urinary Incontinence - Botulinum Toxin A and Male Urinary Incontinence</title>
    <publicationDate>2011-01-31T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE URINARY INCONTINENCE,OTHER INCONTINENCE,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2011 Annual Evidence Update on Male Urinary Incontinence - Botulinum Toxin A and Male Urinary Incontinence&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;A href="nelh:401615:0" name=internalLink&gt;&lt;STRONG&gt;Link to 2011 Annual Evidence Update on Male Urinary Incontinence - contents page &lt;/STRONG&gt;&lt;/A&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Guidelines&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;NICE Guideline: Lower urinary tract symptoms: the management of lower urinary tract symptoms in men. Publication date: 19 May 2010. &lt;A href="nelh:374250:0" name=internalLink&gt;Link to abstract&lt;/A&gt;. &lt;/LI&gt;
&lt;LI&gt;European Association of Urology (EAU): Guidelines on urinary incontinence. &amp;nbsp;Publication date: 01 April 2010. &lt;A href="nelh:148795:0" name=internalLink&gt;Link to abstract&lt;/A&gt;.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Systematic&amp;nbsp;Reviews and Meta-analyses: Evidence&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Anger, J. T., A. Weinberg, et al. (2010). "Outcomes of intravesical botulinum toxin for idiopathic overactive bladder symptoms: a systematic review of the literature." Journal of Urology 183(6): 2258-2264. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20400142" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Ksibi I, Godard AL, Azouvi P, Denys P, Dziri C. Botulinum toxin and refractory non-neurogenic overactive detrusor. Annals of Physical and Rehabilitation Medicine. 2009;52(9):668-83.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19729357" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;STRONG&gt;&lt;A href="nelh:333390:0" name=internalLink&gt;
&lt;P&gt;&lt;STRONG&gt;Link to 2010 Annual Evidence Update on Male Urinary Incontinence contents page&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;STRONG&gt;&lt;A href="nelh:333394:0" name=internalLink&gt;&lt;STRONG&gt;Link to 2010 evidence on Male and Female Quality of Life Studies&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <expiryDate>13/01/2012 00:00:00</expiryDate>
  </document>
  <document>
    <id>401032</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=401032]]&gt;</url>
    <title>2011 Annual Evidence Update on Male Urinary Incontinence - Conservative Management of Male Urinary Incontinence</title>
    <publicationDate>2011-01-31T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE URINARY INCONTINENCE,OTHER INCONTINENCE,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2011 Annual Evidence Update on Male Urinary Incontinence - Conservative Management of Male Urinary Incontinence&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;H2&gt;&lt;A href="nelh:401615:0" name=internalLink&gt;&lt;STRONG&gt;Link to 2011 Annual Evidence Update on Male Urinary Incontinence - contents page &lt;/STRONG&gt;&lt;/A&gt;&lt;/H2&gt;
&lt;H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/H2&gt;
&lt;H2&gt;Guidelines&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;NICE Guideline: Lower urinary tract symptoms: the management of lower urinary tract symptoms in men. Publication date: 19 May 2010. &lt;A href="nelh:374250:0" name=internalLink&gt;Link to abstract&lt;/A&gt;. &lt;/LI&gt;
&lt;LI&gt;European Association of Urology (EAU): Guidelines on conservative treatment of non-neurogenic male LUTS. Publication date: 01 April 2010. &lt;A href="nelh:375208:0" name=internalLink&gt;Link to abstract&lt;/A&gt;.&lt;/LI&gt;
&lt;LI&gt;European Association of Urology (EAU): Guidelines on urinary incontinence. &amp;nbsp;Publication date: 01 April 2010. &lt;A href="nelh:148795:0" name=internalLink&gt;Link to abstract&lt;/A&gt;.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Systematic&amp;nbsp;Reviews and Meta-analyses: Evidence&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;DuBeau, C. E., G. A. Kuchel, et al. (2010). "Incontinence in the frail elderly: report from the 4th International Consultation on Incontinence." Neurourology &amp;amp; Urodynamics 29(1): 165-78. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20025027" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hagglund, D. (2010) "A systematic literature review of incontinence care for persons with dementia: the research evidence." J Clin Nurs. Feb;19(3-4):303-12. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20500269" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;STRONG&gt;&lt;A href="nelh:333390:0" name=internalLink&gt;
&lt;P&gt;&lt;STRONG&gt;Link to 2010 Annual Evidence Update on Male Urinary Incontinence contents page&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;STRONG&gt;&lt;A href="nelh:333394:0" name=internalLink&gt;&lt;STRONG&gt;Link to 2010 evidence on Male and Female Quality of Life Studies&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <expiryDate>13/01/2012 00:00:00</expiryDate>
  </document>
  <document>
    <id>401615</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=401615]]&gt;</url>
    <title>2011 Annual Evidence Update on Male Urinary Incontinence - Contents</title>
    <publicationDate>2011-01-31T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE URINARY INCONTINENCE,URGENCY INCONTINENCE,STRESS INCONTINENCE,OTHER INCONTINENCE,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2011 Annual Evidence Update on Male Urinary Incontinence - Contents&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;This Annual Evidence Update is being launched on&amp;nbsp;31st January 2011 to promote the evidence published in the year since the&amp;nbsp;NICE guidelines on The Management of Lower Urinary Tract Symptoms in Men (published May 2010). [&lt;A href="nelh:374250:0" name=internalLink&gt;&lt;STRONG&gt;Link to NICE guideline&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;STRONG&gt;]&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=center&gt;&amp;nbsp;&lt;IMG style="WIDTH: 160px; HEIGHT: 261px" id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="Dripping tap" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID333390/nelhImp_0001_UIAEUdrippingtap.JPG" width=190 height=300&gt;&lt;/P&gt;
&lt;P align=center&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Introduction to the 2011 AEU from Prof. C. Chapple:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Dear Colleagues, &lt;/P&gt;
&lt;P&gt;The 2011 Annual Evidence Update on male urinary incontinence follows on the success of previous editions with a critical update of the latest information.&amp;nbsp; We now have the NICE male LUTS guideline which complements the female incontinence guideline, which is currently being updated [web address to both of these on NICE website].&lt;/P&gt;
&lt;P&gt;Currently randomised controlled trials are under way looking at green light laser and there is increasing evidence that the male slings may be helpful in patients with mild to moderate incontinence, but the data which is currently available is based on few centres with relatively small series, often lacking consistency in terms of the diagnostic criteria which are chosen.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;There is still no good evidence relating to the efficacy of botulinum toxin A when injected into the human prostate, based on randomised controlled trials and such evidence is eagerly awaited.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;In the urology meetings this year we will be seeing data presented on botulinum toxin A in the management of neurogenic bladder overactivity from a large randomised controlled trial and also data using a beta 3 agonist also derived from a large phase III randomised controlled trial, looking at the treatment of the overactive bladder symptoms usually associated with idiopathic detrusor overactivity.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;Prof Christopher Chapple, BSc, MD, FRCS (Urol), FEBU&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=center&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2011 Annual Evidence Update on Male Urinary Incontinence: Contents&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;OL&gt;&lt;A href="nelh:401030:0" name=internalLink&gt;
&lt;LI&gt;Post-prostatectomy and Urinary Incontinence&lt;/LI&gt;
&lt;LI&gt;&lt;/A&gt;&lt;A href="nelh:401031:0" name=internalLink&gt;Botulinum Toxin A and Male Urinary Incontinence&lt;/A&gt;&amp;nbsp;&lt;/LI&gt;&lt;A href="nelh:401032:0" name=internalLink&gt;
&lt;LI&gt;Conservative Management of Male Urinary Incontinence&lt;/LI&gt;
&lt;LI&gt;&lt;/A&gt;&lt;A href="nelh:401034:0" name=internalLink&gt;Male and Female Quality of Life Studies&lt;A href="nelh:401035:0" name=internalLink&gt;&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;/A&gt;&lt;A href="nelh:401035:0" name=internalLink&gt;Male Stress Urinary Incontinence and Surgery&lt;A href="nelh:401036:0" name=internalLink&gt;&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;/A&gt;&lt;A href="nelh:401036:0" name=internalLink&gt;Male Stress Urinary Incontinence and Drug Treatment&lt;A href="nelh:401037:0" name=internalLink&gt;&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;/A&gt;&lt;A href="nelh:401037:0" name=internalLink&gt;Male Urgency Urinary Incontinence and Surgery&lt;/LI&gt;
&lt;LI&gt;&lt;/A&gt;&lt;A href="nelh:401038:0" name=internalLink&gt;Male Urgency&amp;nbsp;Urinary Incontinence and Drug Treatment&lt;/LI&gt;
&lt;LI&gt;&lt;/A&gt;&lt;A href="nelh:401712:0" name=internalLink&gt;Overactive bladder&lt;/LI&gt;
&lt;LI&gt;&lt;/A&gt;&lt;A href="nelh:392400:0" name=internalLink&gt;Evidence&lt;/A&gt; - All male urinary incontinence references&amp;nbsp;&amp;nbsp;&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/WOMENSHEALTH/ViewResource.aspx?resID=397707" target="_blank"&gt;Link to 2011 AEU on Female Urinary Incontinence&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;A href="nelh:401041:0" name=internalLink&gt;
&lt;P&gt;Click here to see the Methodology used for this AEU&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&lt;A href="http://www.library.nhs.uk/DUETS/SearchResults.aspx?catID=14531" target="_blank"&gt;Click here to see the Treatment Uncertainties for urinary incontinence&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;DUETs - evidence&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Buckley, B. S., A. M. Grant, et al. (2010). "Prioritizing research: Patients, carers,&amp;nbsp;and clinicians working together to identify and prioritize important clinical uncertainties in urinary incontinence." Neurourology &amp;amp; Urodynamics 29(5): 708-14. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Prioritizing%20research%3A%20Patients%2C%20carers%2C%20and%20clinicians%20working%20together%20to%20identify%20and%20prioritize%20important%20clinical%20uncertainties%20in%20urinary%20incontinence" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:333390:0" name=internalLink&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Link to 2010 Annual Evidence Update on Male Urinary Incontinence contents page&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <expiryDate>17/01/2012 00:00:00</expiryDate>
  </document>
  <document>
    <id>392400</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=392400]]&gt;</url>
    <title>2011 Annual Evidence Update on Male Urinary Incontinence - Evidence</title>
    <publicationDate>2011-01-31T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE URINARY INCONTINENCE,URGENCY INCONTINENCE,STRESS INCONTINENCE,OTHER INCONTINENCE,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2011 Annual Evidence Update on Male Urinary Incontinence - Evidence&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;STRONG&gt;
&lt;H2&gt;&lt;/STRONG&gt;&lt;STRONG&gt;&lt;A href="nelh:401615:0" name=internalLink&gt;&lt;STRONG&gt;Link to 2011 Annual Evidence Update on Male Urinary Incontinence - contents page &lt;/STRONG&gt;&lt;/A&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/STRONG&gt;&lt;/H2&gt;
&lt;H2&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;&lt;STRONG&gt;Evidence - adults only&lt;/STRONG&gt;&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Guidelines&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;NICE Guideline: Percutaneous posterior tibial nerve stimulation for overactive bladder syndrome. Publication date: 27 October 2010. &lt;A href="nelh:392563:0" name=internalLink&gt;Link to abstract&lt;/A&gt;. &lt;/LI&gt;
&lt;LI&gt;NICE Guideline: Lower urinary tract symptoms: the management of lower urinary tract symptoms in men. Publication date: 19 May 2010. &lt;A href="nelh:374250:0" name=internalLink&gt;Link to abstract&lt;/A&gt;. &lt;/LI&gt;
&lt;LI&gt;European Association of Urology (EAU): Guidelines on conservative treatment of non-neurogenic male LUTS. Publication date: 01 April 2010. &lt;A href="nelh:375208:0" name=internalLink&gt;Link to abstract&lt;/A&gt;.&lt;/LI&gt;
&lt;LI&gt;European Association of Urology (EAU): Guidelines on urinary incontinence. &amp;nbsp;Publication date: 01 April 2010. &lt;A href="nelh:148795:0" name=internalLink&gt;Link to abstract&lt;/A&gt;.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Clinical Knowledge Summaries - all published 09 August 2010&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Lower urinary tract symptoms in men, age-related (including symptoms of benign prostatic hyperplasia/hypertrophy) [&lt;A href="nelh:383919:0" name=internalLink&gt;Link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;&lt;/A&gt;LUTS in men, age-related (prostatism): Initial assessment of lower urinary tract symptoms (LUTS) [&lt;A href="nelh:383920:0" name=internalLink&gt;Link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;LUTS in men, age-related (prostatism): Nocturnal polyuria [&lt;A href="nelh:383924:0" name=internalLink&gt;Link]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;LUTS in men, age-related (prostatism): Overactive bladder [&lt;A href="nelh:383923:0" name=internalLink&gt;Link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;LUTS in men, age-related (prostatism): Post-micturition dribble [&lt;A href="nelh:383926:0" name=internalLink&gt;Link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;LUTS in men, age-related (prostatism): Stress urinary incontinence [&lt;A href="nelh:383922:0" name=internalLink&gt;Link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;LUTS in men, age-related (prostatism): Urinary retention (acute, acute on chronic, chronic) [&lt;A href="nelh:383921:0" name=internalLink&gt;Link&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;LUTS in men, age-related (prostatism): Voiding (obstructive) symptoms [&lt;A href="nelh:383925:0" name=internalLink&gt;Link&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Male Urinary Incontinence: Systematic reviews&lt;/H2&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Anger, J. T., A. Weinberg, et al. (2010). "Outcomes of intravesical botulinum toxin for idiopathic overactive bladder symptoms: a systematic review of the literature." Journal of Urology 183(6): 2258-2264. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20400142" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Athanasopoulos, A. (2010). "Antimuscarinics and bladder outlet obstruction: From a contraindication to an indication?" Neurourology &amp;amp; Urodynamics 29 Suppl 1: S46-50. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20127792" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Bartoli, S., G. Aguzzi, et al. (2010). "Impact on Quality of Life of Urinary Incontinence and Overactive Bladder: A Systematic Literature Review." Urology 75(3): 491-500.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19962738" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Bosch, J. L. and J. P. Weiss (2010). "The prevalence and causes of nocturia." Journal of Urology 184(2): 440-6. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20620395" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Buckley Brian, S. and M. Lapitan Marie Carmela (2010) Drugs for treatment of urinary retention after surgery in adults. Cochrane Database of Systematic Reviews&amp;nbsp; DOI: 10.1002/14651858.CD008023.pub2&amp;nbsp;[&lt;A href="nelh:389407:0" name=internalLink&gt;Link to Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;DuBeau, C. E., G. A. Kuchel, et al. (2010). "Incontinence in the frail elderly: report from the 4th International Consultation on Incontinence." Neurourology &amp;amp; Urodynamics 29(1): 165-78. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20025027" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hagen, S., L. Sinclair, et al. (2010) Washout policies in long-term indwelling urinary catheterisation in adults. Cochrane Database of Systematic Reviews&amp;nbsp; DOI: 10.1002/14651858.CD004012.pub4 [&lt;A href="nelh:346269:0" name=internalLink&gt;Link to Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hagglund, D. (2010) "A systematic literature review of incontinence care for persons with dementia: the research evidence." J Clin Nurs. Feb;19(3-4):303-12. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20500269" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Herschorn, S., H. Bruschini, et al. (2010). "Surgical treatment of stress incontinence in men." Neurourology &amp;amp; Urodynamics 29(1): 179-190.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20025026" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Irwin, D. E., I. Milsom, et al. (2010). "Dynamic progression of overactive bladder and urinary incontinence symptoms: a systematic review." European Urology 58(4): 532-43. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Dynamic%20progression%20of%20overactive%20bladder%20and%20urinary%20incontinence%20symptoms%3A%20a%20systematic%20review" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Jha, S., M. K. Ammembal, et al. (2010). "Impact of incontinence surgery on sexual function: A systematic review and meta-analysis." Neurourology and Urodynamics 29(6): 1112-1113. [NO PUBMED ABSTRACT AVAILABLE - POSTER ONLY]&lt;/LI&gt;
&lt;LI&gt;Kessler, T. M., L. M. Bachmann, et al. (2010). "Adverse event assessment of antimuscarinics for treating overactive bladder: A network meta-analytic approach." European Urology, Supplements 9(2).&amp;nbsp;[No abstract available]&lt;/LI&gt;
&lt;LI&gt;Loughlin, K. R. and M. M. Prasad (2010). "Post-prostatectomy urinary incontinence: a confluence of 3 factors." Journal of Urology 183(3): 871-877.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20083262" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Walz, J., A. L. Burnett, et al. (2010). "A critical analysis of the current knowledge of surgical anatomy related to optimization of cancer control and preservation of continence and erection in candidates for radical prostatectomy." European Urology 57(2): 179-92. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=A%20critical%20analysis%20of%20the%20current%20knowledge%20of%20surgical%20anatomy%20related%20to%20optimization%20of%20cancer%20control%20and%20preservation%20of%20continence%20and%20erection%20in%20candidates%20for%20radical%20prostatectomy" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Wong Susan, S. W., R. Narahari, et al. (2010) Simple urethral dilatation, endoscopic urethrotomy, and urethroplasty for urethral stricture disease in adult men. Cochrane Database of Systematic Reviews&amp;nbsp; DOI: 10.1002/14651858.CD006934.pub2&amp;nbsp;[&lt;A href="nelh:371984:0" name=internalLink&gt;Link to Cochrane abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Beeckman D, Schoonhoven L, Verhaeghe S, Heyneman A, Defloor T. Prevention and treatment of incontinence-associated dermatitis: literature review. Journal of Advanced Nursing. 2009;65(6):1141-54.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19374674" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Campbell JD, Gries KS, Watanabe JH, Ravelo A, Dmochowski RR, Sullivan SD.&amp;nbsp; Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidence. BMC Urology 2009; 9(1):18 [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19930578" target="_blank"&gt;Link to&amp;nbsp;Pubmed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Chiarelli, P. E., L. A. Mackenzie, et al. (2009). "Urinary incontinence is associated with an increase in falls: a systematic review." Australian Journal of Physiotherapy 55(2): 89-95. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19463079?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Davie, C., T. Cook, et al. (2009). "Pelvic floor muscle training for the management of urinary incontinence following radical prostatectomy." Journal of the Association of Chartered Physiotherapists in Women's Health(105): 4-24.&amp;nbsp;[No abstract available]&lt;/LI&gt;
&lt;LI&gt;Gries, K. S., J. D. Campbell, et al. (2009). "Characterization of treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics." Journal of Urology 181(4 SUPPL. 1). [No abstract available – POSTER ONLY]&lt;/LI&gt;
&lt;LI&gt;Ksibi I, Godard AL, Azouvi P, Denys P, Dziri C. Botulinum toxin and refractory non-neurogenic overactive detrusor. Annals of Physical and Rehabilitation Medicine. 2009;52(9):668-83.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19729357" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lee S, Malhotra B, Creanga D, Carlsson M, Glue P. A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder. BMC Medical Research Methodology. 2009;9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19624824" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Natarajan V, Master V, Ogan K. Effects of obesity and weight loss in patients with nononcological urological disease. Journal of Urology. 2009;181(6):2424-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19371912" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Zeif HJ, Subramonian K. Alpha blockers prior to removal of a catheter for acute urinary retention in adult men. Cochrane Database of Systematic Reviews. 2009(4).&amp;nbsp;[&lt;A href="nelh:327202:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:333390:0" name=internalLink&gt;&lt;/P&gt;&lt;/A&gt;
&lt;H2&gt;Uncertainty in the Effects of Treatments: DUETs&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Buckley, B. S., A. M. Grant, et al. (2010). "Prioritizing research: Patients, carers, and clinicians working together to identify and prioritize important clinical uncertainties in urinary incontinence." Neurourology &amp;amp; Urodynamics 29(5): 708-14. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Prioritizing%20research%3A%20Patients%2C%20carers%2C%20and%20clinicians%20working%20together%20to%20identify%20and%20prioritize%20important%20clinical%20uncertainties%20in%20urinary%20incontinence" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;A href="nelh:333390:0" name=internalLink&gt;
&lt;P&gt;&lt;STRONG&gt;Link to 2010 Annual Evidence Update on Male Urinary Incontinence contents page&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;STRONG&gt;&lt;A href="nelh:333394:0" name=internalLink&gt;&lt;STRONG&gt;Link to 2010 evidence on Male and Female Quality of Life Studies&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <expiryDate>26/10/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>401034</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=401034]]&gt;</url>
    <title>2011 Annual Evidence Update on Male Urinary Incontinence - Male and Female Quality of Life Studies</title>
    <publicationDate>2011-01-31T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE URINARY INCONTINENCE,OTHER INCONTINENCE,QUALITY OF LIFE,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2011 Annual Evidence Update on Male Urinary Incontinence - Male and Female Quality of Life Studies&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;STRONG&gt;&lt;A href="nelh:401615:0" name=internalLink&gt;&lt;STRONG&gt;Link to 2011 Annual Evidence Update on Male Urinary Incontinence - contents page&lt;/STRONG&gt; &lt;/A&gt;&lt;/STRONG&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Guidelines&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;NICE Guideline: Lower urinary tract symptoms: the management of lower urinary tract symptoms in men. Publication date: 19 May 2010. &lt;A href="nelh:374250:0" name=internalLink&gt;Link to abstract&lt;/A&gt;. &lt;/LI&gt;
&lt;LI&gt;European Association of Urology (EAU): Guidelines on conservative treatment of non-neurogenic male LUTS. Publication date: 01 April 2010. &lt;A href="nelh:375208:0" name=internalLink&gt;Link to abstract&lt;/A&gt;.&lt;/LI&gt;
&lt;LI&gt;European Association of Urology (EAU): Guidelines on urinary incontinence. &amp;nbsp;Publication date: 01 April 2010. &lt;A href="nelh:148795:0" name=internalLink&gt;Link to abstract&lt;/A&gt;.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Systematic&amp;nbsp;Reviews and Meta-analyses: Evidence&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Anger, J. T., A. Weinberg, et al. (2010). "Outcomes of Intravesical Botulinum Toxin for Idiopathic Overactive Bladder Symptoms: A Systematic Review of the Literature." Journal of Urology 183(6): 2258-2264.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20400142" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Bartoli, S., G. Aguzzi, et al. (2010). "Impact on quality of life of urinary incontinence and overactive bladder: a systematic literature review." Urology 75(3): 491-500.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19962738" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Dmochowski, R. R., J. M. Blaivas, et al. (2010). "Update of AUA Guideline on the Surgical Management of Female Stress Urinary Incontinence." Journal of Urology 183(5): 1906-1914.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20303102" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kwon, B. E., G. Y. Kim, et al. (2010). "Quality of life of women with urinary incontinence: a systematic literature review." International neurourology journal 14(3): 133-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/21179330" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Gil, K. M., A. M. Somerville, et al. (2009). "Distress and quality of life characteristics associated with seeking surgical treatment for stress urinary incontinence." Health &amp;amp; Quality of Life Outcomes 7.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19196462" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Serati, M., S. Salvatore, et al. (2009). "Female urinary incontinence during intercourse: a review on an understudied problem for women's sexuality." Journal of Sexual Medicine 6(1): 40-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19170835" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Weinberg, A. E., J. T. Anger, et al. (2009). "Quality-of-care indicators for women with overactive bladder: A systematic review of the literature." Journal of Urology 181(4 SUPPL. 1).&amp;nbsp;[No PubMed abstract available]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Other evidence&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Kraus, S. R., J. L. Ruiz-Cerda, et al. (2010). "Efficacy and tolerability of fesoterodine in older and younger subjects with overactive bladder." Urology 76(6): 1350-7.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20974482" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Ternent, L., L. Vale, et al. (2009). "Measuring outcomes of importance to women with stress urinary incontinence." BJOG: An International Journal of Obstetrics &amp;amp; Gynaecology 116(5): 719-25. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19298440" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;STRONG&gt;&lt;A href="nelh:333390:0" name=internalLink&gt;
&lt;P&gt;&lt;STRONG&gt;Link to 2010 Annual Evidence Update on Male Urinary Incontinence contents page&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;STRONG&gt;&lt;A href="nelh:333394:0" name=internalLink&gt;&lt;STRONG&gt;Link to 2010 evidence on Male and Female Quality of Life Studies&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <expiryDate>13/01/2012 00:00:00</expiryDate>
  </document>
  <document>
    <id>401036</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=401036]]&gt;</url>
    <title>2011 Annual Evidence Update on Male Urinary Incontinence - Male Stress Urinary Incontinence and Drug Treatment</title>
    <publicationDate>2011-01-31T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE URINARY INCONTINENCE,STRESS INCONTINENCE,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2011 Annual Evidence Update on Male Urinary Incontinence - Male Stress Urinary Incontinence and Drug Treatment&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;A href="nelh:401615:0" name=internalLink&gt;&lt;STRONG&gt;Link to 2011 Annual Evidence Update on Male Urinary Incontinence - contents page &lt;/STRONG&gt;&lt;/A&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Guidelines&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;NICE Guideline: Lower urinary tract symptoms: the management of lower urinary tract symptoms in men. Publication date: 19 May 2010. &lt;A href="nelh:374250:0" name=internalLink&gt;Link to abstract&lt;/A&gt;. &lt;/LI&gt;
&lt;LI&gt;European Association of Urology (EAU): Guidelines on urinary incontinence. &amp;nbsp;Publication date: 01 April 2010. &lt;A href="nelh:148795:0" name=internalLink&gt;Link to abstract&lt;/A&gt;.&lt;/LI&gt;
&lt;LI&gt;LUTS in men, age-related (prostatism): Stress urinary incontinence [&lt;A href="nelh:383922:0" name=internalLink&gt;Link&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Systematic&amp;nbsp;Reviews and Meta-analyses: Evidence&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Ashok, K. and A. Wang (2010). "Recurrent urinary stress incontinence: an overview." Journal of Obstetrics &amp;amp; Gynaecology Research 36(3): 467-473. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20598022" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Buckley Brian, S. and M. Lapitan Marie Carmela (2010) Drugs for treatment of urinary retention after surgery in adults. Cochrane Database of Systematic Reviews&amp;nbsp; DOI: 10.1002/14651858.CD008023.pub2&amp;nbsp;[&lt;A href="nelh:389407:0" name=internalLink&gt;Link to Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;DuBeau, C. E., G. A. Kuchel, et al. (2010). "Incontinence in the frail elderly: report from the 4th International Consultation on Incontinence." Neurourology &amp;amp; Urodynamics 29(1): 165-78. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20025027" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hagglund, D. (2010) "A systematic literature review of incontinence care for persons with dementia: the research evidence." J Clin Nurs. Feb;19(3-4):303-12. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20500269" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Irwin, D. E., I. Milsom, et al. (2010). "Dynamic progression of overactive bladder and urinary incontinence symptoms: a systematic review." European Urology 58(4): 532-43. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Dynamic%20progression%20of%20overactive%20bladder%20and%20urinary%20incontinence%20symptoms%3A%20a%20systematic%20review" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:333390:0" name=internalLink&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Link to 2010 Annual Evidence Update on Male Urinary Incontinence contents page&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;STRONG&gt;&lt;A href="nelh:333394:0" name=internalLink&gt;&lt;STRONG&gt;Link to 2010 evidence on Male and Female Quality of Life Studies&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <expiryDate>13/01/2012 00:00:00</expiryDate>
  </document>
  <document>
    <id>401035</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=401035]]&gt;</url>
    <title>2011 Annual Evidence Update on Male Urinary Incontinence - Male Stress Urinary Incontinence and Surgery</title>
    <publicationDate>2011-01-31T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE URINARY INCONTINENCE,STRESS INCONTINENCE,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2011 Annual Evidence Update on Male Urinary Incontinence - Male Stress Urinary Incontinence and Surgery&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;A href="nelh:401615:0" name=internalLink&gt;&lt;STRONG&gt;Link to 2011 Annual Evidence Update on Male Urinary Incontinence - contents page &lt;/STRONG&gt;&lt;/A&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Guidelines&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;NICE Guideline: Lower urinary tract symptoms: the management of lower urinary tract symptoms in men. Publication date: 19 May 2010. &lt;A href="nelh:374250:0" name=internalLink&gt;Link to abstract&lt;/A&gt;. &lt;/LI&gt;
&lt;LI&gt;European Association of Urology (EAU): Guidelines on urinary incontinence. &amp;nbsp;Publication date: 01 April 2010. &lt;A href="nelh:148795:0" name=internalLink&gt;Link to abstract&lt;/A&gt;.&lt;/LI&gt;
&lt;LI&gt;LUTS in men, age-related (prostatism): Stress urinary incontinence [&lt;A href="nelh:383922:0" name=internalLink&gt;Link&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Systematic&amp;nbsp;Reviews and Meta-analyses: Evidence&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Ashok, K. and A. Wang (2010). "Recurrent urinary stress incontinence: an overview." Journal of Obstetrics &amp;amp; Gynaecology Research 36(3): 467-473. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20598022" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Herschorn, S., H. Bruschini, et al. (2010). "Surgical treatment of stress incontinence in men." Neurourology &amp;amp; Urodynamics 29(1): 179-190.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20025026" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Jha, S., M. K. Ammembal, et al. (2010). "Impact of incontinence surgery on sexual function: A systematic review and meta-analysis." Neurourology and Urodynamics 29(6): 1112-1113. [NO PUBMED ABSTRACT AVAILABLE - POSTER ONLY]&lt;/LI&gt;
&lt;LI&gt;Latthe, P. M., P. Singh, et al. (2010). "Two routes of transobturator tape procedures in stress urinary incontinence: a meta-analysis with direct and indirect comparison of randomized trials." BJU International 106(1): 68-76.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19912182" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:333390:0" name=internalLink&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Link to 2010 Annual Evidence Update on Male Urinary Incontinence contents page&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;STRONG&gt;&lt;A href="nelh:333394:0" name=internalLink&gt;&lt;STRONG&gt;Link to 2010 evidence on Male and Female Quality of Life Studies&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <expiryDate>13/01/2012 00:00:00</expiryDate>
  </document>
  <document>
    <id>401038</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=401038]]&gt;</url>
    <title>2011 Annual Evidence Update on Male Urinary Incontinence - Male Urgency Urinary Incontinence and Drug Treatment</title>
    <publicationDate>2011-01-31T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE URINARY INCONTINENCE,URGENCY INCONTINENCE,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2011 Annual Evidence Update on Male Urinary Incontinence - Male Urgency Urinary Incontinence and Drug Treatment&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;A href="nelh:401615:0" name=internalLink&gt;&lt;STRONG&gt;Link to 2011 Annual Evidence Update on Male Urinary Incontinence - contents page &lt;/STRONG&gt;&lt;/A&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Guidelines&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;NICE Guideline: Lower urinary tract symptoms: the management of lower urinary tract symptoms in men. Publication date: 19 May 2010. &lt;A href="nelh:374250:0" name=internalLink&gt;Link to abstract&lt;/A&gt;. &lt;/LI&gt;
&lt;LI&gt;European Association of Urology (EAU): Guidelines on urinary incontinence. &amp;nbsp;Publication date: 01 April 2010. &lt;A href="nelh:148795:0" name=internalLink&gt;Link to abstract&lt;/A&gt;.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Systematic&amp;nbsp;Reviews and Meta-analyses: Evidence&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Buckley Brian, S. and M. Lapitan Marie Carmela (2010) Drugs for treatment of urinary retention after surgery in adults. Cochrane Database of Systematic Reviews&amp;nbsp; DOI: 10.1002/14651858.CD008023.pub2&amp;nbsp;[&lt;A href="nelh:389407:0" name=internalLink&gt;Link to Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;DuBeau, C. E., G. A. Kuchel, et al. (2010). "Incontinence in the frail elderly: report from the 4th International Consultation on Incontinence." Neurourology &amp;amp; Urodynamics 29(1): 165-78. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20025027" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hagglund, D. (2010) "A systematic literature review of incontinence care for persons with dementia: the research evidence." J Clin Nurs. Feb;19(3-4):303-12. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20500269" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Irwin, D. E., I. Milsom, et al. (2010). "Dynamic progression of overactive bladder and urinary incontinence symptoms: a systematic review." European Urology 58(4): 532-43. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Dynamic%20progression%20of%20overactive%20bladder%20and%20urinary%20incontinence%20symptoms%3A%20a%20systematic%20review" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Campbell JD, Gries KS, Watanabe JH, Ravelo A, Dmochowski RR, Sullivan SD.&amp;nbsp; Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidence. BMC Urology 2009; 9(1):18 [&lt;A href="nelh:379193:0" name=internalLink&gt;Link to DARE abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;A href="nelh:333390:0" name=internalLink&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Link to 2010 Annual Evidence Update on Male Urinary Incontinence contents page&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;STRONG&gt;&lt;A href="nelh:333394:0" name=internalLink&gt;&lt;STRONG&gt;Link to 2010 evidence on Male and Female Quality of Life Studies&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <expiryDate>13/01/2012 00:00:00</expiryDate>
  </document>
  <document>
    <id>401037</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=401037]]&gt;</url>
    <title>2011 Annual Evidence Update on Male Urinary Incontinence - Male Urgency Urinary Incontinence and Surgery</title>
    <publicationDate>2011-01-31T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE URINARY INCONTINENCE,URGENCY INCONTINENCE,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2011 Annual Evidence Update on Male Urinary Incontinence - Male Urgency Urinary Incontinence and Surgery&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;A href="nelh:401615:0" name=internalLink&gt;&lt;STRONG&gt;Link to 2011 Annual Evidence Update on Male Urinary Incontinence - contents page &lt;/STRONG&gt;&lt;/A&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Guidelines&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;NICE Guideline: Lower urinary tract symptoms: the management of lower urinary tract symptoms in men. Publication date: 19 May 2010. &lt;A href="nelh:374250:0" name=internalLink&gt;Link to abstract&lt;/A&gt;. &lt;/LI&gt;
&lt;LI&gt;European Association of Urology (EAU): Guidelines on urinary incontinence. &amp;nbsp;Publication date: 01 April 2010. &lt;A href="nelh:148795:0" name=internalLink&gt;Link to abstract&lt;/A&gt;.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Systematic&amp;nbsp;Reviews and Meta-analyses: Evidence&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Jha, S., M. K. Ammembal, et al. (2010). "Impact of incontinence surgery on sexual function: A systematic review and meta-analysis." Neurourology and Urodynamics 29(6): 1112-1113. [NO PUBMED ABSTRACT AVAILABLE - POSTER ONLY]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;&lt;STRONG&gt;&lt;A href="nelh:333390:0" name=internalLink&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Link to 2010 Annual Evidence Update on Male Urinary Incontinence contents page&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;STRONG&gt;&lt;A href="nelh:333394:0" name=internalLink&gt;&lt;STRONG&gt;Link to 2010 evidence on Male and Female Quality of Life Studies&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <expiryDate>13/01/2012 00:00:00</expiryDate>
  </document>
  <document>
    <id>401712</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=401712]]&gt;</url>
    <title>2011 Annual Evidence Update on Male Urinary Incontinence - Overactive bladder</title>
    <publicationDate>2011-01-31T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE URINARY INCONTINENCE,MALE BLADDER DISORDERS,OTHER INCONTINENCE,MALE UROGENITAL DISORDERS,OVERACTIVE BLADDER]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2011 Annual Evidence Update on Male Urinary Incontinence - Overactive bladder&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;A href="nelh:401615:0" name=internalLink&gt;&lt;STRONG&gt;Link to 2011 Annual Evidence Update on Male Urinary Incontinence - contents page &lt;/STRONG&gt;&lt;/A&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Guidelines&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;NICE Guideline: Percutaneous posterior tibial nerve stimulation for overactive bladder syndrome. Publication date: 27 October 2010. &lt;A href="nelh:392563:0" name=internalLink&gt;Link to abstract&lt;/A&gt;. &lt;/LI&gt;
&lt;LI&gt;NICE Guideline: Lower urinary tract symptoms: the management of lower urinary tract symptoms in men. Publication date: 19 May 2010. &lt;A href="nelh:374250:0" name=internalLink&gt;Link to abstract&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;European Association of Urology (EAU): Guidelines on urinary incontinence. &amp;nbsp;Publication date: 01 April 2010. &lt;A href="nelh:148795:0" name=internalLink&gt;Link to abstract&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;LUTS in men, age-related (prostatism): Overactive bladder [&lt;A href="nelh:383923:0" name=internalLink&gt;Link&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Systematic&amp;nbsp;Reviews and Meta-analyses: Evidence&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2011&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Meek, P. D., S. D. Evang, et al. (2011). "Overactive bladder drugs and constipation: a meta-analysis of randomized, placebo-controlled trials." Digestive Diseases &amp;amp; Sciences 56(1): 7-18. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20596778" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Anger, J., A. Weinberg, et al. (2010). "Outcomes of intravesical botulinum toxin for idiopathic overactive bladder symptoms: A systematic review of the literature." Neurourology and Urodynamics 29(2). [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Outcomes%20of%20intravesical%20botulinum%20toxin%20for%20idiopathic%20overactive%20bladder%20symptoms%3A%20A%20systematic%20review%20of%20the%20literature" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Athanasopoulos, A. (2010). "Antimuscarinics and bladder outlet obstruction: From a contraindication to an indication?" Neurourology &amp;amp; Urodynamics 29 Suppl 1: S46-50.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Antimuscarinics%20and%20bladder%20outlet%20obstruction%3A%20From%20a%20contraindication%20to%20an%20indication%3F" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Bartoli, S., G. Aguzzi, et al. (2010). "Impact on Quality of Life of Urinary Incontinence and Overactive Bladder: A Systematic Literature Review." Urology 75(3): 491-500.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Impact%20on%20Quality%20of%20Life%20of%20Urinary%20Incontinence%20and%20Overactive%20Bladder%3A%20A%20Systematic%20Literature%20Review" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Irwin, D. E., I. Milsom, et al. (2010). "Dynamic progression of overactive bladder and urinary incontinence symptoms: A systematic review." European Urology 58(4): 532-543.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Dynamic%20progression%20of%20overactive%20bladder%20and%20urinary%20incontinence%20symptoms%3A%20A%20systematic%20review" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kessler, T. M., L. M. Bachmann, et al. (2010). "Adverse event assessment of antimuscarinics for treating overactive bladder: A network meta-analytic approach." European Urology, Supplements 9(2).&amp;nbsp;[No abstract available]&lt;/LI&gt;
&lt;LI&gt;Latthe, P. M., R. Champaneria, et al. (2010). "Systematic review of the accuracy of ultrasound as the method of measuring bladder wall thickness in the diagnosis of detrusor overactivity." International Urogynecology Journal and Pelvic Floor Dysfunction 21(8): 1019-1024.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Systematic%20review%20of%20the%20accuracy%20of%20ultrasound%20as%20the%20method%20of%20measuring%20bladder%20wall%20thickness%20in%20the%20diagnosis%20of%20detrusor%20overactivity" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Siddiqui, N. Y., J. M. Wu, et al. (2010). "Efficacy and adverse events of sacral nerve stimulation for overactive bladder: A systematic review." Neurourology &amp;amp; Urodynamics 29 Suppl 1: S18-23.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Efficacy%20and%20adverse%20events%20of%20sacral%20nerve%20stimulation%20for%20overactive%20bladder%3A%20A%20systematic%20review" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Griebling, T. L., S. R. Kraus, et al. (2009). "Tolterodine extended release is well tolerated in older subjects." Int J Clin Pract 63(8): 1198-204.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Tolterodine%20extended%20release%20is%20well%20tolerated%20in%20older%20subjects" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Gries, K. S., J. D. Campbell, et al. (2009). "Characterization of treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics." Journal of Urology 181(4 SUPPL. 1). [No abstract available – POSTER ONLY]&lt;/LI&gt;
&lt;LI&gt;Lee, S., B. Malhotra, et al. (2009). "A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder." BMC Medical Research Methodology 9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=A%20meta-analysis%20of%20the%20placebo%20response%20in%20antimuscarinic%20drug%20trials%20for%20overactive%20bladder" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;STRONG&gt;&lt;A href="nelh:333390:0" name=internalLink&gt;
&lt;P&gt;&lt;STRONG&gt;Link to 2010 Annual Evidence Update on Male Urinary Incontinence contents page&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;STRONG&gt;&lt;A href="nelh:333394:0" name=internalLink&gt;&lt;STRONG&gt;Link to 2010 evidence on Male and Female Quality of Life Studies&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <expiryDate>17/01/2012 00:00:00</expiryDate>
  </document>
  <document>
    <id>401030</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=401030]]&gt;</url>
    <title>2011 Annual Evidence Update on Male Urinary Incontinence - Post-prostatectomy and Urinary Incontinence</title>
    <publicationDate>2011-01-31T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE URINARY INCONTINENCE,OTHER INCONTINENCE,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2011 Annual Evidence Update on Male Urinary Incontinence - Post-prostatectomy and Urinary Incontinence&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;A href="nelh:401615:0" name=internalLink&gt;&lt;STRONG&gt;Link to 2011 Annual Evidence Update on Male Urinary Incontinence - contents page &lt;/STRONG&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Guidelines&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;NICE Guideline: Lower urinary tract symptoms: the management of lower urinary tract symptoms in men. Publication date: 19 May 2010. &lt;A href="nelh:374250:0" name=internalLink&gt;Link to abstract&lt;/A&gt;. &lt;/LI&gt;
&lt;LI&gt;European Association of Urology (EAU): Guidelines on urinary incontinence. &amp;nbsp;Publication date: 01 April 2010. &lt;A href="nelh:148795:0" name=internalLink&gt;Link to abstract&lt;/A&gt;.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Systematic&amp;nbsp;Reviews and Meta-analyses: Evidence&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Loughlin, K. R. and M. M. Prasad (2010). "Post-prostatectomy urinary incontinence: a confluence of 3 factors." Journal of Urology 183(3): 871-877.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20083262" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Walz, J., A. L. Burnett, et al. (2010). "A critical analysis of the current knowledge of surgical anatomy related to optimization of cancer control and preservation of continence and erection in candidates for radical prostatectomy." European Urology 57(2): 179-92. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=A%20critical%20analysis%20of%20the%20current%20knowledge%20of%20surgical%20anatomy%20related%20to%20optimization%20of%20cancer%20control%20and%20preservation%20of%20continence%20and%20erection%20in%20candidates%20for%20radical%20prostatectomy" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Davie, C., T. Cook, et al. (2009). "Pelvic floor muscle training for the management of urinary incontinence following radical prostatectomy." Journal of the Association of Chartered Physiotherapists in Women's Health(105): 4-24.&amp;nbsp;[No abstract available]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;&lt;/UL&gt;
&lt;UL&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Significant Randomised Controlled Trial&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Goode, P.S., Burgio, K.L., Johnson II, T.M., Clay, O.J., Roth, D.L., Markland, A.D. (2011) "Behavioural Therapy With or Without Biofeedback and Pelvic Floor Electrical Stimulation for Persistent Postprostatectomy Incontinence." JAMA 305(2):151-159. [&lt;A href="http://jama.ama-assn.org/content/305/2/151.abstract" target="_blank"&gt;Link to JAMA abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:333390:0" name=internalLink&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Link to 2010 Annual Evidence Update on Male Urinary Incontinence contents page&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;STRONG&gt;&lt;A href="nelh:333394:0" name=internalLink&gt;&lt;STRONG&gt;Link to 2010 evidence on Male and Female Quality of Life Studies&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <expiryDate>13/01/2012 00:00:00</expiryDate>
  </document>
  <document>
    <id>295340</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.kidney.org.uk/campaigns/Dialysis/Manifesto/dialysis-manifesto.pdf]]&gt;</url>
    <title>A dialysis manifesto- Better dialysis services, saving lives and improving the quality of lives</title>
    <publicationDate>2008-10-04T00:00:00</publicationDate>
    <publisher>National Kidney Federation</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ PERITONEAL DIALYSIS,HAEMODIALYSIS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,DIALYSIS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A report of the findings of the 2007 Dialysis Summit, hosted by The All-Party Parliamentary Kidney Group</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Extract&lt;/EM&gt;&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;Many patients are not offered a choice between different types of dialysis, even though the National Service Framework (NSF) for Renal Services mandates patient choice in its standards of care. Essential components of effective dialysis care, including provision of early vascular and PD catheter access surgery and assessment for pre-emptive transplantation, are lacking in some areas.&lt;/P&gt;
&lt;P&gt;This manifesto, produced from discussions at a summit of all stakeholders in dialysis identifies many of the current challenges facing the field. It identifies 10 key actions to improve dialysis services:&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Increase dialysis provision to match patient numbers and plan for the expected increases in prevalence 
&lt;LI&gt;Enable choice of dialysis for every patient 
&lt;LI&gt;Improve early recognition of patients who will need dialysis 
&lt;LI&gt;Consider pre-emptive transplantation for all patients before dialysis 
&lt;LI&gt;Provide vascular access and PD catheter access surgery early 
&lt;LI&gt;Ensure every patient has an individualised care plan 
&lt;LI&gt;Use the Renal Registry to plan and audit dialysis services 
&lt;LI&gt;Improve the provision of ‘away from unit’ dialysis 
&lt;LI&gt;Implement free car parking at hospitals for all people using dialysis services 
&lt;LI&gt;Maintain the commissioning status of dialysis services as specialised services.&lt;/LI&gt;&lt;/OL&gt;]]&gt;</body>
    <lastReviewDate>01/10/2010 10:39:54</lastReviewDate>
    <expiryDate>01/10/2011 10:39:54</expiryDate>
  </document>
  <document>
    <id>379540</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;db=pubmed&amp;cmd=Search&amp;TransSchema=title&amp;term=A%20Randomized%2C%20Controlled%20Trial%20of%20Early%20versus%20Late%20Initiation%20of%20Dialysis]]&gt;</url>
    <title>A Randomized, Controlled Trial of Early versus Late Initiation of Dialysis</title>
    <publicationDate>2010-06-27T00:00:00</publicationDate>
    <publisher>New England Journal of Medicine</publisher>
    <publicationType>RANDOMISED CONTROLLED TRIAL</publicationType>
    <topics>&lt;![CDATA[ STARTING HAEMODIALYSIS,INTERVENTIONS,HAEMODIALYSIS,LIVING WITH DIALYSIS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES,DIALYSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;ABSTRACT&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background&lt;/STRONG&gt; In clinical practice, there is considerable variation in the timing of the initiation of maintenance dialysis for patients with stage V chronic kidney disease, with a worldwide trend toward early initiation. In this study, conducted at 32 centers in Australia and New Zealand, we examined whether the timing of the initiation of maintenance dialysis influenced survival among patients with chronic kidney disease.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods&lt;/STRONG&gt; We randomly assigned patients 18 years of age or older with progressive chronic kidney disease and an estimated glomerular filtration rate (GFR) between 10.0 and 15.0 ml per minute per 1.73 m2 of body-surface area (calculated with the use of the Cockcroft–Gault equation) to planned initiation of dialysis when the estimated GFR was 10.0 to 14.0 ml per minute (early start) or when the estimated GFR was 5.0 to 7.0 ml per minute (late start). The primary outcome was death from any cause.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results&lt;/STRONG&gt; Between July 2000 and November 2008, a total of 828 adults (mean age, 60.4 years; 542 men and 286 women; 355 with diabetes) underwent randomization, with a median time to the initiation of dialysis of 1.80 months (95% confidence interval [CI], 1.60 to 2.23) in the early-start group and 7.40 months (95% CI, 6.23 to 8.27) in the late-start group. A total of 75.9% of the patients in the late-start group initiated dialysis when the estimated GFR was above the target of 7.0 ml per minute, owing to the development of symptoms. During a median follow-up period of 3.59 years, 152 of 404 patients in the early-start group (37.6%) and 155 of 424 in the late-start group (36.6%) died (hazard ratio with early initiation, 1.04; 95% CI, 0.83 to 1.30; P=0.75). There was no significant difference between the groups in the frequency of adverse events (cardiovascular events, infections, or complications of dialysis).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions&lt;/STRONG&gt; In this study, planned early initiation of dialysis in patients with stage V chronic kidney disease was not associated with an improvement in survival or clinical outcomes. &lt;/P&gt;
&lt;P&gt;(Australian New Zealand Clinical Trials Registry number, 12609000266268.)&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Cooper BA, Branley P, Bulfone L, Collins JF, Craig JC, Fraenkel MB et al. "A Randomized, Controlled Trial of Early Versus Late Initiation of Dialysis". New England Journal of Medicine. Published online June 27, 2010. (10.1056/NEJMoa1000552)&lt;/P&gt;]]&gt;</body>
    <expiryDate>28/06/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>197287</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.cancerhelp.org.uk/trials/trials/trial.asp?freetextsearch=&amp;searchtype=select&amp;trial=5054&amp;trialno=5050&amp;spage=1&amp;objective=0&amp;cancer=0&amp;stage=0&amp;phase=0&amp;treatment=0&amp;location=0]]&gt;</url>
    <title>A study of genetic causes of kidney cancer</title>
    <publicationDate>2002-01-31T00:00:00</publicationDate>
    <publisher>Cancer Research UK</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ RENAL CANCER,NEW RESEARCH,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Details of clinical trial</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Extract from website&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;This study is looking at people who may have an inherited genetic fault or medical condition that increases their risk of developing renal cell carcinoma (RCC), the most common form of kidney cancer. The aim of the study is to find out more about the genetic cause of RCC and more about how gene faults may increase risk.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>06/12/2010 12:32:35</lastReviewDate>
    <expiryDate>06/12/2011 12:32:35</expiryDate>
  </document>
  <document>
    <id>284633</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.eurekalert.org/pub_releases/2008-05/niod-kdw050508.php]]&gt;</url>
    <title>AASK Cohort Study - the African American Study of Kidney Disease and Hypertension</title>
    <publicationDate>2008-05-05T00:00:00</publicationDate>
    <publisher>National Institutes of Health / National Institute of Diabetes and Digestive and Kidney Diseases</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ NEW RESEARCH,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Kidney disease worsens in a fourth of African-Americans despite therapy for hypertension - latest research results from AASK Cohort Study</description>
    <body>&lt;![CDATA[ &lt;P&gt;Extract&lt;/P&gt;
&lt;P&gt;The best available treatment for chronic kidney disease from high blood pressure did not keep the disease from substantially worsening in about a fourth of African-Americans studied, according to long-term results of a National Institutes of Health study published April 28, 2008, in the Archives of Internal Medicine.&lt;/P&gt;
&lt;P&gt;The largest and longest study of chronic kidney disease in African-Americans — the African American Study of Kidney Disease and Hypertension (AASK) — found that the disease substantially worsened in about one-fourth of participants, even with very good blood pressure control and use of kidney-protecting medications, currently the best available treatment. This subgroup of patients either lost half their kidney function or reached kidney failure, also known as end-stage renal disease. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;Original article - Archives of Internal Medicine, 2008, 168 (8): 832-839&lt;/P&gt;
&lt;P&gt;'Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goad on progression of hypertensive chronic kidny disease in African Americans'&lt;/P&gt;
&lt;P&gt;&lt;FONT face="verdana, arial, helvetica, sans-serif" color=#003399 size=4&gt;&lt;STRONG&gt;&lt;FONT face="verdana, arial, helvetica, sans-serif" size=2&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>27/05/2010 10:01:03</lastReviewDate>
    <expiryDate>27/05/2011 10:01:03</expiryDate>
    <relatedLinks>&lt;a href="http://www.eurekalert.org/pub_releases/2008-05/niod-kdw050508.php" title="Link to press release"/&gt;&lt;a href="http://archinte.ama-assn.org/cgi/content/abstract/168/8/832" title="Link to original article - Arch Intern Med. 2008;168(8):832-839."/&gt;</relatedLinks>
    <creator>National Institutes of Health / National Institute of Diabetes and Digestive and Kidney Diseases</creator>
  </document>
  <document>
    <id>224187</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.kidneyresearchuk.org/special-projects/able.php]]&gt;</url>
    <title>ABLE Projects</title>
    <publicationDate>2006-01-31T00:00:00</publicationDate>
    <publisher>Kidney Research Uk</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ PREDISPOSING FACTORS,ETHNIC GROUP,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Summaries of the ABLE Projects</description>
    <body>&lt;![CDATA[ Information about the following projects: 
&lt;P&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Brent Pilot Study 
&lt;LI&gt;The Leicester Project 
&lt;LI&gt;The West London Project 
&lt;LI&gt;The African-Caribbean Project in Birmingham 
&lt;LI&gt;The Diabetes Patient Pathway Project 
&lt;LI&gt;The Organ Donation Project&lt;/LI&gt;&lt;/UL&gt;&lt;/PAGEBODY&gt;&lt;/PAGE&gt;&lt;/ARTICLE&gt;]]&gt;</body>
    <lastReviewDate>06/12/2010 12:32:50</lastReviewDate>
    <expiryDate>06/12/2011 12:32:50</expiryDate>
  </document>
  <document>
    <id>177164</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.renalreg.com/Report-Area/Report%202005/chap-05.pdf]]&gt;</url>
    <title>Access to the renal transplant waiting list, time to listing, diabetic access to transplantation and the influence of social deprivation</title>
    <publicationDate>2005-12-01T00:00:00</publicationDate>
    <publisher>UK Renal Registry and UK Transplant</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ TRANSPLANTATION,ASSESSMENT/SELECTION,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Chapter 5 of the UK Renal Registry Report 2005 prepared jointly with UK Transplant.</description>
    <body>&lt;![CDATA[ Chapter examines patient specific factors and renal unit/centre&amp;nbsp;&amp;nbsp;specific factors that affect access to renal transplantation. There is a useful summary of&amp;nbsp;the main findings.&amp;nbsp;]]&gt;</body>
    <lastReviewDate>23/09/2010 10:06:57</lastReviewDate>
    <expiryDate>23/09/2011 10:06:57</expiryDate>
  </document>
  <document>
    <id>288503</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.bestbets.org/bets/bet.php?id=533]]&gt;</url>
    <title>Accuracy of negative dipstick urinalysis in ruling out urinary tract infection in adults</title>
    <publicationDate>2003-07-01T00:00:00</publicationDate>
    <publisher>Best Bets</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ RENAL TRACT INFECTIONS,UPPER URINARY TRACT INFECTION,LOWER URINARY TRACT INFECTION,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Critically appraised topic from Best Bets</description>
    <body>&lt;![CDATA[ &lt;P&gt;Extract&lt;/P&gt;
&lt;H2 class=noSpacing&gt;Clinical Bottom Line&lt;/H2&gt;
&lt;P&gt;Dipstick urinalysis is of insufficient sensitivity to be used to rule out UTI in patients with one or more symptoms.&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>01/07/2010 14:49:54</lastReviewDate>
    <expiryDate>01/07/2011 14:49:54</expiryDate>
  </document>
  <document>
    <id>331441</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.kidneycare.nhs.uk/Achieving_Autonomy_for_Kidney_Services_FINAL-pdf.cmsdoc]]&gt;</url>
    <title>Achieving Autonomy for Kidney Services: Seven Steps Toolkit 2009</title>
    <publicationDate>2009-11-27T00:00:00</publicationDate>
    <publisher>NHS Kidney Care</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ NATIONAL SERVICE FRAMEWORK FOR RENAL SERVICES/POLICY DOCUMENTS,KIDNEY DISEASE IN CHILDREN AND ADOLESCENTS,COMPLICATIONS OF KIDNEY DISEASE,INHERITED KIDNEY DISEASE,RENOVASCULAR DISEASES,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,ACUTE KIDNEY INJURY,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This is a toolkit for local NHS commissioners and providers.</description>
    <body>&lt;![CDATA[ Contents includes: 
&lt;P&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Using this toolkit 
&lt;LI&gt;Step 1 - Setting the Scene 
&lt;LI&gt;Step 2 - Strategy 
&lt;LI&gt;Step 3 - Service Planning 
&lt;LI&gt;Step 4 - Structure 
&lt;LI&gt;Step 5 - Systems 
&lt;LI&gt;Step 6 - Sustainability 
&lt;LI&gt;Step 7 - Separation&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
    <lastReviewDate>03/11/2010 15:38:37</lastReviewDate>
    <expiryDate>03/11/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>333071</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_109977.pdf]]&gt;</url>
    <title>Achieving Excellence in Kidney Care: Delivering the National Service Framework for Renal Services</title>
    <publicationDate>2009-12-14T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ COMPLICATIONS OF KIDNEY DISEASE,OTHER CONDITIONS - ADULTS,KIDNEY DISEASE IN CHILDREN AND ADOLESCENTS,PERITONEAL DIALYSIS,UK PROFESSIONAL,TRANSPLANTATION,NATIONAL SERVICE FRAMEWORK FOR RENAL SERVICES/POLICY DOCUMENTS,RENAL TRACT INFECTIONS,HAEMODIALYSIS,ACUTE KIDNEY INJURY,ORGANISATIONS,KIDNEY AND BLADDER STONES,GLOMERULONEPHRITIS,RENOVASCULAR DISEASES,INHERITED KIDNEY DISEASE,RENAL CANCER,END-OF-LIFE CARE,QUALITY AND MONITORING,HEALTH MANAGEMENT,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,CLINICAL SYSTEMS IMPROVEMENT,INNOVATION AND IMPROVEMENT,SYSTEMS THINKING,SERVICE REDESIGN,ORGANISATIONS,KIDNEY DISEASES,DIALYSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The National Service Framework for Renal Services set out the first ever set of national standards for the treatment of renal disease. This report highlights progress over the five years since the publication of the National Service Framework.</description>
    <body>&lt;![CDATA[ &lt;P&gt;The report summarises the standards of care, quality requirements and the markers of good practice identified in the NSF, and then looks at progress made in the following areas:&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;A patient-centred service&lt;/LI&gt;
&lt;LI&gt;Prevention, early detection and management of chronic kidney disease&lt;/LI&gt;
&lt;LI&gt;Preparation, choice and dialysis access surgery&lt;/LI&gt;
&lt;LI&gt;Dialysis&lt;/LI&gt;
&lt;LI&gt;NHS Kidney Care – ‘Better Kidney Care for All’&lt;/LI&gt;
&lt;LI&gt;Transplantation&lt;/LI&gt;
&lt;LI&gt;Acute kidney injury (acute renal failure)&lt;/LI&gt;
&lt;LI&gt;End-of-life care&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;BR&gt;The NHS has made significant progress in diagnosing kidney disease through raising awareness and better diagnostic testing, and further advances will be made with initiatives such as NHS Health Checks and NHS Kidney Care.&amp;nbsp; There have also been significant improvements in treatment for those living with kidney disease; as well as increasing available capacity for dialysis, a focus on patient-centred care has led to innovative ways of delivering services for kidney patients whose condition is serious enough to require dialysis.&amp;nbsp; An increase in the number of satellite renal units means that care can be delivered closer to patients’ homes making it easier for them to fit dialysis into their lives.&amp;nbsp; On a national level NHS Kidney Care is working with kidney services to improve patient care. &lt;/P&gt;]]&gt;</body>
    <lastReviewDate>26/11/2010 15:25:52</lastReviewDate>
    <expiryDate>26/11/2011 15:25:52</expiryDate>
  </document>
  <document>
    <id>332400</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=332400]]&gt;</url>
    <title>Acute Kidney Injury: Systematic reviews and meta-analyses</title>
    <publicationDate>2011-01-14T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,ACUTE KIDNEY INJURY,MANAGEMENT,CAUSES AND RISK FACTORS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Acute Kidney Injury: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2011&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Vlasschaert, M. E., S. A. Bejaimal, et al. (2011). "Validity of administrative database coding for kidney disease: a systematic review." Am J Kidney Dis 57(1): 29-43. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/21184918" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Acharya, M. and J. Dunning (2010). "Does the use of non-steroidal anti-inflammatory drugs after cardiac surgery increase the risk of renal failure?" Interactive Cardiovascular and Thoracic Surgery 11(4): 461-467.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20639308" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Arana, E. and F. Catala-Lopez (2010). "[Contrast-induced nephropathy in patients at risk of renal failure undergoing computed tomography: systematic review and meta-analysis of randomized controlled trials]. [Spanish] Nefropatia inducida por contraste en pacientes de riesgo con insuficiencia renal explorados con tomografia computarizada: revision sistematica y metaanalisis de ensayos clinicos aleatorizados." Medicina Clinica 135(8): 343-50. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Contrast-induced%20nephropathy%20in%20patients%20at%20risk%20of%20renal%20failure%20undergoing%20computed%20tomography%3A%20systematic%20review%20and%20meta-analysis%20of%20randomized%20controlled%20trials" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Ashworth, A. and S. T. Webb (2010). "Does the prophylactic administration of N-acetylcysteine prevent acute kidney injury following cardiac surgery?" Interact Cardiovasc Thorac Surg 11(3): 303-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20570977" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Brar, S. S., S. Hiremath, et al. (2010). "A 2010 updated meta-analysis for the prevention of contrast induced nephropathy with sodium bicarbonate: The importance of the small study effect." Journal of the American College of Cardiology 56(13 SUPPL. 1): B76-B77.&amp;nbsp;[No PubMed abstract available]&lt;/LI&gt;
&lt;LI&gt;Brusselaers, N., S. Monstrey, et al. "Outcome of acute kidney injury in severe burns: a systematic review and meta-analysis." Intensive Care Medicine 36(6): 915-25. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20333353" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Casey, E. T., B. P. Gupta, et al. "The dose of continuous renal replacement therapy for acute renal failure: a systematic review and meta-analysis." Renal Failure 32(5): 555-561.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=The%20dose%20of%20continuous%20renal%20replacement%20therapy%20for%20acute%20renal%20failure%3A%20a%20systematic%20review%20and%20meta-analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Dart, A. B., T. C. Mutter, et al. "Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function." Cochrane Database Syst Rev(1): CD007594.&amp;nbsp;[&lt;A href="nelh:341786:0" name=internalLink&gt;Link to Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Dennen, P., I. S. Douglas, et al. "Acute kidney injury in the intensive care unit: an update and primer for the intensivist." Crit Care Med 38(1): 261-75. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19829099" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;From, A. M., F. J. Al Badarin, et al. (2010). "Iodixanol versus low-osmolar contrast media for prevention of contrast induced nephropathy: meta-analysis of randomized, controlled trials." Circulation: Cardiovascular Interventions 3(4): 351-8. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Iodixanol%20versus%20low-osmolar%20contrast%20media%20for%20prevention%20of%20contrast%20induced%20nephropathy%3A%20meta-analysis%20of%20randomized%2C%20controlled%20trials" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Gupta, D., L. Bachegowda, et al. (2010). "Role of plasmapheresis in the management of myeloma kidney: A systematic review." Hemodialysis International 14(4): 355-63. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Role%20of%20plasmapheresis%20in%20the%20management%20of%20myeloma%20kidney%3A%20A%20systematic%20review" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hoste, E. A. J., J. J. De Waele, et al. (2010). "Sodium bicarbonate for prevention of contrast-induced acute kidney injury: A systematic review and meta-analysis." Nephrology Dialysis Transplantation 25(3): 747-758.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19703838" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Jun, M., H. J. Heerspink, et al. "Intensities of renal replacement therapy in acute kidney injury: a systematic review and meta-analysis." Clinical Journal of The American Society of Nephrology: CJASN 5(6): 956-963.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Intensities%20of%20renal%20replacement%20therapy%20in%20acute%20kidney%20injury%3A%20a%20systematic%20review%20and%20meta-analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kanbay, M., B. Kasapoglu, et al. "Acute tubular necrosis and pre-renal acute kidney injury: utility of urine microscopy in their evaluation- a systematic review." International Urology &amp;amp; Nephrology 42(2): 425-433.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed?term=acute%20tubular%20necrosis%20and%20pre-renal%20acute%20kidney%20injury%20utility%20of%20urine%20microscopy%20in%20their%20evaluation%20a%20systematic%20review&amp;amp;cmd=correctspelling" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Karvellas, C., M. Farhat, et al. (2010). "Timing of initiation of renal replacement therapy in acute kidney injury: A meta-analysis." Critical Care Medicine 38.&amp;nbsp;[No PubMed abstract available]&lt;/LI&gt;
&lt;LI&gt;Kunadian, V., A. Zaman, et al. "Sodium bicarbonate for the prevention of contrast induced nephropathy: A meta-analysis of published clinical trials." Eur J Radiol. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20074886" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Laake, J. H. and J. F. Bugge "[Acute renal failure in critically ill patients.]." Tidsskr Nor Laegeforen 130(2): 158-61. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20125208" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Li, Y., X. Tang, et al. "Nutritional support for acute kidney injury." Cochrane Database Syst Rev(1): CD005426. [&lt;A href="nelh:341717:0" name=internalLink&gt;Link to Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Medical Advisory Secretariat (2010). "Kidney and liver organ transplantation in persons with human immunodeficiency virus: An evidence-based analysis." Ontario Health Technology Assessment Series 10(4). [&lt;A href="http://www.health.gov.on.ca/english/providers/program/mas/tech/reviews/pdf/rev_organ_transplant_20100322.pdf" target="_blank"&gt;Link to full-text PDF&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Parikh, C. R., J. C. Lu, et al. (2010). "Tubular proteinuria in acute kidney injury: A critical evaluation of current status and future promise." Annals of Clinical Biochemistry 47(4): 301-312.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20511371" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Park, M., S. G. Coca, et al. (2010). "Prevention and treatment of acute kidney injury in patients undergoing cardiac surgery: a systematic review." American Journal of Nephrology 31(5): 408-418.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Prevention%20and%20treatment%20of%20acute%20kidney%20injury%20in%20patients%20undergoing%20cardiac%20surgery%3A%20a%20systematic%20review" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Quinlivan, R., A. Martinuzzi, et al. (2010). "Pharmacological and nutritional treatment for McArdle disease (Glycogen Storage Disease type V)." Cochrane Database Syst Rev 12: CD003458.&amp;nbsp;[&lt;A href="http://onlinelibrary.wiley.com/o/cochrane/clsysrev/articles/CD003458/frame.html" target="_blank"&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Safdar, A., J. Ma, et al. (2010). "Drug-induced nephrotoxicity caused by amphotericin B lipid complex and liposomal amphotericin B: A review and meta-analysis." Medicine 89(4): 236-244.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20616663" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Seabra, V. F., S. Alobaidi, et al. (2010). "Off-pump coronary artery bypass surgery and acute kidney injury: A meta-analysis of randomized controlled trials." Clinical Journal of the American Society of Nephrology 5(10): 1734-1744.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20671222" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Song, K., S. Jiang, et al. (2010). "Renal Replacement Therapy for Prevention of Contrast-Induced Acute Kidney Injury: A Meta-Analysis of Randomized Controlled Trials." Am J Nephrol 32(5): 497-504. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Renal%20Replacement%20Therapy%20for%20Prevention%20of%20Contrast-Induced%20Acute%20Kidney%20Injury%3A%20A%20Meta-Analysis%20of%20Randomized%20Controlled%20Trials" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Trivedi, H., R. Nadella, et al. (2010). "Hydration with sodium bicarbonate for the prevention of contrast-induced nephropathy: a meta-analysis of randomized controlled trials." Clinical Nephrology 74(4): 288-96. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Hydration%20with%20sodium%20bicarbonate%20for%20the%20prevention%20of%20contrast-induced%20nephropathy%3A%20a%20meta-analysis%20of%20randomized%20controlled%20trials" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Van Wert, R., J. O. Friedrich, et al. (2010) "High-dose renal replacement therapy for acute kidney injury: Systematic review and meta-analysis." Critical Care Medicine 38(5): 1360-9. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20308884" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Walters GD, Willis NS, Craig JC. Interventions for renal vasculitis in adults. A systematic revew. BMC Nephrology 2010, 11:12. [&lt;A href="http://www.biomedcentral.com/1471-2369/11/12" target="_blank"&gt;Link to full-text article&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Wiedermann, C. J., S. Dunzendorfer, et al. (2010). "Hyperoncotic colloids and acute kidney injury: a meta-analysis of randomized trials." Crit Care 14(5): R191. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Hyperoncotic%20colloids%20and%20acute%20kidney%20injury%3A%20a%20meta-analysis%20of%20randomized%20trials" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Wiedermann, C. J., W. Wiedermann, et al. (2010). "Hypoalbuminemia and acute kidney injury: a meta-analysis of observational clinical studies." Intensive Care Medicine 36(10): 1657-65. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Hypoalbuminemia%20and%20acute%20kidney%20injury%3A%20a%20meta-analysis%20of%20observational%20clinical%20studies" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Zhongheng, Z., X. Xiao, et al. (2010). "Intensive- vs less-intensive-dose continuous renal replacement therapy for the intensive care unit-related acute kidney injury: A meta-analysis and systematic review." Journal of Critical Care 25(4): 595-600.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20619597" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Adabag, A. S., A. Ishani, et al. (2009). "Efficacy of N-acetylcysteine in preventing renal injury after heart surgery: a systematic review of randomized trials." Eur Heart J. Aug;30(15):1910-7.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19282300" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Baker, W. L., M. W. Anglade, et al. (2009). "Use of N-acetylcysteine to reduce post-cardiothoracic surgery complications: a meta-analysis." Eur J Cardiothorac Surg 35(3): 521-7. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19147369" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Belsey, J., O. Epstein, et al. (2009). "Systematic review: Adverse event reports for oral sodium phosphate and polyethylene glycol." Alimentary Pharmacology and Therapeutics 29(1): 15-28.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18729847" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Brar, S. S., S. Hiremath, et al. (2009). "Sodium bicarbonate for the prevention of contrast induced-acute kidney injury: a systematic review and meta-analysis." Clin J Am Soc Nephrol 4(10): 1584-92.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19713291" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Brienza, N., M. T. Giglio, et al. (2009). "Does perioperative hemodynamic optimization protect renal function in surgical patients? A meta-analytic study." Crit Care Med 37(6): 2079-90.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19384211" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Brunelli, S. M. (2009). "Association between oral sodium phosphate bowel preparations and kidney injury: a systematic review and meta-analysis." Am J Kidney Dis 53(3): 448-56.&amp;nbsp;[&lt;A href="nelh:331836:0" name=internalLink&gt;Link to&amp;nbsp;DARE abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Choi, G., C. D. Gomersall, et al. (2009). "Principles of antibacterial dosing in continuous renal replacement therapy." Crit Care Med 37(7): 2268-82.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19487930" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Coca, S. G., B. Yusuf, et al. (2009). "Long-term risk of mortality and other adverse outcomes after acute kidney injury: a systematic review and meta-analysis." Am J Kidney Dis 53(6): 961-73.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19346042" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Faber, P. and A. A. Klein (2009). "Acute kidney injury and renal replacement therapy in the intensive care unit." Nurs Crit Care 14(4): 207-12.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19531039" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Gagne, J. J., D. E. Griesdale, et al. (2009). "Aprotinin and the risk of death and renal dysfunction in patients undergoing cardiac surgery: a meta-analysis of epidemiologic studies." Pharmacoepidemiol Drug Saf 18(4): 259-68.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19185048" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Haase, M., R. Bellomo, et al. (2009). "Accuracy of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in Diagnosis and Prognosis in Acute Kidney Injury: A Systematic Review and Meta-analysis." American Journal of Kidney Diseases 54(6): 1012-1024. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19850388" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Heintz, B. H., G. R. Matzke, et al. (2009). "Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis." Pharmacotherapy 29(5): 562-77.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19397464" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Ho, K. M. and D. J. Morgan (2009). "Meta-analysis of N-acetylcysteine to prevent acute renal failure after major surgery." Am J Kidney Dis 53(1): 33-40.&amp;nbsp;[&lt;A href="nelh:326972:0" name=internalLink&gt;Link to&amp;nbsp;DARE abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hoste, E. A., J. J. De Waele, et al. (2009). "Sodium bicarbonate for prevention of contrast-induced acute kidney injury: a systematic review and meta-analysis." Nephrol Dial Transplant. Aug 23. [Epub ahead of print]&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19703838" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Joannidis, M., W. Druml, et al. (2009). "Prevention of acute kidney injury and protection of renal function in the intensive care unit : Expert opinion of the working group for nephrology, ESICM." Intensive Care Med. Nov 17 [Epub ahead of print]&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19921152" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kanbay, M., B. Kasapoglu, et al. (2009). "Acute tubular necrosis and pre-renal acute kidney injury: utility of urine microscopy in their evaluation- a systematic review." Int Urol Nephrol. Nov 17 [Epub ahead of print]&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19921458" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Karajala, V., W. Mansour, et al. (2009). "Diuretics in acute kidney injury." Minerva Anestesiol 75(5): 251-7.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18636060" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Leung, A. K. and W. W. Yan (2009). "Renal replacement therapy in critically ill patients." Hong Kong Med J 15(2): 122-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19342738" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lu, J. C., S. G. Coca, et al. (2009). "Searching for genes that matter in acute kidney injury: a systematic review." Clin J Am Soc Nephrol 4(6): 1020-31.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19443624" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Nigwekar, S. U. and P. Kandula (2009). "N-acetylcysteine in cardiovascular-surgery-associated renal failure: a meta-analysis." Ann Thorac Surg 87(1): 139-47.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19101287" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Nigwekar, S. U., P. Kandula, et al. (2009). "Off-Pump Coronary Artery Bypass Surgery and Acute Kidney Injury: A Meta-analysis of Randomized and Observational Studies." Am J Kidney Dis.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19406542" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Nigwekar, S. U., S. D. Navaneethan, et al. (2009). "Atrial natriuretic peptide for preventing and treating acute kidney injury." Cochrane Database Syst Rev(4): CD006028.&amp;nbsp;[&lt;A href="nelh:327177:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Nigwekar, S. U., S. D. Navaneethan, et al. (2009). "Atrial natriuretic peptide for management of acute kidney injury: a systematic review and meta-analysis." Clin J Am Soc Nephrol 4(2): 261-72.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19073785" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Nordon, I. M., R. J. Hinchliffe, et al. (2009). "Modern treatment of juxtarenal abdominal aortic aneurysms with fenestrated endografting and open repair--a systematic review." Eur J Vasc Endovasc Surg 38(1): 35-41.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19346140" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Reed, M., P. Meier, et al. (2009). "The Relative Renal Safety of Iodixanol Compared With Low-Osmolar Contrast Media. A Meta-Analysis of Randomized Controlled Trials." JACC: Cardiovascular Interventions 2(7): 645-654.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19628188" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Rodriguez-Capote, K., C. M. Balion, et al. (2009). "Utility of urine myoglobin for the prediction of acute renal failure in patients with suspected rhabdomyolysis: a systematic review." Clin Chem 55(12): 2190-7.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19797717" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Umbreit, E. C., J. C. Routh, et al. (2009). "Nonoperative management of nonvascular grade IV blunt renal trauma in children: meta-analysis and systematic review." Urology 74(3): 579-82.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19589574" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Wargo, K. A. and W. M. Banta (2009). "A comprehensive review of the loop diuretics: should furosemide be first line?" Ann Pharmacother 43(11): 1836-47.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19843838" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Alonso, A., J. Lau, et al. (2008). "Biocompatible hemodialysis membranes for acute renal failure." Cochrane Database Syst Rev(1): CD005283. [&lt;A href="nelh:239188:0" name=internalLink&gt;Link to Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Bell, M. (2008). "Acute kidney injury: new concepts, renal recovery." Nephron Clin Pract 109(4): c224-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18802371" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Coca, S. G., R. Yalavarthy, et al. (2008). "Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review." Kidney Int 73(9): 1008-16.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18094679" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Coldstream, F. and A. le May (2008). "A literature review of the potential effects of having a parent with chronic renal failure." J Clin Nurs 17(5A): 98-105.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18298760" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Ghahramani, N., S. Shadrou, et al. (2008). "A systematic review of continuous renal replacement therapy and intermittent haemodialysis in management of patients with acute renal failure." Nephrology (Carlton) 13(7): 570-8.&amp;nbsp;[&lt;A href="nelh:342903:0" name=internalLink&gt;Link to&amp;nbsp;DARE abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hogan, S. E., P. L'Allier, et al. (2008). "Current role of sodium bicarbonate-based preprocedural hydration for the prevention of contrast-induced acute kidney injury: a meta-analysis." Am Heart J 156(3): 414-21.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18760120" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kellum, J. A., M. Leblanc, et al. (2008). "Acute renal failure." Clin Evid (Online) 2008.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19445797" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Landoni, G., G. G. Biondi-Zoccai, et al. (2008). "Fenoldopam reduces the need for renal replacement therapy and in-hospital death in cardiovascular surgery: a meta-analysis." J Cardiothorac Vasc Anesth 22(1): 27-33.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18249327" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Langenberg, C., S. M. Bagshaw, et al. (2008). "The histopathology of septic acute kidney injury: a systematic review." Crit Care 12(2): R38.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18325092" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Pannu, N., S. Klarenbach, et al. (2008). "Renal replacement therapy in patients with acute renal failure: a systematic review." JAMA 299(7): 793-805.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18285591" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Pinsky, M. R., P. Brophy, et al. (2008). "Fluid and volume monitoring." Int J Artif Organs 31(2): 111-26.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18311728" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Ricci, Z., D. Cruz, et al. (2008). "The RIFLE criteria and mortality in acute kidney injury: A systematic review." Kidney Int 73(5): 538-46.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18160961" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Schmitt, R., S. Coca, et al. (2008). "Recovery of kidney function after acute kidney injury in the elderly: a systematic review and meta-analysis." Am J Kidney Dis 52(2): 262-71.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18511164" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Seabra, V. F., E. M. Balk, et al. (2008). "Timing of renal replacement therapy initiation in acute renal failure: a meta-analysis." Am J Kidney Dis 52(2): 272-84.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18562058" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Walters, G., N. S. Willis, et al. (2008). "Interventions for renal vasculitis in adults." Cochrane Database Syst Rev(3): CD003232.&amp;nbsp;[&lt;A href="nelh:293689:0" name=internalLink&gt;Link to Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Bagshaw, S. M., A. Delaney, et al. (2007). "Loop diuretics in the management of acute renal failure: a systematic review and meta-analysis." Crit Care Resusc 9(1): 60-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17352669" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Bagshaw, S. M., C. Langenberg, et al. (2007). "Urinary biomarkers in septic acute kidney injury." Intensive Care Med 33(7): 1285-96.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17487471" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Bagshaw, S. M., C. Langenberg, et al. (2007). "A systematic review of urinary findings in experimental septic acute renal failure." Crit Care Med 35(6): 1592-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17452939" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Barrio, V., C. Quereda, et al. (2007). "[Does continuous veno-venous hemodiafiltration therapy reduce mortality due to acute renal failure as compared to intermittent hemodialysis?]." Nefrologia 27 Suppl 1: 42-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17763635" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Haase, M., R. Bellomo, et al. (2007). "High cut-off point membranes in septic acute renal failure: a systematic review." Int J Artif Organs 30(12): 1031-41.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18203064" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Landoni, G., G. G. Biondi-Zoccai, et al. (2007). "Beneficial impact of fenoldopam in critically ill patients with or at risk for acute renal failure: a meta-analysis of randomized clinical trials." Am J Kidney Dis 49(1): 56-68.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17185146" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Rabindranath, K., J. Adams, et al. (2007). "Intermittent versus continuous renal replacement therapy for acute renal failure in adults." Cochrane Database Syst Rev(3): CD003773.&amp;nbsp;[&lt;A href="nelh:266499:0" name=internalLink&gt;Link to Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Sampath, S., J. L. Moran, et al. (2007). "The efficacy of loop diuretics in acute renal failure: assessment using Bayesian evidence synthesis techniques." Crit Care Med 35(11): 2516-24.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18084840" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Thomas, G., M. C. Rojas, et al. (2007). "Insulin therapy and acute kidney injury in critically ill patients a systematic review." Nephrol Dial Transplant 22(10): 2849-55.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17604310" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2006&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Bagshaw, S. M., C. Langenberg, et al. (2006). "Urinary biochemistry and microscopy in septic acute renal failure: a systematic review." Am J Kidney Dis 48(5): 695-705.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17059988" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Ho, K. M. and D. J. Sheridan (2006). "Meta-analysis of frusemide to prevent or treat acute renal failure." BMJ 333(7565): 420.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16861256" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <expiryDate>05/01/2012 00:00:00</expiryDate>
  </document>
  <document>
    <id>267791</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.acr.org/SecondaryMainMenuCategories/quality_safety/app_criteria/pdf/ExpertPanelonUrologicImaging/AcuteOnsetFlankPainSuspicionofStoneDiseaseDoc1.aspx]]&gt;</url>
    <title>Acute onset flank pain, suspicion of stone disease</title>
    <publicationDate>2008-01-01T00:00:00</publicationDate>
    <publisher>American College of Radiology</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ KIDNEY AND BLADDER STONES,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE BLADDER DISORDERS,BLADDER STONES,KIDNEY DISEASES,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Guideline from American College of Radiology</description>
    <body>&lt;![CDATA[ Covers diagnosis through different methods such as plain abdominal radiography, intravenous pyelogram, ultrasound, computerized tomography and magnetic resonance imaging.]]&gt;</body>
    <lastReviewDate>06/07/2010 11:21:55</lastReviewDate>
    <expiryDate>06/07/2011 11:21:55</expiryDate>
  </document>
  <document>
    <id>301365</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://healthguides.mapofmedicine.com/choices/map/acute_pyelonephritis1.html]]&gt;</url>
    <title>Acute pyelonephritis</title>
    <publicationDate>2007-07-31T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RENAL TRACT INFECTIONS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Web pages from NHS Choices and the Map of Medicine.</description>
    <body>&lt;![CDATA[ This page provides a link to the Map of Medicine view on Acute pyelonephritis.]]&gt;</body>
    <lastReviewDate>26/11/2010 15:25:56</lastReviewDate>
    <expiryDate>26/11/2011 15:25:56</expiryDate>
  </document>
  <document>
    <id>177696</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.merck.com/mmpe/sec17/ch233/ch233b.html?qt=acute%20renal%20failure&amp;alt=sh#sec17-ch233-ch233b-628]]&gt;</url>
    <title>Acute renal failure</title>
    <publicationDate>2007-12-03T00:00:00</publicationDate>
    <publisher>Merck Manual of Diagnosis and Therapy</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MANAGEMENT,CAUSES AND RISK FACTORS,ACUTE KIDNEY INJURY,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Extract from Merck Manual of Diagnosis and Therapy</description>
    <body>&lt;![CDATA[ Resource covers classification and etiology, pathophysiology (prerenal, postrenal, renal), symptoms and signs, diagnosis, prognosis and prophylaxis and treatment.]]&gt;</body>
    <lastReviewDate>23/08/2010 12:03:55</lastReviewDate>
    <expiryDate>23/08/2011 12:03:55</expiryDate>
  </document>
  <document>
    <id>177696</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.merck.com/mmpe/sec17/ch233/ch233b.html?qt=acute%20renal%20failure&amp;alt=sh#sec17-ch233-ch233b-628]]&gt;</url>
    <title>Acute renal failure</title>
    <publicationDate>2007-12-03T00:00:00</publicationDate>
    <publisher>Merck Manual of Diagnosis and Therapy</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MANAGEMENT,CAUSES AND RISK FACTORS,ACUTE KIDNEY INJURY,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Extract from Merck Manual of Diagnosis and Therapy</description>
    <body>&lt;![CDATA[ Resource covers classification and etiology, pathophysiology (prerenal, postrenal, renal), symptoms and signs, diagnosis, prognosis and prophylaxis and treatment.]]&gt;</body>
    <lastReviewDate>23/08/2010 12:03:55</lastReviewDate>
    <expiryDate>23/08/2011 12:03:55</expiryDate>
  </document>
  <document>
    <id>177698</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.emedicine.com/med/topic1595.htm]]&gt;</url>
    <title>Acute renal failure</title>
    <publicationDate>2009-08-17T00:00:00</publicationDate>
    <publisher>eMedicine.com</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ CAUSES AND RISK FACTORS,MANAGEMENT,ACUTE KIDNEY INJURY,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Resource from eMedicine</description>
    <body>&lt;![CDATA[ Covers diagnosis, treatment and medication. Also contains images and references.]]&gt;</body>
    <lastReviewDate>23/08/2010 12:03:58</lastReviewDate>
    <expiryDate>23/08/2011 12:03:58</expiryDate>
  </document>
  <document>
    <id>177698</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.emedicine.com/med/topic1595.htm]]&gt;</url>
    <title>Acute renal failure</title>
    <publicationDate>2009-08-17T00:00:00</publicationDate>
    <publisher>eMedicine.com</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ CAUSES AND RISK FACTORS,MANAGEMENT,ACUTE KIDNEY INJURY,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Resource from eMedicine</description>
    <body>&lt;![CDATA[ Covers diagnosis, treatment and medication. Also contains images and references.]]&gt;</body>
    <lastReviewDate>23/08/2010 12:03:58</lastReviewDate>
    <expiryDate>23/08/2011 12:03:58</expiryDate>
  </document>
  <document>
    <id>177605</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.gpnotebook.co.uk/simplepage.cfm?ID=-227868663]]&gt;</url>
    <title>Acute renal failure - GPnotebook</title>
    <publicationDate>2005-01-31T00:00:00</publicationDate>
    <publisher>GPnotebook</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MANAGEMENT,CAUSES AND RISK FACTORS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,ACUTE KIDNEY INJURY,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A resource from GPnotebook</description>
    <body>&lt;![CDATA[ GPnotebook resource providing links to sections on aetiology of acute renal failure, clinical features, differential diagnosis, investigations, diagnosis, management of acute renal failure, prognosis and renal failure in hepatic failure.]]&gt;</body>
    <lastReviewDate>08/03/2011 09:56:14</lastReviewDate>
    <expiryDate>08/03/2012 09:56:14</expiryDate>
  </document>
  <document>
    <id>155688</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.cambridge-transplant.org.uk/]]&gt;</url>
    <title>Addenbrooke's Hospital, Cambridge, Transplant Unit</title>
    <publicationDate>2005-10-24T00:00:00</publicationDate>
    <publisher>Addenbrooke's Hospital</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ TRANSPLANT CENTRES,TRANSPLANTATION,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Website giving contact details, transplant Unit overview, organ transplant program and information about the transplant ward</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Extract from website&lt;/EM&gt;&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;The Transplant Unit, in close association with the University Department of Surgery, works to provide a transplant programme and associated care for patients locally, nationally and internationally.&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>23/08/2010 12:04:46</lastReviewDate>
    <expiryDate>23/08/2011 12:04:46</expiryDate>
  </document>
  <document>
    <id>384487</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/sites/entrez/19012780]]&gt;</url>
    <title>An ethnography of a children's renal unit: experiences of children and young people with long-term renal illness.</title>
    <publicationDate>2008-12-01T00:00:00</publicationDate>
    <publisher>Journal of Clinical Nursing</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASE IN CHILDREN AND ADOLESCENTS,NEPHROTIC SYNDROME,REFLUX,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>AIM: This study explored the experience of long-term renal illness, including issues concerning compliance with treatment, from the perspectives of children and young people.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Waters, A.L. (2008) An ethnography of a children's renal unit: experiences of children and young people with long-term renal illness. J Clin Nurs. Dec; 17(23): 3103-14. &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;AIM: This study explored the experience of long-term renal illness, including issues concerning compliance with treatment, from the perspectives of children and young people. &lt;/P&gt;
&lt;P&gt;BACKGROUND: Children and young people have difficulty complying with renal treatment; research in this area usually focuses on their compliance with a narrow range of behaviours: compliance with dialysis, tablet taking and dietary and fluid restrictions. Renal compliance studies are usually premised on the assumption that children will automatically comply with treatment and/or that blame for non-compliance rests with the child and family. &lt;/P&gt;
&lt;P&gt;DESIGN: The study, underpinned by a view of children as competent social agents, used ethnography to explore and describe the everyday experience of long-term renal illness. &lt;/P&gt;
&lt;P&gt;METHOD: Ethnographic fieldwork--involving participant observation, informal interviews and the use of children's drawings--took place over 16 months in a hospital renal unit comprising an inpatient ward, a haemodialysis unit and an outpatient clinic. The primary participants were 13 children; 14 carers and 36 staff members also participated. Data were interrogated through descriptive and thematic forms of analysis. RESULTS: This study reveals participants' perspectives on the physical and social impact of renal treatment. It also provides a conceptualisation of life with long-term renal illness that highlights children's management of 'illness labour', their inhabitation 'renal geographical space', 'a renal body' and a 'renal social world'. &lt;/P&gt;
&lt;P&gt;CONCLUSIONS: These findings show how compliance with renal treatment involves particular embodied experiences that are hard for children to manage. Traditional views of compliance/non-compliance render children's embodied experience and their labour in managing dialysis, thirst and their difficulties with tablet taking irrelevant, whilst this study shows these as highly relevant to children. &lt;/P&gt;
&lt;P&gt;RELEVANCE TO CLINICAL PRACTICE: The conceptualisation of children's experience arising in this study provides a new way of considering the embodied experience of children with long-term renal illness.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
    <expiryDate>16/08/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>338652</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_110492]]&gt;</url>
    <title>An overview of the new arrangements under Part IX of the Drug Tariff for the provision of stoma and urology appliances, and related services, in primary care</title>
    <publicationDate>2009-12-22T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ HEALTH MANAGEMENT,FINANCE AND FUNDING,PRIMARY CARE SERVICES,NHS ACTIVITIES,SERVICE SECTORS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE BLADDER DISORDERS,PENILE DISORDERS,MALE URETHRAL DISORDERS,MALE URETERIC DISORDERS,PROSTATE DISORDERS,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The new arrangements, as announced in April 2009 following the Part IX Review for the NHS supply of certain appliances in primary care require changes to the NHS Pharmaceutical Service Regulations, Directions and amendments to the Drug Tariff.</description>
    <body>&lt;![CDATA[ &lt;P&gt;The new arrangements, as announced in April 2009 following the Part IX Review for the NHS supply of certain appliances in primary care require changes to the NHS Pharmaceutical Service Regulations, Directions and amendments to the Drug Tariff.&lt;/P&gt;
&lt;P&gt;The Amendment Regulations - The National Health Service (Pharmaceutical Services) (Appliances) (Amendment) Regulations 2009 - will come into effect on 1 April 2010.&amp;nbsp; They can be found on the Office of Public Sector Information website. Where pharmacies and appliance contractors supply appliances, these amendment regulations make provision for new essential services&amp;nbsp; including emergency supply at the request of the prescriber, and for certain appliances, a home delivery service, provision of wipes and disposal bags and provision of specialist advice. Appliance contractors will also be able to offer repeat dispensing and will be required to operate a system of clinical governance, similar to pharmacies.&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>17/12/2010 11:27:10</lastReviewDate>
    <expiryDate>17/12/2011 11:27:10</expiryDate>
  </document>
  <document>
    <id>177784</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.dopps.org/d_cdArchive/DoppsCD2006/ppt/Hecking_Indicators_NDT2004_D22.ppt#258,3,Slide 3]]&gt;</url>
    <title>Anaemia in hemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS)</title>
    <publicationDate>2004-01-05T00:00:00</publicationDate>
    <publisher>Nephrology Dialysis and Transplantation 2004</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ HAEMODIALYSIS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,DIALYSIS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Presentation from DOPPS</description>
    <body>&lt;![CDATA[ Study examining anaemia management and outcomes based on years 1998-2000 DOPPS data from France, Germany, Italy, Spain and the UK.]]&gt;</body>
    <lastReviewDate>06/07/2010 11:22:03</lastReviewDate>
    <expiryDate>06/07/2011 11:22:03</expiryDate>
  </document>
  <document>
    <id>269262</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.renal.org/eGFR/anaemia.html]]&gt;</url>
    <title>Anaemia in renal disease</title>
    <publicationDate>2009-01-29T00:00:00</publicationDate>
    <publisher>UK CKD eGuide</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ COMPLICATIONS OF KIDNEY DISEASE,ANAEMIA,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>From the UK CKD eGuide</description>
    <body>&lt;![CDATA[ &lt;P&gt;Extract&lt;/P&gt;
&lt;P&gt;&lt;A href="http://kidney.niddk.nih.gov/kudiseases/pubs/glossary/#5" target="_blank"&gt;Anaemia&lt;/A&gt; becomes an increasing problem in CKD as GFR falls. Severe renal anaemia is uncommon before late stage 3 CKD. Other causes need to be considered, but when not present,&lt;FONT color=#000011&gt; Erythropoietin-like drugs (epoetins) and intravenous iron management are the mainstay of management and greatly improved patient symptoms and quality of life&lt;/FONT&gt;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>06/12/2010 12:35:13</lastReviewDate>
    <expiryDate>06/12/2011 12:35:13</expiryDate>
  </document>
  <document>
    <id>333619</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=333619]]&gt;</url>
    <title>Anaemia: Systematic reviews and meta-analyses</title>
    <publicationDate>2010-09-17T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,COMPLICATIONS OF KIDNEY DISEASE,ANAEMIA,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Anaemia: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Gandra, S. R., F. O. Finkelstein, et al. (2010). "Impact of erythropoiesis-stimulating agents on energy and physical function in nondialysis CKD patients with anemia: a systematic review." American Journal of Kidney Diseases 55(3): 519-535. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Impact%20of%20erythropoiesis-stimulating%20agents%20on%20energy%20and%20physical%20function%20in%20nondialysis%20CKD%20patients%20with%20anemia%3A%20a%20systematic%20review" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Johansen, K. L., F. O. Finkelstein, et al. (2010). "Systematic review and meta-analysis of exercise tolerance and physical functioning in dialysis patients treated with erythropoiesis-stimulating agents." American Journal of Kidney Diseases 55(3): 535-549. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Systematic%20review%20and%20meta-analysis%20of%20exercise%20tolerance%20and%20physical%20functioning%20in%20dialysis%20patients%20treated%20with%20erythropoiesis-stimulating%20agents" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Macdougall, I. C. (2010). "Iron supplementation in the non-dialysis chronic kidney disease (ND-CKD) patient: oral or intravenous?" Current Medical Research &amp;amp; Opinion 26(2): 473-82. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20014980" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Heung, M., B. A. Mueller, et al. (2009). "Optimizing anemia management in hospitalized patients with end-stage renal disease." Ann Pharmacother 43(2): 276-82. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19141655" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;McLeod, C., N. Fleeman, et al. (2009). "Deferasirox for the treatment of iron overlaod associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: A systemetic review and economic evaluation." Health Technology Assessment 13(1): iii-93.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19068191" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Kimel, M., N. K. Leidy, et al. (2008). "Does epoetin alfa improve health-related quality of life in chronically ill patients with anemia? Summary of trials of cancer, HIV/AIDS, and chronic kidney disease." Value Health 11(1): 57-75.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18237361" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Rozen-Zvi, B., A. Gafter-Gvili, et al. (2008). "Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis." Am J Kidney Dis 52(5): 897-906.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18845368" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Tonelli M, Klarenbach S, Wiebe N, Shrive F, Hemmelgarn B, Manns B. Erythropoiesis-stimulating agents for anemia of chronic kidney disease: systematic review and economic evaluation. Canadian Agency for Drugs and Technologies in Health (CADTH), 2008; Technology Report No 106: 59. [&lt;A href="nelh:283962:0" name=internalLink&gt;Link to DARE abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Pljesa, S. (2007). "[The use of erythropoietin beta, two to three times per week, once per week and once every other week: meta-analysis of two clinical trials]." Med Pregl 60(3-4): 123-7.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17853722" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2006&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Cremieux, P. Y., M. Van Audenrode, et al. (2006). "The relative dosing of epoetin alfa and darbepoetin alfa in chronic kidney disease." Curr Med Res Opin 22(12): 2329-36.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17257447" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Strippoli, G. F., S. D. Navaneethan, et al. (2006). "Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease." Cochrane Database Syst Rev(4): CD003967.&amp;nbsp;[&lt;A href="nelh:238354:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>26/11/2010 15:25:29</lastReviewDate>
    <expiryDate>26/11/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>385271</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2960827-6/fulltext#]]&gt;</url>
    <title>Analysis of factors that affect outcome after transplantation of kidneys donated after cardiac death in the UK: a cohort study</title>
    <publicationDate>2010-08-19T00:00:00</publicationDate>
    <publisher>The Lancet</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ TRANSPLANT CENTRES,UK TRANSPLANT,PREVENTION OF COMPLICATIONS,RECIPIENT,TRANSPLANT OPERATION,DONOR,ASSESSMENT/SELECTION,TRANSPLANTATION,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Summers DM,  Johnson RJ, Allen J et al. Analysis of factors that affect outcome after transplantation of kidneys donated after cardiac death in the UK: a cohort study. The Lancet 2010, Early Online Publication, August 19 2010</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Extract from abstract:&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;A third of all kidneys from deceased donors in the UK are donated after cardiac death, but concerns have been raised about the long-term outcome of such transplants. We aimed to establish these outcomes for kidneys donated after controlled cardiac death versus brain death, and to identify the factors that affect graft survival and function.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Methods&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;We used data from the UK transplant registry to select a cohort of deceased kidney donors and the corresponding transplant recipients (aged =18 years) for transplantations done between Jan 1, 2000, and Dec 31, 2007. Kaplan-Meier estimates were used to assess graft survival, and multivariate analyses were used to identify factors associated with graft survival and with long-term renal function, which was measured from estimated glomerular filtration rate (eGFR).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.nhs.uk/news/2010/08August/Pages/kidneys-from-heart-deaths-good-for-transplant.aspx" target="_blank"&gt;Link to NHS Choices Behind the Headlines analysis of the research&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
    <expiryDate>23/08/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>346396</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=346396]]&gt;</url>
    <title>April  2010 NHS Evidence - kidney diseases and male urogenital disorders newsletter</title>
    <publicationDate>2010-04-06T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;April  2010 NHS Evidence - kidney diseases and male urogenital disorders newsletter&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Welcome to the kidney diseases and male urogenital disorders specialist collection enewsletter for&amp;nbsp;APRIL 2010. &lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=left&gt;NHS Evidence - kidney diseases and male urogenital disorders is for busy health professionals, providing them with high quality information and keeping them up to date with the latest research and developments in this area. You can now join our mailing list to receive regular updates. &lt;A href="https://www.jiscmail.ac.uk/cgi-bin/webadmin?A0=NHSEVIDENCEKDMU" target="_blank"&gt;Click here for the link&lt;/A&gt;.&lt;/P&gt;
&lt;P align=center&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=center&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage1 height=121 alt="Dr Donal O'Donoghue" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID346396/nelhImp_0000_WKD2010Donal.jpg" width=140 border=0 name=nelh_tempImage1&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage0 height=123 alt="World Kidney Day logo 2010" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID346396/nelhImp_0002_WKD_Logo_2010.jpg" width=175 border=0 name=nelh_tempImage0&gt;&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;The kidney diseases and male urogenital disorders specialist collection attended the 2010 World Kidney Day parliamentary reception on 11th March, at which a number of parliamentarians and renal specialists spoke. The reception was chaired by Dr Evan Harris MP, the co-chair for the All Party Parliamentary Kidney Group. Fiona Loud (chair of the Kidney Alliance) spoke about the importance of "education for everyone", particularly about keeping healthy to prevent diabetes, the commonest cause of chronic kidney disease. Depression is a major issue related to CKD. She also spoke about the Living Donor programme, and urged the parliamentarians to support measures to improve the number of organ donors, and to maintain the focus on renal services throughout the election. Donal O'Donoghue stressed the importance of primary care in identifying kidney disease, and recommended the &lt;A href="http://www.nhs.uk/Tools/Pages/Kidneydisease.aspx" target="_blank"&gt;NHS Choices kidney disease self-assessment tool&lt;/A&gt;. &lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Links to:&lt;/STRONG&gt;&lt;/P&gt;&lt;STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="#kidney"&gt;New Kidney Diseases items&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="#mug"&gt;New Male Urogenital Disorders items&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0005_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&amp;nbsp;RSS FEEDS&amp;nbsp; &lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0006_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;You can receive news from the kidney diseases specialist collection from the RSS feeds we provide:&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/RSS/CMS.aspx?feed=57" target="_blank"&gt;&lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0007_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk/kidney/RSS/CMS.aspx?feed=57" target="_blank"&gt;&lt;A href="http://www.library.nhs.uk/kidney/RSS/CMS.aspx?feed=57" target="_blank"&gt;New Kidney Diseases Resources&lt;/A&gt;&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/RSS/CMS.aspx?feed=136" target="_blank"&gt;&lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0008_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk/kidney/RSS/CMS.aspx?feed=136" target="_blank"&gt;New Male Urogenital Disorders Resources&lt;/A&gt; &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/KIDNEY/RSS/News.aspx" target="_blank"&gt;&lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0008_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk//kidney/News.aspx" target="_blank"&gt;Kidney diseases and male urogenital disorders in the news&lt;/A&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/rss/Directory/MoreAboutRss.aspx" target="_blank"&gt;Click through this link to find out more about RSS feeds.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;JOURNALS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;You can link through to the latest Tables of Contents from all the major kidney, transplant and urology journals from &lt;A href="http://www.library.nhs.uk/KIDNEY/Page.aspx?pagename=EJOURNALS" target="_blank"&gt;this page&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=3&gt;&lt;STRONG&gt;&lt;BIG&gt;Resources added in&amp;nbsp;March 2010&lt;/BIG&gt;&lt;/STRONG&gt; &lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A name=kidney&gt;Chronic Kidney&amp;nbsp;Disease&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;New resources to support quality improvement in chronic kidney disease. 04/03/10. &lt;A href="http://renaltsar.blogspot.com/2010/03/new-resources-to-support-quality.html" target="_blank"&gt;Link to Renal Tsar's blog post&lt;/A&gt;.&lt;/LI&gt;
&lt;LI&gt;BMJ OnExamination Quiz on Renal Failure. Published 18/03/10. &lt;A href="http://www.bmj.com/cgi/content/short/340/mar17_1/c1427?rss=1" target="_blank"&gt;Link to OnExamination Quiz&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;New PCT profiles set to boost quality of kidney care services. Published 11/03/10 by NHS Kidney Care. &lt;A href="http://www.kidneycarematters.nhs.uk/?sID=2&amp;amp;aID=232" target="_blank"&gt;Link to NHS Kidney Care webpage&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;New patient information website: MyKidney.org.uk - from Guy's and St Thomas' NHS Foundation Trust and King's College Hospital. &lt;A href="http://www.mykidney.org.uk/" target="_blank"&gt;Link to MyKidney.Org.UK&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Referrals for Chronic Kidney Disease. Editorial by Richard J Glassock published 24/03/10 in the latest edition of JAMA. &lt;A href="http://jama.ama-assn.org/cgi/content/short/303/12/1201?rss=1" target="_blank"&gt;Link to first 150 words of article&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Nephrology Visits and Health Care Resource Use Before and After Reporting Estimated Glomerular Filtration Rate. Article published 24/03/10 in JAMA. &lt;A href="http://jama.ama-assn.org/cgi/content/short/303/12/1151?rss=1" target="_blank"&gt;Link to JAMA abstract&lt;/A&gt;. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Acute kidney injury&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;NICE guidelines on Acute Kidney Injury. 04/03/10. &lt;A href="http://renaltsar.blogspot.com/2010/03/nice-guidelines-on-acute-kidney-injury.html" target="_blank"&gt;Link to Renal Tsar's blog post&lt;/A&gt;. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Diabetic nephropathy&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;SIGN guideline on the management of diabetes. &lt;A href="http://www.sign.ac.uk/guidelines/fulltext/116/index.html" target="_blank"&gt;Link to the full document on the SIGN website&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Dialysis&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Comparative mortality risk of anaemia management practices in incident haemodialysis patients. Summary of a comparative study published 18/03/10 by the National electronic Library for Medicines. &lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2010---March/17/Comparative-mortality-risk-of-anaemia-management-practices-in-incident-haemodialysis-patients-/" target="_blank"&gt;Link to NeLM summary&lt;/A&gt;. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Transplantation&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Three-way kidney transplant success. News item published 08/03/10 by the BBC. &lt;A href="http://news.bbc.co.uk/1/hi/health/8552162.stm" target="_blank"&gt;Link to BBC news item&lt;/A&gt;. See &lt;A href="http://www.bmj.com/cgi/content/short/340/mar05_3/c1343?rss=1" target="_blank"&gt;here&lt;/A&gt; for the BMJ news item on this story.&lt;/LI&gt;
&lt;LI&gt;Perioperative Mortality and Long-term Survival Following Live Kidney Donation. 12/03/10 published in JAMA. &lt;A href="http://jama.ama-assn.org/cgi/content/short/303/10/959?rss=1" target="_blank"&gt;Link to article&lt;/A&gt;. &lt;/LI&gt;
&lt;LI&gt;New meta-analysis on renal transplant and HIV. &lt;A href="nelh:341851:0" name=internalLink&gt;Link to NHS&amp;nbsp;Evidence- kidney diseases and male urogenital disorders webpage on renal transplant systematic reviews.&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Article on Regulated Payments for Living Kidney Donataion. Published 19/03/10 in Annals of Internal Medicine. &lt;A href="http://www.annals.org/content/152/6/358.short?rss=1" target="_blank"&gt;Link to Annals of Internal Medicine abstract&lt;/A&gt;.&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Guidance for coroners and donor coordinators working with coronors. Published by the Department of Health and Ministry of Justice 29/03/10. &lt;A href="http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_114804" target="_blank"&gt;Link to DH webpage&lt;/A&gt;.&lt;/LI&gt;
&lt;LI&gt;Requested allocation of a deceased donor organ. Guidance published by the Department of Health 29/03/10. &lt;A href="http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_114800" target="_blank"&gt;Link to DH webpage&lt;/A&gt;. &lt;/LI&gt;
&lt;LI&gt;Spanish transplant model would save 20 000 lives&amp;nbsp;a year in EU. Article published in BMJ 30/03/10. &lt;A href="http://www.bmj.com/cgi/content/short/340/mar29_2/c1758?rss=1" target="_blank"&gt;Link to first 150 words of BMJ article&lt;/A&gt;. &lt;/LI&gt;
&lt;LI&gt;Sue Townsend's organ donation appeal. News item published 10/03/10 by the BBC. &lt;A href="http://news.bbc.co.uk/1/hi/programmes/the_daily_politics/8559496.stm" target="_blank"&gt;Link to BBC news item to watch the films&lt;/A&gt;. &lt;/LI&gt;
&lt;LI&gt;'I gave my sister a kidney. I don't know if I'll ever do a better thing'. Article published in the Guardian 13/03/10. &lt;A href="http://www.guardian.co.uk/theguardian/2010/mar/13/i-gave-my-sister-a-kidney" target="_blank"&gt;Link to Guardian article&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;You can now have your kidney removed in 45 minutes, leaving a one-inch scar. Article published in the Guardian 16/03/10. &lt;A href="http://www.guardian.co.uk/lifeandstyle/2010/mar/16/kidney-transplant-45-minutes" target="_blank"&gt;Link to Guardian article&lt;/A&gt;. &lt;/LI&gt;
&lt;LI&gt;'Attitude' is blocking organ donations. News item published 17/03/10 by the BBC. &lt;A href="http://news.bbc.co.uk/1/hi/health/8562709.stm" target="_blank"&gt;Link to BBC news item&lt;/A&gt;. &lt;/LI&gt;
&lt;LI&gt;New guidance allows donors to name who receives their organs when they die. News item published in the BMJ 31/03/10. &lt;A href="http://www.bmj.com/cgi/content/short/340/mar31_4/c1843?rss=1" target="_blank"&gt;Link to first 150 words of BMJ news item&lt;/A&gt;. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Kidney Cancer&lt;/STRONG&gt; &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Working outdoors reduces male kidney cancer risk. News item published 08/03/10 by the Guardian. &lt;A href="http://www.guardian.co.uk/world/2010/mar/08/kidney-cancer-outdoor-working-sunlight" target="_blank"&gt;Link to the Guardian news item&lt;/A&gt;. &lt;/LI&gt;
&lt;LI&gt;New Cochrane Systematic Review: Surgical management of localised renal cell carcinoma. Published March 2010. &lt;A href="nelh:346278:0" name=internalLink&gt;Link to Cochrane abstract&lt;/A&gt;. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A name=mug&gt;Male Urogenital Disorders&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Male Bladder Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Managing simple UTI. Summary of an RCT published 15/03/10 by the NHS National Prescribing Centre. &lt;A href="http://www.npci.org.uk/blog/?p=1118" target="_blank"&gt;Link to RCT summary&lt;/A&gt;.&lt;/LI&gt;
&lt;LI&gt;Hagen S, Sinclair L, Cross S. Washout policies in long-term indwelling urinary catheterisation in adults. Cochrane Database of Systematic Reviews 2010, Issue 3. Art. No.: CD004012. DOI: 10.1002/14651858.CD004012.pub4.&lt;BR&gt;&lt;A href="nelh:346269:0" name=internalLink&gt;Link to Cochrane abstract&lt;/A&gt;. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Prostate Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;2010 Annual Evidence Update on Prostate Cancer. Published 08/03/10 by the cancer specialist collection. &lt;A href="nelh:345246:0" name=internalLink&gt;Link to 2010 AEU on Prostate Cancer contents page&lt;/A&gt;. &lt;/LI&gt;
&lt;LI&gt;BMJ Observation article on prostate screening. Published 18/03/10. &lt;A href="http://www.bmj.com/cgi/content/short/340/mar17_2/c1497?rss=1" target="_blank"&gt;Link to BMJ webpage&lt;/A&gt;.&lt;/LI&gt;
&lt;LI&gt;Fifth of men turned down for prostate cancer screening.&amp;nbsp;News item&amp;nbsp;published 01/03/10 in the Daily Telegraph. &lt;A href="http://www.telegraph.co.uk/health/healthnews/7337659/Fifth-of-men-turned-down-for-prostate-cancer-screening.html" target="_blank"&gt;Link to Daily Telegraph news item&lt;/A&gt;. &lt;/LI&gt;
&lt;LI&gt;'Tame' virus could prove prostate cancer weapon. News item published 09/03/10 by the Daily Telegraph. &lt;A href="http://www.telegraph.co.uk/health/healthnews/7406772/Tame-virus-could-prove-prostate-cancer-weapon.html" target="_blank"&gt;Link to Daily Telegraph news item&lt;/A&gt;. &lt;/LI&gt;
&lt;LI&gt;Baldness 'could be good for your health' say scientists. News item published 16/03/10 by the BBC. &lt;A href="http://news.bbc.co.uk/1/hi/health/8569826.stm" target="_blank"&gt;Link to BBC news item&lt;/A&gt;. &lt;/LI&gt;
&lt;LI&gt;Study finds infertility clue to prostate cancer. News item published 22/03/10 by the BBC. &lt;A href="http://www.guardian.co.uk/science/2010/mar/22/study-infertility-prostate-cancer" target="_blank"&gt;Link to BBC news item&lt;/A&gt;. &lt;/LI&gt;
&lt;LI&gt;Prostate drug dutasteride 'may cut cancer risk'. News item published 31/03/10 by the BBC. &lt;A href="http://news.bbc.co.uk/1/hi/health/8597157.stm" target="_blank"&gt;Link to BBC news item&lt;/A&gt;. &lt;/LI&gt;
&lt;LI&gt;Pharmacies to offer help to men with distressing prostate problems. News item published 31/03/10 by the Bladder and Bowel Foundation. &lt;A href="http://www.bladderandbowelfoundation.org/news-events/news/Pharmacies-offer-help-to-men-with-distressing-prostate-problems.htm" target="_blank"&gt;Link to Bladder and Bowel news item&lt;/A&gt;. &lt;/LI&gt;
&lt;LI&gt;Drug cuts risk of prostate cancer diagnosis - but not in the real world. News item published by the BMJ Group 01/04/10. &lt;A href="http://www.guardian.co.uk/lifeandstyle/besttreatments/2010/apr/01/drug-cuts-risk-of-prostate-cancer-diagnosis-but-not-in" target="_blank"&gt;Link to BMJ Group article&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Penile Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Motivations for seeking treatment for erectile dysfunction. Abstract published 18/03/10 by the National electronic Library for Medicines. &lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/Evidence/Medicines-Management/References/2010---March/17/Motivations-for-seeking-treatment-for-ED-the-womans-perspective/" target="_blank"&gt;Link to NeLM abstract&lt;/A&gt;. &lt;/LI&gt;
&lt;LI&gt;Sports fans in Manchester urged to donate sperm. News item published by the BBC 16/03/10. &lt;A href="http://news.bbc.co.uk/1/hi/england/manchester/8567999.stm" target="_blank"&gt;Link to BBC news item&lt;/A&gt;. &lt;/LI&gt;
&lt;LI&gt;Impotence 'strong predictor' of heart attacks. News item published by the BBC 16/03/10. &lt;A href="http://news.bbc.co.uk/1/hi/health/8564181.stm" target="_blank"&gt;Link to BBC news item.&lt;/A&gt; &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Testicular/Scrotal Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Clinical Knowledge Summaries on Scrotal Swellings. &lt;A href="http://www.library.nhs.uk/kidney/SearchResults.aspx?searchText=scrotal%20swellings&amp;amp;tabID=288" target="_blank"&gt;Link to CKS Topics&lt;/A&gt;. &lt;/LI&gt;
&lt;LI&gt;BMJ Views and Reviews article on Testosterone Replacement Therapy. Published 18/03/10. &lt;A href="http://www.bmj.com/cgi/content/short/340/mar18_2/c1493?rss=1" target="_blank"&gt;Link to BMJ article&lt;/A&gt;. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Urinary tract infection &lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Absolute and relative accuracy of rapid urine tests for urinary tract infection in children. Abstract of a meta-analysis published 24/03/10 by the National electronic Library for Medicines. &lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2010---March/23/Absolute-and-relative-accuracy-of-rapid-urine-tests-for-urinary-tract-infection-in-children-a-meta-analysis/" target="_blank"&gt;Link to NeLM abstract&lt;/A&gt;. &lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Sexually Transmitted Infections&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Sexual health consultation for men who have sex with men. BMJ article published 22/03/10. &lt;A href="http://www.bmj.com/cgi/content/short/340/mar22_2/c958?rss=1" target="_blank"&gt;Link to BMJ webpage&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Men likelier to enjoy sex in old age, study finds. BBC news item published 10/03/10. &lt;A href="http://news.bbc.co.uk/1/hi/health/8558053.stm" target="_blank"&gt;Link to BBC news item&lt;/A&gt;. &lt;/LI&gt;
&lt;LI&gt;Men twice as likely to test positive for chlamydia. News item published 06/03/10&amp;nbsp;by the Daily Telegraph. &lt;A href="http://www.telegraph.co.uk/health/men_shealth/7556449/Men-twice-as-likely-to-test-positive-for-chlamydia.html" target="_blank"&gt;Link to Daily Telegraph news item&lt;/A&gt;. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Fertility&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;The couple who both beat breast cancer. News item published 01/03/10 in the Daily Telegraph. &lt;A href="http://www.telegraph.co.uk/health/7326241/The-couple-who-both-beat-breast-cancer.html" target="_blank"&gt;Link to Daily Telegraph news item&lt;/A&gt;. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;**Subscribe to the NHS Evidence Eyes on Evidence Newsletter**&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;If you would like to receive Eyes on Evidence, the monthly e-bulletin from NHS Evidence, please sign up at &lt;A href="http://www.evidence.nhs.uk/NewsletterSignup.aspx" target="_blank"&gt;http://www.evidence.nhs.uk/NewsletterSignup.aspx&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The bulletin will keep you updated with new and important evidence and key developments on the NHS Evidence portal.&amp;nbsp; It comes out on the second Wednesday of the month and can be sent to any e-mail address that you provide.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>21/02/2011 11:26:58</lastReviewDate>
    <expiryDate>21/02/2012 11:26:58</expiryDate>
  </document>
  <document>
    <id>311240</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=311240]]&gt;</url>
    <title>April 2009 Kidney Diseases Specialist Library newsletter</title>
    <publicationDate>2009-04-06T00:00:00</publicationDate>
    <publisher>Kidney Diseases Specialist Library</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ KIDNEY AND BLADDER STONES,GLOMERULONEPHRITIS,RENOVASCULAR DISEASES,INHERITED KIDNEY DISEASE,RENAL CANCER,END-OF-LIFE CARE,ACUTE KIDNEY INJURY,HAEMODIALYSIS,TRANSPLANTATION,RENAL TRACT INFECTIONS,OTHER CONDITIONS - ADULTS,KIDNEY DISEASE IN CHILDREN AND ADOLESCENTS,COMPLICATIONS OF KIDNEY DISEASE,PERITONEAL DIALYSIS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,DIALYSIS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;April 2009 Kidney Diseases Specialist Library newsletter&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=left&gt;&lt;STRONG&gt;The Kidney Diseases Specialist Library is for busy health professionals, providing them with high quality information and keeping them up to date with the latest research and developments in this area.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=center&gt;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P align=center&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage0 height=250 alt="The KDSL team on World Kidney Day" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID311240/nelhImp_0000_EBLADG2compressed.jpg" width=300 border=0 name=nelh_tempImage0&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;&lt;EM&gt;Photo above: The Kidney&amp;nbsp; Diseases Specialist Library team at the World Kidney Day reception in Parliament, 12th March 2009.&lt;/EM&gt; &lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;The National Library for Health Kidney Diseases Specialist Library will be known as NHS Evidence - Kidney Diseases specialist collection.&lt;/STRONG&gt; &lt;/P&gt;
&lt;P align=left&gt;From 1st April 2009, the National Library for Health (NLH) has transferred to NICE and become NHS Evidence. NHS Evidence will go live on 30 April 2009. NHS Evidence will provide an integrated online portal and a comprehensive source of fast, free, relevant and trustworthy information about clinical and non-clinical evidence and best practice. Health and social care professionals have been closely involved with the design and development of the service, and it has been tested by clinicians throughout its development to ensure it meets their needs. The first version incorporates the best of the National Library for Health; further enhancements will be in place by autumn 2009 and a strong emphasis on quality assurance of information is expected.&lt;/P&gt;
&lt;P align=left&gt;See &lt;A href="http://www.nice.org.uk/aboutnice/nhsevidence/AboutNHSEvidence.jsp" target="_blank"&gt;this page&lt;/A&gt; for more information. &lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2 align=left&gt;&lt;BIG&gt;&lt;FONT size=3&gt;New resources added in&amp;nbsp;March 2009:&lt;/FONT&gt;&lt;/BIG&gt;&lt;/H2&gt;
&lt;H2 align=left&gt;&lt;BIG&gt;&lt;/BIG&gt;&amp;nbsp;&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;Guidance&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/KIDNEY/ViewResource.aspx?resID=311223&amp;amp;tabID=288" target="_blank"&gt;NHS Health Check Vascular Risk Assessment and Management Best Practice Guidance&lt;/A&gt;. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.sciencedaily.com/releases/2009/03/090318090140.htm" target="_blank"&gt;New Kidney Cancer Clinical Guidelines for 2009 - link to Science Daily webpage&lt;/A&gt;. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/KIDNEY/ViewResource.aspx?resID=309490&amp;amp;tabID=288" target="_blank"&gt;Staffordshire, Shropshire and Black Country Newborn Network&lt;/A&gt; - guidelines for staff concerned with the management of neonates, including the care of newborns with renal problems. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/GuidelinesFinder/ViewResource.aspx?resID=308800&amp;amp;tabID=288" target="_blank"&gt;Proteinuria: detection and quantitation in adults using ACR - information for GPs.&lt;/A&gt; &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/GuidelinesFinder/ViewResource.aspx?resID=308803&amp;amp;tabID=288" target="_blank"&gt;Proteinuria: detection and quantitation in adults using ACR - information for laboratories.&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Evidence&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;EM&gt;No new evidence this month&lt;/EM&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Evidence in the News&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;The results of the AURORA trial have been published in the NEJM: &lt;A href="http://content.nejm.org/cgi/content/full/NEJMoa0810177" target="_blank"&gt;Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis&lt;/A&gt;. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/Other-Lib-Updates/SPC-Changes/Dynastat-20mg--40mg-Powder--Solvent-for-Solution-of-Injection-Solution-for-Injection-parecoxib---Revised-SPC/" target="_blank"&gt;National electronic Library for Medicines - story on Parecoxib&lt;/A&gt;.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/Evidence/Guidelines/NICE-recommends-sunitinib-for-the-first-line-treatment-of-advanced-andor-metastatic-renal-cancer/" target="_blank"&gt;NeLM - story on sunitinib&lt;/A&gt;.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.ajkd.org/article/PIIS0272638608014315/abstract?rss=yes" target="_blank"&gt;A systematic review and meta analysis on Sodium Bicarbonate Therapy for Prevention of Contrast-Induced Nephropathy&lt;/A&gt;. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.greenerhealthcare.org/green-nephrology-programme" target="_blank"&gt;The Green Nephrology Programme&lt;/A&gt;. &lt;/LI&gt;
&lt;LI&gt;NeLM: &lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2009---March/12/Systematic-review-suggests-N-acetylcysteine-does-not-prevent-renal-injury-after-cardiac-surgery/" target="_blank"&gt;Systematic review suggests N-acetylcysteine does not prevent renal injury after cardiac surgery.&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Reference&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.renal.org/pages/pages/posts/ra-working-party-on-peritoneal-dialysis-draft-report-jan-200964.php" target="_blank"&gt;RA Working Party on Peritoneal Dialysis Draft Report January 2009&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=310596&amp;amp;tabID=291" target="_blank"&gt;Webpage with links to Nephrology Nursing Resources&lt;/A&gt;. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=308756&amp;amp;tabID=290" target="_blank"&gt;UK Renal Registry Interactive Maps&lt;/A&gt;. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Education/ CPD&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=308757&amp;amp;tabID=291" target="_blank"&gt;Chronic kidney disease: a guide for primary care&lt;/A&gt;. An advanced online educational resource initiated by the Department of Health and the&amp;nbsp;CKD Forum of the British Renal Society. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Patient information&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.worldkidneyday.org/" target="_blank"&gt;World Kidney Day&lt;/A&gt; - basic patient information on this year's theme, blood pressure and kidney disease. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://renaltsar.blogspot.com/2009/03/art-of-care-planning.html" target="_blank"&gt;Donal O'Donoghue on NHS Kidney Care Plans and World Kidney Day 2009&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P align=center&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Other news:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;The Kidney Diseases specialist collection information specialist will be promoting the collection at the joint &lt;A href="https://registrations-online.com/Renal2009/default.aspx?PageID=Home" target="_blank"&gt;Renal Assoication and British Transplant Society 2009 Annual Congress &lt;/A&gt;on 22nd April. Please come and visit the stand!&lt;/DIV&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;We&amp;nbsp;will have a &lt;A href="http://www.britishrenal.org/conferences/brs2009/exhibitors.html#SpecialistLibrary" target="_blank"&gt;stand&lt;/A&gt; at the British Renal Society conference from 1-3 June 2009.&lt;/DIV&gt;&lt;/LI&gt;&lt;/UL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>04/03/2011 11:16:22</lastReviewDate>
    <expiryDate>04/03/2012 11:16:22</expiryDate>
  </document>
  <document>
    <id>187603</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.astral.bham.ac.uk/]]&gt;</url>
    <title>ASTRAL trial</title>
    <publicationDate>2010-01-04T00:00:00</publicationDate>
    <publisher>University of Birmingham</publisher>
    <publicationType>RANDOMISED CONTROLLED TRIAL</publicationType>
    <topics>&lt;![CDATA[ NEW RESEARCH,RENOVASCULAR DISEASES,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Details of ASTRAL Trial</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Extract from website&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;The ASTRAL trial is designed to address the issue of whether renal arterial revascularisation with balloon angioplasty and/or endovascular stenting can safely prevent progressive renal failure among a wide range of patients with ARVD.&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>06/12/2010 12:35:18</lastReviewDate>
    <expiryDate>06/12/2011 12:35:18</expiryDate>
    <relatedLinks>&lt;a href="http://www.astral.bham.ac.uk/" title="Link to Trial homepage"/&gt;&lt;a href="http://www.astral.bham.ac.uk/newsletters/Newsletter%20March%2006v2.pdf" title="Link to latest newsletter"/&gt;</relatedLinks>
    <creator>University of Birmingham</creator>
  </document>
  <document>
    <id>182456</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.dft.gov.uk/adobepdf/164386/fitnesstodrive]]&gt;</url>
    <title>At a glance guide to the current medical standards of fitness to drive</title>
    <publicationDate>2008-02-01T00:00:00</publicationDate>
    <publisher>DVLA</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ PERITONEAL DIALYSIS,LIVING WITH DIALYSIS,HAEMODIALYSIS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES,DIALYSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Information about driving for individuals with renal disorders</description>
    <body>&lt;![CDATA[ &lt;P&gt;Information on driving&amp;nbsp;licences for individuals with chronic renal failure, receiving haemodialysis or continuous ambulatory peritoneal dialysis.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Guidelines intended for use by doctors. &lt;/P&gt;
&lt;P&gt;Patients should consult their doctor about DVLA guidelines and fitness to drive&lt;/P&gt;
&lt;P&gt;Published February 2008&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>23/08/2010 12:04:52</lastReviewDate>
    <expiryDate>23/08/2011 12:04:52</expiryDate>
  </document>
  <document>
    <id>156790</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.era-edta-reg.org/files/presentations/pdf/Lisbon-Tizard0504.pdf]]&gt;</url>
    <title>Auditing and Advancing Paediatric RRT</title>
    <publicationDate></publicationDate>
    <publisher>ERA-EDTA Registry</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ HAEMODIALYSIS,CHILDREN AND ADOLESCENTS ON HAEMODIALYSIS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES,DIALYSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Presentation of available pan-European paediatric outcomes data with focus on UK and Italy</description>
    <body>&lt;![CDATA[ &lt;P&gt;Presentation of tables of statistics relating to paediatric population having RRT. Data from UK, Italy and 13 other Renal Registries.&lt;/P&gt;
&lt;P&gt;Published in 2004&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>23/08/2010 12:04:57</lastReviewDate>
    <expiryDate>23/08/2011 12:04:57</expiryDate>
  </document>
  <document>
    <id>382789</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=382789]]&gt;</url>
    <title>August  2010 NHS Evidence - kidney diseases and male urogenital disorders newsletter</title>
    <publicationDate>2010-08-02T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;August  2010 NHS Evidence - kidney diseases and male urogenital disorders newsletter&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Welcome to the kidney diseases and male urogenital disorders specialist collection enewsletter for&amp;nbsp;AUGUST 2010. &lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=left&gt;NHS Evidence - kidney diseases and male urogenital disorders is for busy health professionals, providing them with high quality information and keeping them up to date with the latest research and developments in this area. You can now join our mailing list to receive regular updates. &lt;A href="https://www.jiscmail.ac.uk/cgi-bin/webadmin?A0=NHSEVIDENCEKDMU" target="_blank"&gt;Click here for the link&lt;/A&gt;.&lt;/P&gt;
&lt;P align=center&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Links to:&lt;/STRONG&gt;&lt;/P&gt;&lt;STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="#kidney"&gt;New Kidney Diseases items&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="#mug"&gt;New Male Urogenital Disorders items&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;&lt;/STRONG&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;NEW UROLOGY MINI TOPIC REVIEW:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Mini topic review: &lt;A href="nelh:381551:0" name=internalLink&gt;Vasectomy and Vasectomy Reversal - by Mr T Evans and Mr D Cranston&lt;/A&gt; (August 2010). &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;NEW FOR AUGUST 2010: RENAL HOT TOPICS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;JAMA&lt;/P&gt;
&lt;P&gt;Tight Blood Pressure Control and Cardiovascular Outcomes Among Hypertensive Patients With Diabetes and Coronary Artery Disease. Rhonda M. Cooper-DeHoff; Yan Gong; Eileen M. Handberg; Anthony A. Bavry; Scott J. Denardo; George L. Bakris; Carl J. Pepine. JAMA. 2010;304(1):61-68. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20606150" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;NEJM&lt;/P&gt;
&lt;P&gt;Molecular Architecture of the Goodpasture Autoantigen in Anti-GBM Nephritis. V Pedchenko, O Bondar, A Fogo, R Vanacore, P Voziyan, A. R Kitching, J Wieslander, C Kashtan, D-B Borza, E G. Neilson, C B. Wilson, and B G. Hudson. N Engl J Med 2010; 363:343-354.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20660402" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. Jones RB, Cohen Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh D, Walsh M, Westman K, Jayne DR; European Vasculitis Study Group. N Engl J Med. 2010 Jul 15;363(3):211-20.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20647198" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Rituximab versus cyclophosphamide for ANCA-associated vasculitis. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U; RAVE-ITN Research Group. N Engl J Med. 2010 Jul 15;363(3):221-32.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20647199" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Sirolimus and Kidney Growth in Autosomal Dominant Polycystic Kidney Disease. Serra AL, Poster D, Kistler AD, Krauer F, Raina S, Young J, Rentsch KM, Spanaus KS, Senn O, Kristanto P, Scheffel H, Weishaupt D, Wüthrich RP. N Engl J Med. 2010 Jun 26&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20581391" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;The Lancet&lt;/P&gt;
&lt;P&gt;Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, Stehouwer CD, Lewington S, Pennells L, Thompson A, Sattar N, White IR, Ray KK, Danesh J. Lancet. 2010 Jun 26;375(9733):2215-22.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20609967" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;IMG id=nelh_tempImage0 height=16 alt=" name=nelh_tempImage0 border=" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0005_feed.gif" width=16 icon? RSS 0?&gt;&amp;nbsp;RSS FEEDS&amp;nbsp; &lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0006_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;You can receive news from the kidney diseases specialist collection from the RSS feeds we provide:&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/RSSFeed.aspx?feed=57" target="_blank"&gt;&lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0007_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk/kidney/RSSFeed.aspx?feed=57" target="_blank"&gt;New Kidney Diseases Resources&lt;/A&gt;&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/RSSFeed.aspx?feed=136" target="_blank"&gt;&lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0008_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk/kidney/RSSFeed.aspx?feed=136" target="_blank"&gt;New Male Urogenital Disorders Resources&lt;/A&gt; &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk//kidney/News.aspx" target="_blank"&gt;&lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0008_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk//kidney/News.aspx" target="_blank"&gt;Kidney diseases and male urogenital disorders in the news&lt;/A&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/rss/Directory/MoreAboutRss.aspx" target="_blank"&gt;Click through this link to find out more about RSS feeds.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;JOURNALS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;You can link through to the latest Tables of Contents from all the major kidney, transplant and urology journals from &lt;A href="http://www.library.nhs.uk/KIDNEY/Page.aspx?pagename=EJOURNALS" target="_blank"&gt;this page&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=3&gt;&lt;STRONG&gt;&lt;BIG&gt;Resources added in&amp;nbsp;July 2010&lt;/BIG&gt;&lt;/STRONG&gt; &lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A name=kidney&gt;Chronic Kidney&amp;nbsp;Disease&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://renaltsar.blogspot.com/2010/07/predicting-kidney-disease-qkidney.html" target="_blank"&gt;Renal Tsar on Predicting kidney disease with the QKidney scores&lt;/A&gt;. A blog item published 06/07/10&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:380644:0" name=internalLink&gt;Clinical Transformation: The Key to Green Nephrology&lt;/A&gt;. A mini review published in Nephron Clin Pract.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.ingentaconnect.com/content/rcgp/bjgp/2010/00000060/00000575/art00004" target="_blank"&gt;Quality-improvement strategies for the management of hypertension in chronic kidney disease in primary care: a systematic review&lt;/A&gt;. Published in Br J Gen Pract June 2010.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.ingentaconnect.com/content/rcgp/bjgp/2010/00000060/00000575/art00005" target="_blank"&gt;Does stage-3 chronic kidney disease matter?: A systematic literature review&lt;/A&gt;. Published in Br J Gen Pract June 2010.&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:381536:0" name=internalLink&gt;End-stage renal disease&lt;/A&gt;. Updated BMJ Clinical Evidence topic.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:382157:0" name=internalLink&gt;Cost-effectiveness of screening and optimal management for diabetes, hypertension, and chronic kidney disease: a modeled analysis&lt;/A&gt;. A new abstract from the NHS Economic Evaluation Database. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:382719:0" name=internalLink&gt;Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease&lt;/A&gt;.&amp;nbsp;A new abstract from the Database of Abstracts of Reviews of Effects.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Acute kidney injury&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:379293:0" name=internalLink&gt;Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome&lt;/A&gt;. A new abstract from the Database of Abstracts of Reviews of Effects.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.bmj.com/cgi/content/extract/341/jul05_1/c3365" target="_blank"&gt;Perioperative acute kidney injury: risk factors, recognition, management, and outcomes&lt;/A&gt; - BMJ clinical review published 05/07/10&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:360389:0" name=internalLink&gt;Efficacy of N-acetylcysteine in preventing renal injury after heart surgery: a systematic review of randomized trials&lt;/A&gt;. A new abstract from the Database of Abstracts of Reviews of Effects.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Renovascular diseases&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:361121:0" name=internalLink&gt;An analysis comparing open surgical and endovascular treatment of atherosclerotic renal artery stenosis&lt;/A&gt;. A new abstract from the Database of Abstracts of Reviews of Effects.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Renal tract infections&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:360990:0" name=internalLink&gt;Antibiotic prophylaxis for children at risk of developing urinary tract infection: a systematic review&lt;/A&gt;. A new abstract from the Database of Abstracts of Reviews of Effects.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:361161:0" name=internalLink&gt;Serum procalcitonin for prediction of renal parenchymal involvement in children with urinary tract infections: a meta-analysis of prospective clinical studies&lt;/A&gt;. A new abstract from the Database of Abstracts of Reviews of Effects.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Kidney stones&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;EM&gt;Nothing new this month. &lt;/EM&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Renal vasculitis&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2010---July/15/Rituximab-versus-cyclophosphamide-in-ANCA-associated-renal-vasculitis/" target="_blank"&gt;Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis&lt;/A&gt;. Published 15/07/10 by the National electronic Library for Medicines. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Dialysis&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://renaltsar.blogspot.com/2010/07/q-hep-b-vaccination-for-predialysis.html" target="_blank"&gt;Renal Tsar Q and A on Hep B vaccination for predialysis patients&lt;/A&gt;. A blog item published 01/07/10&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:360614:0" name=internalLink&gt;Antiplatelet medications in hemodialysis patients: a systematic review of bleeding rates&lt;/A&gt;.&amp;nbsp;A new abstract from the Database of Abstracts of Reviews of Effects.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Transplantation&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2010---July/22/BCSH-and-BTS-guidelines-Diagnosis-and-management-of-post-transplant-lymphoproliferative-disorder-in-adult-solid-organ-transplant-recipients/" target="_blank"&gt;BCSH and BTS guidelines: Diagnosis and management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients&lt;/A&gt;. Links and abstract published 22/07/10 by the National electronic Library for Medicines. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:382128:0" name=internalLink&gt;The cost-effectiveness of organ preservation methods in renal transplantation: US projections based on the machine preservation trial&lt;/A&gt;. A new abstract from the NHS Economic Evaluation Database. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:359377:0" name=internalLink&gt;Mycophenolate mofetil decreases acute rejection and may improve graft survival in renal transplant recipients when compared with azathioprine: a systematic review&lt;/A&gt;. A new abstract from the Database of Abstracts of Reviews of Effects.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Kidney Cancer&lt;/STRONG&gt; &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/Evidence/Medicines-Management/References/2010---July/07/Everolimus-and-pazopanib-two-new-drugs-for-renal-cell-carcinoma/" target="_blank"&gt;Everolimus and pazopanib: two new drugs for renal cell cancer&lt;/A&gt;. Published 07/07/10 by the National electronic Library for Medicines. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:60852:0" name=internalLink&gt;Percutaneous radiofrequency ablation for renal cancer&lt;/A&gt;. New NICE guideline.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A name=mug&gt;Male Urogenital Disorders&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Male Ureteric Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:365530:0" name=internalLink&gt;Cost-effectiveness of medical expulsive therapy using alpha-blockers for the treatment of distal ureteral stones&lt;/A&gt;. A new record from the NHS Economic Evaluation Database.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Male Bladder Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:370690:0" name=internalLink&gt;Solifenacin in the treatment of overactive bladder syndrome in Italian patients- pharmacoeconomic evaluation&lt;/A&gt;. A new record from the NHS Economic Evaluation Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:381738:0" name=internalLink&gt;Bladder neck suspension&lt;/A&gt;. Patient information by the British Association of Urological Surgeons.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:381734:0" name=internalLink&gt;Cystoscopy and stent procedures&lt;/A&gt;. Patient information by the British Association of Urological Surgeons.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:381729:0" name=internalLink&gt;Cystoscopy and litholapaxy - crushing of a bladder stone&lt;/A&gt;. Patient information by the British Association of Urological Surgeons.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:381720:0" name=internalLink&gt;Cystoscopy and hydrostatic bladder distension&lt;/A&gt;. Patient information by the British Association of Urological Surgeons.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:381717:0" name=internalLink&gt;Cystoscopy and evacuation of blood clots&lt;/A&gt;. Patient information by the British Association of Urological Surgeons.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:381710:0" name=internalLink&gt;Botox injections into the bladder&lt;/A&gt;. Patient information by the British Association of Urological Surgeons.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:381705:0" name=internalLink&gt;Bladder tumour resection&lt;/A&gt;. Patient information by the British Association of Urological Surgeons.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:381812:0" name=internalLink&gt;Mitrofanoff procedure - construction of a catheterisable urinary stoma&lt;/A&gt;. Patient information by the British Association of Urological Surgeons.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:381815:0" name=internalLink&gt;Ileal conduit - procedure specific information&lt;/A&gt;. Patient information leaflet by the British Association of Urological Surgeons.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:381810:0" name=internalLink&gt;Radical cystectomy with bladder substitution in men&lt;/A&gt;. This patient information has been produced by the British Association of Urological Surgeons.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:381745:0" name=internalLink&gt;Insertion of an artificial urinary sphincter in men&lt;/A&gt;. Patient information by the British Association of Urological Surgeons.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:381743:0" name=internalLink&gt;Enlargement of the bladder&lt;/A&gt;. Patient information by the British Association of Urological Surgeons.&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Prostate Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:111626:0" name=internalLink&gt;New systematic reviews on prostate cancer and surgery&lt;/A&gt;. Three systematic reviews on prostatectomy have been highlighted by the cancer specialist collection. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:381725:0" name=internalLink&gt;Cystoscopy and insertion or removal of a prostatic stent.&lt;/A&gt; Patient information by the British Association of Urological Surgeons.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:380030:0" name=internalLink&gt;Multi-disciplinary team guidance for managing prostate cancer&lt;/A&gt;. New care guideline published by BAUS.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Penile Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.annals.org/content/153/1/I-44.short?rss=1" target="_blank"&gt;Annals of Internal Medicine- new summary for patients on STDs among men who use erectile dysfunction drugs&lt;/A&gt;. Published 06/07/10&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nejm.org/doi/full/10.1056/NEJMoa1000485?query=current&amp;amp;rss=1" target="_blank"&gt;NEJM article on Adverse Events Associated with Testosterone Administration&lt;/A&gt;. Published 08/07/10.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:380657:0" name=internalLink&gt;Sexual health: erectile dysfunction in primary care&lt;/A&gt;. New BMJ Learning module.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Urethral disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:381740:0" name=internalLink&gt;Cystoscopy and urethral bulking injections&lt;/A&gt;. Patient information by the British Association of Urological Surgeons.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Urinary tract infections&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:360990:0" name=internalLink&gt;Antibiotic prophylaxis for children at risk of developing urinary tract infection- a systematic review&lt;/A&gt;. A new abstract from the Database of Abstracts of Reviews of Effects.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Testicular/Scrotal Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:379268:0" name=internalLink&gt;Management of stage I seminomatous testicular cancer: a systematic review&lt;/A&gt;. A new abstract from the Database of Abstracts of Reviews of Effects. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:367466:0" name=internalLink&gt;A decision analysis of treatments for obstructive azoospermia&lt;/A&gt;. A new record from the CRD NHS Economic Evaluation Database.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Sexually Transmitted Infections&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2010---July/06/Analysis-of-claims-data-on-sexually-transmitted-diseases-among-users-of-drugs-for-erectile-dysfunction-/" target="_blank"&gt;Analysis of claims data on sexually transmitted diseases among users of drugs for erectile dysfunction&lt;/A&gt;. Published 06/07/10 by the National electronic Library for Medicines.&lt;/LI&gt;
&lt;LI&gt;NHS Choices video on &lt;A href="nelh:381533:0" name=internalLink&gt;Genital Warts&lt;/A&gt;. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/LI&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <expiryDate>30/07/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>321834</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=321834]]&gt;</url>
    <title>August 2009 NHS Evidence - kidney diseases newsletter</title>
    <publicationDate>2009-08-04T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ UK TRANSPLANT,RENOVASCULAR DISEASES,INHERITED KIDNEY DISEASE,POLYCYSTIC KIDNEY DISEASE,RENAL CANCER,TRANSPLANTATION,RENAL TRACT INFECTIONS,ACUTE KIDNEY INJURY,ASSESSMENT/SELECTION,COMPLICATIONS OF KIDNEY DISEASE,TRANSPLANT OPERATION,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;August 2009 NHS Evidence - kidney diseases newsletter&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;NHS Evidence - kidney diseases is for busy health professionals, providing them with high quality information and keeping them up to date with the latest research and developments in this area.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=center&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage0 height=172 alt="Crossroads and signs" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID321834/nelhImp_0000_Crossroad_istock_compressed.jpg" width=268 border=0 name=nelh_tempImage0&gt;&lt;/P&gt;
&lt;P align=center&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0005_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&amp;nbsp;RSS FEEDS&amp;nbsp; &lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0006_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;You can receive news from the kidney diseases specialist collection from the RSS feeds we provide:&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;&lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0007_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk/kidney/RSSFeed.aspx?feed=57" target="_blank"&gt;New Resources added to NHS Evidence - kidney diseases&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0008_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk//kidney/News.aspx" target="_blank"&gt;Kidney diseases in the news&lt;/A&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/rss/Directory/MoreAboutRss.aspx" target="_blank"&gt;Click through this link to find out more about RSS feeds.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;JOURNALS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;You can link through to the latest Tables of Contents from all the major kidney journals from &lt;A href="http://www.library.nhs.uk/KIDNEY/Page.aspx?pagename=EJOURNALS" target="_blank"&gt;this page&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;New this month&lt;/STRONG&gt; - &lt;A href="http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.1000097" target="_blank"&gt;The PRISMA Statement&lt;/A&gt;: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009) Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed.1000097&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=3&gt;&lt;STRONG&gt;&lt;BIG&gt;New resources added in July 2009&lt;/BIG&gt;&lt;/STRONG&gt; &lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Influenza pandemic&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:279490:0" name=internalLink&gt;Briefing and guidance for adult renal units in the UK during an influenza pandemic.&lt;/A&gt; Guidance from the Renal Association (08 Jul 2009)&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.renal.org/forum/" target="_blank"&gt;Pandemic flu discussion forum&lt;/A&gt; from the Renal Association.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.renal.org/pages/pages/posts/additional-influenza-briefing-note79.php" target="_blank"&gt;Renal Association website pages on Swine Flu&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Chronic Kidney&amp;nbsp; Disease&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Renal Tsar's blog on &lt;A href="http://renaltsar.blogspot.com/2009/07/centre-for-evidence-based-purchasing.html" target="_blank"&gt;Point of Care testing for Albumin Creatinin Ratio in urine&lt;/A&gt; (09 Jul 2009)&lt;/LI&gt;
&lt;LI&gt;Renal Tsar's blog on &lt;A href="http://renaltsar.blogspot.com/2009/07/parliamentary-q-what-health-education.html" target="_blank"&gt;Parliamentary Q: What health education progs... raise public awareness of kidney disease&lt;/A&gt; (15 July 2009)&lt;/LI&gt;
&lt;LI&gt;Renal Tsar's blog on &lt;A href="http://renaltsar.blogspot.com/2009/07/parliamentary-q.html" target="_blank"&gt;Parliamentary Q: How much... spent on research into kidney disease&lt;/A&gt; (15 July 2009)&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:320802:0" name=internalLink&gt;Aldosterone antagonists for preventing the progression of chronic kidney disease&lt;/A&gt;. Cochrane systematic review (Issue 3, 2009). &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:321767:0" name=internalLink&gt;Chronic Kidney Disease - not diabetic&lt;/A&gt;. Clinical Knowledge Summaries guidance.&lt;/LI&gt;
&lt;LI&gt;BBC News story: &lt;A href="nelh:320561:0" name=internalLink&gt;'I was frightened to get help'&lt;/A&gt; (11 July 2009). &lt;/LI&gt;
&lt;LI&gt;Kidney Research UK news item: &lt;A href="nelh:320565:0" name=internalLink&gt;Baking soda for your kitchen... and your kidneys&lt;/A&gt;. (17 July 2009) &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Henoch-Schonlein Purpura (HSP)&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:320751:0" name=internalLink&gt;Interventions for preventing and treating kidney disease in Henoch-Schonlein Purpura (HSP)&lt;/A&gt;. Cochrane Systematic Review (Issue 3, 2009). &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Complications of kidney disease&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;BBC News story: &lt;A href="nelh:320563:0" name=internalLink&gt;Kidney removed by 'scarless' surgery&lt;/A&gt; (13 July 2009).&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Acute renal failure&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:321585:0" name=internalLink&gt;Helping adolescents and young adults with end stage renal failure&lt;/A&gt;. A working party report from the British Association for Paediatric Nephrology. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Polycystic Kidney Disease&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Renal Tsar's blog on &lt;A href="http://renaltsar.blogspot.com/2009/07/aneurysms-in-pkd-should-we-screen.html" target="_blank"&gt;Aneurysms in PKD - Should we screen?&lt;/A&gt; (09 July 2009)&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Renovascular diseases&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Article: &lt;A href="nelh:319629:0" name=internalLink&gt;Kidney function and risk of cardiovascular disease and mortality in women&lt;/A&gt;&amp;nbsp;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Transplantation&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:320739:0" name=internalLink&gt;Antihypertensive treatment for kidney transplant recipients&lt;/A&gt;. Cochrane systematic review (Issue 3, 2009). &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:321656:0" name=internalLink&gt;Allocation of organs to non-UK EU residents&lt;/A&gt;. Report from the Department of Health (31 July 2009).&lt;/LI&gt;
&lt;LI&gt;BBC News story: &lt;A href="nelh:321583:0" name=internalLink&gt;Private transplants to be banned&lt;/A&gt;. (31 July 2009). &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Renal tract cancer&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;New systematic reviews on &lt;A href="nelh:124716:0" name=internalLink&gt;Treatment and Disease management: Interventional radiology&lt;/A&gt;. NHS Evidence - cancer.&lt;/LI&gt;&lt;/UL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:01:16</lastReviewDate>
    <expiryDate>06/07/2011 11:01:16</expiryDate>
  </document>
  <document>
    <id>319298</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.baus.org.uk/EducationAndTraining/office-of-education]]&gt;</url>
    <title>BAUS Office of Education</title>
    <publicationDate>2010-06-21T00:00:00</publicationDate>
    <publisher>British Association of Urological Surgeons (BAUS)</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Details of the BAUS Office of Education</description>
    <body>&lt;![CDATA[ &lt;P&gt;The Office of Education was established by BAUS in January 1997 in response to increasing demand by trainees and Urologists to have structured educational material delivered to them on a regular basis.&lt;/P&gt;
&lt;P&gt;Whilst the SAC in Urology, in association with the Postgraduate Medical Education and Training Board (PMETB), sets the necessary standards to become a qualified urological surgeon in the UK and the Intercollegiate Board in Urology tests those standards through the FRCS(Urol) Examination, it is the aim of the Office of Education to ensure that adequate teaching is delivered to maintain these standards. &lt;/P&gt;]]&gt;</body>
    <expiryDate>04/08/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>319291</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.baus.org.uk/Sections/andrology]]&gt;</url>
    <title>BAUS Section of Andrology</title>
    <publicationDate>2010-06-21T00:00:00</publicationDate>
    <publisher>British Association of Urological Surgeons (BAUS)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The British Association of Urological Surgeons (BAUS) Section of Andrology</description>
    <body>&lt;![CDATA[ The Section of Andrology was formed in 2003, and its goals are:&lt;BR&gt;&amp;nbsp;&lt;BR&gt;To promote the highest standards of andrology in the UK. &lt;BR&gt;To promote audit and research among British urologists. &lt;BR&gt;To promote and organise education among British urologists.]]&gt;</body>
    <expiryDate>04/08/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>288395</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.bmj.com/cgi/reprint/336/7657/1374]]&gt;</url>
    <title>Becoming a live kidney donor</title>
    <publicationDate>2008-06-14T00:00:00</publicationDate>
    <publisher>BMJ 2008;336;1374-1376</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ TRANSPLANTATION,TRANSPLANT OPERATION,ASSESSMENT/SELECTION,DONOR,RECIPIENT,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Article in BMJ</description>
    <body>&lt;![CDATA[ &lt;P&gt;Extract&lt;/P&gt;
&lt;P&gt;&amp;nbsp;In 2007, Annabel Ferriman gave one of her kidneys to an old&lt;SUP&gt; &lt;/SUP&gt;friend. This is the story of her journey through that process&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;'It was a positive experience for both of us, but some aspects&lt;SUP&gt; &lt;/SUP&gt;of the patient journey, in particular the endless tests leading&lt;SUP&gt; &lt;/SUP&gt;up to the transplant, were so protracted that I was left seething&lt;SUP&gt; &lt;/SUP&gt;with rage. I am recounting the tale partly to encourage other&lt;SUP&gt; &lt;/SUP&gt;people to consider kidney donation, but also in the hope that&lt;SUP&gt; &lt;/SUP&gt;hospitals might make the path for donors a little easier'&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>01/07/2010 14:53:36</lastReviewDate>
    <expiryDate>01/07/2011 14:53:36</expiryDate>
  </document>
  <document>
    <id>321706</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=321706]]&gt;</url>
    <title>Benign Prostate Enlargement: Systematic reviews and meta-analyses</title>
    <publicationDate>2011-02-21T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,PROSTATE DISORDERS,BENIGN PROSTATE ENLARGEMENT,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Benign Prostate Enlargement: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence -&amp;nbsp;kidney diseases and male urogenital disorders&amp;nbsp;has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development&amp;nbsp;strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us &lt;/A&gt;if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2011&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Frieben R, Lin H, Hinh P, Canfield S, Wang R. Male sexual function after minimally invasive surgeries for BPH. Journal of Sexual Medicine. 2011;8. [No PubMed abstract available]. &lt;/LI&gt;
&lt;LI&gt;Liu, L., Zheng, S., Han, P., Wei, Q. (2011). "Phosphodiesterase-5 Inhibitors for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis". Urology 77(1): 123-129. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/21195830" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Ahyai, S.A., Gilling, P., Kaplan, S.A., Kuntz, R.M., Madersbacher, S., Montorsi, F. et al. "Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement." Eur. Urol. 2010 Sep;58(3):384-97. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20825758" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Bach, T., S. J. Xia, et al. (2010). "Thulium: YAG 2 mum cw laser prostatectomy: where do we stand?" World Journal of Urology 28(2): 163-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20204378" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Burke, N., J. P. Whelan, et al. (2010). "Systematic Review and Meta-analysis of Transurethral Resection of the Prostate Versus Minimally Invasive Procedures for the Treatment of Benign Prostatic Obstruction." Urology 75(5): 1015-1022. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19854492" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Cantrell, M. A., H. R. Bream-Rouwenhorst, et al. "Silodosin for benign prostatic hyperplasia." Ann Pharmacother 44(2): 302-10. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20071497" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Emberton, M. (2010). "Medical treatment of benign prostatic hyperplasia: physician and patient preferences and satisfaction." International Journal of Clinical Practice 64(10): 1425-35. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/%2020579137" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Frieben, R. W., H. C. Lin, et al. (2010). "The impact of minimally invasive surgeries for the treatment of symptomatic benign prostatic hyperplasia on male sexual function: a systematic review." Asian Journal of Andrology 12(4): 500-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20473318" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hashim, H. and P. Abrams (2010). "Emerging drugs for the treatment of benign prostatic obstruction." Expert Opinion on Emerging Drugs 15(2): 159-74.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20446824" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hollingsworth, J. M. and J. T. Wei (2010). "Does the combination of an alpha1-adrenergic antagonist with a 5alpha-reductase inhibitor improve urinary symptoms more than either monotherapy?" Current Opinion in Urology 20(1): 1-6.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19881352" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Jiang, Y. and Y. F. Long (2010). "[Effects of finasteride on hematuria associated with benign prostatic hyperplasia: a meta-analysis]." Zhong Hua Nan Ke Xue 16(8): 726-9. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/21090349" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kroeze, S., E. Mayer, et al. (2010). "Has modern TURP evolved over three decades?: A comparative analysis." Journal of Urology 183(4 SUPPL. 1).&amp;nbsp;[&lt;A href="http://www.jurology.com/article/S0022-5347%2810%2902401-8/fulltext" target="_blank"&gt;Link to&amp;nbsp;publisher abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Laydner, H. K., P. Oliveira, et al. (2010). "Phosphodiesterase 5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review." BJU Int. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Phosphodiesterase%205%20inhibitors%20for%20lower%20urinary%20tract%20symptoms%20secondary%20to%20benign%20prostatic%20hyperplasia%3A%20a%20systematic%20review" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lourenco T, Shaw M, Fraser C, Maclennan G, N'Dow J, Pickard R. The clinical effectiveness of transurethral incision of the prostate: a systematic review of randomised controlled trials. World Journal of Urology. 2010;28(1):23-32. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20033744" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Ren, R. M., M. Kou, et al. (2010). "Efficacy and safety of tamsulosin for the treatment of benign prostatic hyperplasia: a meta analysis." Chinese Medical Journal 123(2): 234-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20137377" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Rieken, M., N. Ebinger Mundorff, et al. (2010). "Complications of laser prostatectomy: a review of recent data." World Journal of Urology 28(1): 53-62. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Complications%20of%20laser%20prostatectomy%3A%20a%20review%20of%20recent%20data" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Seki, N. and S. Naito (2010). "Laser prostatectomy as a treatment option for BPH: HoLEP versus PVP." International Journal of Urology 17: A49-A50.&amp;nbsp;[No abstract available]&lt;/LI&gt;
&lt;LI&gt;Tacklind J, Fink HA, MacDonald R, Rutks I, Wilt TJ. Finasteride for benign prostatic hyperplasia. Cochrane Database of Systematic Reviews 2010, Issue 10. Art. No.: CD006015. DOI: 10.1002/14651858.CD006015.pub3. [&lt;A href="nelh:389383:0" name=internalLink&gt;Link to Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Wong, S. S., C. Fraser, et al. (2010). "The fate of conference abstracts: systematic review and meta-analysis of surgical treatments for men with benign prostatic enlargement." World Journal of Urology 28(1): 63-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20049457" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Agbabiaka TB, Pittler MH, Wider B, Ernst E. Serenoa repens (Saw Palmetto): A systematic review of adverse events. Drug Safety. 2009;32(8):637-47. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19591529" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Alcaraz A, Hammerer P, Tubaro A, Schroder FH, Castro R. Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review. European Urology. 2009;55(4):864-73. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19027219" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Descazeaud A, Robert G, Azzousi AR, Ballereau C, Lukacs B, Haillot O, et al. Laser treatment of benign prostatic hyperplasia in patients on oral anticoagulant therapy: a review. BJU International. 2009;103(9):1162-5. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19154457" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Dong Z, Wang Z, Yang K, Liu Y, Gao W, Chen W. Tamsulosin versus terazosin for benign prostatic hyperplasia: a systematic review. Systems Biology in Reproductive Medicine. 2009;55(4):129-36. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19886768" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Garimella PS, Fink HA, Macdonald R, Wilt TJ. Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia. Cochrane Database of Systematic Reviews. 2009(4). [&lt;A href="nelh:327224:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Herrmann TR, Georgiou A, Bach T, Gross AJ, Oelke M. Laser treatments of the prostate vs TURP/ open prostatectomy: systematic review of urodynamic data. Minerva Urologica e Nefrologica. 2009;61(3):309-24. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19773731" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Parsons JK, Im R. Alcohol consumption is associated with a decreased risk of benign prostatic hyperplasia. Journal of Urology. 2009;182(4):1463-8. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19683313" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Roumeguere, T., K. Zouaoui Boudjeltia, et al. (2009). "Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia?" BJU Int. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19239452?dopt=Abstract" target="_blank"&gt;Link to abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Tacklind, J., R. MacDonald, et al. (2009). "Serenoa repens for benign prostatic hyperplasia." Cochrane Database of Systematic Reviews(2). [&lt;A href="nelh:237275:0" name=internalLink&gt;Link to Cochrane summary&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Dedhia, R. C. and K. T. McVary (2008). "Phytotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia." Journal of Urology 179(6): 2119-25.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18423748?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Emberton, M., J. M. Fitzpatrick, et al. (2008). "Progression of benign prostatic hyperplasia: Systematic review of the placebo arms of clinical trials." BJU International 102(8): 981-986.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18549433?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Gallegos, P. J. and L. A. Frazee (2008). "Anticholinergic therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia." Pharmacotherapy 28(3): 356-365.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18294115?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Greco, K. A. and K. T. McVary (2008). "The role of combination medical therapy in benign prostatic hyperplasia." International Journal of Impotence Research 20 Suppl 3: S33-43. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19002123?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lourenco, T., R. Pickard, et al. (2008). "Minimally invasive treatments for benign prostatic enlargement: systematic review of randomised controlled trials." BMJ 337.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18845591?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lourenco, T., R. Pickard, et al. (2008). "Alternative approaches to endoscopic ablation for benign enlargement of the prostate: systematic review of randomised controlled trials." BMJ 337.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18595932?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Nickel, J. C., S. Sander, et al. (2008). "A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia." International Journal of Clinical Practice 62(10): 1547-1559.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18822025?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Oeconomou, A., H. Madersbacher, et al. (2008). "Is botulinum neurotoxin type A (BoNT-A) a novel therapy for lower urinary tract symptoms due to benign prostatic enlargement? A review of the literature." European Urology 54(4): 765-75.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18571306?ordinalpos=3&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Link to abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Parsons, J. K. and C. Kashefi (2008). "Physical Activity, Benign Prostatic Hyperplasia, and Lower Urinary Tract Symptoms." European Urology 53(6): 1228-1235.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18358592?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Schulman, C. C. (2008). "Tamsulosin modified release and oral controlled absorption system in the management of lower urinary tract symptoms suggestive of benign prostatic hyperplasia." Expert Opinion On Drug Metabolism &amp;amp; Toxicology 4(6): 771-82.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18611117?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Seki, N. and S. Naito (2008). "Holmium laser for benign prostatic hyperplasia." Current Opinion in Urology 18(1): 41-5.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18090488?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Armitage, J. N., P. J. Cathcart, et al. (2007). "Epithelializing stent for benign prostatic hyperplasia: a systematic review of the literature." J Urol 177(5): 1619-24.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17437773?dopt=Abstract" target="_blank"&gt;Link to abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Blake-James, B. T., A. Rashidian, et al. (2007). "The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis." BJU Int 99(1): 85-96.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17026588?dopt=Abstract" target="_blank"&gt;Link to abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hoffman, R. M., M. Monga, et al. (2007). "Microwave thermotherapy for benign prostatic hyperplasia." Cochrane Database Syst Rev(4): CD004135.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17943811?dopt=Abstract" target="_blank"&gt;Link to abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Issa, M. M. and K. H. Kraft (2007). "5alpha-reductase inhibition for men with enlarged prostate." J Am Acad Nurse Pract 19(8): 398-407.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17655569?dopt=Abstract" target="_blank"&gt;Link to abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Spatafora, S., G. Conti, et al. (2007). "Evidence-based guidelines for the management of lower urinary tract symptoms related to uncomplicated benign prostatic hyperplasia in Italy: updated summary." Curr Med Res Opin 23(7): 1715-32.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17588302?dopt=Abstract" target="_blank"&gt;Link to abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2006&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Armitage, J. N., A. Rashidian, et al. (2006). "The thermo-expandable metallic stent for managing benign prostatic hyperplasia: a systematic review." BJU Int 98(4): 806-10.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16879446?dopt=Abstract" target="_blank"&gt;Link to abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kaplan, S. A. (2006). "Update on the american urological association guidelines for the treatment of benign prostatic hyperplasia." Reviews in Urology 8 Suppl 4: S10-7.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17215996?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Novara, G., A. Galfano, et al. (2006). "Anticholinergic drugs in patients with bladder outlet obstruction and lower urinary tract symptoms: A systematic review." Eur Urol 50(4): 675-83.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16930813?dopt=Abstract" target="_blank"&gt;Link to abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Rassweiler, J., D. Teber, et al. (2006). "Complications of transurethral resection of the prostate (TURP)--incidence, management, and prevention." Eur Urol 50(5): 969-79; discussion 980.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16469429?dopt=Abstract" target="_blank"&gt;Link to abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:01:21</lastReviewDate>
    <expiryDate>06/07/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>318601</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://learning.bmj.com/learning/search-result.html?moduleId=5003330]]&gt;</url>
    <title>Benign prostatic hyperplasia: an update on diagnosis and management</title>
    <publicationDate>2009-04-01T00:00:00</publicationDate>
    <publisher>BMJ Learning</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,BENIGN PROSTATE ENLARGEMENT,PROSTATE DISORDERS,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>BMJ Learning Module - for BMA Members</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Extract:&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Module type&lt;/STRONG&gt;&amp;nbsp; &amp;nbsp; &lt;/P&gt;
&lt;P&gt;Just in time:&lt;BR&gt;Want a fast, evidence based update? Here are the essentials on everyday conditions. Before you start a learning resource it is best to add it to your plan first.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;What's in this case:&lt;/STRONG&gt; &amp;nbsp;&lt;/P&gt;
&lt;P&gt;This module provides the essential facts on the assessment and treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction secondary to benign prostatic hyperplasia (BPH). It also gives guidance on when to refer patients to secondary care.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Target audience:&lt;/STRONG&gt; &amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;NHS London - Foundation programme&lt;/LI&gt;
&lt;LI&gt;NHS London - GP and trainee CPD&lt;/LI&gt;
&lt;LI&gt;International&lt;/LI&gt;
&lt;LI&gt;GP CPD&lt;/LI&gt;
&lt;LI&gt;Hospital doctor CPD&lt;/LI&gt;
&lt;LI&gt;GP trainee&lt;/LI&gt;
&lt;LI&gt;NHS London - Allied health professionals&lt;/LI&gt;
&lt;LI&gt;Other healthcare professionals&lt;/LI&gt;
&lt;LI&gt;Saudi Pediatric Association Channel&lt;/LI&gt;
&lt;LI&gt;NHS London - Acute and community nursing and midwifery&lt;/LI&gt;
&lt;LI&gt;The Royal New Zealand College of General Practitioners&lt;/LI&gt;
&lt;LI&gt;Practice manager CPD&lt;/LI&gt;
&lt;LI&gt;Foundation programme&lt;/LI&gt;
&lt;LI&gt;NHS London - Leadership and management&lt;/LI&gt;
&lt;LI&gt;NHS London - Hospital doctor CPD&lt;/LI&gt;
&lt;LI&gt;Practice nurse CPD&lt;/LI&gt;
&lt;LI&gt;Medical Students - international &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>27/05/2010 10:01:21</lastReviewDate>
    <expiryDate>27/05/2011 10:01:21</expiryDate>
  </document>
  <document>
    <id>319265</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.bladderandbowelfoundation.org/bladder/bladder-and-bowel-problems/]]&gt;</url>
    <title>Bladder and Bowel Problems</title>
    <publicationDate></publicationDate>
    <publisher>The Bladder and Bowel Foundation</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Information on Bladder and Bowel Problems provided by the Bladder and Bowel Foundation</description>
    <body>&lt;![CDATA[ &lt;P&gt;Information on Bladder and Bowel Problems provided by the Bladder and Bowel Foundation, including:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;SPAN class=Apple-style-span style="WORD-SPACING: 0px; FONT: 16px 'times new roman'; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BORDER-COLLAPSE: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"&gt;&lt;SPAN class=Apple-style-span style="FONT-SIZE: 13px; FONT-FAMILY: Tahoma; TEXT-ALIGN: left"&gt;&lt;A title=Prolapse style="FONT-SIZE: 14px; COLOR: rgb(104,104,168); TEXT-DECORATION: none" href="https://rmsadmin.library.nhs.uk/admin/wizards/cardex/prolapse/" target="_blank"&gt;Prolapse&lt;/A&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
    <lastReviewDate>01/07/2010 14:53:45</lastReviewDate>
    <expiryDate>01/07/2011 14:53:45</expiryDate>
  </document>
  <document>
    <id>319066</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.bladderandbowelfoundation.org/bladder/bladder-problems/]]&gt;</url>
    <title>Bladder Problems</title>
    <publicationDate>2008-06-17T00:00:00</publicationDate>
    <publisher>The Bladder and Bowel Foundation</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE BLADDER DISORDERS,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Information on bladder problems from the Bladder and Bowel Foundation</description>
    <body>&lt;![CDATA[ &lt;P&gt;Information on bladder problems from the Bladder and Bowel Foundation including links to:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A title="Fowler's Syndrome" style="FONT-SIZE: 14px" href="http://www.bladderandbowelfoundation.org/bladder/bladder-problems/fowlers-syndrome/" target="_blank"&gt;&lt;STRONG&gt;Fowler's Syndrome&lt;/STRONG&gt;&lt;/A&gt; 
&lt;LI&gt;&lt;A title="Overactive Bladder" style="FONT-SIZE: 14px" href="http://www.bladderandbowelfoundation.org/bladder/bladder-problems/overactive-bladder/" target="_blank"&gt;&lt;STRONG&gt;Overactive Bladder&lt;/STRONG&gt;&lt;/A&gt; 
&lt;LI&gt;&lt;A title="Stress urinary incontinence" style="FONT-SIZE: 14px" href="http://www.bladderandbowelfoundation.org/bladder/bladder-problems/stress-urinary-incontinence/" target="_blank"&gt;&lt;STRONG&gt;Stress urinary incontinence&lt;/STRONG&gt;&lt;/A&gt; 
&lt;LI&gt;&lt;A title="Urgency and Urge incontinence" style="FONT-SIZE: 14px" href="http://www.bladderandbowelfoundation.org/bladder/bladder-problems/urgency-and-urge-incontinence/" target="_blank"&gt;&lt;STRONG&gt;Urgency and Urge incontinence&lt;/STRONG&gt;&lt;/A&gt; 
&lt;LI&gt;&lt;A title=Frequency style="FONT-SIZE: 14px" href="http://www.bladderandbowelfoundation.org/bladder/bladder-problems/frequency/" target="_blank"&gt;&lt;STRONG&gt;Frequency&lt;/STRONG&gt;&lt;/A&gt; 
&lt;LI&gt;&lt;A title=Nocturia style="FONT-SIZE: 14px" href="http://www.bladderandbowelfoundation.org/bladder/bladder-problems/nocturia/" target="_blank"&gt;&lt;STRONG&gt;Nocturia&lt;/STRONG&gt;&lt;/A&gt; 
&lt;LI&gt;&lt;A title="Nocturnal Enuresis" style="FONT-SIZE: 14px" href="http://www.bladderandbowelfoundation.org/bladder/bladder-problems/nocturnal-enuresis/" target="_blank"&gt;&lt;STRONG&gt;Nocturnal Enuresis&lt;/STRONG&gt;&lt;/A&gt; 
&lt;LI&gt;&lt;A title="Overflow Incontinence" style="FONT-SIZE: 14px" href="http://www.bladderandbowelfoundation.org/bladder/bladder-problems/overflow-incontinence/" target="_blank"&gt;&lt;STRONG&gt;Overflow Incontinence&lt;/STRONG&gt;&lt;/A&gt; 
&lt;LI&gt;&lt;A title="Post micturition dribble" style="FONT-SIZE: 14px" href="http://www.bladderandbowelfoundation.org/bladder/bladder-problems/post-micturition-dribble/" target="_blank"&gt;&lt;STRONG&gt;Post micturition dribble&lt;/STRONG&gt;&lt;/A&gt; 
&lt;LI&gt;&lt;A title="Prostate problems and incontinence" style="FONT-SIZE: 14px" href="http://www.bladderandbowelfoundation.org/bladder/bladder-problems/prostate-problems-and-incontinence/" target="_blank"&gt;&lt;STRONG&gt;Prostate problems and incontinence&lt;/STRONG&gt;&lt;/A&gt; 
&lt;LI&gt;&lt;A title="Painful bladder/Interstital Cystitis" style="FONT-SIZE: 14px" href="http://www.bladderandbowelfoundation.org/bladder/bladder-problems/painful-bladderinterstital-cystitis/" target="_blank"&gt;&lt;STRONG&gt;Painful bladder/Interstital Cystitis&lt;/STRONG&gt;&lt;/A&gt; 
&lt;LI&gt;&lt;A title="Bacterial cystitis" style="FONT-SIZE: 14px" href="http://www.bladderandbowelfoundation.org/bladder/bladder-problems/bacterial-cystitis/" target="_blank"&gt;&lt;STRONG&gt;Bacterial cystitis&lt;/STRONG&gt;&lt;/A&gt; 
&lt;LI&gt;&lt;A title="Urinary tract infection" style="FONT-SIZE: 14px" href="http://www.bladderandbowelfoundation.org/bladder/bladder-problems/urinary-tract-infection/" target="_blank"&gt;&lt;STRONG&gt;Urinary tract infection&lt;/STRONG&gt;&lt;/A&gt; 
&lt;LI&gt;&lt;A title="Childhood bladder problems" style="FONT-SIZE: 14px" href="http://www.bladderandbowelfoundation.org/bladder/bladder-problems/childhood-bladder-problems/" target="_blank"&gt;&lt;STRONG&gt;Childhood bladder problems&lt;/STRONG&gt;&lt;/A&gt; 
&lt;LI&gt;&lt;A title="Urinary retention and difficulty urinating" style="FONT-SIZE: 14px" href="http://www.bladderandbowelfoundation.org/bladder/bladder-problems/urinary-retention-and-difficulty-urinating/" target="_blank"&gt;&lt;STRONG&gt;Urinary retention and difficulty urinating&lt;/STRONG&gt;&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
    <expiryDate>06/07/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>262144</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.bmj.com/cgi/content/full/334/7605/1198]]&gt;</url>
    <title>BMJ analysis: Formula estimation of glomerular filtration rate: have we gone wrong?</title>
    <publicationDate>2007-06-09T00:00:00</publicationDate>
    <publisher>BMJ  2007;334:1198-1200 (9 June)</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ SCREENING OPTIONS,SCREENING TESTS,ASSESSMENT TESTS,ASSESSMENT OF RENAL FUNCTION,GFR AND EGFR,CREATININE CLEARANCE,CREATININE,EGFR,CREATININE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>BMJ Analysis</description>
    <body>&lt;![CDATA[ &lt;P&gt;The following topics are discussed in the article:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Estimating glomerular filtration rate&lt;/LI&gt;
&lt;LI&gt;Clinical indications for assessing glomerular function:&lt;/LI&gt;
&lt;UL&gt;
&lt;LI&gt;Detecting changes in renal function over time&lt;/LI&gt;
&lt;LI&gt;Disease staging in patients with chronic kidney disease&lt;/LI&gt;
&lt;LI&gt;Detecting chronic kidney disease in mixed populations&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;Analytical considerations&lt;/LI&gt;
&lt;LI&gt;Conclusion&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
    <lastReviewDate>23/09/2010 10:07:07</lastReviewDate>
    <expiryDate>23/09/2011 10:07:07</expiryDate>
  </document>
  <document>
    <id>396652</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.bmj.com/content/341/bmj.c6716.short]]&gt;</url>
    <title>BMJ Clinical Review: Investigating and managing chronic scrotal pain</title>
    <publicationDate>2010-12-07T00:00:00</publicationDate>
    <publisher>BMJ</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,TESTICULAR/ SCROTAL DISORDERS,PAIN,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Summary points&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Chronic scrotal pain is an ill understood symptom complex for which evidence based treatments are lacking&lt;/LI&gt;
&lt;LI&gt;Many patients have no identifiable cause to explain their discomfort&lt;/LI&gt;
&lt;LI&gt;Pain can be subclassified as testicular pain syndrome, post-vasectomy pain syndrome, and epididymal pain syndrome&lt;/LI&gt;
&lt;LI&gt;As many as 16% of men undergoing vasectomy develop a chronic pain syndrome&lt;/LI&gt;
&lt;LI&gt;Surgery is a last resort because its efficacy is uncertain, with limited data to support its use&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
    <expiryDate>07/12/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>312831</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://learning.bmj.com/learning/search-result.html?moduleId=10010368]]&gt;</url>
    <title>BMJ Learning - Delayed puberty: an up to date guide</title>
    <publicationDate>2009-04-21T00:00:00</publicationDate>
    <publisher>BMJ Learning</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Interactive case history: Use these interactive modules to learn as we guide you through a real life consultation. Before you start a learning resource it is best to add it to your plan first.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Target audience:&lt;/STRONG&gt;&amp;nbsp; &amp;nbsp; &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Foundation programme 
&lt;LI&gt;International 
&lt;LI&gt;Practice nurse CPD 
&lt;LI&gt;Hospital doctor CPD 
&lt;LI&gt;GP CPD 
&lt;LI&gt;GP trainee 
&lt;LI&gt;Saudi Pediatric Association Channel 
&lt;LI&gt;The Royal New Zealand College of General Practitioners&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
    <lastReviewDate>08/03/2011 09:56:19</lastReviewDate>
    <expiryDate>08/03/2012 09:56:19</expiryDate>
  </document>
  <document>
    <id>319059</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.nelm.nhs.uk/en/NeLM-Area/News/2009---June/19/BMJ-Practice-Rational-testing---assessing-candiduria-in-a-critically-ill-patient/]]&gt;</url>
    <title>BMJ Practice: Rational testing - assessing candiduria in a critically ill patient</title>
    <publicationDate>2009-06-19T00:00:00</publicationDate>
    <publisher>BMJ</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ RENAL TRACT INFECTIONS,UPPER URINARY TRACT INFECTION,LOWER URINARY TRACT INFECTION,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>In this BMJ Practice article the author discusses the assessment of candiduria in critically ill patients by describing a case report and investigation in the patient.</description>
    <body>&lt;![CDATA[ &lt;P&gt;In this BMJ Practice article the author discusses the assessment of candiduria in critically ill patients by describing a case report and investigation in the patient. &lt;/P&gt;
&lt;P&gt;The main learning points highlighted in the article are (direct from source):&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Distinguishing the causes of candiduria (perineal contamination, colonisation of the lower urinary tract, upper tract infection, and "spill" into the urine from blood borne Candida infection) requires a compilation of clinical, microbiological, and radiological data&lt;/LI&gt;
&lt;LI&gt;Though candiduria is most often of little clinical consequence and does not need treating, in some clinical contexts such as critically ill patients, it may be the only manifestation of life threatening disseminated Candida infection, which needs aggressive systemic antifungal treatment&lt;/LI&gt;
&lt;LI&gt;Asymptomatic candiduria in clinical contexts where disseminated infection is unlikely does not usually require treatment. A change of indwelling catheter may be appropriate&lt;/LI&gt;
&lt;LI&gt;Fluconazole is the agent of choice for infection confined to the renal tract because of its water solubility and high urinary concentrations&lt;/LI&gt;
&lt;LI&gt;When candiduria is a manifestation of disseminated infection, treatment should be directed to the primary site(s) of infection, and a triazole, echinocandin, or a lipid preparation of amphotericin B are the agents of choice&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
    <lastReviewDate>01/07/2010 14:00:55</lastReviewDate>
    <expiryDate>01/07/2011 14:00:55</expiryDate>
  </document>
  <document>
    <id>388011</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=388011]]&gt;</url>
    <title>Bone disease and kidney disorders: Systematic reviews and meta-analyses</title>
    <publicationDate>2010-09-17T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ COMPLICATIONS OF KIDNEY DISEASE,BONE DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Bone disease and kidney disorders: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Geary, D. F., E. M. Hodson, et al. (2010). "Interventions for bone disease in children with chronic kidney disease." Cochrane Database of Systematic Reviews(1): CD008327-NaN. [&lt;A href="nelh:341800:0" name=internalLink&gt;Link to Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;No systematic reviews or meta-analyses identified. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;No systematic reviews or meta-analyses identified. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Jamal, S. A., J. A. Hayden, et al. (2007). "Low bone mineral density and fractures in long-term hemodialysis patients: a meta-analysis." Am J Kidney Dis 49(5): 674-81.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Low%20bone%20mineral%20density%20and%20fractures%20in%20long-term%20hemodialysis%20patients%3A%20a%20meta-analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Palmer, S. C., D. O. McGregor, et al. (2007). "Interventions for preventing bone disease in kidney transplant recipients." Cochrane Database Syst Rev(3): CD005015.&amp;nbsp;[&lt;A href="nelh:239029:0" name=internalLink&gt;Link to Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2006&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Mitterbauer, C., C. Schwarz, et al. (2006). "Effects of bisphosphonates on bone loss in the first year after renal transplantation--a meta-analysis of randomized controlled trials." Nephrol Dial Transplant 21(8): 2275-81. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Effects%20of%20bisphosphonates%20on%20bone%20loss%20in%20the%20first%20year%20after%20renal%20transplantation--a%20meta-analysis%20of%20randomized%20controlled%20trials" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <expiryDate>17/09/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>182669</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.kidney.org/professionals/kdoqi/guidelines_pedbone/index.htm]]&gt;</url>
    <title>Bone metabolism and disease in children with chronic kidney disease</title>
    <publicationDate>2005-10-03T00:00:00</publicationDate>
    <publisher>K/DOQI</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASE IN CHILDREN AND ADOLESCENTS,STAFF USE,SPECIALTIES,NEPHROLOGY,MUSCULOSKELETAL,METABOLIC DISEASE,GUIDELINES/EBM,CHILD HEALTH,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>K/DOQI Clinical Practice Guidelines</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Extract from Guideline&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;The clinical features of renal bone disease unique to childhood relate to distinctions between the growing and the fully-grown skeleton. The metabolic process of skeletal modeling throughout growth dictates that pediatric-specific recommendations for the management of the bone disease of CKD be developed. &lt;/P&gt;
&lt;P&gt;Published in 2005&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>23/08/2010 12:05:01</lastReviewDate>
    <expiryDate>23/08/2011 12:05:01</expiryDate>
  </document>
  <document>
    <id>269265</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.kidney.org.uk/Medical-Info/Calcium-Phosphate/index.html]]&gt;</url>
    <title>Bones, Calcium, Phosphate, and Parathyroid hormone in Kidney Failure</title>
    <publicationDate>2009-04-29T00:00:00</publicationDate>
    <publisher>National Kidney Federation</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ COMPLICATIONS OF KIDNEY DISEASE,BONE DISEASE,OTHER,CONDITIONS,ENT AND AUDIOLOGY,HYPERPARATHYROIDISM,THYROID &amp; PARATHYROID DISORDERS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Information about renal bone disease from the National Kidney Federation</description>
    <body>&lt;![CDATA[ &lt;P&gt;Extract&lt;/P&gt;
&lt;P&gt;Problems with calcium, phosphate and a chemical messenger in the blood called parathyroid hormone (PTH for short) can occur in anyone with kidney failure. The level of kidney function at which problems start to become apparent is about 40% of normal, or an eGFR of 40 ml/min. Sometimes there are symptoms – in other words someone feels unwell. In many cases, however, problems can start without any symptoms, and slowly cause irreversible damage to the bones, the heart or blood vessels over a period of years.&lt;/P&gt;
&lt;P&gt;Preventative treatment can reduce the chances of this irreversible damage occurring, but requires a lot of care and energy from the patient (yourself) and the renal team in hospital.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>13/12/2010 11:26:08</lastReviewDate>
  </document>
  <document>
    <id>155653</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.uktransplant.org.uk/ukt/how_to_become_a_donor/religious_perspectives/leaflets/buddhism_and_organ_donation.jsp]]&gt;</url>
    <title>Buddhism and organ donation</title>
    <publicationDate></publicationDate>
    <publisher>UK Transplant NHS</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ TRANSPLANTATION,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A guide to organ donation and Buddhism</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Extracted from website&lt;/EM&gt; &lt;/P&gt;
&lt;P&gt;There are no injunctions in Buddhism for or against organ donation. &lt;BR&gt;&lt;BR&gt;The death process of an individual is viewed as a very important time that should be treated with the greatest care and respect. In some traditions, the moment of death is defined according to criteria which differ from those of modern Western medicine, and there are differing views&amp;nbsp; as to the acceptability of organ transplantation. The needs and wishes of the dying person must not be compromised by the wish to save a life. Each decision will depend on individual circumstances. &lt;/P&gt;
&lt;P&gt;Central to Buddhism is a wish to relieve suffering and there may be circumstances where organ donation may be seen as an act of generosity. Where it is truly the wish of the dying person, it would be seen in that light.&lt;BR&gt;&lt;BR&gt;If there is doubt as to the teachings within the particular tradition to which a person belongs, expert guidance should be sought from a senior teacher within the tradition concerned.&lt;/P&gt;
&lt;P&gt;Published in September&amp;nbsp;2004&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>23/08/2010 12:05:09</lastReviewDate>
    <expiryDate>23/08/2011 12:05:09</expiryDate>
    <relatedLinks>&lt;a href="http://www.uktransplant.org.uk/ukt/how_to_become_a_donor/religious_perspectives/leaflets/buddhism_and_organ_donation.jsp" title="Click here for webpage"/&gt;&lt;a href="http://www.uktransplant.org.uk/ukt/newsroom/fact_sheets/religious_leaflets/buddhism_and_organ_donation/buddhism_and_organ_donation-v2a-2006.pdf" title="Click here for leaflet PDF"/&gt;</relatedLinks>
    <creator>UK Transplant NHS</creator>
  </document>
  <document>
    <id>269298</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.renal.org/eGFR/cvrisk.html]]&gt;</url>
    <title>Cardiovascular risk in CKD</title>
    <publicationDate>2009-01-05T00:00:00</publicationDate>
    <publisher>UK CKD eGuide</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASE,COMPLICATIONS OF KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>From UK CKD eGuide</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Extract&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P class=body&gt;Patients with CKD have greatly increased risks of cardiovascular events and cardiovascular deaths. Furthermore, when events occur, their morbidity and mortality is higher. This increased risk begins at the very earliest stages of CKD, for example when there is microalbuminuria without reduced GFR. These observations reinforce the importance of controlling cardiovascular risk factors&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>23/08/2010 12:05:13</lastReviewDate>
    <expiryDate>23/08/2011 12:05:13</expiryDate>
  </document>
  <document>
    <id>155630</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.hdcn.com/symp/04marc/04marc.htm]]&gt;</url>
    <title>Caring through the end: palliative care along the continuum of CKD</title>
    <publicationDate></publicationDate>
    <publisher>Hypertension, Dialysis and Clinical Nephrology (HDCN)</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ END-OF-LIFE CARE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Source of free CPD material for doctors, nurses and other medical professionals</description>
    <body>&lt;![CDATA[ &lt;P&gt;The CPD resource comprises talks and slide presentations, for which some additional software (such as macromedia flash player) may be needed for access.&lt;/P&gt;
&lt;P&gt;Note : You need to register for a freezone&amp;nbsp;loginID and password to access the free resources&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;'Method of participation:&lt;/B&gt; Listen to the talk, read the PubMed abstracts linked to data slides and talk references, take the post-test, read the abstracts linked to post-test answer feedback material' (website extract)&lt;/P&gt;
&lt;P&gt;Click on&amp;nbsp;Free Zone Index to view the other free resources at a glance.&lt;/P&gt;
&lt;P&gt;Published December 2004&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>23/08/2010 12:05:17</lastReviewDate>
    <expiryDate>23/08/2011 12:05:17</expiryDate>
  </document>
  <document>
    <id>321796</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=321796]]&gt;</url>
    <title>Catheter-related infections: Systematic reviews and meta-analyses</title>
    <publicationDate>2010-09-01T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE BLADDER DISORDERS,CYSTITIS,CATHETER-RELATED INFECTIONS,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Catheter-related infections: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy &lt;/A&gt;for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us &lt;/A&gt;if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Hagen, S., L. Sinclair, et al. (2010). "Washout policies in long-term indwelling urinary catheterisation in adults." Cochrane Database of Systematic Reviews 3. [&lt;A href="nelh:346269:0" name=internalLink&gt;Link to Cochrane review&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Meddings, J., M. A. Rogers, et al. (2010). "Systematic review and meta-analysis: reminder systems to reduce catheter-associated urinary tract infections and urinary catheter use in hospitalized patients." Clinical Infectious Diseases 51(5): 550-60. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/%2020673003" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Getliffe, K., M. Fader, et al. (2007). "Current evidence on intermittent catheterization: sterile single-use catheters or clean reused catheters and the incidence of UTI." J Wound Ostomy Continence Nurs 34(3): 289-96. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17505249?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Griffiths, R. and R. Fernandez (2007). "Strategies for the removal of short-term indwelling urethral catheters in adults." Cochrane Database Syst Rev(2): CD004011. [&lt;A href="nelh:238384:0" name=internalLink&gt;Link to Cochrane summary&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Jahn, P., M. Preuss, et al. (2007). "Types of indwelling urinary catheters for long-term bladder drainage in adults." Cochrane Database Syst Rev(3): CD004997.&amp;nbsp;[&lt;A href="nelh:266529:0" name=internalLink&gt;Link to Cochrane summary&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Moore, K. N., M. Fader, et al. (2007). "Long-term bladder management by intermittent catheterisation in adults and children." Cochrane Database Syst Rev(4): CD006008.&amp;nbsp;[&lt;A href="nelh:270946:0" name=internalLink&gt;Link to Cochrane summary&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:01:25</lastReviewDate>
    <expiryDate>06/07/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>318605</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://learning.bmj.com/learning/search-result.html?moduleId=10012343]]&gt;</url>
    <title>Chlamydia screening: an up to date guide</title>
    <publicationDate>2009-04-01T00:00:00</publicationDate>
    <publisher>BMJ Learning</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ PUBLIC HEALTH,SEXUALLY TRANSMITTED INFECTIONS,GENITOURINARY DISEASES,SERVICES,POPULATION BASED &amp; PREVENTATIVE SERVICES,SCREENING,OUTCOMES,MANAGEMENT &amp; INTERVENTIONS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,BACTERIAL,CHLAMYDIA,MALE SEXUALLY TRANSMITTED INFECTIONS,MONTHLY ADDITIONS,MALE UROGENITAL DISORDERS,2009 AUGUST]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>BMJ Learning Module - for BMA Members
</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Extract&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Module type&lt;/STRONG&gt;&amp;nbsp; &amp;nbsp; &lt;/P&gt;
&lt;P&gt;Interactive case history:&lt;BR&gt;Use these interactive modules to learn as we guide you through a real life consultation. Before you start a learning resource it is best to add it to your plan first.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;What's in this case:&lt;/STRONG&gt; &amp;nbsp;&lt;/P&gt;
&lt;P&gt;Chlamydia screening: an up to date guide&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Target audience:&lt;/STRONG&gt; &amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;NHS London - Foundation programme&lt;/LI&gt;
&lt;LI&gt;NHS London - GP and trainee CPD&lt;/LI&gt;
&lt;LI&gt;International&lt;/LI&gt;
&lt;LI&gt;GP CPD&lt;/LI&gt;
&lt;LI&gt;Hospital doctor CPD&lt;/LI&gt;
&lt;LI&gt;GP trainee&lt;/LI&gt;
&lt;LI&gt;NHS London - Allied health professionals&lt;/LI&gt;
&lt;LI&gt;Other healthcare professionals&lt;/LI&gt;
&lt;LI&gt;Saudi Pediatric Association Channel&lt;/LI&gt;
&lt;LI&gt;NHS London - Emergency medicine CPD&lt;/LI&gt;
&lt;LI&gt;NHS London - Acute and community nursing and midwifery&lt;/LI&gt;
&lt;LI&gt;The Royal New Zealand College of General Practitioners&lt;/LI&gt;
&lt;LI&gt;Practice manager CPD&lt;/LI&gt;
&lt;LI&gt;BMJ Learning Pre-hospital Care&lt;/LI&gt;
&lt;LI&gt;Foundation programme&lt;/LI&gt;
&lt;LI&gt;NHS London - Leadership and management&lt;/LI&gt;
&lt;LI&gt;NHS London - Hospital doctor CPD&lt;/LI&gt;
&lt;LI&gt;Emergency Medicine CPD&lt;/LI&gt;
&lt;LI&gt;Practice nurse CPD&lt;/LI&gt;
&lt;LI&gt;Medical Students - international &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>27/05/2010 10:01:34</lastReviewDate>
    <expiryDate>27/05/2011 10:01:34</expiryDate>
  </document>
  <document>
    <id>321798</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=321798]]&gt;</url>
    <title>Chlamydia: Systematic reviews and meta-analyses</title>
    <publicationDate>2010-09-01T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE SEXUALLY TRANSMITTED INFECTIONS,BACTERIAL,CHLAMYDIA,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Chlamydia: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy &lt;/A&gt;for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Hislop, J., Z. Quayyum, et al. (2010). "Systematic review of the clinical effectiveness and cost-effectiveness of rapid point-of-care tests for the detection of genital chlamydia infection in women and men." Health Technology Assessment (Winchester, England) 14(29): 1-97, iii-iv. [&lt;A href="nelh:376267:0" name=internalLink&gt;Link to HTA abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Uddin, J., S. C. Woodhall, et al. (2010). "Repeat infection with Chlamydia trachomatis after treatment: A systematic review." HIV Medicine 11: 84-85. [No abstract available]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Low, N., N. Bender, et al. (2009). "Effectiveness of chlamydia screening: systematic review." Int J Epidemiol 38(2): 435-48. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19060033?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Gift, T. L., D. R. Blake, et al. (2008). "The cost-effectiveness of screening men for Chlamydia trachomatis: a review of the literature." Sexually Transmitted Diseases 35(11 Suppl): S51-60.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18520977?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Marrazzo, J. M. and D. Scholes (2008). "Acceptability of urine-based screening for Chlamydia trachomatis in asymptomatic young men: a systematic review." Sexually Transmitted Diseases 35(11 Suppl): S28-33.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18418291" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Fung, M., K. C. Scott, et al. (2007). "Chlamydial and gonococcal reinfection among men: a systematic review of data to evaluate the need for retesting." Sex Transm Infect 83(4): 304-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17166889" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Meyers, D. S., H. Halvorson, et al. (2007). "Screening for chlamydial infection: an evidence update for the U.S. Preventive Services Task Force." Ann Intern Med 147(2): 135-42.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17576995?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:01:29</lastReviewDate>
    <expiryDate>06/07/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>155658</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.uktransplant.org.uk/ukt/how_to_become_a_donor/religious_perspectives/leaflets/christianity_and_organ_donation.jsp]]&gt;</url>
    <title>Christianity and organ donation</title>
    <publicationDate></publicationDate>
    <publisher>UK Transplant</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ TRANSPLANTATION,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A guide to organ donations and the Christian belief</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Extract from website&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Organ donation and christianity&lt;/P&gt;
&lt;P&gt;The Lord demonstrated with his own life how, even in sorrow, love enables us to embrace the needs of others. We can choose to donate our organs to save the lives of many people. The decision to donate at the end of life is the beginning of healing for many others. Healing and saving life is a great gift. Jesus sent his twelve disciples out with the imperative to heal disease and illness. &lt;/P&gt;
&lt;P&gt;Published April 2003&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>23/08/2010 12:05:30</lastReviewDate>
    <expiryDate>23/08/2011 12:05:30</expiryDate>
    <relatedLinks>&lt;a href="http://www.uktransplant.org.uk/ukt/how_to_become_a_donor/religious_perspectives/leaflets/christianity_and_organ_donation.jsp" title="Click here for webpage"/&gt;&lt;a href="http://www.uktransplant.org.uk/ukt/newsroom/fact_sheets/religious_leaflets/christianity_and_organ_donation/christianity_and_organ_donation.pdf" title="Click here for leaflet PDF"/&gt;</relatedLinks>
    <creator>UK Transplant</creator>
  </document>
  <document>
    <id>301367</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://healthguides.mapofmedicine.com/choices/map/chronic_kidney_disease1.html]]&gt;</url>
    <title>Chronic kidney disease - suspected</title>
    <publicationDate>2008-12-16T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Web pages from NHS Choices and the Map of Medicine.</description>
    <body>&lt;![CDATA[ This page provides a link to the Map of Medicine view on Chronic Kidney Disease&amp;nbsp;(suspected).]]&gt;</body>
    <lastReviewDate>26/11/2010 15:26:01</lastReviewDate>
    <expiryDate>26/11/2011 15:26:01</expiryDate>
  </document>
  <document>
    <id>308757</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.ckdonline.org/]]&gt;</url>
    <title>Chronic Kidney Disease: a guide for primary care</title>
    <publicationDate>2009-03-13T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ COMPLICATIONS OF KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>An advanced online educational resource initiated by the Department of Health, CKD Forum of the British Renal Society, focusing on the recent reclassification of Chronic Kidney Disease and changes through the recently issued QOF and CKD NICE guidance.</description>
    <body>&lt;![CDATA[ &lt;P&gt;An advanced online educational resource initiated by the Department of Health, CKD Forum of the British Renal Society, focusing on the recent reclassification of Chronic Kidney Disease and changes through the recently issued QOF and CKD NICE guidance.&lt;/P&gt;
&lt;P&gt;The resource includes detailed information in the following areas: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;CKD – Why it has become an important issue – Epidemiology, NEOERICA, NHANES, increase in RRT population and the cost of RRT 
&lt;LI&gt;Causes of CKD – Diabetes, hypertension, obstruction and infection &lt;BR&gt;Medicines Management – pharmacology and modes of action 
&lt;LI&gt;Management of Hypertension – approach to lowering BP, Proteinuria, antihypertensive strategy, ACE inhibitors and ARBs 
&lt;LI&gt;Nutrition – healthy eating, malnutrition and weight management in CKD 
&lt;LI&gt;What to tell patients – Self management, self monitoring and referral 
&lt;LI&gt;Primary care – QOF, when to refer, management plans in primary care &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Each section is presented in an easy to use and engaging manner, populated throughout with illustrations and videos, underpinned with a cross-referenced glossary.&lt;/P&gt;
&lt;P&gt;The resource can be used freely as a reference tool, with a CKD Educational Training Certificate available for a small administration fee. Please click on the green ‘Click here to register now’ button for further information on the various levels of CKD Educational Training Certificate offered.&lt;/P&gt;
&lt;P&gt;Supported by an unrestricted educational grant from BMS, Sanofi-Aventis and Roche Products. The sponsors have had no involvement or control over the scope or content of this tool, neither have they had any review of the final output contained on the website.&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>14/02/2011 11:39:44</lastReviewDate>
    <expiryDate>14/02/2012 11:39:44</expiryDate>
  </document>
  <document>
    <id>284182</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://learning.bmj.com/learning/search-result.html?moduleId=5004312]]&gt;</url>
    <title>Chronic kidney disease: assessment and management in primary care</title>
    <publicationDate>2010-03-31T00:00:00</publicationDate>
    <publisher>BMJ Learning</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ PRESENTATION OF CKD,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>BMJ Learning Module - for BMA Members</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Extract&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Learning outcomes&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;After completing this module you should have developed the confidence and competence to investigate and manage patients with chronic kidney disease. You should: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Know how to investigate a patient with a low estimated glomerular filtration rate (eGFR) 
&lt;LI&gt;Understand the indications for aspirin in patients with chronic kidney disease 
&lt;LI&gt;Understand the indications for lipid lowering therapy in patients with chronic kidney disease 
&lt;LI&gt;Be able to assess and treat hypertension in patients with chronic kidney disease 
&lt;LI&gt;Understand the indications for angiotensin converting enzyme (ACE) inhibitors or angiotensin II receptor blockers in patients with chronic kidney disease 
&lt;LI&gt;Know what follow up is recommended for patients with chronic kidney disease.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>08/03/2011 09:56:26</lastReviewDate>
    <expiryDate>08/03/2012 09:56:26</expiryDate>
  </document>
  <document>
    <id>326234</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://learning.bmj.com/learning/search-result.html?moduleId=10013214]]&gt;</url>
    <title>Chronic kidney disease: early identification and management in adults - in association with NICE</title>
    <publicationDate>2009-09-30T00:00:00</publicationDate>
    <publisher>BMJ Learning</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ PRESENTATION OF CKD,SCREENING OPTIONS,INTERVENTIONS,PREDISPOSING FACTORS,ASSESSMENT OF RENAL FUNCTION,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>An interactive case history from the BMJ.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Module type: Interactive case history&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Use these interactive modules to learn as we guide you through a real life consultation. Before you start a learning resource it is best to add it to your plan first.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;What's in this case:&lt;/STRONG&gt; Chronic kidney disease: early identification and management in adults - in association with NICE&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Target audience:&lt;/STRONG&gt; &amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;STRONG&gt;BMJ&lt;/STRONG&gt;&lt;/LI&gt;
&lt;LI&gt;BMJ Learning Pre-hospital Care&lt;/LI&gt;
&lt;LI&gt;Emergency Medicine CPD&lt;/LI&gt;
&lt;LI&gt;Foundation programme&lt;/LI&gt;
&lt;LI&gt;GP CPD&lt;/LI&gt;
&lt;LI&gt;GP trainee&lt;/LI&gt;
&lt;LI&gt;Hospital doctor CPD&lt;/LI&gt;
&lt;LI&gt;International&lt;/LI&gt;
&lt;LI&gt;Medical Students - international&lt;/LI&gt;
&lt;LI&gt;Other healthcare professionals&lt;/LI&gt;
&lt;LI&gt;Practice manager CPD&lt;/LI&gt;
&lt;LI&gt;Practice nurse CPD&lt;/LI&gt;
&lt;LI&gt;The Royal New Zealand College of General Practitioners&lt;/LI&gt;
&lt;LI&gt;&lt;STRONG&gt;NESC&lt;/STRONG&gt;&lt;/LI&gt;
&lt;LI&gt;NESC - Acute and community nursing and midwifery&lt;/LI&gt;
&lt;LI&gt;NESC - Allied health professionals&lt;/LI&gt;
&lt;LI&gt;NESC - Emergency medicine CPD&lt;/LI&gt;
&lt;LI&gt;NESC - Foundation programme&lt;/LI&gt;
&lt;LI&gt;NESC - GP and trainee CPD&lt;/LI&gt;
&lt;LI&gt;NESC - Hospital doctor CPD&lt;/LI&gt;
&lt;LI&gt;NESC - Leadership and management&lt;/LI&gt;
&lt;LI&gt;&lt;STRONG&gt;NHSLONDON&lt;/STRONG&gt;&lt;/LI&gt;
&lt;LI&gt;NHS London - Acute and community nursing and midwifery&lt;/LI&gt;
&lt;LI&gt;NHS London - Allied health professionals&lt;/LI&gt;
&lt;LI&gt;NHS London - Emergency medicine CPD&lt;/LI&gt;
&lt;LI&gt;NHS London - Foundation programme&lt;/LI&gt;
&lt;LI&gt;NHS London - GP and trainee CPD&lt;/LI&gt;
&lt;LI&gt;NHS London - Hospital doctor CPD&lt;/LI&gt;
&lt;LI&gt;NHS London - Leadership and management&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
    <lastReviewDate>23/09/2010 10:07:14</lastReviewDate>
    <expiryDate>23/09/2011 10:07:14</expiryDate>
  </document>
  <document>
    <id>342015</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.nhsemployers.org/Aboutus/Publications/Documents/Chronic_kidney_disease_FAQs_2nd_ed.pdf]]&gt;</url>
    <title>Chronic Kidney Disease: frequently asked questions</title>
    <publicationDate>2010-01-26T00:00:00</publicationDate>
    <publisher>NHS Employers</publisher>
    <publicationType>CARE PATHWAY</publicationType>
    <topics>&lt;![CDATA[ PRESENTATION OF CKD,ASSESSMENT OF RENAL FUNCTION,PREDISPOSING FACTORS,INTERVENTIONS,SCREENING OPTIONS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A 32-page guide</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Contents&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Introduction &lt;/LI&gt;
&lt;LI&gt;About eGFR &lt;/LI&gt;
&lt;LI&gt;About chronic kidney disease (CKD) &lt;/LI&gt;
&lt;LI&gt;Testing for proteinuria and investigation of people with CKD &lt;/LI&gt;
&lt;LI&gt;Referral in CKD &lt;/LI&gt;
&lt;LI&gt;QOF issues, computer reporting and exception reporting &lt;/LI&gt;
&lt;LI&gt;Management of CKD – summary&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
    <lastReviewDate>11/01/2011 10:22:51</lastReviewDate>
    <expiryDate>11/01/2012 10:22:51</expiryDate>
  </document>
  <document>
    <id>333626</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=333626]]&gt;</url>
    <title>Chronic Kidney Disease: Systematic reviews and meta-analyses</title>
    <publicationDate>2011-02-24T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,PRESENTATION OF CKD,PREDISPOSING FACTORS,ASSESSMENT OF RENAL FUNCTION,INTERVENTIONS,SCREENING OPTIONS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Chronic Kidney Disease: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2011&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Grams ME, Plantinga LC, Hedgeman E, Saran R, Myers GL, Williams DE, et al. Validation of CKD and Related Conditions in Existing Data Sets: A Systematic Review. Am J Kidney Dis. 2011 Jan;57(1):44-54. Epub 2010 Aug 6. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20692079" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Vlasschaert ME, Bejaimal SA, Hackam DG, Quinn R, Cuerden MS, Oliver MJ, et al. Validity of administrative database coding for kidney disease: a systematic review. Am J Kidney Dis. 2011 Jan;57(1):29-43. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/21184918" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Alavian, S. M. and S. V. Tabatabaei (2010). "The effect of diabetes mellitus on immunological response to hepatitis B virus vaccine in individuals with chronic kidney disease: A meta-analysis of current literature." Vaccine 28(22): 3773-7.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20371390" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Athyros, V. G., K. Tziomalos, et al. (2010). "Atorvastatin: safety and tolerability." Expert Opinion on Drug Safety 9(4): 667-74. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20553090" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Barna, M. M., T. Kapoian, et al. (2010). "Sevelamer carbonate." Annals of Pharmacotherapy 44(1): 127-34. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Barna[author]%20AND%20Sevelamer%20carbonate" target="_blank"&gt;Link to Pubmed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Black, C., P. Sharma, et al. (2010) "Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis." Health Technology Assessment (Winchester, England) 14(21): 1-184. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20441712" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Cardinal, H. and F. Madore (2010). "[Are cardioprotective drugs underused after a myocardial infarction in patients who suffer from chronic kidney disease?]. [French] La pharmacopee de prevention cardiovasculaire est-elle sous-utilisee chez les patients souffrant d'insuffisance renale chronique apres un infarctus du myocarde ?" Nephrologie et Therapeutique 6(3): 162-70.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20346746" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Chronic Kidney Disease Prognosis Consortium (et al). (2010). "Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis." The Lancet 375(9731): 2073-2081. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Association%20of%20estimated%20glomerular%20filtration%20rate%20and%20albuminuria%20with%20all-cause%20and%20cardiovascular%20mortality%20in%20general%20population%20cohorts%3A%20a%20collaborative%20meta-analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Gallagher, H., de Lusignan, S., Harris, K., Cates, C. (2010) 'Quality-improvement strategies for the managemetn of hypertension in chronic kidney disease in primary care: a systematic review'. British Journal of General Practice, 60(575), June 2010, pp. e258-e265. [&lt;A href="http://www.ingentaconnect.com/content/rcgp/bjgp/2010/00000060/00000575/art00004" target="_blank"&gt;Link to abstract on publisher's website&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Gandra, S. R., F. O. Finkelstein, et al. (2010). "Impact of erythropoiesis-stimulating agents on energy and physical function in nondialysis CKD patients with anemia: a systematic review." American Journal of Kidney Diseases 55(3): 519-535.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Impact%20of%20erythropoiesis-stimulating%20agents%20on%20energy%20and%20physical%20function%20in%20nondialysis%20CKD%20patients%20with%20anemia%3A%20a%20systematic%20review" target="_blank"&gt;Link to Pubmed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Geary, D. F., E. M. Hodson, et al. "Interventions for bone disease in children with chronic kidney disease." Cochrane Database Syst Rev(1): CD008327. [&lt;A href="nelh:341800:0" name=internalLink&gt;Link to Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Gluba, A., J. Rysz, et al. (2010). "Statins in patients with chronic kidney disease: Why, who and when?" Expert Opinion on Pharmacotherapy 11(16): 2665-2674.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20977401" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Johansen, K. L., F. O. Finkelstein, et al. "Systematic Review and Meta-analysis of Exercise Tolerance and Physical Functioning in Dialysis Patients Treated With Erythropoiesis-Stimulating Agents." Am J Kidney Dis. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20133033" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kandula, P., Dobre, M., Schold, J.D., Schreiber, M.J Jr, Mehrotra, R., Navaneethan, S.D. "Vitamin D Supplementation in Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Observational Studies and Randomized Controlled Trials." Clin J Am Soc Nephrol. 2010 Sep 28 (Epub ahead of print). [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20876671" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lee, M., J. L. Saver, et al. (2010). "Impact of elevated cystatin C level on cardiovascular disease risk in predominantly high cardiovascular risk populations: A meta-analysis." Circulation: Cardiovascular Quality and Outcomes 3(6): 675-683.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20923994" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Macdougall, I. C. (2010). "Iron supplementation in the non-dialysis chronic kidney disease (ND-CKD) patient: oral or intravenous?" Current Medical Research &amp;amp; Opinion 26(2): 473-82.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20014980" target="_blank"&gt;Link to Pubmed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mei, W., Y. Rong, et al. (2010). "Effect of homocysteine interventions on the risk of cardiocerebrovascular events: A meta-analysis of randomised controlled trials." International Journal of Clinical Practice 64(2): 208-215. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Effect%20of%20homocysteine%20interventions%20on%20the%20risk%20of%20cardiocerebrovascular%20events%3A%20A%20meta-analysis%20of%20randomised%20controlled%20trials" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Morton, R.L., Tong, A., Howard, K., Snelling, P., Webster, A.C. (2010) "The views of patients and carers in treatment decision making for chronic kidney disease: systematic review and thematic synthesis of qualitative studies". BMJ 2010;340:c112. [&lt;A href="http://www.bmj.com/cgi/content/short/340/jan19_2/c112?rss=1" target="_blank"&gt;Link to BMJ&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Moseberry, D. and S. B. Nicholas (2010). "The pros and cons of staging chronic kidney disease." Ethnicity &amp;amp; Disease 20(1): 77-81.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Moseberry[author]%20AND%20The%20pros%20and%20cons%20of%20staging%20chronic%20kidney%20disease" target="_blank"&gt;Link to Pubmed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Navaneethan, S.D., Vecchio, M., Johnson, D.W., Saglimbene, Vl, Graziano, G., Pellegrini, F. et al. (2010) "Prevalence and Correlates of Self-Reported Sexual Dysfunction in CKD: A Meta-Analysis of Observational Studies." American Journal of Kidney Diseases. 56(4):670-685. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Prevalence%20and%20Correlates%20of%20Self-Reported%20Sexual%20Dysfunction%20in%20CKD%3A%20A%20Meta-analysis%20of%20Observational%20Studies" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Palmer, S.C, Navaneethan, S.D., Craig, J.C., Johnson, D.W., Tonelli, M., Garg, A.X. et al. (2010) 'Meta-analysis: Erythropoiesis-Stimulating Agents in Patients With Chronic Kidney Disease'. Annals of Internal Medicine. 152(1) pp.23-33. [&lt;A href="http://www.annals.org/content/153/1/23.abstract" target="_blank"&gt;Link to Annals abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Sarafidis, P. A., P. C. Stafylas, et al. "Effect of Thiazolidinediones on Albuminuria and Proteinuria in Diabetes: A Meta-analysis." Am J Kidney Dis. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20110146" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Sharma, P., McCullough, K., Scotland, G.,&amp;nbsp;McNamee, P., Prescott, G., MacLeod, A., et al. (2010) 'Does&amp;nbsp;stage-3 chronic&amp;nbsp;kidney diseases matter?: A&amp;nbsp;systematic literature review'. British Journal of General Practice, 60(575), June 2010, pp. e266-e276. [&lt;A href="http://www.ingentaconnect.com/content/rcgp/bjgp/2010/00000060/00000575/art00005" target="_blank"&gt;Link to abstract on&amp;nbsp;publisher's website&lt;/A&gt;]&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Stoycheff N, Pandya K, Okparavero A, Schiff A, et al. (2010) "Early change in proteinuria as a surrogate outcome in kidney disease progression: a systematic review of previous analyses and creation of a patient-level pooled dataset." Nephrol Dial Transplant 2010 Sep 3 [Epub ahead of print]. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20817671" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Vecchio M, Navaneethan SD, Johnson DW, et al.&amp;nbsp; (2010) 'Treatment options for sexual dysfunction in patients with chronic kidney disease: a systematic review of randomized controlled trials.'&amp;nbsp; Clin J Am Soc Nephrol. Jun;5(6):985-95. Epub 2010 May 24.&amp;nbsp; (Review) [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20498250" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Wali, R. K., M. Iyengar, et al. (2010). "Efficacy and Safety of Carvedilol in Treatment of Heart Failure in Chronic Kidney Disease: A Meta-Analysis of Randomized Trials." Circ Heart Fail. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Efficacy%20and%20Safety%20of%20Carvedilol%20in%20Treatment%20of%20Heart%20Failure%20in%20Chronic%20Kidney%20Disease%3A%20A%20Meta-Analysis%20of%20Randomized%20Trials" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Weir, M. R. and M. Rolfe (2010). "Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors." Clinical Journal of The American Society of Nephrology: CJASN 5(3): 531-48. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20150448" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Afshinnia, F., T. J. Wilt, et al. (2009). "Weight loss and proteinuria: systematic review of clinical trials and comparative cohorts." Nephrol Dial Transplant. Nov 27 [Epub ahead of print] [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19945950" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Anothaisintawee, T., S. Rattanasiri, et al. (2009). "Prevalence of chronic kidney disease: a systematic review and meta-analysis." Clin Nephrol 71(3): 244-54.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19281734" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Bacchus, S., N. O'Mara, et al. (2009). "Meeting new challenges in the management of anemia of chronic kidney disease through collaborative care with pharmacists." Ann Pharmacother 43(11): 1857-66.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19826095" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Bagshaw, S. M., D. R. Townsend, et al. (2009). "Disorders of sodium and water balance in hospitalized patients." Can J Anaesth 56(2): 151-67.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19247764" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Bangash, F. and R. Agarwal (2009). "Masked hypertension and white-coat hypertension in chronic kidney disease: a meta-analysis." Clin J Am Soc Nephrol 4(3): 656-64.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19261815" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Barna, M. M., T. Kapoian, et al. (2009). "Sevelamer Carbonate (January) (CE)." Ann Pharmacother.&amp;nbsp;Dec 2 [Epub ahead of print] [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19955298" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Charytan, D. M., L. Wallentin, et al. (2009). "Early angiography in patients with chronic kidney disease: a collaborative systematic review." Clin J Am Soc Nephrol 4(6): 1032-43.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19423566" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Clement, F. M., S. Klarenbach, et al. (2009). "The impact of selecting a high hemoglobin target level on health-related quality of life for patients with chronic kidney disease: a systematic review and meta-analysis." Arch Intern Med 169(12): 1104-12.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19546410" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Covic, A., P. Kothawala, et al. (2009). "Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease." Nephrol Dial Transplant 24(5): 1506-23.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19001560" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Fouque, D. and M. Laville (2009). "Low protein diets for chronic kidney disease in non diabetic adults." Cochrane Database of Systematic Reviews(3): CD001892-NaN.&amp;nbsp;[&lt;A href="nelh:237154:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Gandra, S.R., Finkelstein, F.O., et al.&amp;nbsp; (2009)&amp;nbsp;"Impact of Erythropoiesis-Stimulating Agents on Energy and Physical Function in Nondialysis CKD Patients with Anemia: A Systematic Review." Am J Kidney Dis. Dec 21 (Epub ahead of print) [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20031287" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Goldsmith, D., P. Kothawala, et al. (2009). "Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of fracture and need for parathyroidectomy in CKD." Am J Kidney Dis 53(6): 1002-13.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19463763" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Heintz, B. H., G. R. Matzke, et al. (2009). "Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis." Pharmacotherapy 29(5): 562-77.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19397464" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Jamal, S. A., D. Fitchett, et al. (2009). "The effects of calcium-based versus non-calcium-based phosphate binders on mortality among patients with chronic kidney disease: A meta-analysis." Nephrology Dialysis Transplantation 24(10): 3168-3174.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19622572" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kanbay, M., D. Goldsmith, et al. (2009). "Phosphate - the silent stealthy cardiorenal culprit in all stages of chronic kidney disease: a systematic review." Blood Purif 27(2): 220-30.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19176951" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Khan, S. S. and M. R. Iraniha (2009). "Diagnosis of renal osteodystrophy among chronic kidney disease patients." Dialysis and Transplantation 38(2): 45-57.&amp;nbsp;[&lt;A href="http://www3.interscience.wiley.com/journal/122197625/abstract?CRETRY=1&amp;amp;SRETRY=0" target="_blank"&gt;Link to abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Korantzopoulos, P., T. Liu, et al. (2009). "Implantable cardioverter defibrillator therapy in chronic kidney disease: a meta-analysis." Europace 11(11): 1469-75.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19812050" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Murray, M. A., G. Brunier, et al. (2009). "A systematic review of factors influencing decision-making in adults living with chronic kidney disease." Patient Educ Couns.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19324509" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Navaneethan, S. D., S. U. Nigwekar, et al. (2009). "Aldosterone antagonists for preventing the progression of chronic kidney disease." Cochrane Database Syst Rev(3): CD007004.&amp;nbsp;[&lt;A href="nelh:320802:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Navaneethan, S. D., S. U. Nigwekar, et al. (2009). "Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis." Clin J Am Soc Nephrol 4(3): 542-51.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19261819" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Navaneethan, S. D., S. C. Palmer, et al. (2009). "Benefits and Harms of Phosphate Binders in CKD: A Systematic Review of Randomized Controlled Trials." American Journal of Kidney Diseases 54(4): 619-637.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19692157" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Navaneethan, S. D., H. Yehnert, et al. (2009). "Weight loss interventions in chronic kidney disease: a systematic review and meta-analysis." Clin J Am Soc Nephrol 4(10): 1565-74.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19808241" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Palmer, S. C., D. O. McGregor, et al. (2009). "Vitamin D compounds for people with chronic kidney disease not requiring dialysis." Cochrane Database Syst Rev(4): CD008175.&amp;nbsp;[&lt;A href="nelh:327267:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Parfrey, P. S., M. Lauve, et al. (2009). "Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: a meta-analysis." Clin J Am Soc Nephrol 4(4): 755-62.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19339417" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Regeniter, A., H. Freidank, et al. (2009). "Evaluation of proteinuria and GFR to diagnose and classify kidney disease: systematic review and proof of concept." Eur J Intern Med 20(6): 556-61.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19782913" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;White, S. L., V. Perkovic, et al. (2009). "Is Low Birth Weight an Antecedent of CKD in Later Life? A Systematic Review of Observational Studies." Am J Kidney Dis.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19339091" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Aldridge, M. D. (2008). "How do families adjust to having a child with chronic kidney failure? A systematic review." Nephrol Nurs J 35(2): 157-62.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18472684" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Balamuthusamy, S., L. Srinivasan, et al. (2008). "Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis." Am Heart J 155(5): 791-805.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18440325" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Bomback, A. S., A. V. Kshirsagar, et al. (2008). "Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review." Am J Kidney Dis 51(2): 199-211.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18215698" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Dale, P. L., J. Hutton, et al. (2008). "Utility of health states in chronic kidney disease: a structured review of the literature." Curr Med Res Opin 24(1): 193-206.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18039434" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Ellis, M. J., C. R. Parikh, et al. (2008). "Chronic kidney disease after hematopoietic cell transplantation: a systematic review." Am J Transplant 8(11): 2378-90.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18925905" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Fabrizi, F., S. V. Ganeshan, et al. (2008). "Antiviral therapy of hepatitis C in chronic kidney diseases: meta-analysis of controlled clinical trials." J Viral Hepat.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18444984" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Germain, M. J. (2008). "Strategies for successfully managing the anemia of chronic kidney disease in the long-term care setting." Consult Pharm 23 Suppl A: 11-7.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18454575" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Khan, S. and C. A. Amedia, Jr. (2008). "Economic burden of chronic kidney disease." J Eval Clin Pract 14(3): 422-34.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18373575" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kimel, M., N. K. Leidy, et al. (2008). "Does epoetin alfa improve health-related quality of life in chronically ill patients with anemia? Summary of trials of cancer, HIV/AIDS, and chronic kidney disease." Value Health 11(1): 57-75.&amp;nbsp;[&lt;A href="nelh:328959:0" name=internalLink&gt;Link to&amp;nbsp;DARE abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kunz, R., C. Friedrich, et al. (2008). "Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease." Ann Intern Med 148(1): 30-48.&amp;nbsp;[&lt;A href="nelh:295936:0" name=internalLink&gt;Link to&amp;nbsp;DARE abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mason, J., K. Khunti, et al. (2008). "Educational interventions in kidney disease care: a systematic review of randomized trials." Am J Kidney Dis 51(6): 933-51.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18440681" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mathew, A., P. J. Devereaux, et al. (2008). "Chronic kidney disease and postoperative mortality: a systematic review and meta-analysis." Kidney Int 73(9): 1069-81.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18288098" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Navaneethan, S. D., S. Aloudat, et al. (2008). "A systematic review of patient and health system characteristics associated with late referral in chronic kidney disease." BMC Nephrol 9: 3.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18298850" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Ormandy, P. (2008). "Information topics important to chronic kidney disease patients: a systematic review." J Ren Care 34(1): 19-27.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18336519" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Philipneri, M. D., L. A. Rocca Rey, et al. (2008). "Delivery patterns of recommended chronic kidney disease care in clinical practice: administrative claims-based analysis and systematic literature review." Clin Exp Nephrol 12(1): 41-52.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18175059" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Rozen-Zvi, B., A. Gafter-Gvili, et al. (2008). "Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis." Am J Kidney Dis 52(5): 897-906.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18845368" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Strippoli, G. F., S. D. Navaneethan, et al. (2008). "Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials." BMJ 336(7645): 645-51.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18299289" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Tonelli M, Klarenbach S, Wiebe N, Shrive F, Hemmelgarn B, Manns B. Erythropoiesis-stimulating agents for anemia of chronic kidney disease: systematic review and economic evaluation. Canadian Agency for Drugs and Technologies in Health (CADTH), 2008; Technology Report No 106: 59 [&lt;A href="nelh:283962:0" name=internalLink&gt;Link to DARE abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Tong, A., A. Lowe, et al. (2008). "Experiences of parents who have children with chronic kidney disease: a systematic review of qualitative studies." Pediatrics 121(2): 349-60.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18245427" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Tong, A., P. Sainsbury, et al. (2008). "Support interventions for caregivers of people with chronic kidney disease: a systematic review." Nephrol Dial Transplant 23(12): 3960-5.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18658178" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Wang, Y., X. Chen, et al. (2008). "Association between obesity and kidney disease: a systematic review and meta-analysis." Kidney Int 73(1): 19-33.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17928825" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Wyatt, C. M., C. Malvestutto, et al. (2008). "The impact of hepatitis C virus coinfection on HIV-related kidney disease: a systematic review and meta-analysis." AIDS 22(14): 1799-807.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18753863" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Zhang, Q. L. and D. Rothenbacher (2008). "Prevalence of chronic kidney disease in population-based studies: systematic review." BMC Public Health 8: 117.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18405348" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Chan, M. R., A. T. Dall, et al. (2007). "Outcomes in patients with chronic kidney disease referred late to nephrologists: a meta-analysis." Am J Med 120(12): 1063-70.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18060927" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Chaturvedi, S. and C. Jones (2007). "Protein restriction for children with chronic renal failure." Cochrane Database Syst Rev(4): CD006863.&amp;nbsp;[&lt;A href="nelh:270967:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Jones-Burton, C., S. L. Seliger, et al. (2007). "Cigarette smoking and incident chronic kidney disease: a systematic review." Am J Nephrol 27(4): 342-51.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17541263" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kestenbaum, B. and V. Belozeroff (2007). "Mineral metabolism disturbances in patients with chronic kidney disease." Eur J Clin Invest 37(8): 607-22.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17635571" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mazzaferro, S., M. Cozzolino, et al. (2007). "[Calcimimetics, phosphate binders, vitamin D and its analogues for treating secondary hyperparathyroidism in chronic kidney disease: guideline from the Italian Society of Nephrology.]." G Ital Nefrol 24 Suppl 37: 107-24.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17347960" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Palmer, S. C., D. O. McGregor, et al. (2007). "Meta-analysis: vitamin D compounds in chronic kidney disease." Ann Intern Med 147(12): 840-53.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18087055" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Phrommintikul, A., S. J. Haas, et al. (2007). "Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis." Lancet 369(9559): 381-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17276778" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Pljesa, S. (2007). "[The use of erythropoietin beta, two to three times per week, once per week and once every other week: meta-analysis of two clinical trials]." Med Pregl 60(3-4): 123-7.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17853722" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Ravani, P., L. Del Vecchio, et al. (2007). "[Erythropoietins and haemoglobin targets to prevent the progression of chronic kidney disease: guideline from the Italian Society of Nephrology.]." G Ital Nefrol 24 Suppl 37: 91-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17347958" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Roderick, P., N. S. Willis, et al. (2007). "Correction of chronic metabolic acidosis for chronic kidney disease patients." Cochrane Database Syst Rev(1): CD001890.&amp;nbsp;[&lt;A href="nelh:237153:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2006&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Charytan, D. and R. E. Kuntz (2006). "The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease." Kidney Int 70(11): 2021-30.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17051142" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Cremieux, P. Y., M. Van Audenrode, et al. (2006). "The relative dosing of epoetin alfa and darbepoetin alfa in chronic kidney disease." Curr Med Res Opin 22(12): 2329-36.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17257447" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Dennis, V. C. and G. L. Albertson (2006). "Doxercalciferol treatment of secondary hyperparathyroidism." Ann Pharmacother 40(11): 1955-65.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17062838" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Fabrizi, F., V. Dixit, et al. (2006). "Meta-analysis: intradermal vs. intramuscular vaccination against hepatitis B virus in patients with chronic kidney disease." Aliment Pharmacol Ther 24(3): 497-506.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16886915" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hudson, J. Q. (2006). "Secondary hyperparathyroidism in chronic kidney disease: focus on clinical consequences and vitamin D therapies." Ann Pharmacother 40(9): 1584-93.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16912241" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Strippoli, G. F., S. D. Navaneethan, et al. (2006).&amp;nbsp;&amp;nbsp;"Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease." Cochrane Database Syst Rev(4): CD003967.&amp;nbsp;[&lt;A href="nelh:238354:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Strippoli, G. F., A. Tong, et al. (2006). "Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients." Cochrane Database Syst Rev(4): CD006254.&amp;nbsp;[&lt;A href="nelh:239225:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Vimalachandra, D., E. M. Hodson, et al. (2006). "Growth hormone for children with chronic kidney disease." Cochrane Database Syst Rev 3: CD003264.&amp;nbsp;[&lt;A href="nelh:237715:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>26/11/2010 15:25:33</lastReviewDate>
    <expiryDate>26/11/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>321799</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=321799]]&gt;</url>
    <title>Chronic prostatitis: Systematic reviews and meta-analyses</title>
    <publicationDate>2011-01-24T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,PROSTATE DISORDERS,PROSTATITIS,CHRONIC PROSTATITIS,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Chronic prostatitis: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2011&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Anothaisintawee, T., Attia, J., Nickel, J.C., Thammakraisorn, S., Numthavaj, P., McEvoy, M., Thakkinstian, A. (2011). "Management of Chronic Prostatitis/ Chronic Pelvic Pain Syndrome: A systematic review and network meta-analysis". JAMA. 395(1):78-86. [&lt;A href="http://jama.ama-assn.org/content/305/1/78.short?rss=1" target="_blank"&gt;Link to JAMA abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;No new systematic reviews. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Dimitrakov, J. and D. Guthrie (2009). "Genetics and phenotyping of urological chronic pelvic pain syndrome." J Urol 181(4): 1550-7. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19230927?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Erickson, B. A., A. J. Schaeffer, et al. (2008). "Chronic prostatitis." Clinical Evidence 2008.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19450305?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Vaidyanathan, R. and V. C. Mishra (2008). "Chronic prostatitis: Current concepts." Indian J Urol 24(1): 22-7.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19468353" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Wang, C. Y. and R. F. Han (2008). "[Acupuncture for chronic prostatitis: a meta-analysis]." Zhonghua Nan Ke Xue 14(9): 853-6.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18998473" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Yang, M., X. Zhao, et al. (2008). "Management of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): A systematic review and meta-analysis of randomized controlled trials (RCTs)." Chinese Journal of Andrology 22(4): 20-26.&amp;nbsp;&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Lee, S. W., M. L. Liong, et al. (2007). "Chronic prostatitis/chronic pelvic pain syndrome: role of alpha blocker therapy." Urol Int 78(2): 97-105.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17293646?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Qiu, M. X., G. B. Xiong, et al. (2007). "[Qingrelishi-category Chinese medicine for chronic prostatitis: a systematic review]." Zhonghua Nan Ke Xue 13(4): 370-7.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17491276" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;2006&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Chen, J. X. and L. S. Hu (2006). "Traditional chinese medicine for the treatment of chronic prostatitis in China: a systematic review and meta-analysis." J Altern Complement Med 12(8): 763-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17034282" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:01:33</lastReviewDate>
    <expiryDate>06/07/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>177613</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.gpnotebook.co.uk/simplepage.cfm?ID=-1214644215]]&gt;</url>
    <title>Chronic renal failure</title>
    <publicationDate>2008-09-01T00:00:00</publicationDate>
    <publisher>GPnotebook</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ CHRONIC KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Resource provided by GPnotebook</description>
    <body>&lt;![CDATA[ Resource provides links to sections on aetiology, history, clinical features, diagnosis and investigations, management, complications and prognosis.]]&gt;</body>
    <expiryDate>01/10/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>177613</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.gpnotebook.co.uk/simplepage.cfm?ID=-1214644215]]&gt;</url>
    <title>Chronic renal failure</title>
    <publicationDate>2008-09-01T00:00:00</publicationDate>
    <publisher>GPnotebook</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ CHRONIC KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Resource provided by GPnotebook</description>
    <body>&lt;![CDATA[ Resource provides links to sections on aetiology, history, clinical features, diagnosis and investigations, management, complications and prognosis.]]&gt;</body>
    <expiryDate>01/10/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>182727</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.emedicine.com/med/topic374.htm]]&gt;</url>
    <title>Chronic Renal Failure</title>
    <publicationDate>2010-01-05T00:00:00</publicationDate>
    <publisher>eMedicine.com</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ ASSESSMENT OF RENAL FUNCTION,PREDISPOSING FACTORS,INTERVENTIONS,PRESENTATION OF CKD,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Resource from eMedicine</description>
    <body>&lt;![CDATA[ &lt;P&gt;Covers information on background, pathophysiology, frequency, tests and treatment, medication and follow-up.&lt;/P&gt;
&lt;P&gt;Updated 23 November 2010. &lt;/P&gt;]]&gt;</body>
    <lastReviewDate>13/12/2010 11:28:00</lastReviewDate>
  </document>
  <document>
    <id>182727</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.emedicine.com/med/topic374.htm]]&gt;</url>
    <title>Chronic Renal Failure</title>
    <publicationDate>2010-01-05T00:00:00</publicationDate>
    <publisher>eMedicine.com</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ ASSESSMENT OF RENAL FUNCTION,PREDISPOSING FACTORS,INTERVENTIONS,PRESENTATION OF CKD,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Resource from eMedicine</description>
    <body>&lt;![CDATA[ &lt;P&gt;Covers information on background, pathophysiology, frequency, tests and treatment, medication and follow-up.&lt;/P&gt;
&lt;P&gt;Updated 23 November 2010. &lt;/P&gt;]]&gt;</body>
    <lastReviewDate>13/12/2010 11:28:00</lastReviewDate>
  </document>
  <document>
    <id>344284</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=344284]]&gt;</url>
    <title>Circumcision: Systematic reviews and meta-analyses</title>
    <publicationDate>2011-01-24T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,PENILE DISORDERS,MALE UROGENITAL DISORDERS,CIRCUMCISION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Circumcision: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Doyle SM, Kahn JG, Hosang N, Carroll PR. The impact of male circumcision on HIV transmission. Journal of Urology. 2010;183(1):21-6. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19913816" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Perera CL, Bridgewater FH, Thavaneswaran P, Maddern GJ. Safety and efficacy of nontherapeutic male circumcision: a systematic review. Annals of Family Medicine. 2010;8(1):64-72.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20065281" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Uthman, O. A., T. A. Popoola, et al. (2010). "Economic evaluations of adult male circumcision for prevention of heterosexual acquisition of HIV in men in sub-Saharan Africa: A systematic review." PLoS ONE 5(3). [&lt;A href="http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0009628" target="_blank"&gt;Link to full-text PLoS ONE article&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Weiss, H. A., N. Larke, et al. (2010). "Complications of circumcision in male neonates, infants and children: a systematic review." BMC Urology 10. [&lt;A href="http://www.biomedcentral.com/1471-2490/10/2" target="_blank"&gt;Link to free full text article&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Wilcken, A., T. Keil, et al. (2010). "Traditional male circumcision in eastern and southern Africa: A systematic review of prevalence and complications." Bulletin of the World Health Organization 88(12): 907-914. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/21124715" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Siegfried N, Muller M, Deeks JJ, Volmink J. Male circumcision for prevention of heterosexual acquisition of HIV in men. Cochrane Database of Systematic Reviews. 2009(2). [&lt;A href="nelh:238225:0" name=internalLink&gt;Link to Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Weiss HA, Hankins CA, Dickson K. Male circumcision and risk of HIV infection in women: a systematic review and meta-analysis. The Lancet Infectious Diseases. 2009;9(11):669-77. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19850225" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Cyna AM, Middleton P. Caudal epidural block versus other methods of postoperative pain relief for circumcision in boys. Cochrane Database of Systematic Reviews. 2008(4). [&lt;A href="nelh:237831:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Millett GA, Flores SA, Marks G, Reed JB, Herbst JH. Circumcision status and risk of HIV and sexually transmitted infections among men who have sex with men: A meta-analysis. JAMA - Journal of the American Medical Association. 2008;300(14):1674-84. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18840841" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mills E, Cooper C, Anema A, Guyatt G. Male circumcision for the prevention of heterosexually acquired HIV infection: A meta-analysis of randomized trials involving 11050 men. HIV Medicine. 2008;9(6):332-5.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18705758" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Muula AS, Prozesky HW, Mataya RH, Ikechebelu JI. Prevalence of complications of male circumcision in Anglophone Africa: a systematic review. BMC Urol. 2007;7:4.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17335574" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Van Howe RS. Genital ulcerative disease and sexually transmitted urethritis and circumcision: a meta-analysis. Int J STD AIDS. 2007 Dec;18(12):799-809.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18073009" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Van Howe RS. Human papillomavirus and circumcision: a meta-analysis. J Infect. 2007 May;54(5):490-6.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16997378" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>24/01/2011 10:58:38</lastReviewDate>
    <expiryDate>24/01/2012 10:58:38</expiryDate>
  </document>
  <document>
    <id>155511</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.renal.org/pages/pages/other-info/ckd.php]]&gt;</url>
    <title>CKD eGuide</title>
    <publicationDate>2009-01-31T00:00:00</publicationDate>
    <publisher>Renal Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ PRESENTATION OF CKD,ASSESSMENT OF RENAL FUNCTION,PREDISPOSING FACTORS,SCREENING OPTIONS,INTERVENTIONS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The aim is to provide quick  online support for the diagnosis and management of chronic kidney disease in the community and elsewhere. Revised January 2009</description>
    <body>&lt;![CDATA[ The &lt;B&gt;CKD eGuide&lt;/B&gt; is derived from the NICE, SIGN and Renal Association guidelines.]]&gt;</body>
    <lastReviewDate>23/08/2010 12:05:39</lastReviewDate>
    <expiryDate>23/08/2011 12:05:39</expiryDate>
  </document>
  <document>
    <id>273529</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.pulsetoday.co.uk/story.asp?sectioncode=35&amp;storycode=4115453&amp;c=2]]&gt;</url>
    <title>CKD targets set for radical overhaul</title>
    <publicationDate>2007-10-24T00:00:00</publicationDate>
    <publisher>Pulse</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ HAEMATURIA/ PROTEINURIA,PRESENTATION OF CKD,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The chronic kidney disease indicators in the quality framework are set to be overhauled after Government advisers recommended substantial changes.</description>
    <body>&lt;![CDATA[ &lt;P&gt;Extract&lt;/P&gt;
&lt;P&gt;GPs are likely to be asked to stratify patients using proteinuria testing – with tough new blood pressure targets for those at highest risk. 
&lt;P&gt;The recommendations to the QOF review aim to ‘close the gap’ to February’s national consensus statement on CKD, which warned the QOF indicators were in need of refinement. 
&lt;P&gt;The consensus statement, by the Royal College of Physicians and the Renal Association, called for ACE inhibitors and ARBs to be targeted at patients with proteinuria, with the option to exception report others.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>04/10/2010 11:43:50</lastReviewDate>
    <expiryDate>04/10/2011 11:43:50</expiryDate>
  </document>
  <document>
    <id>182672</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.kidney.org/professionals/kdoqi/guidelines_bp/index.htm]]&gt;</url>
    <title>Clinical practice guideline on hypertension and antihypertensive agents in chronic kidney disease</title>
    <publicationDate>2004-01-01T00:00:00</publicationDate>
    <publisher>K/DOQI</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ BLOOD PRESSURE,INTERVENTIONS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>K/DOQI Clinical Practice Guidelines</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Extract from guideline&lt;/EM&gt; &lt;/P&gt;
&lt;P align=left&gt;Hypertension is a common complication of CKD, which increases the risk for the two main outcomes of CKD: loss of kidney function sometimes leading to kidney failure, and CVD, both associated with increased mortality. Appropriate evaluation and management of hypertension and use of antihypertensive agents in CKD offers the opportunity to slow the progression of kidney disease and reduce the risk of CVD.&lt;/P&gt;
&lt;P align=left&gt;The Work Group defined three principal goals of antihypertensive therapy in CKD: lowering blood pressure, slowing progression of CKD, and reducing the risk of CVD. The Work Group also recommends considering reducing proteinuria an additional therapeutic goal. &lt;/P&gt;
&lt;P align=left&gt;Published in 2004&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>23/08/2010 12:05:44</lastReviewDate>
    <expiryDate>23/08/2011 12:05:44</expiryDate>
  </document>
  <document>
    <id>267849</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://jasn.asnjournals.org/cgi/content/full/11/7/1340]]&gt;</url>
    <title>Clinical practice guideline on shared decision making in the appropriate initiation of and withdrawal from dialysis</title>
    <publicationDate>2000-02-01T00:00:00</publicationDate>
    <publisher>Renal Physicians Association and American Society of Nephrology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ END-OF-LIFE CARE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Guideline from the Renal Physicians Association and the American Society of Nephrology</description>
    <body>&lt;![CDATA[ &lt;P&gt;Guideline comprised of 9 recommendations:&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Shared decision making 
&lt;LI&gt;Informed consent or refusal 
&lt;LI&gt;Estimating prognosis 
&lt;LI&gt;Conflict resolution 
&lt;LI&gt;Advance directives 
&lt;LI&gt;Withholding or withdrawing dialysis 
&lt;LI&gt;Special patient groups 
&lt;LI&gt;Time limited trials 
&lt;LI&gt;Palliative care.&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;Published in February 2000&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:22:45</lastReviewDate>
    <expiryDate>06/07/2011 11:22:45</expiryDate>
  </document>
  <document>
    <id>182671</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.kidney.org/professionals/kdoqi/guidelines_cvd/index.htm]]&gt;</url>
    <title>Clinical practice guidelines for cardiovascular disease in dialysis patients</title>
    <publicationDate></publicationDate>
    <publisher>K/DOQI</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ COMPLICATIONS OF KIDNEY DISEASE,CARDIOVASCULAR DISEASE,PERITONEAL DIALYSIS,LIVING WITH DIALYSIS,HAEMODIALYSIS,STARTING HAEMODIALYSIS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES,DIALYSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>K/DOQI Clinical Practice Guidelines</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Extract from Guideline&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;These guidelines are organized to facilitate the evaluation, identification, and treatment of patients on dialysis with CVD, recognizing that all patients on dialysis are at increased risk for CVD. They are designed for use by cardiologists, nephrologists, primary-care physicians, and nurse practitioners. CVD in these guidelines is defined as coronary artery disease (CAD), cardiomyopathy, valvular heart disease, arrhythmia, cerebrovascular disease (CBVD), or peripheral vascular disease (PVD). Some or all of these entities may co-exist in the same individual, or develop sequentially over time.&lt;/P&gt;
&lt;P&gt;The intention of the Work Group was not to rewrite existing guidelines or textbooks of cardiovascular medicine. Instead, the Guideline attempts to highlight those aspects of CVD care that are different or have been construed to be different in dialysis patients compared to the general population, either as a consequence of the kidney disease or the dialysis procedure.&lt;/P&gt;
&lt;P&gt;Published in 2005&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>23/08/2010 12:05:55</lastReviewDate>
    <expiryDate>23/08/2011 12:05:55</expiryDate>
  </document>
  <document>
    <id>267862</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/index.htm]]&gt;</url>
    <title>Clinical practice guidelines for hemodialysis adequacy, Update 2006</title>
    <publicationDate></publicationDate>
    <publisher>NKF-K/DOQI</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ STARTING HAEMODIALYSIS,HAEMODIALYSIS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,DIALYSIS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>NKF-K/DOQI guidelines</description>
    <body>&lt;![CDATA[ &lt;P&gt;Contents:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;I:&lt;/A&gt; Clinical Practice Guidelines for Hemodialysis Adequacy 
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/hd_guide1.htm" target="_blank"&gt;Guideline 1.&lt;/A&gt;&amp;nbsp; Initiation of Dialysis 
&lt;LI&gt;&lt;A href="http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/hd_guide2.htm" target="_blank"&gt;Guideline 2.&lt;/A&gt; Methods for Measuring and Expressing the Hemodialysis Dose 
&lt;LI&gt;&lt;A href="http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/hd_guide3.htm" target="_blank"&gt;Guideline 3.&lt;/A&gt; Methods for Postdialysis Blood Sampling 
&lt;LI&gt;&lt;A href="http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/hd_guide4.htm" target="_blank"&gt;Guideline 4.&lt;/A&gt; Minimally Adequate Hemodialysis 
&lt;LI&gt;&lt;A href="http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/hd_guide5.htm" target="_blank"&gt;Guideline 5.&lt;/A&gt; Control of Volume and Blood Pressure 
&lt;LI&gt;&lt;A href="http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/hd_guide6.htm" target="_blank"&gt;Guideline 6.&lt;/A&gt; Preservation of Residual Kidney Function 
&lt;LI&gt;&lt;A href="http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/hd_guide7.htm" target="_blank"&gt;Guideline 7.&lt;/A&gt; Quality Improvement Programs 
&lt;LI&gt;&lt;A href="http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/hd_guide8.htm" target="_blank"&gt;Guideline 8.&lt;/A&gt; Pediatric Hemodialysis Prescription and Adequacy &lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;II:&lt;/A&gt; Clinical Practice Recommendations for Hemodialysis Adequacy 
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/hd_rec1.htm" target="_blank"&gt;Clinical Practice Recommendation for Guideline 1: &lt;/A&gt;Initiation of Dialysis 
&lt;LI&gt;&lt;A href="http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/hd_rec2.htm" target="_blank"&gt;Clinical Practice Recommendations for Guideline 2:&lt;/A&gt; Methods for Measuring and Expressing the Hemodialysis Dose 
&lt;LI&gt;&lt;A href="http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/hd_rec4.htm" target="_blank"&gt;Clinical Practice Recommendations for Guideline 4:&lt;/A&gt; Minimally Adequate Hemodialysis 
&lt;LI&gt;&lt;A href="http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/hd_rec5.htm" target="_blank"&gt;Clinical Practice Recommendation 5:&lt;/A&gt; Dialyzer Membranes and Reuse 
&lt;LI&gt;&lt;A href="http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/hd_rec6.htm" target="_blank"&gt;Clinical Practice Recommendations for Guideline 6: &lt;/A&gt;Preservation of Residual Kidney Function &lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;III:&lt;/A&gt; &lt;A href="http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/hd_rec.htm" target="_blank"&gt;Research Recommendations&lt;/A&gt; &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;Published in 2006&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>23/08/2010 12:05:59</lastReviewDate>
    <expiryDate>23/08/2011 12:05:59</expiryDate>
  </document>
  <document>
    <id>182665</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.kidney.org/professionals/kdoqi/guidelines_updates/doqi_nut.html]]&gt;</url>
    <title>Clinical practice guidelines for nutrition in chronic renal failure</title>
    <publicationDate>2000-07-31T00:00:00</publicationDate>
    <publisher>K/DOQI</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ INTERVENTIONS,DIETARY CHANGE,KIDNEY DISEASE IN CHILDREN AND ADOLESCENTS,HAEMODIALYSIS,LIVING WITH DIALYSIS,CHILD HEALTH,GUIDELINES/EBM,NEPHROLOGY,NUTRITION,SPECIALTIES,RENAL FAILURE,STAFF USE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,DIALYSIS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>NKF K/DOQI Guidelines 2000</description>
    <body>&lt;![CDATA[ &lt;P&gt;Adult and pediatric guidelines for patients on or not on hemodialysis&lt;/P&gt;
&lt;P&gt;Published in 2000&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>23/08/2010 12:06:05</lastReviewDate>
    <expiryDate>23/08/2011 12:06:05</expiryDate>
  </document>
  <document>
    <id>267864</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/index.htm]]&gt;</url>
    <title>Clinical practice guidelines for peritoneal dialysis adequacy</title>
    <publicationDate>2006-10-02T00:00:00</publicationDate>
    <publisher>NKF-K/DOQI</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ PERITONEAL DIALYSIS,STARTING PERITONEAL DIALYSIS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES,DIALYSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>NKF-K/DOQI Guideline</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Contents:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Clinical Practice Guidelines for Peritoneal Dialysis Adequacy&lt;/STRONG&gt; &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/pd_guide1.htm" target="_blank"&gt;Guideline 1.&lt;/A&gt;&amp;nbsp; Initiation of Dialysis 
&lt;LI&gt;&lt;A href="http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/pd_guide2.htm" target="_blank"&gt;Guideline 2.&lt;/A&gt; Peritoneal Dialysis Solute Clearance Targets and Measurements 
&lt;LI&gt;&lt;A href="http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/pd_guide3.htm" target="_blank"&gt;Guideline 3.&lt;/A&gt; Preservation of Residual Kidney Function 
&lt;LI&gt;&lt;A href="http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/pd_guide4.htm" target="_blank"&gt;Guideline 4.&lt;/A&gt; Maintenance of Euvolemia 
&lt;LI&gt;&lt;A href="http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/pd_guide5.htm" target="_blank"&gt;Guideline 5.&lt;/A&gt; Quality Improvement Programs 
&lt;LI&gt;&lt;A href="http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/pd_guide6.htm" target="_blank"&gt;Guideline 6.&lt;/A&gt; Pediatric Peritoneal Dialysis &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Clinical Practice Recommendations for Peritoneal Dialysis Adequacy&lt;/STRONG&gt; &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/pd_rec1.htm" target="_blank"&gt;Clinical Practice Recommendation for Guideline 1: &lt;/A&gt;Initiation of Dialysis 
&lt;LI&gt;&lt;A href="http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/pd_rec2.htm" target="_blank"&gt;Clinical Practice Recommendations for Guideline 2:&lt;/A&gt; Peritoneal Dialysis Prescription Targets and Measurements 
&lt;LI&gt;&lt;A href="http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/pd_rec3.htm" target="_blank"&gt;Clinical Practice Recommendations 3: &lt;/A&gt;Recommended Laboratory Measurements for Peritoneal Membrane Function and Ultrafiltration Volume 
&lt;LI&gt;&lt;A href="http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/pd_rec4.htm" target="_blank"&gt;Clinical Practice Recommendations 4:&lt;/A&gt; Writing the Peritoneal Dialysis Prescription 
&lt;LI&gt;&lt;A href="http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/pd_rec6.htm" target="_blank"&gt;Clinical Practice Recommendations for Guideline 6:&lt;/A&gt; Pediatric Peritoneal Dialysis &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;A href="http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/pd_rec.htm" target="_blank"&gt;&lt;STRONG&gt;Research Recommendations&lt;/STRONG&gt;&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Published in 2006&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:24:00</lastReviewDate>
    <expiryDate>06/07/2011 11:24:00</expiryDate>
  </document>
  <document>
    <id>267868</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/index.htm]]&gt;</url>
    <title>Clinical practice guidelines for vascular access, Update 2006</title>
    <publicationDate></publicationDate>
    <publisher>NKF-K/DOQI</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ ACCESS,HAEMODIALYSIS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,DIALYSIS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Guideline from NKF-K/DOQI</description>
    <body>&lt;![CDATA[ &lt;P&gt;Contents: &lt;/P&gt;
&lt;LI&gt;I. Clinical Practice Guidelines for Vascular Access 
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/va_guide1.htm" target="_blank"&gt;Guideline 1.&lt;/A&gt; Patient Preparation for Permanent Hemodialysis Access 
&lt;LI&gt;&lt;A href="http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/va_guide2.htm" target="_blank"&gt;Guideline 2&lt;/A&gt;. Selection and Placement of Hemodialysis Access 
&lt;LI&gt;&lt;A href="http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/va_guide3.htm" target="_blank"&gt;Guideline 3&lt;/A&gt;. Cannulation of Fistulae and Grafts and Accession of Hemodialysis Catheters and Port Catheter Systems 
&lt;LI&gt;&lt;A href="http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/va_guide4.htm" target="_blank"&gt;Guideline 4.&lt;/A&gt; Detection of Access Dysfunction: Monitoring, Surveillance, and Diagnostic Testing 
&lt;LI&gt;&lt;A href="http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/va_guide5.htm" target="_blank"&gt;Guideline 5.&lt;/A&gt; Treatment of Fistula Complications 
&lt;LI&gt;&lt;A href="http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/va_guide6.htm" target="_blank"&gt;Guideline 6.&lt;/A&gt; Treatment of Arteriovenous Graft Complications 
&lt;LI&gt;&lt;A href="http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/va_guide7.htm" target="_blank"&gt;Guideline 7.&lt;/A&gt; Prevention and Treatment of Catheter and Port Complications 
&lt;LI&gt;&lt;A href="http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/va_guide8.htm" target="_blank"&gt;Guideline 8.&lt;/A&gt; Clinical Outcome Goals &lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;II. Clinical Practice Recommendations for Vascular Access 
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/va_rec1.htm" target="_blank"&gt;Clinical Practice Recommendations for Guideline 1:&lt;/A&gt; Patient Preparation for Permanent Hemodialysis Access 
&lt;LI&gt;&lt;A href="http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/va_rec2.htm" target="_blank"&gt;Clinical Practice Recommendations for Guideline 2:&lt;/A&gt; Selection and Placement of Hemodialysis Access 
&lt;LI&gt;&lt;A href="http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/va_rec3.htm" target="_blank"&gt;Clinical Practice Recommendations for Guideline 3:&lt;/A&gt; Cannulation of Fistulae and Grafts and Accession of Dialysis Catheters and Ports 
&lt;LI&gt;&lt;A href="http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/va_rec4.htm" target="_blank"&gt;Clinical Practice Recommendations for Guideline 4:&lt;/A&gt; Detection of Access Dysfunction: Monitoring, Surveillance, and Diagnostic Testing 
&lt;LI&gt;&lt;A href="http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/va_rec5.htm" target="_blank"&gt;Clinical Practice Recommendations for Guideline 5:&lt;/A&gt; Treatment of Fistula Complications 
&lt;LI&gt;&lt;A href="http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/va_rec7.htm" target="_blank"&gt;Clinical Practice Recommendations for Guideline 7: &lt;/A&gt;Prevention and Treatment of Catheter and Port Complications 
&lt;LI&gt;&lt;A href="http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/va_rec8.htm" target="_blank"&gt;Clinical Practice Recommendation 8:&lt;/A&gt; Vascular Access in Pediatric Patients &lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;&lt;A href="http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/va_rec.htm" target="_blank"&gt;III. Research Recommendations&lt;/A&gt; 
&lt;P&gt;&amp;nbsp;&lt;/P&gt;Published in 2006&lt;/LI&gt;]]&gt;</body>
    <lastReviewDate>23/08/2010 12:06:09</lastReviewDate>
    <expiryDate>23/08/2011 12:06:09</expiryDate>
  </document>
  <document>
    <id>380644</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.sustainabilityforhealth.org/clinicaltransformation/topic-reviews/clinical-transformation-the-key-to-green-nephrology--2]]&gt;</url>
    <title>Clinical Transformation: The Key to Green Nephrology</title>
    <publicationDate>2010-07-01T00:00:00</publicationDate>
    <publisher>Sustainability for Health: An Evidence Base for Action from the Campaign for Greener Healthcare</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RENAL TRACT INFECTIONS,TRANSPLANTATION,ACUTE KIDNEY INJURY,OTHER CONDITIONS - ADULTS,KIDNEY DISEASE IN CHILDREN AND ADOLESCENTS,COMPLICATIONS OF KIDNEY DISEASE,KIDNEY AND BLADDER STONES,GLOMERULONEPHRITIS,RENOVASCULAR DISEASES,INHERITED KIDNEY DISEASE,RENAL CANCER,END-OF-LIFE CARE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES,DIALYSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Andrew Connor, Frances Mortimer, Charles Tomson Nephron Clin Pract 2010;116:c200-c206 (DOI: 10.1159/000317200)</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Abstract&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Climate change represents a major global public health threat. The very provision of healthcare itself has a significant untoward effect on the environment, to which kidney care is likely to contribute disproportionately. In this article we describe the four principles we believe will underpin a successful transformation to lower carbon kidney care: disease prevention, patient empowerment, lean service delivery and the preferential use of low-carbon technologies. We illustrate their application and their co-benefits, such as improvements in patient care and reductions in cost, with examples.&lt;/P&gt;]]&gt;</body>
    <expiryDate>13/07/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>155497</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://renux.dmed.ed.ac.uk/EdREN/Handbookbits/HDBKtrials.html]]&gt;</url>
    <title>Clinical Trials at Edinburgh Royal Infirmary</title>
    <publicationDate>2009-12-02T00:00:00</publicationDate>
    <publisher>Renal Unit, Royal Infirmary, Edinburgh</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ NEW RESEARCH,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Details of local and multi-centre trials at Edinburgh</description>
    <body>&lt;![CDATA[ &lt;P&gt;Details of six local and multi-centre research trials; excludes transplant unit trials. &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Causes of nephritis (local) 
&lt;LI&gt;Immunopathogenesis of Goodpasture's disease (local) 
&lt;LI&gt;Small vessel vasculitis (European multicentre) 
&lt;LI&gt;Therapy for Membranous Nephropathy (MRC multicentre trial) 
&lt;LI&gt;ASTRAL - trial of interventions in renal artery stenosis (multicentre) 
&lt;LI&gt;Genetics of SLE (multicentre) &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;This page last updated November 30, 2006.&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>13/12/2010 11:36:43</lastReviewDate>
    <expiryDate>13/12/2011 11:36:43</expiryDate>
  </document>
  <document>
    <id>182235</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://ndt.oxfordjournals.org/cgi/reprint/16/4/765]]&gt;</url>
    <title>Clinicopathological correlation in biopsy-proven atherosclerotic nephropathy: implications for renal functional outcome in atherosclerotic renovascular disease</title>
    <publicationDate>2001-10-01T00:00:00</publicationDate>
    <publisher>Nephrology Dialysis and Transplantation</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ RENOVASCULAR DISEASES,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Article from Nephrology Dialysis and Transplantation, 2001, 36, 765-770</description>
    <body>&lt;![CDATA[ &lt;P&gt;Atherosclerotic renovascular disease (ARVD) is commonly associated with renal failure. It is now recognized that intrarenal damage, (ischaemic or atherosclerotic nephropathy) is a major contributor to the renal impairment in these patients. In this study the impact of histological changes upon renal functional outcome was investigated in patients with atherosclerotic nephropathy. &lt;/P&gt;
&lt;P&gt;Published in 2001&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>23/08/2010 12:06:28</lastReviewDate>
    <expiryDate>23/08/2011 12:06:28</expiryDate>
  </document>
  <document>
    <id>224336</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.nelm.nhs.uk/en/NeLM-Area/News/489074/489207/489217/]]&gt;</url>
    <title>Complete normalisation of haemoglobin level in patients with chronic kidney disease and anaemia of no benefit</title>
    <publicationDate>2006-11-16T00:00:00</publicationDate>
    <publisher>N Engl J Med 2006; 355: 2071-2084, 2085-2098, 2144-2146</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ COMPLICATIONS OF KIDNEY DISEASE,ANAEMIA,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Two studies published in the New England Journal of Medicine examine the optimal target level for haemoglobin (Hb) in patients with chronic kidney disease who do not yet need renal-replacement therapy</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Extract from abstract&lt;/STRONG&gt;&lt;/EM&gt; &lt;/P&gt;
&lt;P&gt;Details of the 3 year CREATE (Cardiovascular Risk Reduction by Early Anemia Treatment with Epoetin Beta) trial, and the&amp;nbsp;CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) trial.&lt;/P&gt;
&lt;P&gt;An accompanying editorial noted that neither of these studies had the anticipated result i.e. normalisation of the haemoglobin level would be beneficial. It suggests that “taken together, these two studies suggest caution in the full correction of anaemia in patients with chronic kidney disease.” It notes that there are several ongoing multicentre trials of complete vs partial correction of anaemia in patients with chronic kidney disease.&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>23/08/2010 12:06:57</lastReviewDate>
    <expiryDate>23/08/2011 12:06:57</expiryDate>
  </document>
  <document>
    <id>182657</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.renal.org/CKDguide/full/Conciseguid141205.pdf]]&gt;</url>
    <title>Concise Guide - UK CKD Guidelines (2005)</title>
    <publicationDate>2005-12-01T00:00:00</publicationDate>
    <publisher>Renal Association and RCP</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ PREDISPOSING FACTORS,PRESENTATION OF CKD,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Shorter version of UK CKD Guidelines
</description>
    <body>&lt;![CDATA[ Guidelines developed to promote the optimal management of patients with CKD within the NHS, including the identification of those who would benefit from referral to specialist services.]]&gt;</body>
    <lastReviewDate>23/08/2010 12:07:00</lastReviewDate>
    <expiryDate>23/08/2011 12:07:00</expiryDate>
  </document>
  <document>
    <id>156053</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.ispd.org/guidelines/Consensus__Change_20_.pdf]]&gt;</url>
    <title>Consensus guidelines for the treatment of peritonitis in pediatric patients receiving peritoneal dialysis</title>
    <publicationDate>2000-10-02T00:00:00</publicationDate>
    <publisher>International Society for Peritoneal Dialysis</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ PERITONEAL DIALYSIS,PREVENTION OF INFECTIONS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,DIALYSIS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Guideline published by the International Society for Peritoneal Dialysis</description>
    <body>&lt;![CDATA[ &lt;P&gt;Guidelines comprises following:&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Diagnosis of peritonitis&lt;/LI&gt;
&lt;LI&gt;Empiric therapy of peritonitis&lt;/LI&gt;
&lt;LI&gt;Modification of APD regimen for treatment of peritonitis&lt;/LI&gt;
&lt;LI&gt;Modification of therapy for gram-positive peritonitis&lt;/LI&gt;
&lt;LI&gt;Modification of therapy for gram-negative peritonitis&lt;/LI&gt;
&lt;LI&gt;Modification of therapy for culture-negative peritonitis&lt;/LI&gt;
&lt;LI&gt;Modification of therapy for fungal peritonitis&lt;/LI&gt;
&lt;LI&gt;Evaluation of primary treatment response&lt;/LI&gt;
&lt;LI&gt;Approach to patients who fail to demonstrate clinical improvement&lt;/LI&gt;
&lt;LI&gt;Approach to the patient with relapsing peritonitis&lt;/LI&gt;
&lt;LI&gt;Adjunctive therapy for peritonitis&lt;/LI&gt;
&lt;LI&gt;Indications for catheter removal and replacement&lt;/LI&gt;
&lt;LI&gt;Prophylactic antibiotic therapy &lt;/LI&gt;
&lt;LI&gt;Diagnosis of catheter exit-site infection&lt;/LI&gt;
&lt;LI&gt;Treatment of catheter exit-site infection&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Originally published in 2000&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>23/08/2010 12:07:04</lastReviewDate>
    <expiryDate>23/08/2011 12:07:04</expiryDate>
  </document>
  <document>
    <id>268131</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.cmaj.ca/cgi/reprint/173/10/S1]]&gt;</url>
    <title>Consensus guidelines on eligibility for kidney transplantation</title>
    <publicationDate>2005-11-08T00:00:00</publicationDate>
    <publisher>Canadian Medical Association Journal</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ TRANSPLANTATION,ASSESSMENT/SELECTION,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Guidelines from the Canadian Society of Transplantation</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Contents&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Recommendations pertaining to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;General considerations,&lt;/LI&gt;
&lt;LI&gt;Timing of referral, &lt;/LI&gt;
&lt;LI&gt;Renal function,&lt;/LI&gt;
&lt;LI&gt;Age and functional capacity &lt;/LI&gt;
&lt;LI&gt;Obesity &lt;/LI&gt;
&lt;LI&gt;Cause of end-stage renal disease &lt;/LI&gt;
&lt;LI&gt;Systemic diseases &lt;/LI&gt;
&lt;LI&gt;Infections &lt;/LI&gt;
&lt;LI&gt;Malignancy &lt;/LI&gt;
&lt;LI&gt;Pulmonary disease &lt;/LI&gt;
&lt;LI&gt;Cardiac disease &lt;/LI&gt;
&lt;LI&gt;Cerebral vascular disease /peripheral vascular disease &lt;/LI&gt;
&lt;LI&gt;Gastrointestinal disease &lt;/LI&gt;
&lt;LI&gt;Liver disease &lt;/LI&gt;
&lt;LI&gt;Genitourinary disease&lt;/LI&gt;
&lt;LI&gt;Hematologic disorders &lt;/LI&gt;
&lt;LI&gt;Hyperparathyroidism &lt;/LI&gt;
&lt;LI&gt;Psychosocial considerations&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:24:06</lastReviewDate>
    <expiryDate>06/07/2011 11:24:06</expiryDate>
  </document>
  <document>
    <id>273525</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.renal.org/CKDguide/consensus.html]]&gt;</url>
    <title>Consensus statement on management of early CKD</title>
    <publicationDate>2007-02-06T00:00:00</publicationDate>
    <publisher>Royal College of Physicians of Edinburgh, UK Renal Association and Scottish Renal Association</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ PRESENTATION OF CKD,HAEMATURIA/ PROTEINURIA,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Published at the conclusion of a consensus conference convened by the Royal College of Physicians of Edinburgh (RCPE) with the UK and Scottish Renal Associations in February 2007</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Extract&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;A UK-wide consensus statement on early chronic kidney disease was produced and published at the conclusion of a consensus conference convened by the &lt;A href="http://www.rcpe.ac.uk/" target="_blank"&gt;Royal College of Physicians of Edinburgh (RCPE)&lt;/A&gt; with the UK and Scottish Renal Associations in February 2007. The statement includes a number of recommendations aimed at improving the detection, classification, treatment and organisation of care for this condition that is thought to affect about 10% of the population.&lt;/P&gt;
&lt;P&gt;Contents&lt;/P&gt;
&lt;UL&gt;
&lt;LI class=body&gt;&lt;A href="http://www.renal.org/CKDguide/consensus.html#Anchor-WHAT-49575" target="_blank"&gt;What is early CKD&lt;/A&gt; 
&lt;LI class=body&gt;&lt;A href="http://www.renal.org/CKDguide/consensus.html#Anchor-IMPROVING-47857" target="_blank"&gt;Improving detection&lt;/A&gt; 
&lt;LI class=body&gt;&lt;A href="http://www.renal.org/CKDguide/consensus.html#Anchor-IMPROVING-11481" target="_blank"&gt;Improving classification&lt;/A&gt; 
&lt;LI class=body&gt;&lt;A href="http://www.renal.org/CKDguide/consensus.html#Anchor-IMPROVING-35882" target="_blank"&gt;Improving organisation of care&lt;/A&gt; 
&lt;LI class=body&gt;&lt;A href="http://www.renal.org/CKDguide/consensus.html#Anchor-CLINICAL-14210" target="_blank"&gt;Clinical recommendations&lt;/A&gt; 
&lt;UL&gt;
&lt;LI class=body&gt;&lt;A href="http://www.renal.org/CKDguide/consensus.html#Anchor-CLINICAL-14210" target="_blank"&gt;Lifestyle&lt;/A&gt; 
&lt;LI class=body&gt;&lt;A href="http://www.renal.org/CKDguide/consensus.html#Anchor-CLINICAL-14210" target="_blank"&gt;Blood pressure&lt;/A&gt; 
&lt;LI class=body&gt;&lt;A href="http://www.renal.org/CKDguide/consensus.html#Anchor-Cardiovascular-23240" target="_blank"&gt;Cardiovascular&lt;/A&gt; 
&lt;LI class=body&gt;&lt;A href="http://www.renal.org/CKDguide/consensus.html#Anchor-Bone-3800" target="_blank"&gt;Bone Mineral&lt;/A&gt; 
&lt;LI class=body&gt;&lt;A href="http://www.renal.org/CKDguide/consensus.html#Anchor-Anaemia-35326" target="_blank"&gt;Anaemia&lt;/A&gt; 
&lt;LI class=body&gt;&lt;A href="http://www.renal.org/CKDguide/consensus.html#Anchor-Medicines-44867" target="_blank"&gt;Medicines management&lt;/A&gt; 
&lt;LI class=body&gt;&lt;A href="http://www.renal.org/CKDguide/consensus.html#Anchor-Research-33869" target="_blank"&gt;Research&lt;/A&gt; &lt;/LI&gt;&lt;/UL&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;Published in February 2007&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>04/10/2010 11:43:57</lastReviewDate>
    <expiryDate>04/10/2011 11:43:57</expiryDate>
  </document>
  <document>
    <id>334840</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.greenerhealthcare.org/nephrology-resources/conserving-water]]&gt;</url>
    <title>Conserving water in haemodialysis: case study and how-to guide</title>
    <publicationDate>2010-01-14T00:00:00</publicationDate>
    <publisher>The Campaign for Greener Healthcare</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ HAEMODIALYSIS,LIVING WITH DIALYSIS,PREVENTION OF INFECTIONS,ACCESS,STARTING HAEMODIALYSIS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,DIALYSIS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Case studies of Canterbury Dialysis Unit and Ashford Dialysis Unit.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Background to case studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Haemodialysis has a considerable environmental impact, commonly requiring frequent patient travel, using large amounts of electricity and producing significant plastic and packaging waste. Furthermore, it consumes vast quantities of water. Producing the 120 litres of dialysate required for a typical four hour session requires approximately 400 litres of mains water. Reverse osmosis is an important step in the purification process that this water undergoes (see figure 1). Reverse osmosis systems vary in efficiency, but commonly reject up to two thirds of the water presented to them. Termed ‘reject water’, this high grade grey water does not come into contact with the patient at any stage and poses no infection risk, yet it is needlessly ‘lost to drain’ in almost all dialysis facilities. This guide outlines a simple methodology for salvaging reject water so that it can be put to an alternative use, such as in the hospital laundry or sanitation systems, to produce steam for equipment sterilisation or to feed low-pressure boilers.&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>17/12/2010 11:27:04</lastReviewDate>
    <expiryDate>17/12/2011 11:27:04</expiryDate>
  </document>
  <document>
    <id>333628</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=333628]]&gt;</url>
    <title>Continuous Renal Replacement Therapy: Systematic reviews and meta-analyses</title>
    <publicationDate>2011-01-17T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,HAEMODIALYSIS,PERITONEAL DIALYSIS,KIDNEY DISEASES,DIALYSIS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Continuous Renal Replacement Therapy: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Casey, E. T., B. P. Gupta, et al. "The dose of continuous renal replacement therapy for acute renal failure: a systematic review and meta-analysis." Renal Failure 32(5): 555-61. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=The%20dose%20of%20continuous%20renal%20replacement%20therapy%20for%20acute%20renal%20failure%3A%20a%20systematic%20review%20and%20meta-analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;McCann, M. and Z. E. Moore "Interventions for preventing infectious complications in haemodialysis patients with central venous catheters." Cochrane Database Syst Rev(1): CD006894. [&lt;A href="nelh:341736:0" name=internalLink&gt;Link to Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Morton, R. L., A. Tong, et al. "The views of patients and carers in treatment decision making for chronic kidney disease: systematic review and thematic synthesis of qualitative studies." BMJ 340: c112. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20085970" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Oudemans-van Straaten, H. M. "Citrate anticoagulation for continuous renal replacement therapy in the critically ill." Blood Purif 29(2): 191-6. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20093826" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Segura-Orti, E. "[Exercise in hemodyalisis patients: a literature systematic review.]." Nefrologia. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20098466" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Tai, D. J., T. W. Lim, et al. "Cardiovascular Effects of Angiotensin Converting Enzyme Inhibition or Angiotensin Receptor Blockade in Hemodialysis: A Meta-Analysis." Clin J Am Soc Nephrol. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20133488" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Tordoir, J. H., M. M. van Loon, et al. "Surgical Techniques to Improve Cannulation of Hemodialysis Vascular Access." Eur J Vasc Endovasc Surg. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20060754" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Van Wert, R., J. O. Friedrich, et al. "High-dose renal replacement therapy for acute kidney injury: Systematic review and meta-analysis." Critical Care Medicine 38(5): 1360-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=High-dose%20renal%20replacement%20therapy%20for%20acute%20kidney%20injury%3A%20Systematic%20review%20and%20meta-analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Whalley, G., R. Simpson, et al. (2010). "Systematic review of the impact of renal replacement therapy on left ventricular mass." Heart Lung and Circulation 19: S53-S54.&amp;nbsp;[No abstract available]&lt;/LI&gt;
&lt;LI&gt;Zhongheng, Z., X. Xiao, et al. (2010). "Intensive- vs less-intensive-dose continuous renal replacement therapy for the intensive care unit-related acute kidney injury: A meta-analysis and systematic review." Journal of Critical Care 25(4): 595-600. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20619597" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Choi, G., C. D. Gomersall, et al. (2009). "Principles of antibacterial dosing in continuous renal replacement therapy." Crit Care Med 37(7): 2268-82. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19487930" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Heintz, B. H., G. R. Matzke, et al. (2009). "Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis." Pharmacotherapy 29(5): 562-77.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19397464" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Leung, A. K. and W. W. Yan (2009). "Renal replacement therapy in critically ill&amp;nbsp;patients." Hong Kong Med J 15(2): 122-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19342738" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Li, A. M., C. D. Gomersall, et al. (2009). "A systematic review of antibiotic dosing regimens for septic patients receiving continuous renal replacement therapy: do current studies supply sufficient data?" J Antimicrob Chemother 64(5): 929-37.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19706668" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Moriyama, B., S. A. Henning, et al. (2009). "Continuous-infusion beta-lactam antibiotics during continuous venovenous hemofiltration for the treatment of resistant gram-negative bacteria." Ann Pharmacother 43(7): 1324-37.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19584386" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Tillman, J. (2009). "Heparin versus citrate for anticoagulation in critically ill patients treated with continuous renal replacement therapy." Nurs Crit Care 14(4): 191-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19531037" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Ghahramani, N., S. Shadrou, et al. (2008). "A systematic review of continuous renal replacement therapy and intermittent haemodialysis in management of patients with acute renal failure." Nephrology (Carlton) 13(7): 570-8.&amp;nbsp;[&lt;A href="nelh:342903:0" name=internalLink&gt;Link to&amp;nbsp;DARE abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Rabindranath, K., J. Adams, et al. (2007). "Intermittent versus continuous renal replacement therapy for acute renal failure in adults." Cochrane Database Syst Rev(3): CD003773.&amp;nbsp;[&lt;A href="nelh:266499:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>26/11/2010 15:25:38</lastReviewDate>
    <expiryDate>26/11/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>224599</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://content.nejm.org/cgi/reprint/355/20/2085.pdf?andorexacttitleabs=and&amp;search_tab=articles&amp;tocsectionid=Original+Articles&amp;tocsectionid=Special+Reports&amp;tocsectionid=Special+Articles&amp;tocsectionid=Videos+in+Clinical+Medicine&amp;tocsectionid=Clinical+Practic]]&gt;</url>
    <title>Correction of Anemia with Epoetin Alfa</title>
    <publicationDate>2006-11-16T00:00:00</publicationDate>
    <publisher>New England Journal of Medicine</publisher>
    <publicationType>RANDOMISED CONTROLLED TRIAL</publicationType>
    <topics>&lt;![CDATA[ COMPLICATIONS OF KIDNEY DISEASE,ANAEMIA,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Article from CHOIR Trial in New England Journal of Medicine, November 16, 355, 2085-2098
[CHOIR Trial - Correction of Hemoglobin and Outcomes in Renal Insufficiency]</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Background&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Anemia, a common complication of chronic kidney disease,usually develops as a consequence of erythropoietin deficiency.Recombinant human erythropoietin (epoetin alfa)is indicated for the correction of anemia associated with this condition.However,the optimal level of hemoglobin correction is not defined.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;In this open-label trial,we studied 1432 patients with chronic kidney disease,715 of whom were randomly assigned to receive a dose of epoetin alfa targeted to achieve a hemoglobin level of 13.5 g per deciliter and 717 of whom were assigned to receive a dose targeted to achieve a level of 11.3 g per deciliter.The median study duration was 16 months.The primary end point was a composite of death,myocardial infarction,hospitalization for congestive heart failure (without renal replacement therapy), and stroke.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;A total of 222 composite events occurred:125 events in the high-hemoglobin group, as compared with 97 events in the low-hemoglobin group (hazard ratio,1.34;95% confidence interval,1.03 to 1.74;P =0.03).There were 65 deaths (29.3%),101 hospitalizations for congestive heart failure (45.5%),25 myocardial infarctions (11.3%), and 23 strokes (10.4%).Seven patients (3.2%)were hospitalized for congestive heart failure and myocardial infarction combined,and one patient (0.5%)died after having a stroke.Improvements in the quality of life were similar in the two groups.More patients in the high-hemoglobin group had at least one serious adverse event.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;The use of a target hemoglobin level of 13.5 g per deciliter (as compared with 11.3 g per deciliter)was associated with increased risk and no incremental improvement in the quality of life.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>13/12/2010 11:36:47</lastReviewDate>
    <expiryDate>13/12/2011 11:36:47</expiryDate>
  </document>
  <document>
    <id>155758</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.renal.org/unit/index.pl?c=walsgrave]]&gt;</url>
    <title>Coventry - Walsgrave Hospital</title>
    <publicationDate></publicationDate>
    <publisher>Renal Asssociation</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ TRANSPLANTATION,TRANSPLANT CENTRES,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Contact details</description>
    <body>&lt;![CDATA[ Only contact details are available from this webpage.]]&gt;</body>
    <lastReviewDate>23/08/2010 12:07:08</lastReviewDate>
    <expiryDate>23/08/2011 12:07:08</expiryDate>
  </document>
  <document>
    <id>312740</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/Pathways/kidneydisease/Pages/InfoScriptCreate.aspx]]&gt;</url>
    <title>Create an information prescription for Kidney disease</title>
    <publicationDate>2009-04-21T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MANAGEMENT,ACUTE KIDNEY INJURY,OTHERS,INTERVENTIONS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Create a pack containing all the facts you need on Kidney disease and where to get help in your area; it's easy to do and there are only three steps.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;What is an information prescription?&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Patients and carers have told us they want to know how to find information they can trust and rely on. Information prescriptions are being developed as a quick and easy way to provide this information about your condition and local services.&lt;/P&gt;
&lt;P&gt;These information prescriptions bring together a wealth of information sources already available through NHS Choices to make it easier for you to find the information you need.&lt;/P&gt;
&lt;P&gt;This webpage enables you to create an information prescription for kidney disease.&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>04/03/2011 11:17:28</lastReviewDate>
    <expiryDate>04/03/2012 11:17:28</expiryDate>
  </document>
  <document>
    <id>155942</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.helpthehospices.org.uk/clip/]]&gt;</url>
    <title>Current learning in palliative care index</title>
    <publicationDate></publicationDate>
    <publisher>Help the Hospices</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ END-OF-LIFE CARE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>15 minute tutorials on various aspects of palliative care</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Extract from website&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Helping others to learn about caring for people with advanced disease has always been a fundamental part of effective palliative care.&amp;nbsp; The aim is to resource existing professionals, carers and teams with the knowledge and skills needed in their daily work. &lt;/P&gt;
&lt;P&gt;The CLIP worksheets grew from the idea of a "coffee update".&amp;nbsp; The principle was to develop a flexible learning material that could be used over a coffee break, but could also be used in a variety of settings.&lt;/P&gt;
&lt;P&gt;All the CLIP worksheets have been adapted as online tutorials, with permission, by Help the Hospices from Helping the Patient with Advanced Disease: a Workbook by Regnard C, ed. Radcliffe Medical Press 2004.&lt;/P&gt;
&lt;P&gt;Published in 2006&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>23/08/2010 12:07:39</lastReviewDate>
    <expiryDate>23/08/2011 12:07:39</expiryDate>
  </document>
  <document>
    <id>224554</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.emedicine.com/med/topic3189.htm]]&gt;</url>
    <title>Cystic Diseases of the Kidney</title>
    <publicationDate>2009-07-12T00:00:00</publicationDate>
    <publisher>eMedicine.com</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ INHERITED KIDNEY DISEASE,POLYCYSTIC KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Information from eMedicine.com</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Extract from website&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;Renal cysts occur in one third of people older than 50 years. While most are simple cysts, renal cystic disease has multiple etiologies. Broad categories of cystic disease include the following: &lt;/P&gt;
&lt;P&gt;
&lt;UL&gt;
&lt;LI&gt;Congenital - Congenital cystic dysplasia 
&lt;P&gt;&lt;/P&gt;
&lt;LI&gt;Genetic - Autosomal recessive polycystic kidney disease (ARPKD), autosomal dominant polycystic kidney disease (ADPKD), nephronophthisis-medullary cystic kidney disease complex (NMCD) 
&lt;P&gt;&lt;/P&gt;
&lt;LI&gt;Acquired - Simple cysts, acquired cystic disease 
&lt;P&gt;&lt;/P&gt;
&lt;LI&gt;Cysts associated with systemic disease - Von Hippel-Lindau syndrome (VHLS), tuberous sclerosis (TS) 
&lt;P&gt;&lt;/P&gt;
&lt;LI&gt;Malignancy - Renal cell carcinoma (RCC)&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;The most common larger cysts are acquired cysts, simple cysts, and cysts with ADPKD. Smaller cysts are associated with ARPKD, NMCD, and medullary sponge kidney (MSK). In adults, renal angiomyolipomas and RCC also may demonstrate cystic lesions.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>13/12/2010 11:36:52</lastReviewDate>
    <expiryDate>13/12/2011 11:36:52</expiryDate>
  </document>
  <document>
    <id>321803</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=321803]]&gt;</url>
    <title>Cystitis: Systematic reviews and meta-analyses</title>
    <publicationDate>2010-11-25T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CYSTITIS,MALE BLADDER DISORDERS,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Cystitis: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Falagas, M. E., E. K. Vouloumanou, et al. (2010). "Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials." Journal of Antimicrobial Chemotherapy 65(9): 1862-1877. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Fosfomycin%20versus%20other%20antibiotics%20for%20the%20treatment%20of%20cystitis%3A%20a%20meta-analysis%20of%20randomized%20controlled%20trials" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Tirumuru, S., D. Al Kurdi, et al. (2010). "Intravesical botulinum toxin a injections in the treatment of painful bladder syndrome / interstitial cystitis: A systematic review." Neurourology and Urodynamics 29(6): 1147-1148. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20449567" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Homma, Y., T. Ueda, et al. (2009). "Japanese guideline for diagnosis and treatment of interstitial cystitis." Int J Urol 16(1): 4-16. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19120522" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Fall, M., F. Oberpenning, et al. (2008). "Treatment of Bladder Pain Syndrome/Interstitial Cystitis 2008: Can We Make Evidence-Based Decisions?" European Urology 54(1): 65-78.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18403099?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mourtzoukou, E. G., C. Iavazzo, et al. (2008). "Resiniferatoxin in the treatment of interstitial cystitis: A systematic review." International Urogynecology Journal and Pelvic Floor Dysfunction 19(11): 1571-1576.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18563284?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Dawson, T. E. and J. Jamison (2007). "Intravesical treatments for painful bladder syndrome/ interstitial cystitis." Cochrane Database Syst Rev(4): CD006113.&amp;nbsp;[&lt;A href="nelh:270939:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Dimitrakov, J., K. Kroenke, et al. (2007). "Pharmacologic management of painful bladder syndrome/interstitial cystitis: a systematic review." Arch Intern Med 167(18): 1922-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17923590?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:01:37</lastReviewDate>
    <expiryDate>06/07/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>332101</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=332101]]&gt;</url>
    <title>December 2009 NHS Evidence - kidney diseases and male urogenital disorders newsletter</title>
    <publicationDate>2009-12-07T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;December 2009 NHS Evidence - kidney diseases and male urogenital disorders newsletter&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Welcome to the kidney diseases and male urogenital disorders specialist collection enewsletter for December 2009. &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;NHS Evidence - kidney diseases and male urogenital disorders is for busy health professionals, providing them with high quality information and keeping them up to date with the latest research and developments in this area. You can now join our mailing list to receive regular updates. &lt;A href="https://www.jiscmail.ac.uk/cgi-bin/webadmin?A0=NHSEVIDENCEKDMU" target="_blank"&gt;Click here for the link&lt;/A&gt;.&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=center&gt;&lt;IMG id=nelh_tempImage0 height=135 alt="Newspaper stack" src="/libraryImages/kidney/contentID332101/nelhImp_0001_Newspapersstack_istock_vsmall_08jan09.jpg" width=211 border=0 name=nelh_tempImage0&gt;&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;****2009 Annual Evidence Update on Post Transplant Lymphoproliferative Disorders in Renal Transplant patients 7-11 December 2009. **** &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;This Annual Evidence Update is being launched on Monday 7th December 2009 to link to and raise awareness of the Guidelines on the surveillance, diagnosis and management of post transplant lymphoproliferative disorders in adult solid organ transplant recipients, recently published by the British Transplant Society.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;STRONG&gt;&lt;A href="nelh:329868:0" name=internalLink&gt;&lt;STRONG&gt;&lt;STRONG&gt;Click here for the contents page&lt;/STRONG&gt;&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Links to:&lt;/STRONG&gt;&lt;/P&gt;&lt;STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="#kidney"&gt;New Kidney Diseases items&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="#mug"&gt;New Male Urogenital Disorders items&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0005_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&amp;nbsp;RSS FEEDS&amp;nbsp; &lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0006_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;You can receive news from the kidney diseases specialist collection from the RSS feeds we provide:&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/RSS/CMS.aspx?feed=57" target="_blank"&gt;&lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0007_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk/kidney/RSS/CMS.aspx?feed=57" target="_blank"&gt;New Kidney Diseases Resources&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/RSS/CMS.aspx?feed=136" target="_blank"&gt;&lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0008_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk/kidney/RSS/CMS.aspx?feed=136" target="_blank"&gt;New Male Urogenital Disorders Resources&lt;/A&gt; &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/KIDNEY/RSS/News.aspx" target="_blank"&gt;&lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0008_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk//kidney/News.aspx" target="_blank"&gt;Kidney diseases and male urogenital disorders in the news&lt;/A&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/rss/Directory/MoreAboutRss.aspx" target="_blank"&gt;Click through this link to find out more about RSS feeds.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;JOURNALS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;You can link through to the latest Tables of Contents from all the major kidney, transplant and urology journals from &lt;A href="http://www.library.nhs.uk/KIDNEY/Page.aspx?pagename=EJOURNALS" target="_blank"&gt;this page&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=3&gt;&lt;STRONG&gt;&lt;BIG&gt;New resources added in&amp;nbsp;November 2009&lt;/BIG&gt;&lt;/STRONG&gt; &lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A name=kidney&gt;Chronic Kidney&amp;nbsp; Disease&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:328959:0" name=internalLink&gt;Does epoetin alfa improve health-related quality of life in chronically ill patients with anemia: summary of trials of cancer, HIV/AIDS, and chronic kidney disease&lt;/A&gt;. Database of Abstracts of Reviews of Effects (DARE) abstract.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:329446:0" name=internalLink&gt;Effectiveness and efficiency of primary care based case management for chronic diseases: systematic review and meta-analysis of randomized and non-randomized trials. (Protocol for a systematic review)&lt;/A&gt;. CRD Health Technology Assessment Database (HTA) abstract and links. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:329228:0" name=internalLink&gt;IV placement in chronic kidney disease patients&lt;/A&gt;. HTA abstract and links. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:329471:0" name=internalLink&gt;Renal replacement therapy in advanced chronic kidney disease&lt;/A&gt;. HTA abstract and links. &lt;/LI&gt;
&lt;LI&gt;NICE guideline on &lt;A href="nelh:328348:0" name=internalLink&gt;Depression in adults with a chronic physical health problem: treatment and management&lt;/A&gt;.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2009---November/19/BNF-advice-on-dose-adjustment-in-renal-impairment-now-expressed-in-terms-of-eGFR-rather-than-creatinine-clearance/" target="_blank"&gt;BNF advice on dose adjustment in renal impairment now expressed in terms of eGFR rather than creatinine clearance&lt;/A&gt;. Analysis by the National electronic Library for Medicines (19/11/09)&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:331432:0" name=internalLink&gt;So Just What Can I Eat? Nutritional Care in Patients with Diabetes Mellitus and Chronic Kidney Disease&lt;/A&gt;. Nephrology Nursing Journal article. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:331441:0" name=internalLink&gt;Achieving Autonomy for Kidney Services: Seven Steps Toolkit 2009&lt;/A&gt;. Service guidance from NHS Kidney Care. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Acute kidney injury&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:329033:0" name=internalLink&gt;N-acetylcysteine to reduce renal failure after cardiac surgery: a systematic review and meta-analysis&lt;/A&gt;. DARE abstract.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Renovascular disease&lt;/STRONG&gt;&lt;/P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.kidneyresearchuk.org/news/kidney-research-news-articles.php?id=846" target="_blank"&gt;Treatment to open blocked kidney arteries shows no real benefit&lt;/A&gt;. Kidney Research UK news item:&amp;nbsp; &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;End stage renal disease&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:329454:0" name=internalLink&gt;Intradialytic parenteral nutrition (IDPN) for end-stage renal disease in adults&lt;/A&gt;. HTA abstract and links. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Diabetic nephropathy&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:328420:0" name=internalLink&gt;Commentary on Diabetic Nephropathy for the 2009 Diabetes Annual Evidence Update&lt;/A&gt;. This editorial has been written by Dr Edward Sharples for the diabetes specialist collection.&amp;nbsp; &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Dialysis&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:329471:0" name=internalLink&gt;Review of the starting criteria in dialysis programs and assessment of the efficacy and effectiveness of an early start&lt;/A&gt;. HTA abstract and links. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:329751:0" name=internalLink&gt;NHS Choices video on home haemodialysis&lt;/A&gt;. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:329749:0" name=internalLink&gt;NHS Choices video on dialysis &lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Transplantation&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:329094:0" name=internalLink&gt;Estimated benefits of transplantation of kidneys from donors at increased risk for HIV or hepatitis C infection&lt;/A&gt;. NHS Economic Evaluation Database&amp;nbsp;(NEED) abstract. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:329524:0" name=internalLink&gt;Selective IgG Apheresis for ABO-incompatible kidney transplantation&lt;/A&gt;. Systematic Review. HTA abstract. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:329780:0" name=internalLink&gt;KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients&lt;/A&gt;.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:330696:0" name=internalLink&gt;Legal issues relevant to non-heartbeating organ donation&lt;/A&gt;. Department of Health. &lt;/LI&gt;
&lt;LI&gt;Organ transplants using 'risky donors' rising. &lt;A href="http://news.bbc.co.uk/1/hi/health/8374269.stm" target="_blank"&gt;Link to BBC news item&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Call to put organ donor register in polling stations. &lt;A href="http://news.bbc.co.uk/1/hi/uk/8381204.stm" target="_blank"&gt;Link to BBC news item&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Organ transplants' hidden risk. &lt;A href="http://news.bbc.co.uk/1/hi/health/8374764.stm" target="_blank"&gt;Link to BBC news item&lt;/A&gt;. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Kidney Cancer&lt;/STRONG&gt; &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:329317:0" name=internalLink&gt;Sunitinib for the management of renal cell carcinoma&lt;/A&gt;. HTA abstract.&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:329333:0" name=internalLink&gt;Sunitinib in metastatic renal-cell cancer: efficacy and safety&lt;/A&gt;. HTA abstract.&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;NHS Evidence – cancer: &lt;A href="nelh:124720:0" name=internalLink&gt;Two systematic reviews on kidney cancer and surgery as treatment management highlighted&lt;/A&gt;.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A name=mug&gt;Male Urogenital Disorders&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:329279:0" name=internalLink&gt;Green light laser urological indications&lt;/A&gt;. HTA abstract.&lt;/LI&gt;
&lt;LI&gt;One for the lads, or lavs? &lt;A href="http://www.guardian.co.uk/commentisfree/2009/nov/19/international-mens-world-toilet-day" target="_blank"&gt;Link to Guardian news item&lt;/A&gt;.&amp;nbsp; &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Male Bladder Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:329031:0" name=internalLink&gt;The effectiveness of nurse led 2-D ultrasound guided insertion of peripherally inserted central catheters in adult patients: a systematic review&lt;/A&gt;. DARE abstract. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:329376:0" name=internalLink&gt;Biopatch antimicrobial dressing (Integra LifeSciences Corp. and Ethicon Inc., a division of Johnson &amp;amp; Johnson Co.) for prevention of catheter- and device-related bloodstream infections&lt;/A&gt;. HTA abstract.&lt;/LI&gt;
&lt;LI&gt;Doctors' warning on ketamine risk. &lt;A href="http://news.bbc.co.uk/newsbeat/hi/health/newsid_10000000/newsid_10003100/10003110.stm" target="_blank"&gt;Link to BBC news item&lt;/A&gt;. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:124789:0" name=internalLink&gt;Systematic review on surgery for bladder cancer&lt;/A&gt;. NHS Evidence – cancer. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Prostate Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:329046:0" name=internalLink&gt;Adjuvant radiotherapy following radical prostatectomy for pathologic T3 or margin-positive prostate cancer: guideline recommendations&lt;/A&gt;. DARE abstract.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:329224:0" name=internalLink&gt;3.0 Tesla (3T) Magnetic Resonance Imaging (MRI) for Prostate Cancer&lt;/A&gt;. HTA abstract&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:329469:0" name=internalLink&gt;High-intensity focused ultrasound for prostate cancer [Le traitement du cancer de la prostate par ultrasons focalises de haute intensite - in French only]&lt;/A&gt; HTA abstract&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:329257:0" name=internalLink&gt;Intensity modulated radiotherapy (IMRT) for prostate cancer&lt;/A&gt;. HTA abstract&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:329203:0" name=internalLink&gt;Non-drug local procedures in the treatment of benign prostatic hyperplasia&lt;/A&gt;. HTA abstract&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:329476:0" name=internalLink&gt;Photoselective vaporization for benign prostatic hyperplasia with KTP (potassium-titanyl-phosphate) laser or GreenLight&lt;/A&gt;. HTA abstract&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:329457:0" name=internalLink&gt;Robot Assisted Radical Prostatectomy (RARP) [Prostatectomie radicale assistee par robot - in French only] (project). &lt;/A&gt;HTA abstract&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:329305:0" name=internalLink&gt;Robot-assisted surgery in prostate cancer&lt;/A&gt;. HTA abstract&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:329144:0" name=internalLink&gt;Systematic review and economic modelling of effectiveness and cost utility of surgical treatments for men with benign prostatic enlargement&lt;/A&gt;. HTA abstract&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:329150:0" name=internalLink&gt;Use of classical and novel biomarkers as prognostic risk factors for localised prostate cancer: a systematic review&lt;/A&gt;. HTA abstract&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:329242:0" name=internalLink&gt;Usefulness of high-intensity focused ultrasound in prostate cancer&lt;/A&gt;. HTA abstract&lt;/LI&gt;
&lt;LI&gt;Darcus Howe: My battle with prostate cancer. &lt;A href="http://www.guardian.co.uk/lifeandstyle/2009/nov/17/darcus-howe-surviving-prostate-cancer" target="_blank"&gt;Link to Guardian article&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:111522:0" name=internalLink&gt;Literature review on psychosocial care for prostate cancer&lt;/A&gt;. NHS Evidence – cancer. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:111500:0" name=internalLink&gt;Systematic review on Biological therapy for prostate cancer&lt;/A&gt;. NHS Evidence – cancer. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Penile Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:329093:0" name=internalLink&gt;Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis&lt;/A&gt;. DARE abstract.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:329165:0" name=internalLink&gt;Rapid Review - Non-therapeutic male circumcision. Report No. 65&lt;/A&gt;. HTA abstract.&lt;/LI&gt;
&lt;LI&gt;Penis tissue replaced in the lab. &lt;A href="http://news.bbc.co.uk/1/hi/health/8347008.stm" target="_blank"&gt;Link to BBC news item&lt;/A&gt;. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Male Urethral Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:329176:0" name=internalLink&gt;Dipsticks and diagnostic algorithms in urinary tract infection: development and validation, randomised trial, economic analysis, observational cohort, and qualitative study&lt;/A&gt;. HTA abstract. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:329282:0" name=internalLink&gt;Evaluation of home care utility: pneumonia, cerebrovascular disease, urinary tract infections and postsurgical infections&lt;/A&gt;.&amp;nbsp;&amp;nbsp;HTA abstract. &lt;/LI&gt;
&lt;LI&gt;Health Protection Agency care guideline on &lt;A href="nelh:328908:0" name=internalLink&gt;Diagnosis of UTI: quick reference guide for primary care&lt;/A&gt;. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Testicular/Scrotal Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:124734:0" name=internalLink&gt;Systematic review on testicular cancer and diagnostic imaging&lt;/A&gt;. NHS Evidence – cancer. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:124748:0" name=internalLink&gt;Testicular cancer: Treatment and Disease management: Surgery&lt;/A&gt;. Systematic review added by NHS Evidence – cancer team. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Male urinary incontinence&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:329034:0" name=internalLink&gt;Treatment interventions in nursing home residents with urinary incontinence: a systematic review of randomized trials&lt;/A&gt;. DARE&amp;nbsp;abstract.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:329506:0" name=internalLink&gt;New minimally invasive methods in the treatment of stress urinary incontinence. Systematic review&lt;/A&gt;. HTA abstract and links. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:329527:0" name=internalLink&gt;Retroluminal transobturatoric reposition sling for the treatment of stress urinary incontinence in men. Systematic Review&lt;/A&gt;. HTA&amp;nbsp;abstract and links. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Sexually Transmitted Infections&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:328971:0" name=internalLink&gt;The impact of HIV treatment on risk behaviour in developing countries: a systematic review&lt;/A&gt;. DARE abstract. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:329171:0" name=internalLink&gt;Non-occupational post-exposure prophylaxis for HIV: a systematic review&lt;/A&gt;. HTA abstract and links. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Fertility&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:328980:0" name=internalLink&gt;Do sperm DNA integrity tests predict pregnancy with in vitro fertilization?&lt;/A&gt; DARE abstract. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;**Subscribe to the NHS Evidence Eyes on Evidence Newsletter**&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;If you would like to receive Eyes on Evidence, the monthly e-bulletin from NHS Evidence, please sign up at &lt;A href="http://www.evidence.nhs.uk/NewsletterSignup.aspx" target="_blank"&gt;http://www.evidence.nhs.uk/NewsletterSignup.aspx&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The bulletin will keep you updated with new and important evidence and key developments on the NHS Evidence portal.&amp;nbsp; It comes out on the second Wednesday of the month and can be sent to any e-mail address that you provide.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>03/11/2010 15:38:28</lastReviewDate>
    <expiryDate>03/11/2011 15:38:28</expiryDate>
  </document>
  <document>
    <id>395175</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=395175]]&gt;</url>
    <title>December 2010 NHS Evidence - kidney diseases and male urogenital disorders newsletter</title>
    <publicationDate>2010-12-07T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;December 2010 NHS Evidence - kidney diseases and male urogenital disorders newsletter&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Welcome to the kidney diseases and male urogenital disorders specialist collection enewsletter for&amp;nbsp;DECEMBER 2010. &lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=left&gt;NHS Evidence - kidney diseases and male urogenital disorders is for busy health professionals, providing them with high quality information and keeping them up to date with the latest research and developments in this area. You can now join our mailing list to receive regular updates. &lt;A href="https://www.jiscmail.ac.uk/cgi-bin/webadmin?A0=NHSEVIDENCEKDMU" target="_blank"&gt;Click here for the link&lt;/A&gt;.&lt;/P&gt;
&lt;P align=center&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Links to:&lt;/STRONG&gt;&lt;/P&gt;&lt;STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="#kidney"&gt;New Kidney Diseases items&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="#mug"&gt;New Male Urogenital Disorders items&lt;/A&gt;&lt;/STRONG&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=center&gt;&lt;IMG style="WIDTH: 296px; HEIGHT: 197px" id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="Doctor using laptop" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID395175/nelhImp_0000_DoctorworkingonlaptopNov10.jpg" width=218 height=186&gt;&lt;/P&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;FONT size=2&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;IMG id=nelh_tempImage0 alt=" name=nelh_tempImage0 border=" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0005_feed.gif" width=16 height=16 0? RSS icon?&gt;&amp;nbsp;RSS FEEDS&amp;nbsp; &lt;IMG id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0006_feed.gif" width=16 height=16&gt;&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;You can receive news from the kidney diseases specialist collection from the RSS feeds we provide:&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/RSSFeed.aspx?feed=57" target="_blank"&gt;&lt;IMG id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0007_feed.gif" width=16 height=16&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk/kidney/RSSFeed.aspx?feed=57" target="_blank"&gt;New Kidney Diseases Resources&lt;/A&gt;&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/RSSFeed.aspx?feed=136" target="_blank"&gt;&lt;IMG id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0008_feed.gif" width=16 height=16&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk/kidney/RSSFeed.aspx?feed=136" target="_blank"&gt;New Male Urogenital Disorders Resources&lt;/A&gt; &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk//kidney/News.aspx" target="_blank"&gt;&lt;IMG id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0008_feed.gif" width=16 height=16&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk//kidney/News.aspx" target="_blank"&gt;Kidney diseases and male urogenital disorders in the news&lt;/A&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/rss/Directory/MoreAboutRss.aspx" target="_blank"&gt;Click through this link to find out more about RSS feeds.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;JOURNALS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;You can link through to the latest Tables of Contents from all the major kidney, transplant and urology journals from &lt;A href="http://www.library.nhs.uk/KIDNEY/Page.aspx?pagename=EJOURNALS" target="_blank"&gt;this page&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=3&gt;&lt;STRONG&gt;&lt;BIG&gt;Resources added in&amp;nbsp;November 2010&lt;/BIG&gt;&lt;/STRONG&gt; &lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A name=kidney&gt;Chronic Kidney&amp;nbsp;Disease&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Population based screening for chronic kidney disease- cost effectiveness study. New study published in the BMJ (08/11/10). &lt;A href="http://www.bmj.com/content/341/bmj.c5869" target="_blank"&gt;Link to abstract&lt;/A&gt;.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:382553:0" name=internalLink&gt;Weight loss and proteinuria- systematic review of clinical trials and comparative cohorts&lt;/A&gt;. A new record from the CRD Database of Abstracts of Reviews of Effects. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:341852:0" name=internalLink&gt;Renal function- Systematic reviews and meta-analyses&lt;/A&gt;. New systematic reviews identified by the specialist collection team have been added to this page.&lt;/LI&gt;
&lt;LI&gt;Kidney International article - Do meta-analyses in nephrology change the way we treat patients. Mohan S and Radhakrishnan J (Published online 15/11/10). &lt;A href="http://www.nature.com/ki/journal/v78/n11/full/ki2010323a.html" target="_blank"&gt;Link to abstract&lt;/A&gt;.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.kidneycarematters.nhs.uk/Default.aspx?sID=1" target="_blank"&gt;Kidney Care Matters - November 2010&lt;/A&gt;. NHS Kidney Care. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:338797:0" name=internalLink&gt;Genetics of Kidney Diseases- Systematic Reviews and Meta-analyses&lt;/A&gt;. New systematic reviews identified by the specialist collection team have been added to this page.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:346856:0" name=internalLink&gt;Pregnancy and Kidney Diseases- Systematic reviews and meta-analyses.&lt;/A&gt; New systematic reviews identified by the specialist collection team have been added to this page.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.ox.ac.uk/media/news_stories/2010/101122_1.html" target="_blank"&gt;SHARP trial results - Cholesterol drug shows benefits for kidney patients&lt;/A&gt;. Oxford University Clinical Trial Service Unit. Published 23/11/10. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.kidneycarematters.nhs.uk/SE/Default.aspx?iID=6&amp;amp;aID=12" target="_blank"&gt;NHS Kidney Care - Self Care Week&lt;/A&gt;. NHS Kidney Care 18/11/10.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://renaltsar.blogspot.com/2010/11/patient-activation-staff-morale-and.html" target="_blank"&gt;Renal Tsar on Patient activation and staff morale&lt;/A&gt;. Published 16/11/10 by Dr Donal O'Donoghue. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:333626:0" name=internalLink&gt;Chronic Kidney Disease- Systematic reviews and meta-analyses&lt;/A&gt;. New systematic reviews identified by the specialist collection team have been added to this page.&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Diabetic nephropathy&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:393494:0" name=internalLink&gt;2010 Annual Evidence Update on Diabetes - Commentary on Diabetic Nephropathy by Dr Edward Sharples&lt;/A&gt; (08/11/10). &lt;/LI&gt;
&lt;LI&gt;Into the light- Diabetic nephropathy and vitamin D. New article published in the Lancet (05/11/10). &lt;A href="http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2961304-9/fulltext" target="_blank"&gt;Link to abstract&lt;/A&gt;.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:333667:0" name=internalLink&gt;Diabetic Nephropathy- Systematic reviews and meta-analyses&lt;/A&gt;. New systematic reviews identified by the specialist collection team have been added to this page.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Hypertension&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:379079:0" name=internalLink&gt;The effect of pharmaceutical care programs on blood pressure control in individuals with hypertension- a meta-analysis&lt;/A&gt;. A new record from the Database of Abstracts of Reviews of Effects.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:338975:0" name=internalLink&gt;Hypertension- Systematic reviews and meta-analyses&lt;/A&gt;. New systematic reviews identified by the specialist collection team have been added to this page.&lt;/LI&gt;
&lt;LI&gt;Renal sympathetic denervation in patients with treatment-resistant hypertension - The Symplicity HTN-2 Trial - a randomised controlled trial. Published 18/11/10 by the Symplicity HTN-2 Investigators in the Lancet. &lt;A href="http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2962039-9/abstract" target="_blank"&gt;Link to abstract&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Acute kidney injury&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:359546:0" name=internalLink&gt;Does perioperative hemodynamic optimization protect renal function in surgical patients- A meta-analytic study&lt;/A&gt;. A new record from the CRD Database of Abstracts of Reviews of Effects. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:393447:0" name=internalLink&gt;Northern Ireland guidelines for acute kidney injury&lt;/A&gt;. Published by GAIN. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:332400:0" name=internalLink&gt;Acute Kidney Injury- Systematic reviews and meta-analyses&lt;/A&gt;. New systematic reviews identified by the specialist collection team have been added to this page.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;End-Stage Renal Disease&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:393960:0" name=internalLink&gt;2010 Annual Evidence Update on End of Life Care&lt;/A&gt;. NHS Evidence - commissioning and NHS Evidence - innovation and improvement specialist collections.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://renaltsar.blogspot.com/2010/11/age-old-problem.html" target="_blank"&gt;Renal Tsar on An age old problem&lt;/A&gt;. Dr Donal O'Donoghue (11/11/10).&amp;nbsp;&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:338779:0" name=internalLink&gt;End-Stage Renal Disease- Systematic reviews and meta-analyses&lt;/A&gt;. New systematic reviews identified by the specialist collection team have been added to this page.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Renovascular diseases&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;P&gt;&lt;A href="nelh:341905:0" name=internalLink&gt;Renovascular disease- Systematic reviews and meta-analyses&lt;/A&gt;. New systematic reviews identified by the specialist collection team have been added to this page.&lt;/P&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Glomerulonephritis&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:359506:0" name=internalLink&gt;ACEI ARB therapy for IgA nephropathy- a meta analysis of randomised controlled trials&lt;/A&gt;. A new record from the CRD Database of Abstracts of Reviews of Effects.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:341907:0" name=internalLink&gt;Systemic lupus erythematosus- Systematic reviews and meta-analyses&lt;/A&gt;. New systematic reviews identified by the specialist collection team have been added to this page.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:338800:0" name=internalLink&gt;Glomerulonephritis- Systematic reviews and meta-analyses&lt;/A&gt;. New systematic reviews identified by the specialist collection team have been added to this page.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Other renal conditions&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;No new resources this month. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Renal tract infections&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;No new records this month.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Kidney stones&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:339010:0" name=internalLink&gt;Kidney and bladder stones- Systematic reviews and meta-analyses&lt;/A&gt;. New systematic reviews identified by the specialist collection team have been added to this page.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Renal vasculitis&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;No new resources this month. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Haemodialysis&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:358522:0" name=internalLink&gt;Meta-analysis of mortality in dialysis patients with an implantable cardioverter defibrillator&lt;/A&gt;. A new record from the CRD Database of Abstracts of Reviews of Effects.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:393857:0" name=internalLink&gt;Human albumin for intradialytic hypotension in haemodialysis patients&lt;/A&gt;. A new Cochrane systematic review.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:393833:0" name=internalLink&gt;Improving Choice - Listening to Patient Stories&lt;/A&gt;. A new report from NHS Kidney Care. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:333679:0" name=internalLink&gt;Dialysis- Systematic reviews and meta-analyses&lt;/A&gt;. New systematic reviews identified by the specialist collection team have been added to this page.&lt;/LI&gt;
&lt;LI&gt;RCT - In-Center Hemodialysis Six Times per Week versus Three Times per Week. The FHN Trial Group. Published 20/11/10 in the NEJM. &lt;A href="http://www.nejm.org/doi/full/10.1056/NEJMoa1001593" target="_blank"&gt;Link to abstract&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/Evidence/Medicines-Management/References/2010---November/16/Improving-medication-safety-in-chronic-kidney-disease-patients-on-dialysis-through-medication-reconciliation/" target="_blank"&gt;Improving medication safety in chronic kidney disease patients on dialysis through medication reconciliation&lt;/A&gt;. National electronic Library for Medicines (16/11/10). &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Peritoneal Dialysis&lt;/STRONG&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;P&gt;&lt;A href="nelh:339142:0" name=internalLink&gt;Peritoneal dialysis- Systematic reviews and meta-analyses&lt;/A&gt;. New systematic reviews identified by the specialist collection team have been added to this page.&lt;/P&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Transplantation&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://renaltsar.blogspot.com/2010/10/q-transplant-chances.html" target="_blank"&gt;Renal Tsar Q and A - Transplant chances&lt;/A&gt;. Published 01/11/10 by Dr Donal O'Donoghue. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:341851:0" name=internalLink&gt;Renal transplant- Systematic reviews and meta-analyses&lt;/A&gt;. New systematic reviews identified by the specialist collection team have been added to this page.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:339086:0" name=internalLink&gt;Living kidney donors- Systematic reviews and meta-analyses&lt;/A&gt;. New systematic reviews identified by the specialist collection team have been added to this page.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:339131:0" name=internalLink&gt;Nephrectomy- Systematic reviews and meta-analyses&lt;/A&gt;. New systematic reviews identified by the specialist collection team have been added to this page.&lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Kidney Cancer&lt;/STRONG&gt; &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:391365:0" name=internalLink&gt;Cost-effectiveness of temsirolimus for first line treatment of advanced renal cell carcinoma&lt;/A&gt;. A new record from the CRD NHS Economic Evaluation Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:391367:0" name=internalLink&gt;Cost-effectiveness of sorafenib for second-line treatment of advanced renal cell carcinoma&lt;/A&gt;. A new record from the CRD NHS Economic Evaluation Database.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A name=mug&gt;Male Urogenital Disorders&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Male Ureteric Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:321952:0" name=internalLink&gt;Vesico-ureter-reflux- Systematic reviews and meta-analyses&lt;/A&gt;. New systematic reviews identified by the specialist collection team have been added to this page.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Male Bladder Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:339010:0" name=internalLink&gt;Kidney and bladder stones- Systematic reviews and meta-analyses&lt;/A&gt;. New systematic reviews identified by the specialist collection team have been added to this page.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:321826:0" name=internalLink&gt;Male bladder disorders- Systematic reviews and meta-analyses&lt;/A&gt;. New systematic reviews identified by the specialist collection team have been added to this page.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:393263:0" name=internalLink&gt;Bladder cancer surveillance UPDATE&lt;/A&gt;. A new record from the CRD Health Technology Assessment Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:393067:0" name=internalLink&gt;Screening adults for bladder cancer- update of the 2004 evidence review for the US Preventive Services Task Force&lt;/A&gt;. A new record from the CRD Database of Abstracts of Reviews of Effects.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:394688:0" name=internalLink&gt;New content - systematic reviews and meta analyses on overactive bladder&lt;/A&gt;. The specialist collection team have retrieved the high-level evidence on overactive bladder published 2006 - 2010.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Prostate Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:393255:0" name=internalLink&gt;Improvement in the quality of information on colorectal and prostate cancer in the cancer population register of the Basque Country&lt;/A&gt;. A new record from the CRD Health Technology Assessment Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:351983:0" name=internalLink&gt;Survival in men with nonmetastatic prostate cancer treated with hormone therapy- a quantitative systematic review&lt;/A&gt;. A new record from the CRD Database of Abstracts of Reviews of Effects.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:360054:0" name=internalLink&gt;Higher-than-conventional radiation doses in localized prostate cancer treatment- a meta-analysis of randomized controlled trials&lt;/A&gt;. A new record from the CRD Database of Abstracts of Reviews of Effects.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:382388:0" name=internalLink&gt;Efficacy and safety of tamsulosin for the treatment of benign prostatic hyperplasia- a meta analysis&lt;/A&gt;. A new record from the CRD Database of Abstracts of Reviews of Effects. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:393854:0" name=internalLink&gt;Radical prostatectomy versus watchful waiting for prostate cancer&lt;/A&gt;. A new Cochrane systematic review. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/Evidence/Medicines-Management/References/2010---November/04/Reimbursement-policy-and-androgen-deprivation-therapy-for-prostate-cancer/" target="_blank"&gt;Reimbursement policy and androgen-deprivation therapy for prostate cancer&lt;/A&gt;. National electronic Library for Medicines (05/11/10).&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2010---November/02/Studies-examine-impact-of-androgen-deprivation-therapy-on-physical-and-cognitive-function-and-quality-of-life-in-men-with-non-metastatic-prostate-cancer/" target="_blank"&gt;Impact of androgen deprivation therapy on physical and cognitive function and quality of life in men with non-metastatic prostate cancer&lt;/A&gt;. National electronic Library for Medicines (04/11/10).&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:393187:0" name=internalLink&gt;Zibotentan for metastatic castration resistant prostate cancer - first line&lt;/A&gt;. A new record from the CRD Health Technology Assessment Database.&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:393265:0" name=internalLink&gt;Sipuleucel-T for hormone-resistant metastatic prostate cancer&lt;/A&gt;. A new record from the CRD Health Technology Assessment Database. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:393268:0" name=internalLink&gt;Prostate cancer screening&lt;/A&gt;. A new record from the CRD Health Technology Assessment Database.&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Penile Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;No new resources this month. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Urethral disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;No new resources this month. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Urinary tract infections&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:368139:0" name=internalLink&gt;Cost effectiveness of management strategies for urinary tract infections- results from randomised controlled trial&lt;/A&gt;. A new record from the CRD NHS Economic Evaluation Database&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Testicular/Scrotal Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;No new resources this month. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Male Urinary Incontinence&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:394388:0" name=internalLink&gt;New NICE Bites topic on Nocturnal Enuresis&lt;/A&gt;. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Sexually Transmitted Infections&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;No new resources this month. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Fertility&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:393209:0" name=internalLink&gt;Sperm DNA fragmentation and annexin column use in assisted reproductive treatments&lt;/A&gt;. A new record from the CRD Health Technology Assessment Database.&lt;/LI&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <expiryDate>30/11/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>236186</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/assetRoot/04/11/97/42/04119742.pdf]]&gt;</url>
    <title>Delivering the National Service Framework for Renal Services</title>
    <publicationDate>2005-09-30T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ NATIONAL SERVICE FRAMEWORK FOR RENAL SERVICES/POLICY DOCUMENTS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Publication from Department of Health</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Extract from webpage&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;This document presents a summary of progress to date towards achieving the standards and early actions set out in the National Service Framework (NSF) for Renal Services, together with a review of the modernisation programme supporting delivery of the NSF.&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>11/01/2011 10:23:09</lastReviewDate>
    <expiryDate>11/01/2012 10:23:09</expiryDate>
  </document>
  <document>
    <id>187867</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.projects.ex.ac.uk/diabetesgenes/]]&gt;</url>
    <title>Diabetesgenes. org - Renal Cysts and Diabetes</title>
    <publicationDate>2009-01-05T00:00:00</publicationDate>
    <publisher>University of Exeter</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ FAMILY HISTORY,INHERITED KIDNEY DISEASE,PREDISPOSING FACTORS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Website covering RCAD (Renal Cysts and Diabetes)</description>
    <body>&lt;![CDATA[ &lt;P&gt;GENETIC TYPES OF DIABETES INCLUDING MATURITY-ONSET DIABETES OF THE YOUNG (MODY)&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Diabetesgenes.org aims to provide information for patients and professionals on research and clinical care in genetic types of diabetes.&lt;/P&gt;
&lt;P&gt;This website is run by the Diabetes Research department and the Centre for Molecular Genetics at the Peninsula Medical School and Royal Devon and Exeter Hospital, Exeter, UK.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
    <expiryDate>03/11/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>333667</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=333667]]&gt;</url>
    <title>Diabetic Nephropathy: Systematic reviews and meta-analyses</title>
    <publicationDate>2011-02-18T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,NEPHROPATHY,CHRONIC COMPLICATIONS,DIAGNOSIS,CONDITION MANAGEMENT,CAUSES,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,PREDISPOSING FACTORS,DIABETES,INTERVENTIONS,DIABETIC METABOLIC CONTROL,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Diabetic Nephropathy: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2011&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Mooyaart AL, Valk EJ, van Es LA, Bruijn JA, de Heer E, Freedman BI, et al. Genetic associations in diabetic nephropathy: a meta-analysis. Diabetologia. 2011;54(3):544-53. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/21127830" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Alavian, S. M. and S. V. Tabatabaei "The effect of diabetes mellitus on immunological response to hepatitis B virus vaccine in individuals with chronic kidney disease: A meta-analysis of current literature." Vaccine 28(22): 3773-7. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=The%20effect%20of%20diabetes%20mellitus%20on%20immunological%20response%20to%20hepatitis%20B%20virus%20vaccine%20in%20individuals%20with%20chronic%20kidney%20disease%3A%20A%20meta-analysis%20of%20current%20literature" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Athyros, V. G., K. Tziomalos, et al. "Atorvastatin: safety and tolerability." Expert Opinion on Drug Safety 9(4): 667-74.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20553090" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Crasto, W., L. J. Gray, et al. (2010). "Systematic review and meta-analysis examining the prevalence of diabetic nephropathy in South Asians and white Europeans with type 2 diabetes." Diabetic Medicine 27(2 SUPPL. 1).&amp;nbsp;[No&amp;nbsp;abstract available]&lt;/LI&gt;
&lt;LI&gt;Cui, W. P., B. Du, et al. (2010). "Statins for early diabetic kidney disease: A systematic review." Chinese Journal of Evidence-Based Medicine 10(1): 81-88.&amp;nbsp;[No abstract available]&lt;/LI&gt;
&lt;LI&gt;Hakim, F. A. and A. Pflueger "Role of oxidative stress in diabetic kidney disease." Med Sci Monit 16(2): RA37-48. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20110930" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hills, C. E. and P. E. Squires (2010). "TGF-beta1-induced epithelial-to-mesenchymal transition and therapeutic intervention in diabetic nephropathy." American Journal of Nephrology 31(1): 68-74.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=TGF-beta1-induced%20epithelial-to-mesenchymal%20transition%20and%20therapeutic%20intervention%20in%20diabetic%20nephropathy" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Li J, Wu HM, Zhang L, Zhu B, Dong BR. (2010) "Heparin and related substances for preventing diabetic kidney disease." Cochrane Database Syst Rev. 2010 Sep 8;9. [&lt;A href="nelh:387485:0" name=internalLink&gt;Link to Cochrane abstract&lt;/A&gt;].&lt;/LI&gt;
&lt;LI&gt;Li, M., W. Wang, et al. (2010). "Meta-analysis of the clinical value of Astragalus membranaceus in diabetic nephropathy." J Ethnopharmacol. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Meta-analysis%20of%20the%20clinical%20value%20of%20Astragalus%20membranaceus%20in%20diabetic%20nephropathy" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Long, X., F. Wang, et al. (2010). "Tongxinluo capsule for diabetic kidney disease: A systematic review." Chinese Journal of Evidence-Based Medicine 10(1): 73-80.&amp;nbsp;[No abstract available]&lt;/LI&gt;
&lt;LI&gt;McKnight, A. J., C. C. Patterson, et al. (2010). "Genetic polymorphisms in nitric oxide synthase 3 gene and implications for kidney disease: a meta-analysis." American Journal of Nephrology 32(5): 476-81. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20962522" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Patel, M., R. Fowkes, et al. (2010). "The impact of thiazolidinediones on microalbuminuria in adults with type 2 diabetes mellitus: A systematic review." Endocrine Abstracts 21.&amp;nbsp;[No abstract available]&lt;/LI&gt;
&lt;LI&gt;Salpeter, S. R., E. Greyber, et al. (2010). "Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus." Cochrane Database of Systematic Reviews(4): CD002967-NaN.&amp;nbsp;[&lt;A href="http://www.library.nhs.uk/Diabetes/ViewResource.aspx?resID=237955&amp;amp;tabID=289" target="_blank"&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Sarafidis, P. A., P. C. Stafylas, et al. "Effect of Thiazolidinediones on Albuminuria and Proteinuria in Diabetes: A Meta-analysis." Am J Kidney Dis. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20110146" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Suckling, R. J., F. J. He, et al. (2010). "Altered dietary salt intake for preventing and treating diabetic kidney disease." Cochrane Database Syst Rev 12: CD006763. [&lt;A href="nelh:396825:0" name=internalLink&gt;Link to Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Wang H, Deng JL, Yue J, Li J, Hou YB. Prostaglandin E1 for preventing the progression of diabetic kidney disease. Cochrane Database of Systematic Reviews 2010, Issue 5. Art. No.: CD006872. DOI: 10.1002/14651858.CD006872.pub2. [&lt;A href="nelh:374522:0" name=internalLink&gt;Link to Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Zeng, Z., L. Li, et al. (2010) "A meta-analysis of three polymorphisms in the endothelial nitric oxide synthase gene (NOS3) and their effect on the risk of diabetic nephropathy." Human Genetics 127(4): 373-81. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20049477" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Magee, G. M., R. W. Bilous, et al. (2009). "Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis." Diabetologia 52(4): 691-7.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19198800" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Wang, F., G. G. Wang, et al. (2009). "Sodium ferulate for diabetic kidney disease: A systematic review." Chinese Journal of Evidence-Based Medicine 9(6): 652-669.&amp;nbsp;[No abstract available]&lt;/LI&gt;
&lt;LI&gt;Wang, F. and H. M. Wu (2009). "Xuezhikang for diabetic kidney disease: A systematic review of randomized controlled trials." Chinese Journal of Evidence-Based Medicine 9(1): 63-70..&amp;nbsp;[No abstract available]&lt;/LI&gt;
&lt;LI&gt;Wang, H., G. L. Zhang, et al. (2009). "Spironolactone for diabetic nephropathy: A systematic review." Chinese Journal of Evidence-Based Medicine 9(1): 71-75.&amp;nbsp;[No abstract available]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Fabrizi, F., P. Messa, et al. (2008). "Hepatitis C virus infection and post-transplant diabetes mellitus among renal transplant patients: a meta-analysis." Int J Artif Organs 31(8): 675-82.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18825640" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;McCormick, B. B., A. Sydor, et al. (2008). "The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis." Am J Kidney Dis 52(3): 454-63.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18433957" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Ng, D. P., B. C. Tai, et al. (2008). "Is the presence of retinopathy of practical value in defining cases of diabetic nephropathy in genetic association studies? The experience with the ACE insertion/deletion polymorphism in 53 studies comprising 17,791 subjects." Diabetes 57(9): 2541-6.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18523141" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Pan, Y., L. L. Guo, et al. (2008). "Low-protein diet for diabetic nephropathy: a meta-analysis of randomized controlled trials." Am J Clin Nutr 88(3): 660-6.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18779281" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Sarafidis, P. A., P. C. Stafylas, et al. (2008). "Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis." Am J Hypertens 21(8): 922-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18535536" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Jennings, D. L., J. S. Kalus, et al. (2007). "Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis." Diabet Med 24(5): 486-93.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17367311" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Nelson, R. G. and K. R. Tuttle (2007). "The new KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and CKD." Blood Purif 25(1): 112-4. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17170547" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Robertson, L., N. Waugh, et al. (2007). "Protein restriction for diabetic renal disease." Cochrane Database Syst Rev(4): CD002181.&amp;nbsp;[&lt;A href="nelh:237541:0" name=internalLink&gt;Link to Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2006&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Strippoli, G. F., C. Bonifati, et al. (2006). "Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease." Cochrane Database Syst Rev(4): CD006257. [&lt;A href="nelh:239226:0" name=internalLink&gt;Link to Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>26/11/2010 15:25:42</lastReviewDate>
    <expiryDate>26/11/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>290663</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.nelm.nhs.uk/en/NeLM-Area/News/2008---July/22/Diagnosis-and-treatment-of-coronary-artery-disease-in-patients-with-chronic-kidney-disease/]]&gt;</url>
    <title>Diagnosis and treatment of coronary artery disease in patients with chronic kidney disease</title>
    <publicationDate>2008-07-22T00:00:00</publicationDate>
    <publisher>Heart 2008; 94:1080 -1088</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ COMPLICATIONS OF KIDNEY DISEASE,CARDIOVASCULAR DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Abstract from National electronic Library for Medicines</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Extract from article&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;This article presents&amp;nbsp; the current available evidence regarding both medical and interventional management&amp;nbsp; strategies for coronary artery disease (CAD) in patients with chronic kidney disease (CKD), focusing on patients with stage IV–V renal failure (glomerular filtration rate (GFR) &amp;lt;15 ml/min). &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>01/07/2010 14:55:03</lastReviewDate>
    <expiryDate>01/07/2011 14:55:03</expiryDate>
  </document>
  <document>
    <id>290668</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.mhra.gov.uk/Safetyinformation/Generalsafetyinformationandadvice/Product-specificinformationandadvice/Dialysis/index.htm]]&gt;</url>
    <title>Dialysis</title>
    <publicationDate>2008-07-16T00:00:00</publicationDate>
    <publisher>MHRA</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ PERITONEAL DIALYSIS,HAEMODIALYSIS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES,DIALYSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Information and advice page from the Medicines and Healthcare products Regulatory Agency (MHRA)</description>
    <body>&lt;![CDATA[ Web page includes background information on haemodialysis and peritoneal dialysis, incident reports for 2007 (with a link to medical device alerts issued before 2007) and generic issues.]]&gt;</body>
    <lastReviewDate>01/07/2010 14:55:12</lastReviewDate>
    <expiryDate>01/07/2011 14:55:12</expiryDate>
  </document>
  <document>
    <id>389325</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.kidneycare.nhs.uk/_Ourworkprogrammes-Renalreplacementtherapies-Dialysiscapacitysurvey.aspx]]&gt;</url>
    <title>Dialysis Capacity Survey</title>
    <publicationDate>2010-10-01T00:00:00</publicationDate>
    <publisher>NHS Kidney Care</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES,DIALYSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This project aims to capture the national profile of dialysis services across England, to help ensure that kidney services can be prioritised at a national level.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;What does this project aim to achieve?&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;This project aims to capture the national profile of dialysis services across England, to help ensure that kidney services can be prioritised at a national level.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;STRONG&gt;How is this being achieved?&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;NHS Kidney Care is working with local kidney care networks to gather information about kidney services in England. A spreadsheet (Excel 29KB) has been developed in collaboration with the Renal Association, which will capture the current provision of service, as well as the capacity available nationally. It requests information about current patients and capacity (at 30 September 2009), as well as plans for expansion between 2009/10 and 2014/15. Each local network has been asked to complete the spreadsheet, so that a national profile can be compiled.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The national profile is expected to be complete in Spring 2010.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;STRONG&gt;What are the key deliverables?&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Once the national profile has been developed, it will be shared with all renal clinical directors in England, for use in discussions with local commissioners.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Dialysis Capacity Survey Results&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;BR&gt;&lt;A href="http://www.kidneycare.nhs.uk/Library/DialysisCapacitySurvey2009_Results_Sept2010.pdf" target="_blank"&gt;Download the results from the first Dialysis Capacity Survey&lt;/A&gt;&amp;nbsp;(Link to full-text PDF)&lt;/P&gt;]]&gt;</body>
    <expiryDate>06/10/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>333679</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=333679]]&gt;</url>
    <title>Dialysis: Systematic reviews and meta-analyses</title>
    <publicationDate>2011-03-01T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,HAEMODIALYSIS,KIDNEY DISEASES,DIALYSIS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Dialysis: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Alavian, S. M. and S. V. Tabatabaeir. (2010). "Effects of oral levamisole as an adjuvant to hepatitis B vaccine in adults with end-stage renal disease: a meta-analysis of controlled clinical trials." Clin Ther 32(1): 1-10. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20171406" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Assimon, M. M., S. Mousa, et al. (2010)&amp;nbsp;"The effect of sevelamer hydrochloride and calcium-based phosphate binders on mortality in hemodialysis patients: a need for more research." Consultant Pharmacist 25(1): 41-54. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20211816" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Bennett, P. N., L. Breugelmans, et al. (2010). "Sustaining a hemodialysis exercise program: a review." Seminars in Dialysis 23(1): 62-73. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Sustaining%20a%20hemodialysis%20exercise%20program%3A%20a%20review" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Browne, T., J.R. Merighi. (2010) "Barriers to adult hemodialysis patients' self-management of oral medications." Am J Kidney Dis Sep;56(3):547-57. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20430501" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Casey, E. T., B. P. Gupta, et al. (2010) "The dose of continuous renal replacement therapy for acute renal failure: a systematic review and meta-analysis." Renal Failure 32(5): 555-61.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=The%20dose%20of%20continuous%20renal%20replacement%20therapy%20for%20acute%20renal%20failure%3A%20a%20systematic%20review%20and%20meta-analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Chua, D., A. Lo, et al. (2010). "Spironolactone use in heart failure patients with end-stage renal disease on hemodialysis: is it safe?" Clin Cardiol 33(10): 604-8. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Spironolactone%20use%20in%20heart%20failure%20patients%20with%20end-stage%20renal%20disease%20on%20hemodialysis%3A%20is%20it%20safe%3F" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Coleman, C. I., L. A. Tuttle, et al. (2010). "Antiplatelet agents for the prevention of arteriovenous fistula and graft thrombosis: A meta analysis." International Journal of Clinical Practice 64(9): 1239-1244. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20455955" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Danquah, F. V. N., J. Wasserman, et al. (2010). "Quality of life measures for patients on hemodialysis: a review of psychometric properties." Nephrology Nursing Journal 37(3): 255-271.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Quality%20of%20life%20measures%20for%20patients%20on%20hemodialysis%3A%20a%20review%20of%20psychometric%20properties" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Fabrizi, F., V. Dixit, et al. (2010) "Pegylated interferon monotherapy of chronic hepatitis C in dialysis patients: Meta-analysis of clinical trials." Journal of Medical Virology 82(5): 768-75. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20336712" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Fabrizi, F., V. Dixit, et al. (2010). "Meta-analysis: Levamisole improves the immune response to hepatitis B vaccine in dialysis patients." Alimentary Pharmacology and Therapeutics 32(6): 756-762.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20662784" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Fortin PM, Bassett K, Musini VM. Human albumin for intradialytic hypotension in haemodialysis patients. Cochrane Database of Systematic Reviews 2010, Issue 11. Art. No.: CD006758. DOI: 10.1002/14651858.CD006758.pub2. [&lt;A href="nelh:393857:0" name=internalLink&gt;Link to Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Herselman, M., N. Esau, et al. (2010)&amp;nbsp;"Relationship between serum protein and mortality in adults on long-term hemodialysis: exhaustive review and meta-analysis." Nutrition 26(1): 10-32.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20005464" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Herselman, M., Esau, N., Kruger, J.-M., Labadarios, D., Moosa, M.R. (2010) "Relationship between Body Mass Index and Mortality in Adults on Maintenance Hemodialysis: A Systematic Review". Journal of Renal Nutrition. 20(5) pp.281-292.e7. [&lt;A href="http://www.jrnjournal.org/article/PIIS1051227610000816/abstract?rss=yes" target="_blank"&gt;Link to Journal abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Johansen, K. L., F. O. Finkelstein, et al. "Systematic Review and Meta-analysis of Exercise Tolerance and Physical Functioning in Dialysis Patients Treated With Erythropoiesis-Stimulating Agents." Am J Kidney Dis. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20133033" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Jun, M., H. J. Heerspink, et al. "Intensities of renal replacement therapy in acute kidney injury: a systematic review and meta-analysis." Clinical Journal of The American Society of Nephrology: CJASN 5(6): 956-63.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Intensities%20of%20renal%20replacement%20therapy%20in%20acute%20kidney%20injury%3A%20a%20systematic%20review%20and%20meta-analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Khalil, A. A. and S. K. Frazier. (2010)&amp;nbsp;"Depressive symptoms and dietary nonadherence in patients with end-stage renal disease receiving hemodialysis: a review of quantitative evidence." Issues in Mental Health Nursing 31(5): 324-30.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20394478" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kian, K. and A. Asif (2010). "Status of research in vascular access for dialysis." Nephrology Dialysis Transplantation 25(11): 3682-6. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Status%20of%20research%20in%20vascular%20access%20for%20dialysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Landreneau, K., K. Lee, et al. (2010). "Quality of life in patients undergoing hemodialysis and renal transplantation--a meta-analytic review." Nephrology Nursing Journal: Journal of the American Nephrology Nurses' Association 37(1): 37-44.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Quality%20of%20life%20in%20patients%20undergoing%20hemodialysis%20and%20renal%20transplantation--a%20meta-analytic%20review" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Matteson, M. L. and C. Russell (2010). "Interventions to improve hemodialysis adherence: A systematic review of randomized-controlled trials." Hemodialysis International 14(4): 370-82. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Interventions%20to%20improve%20hemodialysis%20adherence%3A%20A%20systematic%20review%20of%20randomized-controlled%20trials" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;McCann, M. and Z. E. Moore "Interventions for preventing infectious complications in haemodialysis patients with central venous catheters." Cochrane Database Syst Rev(1): CD006894. [&lt;A href="nelh:341736:0" name=internalLink&gt;Link to Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Morton, R. L., A. Tong, et al. "The views of patients and carers in treatment decision making for chronic kidney disease: systematic review and thematic synthesis of qualitative studies." BMJ 340: c112. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20085970" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Oudemans-van Straaten, H. M. "Citrate anticoagulation for continuous renal replacement therapy in the critically ill." Blood Purif 29(2): 191-6. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20093826" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Piccoli, G. B., A. Conijn, et al. (2010). "Pregnancy in dialysis patients: is the evidence strong enough to lead us to change our counseling policy?" Clinical Journal of The American Society of Nephrology: CJASN 5(1): 62-71.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Pregnancy%20in%20dialysis%20patients%3A%20is%20the%20evidence%20strong%20enough%20to%20lead%20us%20to%20change%20our%20counseling%20policy%3F" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;San Miguel, S. (2010). "Haemodialysis dry weight assessment: a literature review." Renal Society of Australasia Journal 6(1): 19-25.&amp;nbsp;[No abstract available]&lt;/LI&gt;
&lt;LI&gt;Segura-Orti, E. "[Exercise in hemodyalisis patients: a literature systematic review.]." Nefrologia. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20098466" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Simpson, R., R. N. Doughty, et al. (2010). "Systematic review of the impact of renal replacement therapy on left ventricular mass." Heart Lung and Circulation 19. [No PubMed abstract available]&lt;/LI&gt;
&lt;LI&gt;Song, K., S. Jiang, et al. (2010). "Renal Replacement Therapy for Prevention of Contrast-Induced Acute Kidney Injury: A Meta-Analysis of Randomized Controlled Trials." Am J Nephrol 32(5): 497-504. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Renal%20Replacement%20Therapy%20for%20Prevention%20of%20Contrast-Induced%20Acute%20Kidney%20Injury%3A%20A%20Meta-Analysis%20of%20Randomized%20Controlled%20Trials" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Tai, D. J., T. W. Lim, et al. "Cardiovascular Effects of Angiotensin Converting Enzyme Inhibition or Angiotensin Receptor Blockade in Hemodialysis: A Meta-Analysis." Clin J Am Soc Nephrol. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20133488" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Tordoir, J. H., M. M. van Loon, et al. "Surgical Techniques to Improve Cannulation of Hemodialysis Vascular Access." Eur J Vasc Endovasc Surg.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20060754" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Van Wert, R., J. O. Friedrich, et al. (2010) "High-dose renal replacement therapy for acute kidney injury: Systematic review and meta-analysis." Critical Care Medicine 38(5): 1360-9. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20308884" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Wang, C., J. Sun, et al. (2010). "Hepatitis B virus infection and related factors in hemodialysis patients in China systematic review and meta-analysis." Renal Failure 32(10): 1255-1264.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20954991" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Zhang, Q., M. Li, et al. (2010). "Meta-analysis comparing sevelamer and calcium-based phosphate binders on cardiovascular calcification in hemodialysis patients." Nephron - Clinical Practice 115(4): c259-c267.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20424476" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Agarwal, R. and A. D. Sinha (2009). "Cardiovascular protection with antihypertensive drugs in dialysis patients: systematic review and meta-analysis." Hypertension 53(5): 860-6. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19273737" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Antoniou, G. A., M. K. Lazarides, et al. (2009). "Lower-extremity arteriovenous access for haemodialysis: a systematic review." Eur J Vasc Endovasc Surg 38(3): 365-72.&amp;nbsp;[&lt;A href="nelh:360121:0" name=internalLink&gt;Link to&amp;nbsp;DARE abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Athappan, G. and T. Ponniah (2009). "Clinical outcomes of dialysis patients after implantation of DES: meta analysis and systematic review of literature." Minerva Cardioangiol 57(3): 291-7.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19513010" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Deved, V., P. Poyah, et al. (2009). "Ascorbic Acid for Anemia Management in Hemodialysis Patients: A Systematic Review and Meta-analysis." American Journal of Kidney Diseases 54(6): 1089-1097.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19783342" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Faber, P. and A. A. Klein (2009). "Acute kidney injury and renal replacement therapy in the intensive care unit." Nurs Crit Care 14(4): 207-12.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19531039" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Fram, D. S., M. Taminato, et al. (2009). "Prevention of catheter-related bloodstream infections in patients on hemodialysis [Portuguese]." Acta Paulista de Enfermagem 22: 564-569.&amp;nbsp;[No abstract available]&lt;/LI&gt;
&lt;LI&gt;Glass, C., M. Johansson, et al. (2009). "A meta-analysis of preoperative duplex ultrasound vessel diameters for successful radiocephalic fistula placement." Journal for Vascular Ultrasound 33(2): 65-68.&amp;nbsp;[No abstract available]&lt;/LI&gt;
&lt;LI&gt;Haiyang, Z. and X. Chenggang (2009). "Comparison of intermittent intravenous and oral calcitriol in the treatment of secondary hyperparathyroidism in chronic hemodialysis patients: a meta-analysis of randomized controlled trials." Clin Nephrol 71(3): 276-85.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19281738" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Heerspink, H. J., T. Ninomiya, et al. (2009). "Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials." Lancet 373(9668): 1009-15.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19249092" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Heintz, B. H., G. R. Matzke, et al. (2009). "Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis." Pharmacotherapy 29(5): 562-77.&amp;nbsp;[&lt;A href="https://rmsadmin.library.nhs.uk/admin/wizards/articles/Antimicrobial%20dosing%20concepts%20and%20recommendations%20for%20critically%20ill%20adult%20patients%20receiving%20continuous%20renal%20replacement%20therapy%20or%20intermittent%20hemodialysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Heinz, J., S. Kropf, et al. (2009). "Homocysteine as a Risk Factor for Cardiovascular Disease in Patients Treated by Dialysis: A Meta-analysis." Am J Kidney Dis.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19359080" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hiremath, S., R. M. Holden, et al. (2009). "Antiplatelet Medications in Hemodialysis Patients: A Systematic Review of Bleeding Rates." Clin J Am Soc Nephrol.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19578002" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hosseini Moghaddam, S. M., S. M. Alavian, et al. (2009). "Therapeutic aspects of hepatitis C in hemodialysis patients." Am J Nephrol 29(2): 123-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18719345" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Leung, A. K. and W. W. Yan (2009). "Renal replacement therapy in critically ill patients." Hong Kong Med J 15(2): 122-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19342738" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mendelssohn, D. C., C. Malmberg, et al. (2009). "An integrated review of "unplanned" dialysis initiation: reframing the terminology to "suboptimal" initiation." BMC Nephrol 10: 22.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19674452" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Moriyama, B., S. A. Henning, et al. (2009). "Continuous-infusion beta-lactam antibiotics during continuous venovenous hemofiltration for the treatment of resistant gram-negative bacteria." Ann Pharmacother 43(7): 1324-37.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19584386" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Navaneethan, S. D., S. U. Nigwekar, et al. (2009). "HMG CoA reductase inhibitors (statins) for dialysis patients." Cochrane Database Syst Rev(3): CD004289.&amp;nbsp;[&lt;A href="nelh:238565:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Nevis, I. F., A. Mathew, et al. (2009). "Optimal method of coronary revascularization in patients receiving dialysis: systematic review." Clin J Am Soc Nephrol 4(2): 369-78.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19218473" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Piccoli, G. B., A. Conijn, et al. (2009). "Pregnancy in Dialysis Patients: Is the Evidence Strong Enough to Lead Us to Change Our Counseling Policy?" Clin J Am Soc Nephrol.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19965547" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Rabindranath, K. S., T. Bansal, et al. (2009). "Systematic review of antimicrobials for the prevention of haemodialysis catheter-related infections." Nephrol Dial Transplant 24(12): 3763-74.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19592599" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Sakhuja, R., M. Keebler, et al. (2009). "Meta-analysis of mortality in dialysis patients with an implantable cardioverter defibrillator." Am J Cardiol 103(5): 735-41.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19231344" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Scheltinga, M. R., F. van Hoek, et al. (2009). "Time of onset in haemodialysis access-induced distal ischaemia (HAIDI) is related to the access type." Nephrol Dial Transplant 24(10): 3198-204. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19403932" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Schmid, H., B. Hartmann, et al. (2009). "Adherence to prescribed oral medication in adult patients undergoing chronic hemodialysis: a critical review of the literature." Eur J Med Res 14(5): 185-90.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19541573" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Sigrist, M. K., A. Levin, et al. (2009). "Systematic Review of Evidence for the Use of Intradialytic Parenteral Nutrition in Malnourished Hemodialysis Patients." J Ren Nutr.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19788956" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Thanacoody, R. H. (2009). "Extracorporeal elimination in acute valproic acid poisoning." Clin Toxicol (Phila) 47(7): 609-16.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19656009" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Tillman, J. (2009). "Heparin versus citrate for anticoagulation in critically ill patients treated with continuous renal replacement therapy." Nurs Crit Care 14(4): 191-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19531037" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Tonelli, M., N. Wiebe, et al. (2009). "Trace elements in hemodialysis patients: a systematic review and meta-analysis." BMC Med 7: 25.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19454005" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Tordoir, J. H., A. S. Bode, et al. (2009). "Surgical or endovascular repair of thrombosed dialysis vascular access: is there any evidence?" J Vasc Surg 50(4): 953-6.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19786244" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Voormolen, E. H., A. K. Jahrome, et al. (2009). "Nonmaturation of arm arteriovenous fistulas for hemodialysis access: A systematic review of risk factors and results of early treatment." J Vasc Surg 49(5): 1325-36.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19394557" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Wetmore, J. B. and T. I. Shireman (2009). "The ABCs of cardioprotection in dialysis patients: a systematic review." Am J Kidney Dis 53(3): 457-66.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19022545" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Zhou, H. and C. Xu (2009). "Comparison of intermittent intravenous and oral calcitriol in the treatment of secondary hyperparathyroidism in chronic hemodialysis patients: A meta-analysis of randomized controlled trials." Clinical Nephrology 71(3): 276-285.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19281738" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Alonso, A., J. Lau, et al. (2008). "Biocompatible hemodialysis membranes for acute renal failure." Cochrane Database Syst Rev(1): CD005283.&amp;nbsp;[&lt;A href="nelh:239188:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Casey, E. T., M. H. Murad, et al. (2008). "Surveillance of arteriovenous hemodialysis access: a systematic review and meta-analysis." J Vasc Surg 48(5 Suppl): 48S-54S.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19000593" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Fabrizi, F., V. Dixit, et al. (2008). "Interferon monotherapy of chronic hepatitis C in dialysis patients: meta-analysis of clinical trials." J Viral Hepat 15(2): 79-88.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18184190" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Frank, S. T., B. Krumm, et al. (2008). "Cocaine-induced dopamine overflow within the nucleus accumbens measured by in vivo microdialysis: a meta-analysis." Synapse 62(4): 243-52.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18236471" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Ghahramani, N., S. Shadrou, et al. (2008). "A systematic review of continuous renal replacement therapy and intermittent haemodialysis in management of patients with acute renal failure." Nephrology (Carlton) 13(7): 570-8.&amp;nbsp;[&lt;A href="nelh:342903:0" name=internalLink&gt;Link to&amp;nbsp;DARE abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Gordon, C. E., K. Uhlig, et al. (2008). "Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: a systematic review of the literature and meta-analysis of treatment efficacy and harms." Am J Kidney Dis 51(2): 263-77.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18215704" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Jaffer, Y., N. M. Selby, et al. (2008). "A meta-analysis of hemodialysis catheter locking solutions in the prevention of catheter-related infection." Am J Kidney Dis 51(2): 233-41.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18215701" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;James, M. T., J. Conley, et al. (2008). "Meta-analysis: antibiotics for prophylaxis against hemodialysis catheter-related infections." Ann Intern Med 148(8): 596-605.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18413621" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Just, P. M., M. C. Riella, et al. (2008). "Economic evaluations of dialysis treatment modalities." Health Policy 86(2-3): 163-80.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18243397" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Labriola, L., R. Crott, et al. (2008). "Preventing haemodialysis catheter-related bacteraemia with an antimicrobial lock solution: a meta-analysis of prospective randomized trials." Nephrol Dial Transplant 23(5): 1666-72.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18065789" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Liem, Y. S., J. L. Bosch, et al. (2008). "Preference-based quality of life of patients on renal replacement therapy: a systematic review and meta-analysis." Value Health 11(4): 733-41.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18194399" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lynch, K. E., H. I. Feldman, et al. (2008). "Effects of L-carnitine on dialysis-related hypotension and muscle cramps: a meta-analysis." Am J Kidney Dis 52(5): 962-71.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18706751" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Murad, M. H., M. B. Elamin, et al. (2008). "Autogenous versus prosthetic vascular access for hemodialysis: a systematic review and meta-analysis." J Vasc Surg 48(5 Suppl): 34S-47S.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19000592" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Pannu, N., S. Klarenbach, et al. (2008). "Renal replacement therapy in patients with acute renal failure: a systematic review." JAMA 299(7): 793-805.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18285591" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Punal, J., L. V. Lema, et al. (2008). "Clinical effectiveness and quality of life of conventional haemodialysis versus short daily haemodialysis: a systematic review." Nephrol Dial Transplant 23(8): 2634-46.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18390567" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Seabra, V. F., E. M. Balk, et al. (2008). "Timing of renal replacement therapy initiation in acute renal failure: a meta-analysis." Am J Kidney Dis 52(2): 272-84.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18562058" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Yahav, D., B. Rozen-Zvi, et al. (2008). "Antimicrobial lock solutions for the prevention of infections associated with intravascular catheters in patients undergoing hemodialysis: systematic review and meta-analysis of randomized, controlled trials." Clin Infect Dis 47(1): 83-93.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18498236" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Yarlagadda, S. G., S. G. Coca, et al. (2008). "Marked variation in the definition and diagnosis of delayed graft function: a systematic review." Nephrol Dial Transplant 23(9): 2995-3003.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18408075" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Barrio, V., C. Quereda, et al. (2007). "[Does continuous veno-venous hemodiafiltration therapy reduce mortality due to acute renal failure as compared to intermittent hemodialysis?]." Nefrologia 27 Suppl 1: 42-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17763635" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Elliott, M. J., D. Zimmerman, et al. (2007). "Warfarin anticoagulation in hemodialysis patients: a systematic review of bleeding rates." Am J Kidney Dis 50(3): 433-40.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17720522" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Fabrizi, F., B. Takkouche, et al. (2007). "The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies." J Viral Hepat 14(10): 697-703.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17875004" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Garside, R., M. Pitt, et al. (2007). "The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation." Health Technol Assess 11(18): iii, xi-xiii, 1-167.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17462168" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Jamal, S. A., J. A. Hayden, et al. (2007). "Low bone mineral density and fractures in long-term hemodialysis patients: a meta-analysis." Am J Kidney Dis 49(5): 674-81.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17472850" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Johnson, D. W., A. M. Craven, et al. (2007). "Modification of cardiovascular risk in hemodialysis patients: an evidence-based review." Hemodial Int 11(1): 1-14.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17257349" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lazarides, M. K., G. S. Georgiadis, et al. (2007). "A meta-analysis of dialysis access outcome in elderly patients." J Vasc Surg 45(2): 420-426.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17264030" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Liem, Y. S., J. L. Bosch, et al. (2007). "Quality of life assessed with the Medical Outcomes Study Short Form 36-Item Health Survey of patients on renal replacement therapy: a systematic review and meta-analysis." Value Health 10(5): 390-7.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17888104" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Navaneethan, S. D., G. Viswanathan, et al. (2007). "Choice of extracorporeal dialysis modality: can it be evidence based?" Minerva Urol Nefrol 59(3): 261-7.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17912223" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Rabindranath, K., J. Adams, et al. (2007). "Intermittent versus continuous renal replacement therapy for acute renal failure in adults." Cochrane Database Syst Rev(3): CD003773.&amp;nbsp;[&lt;A href="nelh:266499:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Tonelli, M., N. Wiebe, et al. (2007). "Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients." Nephrol Dial Transplant 22(10): 2856-66.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17906326" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2006&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Falagas, M. E., K. N. Fragoulis, et al. (2006). "Oral rifampin for prevention of S. aureus carriage-related infections in patients with renal failure--a meta-analysis of randomized controlled trials." Nephrol Dial Transplant 21(9): 2536-42.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16705024" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Rabindranath, K. S., G. F. Strippoli, et al. (2006). "Haemodiafiltration, haemofiltration and haemodialysis for end-stage kidney disease." Cochrane Database Syst Rev(4): CD006258.&amp;nbsp;[&lt;A href="nelh:239227:0" name=internalLink&gt;Link to Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>26/11/2010 15:25:46</lastReviewDate>
    <expiryDate>26/11/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>388051</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=388051]]&gt;</url>
    <title>Diet, nutrition and kidney diseases: Systematic reviews and meta-analyses</title>
    <publicationDate>2010-09-20T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ INTERVENTIONS,DIETARY CHANGE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Diet, nutrition and kidney diseases: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Afshinnia, F., T. J. Wilt, et al. (2010). "Weight loss and proteinuria: Systematic review of clinical trials and comparative cohorts." Nephrology Dialysis Transplantation 25(4): 1173-1183. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Weight%20loss%20and%20proteinuria%3A%20Systematic%20review%20of%20clinical%20trials%20and%20comparative%20cohorts" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Herselman, M., N. Esau, et al. "Relationship between serum protein and mortality in adults on long-term hemodialysis: exhaustive review and meta-analysis." Nutrition 26(1): 10-32.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Relationship%20between%20serum%20protein%20and%20mortality%20in%20adults%20on%20long-term%20hemodialysis%3A%20exhaustive%20review%20and%20meta-analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Khalil, A. A. and S. K. Frazier "Depressive symptoms and dietary nonadherence in patients with end-stage renal disease receiving hemodialysis: a review of quantitative evidence." Issues in Mental Health Nursing 31(5): 324-30.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Depressive%20symptoms%20and%20dietary%20nonadherence%20in%20patients%20with%20end-stage%20renal%20disease%20receiving%20hemodialysis%3A%20a%20review%20of%20quantitative%20evidence" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Li, Y., X. Tang, et al. (2010). "Nutritional support for acute kidney injury." Cochrane Database of Systematic Reviews(1): CD005426-NaN.&amp;nbsp;[&lt;A href="nelh:341717:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Marik, P. E. and J. C. Preiser "Toward understanding tight glycemic control in the ICU: a systematic review and metaanalysis." Chest 137(3): 544-51.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Toward%20understanding%20tight%20glycemic%20control%20in%20the%20ICU%3A%20a%20systematic%20review%20and%20metaanalysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Alexander, D. D. and C. A. Cushing (2009). "Quantitative assessment of red meat or processed meat consumption and kidney cancer." Cancer Detect Prev 32(5-6): 340-51.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Quantitative%20assessment%20of%20red%20meat%20or%20processed%20meat%20consumption%20and%20kidney%20cancer" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Fink, H. A., J. W. Akornor, et al. (2009). "Diet, Fluid, or Supplements for Secondary Prevention of Nephrolithiasis: A Systematic Review and Meta-Analysis of Randomized Trials." Eur Urol.&amp;nbsp;[&lt;A href="nelh:379387:0" name=internalLink&gt;Link to&amp;nbsp;DARE abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Fouque, D. and M. Laville (2009). "Low protein diets for chronic kidney disease in non diabetic adults." Cochrane Database Syst Rev(3): CD001892.&amp;nbsp;[&lt;A href="nelh:237154:0" name=internalLink&gt;Link to Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Fry, K., A. Patwardhan, et al. (2009). "Development of evidence-based guidelines for the nutritional management of adult kidney transplant recipients." J Ren Nutr 19(1): 101-4.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Development%20of%20evidence-based%20guidelines%20for%20the%20nutritional%20management%20of%20adult%20kidney%20transplant%20recipients" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Miller, E. R., 3rd, S. P. Juraschek, et al. (2009). "The effect of n-3 long-chain polyunsaturated fatty acid supplementation on urine protein excretion and kidney function: meta-analysis of clinical trials." Am J Clin Nutr 89(6): 1937-45.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=The%20effect%20of%20n-3%20long-chain%20polyunsaturated%20fatty%20acid%20supplementation%20on%20urine%20protein%20excretion%20and%20kidney%20function%3A%20meta-analysis%20of%20clinical%20trials" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Navaneethan, S. D., H. Yehnert, et al. (2009). "Weight loss interventions in chronic kidney disease: a systematic review and meta-analysis." Clin J Am Soc Nephrol 4(10): 1565-74.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Weight%20loss%20interventions%20in%20chronic%20kidney%20disease%3A%20a%20systematic%20review%20and%20meta-analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Sigrist, M. K., A. Levin, et al. (2009). "Systematic Review of Evidence for the Use of Intradialytic Parenteral Nutrition in Malnourished Hemodialysis Patients." J Ren Nutr.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Systematic%20Review%20of%20Evidence%20for%20the%20Use%20of%20Intradialytic%20Parenteral%20Nutrition%20in%20Malnourished%20Hemodialysis%20Patients" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Heaney, R. P. (2008). "Calcium supplementation and incident kidney stone risk: a systematic review." J Am Coll Nutr 27(5): 519-27.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Calcium%20supplementation%20and%20incident%20kidney%20stone%20risk%3A%20a%20systematic%20review" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Pan, Y., L. L. Guo, et al. (2008). "Low-protein diet for diabetic nephropathy: a meta-analysis of randomized controlled trials." Am J Clin Nutr 88(3): 660-6.&amp;nbsp;[&lt;A href="nelh:331780:0" name=internalLink&gt;Link to DARE abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Rozen-Zvi, B., A. Gafter-Gvili, et al. (2008). "Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis." Am J Kidney Dis 52(5): 897-906.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Intravenous%20versus%20oral%20iron%20supplementation%20for%20the%20treatment%20of%20anemia%20in%20CKD%3A%20systematic%20review%20and%20meta-analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Wang, Y., X. Chen, et al. (2008). "Association between obesity and kidney disease: a systematic review and meta-analysis." Kidney Int 73(1): 19-33.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Association%20between%20obesity%20and%20kidney%20disease%3A%20a%20systematic%20review%20and%20meta-analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Chaturvedi, S. and C. Jones (2007). "Protein restriction for children with chronic kidney disease." Cochrane Database Syst Rev(4): CD006863.&amp;nbsp;[&lt;A href="nelh:270967:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Faramawi, M. F., E. Johnson, et al. (2007). "Consumption of different types of meat and the risk of renal cancer: meta-analysis of case-control studies." Cancer Causes Control 18(2): 125-33.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Consumption%20of%20different%20types%20of%20meat%20and%20the%20risk%20of%20renal%20cancer%3A%20meta-analysis%20of%20case-control%20studies" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Robertson, L., N. Waugh, et al. (2007). "Protein restriction for diabetic renal disease." Cochrane Database Syst Rev(4): CD002181.&amp;nbsp;[&lt;A href="nelh:237541:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <expiryDate>20/09/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>294833</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://bmb.oxfordjournals.org/cgi/reprint/73-74/1/35]]&gt;</url>
    <title>Dilemmas in the management of renal artery stenosis</title>
    <publicationDate>2005-09-07T00:00:00</publicationDate>
    <publisher>British Medical Bulletin 2005 73-74(1) 35-55</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RENOVASCULAR DISEASES,IN ADULTS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Contents of article:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;vigorous&lt;SUP&gt; &lt;/SUP&gt;control of hypertension and hyperlipidemia, &lt;/LI&gt;
&lt;LI&gt;use of antiplatelet&lt;SUP&gt; &lt;/SUP&gt;agents, &lt;/LI&gt;
&lt;LI&gt;cessation of smoking and lifestyle modification including&lt;SUP&gt; &lt;/SUP&gt;reduced dietary intake of salt and increased exercise. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Outcomes: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Specific&lt;SUP&gt; &lt;/SUP&gt;considerations include statins and antihypertensive therapy.&lt;/LI&gt;
&lt;LI&gt;Current evidence for renal revascularization &lt;/LI&gt;
&lt;LI&gt;Definite indications for renal revascularization &lt;/LI&gt;
&lt;LI&gt;Prognosis for patients with Atherosclerotic renovascular disease &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;FONT size=+1&gt;&lt;BR&gt;&lt;/FONT&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>25/08/2010 12:30:12</lastReviewDate>
    <expiryDate>25/08/2011 12:30:12</expiryDate>
  </document>
  <document>
    <id>155938</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.kidney.org.uk/Medical-Info/other/discontinuing-treatment.html]]&gt;</url>
    <title>Discontinuing treatment: key issues and ethical dilemmas</title>
    <publicationDate>2009-04-26T00:00:00</publicationDate>
    <publisher>National Kidney Federation</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ END-OF-LIFE CARE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Article about developing renal palliative care services, and taking forward the NSF end of life module.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Extract from website&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Stopping dialysis presents health care professionals with both a unique opportunity and an important challenge in the care of their patients. Between 12 and 18% of patients may choose to stop dialysis as the burden of symptoms from co-morbidity, the presence of other life threatening illness or the burden of dialysis comes to outweigh its benefits. Key areas for consideration at this time include:&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Effective communication both between health care professionals and the patient and family and also between professionals themselves 
&lt;LI&gt;Making sure reversible factors are excluded 
&lt;LI&gt;The use of advance directives 
&lt;LI&gt;Ensuring that patients have capacity to make decisions 
&lt;LI&gt;The involvement and support to family or other carers as the decision is made. &lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>25/08/2010 12:30:20</lastReviewDate>
    <expiryDate>25/08/2011 12:30:20</expiryDate>
  </document>
  <document>
    <id>156030</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.emrn.org.uk/documents/Report%20Service%20Implementation%20Renal%20DOAS301205.pdf]]&gt;</url>
    <title>Do Once and Share (DOAS) Renal Action Team Final Report</title>
    <publicationDate>2005-12-30T00:00:00</publicationDate>
    <publisher>NHS Connecting for Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ ASSESSMENT OF RENAL FUNCTION,PRESENTATION OF CKD,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Report of the Do Once and Share Initiative</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Develop a systematic approach to renal disease across primary and secondary care to help join up expertise and to reduce variation in care making the best the norm. &lt;/LI&gt;
&lt;LI&gt;To reduce unknowing duplication and create national consistency, with local sustainability&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Contents&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Background&lt;/LI&gt;
&lt;LI&gt;Project Objectives&lt;/LI&gt;
&lt;LI&gt;SHA Executive Summary&lt;/LI&gt;
&lt;LI&gt;Detailed report on work within Scope&lt;/LI&gt;
&lt;LI&gt;Update on project constraints and risks&lt;/LI&gt;
&lt;LI&gt;Details of any contingencies implemented&lt;/LI&gt;
&lt;LI&gt;Deliverables&lt;/LI&gt;
&lt;LI&gt;Additional Information and recommendations&lt;/LI&gt;
&lt;LI&gt;Clinical Lead comments and conclusions&lt;/LI&gt;
&lt;LI&gt;DOAS Programme Comments&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:24:31</lastReviewDate>
    <expiryDate>06/07/2011 11:24:31</expiryDate>
  </document>
  <document>
    <id>177594</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.annals.org/cgi/reprint/145/2/147.pdf]]&gt;</url>
    <title>Do statins protect the kidney by reducing proteinuria?</title>
    <publicationDate>2006-07-18T00:00:00</publicationDate>
    <publisher>Annals of Internal Medicine</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ CHOLESTEROL REDUCTION,INTERVENTIONS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Editorial by M. Tonelli from Annals of Internal Medicine</description>
    <body>&lt;![CDATA[ A review of current evidence.]]&gt;</body>
    <lastReviewDate>25/08/2010 12:30:47</lastReviewDate>
    <expiryDate>25/08/2011 12:30:47</expiryDate>
  </document>
  <document>
    <id>177756</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.dopps.org/doppsSitemap.aspx]]&gt;</url>
    <title>DOPPS SiteMap</title>
    <publicationDate>2009-10-05T00:00:00</publicationDate>
    <publisher>Arbor Research Collaborative for Health</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DOPPS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Structure of Dialysis Outcomes and Practice Patterns Study (DOPPS)</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Overview of structure of DOPPS - research, people and resources&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;The DOPPS is coordinated by the Arbor Research Collaborative for Health in collaboration with investigators in each of the DOPPS countries (Australia, Belgium, Canada, France, Germany, Italy, Japan, New Zealand, Spain, Sweden, the United Kingdom, and the United States).&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:24:35</lastReviewDate>
    <expiryDate>06/07/2011 11:24:35</expiryDate>
  </document>
  <document>
    <id>283593</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_083968]]&gt;</url>
    <title>Driving Service Improvement through Patient Focus</title>
    <publicationDate>2008-04-07T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ NATIONAL SERVICE FRAMEWORK FOR RENAL SERVICES/POLICY DOCUMENTS,ACUTE KIDNEY INJURY,KIDNEY DISEASE IN CHILDREN AND ADOLESCENTS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Report of the Phase II Renal Action Learning Sets 2006-2007 and supporting information</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Extract&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P class=introText&gt;Following the success of the first renal action learning sets, the Department of Health commissioned a second phase of this programme comprising six sets which ran from October 2006 to October 2007. These sets focussed on three areas of service improvement using action learning: the pre-dialysis year; transition from paediatric to adult services and acute renal failure. The final report covers the methods used by the sets, and the learning that they gained over the year. It is supported by a pack of detailed supporting information.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>08/03/2011 09:56:34</lastReviewDate>
    <expiryDate>08/03/2012 09:56:34</expiryDate>
  </document>
  <document>
    <id>155685</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.southasian.org.uk/organdonation_renalfailure2004.html]]&gt;</url>
    <title>Early management of renal failure: prevention or prevarication</title>
    <publicationDate>2004-06-18T00:00:00</publicationDate>
    <publisher>South Asian Development Partnership</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ PREDISPOSING FACTORS,SCREENING OPTIONS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Second National Symposium, British Library June 2004</description>
    <body>&lt;![CDATA[ &lt;P&gt;Symposium covering main concerns of south asian communities with regard to early detection of renal failure.&lt;/P&gt;
&lt;P&gt;The Symposium was divided into 3 sessions - Identifying the problem, Experiencing the problem, and Solving the problem.&lt;/P&gt;
&lt;P&gt;Identifying the problem- Opening speech, epidemiology of renal failure, managing cardiovascular risk in&amp;nbsp;CKD, Managing Diabetes and Renal Disease&lt;/P&gt;
&lt;P&gt;Experiencing the problem -&amp;nbsp;Expert patient experience of&amp;nbsp;renal diagnosis and referral, GPs and renal medicine, challenges of collaborative relationship, benefits of&amp;nbsp;early referral in treatment, identification of CKD- the NeoErica Project&lt;/P&gt;
&lt;P&gt;Solving the problem - renal guidelines for&amp;nbsp;primary care&amp;nbsp;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>23/09/2010 10:14:51</lastReviewDate>
    <expiryDate>23/09/2011 10:14:51</expiryDate>
    <relatedLinks>&lt;a href="http://www.southasian.org.uk/organdonation_renalfailure2004.html" title="Click here for website"/&gt;&lt;a href="http://www.southasian.org.uk/images/RenalFailurebooklet2004.pdf" title="Click here for full text of report (PDF)"/&gt;</relatedLinks>
    <creator>South Asian Development Partnership</creator>
  </document>
  <document>
    <id>156284</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://kidney.niddk.nih.gov/kudiseases/pubs/eatright/index.htm]]&gt;</url>
    <title>Eat right to feel right on hemodialysis</title>
    <publicationDate>2008-08-04T00:00:00</publicationDate>
    <publisher>National Kidney and Urologic Diseases Information Clearinghouse (NKUDIC)</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ INTERVENTIONS,DIETARY CHANGE,STARTING HAEMODIALYSIS,STARTING PERITONEAL DIALYSIS,LIVING WITH DIALYSIS,HAEMODIALYSIS,PERITONEAL DIALYSIS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,DIALYSIS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Website providing information on diet whilst on hemodialysis</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Extract from website&lt;/EM&gt;&lt;/P&gt;
&lt;H3&gt;How to Use This Publication&lt;/H3&gt;
&lt;P&gt;When you start hemodialysis, you must make many changes in your life. Watching the foods you eat will make you healthier. This publication will help you choose the right foods.&lt;/P&gt;
&lt;P&gt;Print this publication and use it with a dietitian to help you learn how to eat right to feel right on hemodialysis. Read one section at a time. Then go through the exercise with your dietitian.&lt;/P&gt;
&lt;P&gt;Once you have completed every exercise, keep a copy of this publication to remind yourself of foods you can eat and foods you need to avoid.&lt;/P&gt;
&lt;P&gt;Published December 2006&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>23/09/2010 10:15:04</lastReviewDate>
    <expiryDate>23/09/2011 10:15:04</expiryDate>
  </document>
  <document>
    <id>155719</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.renal.org/unit/index.pl?c=edin]]&gt;</url>
    <title>Edinburgh Renal Unit</title>
    <publicationDate>2006-10-11T00:00:00</publicationDate>
    <publisher>Renal Association</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ TRANSPLANT CENTRES,TRANSPLANTATION,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Contact details and background information</description>
    <body>&lt;![CDATA[ &lt;P&gt;A Renal Transplant service is provided to Lothian, the Borders, Fife, and Tayside, a population of 1.8 million.&lt;/P&gt;
&lt;P&gt;About 60-70 renal transplants are performed annually.&lt;/P&gt;
&lt;P&gt;See also&amp;nbsp;the EdREN website, &lt;A href="http://www.edren.org/" target="_blank"&gt;www.edren.org&lt;/A&gt;, where you can find a large amount of information about kidney diseases, the protocols we use, and more about the unit and its history.&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>23/09/2010 10:15:16</lastReviewDate>
    <expiryDate>23/09/2011 10:15:16</expiryDate>
    <relatedLinks>&lt;a href="http://www.renal.org/unit/index.pl?c=edin" title="Click here for webpage"/&gt;&lt;a href="http://renux.dmed.ed.ac.uk/edren/" title="Click here for EdREN"/&gt;</relatedLinks>
    <creator>Edinburgh Renal Unit</creator>
  </document>
  <document>
    <id>155495</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://renux.dmed.ed.ac.uk/EdREN/EdRenHDBKhome.html]]&gt;</url>
    <title>EdRen Handbook</title>
    <publicationDate>2009-11-29T00:00:00</publicationDate>
    <publisher>Renal Unit Royal Infirmary of Edinburgh</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ HAEMODIALYSIS,TRANSPLANTATION,RENAL TRACT INFECTIONS,PERITONEAL DIALYSIS,KIDNEY DISEASE IN CHILDREN AND ADOLESCENTS,OTHER CONDITIONS - ADULTS,COMPLICATIONS OF KIDNEY DISEASE,CARDIOVASCULAR DISEASE,SLE-RELATED,ANAEMIA,UPPER URINARY TRACT INFECTION,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,ACUTE KIDNEY INJURY,KIDNEY DISEASES,DIALYSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>An online handbook produced by the Royal Infirmary of Edinburgh Renal Unit</description>
    <body>&lt;![CDATA[ &lt;P&gt;Brief information on wide range of renal topics for doctors and other medical staff.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This page was last updated&amp;nbsp;29 November 2009.&lt;/P&gt;]]&gt;</body>
    <expiryDate>01/09/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>155474</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.edtnaerca.org/pages/education/journalclub/previoussummaries.php]]&gt;</url>
    <title>EDTNA/ERCA Journal Club Discussion Summaries</title>
    <publicationDate></publicationDate>
    <publisher>EDTNA/ERCA</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ ACCESS,PERITONEAL DIALYSIS,ACCESS,HAEMODIALYSIS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES,DIALYSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Summaries of online discussions on research papers selected mainly from the EDTNA/ERCA Journal, and other renal publications, or online presentations/websites</description>
    <body>&lt;![CDATA[ &lt;P&gt;Summaries of discussions since&amp;nbsp;2001 mainly on haemodialysis and access topics.&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>23/09/2010 10:17:48</lastReviewDate>
    <expiryDate>23/09/2011 10:17:48</expiryDate>
  </document>
  <document>
    <id>177603</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://jasn.asnjournals.org/cgi/reprint/14/6/1605]]&gt;</url>
    <title>Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease</title>
    <publicationDate>2003-06-02T00:00:00</publicationDate>
    <publisher>Journal of the American Society of Nephrology</publisher>
    <publicationType>RANDOMISED CONTROLLED TRIAL</publicationType>
    <topics>&lt;![CDATA[ INTERVENTIONS,CHOLESTEROL REDUCTION,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Article from Journal of the American Society of Nephrology</description>
    <body>&lt;![CDATA[ Results of a study showing that "pravastatin may slow renal function loss in individuals with moderate to severe kidney disease, especially those with proteinuria" [&lt;EM&gt;extract from full text&lt;/EM&gt;].]]&gt;</body>
    <lastReviewDate>06/07/2010 11:24:39</lastReviewDate>
    <expiryDate>06/07/2011 11:24:39</expiryDate>
  </document>
  <document>
    <id>212288</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.renal.org/eGFR/resources/index.html]]&gt;</url>
    <title>eGFR resources page - Information to support eGFR reporting</title>
    <publicationDate>2007-01-17T00:00:00</publicationDate>
    <publisher>Renal Association</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ SCREENING OPTIONS,SCREENING TESTS,ASSESSMENT TESTS,ASSESSMENT OF RENAL FUNCTION,GFR AND EGFR,EGFR,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Web page of links from the Renal Association</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Extract from webpage&lt;/EM&gt; &lt;/P&gt;
&lt;P class=body&gt;&lt;B&gt;eGFR&lt;/B&gt; (&lt;B&gt;e&lt;/B&gt;stimated &lt;B&gt;G&lt;/B&gt;lomerular &lt;B&gt;F&lt;/B&gt;iltration &lt;B&gt;R&lt;/B&gt;ate) reporting is seen as a key element in achieving earlier detection of serious CKD, and early institution of preventive measures. The UK CKD guidelines (2005) and many other guidelines internationally support the general introduction of eGFR reporting. &lt;/P&gt;
&lt;P class=body&gt;Introduction of eGFR reporting is likely to lead to many extra patients being identified as having CKD, especially in older age groups. It is widely agreed that it both unfeasible and unnecessary that all of these should be referred to nephrologists. The UK CKD guidelines support the management of most patients with moderate GFR reduction (down to 30mls/min/1.73m&lt;SUP&gt;2&lt;/SUP&gt; if stable, and with low levels of urinary protein/blood) in the community. &lt;/P&gt;
&lt;P class=body&gt;This page accommodates discussions and links to a large number of resources to support the introduction of eGFR reporting in the UK.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>04/10/2010 11:44:42</lastReviewDate>
    <expiryDate>04/10/2011 11:44:42</expiryDate>
  </document>
  <document>
    <id>385325</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/sites/entrez/20554576]]&gt;</url>
    <title>Electronic consultation as an alternative to hospital referral for patients with chronic kidney disease: a novel application for networked electronic health records to improve the accessibility and efficiency of healthcare.</title>
    <publicationDate>2010-06-16T00:00:00</publicationDate>
    <publisher>Quality and Safety in Health Care</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ COMPLICATIONS OF KIDNEY DISEASE,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Stoves J, Connolly J, Cheung CK, Grange A, Rhodes P, O'Donoghue D, Wright J. Electronic consultation as an alternative to hospital referral for patients with chronic kidney disease: a novel application for networked electronic health records to improve the accessibility and efficiency of healthcare. Qual Saf Health Care 2010 Jun 16.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Abstract&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Problem&lt;/STRONG&gt; Chronic kidney disease is increasingly recognised in the UK, leading to a greater demand for specialist services. Traditional means of meeting this demand rely on GP referral of patients to see a nephrologist. Hospital assessment may be inconvenient for patients and inefficient for health services. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Setting&lt;/STRONG&gt; 17 general practices and a secondary care nephrology service in Bradford, UK. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Design&lt;/STRONG&gt; A before and after evaluation comparing nephrology referrals from implementation and non-implementation practices following the introduction of electronic consultations (e-consultations) for chronic kidney disease. Key measures for improvement The number, appropriateness and quality of new referrals (paper and electronic) from primary care, the timeliness of responses and the satisfaction of patients and health professionals with the new service. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Strategies for change&lt;/STRONG&gt; Electronic sharing of primary care electronic health records with the nephrology service was introduced to implementation practices. Participating GPs attended education workshops and received paper and e-guidance about the new service. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Effects of change&lt;/STRONG&gt; There was a significant reduction in paper referrals from implementation practices. E-consultation provided nephrologists with access to more clinical information. GPs reported that the service was convenient, provided timely and helpful advice, and avoided outpatient referrals. Specialist recommendations were well followed, and GPs felt more confident about managing chronic kidney disease in the community. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Lessons learnt&lt;/STRONG&gt; E-consultation promotes effective management of patients with mild-to-moderate chronic kidney disease in primary care, allowing specialist resources to be directed towards supporting patients with more complex needs. There is a potential role for e-consultation in other chronic disease specialties.&lt;/P&gt;]]&gt;</body>
    <expiryDate>24/08/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>381536</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://clinicalevidence.bmj.com/ceweb/conditions/knd/2002/2002.jsp?rss=true]]&gt;</url>
    <title>End-stage renal disease</title>
    <publicationDate>2010-07-26T00:00:00</publicationDate>
    <publisher>BMJ</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ TRANSPLANTATION,HAEMODIALYSIS,ACUTE KIDNEY INJURY,PERITONEAL DIALYSIS,COMPLICATIONS OF KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES,DIALYSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A BMJ Clinical Evidence topic</description>
    <body>&lt;![CDATA[ &lt;P&gt;Here is a list of clinical questions we have addressed in this review.&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;What are the effects of different doses for peritoneal dialysis?&lt;/LI&gt;
&lt;LI&gt;What are the effects of different doses and membrane fluxes for haemodialysis?&lt;/LI&gt;
&lt;LI&gt;What are the effects of interventions aimed at preventing secondary complications?&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;What are the effects of different doses for peritoneal dialysis?&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Unlikely to be beneficial&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Increased-dose peritoneal dialysis (no more effective than standard-dose dialysis in reducing overall mortality)&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;What are the effects of different doses and membrane fluxes for haemodialysis?&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Unlikely to be beneficial&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;High membrane-flux haemodialysis (no more effective than low membrane-flux haemodialysis in reducing all-cause mortality)&lt;/LI&gt;
&lt;LI&gt;Increased-dose haemodialysis (no more effective than standard-dose haemodialysis in reducing all-cause mortality)&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;What are the effects of interventions aimed at preventing secondary complications?&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Likely to be beneficial&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Cinacalcet (improves control of secondary hyperparathyroidism compared with placebo)&lt;/LI&gt;
&lt;LI&gt;Mupirocin (reduces Staphylococcus aureus catheter infections compared with placebo or no treatment)&lt;/LI&gt;
&lt;LI&gt;Sevelamer (reduces progression of coronary artery and aortic calcification compared with calcium salts)&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Trade off between benefits and harms&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Erythropoietin or darbepoetin (maintain haemoglobin levels but associated with increased mortality and cardiovascular events in people with cardiovascular disease)&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Unknown effectiveness&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Statins in people with end-stage renal disease and normal lipid profiles&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
    <expiryDate>26/07/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>338779</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=338779]]&gt;</url>
    <title>End-Stage Renal Disease: Systematic reviews and meta-analyses</title>
    <publicationDate>2011-02-16T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,ACUTE KIDNEY INJURY,END-OF-LIFE CARE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;End-Stage Renal Disease: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2011&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Wyne, A., Rai, R., Cuerden, M., Clark, W.F., Suri, R.S. (2011) "Opioid and Benozdiazepine Use in End-Stage Renal Disease: A Systematic Review". CJASN. February 6(2); pp.326-333. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/21071517" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Abdel-Latif, A., D. Mukherjee, et al. (2010). "Drug-eluting stents in patients with end-stage renal disease: Meta-analysis and systematic review of the literature." Catheterization and Cardiovascular Interventions 76(7): 942-948. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20506492" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Alavian, S. M. and S. V. Tabatabaeir. (2010). "Effects of oral levamisole as an adjuvant to hepatitis B vaccine in adults with end-stage renal disease: a meta-analysis of controlled clinical trials." Clin Ther 32(1): 1-10. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20171406" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Chua, D., A. Lo, et al. (2010). "Spironolactone use in heart failure patients with end-stage renal disease on hemodialysis: is it safe?" Clin Cardiol 33(10): 604-8. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Spironolactone%20use%20in%20heart%20failure%20patients%20with%20end-stage%20renal%20disease%20on%20hemodialysis%3A%20is%20it%20safe%3F" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Khalil, A. A. and S. K. Frazier. (2010)&amp;nbsp;"Depressive symptoms and dietary nonadherence in patients with end-stage renal disease receiving hemodialysis: a review of quantitative evidence." Issues in Mental Health Nursing 31(5): 324-30. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20394478" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kun Hyung, K., L. Myeong Soo, et al. (2010). "Role of acupressure in symptom management in patients with end-stage renal disease: a systematic review." Journal of Palliative Medicine 13(7): 885-893. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Role%20of%20acupressure%20in%20symptom%20management%20in%20patients%20with%20end-stage%20renal%20disease%3A%20a%20systematic%20review" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Schmid, H., H. Schiffl, et al. (2010). "Pharmacotherapy of end-stage renal disease." Expert Opinion on Pharmacotherapy 11(4): 597-613.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Pharmacotherapy%20of%20end-stage%20renal%20disease" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Agarwal, R., S. M. Brunelli, et al. (2009). "Gadolinium-based contrast agents and nephrogenic systemic fibrosis: a systematic review and meta-analysis." Nephrol Dial Transplant 24(3): 856-63. [&lt;A href="nelh:359577:0" name=internalLink&gt;Link to&amp;nbsp;DARE abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Desai, A. A., A. Nissenson, et al. (2009). "The relationship between laboratory-based outcome measures and mortality in end-stage renal disease: a systematic review." Hemodial Int 13(3): 347-59.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19583604" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Heung, M., B. A. Mueller, et al. (2009). "Optimizing anemia management in hospitalized patients with end-stage renal disease." Ann Pharmacother 43(2): 276-82.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19141655" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hiremath, S., R. M. Holden, et al. (2009). "Antiplatelet Medications in Hemodialysis Patients: A Systematic Review of Bleeding Rates." Clin J Am Soc Nephrol.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19578002" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Parfrey, P. S., M. Lauve, et al. (2009). "Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: a meta-analysis." Clin J Am Soc Nephrol 4(4): 755-62.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19339417" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Dale, P. L., J. Hutton, et al. (2008). "Utility of health states in chronic kidney disease: a structured review of the literature." Curr Med Res Opin 24(1): 193-206.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18039434" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Janssen, D. J., M. A. Spruit, et al. (2008). "Daily symptom burden in end-stage chronic organ failure: a systematic review." Palliat Med 22(8): 938-48.&amp;nbsp;[&lt;A href="https://rmsadmin.library.nhs.uk/admin/wizards/articles/Daily[Title]%20AND%20symptom[Title]%20AND%20burden[Title]%20AND%20end-stage[Title]%20AND%20chronic[Title]%20AND%20organ[Title]%20AND%20failure[Title]%20AND%20systematic[Title]%20AND%20review[Title]" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Karamanidou, C., J. Clatworthy, et al. (2008). "A systematic review of the prevalence and determinants of nonadherence to phosphate binding medication in patients with end-stage renal disease." BMC Nephrol 9: 2.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=A%20systematic%20review%20of%20the%20prevalence%20and%20determinants%20of%20nonadherence%20to%20phosphate%20binding%20medication%20in%20patients%20with%20end-stage%20renal%20disease" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Murad, M. H., A. N. Sidawy, et al. (2008). "Timing of referral for vascular access placement: a systematic review." J Vasc Surg 48(5 Suppl): 31S-3S.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Timing%20of%20referral%20for%20vascular%20access%20placement%3A%20a%20systematic%20review" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Nigwekar, S. U., M. Wolf, et al. (2008). "Calciphylaxis from nonuremic causes: a systematic review." Clin J Am Soc Nephrol 3(4): 1139-43.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Calciphylaxis%20from%20nonuremic%20causes%3A%20a%20systematic%20review" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Osborn, G., X. Escofet, et al. (2008). "Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts." Cochrane Database Syst Rev(4): CD002786.&amp;nbsp;[&lt;A href="http://mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD002786/frame.html" target="_blank"&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Spiegel, B. M., G. Melmed, et al. (2008). "Biomarkers and health-related quality of life in end-stage renal disease: a systematic review." Clin J Am Soc Nephrol 3(6): 1759-68.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18832106" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Albers, M., M. Romiti, et al. (2007). "An updated meta-analysis of infrainguinal arterial reconstruction in patients with end-stage renal disease." J Vasc Surg 45(3): 536-42.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=An%20updated%20meta-analysis%20of%20infrainguinal%20arterial%20reconstruction%20in%20patients%20with%20end-stage%20renal%20disease" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Garside, R., M. Pitt, et al. (2007). "The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation." Health Technol Assess 11(18): iii, xi-xiii, 1-167.&amp;nbsp;[&lt;A href="nelh:273046:0" name=internalLink&gt;Link to abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hall, Y. N. and G. M. Chertow (2007). "End stage renal disease." Clin Evid (Online) 2007.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19450356" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Murtagh, F. E., J. Addington-Hall, et al. (2007). "The prevalence of symptoms in end-stage renal disease: a systematic review." Adv Chronic Kidney Dis 14(1): 82-99.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17200048" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Rabindranath, K. S., J. Adams, et al. (2007). "Continuous ambulatory peritoneal dialysis versus automated peritoneal dialysis for end-stage renal disease." Cochrane Database Syst Rev(2): CD006515.&amp;nbsp;[&lt;A href="nelh:260055:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2006&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Fabrizi, F., S. V. Ganeshan, et al. (2006). "Meta-analysis: the adjuvant role of granulocyte macrophage-colony stimulating factor on immunological response to hepatitis B virus vaccine in end-stage renal disease." Aliment Pharmacol Ther 24(5): 789-96.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Meta-analysis%3A%20the%20adjuvant%20role%20of%20granulocyte%20macrophage-colony%20stimulating%20factor%20on%20immunological%20response%20to%20hepatitis%20B%20virus%20vaccine%20in%20end-stage%20renal%20disease" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Rabindranath, K. S., G. F. Strippoli, et al. (2006). "Haemodiafiltration, haemofiltration and haemodialysis for end-stage kidney disease." Cochrane Database Syst Rev(4): CD006258.&amp;nbsp;[&lt;A href="nelh:239227:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>21/12/2010 10:52:12</lastReviewDate>
    <expiryDate>21/01/2012 00:00:00</expiryDate>
  </document>
  <document>
    <id>325077</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.renal.org/pages/media/eNews/renal%20contacts%20letter%2025-06-09.pdf]]&gt;</url>
    <title>Enhanced surveillance of Meticillin resistant Staphylococcus aureus (MRSA)</title>
    <publicationDate>2009-09-17T00:00:00</publicationDate>
    <publisher>Renal Association</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ PREVENTION OF INFECTIONS,PERITONEAL DIALYSIS,HAEMODIALYSIS,PREVENTION OF INFECTIONS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES,DIALYSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>All NHS Trusts in England are required by the Department of Health to report every episode of MRSA bacteraemia. These data are entered onto a web-based data capture system managed by the Health Protection Agency and Trusts rate of MRSA bacteraemia reported every quarter.</description>
    <body>&lt;![CDATA[ &lt;P&gt;All NHS Trusts in England are required by the Department of Health to report every episode of MRSA bacteraemia. These data are entered onto a web based data capture system managed by the Health Protection Agency and Trusts rate of MRSA bacteraemia reported every quarter.&lt;BR&gt;&lt;A href="http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1229502457803" target="_blank"&gt;http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1229502457803&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;A significant proportion of these MRSA bacteraemias occur in patients receiving dialysis. For this reason, in 2007 the facility to capture additional data on those patients with MRSA bacteraemia and in established renal failure was added to the system for reporting MRSA bacteraemia. &lt;A href="http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1194947399620" target="_blank"&gt;http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1194947399620&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;In the first year of this enhanced surveillance 188 MRSA bacteraemia were reported in patients in established renal failure (ERF) and the data was analysed and reported in conjunction with the UK Renal Registry. &lt;A href="http://www.online.karger.com/ProdukteDB/produkte.asp?Doi=210001" target="_blank"&gt;http://www.online.karger.com/ProdukteDB/produkte.asp?Doi=210001&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>17/09/2010 16:39:25</lastReviewDate>
    <expiryDate>17/09/2011 16:39:25</expiryDate>
  </document>
  <document>
    <id>260747</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.emea.europa.eu/pdfs/human/press/pus/49618807en.pdf]]&gt;</url>
    <title>Epoetins and the risk of tumour growth progression and thromboembolic events in cancer patients and cardiovascular risks in patients with chronic kidney disease</title>
    <publicationDate>2007-10-23T00:00:00</publicationDate>
    <publisher>European Medicines Agency</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ COMPLICATIONS OF KIDNEY DISEASE,ANAEMIA,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Public statement from European Medicines Agency</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Extract&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;The European Medicines Agency is reviewing the safety of all centrally-authorised epoetins. The safety review has been initiated because new data from both unpublished and published studies suggest an increased risk of serious cardiovascular complications in patients with chronic renal failure. Epoetins are used for the treatment of anaemia in patients with chronic renal failure.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
    <expiryDate>05/10/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>323910</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://learning.bmj.com/learning/search-result.html?moduleId=5000066&amp;utm_campaign=6032015&amp;utm_content=34320616762&amp;utm_medium=email&amp;utm_source=Emailvision]]&gt;</url>
    <title>Erectile dysfunction: diagnosis and treatment</title>
    <publicationDate>2009-09-01T00:00:00</publicationDate>
    <publisher>BMJ Learning</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,ERECTILE DYSFUNCTION,PENILE DISORDERS,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>BMJ Learning Module - for BMA Members</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Module type&lt;/STRONG&gt;&amp;nbsp; &amp;nbsp; &lt;STRONG&gt;&lt;/P&gt;&lt;/STRONG&gt;
&lt;P&gt;&lt;STRONG&gt;Just in time:&lt;/STRONG&gt;&lt;BR&gt;Want a fast, evidence based update? Here are the essentials on everyday conditions. Before you start a learning resource it is best to add it to your plan first.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;What's in this case:&lt;/STRONG&gt;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Just in Time: erectile dysfunction: diagnosis and treatment&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Target audience:&lt;/STRONG&gt; &amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;NHS London - GP and trainee CPD&lt;/LI&gt;
&lt;LI&gt;International&lt;/LI&gt;
&lt;LI&gt;Practice nurse CPD&lt;/LI&gt;
&lt;LI&gt;GP CPD&lt;/LI&gt;
&lt;LI&gt;GP trainee&lt;/LI&gt;
&lt;LI&gt;NHS London - Allied health professionals&lt;/LI&gt;
&lt;LI&gt;Saudi Pediatric Association Channel&lt;/LI&gt;
&lt;LI&gt;Other healthcare professionals&lt;/LI&gt;
&lt;LI&gt;NHS London - Acute and community nursing and midwifery&lt;/LI&gt;
&lt;LI&gt;The Royal New Zealand College of General Practitioners&lt;/LI&gt;
&lt;LI&gt;Medical Students - international &lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
    <lastReviewDate>17/09/2010 16:39:31</lastReviewDate>
    <expiryDate>17/09/2011 16:39:31</expiryDate>
  </document>
  <document>
    <id>321806</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=321806]]&gt;</url>
    <title>Erectile dysfunction: Systematic reviews and meta-analyses</title>
    <publicationDate>2011-02-21T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,SEXUAL DYSFUNCTION,CHRONIC COMPLICATIONS,CONDITION MANAGEMENT,CAUSES,PREVENTION,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,PENILE DISORDERS,ERECTILE DYSFUNCTION,MALE UROGENITAL DISORDERS,CIRCUMCISION,PREMATURE EJACULATION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Erectile dysfunction: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.cebm.net/critical_appraisal.asp" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2011&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Frieben R, Lin H, Hinh P, Canfield S, Wang R. Male sexual function after minimally invasive surgeries for BPH. Journal of Sexual Medicine. 2011;8. [No PubMed abstract available]&lt;/LI&gt;
&lt;LI&gt;Linn D, Laumann E, Lewis R, Xu H, Paymon N, Rutherford R. Response rate and number of respondents do not affect the overall prevalence rate of erectile dysfunction: A meta-analysis of worldwide epidemiological literature. Journal of Sexual Medicine. 2011;8.&amp;nbsp;[No PubMed abstract available]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Basson, R., P. Rees, et al. (2010). "Sexual function in chronic illness." Journal of Sexual Medicine 7(1 Pt 2): 374-88. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20092445" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Dorsey, P., C. Keel, et al. (2010). "Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction." Expert Opinion on Pharmacotherapy 11(7): 1109-1122. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20402554" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Eardley, I. (2010). "Oral therapy for erectile dysfunction." Arch Esp Urol 63(8): 703-14.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/21045254" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Everaert, K., W. I. de Waard, et al. (2010). "Neuroanatomy and neurophysiology related to sexual dysfunction in male neurogenic patients with lesions to the spinal cord or peripheral nerves." Spinal Cord 48(3): 182-191.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/2020048757" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Frieben, R. W., H. C. Lin, et al. (2010). "The impact of minimally invasive surgeries for the treatment of symptomatic benign prostatic hyperplasia on male sexual function: a systematic review." Asian Journal of Andrology 12(4): 500-508.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20473318" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hatzimouratidis, K., E. Amar, et al. (2010). "Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation." European Urology 57(5): 804-14.&amp;nbsp;[&lt;A href="nelh:143318:0" name=internalLink&gt;Internal link to abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Jha, S., M. K. Ammembal, et al. (2010). "Impact of incontinence surgery on sexual function: A systematic review and meta-analysis." Neurourology and Urodynamics 29(6): 1112-1113.&amp;nbsp;[Link to PubMed abstract]&lt;/LI&gt;
&lt;LI&gt;Li, X., Z. Dong, et al. (2010). "Sildenafil versus continuous positive airway pressure for erectile dysfunction in men with obstructive sleep apnea: a meta-analysis." Aging Male 13(2): 82-86.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20001468" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Martinez-Salamanca, J. I., C. Martinez-Ballesteros, et al. (2010). "[Penile morphometric changes after radical prostatectomy: Evidence-based]. [Spanish] Cambios morfometricos peneanos tras prostatectomia radical: revision de la evidencia." Actas Urologicas Espanolas 34(7): 579-85.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20540873" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Montorsi, F., G. Adaikan, et al. (2010). "Summary of the recommendations on sexual dysfunctions in men." Journal of Sexual Medicine 7(11): 3572-88.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/21040491" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Ruiz-Aragón J, Márquez-Peláez S, Luque Romero LG. (2010). "[Erectile dysfunction in patients with prostate cancer who have undergone surgery: Systematic review of literature]. [Spanish] Actas Urologicas Espanolas 34(8): 677-85.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20800031" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Segraves, R. T. (2010). "Considerations for diagnostic criteria for erectile dysfunction in DSM V." Journal of Sexual Medicine 7(2 Pt 1): 654-60.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20492414" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Sommer, F., I. Goldstein, et al. (2010). "Bicycle Riding and Erectile Dysfunction: A Review." Journal of Sexual Medicine 7(7): 2346-2358.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20102446" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Vignozzi, L., G. Corona, et al. (2010). "Clinical and therapeutic aspects of Klinefelter's syndrome: sexual function." Molecular Human Reproduction 16(6): 418-24. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20348547" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Walz, J., A. L. Burnett, et al. (2010). "A critical analysis of the current knowledge of surgical anatomy related to optimization of cancer control and preservation of continence and erection in candidates for radical prostatectomy." European Urology 57(2): 179-192.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19931974" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Abdel Aziz MT, Mostafa T, Atta H, Wassef MA, Fouad HH, Rashed LA, et al. Putative role of carbon monoxide signaling pathway in penile erectile function. Journal of Sexual Medicine. 2009;6(1):49-60. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19170836" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Babaei, A. R., M. R. Safarinejad, et al. (2009). "Penile revascularization for erectile dysfunction: a systematic review and meta-analysis of effectiveness and complications." Urology Journal 6(1): 1-7. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19241332" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Chitaley K. Type 1 and Type 2 diabetic-erectile dysfunction: same diagnosis (ICD-9), different disease? Journal of Sexual Medicine. 2009;6 Suppl 3:262-8. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19267848" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Costa C, Virag R. The endothelial-erectile dysfunction connection: An essential update. Journal of Sexual Medicine. 2009;6(9):2390-404.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19523038" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Feeley RJ, Traish AM. Obesity and erectile dysfunction: is androgen deficiency the common link? Thescientificworldjournal. 2009;9:676-84.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19649506" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hatzimouratidis K. Phosphodiesterase type 5 inhibitors: a viable treatment option for lower urinary tract symptoms? Expert Opinion on Investigational Drugs. 2009;18(3):245-54.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19243276" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hatzimouratidis K, Burnett AL, Hatzichristou D, McCullough AR, Montorsi F, Mulhall JP. Phosphodiesterase Type 5 Inhibitors in Postprostatectomy Erectile Dysfunction: A Critical Analysis of the Basic Science Rationale and Clinical Application. European Urology. 2009;55(2):334-47.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18986755" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hidalgo-Tamola J, Chitaley K. Review type 2 diabetes mellitus and erectile dysfunction. Journal of Sexual Medicine. 2009;6(4):916-26.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19067787" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lee MS, Shin BC, Ernst E. Acupuncture for treating erectile dysfunction: A systematic review. BJU International. 2009;104(3):366-70.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19239450" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lin CS. Phosphodiesterase type 5 regulation in the penile corpora cavernosa. Journal of Sexual Medicine. 2009;6 Suppl 3:203-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19267844" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Malavige, L. S. and J. C. Levy (2009). "Erectile dysfunction in diabetes mellitus." J Sex Med 6(5): 1232-47.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19210706?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mirone V, Imbimbo C, Fusco F, Verze P, Creta M, Tajana G. Androgens and morphologic remodeling at penile and cardiovascular levels: a common piece in complicated puzzles? European Urology. 2009;56(2):309-16.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19147269" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mulhall, J. P. (2009). "Defining and reporting erectile function outcomes after radical prostatectomy: challenges and misconceptions." Journal of Urology 181(2): 462-71.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19084865" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Nehra, A. (2009). "Erectile dysfunction and cardiovascular disease: efficacy and safety of phosphodiesterase type 5 inhibitors in men with both conditions." Mayo Clinic Proceedings 84(2): 139-48.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19181648?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Podlasek, C. A. (2009). "Sonic hedgehog, apoptosis, and the penis." J Sex Med 6 Suppl 3: 334-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19267857?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Shindel AW. 2009 update on phosphodiesterase type 5 inhibitor therapy part 1: Recent studies on routine dosing for penile rehabilitation, lower urinary tract symptoms, and other indications (CME). Journal of Sexual Medicine. 2009;6(7):1794-808; quiz 3, 809-10.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19575771" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Tal, R., H. H. Alphs, et al. (2009). "Erectile Function Recovery Rate after Radical Prostatectomy: A Meta-Analysis." J Sex Med.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19515209" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Tamler R. Diabetes, obesity, and erectile dysfunction. Gender Medicine. 2009;6(SUPPL. 1):4-16.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19318216" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Tsertsvadze A, Fink HA, Yazdi F, MacDonald R, Bella AJ, Ansari MT, et al. Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: A systematic review and meta-analysis. Annals of Internal Medicine. 2009;151(9):650-61.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19884626" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Tsertsvadze A, Yazdi F, Fink HA, MacDonald R, Wilt TJ, Bella AJ, et al. Oral Sildenafil Citrate (Viagra) for Erectile Dysfunction: A Systematic Review and Meta-analysis of Harms. Urology. 2009;74(4):831-6.e8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19592078" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Zhang F, Wu B, Gao S. [Incidences of erectile dysfunction and retrograde ejaculation after suprapubic prostatectomy and transurethral resection of the prostate in Chinese men: a meta-analysis]. Zhong Hua Nan Ke Xue. 2009;15(8):738-41.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19852279" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Akbal, C., I. Tinay, et al. (2008). "Erectile dysfunction following radiotherapy and brachytherapy for prostate cancer: pathophysiology, prevention and treatment." International Urology &amp;amp; Nephrology 40(2): 355-63.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17960489" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Bekkering, G. E., A. M. Abou-Setta, et al. (2008). "The application of quantitative methods for identifying and exploring the presence of bias in systematic reviews: PDE-5 inhibitors for erectile dysfunction." International Journal of Impotence Research 20(3): 264-277.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18059501" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Chen, Z. X., H. Q. Wang, et al. (2008). "[Selective serotonin reuptake inhibitor is more likely to induce sexual dysfunction than mirtazapine in treating depression]." Zhong Hua Nan Ke Xue 14(10): 896-9.&amp;nbsp;[&lt;A href="https://rmsadmin.library.nhs.uk/admin/wizards/articles/19157098" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Cyna, A. M. and P. Middleton (2008). "Caudal epidural block versus other methods of postoperative pain relief for circumcision in boys." Cochrane Database of Systematic Reviews(4).&amp;nbsp;[&lt;A href="nelh:237831:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Eardley, I., J. C. Lee, et al. (2008). "Global experiences with vardenafil in men with erectile dysfunction and underlying conditions." International Journal of Clinical Practice 62(10): 1594-603.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18822030" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Erdemir, F., A. Harbin, et al. (2008). "5-alpha reductase inhibitors and erectile dysfunction: the connection." Journal of Sexual Medicine 5(12): 2917-24.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19090946" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Feifer, A. and S. Carrier (2008). "Pharmacotherapy for erectile dysfunction." Expert Opinion on Investigational Drugs 17(5): 679-90.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18447594" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hackett, G., P. Kell, et al. (2008). "British society for sexual medicine guidelines on the management of erectile dysfunction." Journal of Sexual Medicine 5(8): 1841-1865.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18298470" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hatzimouratidis, K., A. L. Burnett, et al. (2008).&amp;nbsp;"Phosphodiesterase Type 5 Inhibitors in Postprostatectomy Erectile Dysfunction: A Critical Analysis of the Basic Science Rationale and Clinical Application." Eur Urol.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18986755" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hernando-Berrios, M., M. S. Rivera-Martinez, et al. (2008). "[Non-pharmacological interventions for the treatment of erectile dysfunction in adult men: systematic review]. [Spanish] Intervenciones no farmacologicas para el tratamiento de la disfuncion erectil en varones adultos: revision sistematica." Enfermeria Clinica 18(2): 64-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18448044" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Jang, D. J., M. S. Lee, et al. (2008). "Red ginseng for treating erectile dysfunction: A systematic review." British Journal of Clinical Pharmacology 66(4): 444-450.&amp;nbsp;[&lt;A href="nelh:342895:0" name=internalLink&gt;Link to&amp;nbsp;DARE abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Jankowski, J. T., A. D. Seftel, et al. (2008). "Erectile dysfunction and sleep related disorders." Journal of Urology 179(3): 837-41.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18221960?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Melnik, T., B. G. O. Soares, et al. (2008). "The effectiveness of psychological interventions for the treatment of erectile dysfunction: Systematic review and meta-analysis, including comparisons to sildenafil treatment, intracavernosal injection, and vacuum devices." Journal of Sexual Medicine 5(11): 2562-2574.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18564156" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Miner, M. and K. L. Billups (2008). "Erectile dysfunction and dyslipidemia: relevance and role of phosphodiesterase type-5 inhibitors and statins." Journal of Sexual Medicine 5(5): 1066-78.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18331271" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Naumann, M., Y. So, et al. (2008). "Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology." Neurology 70(19): 1707-14.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18458231?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Axilrod, A. C. (2007). "Phosphodiesterase type 5 inhibitor therapy: identifying and exploring what attributes matter more to clinicians and patients in the management of erectile dysfunction." Curr Med Res Opin 23(12): 3189-98.&amp;nbsp;[&lt;A href="https://rmsadmin.library.nhs.uk/admin/wizards/articles/17991309" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Baksheev, V. I. and N. M. Kolomoets(2007).&amp;nbsp;"[Phosphodiesterase inhibitors in clinical practice. The present and the future. Part I]." Klin Med (Mosk) 85(3): 4-11.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17523395?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Bella, A. J., L. X. Deyoung, et al. (2007). "Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications." Eur Urol 52(4): 990-1005.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17646047" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Berner, M. M., M. Hagen, et al. (2007). "Management of sexual dysfunction due to antipsychotic drug therapy." Cochrane Database Syst Rev(1): CD003546.&amp;nbsp;[&lt;A href="nelh:238069:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Bolona, E. R., M. V. Uraga, et al. (2007). "Testosterone use in men with sexual dysfunction: a systematic review and meta-analysis of randomized placebo-controlled trials." Mayo Clin Proc 82(1): 20-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17285782?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Briganti, A., A. Salonia, et al. (2007). "Management of erectile dysfunction after radical prostatectomy in 2007." World J Urol 25(2): 143-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17340159?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Burnett, A. L., G. Aus, et al. (2007). "Erectile function outcome reporting after clinically localized prostate cancer treatment." J Urol 178(2): 597-601.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17570435?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Chen, J., G. Keren-Paz, et al. (2007). "The role of phosphodiesterase type 5 inhibitors in the management of premature ejaculation: a critical analysis of basic science and clinical data." Eur Urol 52(5): 1331-9.&amp;nbsp;[&lt;A href="https://rmsadmin.library.nhs.uk/admin/wizards/articles/17728050" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Cheng, J. Y., E. M. Ng, et al. (2007). "Alcohol consumption and erectile dysfunction: meta-analysis of population-based studies." Int J Impot Res 19(4): 343-52.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17538641" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Cheng, J. Y., E. M. Ng, et al. (2007). "Prevalence of erectile dysfunction in Asian populations: a meta-analysis." Int J Impot Res 19(3): 229-44.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16929338" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Cheng, J. Y., E. M. Ng, et al. (2007). "Physical activity and erectile dysfunction: meta-analysis of population-based studies." Int J Impot Res 19(3): 245-52.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16929337" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Melnik, T., B. G. Soares, et al. (2007). "Psychosocial interventions for erectile dysfunction." Cochrane Database Syst Rev(3): CD004825.&amp;nbsp;[&lt;A href="nelh:266509:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Miles, C. L., B. Candy, et al. (2007). "Interventions for sexual dysfunction following treatments for cancer." Cochrane Database Syst Rev(4): CD005540.&amp;nbsp;[&lt;A href="nelh:270909:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Shabsigh, R., S. Duval, et al. (2007). "Efficacy of vardenafil for the treatment of erectile dysfunction in men with hypertension: a meta-analysis of clinical trial data." Curr Med Res Opin 23(10): 2453-60.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17727740" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Vardi, M. and A. Nini (2007). "Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitus." Cochrane Database Syst Rev(1): CD002187.&amp;nbsp;[&lt;A href="nelh:237544:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Wang, W. F., L. Chang, et al. (2007). "Selective serotonin reuptake inhibitors in the treatment of premature ejaculation." Chin Med J (Engl) 120(11): 1000-6.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17624269?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;2006&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Blonde, L. (2006). "Sildenafil citrate for erectile dysfunction in men with diabetes and cardiovascular risk factors: a retrospective analysis of pooled data from placebo-controlled trials." Curr Med Res Opin 22(11): 2111-20.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17076971" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Costa, A. M., M. S. Lima, et al. (2006). "A systematic review on clinical management of antipsychotic-induced sexual dysfunction in schizophrenia." Sao Paulo Med J 124(5): 291-7.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17262163?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Deforge, D., J. Blackmer, et al. (2006). "Male erectile dysfunction following spinal cord injury: a systematic review." Spinal Cord 44(8): 465-73.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16317419?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Dubbelman, Y. D., G. R. Dohle, et al. (2006). "Sexual function before and after radical retropubic prostatectomy: A systematic review of prognostic indicators for a successful outcome." Eur Urol 50(4): 711-8; discussion 718-20.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16846679" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kaminetsky, J. (2006). "Comorbid LUTS and erectile dysfunction: optimizing their management." Curr Med Res Opin 22(12): 2497-506.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17265598" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Montorsi, P., P. M. Ravagnani, et al. (2006). "Association between erectile dysfunction and coronary artery disease: Matching the right target with the right test in the right patient." Eur Urol 50(4): 721-31.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16901623" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:01:40</lastReviewDate>
    <expiryDate>02/08/2012 00:00:00</expiryDate>
  </document>
  <document>
    <id>287476</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.medicine.ox.ac.uk/bandolier/band156/b156-3.html]]&gt;</url>
    <title>Estimated glomerular filtration rate (eGFR): Bandolier</title>
    <publicationDate>2007-01-01T00:00:00</publicationDate>
    <publisher>Bandolier 156</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ EGFR,GFR AND EGFR,SCREENING TESTS,ASSESSMENT OF RENAL FUNCTION,ASSESSMENT TESTS,SCREENING OPTIONS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Article from Bandolier</description>
    <body>&lt;![CDATA[ &lt;P&gt;Covers:&lt;/P&gt;
&lt;P&gt;eGFR and age&lt;/P&gt;
&lt;P&gt;eGFR and mortality&lt;/P&gt;
&lt;DT&gt;eGFR and diabetes 
&lt;DT&gt;&amp;nbsp; 
&lt;DT&gt;eGFR, heart failure and MI 
&lt;DT&gt;&amp;nbsp; 
&lt;DT&gt;
&lt;DT&gt;Published in Feb 2007 &lt;/DT&gt;]]&gt;</body>
    <expiryDate>02/06/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>155682</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.southasian.org.uk/organdonation_ethnicity.html]]&gt;</url>
    <title>Ethnicity and renal failure: disparity or diversity</title>
    <publicationDate>2003-05-09T00:00:00</publicationDate>
    <publisher>South Asian Development Partnership</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ PREDISPOSING FACTORS,ETHNIC GROUP,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,DISEASES AND CONDITIONS,ETHNICITY AND HEALTH,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A National Symposium in 2003</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Extract from website&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;The symposium outlined the current epidemiological data on ethnicity, identified causal factors and presented innovative UK and American initiatives designed to reach and treat ‘at risk’ groups. The aim of the symposium was to raise the profile of the Ethnicity and Diversity in Renal Failure and to promote the concept of inclusive and networked care as away to tackle primary prevention, organ donation, health planning and health provision.&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>23/09/2010 12:12:55</lastReviewDate>
    <expiryDate>23/09/2011 12:12:55</expiryDate>
    <relatedLinks>&lt;a href="http://www.southasian.org.uk/organdonation_ethnicity.html" title="Click here for website"/&gt;&lt;a href="http://www.southasian.org.uk/images/Ethnici4.pdf" title="Click here fore Full Symposium Report (PDF)"/&gt;</relatedLinks>
    <creator>South Asian Development Partnership</creator>
  </document>
  <document>
    <id>182561</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://ndt.oxfordjournals.org/content/vol14/suppl_5/]]&gt;</url>
    <title>European Best Practice Guideline for Anaemia</title>
    <publicationDate>1999-09-01T00:00:00</publicationDate>
    <publisher>Nephrology Dialysis and Transplantation</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ COMPLICATIONS OF KIDNEY DISEASE,ANAEMIA,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Index page of guidelines</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Contains links to the following:&lt;/STRONG&gt; &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Guideline 1: When to begin the work-up of a patient for the diagnosis of anaemia 
&lt;LI&gt;Guideline 2: Evaluation of anaemia in uraemic patients 
&lt;LI&gt;Guideline 3: Diagnosis of the anaemia of chronic renal failure 
&lt;LI&gt;Guideline 4: Indications for starting treatment with epoetin Target 
&lt;LI&gt;Guideline 5: Target haemoglobin concentration for the treatment of the anaemia of chronic renal failure Target 
&lt;LI&gt;Guideline 6: Assessing and optimizing iron stores 
&lt;LI&gt;Guideline 7: Frequency of monitoring iron stores and availability during treatment and follow-up 
&lt;LI&gt;Guideline 8: Administration of supplemental iron 
&lt;LI&gt;Guideline 9: Route of administration of epoetin 
&lt;LI&gt;Guideline 10: Initial epoetin administration 
&lt;LI&gt;Guideline 11: Monitoring of haemoglobin concentration during epoetin treatment 
&lt;LI&gt;Guideline 12: Titration of epoetin dosage 
&lt;LI&gt;Guideline 13: Epoetin dosage perioperatively, during intercurrent illness and after transplantation 
&lt;LI&gt;Guideline 14: Causes of an inadequate response to epoetin treatment 
&lt;LI&gt;Guideline 15: Management of patients resistant to epoetin 
&lt;LI&gt;Guideline 16: Red blood cell transfusions in patients with chronic renal failure 
&lt;LI&gt;Guideline 17: Possible adverse effects of epoetin treatment: hypertension 
&lt;LI&gt;Guideline 18: Possible adverse effects of epoetin treatment: access thrombosis 
&lt;LI&gt;Appendix I: Designation of strength of available evidence to support guidelines 
&lt;LI&gt;Appendix II: Haematology methodology 
&lt;LI&gt;Appendix III: Use of intravenous iron in patients receiving epoetin&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
    <lastReviewDate>03/11/2010 15:40:36</lastReviewDate>
    <expiryDate>03/11/2011 15:40:36</expiryDate>
  </document>
  <document>
    <id>155466</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://eesc.europa.eu/self-and-coregulation/documents/codes/private/086-private-act.pdf]]&gt;</url>
    <title>European Guidelines for the Nutritional Care of Adult Renal Patients</title>
    <publicationDate>2002-10-01T00:00:00</publicationDate>
    <publisher>EDTNA/ERCA</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ INTERVENTIONS,DIETARY CHANGE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Guideline issued by the European Dialysis and Transplantation Nurses Association/European Renal Care Association - Dietitians Special Interest Group in 2002</description>
    <body>&lt;![CDATA[ &lt;P&gt;Guideline aimed at improving nutrition and promoting best practice. Guideline covers adults and does not cover paediatrics, nephrotic syndrome, transplantation, diabetes or acute renal care.&lt;/P&gt;
&lt;P&gt;Published October 2002&lt;/P&gt;]]&gt;</body>
    <expiryDate>05/10/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>261602</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://ec.europa.eu/health/ph_threats/human_substance/documents/ebs272d_en.pdf]]&gt;</url>
    <title>Europeans and organ donations</title>
    <publicationDate>2007-05-30T00:00:00</publicationDate>
    <publisher>European Commission</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ ASSESSMENT/SELECTION,TRANSPLANTATION,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Eurobarometer report from the European Commission</description>
    <body>&lt;![CDATA[ &lt;P&gt;Proposals for a European organ donor card, to tackle record waiting lists for transplants published in a European Commission&amp;nbsp;report May 30th 2007.&lt;/P&gt;
&lt;P&gt;Britain&amp;nbsp;has one of the highest family refusal rates in the EU, with 42 per cent of relatives blocking organ removal, compared with 17 per cent in Spain, 29 per cent in Italy and 30 per cent in France. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>01/07/2010 14:08:17</lastReviewDate>
    <expiryDate>01/07/2011 14:08:17</expiryDate>
  </document>
  <document>
    <id>187607</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.vasculitis.org/]]&gt;</url>
    <title>EUVAS</title>
    <publicationDate>2010-02-24T00:00:00</publicationDate>
    <publisher>EUVAS</publisher>
    <publicationType>RANDOMISED CONTROLLED TRIAL</publicationType>
    <topics>&lt;![CDATA[ NEW RESEARCH,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Details of the European Vasculitis Study Group actvities</description>
    <body>&lt;![CDATA[ &lt;P&gt;Trials actively recruiting: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;PEXIVAS (Plasma exchange and glucocorticoid dosing in the treatment of ANCA-associated vasculitis) This is the largest international multicentre trial so far. The first patients will be included in Spring 2010.&lt;/LI&gt;
&lt;LI&gt;MYCYC (Randomised clinical trial of mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA associated vasculitis). The first patient was included in June 2007. A report on MYCYC's progress appears regularly. &lt;/LI&gt;
&lt;LI&gt;REMAIN (long-term low dose immunosuppression versus treatment withdrawal for renal vasculitis). The protocol was revised in January 2006.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
    <expiryDate>03/11/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>379539</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;db=pubmed&amp;cmd=Search&amp;TransSchema=title&amp;term=Everolimus%20in%20Patients%20with%20Autosomal%20Dominant%20Polycystic%20Kidney%20Disease]]&gt;</url>
    <title>Everolimus in Patients with Autosomal Dominant Polycystic Kidney Disease</title>
    <publicationDate>2010-06-26T00:00:00</publicationDate>
    <publisher>New England Journal of Medicine</publisher>
    <publicationType>RANDOMISED CONTROLLED TRIAL</publicationType>
    <topics>&lt;![CDATA[ POLYCYSTIC KIDNEY DISEASE,IN ADULTS,INHERITED KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;433 patients with ADPKD were randomly assigned to either placebo or mTOR inhibitor everolimus over two years. The authors conclude that "everolimus slowed the increase in total kidney volume of patients with ADPKD but did not slow the decline in progressive renal impairment", compared to placebo. &lt;/P&gt;
&lt;P&gt;(EudraCT number, 2006-001485-16; ClinicalTrials.gov number, NCT00414440 [ClinicalTrials.gov] .)&lt;/P&gt;
&lt;P&gt;Walz G, Budde K, Mannaa M, Nurnberger J, Wanner C, Sommerer C, et al. "Everolimus in Patients with Autosomal Dominant Polycystic Kidney Disease." New England Journal of Medicine. Published online June 26, 2010 (10.1056/NEJMoa1003491)&lt;/P&gt;]]&gt;</body>
    <expiryDate>28/06/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>288185</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.blackwell-synergy.com/doi/pdf/10.1111/j.1747-0080.2006.00100.x]]&gt;</url>
    <title>Evidence based practice guidelines for the nutritional management of CKD</title>
    <publicationDate>2006-07-03T00:00:00</publicationDate>
    <publisher>Dietitians Association of Australia</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ INTERVENTIONS,DIETARY CHANGE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Guidelines published in Nutrition and Dietetics 2006, Vol 63, supp 2, by the Dietitians Association of Australia</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Extract &lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;The purpose of these guidelines is to provide dietitians with a summary of evidence based clinical guidelines related to the dietetic management of adult patients with chronic kidney disease. The patient target group is any adult patient fulfilling the definition and diagnostic criteria of Chronic Kidney Disease (CKD), excluding those with nephrotic syndrome. These guidelines by definition also exclude acute renal failure and transplantation.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>23/09/2010 16:43:19</lastReviewDate>
    <expiryDate>23/09/2011 16:43:19</expiryDate>
  </document>
  <document>
    <id>251072</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.nature.com/ncpneph/journal/v3/n3/full/ncpneph0421.html]]&gt;</url>
    <title>Evidence-based treatment recommendations for uraemic bleeding</title>
    <publicationDate>2006-12-08T00:00:00</publicationDate>
    <publisher>Nature Clinical Practice Nephrology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ COMPLICATIONS OF KIDNEY DISEASE,OTHER,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Review published in Nature Clinical Practice Nephrology 2007; 3: 138-153</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Extract from article&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;A review published in Nature Clinical Practice Nephrology has described the pathophysiology and management of uraemic bleeding syndrome. The review describes the evidence base for the following treatment options: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;dialysis &lt;/LI&gt;
&lt;LI&gt;erythropoietin &lt;/LI&gt;
&lt;LI&gt;cryoprecipitate &lt;/LI&gt;
&lt;LI&gt;desmopressin, and &lt;/LI&gt;
&lt;LI&gt;conjugated estrogens&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;Additionally, the review presents an evidence-based treatment algorithm to help guide clinicians through most clinical scenarios to manage the condition&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>23/09/2010 12:17:04</lastReviewDate>
    <expiryDate>23/09/2011 12:17:04</expiryDate>
  </document>
  <document>
    <id>156433</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/assetRoot/04/13/69/98/04136998.pdf]]&gt;</url>
    <title>Example of good practice - adolescent diagnosed with kidney disease</title>
    <publicationDate></publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>CARE PATHWAY</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASE IN CHILDREN AND ADOLESCENTS,NATIONAL SERVICE FRAMEWORK FOR RENAL SERVICES/POLICY DOCUMENTS,IN CHILDREN,RENOVASCULAR DISEASES,INHERITED KIDNEY DISEASE,SPECIALTIES,CONGENITAL ABNORMALITIES,GUIDELINES/EBM,CHILD HEALTH,NEPHROLOGY,STAFF USE,CHILDREN'S NSF,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Flow diagram for patient journey</description>
    <body>&lt;![CDATA[ One of 4 Good Practice Guides published by the Department of Health]]&gt;</body>
    <lastReviewDate>23/09/2010 12:17:12</lastReviewDate>
    <expiryDate>23/09/2011 12:17:12</expiryDate>
  </document>
  <document>
    <id>156430</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/assetRoot/04/13/69/96/04136996.pdf]]&gt;</url>
    <title>Example of good practice - child diagnosed with kidney disease before birth</title>
    <publicationDate>2006-07-03T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>CARE PATHWAY</publicationType>
    <topics>&lt;![CDATA[ SCREENING OPTIONS,PRENATAL SCREENING,KIDNEY DISEASE IN CHILDREN AND ADOLESCENTS,STAFF USE,NEPHROLOGY,CHILD HEALTH,GUIDELINES/EBM,FETAL MEDICINE,CONGENITAL ABNORMALITIES,SPECIALTIES,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Care Pathway issued by Department of Health July 2006</description>
    <body>&lt;![CDATA[ &lt;P&gt;One of 4 Good Practice Guides - in form of algorithm&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>23/09/2010 12:17:18</lastReviewDate>
    <expiryDate>23/09/2011 12:17:18</expiryDate>
  </document>
  <document>
    <id>156436</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/assetRoot/04/13/70/00/04137000.pdf]]&gt;</url>
    <title>Example of good practice - end of life care pathway (child or adolescent)</title>
    <publicationDate></publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>CARE PATHWAY</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASE IN CHILDREN AND ADOLESCENTS,END-OF-LIFE CARE,GUIDELINES/EBM,CHILD HEALTH,SPECIALTIES,STAFF USE,PALLIATIVE CARE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Flow diagram showing links with professional inputs</description>
    <body>&lt;![CDATA[ One of 4 Good Practice Guides published by the Department of Health July 2006]]&gt;</body>
    <lastReviewDate>23/09/2010 12:17:30</lastReviewDate>
    <expiryDate>23/09/2011 12:17:30</expiryDate>
  </document>
  <document>
    <id>156435</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/assetRoot/04/13/69/99/04136999.pdf]]&gt;</url>
    <title>Example of good practice - transition from child to adult service</title>
    <publicationDate></publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>CARE PATHWAY</publicationType>
    <topics>&lt;![CDATA[ NATIONAL SERVICE FRAMEWORK FOR RENAL SERVICES/POLICY DOCUMENTS,KIDNEY DISEASE IN CHILDREN AND ADOLESCENTS,CHILDREN'S NSF,STAFF USE,CHILD HEALTH,GUIDELINES/EBM,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Flow chart of patient journey</description>
    <body>&lt;![CDATA[ One of 4 Good Practice Guides published by the Department of Health July 2006]]&gt;</body>
    <lastReviewDate>23/09/2010 12:17:39</lastReviewDate>
    <expiryDate>23/09/2011 12:17:39</expiryDate>
  </document>
  <document>
    <id>388052</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=388052]]&gt;</url>
    <title>Exercise and kidney diseases: Systematic reviews and meta-analyses</title>
    <publicationDate>2010-09-20T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ OTHERS,INTERVENTIONS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Exercise and kidney diseases: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Afshinnia, F., T. J. Wilt, et al. (2010). "Weight loss and proteinuria: Systematic review of clinical trials and comparative cohorts." Nephrology Dialysis Transplantation 25(4): 1173-1183. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Weight%20loss%20and%20proteinuria%3A%20Systematic%20review%20of%20clinical%20trials%20and%20comparative%20cohorts" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Bennett, P. N., L. Breugelmans, et al. (2010). "Sustaining a hemodialysis exercise program: a review." Seminars in Dialysis 23(1): 62-73.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Sustaining%20a%20hemodialysis%20exercise%20program%3A%20a%20review" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Johansen, K. L., F. O. Finkelstein, et al. (2010). "Systematic review and meta-analysis of exercise tolerance and physical functioning in dialysis patients treated with erythropoiesis-stimulating agents." American Journal of Kidney Diseases 55(3): 535-48.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Systematic%20review%20and%20meta-analysis%20of%20exercise%20tolerance%20and%20physical%20functioning%20in%20dialysis%20patients%20treated%20with%20erythropoiesis-stimulating%20agents" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Segura-Orti, E. (2010). "Exercise in haemodialysis patients: a literature systematic review [Spanish] Ejercicio en pacientes en hemodialisis: revision sistematica de la literatura." Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 30(2): 236-246.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Exercise%20in%20haemodyalisis%20patients%3A%20a%20literature%20systematic%20review" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Gillison, F. B., S. M. Skevington, et al. (2009). "The effects of exercise interventions on quality of life in clinical and healthy populations; a meta-analysis." Social Science and Medicine 68(9): 1700-1710.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=effects%20of%20exercise%20interventions%20on%20quality%20of%20life%20in%20clinical%20and%20healthy%20populations%3B%20a%20meta-analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Macdonald, J. H., D. Kirkman, et al. (2009). "Kidney transplantation: a systematic review of interventional and observational studies of physical activity on intermediate outcomes." Adv Chronic Kidney Dis 16(6): 482-500.&amp;nbsp;[&lt;A href="nelh:360817:0" name=internalLink&gt;Link to&amp;nbsp;DARE abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Navaneethan, S. D., H. Yehnert, et al. (2009). "Weight loss interventions in chronic kidney disease: a systematic review and meta-analysis." Clin J Am Soc Nephrol 4(10): 1565-74.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Weight%20loss%20interventions%20in%20chronic%20kidney%20disease%3A%20a%20systematic%20review%20and%20meta-analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <expiryDate>20/09/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>306006</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=306006]]&gt;</url>
    <title>February 2009 Kidney Diseases Specialist Library Newsletter</title>
    <publicationDate>2009-02-09T00:00:00</publicationDate>
    <publisher>Kidney Diseases Specialist Library</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Newsletter&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=left&gt;&lt;STRONG&gt;The Kidney Diseases Specialist Library is for busy health professionals, providing them with high quality information and keeping them up to date with the latest research and developments in this area.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=center&gt;&amp;nbsp;&amp;nbsp;&lt;IMG id=nelh_tempImage0 height=135 alt="Kidney Cross section" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID306006/nelhImp_0000_KidneyCrosssection_istock_vsmall_08jan09.jpg" width=217 border=0 name=nelh_tempImage0&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2 align=left&gt;&lt;BIG&gt;New resources in January 2009:&lt;/BIG&gt;&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;Guidance&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=155511&amp;amp;tabID=288" target="_blank"&gt;The CKD eGuide has been updated&lt;/A&gt; - Renal Association&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=305877&amp;amp;tabID=288" target="_blank"&gt;Personal Health Budgets&lt;/A&gt; - Department of Health&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=303549&amp;amp;tabID=288" target="_blank"&gt;New Guidelines for acute management of first presentation of renal or ureteric lithiasis&lt;/A&gt; - British Association of Urological Surgeons&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/KIDNEY/ViewResource.aspx?resID=305174&amp;amp;tabID=288" target="_blank"&gt;New guidance on Machine perfusion systems and cold static storage of kidneys from deceased donors&lt;/A&gt; -&amp;nbsp; NICE&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=304731&amp;amp;tabID=288" target="_blank"&gt;Commissioning guide on Supporting people with long term conditions and personalised care planning&lt;/A&gt; - Department of Health&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=301399&amp;amp;tabID=288" target="_blank"&gt;Febuxostat for the management of hyperuricaemia in people with gout&lt;/A&gt; - NICE&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Evidence&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://content.nejm.org/cgi/content/short/360/5/459?rss=1&amp;amp;query=current" target="_blank"&gt;NEJM article on Long Term Consequences of Kidney Donation&lt;/A&gt; - New England Journal of Medicine Jan 29 2009&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=304876&amp;amp;tabID=289" target="_blank"&gt;Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura&lt;/A&gt; - The Cochrane Database of Systematic Reviews Issue 1 2009&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=304902&amp;amp;tabID=289" target="_blank"&gt;Steroid avoidance or withdrawal for kidney transplant recipients&lt;/A&gt; - The Cochrane Database of Systematic Reviews Issue 1 2009&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://medicine.plosjournals.org/perlserv/?request=get-document&amp;amp;doi=10.1371/journal.pmed.1000016&amp;amp;ct=1&amp;amp;SESSID=866165d87771b3eff79b5c005f52e89b" target="_blank"&gt;Reduced Glomerular Filtration Rate and Its Association with Clinical Outcome in Older Patients at Risk of Vascular Events Secondary Analysis&lt;/A&gt; - PLoS Med 2009&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.bmj.com/cgi/content/extract/338/jan16_1/a3021" target="_blank"&gt;BMJ Clinical Review on the Assessment and management of nonvisible haematuria in primary care&lt;/A&gt; - BMJ 2009 338 a3021&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)60001-5/abstract" target="_blank"&gt;Review published in the Lancet on eculizumab for paroxysmal nocturnal haemoglobinuria&lt;/A&gt; - The Lancet &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=303916&amp;amp;tabID=289" target="_blank"&gt;A meta analysis on Interferon therapy for HCV-associated glomerulonephritis&lt;/A&gt; - Database of Abstracts of Reviews of Effects&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=303961&amp;amp;tabID=289" target="_blank"&gt;A review of the effectiveness and safety of different hemodialysis modalities&lt;/A&gt; - Database of Abstracts of Reviews of Effects&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=303955&amp;amp;tabID=289" target="_blank"&gt;Does warfarin safely prevent clotting of hemodialysis catheters a review of efficacy and safety&lt;/A&gt; - Database of Abstracts of Reviews of Effects&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=303915&amp;amp;tabID=289" target="_blank"&gt;Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy a meta analysis&lt;/A&gt; - Database of Abstracts of Reviews of Effects&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/duets/" target="_blank"&gt;New UK DUETs website&lt;/A&gt; – UK Database of Uncertainties&amp;nbsp;about the Effects of Treatment&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk//en/NeLM-Area/Evidence/Medicines-Q--A/What-factors-need-to-be-considered-when-dosing-patients-with-renal-impairment/" target="_blank"&gt;New information about factors to consider when dosing patients with renal impairment&lt;/A&gt; - South West Medicines Information and Training&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Reference&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=305545&amp;amp;tabID=290" target="_blank"&gt;18 week CKD pathways updated&lt;/A&gt; - 18 Weeks website&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=303564&amp;amp;tabID=290" target="_blank"&gt;Renal NSF Update for December 2008&lt;/A&gt; - NHS Kidney Care&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Education/ CPD&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/KIDNEY/ViewResource.aspx?resID=305077&amp;amp;tabID=291" target="_blank"&gt;Interactive case history from BMJ Learning on UTIs in Children&lt;/A&gt; - BMJ Learning&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Patient information&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=303650&amp;amp;tabID=292" target="_blank"&gt;New Kidney Disease Self Assessment tool&lt;/A&gt; - NHS Choices&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=303566&amp;amp;tabID=292" target="_blank"&gt;New NHS Choices Guide on Understanding Kidney Disease&lt;/A&gt; - NHS Choices&lt;/LI&gt;&lt;/UL&gt;
&lt;P align=center&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;&lt;STRONG&gt;Please take five minutes to fill in our new survey of library users: This is an eight-question survey which will provide vital information to the Kidney Diseases Specialist Library team. &lt;/STRONG&gt;&lt;A href="http://www.insitefulsurveys.com/Survey.asp?SI=110700812422" target="_blank"&gt;&lt;STRONG&gt;Link to the survey&lt;/STRONG&gt;&lt;/A&gt;&lt;STRONG&gt;.&lt;/STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>11/01/2011 10:21:50</lastReviewDate>
    <expiryDate>11/01/2012 10:21:50</expiryDate>
  </document>
  <document>
    <id>343124</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=343124]]&gt;</url>
    <title>February 2010 NHS Evidence - kidney diseases and male urogenital disorders newsletter</title>
    <publicationDate>2010-02-04T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;February 2010 NHS Evidence - kidney diseases and male urogenital disorders newsletter&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Welcome to the kidney diseases and male urogenital disorders specialist collection enewsletter for&amp;nbsp;February 2010. &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;NHS Evidence - kidney diseases and male urogenital disorders is for busy health professionals, providing them with high quality information and keeping them up to date with the latest research and developments in this area. You can now join our mailing list to receive regular updates. &lt;A href="https://www.jiscmail.ac.uk/cgi-bin/webadmin?A0=NHSEVIDENCEKDMU" target="_blank"&gt;Click here for the link&lt;/A&gt;.&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=center&gt;&lt;STRONG&gt;***** Quick survey open to library users to find out what information you need and what you think of our Annual Evidence Updates and Treatment Uncertainties: &lt;/STRONG&gt;&lt;STRONG&gt;&lt;A href="http://www.surveymonkey.com/s/GGMQ5T8" target="_blank"&gt;http://www.surveymonkey.com/s/GGMQ5T8&lt;/A&gt; &lt;/STRONG&gt;&lt;STRONG&gt;*****&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P align=center&gt;&lt;IMG id=nelh_tempImage0 height=174 alt="Female nurse online" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID343124/nelhImp_0000_Femalenurseonline.jpg" width=263 border=0 name=nelh_tempImage0&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Links to:&lt;/STRONG&gt;&lt;/P&gt;&lt;STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="#kidney"&gt;New Kidney Diseases items&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="#mug"&gt;New Male Urogenital Disorders items&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0005_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&amp;nbsp;RSS FEEDS&amp;nbsp; &lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0006_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;You can receive news from the kidney diseases specialist collection from the RSS feeds we provide:&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/RSS/CMS.aspx?feed=57" target="_blank"&gt;&lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0007_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk/kidney/RSS/CMS.aspx?feed=57" target="_blank"&gt;&lt;A href="http://www.library.nhs.uk/kidney/RSS/CMS.aspx?feed=57" target="_blank"&gt;New Kidney Diseases Resources&lt;/A&gt;&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/RSS/CMS.aspx?feed=136" target="_blank"&gt;&lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0008_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk/kidney/RSS/CMS.aspx?feed=136" target="_blank"&gt;New Male Urogenital Disorders Resources&lt;/A&gt; &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/KIDNEY/RSS/News.aspx" target="_blank"&gt;&lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0008_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk//kidney/News.aspx" target="_blank"&gt;Kidney diseases and male urogenital disorders in the news&lt;/A&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/rss/Directory/MoreAboutRss.aspx" target="_blank"&gt;Click through this link to find out more about RSS feeds.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;JOURNALS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;You can link through to the latest Tables of Contents from all the major kidney, transplant and urology journals from &lt;A href="http://www.library.nhs.uk/KIDNEY/Page.aspx?pagename=EJOURNALS" target="_blank"&gt;this page&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=3&gt;&lt;STRONG&gt;&lt;BIG&gt;New resources added in&amp;nbsp;January 2010&lt;/BIG&gt;&lt;/STRONG&gt; &lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A name=kidney&gt;Chronic Kidney&amp;nbsp;Disease&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;NEW website for NHS Kidney Care: &lt;A href="http://www.kidneycare.nhs.uk/" target="_blank"&gt;http://www.kidneycare.nhs.uk/&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:338644:0" name=internalLink&gt;Annual Evidence Update 18 January 2010: Patient and carer involvement in chronic disease. Contents page&lt;/A&gt;. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:341800:0" name=internalLink&gt;Interventions for bone disease in children with chronic kidney disease&lt;/A&gt;. Cochrane systematic review 2010.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:342015:0" name=internalLink&gt;Chronic Kidney Disease: frequently asked questions&lt;/A&gt;. Care pathway from NHS Employers.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/Evidence/Medicines-Q--A/What-is-the-rationale-and-evidence-for-combining-angiotensin-converting-enzyme-inhibitors-with-angiotensin-receptor-blockers-in-renal-disease/" target="_blank"&gt;What is the rationale and evidence for combining angiotensin converting enzyme inhibitors with angiotensin II receptor blockers in renal disease?&lt;/A&gt; National electronic Library for Medicines (22/01/10). &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:333626:0" name=internalLink&gt;Chronic Kidney Disease: Systematic Reviews and Meta-analyses.&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Acute kidney injury&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:341786:0" name=internalLink&gt;Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function&lt;/A&gt;. Cochrane systematic review 2010.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:341717:0" name=internalLink&gt;Nutritional support for acute kidney injury&lt;/A&gt;. Cochrane systematic review 2010.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:332400:0" name=internalLink&gt;Acute Kidney Injury: Systematic reviews and meta-analyses&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Hypertension&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:341774:0" name=internalLink&gt;Roselle&amp;nbsp;for hypertension in adults&lt;/A&gt;. Cochrane systematic review 2010. &lt;A href="nelh:333619:0" name=internalLink&gt;&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Renovascular disease&lt;/STRONG&gt;&lt;/P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:334152:0" name=internalLink&gt;Aprotinin and the risk of death and renal dysfunction in patients undergoing cardiac surgery: a meta-analysis of epidemiologic studies&lt;/A&gt;. DARE abstract.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:341905:0" name=internalLink&gt;Renovascular disease: Systematic reviews and meta-analyses&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Diabetic nephropathy&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:333667:0" name=internalLink&gt;Diabetic Nephropathy: Systematic reviews and meta-analyses&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Dialysis&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:334841:0" name=internalLink&gt;Let's talk renal rubbish&lt;/A&gt;. Podcast from the Campaign for Greener Healthcare. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:334840:0" name=internalLink&gt;Conserving water in haemodialysis: case study and how-to guide&lt;/A&gt;.&amp;nbsp;Campaign for Greener Healthcare. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:341736:0" name=internalLink&gt;Interventions for preventing infectious complications in haemodialysis patients with central venous catheters&lt;/A&gt;.&amp;nbsp;&amp;nbsp;Cochrane systematic review 2010.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:341647:0" name=internalLink&gt;Kidney dialysis: developing costs to deliver an equitable and high quality service; final report&lt;/A&gt;. Department of Health commissioning report. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:259762:0" name=internalLink&gt;Renal Association guidelines – haemodialysis&lt;/A&gt;. Published 2007, updated December 2009.&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Transplantation&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:334140:0" name=internalLink&gt;A meta-analysis of mini-open versus standard open and laparoscopic living donor nephrectomy&lt;/A&gt; - DARE abstract.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:341851:0" name=internalLink&gt;Renal transplant: Systematic reviews and meta-analyses&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Kidney Cancer&lt;/STRONG&gt; &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2010---January/20/Risk-of-sarcopenia-with-sorafenib-in-patients-with-advanced-renal-cell-carcinoma-/" target="_blank"&gt;Risk of sarcopenia with sorafenib in patients with advanced renal cell carcinoma&lt;/A&gt;&amp;nbsp;National electronic Library for Medicines (20/01/10).&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/Evidence/Disease-Focused-Reviews/NHS-Health-Technology-Assessment-Bevacizumab-sorafenib-and-sunitinib-for-renal-cell-carcinoma/" target="_blank"&gt;NHS Health Technology Assessment: Bevacizumab, sorafenib and sunitinib for renal cell carcinoma&lt;/A&gt;. National electronic Library for Medicines (13/01/10).&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/SearchResults.aspx?catID=12107&amp;amp;tabID=289&amp;amp;" target="_blank"&gt;Kidney cancer: systematic reviews and meta-analyses&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Kidney stones&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:339010:0" name=internalLink&gt;Kidney stones: Systematic reviews and meta-analyses&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A name=mug&gt;&lt;/A&gt;&lt;A name=mug&gt;Male Urogenital Disorders&lt;/A&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Male Bladder Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:334216:0" name=internalLink&gt;Ancillary bladder tumor-associated antigen (BTA) testing for bladder cancer screening and detection&lt;/A&gt;. HTA.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:334217:0" name=internalLink&gt;Ancillary hyaluronic acid (HA)/Hyaluronidase (HAase) testing for bladder cancer screening and detection&lt;/A&gt;. HTA.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:334218:0" name=internalLink&gt;Ancillary ImmunoCyt/uCyt+ testing for bladder cancer screening and detection&lt;/A&gt;. HTA.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:334219:0" name=internalLink&gt;Ancillary nuclear matrix protein 22 (NMP22) testing for bladder cancer screening and detection&lt;/A&gt;. HTA.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:334220:0" name=internalLink&gt;Ancillary urinary cytokeratin (CK) tests for bladder cancer screening and detection&lt;/A&gt;. HTA.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:334221:0" name=internalLink&gt;Ancillary urinary microsatellite analysis (MA) for bladder cancer screening and detection&lt;/A&gt;. HTA.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:334222:0" name=internalLink&gt;Ancillary urinary survivin testing for bladder cancer screening and detection&lt;/A&gt;. HTA.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:334223:0" name=internalLink&gt;Ancillary urinary telomerase testing for bladder cancer screening and detection&lt;/A&gt;. HTA.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:334224:0" name=internalLink&gt;Ancillary UroVysion fluorescence in situ hybridization (FISH) testing for bladder cancer screening and detection&lt;/A&gt;. HTA.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:334251:0" name=internalLink&gt;Electrical percutaneous tibial nerve stimulation for urinary voiding dysfunction&lt;/A&gt;. HTA. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Prostate Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:334202:0" name=internalLink&gt;Active surveillance and radical prostatectomy for clinically localized, low-risk prostate cancer&lt;/A&gt;. HTA. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.tin.nhs.uk/sys_upl/templates/PT_Directory_RSS/PT_Directory_RSS_details.asp?id=132725&amp;amp;pgid=1523&amp;amp;tid=153" target="_blank"&gt;Prostate cancer false positive rate&lt;/A&gt;. News item from the NHS Improvement Network (13/01/10).&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:111428:0" name=internalLink&gt;New systematic reviews identified by NHS Evidence - cancer&lt;/A&gt;.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Testicular/Scrotal Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Systematic review: &lt;A href="nelh:224623:0" name=internalLink&gt;Management of Stage I Seminomatous Testicular Cancer: a Systematic Review, 2009&lt;/A&gt;.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Male Urinary Incontinence&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:333390:0" name=internalLink&gt;2010 Annual Evidence Update on Male Urinary Incontinence - link to contents page&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Sexually Transmitted Infections&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:334103:0" name=internalLink&gt;Cognitive-behavioral stress management interventions for persons living with HIV: a review and critique of the literature&lt;/A&gt;. DARE abstract. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:334166:0" name=internalLink&gt;Directly observed antiretroviral therapy: a systematic review and meta-analysis of randomised clinical trials&lt;/A&gt;. DARE abstract. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:334139:0" name=internalLink&gt;Effects and effectiveness of life skills education for HIV prevention in young people&lt;/A&gt;. DARE abstract. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:341793:0" name=internalLink&gt;Massage therapy for people with HIV/AIDS&lt;/A&gt;.&amp;nbsp;Cochrane systematic review 2010.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:341762:0" name=internalLink&gt;Psychosocial interventions for reducing injection and sexual risk behaviour for preventing HIV in drug users&lt;/A&gt;.&amp;nbsp;Cochrane systematic review 2010.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Fertility&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:338640:0" name=internalLink&gt;Infertility provision in England&lt;/A&gt;. Published December 2009. Guideline from the Royal College of Nursing.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;**Subscribe to the NHS Evidence Eyes on Evidence Newsletter**&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;If you would like to receive Eyes on Evidence, the monthly e-bulletin from NHS Evidence, please sign up at &lt;A href="http://www.evidence.nhs.uk/NewsletterSignup.aspx" target="_blank"&gt;http://www.evidence.nhs.uk/NewsletterSignup.aspx&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The bulletin will keep you updated with new and important evidence and key developments on the NHS Evidence portal.&amp;nbsp; It comes out on the second Wednesday of the month and can be sent to any e-mail address that you provide.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>11/01/2011 10:21:55</lastReviewDate>
    <expiryDate>11/01/2012 10:21:55</expiryDate>
  </document>
  <document>
    <id>405435</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=405435]]&gt;</url>
    <title>February 2011 NHS Evidence - kidney diseases and male urogenital disorders newsletter</title>
    <publicationDate>2011-02-01T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;February 2011 NHS Evidence - kidney diseases and male urogenital disorders newsletter&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Welcome to the kidney diseases and male urogenital disorders specialist collection enewsletter for&amp;nbsp;FEBRUARY 2011. &lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=left&gt;NHS Evidence - kidney diseases and male urogenital disorders is for busy health professionals, providing them with high quality information and keeping them up to date with the latest research and developments in this area.&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;New this month:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;&lt;A href="nelh:402372:0" name=internalLink&gt;New mini topic review on Recent Clinical Trials in Adult Polycystic Kidney Disease&lt;/A&gt;. &lt;/DIV&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;&lt;A href="nelh:401615:0" name=internalLink&gt;2011 Annual Evidence Update&amp;nbsp;on Male Urinary Incontinence&lt;/A&gt;.&lt;/DIV&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;&lt;A href="http://www.library.nhs.uk/WOMENSHEALTH/ViewResource.aspx?resID=397707" target="_blank"&gt;2011 Annual Evidence Update on Female Urinary Incontinence&lt;/A&gt;.&lt;/DIV&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P align=left&gt;&lt;STRONG&gt;**Please note - this newsletter will no longer be provided from 1st April 2011.**&lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Links to:&lt;/STRONG&gt;&lt;/P&gt;&lt;STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="#kidney"&gt;New Kidney Diseases items&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="#mug"&gt;New Male Urogenital Disorders items&lt;/A&gt;&lt;/STRONG&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P align=center&gt;&amp;nbsp;&amp;nbsp;&lt;IMG style="WIDTH: 212px; HEIGHT: 227px" id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="Examining the Evidence" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID405435/nelhImp_0000_ExaminingtheevidenceNov10.jpg" width=216 height=253&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;FEBRUARY 2011: RENAL HOT TOPICS &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;JAMA&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Thomas F. Hiemstra, Michael Walsh, Alfred Mahr, Caroline O. Savage, Kirsten de Groot, Lorraine Harper, Thomas Hauser, Irmgard Neumann, Vladimir Tesar, Karl-Martin Wissing, Christian Pagnoux, Wilhelm Schmitt, David R. W. Jayne , for the European Vasculitis Study Group (EUVAS). Mycophenolate Mofetil vs Azathioprine for Remission Maintenance in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: A Randomized Controlled Trial. JAMA. 2010;304(21):2381-2388. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/21060104" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;EM&gt;156 patients randomly assigned to azathiopine or mycophenolate after standard induction treatment with cyclophosphamide. The primary endpoint was time to relapse, with relapse being more frequent in the mycophenolate group. &lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The Lancet &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Matthew T James, Brenda R Hemmelgarn, Natasha Wiebe, Neesh Pannu, Braden J Manns, Scott W Klarenbach, Marcello Tonelli, for the Alberta Kidney Disease Network. Glomerular filtration rate, proteinuria, and the incidence and consequences of acute kidney injury: a cohort study. The Lancet 2010; 376: 2096-2104. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/21094997" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;EM&gt;Cohort study of 920 985 adults residing in Alberta, Canada over a 5 year period. The presence of proteinuria was associated with a 4-fold increase in risk in admission to hospital, and&amp;nbsp; relatice increase in risk of requiring renal replacement therapy in AKI.&lt;/EM&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Symplicity HTN-2 Investigators.&amp;nbsp; Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. The Lancet 2010; 376:1903-1910. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/21093036" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;EM&gt;In a multicentre, prospective, randomised trial, patients who had a baseline systolic blood pressure of 160 mm Hg or more (=150 mm Hg for patients with type 2 diabetes), despite taking three or more antihypertensive drugs, were randomly allocated in a one-to-one ratio to undergo renal denervation with previous treatment or to maintain previous treatment alone. At 6 months, 41 (84%) of 49 patients who underwent renal denervation had a reduction in systolic blood pressure of 10 mm Hg or more, compared with 18 (35%) of 51 controls (p&amp;lt;0•0001).&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;NEJM&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;The FHN Trial Group. In-Center Hemodialysis Six Times per Week versus Three Times per Week. N Engl J Med 2010; 363:2287-2300. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/21091062" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&amp;nbsp;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;EM&gt;Patients were randomly assigned to undergo hemodialysis six times per week (frequent hemodialysis, 125 patients) or three times per week (conventional hemodialysis, 120 patients) for 12 months. Frequent hemodialysis was associated with improved control of hypertension and hyperphosphatemia, although there was a higher requirement for access assessment and revision in this group, a potentially importance co-morbidity. Despite this, the hazard ratio for death and changes in LV mass were significantly lower in the frequently dialysed group.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;CJASN&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Kandula P, Dobre M, Schold JD, Schreiber MJ Jr, Mehrotra R, Navaneethan SD.&amp;nbsp;Vitamin D Supplementation in Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Observational Studies and Randomized Controlled Trials. CJASN January 2011 6): (1) 50-62; published ahead of print September 28, 2010, doi:10.2215/CJN.03940510. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20876671" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;IMG id=nelh_tempImage0 alt=" name=nelh_tempImage0 border=" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0005_feed.gif" width=16 height=16 0? RSS icon?&gt;&amp;nbsp;RSS FEEDS&amp;nbsp; &lt;IMG id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0006_feed.gif" width=16 height=16&gt;&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;You can receive news from the kidney diseases specialist collection from the RSS feeds we provide:&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/RSSFeed.aspx?feed=57" target="_blank"&gt;&lt;IMG id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0007_feed.gif" width=16 height=16&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="https://rmsadmin.library.nhs.uk/admin/wizards/articles/kidney" target="_blank"&gt;New Kidney Diseases Resources&lt;/A&gt;&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/RSSFeed.aspx?feed=136" target="_blank"&gt;&lt;IMG id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0008_feed.gif" width=16 height=16&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk/kidney/RSSFeed.aspx?feed=136" target="_blank"&gt;New Male Urogenital Disorders Resources&lt;/A&gt; &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk//kidney/News.aspx" target="_blank"&gt;&lt;IMG id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0008_feed.gif" width=16 height=16&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk//kidney/News.aspx" target="_blank"&gt;Kidney diseases and male urogenital disorders in the news&lt;/A&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/rss/Directory/MoreAboutRss.aspx" target="_blank"&gt;Click through this link to find out more about RSS feeds.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;JOURNALS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;You can link through to the latest Tables of Contents from all the major kidney, transplant and urology journals from &lt;A href="http://www.library.nhs.uk/KIDNEY/Page.aspx?pagename=EJOURNALS" target="_blank"&gt;this page&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=3&gt;&lt;STRONG&gt;&lt;BIG&gt;Resources added in&amp;nbsp;January 2011&lt;/BIG&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A name=kidney&gt;Chronic Kidney&amp;nbsp;Disease&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/KIDNEY/ViewResource.aspx?resID=333624" target="_blank"&gt;Kidney diseases evidence updated - systematic reviews and meta analyses&lt;/A&gt;. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://cjasn.asnjournals.org/content/6/1/114.short?rss=1" target="_blank"&gt;Proteinuria Induced by Parenteral Iron in Chronic Kidney Disease - A Comparative Randomized Controlled Trial&lt;/A&gt;. New RCT published in the Clinical Journal of the American Society of Nephrology (CJASN).&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://cjasn.asnjournals.org/content/6/1/50.short?rss=1" target="_blank"&gt;Vitamin D Supplementation in Chronic Kidney Disease - A Systematic Review and Meta-Analysis of Observational Studies and Randomized Controlled Trials&lt;/A&gt;. New systematic review published in the Clinical Journal of the American Society of Nephrology (CJASN).&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://renaltsar.blogspot.com/2011/01/how-do-quality-accounts-measure-up.html" target="_blank"&gt;Renal Tsar - How do quality accounts measure up?&lt;/A&gt; Dr Donal O'Donoghue (19/01/11).&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:385505:0" name=internalLink&gt;Weight loss interventions in chronic kidney disease- a systematic review and meta-analysis&lt;/A&gt;. CRD Database of Abstracts of Reviews of Effects. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://renaltsar.blogspot.com/2011/02/care-record-guarantee.html" target="_blank"&gt;Renal Tsar - The Care Record Guarantee.&lt;/A&gt; Dr Donal O'Donoghue (02/01/11).&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://renaltsar.blogspot.com/2011/02/bumpter-return-to-national-vascular.html" target="_blank"&gt;Renal Tsar - Bumper return to the national vascular audit&lt;/A&gt;. Dr Donal O'Donoghue (02/01/11).&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:357404:0" name=internalLink&gt;Educational interventions in kidney disease care- a systematic review of randomized trials&lt;/A&gt;. CRD Database of Abstracts of Reviews of Effects.&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Diabetic nephropathy&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;No new resources this month.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Hypertension&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/Evidence/Medicines-Management/References/2011---January/24/Pharmacist-interventions-to-enhance-blood-pressure-control-and-adherence-to-antihypertensive-therapy-review-and-meta-analysis/" target="_blank"&gt;Pharmacist interventions to enhance blood pressure control and adherence to antihypertensive therapy- review and meta-analysis&lt;/A&gt;. National electronic Library for Medicines (24/01/11).&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2011---January/26/Pay-for-performance-doesnt-seem-to-improve-quality-of-care-in-hypertension/" target="_blank"&gt;Pay for performance doesn't seem to improve quality of care in hypertension&lt;/A&gt;. National electronic Library for Medicines (27/01/11).&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2011---January/24/Meta-analysis-pharmacist-interventions-to-improve-anti-hypertensive-adherence-and-BP-control/" target="_blank"&gt;Meta-analysis- pharmacist interventions to improve anti-hypertensive adherence and BP control&lt;/A&gt;. National electronic Library for Medicines (25/01/11).&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:404488:0" name=internalLink&gt;Drug treatment of hypertension - update search&amp;nbsp;[rapid report]. &lt;/A&gt;CRD Health Technology Assessment Database. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:377013:0" name=internalLink&gt;Home blood pressure monitoring&lt;/A&gt;. CRD Health Technology Assessment Database. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:404491:0" name=internalLink&gt;Increase of physical activity in essential hypertension - rapid report&lt;/A&gt;. CRD Health Technology Assessment Database. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Acute kidney injury&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:332400:0" name=internalLink&gt;Updated systematic reviews and meta analyses on Acute Kidney Injury&lt;/A&gt;. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;End-Stage Renal Disease&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20833832" target="_blank"&gt;The Lived Experiences of Children and Adolescents With End-Stage Renal Disease&lt;/A&gt;. A new article from Qualitative Health Research about children's perceptions of ESRD.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Renovascular diseases&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;No new resources this month.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Glomerulonephritis&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/21068142" target="_blank"&gt;The incidence of primary glomerulonephritis worldwide- a systematic review of the literature&lt;/A&gt;. A new systematic review published in Nephrol. Dial. Transplant.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Other renal conditions&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:238102:0" name=internalLink&gt;Interventions for idiopathic steroid-resistant nephrotic syndrome in children&lt;/A&gt;. A new Cochrane systematic review.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://cjasn.asnjournals.org/content/6/1/63.short?rss=1" target="_blank"&gt;Daily Corticosteroids Reduce Infection-associated Relapses in Frequently Relapsing Nephrotic Syndrome - A Randomized Controlled Trial&lt;/A&gt;. New RCT published in the Clinical Journal of the American Society of Nephrology (CJASN).&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:402372:0" name=internalLink&gt;New mini topic review on Recent Clinical Trials in Adult Polycystic Kidney Disease&lt;/A&gt;. This mini topic review covers six trials published in 2010 about adult polycystic kidney disease. Written by Dr Edward Sharples&lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Renal tract infections&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://clinicalevidence.bmj.com/ceweb/conditions/woh/0807/0807.jsp?rss=true" target="_blank"&gt;Clinical Evidence topic - Acute pyelonephritis in non-pregnant women&lt;/A&gt;. Published by BMJ Clinical Evidence.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Kidney stones&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/Evidence/Medicines-Management/References/2011---January/10/Drugs-for-kidney-stones/" target="_blank"&gt;Drugs for kidney stones&lt;/A&gt;. National electronic Library for Medicines (11/01/11)&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Renal vasculitis&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;No new resources this month.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Haemodialysis&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/Evidence/Medicines-Management/References/2011---January/25/Sevelamer-prescriptions-after-reporting-of-the-Dialysis-Clinical-Outcomes-Revisited-DCOR-trial-findings/" target="_blank"&gt;Sevelamer prescriptions after reporting of the Dialysis Clinical Outcomes Revisited -DCOR- Trial Findings&lt;/A&gt;. National electronic Library for Medicines (25/01/11).&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://renaltsar.blogspot.com/2011/01/q-best-practice-tariff-for-adult.html" target="_blank"&gt;Renal Tsar - Best Practice Tariff for Adult Haemodialysis&lt;/A&gt;. Dr Donal O'Donoghue (19/01/11).&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://renaltsar.blogspot.com/2011/01/eliminating-mixed-sex-accommodation.html" target="_blank"&gt;Renal Tsar - Eliminating mixed sex accommodation - what does it mean for dialysis units&lt;/A&gt;. Dr Donal O'Donoghue (19/01/11).&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:368403:0" name=internalLink&gt;Cost-effectiveness of frequent in-center hemodialysis&lt;/A&gt;. NHS Economic Evaluation Database. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2011---January/27/Weekly-alteplase-better-than-heparin-alone-as-a-central-catheter-lock-in-haemodialysis/" target="_blank"&gt;Weekly alteplase better than heparin alone as a central catheter lock in haemodialysis.&lt;/A&gt; National electronic Library for Medicines (28/01/11).&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nejm.org/doi/full/10.1056/NEJMe1013952" target="_blank"&gt;New England Journal of Medicine editorial on Haemodialysis&lt;/A&gt;. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Peritoneal Dialysis&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2011---January/21/Update-on-European-Medicines-Agencys-review-of-the-manufacture-of-Baxters-peritoneal-dialysis-solutions-and-potential-presence-of-endotoxins-/" target="_blank"&gt;Update on European Medicines Agency review of the manufacture of Baxters peritoneal dialysis solutions and potential presence of endotoxins&lt;/A&gt;. National electronic Library for Medicines (24/01/11).&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://renaltsar.blogspot.com/2011/01/nice-guideline-on-peritoneal-dialysis.html" target="_blank"&gt;Renal Tsar - NICE Guideline on Peritoneal Dialysis&lt;/A&gt;. Dr Donal O'Donoghue (26/01/11).&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Transplantation&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/Evidence/Drug-Specific-Reviews/SMC-accepts-valganciclovir-Valcyte-for-restricted-use-in-prevention-of-CMV-disease-in-solid-organ-transplant-recipients/" target="_blank"&gt;SMC accepts valganciclovir for restricted use in prevention of CMV disease in solid organ transplant recipients&lt;/A&gt;. National electronic Library for Medicines (19/01/11).&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/21257239?dopt=Abstract" target="_blank"&gt;Cardiac Testing for Coronary Artery Disease in Potential Kidney Transplant Recipients - A Systematic Review of Test Accuracy Studies&lt;/A&gt;. Systematic review published in the American Journal of Kidney Diseases.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:382518:0" name=internalLink&gt;Thyroid cancer and renal transplantation- a meta-analysis&lt;/A&gt;. CRD Database of Abstracts of Reviews of Effects.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:359513:0" name=internalLink&gt;Valganciclovir for cytomegalovirus prevention in solid organ transplant patients- an evidence-based reassessment of safety and efficacy&lt;/A&gt;. CRD Database of Abstracts of Reviews of Effects.&lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Kidney Cancer&lt;/STRONG&gt; &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:323783:0" name=internalLink&gt;Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma&lt;/A&gt;. CRD Health Technology Assessment Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:310198:0" name=internalLink&gt;Sunitinib for the first-line treatment of advanced and or metastatic renal cell carcinoma&lt;/A&gt;. CRD Health Technology Assessment Database.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;&lt;A name=mug&gt;&lt;FONT size=2&gt;Male Urogenital Disorders&lt;/FONT&gt;&lt;/A&gt;&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.baus.org.uk/Updates/news/news-archive/2011/jan/jan" target="_blank"&gt;BAUS President's Newsletter for January 2011&lt;/A&gt;.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nice.org.uk/usingguidance/commissioningguides/luts/LUTS.jsp?domedia=1&amp;amp;mid=C8C223E2-19B9-E0B5-D4123C1DE7730766" target="_blank"&gt;The management of lower urinary tract symptoms in men commissioning guide&lt;/A&gt;. NICE Commissioning Guide.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Male Ureteric Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;No new resources this month.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Male Bladder Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:382440:0" name=internalLink&gt;Photodynamic diagnosis in non-muscle-invasive bladder cancer- a systematic review and cumulative analysis of prospective studies&lt;/A&gt;. CRD Database of Abstracts of Reviews of Effects.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:404489:0" name=internalLink&gt;L-methionine in patients with neurogenic bladder disorders&lt;/A&gt;. CRD Health Technology Assessment Database.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Prostate Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:402171:0" name=internalLink&gt;New CKS topics on Prostate cancer&lt;/A&gt;. Clinical Knowledge Summaries.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nhs.uk/news/2011/02February/Pages/fus-protein-in-prostate-cancer.aspx" target="_blank"&gt;Protein may fight prostate cancer&lt;/A&gt;. A Behind the Headlines analysis of recent news articles. (02/02/11).&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:404335:0" name=internalLink&gt;The most often used androgen receptor blockers in prostate cancer - systematic review&lt;/A&gt;. CRD Health Technology Assessment Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:404400:0" name=internalLink&gt;Denosumab for the treatment of therapy-induced bone loss in non-metastatic prostate cancer - terminated appraisal&lt;/A&gt;. CRD Health Technology Assessment Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:404493:0" name=internalLink&gt;Interstitial brachytherapy in localised prostate cancer - rapid report&lt;/A&gt;. CRD Health Technology Assessment Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:404486:0" name=internalLink&gt;Non-drug local procedures for treatment of benign prostatic syndrome - Update - rapid report&lt;/A&gt;. CRD Health Technology Assessment Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:404376:0" name=internalLink&gt;Open laparoscopic and robot-assisted laparoscopic radical prostatectomy for localised prostate cancer&lt;/A&gt;. CRD Health Technology Assessment Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:404916:0" name=internalLink&gt;Management of chronic prostatitis or chronic pelvic pain syndrome- a systematic review and network meta-analysis&lt;/A&gt;. CRD Database of Abstracts of Reviews of Effects.&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Penile Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:328116:0" name=internalLink&gt;Penile cancer systematic reviews&lt;/A&gt;. New systematic reviews identified by the team at NHS Evidence - cancer.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Urethral disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;No new resources this month.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Urinary tract infections&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;No new resources this month.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Testicular/Scrotal Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/Evidence/Medicines-Management/References/2011---January/28/Protection-from-scrotal-hyperthermia-in-laptop-computer-users/" target="_blank"&gt;Protection from scrotal hyperthermia in laptop computer users&lt;/A&gt;. National electronic Library for Medicines (28/01/11).&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://clinicalevidence.bmj.com/ceweb/conditions/msh/1807/1807.jsp?rss=true" target="_blank"&gt;Clinical Evidence topic - Testicular cancer - seminoma&lt;/A&gt;. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Male Urinary Incontinence&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://jama.ama-assn.org/content/305/2/151.short?rss=1" target="_blank"&gt;New RCT - Behavioral Therapy With or Without Biofeedback and Pelvic Floor Electrical Stimulation for Persistent Postprostatectomy Incontinence&lt;/A&gt;. By Goode PS et al.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:401615:0" name=internalLink&gt;2011 Annual Evidence Update on Male Urinary Incontinence&lt;/A&gt;. Links to contents page.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/SearchResults.aspx?tabID=288&amp;amp;optID=32188" target="_blank"&gt;New CKS topics on Enuresis. Clinical Knowledge Summaries.&lt;/A&gt; &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Sexually Transmitted Infections&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:385907:0" name=internalLink&gt;Cost-effectiveness of nationwide hepatitis B catch-up vaccination among children and adolescents in China.&lt;/A&gt; NHS Economic Evaluation Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:391355:0" name=internalLink&gt;A cost-effectiveness analysis of the Chlamydia Monday- a community-based intervention to decrease the prevalence of chlamydia in Sweden&lt;/A&gt;. NHS Economic Evaluation Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:403091:0" name=internalLink&gt;Interventions to modify sexual risk behaviours for preventing HIV in homeless youth&lt;/A&gt;. A new Cochrane systematic review.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:403113:0" name=internalLink&gt;Sperm washing to prevent HIV transmission from HIV-infected men but allowing conception in sero-discordant couples&lt;/A&gt;. A new Cochrane systematic review.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:404322:0" name=internalLink&gt;Antiretroviral therapy for HIV infection in patients naive to prior treatment- a systematic review of effectiveness and cost-effectiveness&lt;/A&gt;. CRD Health Technology Assessment Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:404419:0" name=internalLink&gt;Tenofovir disoproxil for the treatment of chronic hepatitis B&lt;/A&gt;. CRD Health Technology Assessment Database.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Fertility&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:403092:0" name=internalLink&gt;Antioxidants for male subfertility&lt;/A&gt;. A new Cochrane systematic review.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <expiryDate>01/02/2012 00:00:00</expiryDate>
  </document>
  <document>
    <id>197498</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=AbstractPlus&amp;list_uids=16952054&amp;query_hl=5&amp;itool=pubmed_DocSum]]&gt;</url>
    <title>Focal and segmental glomerulosclerosis</title>
    <publicationDate>2006-11-01T00:00:00</publicationDate>
    <publisher>Cell Mol Life Sci</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ PRIMARY GLOMERULAR DISEASE,GLOMERULONEPHRITIS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A review article from Cell Mol Life Sci 2006, 63, (21) p2506-11</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Extract from abstract&lt;/STRONG&gt;&lt;/EM&gt; &lt;/P&gt;
&lt;P&gt;An increasing cause of end-stage renal disease is the pathological lesion focal and segmental glomerulosclerosis (FSGS). FSGS is characterized by proteinuria and frequently nephrotic syndrome with ensuing renal failure&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>04/10/2010 11:44:50</lastReviewDate>
    <expiryDate>04/10/2011 11:44:50</expiryDate>
  </document>
  <document>
    <id>306784</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.institute.nhs.uk/quality_and_value/high_volume_care/focus_on%3a_renal.html]]&gt;</url>
    <title>Focus on: preparing for end stage renal disease</title>
    <publicationDate>2009-02-19T00:00:00</publicationDate>
    <publisher>NHS Institute for Innovation and Improvement</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ TRANSPLANTATION,ACUTE KIDNEY INJURY,HAEMODIALYSIS,PERITONEAL DIALYSIS,END-OF-LIFE CARE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES,DIALYSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The aim of this project is to identify clinical pathways and processes that give renal patients easier, more efficient access to their chosen treatment option.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&amp;nbsp;As part of the project we are examining the following issues:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;planning a pre-emptive transplant – options,choice and education 
&lt;LI&gt;planning the transplant assessment 
&lt;LI&gt;preparing the patient and their relatives, carers and potential donor for dialysis and therapy options 
&lt;LI&gt;how a multi-skilled renal team impacts on the pathway and ensures timely interventions 
&lt;LI&gt;the organisation of processes and information throughout the patient journey 
&lt;LI&gt;evidence of support and guidance for service development provided by trusts and commissioners.&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
    <lastReviewDate>11/01/2011 10:23:13</lastReviewDate>
    <expiryDate>11/01/2012 10:23:13</expiryDate>
  </document>
  <document>
    <id>155702</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.renal.org/unit/index.pl?c=newcastle]]&gt;</url>
    <title>Freeman Hospital Newcastle upon Tyne Transplantation Unit</title>
    <publicationDate>2009-08-24T00:00:00</publicationDate>
    <publisher>Freeman Hospital</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ TRANSPLANTATION,TRANSPLANT CENTRES,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Webpage giving contacts and background. A new dedicated renal medicine centre is due to be opened in 2008.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Extract from website&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Renal transplantation is managed jointly by physicians and surgeons which started with live renal transplantation in the mid 1960's and has developed into a leading renal transplant and research unit. The unit has an active programme of living related and living unrelated transplantation and has developed cadaveric renal transplantation research into organ donation and renal preservation. An active research programme to transplant immunology and rejection associated with the University of Newcastle upon Tyne Medical School. &lt;BR&gt;&lt;BR&gt;&lt;BR&gt;Educational Opportunities &lt;BR&gt;&lt;BR&gt;Education links to the University of Northumbria and University of Newcastle upon Tyne provide opportunities for the development of all staff. Speciality nursing, medical undergraduate and postgraduate education and training. &lt;BR&gt;&lt;BR&gt;&lt;BR&gt;The Future &lt;BR&gt;&lt;BR&gt;As part of the agreed PFI project for modernising the Newcastle hospitals a new dedicated renal/renal transplant unit is being built (due to open 2008). &lt;BR&gt;&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
    <expiryDate>01/09/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>187880</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=AbstractPlus&amp;list_uids=15752239&amp;query_hl=3&amp;itool=pubmed_docsum]]&gt;</url>
    <title>Genetic factors in end-stage renal disease</title>
    <publicationDate>2005-04-04T00:00:00</publicationDate>
    <publisher>Kidney International [Supplement]</publisher>
    <publicationType>OBSERVATIONAL STUDY</publicationType>
    <topics>&lt;![CDATA[ PREDISPOSING FACTORS,FAMILY HISTORY,PALLIATIVE AND SUPPORTIVE CARE,CONDITIONS,SYMPTOM MANAGEMENT,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,RENAL DISEASES,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Abstract of article in Kidney International. (2005 Apr;(94): S46-9).</description>
    <body>&lt;![CDATA[ Article from Kidney Int Suppl. 2005 Apr;(94):S46-9. Please contact your local health library for help with obtaining the full text.]]&gt;</body>
    <expiryDate>03/11/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>338797</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=338797]]&gt;</url>
    <title>Genetics of Kidney Diseases: Systematic Reviews and Meta-analyses</title>
    <publicationDate>2011-03-04T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,INHERITED KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Genetics of Kidney Diseases: Systematic Reviews and Meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2011&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Mooyaart AL, Valk EJ, van Es LA, Bruijn JA, de Heer E, Freedman BI, et al. Genetic associations in diabetic nephropathy: a meta-analysis. Diabetologia. 2011;54(3):544-53. [&lt;A href="https://rmsadmin.library.nhs.uk/admin/wizards/articles/Mooyaart%20AL,%20Valk%20EJ,%20van%20Es%20LA,%20Bruijn%20JA,%20de%20Heer%20E,%20Freedman%20BI,%20et%20al.%20Genetic%20associations%20in%20diabetic%20nephropathy:%20a%20meta-analysis.%20Diabetologia.%202011;54(3):544-53." target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Barry, A., Levine, M. (2010) "A systematic review of the effect of the CYP3A5 genotype on the apparent oral clearance of tacrolimus in renal transplant recipients." Ther Drug Monit. 2010 Dec;32(6):708-14. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20864901?dopt=Abstract" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Chen, Y. Z., Q. Gao, et al. (2010). "Systematic review of TCF2 anomalies in renal cysts and diabetes syndrome/maturity onset diabetes of the young type 5." Chin Med J (Engl) 123(22): 3326-33.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/21163139" target="_blank"&gt;Link to&amp;nbsp;PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;El Dib, R. P. and G. M. Pastores (2010). "Enzyme replacement therapy for Anderson-Fabry disease." Cochrane Database of Systematic Reviews 5. [&lt;A href="nelh:374525:0" name=internalLink&gt;Link to Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lee, Y. H., J. H. Woo, et al. (2010). "Functional monocyte chemoattractant protein-1 promoter -2518 polymorphism and systemic lupus erythematosus: a meta-analysis." Molecular Biology Reports 37(7): 3421-6.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19941075" target="_blank"&gt;Link to&amp;nbsp;PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Li, L. H., H. Yuan, et al. (2010). "Role of the Fcgamma receptor IIIA-V/F158 polymorphism in susceptibility to systemic lupus erythematosus and lupus nephritis: a meta-analysis." Scandinavian Journal of Rheumatology 39(2): 148-54. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Role%20of%20the%20Fcgamma%20receptor%20IIIA-V%2FF158%20polymorphism%20in%20susceptibility%20to%20systemic%20lupus%20erythematosus%20and%20lupus%20nephritis%3A%20a%20meta-analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Linthorst, G. E., M. G. Bouwman, et al. (2010)&amp;nbsp;"Screening for Fabry disease in high-risk populations: a systematic review." Journal of Medical Genetics 47(4): 217-22. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19797197" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;McKnight, A. J., C. C. Patterson, et al. (2010). "Genetic Polymorphisms in Nitric Oxide Synthase 3 Gene and Implications for Kidney Disease: A Meta-Analysis." Am J Nephrol 32(5): 476-481. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Genetic%20Polymorphisms%20in%20Nitric%20Oxide%20Synthase%203%20Gene%20and%20Implications%20for%20Kidney%20Disease%3A%20A%20Meta-Analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Noon, A. P., N. Vlatkovic, et al. (2010). "p53 and MDM2 in renal cell carcinoma: biomarkers for disease progression and future therapeutic targets?" Cancer 116(4): 780-90.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=p53%20and%20MDM2%20in%20renal%20cell%20carcinoma%3A%20biomarkers%20for%20disease%20progression%20and%20future%20therapeutic%20targets%3F" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Pattaro, C., A. De Grandi, et al. "A meta-analysis of genome-wide data from five European isolates reveals an association of COL22A1, SYT1, and GABRR2 with serum creatinine level." BMC Medical Genetics 11.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=A%20meta-analysis%20of%20genome-wide%20data%20from%20five%20European%20isolates%20reveals%20an%20association%20of%20COL22A1%2C%20SYT1%2C%20and%20GABRR2%20with%20serum%20creatinine%20level" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Qiu, R., G. Bing, et al. (2010). "Xp11.2 Translocation renal cell carcinomas have a poorer prognosis than non-Xp11.2 translocation carcinomas in children and young adults: a meta-analysis." International Journal of Surgical Pathology 18(6): 458-64.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20643670" target="_blank"&gt;Link to&amp;nbsp;PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Takeda, A., K. Cooper, et al. (2010). "Recombinant human growth hormone for the treatment of growth disorders in children: a systematic review and economic evaluation." Health Technology Assessment (Winchester, England) 14(42): 1-209, iii-iv. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20849734" target="_blank"&gt;Link to&amp;nbsp;PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;von Vigier, R. O., M. T. Ortisi, et al. (2010) "Hypokalemic rhabdomyolysis in congenital tubular disorders: a case series and a systematic review." Pediatric Nephrology 25(5): 861-6. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20033223" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Zeng, Z., L. Li, et al. (2010) "A meta-analysis of three polymorphisms in the endothelial nitric oxide synthase gene (NOS3) and their effect on the risk of diabetic nephropathy." Human Genetics 127(4): 373-81. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20049477" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Bates, J. S., C. J. Lessard, et al. (2009). "Meta-analysis and imputation identifies a 109 kb risk haplotype spanning TNFAIP3 associated with lupus nephritis and hematologic manifestations." Genes Immun. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19387456" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lu, J. C., S. G. Coca, et al. (2009). "Searching for genes that matter in acute kidney injury: a systematic review." Clin J Am Soc Nephrol 4(6): 1020-31.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19443624" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Ng, D. P., B. C. Tai, et al. (2008). "Is the presence of retinopathy of practical value in defining cases of diabetic nephropathy in genetic association studies? The experience with the ACE insertion/deletion polymorphism in 53 studies comprising 17,791 subjects." Diabetes 57(9): 2541-6.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18523141" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Thakkinstian, A., S. Dmitrienko, et al. (2008). "Association between cytokine gene polymorphisms and outcomes in renal transplantation: a meta-analysis of individual patient data." Nephrol Dial Transplant 23(9): 3017-23.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18408074" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Park, W. D. and M. D. Stegall (2007). "A meta-analysis of kidney microarray datasets: investigation of cytokine gene detection and correlation with rt-PCR and detection thresholds." BMC Genomics 8: 88.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17397532" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>21/12/2010 10:52:16</lastReviewDate>
    <expiryDate>21/12/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>321807</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=321807]]&gt;</url>
    <title>Genital warts: Systematic reviews and meta-analyses</title>
    <publicationDate>2010-09-09T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,PENILE DISORDERS,MALE SEXUALLY TRANSMITTED INFECTIONS,VIRAL,GENITAL WARTS (HPV),CIRCUMCISION,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Genital warts: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Backes, D. M., R. J. Kurman, et al. (2009). "Systematic review of human papillomavirus prevalence in invasive penile cancer." Cancer Causes &amp;amp; Control 20(4): 449-57. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19082746?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Gotovtseva, E. P., A. S. Kapadia, et al. (2008). "Optimal frequency of imiquimod (aldara) 5% cream for the treatment of external genital warts in immunocompetent adults: a meta-analysis." Sex Transm Dis 35(4): 346-51.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18360317" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Klug, S. J., M. Hukelmann, et al. (2008). "Knowledge about infection with human papillomavirus: a systematic review." Prev Med 46(2): 87-98.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17942147?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Van Howe, R. S. (2007). "Human papillomavirus and circumcision: a meta-analysis." J Infect 54(5): 490-6.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16997378?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:01:44</lastReviewDate>
    <expiryDate>06/07/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>251481</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.globaldialysis.com/]]&gt;</url>
    <title>Global Dialysis</title>
    <publicationDate>2009-06-08T00:00:00</publicationDate>
    <publisher>Global Dialysis</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ HAEMODIALYSIS,LIVING WITH DIALYSIS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES,DIALYSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Website featuring single, free to use, directory of dialysis centres. The directory is the largest database of dialysis centres in the world.</description>
    <body>&lt;![CDATA[ &lt;STRONG&gt;&lt;I&gt;Extract&lt;/I&gt; &lt;/STRONG&gt;
&lt;P&gt;Originally launched in January 2000 by Valda and Russell England, Global Dialysis was born out of the frustrations of trying to find dialysis centres for travelling. Information was gathered from the worldwide dialysis community with the aim of creating a single, free to use, directory of dialysis centres. &lt;/P&gt;
&lt;P&gt;The directory of dialysis centres has steadily grown to over 14,000 in 154 countries making it the largest database of dialysis centres available in the world. &lt;/P&gt;]]&gt;</body>
    <lastReviewDate>08/03/2011 09:56:58</lastReviewDate>
    <expiryDate>08/03/2012 09:56:58</expiryDate>
  </document>
  <document>
    <id>338800</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=338800]]&gt;</url>
    <title>Glomerulonephritis: Systematic reviews and meta-analyses</title>
    <publicationDate>2011-01-28T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,GLOMERULONEPHRITIS,PRIMARY GLOMERULAR DISEASE,SECONDARY GLOMERULAR DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Glomerulonephritis: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Chen, Y. Z., Q. Gao, et al. (2010). "Meta-analysis of Tripterygium wilfordii hook F in the immunosuppressive treatment of IgA nephropathy." Intern Med 49(19): 2049-55. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Meta-analysis%20of%20Tripterygium%20wilfordii%20hook%20F%20in%20the%20immunosuppressive%20treatment%20of%20IgA%20nephropathy" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;McGrogan A, Franssen CF, de Vries CS. (2010) "The incidence of primary glomerulonephritis worldwide: a systematic review of the literature." Nephrol Dial Transplant. Nov 10. [Epub ahead of print] [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/21068142" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mok, C. C., T. T. Cheung, et al. (2010) "Minimal mesangial lupus nephritis: a systematic review." Scandinavian Journal of Rheumatology 39(3): 181-9. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20166847" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Touma, Z., D. D. Gladman, et al. (2010). "Mycophenolate Mofetil for Induction Treatment of Lupus Nephritis: A Systematic Review and Metaanalysis." J Rheumatol. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Mycophenolate%20Mofetil%20for%20Induction%20Treatment%20of%20Lupus%20Nephritis%3A%20A%20Systematic%20Review%20and%20Metaanalysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Touma, Z., M. Urowitz, et al. (2010). "Systematic review and meta-analysis of randomized trials for mycophenolic acid and mycophenolate mofetil for induction treatment of lupus nephritis." Journal of Rheumatology 37(6 SUPPL. 2): 1310-1311. [No PubMed abstract available]&lt;/LI&gt;
&lt;LI&gt;Walters GD, Willis NS, Craig JC. Interventions for renal vasculitis in adults. A systematic revew. BMC Nephrology 2010, 11:12. [&lt;A href="http://www.biomedcentral.com/1471-2369/11/12" target="_blank"&gt;Link to full-text article&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Zhang, Y., J. H. Zhou, et al. (2010). "Treatment of hepatitis B virus-associated glomerulonephritis: a meta-analysis." World Journal of Gastroenterology 16(6): 770-7. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Treatment%20of%20hepatitis%20B%20virus-associated%20glomerulonephritis%3A%20a%20meta-analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Cheng, J., W. Zhang, et al. (2009). "ACEI/ARB therapy for IgA nephropathy: a meta analysis of randomised controlled trials." Int J Clin Pract 63(6): 880-8. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19490198" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Cheng, J., X. Zhang, et al. (2009). "Efficacy and Safety of Glucocorticoids Therapy for IgA Nephropathy: A Meta-Analysis of Randomized Controlled Trials." Am J Nephrol 30(4): 315-322.&amp;nbsp;[&lt;A href="nelh:360824:0" name=internalLink&gt;Link to&amp;nbsp;DARE abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Xu, G., W. Tu, et al. (2009). "Mycophenolate mofetil treatment for IgA nephropathy: a meta-analysis." Am J Nephrol 29(5): 362-7.&amp;nbsp;[&lt;A href="nelh:342979:0" name=internalLink&gt;Link to&amp;nbsp;DARE abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Catapano, F., P. Chiodini, et al. (2008). "Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression." Am J Kidney Dis 52(3): 475-85.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18468748" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Tan, C. H., P. T. Loh, et al. (2008). "Mycophenolate mofetil in the treatment of IgA nephropathy: a systematic review." Singapore Med J 49(10): 780-5.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18946610" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Fabrizi, F., A. Bruchfeld, et al. (2007). "Interferon therapy for HCV-associated glomerulonephritis: meta-analysis of controlled trials." Int J Artif Organs 30(3): 212-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17417760" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>21/12/2010 10:52:20</lastReviewDate>
    <expiryDate>21/12/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>321811</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=321811]]&gt;</url>
    <title>Gonorrhea: Systematic reviews and meta-analyses</title>
    <publicationDate>2010-09-09T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE SEXUALLY TRANSMITTED INFECTIONS,BACTERIAL,GONORRHEA,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Gonorrhea: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Fung, M., K. C. Scott, et al. (2007). "Chlamydial and gonococcal reinfection among men: a systematic review of data to evaluate the need for retesting." Sex Transm Infect 83(4): 304-9. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17166889" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:04:19</lastReviewDate>
    <expiryDate>06/07/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>156389</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/assetRoot/04/05/95/11/04059511.pdf]]&gt;</url>
    <title>Good Practice Guidelines for Renal Dialysis/Transplantation Units - Prevention and control of blood-borne virus infection</title>
    <publicationDate>2002-09-02T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ HEALTH MANAGEMENT,SERVICE SECTORS,QUALITY AND MONITORING,PATIENT SAFETY,RISK MANAGEMENT,ACUTE SERVICES,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,HAEMODIALYSIS,PREVENTION OF INFECTIONS,KIDNEY DISEASES,DIALYSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Guidance based on recommendations of the working group convened by the Public Health Laboratory Service (PHLS)</description>
    <body>&lt;![CDATA[ &lt;P&gt;Topics of relevance to renal haemodialysis units and ICU units undertaking haemodialysis: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Potential viral hazards in dialysis units &lt;/LI&gt;
&lt;LI&gt;Survey of practice in UK dialysis units &lt;/LI&gt;
&lt;LI&gt;Health and safety requirements and principles of clinical governance &lt;/LI&gt;
&lt;LI&gt;Immunisation against hepatitis B &lt;/LI&gt;
&lt;LI&gt;Testing patients for BBV infection &lt;/LI&gt;
&lt;LI&gt;Routine precautions against BBV infection &lt;/LI&gt;
&lt;LI&gt;Management of BBV infected patients &lt;/LI&gt;
&lt;LI&gt;Equipment and prevention of BBV transmission &lt;/LI&gt;
&lt;LI&gt;Occupational health and staff fitness to work in dialysis units &lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
    <lastReviewDate>23/09/2010 16:45:41</lastReviewDate>
    <expiryDate>23/09/2011 16:45:41</expiryDate>
  </document>
  <document>
    <id>182673</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.kidney.org/professionals/kdoqi/guidelines_bone/index.htm]]&gt;</url>
    <title>Guidelines for bone metabolism and disease in chronic kidney disease (adults)</title>
    <publicationDate>2003-10-01T00:00:00</publicationDate>
    <publisher>K/DOQI</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ COMPLICATIONS OF KIDNEY DISEASE,BONE DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>K/DOQI Clinical Practice Guideline</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Extract from guidelines&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Disturbances in mineral and bone metabolism are common in patients with CKD. A large body of evidence indicates that these derangements are associated with increased mortality and morbidity. These patients have bone pain, increased incidence of bone fractures and deformity, myopathy and muscle pain, and ruptures of tendons. Hyperphosphatemia also appears to be associated with increased mortality, and elevated blood levels of PTH exert significant adverse effects on the function of almost every organ.&lt;/P&gt;
&lt;P&gt;Importantly, the long-term effects of these derangements on soft tissue calcification have become an area of growing concern in the care of CKD patients. Calcification of the lung leads to impaired pulmonary function, pulmonary fibrosis, pulmonary hypertension, right ventricular hypertrophy, and right-side congestive heart failure. Calcification of the myocardium, coronary arteries, and cardiac valves results in congestive heart failure, cardiac arrhythmias, ischemic heart disease, and death. Vascular calcification leads to ischemic lesions, soft-tissue necrosis, and difficulties for kidney transplantation.&lt;/P&gt;
&lt;P&gt;The processes causing disordered mineral metabolism and bone disease have their onset in the early stages of CKD, continue throughout the course of progressive loss of kidney function, and may be influenced beneficially or adversely by the various therapeutic approaches now used. Thus, prevention of the disturbances in mineral and bone metabolism and their management early in the course of chronic kidney disease are extremely important in improving the quality of life and longevity of CKD patients.&lt;/P&gt;
&lt;P&gt;The present clinical practice guidelines were developed to provide an integrated clinical action plan to the management of this complex problem throughout the course of CKD. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>26/11/2010 15:26:05</lastReviewDate>
    <expiryDate>26/11/2011 15:26:05</expiryDate>
  </document>
  <document>
    <id>155478</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.edtnaerca.org/pdf/education/WTguidelinesmicrob.pdf]]&gt;</url>
    <title>Guidelines for the control and monitoring of microbiological contamination in water for dialysis</title>
    <publicationDate>2002-10-07T00:00:00</publicationDate>
    <publisher>EDTNA/ERCA</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ HAEMODIALYSIS,PERITONEAL DIALYSIS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,DIALYSIS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Guideline from EDTNA/ERCA</description>
    <body>&lt;![CDATA[ &lt;P&gt;These guidelines apply to the control and monitoring of microbiological contamination in:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;water used for preparation of dialysis fluid in all settings, including patients’ homes and acute care units&lt;/LI&gt;
&lt;LI&gt;water used for in-house production of liquid concentrates&lt;/LI&gt;
&lt;LI&gt;water used for reprocessing dialysers&lt;/LI&gt;
&lt;LI&gt;water used for preparation of ultrapure dialysis fluid by equipment fitted with additional point-of-use filtration&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
    <lastReviewDate>23/09/2010 16:49:39</lastReviewDate>
    <expiryDate>23/09/2011 16:49:39</expiryDate>
  </document>
  <document>
    <id>268358</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.clinicalguidelines.scot.nhs.uk/Renal%20Unit%20Guidelines/Acute%20Haemodialysis.pdf]]&gt;</url>
    <title>Guidelines for the management of acute haemodialysis</title>
    <publicationDate>2005-11-01T00:00:00</publicationDate>
    <publisher>Renal Clinicians Group</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CHILDREN AND ADOLESCENTS ON HAEMODIALYSIS,HAEMODIALYSIS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES,DIALYSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Guidelines developed for children undergoing haemodialysis</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Contents:&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Access, lines, catheter, dialyser, blood flow, prime, ultrafiltration, clearance, anticoagulation, and vitamins for children in haemodialysis.&lt;/P&gt;
&lt;P&gt;Published November 2005&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>23/09/2010 16:50:06</lastReviewDate>
    <expiryDate>23/09/2011 16:50:06</expiryDate>
  </document>
  <document>
    <id>155878</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.renal.org/unit/index.pl?c=guys]]&gt;</url>
    <title>Guy's and St Thomas' Hospital Renal Unit</title>
    <publicationDate></publicationDate>
    <publisher>Guy's and St Thomas' Hospital</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ TRANSPLANT CENTRES,TRANSPLANTATION,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Background information on renal services</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Extract from website&lt;/EM&gt; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Transplants&lt;/STRONG&gt;&lt;BR&gt;The unit is the major transplant unit for South East Thames, transplanting patients for both the King’s and Kent and Canterbury Renal Units.&amp;nbsp; Last year, the unit carried out 114 transplant operations, a growing number of which receive kidneys from a living donor.&amp;nbsp; The Trust&amp;nbsp;has one of the largest living donor kidney&amp;nbsp;transplant programme in the UK and a nurse consultant has recently been appointed to facilitate future service developments in this area of transplantation.&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>23/09/2010 16:50:15</lastReviewDate>
    <expiryDate>23/09/2011 16:50:15</expiryDate>
  </document>
  <document>
    <id>317840</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.healthcareworkforce.nhs.uk/renal/]]&gt;</url>
    <title>Healthcare workforce portal: Renal</title>
    <publicationDate>2009-06-01T00:00:00</publicationDate>
    <publisher>Skills for Health</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASE IN CHILDREN AND ADOLESCENTS,OTHER CONDITIONS - ADULTS,COMPLICATIONS OF KIDNEY DISEASE,PERITONEAL DIALYSIS,ORGANISATIONS,ACUTE KIDNEY INJURY,HAEMODIALYSIS,RENAL TRACT INFECTIONS,NATIONAL SERVICE FRAMEWORK FOR RENAL SERVICES/POLICY DOCUMENTS,TRANSPLANTATION,KIDNEY AND BLADDER STONES,GLOMERULONEPHRITIS,RENOVASCULAR DISEASES,INHERITED KIDNEY DISEASE,RENAL CANCER,END-OF-LIFE CARE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,DIALYSIS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This section features examples of best practice, sample job descriptions, case studies, plus supporting documentation and links.</description>
    <body>&lt;![CDATA[ &lt;P&gt;Skills for Health - Workforce Projects Team (WPT) are leading the way in providing integrated workforce planning solutions in long term conditions. Supporting, caring for and treating people with long term conditions is expected to become one of the dominant healthcare themes of the 21st Century and WPT have been commissioned by the Department of Health to provide resources, tools and information.&lt;/P&gt;
&lt;P&gt;To find out more about renal and other long term conditions, visit &lt;A href="http://www.healthcareworkforce.nhs.uk/renal" target="_blank"&gt;www.healthcareworkforce.nhs.uk/renal&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>01/07/2010 14:09:54</lastReviewDate>
    <expiryDate>01/07/2011 14:09:54</expiryDate>
  </document>
  <document>
    <id>177795</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.dopps.org/d_cdArchive/DoppsCD2006/ppt/Fukuhara_QoL_KI2003_D17.ppt#258,3,Health-related Quality of Life among Dialysis Patients on Three Continents: The Dialysis Outcomes and Practice Patterns Study (DOPPS)]]&gt;</url>
    <title>Health-related quality of life among dialysis patients on three continents: the Dialysis Outcomes and Practice Patterns Study (DOPPS)</title>
    <publicationDate>2003-01-01T00:00:00</publicationDate>
    <publisher>Kidney International 64, 1903-1910, 2003</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ LIVING WITH DIALYSIS,HAEMODIALYSIS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES,DIALYSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Presentation from DOPPS</description>
    <body>&lt;![CDATA[ Study based on use of DOPPS data from USA, Euro-DOPPS (France, Germany, Italy, Spain, and UK), and Japan, using a Kidney Disease Quality of Life&amp;nbsp;questionnaire.]]&gt;</body>
    <lastReviewDate>06/07/2010 11:25:16</lastReviewDate>
    <expiryDate>06/07/2011 11:25:16</expiryDate>
  </document>
  <document>
    <id>319075</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.bladderandbowelfoundation.org/bladder/healthy-bladder/]]&gt;</url>
    <title>Healthy Bladder</title>
    <publicationDate></publicationDate>
    <publisher>The Bladder and Bowel Foundation</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE BLADDER DISORDERS,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Information on maintaining a healthy bladder</description>
    <body>&lt;![CDATA[ &lt;P&gt;Information about&amp;nbsp;Information on maintaining a healthy bladder, including:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A title="How the bladder works" style="FONT-SIZE: 14px" href="http://www.bladderandbowelfoundation.org/bladder/healthy-bladder/how-the-bladder-works/" target="_blank"&gt;&lt;STRONG&gt;How the bladder works&lt;/STRONG&gt;&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A title="How to maintain a healthy bladder" style="FONT-SIZE: 14px" href="http://www.bladderandbowelfoundation.org/bladder/healthy-bladder/how-to-maintain-a-healthy-bladder/" target="_blank"&gt;&lt;STRONG&gt;How to maintain a healthy bladder&lt;/STRONG&gt;&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A title="Pelvic Floor Exercises" style="FONT-SIZE: 14px" href="http://www.bladderandbowelfoundation.org/bladder/healthy-bladder/pelvic-floor-exercises/" target="_blank"&gt;&lt;STRONG&gt;Pelvic Floor Exercises&lt;/STRONG&gt;&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A title="Pilates helped my pelvic floor" style="FONT-SIZE: 14px" href="http://www.bladderandbowelfoundation.org/bladder/healthy-bladder/pilates-helped-my-pelvic-floor/" target="_blank"&gt;&lt;STRONG&gt;Pilates helped my pelvic floor&lt;/STRONG&gt;&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A title="How to approach your doctor about your bladder problems" style="FONT-SIZE: 14px" href="http://www.bladderandbowelfoundation.org/bladder/healthy-bladder/how-to-approach-your-doctor-about-your-bladder-problems/" target="_blank"&gt;&lt;STRONG&gt;How to approach your doctor about your bladder problems&lt;/STRONG&gt;&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A title="Bladder investigations and tests" style="FONT-SIZE: 14px" href="http://www.bladderandbowelfoundation.org/bladder/healthy-bladder/bladder-investigations-and-tests/" target="_blank"&gt;&lt;STRONG&gt;Bladder investigations and tests&lt;/STRONG&gt;&lt;/A&gt;&lt;BR&gt;&lt;A title=Biofeedback style="FONT-SIZE: 14px" href="http://www.bladderandbowelfoundation.org/bladder/healthy-bladder/biofeedback/" target="_blank"&gt;&lt;STRONG&gt;Biofeedback&lt;/STRONG&gt;&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
    <lastReviewDate>01/07/2010 14:10:08</lastReviewDate>
    <expiryDate>01/07/2011 14:10:08</expiryDate>
  </document>
  <document>
    <id>321585</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.renal.org/pages/media/download_gallery/RA%20BAPN_Helping%20Adolescents%20and%20Young%20Adults%20with%20ESRF_July%202009.pdf]]&gt;</url>
    <title>Helping adolescents and young adults with end stage renal failure</title>
    <publicationDate>2009-07-30T00:00:00</publicationDate>
    <publisher>Renal Association</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ ACUTE KIDNEY INJURY,KIDNEY DISEASE IN CHILDREN AND ADOLESCENTS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A working party report from the BAPN.</description>
    <body>&lt;![CDATA[ A new working party report from the British Association for Paediatric Nephrology.]]&gt;</body>
    <lastReviewDate>01/07/2010 14:58:29</lastReviewDate>
    <expiryDate>01/07/2011 14:58:29</expiryDate>
  </document>
  <document>
    <id>177782</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.dopps.org/d_cdArchive/DoppsCD2006/ppt/Hecking_Indicators_NDT2004_D22.ppt#258,3,Slide 3]]&gt;</url>
    <title>Hemodialysis prescription, adherence, and nutritional indicators in five European countries: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS)</title>
    <publicationDate>2004-10-04T00:00:00</publicationDate>
    <publisher>DOPPS</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ HAEMODIALYSIS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES,DIALYSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Presentation from DOPPS</description>
    <body>&lt;![CDATA[ Just over 4500 patients from 101 randomly selected dialysis facilities in France, Germany, Italy, Spain and the UK were studied.]]&gt;</body>
    <lastReviewDate>06/07/2010 11:25:01</lastReviewDate>
    <expiryDate>06/07/2011 11:25:01</expiryDate>
  </document>
  <document>
    <id>338824</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=338824]]&gt;</url>
    <title>Henoch-Schönlein purpura: Systematic reviews and meta-analyses</title>
    <publicationDate>2011-01-17T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,COMPLICATIONS OF KIDNEY DISEASE,KIDNEY DISEASE IN CHILDREN AND ADOLESCENTS,GLOMERULONEPHRITIS,SECONDARY GLOMERULAR DISEASE,OTHER,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Henoch-Schönlein purpura: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Han, S. S., H. K. Sun, et al. (2010). "Outcome of renal allograft in patients with henoch-schonlein nephritis: Single-center experience and systematic review." Transplantation 89(6): 721-726. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20010329" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Chartapisak, W., S. Opastiraku, et al. (2009). "Prevention and treatment of renal disease in Henoch-Schönlein purpura: a systematic review." Arch Dis Child 94(2): 132-7.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18701559" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Chartapisak, W., S. Opastirakul, et al. (2009). "Interventions for preventing and treating kidney disease in Henoch-Schönlein Purpura (HSP)." Cochrane Database Syst Rev(3): CD005128.&amp;nbsp;[&lt;A href="nelh:320751:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Zaffanello, M., M. Brugnara, et al. (2009). "Adjuvant treatments for Henoch-Schönlein purpura nephritis in children: A systematic review." Current Therapeutic Research - Clinical and Experimental 70(3): 254-265.&amp;nbsp;[&lt;A href="http://www.sciencedirect.com/science?_ob=ArticleURL&amp;amp;_udi=B6VS8-4WSHDST-7&amp;amp;_user=126524&amp;amp;_coverDate=06%2F30%2F2009&amp;amp;_rdoc=7&amp;amp;_fmt=high&amp;amp;_orig=browse&amp;amp;_srch=doc-info%28%23toc%236256%232009%23999299996%231320079%23FLP%23display%23Volume%29&amp;amp;_cdi=6256&amp;amp;_sort=d&amp;amp;_docanchor=&amp;amp;_ct=7&amp;amp;_acct=C000010360&amp;amp;_version=1&amp;amp;_urlVersion=0&amp;amp;_userid=126524&amp;amp;md5=7549a1ffe95a4e2dadb0d8ef45319ad5" target="_blank"&gt;Link to abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;No systematic reviews.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Weiss, P. F., J. A. Feinstein, et al. (2007). "Effects of corticosteroid on Henoch-Schönlein purpura: a systematic review." Pediatrics 120(5): 1079-87.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17974746" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Zaffanello, M., M. Brugnara, et al. (2007). "Therapy for children with henoch-schönlein purpura nephritis: a systematic review." ScientificWorldJournal 7: 20-30.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17221139" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2006&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;No systematic reviews.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>21/12/2010 10:52:24</lastReviewDate>
    <expiryDate>21/12/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>321810</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=321810]]&gt;</url>
    <title>Hepatitis B: Systematic reviews and meta-analyses</title>
    <publicationDate>2011-01-24T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE SEXUALLY TRANSMITTED INFECTIONS,VIRAL,HEPATITIS B,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Hepatitis B: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2011&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Cho, L. Y., J. J. Yang, et al. (2011). "Coinfection of hepatitis B and C viruses and risk of hepatocellular carcinoma: systematic review and meta-analysis." International Journal of Cancer 128(1): 176-84. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20232388" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Alavian, S. M., F. Fallahian, et al. (2010). "Implementing strategies for hepatitis B vaccination." Saudi Journal of Kidney Diseases &amp;amp; Transplantation 21(1): 10-22. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20061687" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Alavian, S. M. and S. V. Tabatabaei (2010). "Effects of oral levamisole as an adjuvant to hepatitis B vaccine in adults with end-stage renal disease: a meta-analysis of controlled clinical trials." Clinical Therapeutics 32(1): 1-10.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20171406" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Alavian, S. M. and S. V. Tabatabaei (2010). "The effect of diabetes mellitus on immunological response to hepatitis B virus vaccine in individuals with chronic kidney disease: A meta-analysis of current literature." Vaccine 28(22): 3773-3777.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20371390" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Almeida, A. M., A. Q. Ribeiro, et al. (2010). "The efficacy of adefovir dipivoxil, entecavir and telbivudine for chronic hepatitis B treatment: A systematic review [Portuguese] Eficacia do adefovir dipivoxil, entecavir e telbivudina para o tratamento da hepatite cronica B: Revisao sistematica." Revista da Sociedade Brasileira de Medicina Tropical 43(4): 440-451. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20802947" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Barth, R. E., Q. Huijgen, et al. (2010). "Hepatitis B/C and HIV in sub-Saharan Africa: An association between highly prevalent infectious diseases. A systematic review and meta-analysis." International Journal of Infectious Diseases 14(12): e1024-e1031.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20870439" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Dakin, H., C. Fidler, et al. (2010). "Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naive patients with chronic hepatitis B." Value in Health 13(8): 934-945.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20825624" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Fabrizi, F., V. Dixit, et al. (2010). "Meta-analysis: Levamisole improves the immune response to hepatitis B vaccine in dialysis patients." Alimentary Pharmacology and Therapeutics 32(6): 756-762.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20662784" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Giacchino, R. and B. Cappelli (2010). "Treatment of viral hepatitis B in children." Expert Opinion on Pharmacotherapy 11(6): 889-903.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20201732" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hynicka, L. M., N. Yunker, et al. (2010). "A review of oral antiretroviral therapy for the treatment of chronic hepatitis B." Annals of Pharmacotherapy 44(7-8): 1271-86.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20587747" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Poorolajal, J., M. Mahmoodi, et al. (2010). "Long-term protection provided by hepatitis B vaccine and need for booster dose: a meta-analysis." Vaccine 28(3): 623-631.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19887132" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Qin, X. K., P. Li, et al. (2010). "Xiaochaihu Tang for treatment of chronic hepatitis B: A systematic review of randomized trials." Journal of Chinese Integrative Medicine 8(4): 312-320.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20388470" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Tang, Q. Y., Q. He, et al. (2010). "Gansu for chronic hepatitis B: A systematic review." Chinese Journal of Evidence-Based Medicine 10(8): 978-984.&amp;nbsp;[No PubMed abstract available]&lt;/LI&gt;
&lt;LI&gt;Wang, C., J. Sun, et al. (2010). "Hepatitis B virus infection and related factors in hemodialysis patients in China systematic review and meta-analysis." Renal Failure 32(10): 1255-1264.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20954991" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Wong, G. L. H., K. K. L. Yiu, et al. (2010). "Meta-analysis: Reduction in hepatic events following interferon-alfa therapy of chronic hepatitis B." Alimentary Pharmacology and Therapeutics 32(9): 1059-1068.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20807216" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Woo, G., G. Tomlinson, et al. (2010). "Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: A systematic review and Bayesian meta-analyses." Gastroenterology 139(4): 1218-1229.e5.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20600036" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Zhang, Y., J. H. Zhou, et al. (2010). "Treatment of hepatitis B virus-associated glomerulonephritis: a meta-analysis." World Journal of Gastroenterology 16(6): 770-777.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20135728" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Zhao, S., L. Tang, et al. (2010). "Comparison of the efficacy of lamivudine and telbivudine in the treatment of chronic hepatitis B: a systematic review." Virology Journal 7.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20815890" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Zhao, S. S., X. G. Fan, et al. (2010). "Adefovir versus adefovir-thymosin alpha-1 combination therapy for chronic hepatitis B: A systematic review." Chinese Journal of Evidence-Based Medicine 10(8): 972-977.&amp;nbsp;[No PubMed abstract available]&lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Ali SA, Donahue RM, Qureshi H, Vermund SH. Hepatitis B and hepatitis C in Pakistan: prevalence and risk factors. International Journal of Infectious Diseases. 2009;13(1):9-19. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18835208" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Bar-On ES, Goldberg E, Fraser A, Vidal L, Hellmann S, Leibovici L. Combined DTP-HBV-HIB vaccine versus separately administered DTP-HBV and HIB vaccines for primary prevention of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae B (HIB). Cochrane Database of Systematic Reviews. 2009(3).&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19588375" target="_blank"&gt;Link to&amp;nbsp;PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Jones J, Shepherd J, Baxter L, Gospodarevskaya E, Hartwell D, Harris P, et al. Adefovir dipivoxil and pegylated interferon alpha for the treatment of chronic hepatitis B: An updated systematic review and economic evaluation. Health Technology Assessment. 2009;13(35):iii-172.&amp;nbsp;[&lt;A href="nelh:308320:0" name=internalLink&gt;Link to&amp;nbsp;HTA abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lanini, S., V. Puro, et al. (2009). "Patient to patient transmission of hepatitis B virus: a systematic review of reports on outbreaks between 1992 and 2007." BMC Medicine 7. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19356228" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lin, K. and J. Vickery (2009). "Screening for hepatitis B virus infection in pregnant women: evidence for the U.S. Preventive Services Task Force reaffirmation recommendation statement." Annals of Internal Medicine 150(12): 874-6.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19528566?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Liu S, Zhang H, Gu C, Yin J, He Y, Xie J, et al. Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis. Journal of the National Cancer Institute. 2009;101(15):1066-82.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19574418" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Miyake Y, Kobashi H, Yamamoto K. Meta-analysis: The effect of interferon on development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Journal of Gastroenterology. 2009;44(5):470-5.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19308310" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Nikolopoulos GK, Paraskevis D, Hatzitheodorou E, Moschidis Z, Sypsa V, Zavitsanos X, et al. Impact of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: a cohort study and meta-analysis. Clinical Infectious Diseases. 2009;48(12):1763-71.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19435436" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Shamliyan TA, MacDonald R, Shaukat A, Taylor BC, Yuan JM, Johnson JR, et al. Antiviral therapy for adults with chronic hepatitis B: A systematic review for a National Institutes of Health Consensus Development Conference. Annals of Internal Medicine. 2009;150(2):111-24.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19124812" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Taylor, B. C., J. M. Yuan, et al. (2009). "Clinical outcomes in adults with chronic hepatitis B in association with patient and viral characteristics: A systematic review of evidence." Hepatology 49(5 Suppl): S85-95.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19399797" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Ayoub, W. S. and E. B. Keeffe (2008). "Review article: Current antiviral therapy of chronic hepatitis B." Alimentary Pharmacology and Therapeutics 28(2): 167-177.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18466358?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Desmond, C. P., A. Bartholomeusz, et al. (2008). "A systematic review of T-cell epitopes in hepatitis B virus: Identification, genotypic variation and relevance to antiviral therapeutics." Antiviral Therapy 13(2): 161-175.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18505168" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hwang, S. H., H. B. Oh, et al. (2008). "[Meta-analysis for the pooled sensitivity and specificity of hepatitis B surface antigen rapid tests]." Korean Journal Of Laboratory Medicine 28(2): 160-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18458514" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Katz, L. H., A. Fraser, et al. (2008). "Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: Systematic review and meta-analysis." Journal of Viral Hepatitis 15(2): 89-102.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18184191" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kumar, M. and S. K. Sarin (2008). "Systematic review: combination therapies for treatment-naive chronic hepatitis B." Aliment Pharmacol Ther 27(12): 1187-209.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18373730?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Li, L., Q. He, et al. (2008). "Effectiveness and safety of Fuzheng Huayu capsule for liver fibrosis of chronic hepatitis B: A systematic review." Chinese Journal of Evidence-Based Medicine 8(10): 892-897.&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Loomba, R., A. Rowley, et al. (2008). "Systematic review: The effect of preventive lamivudine on hepatitis B reactivation during chemotherapy." Annals of Internal Medicine 148(7): 519-528.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18378948" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Loomba, R., A. K. Rowley, et al. (2008). "Hepatitis B Immunoglobulin and Lamivudine Improve Hepatitis B-Related Outcomes After Liver Transplantation: Meta-Analysis." Clinical Gastroenterology and Hepatology 6(6): 696-700.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18456569" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lui, Y. Y. and H. L. Chan (2008). "A review of telbivudine for the management of chronic hepatitis B virus infection." Expert Opinion On Drug Metabolism &amp;amp; Toxicology 4(10): 1351-61.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18798704?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Morillo Verdugo, R., A. Madrazo Berenguer, et al. (2008). "[Drugs treatment of hepatitis B]. [Spanish] Tratamiento farmacologico de la hepatitis B." Farmacia Hospitalaria 32(4): 234-48.&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Pellicelli, A. M., G. Barbaro, et al. (2008). "Management of chronic hepatitis in drug addicts: A systematic review." Clinica Terapeutica 159(1): 41-49.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18399262?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Practice Committee of American Society for Reproductive, M. (2008). "Hepatitis and reproduction." Fertil Steril 90(5 Suppl): S226-35.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=%22Fertility%20and%20sterility%22[Jour]%20AND%202008[pdat]%20AND%20Hepatitis%20and%20reproduction" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Wang, S. L., N. L. Yao, et al. (2008). "Kushenin for chronic hepatitis B: A systematic review." Chinese Journal of Evidence-Based Medicine 8(2): 102-119.&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Wilt, T. J., T. Shamliyan, et al. (2008). "Management of chronic hepatitis B." Evidence Report/Technology Assessment(174): 1-671.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=2008[pdat]%20AND%20Wilt%20T[author]%20AND%20Management%20of%20chronic%20hepatitis%20B" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Zhang, Y., J. J. Zhou, et al. (2008). "Effects of psychotherapy on depression and anxiety of patients with chronic hepatitis B: A meta-analysis." World Chinese Journal of Digestology 16(1): 101-104.&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Matthews, S. J. (2007). "Telbivudine for the management of chronic hepatitis B virus infection." Clinical Therapeutics 29(12): 2635-53.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18201580?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Rambaldi, A., B. P. Jacobs, et al. (2007). "Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases." Cochrane Database Syst Rev(4): CD003620.&amp;nbsp;[&lt;A href="nelh:237980:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Rhodes, S. D. and L. J. Yee (2007). "Using hepatitis A and B vaccination as a paradigm for effective HIV vaccine delivery." Sex Health 4(2): 121-7.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17524290" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Rudin, D. (2007). "Lamivudine and interferon versus lamivudine monotherapy for HBeAg-positive hepatitis B treatment: a meta-analysis of randomized, controlled trials." Adv Ther 24(4): 784-95.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17901027?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Takeda, A., J. Jones, et al. (2007). "A systematic review and economic evaluation of adefovir dipivoxil and pegylated interferon-alpha-2a for the treatment of chronic hepatitis B." J Viral Hepat 14(2): 75-88.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17244247?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Wang, H. F., Q. Li, et al. (2007). "[Use of bicyclol in treatment of chronic hepatitis B virus infection: a systematic review]." Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 21(2): 165-7.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17653325?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;2006&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Fabrizi, F., V. Dixit, et al. (2006). "Meta-analysis: intradermal vs. intramuscular vaccination against hepatitis B virus in patients with chronic kidney disease." Aliment Pharmacol Ther 24(3): 497-506.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16886915" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Fabrizi, F., V. Dixit, et al. (2006). "Meta-analysis: anti-viral therapy of hepatitis B virus-associated glomerulonephritis." Aliment Pharmacol Ther 24(5): 781-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16918881" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kohrt, H. E., D. L. Ouyang, et al. (2006). "Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection." Aliment Pharmacol Ther 24(7): 1003-16.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16984494?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Shepherd, J., J. Jones, et al. (2006). "Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation." Health Technol Assess 10(28): iii-iv, xi-xiv, 1-183.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16904047?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Wu, T., H. Roger, et al. (2006). "Bicyclol for chronic hepatitis B." Cochrane Database Syst Rev(4): CD004480.&amp;nbsp;[&lt;A href="nelh:238692:0" name=internalLink&gt;Link to Cochrane abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:04:23</lastReviewDate>
    <expiryDate>06/07/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>338926</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=338926]]&gt;</url>
    <title>Hepatorenal syndrome: Systematic reviews and meta-analyses</title>
    <publicationDate>2011-01-17T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,ACUTE KIDNEY INJURY,MANAGEMENT,CAUSES AND RISK FACTORS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Hepatorenal syndrome: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Gluud, L. L., K. Christensen, et al. (2010). "Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome." Hepatology 51(2): 576-84. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19885875" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Sagi, S.V., Mittal, S., Kasturi, K.S., Sood, G.K. (2010) "Terlipressin therapy for reversal of type 1 hepatorenal syndrome: A meta-analysis of randomized controlled trials." J Gastroenterol Hepatol. 2010 Jan 14 (Epub ahead of print) [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20074149" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Fabrizi, F., V. Dixit, et al. (2009). "Terlipressin for hepatorenal syndrome: A meta-analysis of randomized trials." Int J Artif Organs 32(3): 133-40. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19440988" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Gluud, L. L., K. Christensen, et al. (2009). "Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome." Hepatology.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19885875" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Karwa, R. and C. B. Woodis (2009). "Midodrine and octreotide in treatment of cirrhosis-related hemodynamic complications." Ann Pharmacother 43(4): 692-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19299324" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;No systematic reviews.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Tandon, P., V. G. Bain, et al. (2007). "Systematic review: renal and other clinically relevant outcomes in hepatorenal syndrome trials." Aliment Pharmacol Ther 25(9): 1017-28.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17439502" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;2006&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Fabrizi, F., V. Dixit, et al. (2006). "Meta-analysis: terlipressin therapy for the hepatorenal syndrome." Aliment Pharmacol Ther 24(6): 935-44.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16948805" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Gluud, L. L., M. S. Kjaer, et al. (2006). "Terlipressin for hepatorenal syndrome." Cochrane Database Syst Rev(4): CD005162.&amp;nbsp;[&lt;A href="nelh:316713:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>21/12/2010 10:52:28</lastReviewDate>
    <expiryDate>21/12/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>312837</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://learning.bmj.com/learning/search-result.html?moduleId=5004463]]&gt;</url>
    <title>Herpes simplex type 1 oral infection: a guide to diagnosis and treatment</title>
    <publicationDate>2009-04-21T00:00:00</publicationDate>
    <publisher>BMJ Learning</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,VIRAL,HERPES,MALE SEXUALLY TRANSMITTED INFECTIONS,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Want a fast, evidence based update? Here are the essentials on everyday conditions. Before you start a learning resource it is best to add it to your plan first.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Target audience:&lt;/STRONG&gt;&amp;nbsp; &amp;nbsp; &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Foundation programme&lt;/LI&gt;
&lt;LI&gt;International&lt;/LI&gt;
&lt;LI&gt;Practice nurse CPD&lt;/LI&gt;
&lt;LI&gt;Hospital doctor CPD&lt;/LI&gt;
&lt;LI&gt;GP CPD&lt;/LI&gt;
&lt;LI&gt;GP trainee&lt;/LI&gt;
&lt;LI&gt;Saudi Pediatric Association Channel&lt;/LI&gt;
&lt;LI&gt;Other healthcare professionals&lt;/LI&gt;
&lt;LI&gt;The Royal New Zealand College of General Practitioners&lt;/LI&gt;
&lt;LI&gt;Practice manager CPD&lt;/LI&gt;
&lt;LI&gt;Medical Students - international &lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
    <lastReviewDate>08/03/2011 09:57:10</lastReviewDate>
    <expiryDate>08/03/2012 09:57:10</expiryDate>
  </document>
  <document>
    <id>321813</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=321813]]&gt;</url>
    <title>Herpes: Systematic reviews and meta-analyses</title>
    <publicationDate>2010-09-09T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE SEXUALLY TRANSMITTED INFECTIONS,HERPES,VIRAL,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Herpes: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Cernik, C., K. Gallina, et al. (2008). "The treatment of herpes simplex infections: An evidence-based review." Archives of Internal Medicine 168(11): 1137-1144. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18541820?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hollier, L. M. and G. D. Wendel (2008). "Third trimester antiviral prophylaxis for preventing maternal genital herpes simplex virus (HSV) recurrences and neonatal infection." Cochrane Database of Systematic Reviews(1). [&lt;A href="nelh:279145:0" name=internalLink&gt;Link to Cochrane abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Lebrun-Vignes, B., A. Bouzamondo, et al. (2007). "A meta-analysis to assess the efficacy of oral antiviral treatment to prevent genital herpes outbreaks." J Am Acad Dermatol 57(2): 238-46. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17416440" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:04:27</lastReviewDate>
    <expiryDate>06/07/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>197297</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.cancerhelp.org.uk/help/default.asp?page=5511#hifu]]&gt;</url>
    <title>High intensity focused ultrasound treatment (HIFU) for kidney cancer that cannot be removed with an operation</title>
    <publicationDate></publicationDate>
    <publisher>Cancer Research UK</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ NEW RESEARCH,RENAL CANCER,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Details about HIFU</description>
    <body>&lt;![CDATA[ &lt;P&gt;Extract from website&lt;/P&gt;
&lt;P&gt;High intensity ultrasound beams can kill body cells if the beam is focused directly onto them using a special machine. Doctors hope that HIFU can be used to treat kidney cancer without damaging healthy cells, but they are not sure yet how well this will work. &lt;/P&gt;
&lt;P&gt;There has been a clinical trial in the UK looking at HIFU for kidney cancer that can't be removed by an operation. And another trial looking at HIFU before surgery. These trials are no longer recruiting and the results are awaited.&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>03/11/2010 15:42:24</lastReviewDate>
    <expiryDate>03/11/2011 15:42:24</expiryDate>
  </document>
  <document>
    <id>155657</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.uktransplant.org.uk/ukt/how_to_become_a_donor/religious_perspectives/leaflets/hindu_dharma_and_organ_donation.jsp]]&gt;</url>
    <title>Hindu Dharma and organ donation</title>
    <publicationDate></publicationDate>
    <publisher>UK Transplant</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ TRANSPLANTATION,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A guide to organ donation and hindu dharma</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Extract from website&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;There are many references that support the concept of organ donation in Hindu scriptures.&lt;I&gt; Daan&lt;/I&gt; is the original word in Sanskrit for donation meaning selfless giving. In the list of the ten &lt;I&gt;Niyamas&lt;/I&gt; (virtuous acts) &lt;I&gt;Daan&lt;/I&gt; comes third.&lt;/P&gt;
&lt;P&gt;Hindi, Gujarati, and Punjabi translations are available. &lt;/P&gt;]]&gt;</body>
    <lastReviewDate>23/09/2010 16:50:46</lastReviewDate>
    <expiryDate>23/09/2011 16:50:46</expiryDate>
    <relatedLinks>&lt;a href="http://www.uktransplant.org.uk/ukt/how_to_become_a_donor/religious_perspectives/leaflets/hindu_dharma_and_organ_donation.jsp" title="Click here for webpage"/&gt;&lt;a href="http://www.uktransplant.org.uk/ukt/newsroom/fact_sheets/religious_leaflets/hindu_dharma_and_organ_donation/hindu_dharrma_and_organ_donation.pdf" title="Click here for leaflet PDF"/&gt;&lt;a href="http://www.uktransplant.org.uk/ukt/newsroom/fact_sheets/religious_leaflets/hindu_dharma_and_organ_donation/hindu-hindi_and_organ_donation.pdf" title="Click here for leaflet PDF (Hindi)"/&gt;&lt;a href="http://www.uktransplant.org.uk/ukt/newsroom/fact_sheets/religious_leaflets/hindu_dharma_and_organ_donation/hindu-gujarati_and_organ_donation.pdf" title="Click here for leaflet PDF (Gujarati)"/&gt;&lt;a href="http://www.uktransplant.org.uk/ukt/newsroom/fact_sheets/religious_leaflets/hindu_dharma_and_organ_donation/hindu-punjabi_and_organ_donation.pdf" title="Click here for leaflet PDF (Punjabi)"/&gt;</relatedLinks>
    <creator>UK Transplant</creator>
  </document>
  <document>
    <id>283989</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/Tools/Pages/transplant.aspx?Tag=]]&gt;</url>
    <title>History of donation</title>
    <publicationDate></publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ TRANSPLANTATION,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>An interactive online tool, which sets out the history of organ and blood donation.</description>
    <body>&lt;![CDATA[ Interactive timeline from 1902 to 2007 outlining significant events in the history of donation.]]&gt;</body>
    <lastReviewDate>08/03/2011 09:57:14</lastReviewDate>
    <expiryDate>08/03/2012 09:57:14</expiryDate>
  </document>
  <document>
    <id>321812</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=321812]]&gt;</url>
    <title>HIV and male urogenital disorders: Systematic reviews and meta-analyses</title>
    <publicationDate>2011-02-21T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,PENILE DISORDERS,MALE SEXUALLY TRANSMITTED INFECTIONS,VIRAL,HIV,MALE UROGENITAL DISORDERS,CIRCUMCISION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;HIV and male urogenital disorders: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2011&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Blank LJ, Rompalo AM, Erbelding EJ, Zenilman JM, Ghanem KG. Treatment of syphilis in HIV-infected subjects: A systematic review of the literature. Sexually Transmitted Infections. 2011;87(1):9-16. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20924048" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Eke AC, Oragwu C. Sperm washing to prevent HIV transmission from HIV-infected men but allowing conception in sero-discordant couples. Cochrane Database of Systematic Reviews. 2011;1. [&lt;A href="nelh:403113:0" name=internalLink&gt;Link to Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kucirka LM, Montgomery RA, Ellison T, Wolf J, Segev DL. Risk of window period HIV and HCV infection in CDC high risk donors: A systematic review and meta-analysis. American Journal of Transplantation. 2011;11.&amp;nbsp;[No PubMed abstract available]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Anderson, B. L., E. B. Beyer, et al. (2010). "The effects of aerobic exercise and/or progressive resistance exercise on individuals with HIV waisting syndrome: A systematic review." Rehabilitation Oncology 28(1). [No abstract available]&lt;/LI&gt;
&lt;LI&gt;Baggaley, R. F., R. G. White, et al. (2010). "HIV transmission risk through anal intercourse: Systematic review, meta-analysis and implications for HIV prevention." International Journal of Epidemiology 39(4): 1048-1063. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20406794" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Barth, R. E., Q. Huijgen, et al. (2010). "Hepatitis B/C and HIV in sub-Saharan Africa: An association between highly prevalent infectious diseases. A systematic review and meta-analysis." International Journal of Infectious Diseases 14(12): e1024-e1031.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20870439" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Beyrer, C., S. D. Baral, et al. (2010). "The expanding epidemics of HIV type 1 among men who have sex with men in low- and middle-income countries: diversity and consistency." Epidemiologic Reviews 32(1): 137-51.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20573756" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Doyle, S. M., J. G. Kahn, et al. (2010). "The impact of male circumcision on HIV transmission." Journal of Urology 183(1): 21-26.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19913816" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Gao, L., F. Zhou, et al. (2010). "HIV/TB co-infection in mainland China: a meta-analysis." PLoS ONE [Electronic Resource] 5(5).&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20505769" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Landin, L., J. C. Rodriguez-Perez, et al. (2010). "Kidney transplants in HIV-positive recipients under HAART. A comprehensive review and meta-analysis of 12 series." Nephrol Dial Transplant 25(9): 3106-15. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20228071" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mahto, M., M. Nathan, et al. (2010). "More than a decade on: review of the use of imiquimod in lower anogenital intraepithelial neoplasia." International Journal of STD &amp;amp; AIDS 21(1): 8-16.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20029061" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Uthman, O. A., T. A. Popoola, et al. (2010). "Economic evaluations of adult male circumcision for prevention of heterosexual acquisition of HIV in men in sub-Saharan Africa: A systematic review." PLoS ONE 5(3).&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20224784" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Boily, M. C., R. F. Baggaley, et al. (2009). "Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies." Lancet Infect Dis 9(2): 118-29. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19179227" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Chida Y, Vedhara K. Adverse psychosocial factors predict poorer prognosis in HIV disease: a meta-analytic review of prospective investigations. Brain, Behavior, &amp;amp; Immunity. 2009;23(4):434-45. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19486650" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Gao L, Zhang L, Jin Q. Meta-analysis: prevalence of HIV infection and syphilis among MSM in China. Sexually Transmitted Infections. 2009;85(5):354-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19351623" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kaur G, Mehra N. Genetic determinants of HIV-1 infection and progression to AIDS: susceptibility to HIV infection. Tissue Antigens. 2009;73(4):289-301.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19317737" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;King E, De Silva M, Stein A, Patel V. Interventions for improving the psychosocial well-being of children affected by HIV and AIDS. Cochrane Database Syst Rev. 2009(2):CD006733.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19370650" target="_blank"&gt;Link to&amp;nbsp;PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kredo T, Van der Walt JS, Siegfried N, Cohen K. Therapeutic drug monitoring of antiretrovirals for people with HIV. Cochrane Database of Systematic Reviews. 2009(3).&amp;nbsp;[&lt;A href="nelh:320793:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Nikolopoulos GK, Paraskevis D, Hatzitheodorou E, Moschidis Z, Sypsa V, Zavitsanos X, et al. Impact of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: a cohort study and meta-analysis. Clinical Infectious Diseases. 2009;48(12):1763-71.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19435436" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Noar, S. M., H. G. Black, et al. (2009). "Efficacy of computer technology-based HIV prevention interventions: A meta-analysis." AIDS 23(1): 107-115.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19050392" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Noar, S. M., P. Palmgreen, et al. (2009). "A 10-year systematic review of HIV/AIDS mass communication campaigns: Have we made progress?" J Health Commun 14(1): 15-42.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19180369" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Siegfried, N., M. Muller, et al. (2009). "Male circumcision for prevention of heterosexual acquisition of HIV in men." Cochrane Database of Systematic Reviews(2).&amp;nbsp;[&lt;A href="nelh:238225:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Silberstein, J., T. Downs, et al. (2009). "HIV and prostate cancer: a systematic review of the literature." Prostate Cancer &amp;amp; Prostatic Diseases 12(1): 6-12.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18711409?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Spaulding AB, Brickley DB, Kennedy C, Almers L, Packel L, Mirjahangir J, et al. Linking family planning with HIV/AIDS interventions: A systematic review of the evidence. AIDS. 2009;23(SUPPL. 1):S79-S88.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20081392" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Albarracin, J., D. Albarracin, et al. (2008). "Effects of HIV-prevention interventions for samples with higher and lower percents of Latinos and Latin Americans: A meta-analysis of change in condom use and knowledge." AIDS and Behavior 12(4): 521-543.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17265011" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Benfield, T., C. Atzori, et al. (2008). "Second-line salvage treatment of AIDS-associated Pneumocystis jirovecii pneumonia: A case series and systematic review." Journal of Acquired Immune Deficiency Syndromes 48(1): 63-67.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18360286" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Daucher, M., D. A. Price, et al. (2008). "Virological outcome after structured interruption of antiretroviral therapy for human immunodeficiency virus infection is associated with the functional profile of virus-specific CD8+ T cells." J Virol 82(8): 4102-14.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18234797" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Gupta, R., A. Hill, et al. (2008). "Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials." Clinical Infectious Diseases 47(5): 712-22.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18662137" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hargreaves, J. R., C. P. Bonell, et al. (2008). "Systematic review exploring time trends in the association between educational attainment and risk of HIV infection in sub-Saharan Africa." AIDS 22(3): 403-414.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18195567" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Johnson, L. F. and D. A. Lewis (2008). "The effect of genital tract infections on HIV-1 shedding in the genital tract: a systematic review and meta-analysis." Sex Transm Dis 35(11): 946-59.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18685546" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Malekinejad, M., L. G. Johnston, et al. (2008). "Using respondent-driven sampling methodology for HIV biological and behavioral surveillance in international settings: A systematic review." AIDS and Behavior 12(SUPPL. 1): S105-S130.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18561018?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Malta, M., S. A. Strathdee, et al. (2008). "Adherence to antiretroviral therapy for human immunodeficiency virus/acquired immune deficiency syndrome among drug users: A systematic review." Addiction 103(8): 1242-1257.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18855813?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Marr, P. and S. Walmsley (2008). "Reassessment of enfuvirtide's role in the management of HIV-1 infection." Expert Opinion on Pharmacotherapy 9(13): 2349-62.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18710359" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Martinez-Cajas, J. L., N. Pant-Pai, et al. (2008). "Role of genetic diversity amongst HIV-1 non-B subtypes in drug resistance: A systematic review of virologic and biochemical evidence." AIDS Reviews 10(4): 212-223.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19092977" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mathers, B. M., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18817968" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Millett, G. A., S. A. Flores, et al. (2008). "Circumcision status and risk of HIV and sexually transmitted infections among men who have sex with men: A meta-analysis." JAMA - Journal of the American Medical Association 300(14): 1674-1684.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18840841?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mills, E., C. Cooper, et al. (2008). "Male circumcision for the prevention of heterosexually acquired HIV infection: A meta-analysis of randomized trials involving 11050 men." HIV Medicine 9(6): 332-335.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18705758" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mills, E. J., S. Kelly, et al. (2008). "Antiretroviral effects on HIV-1 RNA, CD4 cell count and progression to AIDS or death: A meta-regression analysis." HIV Medicine 9(10): 849-857.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18795965?ordinalpos=16&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Noar, S. M. (2008). "Behavioral interventions to reduce HIV-related sexual risk behaviour: Review and synthesis of meta-analytic evidence." AIDS and Behavior 12(3): 335-353.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17896176" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Nwachukwu, C. E. and J. U. Okebe (2008). "Antimotility agents for chronic diarrhoea in people with HIV/AIDS." Cochrane Database Syst Rev(4): CD005644.&amp;nbsp;[&lt;A href="nelh:295708:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;O'Brien, K., A. M. Tynan, et al. (2008). "Effects of progressive resistive exercise in adults living with HIV/AIDS: Systematic review and meta-analysis of randomized trials." AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV 20(6): 631-653.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18576165?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Powers, M., C. Poole, et al. (2008). "Rethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysis." The Lancet Infectious Diseases 8(9): 553-563.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18684670" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Prost, A., J. Elford, et al. (2008). "Social, behavioural, and intervention research among people of Sub-Saharan African origin living with HIV in the UK and Europe: literature review and recommendations for intervention." AIDS &amp;amp; Behavior 12(2): 170-94.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17497218" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Seminari, E., A. De Silvestri, et al. (2008). "CD4+ guided antiretroviral treatment interruption in HIV infection: A meta-analysis." AIDS Reviews 10(4): 236-244.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19092979?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Singh, H. K., A. Gupta, et al. (2008). "The Indian pediatric HIV epidemic: A systematic review." Current HIV Research 6(5): 419-432.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18855652" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Yu, C., Y. H. Sun, et al. (2008). "Meta-analysis of effect on HIV/AIDS intervention in floating population." Chinese Journal of Evidence-Based Medicine 8(5): 322-327.&amp;nbsp;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Rhodes, S. D. and L. J. Yee (2007). "Using hepatitis A and B vaccination as a paradigm for effective HIV vaccine delivery." Sex Health 4(2): 121-7.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17524290" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Young, T. N., F. J. Arens, et al. (2007). "Antiretroviral post-exposure prophylaxis (PEP) for occupational HIV exposure." Cochrane Database Syst Rev(1): CD002835.&amp;nbsp;[&lt;A href="nelh:237395:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2006&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Bartlett, J. A., M. J. Fath, et al. (2006). "An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults." AIDS 20(16): 2051-64.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17053351" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hutchinson, A. B., B. M. Branson, et al. (2006). "A meta-analysis of the effectiveness of alternative HIV counseling and testing methods to increase knowledge of HIV status." AIDS 20(12): 1597-604.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16868440" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lin, D., M. J. Tucker, et al. (2006). "Increased adverse drug reactions to antimicrobials and anticonvulsants in patients with HIV infection." Ann Pharmacother 40(9): 1594-601.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16912251?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Pai, N. P., J. Lawrence, et al. (2006). "Structured treatment interruptions (STI) in chronic unsuppressed HIV infection in adults." Cochrane Database Syst Rev 3: CD006148.&amp;nbsp;[&lt;A href="nelh:239230:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Rueda, S., L. Y. Park-Wyllie, et al. (2006). "Patient support and education for promoting adherence to highly active antiretroviral therapy for HIV/AIDS." Cochrane Database Syst Rev 3: CD001442.&amp;nbsp;[&lt;A href="nelh:237286:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Simoni, J. M., C. R. Pearson, et al. (2006). "Efficacy of interventions in improving highly active antiretroviral therapy adherence and HIV-1 RNA viral load. A meta-analytic review of randomized controlled trials." J Acquir Immune Defic Syndr 43 Suppl 1: S23-35.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17133201" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:04:32</lastReviewDate>
    <expiryDate>06/07/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>312840</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://learning.bmj.com/learning/search-result.html?moduleId=6052273]]&gt;</url>
    <title>HIV infection: diagnostic picture tests</title>
    <publicationDate>2009-04-21T00:00:00</publicationDate>
    <publisher>BMJ Learning</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE SEXUALLY TRANSMITTED INFECTIONS,HIV,VIRAL,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Use these interactive modules to learn as we guide you through a real life consultation. Before you start a learning resource it is best to add it to your plan first.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Target audience:&lt;/STRONG&gt;&amp;nbsp; &amp;nbsp; &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Foundation programme&lt;/LI&gt;
&lt;LI&gt;International&lt;/LI&gt;
&lt;LI&gt;Practice nurse CPD&lt;/LI&gt;
&lt;LI&gt;Hospital doctor CPD&lt;/LI&gt;
&lt;LI&gt;GP CPD&lt;/LI&gt;
&lt;LI&gt;GP trainee&lt;/LI&gt;
&lt;LI&gt;Saudi Pediatric Association Channel&lt;/LI&gt;
&lt;LI&gt;Other healthcare professionals&lt;/LI&gt;
&lt;LI&gt;The Royal New Zealand College of General Practitioners&lt;/LI&gt;
&lt;LI&gt;Medical Students - international &lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
    <lastReviewDate>08/03/2011 09:57:17</lastReviewDate>
    <expiryDate>08/03/2012 09:57:17</expiryDate>
  </document>
  <document>
    <id>334766</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=334766]]&gt;</url>
    <title>Home haemodialysis references</title>
    <publicationDate>2010-02-18T00:00:00</publicationDate>
    <publisher>NHS Kidney Care</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ HAEMODIALYSIS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES,HOME HAEMODIALYSIS,DIALYSIS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Home haemodialysis references&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;This is a list of some useful references to evidence about home haemodialysis:&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;David, S., Kumpers, P., Eisenbach, G.M., Haller, H., Kielstein, J.T. "Prospective evaluation of an in-centre conversion from conventional haemodialysis to an intensified nocturnal strategy." Nephrol Dial Transplant. 2009 Jul;24(7):2232-40. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19208770" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Greene, T. "Randomized and Observational Studies in Nephrology: How Strong is the Evidence?" American Journal of Kidney Diseases, March 2009, 53(3): 377-388. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19185399" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Howard, K., Salkeld, G., White, S., McDonald, S., et al. "The cost-effectiveness of increasing kidney transplantation and home-based dialysis." Nephrology (Carlton). 2009 Feb;14(1):123-32. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19207859" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Johansen, K.L., Zhang, R., Huang, Y., Chen, S.C. et al. "Survival and hospitalization among patients using nocturnal and short daily compared to conventional hemodialysis: a USRDS study." Kidney Int. 2009 Nov;76(9):984-90. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19692997" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Pauly, R.P., Gill, J.S., Rose, C.L., Asad, R.A., et al. "Survival among nocturnal home haemodialysis patients compared to kidney transplant recipients." Nephrol Dial Transplant. 2009 Sep;24(9):2915-9. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19584107" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Baboolal, K., McEwan, P., Sondhi, S., Spiewanowski, P. et al. "The cost of renal dialysis in a UK setting - a multicentre study." Nephrol Dial Transplant. 2008 Jun;23(6):1982-9. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18174268" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kjellstrand, C.M., Buoncristiani, U., Ting, G., Traeger, J. et al. "Short daily haemodialysis: survival in 415 patients treated for 1006 patient-years." Nephrol Dial Transplant. 2008 Oct;23(10):3283-9. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18458034" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lockridge, R.S. Jr., Moran, J. "Short daily hemodialysis and nocturnal hemodialysis at home: practical considerations." Semin Dial. 2008 Jan-Feb;21(1):49-53.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18251958" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Malmstrom, R.K., Roine, R.P., Heikkila, A., Rasanen, P., et al. "Cost analysis and health-related quality of life of home and self-care satellite haemodialysis." Nephrol Dial Transplant. 2008 Jun;24(6):1990-6. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18223263" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Pauly, R.P., Copland, M., Komenda, P., Levin, A., et al. "Utility and limitations of a multicenter nocturnal home hemodialysis cohort." Clin J Am Soc Nephrol. Nov 2008, 3(6):1846-51.&amp;nbsp;&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18832105" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Culleton, B.F., Walsh, M., Klarenbach, S.W, Mortis, G. et al. "Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial." JAMA 2007 Sep 19;298(11):1291-9. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17878421" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2006&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Jacobs, C. "Costs and benefits of improving renal failure treatment - where do we go?" Nephrol Dial Transplant. Aug 2006, 21(8):2049-2052.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16627607" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Jassal, S.V., Devins, G.M., Chan, C.T., Bozanovic, R. et al. "Improvements in cognition in patients converting from thrice weekly hemodialysis to nocturnal hemodialysis: a longitudinal pilot study." Kidney Int. 2006 Sep;70(5):956-62. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16837916" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2005&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;[No author] "Home haemodialysis is an effective alternative to hospital or satellite unit haemodialysis." Evidence-Based Healthcare and Public Health, Apr 2005, 9(2):123-124.&amp;nbsp;[&lt;A href="http://www.sciencedirect.com/science?_ob=MImg&amp;amp;_imagekey=B7MFB-4FRKVPK-3-3&amp;amp;_cdi=23254&amp;amp;_user=126524&amp;amp;_orig=browse&amp;amp;_coverDate=04%2F30%2F2005&amp;amp;_sk=999909997&amp;amp;view=c&amp;amp;wchp=dGLbVzb-zSkWz&amp;amp;md5=f0a77d17de1e695bdc2d2a3f80457c6f&amp;amp;ie=/sdarticle.pdf" target="_blank"&gt;Link to full-text PDF&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Agar, J.W. "Nocturnal haemodialysis in Australia and New Zealand." Nephrology (Carlton). 2005 Jun; 10(3):222-30. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15958033" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Walsh, M., Culleton, B., Tonelli, M., Manns, B. "A systematic review of the effect of nocturnal hemodialysis on blood pressure, left ventricular hypertrophy, anemia, mineral metabolism, and health-related quality of life." Kidney Int. 2005 Apr;67(4):1500-8. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15780103" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2004&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Chan, C.T. "Cardiovascular effects of frequent intensive hemodialysis." Seminars in Dialysis, March 2004, 17(2):99-103.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/15043609" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mowatt, G., Vale, L., MacLeod, A. "Systematic review of the effectiveness of home versus hospital or satellite unit hemodialysis for people with end-stage renal failure." Int J Tech Ass in Health Care, 2004, 20(3):258-68.&amp;nbsp; [&lt;A href="nelh:254175:0" name=internalLink&gt;Link to abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Vale, L., Cody, J., Wallace, S., Daly, C., et al. "Continuous ambulatory peritoneal dialysis (CAPD) versus hospital or home haemodialysis for end-stage renal disease in adults." Cochrane Database of Systematic Reviews, 2004, 4.&amp;nbsp;&amp;nbsp;[&lt;A href="nelh:238350:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>21/12/2010 10:52:32</lastReviewDate>
    <expiryDate>21/12/2011 10:52:32</expiryDate>
  </document>
  <document>
    <id>224318</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.bmj.com/cgi/reprint/333/7571/733]]&gt;</url>
    <title>How to measure renal function in clinical practice</title>
    <publicationDate>2006-10-07T00:00:00</publicationDate>
    <publisher>British Medical Journal</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ ASSESSMENT TESTS,ASSESSMENT OF RENAL FUNCTION,SCREENING TESTS,SCREENING OPTIONS,CREATININE CLEARANCE,GFR AND EGFR,CREATININE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This article in the BMJ describes routine and more specialised methods of assessing renal function and discusses estimated glomerular filtration rate</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Extract from the National electronic Library for Medicines website&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;The following topics are discussed:&lt;BR&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Creatinine &lt;/LI&gt;
&lt;LI&gt;Creatinine clearance &lt;/LI&gt;
&lt;LI&gt;Urea &lt;/LI&gt;
&lt;LI&gt;Mean of urea and creatinine clearance &lt;/LI&gt;
&lt;LI&gt;Inulin clearance &lt;/LI&gt;
&lt;LI&gt;Radioisotopic methods &lt;/LI&gt;
&lt;LI&gt;Radiocontrast agents &lt;/LI&gt;
&lt;LI&gt;Cystatin C &lt;/LI&gt;
&lt;LI&gt;Prediction formulas &lt;/LI&gt;
&lt;LI&gt;Cockcroft and Gault equation &lt;/LI&gt;
&lt;LI&gt;Modification of diet in renal disease formula &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;BR&gt;The review advises that estimated GFR should be used as a guide to renal function in conjunction with advice on renal disease from the Renal Association's website (www.renal.org/eGFR/). It also provides the following tips for non-specialists&amp;nbsp;if the estimated glomerular filtration rate is &amp;lt; 60 ml/min:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Review previous results or repeat the measurement to assess if renal function is stable or declining&lt;/LI&gt;
&lt;LI&gt;Measure BP and test urine for protein and blood&lt;/LI&gt;
&lt;LI&gt;Review drugs for potentially nephrotoxic agents, such as ACE inhibitors or AII receptor blockers, diuretics, NSAIDs, and antibiotics.&lt;/LI&gt;
&lt;LI&gt;Check for urinary symptoms, signs of fluid retention or hypovolaemia, and palpable bladder&lt;/LI&gt;
&lt;LI&gt;Enter into a chronic disease management programme and decide whether referral to a renal clinic is appropriate, using local guidelines or those from the Renal Association&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
    <lastReviewDate>13/12/2010 11:39:45</lastReviewDate>
    <expiryDate>13/12/2011 11:39:45</expiryDate>
  </document>
  <document>
    <id>155610</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://renux.dmed.ed.ac.uk/edren/Unitbits/ACEIstart.html]]&gt;</url>
    <title>How to start an ACE inhibitor</title>
    <publicationDate>2005-03-08T00:00:00</publicationDate>
    <publisher>EdRen Info</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ INTERVENTIONS,BLOOD PRESSURE,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Guideline for medical practitioners from EdREN, Renal Unit, Royal Infirmary, Edinburgh</description>
    <body>&lt;![CDATA[ Short guideline on what needs to be known before starting ACE inhibitors, risk factors for hyperkalaemia and renal impairment, which ACE inhibitor to use, other drugs and diet, dose titration, side effects, alternative agents and links to further information.]]&gt;</body>
    <lastReviewDate>23/09/2010 16:50:53</lastReviewDate>
    <expiryDate>23/09/2011 16:50:53</expiryDate>
  </document>
  <document>
    <id>301804</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://healthguides.mapofmedicine.com/choices/map/hypercalcaemia1.html]]&gt;</url>
    <title>Hypercalcaemia - suspected</title>
    <publicationDate>2008-12-22T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ OTHER CONDITIONS - ADULTS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Web pages from NHS Choices and the Map of Medicine.</description>
    <body>&lt;![CDATA[ This page provides a link to the Map of Medicine view on suspected hypercalcaemia.]]&gt;</body>
    <lastReviewDate>26/11/2010 15:26:09</lastReviewDate>
    <expiryDate>26/11/2011 15:26:09</expiryDate>
  </document>
  <document>
    <id>338975</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=338975]]&gt;</url>
    <title>Hypertension: Systematic reviews and meta-analyses</title>
    <publicationDate>2011-02-18T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,PREDISPOSING FACTORS,BLOOD PRESSURE,INTERVENTIONS,BLOOD PRESSURE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Hypertension: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2011&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Agarwal, R., Bills, J.E., Hecht, T.J., Light, R.P. (2011) Role of home blood pressure monitoring in overcoming therapeutic inertia and improving hypertension control: a systematic review and meta-analysis. Hypertension Jan; 57(1): 29-38. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/21115879" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Morgado MP, Morgado SR, Mendes LC, Pereira LJ, Castelo-Branco M. (2011) "Pharmacist interventions to enhance blood pressure control and adherence to antihypertensive therapy: Review and meta-analysis." Am J Health Syst Pharm. 2011 Feb 1;68(3):241-53. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/21258029" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Trevisol DJ, Moreira LB, Kerkhoff A, Fuchs SC, Fuchs FD. Health-related quality of life and hypertension: a systematic review and meta-analysis of observational studies. J Hypertens. 2011 Feb;29(2):179-88. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/21045726" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Zou Z, Xu FY, Wang L, An MM, Zhang H, Shi XY. Antihypertensive and renoprotective effects of trandolapril/verapamil combination: a meta-analysis of randomized controlled trials. Journal of Human Hypertension. 2011;25(3):203-10. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20535140" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Alviar, C. L., S. Devarapally, et al. (2010). "Efficacy and safety of dual calcium channel (CCB) therapy." Journal of Clinical Hypertension 12. [No abstract available]&lt;/LI&gt;
&lt;LI&gt;Chrysant, S. G. (2010). "The role of Angiotensin receptor blocker and calcium channel blocker combination therapy in treating hypertension: focus on recent studies." American Journal of Cardiovascular Drugs 10(5): 315-20. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20860414" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Clark CE, Smith LF, Taylor RS, Campbell JL. (2010) "Nurse led interventions to improve control of blood pressure in people with hypertension: systematic review and meta-analysis." BMJ Aug 23; 341:c3995. [&lt;A href="http://www.bmj.com/content/341/bmj.c3995.full.pdf" target="_blank"&gt;Link to free full-text article in PDF&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Czernichow, S., Zanchetti, A., Turnbull, F., Barzi, F., Ninomiya, T., Kengne, A-P, et al. (2010) "The effects of blood pressure reduction and of different blood pressure-lowering regiments on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials". Journal of Hypertension, 29(1): 4-16. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20881867" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Dunn, B. L., A. C. Teusink, et al. (2010). "Management of hypertension in renal transplant patients: a comprehensive review of nonpharmacologic and pharmacologic treatment strategies." Ann Pharmacother 44(7-8): 1259-70. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Management%20of%20hypertension%20in%20renal%20transplant%20patients%3A%20a%20comprehensive%20review%20of%20nonpharmacologic%20and%20pharmacologic%20treatment%20strategies" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Gallagher H, de Lusignan S, Harris K, Cates C. (2010) "Quality-improvement strategies for the management of hypertension in chronic kidney disease in primary care: a systematic review". Br J Gen Pract, 60 (575), pp.e258-e265. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20529489" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Glynn LG, Murphy AW, Smith SM, et al. Self-monitoring and other non-pharmacological interventions to improve the management of hypertension in primary care: a systematic review. Br J Gen Pract. 2010 Dec;60(581):e476-88. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/21144192?dopt=Abstract" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Hackam, D. G., N. A. Khan, et al. "The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy." Canadian Journal of Cardiology 26(5): 249-58.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=The%202010%20Canadian%20Hypertension%20Education%20Program%20recommendations%20for%20the%20management%20of%20hypertension%3A%20part%202%20-%20therapy" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kandler, M. R., G. T. Mah, et al. (2010). "Hydralazine for essential hypertension." Cochrane Database of Systematic Reviews 8.&amp;nbsp;[&lt;A href="http://onlinelibrary.wiley.com/o/cochrane/clsysrev/articles/CD004934/frame.html" target="_blank"&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Marrs, J. C. (2010). "Spironolactone management of resistant hypertension." Ann Pharmacother 44(11): 1762-9. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20978214" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Nguyen, H. M., K. Ma, et al. (2010). "Clevidipine for the treatment of severe hypertension in adults." Clinical Therapeutics 32(1): 11-23.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Clevidipine%20for%20the%20treatment%20of%20severe%20hypertension%20in%20adults" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Ni Y, Chen Y, Huang W.&amp;nbsp; The effect of pharmaceutical care programs on blood pressure control in individuals with hypertension: a meta-analysis. Journal of Pharmacy Technology 2009; 25(5): 292-29. [&lt;A href="nelh:379079:0" name=internalLink&gt;Link to DARE abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Robert N, Wong GWK, Wright JM. (2010) "Effect of cyclosporine on blood pressure". Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD007893. DOI: 10.1002/14651858.CD007893.pub2.&amp;nbsp;[&lt;A href="http://mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD007893/frame.html" target="_blank"&gt;Link to Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Sep, S., L. Smits, et al. (2010). "Prediction tests for recurrent hypertensive disease in pregnancy, a systematic review." Hypertension in Pregnancy 29(2): 206-230. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Prediction%20tests%20for%20recurrent%20hypertensive%20disease%20in%20pregnancy%2C%20a%20systematic%20review" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Steichen, O., L. Amar, et al. "Primary stenting for atherosclerotic renal artery stenosis." Journal of Vascular Surgery 51(6): 1574-1580.e1.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20488331" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Agarwal, R. and A. D. Sinha (2009). "Cardiovascular protection with antihypertensive drugs in dialysis patients: systematic review and meta-analysis." Hypertension 53(5): 860-6.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19273737" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Arguedas, J. A., M. I. Perez, et al. (2009). "Treatment blood pressure targets for hypertension." Cochrane Database Syst Rev(3): CD004349.&amp;nbsp;[&lt;A href="nelh:320743:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Bangash, F. and R. Agarwal (2009). "Masked hypertension and white-coat hypertension in chronic kidney disease: a meta-analysis." Clin J Am Soc Nephrol 4(3): 656-64.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19261815" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Heerspink, H. J., T. Ninomiya, et al. (2009). "Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials." Lancet 373(9668): 1009-15.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19249092" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Witham MD, Nadir MA, Struthers AD.&amp;nbsp; (2009) "Effect of vitamin D on blood pressure: a systematic review and meta-analysis." Journal of Hypertension; 27(10): 1948-1954. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19587609" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Zhu, X., K. Stergiopoulos, et al. (2009). "Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis." Acta Oncol 48(1): 9-17.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18752081" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Bobrie, G., P. Clerson, et al. (2008). "Masked hypertension: a systematic review." J Hypertens 26(9): 1715-25.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18698202" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Khan, N. A., B. Hemmelgarn, et al. (2008). "The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy." Can J Cardiol 24(6): 465-75.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18548143" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kienitz, T. and M. Quinkler (2008). "Testosterone and blood pressure regulation." Kidney Blood Press Res 31(2): 71-9.&amp;nbsp;[Link to PubMed abstract]&lt;/LI&gt;
&lt;LI&gt;Matchar, D. B., D. C. McCrory, et al. (2008). "Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension." Ann Intern Med 148(1): 16-29.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17984484" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Wu, S., J. J. Chen, et al. (2008). "Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis." Lancet Oncol 9(2): 117-23.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18221915" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Corrao, G., L. Scotti, et al. (2007). "Hypertension, antihypertensive therapy and renal-cell cancer: a meta-analysis." Curr Drug Saf 2(2): 125-33.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18690958" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Sheridan, S. (2007). "Primary prevention of CVD: treating hypertension." Clin Evid (Online) 2007.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19454053" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2006&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Boudville, N., G. V. Prasad, et al. (2006). "Meta-analysis: risk for hypertension in living kidney donors." Ann Intern Med 145(3): 185-96. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16880460" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>11/01/2011 10:22:00</lastReviewDate>
    <expiryDate>11/01/2012 00:00:00</expiryDate>
  </document>
  <document>
    <id>301805</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://healthguides.mapofmedicine.com/choices/map/hypocalcaemia1.html]]&gt;</url>
    <title>Hypocalcaemia - suspected</title>
    <publicationDate>2008-12-22T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ OTHER CONDITIONS - ADULTS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Web pages from NHS Choices and the Map of Medicine.</description>
    <body>&lt;![CDATA[ This page provides a link to the Map of Medicine view on suspected hypocalcaemia.]]&gt;</body>
    <lastReviewDate>26/11/2010 15:26:13</lastReviewDate>
    <expiryDate>26/11/2011 15:26:13</expiryDate>
  </document>
  <document>
    <id>301806</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://healthguides.mapofmedicine.com/choices/map/hypokalaemia1.html]]&gt;</url>
    <title>Hypokalaemia - suspected</title>
    <publicationDate>2008-12-22T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ OTHER CONDITIONS - ADULTS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Web pages from NHS Choices and the Map of Medicine.</description>
    <body>&lt;![CDATA[ This page provides a link to the Map of Medicine view on suspected Hypokalaemia.]]&gt;</body>
    <lastReviewDate>26/11/2010 15:26:16</lastReviewDate>
    <expiryDate>26/11/2011 15:26:16</expiryDate>
  </document>
  <document>
    <id>321814</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=321814]]&gt;</url>
    <title>Hypospadias: Systematic reviews and meta-analyses</title>
    <publicationDate>2011-01-24T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,PENILE DISORDERS,HYPOSPADIAS,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Hypospadias: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Castagnetti, M. and A. El-Ghoneimi (2010). "Surgical management of primary severe hypospadias in children: Systematic 20-year review." Journal of Urology 184(4): 1469-1474. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20727541" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Wilkinson, D. J., P. Farrelly, et al. (2010). "Outcomes in distal hypospadias: A systematic review of the Mathieu and tubularized incised plate repairs." J Pediatr Urol. Dec 13 [Epub ahead of print]&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/21159560" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Yiee, J. H. and L. S. Baskin (2010). "Environmental factors in genitourinary development." Journal of Urology 184(1): 34-41. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=%22The%20Journal%20of%20urology%22[Jour]%20AND%202010[pdat]%20AND%20Environmental%20factors%20in%20genitourinary%20development" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Lan YP, Huang ZH, Zuo YX. Effectiveness of caudal bupivacaine with neostigmine for postoperative pain management after hypospadias surgery in children: A systematic review. Chinese Journal of Evidence-Based Medicine. 2009;9(6):670-3. [No link to abstract]&lt;/LI&gt;
&lt;LI&gt;Rocheleau, C. M., P. A. Romitti, et al. (2009). "Pesticides and hypospadias: a meta-analysis." Journal of pediatric urology 5(1): 17-24. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18848807" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Schonbucher, V. B., D. M. Weber, et al. (2008). "Psychosocial adjustment, health-related quality of life, and psychosexual development of boys with hypospadias: a systematic review." Journal of Pediatric Psychology 33(5): 520-35. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18056145" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Markiewicz, M. R., M. A. Lukose, et al. (2007). "The oral mucosa graft: a systematic review." J Urol 178(2): 387-94. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17561150?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:19:55</lastReviewDate>
    <expiryDate>06/07/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>388074</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=388074]]&gt;</url>
    <title>Immunosuppression and kidney diseases: Systematic reviews and meta-analyses</title>
    <publicationDate>2010-09-20T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ COMPLICATIONS OF KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,ACUTE KIDNEY INJURY,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Immunosuppression and kidney diseases: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Alavian, S. M. and S. V. Tabatabaei "Effects of oral levamisole as an adjuvant to hepatitis B vaccine in adults with end-stage renal disease: a meta-analysis of controlled clinical trials." Clin Ther 32(1): 1-10. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Effects%20of%20oral%20levamisole%20as%20an%20adjuvant%20to%20hepatitis%20B%20vaccine%20in%20adults%20with%20end-stage%20renal%20disease%3A%20a%20meta-analysis%20of%20controlled%20clinical%20trials" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Alavian, S. M. and S. V. Tabatabaei "The effect of diabetes mellitus on immunological response to hepatitis B virus vaccine in individuals with chronic kidney disease: A meta-analysis of current literature." Vaccine 28(22): 3773-7.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=The%20effect%20of%20diabetes%20mellitus%20on%20immunological%20response%20to%20hepatitis%20B%20virus%20vaccine%20in%20individuals%20with%20chronic%20kidney%20disease%3A%20A%20meta-analysis%20of%20current%20literature" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <expiryDate>20/09/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>338983</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=338983]]&gt;</url>
    <title>Immunosuppression and organ transplant: Systematic reviews and meta-analyses</title>
    <publicationDate>2011-01-17T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,TRANSPLANTATION,IMMUNOSUPPRESSIVE DRUGS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Immunosuppression and organ transplant: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Dobbels, F., T. Ruppar, et al. (2010). "Adherence to the immunosuppressive regimen in pediatric kidney transplant recipients: A systematic review." Pediatric Transplantation 14(5): 603-613. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20214741" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Gijsen, V. M., S. N. De Wildt, et al. (2010). "Tacrolimus-induced nephrotoxicity and genetic variability: A systematic review." Clinical Pharmacology and Therapeutics 87. [No PubMed abstract available]&lt;/LI&gt;
&lt;LI&gt;Karamchandani, D., R. Arias-Amaya, et al. "Thyroid cancer and renal transplantation: A meta-analysis." Endocrine-Related Cancer 17(1): 159-167.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Thyroid%20cancer%20and%20renal%20transplantation%3A%20A%20meta-analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lee, Y. H., J. H. Woo, et al. (2010). "Induction and maintenance therapy for lupus nephritis: a systematic review and meta-analysis." Lupus 19(6): 703-10.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Induction%20and%20maintenance%20therapy%20for%20lupus%20nephritis%3A%20a%20systematic%20review%20and%20meta-analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Ontario Health Technology Advisory Committee (2010). "Kidney and liver organ transplantation in persons with human immunodeficiency virus: An evidence-based analysis." Ontario Health Technology Assessment Series 10(4). [&lt;A href="http://www.health.gov.on.ca/english/providers/program/ohtac/tech/recommend/rec_organ_transplant_20100322.pdf" target="_blank"&gt;Link to full-text PDF&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Robert, N., G. W. Wong, et al. (2010). "Effect of cyclosporine on blood pressure." Cochrane Database of Systematic Reviews(1): CD007893-NaN.&amp;nbsp;[&lt;A href="http://onlinelibrary.wiley.com/o/cochrane/clsysrev/articles/CD007893/frame.html" target="_blank"&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;No systematic reviews&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Bonaros, N., B. Mayer, et al. (2008). "CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis." Clin Transplant 22(1): 89-97. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18217909" target="_blank"&gt;Link to Pubmed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hodson, E. M., J. C. Craig, et al. (2008). "Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients." Cochrane Database Syst Rev(2): CD003774. [&lt;A href="nelh:238496:0" name=internalLink&gt;Link to Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Sanchez-Fructuoso, A. I. (2008). "Everolimus: an update on the mechanism of action, pharmacokinetics and recent clinical trials." Expert Opin Drug Metab Toxicol 4(6): 807-19. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18611120" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Gutierrez-Dalmau, A. and J. M. Campistol (2007). "Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review." Drugs 67(8): 1167-98.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17521218" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hodson, E. M., C. A. Jones, et al. (2007). "Immunoglobulins, vaccines or interferon for preventing cytomegalovirus disease in solid organ transplant recipients." Cochrane Database Syst Rev(2): CD005129.&amp;nbsp;[&lt;A href="nelh:259988:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2006&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;No systematic reviews. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;A href="nelh:329868:0" name=internalLink&gt;
&lt;P&gt;&lt;STRONG&gt;See the 2009 Annual Evidence Update on Post-Transplant Lymphoproliferative Disorder in Renal Transplant Patients&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>21/12/2010 10:52:46</lastReviewDate>
    <expiryDate>21/12/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>236189</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/assetRoot/04/13/55/62/04135562.pdf]]&gt;</url>
    <title>Implementing the Renal NSF ; The Renal Action Learning Sets; sharing the work in progress</title>
    <publicationDate>2006-05-31T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ NATIONAL SERVICE FRAMEWORK FOR RENAL SERVICES/POLICY DOCUMENTS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Publication from Department of Health</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Extract&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;This Report follows the Renal Action Learning Sets Sharing Event in January 2006. It provides a summary of the work of the learning sets and includes a note from the project lead and the national facilitator as well as the slides from the day. Also included is some valuable information which resulted from the lively discussions which took place on the day.&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>11/01/2011 10:23:17</lastReviewDate>
    <expiryDate>11/01/2012 10:23:17</expiryDate>
  </document>
  <document>
    <id>344168</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.kidneycare.nhs.uk/ImprovingChoiceforKidneyPatients_HomeHaemodialysis_Report_Feb2010-pdf.cmsdoc]]&gt;</url>
    <title>Improving Choice for Kidney Patients: Report</title>
    <publicationDate>2010-02-18T00:00:00</publicationDate>
    <publisher>NHS Kidney Care</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ HAEMODIALYSIS,COMMISSIONING,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,DISEASE/CONDITION GROUPS,ENDOCRINE,SERVICE PROVISION,ASSESSMENT AND PLANNING,SERVICE DEVELOPMENT,PATIENT AND PUBLIC ENGAGEMENT,PATIENT CHOICE,COMMISSIONING PROCESS,KIDNEY DISEASES,DIALYSIS,HOME HAEMODIALYSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Improving Choice for Kidney Patients: Home Haemodialysis February 2010</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Contents:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Foreword by National Clinical Director for Kidney Care 
&lt;LI&gt;Introduction by Director, NHS Kidney Care 
&lt;LI&gt;1. Executive Summary 
&lt;LI&gt;2. Background 
&lt;LI&gt;2.1 Provision of Home Haemodialysis across England 
&lt;LI&gt;2.2 A Summary of the Clinical Evidence 
&lt;LI&gt;3. Perceived Barriers to improving choice for kidney patients 
&lt;LI&gt;3.1 What Works in Renal Units 
&lt;LI&gt;3.2 The patients’ perspective 
&lt;LI&gt;3.3 Costs and Tariff 
&lt;LI&gt;4. Recommendations 
&lt;LI&gt;5. Conclusion 
&lt;LI&gt;6. Acknowledgements &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Appendices:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Increasing choice and uptake of self-care therapies: Literature Review 
&lt;LI&gt;Workshop to identify barriers to home dialysis therapies 
&lt;LI&gt;Home Haemodialysis Patient Stories &lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
    <lastReviewDate>20/01/2011 10:27:55</lastReviewDate>
    <expiryDate>20/01/2012 10:27:55</expiryDate>
  </document>
  <document>
    <id>393833</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.kidneycare.nhs.uk/Library/ImprovingChoiceListeningtoPatientStoriesFINAL.pdf]]&gt;</url>
    <title>Improving Choice: Listening to Patient Stories</title>
    <publicationDate>2010-11-10T00:00:00</publicationDate>
    <publisher>NHS Kidney Care</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ PERITONEAL DIALYSIS,HAEMODIALYSIS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES,DIALYSIS,HOME HAEMODIALYSIS,HOME DIALYSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>In order to try and increase the numbers of patients who are given the option to dialyse at home, NHS Kidney Care has launched a report: "Improving Choice: Listening to Patient Stories". There are also two short films, which show the stories of home dialysis patients and their partners.</description>
    <body>&lt;![CDATA[ &lt;P&gt;Contents of the report includes the following:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Foreword &lt;/LI&gt;
&lt;LI&gt;Background &lt;/LI&gt;
&lt;LI&gt;How do people discover home dialysis? &lt;/LI&gt;
&lt;LI&gt;What factors influence the decision to dialyse at home? &lt;/LI&gt;
&lt;LI&gt;What training is required for home dialysis? &lt;/LI&gt;
&lt;LI&gt;What adaptation is required for home dialysis? &lt;/LI&gt;
&lt;LI&gt;What are the advantages of dialysing at home? &lt;/LI&gt;
&lt;LI&gt;What are the costs and challenges of dialysing at home? &lt;/LI&gt;
&lt;LI&gt;What improvements are yet to be made? &lt;/LI&gt;
&lt;LI&gt;What advice would those using home dialysis give to those considering it?&lt;/LI&gt;
&lt;LI&gt;Summary &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;A href="http://www.kidneycare.nhs.uk/_Whatworks-Shortfilms.aspx" target="_blank"&gt;Link to webpage with short films: Listening to patient stories&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
    <expiryDate>10/11/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>177806</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://bmj.bmjjournals.com/cgi/reprint/331/7523/976?ijkey=33ce651453fa23141b40c1828e91ae2c18b4f86b]]&gt;</url>
    <title>Improving surveillance of MRSA bacteraemia</title>
    <publicationDate></publicationDate>
    <publisher>BMJ Publishing</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ PREVENTION OF INFECTIONS,HAEMODIALYSIS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,DIALYSIS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Editorial from British Medical Journal, 2005, 331, 976-977</description>
    <body>&lt;![CDATA[ &lt;FONT face=New-Baskerville-RomanA color=#292526 size=1&gt;
&lt;P&gt;Extract from editorial&lt;/P&gt;
&lt;P&gt;Lack of timely access to surgery to create arterio-venous fistulae for dialysis, resulting in prolonged use of intravenous lines,is a risk factor for infection in renal units.&lt;/P&gt;&lt;/FONT&gt;&lt;FONT face=New-Baskerville-RomanA color=#292526 size=1&gt;
&lt;P&gt;&lt;/FONT&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>23/09/2010 16:51:12</lastReviewDate>
    <expiryDate>23/09/2011 16:51:12</expiryDate>
  </document>
  <document>
    <id>321815</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=321815]]&gt;</url>
    <title>Infertility: Systematic reviews and meta-analyses</title>
    <publicationDate>2011-02-21T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,FERTILITY,MALE UROGENITAL DISORDERS,INFERTILITY]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Infertility: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2011&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Li, Y., H. Lin, et al. (2011). "Association between socio-psycho-behavioral factors and male semen quality: systematic review and meta-analyses." Fertility &amp;amp; Sterility 95(1): 116-23.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20674912" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Zini A. Are sperm chromatin and DNA defects relevant in the clinic? Systems Biology in Reproductive Medicine. 2011;57(1-2):78-85. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/21208147" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Anderson, K., R. J. Norman, et al. (2010). "Preconception lifestyle advice for people with subfertility." Cochrane Database of Systematic Reviews 4. [&lt;A href="nelh:372001:0" name=internalLink&gt;Link to Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Basaria, S. (2010). "Androgen abuse in athletes: detection and consequences." Journal of Clinical Endocrinology &amp;amp; Metabolism 95(4): 1533-43. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20139230" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Cantineau, A. E., M. J. Janssen, et al. (2010). "Synchronised approach for intrauterine insemination in subfertile couples." Cochrane Database of Systematic Reviews 4. [&lt;A href="nelh:371985:0" name=internalLink&gt;Link to Cochrane review&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Castilla, J. A., S. Zamora, et al. (2010). "Sperm chromatin structure assay and classical semen parameters: systematic review." Reproductive Biomedicine Online 20(1): 114-124. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20158996" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Chachamovich, J. R., E. Chachamovich, et al. (2010). "Investigating quality of life and health-related quality of life in infertility: a systematic review." Journal of Psychosomatic Obstetrics &amp;amp; Gynecology 31(2): 101-110.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20443659" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Fullerton, G., M. Hamilton, et al. (2010). "Should non-mosaic Klinefelter syndrome men be labelled as infertile in 2009?" Human Reproduction 25(3): 588-597.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20085911" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Gourounti, K., F. Anagnostopoulos, et al. (2010). "Psychosocial predictors of infertility related stress." Human Reproduction 25: i51-i52.&amp;nbsp;[No abstract available]&lt;/LI&gt;
&lt;LI&gt;Hotaling, J., J. Smith, et al. (2010). "Isolated teratospermia does not appear to predict clinical pregnancy following in vitro fertilization or in vitro fertilization with intracytoplasmic sperm injection: A systematic review and meta-analysis." Journal of Urology 183(4 SUPPL. 1). [No PubMed abstract available]&lt;/LI&gt;
&lt;LI&gt;Hotaling, J. M., J. F. Smith, et al. (2010). "The relationship between isolated teratozoospermia and clinical pregnancy after in vitro fertilization with or without intracytoplasmic sperm injection: a systematic review and meta-analysis." Fertil Steril.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/21030014" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Joshi, N., Y. Loke, et al. (2010). "The reproductive safety of disease modifying anti-rheumatic drugs and biologic agents in men: A systematic review." Rheumatology 49: i90-i91.&amp;nbsp;[No abstract available]&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Lend, A. K., A. Belousova, et al. (2010). "Follicle-stimulating hormone receptor gene haplotypes and male infertility in estonian population and meta-analysis." Systems Biology in Reproductive Medicine 56(1): 84-90.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20170288" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;MacDonald, A. A., G. P. Herbison, et al. (2010). "The impact of body mass index on semen parameters and reproductive hormones in human males: a systematic review with meta-analysis." Human Reproduction Update 16(3): 293-311.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19889752" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Merzenich, H., H. Zeeb, et al. (2010). "Decreasing sperm quality: a global problem?" BMC Public Health 10.&amp;nbsp;[&lt;A href="http://www.biomedcentral.com/1471-2458/10/24" target="_blank"&gt;Link to free full text&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Messina, M. (2010). "Soybean isoflavone exposure does not have feminizing effects on men: a critical examination of the clinical evidence." Fertility &amp;amp; Sterility 93(7): 2095-2104.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Soybean%20isoflavone%20exposure%20does%20not%20have%20feminizing%20effects%20on%20men%3A%20a%20critical%20examination%20of%20the%20clinical%20evidence" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Nenonen, H., A. Giwercman, et al. (2010). "Non-linear association between androgen receptor CAG repeat length and risk of male subfertility: A meta-analysis." International Journal of Andrology 33. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20579136" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;O'Flynn O'Brien, K. L., A. C. Varghese, et al. (2010). "The genetic causes of male factor infertility: a review." Fertility &amp;amp; Sterility 93(1): 1-12.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20103481" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Ross, C., A. Morriss, et al. (2010). "A systematic review of the effect of oral antioxidants on male infertility." Reproductive Biomedicine Online 20(6): 711-723.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20378409" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Sartorius, G. A. and E. Nieschlag (2010). "Paternal age and reproduction." Human Reproduction Update 16(1): 65-79.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Sartorius[author]%20AND%20Paternal%20age%20and%20reproduction" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Setti, A., R. Ferreira, et al. (2010). "Intracytoplasmic sperm injection outcome versus intracytoplasmic morphologically selected sperm injection outcome: A meta-analysis." Fertility and Sterility 94(4 SUPPL. 1): S254-S255. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20800549" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Showell, M. G., J. Brown, et al. (2010). "Oral anti-oxidant use for male partners of couples undergoing fertility treatments." Human Reproduction 25: i119-i120.&amp;nbsp;[&lt;A href="http://www.posters2view.com/eshre2010/view.php?nu=6" target="_blank"&gt;Link to poster as PDF&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Soutza Setti, A., R. Ferreira, et al. (2010). "Intracytoplasmic sperm injection outcome versus intracytoplasmic morphologically selected sperm injection outcome: A meta-Analysis." Fertility and Sterility 94(4 SUPPL. 1): S254-S255.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20800549" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Souza Setti, A., R. C. Ferreira, et al. (2010). "Intracytoplasmic sperm injection outcome versus intracytoplasmic morphologically selected sperm injection outcome: a meta-analysis." Reproductive Biomedicine Online 21(4): 450-5.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20800549" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Stouffs, K., W. Lissens, et al. (2010). "What about gr/gr deletions and male infertility? Systematic review and meta-analysis." Hum Reprod Update.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20959348" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Tao, L., Q. H. Guo, et al. (2010). "Swim-up and density gradient centrifugation preparation techniques for intrauterine insemination: A systematic review." Journal of Clinical Rehabilitative Tissue Engineering Research 14(18): 3310-3313.&amp;nbsp;[No abstract available]&lt;/LI&gt;
&lt;LI&gt;Toulis, K. A., P. K. Iliadou, et al. (2010). "Inhibin B and Anti-Mllerian Hormone as markers of persistent spermatogenesis in men with non-obstructive azoospermia: A metaanalysis of diagnostic accuracy studies." International Journal of Andrology 33.&amp;nbsp;[&lt;A href="http://www.ingentaconnect.com/content/oup/humupd/2010/00000016/00000006/art00013" target="_blank"&gt;Link to abstract from publisher's website&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Weedin, J. W., M. Khera, et al. (2010). "Varicocele repair in patients with nonobstructive azoospermia: a meta-analysis." Journal of Urology 183(6): 2309-15.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20400156" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Woldringh, G. H., D. E. Besselink, et al. (2010). "Karyotyping, congenital anomalies and follow-up of children after intracytoplasmic sperm injection with non-ejaculated sperm: a systematic review." Human Reproduction Update 16(1): 12-19.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=2010[pdat]%20AND%20Karyotyping%2C%20congenital%20anomalies%20and%20follow-up%20of%20children%20after%20intracytoplasmic%20sperm%20injection%20with%20non-ejaculated%20sperm%3A%20a%20systematic%20review" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Wyns, C., M. Curaba, et al. (2010). "Options for fertility preservation in prepubertal boys." Human Reproduction Update 16(3): 312-328.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20047952" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;AbdelHafez, F., M. Bedaiwy, et al. (2009). "Techniques for cryopreservation of individual or small numbers of human spermatozoa: a systematic review." Hum Reprod Update 15(2): 153-64. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19109313" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Abou-Setta AM, D'Angelo A, Sallam HN, Hart RJ, Al-Inany HG. Post-embryo transfer interventions for in vitro fertilization and intracytoplasmic sperm injection patients. Cochrane Database Syst Rev. 2009(4):CD006567.&amp;nbsp;[&lt;A href="nelh:327210:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Agarwal, A., R. K. Sharma, et al. (2009). "Role of oxidative stress in pathogenesis of varicocele and infertility." Urology 73(3): 461-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19167039?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Baruffi, R. L., A. L. Mauri, et al. (2009). "Single-embryo transfer reduces clinical pregnancy rates and live births in fresh IVF and Intracytoplasmic Sperm Injection (ICSI) cycles: a meta-analysis." Reproductive Biology &amp;amp; Endocrinology 7.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19389258?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Cantineau, A. E., B. J. Cohlen, et al. (2009). "Intra-uterine insemination versus fallopian tube sperm perfusion for non-tubal infertility." Cochrane Database of Systematic Reviews(2).&amp;nbsp;[&lt;A href="nelh:237329:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Cayan S, Shavakhabov S, Kadioglu A. Treatment of palpable varicocele review in infertile men: A meta-analysis to define the best technique. Journal of Andrology. 2009;30(1):33-40.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18772487" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Cornwall GA. New insights into epididymal biology and function. Human Reproduction Update. 2009;15(2):213-27.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19136456" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evers JLH, Collins J, Clarke J. Surgery or embolisation for varicoceles in subfertile men. Cochrane Database of Systematic Reviews. 2009(1).&amp;nbsp;[&lt;A href="nelh:236643:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hammerli, K., H. Znoj, et al. (2009). "The efficacy of psychological interventions for infertile patients: a meta-analysis examining mental health and pregnancy rate." Human Reproduction Update 15(3): 279-95.&amp;nbsp;[&lt;A href="https://rmsadmin.library.nhs.uk/admin/wizards/articles/19196795" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kyrou, D., E. M. Kolibianakis, et al. (2009). "How to improve the probability of pregnancy in poor responders undergoing in vitro fertilization: a systematic review and meta-analysis." Fertil Steril 91(3): 749-66.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18639875?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Peng, X., X. Zeng, et al. (2009). "The association risk of male subfertility and testicular cancer: a systematic review." PLoS ONE [Electronic Resource] 4(5).&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19440348?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Li Y, Wang LA, Wu TX. [Association of male infertility with (CAG)n polymorphism of the androgen receptor gene: a meta-analysis]. Zhonghua Nan Ke Xue. 2009 Sep;15(9):809-13.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19947564" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Pandian Z, Bhattacharya S, Ozturk O, Serour G, Templeton A. Number of embryos for transfer following in-vitro fertilisation or intra-cytoplasmic sperm injection. Cochrane Database of Systematic Reviews. 2009(2).&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19370588" target="_blank"&gt;Link to&amp;nbsp;PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Petersen CG, Oliveira JBA, Mauri AL, Massaro FC, Baruffi RLR, Pontes A, et al. Relationship between visualization of meiotic spindle in human oocytes and ICSI outcomes: A meta-analysis. Reproductive Biomedicine Online. 2009;18(2):235-43.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19192344" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Stouffs K, Tournaye H, Liebaers I, Lissens W. Male infertility and the involvement of the X chromosome. Human Reproduction Update. 2009;15(6):623-37.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19515807" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Visser L, Westerveld GH, Korver CM, Van Daalen SKM, Hovingh SE, Rozen S, et al. Y chromosome gr/gr deletions are a risk factor for low semen quality. Human Reproduction. 2009;24(10):2667-73. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19602516" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Waylen, A. L., M. Metwally, et al. (2009). "Effects of cigarette smoking upon clinical outcomes of assisted reproduction: a meta-analysis." Hum Reprod Update 15(1): 31-44.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18927070" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Xue Y, Zhang YG, Wang L, Lu YP. Carnitine in the treatment of idiopathic asthenozoospermia: A systematic review. Chinese Journal of Evidence-Based Medicine. 2009;9(3):337-45. [No abstract link]&lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Abu-Musa, A. A., L. Kobeissi, et al. (2008). "Effect of war on fertility: A review of the literature." Reproductive Biomedicine Online 17(SUPPL. 1): 43-53.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18644222?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Bertelsmann, H., H. De Carvalho Gomes, et al. (2008). "The risk of malformation following assisted reproduction." Deutsches Arzteblatt 105(1-2): 11-17.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19578448?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Besselink, D. E., C. Farquhar, et al. (2008). "Cervical insemination versus intra-uterine insemination of donor sperm for subfertility." Cochrane Database of Systematic Reviews(2).&amp;nbsp;[&lt;A href="nelh:236549:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Bhatt, T. and A. Baibergenova (2008). "A comparison of the cost-effectiveness of in vitro fertilization strategies and stimulated intrauterine insemination in a Canadian health economic model." Journal of Obstetrics &amp;amp; Gynaecology Canada: JOGC 30(5): 411-20.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18505665" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Collins, J. A., K. T. Barnhart, et al. (2008). "Do sperm DNA integrity tests predict pregnancy with in vitro fertilization?" Fertility and Sterility 89(4): 823-831.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17644094?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Deepinder, F., M. Cocuzza, et al. (2008). "Should seminal oxidative stress measurement be offered routinely to men presenting for infertility evaluation?" Endocrine Practice 14(4): 484-91.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18558605" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Ebisch, I. M., C. M. Thomas, et al. (2008). "Review of the role of the plasminogen activator system and vascular endothelial growth factor in subfertility." Fertility &amp;amp; Sterility 90(6): 2340-50.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18249395" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Elizur, S. E. and T. Tulandi (2008). "Drugs in infertility and fetal safety." Fertility and Sterility 89(6): 1595-1602.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18519067?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Gelbaya, T. A., M. Kyrgiou, et al. (2008). "The use of estradiol for luteal phase support in in vitro fertilization/intracytoplasmic sperm injection cycles: a systematic review and meta-analysis." Fertility and Sterility 90(6): 2116-2125.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18178194" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hammoud, A. O., M. Gibson, et al. (2008). "Impact of male obesity on infertility: a critical review of the current literature." Fertility &amp;amp; Sterility 90(4): 897-904.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18929048" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Leniaud, L. and R. Levy (2008). "Nutrition and male infertility: A systematic review." Cahiers de Nutrition et de Dietetique 43(4): 198-208.&lt;/LI&gt;
&lt;LI&gt;Liu, D. F., H. Jiang, et al. (2008). "[A meta-analysis of Ureaplasma urealyticum infection and Chinese male infertility]." Zhonghua Nan Ke Xue 14(7): 618-23.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18686383?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Martin, R. H. (2008). "Cytogenetic determinants of male fertility." Human Reproduction Update 14(4): 379-90.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18535003" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Ombelet, W., I. Cooke, et al. (2008). "Infertility and the provision of infertility medical services in developing countries." Human Reproduction Update 14(6): 605-21.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18820005?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Pandian, Z., V. A. Akande, et al. (2008). "Surgery for tubal infertility." Cochrane Database of Systematic Reviews(3).&amp;nbsp;[&lt;A href="nelh:293653:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Perry, M. J. (2008). "Effects of environmental and occupational pesticide exposure on human sperm: A systematic review." Human Reproduction Update 14(3): 233-242.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18281240?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Practice Committee of American Society for Reproductive, M. (2008). "Correct coding for laboratory procedures during assisted reproductive technology cycles." Fertil Steril 90(5 Suppl): S202-5.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19007631?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Practice Committee of American Society for Reproductive, M. (2008). "Guidelines for reducing the risk of viral transmission during fertility treatment." Fertil Steril 90(5 Suppl): S156-62.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19007616?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Practice Committee of Society for Assisted Reproductive (2008). "2008 Guidelines for gamete and embryo donation: a Practice Committee report." Fertil Steril 90(5 Suppl): S30-44.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19007645" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Practice Committee of the American Society for Reproductive, M. (2008). "Progesterone supplementation during the luteal phase and in early pregnancy in the treatment of infertility: an educational bulletin." Fertil Steril 89(4): 789-92.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19007614?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Practice Committee of the Society for Assisted Reproductive, T. and M. Practice Committee of the American Society for Reproductive (2008). "Guidelines for development of an emergency plan for in vitro fertilization programs." Fertil Steril 89(4): 793-5.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19007610?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Van Peperstraten, A., M. L. Proctor, et al. (2008). "Techniques for surgical retrieval of sperm prior to intra-cytoplasmic sperm injection (ICSI) for azoospermia." Cochrane Database of Systematic Reviews(2).&amp;nbsp;[&lt;A href="nelh:237370:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Zini, A., J. M. Boman, et al. (2008). "Sperm DNA damage is associated with an increased risk of pregnancy loss after IVF and ICSI: systematic review and meta-analysis." Hum Reprod 23(12): 2663-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18757447" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Agarwal, A., F. Deepinder, et al. (2007). "Efficacy of varicocelectomy in improving semen parameters: new meta-analytical approach." Urology 70(3): 532-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17905111" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Attia, A. M., H. G. Al-Inany, et al. (2007). "Gonadotrophins for idiopathic male factor subfertility." Cochrane Database Syst Rev(4): CD005071.&amp;nbsp;[&lt;A href="nelh:239055:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Bensdorp, A. J., B. J. Cohlen, et al. (2007). "Intra-uterine insemination for male subfertility." Cochrane Database Syst Rev(3): CD000360.&amp;nbsp;[&lt;A href="nelh:236576:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Boomsma, C. M., M. J. Heineman, et al. (2007). "Semen preparation techniques for intrauterine insemination." Cochrane Database Syst Rev(4): CD004507.&amp;nbsp;[&lt;A href="nelh:238705:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Donoso, P., H. Tournaye, et al. (2007). "Which is the best sperm retrieval technique for non-obstructive azoospermia? A systematic review." Hum Reprod Update 13(6): 539-49.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17895238" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Marmar, J. L., A. Agarwal, et al. (2007). "Reassessing the value of varicocelectomy as a treatment for male subfertility with a new meta-analysis." Fertil Steril 88(3): 639-48.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18078850?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Sadeghi-Nejad, H. and F. Farrokhi (2007). "Genetics of azoospermia: current knowledge, clinical implications, and future directions. Part II: Y chromosome microdeletions." Urology Journal 4(4): 192-206.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18270942" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Tuttelmann, F., E. Rajpert-De Meyts, et al. (2007). "Gene polymorphisms and male infertility--a meta-analysis and literature review." Reprod Biomed Online 15(6): 643-58.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18062861" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Wagner, L., J. Tostain, et al. (2007). "[Varicocele and male infertility: AFU 2006 guidelines]." Prog Urol 17(1): 12-7.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17373231" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Zhou, X., F. Liu, et al. (2007). "Effect of L-carnitine and/or L-acetyl-carnitine in nutrition treatment for male infertility: a systematic review." Asia Pac J Clin Nutr 16 Suppl 1: 383-90.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17392136" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;2006&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Lera, S., S. Macchia, et al. (2006). "Standardizing the methodology of sperm cell test with Paracentrotus lividus." Environ Monit Assess 122(1-3): 101-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16738765" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Li, Z., L. Wang, et al. (2006). "Correlation of sperm DNA damage with IVF and ICSI outcomes: a systematic review and meta-analysis." J Assist Reprod Genet 23(9-10): 367-76.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17019633" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Practice Committee of the American Society for Reproductive, M. (2006). "Guidelines for reducing the risk of viral transmission during fertility treatment." Fertil Steril 86(5 Suppl): S11-7.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17055801?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Practice Committee of the American Society for Reproductive, M. and T. Practice Committee of the Society for Assisted Reproductive (2006). "2006 Guidelines for Gamete and Embryo Donation." Fertil Steril 86(5 Suppl): S38-50.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17055844?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Verhulst, S. M., B. J. Cohlen, et al. (2006). "Intra-uterine insemination for unexplained subfertility." Cochrane Database Syst Rev(4): CD001838.&amp;nbsp;[&lt;A href="nelh:237128:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Yossry, M., M. Aboulghar, et al. (2006). "In vitro fertilisation versus tubal reanastomosis (sterilisation reversal) for subfertility after tubal sterilisation." Cochrane Database Syst Rev 3: CD004144.&amp;nbsp;[&lt;A href="nelh:238723:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:19:59</lastReviewDate>
    <expiryDate>09/08/2012 00:00:00</expiryDate>
  </document>
  <document>
    <id>319325</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.tht.org.uk/informationresources/otherstis/]]&gt;</url>
    <title>Information Resources: Get it checked. Get it treated.</title>
    <publicationDate></publicationDate>
    <publisher>Terrence Higgins Trust</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE SEXUALLY TRANSMITTED INFECTIONS,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Terrence Higgins Trust Information Resources: Get it checked. Get it treated.
</description>
    <body>&lt;![CDATA[ &lt;P&gt;Terrence Higgins Trust Information Resources: Get it checked. Get it treated.&lt;/P&gt;
&lt;P&gt;If you are sexually active you may be at risk of catching an STI. Find out how to reduce the risk, and what to do if you have symptoms of an STI.&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>01/07/2010 14:58:37</lastReviewDate>
    <expiryDate>01/07/2011 14:58:37</expiryDate>
  </document>
  <document>
    <id>319323</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.tht.org.uk/informationresources/hivandaids/]]&gt;</url>
    <title>Information Resources: HIV and AIDS</title>
    <publicationDate></publicationDate>
    <publisher>Terrence Higgins Trust</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE SEXUALLY TRANSMITTED INFECTIONS,VIRAL,HIV,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Terrence Higgins Trust Information Resources about HIV and AIDS</description>
    <body>&lt;![CDATA[ &lt;P&gt;Terrence Higgins Trust Information Resources about HIV and AIDS&lt;/P&gt;
&lt;P&gt;What is HIV, how it is transmitted, and what are its effects on the human body? We have a range of information on HIV testing, treatment, side-effects as well as advice on living with HIV.&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>01/07/2010 14:58:44</lastReviewDate>
    <expiryDate>01/07/2011 14:58:44</expiryDate>
  </document>
  <document>
    <id>319328</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.tht.org.uk/informationresources/professionals/]]&gt;</url>
    <title>Information Resources: Information for professionals</title>
    <publicationDate></publicationDate>
    <publisher>Terrence Higgins Trust</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Terrence Higgins Trust Information Information for professionals</description>
    <body>&lt;![CDATA[ &lt;P&gt;Terrence Higgins Trust Information Information for professionals&lt;/P&gt;
&lt;P&gt;We can offer advice for professionals on HIV-related legal issues in immigration, housing, community care, welfare rights, human rights and other areas of social welfare law.&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>01/07/2010 14:58:52</lastReviewDate>
    <expiryDate>01/07/2011 14:58:52</expiryDate>
  </document>
  <document>
    <id>319319</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.tht.org.uk/informationresources/sexandsexuality/]]&gt;</url>
    <title>Information Resources: Sex &amp; Sexuality</title>
    <publicationDate></publicationDate>
    <publisher>Terrence Higgins Trust</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE SEXUALLY TRANSMITTED INFECTIONS,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Terrence Higgins Trust Information Resources about sex and sexuality</description>
    <body>&lt;![CDATA[ &lt;P&gt;Terrence Higgins Trust Information Resources: Sex &amp;amp; sexuality&lt;/P&gt;
&lt;P&gt;Growing up and entering the world of sex and relationships can seem confusing and worrying at first - we're here to answer your questions and give you some support.&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>01/07/2010 14:59:01</lastReviewDate>
    <expiryDate>01/07/2011 14:59:01</expiryDate>
  </document>
  <document>
    <id>156484</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.kidney.org/professionals/kls/pdf/icd9codes.pdf]]&gt;</url>
    <title>International Classification of Diseases (ICD-9) Codes for Chronic Kidney Disease</title>
    <publicationDate>2005-09-29T00:00:00</publicationDate>
    <publisher>National Kidney Foundation</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ CHRONIC KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Webpage from US National Kidney Foundation outlining new ICD codes</description>
    <body>&lt;![CDATA[ Summary table with brief description of 5 stages of CKD.]]&gt;</body>
    <lastReviewDate>23/09/2010 16:51:07</lastReviewDate>
    <expiryDate>23/09/2011 16:51:07</expiryDate>
  </document>
  <document>
    <id>313464</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.biomedcentral.com/1471-2369/10/2]]&gt;</url>
    <title>Intradialytic versus home based exercise training in hemodialysis patients: a randomised controlled trial</title>
    <publicationDate>2009-01-29T00:00:00</publicationDate>
    <publisher>BMC Nephrology</publisher>
    <publicationType>RANDOMISED CONTROLLED TRIAL</publicationType>
    <topics>&lt;![CDATA[ NEW RESEARCH,HAEMODIALYSIS,LIVING WITH DIALYSIS,PREVENTION OF INFECTIONS,ACCESS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES,DIALYSIS,HOME HAEMODIALYSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A study protocol.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Abstract extract&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Exercise training in hemodialysis patients improves fitness, physical function, quality of life and markers of cardiovascular disease such as arterial stiffness. The majority of trials investigating this area have used supervised exercise training during dialysis (intradialytic), which may not be feasible for some renal units. The aim of this trial is to compare the effects of supervised intradialytic with unsupervised home-based exercise training on physical function and arterial stiffness.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Methods and design&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;This is a randomised, controlled clinical trial. A total of 72 hemodialysis patients will be randomised to receive either six months of intradialytic exercise training, home-based exercise training or usual care. Intradialytic patients will undergo three training sessions per week on a cycle ergometer and home-based patients will be provided with a walking program to achieve the same weekly physical activity. Primary outcome measures are six-minute walk distance (6 MWD) and aortic pulse wave velocity (PWV). Secondary outcome measures include augmentation index, peripheral and central blood pressures, physical activity and self-reported health. Measures will be made at baseline, three and six months.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Discussion&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;The results of this study will help determine the efficacy of home-based exercise training in hemodialysis patients. This may assist in developing exercise guidelines specific for these patients.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Trial Registration&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;ACTRN12608000247370&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>08/03/2011 10:00:54</lastReviewDate>
    <expiryDate>08/03/2012 10:00:54</expiryDate>
  </document>
  <document>
    <id>288525</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.bestbets.org/bets/bet.php?id=675]]&gt;</url>
    <title>Intravenous NSAID's in the Management of Renal Colic</title>
    <publicationDate>2006-01-05T00:00:00</publicationDate>
    <publisher>Best Bets</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ KIDNEY AND BLADDER STONES,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Critically appraised topic by Best Bets</description>
    <body>&lt;![CDATA[ &lt;P&gt;Extract&lt;/P&gt;
&lt;P&gt;Clinical Bottom Line&lt;/P&gt;
&lt;P&gt;Intravenous NSAID's should be the first-line treatment for patients presenting to the ED with acute renal colic.&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>01/07/2010 15:00:21</lastReviewDate>
    <expiryDate>01/07/2011 15:00:21</expiryDate>
  </document>
  <document>
    <id>289371</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.emrn.org.uk/documents/Promoting%20good%20CKD%20management%20RCGP.pdf]]&gt;</url>
    <title>Introducing eGFR - Promoting good CKD management</title>
    <publicationDate>2008-01-01T00:00:00</publicationDate>
    <publisher>Royal College of General Practitioners</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ ASSESSMENT OF RENAL FUNCTION,ASSESSMENT TESTS,GFR AND EGFR,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Leaflet giving information taken from 'UK Guidelines for Identification, Management and Referral of Chronic Kidney Disease in Adults'</description>
    <body>&lt;![CDATA[ &lt;P&gt;Leaflet covers:&lt;/P&gt;
&lt;P&gt;What is eGFR?&lt;/P&gt;
&lt;P&gt;Why the change?&lt;/P&gt;
&lt;P&gt;The 5 stages of chronic kidney disease &lt;/P&gt;
&lt;P&gt;If eGFR 60-89 ml/min&lt;/P&gt;
&lt;P&gt;If eGFR less than 60 ml/min&lt;/P&gt;
&lt;P&gt;Information needed on referral &lt;/P&gt;
&lt;P&gt;Criteria for referral &lt;/P&gt;
&lt;P&gt;Management of CKD&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp; - All stages &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp; - CKD Stage 3 additional managment to include &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp; - CKD Stages 4/5 additional management &lt;/P&gt;
&lt;P&gt;Minimum frequency of testing &lt;/P&gt;]]&gt;</body>
    <lastReviewDate>01/07/2010 15:00:29</lastReviewDate>
    <expiryDate>01/07/2011 15:00:29</expiryDate>
  </document>
  <document>
    <id>155667</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.uktransplant.org.uk/ukt/how_to_become_a_donor/religious_perspectives/leaflets/islam_and_organ_donation.jsp]]&gt;</url>
    <title>Islam and organ donation</title>
    <publicationDate></publicationDate>
    <publisher>UK Transplant</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ TRANSPLANTATION,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A guide to organ donations within muslim beliefs</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Extract from website&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;One of the basic aims of the Muslim faith is the saving of life. This is a fundamental aim of the Shariah and Allah greatly rewards those who save others from death. &lt;/P&gt;
&lt;P&gt;Violating the human body, whether living or dead, is normally forbidden in Islam. The Shariah, however, waives this prohibition in a number of instances: firstly in cases of necessity; and secondly in saving another person's life. It is this Islamic legal maxim al-darurat tubih al-mahzurat (necessities overrule prohibition) that has great relevance to organ donation.&lt;/P&gt;
&lt;P&gt;The Muslim Law (Shariah) Council of Great Britain resolved that: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;the medical profession is the proper authority to define signs of death 
&lt;LI&gt;current medical knowledge considers brain stem death to be a proper definition of death 
&lt;LI&gt;the council accepts brain stem death as constituting the end of life for the purpose of organ transplantation 
&lt;LI&gt;the council supports organ transplantation as a means of alleviating pain or saving life on the basis of the rules of the Shariah 
&lt;LI&gt;Muslims may carry donor cards 
&lt;LI&gt;the next of kin of a dead person, in the absence of a donor card or an expressed wish to donate their organs, may give permission to obtain organs from the body to save other people's lives 
&lt;LI&gt;organ donation must be given freely without reward 
&lt;LI&gt;trading in organs is prohibited. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>23/09/2010 16:52:05</lastReviewDate>
    <expiryDate>23/09/2011 16:52:05</expiryDate>
    <relatedLinks>&lt;a href="http://www.uktransplant.org.uk/ukt/how_to_become_a_donor/religious_perspectives/leaflets/islam_and_organ_donation.jsp" title="Click here for webpage"/&gt;&lt;a href="http://www.uktransplant.org.uk/ukt/newsroom/fact_sheets/religious_leaflets/islam_and_organ_donation/islam_and_organ_donation.pdf" title="Click here for leaflet PDF (English)"/&gt;&lt;a href="http://www.uktransplant.org.uk/ukt/newsroom/fact_sheets/religious_leaflets/islam_and_organ_donation/islam-urdu_and_organ_donation.pdf" title="Click here for leaflet PDF (Urdu)"/&gt;&lt;a href="http://www.uktransplant.org.uk/ukt/newsroom/fact_sheets/religious_leaflets/islam_and_organ_donation/islam-gujarati_and_organ_donation.pdf" title="Click here for leaflet PDF (Gujarati)"/&gt;&lt;a href="http://www.uktransplant.org.uk/ukt/newsroom/fact_sheets/religious_leaflets/islam_and_organ_donation/islam-punjabi_and_organ_donation.pdf" title="Click here for leaflet PDF (Punjabi)"/&gt;&lt;a href="http://www.uktransplant.org.uk/ukt/newsroom/fact_sheets/religious_leaflets/islam_and_organ_donation/islam-bengali_and_organ_donation.pdf" title="Click here for leaflet PDF (Bengali)"/&gt;</relatedLinks>
    <creator>Uk Transplant</creator>
  </document>
  <document>
    <id>334286</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=334286]]&gt;</url>
    <title>January 2010 NHS Evidence - kidney diseases and male urogenital disorders newsletter</title>
    <publicationDate>2010-01-08T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;January 2010 NHS Evidence - kidney diseases and male urogenital disorders newsletter&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Welcome to the kidney diseases and male urogenital disorders specialist collection enewsletter for&amp;nbsp;January 2010. &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;NHS Evidence - kidney diseases and male urogenital disorders is for busy health professionals, providing them with high quality information and keeping them up to date with the latest research and developments in this area. You can now join our mailing list to receive regular updates. &lt;A href="https://www.jiscmail.ac.uk/cgi-bin/webadmin?A0=NHSEVIDENCEKDMU" target="_blank"&gt;Click here for the link&lt;/A&gt;.&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=center&gt;&lt;STRONG&gt;***** Please help us to help you - if you are a renal healthcare professional or have an interest in kidney diseases, please complete our survey: &lt;/STRONG&gt;&lt;A href="http://www.surveymonkey.com/s/SHP9NTB" target="_blank"&gt;&lt;STRONG&gt;http://www.surveymonkey.com/s/SHP9NTB&lt;/STRONG&gt;&lt;/A&gt;&lt;STRONG&gt; *****&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P align=center&gt;&lt;IMG id=nelh_tempImage0 height=184 alt="Computer mouse and books" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID334286/nelhImp_0000_Ereading_computermouseandbooks.jpg" width=291 border=0 name=nelh_tempImage0&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Links to:&lt;/STRONG&gt;&lt;/P&gt;&lt;STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="#kidney"&gt;New Kidney Diseases items&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="#urogenital"&gt;New Male Urogenital Disorders items&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0005_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&amp;nbsp;RSS FEEDS&amp;nbsp; &lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0006_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;You can receive news from the kidney diseases specialist collection from the RSS feeds we provide:&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/RSS/CMS.aspx?feed=57" target="_blank"&gt;&lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0007_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk/kidney/RSS/CMS.aspx?feed=57" target="_blank"&gt;&lt;A name=kidney&gt;New Kidney Diseases Resources&lt;/A&gt;&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/RSS/CMS.aspx?feed=136" target="_blank"&gt;&lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0008_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk/kidney/RSS/CMS.aspx?feed=136" target="_blank"&gt;New Male Urogenital Disorders Resources&lt;/A&gt; &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/KIDNEY/RSS/News.aspx" target="_blank"&gt;&lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0008_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk//kidney/News.aspx" target="_blank"&gt;Kidney diseases and male urogenital disorders in the news&lt;/A&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/rss/Directory/MoreAboutRss.aspx" target="_blank"&gt;Click through this link to find out more about RSS feeds.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;JOURNALS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;You can link through to the latest Tables of Contents from all the major kidney, transplant and urology journals from &lt;A href="http://www.library.nhs.uk/KIDNEY/Page.aspx?pagename=EJOURNALS" target="_blank"&gt;this page&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=3&gt;&lt;STRONG&gt;&lt;BIG&gt;New resources added in&amp;nbsp;December 2009&lt;/BIG&gt;&lt;/STRONG&gt; &lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A name=kidney&gt;Chronic Kidney&amp;nbsp;Disease&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:331840:0" name=internalLink&gt;Antiviral therapy of hepatitis C in chronic kidney diseases: meta-analysis of controlled clinical trials&lt;/A&gt;. Database of Abstracts of Reviews of Effects (DARE) abstract.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:333071:0" name=internalLink&gt;Achieving Excellence in Kidney Care: Delivering the National Service Framework for Renal Services. &lt;/A&gt;Report published by the Department of Health. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2010---January/05/Reduced-level-of-consciousness-from-baclofen-in-people-with-low-kidney-function/" target="_blank"&gt;Reduced level of consciousness from baclofen in people with low kidney function&lt;/A&gt;. Analysis by the National electronic Library for Medicines (05/01/10).&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:333626:0" name=internalLink&gt;Chronic Kidney Disease: Systematic Reviews and Meta-analyses (2006-2009).&lt;/A&gt;&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Acute kidney injury&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:331885:0" name=internalLink&gt;Systematic review: sodium bicarbonate treatment regimens for the prevention of contrast-induced nephropathy&lt;/A&gt;. Database of Abstracts of Reviews of Effects (DARE) abstract. &lt;/LI&gt;
&lt;LI&gt;
&lt;P&gt;&lt;A href="nelh:331836:0" name=internalLink&gt;Association between oral sodium phosphate bowel preparations and kidney injury: a systematic review and meta-analysis&lt;/A&gt;. Database of Abstracts of Reviews of Effects (DARE) abstract.&lt;/P&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;P&gt;&lt;A href="nelh:332400:0" name=internalLink&gt;Systematic reviews and meta-analyses on Acute Kidney Injury (2006-2009)&lt;/A&gt;. &lt;/P&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Anaemia&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:333619:0" name=internalLink&gt;Anaemia: Systematic reviews and meta-analyses (2006-2009).&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Renovascular disease&lt;/STRONG&gt;&lt;/P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:332026:0" name=internalLink&gt;Renal stenting for treatment of renal stenosis in patients with hypertension&lt;/A&gt;. CRD Health Technology Assessment Database abstract. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Diabetic nephropathy&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:331780:0" name=internalLink&gt;Low-protein diet for diabetic nephropathy: a meta-analysis of randomized controlled trials&lt;/A&gt;. Database of Abstracts of Reviews of Effects (DARE) abstract.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:333667:0" name=internalLink&gt;Diabetic Nephropathy: Systematic reviews and meta-analyses. (2006-2009). &lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Dialysis&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2009---December/09/Use-of-contra-indicated-medications-in-dialysis-patients-undergoing-PCI/" target="_blank"&gt;Use of contra-indicated medications in dialysis patients undergoing PCI.&lt;/A&gt; Analysis by the National electronic Library for Medicines (09/12/09).&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:333628:0" name=internalLink&gt;Continuous Renal Replacement Therapy: Systematic reviews and meta-analyses (2006-2009).&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:333679:0" name=internalLink&gt;Dialysis: Systematic reviews and meta-analyses (2006-2009). &lt;/A&gt;&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Transplantation&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:331788:0" name=internalLink&gt;Commercialization of kidney transplants: a systematic review of outcomes in recipients and donors&lt;/A&gt;. Database of Abstracts of Reviews of Effects (DARE) abstract.&lt;/LI&gt;
&lt;LI&gt;'Risky donor' kidney transplants prove successful. &lt;A href="http://news.bbc.co.uk/1/hi/health/8398770.stm" target="_blank"&gt;Link to BBC news item&lt;/A&gt;. (07/12/09).&lt;/LI&gt;
&lt;LI&gt;Kidney removal as day case surgery. &lt;A href="http://news.bbc.co.uk/1/hi/health/8385142.stm" target="_blank"&gt;Link to BBC news item&lt;/A&gt; (07.12.09).&lt;/LI&gt;
&lt;LI&gt;Israeli organ donors to get transplant priority. &lt;A href="http://news.bbc.co.uk/1/hi/health/8416443.stm" target="_blank"&gt;Link to BBC news item&lt;/A&gt;. (17/12/09).&lt;/LI&gt;
&lt;LI&gt;Wales seeks organ opt-out powers. &lt;A href="http://news.bbc.co.uk/1/hi/wales/8420678.stm" target="_blank"&gt;Link to BBC news item&lt;/A&gt;. (18/12/09).&lt;/LI&gt;
&lt;LI&gt;Live transplants hit 3,000 figure. &lt;A href="http://news.bbc.co.uk/1/hi/health/8425348.stm" target="_blank"&gt;Link to BBC news item&lt;/A&gt;. (22/12/09). &lt;/LI&gt;
&lt;LI&gt;Preparing for life after death. &lt;A href="http://news.bbc.co.uk/1/hi/health/8428190.stm" target="_blank"&gt;Link to BBC Opinion item&lt;/A&gt;. (24/12/09). &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Kidney Cancer&lt;/STRONG&gt; &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:332001:0" name=internalLink&gt;Percutaneous cryoablation for treatment of renal cell cancer&lt;/A&gt;. CRD Health Technology Assessment Database abstract. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:332021:0" name=internalLink&gt;Radiofrequency ablation for renal tumors&lt;/A&gt;. CRD Health Technology Assessment Database abstract. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Kidney stones&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:331985:0" name=internalLink&gt;Modulith SLX Lithotripter (Storz Medical AG) for treatment of renal calculi&lt;/A&gt;. CRD Health Technology Assessment Database abstract. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A name=mug&gt;&lt;A name=urogenital&gt;Male Urogenital Disorders&lt;/A&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Male Bladder Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;P&gt;&lt;A href="nelh:332045:0" name=internalLink&gt;StatLock stabilization devices (Bard Medical) to reduce needlesticks and catheter-related infection&lt;/A&gt;. CRD Health Technology Assessment Database abstract. &lt;/P&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Prostate Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:332011:0" name=internalLink&gt;Potassium-titanyl-phosphate (KTP) laser photoselective vaporization prostatectomy (PVP) for benign prostatic hyperplasia (GreenLight PV; Laserscope)&lt;/A&gt;. CRD Health Technology Assessment Database abstract. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:332015:0" name=internalLink&gt;Prostate saturation biopsy for diagnosis of prostate cancer&lt;/A&gt;. CRD Health Technology Assessment Database abstract. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:331823:0" name=internalLink&gt;Combined magnetic resonance imaging and magnetic resonance spectroscopy imaging in the diagnosis of prostate cancer: a systematic review and meta-analysis&lt;/A&gt;. Database of Abstracts of Reviews of Effects (DARE) abstract.&lt;/LI&gt;
&lt;LI&gt;
&lt;P&gt;&lt;A href="nelh:331766:0" name=internalLink&gt;Statin use and the risk of prostate cancer: a metaanalysis of 6 randomized clinical trials and 13 observational studies&lt;/A&gt;. Database of Abstracts of Reviews of Effects (DARE) abstract.&lt;/P&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;P&gt;&lt;A href="nelh:111626:0" name=internalLink&gt;Latest systematic reviews on Surgery for prostate cancer&lt;/A&gt;.&lt;/P&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;P&gt;Reclassification encourages men to play a more active role in their healthcare. &lt;A href="http://www.mhra.gov.uk/NewsCentre/Pressreleases/CON065433" target="_blank"&gt;News item from the Medicines and Healthcare products Regulatory Agency &lt;/A&gt;(03/12/09).&lt;/P&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Penile Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;GMC criticises circumcision care. &lt;A href="http://news.bbc.co.uk/1/hi/england/essex/8399630.stm" target="_blank"&gt;Link to BBC news item&lt;/A&gt;. (07/12/09).&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Male urinary incontinence&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Male lower urinary tract symptoms (LUTS): guideline consultation. &lt;A href="http://www.nice.org.uk/guidance/index.jsp?action=folder&amp;amp;o=45292" target="_blank"&gt;Link to NICE webpage for consultation&lt;/A&gt;.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Sexually Transmitted Infections&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:331896:0" name=internalLink&gt;Assessment of the routine, occupation-based gonorrhea and syphilis screening program in Moscow, Russia: an analysis of sexually transmitted infection prevalence and cost-effectiveness.&lt;/A&gt; NHS Economic Evaluation Database (NEED) abstract.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;**Subscribe to the NHS Evidence Eyes on Evidence Newsletter**&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;If you would like to receive Eyes on Evidence, the monthly e-bulletin from NHS Evidence, please sign up at &lt;A href="http://www.evidence.nhs.uk/NewsletterSignup.aspx" target="_blank"&gt;http://www.evidence.nhs.uk/NewsletterSignup.aspx&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The bulletin will keep you updated with new and important evidence and key developments on the NHS Evidence portal.&amp;nbsp; It comes out on the second Wednesday of the month and can be sent to any e-mail address that you provide.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>13/12/2010 11:25:09</lastReviewDate>
  </document>
  <document>
    <id>399788</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=399788]]&gt;</url>
    <title>January 2011 NHS Evidence - kidney diseases and male urogenital disorders newsletter</title>
    <publicationDate>2011-01-05T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;January 2011 NHS Evidence - kidney diseases and male urogenital disorders newsletter&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Welcome to the kidney diseases and male urogenital disorders specialist collection enewsletter for&amp;nbsp;JANUARY 2011. &lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=left&gt;NHS Evidence - kidney diseases and male urogenital disorders is for busy health professionals, providing them with high quality information and keeping them up to date with the latest research and developments in this area.&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;***If you subscribe to our JISCMAIL listing, you should have received an email about changes to the service and transfer of subscriber details to the new providers. If you &lt;STRONG&gt;DO NOT&lt;/STRONG&gt; wish your details to be transferred, please make sure you let &lt;STRONG&gt;Eli Bastin&lt;/STRONG&gt; know by 28th January - please use the &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;Contact Us page&lt;/A&gt; to do so. &lt;STRONG&gt;If you do not opt out by this date, it will be assumed that you are happy to have your details transferred&lt;/STRONG&gt;.***&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Links to:&lt;/STRONG&gt;&lt;/P&gt;&lt;STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="#kidney"&gt;New Kidney Diseases items&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="#mug"&gt;New Male Urogenital Disorders items&lt;/A&gt;&lt;/STRONG&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P align=center&gt;&lt;IMG style="WIDTH: 162px; HEIGHT: 185px" id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="Medical uncertainties" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID399788/nelhImp_0000_HealthcarequestionsoruncertaintiesNov10.jpg" width=109 height=130&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;IMG id=nelh_tempImage0 alt=" name=nelh_tempImage0 border=" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0005_feed.gif" width=16 height=16 0? RSS icon?&gt;&amp;nbsp;RSS FEEDS&amp;nbsp; &lt;IMG id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0006_feed.gif" width=16 height=16&gt;&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;You can receive news from the kidney diseases specialist collection from the RSS feeds we provide:&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/RSSFeed.aspx?feed=57" target="_blank"&gt;&lt;IMG id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0007_feed.gif" width=16 height=16&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk/kidney/RSSFeed.aspx?feed=57" target="_blank"&gt;New Kidney Diseases Resources&lt;/A&gt;&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/RSSFeed.aspx?feed=136" target="_blank"&gt;&lt;IMG id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0008_feed.gif" width=16 height=16&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk/kidney/RSSFeed.aspx?feed=136" target="_blank"&gt;New Male Urogenital Disorders Resources&lt;/A&gt; &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk//kidney/News.aspx" target="_blank"&gt;&lt;IMG id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0008_feed.gif" width=16 height=16&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk//kidney/News.aspx" target="_blank"&gt;Kidney diseases and male urogenital disorders in the news&lt;/A&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/rss/Directory/MoreAboutRss.aspx" target="_blank"&gt;Click through this link to find out more about RSS feeds.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;JOURNALS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;You can link through to the latest Tables of Contents from all the major kidney, transplant and urology journals from &lt;A href="http://www.library.nhs.uk/KIDNEY/Page.aspx?pagename=EJOURNALS" target="_blank"&gt;this page&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=3&gt;&lt;STRONG&gt;&lt;BIG&gt;Resources added in&amp;nbsp;December 2010&lt;/BIG&gt;&lt;/STRONG&gt; &lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A name=kidney&gt;Chronic Kidney&amp;nbsp;Disease&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:396838:0" name=internalLink&gt;Interventions for treating sexual dysfunction in patients with chronic kidney disease&lt;/A&gt;. A new Cochrane systematic review.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:377234:0" name=internalLink&gt;Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment&lt;/A&gt;. A new item from the CRD NHS Economic Evaluation Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:398690:0" name=internalLink&gt;New patient information leaflet about preventing kidney disease in African Asian and Caribbean communities&lt;/A&gt;. Published by Kings College Hospital.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.kidneycarematters.nhs.uk/Default.aspx" target="_blank"&gt;December issue of Kidney Care Matters available&lt;/A&gt; - NHS Kidney Care&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://renaltsar.blogspot.com/2010/12/three-national-cquin-goals-for-kidney.html" target="_blank"&gt;Renal Tsar's blog - Three national CQUIN goals for kidney care&lt;/A&gt;. Dr Donal O'Donoghue (07/12/10).&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://renaltsar.blogspot.com/2010/12/christmas-message-2010.html" target="_blank"&gt;Renal Tsar - Christmas message 2010&lt;/A&gt;. Dr Donal O'Donoghue&amp;nbsp; (20/12/10). &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://renaltsar.blogspot.com/2010/12/health-survey-england-confirms-ckd-is.html" target="_blank"&gt;Renal Tsar - Health Survey England confirms CKD is common and shines a light on proteinuria&lt;/A&gt;. Dr Donal O'Donoghue&amp;nbsp; (20/12/10). &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://renaltsar.blogspot.com/2010/12/nhs-outcome-framework-highlights-ckd.html" target="_blank"&gt;Renal Tsar - NHS Outcome Framework highlights CKD but misses AKI&lt;/A&gt;. Dr Donal O'Donoghue&amp;nbsp; (21/12/10).&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://renaltsar.blogspot.com/2010/12/transition-arrangements-for-nhs.html" target="_blank"&gt;Renal Tsar - Transition arrangements for the NHS&lt;/A&gt;. Dr Donal O'Donoghue&amp;nbsp; (23/12/10). &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Diabetic nephropathy&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:396825:0" name=internalLink&gt;Altered dietary salt intake for preventing and treating diabetic kidney disease&lt;/A&gt;. A new Cochrane systematic review.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Hypertension&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;U&gt;&lt;FONT color=#0000ff&gt;&lt;/FONT&gt;&lt;/U&gt;&lt;A href="nelh:364113:0" name=internalLink&gt;The clinical and economic burden of nonadherence with antihypertensive and lipid-lowering therapy in hypertensive patients&lt;/A&gt;. A new item from the CRD NHS Economic Evaluation Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/SearchResults.aspx?searchText=Hypertension+in+pregnancy&amp;amp;tabID=288&amp;amp;" target="_blank"&gt;Hypertension in pregnancy&lt;/A&gt; - Clinical Knowledge Summaries. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:379121:0" name=internalLink&gt;Effect of cocoa products on blood pressure - systematic review and meta-analysis&lt;/A&gt;. A new item from the CRD Database of Abstracts of Reviews of Effects.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:379295:0" name=internalLink&gt;Compliance safety and effectiveness of fixed-dose combinations of antihypertensive agents- a meta-analysis&lt;/A&gt;. A new item from the CRD Database of Abstracts of Reviews of Effects.&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Acute kidney injury&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;No new resources this month.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;End-Stage Renal Disease&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;No new resources this month.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Renovascular diseases&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;No new resources this month.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Glomerulonephritis&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:382430:0" name=internalLink&gt;Treatment of hepatitis B virus-associated glomerulonephritis - a meta-analysis&lt;/A&gt;. A new item from the CRD Database of Abstracts of Reviews of Effects.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Other renal conditions&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:379293:0" name=internalLink&gt;Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome.&lt;/A&gt;&amp;nbsp; A new item from the CRD Database of Abstracts of Reviews of Effects.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Renal tract infections&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;No new resources this month.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Kidney stones&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;No new resources this month.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Renal vasculitis&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;No new resources this month.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Haemodialysis&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:385703:0" name=internalLink&gt;Pegylated interferon monotherapy of chronic hepatitis C in dialysis patients - meta-analysis of clinical trials&lt;/A&gt;. A new item from the CRD Database of Abstracts of Reviews of Effects.&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Peritoneal Dialysis&lt;/STRONG&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2010---December/17/European-Medicines-Agency-recommends-action-plan-to-deal-with-possible-presence-of-endotoxins-in-Baxter-peritoneal-dialysis-solutions/" target="_blank"&gt;European Medicines Agency recommends action plan to deal with possible presence of endotoxins in Baxter peritoneal dialysis solutions&lt;/A&gt;. National electronic Library for Medicines (20/12/10)&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Transplantation&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:379343:0" name=internalLink&gt;Clinical pharmacy services and solid organ transplantation - a literature review&lt;/A&gt;. A new item from the CRD Database of Abstracts of Reviews of Effects.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/Evidence/Medicines-Management/References/2010---December/17/Generic-or-branded-mycophenolate---what-strategy-should-the-NHS-adopt/" target="_blank"&gt;Generic or branded mycophenolate - what strategy should the NHS adopt&lt;/A&gt;. National electronic Library for Medicines (17/12/10). &lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Kidney Cancer&lt;/STRONG&gt; &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;No new resources this month.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;&lt;A name=mug&gt;Male Urogenital Disorders&lt;/A&gt;&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:111428:0" name=internalLink&gt;Systematic review on Influence of obesity on the incidence and treatment of genitourinary malignancies&lt;/A&gt;. A new systematic review by Stewart and Freedland, published in Urologic Oncology.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Male Ureteric Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2010---December/14/Tamsulosin-hydrochloride-of-no-use-for-the-management-of-distal-ureteral-stones-/" target="_blank"&gt;Tamsulosin hydrochloride of no use for the management of distal ureteral stones&lt;/A&gt;. National electronic Library for Medicines (15/12/10).&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:395353:0" name=internalLink&gt;Stone cone nitinol retrieval coil to prevent retrograde migration of ureteral calculi during intracorporeal lithotripsy&lt;/A&gt;. A new item from the Health Technology Assessment Database.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Male Bladder Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:395319:0" name=internalLink&gt;Photodynamic diagnosis in bladder cancer detection and treatment&lt;/A&gt;. A new item from the Health Technology Assessment Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:395535:0" name=internalLink&gt;Bladder tumor antigen test&lt;/A&gt;. A new item from the Health Technology Assessment Database.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Prostate Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:395287:0" name=internalLink&gt;Comparative evaluation of radiation treatments for clinically localized prostate cancer- an update&lt;/A&gt;. A new item from the Health Technology Assessment Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:395541:0" name=internalLink&gt;High intensity focused ultrasound&lt;/A&gt;. A new item from the Health Technology Assessment Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:395313:0" name=internalLink&gt;Economic evaluation of population-based PSA screening for prostate cancer&lt;/A&gt;. A new item from the Health Technology Assessment Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://jama.ama-assn.org/content/304/24/2687.3.short?rss=1" target="_blank"&gt;Health Agencies Update - Prostate Drug Warnings&lt;/A&gt; (23/12/10).&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.newscientist.com/article/dn19894-is-mitochondrial-dna-the-secret-of-prostate-cancer.html?DCMP=OTC-rss&amp;amp;nsref=online-news" target="_blank"&gt;Is mitochondrial DNA the secret of prostate cancer?&lt;/A&gt; New Scientist article (21/12/10). &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Penile Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;No new resources this month.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Urethral disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;No new resources this month.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Urinary tract infections&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:364115:0" name=internalLink&gt;Management of childhood urinary tract infections - an economic modeling study&lt;/A&gt;. A new item from the CRD NHS Economic Evaluation Database.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Testicular/Scrotal Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:396652:0" name=internalLink&gt;BMJ Clinical Review on Investigating and Managing Chronic Scrotal Pain &lt;/A&gt;&amp;nbsp;- by Keoghane SR and Sullivan ME. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Male Urinary Incontinence&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:378902:0" name=internalLink&gt;Cost-effectiveness of sacral neuromodulation versus intravesical botulinum A toxin for treatment of refractory urge incontinence&lt;/A&gt;. A new item from the CRD NHS Economic Evaluation Database.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Sexually Transmitted Infections&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:396653:0" name=internalLink&gt;My week- Peter Carey - consultant in genitourinary medicine&lt;/A&gt;. Published by the Guardian (07/12/10). &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:394592:0" name=internalLink&gt;2010 Annual Evidence Update - Sexual Health- HIV AIDS - Behaviour change in high-risk populations - home page&lt;/A&gt;. National Library for Public Health&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Fertility&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;No new resources this month.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <expiryDate>05/01/2012 00:00:00</expiryDate>
  </document>
  <document>
    <id>343360</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=343360]]&gt;</url>
    <title>Journal Update: January 2010</title>
    <publicationDate>2010-02-01T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ NEW RESEARCH,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Journal Update: January 2010&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Journal Update: January 2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Abboud H, Henrich WL. Stage IV Chronic Kidney Disease. NEJM 362: 56-65 (2010) [&lt;A href="http://content.nejm.org/cgi/content/extract/362/1/56" target="_blank"&gt;Link to NEJM&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The Clinical Practice feature of the New England Journal of Medicine has reviewed the management and investigation of a patient with stage IV Chronic Kidney Disease.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The article summaries the relative incidence of CKD stage IV, causes and management, both in terms of reduction of progressive renal damage, and the complications of CKD that are common at this range of renal function.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>11/01/2011 10:22:06</lastReviewDate>
    <expiryDate>11/01/2012 10:22:06</expiryDate>
  </document>
  <document>
    <id>155673</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.uktransplant.org.uk/ukt/how_to_become_a_donor/religious_perspectives/leaflets/judaism_and_organ_donation.jsp]]&gt;</url>
    <title>Judaism and organ donation</title>
    <publicationDate></publicationDate>
    <publisher>UK Transplant</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ TRANSPLANTATION,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A guide to organ donation and the Jewish faith</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Extract from website&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Most donated organs come from people who die from a severe brain injury and who receive treatment on a ventilator in an intensive care unit. The brain injury damages vital centres in the brain stem which are essential to maintain life. It is not the same as a 'coma' or 'persistive vegetative state'. No one can live once these centres have been destroyed. Tests are carried out to strict guidelines and show conclusively when this has happened.&lt;/P&gt;
&lt;P&gt;In addition to the above, Jewish patients will require agreement from their Rabbinic authority that death as defined by Jewish law has definitely occurred. &lt;/P&gt;
&lt;P&gt;&lt;SPAN class=jud&gt;&lt;B&gt;Judaism and organ donation&lt;/B&gt;&lt;/SPAN&gt;&lt;BR&gt;In principle Judaism sanctions and encourages organ donation in order to save lives (pikuach nefesh). &lt;/P&gt;
&lt;P&gt;This principle can sometimes override the strong objections to any unnecessary interference with the body after death, and the requirement for immediate burial of the complete body.&lt;/P&gt;
&lt;P&gt;It is understandable that there will be worries about organ donation. At a time of stress and grief, linked to sudden unexpected illness and death, reaching a decision about donation can be difficult for a family. It is at this time that halachic guidance is so important.&lt;/P&gt;
&lt;P&gt;Judaism insists that no organ may be removed from a donor until death - as defined in Jewish law - has definitely occurred. This can cause problems concerning heart, lung and similar transplants where time is of the essence.&lt;/P&gt;
&lt;P&gt;Judaism insists that honour and respect are due to the dead (kavod hamet). After donation, the avoidance of unnecessary further interference with the body, and the need for immediate interment, are again of prime concern.&lt;/P&gt;
&lt;P&gt;As all cases are different, Jewish law requires consultation with a competent Rabbinic authority before consent is granted. &lt;/P&gt;
&lt;P&gt;These guidelines have been prepared in consultation with the Office of the Chief Rabbi&lt;BR&gt;Please contact the Office of the Chief Rabbi, or another competent Halachic authority&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>23/09/2010 16:52:10</lastReviewDate>
    <expiryDate>23/09/2011 16:52:10</expiryDate>
    <relatedLinks>&lt;a href="http://www.uktransplant.org.uk/ukt/how_to_become_a_donor/religious_perspectives/leaflets/judaism_and_organ_donation.jsp" title="Click here for webpage"/&gt;&lt;a href="http://www.uktransplant.org.uk/ukt/newsroom/fact_sheets/religious_leaflets/judaism_and_organ_donation/judaism_and_organ_donation_v2.pdf" title="Click here for leaflet PDF"/&gt;</relatedLinks>
    <creator>UK Transplant</creator>
  </document>
  <document>
    <id>316973</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=316973]]&gt;</url>
    <title>July 2009 NHS Evidence - kidney diseases newsletter</title>
    <publicationDate>2009-07-03T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ INHERITED KIDNEY DISEASE,RENOVASCULAR DISEASES,KIDNEY AND BLADDER STONES,COMPLICATIONS OF KIDNEY DISEASE,PERITONEAL DIALYSIS,ACUTE KIDNEY INJURY,HAEMODIALYSIS,TRANSPLANTATION,RENAL TRACT INFECTIONS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES,DIALYSIS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;July 2009 NHS Evidence - kidney diseases newsletter&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;NHS Evidence - kidney diseases is for busy health professionals, providing them with high quality information and keeping them up to date with the latest research and developments in this area.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=center&gt;&lt;IMG id=nelh_tempImage0 style="WIDTH: 205px; HEIGHT: 182px" height=177 alt="BRS conference stand" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0000_Image135.jpg" width=195 border=0 name=nelh_tempImage0&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage1 style="WIDTH: 185px; HEIGHT: 181px" height=176 alt="BRS conference delegates" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0001_Image165.jpg" width=169 border=0 name=nelh_tempImage1&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Images above and below were taken at the British Renal Society conference in Birmingham, 1-3rd June 2009 and show the NHS Evidence - kidney diseases stand. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="/libraryImages/kidney/contentID316973/nelhImp_0005_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&amp;nbsp;RSS FEEDS&amp;nbsp; &lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="/libraryImages/kidney/contentID316973/nelhImp_0006_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;You can receive news from the kidney diseases specialist collection from the RSS feeds we provide:&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;&lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="/libraryImages/kidney/contentID316973/nelhImp_0007_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk/kidney/RSSFeed.aspx?feed=57" target="_blank"&gt;New Resources added to NHS Evidence - kidney diseases&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="/libraryImages/kidney/contentID316973/nelhImp_0008_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk//kidney/News.aspx" target="_blank"&gt;Kidney diseases in the news&lt;/A&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/rss/Directory/MoreAboutRss.aspx" target="_blank"&gt;Click through this link to find out more about RSS feeds.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;JOURNALS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;You can link through to the latest Tables of Contents from all the major kidney journals from &lt;A href="http://www.library.nhs.uk/KIDNEY/Page.aspx?pagename=EJOURNALS" target="_blank"&gt;this page&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BIG&gt;New resources added in June 2009&lt;/BIG&gt;&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Chronic Kidney&amp;nbsp; Disease&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/Evidence/Medicines-Q--A/Which-bowel-cleansing-solutions-are-suitable-for-use-in-people-with-renal-impairment/" target="_blank"&gt;Which bowel cleansing solutions are suitable for use in people with renal impairment?&lt;/A&gt; A summary by the National electronic Library for Medicines (04/06/09) with a link to the &lt;A href="http://www.nelm.nhs.uk/en/Download/?file=MDs1MTA2Njc7L3VwbG9hZC9kb2N1bWVudHMvRXZpZGVuY2UvTWVkaWNpbmVzIFEgJmFtcDsgQS9ib3dlbF9jbGVhbnNlcnNfaW5fUklfUUFfZG9jX0ZJTkFMLmRvYw__.doc" target="_blank"&gt;Word document&lt;/A&gt;.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.ehiprimarycare.com/news/4911/map_of_medicine_use_cuts_poor_referrals" target="_blank"&gt;Map of Medicine use cuts poor referrals &lt;/A&gt;- News item from eHealth Insider about the impact of Map of Medicine use by primary care practitioners on chronic kidney disease referrals. (08/06/09)&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/KIDNEY/ViewResource.aspx?resID=314208&amp;amp;tabID=289" target="_blank"&gt;Meta-analysis: intradermal vs. intramuscular vaccination against hepatitis B virus in patients with chronic kidney disease.&lt;/A&gt; A DARE abstract (April 2009)&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2009---June/15/Sevelamer-carbonate-Renvela-approved-in-EU-for-chronic-kidney-disease-/" target="_blank"&gt;Sevelamer carbonate (Renvela) approved in EU for chronic kidney disease&lt;/A&gt;. A summary by the National electronic Library for Medicines (15/06/09). &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=317840&amp;amp;tabID=290" target="_blank"&gt;Healthcare workforce portal: Renal&lt;/A&gt;. A specialist website from the Skills for Health - Workforce Projects Team. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2009---June/23/Systematic-review-High-target-haemoglobin-levels-do-not-improve-quality-of-life-for-patients-with-chronic-kidney-disease-/" target="_blank"&gt;Systematic review: High target haemoglobin levels do not improve quality of life for patients with chronic kidney disease?&lt;/A&gt;&amp;nbsp; A summary by the National electronic Library for Medicines (23/06/09). &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=318848&amp;amp;tabID=290" target="_blank"&gt;NSF for Renal Services Update - June 2009&lt;/A&gt; - published by the Department of Health/ Dr Donal O'Donoghue. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=319195&amp;amp;tabID=290" target="_blank"&gt;New GMS Contract QOF Implementation - Dataset And Business Rules - Chronic Kidney Disease (CKD).&lt;/A&gt; The business rules for the new CKD domain of the Quality and Outcomes Framework provide the definition and codes for ckd. Published 1st July. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2009---July/02/Review-Anaemia-diabetes-and-chronic-kidney-disease/" target="_blank"&gt;Review: Anaemia, diabetes, and chronic kidney disease&lt;/A&gt;. A summary by the National electronic Library for Medicines (02/07/09).&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Complications of kidney disease&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Cheng J, Zhang X et al. (2009) &lt;A href="http://www.library.nhs.uk/KIDNEY/ViewResource.aspx?resID=318441&amp;amp;tabID=289" target="_blank"&gt;Efficacy and Safety of Glucocorticoids Therapy for IgA Nephropathy: A Meta-Analysis of Randomized Controlled Trials.&lt;/A&gt; &lt;EM&gt;American Journal of Nephrology. &lt;/EM&gt;2009, 30 (4); 315-322. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Acute renal failure&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=317163&amp;amp;tabID=290" target="_blank"&gt;Acute kidney injury: adding insult to injury&lt;/A&gt;. NCEPOD Report (11 June 2009). &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Renovascular diseases&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/KIDNEY/ViewResource.aspx?resID=316713&amp;amp;tabID=289" target="_blank"&gt;Meta-analysis: terlipressin therapy for the hepatorenal syndrome&lt;/A&gt; (DARE abstract - June 2009)&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Renal tract infections&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/KIDNEY/ViewResource.aspx?resID=316820&amp;amp;tabID=289" target="_blank"&gt;Short- versus long-course antibiotic therapy for acute pyelonephritis in adolescents and adults: a meta-analysis of randomized controlled trials&lt;/A&gt; (DARE abstract&amp;nbsp;- June 2009)&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2009---June/19/BMJ-Practice-Rational-testing---assessing-candiduria-in-a-critically-ill-patient/" target="_blank"&gt;BMJ Practice: Rational testing - assessing candiduria in a critically ill patient&lt;/A&gt;. A summary by the National electronic Library for Medicines (19/06/09). &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Kidney and bladder stones&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/KIDNEY/ViewResource.aspx?resID=316791&amp;amp;tabID=289" target="_blank"&gt;Diagnostic performance of low-dose CT for the detection of urolithiasis: a meta-analysis&lt;/A&gt; (DARE abstract&amp;nbsp;- June 2009)&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/KIDNEY/ViewResource.aspx?resID=316731&amp;amp;tabID=289" target="_blank"&gt;The effect of shock wave rate on the outcome of shock wave lithotripsy: a meta-analysis&lt;/A&gt; (DARE abstract- June 2009)&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Haemodialysis&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/KIDNEY/ViewResource.aspx?resID=316767&amp;amp;tabID=289" target="_blank"&gt;Antimicrobial lock solutions for the prevention of infections associated with intravascular catheters in patients undergoing hemodialysis: systematic review and meta-analysis of randomized, controlled trials&lt;/A&gt; (DARE abstract&amp;nbsp;- June 2009)&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/KIDNEY/ViewResource.aspx?resID=314589&amp;amp;tabID=28" target="_blank"&gt;GUIDELINE: Standards and recommendations for the provision of renal replacement therapy on intensive care units in the United Kingdom&lt;/A&gt;. Guidance from the Intensive Care Society, published January 2009. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Peritoneal dialysis&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/KIDNEY/ViewResource.aspx?resID=316714&amp;amp;tabID=289" target="_blank"&gt;Meta-analysis: peritoneal membrane transport, mortality, and technique failure in peritoneal dialysis &lt;/A&gt;(DARE - June 2009)&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Transplantation&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/KIDNEY/ViewResource.aspx?resID=316849&amp;amp;tabID=289" target="_blank"&gt;Cost-effectiveness of colorectal cancer screening in renal transplant recipients &lt;/A&gt;(NEED - June 2009)&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/KIDNEY/ViewResource.aspx?resID=316605&amp;amp;tabID=290" target="_blank"&gt;3 June 2009 - Progress towards pig transplants&lt;/A&gt;: An NHS Choices Behind the Headlines story. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/Other-Lib-Updates/SPC-Changes/Prograf-tacrolimus-5mgml-Concentrate-for-Solution-for-Infusion---Revised-SPC/" target="_blank"&gt;Prograf (tacrolimus) 5mg/ml Concentrate for Solution for Infusion - Revised SPC&lt;/A&gt;. A summary by the National electronic Library for Medicines (21/06/09). &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Renal tract cancer&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=124711&amp;amp;tabID=289" target="_blank"&gt;Kidney cancer: Treatment and Disease management: Biological Therapy&lt;/A&gt; - The cancer specialist collection have added the latest systematic reviews on this topic to the page. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2009---June/03/Final-results-from-Phase-III-trial-comparing-sunitinib-and-interferon-alfa-in-first-line-treatment-of-metastatic-renal-cell-carcinoma-/" target="_blank"&gt;Final results from Phase III trial comparing sunitinib and interferon-alfa in first-line treatment of metastatic renal cell carcinoma.&lt;/A&gt; A summary by the National electronic Library for Medicines (03/06/09).&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=center&gt;&lt;IMG id=nelh_tempImage0 height=121 alt="BRS conference delegates" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0002_Image167.jpg" width=127 border=0 name=nelh_tempImage0&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage1 height=122 alt="Kidney diseases information specialist" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0003_Image170a.jpg" width=131 border=0 name=nelh_tempImage1&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P align=center&gt;&lt;IMG id=nelh_tempImage0 height=119 alt="BRS conference delegates" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0004_Image166.jpg" width=192 border=0 name=nelh_tempImage0&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>27/05/2010 10:00:35</lastReviewDate>
    <expiryDate>27/05/2011 10:00:35</expiryDate>
  </document>
  <document>
    <id>379784</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=379784]]&gt;</url>
    <title>July 2010 NHS Evidence - kidney diseases and male urogenital disorders newsletter</title>
    <publicationDate>2010-07-01T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;July 2010 NHS Evidence - kidney diseases and male urogenital disorders newsletter&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Welcome to the kidney diseases and male urogenital disorders specialist collection enewsletter for&amp;nbsp;JULY 2010. &lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=left&gt;NHS Evidence - kidney diseases and male urogenital disorders is for busy health professionals, providing them with high quality information and keeping them up to date with the latest research and developments in this area. You can now join our mailing list to receive regular updates. &lt;A href="https://www.jiscmail.ac.uk/cgi-bin/webadmin?A0=NHSEVIDENCEKDMU" target="_blank"&gt;Click here for the link&lt;/A&gt;.&lt;/P&gt;
&lt;P align=center&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Links to:&lt;/STRONG&gt;&lt;/P&gt;&lt;STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="#kidney"&gt;New Kidney Diseases items&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="#mug"&gt;New Male Urogenital Disorders items&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;&lt;/STRONG&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;NEW KIDNEY DISEASES MINI TOPIC REVIEWS:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;The most recent mini topic review is by Michael Reschen MB MRCP(UK) and Christopher G Winearls MB (Cape Town), D.Phil(Oxon) FRCP (London): &lt;A href="nelh:378555:0" name=internalLink&gt;The TREAT Trial&lt;/A&gt; (June 2010).&lt;/LI&gt;
&lt;LI&gt;An introductory article by Edward Sharples on Anaemia Management in CKD Patients is also now available on the specialist collection: &lt;A href="nelh:378576:0" name=internalLink&gt;Anaemia Management in CKD Patients - a mini-review&lt;/A&gt; (June 2010).&lt;/LI&gt;
&lt;LI&gt;See also the latest mini topic review published by the Surgery, anaesthesia, perioperative and critical care specialist collection: &lt;A href="nelh:342401:0" name=internalLink&gt;Cardiac surgery-associated acute kidney injury&lt;/A&gt;, by Drs Amit Srivastava and Stephen T Webb (June 2010). &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;NEW UROLOGY MINI TOPIC REVIEWS:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Pete Acher and Alastair Henderson have written a mini topic review on &lt;A href="nelh:379520:0" name=internalLink&gt;Holmium laser surgery for benign prostatic enlargement&lt;/A&gt; (June 2010).&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Do you use medicines information? Click here to take part in a short survey and tell us your views:&lt;/P&gt;
&lt;P&gt;&lt;A href="http://surveys.viewscount.com/vc/medicalinformationsurvey" target="_blank"&gt;http://surveys.viewscount.com/vc/medicalinformationsurvey&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;IMG id=nelh_tempImage0 height=16 alt=" name=nelh_tempImage0 border=" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0005_feed.gif" width=16 0? RSS icon?&gt;&amp;nbsp;RSS FEEDS&amp;nbsp; &lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0006_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;You can receive news from the kidney diseases specialist collection from the RSS feeds we provide:&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/RSSFeed.aspx?feed=57" target="_blank"&gt;&lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0007_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk/kidney/RSSFeed.aspx?feed=57" target="_blank"&gt;New Kidney Diseases Resources&lt;/A&gt;&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/RSSFeed.aspx?feed=136" target="_blank"&gt;&lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0008_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk/kidney/RSSFeed.aspx?feed=136" target="_blank"&gt;New Male Urogenital Disorders Resources&lt;/A&gt; &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk//kidney/News.aspx" target="_blank"&gt;&lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0008_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk//kidney/News.aspx" target="_blank"&gt;Kidney diseases and male urogenital disorders in the news&lt;/A&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/rss/Directory/MoreAboutRss.aspx" target="_blank"&gt;Click through this link to find out more about RSS feeds.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;JOURNALS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;You can link through to the latest Tables of Contents from all the major kidney, transplant and urology journals from &lt;A href="http://www.library.nhs.uk/KIDNEY/Page.aspx?pagename=EJOURNALS" target="_blank"&gt;this page&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=3&gt;&lt;STRONG&gt;&lt;BIG&gt;Resources added in&amp;nbsp;June 2010&lt;/BIG&gt;&lt;/STRONG&gt; &lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A name=kidney&gt;Chronic Kidney&amp;nbsp;Disease&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:378713:0" name=internalLink&gt;Wearable artificial kidney (WAK): Portable dialysis for patients with chronic kidney disease&lt;/A&gt;. A new item from the CRD Health Technology Assessment Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:379435:0" name=internalLink&gt;Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis&lt;/A&gt;. A new abstract from the Database of Abstracts of Reviews of Effects.&lt;/LI&gt;
&lt;LI&gt;New introductory article and guest editorial on &lt;A href="nelh:378576:0" name=internalLink&gt;Anaemia Management in CKD Patients&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2010---June/14/Horizon-scanning-Allopurinol-may-slow-progression-of-renal-disease-and-reduce-cardiovascular-risk-in-chronic-kidney-disease/" target="_blank"&gt;Allopurinol may slow progression of renal disease and reduce cardiovascular risk in chronic kidney disease&lt;/A&gt;. Published 21/06/10 by the National electronic Library for Medicines.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Acute kidney injury&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:358504:0" name=internalLink&gt;Nephrotoxicity of iso-osmolar iodixanol compared with nonionic low-osmolar contrast media: meta-analysis of randomized controlled trials&lt;/A&gt;. A new abstract from the Database of Abstracts of Reviews of Effects.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:379119:0" name=internalLink&gt;Utility of urine myoglobin for the prediction of acute renal failure in patients with suspected rhabdomyolysis: a systematic review&lt;/A&gt;. A new abstract from the Database of Abstracts of Reviews of Effects.&lt;/LI&gt;
&lt;LI&gt;Mini topic review on &lt;A href="nelh:342401:0" name=internalLink&gt;Cardiac surgery-associated acute kidney injury&lt;/A&gt;. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Polycystic kidney disease&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:379539:0" name=internalLink&gt;Everolimus in Patients with Autosomal Dominant Polycystic Kidney Disease&lt;/A&gt;. A new RCT published in the NEJM.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:379536:0" name=internalLink&gt;Sirolimus and Kidney Growth in Autosomal Dominant Polycystic Kidney Disease&lt;/A&gt;. New RCT published in NEJM. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Kidney stones&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:379387:0" name=internalLink&gt;Diet, fluid, or supplements for secondary prevention of nephrolithiasis: a systematic review and meta-analysis of randomized trials&lt;/A&gt;. A new abstract from the Database of Abstracts of Reviews of Effects.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Renal vasculitis&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Systematic review on &lt;A href="http://www.biomedcentral.com/1471-2369/11/12" target="_blank"&gt;Interventions for renal vasculitis in adults&lt;/A&gt; by Walters GD, Willis NS, Craig JC, published in BMC Nephrology. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Dialysis&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:370197:0" name=internalLink&gt;The cost-effectiveness of increasing kidney transplantation and home-based dialysis&lt;/A&gt;. A new abstract from the NHS Economic Evaluation Database. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:378713:0" name=internalLink&gt;Wearable artificial kidney (WAK): Portable dialysis for patients with chronic kidney disease&lt;/A&gt;. A new item from the CRD Health Technology Assessment Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:356941:0" name=internalLink&gt;Ultrasound monitoring to detect access stenosis in hemodialysis patients: a systematic review&lt;/A&gt;. A new abstract from the Database of Abstracts of Reviews of Effects.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:379111:0" name=internalLink&gt;Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in peritoneal dialysis: systematic review and meta-analysis of randomized controlled trials&lt;/A&gt;. A new abstract from the Database of Abstracts of Reviews of Effects.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:379540:0" name=internalLink&gt;A Randomized Controlled Trial of Early versus Late Initiation of Dialysis&lt;/A&gt;. A new RCT published by the NEJM.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Transplantation&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:370197:0" name=internalLink&gt;The cost-effectiveness of increasing kidney transplantation and home-based dialysis&lt;/A&gt;. A new abstract from the NHS Economic Evaluation Database. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:378714:0" name=internalLink&gt;LifePort kidney transporter: Portable donor kidney transporter/ perfuser&lt;/A&gt;. A new item from the CRD Health Technology Assessment Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:378803:0" name=internalLink&gt;Belatacept for prophylaxis of organ rejection in renal transplantation&lt;/A&gt;. A new item from the CRD Health Technology Assessment Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:379219:0" name=internalLink&gt;Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk: a meta-analysis&lt;/A&gt;. A new abstract from the Database of Abstracts of Reviews of Effects.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Kidney Cancer&lt;/STRONG&gt; &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:378820:0" name=internalLink&gt;Pazopanib (GW786034) for advanced and/or metastatic renal cell carcinoma - first/second line&lt;/A&gt;. A new item from the CRD Health Technology Assessment Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:378754:0" name=internalLink&gt;Everolimus: efficiency, efficacy and safety&lt;/A&gt;. A new item from the CRD Health Technology Assessment Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:378827:0" name=internalLink&gt;Everolimus for advanced and/or metastatic renal cell carcinoma - second line&lt;/A&gt;. A new item from the CRD Health Technology Assessment Database.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A name=mug&gt;Male Urogenital Disorders&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Male Ureteric Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:378914:0" name=internalLink&gt;Cost-effectiveness of treating ureteral stones in a Taipei city hospital: shock wave lithotripsy versus ureteroscopy plus lithoclast&lt;/A&gt;. A new abstract from the NHS Economic Evaluation Database. &lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Male Bladder Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:378715:0" name=internalLink&gt;NMP22 BladderChek Diagnostic test for bladder cancer: update&lt;/A&gt;. A new item from the CRD Health Technology Assessment Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:379193:0" name=internalLink&gt;Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidence&lt;/A&gt;. A new abstract from the Database of Abstracts of Reviews of Effects.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:379558:0" name=internalLink&gt;OTC Tamsulosin - 400 micrograms: practice guidance&lt;/A&gt;. Published March 2010.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Prostate Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:378906:0" name=internalLink&gt;Cost-effectiveness of MR lymphography for the detection of lymph node metastases in patients with prostate cancer&lt;/A&gt;. A new abstract from the NHS Economic Evaluation Database. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:378829:0" name=internalLink&gt;Dutasteride (Avodart) for prevention of prostate cancer&lt;/A&gt;. A new item from the CRD Health Technology Assessment Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:378860:0" name=internalLink&gt;Da Vinci robotic surgical system for gynecologic and urologic oncology&lt;/A&gt;. A new item from the CRD Health Technology Assessment Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:357833:0" name=internalLink&gt;A systematic review of physical activity in prostate cancer survivors: outcomes, prevalence, and determinants&lt;/A&gt;. A new abstract from the Database of Abstracts of Reviews of Effects. &lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Penile Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:378688:0" name=internalLink&gt;Haematospermia&lt;/A&gt;. New guidance from Clinical Knowledge Summaries. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:378689:0" name=internalLink&gt;Haematospermia: Assessment of haematospermia&lt;/A&gt;. New guidance from Clinical Knowledge Summaries. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:378690:0" name=internalLink&gt;Haematospermia: Haematospermia&lt;/A&gt;. New guidance from Clinical Knowledge Summaries. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:360241:0" name=internalLink&gt;Acupuncture for treating erectile dysfunction: a systematic review&lt;/A&gt;. A new abstract from the Database of Abstracts of Reviews of Effects.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Urinary tract infection&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:378902:0" name=internalLink&gt;Cost-effectiveness of sacral neuromodulation versus intravesical botulinum A toxin for treatment of refractory urge incontinence&lt;/A&gt;. A new abstract from the NHS Economic Evaluation Database. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Testicular/Scrotal Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:378899:0" name=internalLink&gt;A decision analysis of treatments for nonobstructive azoospermia associated with varicocele&lt;/A&gt;. A new abstract from the NHS Economic Evaluation Database. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:34519:0" name=internalLink&gt;2010 United Kingdom national guideline for the management of epididymo-orchitis&lt;/A&gt;. New guideline, published May 2010, replaces previous guidance of January 2001. Royal Pharmaceutical Society&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Sexually Transmitted Infections&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:378706:0" name=internalLink&gt;Herpes simplex - genital: Diagnosis of herpes simplex - genital&lt;/A&gt;. New guidance from Clinical Knowledge Summaries. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:365844:0" name=internalLink&gt;Preventing sexually transmitted infections among incarcerated men who have sex with men: a cost-effectiveness analysis&lt;/A&gt;. A new abstract from the NHS Economic Evaluation Database. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:378712:0" name=internalLink&gt;Rapid urine test for Chlamydia trachomatis&lt;/A&gt;. A new item from the CRD Health Technology Assessment Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:379556:0" name=internalLink&gt;Sexual health toolkit&lt;/A&gt;. New guideline, published March 2010&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/LI&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <expiryDate>01/07/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>316971</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=316971]]&gt;</url>
    <title>June 2009 NHS Evidence - kidney diseases newsletter</title>
    <publicationDate>2009-06-08T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ ACUTE KIDNEY INJURY,COMPLICATIONS OF KIDNEY DISEASE,INHERITED KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;June 2009 NHS Evidence - kidney diseases newsletter&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;NHS Evidence - kidney diseases is for busy health professionals, providing them with high quality information and keeping them up to date with the latest research and developments in this area.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=center&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage0 height=193 alt="patient on dialysis" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316971/nelhImp_0000_Patientreceivingdialysis_nhsphotolibrary_08jan09.jpg" width=332 border=0 name=nelh_tempImage0&gt;&lt;/P&gt;
&lt;H2&gt;&lt;BIG&gt;&lt;/BIG&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;&lt;BIG&gt;New Resources added in May 2009:&lt;/BIG&gt;&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;Guidance&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=312536&amp;amp;tabID=288" target="_blank"&gt;Diabetic nephropathy&lt;/A&gt; - British National Formulary for Children (Published 1 July 2008)&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=314194&amp;amp;tabID=288" target="_blank"&gt;Pyelonephritis: acute&lt;/A&gt;&amp;nbsp;- Clinical Knowledge Summaries (Published 30 Mar 2009) &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=314196&amp;amp;tabID=288" target="_blank"&gt;Renal Colic: acute&lt;/A&gt; - Clinical Knowledge Summaries (published 30 Mar 2009)&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Evidence&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=315169&amp;amp;tabID=289" target="_blank"&gt;&lt;STRONG&gt;&lt;BIG&gt;2009 Annual Evidence Update on Proteinuria and eGFR&lt;/BIG&gt;&lt;/STRONG&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Comments from the renal External Reference Group members:&lt;/P&gt;
&lt;P&gt;"Very well done. Ed Sharples and David Goldsmith have provided insightful (and neutral) commentaries, which fit well with... clinical consensus on the topic." Robert MacTier&lt;/P&gt;
&lt;P&gt;"Clear and easy to navigate, succinct and balanced summaries. Thumbs up from the Cochrane Renal group and other associated entities." Angela Webster&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Database of Abstracts of Reviews of Effects:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=314222&amp;amp;tabID=289" target="_blank"&gt;Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=314203&amp;amp;tabID=289" target="_blank"&gt;Measured creatinine clearance from timed urine collections substantially overestimates glomerular filtration rate in patients with liver cirrhosis: a systematic review and individual patient meta-analysis&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=314221&amp;amp;tabID=289" target="_blank"&gt;Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=314208&amp;amp;tabID=289" target="_blank"&gt;Meta-analysis: intradermal vs. intramuscular vaccination against hepatitis B virus in patients with chronic kidney disease&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/KIDNEY/ViewResource.aspx?resID=314268&amp;amp;tabID=289" target="_blank"&gt;Performance of creatinine-based estimates of GFR in kidney transplant recipients: a systematic review&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/KIDNEY/ViewResource.aspx?resID=314242&amp;amp;tabID=289" target="_blank"&gt;Preventing haemodialysis catheter-related bacteraemia with an antimicrobial lock solution: a meta-analysis of prospective randomized trials&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/KIDNEY/ViewResource.aspx?resID=314220&amp;amp;tabID=289" target="_blank"&gt;Renal replacement therapy in patients with acute renal failure: a systematic review&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;NHS Economic Evaluation Database&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=314337&amp;amp;tabID=289" target="_blank"&gt;Comparison of Tinzaparin and unfractionated heparin as anticoagulation on haemodialysis: equal safety, efficacy and economical parity&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Also...&lt;/STRONG&gt; &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=124711&amp;amp;tabID=289" target="_blank"&gt;Updated evidence on Kidney Cancer from the cancer specialist collection&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Evidence in the News&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2009---May/05/MHRA-Drug-Safety-Update-Reminder-on-renal-failure-and-impairment-with-NSAIDs/" target="_blank"&gt;MHRA Drug Safety Update: Reminder on renal failure and impairment with NSAIDs&lt;/A&gt; - from NeLM news service 05/05/09&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.eurekalert.org/pub_releases/2009-05/bc-sbr051109.php" target="_blank"&gt;Sodium bicarbonate reduces incidence of contrast-induced nephropathy&lt;/A&gt; - from EurekAlert 12/05/09 &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2009---May/19/Candesartan-and-telmisartan-do-not-reduce-progression-of-early-kidney-disease/" target="_blank"&gt;Candesartan and telmisartan do not reduce progression of early kidney disease&lt;/A&gt; - from NeLM news service 19/05/09&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2009---May/19/Evidence-used-for-guidelines-on-ACE-inhibitor-ARB-use-in-CKD-not-representative-of-older-people/" target="_blank"&gt;Evidence used for guidelines on ACE-inhibitor, ARB use in CKD not representative of older people&lt;/A&gt; - from NeLM news service 19/05/09&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2009---May/20/Meta-analysis-antihypertensive-drugs-are--more-or-less--all-equally-effective/" target="_blank"&gt;Meta-analysis: antihypertensive drugs are – more or less – all equally effective&lt;/A&gt; - from NeLM news service 20/05/09&lt;/LI&gt;
&lt;LI&gt;Schneckner, B. et al. (2009) &lt;A href="http://www.biomedcentral.com/1471-2369/10/11" target="_blank"&gt;Diagnostic yield of renal biopsies: a retrospective single center review&lt;/A&gt;. BMC Nephrology. 10:11.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/KIDNEY/ViewResource.aspx?resID=316605&amp;amp;tabID=290" target="_blank"&gt;Progress towards pig transplants &lt;/A&gt;- NHS Choices Behind the Headlines review 03/06/09 &amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2009---June/03/Final-results-from-Phase-III-trial-comparing-sunitinib-and-interferon-alfa-in-first-line-treatment-of-metastatic-renal-cell-carcinoma-/" target="_blank"&gt;Final results from Phase III trial comparing sunitinib and interferon-alfa in first-line treatment of metastatic renal cell carcinoma&lt;/A&gt; - from NeLM news service 03/06/09&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/Evidence/Medicines-Q--A/Which-bowel-cleansing-solutions-are-suitable-for-use-in-people-with-renal-impairment/" target="_blank"&gt;Which bowel cleansing solutions are suitable for use in people with renal impairment?&lt;/A&gt; - from NeLM news service 04/06/0/9 &lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Reference materials&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=314820&amp;amp;tabID=290" target="_blank"&gt;Bladder and kidneys &lt;/A&gt;- BMJ Best Treatments resources&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.kidneycare.nhs.uk/Default.aspx?sID=2" target="_blank"&gt;NHS Kidney Care Matters Online&lt;/A&gt; - June newsletter&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=315270&amp;amp;tabID=290" target="_blank"&gt;Specialised Renal Services (Adult): Definition No. 11&lt;/A&gt; - NHS National Specialised Commissioning Group (Published 19 May 2009)&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://renaltsar.blogspot.com/2009/05/programme-budgeting-in-kidney-care-17b.html" target="_blank"&gt;Programme budgeting in Kidney Care&lt;/A&gt; - from the Renal Tsar's blog (28/05/09)&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Patient Information&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/KIDNEY/ViewResource.aspx?resID=314483&amp;amp;tabID=292" target="_blank"&gt;Kidney transplant: Tony's story&lt;/A&gt; - video from NHS Choices&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nhs.uk/video/pages/medialibrary.aspx?Id={E3082523-8134-4D42-9903-3766AF4349BD}&amp;amp;Uri=video/2009/May/Pages/Urinarytractinfections.aspx" target="_blank"&gt;Urinary tract infections&lt;/A&gt; - video from NHS Choices&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>27/05/2010 10:00:39</lastReviewDate>
    <expiryDate>27/05/2011 10:00:39</expiryDate>
  </document>
  <document>
    <id>377132</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=377132]]&gt;</url>
    <title>June 2010 NHS Evidence - kidney diseases and male urogenital disorders newsletter</title>
    <publicationDate>2010-06-01T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;June 2010 NHS Evidence - kidney diseases and male urogenital disorders newsletter&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Welcome to the kidney diseases and male urogenital disorders specialist collection enewsletter for&amp;nbsp;JUNE 2010. &lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=left&gt;NHS Evidence - kidney diseases and male urogenital disorders is for busy health professionals, providing them with high quality information and keeping them up to date with the latest research and developments in this area. You can now join our mailing list to receive regular updates. &lt;A href="https://www.jiscmail.ac.uk/cgi-bin/webadmin?A0=NHSEVIDENCEKDMU" target="_blank"&gt;Click here for the link&lt;/A&gt;.&lt;/P&gt;
&lt;P align=center&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Links to:&lt;/STRONG&gt;&lt;/P&gt;&lt;STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="#kidney"&gt;New Kidney Diseases items&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="#mug"&gt;New Male Urogenital Disorders items&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;On Monday 24th May, the specialist collection launched the third Annual Evidence Update on Proteinuria and eGFR:&lt;/P&gt;
&lt;P&gt;The 2010 update on the topics of eGFR and proteinuria focuses on the new evidence underpinning the importance of microalbuminuria and proteinuria as a marker of renal and cardiovascular disease and progression. Two commentaries highlight the new evidence for pre-eclampsia as a risk factor for CKD, and the ongoing debates around eGFR, old age and CKD classifications.&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:372689:0" name=internalLink&gt;Link to 2010 AEU on&amp;nbsp;Proteinuria and eGFR contents page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;IMG id=nelh_tempImage0 height=16 alt=" name=nelh_tempImage0 border=" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0005_feed.gif" width=16 icon? RSS 0?&gt;&amp;nbsp;RSS FEEDS&amp;nbsp; &lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0006_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&lt;/STRONG&gt; 
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;You can receive news from the kidney diseases specialist collection from the RSS feeds we provide:&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/RSSFeed.aspx?feed=57" target="_blank"&gt;&lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0007_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk/kidney/RSSFeed.aspx?feed=57" target="_blank"&gt;New Kidney Diseases Resources&lt;/A&gt;&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/RSSFeed.aspx?feed=136" target="_blank"&gt;&lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0008_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk/kidney/RSSFeed.aspx?feed=136" target="_blank"&gt;New Male Urogenital Disorders Resources&lt;/A&gt; &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk//kidney/News.aspx" target="_blank"&gt;&lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0008_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk//kidney/News.aspx" target="_blank"&gt;Kidney diseases and male urogenital disorders in the news&lt;/A&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/rss/Directory/MoreAboutRss.aspx" target="_blank"&gt;Click through this link to find out more about RSS feeds.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;JOURNALS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;You can link through to the latest Tables of Contents from all the major kidney, transplant and urology journals from &lt;A href="http://www.library.nhs.uk/KIDNEY/Page.aspx?pagename=EJOURNALS" target="_blank"&gt;this page&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=3&gt;&lt;STRONG&gt;&lt;BIG&gt;Resources added in&amp;nbsp;May 2010&lt;/BIG&gt;&lt;/STRONG&gt; &lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A name=kidney&gt;Chronic Kidney&amp;nbsp;Disease&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;2010 Annual Evidence Update on Proteinuria and eGFR - &lt;A href="nelh:372689:0" name=internalLink&gt;link to contents page&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:374655:0" name=internalLink&gt;Implantable cardioverter defibrillator therapy in chronic kidney disease: a meta-analysis&lt;/A&gt;. A new abstract from the Database of Abstracts of Reviews of Effects. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:283962:0" name=internalLink&gt;Erythropoiesis-stimulating agents for anemia of chronic kidney disease: systematic review and economic evaluation&lt;/A&gt;. A new abstract from the Database of Abstracts of Reviews of Effects. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:376774:0" name=internalLink&gt;Biofeedback for the treatment of hypertension&lt;/A&gt;. A new item from the CRD Health Technology Assessment Database.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Acute kidney injury&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;EM&gt;Nothing this month. &lt;/EM&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Diabetic nephropathy&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:374522:0" name=internalLink&gt;Prostaglandin E1 for preventing the progression of diabetic kidney disease&lt;/A&gt;. New Cochrane systematic review. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:374776:0" name=internalLink&gt;Statins for early diabetic kidney disease: a systematic review&lt;/A&gt;. A new abstract from the Database of Abstracts of Reviews of Effects. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:374775:0" name=internalLink&gt;Tongxinluo capsule for diabetic kidney disease: a systematic review&lt;/A&gt;. A new abstract from the Database of Abstracts of Reviews of Effects. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:376367:0" name=internalLink&gt;Optimal strategies for monitoring kidney disease in diabetes: properties of monitoring tests, progression of renal dysfunction and impact of treatment&lt;/A&gt;. A new item from the CRD Health Technology Assessment Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:376809:0" name=internalLink&gt;Pancreas-after-kidney (PAK) transplantation in diabetic patients&lt;/A&gt;. A new item from the CRD Health Technology Assessment Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:376916:0" name=internalLink&gt;Simultaneous pancreas-kidney (SPK) transplantation in diabetic patients&lt;/A&gt;. A new item from the CRD Health Technology Assessment Database.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Other kidney conditions - SLE and inherited&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:376494:0" name=internalLink&gt;Belimumab (Benlysta) for active systemic lupus erythematosus&lt;/A&gt;. A new item from the CRD Health Technology Assessment Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:376483:0" name=internalLink&gt;Everolimus for autosomal dominant polycystic kidney disease with renal impairment&lt;/A&gt;. A new item from the CRD Health Technology Assessment Database.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Renal tract infections&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:374467:0" name=internalLink&gt;Pyelonephritis - acute: Diagnosis of acute pyelonephritis&lt;/A&gt;. New&amp;nbsp;guidance from Clinical Knowledge Summaries. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Dialysis&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:375561:0" name=internalLink&gt;Heparin versus citrate for anticoagulation in critically ill patients treated with continuous renal replacement therapy&lt;/A&gt;. A new abstract from the Database of Abstracts of Reviews of Effects. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:376658:0" name=internalLink&gt;Home hemodialysis&lt;/A&gt;. A new item from the CRD Health Technology Assessment Database.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Transplantation&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:376978:0" name=internalLink&gt;Budget impact analysis for renal transplantation&lt;/A&gt;. A new item from the CRD Health Technology Assessment Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:376578:0" name=internalLink&gt;Everolimus (Certican) for prophylaxis of organ rejection in renal or cardiac transplantation&lt;/A&gt;. A new item from the CRD Health Technology Assessment Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:374133:0" name=internalLink&gt;Guidelines for the detection and characterisation of clinically relevant antibodies in allotransplantation&lt;/A&gt;. Published 15 March 2010 by the British Transplantation Society. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Kidney Cancer&lt;/STRONG&gt; &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:374743:0" name=internalLink&gt;Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation&lt;/A&gt;. A new abstract from the Database of Abstracts of Reviews of Effects.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:375567:0" name=internalLink&gt;Positron emission tomography for nine cancers (bladder, brain, cervical, kidney, ovarian, pancreatic, prostate, small cell lung, testicular)&lt;/A&gt;. A new abstract from the Database of Abstracts of Reviews of Effects. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:377081:0" name=internalLink&gt;Everolimus (Afinitor) for advanced/metastatic kidney cancer&lt;/A&gt;. A new item from the CRD Health Technology Assessment Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:376590:0" name=internalLink&gt;Off-label uses of Sorafenib and Sunitinib&lt;/A&gt;. A new item from the CRD Health Technology Assessment Database.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A name=mug&gt;Male Urogenital Disorders&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;NEW NICE GUIDELINE: &lt;A href="nelh:374250:0" name=internalLink&gt;Lower urinary tract symptoms: the management of lower urinary tract symptoms in men&lt;/A&gt;.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:375208:0" name=internalLink&gt;Guidelines on conservative treatment of non-neurogenic male LUTS&lt;/A&gt;. Published April 2010 by the European Association of Urology. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Male Bladder Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:376915:0" name=internalLink&gt;Silver-coated urinary catheters for prevention of urinary tract infections&lt;/A&gt;. A new item from the CRD Health Technology Assessment Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:376929:0" name=internalLink&gt;Ureteral bulking agents for vesicoureteral reflux disease&lt;/A&gt;. A new item from the CRD Health Technology Assessment Database.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Prostate Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:374455:0" name=internalLink&gt;Prostatitis - acute: Diagnosis of acute prostatitis&lt;/A&gt;. New guidance from Clinical Knowledge Summaries. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:374456:0" name=internalLink&gt;Prostatitis - chronic: Diagnosis of chronic prostatitis&lt;/A&gt;. New guidance from Clinical Knowledge Summaries. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:374619:0" name=internalLink&gt;Bipolar versus monopolar transurethral resection of the prostate: a systematic review and meta-analysis of randomized controlled trials&lt;/A&gt;. A new abstract from the Database of Abstracts of Reviews of Effects. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:374699:0" name=internalLink&gt;Tamsulosin versus terazosin for benign prostatic hyperplasia: a systematic review&lt;/A&gt;. A new abstract from the Database of Abstracts of Reviews of Effects. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:375524:0" name=internalLink&gt;Adjuvant radiotherapy following radical prostatectomy for pathologic T3 or margin-positive prostate cancer: guideline recommendations&lt;/A&gt;. A new abstract from the Database of Abstracts of Reviews of Effects. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:375499:0" name=internalLink&gt;Comparative effectiveness of therapies for clinically localized prostate cancer&lt;/A&gt;. A new abstract from the Database of Abstracts of Reviews of Effects. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:375502:0" name=internalLink&gt;The use of bisphosphonates in men with hormone-refractory prostate cancer&lt;/A&gt;. A new abstract from the Database of Abstracts of Reviews of Effects. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:376524:0" name=internalLink&gt;Cabazitaxel (XRP-6258) for hormone refractory, metastatic prostate cancer - second line after docetaxel&lt;/A&gt;. A new item from the CRD Health Technology Assessment Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:376817:0" name=internalLink&gt;Conformal and intensity-modulated radiation therapy for prostate cancer&lt;/A&gt;. A new item from the CRD Health Technology Assessment Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:376820:0" name=internalLink&gt;Cryoablation for prostate cancer&lt;/A&gt;. A new item from the CRD Health Technology Assessment Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:377005:0" name=internalLink&gt;Holmium laser enucleation of benign prostatic hyperplasia&lt;/A&gt;. A new item from the CRD Health Technology Assessment Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:376281:0" name=internalLink&gt;Intensity modulated radiotherapy for the treatment of prostate cancer: a systematic review and economic evaluation&lt;/A&gt;. A new item from the CRD Health Technology Assessment Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:376720:0" name=internalLink&gt;Laparoscopic radical prostatectomy&lt;/A&gt;. A new item from the CRD Health Technology Assessment Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:377009:0" name=internalLink&gt;Laser treatment for benign prostatic hyperplasia: defining assessment indicators&lt;/A&gt;. A new item from the CRD Health Technology Assessment Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:377085:0" name=internalLink&gt;Management options for low-risk prostate cancer: a report on comparative effectiveness and value&lt;/A&gt;. A new item from the CRD Health Technology Assessment Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:376447:0" name=internalLink&gt;Prostate trials office (PROTO): co-ordinating trials of new technologies in the treatment of BPH&lt;/A&gt;. A new item from the CRD Health Technology Assessment Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:257718:0" name=internalLink&gt;Proton beam therapy for prostate cancer&lt;/A&gt;. A new item from the CRD Health Technology Assessment Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:376911:0" name=internalLink&gt;Robotic-assisted prostatectomy&lt;/A&gt;. A new item from the CRD Health Technology Assessment Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:376912:0" name=internalLink&gt;Saw palmetto for benign prostatic hyperplasia&lt;/A&gt;. A new item from the CRD Health Technology Assessment Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:376543:0" name=internalLink&gt;Silodosin for benign prostatic hyperplasia&lt;/A&gt;. A new item from the CRD Health Technology Assessment Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:376744:0" name=internalLink&gt;Simultaneous irradiation (ProstRcision) for localized prostate cancer&lt;/A&gt;. A new item from the CRD Health Technology Assessment Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:376607:0" name=internalLink&gt;Special report: recent developments in prostate cancer genetics and genetic testing&lt;/A&gt;. A new item from the CRD Health Technology Assessment Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:377022:0" name=internalLink&gt;Symptomatic benign prostatic obstruction (BPO)&lt;/A&gt;. A new item from the CRD Health Technology Assessment Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:376421:0" name=internalLink&gt;The ProtecT trial - evaluating the effectiveness of treatments for clinically localised prostate cancer&lt;/A&gt;. A new item from the CRD Health Technology Assessment Database.&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Penile Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:374803:0" name=internalLink&gt;Male circumcision at different ages in Rwanda: a cost-effectiveness study&lt;/A&gt;. A new abstract from the NHS Economic Evaluation Database. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Urinary tract infection&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:376397:0" name=internalLink&gt;The Diagnosis of Urinary Tract infection in Young children (DUTY) study&lt;/A&gt;. A new item from the CRD Health Technology Assessment Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:376443:0" name=internalLink&gt;The PLUTO Trial: Percutaneous shunting in Lower Urinary Tract Obstruction&lt;/A&gt;. A new item from the CRD Health Technology Assessment Database.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Testicular/Scrotal Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:374499:0" name=internalLink&gt;Varicocele: Diagnosis of varicocele&lt;/A&gt;. New guidance from Clinical Knowledge Summaries. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:375583:0" name=internalLink&gt;Testosterone and depression: systematic review and meta-analysis&lt;/A&gt;. A new abstract from the Database of Abstracts of Reviews of Effects. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Urinary incontinence&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:377051:0" name=internalLink&gt;Behavioural interventions for urinary incontinence in community-dwelling seniors: an evidence-based analysis&lt;/A&gt;. A new item from the CRD Health Technology Assessment Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:376788:0" name=internalLink&gt;Pelvic floor electrical stimulation for the treatment of urinary incontinence&lt;/A&gt;. A new item from the CRD Health Technology Assessment Database.&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Sexually Transmitted Infections&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:374414:0" name=internalLink&gt;Gonorrhoea: Diagnosis of gonorrhoea&lt;/A&gt;. New guidance from Clinical Knowledge Summaries. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:374809:0" name=internalLink&gt;Congenital syphilis: an economic evaluation of a prevention program in China&lt;/A&gt;. A new abstract from the NHS Economic Evaluation Database. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:376355:0" name=internalLink&gt;Clinical and cost-effectiveness of technologies for testing and treating sexual partners of people with sexually transmitted infections: Evidence synthesis and mathematical modelling study&lt;/A&gt;. A new item from the CRD Health Technology Assessment Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:376871:0" name=internalLink&gt;Rapid antibody testing for HIV&lt;/A&gt;. A new item from the CRD Health Technology Assessment Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:376267:0" name=internalLink&gt;Systematic review of the clinical and cost-effectiveness of rapid point-of-care tests for the detection of genital Chlamydia infection in women and men&lt;/A&gt;. A new item from the CRD Health Technology Assessment Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:376247:0" name=internalLink&gt;The effectiveness and cost-effectiveness of behavioural interventions for the prevention of sexually transmitted infections in young people aged 13-19: a systematic review and economic evaluation&lt;/A&gt;. A new item from the CRD Health Technology Assessment Database.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Fertility&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;EM&gt;Nothing this month.&lt;/EM&gt; &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;**Subscribe to the NHS Evidence Eyes on Evidence Newsletter**&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;If you would like to receive Eyes on Evidence, the monthly e-bulletin from NHS Evidence, please sign up at &lt;A href="http://www.evidence.nhs.uk/NewsletterSignup.aspx" target="_blank"&gt;http://www.evidence.nhs.uk/NewsletterSignup.aspx&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The bulletin will keep you updated with new and important evidence and key developments on the NHS Evidence portal.&amp;nbsp; It comes out on the second Wednesday of the month and can be sent to any e-mail address that you provide.&lt;/P&gt;
&lt;P&gt;&lt;/LI&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <expiryDate>01/06/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>329780</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://kdigo.org/pdf/KDIGO%20Txp%20GL%20publ%20version.pdf]]&gt;</url>
    <title>KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients</title>
    <publicationDate>2009-11-11T00:00:00</publicationDate>
    <publisher>Wiley-Blackwell</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ TRANSPLANT OPERATION,IMMUNOSUPPRESSIVE DRUGS,UK TRANSPLANT,TRANSPLANT CENTRES,PREVENTION OF COMPLICATIONS,ASSESSMENT/SELECTION,TRANSPLANTATION,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This Clinical Practice Guideline document is based upon the best information available as of March 2009. It is designed to provide information and assist decisionmaking. It is not intended to define a standard of care, and should not be construed as one, nor should it be interpreted as prescribing an exclusive course of management.</description>
    <body>&lt;![CDATA[ &lt;P&gt;This Clinical Practice Guideline document is based upon the best information available as of March 2009. It is designed to provide information and assist decisionmaking. It is not intended to define a standard of care, and should not be construed as one, nor should it be interpreted as prescribing an exclusive course of management.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;TABLE OF CONTENTS&lt;/STRONG&gt;&lt;/P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;Disclaimer&lt;/LI&gt;
&lt;LI&gt;Work Group Membership&lt;/LI&gt;
&lt;LI&gt;KDIGO Board Members&lt;/LI&gt;
&lt;LI&gt;Abbreviations and Acronyms&lt;/LI&gt;
&lt;LI&gt;Reference Keys&lt;/LI&gt;
&lt;LI&gt;Abstract&lt;/LI&gt;
&lt;LI&gt;Foreword&lt;/LI&gt;
&lt;LI&gt;Guideline Scope and Intended Users&lt;/LI&gt;
&lt;LI&gt;Chapter 1: Induction Therapy&lt;/LI&gt;
&lt;LI&gt;Chapter 2: Initial Maintenance Immunosuppressive Medications&lt;/LI&gt;
&lt;LI&gt;Chapter 3: Long-Term Maintenance Immunosuppressive Medications&lt;/LI&gt;
&lt;LI&gt;Chapter 4: Strategies to Reduce Drug Costs&lt;/LI&gt;
&lt;LI&gt;Chapter 5: Monitoring Immunosuppressive Medications&lt;/LI&gt;
&lt;LI&gt;Chapter 6: Treatment of Acute Rejection&lt;/LI&gt;
&lt;LI&gt;Chapter 7: Treatment of Chronic Allograft Injury&lt;/LI&gt;
&lt;LI&gt;Chapter 8: Monitoring Kidney Allograft Function&lt;/LI&gt;
&lt;LI&gt;Chapter 9: Kidney Allograft Biopsy&lt;/LI&gt;
&lt;LI&gt;Chapter 10: Recurrent Kidney Disease&lt;/LI&gt;
&lt;LI&gt;Chapter 11: Preventing, Detecting, and Treating Nonadherence&lt;/LI&gt;
&lt;LI&gt;Chapter 12: Vaccination&lt;/LI&gt;
&lt;LI&gt;Chapter 13: Viral Diseases&lt;/LI&gt;
&lt;UL&gt;
&lt;LI&gt;13.1: BK Polyoma Virus&lt;/LI&gt;
&lt;LI&gt;13.2: Cytomegalovirus&lt;/LI&gt;
&lt;LI&gt;13.3: Epstein-Barr Virus and Post-Transplant Lymphoproliferative Disease&lt;/LI&gt;
&lt;LI&gt;13.4: Herpes Simplex Virus 1, 2 and Varicella Zoster Virus&lt;/LI&gt;
&lt;LI&gt;13.5: Hepatitis C Virus&lt;/LI&gt;
&lt;LI&gt;13.6: Hepatitis B Virus&lt;/LI&gt;
&lt;LI&gt;13.7: Human Immunodeficiency Virus&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;Chapter 14: Other Infections&lt;/LI&gt;
&lt;UL&gt;
&lt;LI&gt;14.1: Urinary Tract Infection&lt;/LI&gt;
&lt;LI&gt;14.2: Pneumocystis Jirovecii Pneumonia&lt;/LI&gt;
&lt;LI&gt;14.3: Tuberculosis&lt;/LI&gt;
&lt;LI&gt;14.4: Candida Prophylaxis&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;Chapter 15: Diabetes Mellitus&lt;/LI&gt;
&lt;UL&gt;
&lt;LI&gt;15.1: Screening for New-Onset Diabetes after Transplantation&lt;/LI&gt;
&lt;LI&gt;15.2: Managing NODAT or Diabetes Present at Transplantation&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;Chapter 16: Hypertension, Dyslipidemias, Tobacco Use, and Obesity&lt;/LI&gt;
&lt;UL&gt;
&lt;LI&gt;16.1: Hypertension&lt;/LI&gt;
&lt;LI&gt;16.2: Dyslipidemias&lt;/LI&gt;
&lt;LI&gt;16.3: Tobacco Use&lt;/LI&gt;
&lt;LI&gt;16.4: Obesity&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;Chapter 17: Cardiovascular Disease Management&lt;/LI&gt;
&lt;LI&gt;Chapter 18: Cancer of the Skin and Lip&lt;/LI&gt;
&lt;LI&gt;Chapter 19: Non–Skin Malignancies&lt;/LI&gt;
&lt;LI&gt;Chapter 20: Managing Cancer with Reduction of Immunosuppressive Medication&lt;/LI&gt;
&lt;LI&gt;Chapter 21: Transplant Bone Disease&lt;/LI&gt;
&lt;LI&gt;Chapter 22: Hematological Complications&lt;/LI&gt;
&lt;LI&gt;Chapter 23: Hyperuricemia and Gout&lt;/LI&gt;
&lt;LI&gt;Chapter 24: Growth and Development&lt;/LI&gt;
&lt;LI&gt;Chapter 25: Sexual Function and Fertility&lt;/LI&gt;
&lt;UL&gt;
&lt;LI&gt;25.1: Sexual Function&lt;/LI&gt;
&lt;LI&gt;25.2: Female Fertility&lt;/LI&gt;
&lt;LI&gt;25.3: Male Fertility&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;Chapter 26: Lifestyle&lt;/LI&gt;
&lt;LI&gt;Chapter 27: Mental Health&lt;/LI&gt;
&lt;LI&gt;Appendix: Methods for Guideline Development&lt;/LI&gt;
&lt;LI&gt;Biographic and Disclosure Information&lt;/LI&gt;
&lt;LI&gt;Acknowledgments&lt;/LI&gt;
&lt;LI&gt;References&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
    <lastReviewDate>25/10/2010 13:47:08</lastReviewDate>
    <expiryDate>25/10/2011 13:47:08</expiryDate>
  </document>
  <document>
    <id>339010</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=339010]]&gt;</url>
    <title>Kidney and bladder stones: Systematic reviews and meta-analyses</title>
    <publicationDate>2011-01-24T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY AND BLADDER STONES,MALE BLADDER DISORDERS,BLADDER STONES,MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Kidney and bladder stones: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Borges, C.F., Fregonesi, A., Silva, D.C., Sasse, A.D. (2010) "Systematic review and meta-analysis of nephrostomy placement versus tubeless percutaneous nephrolithotomy." J Endourol. Oct 19 [Epub ahead of print] [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Systematic%20Review%20and%20Meta-Analysis%20of%20Nephrostomy%20Placement%20Versus%20Tubeless%20Percutaneous%20Nephrolithotomy" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Castagnetti, M. and W. Rigamonti (2010). "Extracorporeal shock wave lithotripsy for the treatment of urinary stones in children." Archivio Italiano di Urologia, Andrologia 82(1): 49-50. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20593721" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;D'Armiento, M., R. Autorino, et al. (2010). "PCNL in Italy." Archivio Italiano di Urologia, Andrologia 82(1): 26-9. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=PCNL%20in%20Italy" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Fink, H., R. MacDonald, et al. (2010). "Pharmacologic interventions for secondary prevention of urolithiasis: A systematic review and meta-analysis of randomized trials." Journal of General Internal Medicine 25.&amp;nbsp;[No PubMed abstract available]&lt;/LI&gt;
&lt;LI&gt;Gou, J., Q. Dong, et al. (2010). "Necessity and safety of ureteral stenting after ureteroscopic lithotripsy in treatment of ureteral calculi: A systematic review." Chinese Journal of Evidence-Based Medicine 10(9): 1096-1101.&amp;nbsp;[No PubMed abstract available]&lt;/LI&gt;
&lt;LI&gt;Hyams, E. S., A. Bruhn, et al. (2010). "Heterogeneity in the reporting of disease characteristics and treatment outcomes in studies evaluating treatments for nephrolithiasis." Journal of Endourology 24(9): 1411-4. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20629563" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Liu, L., S. Zheng, et al. (2010). "Systematic review and meta-analysis of percutaneous nephrolithotomy for patients in the supine versus prone position." Journal of Endourology 24(12): 1941-6.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20858062" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Ramsey, S., A. Robertson, et al. (2010). "Evidence-based drainage of infected hydronephrosis secondary to ureteric calculi." Journal of Endourology 24(2): 185-9. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20063999" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Skolarikos, A., M. P. Laguna, et al. (2010). "The role for active monitoring in urinary stones: A systematic review." Journal of Endourology 24(6): 923-930. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20482232" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Skolarikos, A., H. Mitsogiannis, et al. (2010). "Indications, prediction of success and methods to improve outcome of shock wave lithotripsy of renal and upper ureteral calculi." Archivio Italiano di Urologia, Andrologia 82(1): 56-63. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Indications%2C%20prediction%20of%20success%20and%20methods%20to%20improve%20outcome%20of%20shock%20wave%20lithotripsy%20of%20renal%20and%20upper%20ureteral%20calculi" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Wang, K. J., L. H. Jiang, et al. (2010). "Urologist versus radiologist for percutaneous nephrolithotomy access under fluoroscopic guidance: A systematic review." European Urology, Supplements 9(2). [No PubMed abstract available]&lt;/LI&gt;
&lt;LI&gt;Wang, K. J., P. Wu, et al. (2010). "Supine versus prone position in percutaneous nephrolithotomy: A systematic review." European Urology, Supplements 9(2): 133-134. [No PubMed abstract available]&lt;/LI&gt;
&lt;LI&gt;Zheng, S., L. R. Liu, et al. (2010). "Tamsulosin as adjunctive treatment after shockwave lithotripsy in patients with upper urinary tract stones: a systematic review and meta-analysis." Scandinavian Journal of Urology &amp;amp; Nephrology 44(6): 425-32. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/21080841" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Zhu, Y., D. Duijvesz, et al. (2010). "alpha-Blockers to assist stone clearance after extracorporeal shock wave lithotripsy: A meta-analysis." BJU International 106(2): 256-261. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=alpha-Blockers%20to%20assist%20stone%20clearance%20after%20extracorporeal%20shock%20wave%20lithotripsy%3A%20A%20meta-analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Zilberman, D. E., M. E. Lipkin, et al. (2010). "Tubeless percutaneous nephrolithotomy--the new standard of care?" J Urol 184(4): 1261-6. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20723920" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Basiri A, Mohammadi Sichani M. Supine percutaneous nephrolithotomy, is it really effective? A systematic review of literature. Urology Journal. 2009;6(2):73-7. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19472122" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Escribano, J., A. Balaguer, et al. (2009). "Pharmacological interventions for preventing complications in idiopathic hypercalciuria." Cochrane Database Syst Rev(1): CD004754. [&lt;A href="nelh:304886:0" name=internalLink&gt;Link to Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Ferrandino MN, Monga M, Preminger GM. Adjuvant therapy after surgical stone management. Advances in Chronic Kidney Disease. 2009;16(1):52-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19095206" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Fink, H. A., J. W. Akornor, et al. (2009). "Diet, Fluid, or Supplements for Secondary Prevention of Nephrolithiasis: A Systematic Review and Meta-Analysis of Randomized Trials." Eur Urol. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19321253" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Liu, Y., W. Jia, et al. (2009). "Tubeless approach with a ureteral stent versus nephrostomy tube for drainage following percutaneous nephrolithotomy: A systematic review." Chinese Journal of Evidence-Based Medicine 9(2): 230-238.&amp;nbsp;[No abstract available]&lt;/LI&gt;
&lt;LI&gt;Natarajan V, Master V, Ogan K. Effects of obesity and weight loss in patients with nononcological urological disease. Journal of Urology. 2009;181(6):2424-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19371912" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Schuler, T. D., R. Shahani, et al. (2009). "Medical expulsive therapy as an adjunct to improve shockwave lithotripsy outcomes: a systematic review and meta-analysis." J Endourol 23(3): 387-93.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19245302" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Seitz, C., E. Liatsikos, et al. (2009). "Medical Therapy to Facilitate the Passage of Stones: What Is the Evidence?" Eur Urol.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19560860" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Semins, M. J. and B. R. Matlaga (2009). "Ureteroscopy during pregnancy." Indian Journal of Urology 25(3): 291-295.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19881118" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Semins, M. J., B. J. Trock, et al. (2009). "The safety of ureteroscopy during pregnancy: a systematic review and meta-analysis." J Urol 181(1): 139-43.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19012926" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Srisubat, A., S. Potisat, et al. (2009). "Extracorporeal shock wave lithotripsy (ESWL) versus percutaneous nephrolithotomy (PCNL) or retrograde intrarenal surgery (RIRS) for kidney stones." Cochrane Database Syst Rev(4): CD007044.&amp;nbsp;[&lt;A href="nelh:327234:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Tzortzis V, Mamoulakis C, Rioja J, Gravas S, Michel MC, de la Rosette JJ. Medical expulsive therapy for distal ureteral stones. Drugs. 2009;69(6):677-92.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19405549" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Zhu, Y., D. Duijvesz, et al. (2009). "alpha-Blockers to assist stone clearance after extracorporeal shock wave lithotripsy: a meta-analysis." BJU Int.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19889063" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;de la Rosette, J. J., P. Tsakiris, et al. (2008). "Beyond prone position in percutaneous nephrolithotomy: a comprehensive review." Eur Urol 54(6): 1262-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18707807" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Heaney, R. P. (2008). "Calcium supplementation and incident kidney stone risk: a systematic review." J Am Coll Nutr 27(5): 519-27.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=2008[pdat]%20AND%20Calcium%20supplementation%20and%20incident%20kidney%20stone%20risk%3A%20a%20systematic%20review" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Losek, R. L. and L. S. Mauro (2008). "Efficacy of tamsulosin with extracorporeal shock wave lithotripsy for passage of renal and ureteral calculi." Ann Pharmacother 42(5): 692-7.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Efficacy%20of%20tamsulosin%20with%20extracorporeal%20shock%20wave%20lithotripsy%20for%20passage%20of%20renal%20and%20ureteral%20calculi" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Semins, M. J., B. J. Trock, et al. (2008). "The effect of shock wave rate on the outcome of shock wave lithotripsy: a meta-analysis." J Urol 179(1): 194-7; discussion 197.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18001796" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Dasgupta, R., J. Glass, et al. (2007). "Kidney stones." Clin Evid (Online) 2007.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=%22Clinical%20evidence%22[Jour]%20AND%202007[pdat]%20AND%20Kidney%20stones" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2006&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;No systematic reviews. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>21/12/2010 10:52:50</lastReviewDate>
    <expiryDate>21/12/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>301368</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://healthguides.mapofmedicine.com/choices/map/kidney_cancer1.html]]&gt;</url>
    <title>Kidney cancer - suspected</title>
    <publicationDate>2008-12-16T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RENAL CANCER,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Web pages from NHS Choices and the Map of Medicine.</description>
    <body>&lt;![CDATA[ This page provides a link to the Map of Medicine view on suspected Kidney cancer.]]&gt;</body>
    <lastReviewDate>26/11/2010 15:26:20</lastReviewDate>
    <expiryDate>26/11/2011 15:26:20</expiryDate>
  </document>
  <document>
    <id>389328</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.kidneycare.nhs.uk/Library/KidneyDiseaseKeyFacts.pdf]]&gt;</url>
    <title>Kidney Disease: Key Facts and Figures</title>
    <publicationDate>2010-09-01T00:00:00</publicationDate>
    <publisher>NHS Kidney Care</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ PRESENTATION OF CKD,INTERVENTIONS,SCREENING OPTIONS,PREDISPOSING FACTORS,ASSESSMENT OF RENAL FUNCTION,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Contents&lt;/STRONG&gt;&lt;/P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;P&gt;Introduction &lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Kidney disease common definitions &lt;BR&gt;1.1 Chronic kidney disease &lt;BR&gt;1.2 Acute kidney injury&lt;BR&gt;1.3 End stage renal disease&lt;/LI&gt;
&lt;LI&gt;How common is kidney disease in England? &lt;BR&gt;2.1 Prevalence of chronic kidney disease &lt;BR&gt;2.2 Incidence of acute kidney injury &lt;BR&gt;2.3 Incidence and prevalence of renal replacement therapy &lt;BR&gt;2.4 Kidney Cancer &lt;/LI&gt;
&lt;LI&gt;What are the health burdens and complications of kidney disease? &lt;BR&gt;3.1 Morbidity and mortality associated with chronic kidney disease &lt;BR&gt;3.2 Acute kidney injury &lt;BR&gt;3.3 Quality of life for people on renal replacement therapy&lt;BR&gt;3.4 Survival on renal replacement therapy &lt;BR&gt;3.5 Mortality from different types of kidney disease &lt;BR&gt;3.6 Mortality and years of life lost from chronic renal failure &lt;/LI&gt;
&lt;LI&gt;What is the cost of kidney disease? &lt;BR&gt;4.1 Cost of healthcare &lt;BR&gt;4.2 Programme budgeting information &lt;BR&gt;4.3 NHS reference cost information&lt;BR&gt;4.4 Healthcare expenditure on kidney disease &lt;BR&gt;4.5 Prescribing costs4.6 Further sources of kidney disease cost information-NHS Comparators &lt;/LI&gt;
&lt;LI&gt;What makes people at risk of developing kidney disease? &lt;BR&gt;5.1 Age &lt;BR&gt;5.2 Gender &lt;BR&gt;5.3 Inheritance of kidney disease &lt;BR&gt;5.4 Ethnicity &lt;BR&gt;5.5 Socio-economic status 5.6 Obesity &lt;BR&gt;5.7 Hypertension &lt;BR&gt;5.8 Diabetes mellitus&lt;BR&gt;5.9 Smoking &lt;/LI&gt;
&lt;LI&gt;Opportunities for prevention and treatment, what can be done? &lt;BR&gt;6.1 Health Survey for England data &lt;BR&gt;6.2 Addressing health inequalities&lt;BR&gt;6.3 Primary prevention of chronic kidney disease &lt;BR&gt;6.4 NICE guidelines and standards for chronic kidney disease &lt;BR&gt;6.5 General Practice Quality and Outcomes Framework &lt;BR&gt;6.6 Indicators for quality improvement &lt;BR&gt;6.7 GP e-learning &lt;BR&gt;6.8 Anaemia management in chronic kidney disease&lt;BR&gt;6.9 Management of end stage renal disease &lt;BR&gt;6.10 End of life care for advanced kidney disease &lt;BR&gt;6.11 Kidney transplant &lt;BR&gt;6.12 Peritoneal dialysis &lt;BR&gt;6.13 Haemodialysis &lt;/LI&gt;
&lt;LI&gt;What is cost effective? &lt;BR&gt;7.1 Early detection and management of chronic kidney disease &lt;BR&gt;7.2 NICE chronic kidney disease guidance &lt;BR&gt;7.3 Timely referral for renal replacement therapy &lt;BR&gt;7.4 Transplantation in end stage renal disease &lt;/LI&gt;
&lt;LI&gt;What is being done? &lt;BR&gt;8.1 Primary prevention &lt;BR&gt;8.2 Vascular Risk Assessment Programme (NHS Health Check) &lt;BR&gt;8.3 Chronic kidney disease detection and management in primary care &lt;BR&gt;8.4 Acceptance rates and prevalence of renal replacement therapy &lt;BR&gt;8.5 Prevalence of renal replacement therapy &lt;/LI&gt;
&lt;LI&gt;How are kidney services arranged and commissioned? &lt;BR&gt;9.1 How services have been delivered &lt;BR&gt;9.2 Kidney Care Networks &lt;BR&gt;9.3 Hospital based kidney care &lt;BR&gt;9.4 Patient awareness &lt;/LI&gt;
&lt;LI&gt;Acknowledgements &lt;/LI&gt;
&lt;LI&gt;Glossary and abbreviations&lt;/LI&gt;
&lt;LI&gt;References&amp;nbsp;&amp;nbsp;&lt;/LI&gt;&lt;BR&gt;&lt;/OL&gt;
&lt;P&gt;&lt;/P&gt;]]&gt;</body>
    <expiryDate>06/10/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>333624</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=333624]]&gt;</url>
    <title>Kidney Diseases: Systematic Reviews and Meta-analyses</title>
    <publicationDate>2011-01-17T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,ACUTE KIDNEY INJURY,COMPLICATIONS OF KIDNEY DISEASE,INHERITED KIDNEY DISEASE,RENOVASCULAR DISEASES,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>The kidney diseases and male urogenital disorders specialist collection team have performed systematic searches to identify up-to-date, high quality evidence for a given topic.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Kidney Diseases: Systematic Reviews and Meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;The specialist collection team have performed systematic searches to identify up-to-date, high quality evidence for a given topic.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;We use the Cochrane Collaboration's definition of a systematic review when sifting and reviewing references:&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;"A review of a clearly formulated question that uses systematic and explicit methods to identify, select, and critically appraise relevant research, and to collect and analyse data from the studies that are included in the review. Statistical methods (meta-analysis) may or may not be used to analyse and summarise the results of the included studies."&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.cochrane.org/glossary/5#letters" target="_blank"&gt;Link to The Cochrane Collaboration Glossary&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;KIDNEY DISEASES:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:332400:0" name=internalLink&gt;Acute Kidney Injury&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:333619:0" name=internalLink&gt;Anaemia&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:388011:0" name=internalLink&gt;Bone disease and kidney disorders&lt;/A&gt;&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:333626:0" name=internalLink&gt;Chronic Kidney Disease&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:333628:0" name=internalLink&gt;Continuous Renal Replacement Therapy&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:333667:0" name=internalLink&gt;Diabetic Nephropathy&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:333679:0" name=internalLink&gt;Dialysis&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:388051:0" name=internalLink&gt;Diet, nutrition and kidney diseases&lt;/A&gt;&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:338779:0" name=internalLink&gt;End-Stage Renal Disease&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:388052:0" name=internalLink&gt;Exercise and kidney diseases&lt;/A&gt;&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:338797:0" name=internalLink&gt;Genetics of Kidney Diseases&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:338800:0" name=internalLink&gt;Glomerulonephritis&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:338824:0" name=internalLink&gt;Henoch-Schönlein purpura&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:338926:0" name=internalLink&gt;Hepatorenal syndrome&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:338975:0" name=internalLink&gt;Hypertension&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:388074:0" name=internalLink&gt;Immunosuppression and kidney diseases&lt;/A&gt;&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:338983:0" name=internalLink&gt;Immunosuppression and organ transplant&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:339010:0" name=internalLink&gt;Kidney and bladder stones&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:339086:0" name=internalLink&gt;Living kidney donors&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:339088:0" name=internalLink&gt;Multicystic dysplastic kidneys&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:339131:0" name=internalLink&gt;Nephrectomy&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:339132:0" name=internalLink&gt;Nephritic syndrome&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:339141:0" name=internalLink&gt;Nephropathies&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:388099:0" name=internalLink&gt;Nephrotic syndrome&lt;/A&gt;&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:388106:0" name=internalLink&gt;Obesity and kidney diseases&lt;/A&gt;&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:339142:0" name=internalLink&gt;Peritoneal dialysis&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:341848:0" name=internalLink&gt;Polycystic kidney disease&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:346856:0" name=internalLink&gt;Pregnancy and kidney diseases&lt;/A&gt;&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:341847:0" name=internalLink&gt;Proteinuria&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/SearchResults.aspx?searchText=%22prostate%20cancer%22%20%22nhs%20evidence%20-%20cancer%22&amp;amp;tabID=289" target="_blank"&gt;Renal cancer&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:341852:0" name=internalLink&gt;Renal function&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:339078:0" name=internalLink&gt;Renal laparoscopy&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:341851:0" name=internalLink&gt;Renal transplant&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:341905:0" name=internalLink&gt;Renovascular disease&lt;/A&gt;&lt;/LI&gt;&lt;A href="nelh:341907:0" name=internalLink&gt;
&lt;LI&gt;Systemic lupus erythematosus&lt;/LI&gt;
&lt;LI&gt;&lt;/A&gt;&lt;A href="nelh:339087:0" name=internalLink&gt;Renal systematic review methodology papers&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;A href="nelh:339087:0" name=internalLink&gt;
&lt;UL&gt;&lt;/A&gt;&lt;/UL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>06/12/2010 12:28:11</lastReviewDate>
    <expiryDate>06/12/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>301369</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://healthguides.mapofmedicine.com/choices/map/kidney_stones1.html]]&gt;</url>
    <title>Kidney stones - suspected</title>
    <publicationDate>2008-12-16T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ KIDNEY AND BLADDER STONES,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Web pages from NHS Choices and the Map of Medicine.</description>
    <body>&lt;![CDATA[ This page provides a link to the Map of Medicine view on suspected Kidney stones.]]&gt;</body>
    <lastReviewDate>26/11/2010 15:26:23</lastReviewDate>
    <expiryDate>26/11/2011 15:26:23</expiryDate>
  </document>
  <document>
    <id>177778</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.dopps.org/d_cdArchive/DoppsCD2006/ppt/Satayathum_tx_KI2005_D37.ppt#258,3,Kidney Transplantation and Wait-Listing Rates from the International Dialysis Outcomes and Practice Patterns Study (DOPPS)]]&gt;</url>
    <title>Kidney transplantation and wait-listing rates from the International Dialysis Outcomes and Practice Patterns Study (DOPPS)</title>
    <publicationDate>2005-10-03T00:00:00</publicationDate>
    <publisher>Kidney International Vol 68 (1) p 330-337</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ TRANSPLANTATION,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Powerpoint presentation from DOPPS</description>
    <body>&lt;![CDATA[ Presentation describes variations in kidney transplant&amp;nbsp;waitlisting in 12 countries, and transplantation rates in 7 countries and associations with patient characteristics.&amp;nbsp;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:25:57</lastReviewDate>
    <expiryDate>06/07/2011 11:25:57</expiryDate>
  </document>
  <document>
    <id>155501</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://renux.dmed.ed.ac.uk/EdREN/Teachingbits/UTI.html]]&gt;</url>
    <title>Learning resource for students - Urinary tract infections</title>
    <publicationDate></publicationDate>
    <publisher>EdRen</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ RENAL TRACT INFECTIONS,LOWER URINARY TRACT INFECTION,UPPER URINARY TRACT INFECTION,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A learning resource from EdREN at the Renal Unit of the Royal Infirmary, Edinburgh</description>
    <body>&lt;![CDATA[ Fact sheet covering predisposing factors, presentation, and UTIs in pregnancy. Management is not covered as this is covered in standard textbooks.]]&gt;</body>
    <lastReviewDate>23/09/2010 16:52:36</lastReviewDate>
    <expiryDate>23/09/2011 16:52:36</expiryDate>
  </document>
  <document>
    <id>330696</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_108825]]&gt;</url>
    <title>Legal issues relevant to non-heartbeating organ donation</title>
    <publicationDate>2009-11-20T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ EMERGENCY CARE,HEALTH MANAGEMENT,POLICY,ETHICS AND STANDARDS,TISSUE DONATION,CONSENT,CLINICAL LIBRARY,ORGANISATIONAL AND OTHER ISSUES,SURGERY,SURGERY,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,TRANSPLANTATION,TRANSPLANT OPERATION,ASSESSMENT/SELECTION,UK TRANSPLANT,TRANSPLANT CENTRES,CLINICAL TOPICS,CRITICAL CARE,KIDNEY DISEASES,CAPACITY,TRANSPLANTATION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The Department of Health's view of the legal position in relation to the action that can be lawfully taken prior to death to support non-heartbeating donation, produced in response to Recommendation 3 of the Organ Donation Taskforce Report which states that 'urgent attention is required to resolve outstanding legal, ethical and professional issues in order to ensure that all clinicians are supported and are able to work within a clear and unambiguous framework of good practice.' The intention is that those working in this area will be able to use it to draw up more detailed guidance to support clinical practice. This guidance is only applicable in England and Wales.</description>
    <body>&lt;![CDATA[ The Department of Health's view of the legal position in relation to the action that can be lawfully taken prior to death to support non-heartbeating donation, produced in response to Recommendation 3 of the Organ Donation Taskforce Report which states that 'urgent attention is required to resolve outstanding legal, ethical and professional issues in order to ensure that all clinicians are supported and are able to work within a clear and unambiguous framework of good practice.' The intention is that those working in this area will be able to use it to draw up more detailed guidance to support clinical practice. This guidance is only applicable in England and Wales.]]&gt;</body>
    <lastReviewDate>25/10/2010 13:47:19</lastReviewDate>
    <expiryDate>25/10/2011 13:47:19</expiryDate>
  </document>
  <document>
    <id>155739</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.renal.org/unit/index.pl?c=leics]]&gt;</url>
    <title>Leicester Renal Unit, Leicester General Hospital</title>
    <publicationDate></publicationDate>
    <publisher>Renal Association</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ TRANSPLANTATION,TRANSPLANT CENTRES,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Contact details and background information</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Extract from webpage&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Leicester General Hospital (LGH) is part of the University Hospitals of Leicester NHS Trust and provides a specialist renal service for the total population Leicestershire, Lincolnshire and Northamptonshire as well as a proportion of the population of Cambridgeshire. The total population served is approximately 2.3 million. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Transplantation&lt;/B&gt; &lt;BR&gt;An active live donor and cadaver (including non-heart beating donor) transplant service is led by Professor M Nicholson. The 14-bedded Transplant Ward cares for both donors and recipients. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The Live Donor Service has a dedicated Senior Nursing team who manage the service and prepares both the donor and patient for transplant. Laparascopic Donor nephrectomy is available. On average, 25 live donor transplants are undertaken each year. This is an expanding service. The cadaver transplant service has 4wte donor nurses and has recently combined rotas with the Trent Network to manage resources more effectively. Approximately 25 cadaver transplants are performed each year.&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>23/09/2010 16:52:43</lastReviewDate>
    <expiryDate>23/09/2011 16:52:43</expiryDate>
  </document>
  <document>
    <id>334841</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.greenerhealthcare.org/podcasts/2009/12/lets-talk-renal-rubbish-mary-thomson]]&gt;</url>
    <title>Let's talk renal rubbish</title>
    <publicationDate>2010-01-14T00:00:00</publicationDate>
    <publisher>The Campaign for Greener Healthcare</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ HAEMODIALYSIS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES,DIALYSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A podcast by Mary Thomson</description>
    <body>&lt;![CDATA[ &lt;P&gt;Mary Thomson has worked in renal nursing for almost 20 years, but in 2005-2008 she took a break and worked in the community, developing a programme for children aged 7-11 yrs to encourage active citizenship. A favourite activity was a visit to the local landfill site, where they saw composting &amp;amp; recycling on a huge scale.&lt;/P&gt;
&lt;P&gt;Returning to the renal unit, Mary was taken aback by the lack of facilitates for segregating waste - 2 different coloured bags - take your pick! The plastic dialysate bottles being put to landfill and not even crushed! She decided to survey colleagues, asking about their recycling practices at home and aiming to find out "what happens to us when we come through the double doors to work"?&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.greenerhealthcare.org/audio/download/254/Lets%20talk%20renal%20rubbish%20with%20Mary%20Thomson.mp3" target="_blank"&gt;Download audio file&lt;/A&gt;&amp;nbsp;(MP3)&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>17/12/2010 11:27:00</lastReviewDate>
    <expiryDate>17/12/2011 11:27:00</expiryDate>
  </document>
  <document>
    <id>155950</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.endoflifecareforadults.nhs.uk/case-studies/lcp]]&gt;</url>
    <title>Liverpool Care of the Dying Pathway (LCP) Leaflet</title>
    <publicationDate>2007-09-03T00:00:00</publicationDate>
    <publisher>Marie Curie</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ END-OF-LIFE CARE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Basic information about the LCP</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;&amp;nbsp;Extract from website&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;General leaflet about the LCP including its key benefits, how the LCP links with other services, and information about how to get involved with the LCP.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>23/09/2010 16:52:58</lastReviewDate>
    <expiryDate>23/09/2011 16:52:58</expiryDate>
  </document>
  <document>
    <id>288233</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_085320]]&gt;</url>
    <title>Liverpool Care Pathway (LCP) guidelines for LCP drug prescribing in advanced chronic kidney disease</title>
    <publicationDate>2008-06-09T00:00:00</publicationDate>
    <publisher>National LCP Renal Steering Group</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ END-OF-LIFE CARE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Prescribing guidelines to ensure best practice in the care of kidney patients during the last weeks or days of their lives</description>
    <body>&lt;![CDATA[ &lt;P&gt;Extract&lt;/P&gt;
&lt;P&gt;Part of the LCP programme to extend LCP to kidney disease.&amp;nbsp;&amp;nbsp;The guidelines were developed by an expert project group, overseen by the LCP Renal Steering Group, and have been endorsed by the Department of Health, the Renal Association and the British Renal Society.&lt;/P&gt;
&lt;P&gt;Contents:&lt;/P&gt;
&lt;P&gt;Introduction&lt;/P&gt;
&lt;P&gt;Pain guidelines&lt;/P&gt;
&lt;P&gt;Opoid conversion table&lt;/P&gt;
&lt;P&gt;Terminal restlessness and agitation guidelines&lt;/P&gt;
&lt;P&gt;Respiratory tract secretions guidelines&lt;/P&gt;
&lt;P&gt;Nausea and vomiting guidelines&lt;/P&gt;
&lt;P&gt;Dyspnoea guidelines&lt;/P&gt;
&lt;P&gt;Project group&lt;/P&gt;
&lt;P&gt;Bibliography&lt;/P&gt;
&lt;P&gt;Contact details&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>23/09/2010 16:53:06</lastReviewDate>
    <expiryDate>23/09/2011 16:53:06</expiryDate>
  </document>
  <document>
    <id>155934</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.cambridge-transplant.org.uk/program/renal/DonorAndRecipientPerspectives.pdf]]&gt;</url>
    <title>Living Donor Kidney Transplantation - Donor and Recipient Perspectives</title>
    <publicationDate>2001-01-01T00:00:00</publicationDate>
    <publisher>In-Vivo Communications UK Ltd</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ TRANSPLANTATION,ASSESSMENT/SELECTION,RECIPIENT,DONOR,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A report looking at donation of a kidney from live donors, who are often related to the recipient, and the receiving individuals.</description>
    <body>&lt;![CDATA[ &lt;P&gt;Report has the following sections:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Making the decision&lt;/LI&gt;
&lt;LI&gt;Match-making&lt;/LI&gt;
&lt;LI&gt;What happens next?&lt;/LI&gt;
&lt;LI&gt;A testing time&lt;/LI&gt;
&lt;LI&gt;What if I am not a suitable donor?&lt;/LI&gt;
&lt;LI&gt;Preparing for the operation&lt;/LI&gt;
&lt;LI&gt;What happens during the operation?&lt;/LI&gt;
&lt;LI&gt;The road to recovery&lt;/LI&gt;
&lt;LI&gt;No more dialysis!&lt;/LI&gt;
&lt;LI&gt;Life with one kidney&lt;/LI&gt;
&lt;LI&gt;Looking after your transplant&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
    <expiryDate>01/09/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>339086</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=339086]]&gt;</url>
    <title>Living kidney donors: Systematic reviews and meta-analyses</title>
    <publicationDate>2010-11-15T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ TRANSPLANT OPERATION,ASSESSMENT/SELECTION,DONOR,TRANSPLANTATION,UK TRANSPLANT,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Living kidney donors: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Butt, Z., S. E. Jensen, et al. (2010). "What is the quality of life impact of living donor nephrectomy?" Clinical and Translational Science 3(2). [No abstract available]&lt;/LI&gt;
&lt;LI&gt;Greco, F., M. R. Hoda, et al. (2010). "Laparoscopic living-donor nephrectomy: analysis of the existing literature." European Urology 58(4): 498-509. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Laparoscopic%20living-donor%20nephrectomy%3A%20analysis%20of%20the%20existing%20literature" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Antcliffe, D., T. G. Nanidis, et al. (2009). "A meta-analysis of mini-open versus standard open and laparoscopic living donor nephrectomy." Transpl Int 22(4): 463-74.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19175543" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Iordanous, Y., N. Seymour, et al. (2009). "Recipient Outcomes for Expanded Criteria Living Kidney Donors: The Disconnect Between Current Evidence and Practice." Am J Transplant.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19459792" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Kranenburg, L., W. Zuidema, et al. (2008). "The psychological evaluation of Samaritan kidney donors: a systematic review." Psychol Med 38(2): 177-85.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17617934" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Young, A., L. Storsley, et al. (2008). "Health outcomes for living kidney donors with isolated medical abnormalities: a systematic review." Am J Transplant 8(9): 1878-90.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18671676" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Shokeir, A. A. (2007). "Open versus laparoscopic live donor nephrectomy: a focus on the safety of donors and the need for a donor registry." J Urol 178(5): 1860-6.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17868736" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Yang, R. C., H. Thiessen-Philbrook, et al. (2007). "Insurability of living organ donors: a systematic review." Am J Transplant 7(6): 1542-51.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17430400" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Young, A., I. F. Nevis, et al. (2007). "Do biochemical measures change in living kidney donors? A systematic review." Nephron Clin Pract 107(3): c82-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17890875" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2006&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Clemens, K. K., H. Thiessen-Philbrook, et al. (2006). "Psychosocial health of living kidney donors: a systematic review." Am J Transplant 6(12): 2965-77.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17294524" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Garg, A. X., N. Muirhead, et al. (2006). "Proteinuria and reduced kidney function in living kidney donors: A systematic review, meta-analysis, and meta-regression." Kidney Int 70(10): 1801-10. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17003822" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>21/12/2010 10:52:53</lastReviewDate>
    <expiryDate>21/12/2011 10:52:53</expiryDate>
  </document>
  <document>
    <id>182509</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://ndt.oxfordjournals.org/cgi/reprint/17/suppl_4/55]]&gt;</url>
    <title>Long term management of the transplant recipient - Paediatrics</title>
    <publicationDate>2002-04-01T00:00:00</publicationDate>
    <publisher>European Best Practice Guidelines Expert Group on Renal Transplantation</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ TRANSPLANTATION,KIDNEY DISEASE IN CHILDREN AND ADOLESCENTS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Section IV.II of European Best Practice Guidelines (EBPG)</description>
    <body>&lt;![CDATA[ European Best Practice Guideline]]&gt;</body>
    <expiryDate>05/10/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>387221</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://learning.bmj.com/learning/search-result.html?moduleId=10016753&amp;utm_campaign=7892495&amp;utm_content=50109010011&amp;utm_medium=email&amp;utm_source=Emailvision]]&gt;</url>
    <title>Lower urinary tract symptoms in men: a guide to management - in association with NICE</title>
    <publicationDate>2010-09-06T00:00:00</publicationDate>
    <publisher>BMJ Learning</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE URINARY INCONTINENCE,PENILE DISORDERS,MALE BLADDER DISORDERS,TESTICULAR/ SCROTAL DISORDERS,PROSTATE DISORDERS,MALE URETERIC DISORDERS,MALE URETHRAL DISORDERS,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>BMJ Learning Module - for BMA Members</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Module type&lt;/STRONG&gt;&amp;nbsp; &amp;nbsp; &lt;/P&gt;
&lt;P&gt;Interactive case history&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Use these interactive modules to learn as we guide you through a real life consultation. Before you start a learning resource it is best to add it to your plan first.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;What's in this case:&lt;/STRONG&gt; &amp;nbsp;&lt;/P&gt;
&lt;P&gt;Lower urinary tract symptoms in men: a guide to management - in association with NICE&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Target audience&lt;/STRONG&gt; &amp;nbsp;&lt;/P&gt;
&lt;P&gt;All audiences&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Author:&lt;/STRONG&gt; &amp;nbsp;&lt;/P&gt;
&lt;P&gt;BMJ Learning with NICE&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Biography: &amp;nbsp;This module has been produced by BMJ Learning in collaboration with NICE.&lt;BR&gt;Resource provider: &amp;nbsp;BMJ&lt;/P&gt;]]&gt;</body>
    <expiryDate>06/09/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>156068</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.ndt-educational.org/moronicase.asp]]&gt;</url>
    <title>Lupus Nephritis:case presentation</title>
    <publicationDate>2003-12-08T00:00:00</publicationDate>
    <publisher>ERA-EDTA in collaboration with Renal Pathology Society</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ OTHER CONDITIONS - ADULTS,SLE-RELATED,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Case presentation from CME Course on Renal Pathology</description>
    <body>&lt;![CDATA[ &lt;P&gt;5 questions with multiple choice answers&lt;/P&gt;
&lt;P&gt;1. What is the probability of have a focal or diffuse proliferative lupus nephritis at renal biopsy (class III or ClassIV WHO) in a patient with urinary abnormalities without nephrotic syndrome or renal insufficiency?&lt;/P&gt;
&lt;P&gt;2. What would you do with therapy when a patient with diffuse proliferative lupus nephritis enters complete clinical remission?&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;3. The literature being controversial as regards the significance of anti-DNA antibodies, what could be the most useful serological test to confirm the clinical diagnosis of a renal flare?&lt;/P&gt;
&lt;P&gt;4. What is the rate of transformation of diffuse proliferative lupus nephritis (Class IV) into membranous lupus nephritis (Class V) ?&lt;/P&gt;
&lt;P&gt;5. What therapy would you administer to a patient with lupus nephritis and positive antiphospholipid antibodies after a serious thrombotic event? &lt;/P&gt;
&lt;P align=center&gt;&lt;FONT face="Verdana, Arial, Helvetica, sans-serif" size=2&gt;&lt;/FONT&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:26:08</lastReviewDate>
    <expiryDate>06/07/2011 11:26:08</expiryDate>
  </document>
  <document>
    <id>321826</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=321826]]&gt;</url>
    <title>Male bladder disorders: Systematic reviews and meta-analyses</title>
    <publicationDate>2010-11-15T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE BLADDER DISORDERS,MALE UROGENITAL DISORDERS,OVERACTIVE BLADDER]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Male bladder disorders: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Buckley BS, Lapitan MCM. Drugs for treatment of urinary retention after surgery in adults. Cochrane Database of Systematic Reviews 2010, Issue 10. Art. No.: CD008023. DOI: 10.1002/14651858.CD008023.pub2. [&lt;A href="nelh:389407:0" name=internalLink&gt;Link to Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kanai, A. and K. E. Andersson (2010). "Bladder afferent signaling: recent findings." Journal of Urology 183(4): 1288-1295. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20171668" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Morris, R. K., G. L. Malin, et al. (2010). "Systematic review of the effectiveness of antenatal intervention for the treatment of congenital lower urinary tract obstruction." BJOG: An International Journal of Obstetrics and Gynaecology 117(4): 382-390. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Systematic%20review%20of%20the%20effectiveness%20of%20antenatal%20intervention%20for%20the%20treatment%20of%20congenital%20lower%20urinary%20tract%20obstruction" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;&lt;STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;/STRONG&gt;Biastre, K. and T. Burnakis (2009). "Trospium chloride treatment of overactive bladder." Ann Pharmacother 43(2): 283-95. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19193592?ordinalpos=3&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Elgavish, A. (2009). "Epigenetic reprogramming: a possible etiological factor in bladder pain syndrome/interstitial cystitis?" Journal of Urology 181(3): 980-4.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19150095" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Game, X., P. Mouracade, et al. (2009). "Botulinum toxin-A (Botox) intradetrusor injections in children with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review." Journal of pediatric urology 5(3): 156-64.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19264554" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Krishnamoorthy S, Kekre NS. Detrusor underactivity: To tone or not to tone the bladder? Indian Journal of Urology. 2009;25(3):407-8. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19881143" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Ksibi I, Godard AL, Azouvi P, Denys P, Dziri C. Botulinum toxin and refractory non-neurogenic overactive detrusor. Annals of Physical and Rehabilitation Medicine. 2009;52(9):668-83.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19729357" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Roosen A, Chapple CR, Dmochowski RR, Fowler CJ, Gratzke C, Roehrborn CG, et al. A Refocus on the Bladder as the Originator of Storage Lower Urinary Tract Symptoms: A Systematic Review of the Latest Literature. European Urology. 2009;56(5):810-20.&amp;nbsp;[&lt;A href="https://rmsadmin.library.nhs.uk/admin/wizards/articles/A%20Refocus%20on%20the%20Bladder%20as%20the%20Originator%20of%20Storage%20Lower%20Urinary%20Tract%20Symptoms:%20A%20Systematic%20Review%20of%20the%20Latest%20Literature" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Somani BK, Nabi G, Wong S, Lyttle M, Atiemo K, McPherson G, et al. How Close Are We to Knowing Whether Orthotopic Bladder Replacement Surgery Is the New Gold Standard?-Evidence From a Systematic Review Update. Urology. 2009;74(6):1331-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19800669" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Tuon, F. F., V. S. Amato, et al. (2009). "Bladder irrigation with amphotericin B and fungal urinary tract infection-systematic review with meta-analysis." Int J Infect Dis.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19155184" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Chapple, C. R., V. Khullar, et al. (2008). "The Effects of Antimuscarinic Treatments in Overactive Bladder: An Update of a Systematic Review and Meta-Analysis." European Urology 54(3): 543-562.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18599186?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;DeLong, W. B., N. Polissar, et al. (2008). "Timing of surgery in cauda equina syndrome with urinary retention: Meta-analysis of observational studies." Journal of Neurosurgery: Spine 8(4): 305-320.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18377315" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Drake, M. J. (2008). "Emerging drugs for treatment of overactive bladder and detrusor overactivity." Expert Opinion on Emerging Drugs 13(3): 431-46.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18764721?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Drekonja, D. M., M. A. Kuskowski, et al. (2008). "Antimicrobial urinary catheters: A systematic review." Expert Review of Medical Devices 5(4): 495-506.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18573048?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Feifer, A. and J. Corcos (2008). "Contemporary role of suprapubic cystostomy in treatment of neuropathic bladder dysfunction in spinal cord injured patients." Neurourology &amp;amp; Urodynamics 27(6): 475-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18551568" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Guerra, L. A., D. Moher, et al. (2008). "Intravesical Oxybutynin for Children With Poorly Compliant Neurogenic Bladder: A Systematic Review." Journal of Urology 180(3): 1091-1097.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18639290" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Karsenty, G., P. Denys, et al. (2008). "Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review." Eur Urol 53(2): 275-87.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17988791" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Michel, M. C. (2008). "Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome." Expert Opinion on Pharmacotherapy 9(10): 1787-96.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18570610" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mota, D. M. and A. J. Barros (2008). "Toilet training: methods, parental expectations and associated dysfunctions." Jornal de Pediatria 84(1): 9-17.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18264618" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Novara, G., A. Galfano, et al. (2008). "A Systematic Review and Meta-Analysis of Randomized Controlled Trials with Antimuscarinic Drugs for Overactive Bladder." European Urology 54(4): 740-764.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18632201?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Salvatore, S., M. Serati, et al. (2008). "Tolterodine for the treatment of overactive bladder." Expert Opinion on Pharmacotherapy 9(7): 1249-1255.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=%22Expert%20opinion%20on%20pharmacotherapy%22[Jour]%20AND%202008[pdat]%20AND%20salvatore[author]%20AND%20Tolterodine%20for%20the%20treatment%20of%20overactive%20bladder" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Schout, B. M. A., A. J. M. Hendrikx, et al. (2008). "Update on Training Models in Endourology: A Qualitative Systematic Review of the Literature between January 1980 and April 2008." European Urology 54(6): 1247-1261.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18597924?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Duthie, J., D. I. Wilson, et al. (2007). "Botulinum toxin injections for adults with overactive bladder syndrome." Cochrane Database Syst Rev(3): CD005493.&amp;nbsp;[&lt;A href="nelh:266549:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Roxburgh, C., J. Cook, et al. (2007). "Anticholinergic drugs versus other medications for overactive bladder syndrome in adults." Cochrane Database Syst Rev(3): CD003190.&amp;nbsp;[&lt;A href="nelh:266489:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2006&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Abrams, P., W. Artibani, et al. (2006). "Assessment of treatment outcomes in patients with overactive bladder: importance of objective and subjective measures." Urology 68(2 Suppl): 17-28.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16908337" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Alhasso, A. A., J. McKinlay, et al. (2006). "Anticholinergic drugs versus non-drug active therapies for overactive bladder syndrome in adults." Cochrane Database Syst Rev(4): CD003193.&amp;nbsp;[&lt;A href="nelh:237813:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Khullar, V., C. Chapple, et al. (2006). "The effects of antimuscarinics on health-related quality of life in overactive bladder: a systematic review and meta-analysis." Urology 68(2 Suppl): 38-48.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16908339?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Maniscalco, M., D. Singh-Franco, et al. (2006). "Solifenacin succinate for the treatment of symptoms of overactive bladder." Clin Ther 28(9): 1247-72.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17062299?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;McPhail, M. J., M. Abu-Hilal, et al. (2006). "A meta-analysis comparing suprapubic and transurethral catheterization for bladder drainage after abdominal surgery." Br J Surg 93(9): 1038-44.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16804872" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Nabi, G., J. D. Cody, et al. (2006). "Anticholinergic drugs versus placebo for overactive bladder syndrome in adults." Cochrane Database Syst Rev(4): CD003781.&amp;nbsp;[&lt;A href="nelh:238499:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Novara, G., A. Galfano, et al. (2006). "Anticholinergic drugs in patients with bladder outlet obstruction and lower urinary tract symptoms: A systematic review." Eur Urol 50(4): 675-83.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16930813?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Patel, A. K., J. M. Patterson, et al. (2006). "The emerging role of intravesical botulinum toxin therapy in idiopathic detrusor overactivity." Int J Clin Pract Suppl(151): 27-32.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17169008" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Patel, A. K., J. M. Patterson, et al. (2006). "Botulinum toxin injections for neurogenic and idiopathic detrusor overactivity: A critical analysis of results." Eur Urol 50(4): 684-709; discussion 709-10.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16934391" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Rasco, D. W., V. Assikis, et al. (2006). "Integrating metastasectomy in the management of advanced urological malignancies-where are we in 2005?" J Urol 176(5): 1921-6.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17070212" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Tulikangas, P. K., A. Ayers, et al. (2006). "A meta-analysis comparing trials of antimuscarinic medications funded by industry or not." BJU Int 98(2): 377-80.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16879680" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:20:03</lastReviewDate>
    <expiryDate>06/07/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>321990</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=321990]]&gt;</url>
    <title>Male breast cancer: Systematic reviews and meta-analyses</title>
    <publicationDate>2010-09-09T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Male breast cancer: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Grenader, T., A. Goldberg, et al. (2008). "Second cancers in patients with male breast cancer: a literature review." Journal of Cancer Survivorship 2(2): 73-8. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18648975?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Agrawal A, Ayantunde AA, Rampaul R, Robertson JF. Male breast cancer: a review of clinical management. Breast Cancer Res Treat. 2007 May; 103(1):11-21. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17033919" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>16/07/2010 14:33:22</lastReviewDate>
    <expiryDate>16/07/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>321988</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=321988]]&gt;</url>
    <title>Male contraceptives: Systematic reviews and meta-analyses</title>
    <publicationDate>2010-09-09T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,FERTILITY,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Male contraceptives: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Grimes, D. A., L. M. Lopez, et al. (2007). "Steroid hormones for contraception in men." Cochrane Database Syst Rev(2): CD004316. [&lt;A href="nelh:238586:0" name=internalLink&gt;Link to Cochrane abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;2006&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Leridon, H. (2006). "Demographic effects of the introduction of steroid contraception in developed countries." Hum Reprod Update 12(5): 603-16. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16775191?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>16/07/2010 14:33:27</lastReviewDate>
    <expiryDate>16/07/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>321989</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=321989]]&gt;</url>
    <title>Male public health: Systematic reviews and meta-analyses</title>
    <publicationDate>2010-09-09T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Male public health: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Robertson, L. M., F. Douglas, et al. (2008). "What works with men? A systematic review of health promoting interventions targeting men." BMC Health Services Research 8. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18598339" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>16/07/2010 14:33:31</lastReviewDate>
    <expiryDate>16/07/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>321825</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=321825]]&gt;</url>
    <title>Male Sexually Transmitted Infections:  Systematic reviews and meta-analyses</title>
    <publicationDate>2010-09-10T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE SEXUALLY TRANSMITTED INFECTIONS,PENILE DISORDERS,CIRCUMCISION,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Male Sexually Transmitted Infections:  Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Bailey JV, Murray E, Rait G, Mercer CH, Morris RW, Peacock R, Cassell J, Nazareth I. (2010) "Interactive computer-based interventions for sexual health promotion". Cochrane Database Syst Rev. 2010 Sep 8;9. [&lt;A href="nelh:387486:0" name=internalLink&gt;Link to Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Caceres, C. F., K. Konda, et al. (2008). "Epidemiology of male same-sex behaviour and associated sexual health indicators in low- and middle-income countries: 2003-2007 Estimates." Sexually Transmitted Infections 84(SUPPL. 1): i49-i56. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18647866" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Darbes, L., N. Crepaz, et al. (2008). "The efficacy of behavioral interventions in reducing HIV risk behaviors and incident sexually transmitted diseases in heterosexual African Americans." AIDS 22(10): 1177-1194.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18525264" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lin, J. S., E. Whitlock, et al. (2008). "Behavioral counseling to prevent sexually transmitted infections: A systematic review for the U.S. Preventive Services Task Force." Annals of Internal Medicine 149(7): 497-508.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18838730?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Trelle, S., A. Shang, et al. (2007). "Improved effectiveness of partner notification for patients with sexually transmitted infections: systematic review." BMJ 334(7589): 354.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17237298" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Van Howe, R. S. (2007). "Genital ulcerative disease and sexually transmitted urethritis and circumcision: a meta-analysis." Int J STD AIDS 18(12): 799-809.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18073009" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Van Howe, R. S. (2007). "Human papillomavirus and circumcision: a meta-analysis." J Infect 54(5): 490-6.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16997378?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;2006&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Centers for Disease, C., Prevention, et al. (2006). "Sexually transmitted diseases treatment guidelines, 2006." MMWR Recomm Rep 55(RR-11): 1-94.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=%22MMWR.%20Recommendations%20and%20reports%20%3A%20Morbidity%20and%20mortality%20weekly%20report.%20Recommendations%20and%20reports%20%2F%20Centers%20for%20Disease%20Control%22[Jour]%20AND%202006[pdat]%20AND%20Sexually%20transmitted%20diseases%20treatment%20guidelines%2C%202006" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:20:07</lastReviewDate>
    <expiryDate>06/07/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>321828</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=321828]]&gt;</url>
    <title>Male ureteric disorders: Systematic reviews and meta-analyses</title>
    <publicationDate>2010-11-25T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE URETERIC DISORDERS,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Male ureteric disorders: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Lamb, A. D., S. L. Vowler, et al. (2010). "Meta-analysis demonstrating beneficial effect of alpha blockers on ureteric stent discomfort." Journal of Endourology 24. [No PubMed abstract available].&lt;/LI&gt;
&lt;LI&gt;Singh, I. and A. K. Hemal (2010). "Robot-assisted pyeloplasty: review of the current literature, technique and outcome." Canadian Journal of Urology 17(2): 5099-108. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20398449" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Buscarini, M. and M. Conlin (2008). "Update on flexible ureteroscopy." Urologia Internationalis 80(1): 1-7. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18204225?ordinalpos=3&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Demede, D. and P. Mouriquand (2008). "Vesicoureteral reflux: why we can't agree on its management! An evidence based approach." Arch Esp Urol 61(2): 160-6.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18491730" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Escribano Subias, J. and G. Fraga Rodriguez (2008). "[Conservative versus interventional treatment of primary vesicoureteral reflux in children]. [Spanish] Tratamiento medico-conservador versus intervencionista del reflujo vesicoureteral primario en el nino." Archivos Espanoles de Urologia 61(2): 229-35.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18491739" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Makarov, D. V., B. J. Trock, et al. (2008). "The Effect of Ureteral Stent Placement on Post-ureteroscopy Complications: A Meta-analysis." Urology 71(5): 796-800.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18342924" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Schout, B. M. A., A. J. M. Hendrikx, et al. (2008). "Update on Training Models in Endourology: A Qualitative Systematic Review of the Literature between January 1980 and April 2008." European Urology 54(6): 1247-1261.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18597924?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Nabi, G., J. Cook, et al. (2007). "Outcomes of stenting after uncomplicated ureteroscopy: systematic review and meta-analysis." BMJ 334(7593): 572.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17311851" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2006&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Maillart, E., L. Laueriere, et al. (2006). "[Is there an evidence-based management of idiopathic retroperitoneal fibrosis?]." Rev Med Interne 27(11): 854-7.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16872722?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:20:16</lastReviewDate>
    <expiryDate>06/07/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>321827</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=321827]]&gt;</url>
    <title>Male urethral disorders:  Systematic reviews and meta-analyses</title>
    <publicationDate>2010-11-25T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE URETHRAL DISORDERS,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Male urethral disorders:  Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Martinez-Pineiro L, Djakovic N, Plas N, Mor Y, Santucci RA, Serafetinidis E, et al. EAU Guidelines on Urethral Trauma. Eur Urol.&amp;nbsp; Jan 20. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20122789" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Routh, J. C., S. M. McGee, et al. (2010). "Predicting renal outcomes in children with anterior urethral valves: A systematic review." Journal of Urology 184(4 SUPPL.): 1615-1619. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20728183" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;None retrieved.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Daneshgari, F., W. Kong, et al. (2008). "Complications of mid urethral slings: important outcomes for future clinical trials." Journal of Urology 180(5): 1890-7.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18801499" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hosseini, J. and K. Tavakkoli Tabassi (2008). "Surgical repair of posterior urethral defects: review of literature and presentation of experiences." Urology Journal 5(4): 215-22.&amp;nbsp;[Li&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19101893" target="_blank"&gt;nk to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Markiewicz, M. R., J. L. DeSantis, et al. (2008). "Morbidity associated with oral mucosa harvest for urological reconstruction: an overview." Journal of Oral &amp;amp; Maxillofacial Surgery 66(4): 739-44.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18355598" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Moreno Sierra, J., S. Prieto Nogal, et al. (2008). "[The usefulness of laser in the treatment of urethral stenosis]. [Spanish] Utilidad del laser en el tratamiento de las estenosis uretrales." Archivos Espanoles de Urologia 61(9): 978-84.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19140578" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Schonbucher, V. B., D. M. Weber, et al. (2008). "Psychosocial adjustment, health-related quality of life, and psychosexual development of boys with hypospadias: a systematic review." Journal of Pediatric Psychology 33(5): 520-35.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18056145" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Schout, B. M. A., A. J. M. Hendrikx, et al. (2008). "Update on Training Models in Endourology: A Qualitative Systematic Review of the Literature between January 1980 and April 2008." European Urology 54(6): 1247-1261.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18597924?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Sung, V. W., M. D. Schleinitz, et al. (2007). "Comparison of retropubic vs transobturator approach to midurethral slings: a systematic review and meta-analysis." Am J Obstet Gynecol 197(1): 3-11. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17618742" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:20:20</lastReviewDate>
    <expiryDate>06/07/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>321830</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=321830]]&gt;</url>
    <title>Male urinary incontinence: Systematic reviews and meta-analyses</title>
    <publicationDate>2011-02-21T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE URINARY INCONTINENCE,MALE BLADDER DISORDERS,MALE UROGENITAL DISORDERS,OVERACTIVE BLADDER]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Male urinary incontinence: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2011&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Roe B, Flanagan L, Jack B, Barrett J, Chung A, Shaw C, et al. Systematic review of the management of incontinence and promotion of continence in older people in care homes: descriptive studies with urinary incontinence as primary focus. Journal of Advanced Nursing. 2011;67(2):228-50. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/21105895" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Anger, J. T., A. Weinberg, et al. (2010). "Outcomes of intravesical botulinum toxin for idiopathic overactive bladder symptoms: a systematic review of the literature." Journal of Urology 183(6): 2258-2264. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20400142" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Bartoli, S., G. Aguzzi, et al. (2010). "Impact on Quality of Life of Urinary Incontinence and Overactive Bladder: A Systematic Literature Review." Urology 75(3): 491-500.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19962738" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Bosch, J. L. and J. P. Weiss (2010). "The prevalence and causes of nocturia." Journal of Urology 184(2): 440-6.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20620395" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Buckley, B. S., A. M. Grant, et al. (2010). "Prioritizing research: Patients, carers, and clinicians working together to identify and prioritize important clinical uncertainties in urinary incontinence." Neurourology &amp;amp; Urodynamics 29(5): 708-14.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19771595" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hagglund, D. (2010). "A systematic literature review of incontinence care for persons with dementia: the research evidence." Journal of Clinical Nursing 19(3-4): 303-312.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/%2020500269" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hollingsworth, J. M. and J. T. Wei (2010). "Does the combination of an alpha1-adrenergic antagonist with a 5alpha-reductase inhibitor improve urinary symptoms more than either monotherapy?" Current Opinion in Urology 20(1): 1-6.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19881352" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Irwin, D. E., I. Milsom, et al. (2010). "Dynamic progression of overactive bladder and urinary incontinence symptoms: A systematic review." European Urology 58(4): 532-543. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20573443" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kessler, T. M., L. M. Bachmann, et al. (2010). "Adverse event assessment of antimuscarinics for treating overactive bladder: A network meta-analytic approach." European Urology, Supplements 9(2).&amp;nbsp;[No abstract available]&lt;/LI&gt;
&lt;LI&gt;Loughlin, K. R. and M. M. Prasad (2010). "Post-prostatectomy urinary incontinence: a confluence of 3 factors." Journal of Urology 183(3): 871-877.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20083262" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Siddiqui, N. Y., J. M. Wu, et al. (2010). "Efficacy and adverse events of sacral nerve stimulation for overactive bladder: A systematic review." Neurourology &amp;amp; Urodynamics 29 Suppl 1: S18-23.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20419795" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Walz, J., A. L. Burnett, et al. (2010). "A critical analysis of the current knowledge of surgical anatomy related to optimization of cancer control and preservation of continence and erection in candidates for radical prostatectomy." European Urology 57(2): 179-92. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19931974" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Bauer RM, Bastian PJ, Gozzi C, Stief CG. Postprostatectomy incontinence: all about diagnosis and management. European Urology. 2009;55(2):322-33. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18963418" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Beeckman D, Schoonhoven L, Verhaeghe S, Heyneman A, Defloor T. Prevention and treatment of incontinence-associated dermatitis: literature review. Journal of Advanced Nursing. 2009;65(6):1141-54.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19374674" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Bergmann M, Corigliano T, Ataia I, Renella R, Simonetti GD, Bianchetti MG, et al. Childhood extraordinary daytime urinary frequency-a case series and a systematic literature review. Pediatric Nephrology. 2009;24(4):789-95.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19093136" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Biastre K, Burnakis T. Trospium chloride treatment of overactive bladder. Annals of Pharmacotherapy. 2009;43(2):283-95. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19193592" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Campbell JD, Gries KS, Watanabe JH, Ravelo A, Dmochowski RR, Sullivan SD.&amp;nbsp; Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidence. BMC Urology 2009; 9(1):18 [&lt;A href="nelh:379193:0" name=internalLink&gt;Link to DARE abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Chiarelli, P. E., L. A. Mackenzie, et al. (2009). "Urinary incontinence is associated with an increase in falls: a systematic review." Australian Journal of Physiotherapy 55(2): 89-95. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19463079?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;DasGupta, R. and F. L. Murphy (2009). "Botulinum toxin in paediatric urology: A systematic literature review." Pediatric Surgery International 25(1): 19-23.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18953547?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Game X, Mouracade P, Chartier-Kastler E, Viehweger E, Moog R, Amarenco G, et al. Botulinum toxin-A (Botox) intradetrusor injections in children with neurogenic detrusor overactivity/neurogenic overactive bladder: A systematic literature review. Journal of pediatric urology. 2009;5(3):156-64.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19264554" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Herbison GP, Arnold EP. Sacral neuromodulation with implanted devices for urinary storage and voiding dysfunction in adults. Cochrane Database of Systematic Reviews. 2009(2). [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19370596" target="_blank"&gt;Link to&amp;nbsp;PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Ksibi I, Godard AL, Azouvi P, Denys P, Dziri C. Botulinum toxin and refractory non-neurogenic overactive detrusor. Annals of Physical and Rehabilitation Medicine. 2009;52(9):668-83.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19729357" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lee S, Malhotra B, Creanga D, Carlsson M, Glue P. A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder. BMC Medical Research Methodology. 2009;9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19624824" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mathis S, Guba B, Adlbrecht C, Pramesberger C. Stress urinary incontinence. Evidence for 4 minimally invasive methods of treating - Systematic overview. Urologe - Ausgabe A. 2009;48(11):1330-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19690828" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Natarajan V, Master V, Ogan K. Effects of obesity and weight loss in patients with nononcological urological disease. Journal of Urology. 2009;181(6):2424-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19371912" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Offermans, M. P., M. F. Du Moulin, et al. (2009). "Prevalence of urinary incontinence and associated risk factors in nursing home residents: a systematic review." Neurourology &amp;amp; Urodynamics 28(4): 288-94.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19191259?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Tzefos M, Dolder C, Olin JL. Fesoterodine for the treatment of overactive bladder. Ann Pharmacother. 2009 Dec;43(12):1992-2000.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19920160" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Zeif HJ, Subramonian K. Alpha blockers prior to removal of a catheter for acute urinary retention in adult men. Cochrane Database of Systematic Reviews. 2009(4).&amp;nbsp;[&lt;A href="nelh:327202:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Fader, M., A. M. Cottenden, et al. (2008). "Absorbent products for moderate-heavy urinary and/or faecal incontinence in women and men." Cochrane Database of Systematic Reviews(4).&amp;nbsp;[&lt;A href="nelh:295760:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Fink, H. A., B. C. Taylor, et al. (2008). "Treatment interventions in nursing home residents with urinary incontinence: A systematic review of randomized trials." Mayo Clinic Proceedings 83(12): 1332-1343.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19046552?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;MacDonald, R., M. Monga, et al. (2008). "Neurotoxin treatments for urinary incontinence in subjects with spinal cord injury or multiple sclerosis: A systematic review of effectiveness and adverse effects." Journal of Spinal Cord Medicine 31(2): 157-165.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18581662" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Marshall, L. L. and W. Baliey (2008). "Urinary incontinence management in geriatric patients." Consultant Pharmacist 23(9): 681-94.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19032011?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Thomas, L. H., S. Cross, et al. (2008). "Treatment of urinary incontinence after stroke in adults." Cochrane Database of Systematic Reviews(1).&amp;nbsp;[&lt;A href="nelh:238685:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Allen, H. A., J. C. Austin, et al. (2007). "Initial trial of timed voiding is warranted for all children with daytime incontinence." Urology 69(5): 962-5.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17482943" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hunter, K. F., C. M. Glazener, et al. (2007). "Conservative management for postprostatectomy urinary incontinence." Cochrane Database Syst Rev(2): CD001843.&amp;nbsp;[&lt;A href="nelh:237130:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;MacDonald, R., H. A. Fink, et al. (2007). "Botulinum toxin for treatment of urinary incontinence due to detrusor overactivity: a systematic review of effectiveness and adverse effects." Spinal Cord 45(8): 535-41.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17453012" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;MacDonald, R., H. A. Fink, et al. (2007). "Pelvic floor muscle training to improve urinary incontinence after radical prostatectomy: a systematic review of effectiveness." BJU Int 100(1): 76-81.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17433028?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mochtar, C. A., P. C. Kauer, et al. (2007). "Urinary leakage after laparoscopic radical prostatectomy: a systematic review." J Endourol 21(11): 1371-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18042033?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Romero Otero, J. and J. I. Martinez-Salamanca (2007). "[Critical comparative analysis between open, laparoscopic and robotic radical prostatectomy: urinary continence and sexual function (part II)]." Arch Esp Urol 60(7): 767-76.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17937336" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Shamliyan, T., J. Wyman, et al. (2007). "Prevention of urinary and fecal incontinence in adults." Evidence Report/Technology Assessment(161): 1-379.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18457475?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;2006&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Cambio, A. J. and C. P. Evans (2006). "Minimising postoperative incontinence following radical prostatectomy: considerations and evidence." Eur Urol 50(5): 903-13; discussion 913. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16956715" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Klassen, T. P., D. Kiddoo, et al. (2006). "The effectiveness of different methods of toilet training for bowel and bladder control." Evid Rep Technol Assess (Full Rep)(147): 1-57.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17764212" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Nahon, I., G. Dorey, et al. (2006). "Systematic review of the treatment of post-prostatectomy incontinence." Urol Nurs 26(6): 461-75, 482. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17253081?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;van Gerwen, M. and A. L. Lagro-Janssen (2006). "[Diagnostic value of patient history and physical examination in elderly patients with urinary incontinence; a literature review]." Ned Tijdschr Geneeskd 150(32): 1771-5.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16948239?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Wilbert-Herr, I. S., U. Hurlimann, et al. (2006). "[Managing urinary incontinence in stroke rehabilitation--a review]." Rehabilitation (Stuttg) 45(5): 289-98.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17024613" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:20:25</lastReviewDate>
    <expiryDate>02/08/2012 00:00:00</expiryDate>
  </document>
  <document>
    <id>323304</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=323304]]&gt;</url>
    <title>Male Urogenital Disorders: Systematic Reviews and Meta-analyses</title>
    <publicationDate>2010-11-22T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,VIRAL,BACTERIAL,FERTILITY,HYPOSPADIAS,URINARY RETENTION,MALE SEXUALLY TRANSMITTED INFECTIONS,URETEROCELE,MALE URETHRAL DISORDERS,URETERIC OBSTRUCTION,URETERIC STONES,PENILE PAIN,MALE URETERIC DISORDERS,PROSTATITIS,TESTICULAR/ SCROTAL DISORDERS,BENIGN PROSTATE ENLARGEMENT,PROSTATE CANCER,MALE URINARY INCONTINENCE,MALE BLADDER DISORDERS,ERECTILE DYSFUNCTION,PENILE DISORDERS,CYSTITIS,BLADDER STONES,PEYRONIE'S DISEASE,PRIAPISM,PROSTATE DISORDERS,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Male Urogenital Disorders: Systematic Reviews and Meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;The specialist collection team have performed systematic searches to identify up-to-date, high quality evidence for a given topic.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;We use the Cochrane Collaboration's definition of a systematic review when sifting and reviewing references:&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;"A review of a clearly formulated question that uses systematic and explicit methods to identify, select, and critically appraise relevant research, and to collect and analyse data from the studies that are included in the review. Statistical methods (meta-analysis) may or may not be used to analyse and summarise the results of the included studies."&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.cochrane.org/glossary/5#letters" target="_blank"&gt;Link to The Cochrane Collaboration Glossary&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;MALE UROGENITAL DISORDERS:&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:321706:0" name=internalLink&gt;Benign Prostate Enlargement: Systematic reviews and meta-analyses&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:339010:0" name=internalLink&gt;Bladder stones: Systematic reviews and meta-analyses&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:321796:0" name=internalLink&gt;Catheter-related infections: Systematic reviews and meta-analyses&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:321798:0" name=internalLink&gt;Chlamydia: Systematic reviews and meta-analyses&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:321799:0" name=internalLink&gt;Chronic prostatitis: Systematic reviews and meta-analyses&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:344284:0" name=internalLink&gt;Circumcision: Systematic reviews and meta-analyses&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:321803:0" name=internalLink&gt;Cystitis: Systematic reviews and meta-analyses&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:321806:0" name=internalLink&gt;Erectile dysfunction: Systematic reviews and meta-analyses&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:321807:0" name=internalLink&gt;Genital warts: Systematic reviews and meta-analyses&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:321811:0" name=internalLink&gt;Gonorrhea: Systematic reviews and meta-analyses&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:321810:0" name=internalLink&gt;Hepatitis B: Systematic reviews and meta-analyses&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:321813:0" name=internalLink&gt;Herpes: Systematic reviews and meta-analyses&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:321812:0" name=internalLink&gt;HIV and male urogenital disorders: Systematic reviews and meta-analyses&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:321814:0" name=internalLink&gt;Hypospadias: Systematic reviews and meta-analyses&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:321815:0" name=internalLink&gt;Infertility: Systematic reviews and meta-analyses&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:321826:0" name=internalLink&gt;Male bladder disorders: Systematic reviews and meta-analyses&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:321990:0" name=internalLink&gt;Male breast cancer: Systematic reviews and meta-analyses&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:321988:0" name=internalLink&gt;Male contraceptives: Systematic reviews and meta-analyses&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:321989:0" name=internalLink&gt;Male public health: Systematic reviews and meta-analyses&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:321825:0" name=internalLink&gt;Male Sexually Transmitted Infections: Systematic reviews and meta-analyses&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:321828:0" name=internalLink&gt;Male ureteric disorders: Systematic reviews and meta-analyses&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:321827:0" name=internalLink&gt;Male urethral disorders: Systematic reviews and meta-analyses&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:321830:0" name=internalLink&gt;Male urinary incontinence: Systematic reviews and meta-analyses&lt;/A&gt;&lt;/LI&gt;&lt;A href="nelh:394688:0" name=internalLink&gt;
&lt;LI&gt;Overactive bladder: Systematic reviews and meta-analyses&lt;/LI&gt;
&lt;LI&gt;&lt;/A&gt;&lt;A href="nelh:321832:0" name=internalLink&gt;Penile disorders: Systematic reviews and meta-analyses&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:321928:0" name=internalLink&gt;Penile pain: Systematic reviews and meta-analyses&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:321991:0" name=internalLink&gt;Penile surgery: Systematic reviews and meta-analyses&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:321929:0" name=internalLink&gt;Peyronie's disease: Systematic reviews and meta-analyses&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:321939:0" name=internalLink&gt;Priapism: Systematic reviews and meta-analyses&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:321938:0" name=internalLink&gt;Prostate disorders and surgical procedures: Systematic reviews and meta-analyses&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:321940:0" name=internalLink&gt;Prostatitis: Systematic reviews and meta-analyses&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:321941:0" name=internalLink&gt;Stress incontinence: Systematic reviews and meta-analyses&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:321943:0" name=internalLink&gt;Testicular/ scrotal disorders: Systematic reviews and meta-analyse&lt;/A&gt;s&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:321993:0" name=internalLink&gt;Testosterone: Systematic reviews and meta-analyses&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:321946:0" name=internalLink&gt;Ureteric obstruction: Systematic reviews and meta-analyses&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:321947:0" name=internalLink&gt;Ureteric stones: Systematic reviews and meta-analyses&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:321948:0" name=internalLink&gt;Ureterocele: Systematic reviews and meta-analyses&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:386835:0" name=internalLink&gt;Urethral stricture: Systematic reviews and meta-analyses&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:321992:0" name=internalLink&gt;Urethroplasty: Systematic reviews and meta-analyses&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:321949:0" name=internalLink&gt;Urinary retention: Systematic reviews and meta-analyses&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:321994:0" name=internalLink&gt;Urinary tract infections: Systematic reviews and meta-analyses&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;U&gt;&lt;A href="nelh:386850:0" name=internalLink&gt;&lt;U&gt;Urological chronic pelvic pain: Systematic reviews and meta-analyses&lt;/U&gt;&lt;/A&gt;&lt;/U&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:321950:0" name=internalLink&gt;Varicocele: Systematic reviews and meta-analyses&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:321951:0" name=internalLink&gt;Vasectomy: Systematic reviews and meta-analyses&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:321952:0" name=internalLink&gt;Vesico-ureter-reflux: Systematic reviews and meta-analyses&lt;/A&gt;&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>23/08/2010 12:03:01</lastReviewDate>
    <expiryDate>23/08/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>182512</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.pharmj.com/pdf/cpd/pj_20041023_anaemia.pdf]]&gt;</url>
    <title>Managing anaemia in renal failure</title>
    <publicationDate>2004-10-23T00:00:00</publicationDate>
    <publisher>The Pharmaceutical Journal</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ COMPLICATIONS OF KIDNEY DISEASE,ANAEMIA,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Review of use of Erythropoiesis-stimulating Agents (ESAs) and comments on the European Best Practice Guidelines published in May 2004</description>
    <body>&lt;![CDATA[ &lt;P&gt;Extract from review&lt;/P&gt;
&lt;P&gt;Over the past decade, effective management [of anaemia in CKD] has become possible using safer intravenous iron preparations and genetically engineered erythropoiesis-stimulating agents&amp;nbsp; (ESAs). This CPD article reviews the situation with regard to the latest European Best Practice Guideline., and the Renal Association standards.&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>23/09/2010 16:56:43</lastReviewDate>
    <expiryDate>23/09/2011 16:56:43</expiryDate>
  </document>
  <document>
    <id>344786</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=344786]]&gt;</url>
    <title>March 2010 NHS Evidence - kidney diseases and male urogenital disorders newsletter</title>
    <publicationDate>2010-03-01T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;March 2010 NHS Evidence - kidney diseases and male urogenital disorders newsletter&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Welcome to the kidney diseases and male urogenital disorders specialist collection enewsletter for&amp;nbsp;MARCH 2010. &lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=left&gt;NHS Evidence - kidney diseases and male urogenital disorders is for busy health professionals, providing them with high quality information and keeping them up to date with the latest research and developments in this area. You can now join our mailing list to receive regular updates. &lt;A href="https://www.jiscmail.ac.uk/cgi-bin/webadmin?A0=NHSEVIDENCEKDMU" target="_blank"&gt;Click here for the link&lt;/A&gt;.&lt;/P&gt;
&lt;P align=center&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage0 height=233 alt="Modern education and online learning" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID344786/nelhImp_0000_Moderneducationandonlinelearning.jpg" width=319 border=0 name=nelh_tempImage0&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2 align=left&gt;&lt;BIG&gt;***** Quick survey open to library users to find out what information you need and what you think of our Annual Evidence Updates and Treatment Uncertainties: &lt;A href="http://www.surveymonkey.com/s/GGMQ5T8" target="_blank"&gt;http://www.surveymonkey.com/s/GGMQ5T8&lt;/A&gt; *****&lt;/H2&gt;&lt;/BIG&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Links to:&lt;/STRONG&gt;&lt;/P&gt;&lt;STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="#kidney"&gt;New Kidney Diseases items&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="#mug"&gt;New Male Urogenital Disorders items&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0005_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&amp;nbsp;RSS FEEDS&amp;nbsp; &lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0006_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;You can receive news from the kidney diseases specialist collection from the RSS feeds we provide:&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/RSS/CMS.aspx?feed=57" target="_blank"&gt;&lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0007_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk/kidney/RSS/CMS.aspx?feed=57" target="_blank"&gt;&lt;A href="http://www.library.nhs.uk/kidney/RSS/CMS.aspx?feed=57" target="_blank"&gt;New Kidney Diseases Resources&lt;/A&gt;&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/RSS/CMS.aspx?feed=136" target="_blank"&gt;&lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0008_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk/kidney/RSS/CMS.aspx?feed=136" target="_blank"&gt;New Male Urogenital Disorders Resources&lt;/A&gt; &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/KIDNEY/RSS/News.aspx" target="_blank"&gt;&lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0008_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk//kidney/News.aspx" target="_blank"&gt;Kidney diseases and male urogenital disorders in the news&lt;/A&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/rss/Directory/MoreAboutRss.aspx" target="_blank"&gt;Click through this link to find out more about RSS feeds.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;JOURNALS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;You can link through to the latest Tables of Contents from all the major kidney, transplant and urology journals from &lt;A href="http://www.library.nhs.uk/KIDNEY/Page.aspx?pagename=EJOURNALS" target="_blank"&gt;this page&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=3&gt;&lt;STRONG&gt;&lt;BIG&gt;Resources added in&amp;nbsp;February 2010&lt;/BIG&gt;&lt;/STRONG&gt; &lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A name=kidney&gt;Chronic Kidney&amp;nbsp;Disease&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:343003:0" name=internalLink&gt;Effect of medication dosing frequency on adherence in chronic diseases&lt;/A&gt;. A DARE Abstract.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:342986:0" name=internalLink&gt;E-health self-care interventions for persons with chronic illnesses: review and future directions&lt;/A&gt;. A DARE abstract.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2010---February/18/Does-adding-a-CCB-rather-than-diuretic-to-an-ACE-inhibitor-increase-renal-protection/" target="_blank"&gt;Does adding a CCB rather than diuretic to an ACE-inhibitor increase renal protection?&lt;/A&gt; From the National electronic Library for Medicines (18/02/10)&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Acute kidney injury&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:343000:0" name=internalLink&gt;High-dose N-acetylcysteine for the prevention of contrast-induced nephropathy&lt;/A&gt;. A DARE abstract.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2010---February/26/Clinical-decision-support-system-to-determine-quality-of-antimicrobial-dosing-in-ICU-patients-with-renal-insufficiency/" target="_blank"&gt;Clinical decision support system to determine quality of antimicrobial dosing in ICU patients with renal insufficiency&lt;/A&gt;. From the National electronic Library for Medicines (26/02/10).&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Hypertension&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;EM&gt;No new items this month. &lt;/EM&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Renovascular disease&lt;/STRONG&gt;&lt;/P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;Guest editorial: &lt;A href="nelh:343358:0" name=internalLink&gt;Implications of the ASTRAL (Angioplasty and Stenting for Renal Artery Lesions) trial for current management of atherosclerotic renovascular disease (ARVD)&lt;/A&gt;. By Professor Philip A Kalra. (09/02/10)&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Diabetic nephropathy&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:328666:0" name=internalLink&gt;NHS Diabetes commissioning resource&lt;/A&gt;. Published 1 March 2010.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Glomerulonephritis&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:342979:0" name=internalLink&gt;Mycophenolate mofetil treatment for IgA nephropathy: a meta-analysis&lt;/A&gt;. A DARE abstract.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Dialysis&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:342903:0" name=internalLink&gt;A systematic review of continuous renal replacement therapy and intermittent haemodialysis in management of patients with acute renal failure&lt;/A&gt;. A DARE abstract.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.kidneycare.nhs.uk/Ourworkprogrammes-Hometherapies-Hometherapiesresources.cms" target="_blank"&gt;NHS Kidney Care Home Haemodialysis resources&lt;/A&gt;. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Transplantation&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:343021:0" name=internalLink&gt;The effectiveness and cost-effectiveness of methods of storing donated kidneys from deceased donors: a systematic review and economic evaluation&lt;/A&gt;. A Health Technology Assessment abstract. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2010---February/22/Horizon-scanning-Belatacept-as-immunosuppression-after-kidney-transplant/" target="_blank"&gt;Horizon scanning: Belatacept as immunosuppression after kidney transplant.&lt;/A&gt; From the National electronic Library for Medicines (22/02/10).&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2010---February/12/Cohort-study-Effect-of-reduced-immunosuppression-after-kidney-transplant-failure-on-risk-of-cancer/" target="_blank"&gt;Cohort study: Effect of reduced immunosuppression after kidney transplant failure on risk of cancer&lt;/A&gt;. From the National electronic Library for Medicines (12/02/10).&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Kidney Cancer&lt;/STRONG&gt; &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2010---February/19/European-CHMP-issues-positive-opinion-on-marketing-authorisation-application-for-pazopanib-Votrient-as-treatment-of-advanced-renal-cell-carcinoma/" target="_blank"&gt;European CHMP issues positive opinion on marketing authorisation application for pazopanib (Votrient®) as treatment of advanced renal cell carcinoma&lt;/A&gt;. From the National electronic Library for Medicines (19/02/10).&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Kidney stones&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:339010:0" name=internalLink&gt;Kidney and bladder stones: Systematic reviews and meta-analyses&lt;/A&gt; (Updated February 2010). &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A name=mug&gt;Male Urogenital Disorders&lt;/A&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Male Bladder Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/Evidence/Drug-Specific-Reviews/SMC-accepts-trospium-film-coated-tablets-Flotros-for-overactive-bladder/" target="_blank"&gt;SMC accepts trospium film-coated tablets (Flotros®) for overactive bladder&lt;/A&gt;. From the National electronic Library for Medicines (08/02/10).&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Prostate Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Updated systematic reviews and meta-analyses: &lt;A href="nelh:321706:0" name=internalLink&gt;Benign Prostate Enlargement&lt;/A&gt; (February 2010).&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Penile Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:342895:0" name=internalLink&gt;Red ginseng for treating erectile dysfunction: a systematic review&lt;/A&gt;. A DARE abstract.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:344284:0" name=internalLink&gt;Circumcision: Systematic reviews and meta-analyses &lt;/A&gt;(New for February 2010).&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:321814:0" name=internalLink&gt;Hypospadias: Systematic reviews and meta-analyses&lt;/A&gt; (Updated February 2010). &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Testicular/Scrotal Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;EM&gt;No new items this month. &lt;/EM&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Male Urinary Incontinence&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:333390:0" name=internalLink&gt;2010 Annual Evidence Update on Male Urinary Incontinence - link to contents page&lt;/A&gt;&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Urinary tract infection - Clinical Knowledge Summaries&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:342799:0" name=internalLink&gt;Urinary tract infection (lower) – men&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:342800:0" name=internalLink&gt;Urinary tract infection (lower) - men: Lower urinary tract infection in men&lt;/A&gt; &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:342801:0" name=internalLink&gt;Urinary tract infection (lower) - men: Urinary tract infection in men with an indwelling catheter&lt;/A&gt; &lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Sexually Transmitted Infections&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:343078:0" name=internalLink&gt;Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failure&lt;/A&gt;. An abstract from the NHS Economic Evaluation Database. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Fertility&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:321815:0" name=internalLink&gt;Infertility: Systematic reviews and meta-analyses&lt;/A&gt; (Updated February 2010).&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;**Subscribe to the NHS Evidence Eyes on Evidence Newsletter**&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;If you would like to receive Eyes on Evidence, the monthly e-bulletin from NHS Evidence, please sign up at &lt;A href="http://www.evidence.nhs.uk/NewsletterSignup.aspx" target="_blank"&gt;http://www.evidence.nhs.uk/NewsletterSignup.aspx&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The bulletin will keep you updated with new and important evidence and key developments on the NHS Evidence portal.&amp;nbsp; It comes out on the second Wednesday of the month and can be sent to any e-mail address that you provide.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>14/02/2011 11:39:20</lastReviewDate>
    <expiryDate>14/02/2012 11:39:20</expiryDate>
  </document>
  <document>
    <id>407812</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=407812]]&gt;</url>
    <title>March 2011 NHS Evidence - kidney diseases and male urogenital disorders newsletter</title>
    <publicationDate>2011-03-07T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;March 2011 NHS Evidence - kidney diseases and male urogenital disorders newsletter&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Welcome to the last kidney diseases and male urogenital disorders specialist collection enewsletter for&amp;nbsp;MARCH 2011. &lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=left&gt;NHS Evidence - kidney diseases and male urogenital disorders is for busy health professionals, providing them with high quality information and keeping them up to date with the latest research and developments in this area.&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;New this month:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;&lt;STRONG&gt;&lt;A href="#changes"&gt;Changes to the specialist collections&lt;/A&gt;&lt;/STRONG&gt;&lt;/DIV&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;&lt;STRONG&gt;&lt;A href="#hot"&gt;Renal Hot Topics&lt;/A&gt;&lt;/STRONG&gt;&lt;/DIV&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;&lt;STRONG&gt;&lt;A href="#mini"&gt;New Mini Topic Review on Kidney Stones&lt;/A&gt;&lt;/STRONG&gt;&lt;/DIV&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;&lt;STRONG&gt;&lt;A href="#prostate"&gt;2011 Annual Evidence Update on Prostate Cancer&lt;/A&gt;&lt;/STRONG&gt;&lt;/DIV&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Links to:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;&lt;STRONG&gt;
&lt;LI&gt;&lt;A href="#kidney"&gt;New Kidney Diseases items&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="#mug"&gt;New Male Urogenital Disorders items&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=center&gt;&amp;nbsp;&amp;nbsp;&lt;IMG style="WIDTH: 182px; HEIGHT: 183px" id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="Examining the Evidence" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID405435/nelhImp_0000_ExaminingtheevidenceNov10.jpg" width=216 height=253&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="Man with woman - prostate cancer AEU" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID407812/nelhImp_0000_ManwithwomanNov10.jpg" width=196 height=189&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A name=changes&gt;Changes to the Specialist Collections&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;A new specialist evidence service to replace the kidney diseases and male urogenital disorders specialist collection.&lt;/P&gt;
&lt;P&gt;As you know, this specialist collection&amp;nbsp;provides access to specialised information on behalf of NICE (NHS Evidence).&amp;nbsp; &lt;/P&gt;
&lt;P&gt;From May 2011, NICE (NHS Evidence) will launch a new specialist evidence service to replace&amp;nbsp;the kidney diseases and male urogenital disorders specialist collection and the other 29 Specialist Collections. &lt;/P&gt;
&lt;P&gt;The new service will be easy to search and provide access to a much wider choice of quality specialist evidence content.&lt;/P&gt;
&lt;P&gt;Users will be able to browse new clinical and public health topic pages – developed by experts - which will bring together the latest guidelines, high quality patient information, ongoing trials and other selected information including access to NICE pathways. NICE Pathways will allow users to easily visualise and browse associated NICE products online, guided through supporting documents making NICE guidance easier to navigate.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Newsletters &lt;BR&gt;&lt;/STRONG&gt;In view of the change to the new service this newsletter for March 2011 will be the last one.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;NHS Evidence will continue to identify significant new evidence and will disseminate this quality assured, significant, new evidence via its monthly Eyes on Evidence bulletin. &lt;/P&gt;
&lt;P&gt;The bulletin will provide a link to new, significant evidence for that month. . Later in the year a personalised update function will be introduced which will allow you to specify exactly what you wish to be notified about.&lt;/P&gt;
&lt;P&gt;If you have already agreed to pass on your contact details to NICE you will receive the Eyes on Evidence bulletin. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;OTHER CHANGES&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Evidence Updates&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Evidence Updates will continue to be produced by NHS Evidence to raise awareness of new evidence and will reflect prioritised topics, where there are accredited guidelines. &lt;/P&gt;
&lt;P&gt;There will be some core, consistent topics, but new topics may be added on an annual basis to increase the coverage of accredited guideline topics over time. &lt;/P&gt;
&lt;P&gt;Evidence Updates themselves will be available by searching on the relevant topic term on NHS Evidence, or by accessing the guideline panel in the new redesigned site, or through features in Eyes on Evidence.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;Forthcoming Evidence Updates will be advertised on&amp;nbsp; lis-medical, lis-nursing, Corecontent, Nelm, Chain, CKS and Wiley and on a dedicated web page on NHS Evidence.&amp;nbsp; They will also continue to be submitted as journal articles for publication by NICE with input from the Clinical Leads. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Stakeholder Engagement: Evidence Associates &lt;BR&gt;&lt;/STRONG&gt;NICE will continue to engage with specialist community stakeholders through a new network of Evidence Associates.&lt;/P&gt;
&lt;P&gt;If you want to find out more about how to become an&amp;nbsp; Evidence Associate&amp;nbsp; then please contact Frances Abebreseh at NICE by emailing: &lt;A href="mailto:frances.abebreseh@nice.org.uk" target="_blank"&gt;frances.abebreseh@nice.org.uk&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Evidence Associates will be invited to take part in the Evidence Update process, answering questions or contributing to the horizon scanning process of identifying new significant evidence. Evidence Associates may also want to be involved in the production or co-authoring of feature articles for the Eyes on Evidence bulletin or press articles.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Specialist Collections web pages&lt;/STRONG&gt; (on &lt;A href="http://www.library.nhs.uk/" target="_blank"&gt;www.library.nhs.uk&lt;/A&gt;)&lt;BR&gt;From May 2011 the kidney diseases and male urogenital disorders’s web pages will no longer exist as the specialist resources for kidney diseases and male urogenital disorders will be accessible via the redesigned NHS Evidence site.&amp;nbsp; If you have added these pages to your bookmarks and favourites then these links will still work for a short period until early May 2011 then but they will then be redirected to the main NHS Evidence site. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;UK DUETS&lt;BR&gt;&lt;/STRONG&gt;UK DUETS will continue to be available via a dedicated web page on NHS Evidence. Uncertainty records will be available in the search results as well as under the On-going Research panel of the future topic pages. Work is on-going with users of UK DUETS and the NICE Research Recommendations database to build an integrated approach to the capture of Research Uncertainties. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Who to contact &lt;BR&gt;&lt;/STRONG&gt;From April 2011, if you have queries you can contact NHS Evidence directly by emailing &lt;A href="mailto:contactus@evidence.nhs.uk" target="_blank"&gt;contactus@evidence.nhs.uk&lt;/A&gt; or calling 0845 003 77 44. &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A name=hot&gt;MARCH&amp;nbsp;2011: RENAL HOT TOPICS &lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;New England Journal of Medicine&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Inglehart JK. (2011) "Bundled Payment for ESRD — Including ESAs in Medicare's Dialysis Package". N Engl J Med 364(7):593-595. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/21323538" target="_blank"&gt;Link to PubMed&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Rettig RA. (2011) "Special Treatment — The Story of Medicare's ESRD Entitlement". N Engl J Med 364(7):596-598. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/21323539" target="_blank"&gt;Link to PubMed&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Stanescu HC et al. (2011). "Risk HLA-DQA1 and PLA2R1 Alleles in Idiopathic Membranous Nephropathy". N Engl J Med 364(7):616-626. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/21323541" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hemmelgarn BR et al. for the Prevention of Dialysis Catheter Lumen Occlusion with rt-PA versus Heparin (PreCLOT) Study Group. (2011). "Prevention of Dialysis Catheter Malfunction with Recombinant Tissue Plasminogen Activator". N Engl J Med 364(4):303-312. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/21268722" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Archives of Internal Medicine&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Ishani A et al. (2011) "The Magnitude of Acute Serum Creatinine Increase After Cardiac Surgery and the Risk of Chronic Kidney Disease, Progression of Kidney Disease, and Death." Arch Intern Med. 2011;171(3):226-233. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/21325112" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mehrotra R et al. (2011) "Similar Outcomes With Hemodialysis and Peritoneal Dialysis in Patients With End-Stage Renal Disease." Arch Intern Med. 2011;171(2):110-118. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20876398" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;The Lancet&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Budde K et al. (2011) Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet 377(9768); 837-847. [&lt;A href="http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2962318-5/abstract?rss=yes" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Annals of Internal Medicine&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Clase CM et al. (2011) "Estimated&amp;nbsp;Glomerular Filtration Rate and Albuminuria as Predictors of Outcomes in Patients With High Cardiovascular Risk: A Cohort Study." 154(5):310-318. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/21357908" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&amp;nbsp;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=3&gt;&lt;STRONG&gt;&lt;BIG&gt;Resources added in&amp;nbsp;February 2011&lt;/BIG&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A name=kidney&gt;Chronic Kidney&amp;nbsp;Disease&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:333626:0" name=internalLink&gt;Chronic Kidney Disease: Systematic reviews and meta-analyses&lt;/A&gt;. Updated 24 Feb 2011.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.kidneycarematters.nhs.uk/Default.aspx" target="_blank"&gt;Kidney Care Matters - March 2011&lt;/A&gt;. NHS Kidney Care.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:182326:0" name=internalLink&gt;Anaemia management in people with chronic kidney disease&lt;/A&gt;. Updated NICE guideline.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/Evidence/Guidelines/NICE-issues-clinical-guideline-on-the-management-of-anaemia-in-people-with-chronic-kidney-disease/" target="_blank"&gt;NICE issues clinical guideline on the management of anaemia in people with chronic kidney disease&lt;/A&gt;. National electronic Library for Medicines (10 Feb 2011).&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2011---February/09/NICE-costing-report-on-the-implementation-of-clinical-guideline-for-the-management-of-anaemia-in-people-with-chronic-kidney-disease/" target="_blank"&gt;NICE costing report on the implementation of clinical guideline for the management of anaemia in people with chronic kidney disease&lt;/A&gt;. National electronic Library for Medicines (10 Feb 2011).&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://renaltsar.blogspot.com/2011/02/nhs-evidence-highlights-iv-iron-savings.html" target="_blank"&gt;Renal Tsar - NHS Evidence highlights IV Iron savings&lt;/A&gt; (Thu, 17 Feb 2011). &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://renaltsar.blogspot.com/2011/02/q-how-can-we-get-individual-care-plans.html" target="_blank"&gt;Renal Tsar - Q and A - How can we get individual Care Plans to become universally applied to all chronically ill patients&lt;/A&gt; (Fri, 04 Feb 2011).&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:407005:0" name=internalLink&gt;Phosphate binders for preventing and treating bone disease in chronic kidney disease patients&lt;/A&gt;. A new Cochrane systematic review by Navaneethan Sankar D et al. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://renaltsar.blogspot.com/2011/02/paying-for-value-not-volume.html" target="_blank"&gt;Renal Tsar - Paying for value not volume&lt;/A&gt; (Thu, 10 Feb 2011). &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://renaltsar.blogspot.com/2011/02/barnsley-renal-unit-have-been-running.html" target="_blank"&gt;Renal Tsar - Personal Health Budgets for renal patient transport&lt;/A&gt; (Tue, 01 Mar 2011).&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://renaltsar.blogspot.com/2011/03/q-a-coding-conundrum-for-ckd.html" target="_blank"&gt;Renal Tsar - Q and A on A Coding conundrum for CKD&lt;/A&gt; (Tue, 01 Mar 2011). &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.kidneyresearchuk.org/news/kidney-research-news-articles.php?id=1222" target="_blank"&gt;World Kidney Day 2011: Thursday 10 March 2011&lt;/A&gt;. Kidney Research UK. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Diabetic nephropathy&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:333667:0" name=internalLink&gt;Diabetic nephropathy: Systematic reviews and meta-analyses&lt;/A&gt;. Updated 18 Feb 2011. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Other kidney conditions - SLE and inherited&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2011---February/07/Phase-III-study-of-belimumab-suggests-modest-efficacy-in-active-SLE-/" target="_blank"&gt;Phase III study of belimumab suggests modest efficacy in active SLE&lt;/A&gt;. National electronic Library for Medicines (08 Feb 2011).&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2961354-2/abstract?rss=yes" target="_blank"&gt;Efficacy and safety of belimumab in patients with active systemic lupus erythematosus - a randomised placebo-controlled phase 3 trial.&lt;/A&gt; RCT published in the Lancet by Navarra SV et al. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:406725:0" name=internalLink&gt;NHS Kidney Care - Supporting Young Adults with Kidney Disease&lt;/A&gt;.&amp;nbsp; NHS Kidney Care. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:338797:0" name=internalLink&gt;Genetics of Kidney Diseases: Systematic Reviews and Meta-analyses&lt;/A&gt;. Updated 04 March 2011.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Hypertension&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2011---February/22/NHS-Choices-assessment-New-blood-pressure-measurement-method-may-more-accurately-predict-aortic-systolic-pressure/" target="_blank"&gt;NHS Choices assessment- New blood pressure measurement method may more accurately predict aortic systolic pressure&lt;/A&gt;. National electronic Library for Medicines (23 Feb 2011). &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2011---February/22/NICE-consultshttp://www.nelm.nhs.uk/en/NeLM-Area/News/2011---February/22/NICE-consults-on-draft-update-to-hypertension-guideline-/-on-draft-update-to-hypertension-guideline-/" target="_blank"&gt;NICE consults on draft update to hypertension guideline&lt;/A&gt;.&amp;nbsp; National electronic Library for Medicines&amp;nbsp; (23 Feb 2011). &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/Evidence/Medicines-Management/References/2011---February/11/Home-blood-pressure-monitoring-plays-a-key-role-in-hypertension-management/" target="_blank"&gt;Home blood pressure monitoring plays a key role in hypertension management - review of applications effectiveness and technique for pharmacists&lt;/A&gt;. National electronic Library for Medicines (11 Feb 2011). &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:338975:0" name=internalLink&gt;Hypertension: Systematic reviews and meta-analyses&lt;/A&gt;. Updated 18 Feb 2011. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Acute kidney injury&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://renaltsar.blogspot.com/2011/02/hsj-highlights-increasing-acute-kidney.html" target="_blank"&gt;Renal Tsar - HSJ highlights increasing acute kidney injury costs&lt;/A&gt; (Wed, 09 Feb 2011).&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;End-Stage Renal Disease&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:338779:0" name=internalLink&gt;End-Stage Renal Disease: Systematic reviews and meta-analyses.&lt;/A&gt; Updated 16 Feb 2011.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/21035932" target="_blank"&gt;Prediction of ESRD and death among people with CKD - the Chronic Renal Impairment in Birmingham prospective cohort study&lt;/A&gt;. New cohort study published in the American Journal of Kidney Diseases by Landray MJ et al.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Renovascular diseases&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;No new resources this month.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Glomerulonephritis&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:388099:0" name=internalLink&gt;Nephrotic syndrome: Systematic reviews and meta-analyses&lt;/A&gt;. Updated 18 Feb 2011.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Other renal conditions&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;No new resources this month.&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Renal tract infections&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;No new resources this month.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Kidney stones&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/KIDNEY/ViewResource.aspx?resID=407610" target="_blank"&gt;Mini Topic Review on Kidney Stones&lt;/A&gt; by&amp;nbsp;Kathie Wong and Kay Thomas&lt;/A&gt;&lt;A name=mini&gt;&lt;/A&gt;&amp;nbsp; - March 2011. &lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Renal vasculitis&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;No new resources this month.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Haemodialysis&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:333679:0" name=internalLink&gt;Dialysis: Systematic reviews and meta-analyses&lt;/A&gt;. Updated 01 March 2011.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Peritoneal Dialysis&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;No new resources this month.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Transplantation&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://jama.ama-assn.org/content/305/8/773.short?rss=1" target="_blank"&gt;Transmission of Multidrug-Resistant Escherichia coli Through Kidney Transplantation - California and Texas 2009&lt;/A&gt;. Report by Centers for Disease Control and Prevention Morbidity and Mortality Weekley - Report in JAMA.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2011---February/21/ZEUS-study-evaluates-use-of-everolimus-based-calcineurin-inhibitor-free-regimen-in-recipients-of-de-novo-kidney-transplants/" target="_blank"&gt;ZEUS study evaluates use of everolimus-based calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants&lt;/A&gt;. National electronic Library for Medicines (22 Feb 2011).&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/KIDNEY/ViewResource.aspx?resID=406794&amp;amp;tabID=288" target="_blank"&gt;Guidance on the microbiological safety of human organs tissues and cells used in transplantation&lt;/A&gt;.&amp;nbsp; Department of Health.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/KIDNEY/ViewResource.aspx?resID=182023&amp;amp;tabID=288" target="_blank"&gt;Guidelines for antibody incompatible transplantation&lt;/A&gt;. Updated British Transplantation Society guidance.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:339131:0" name=internalLink&gt;Nephrectomy: Systematic reviews and meta-analyses&lt;/A&gt;. Updated 18 Feb 2011.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:341851:0" name=internalLink&gt;Renal transplant: Systematic reviews and meta-analyses&lt;/A&gt;. Updated 04 March 2011.&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Kidney Cancer&lt;/STRONG&gt; &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:124694:0" name=internalLink&gt;New systematic review on diabetes mellitus and the incidence of kidney cancer&lt;/A&gt;. NHS Evidence - cancer.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/Evidence/Guidelines/NICE-issues-guidance-on-pazopanib-for-the-first-line-treatment-of-metastatic-renal-cell-carcinoma-/" target="_blank"&gt;NICE issues guidance on pazopanib for the first-line treatment of metastatic renal cell carcinoma&lt;/A&gt;. National electronic Library for Medicines (24 Feb 2011). &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/KIDNEY/ViewResource.aspx?resID=407249&amp;amp;tabID=288" target="_blank"&gt;Pazopanib for the first-line treatment of advanced renal cell carcinoma&lt;/A&gt;. NICE technology appraisal guidance. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;&lt;A name=mug&gt;&lt;FONT size=2&gt;Male Urogenital Disorders&lt;/FONT&gt;&lt;/A&gt;&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:405476:0" name=internalLink&gt;The management of lower urinary tract symptoms in men - Commissioning Guide&lt;/A&gt;. NICE. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Male Ureteric Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;No new resources this month.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Male Bladder Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:124838:0" name=internalLink&gt;New systematic reviews on bladder cancer&lt;/A&gt;. NHS Evidence - cancer. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Prostate Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=405400" target="_blank"&gt;2011 Annual Evidence Update on Prostate Cancer&lt;/A&gt;&lt;/A&gt;. Launched 07 March 2011. Produced by NHS Evidence - cancer and NHS Evidence - kidney diseases and male urogenital disorders.&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2011---February/252/Denosumab-vs-zoledronic-acid-for-treatment-of-bone-metastases-in-men-with-castration-resistant-prostate-cancer-RCT/" target="_blank"&gt;Denosumab vs zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer - RCT&lt;/A&gt;. National electronic Library for Medicines (01 March 2011).&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.bbc.co.uk/news/health-12498829" target="_blank"&gt;BBC Video clip on HIFU and prostate cancer&lt;/A&gt;. 22 Feb 2011.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Penile Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:321806:0" name=internalLink&gt;Erectile dysfunction: Systematic reviews and meta-analyses&lt;/A&gt;. Updated 21 Feb 2011&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Urethral disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;No new resources this month.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Urinary tract infections&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;No new resources this month.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Testicular/Scrotal Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:407021:0" name=internalLink&gt;Screening for testicular cancer&lt;/A&gt;. A new Cochrane systematic review by Ilic Dragan and Misso ML. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Male Urinary Incontinence&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:321830:0" name=internalLink&gt;Male urinary incontinence: Systematic reviews and meta-analyses&lt;/A&gt;. Updated 21 Feb 2011.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Sexually Transmitted Infections&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:321812:0" name=internalLink&gt;HIV and male urogenital disorders: Systematic reviews and meta-analyses&lt;/A&gt;. Updated 21 Feb 2011. &amp;nbsp;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Fertility&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:321815:0" name=internalLink&gt;Infertility: Systematic reviews and meta-analyses&lt;/A&gt;. Updated 21 Feb 2011. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Many thanks for using and benefiting from this specialist collection for the last four-five years. The specialist collection team wish you all the best. &lt;/H2&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <expiryDate>04/03/2012 00:00:00</expiryDate>
  </document>
  <document>
    <id>313844</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=313844]]&gt;</url>
    <title>May 2009 NHS Evidence - kidney diseases newsletter</title>
    <publicationDate>2009-05-05T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ END-OF-LIFE CARE,RENOVASCULAR DISEASES,INHERITED KIDNEY DISEASE,RENAL CANCER,KIDNEY AND BLADDER STONES,GLOMERULONEPHRITIS,PERITONEAL DIALYSIS,COMPLICATIONS OF KIDNEY DISEASE,DOPPS,OTHER CONDITIONS - ADULTS,KIDNEY DISEASE IN CHILDREN AND ADOLESCENTS,RENAL TRACT INFECTIONS,NATIONAL SERVICE FRAMEWORK FOR RENAL SERVICES/POLICY DOCUMENTS,HAEMODIALYSIS,TRANSPLANTATION,CHRONIC KIDNEY DISEASE,ACUTE KIDNEY INJURY,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,DIALYSIS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;May 2009 NHS Evidence - kidney diseases newsletter&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;NHS Evidence - kidney diseases is for busy health professionals, providing them with high quality information and keeping them up to date with the latest research and developments in this area.&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=center&gt;&lt;IMG id=nelh_tempImage0 style="WIDTH: 282px; HEIGHT: 183px" height=200 alt="RA BTS kidney diseases stand" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID313844/nelhImp_0000_RABTSstand.jpg" width=300 border=0 name=nelh_tempImage0&gt;&amp;nbsp; &lt;IMG id=nelh_tempImage0 style="WIDTH: 147px; HEIGHT: 183px" height=138 alt="RA BTS Conference" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID313844/nelhImp_0001_RABTSconference.jpg" width=102 border=0 name=nelh_tempImage0&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Photographs above taken on 22nd April at the Joint RA/BTS Conference in Liverpool. &lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;&lt;BIG&gt;New resources added in April 2009:&lt;/BIG&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Guidance&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=312536&amp;amp;tabID=288" target="_blank"&gt;Diabetic nephropathy&lt;/A&gt; - subsection of the BNF for Children: &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Evidence&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;The Cochrane Database of Systematic Reviews: Issue 2, 2009&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/KIDNEY/ViewResource.aspx?resID=312179&amp;amp;tabID=289" target="_blank"&gt;HMG CoA reductase inhibitors (statins) for kidney transplant recipients&lt;/A&gt; &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/viewResource.aspx?resid=312247" target="_blank"&gt;HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=238565&amp;amp;tabID=289" target="_blank"&gt;HMG CoA reductase inhibitors (statins) for dialysis patients&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Database of Abstracts of Reviews of Effects:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/KIDNEY/ViewResource.aspx?resID=312355&amp;amp;tabID=289" target="_blank"&gt;Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/KIDNEY/ViewResource.aspx?resID=312250&amp;amp;tabID=289" target="_blank"&gt;Effects of bisphosphonates on bone loss in the first year after renal transplantation: a meta-analysis of randomized controlled trials&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/KIDNEY/ViewResource.aspx?resID=312295&amp;amp;tabID=289" target="_blank"&gt;Fenoldopam reduces the need for renal replacement therapy and in-hospital death in cardiovascular surgery: a meta-analysis&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/KIDNEY/ViewResource.aspx?resID=312345&amp;amp;tabID=289" target="_blank"&gt;Impact of presumed consent for organ donation on donation rates: a systematic review&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/KIDNEY/ViewResource.aspx?resID=312302&amp;amp;tabID=289" target="_blank"&gt;Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;NHS Economic Evaluation Database:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/KIDNEY/ViewResource.aspx?resID=312386&amp;amp;tabID=289" target="_blank"&gt;An economic evaluation of sevelamer in patients new to dialysis&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/KIDNEY/ViewResource.aspx?resID=312368&amp;amp;tabID=289" target="_blank"&gt;Cost-effectiveness of irbesartan 300 mg given early versus late in patients with hypertension and a history of type 2 diabetes and renal disease: a Canadian perspective&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Link to &lt;A href="http://www.library.nhs.uk/kidney/SearchResults.aspx?searchText=Link+to+Pubmed+abstract&amp;amp;tabID=288&amp;amp;pgIndex=0" target="_blank"&gt;Systematic reviews and meta-analyses published online on Pubmed during April 2009&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Evidence in the News&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.npci.org.uk/blog/?p=323" target="_blank"&gt;Rosuvastatin has no CV benefits in patients undergoing haemodialysis&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2009---April/30/Revised-vascular-programme-briefing-packs-April-2009/" target="_blank"&gt;Revised vascular programme briefing packs April 2009&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Reference&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=311550&amp;amp;tabID=290" target="_blank"&gt;Renal NSF Update for April 2009&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=312740&amp;amp;tabID=290" target="_blank"&gt;Create an Information Prescription for Kidney Disease&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.ic.nhs.uk/services/national-clinical-audit-support-programme-ncasp/kidney-care/patient-transport/patient-transport-survey-2008:-high-level-results" target="_blank"&gt;Patient Transport Survey&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Other resources:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Lifegivers: BBC TV series broadcast in April: &lt;A href="http://www.bbc.co.uk/lifegivers/" target="_blank"&gt;http://www.bbc.co.uk/lifegivers/&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Dr Donal O'Donoghue's Blog: latest: &lt;A href="http://renaltsar.blogspot.com/2009/04/sequins-and-quips.html" target="_blank"&gt;http://renaltsar.blogspot.com/2009/04/sequins-and-quips.html&lt;/A&gt;&amp;nbsp; &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>08/03/2011 09:56:01</lastReviewDate>
    <expiryDate>08/03/2012 09:56:01</expiryDate>
  </document>
  <document>
    <id>373095</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=373095]]&gt;</url>
    <title>May 2010 NHS Evidence - kidney diseases and male urogenital disorders newsletter</title>
    <publicationDate>2010-05-04T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;May 2010 NHS Evidence - kidney diseases and male urogenital disorders newsletter&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Welcome to the kidney diseases and male urogenital disorders specialist collection enewsletter for&amp;nbsp;MAY 2010. &lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=left&gt;NHS Evidence - kidney diseases and male urogenital disorders is for busy health professionals, providing them with high quality information and keeping them up to date with the latest research and developments in this area. You can now join our mailing list to receive regular updates. &lt;A href="https://www.jiscmail.ac.uk/cgi-bin/webadmin?A0=NHSEVIDENCEKDMU" target="_blank"&gt;Click here for the link&lt;/A&gt;.&lt;/P&gt;
&lt;P align=center&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Links to:&lt;/STRONG&gt;&lt;/P&gt;&lt;STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="#kidney"&gt;New Kidney Diseases items&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="#mug"&gt;New Male Urogenital Disorders items&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Come and find us on Stand P3 at the British Renal Society/ Renal Association conference 17 - 20th May in Manchester!&amp;nbsp;&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;IMG id=nelh_tempImage0 height=16 alt=" name=nelh_tempImage0 border=" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0005_feed.gif" width=16 0? RSS icon?&gt;&amp;nbsp;RSS FEEDS&amp;nbsp; &lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0006_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&lt;/STRONG&gt; 
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;You can receive news from the kidney diseases specialist collection from the RSS feeds we provide:&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/RSSFeed.aspx?feed=57" target="_blank"&gt;&lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0007_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk/kidney/RSSFeed.aspx?feed=57" target="_blank"&gt;New Kidney Diseases Resources&lt;/A&gt;&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/RSSFeed.aspx?feed=136" target="_blank"&gt;&lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0008_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk/kidney/RSSFeed.aspx?feed=136" target="_blank"&gt;New Male Urogenital Disorders Resources&lt;/A&gt; &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk//kidney/News.aspx" target="_blank"&gt;&lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0008_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk//kidney/News.aspx" target="_blank"&gt;Kidney diseases and male urogenital disorders in the news&lt;/A&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/rss/Directory/MoreAboutRss.aspx" target="_blank"&gt;Click through this link to find out more about RSS feeds.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;JOURNALS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;You can link through to the latest Tables of Contents from all the major kidney, transplant and urology journals from &lt;A href="http://www.library.nhs.uk/KIDNEY/Page.aspx?pagename=EJOURNALS" target="_blank"&gt;this page&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=3&gt;&lt;STRONG&gt;&lt;BIG&gt;Resources added in&amp;nbsp;April 2010&lt;/BIG&gt;&lt;/STRONG&gt; &lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A name=kidney&gt;Chronic Kidney&amp;nbsp;Disease&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:358348:0" name=internalLink&gt;Effect of sodium iron ethylenediaminetetra-acetate (NaFeEDTA) on haemoglobin and serum ferritin in iron-deficient populations: a systematic review and meta-analysis of randomised and quasi-randomised controlled trials&lt;/A&gt;.&amp;nbsp;A new abstract from the Database of Abstracts of Reviews of Effects. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:283962:0" name=internalLink&gt;Erythropoiesis-stimulating agents for anemia of chronic kidney disease: systematic review and economic evaluation&lt;/A&gt;.&amp;nbsp;A new abstract from the Database of Abstracts of Reviews of Effects.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:359474:0" name=internalLink&gt;Telmisartan versus angiotension-converting enzyme inhibitors in the treatment of hypertension: a meta-analysis of randomized controlled trials&lt;/A&gt;. A new abstract from the Database of Abstracts of Reviews of Effects.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:359047:0" name=internalLink&gt;Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach&lt;/A&gt;. A new abstract from the Database of Abstracts of Reviews of Effects.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:370203:0" name=internalLink&gt;Cost-effectiveness of the oral adsorbent AST-120 versus placebo for chronic kidney disease&lt;/A&gt;. A new abstract from the NHS Economic Evaluation Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2010---April/09/Early-recognition-and-prevention-of-chronic-kidney-disease/" target="_blank"&gt;Early recognition and prevention of chronic kidney disease&lt;/A&gt;. Abstract from the National electronic Library for Medicines (06/04/10)&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.renal.org/Libraries/Tsars/RenalNSFUpdate27April2010.sflb.ashx" target="_blank"&gt;Renal NSF update for April 2010&lt;/A&gt;. Link to PDF. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Acute kidney injury&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:359577:0" name=internalLink&gt;Gadolinium-based contrast agents and nephrogenic systemic fibrosis: a systematic review and meta-analysis&lt;/A&gt;. A new abstract from the Database of Abstracts of Reviews of Effects.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:313475:0" name=internalLink&gt;Sodium bicarbonate for the prevention of contrast-induced nephropathy: a meta-analysis of 17 randomized trials&lt;/A&gt;. A new abstract from the Database of Abstracts of Reviews of Effects.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:359787:0" name=internalLink&gt;Sodium bicarbonate-based hydration prevents contrast-induced nephropathy: a meta-analysis&lt;/A&gt;. A new abstract from the Database of Abstracts of Reviews of Effects.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:358909:0" name=internalLink&gt;The role of natriuretic peptide administration in cardiovascular surgery-associated renal dysfunction: a systematic review and meta-analysis of randomized controlled trials&lt;/A&gt;. A new abstract from the Database of Abstracts of Reviews of Effects.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Diabetic nephropathy&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2010---April/07/Joint-British-Diabetes-Societies-Inpatient-Care-Group-guidance-on-the-management-of-diabetic-ketoacidosis/" target="_blank"&gt;Joint British Diabetes Societies Inpatient Care Group guidance on the management of diabetic ketoacidosis&lt;/A&gt;. Abstract from the National electronic Library for Medicines (07/04/10)&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2010---April/28/Effect-of-B-vitamin-therapy-on-progression-of-diabetic-nephropathy-/" target="_blank"&gt;Effect of B-vitamin therapy on progression of diabetic nephropathy&lt;/A&gt;. Abstract from the National electronic Library for Medicines (28/04/10)&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Glomerulonephritis&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:360824:0" name=internalLink&gt;Efficacy and safety of glucocorticoids therapy for IgA nephropathy: a meta-analysis of randomized controlled trials&lt;/A&gt;.&amp;nbsp;A new abstract from the Database of Abstracts of Reviews of Effects.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:360302:0" name=internalLink&gt;Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression&lt;/A&gt;. A new abstract from the Database of Abstracts of Reviews of Effects.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Dialysis&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:358084:0" name=internalLink&gt;Autogenous versus prosthetic vascular access for hemodialysis: a systematic review and meta-analysis&lt;/A&gt;. A new abstract from the Database of Abstracts of Reviews of Effects. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:360121:0" name=internalLink&gt;Lower-extremity arteriovenous access for haemodialysis: a systematic review&lt;/A&gt;. A new abstract from the Database of Abstracts of Reviews of Effects.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:358086:0" name=internalLink&gt;Surveillance of arteriovenous hemodialysis access: a systematic review and meta-analysis&lt;/A&gt;. A new abstract from the Database of Abstracts of Reviews of Effects.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Transplantation&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:359595:0" name=internalLink&gt;Does the evidence support the use of mycophenolate mofetil therapeutic drug monitoring in clinical practice? A systematic review&lt;/A&gt;.&amp;nbsp;A new abstract from the Database of Abstracts of Reviews of Effects. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:360817:0" name=internalLink&gt;Kidney transplantation: a systematic review of interventional and observational studies of physical activity on intermediate outcomes&lt;/A&gt;. A new abstract from the Database of Abstracts of Reviews of Effects.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:359968:0" name=internalLink&gt;Recipient outcomes for expanded criteria living kidney donors: the disconnect between current evidence and practice&lt;/A&gt;. A new abstract from the Database of Abstracts of Reviews of Effects. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:371971:0" name=internalLink&gt;Developing robust reference costs for kidney transplantation in adults&lt;/A&gt;. A report from NHS Kidney Care. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Kidney Cancer&lt;/STRONG&gt; &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:359318:0" name=internalLink&gt;Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis&lt;/A&gt;. A new abstract from the Database of Abstracts of Reviews of Effects.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:359845:0" name=internalLink&gt;Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness&lt;/A&gt;. A new abstract from the Database of Abstracts of Reviews of Effects.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2010---April/07/Interferon-alfa--bevacizumab-in-the-treatment-of-metastatic-renal-cell-carcinoma/" target="_blank"&gt;Interferon alfa bevacizumab in the treatment of metastatic renal cell carcinoma&lt;/A&gt;. Abstract from the National electronic Library for Medicines (06/04/10)&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A name=mug&gt;Male Urogenital Disorders&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:347340:0" name=internalLink&gt;2010 Annual Evidence Update on Acupuncture - Male urogenital diseases&lt;/A&gt;. Published by the complementary and alternative medicine specialist collection. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Male Bladder Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:357922:0" name=internalLink&gt;A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder&lt;/A&gt;. A new abstract from the Database of Abstracts of Reviews of Effects. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Prostate Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:359857:0" name=internalLink&gt;Acupuncture for treating hot flushes in men with prostate cancer: a systematic review&lt;/A&gt;. A new abstract from the Database of Abstracts of Reviews of Effects. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:358144:0" name=internalLink&gt;Diet and dietary supplement intervention trials for the prevention of prostate cancer recurrence: a review of the randomized controlled trial evidence&lt;/A&gt;. A new abstract from the Database of Abstracts of Reviews of Effects. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:358680:0" name=internalLink&gt;The role of magnetic resonance imaging in targeting prostate cancer in patients with previous negative biopsies and elevated prostate-specific antigen levels&lt;/A&gt;. A new abstract from the Database of Abstracts of Reviews of Effects.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Penile Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2010---April/29/Intraurethral-alprostadil-vs-sildenafil-for-recovery-of-erectile-function-after-radical-prostatectomy/" target="_blank"&gt;Intraurethral alprostadil vs. sildenafil for recovery of erectile function after radical prostatectomy&lt;/A&gt;. Abstract from the National electronic Library for Medicines (29/04/10)&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Urethral Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:371984:0" name=internalLink&gt;Simple urethral dilatation, endoscopic urethrotomy, and urethroplasty for urethral stricture disease in adult men&lt;/A&gt;. New Cochrane systematic review. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Testicular/Scrotal Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;EM&gt;No new resources&amp;nbsp;this month. &lt;/EM&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Urinary tract infection &lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:358412:0" name=internalLink&gt;Immunoactive prophylaxis of recurrent urinary tract infections: a meta-analysis&lt;/A&gt;. A new abstract from the Database of Abstracts of Reviews of Effects. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2010---April/13/Study-evaluates-interactions-between-antibacterials-used-for-urinary-tract-infections-and-warfarin/" target="_blank"&gt;Study evaluates interactions between antibacterials used for urinary tract infections and warfarin&lt;/A&gt;. Abstract from the National electronic Library for Medicines (06/04/10)&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Sexually Transmitted Infections&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:371980:0" name=internalLink&gt;5-FU for genital warts in non-immunocompromised individuals&lt;/A&gt;. New Cochrane systematic review. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:357804:0" name=internalLink&gt;Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials&lt;/A&gt;. A new abstract from the Database of Abstracts of Reviews of Effects. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:359430:0" name=internalLink&gt;Non-occupational postexposure prophylaxis for HIV: a systematic review&lt;/A&gt;. A new abstract from the Database of Abstracts of Reviews of Effects. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:365855:0" name=internalLink&gt;Cost and effectiveness of Chlamydia screening among male military recruits: Markov modeling of complications averted through notification of prior female partners&lt;/A&gt;. A new abstract from the NHS Economic Evaluation Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:367749:0" name=internalLink&gt;Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness&lt;/A&gt;. A new abstract from the NHS Economic Evaluation Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:365154:0" name=internalLink&gt;Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model&lt;/A&gt;. A new abstract from the NHS Economic Evaluation Database.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Fertility&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:372001:0" name=internalLink&gt;Preconception lifestyle advice for people with subfertility&lt;/A&gt;. New Cochrane systematic review. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:371985:0" name=internalLink&gt;Synchronised approach for intrauterine insemination in subfertile couples&lt;/A&gt;. New Cochrane systematic review. &lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;**Subscribe to the NHS Evidence Eyes on Evidence Newsletter**&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;If you would like to receive Eyes on Evidence, the monthly e-bulletin from NHS Evidence, please sign up at &lt;A href="http://www.evidence.nhs.uk/NewsletterSignup.aspx" target="_blank"&gt;http://www.evidence.nhs.uk/NewsletterSignup.aspx&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The bulletin will keep you updated with new and important evidence and key developments on the NHS Evidence portal.&amp;nbsp; It comes out on the second Wednesday of the month and can be sent to any e-mail address that you provide.&lt;/P&gt;&lt;/LI&gt;
&lt;UL&gt;&lt;/UL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <expiryDate>04/05/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>155619</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.hdcn.com/symp/05asn/01/05asn01.htm]]&gt;</url>
    <title>Medical crossfire: an expert panel debates key clinical issues in mineral metabolism and mortality in CKD</title>
    <publicationDate>2005-11-01T00:00:00</publicationDate>
    <publisher>Hypertension, Dialysis and Clinical Nephrology (HDCN)</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ COMPLICATIONS OF KIDNEY DISEASE,OTHER,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Source of free CPD material for doctors, nurses and other medical professionals.
</description>
    <body>&lt;![CDATA[ &lt;P&gt;The CPD resource comprises talks and slide presentations, for which some additional software (such as macromedia flash player) may be needed for access.&lt;/P&gt;
&lt;P&gt;Note : You need to register for a freezone&amp;nbsp;loginID and password to access the free resources&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;'Method of participation:&lt;/B&gt; Listen to the talk, read the PubMed abstracts linked to data slides and talk references, take the post-test, read the abstracts linked to post-test answer feedback material' (website extract)&lt;/P&gt;
&lt;P&gt;Click on&amp;nbsp;Free Zone Index to view the other free resources at a glance.&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:26:17</lastReviewDate>
    <expiryDate>06/07/2011 11:26:17</expiryDate>
  </document>
  <document>
    <id>319025</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.menshealthforum.org.uk/publications/20249-mens-health-forum-publications]]&gt;</url>
    <title>Men's Health Forum Publications</title>
    <publicationDate>2009-12-01T00:00:00</publicationDate>
    <publisher>Men's Health Forum</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ ORGANISATIONS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Men's Health Forum Publications including brief outlines and, where available, links and downloads for the Forum's publications.
</description>
    <body>&lt;![CDATA[ Men's Health Forum Publications including brief outlines and, where available, links and downloads for the Forum's publications.&lt;BR&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;All publications related to the Forum's gender duty work are available under the&amp;nbsp;Gender Equality Duty section of the site.&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>01/07/2010 14:12:27</lastReviewDate>
    <expiryDate>01/07/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>187609</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.ukmf.org.uk/pdf/merit.pdf]]&gt;</url>
    <title>MERIT trial</title>
    <publicationDate>2003-02-03T00:00:00</publicationDate>
    <publisher>Leukaemia Research Fund/Cancer Research Uk</publisher>
    <publicationType>RANDOMISED CONTROLLED TRIAL</publicationType>
    <topics>&lt;![CDATA[ NEW RESEARCH,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Details of the myeloma renal impairment trial</description>
    <body>&lt;![CDATA[ &lt;FONT face=TimesNewRomanPSMT&gt;
&lt;P&gt;Study of whether&amp;nbsp;the addition of plasma exchange (PE) to chemotherapy increase the likelihood of renal recovery in patients with acute renal failure associated with newly diagnosed myeloma.&lt;/P&gt;&lt;/FONT&gt;]]&gt;</body>
    <lastReviewDate>23/09/2010 16:56:51</lastReviewDate>
    <expiryDate>23/09/2011 16:56:51</expiryDate>
  </document>
  <document>
    <id>262141</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.bmj.com/cgi/content/full/334/7605/1220]]&gt;</url>
    <title>Mild renal impairment increases cardiovascular risk</title>
    <publicationDate>2007-06-09T00:00:00</publicationDate>
    <publisher>European Heart Journal 2007;28:478-83:</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ COMPLICATIONS OF KIDNEY DISEASE,CARDIOVASCULAR DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Extract from BMJ - review of Belgian study in European Heart Journal</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;SUP&gt;Extract&lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;Renal impairment seems to have a detrimental&lt;SUP&gt; &lt;/SUP&gt;effect on cardiovascular risk at an early stage, even among&lt;SUP&gt; &lt;/SUP&gt;apparently healthy adults. This study suggests that risk starts&lt;SUP&gt; &lt;/SUP&gt;to rise once GFR falls below about 90 ml/min/1.73m&lt;SUP&gt;2&lt;/SUP&gt;, a substantially&lt;SUP&gt; &lt;/SUP&gt;higher cut-off point than previous estimates and one that the&lt;SUP&gt; &lt;/SUP&gt;authors describe as "near normal."&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;]]&gt;</body>
    <expiryDate>30/10/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>323305</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=323305]]&gt;</url>
    <title>Mini Topic Review: Acidosis and CKD</title>
    <publicationDate>2009-08-25T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ ASSESSMENT OF RENAL FUNCTION,PREDISPOSING FACTORS,INTERVENTIONS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Mini Topic Review: Acidosis and CKD&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Ione Ashurst and Muhammad M Yaqoob&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Metabolic acidosis is a common complication in patients with advanced chronic kidney disease (CKD), particularly when glomerular filtration rate falls below 30 ml/min.&amp;nbsp; This, in turn, may bring about a variety of sequelae such as stunted growth in children, loss of bone and muscle mass, negative nitrogen balance and possible acceleration of progression of chronic kidney disease.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;CKD patients who took oral sodium bicarbonate supplements slowed their progression to end-stage renal disease (ESRD) and improved their nutritional status, according to a British study that researchers say is the first randomized, controlled trial to show these positive effects (1).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The researchers recruited 134 adult CKD patients (creatinine clearance [CrCL] 15-30 mL/min/1.73 m2) and serum bicarbonate levels of 16-20 mmol/L. They randomly assigned 67 patients to receive supplementation with oral sodium bicarbonate (600 mg tablets three times daily increased as needed to achieve and maintain a bicarbonate level of 23 mmol/L) and 67 patients to receive standard care for two years. The primary end points were the rate of CrCL decline, the proportion of patients with rapid decline of CrCl (greater than 3 mL/min/1.73 m2/year), and ESRD (CrCl less than 10 mL/min/1.73 m2).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;After two years of follow-up, the researchers found that the mean CrCl decline was significantly slower in the treatment group than the control arm (1.88 vs. 5.93 mL/min/1.73 m2), according to findings published in the Journal of the American Society of Nephrology (2009; published online ahead of print) (1).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Furthermore, a rapid decline in CrCl occurred in 9% of the sodium bicarbonate group versus 45% of controls, which translated into a significant 85% reduction in relative risk. Only 6.5% of the sodium bicarbonate group progressed to ESRD requiring dialysis compared with 33% of controls.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;A significant increment was observed in dietary protein intake (DPI) in the treatment group compared with controls. In addition, normalized protein nitrogen appearance (nPNA) decreased in the bicarbonate group—suggesting reduced protein breakdown—and increased in the control arm. This increase in DPI and decrease in nPNA resulted in an increment in the lean body mass in the treatment group compared with no change in the controls.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Serum albunin levels increased in the sodium bicarbonate group but remained stable in the control group. At the end of the study, albumin levels were significantly higher in the sodium bicarbonate arm.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The positive renal effects of sodium bicarbonate supplementation were observed in the absence of any effects on BP control or proteinuria, which are two important factors relevant to CKD progression. The finding is suggestive of a specific independent role of low plasma bicarbonate: &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;“Absence of a deleterious effect on BP despite increased sodium intake is of particular interest but is consistent with the results of other studies suggest that sodium salts other than sodium chloride have a negligible effect on BP”.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The study’s findings are consistent with those of another study published recently in the American Journal of Kidney Diseases (2009; published online ahead of print) (2). In a study of 5,422 individuals, this study showed that low serum bicarbonate levels are associated with kidney disease progression independent of baseline estimated glomerular filtration rate (eGFR) and other clinical, demographic, and socioeconomic factors.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The findings of both these studies highlight the importance of metabolic acidosis in the progression of CKD. It confirms experimental evidence from 1980s that in subtotal nephrectomy models of experimental uraemia bicarbonate supplementation led to an attenuation of tubulointerstitial fibrosis and progression of renal failure. The findings of the Journal of the American Society of Nephrology study demonstrate a significant beneficial effect of correction of acidosis both for progression of CKD and improvement of nutritional status of patients with stage IV/V CKD in the predialysis phase. However, this study can be criticised by a lack of placebo use and absence of double blind design. Like any other single centre study, reproducibility and generalizability of this report will require further validation by a double blind placebo controlled multi-centre trial. &lt;BR&gt;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;It is recommended that patients with CKD and acidosis may benefit by bicarbonate supplementation: a strategy which is relatively safe, cheap and well tolerated by patients. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;I de Brito-Ashurst, Consultant, Department of Renal Medicine and Transplantation, William Harvey Research Institute and Barts and the London NHS Trust, London, United Kingdom. &lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;MM Yaqoob, Professor of Nephrology, Department of Renal Medicine and Transplantation, William Harvey Research Institute and Barts and the London NHS Trust, London, United Kingdom.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;1. de Brito-Ashurst I, Varagunam M, Raftery MJ, Yaqoob MM. Bicarbonate Supplementation Slows Progression of CKD and Improves Nutritional Status. J&amp;nbsp; Am Soc Nephrol. 2009 Jul 16. [Epub ahead of print] [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19608703" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;2. Shah SN, Abramowitz M, Hostetter TH, Melamed ML. Serum bicarbonate levels&amp;nbsp; and the progression of kidney disease: a cohort study. Am J Kidney Dis. 2009 Aug;54(2):270-7. Epub 2009 Apr 25. PubMed PMID: 19394734. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19394734" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;] &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>23/08/2010 12:03:05</lastReviewDate>
    <expiryDate>23/08/2011 12:03:05</expiryDate>
  </document>
  <document>
    <id>378576</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=378576]]&gt;</url>
    <title>Mini Topic Review: Anaemia Management in CKD patients - A mini-review</title>
    <publicationDate>2010-06-23T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ ANAEMIA,COMPLICATIONS OF KIDNEY DISEASE,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Mini Topic Review: Anaemia Management in CKD patients - A mini-review&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Anaemia Management in CKD patients: A mini-review&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Edward Sharples, Consultant in Nephrology and Transplant Medicine, Churchill Hospital, Oxford, and specialist collection clinical lead.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Introduction&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The results of large randomised trials in anaemia management in patients with CKD have led to a great deal of discussion, particularly following the publication of the TREAT study last year (1). A commentary on this study and its implications for clinical care by Mike Reschen and Christopher Winearls makes up the main content of this mini-review [&lt;A href="nelh:378555:0" name=internalLink&gt;Link to Guest Editorial on the TREAT trial&lt;/A&gt;].&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;A number of large observational studies have also reported recently, and may add usefully to the evidence on which ESA strategy is best adopted – late intervention with haemoglobin concentrations &amp;lt;10.0 g/dl, or early intervention with a haemoglobin falling to below 11 g/dl, which has been the mainstay of international clinical guidelines over the last few years, but have now been questioned following publication of TREAT.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Observational cohort studies based on current clinical practice in anaemia management should highlight and confirm whether the adverse outcomes associated with more aggressive ESA therapy targeting higher haemoglobins in a restricted study population are mirrored by similar findings in more standard, heterogeneous populations. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Seliger et al (2) performed a retrospective cohort study in patients with moderate to advanced CKD. Grouping of the population was defined by early (HB 10-11 g/dl) or late (8-10 g/dl) initiation of ESA treatment. There was no significant difference in mortality with early initiation (mortality 13.7/ 100 patient years) when compared with late initiation (14.9/ 100 pt yrs), with a non-significant hazards ratio for benefit of early start (HR 0.09, 95% CI 0.74-1.1). Late initiation was associated with increased hospitalization and increased requirement for blood transfusion, both of which may contribute to co-morbidity and potential adverse clinical events (2).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The ANSWER study was a prospective observational study of 2310 incident haemodialysis patients in 147 centres in Spain. Median follow-up from initation of dialysis was 24 months. Overall, mortality was 13.8/100 patient years, and there was a strong association between time-dependent haemoglobin concentration and relative risk of mortality, with a decreasing risk associated with higher haemoglobin quartiles. Over all quartiles, there was a positive association between high ESA doses and relative risk of mortality (3).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;A similar finding was made in a retrospective assessment of Medicare ESRD data including 269717 patients. The highest mortality rate was in patients with haemocrits less than 30%, and lowest for those patients with haemocrits 36% or higher. However, the centres that used high ESA dosing in patients with haemocrits 33-36% had increased mortality, and an increased risk was also seen with high intravenous iron use (4).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;These observational cohort studies include large numbers of heterogeneous CKD patients. Overall, there is an association between worsening anaemia and an increased risk of mortality, which may in part relate to chronic inflammation and ESA-hyporesponsiveness. In this group of high-risk patients, targeting a high haemoglobin with ever increasing doses of ESA is very likely to be associated with a worse outcome. Interestingly, these large studies still suggest that in ESA responders requiring low doses of ESA to maintain good concentrations of haemoglobin exhibit the lowest risk of mortality. A one-size fits all concept of anaemia management is destined to increase risk for some, whereas a policy of delayed initiation of ESA therapy will lead to more hospitalization and co-morbidity. A systematic review of the beneficial effects of ESA therapy on quality of life, exercise tolerance and fatigue scores, published by Gandra in the American Journal of Kidney diseases, have shown that the majority of studies (10/14) show significant improvements in energy and physical function (5). There is little evidence from these observational cohorts, and the four large RCTs to target HB &amp;gt;12 g/dl, but there remains debate over whether the results of TREAT should led to a delayed start of ESA therapy in relatively asymptomatic patients.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009 Nov 19;361(21):2019-32. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19880844" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Seliger et al&amp;nbsp;&amp;nbsp;[Link to PubMed abstract]&lt;/LI&gt;
&lt;LI&gt;Fort J et al on behalf of ANSWER investigators. Mortality in incident haemodialysis patients: time dependent haemoglobin levels and erythropoiesis-stimulating agent dose are independent predictive factors in the ANSWER study. Nephrol Dial Transplant 2010; e-published. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20176608" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Brookhart MA, Schneeweiss S, Avorn J, Bradbury BD, Liu J, Winkelmayer WC. Comparative mortality risk of anemia management practices in incident hemodialysis patients. JAMA. 2010 Mar 3;303(9):857-64. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/pubmed/20197532" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Gandra SR, Finkelstein FO, Bennett AV, Lewis EF, Brazg T, Martin ML. Impact of erythropoiesis-stimulating agents on energy and physical function in nondialysis CKD patients with anemia: a systematic review. Am J Kidney Dis. 2010 Mar;55(3):519-34. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20031287" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <expiryDate>23/06/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>392720</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=392720]]&gt;</url>
    <title>Mini Topic Review: Circumcision</title>
    <publicationDate>2010-11-01T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,PENILE DISORDERS,MALE UROGENITAL DISORDERS,CIRCUMCISION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Mini Topic Review: Circumcision&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Circumcision&lt;/STRONG&gt; &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;Dr J Manley &lt;BR&gt;Mr D Cranston&lt;BR&gt;Department of Urology Churchill Hospital Oxford OX3 7LJ&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Introduction&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Male circumcision is one of the oldest surgical procedures known to man and has been performed throughout the world for thousands of years for medical, cultural and religious reasons. It involves the removal of the foreskin which covers the glans penis, protecting it from friction and dryness by maintaining the sub-preputial space in a state of wetness with prostatic, vesicular and urethral secretions (1).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Circumcision has been performed for religious reasons as part of Judaism from the time of the book of Genesis where it appears as a sign of God’s covenant with Abraham and his descendants. Early Egyptian mummies (1300 BC) show evidence of circumcision and when Columbus found the ‘New World’ he noted that many of the natives were circumcised (2).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The popularity of the procedure varies greatly throughout the world largely depending upon cultural and religious beliefs. In the UK in 2000 15.8% of males aged 16-44 reported being circumcised in a British national survey of sexual attitudes and lifestyles (3).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Circumcision can be classified by either the age of the patient (neonate, child or adult), or as either therapeutic, or non-therapeutic. There are a number of indications for therapeutic circumcision and these will be discussed later. Non-therapeutic circumcision remains a controversial medico-legal and ethical topic, the most recent British Medical Association guidelines state: “male circumcision is not grounded in statute; however judicial review assumes that, provided both parents consent, non-therapeutic male circumcision is lawful” (4). At the present time non-therapeutic neo-natal circumcision is not covered by the NHS.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Ritual neonatal circumcision is practiced by many ethnic groups including Muslims, native Australians, many Christian Americans and Jews. It is often performed in the community by non-medical professionals. In Israel circumcision is usually performed when the baby is 8 days old by a “Mohel” who is specially trained in circumcision. It is done under clean (but non-sterile) conditions with no anaesthesia (5).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Indications&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Therapeutic circumcision is commonly done for a number of medical complaints, most commonly phimosis and paraphimosis due to a tight foreskin. This in turn may be due to inflammatory conditions such as balanitis. Occasionally other conditions such as penile lymphoedema, trauma or penile carcinoma may necessitate circumcision. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;There is increasing evidence of the public health benefits of widespread circumcision in areas with high prevalence of HIV, cervical and penile cancer. Circumcision reduces the infection rate of HIV, human papilloma virus and herpes simplex virus 2. This is probably due to elimination of the harbouring of human papilloma virus under the foreskin thus limiting the spread of the virus (6-7).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Surgical technique&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The procedure itself is usually done under general anaesthetic in children and adults with a local nerve block.&amp;nbsp; A dorsal penile nerve block is given by injecting local anaesthetic into the deep fascia (Buck’s fascia) of the penis near to the pubis, this may be accompanied by a penile nerve block. The most common procedure is the sleeve circumcision which is appropriate for both children and adults. This involves one incision 1cm proximal to the coronal sulcus below the glans and an external incision below the tight band on the penis taking care not to remove an excessive amount of skin. Bleeding is controlled by fine ligatures and/or bipolar electrocautery. The edges of the sleeve are approximated with fine absorbable sutures. A sterile dressing of petroleum gauze can then be applied over the sutures although this usually comes off within a few hours. If it says on, the dressing should be removed 24-48 hours post-operatively and the patient advised to wear loose fitting underwear and gently wash the wound daily for seven days. The patient may need as required simple analgesia for a few days post-operatively.&amp;nbsp; To prevent wound breakdown the patient should refrain from intercourse for four to six weeks.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;As with any surgical procedure there are side effects related to the anaesthetic and procedure itself. The most common complications are bleeding and infection. The majority of haemorrhages are relatively minor and direct pressure results in haemostasis. Cases of more extensive bleeding relate to anatomically anomalous vessels or bleeding disorders. Infection occurs after circumcision in up to 10 per cent of patients. In the majority of cases this is usually mild and manifested by local inflammatory changes, but occasionally there is ulceration and suppuration. Most infections are of little consequence and settle with local treatment; however rare cases of Fourniere’s gangrene have been reported. Other rare complications include meatal stenosis, urethrocutaneous fistula and some patients report decreased penile sensation (8).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;&amp;nbsp;&lt;BR&gt;Conclusion&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Circumcision is an ancient surgical procedure performed at all stages of life for both medical and cultural reasons by both non-medical and medical practitioners. The procedure is not without complications, however serious adverse effects are rare. The promotion of circumcision in areas with a high incidence of HIV and sexually transmitted infection confers public health benefits.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Prakash S, Raghuram R et al. Sub-preputial wetness - Its nature. Ann. Nat. Med. Sci (India) 1982; 18(3):109-112. [&lt;A href="http://www.cirp.org/library/anatomy/prakash/" target="_blank"&gt;Link to full text webpage&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Dunsmuir W, Gordon E. The history of circumcision. British Journal of Urology International 1999; 8(1): 1-12. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/10349408" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Dave S, Johnson A et al. Male circumcision in Britain: findings from a national probability sample survey. Sexually Transmitted Infection 2003; 79: 499-500. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/14663134" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Medical Ethics Committee, British Medical Association, 4 April 2003, Revised 15 June 2006. &lt;/LI&gt;
&lt;LI&gt;Chaim J.B, Pinhas M. et al. Complications of Circumcision in Israel: A One Year Multicenter Survey.&amp;nbsp; Israel Medical Association Journal. 2005 ;7(6): 368-70. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/15984378" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Austin P.F. Circumcision. Current Opinion Urology. 2010; 20(4): 318-22. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20531091" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hargreave T. Male circumcision: towards a World Health Organisation normative practice in resource limited settings.&amp;nbsp; Asian Journal of Andrology (2010) 12: 628–638. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20639909" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Williams N, Kapila L. Complications of circumcision. British Journal of Surgery. 1993; 80: 1231-1236. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/8242285" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <expiryDate>01/11/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>379520</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=379520]]&gt;</url>
    <title>Mini Topic Review: Holmium laser surgery for benign prostatic enlargement</title>
    <publicationDate>2010-06-25T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,BENIGN PROSTATE ENLARGEMENT,PROSTATE DISORDERS,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Mini Topic Review: Holmium laser surgery for benign prostatic enlargement&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;NHS Evidence: Holmium laser surgery for benign prostatic enlargement.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Pete Acher&lt;BR&gt;Urology SpR, South Thames, Guy’s Hospital, London SE1 9RT&lt;/P&gt;
&lt;P&gt;Alastair Henderson&lt;BR&gt;Consultant Urological Surgeon, Maidstone &amp;amp; Tunbridge Wells NHS Trust&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Introduction&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Surgical relief of bladder outflow obstruction that is secondary to benign prostatic enlargement (BPE) has traditionally involved either transurethral resection of the prostate (TURP) or open prostatectomy [1]. Both methods aim to remove the obstructing adenoma leaving the prostatic capsule intact to re-epithelialise and form a conduit for urine from bladder to urethra.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;TURP is a minimally invasive option: a resectoscope is passed down the urethra and a diathermy loop is maneuvered to resect chips of prostate. If (as is usually the case) monopolar diathermy is used, an irrigant solution such as glycine is used to maintain vision. Some of this solution is invariably absorbed systemically and causes a dilutional hyponatraemia; in severe cases this may manifest as TUR syndrome with associated morbidity.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The procedure time is therefore limited to approximately one hour. A further limitation is that bleeding may interfere with the operator’s vision and require postoperative irrigation through an irrigating catheter. Larger prostates are therefore dealt with either by a two stage TURP, or alternatively by open prostatectomy. This latter procedure uses the surgeon’s finger to enucleate the adenoma from the prostatic capsule. Whilst associated with the morbidities of open surgery as well as a longer postoperative hospital stay and higher transfusion rates, it is considered an effective treatment for BPE. Smaller prostates with little adenoma may be managed transurethrally with a bladder neck incision.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Holmium laser enucleation of the prostate (HoLEP)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The holmium laser (Ho:YAG) has been developed as an alternative to TURP and open prostatectomy. The laser is used to dissect the adenoma from the capsule in a similar manner to the open procedure, but endoscopically. The adenoma is placed into the distended bladder where it is morcellated and extracted; the tissue may then be analysed for histological features of cancer. The laser energy has excellent haemostatic properties and since saline is used as irrigant there is no risk of TUR syndrome. Thus the procedure is not limited by prostate size. The disadvantages are the initial start up costs of the equipment, and the so-called “surgical learning curve” for practitioners new to the procedure.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Evidence&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;A recent Health Technology Assessment included a meta-analysis of randomized controlled trials that compared TURP with HoLEP [2]. Five studies were included that evaluated over five hundred men. At one year, men in the HoLEP groups had significantly improved peak urine flow rates and lower (though not significantly so) subjective symptom scores suggesting that HoLEP is at least as effective, if not more, than TURP. Blood transfusion rates in the TURP groups were nine times those in the HoLEP groups (significant) and there was a non-significant trend towards less retention in the HoLEP patients. Men undergoing HoLEP had a hospital stay of one day less than their TURP counterparts, although the operating time was on average 17 minutes longer – both these differences were significant.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;A study from India evaluated the absorption of irrigant fluid during HoLEP in 53 patients and found that 26% absorbed between 200 and 930 mL of saline, but with no change in serum sodium levels [3]. The authors concluded that there was no risk of TUR syndrome.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Kuntz and Lehrich randomized 120 patients with prostate adenomas of 100g (beyond the considered upper limit for a safe TURP) to either HoLEP or open prostatectomy [4]. Objective peak flow rates and subjective symptom outcomes were similar for the groups at six months and these results were maintained at five year review [5]. The HoLEP procedures took longer (136 vs. 91 minutes), hospital stay was shorter (70 vs. 251 hours) and there were no blood transfusions in the HoLEP group (13.3% in the open group).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Evidence for learning curve differences between TURP and HoLEP is scarce and in any case difficult to measure meaningfully. Experienced practitioners however, do recommend that case selection is important to achieve favourable outcomes early in the series of surgeon new to HoLEP [6]. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The Health Technology assessment used Markov modelling and Monte Carlo simulation to assess the costs of HoLEP versus TURP and found the former to be less costly, although there were limitations to the study [2].&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Greenlight laser&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The Greenlight laser uses energy to vapourise the obstructing adenoma. This also can be carried out with saline irrigation therefore obviating TUR syndrome, and is reported to have excellent haemostatic properties. With patience large prostates may be treated. Several short term (12 to 18 month) randomized controlled trials have reported clinical efficacy comparable with TURP. There are, however, concerns regarding long term outcomes, in particular the need for repeat surgical intervention [2]. The most recent NICE guidelines therefore only recommend greenlight laser vapourisation of the prostate as part of a randomized controlled trial [7].&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Conclusion&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;There is good evidence to show that HoLEP is least as effective as TURP and open prostatectomy for the surgical treatment of BPE. It results in shorter hospital stay with no risk of TUR syndrome and reduced bleeding requiring transfusion. Prostate size does not limit the procedure. As with any surgical procedure, the unit’s experience is likely to be important in determining outcomes. Cost effectiveness studies have limitations, but it is probable that the initial costs of equipment and longer operating times are offset by shorter hospital stay and the need for re-operation.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;BR&gt;[1] Emberton M et al. The National Prostatectomy Audit: the clinical management of patients during hospital admission. BJU 1995;75:301-316 [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/7735797" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;[2] Lourenco T, Armstrong N, N'Dow J, Nabi G, et al. Systematic review and economic modelling of effectiveness and cost utility of surgical treatments for men with benign prostatic enlargement. Health Technol Assess 2008;12(35):1-516. &lt;A href="http://www.hta.ac.uk/execsumm/summ1235.shtml" target="_blank"&gt;http://www.hta.ac.uk/execsumm/summ1235.shtml&lt;/A&gt;&lt;BR&gt;[3] Shah HN, Kausik V, Hedge S et al. Evaluation of fluid absorption during holmium laser enucleation of prostate by breath ethanol technique.&amp;nbsp;J Urol 2006;175:537-540 [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16406990" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;[4] Kuntz RM, Lehrich K. Transurethral holmium laser enucleation versus transvesical open enucleation for prostate adenoma greater than 100 gm.:: a randomised prospective trial of 120 patients. J Urol 2002;168:1465-1469. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/12352419" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;[5] Kuntz RM, Lehrich K, Ahyai SA. Holmium laser enucleation of the prostate versus open prostatectomy for prostates greater than 100 grams: 5-year follow-up results of a randomised clinical trial. Eur Urol 2008;53:160-168. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17869409" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;[6] Placer J, Gelabert-Mas A, Vallmanya F, Manresa JM&amp;nbsp;et al. Holmium laser enucleation of prostate: outcome and complications of self-taught learning curve. Urology 2009;73:1042-8. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19394500" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;[7] NICE. Lower&amp;nbsp;urinary tract symptoms: The management of lower urinary tract symptoms&amp;nbsp;&amp;nbsp;in men. May 2010. Link:&amp;nbsp;&lt;A href="http://www.nice.org.uk/nicemedia/live/12984/48557/48557.pdf" target="_blank"&gt;http://www.nice.org.uk/nicemedia/live/12984/48557/48557.pdf&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <expiryDate>25/06/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>343358</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=343358]]&gt;</url>
    <title>Mini Topic Review: Implications of the ASTRAL (Angioplasty and Stenting for Renal Artery Lesions) trial for current management of atherosclerotic renovascular disease (ARVD)</title>
    <publicationDate>2010-02-09T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ RENOVASCULAR DISEASES,IN ADULTS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Mini topic review by Professor Philip A Kalra, Consultant and Honorary Professor in Nephrology, Salford Royal Hospital and University of Manchester</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Mini Topic Review: Implications of the ASTRAL (Angioplasty and Stenting for Renal Artery Lesions) trial for current management of atherosclerotic renovascular disease (ARVD)&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Implications of the ASTRAL (Angioplasty and Stenting for Renal Artery Lesions) trial for current management of atherosclerotic renovascular disease (ARVD)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Professor Philip A Kalra, Consultant and Honorary Professor in Nephrology, Salford Royal Hospital and University of Manchester&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Endovascular procedures to correct renal artery stenosis (RAS) have been available for over two decades, but there has been uncertainty regarding the outcomes after renal revascularization and there has been a requirement for adequately powered randomised control trials (RCT). The Angioplasty and Stenting for Renal Artery Lesions (ASTRAL) trial randomised patients equally between angioplasty and/or stenting plus medical therapy versus medical therapy alone. Entry criteria were patients with anatomically significant atherosclerotic RAS, unilateral or bilateral but with no prior revascularization, who would normally be considered for revascularization but in whom clinicians were uncertain regarding the likely outcomes of this therapy. The primary end point was rate of decline of renal function, and secondary endpoints were blood pressure control, occurrence of renal or serious vascular events and mortality. The trial had broad eligibility criteria so that these outcomes could be investigated in a clinically relevant population.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;There were 806 patients randomised between 2000-2007 from 57 centres (53 UK based and 4 in Australasia). At baseline mean age of all patients was 70 years, serum creatinine 179 ?mol/l, estimated GFR 40ml/min and blood pressure 151/76 mm Hg. Average RAS at entry was 76%; 30% were diabetic and 49%, 40% and 19% had a previous history of coronary heart disease, peripheral vascular disease and stroke, respectively. 80% were treated with statins, 75% anti-platelet drugs and 98% were receiving antihypertensive therapy. At data lock mean follow up was 34 months. Repeated measures analysis showed no significant differences between the two arms of the study in renal function, systolic or diastolic blood pressure, cardiovascular or renal events or mortality during follow-up. There was a small rise in creatinine (18 ?mol/l) in both groups at 12 months, which remained stable thereafter; systolic blood pressure had decreased by 5 mmHg in both groups at this time point. During follow up combined cardiovascular events occurred at approximately 10% per year in both groups, with mortality 8% per year. Notably 6.8% of patients treated with revascularization suffered a major complication, including serious renal arterial damage, atheroembolization with limb ischaemia, or hospitalisation due to acute kidney injury (AKI) or significant groin haematoma.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;What conclusions can we draw from ASTRAL, and what are the implications for current management of atherosclerotic RAS? ASTRAL is by far the largest published RCT in ARVD and in patients with a range of radiologically significant RAS lesions, there was no benefit in any outcome measure from additional revascularization when both groups were treated with optimal medical therapy. However, it is acknowledged that the vast majority of recruited patients were likely to have relatively clinically asymptomatic disease (eg presenting for investigation of chronic kidney disease (CKD) with hypertension) and in these situations the RAS can be an incidental finding and not pathophysiologically significant. Given that significant complications do occur from revascularization procedures even in experienced hands, key implications are that asymptomatic patients should not be referred for revascularization for the purpose of improving blood pressure control, renal function or preserving functional mass, and this particularly applies to those patients whose RAS is detected incidentally during other investigative procedures (eg during investigation of coronary or peripheral arterial disease). Further, there would appear to be little benefit in screening asymptomatic CKD patients for ARVD – our current medical vascular protective strategies appear to be quite effective at reducing cardiovascular morbidity and mortality in these high-risk patients, and a case could be made for treating them with medical therapy and only pursuing the RAS diagnosis if clinical deterioration occurs (eg progressive CKD or recalcitrant hypertension). Some sub-groups of ARVD patients probably do benefit from revascularization, and a future goal is to be able to confidently identify these patients. In the meantime, it would be reasonable for endovascular renal revascularization to be restricted to patients with clinical deterioration or to those presenting with AKI or flash pulmonary oedema, patients in whom current consensus suggests benefit from intervention – such latter patients were not investigated within ASTRAL.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Reference&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;ASTRAL Investigators, Wheatley K, Ives N, Gray R, Kalra PA, Moss JG, Baigent C, Carr S, Chalmers N, Eadington D, Hamilton G, Lipkin G, Nicholson A, Scoble J. Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med. 2009 Nov 12;361(20):1953-62. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19907042" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>11/01/2011 10:22:10</lastReviewDate>
    <expiryDate>11/01/2012 10:22:10</expiryDate>
  </document>
  <document>
    <id>407610</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=407610]]&gt;</url>
    <title>Mini Topic Review: Kidney Stones</title>
    <publicationDate>2011-03-01T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY AND BLADDER STONES,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Mini Topic Review: Kidney Stones&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Kathie Wong &lt;BR&gt;Core Trainee, Guy's and St. Thomas' Hospital London&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Kay Thomas&lt;BR&gt;Consultant Urologist, Guy's and St. Thomas' Hospital London&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Introduction&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Kidney stones are common, with an annual incidence of 1-2 per 1000 people in the United Kingdom. The peak age for developing stones is between 30-50, with males more commonly affected than females (3:1). The exact aetiology is unknown however there are two main mechanisms: heterogeneous nucleation and supersaturation of crystals forming substances in the urine. The composition of stones are 75% calcium (calcium oxalate or calcium phosphate), 15% struvite, 6% uric acid and 2% cystine. Several underlying conditions predisposes to the formation of these stones including hyperparathyroidism, gastrointestinal diseases i.e. Crohn’s or malabsorption, and immobility. Struvite stones (magnesium ammonium phosphate) are associated with chronic urinary tract infection (UTI) with gram-negative rods (E. coli, klebsiella, proteus). Cystine stones arise from an intrinsic transport defect resulting in failure of renal tubular reabsorption of amino acids; cystine, ornithine, lysine and arginine. Only cystine is clinically relevant as the others are soluble in concentrations found in urine [1].&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Presentation&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Stones cause symptoms as they proceed distally from the kidney and become lodged and obstructed in narrow areas of the urinary tract, particularly the pelvic ureteric junction (PUJ), pelvic brim and vesicoureteric junction (VUJ). The nature of the symptoms may reflect its location: stones lodged at the PUJ may cause deep flank pain, as the stones travel lower down the ureters the pain may radiate into the groin and at the VUJ, they may cause irritative lower urinary symptoms such as frequency and dysuria. Once the stones enter the bladder, they are usually asymptomatic and can be passed easily on urination. The classic renal colic patient is writhing around in pain and unable to lie still. The presence of a fever warrants concern regarding possible presence of infected hydronephrosis, pyelonephritis or abscess. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;STRONG&gt;Investigations &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Diagnosis should be confirmed with appropriate imaging. An abdominal film detects calcium stones, struvite and cystine stones which are poorly radiopaque,&amp;nbsp;and&amp;nbsp;uric acid and urate stones which are radiolucent. For an acute stone episode, the gold standard was an intravenous pyelography (IVP), although more recently, this has been superseded by a non-contrast CT scan which offers the advantage of helping to exclude other causes [2,3,4]. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Investigations for an acute stone episode include urine dipstick and culture, renal function tests, inflammatory markers and calcium, phosphate and urate. Serum analysis of cystine can be evaluated in suspected patients. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;It is recommended by the European Association of Urology that all patients should have at least one stone analysed [2]. More specific tests may be&amp;nbsp; required for those with bilateral disease, recurrent stones e.g. parathyroid hormone, 24-hour urine for metabolic evaluation.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Management&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;An acute stone episode should be treated with analgesia with clinical trials showing that NSAIDS in particular diclofenac can provide effective relief. Small stones &amp;lt;5mm have a 65% chance of passing spontaneously. Stones between 5-10mm have a 47% chance of passing spontaneously and can be expedited by administration of an alpha-blocker such as tamsulosin [5]. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Active stone removal is recommended in the following: stone diameter is &amp;gt;7mm due to a low rate of spontaneous passage, when adequate pain relief cannot be achieved, stone obstruction associated with infection, in a single kidney with obstruction and bilateral obstruction [2]. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Prevention of stones is focused on dietary and lifestyle measures with the essential factor being adequate hydration [6]. A diet low in protein and salt can be beneficial for all stone formers except struvite. Uric acid and cystine stone formers often have acidic urine, therefore alkalinisation with potassium citrate may be recommended.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Medical therapy&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Medical expulsive therapy with alpha blockers e.g. tamsulosin has been shown to increase the rate of spontaneous stone passage and decrease time to stone passage [5]. Patients may require further intervention due to stone size, continual obstruction or pain. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Extracorporeal shockwave lithotripsy (ESWL)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Extracorporeal shockwave lithotripsy is a non-invasive method of fragmenting stones into smaller fragments that can then be expulsed spontaneously. Reported success rates have been 66-99% for stones &amp;lt;20mm and 45-60% for stones &amp;gt;20mm. For stones greater than 20mm in diameter, a JJ stent is recommended prior to treatment to prevent obstruction although it has not been shown to improve stone-free rates. Complications of ESWL are more frequent with larger stones and include pain, hydronephrosis secondary to Steinstrasse, fever, and occasional urosepsis&amp;nbsp;or renal haematoma.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Ureteroscopy (URS)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Ureteroscopy can be performed for stones in the ureter or kidney, in patients who have failed ESWL or are unsuitable for percutaneous nephrolithotomy (obese or anticoagulated) [7]. Using a flexible or rigid ureteroscope several techniques can then be employed to disintegrate the stone. Holmium laser (Ho:YAG) is the preferred method when using a flexible URS. Ballistic lithotripters (pneumatic or electropneumatic) can be used where the stones are accessible via a semi-rigid scope. The fragmented pieces can then be extracted with a basket or grasping device. A ureteric stent may be inserted if there has been any evidence of ureteric injury, stricture, in solitary kidney, renal insufficiency, large residual stone burden or concern about infection. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Percutaneous nephrolithotomy (PCNL)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;For stones in the kidney, percutaneous removal of renal stones can be performed to remove stones where ESWL is unsuitable for example, large stones and stones in the lower pole [8]. Access is achieved via a puncture directly into the kidney under image guidance. Large stones need to be fragmented with laser or hydro-pneumatic probes prior to removal. Complications include incomplete clearance, sepsis, bleeding, and inadvertent puncture to surrounding organs (bowel, lung) [9]. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Open Surgery&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Open surgery is now only reserved for difficult cases e.g. complex stone burden and in centres where equipment, expertise and experience of surgical treatment is available [10]. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="MARGIN-RIGHT: 0px" dir=ltr&gt;&lt;BR&gt;[1]&amp;nbsp;Thomas K, Bultitude M, Doherty A. Cystinuria UK.&amp;nbsp; 2010. Link: &lt;A href="http://www.cystinuriauk.co.uk/" target="_blank"&gt;http://www.cystinuriauk.co.uk/&lt;/A&gt; [accessed 23 February 2011]&lt;BR&gt;[2]&amp;nbsp;Türk C, T K, A P, et al. Guidelines on Urolithiasis European Association of Urology, 2010. [&lt;A href="http://www.library.nhs.uk/KIDNEY/ViewResource.aspx?resID=148803&amp;amp;tabID=288" target="_blank"&gt;Link to abstract&lt;/A&gt;]&lt;BR&gt;[3]&amp;nbsp;Shine S. Urinary calculus: IVU vs. CT renal stone? A critically appraised topic. Abdom Imaging. 2008 2008 Jan-Feb: 33:41-3. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17786506" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;[4]&amp;nbsp;Worster A, Preyra I, Weaver B, Haines T. The accuracy of noncontrast helical computed tomography versus intravenous pyelography in the diagnosis of suspected acute urolithiasis: a meta-analysis. Ann Emerg Med. 2002 Sep: 40:280-6. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/12192351" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;[5]&amp;nbsp;Hollingsworth JM, Rogers MA, Kaufman SR, et al. Medical therapy to facilitate urinary stone passage: a meta-analysis. Lancet. 2006 Sep: 368:1171-9. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17011944" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;[6]&amp;nbsp;Borghi L, Meschi T, Schianchi T, et al. Urine volume: stone risk factor and preventive measure. Nephron. 1999: 81 Suppl 1:31-7. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/9873212" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;[7]&amp;nbsp;Bultitude MF, Tiptaft RC, Dasgupta P, Glass JM. Treatment of urolithiasis in the morbidly obese. Obes Surg. 2004 Mar: 14:300-4. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/15072647" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;[8]&amp;nbsp;Raman JD, Pearle MS. Management options for lower pole renal calculi. Curr Opin Urol. 2008 Mar: 18:214-9. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18303547" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;[9]&amp;nbsp;Thomas K, Smith NC, Hegarty N, Glass JM. The Guy's Stone Score-Grading the Complexity of Percutaneous Nephrolithotomy Procedures. Urology. 2011 Feb. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/21333334" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;[10]&amp;nbsp;Paik ML, Wainstein MA, Spirnak JP, Hampel N, Resnick MI. Current indications for open stone surgery in the treatment of renal and ureteral calculi. J Urol. 1998 Feb: 159:374-8; discussion 8-9. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/9649242" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <expiryDate>01/03/2012 00:00:00</expiryDate>
  </document>
  <document>
    <id>378555</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=378555]]&gt;</url>
    <title>Mini Topic Review: The TREAT Trial</title>
    <publicationDate>2010-06-23T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ COMPLICATIONS OF KIDNEY DISEASE,ANAEMIA,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Mini Topic Review: The TREAT Trial&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;The &lt;EM&gt;TREAT&lt;/EM&gt; Trial&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Michael Reschen MB MRCP(UK) and Christopher G Winearls MB (Cape Town), D.Phil(Oxon) FRCP (London)&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Oxford Kidney Unit&lt;BR&gt;The Churchill&lt;BR&gt;Oxford Radcliffe Hospital NHS Trust&lt;BR&gt;Oxford OX3 7LJ&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Read the introductory article by Edward Sharples on Anaemia in CKD Patients first - [&lt;A href="nelh:378576:0" name=internalLink&gt;Link to mini-review&lt;/A&gt;].&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;The use of &lt;STRONG&gt;E&lt;/STRONG&gt;rythropoiesis &lt;STRONG&gt;S&lt;/STRONG&gt;timulating &lt;STRONG&gt;A&lt;/STRONG&gt;gents (ESAs) to treat anaemia in patients with CKD has become routine (1).&amp;nbsp; The initial justification was simply the relief of symptoms of anaemia and the avoidance of blood transfusion, and was later reinforced by post hoc epidemiological studies showing lower mortality in patients with higher haemoglobin concentrations irrespective of the ESA dose (2). What has not been established by systematic controlled clinical trials is the threshold haemoglobin at which treatment should be started, the target haemoglobin or whether treatment does have beneficial effects on survival and the incidence of cardiovascular events.&amp;nbsp; Three randomised trials (the Amgen Normal Hematocrit Study, CHOIR and CREATE) comparing different target haemoglobins had failed to show any improvement in outcomes in CKD patients randomised to normal haemoglobin concentrations and one showed an adverse effect (3,4,5). The results of a fourth trial were published in November 2009 (6). The completion of this trial was particularly welcome because of the uncertainties that arose from those posing similar questions. There had even been calls for it to be abandoned.&amp;nbsp; It was different in a particularly important respect – it was placebo controlled ignoring the supposition that withholding an ESA was harmful and examined the potential harm of intervention. How do the results alter how patients with CKD should be treated?&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;TREAT&lt;/STRONG&gt;&amp;nbsp; (The &lt;STRONG&gt;T&lt;/STRONG&gt;rial to &lt;STRONG&gt;R&lt;/STRONG&gt;educe Cardiovascular &lt;STRONG&gt;E&lt;/STRONG&gt;vents with &lt;STRONG&gt;A&lt;/STRONG&gt;ranesp &lt;STRONG&gt;T&lt;/STRONG&gt;herapy) was a large international, double blind randomized placebo-controlled multi-centre study designed to establish whether&amp;nbsp; ESA treatment of anaemia in patients with type 2 diabetes and chronic kidney disease (not receiving renal replacement therapy) improved their survival, reduced cardiovascular events, delayed progression of renal dysfunction and improved their quality of life. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;4038 patients were randomized; 2012 to darbepoetin alfa to achieve a target a haemoglobin of ~13g/dL and 2026 to placebo with the option of rescue therapy if the Hb was &amp;lt;9g/dL. The primary endpoints were the composite outcomes of death or a cardiovascular event (no fatal myocardial infarction, congestive heart failure, stroke, or hospitalisation for myocardial ischaemia) and of death or end stage renal disease. Follow-up data was available for 87% of patients and the trial was terminated at 29 months after the number of pre-specified events to achieve adequate statistical power was reached. The baseline characteristics of the two groups were similar with a median age of 68 and a relatively high level of co-morbidity with 65% of patients having suffered a cardiovascular event previously. There were slightly more patients with cardiac failure in the placebo group (35% versus 31%). &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Treatment with darbopoetin at a median dose of 176ug/month increased the haemoglobin from a median of 10.5g/dl to a median of 12.5g/dl. The placebo arm median haemoglobin was 10.4g/dL at randomisation and 10.6g/dl after treatment. There was no significant difference between the groups in terms of the primary composite outcome of death, cardiovascular events or end-stage renal failure. Overall the risk of death or major cardiovascular event in this cohort of CKD patients was 31% during the study period. There was a significant excess of strokes in the darbopoetin treatment group 101 (5.0%) versus 53 (2.6%) in the placebo arm – a hazard ratio of 1.92. The proportion of non-haemorrhagic strokes was the same in each arm. An important finding was a significantly increased risk of death from cancer in the small subgroup of patients who had a known malignancy at baseline. There was also an increased number of thrombo-embolic events.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Potential benefits of darbopoetin therapy included: a significant reduction in the number of blood transfusions and the number of cardiac revascularization procedures. Patient reported outcomes in two different quality of life surveys showed a modest but statistically significant benefit on fatigue. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The investigators concluded that for many patients with diabetes and CKD there was survival or cardiovascular event reduction benefit from a strategy targeting haemoglobin level of 13.5 g/dl versus above 9 g/dl, and that the increased risk of stroke made ESA treatment possibly harmful in this group of patients. These findings have been interpreted to mean that treatment of moderate anaemia in CKD patients confers modest benefit, does not improve survival or protect from cardiovascular events. The modest benefits come at a cost of an increased risk of stroke.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This is too glib. The conclusions need to be more specific. A general policy of attempting to achieve a Hb of 13g/dl in diabetic patients with CKD and Hb concentrations of ~10g/dL cannot be defended.&amp;nbsp; There is no proven survival nor a protective effect but a definite increased risk of stroke and possibly an adverse influence on pre-existing cancers. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Some nephrologists find the results of this trial perplexing and are reluctant to use its findings to dictate their clinical practice. They recognise that administering an ESA to patient with CKD has effects other than those on the erythron some of which may be the consequence of an increase in red cell production e.g. those on iron flux; blood pressure; blood rheology, platelet function. There may also be direst effects on the endothelium.&amp;nbsp; The pathophysiological effects may be related to the rate of change of red cell production and the dose of the ESA. These effects provide the basis of a plausible hypothesis for an increased risk of cardiovascular events in a patient population with a huge excess risk already. They believe that treatment of anaemia should imitate normal physiology, maintaining iron balance and red cell production to compensate for loss, senescence and destruction to achieve an haemoglobin concentration which prevents symptoms and the need to transfuse.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;However there are too many questions and paradoxes for them to believe that ESA treatment is intrinsically dangerous and of minimal benefit except in special circumstances (7).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;The HR for cardiovascular events varied according to eGFR. They were not different in patients with eGFRs &amp;lt;45ml/min but significantly higher in those with eGFRs of 45-60ml/min treated with darbepoetin. Is it possible that the anaemia in this group was caused by more than CKD?&lt;/LI&gt;
&lt;LI&gt;The use of iron was different in the two arms. &lt;/LI&gt;
&lt;LI&gt;The HR for the cardiovascular composite endpoints varied between regions (lowest in Western Europe and Australia (0.66) and highest in Russia (1.26)). It varied by ethnicity – highest in Blacks.(1.27) vs Whites (0.99)&lt;/LI&gt;
&lt;LI&gt;Both non- haemorrhagic and haemorrhagic strokes were more common in the darbepoetin treatment arm implying effects on different mechanisms.&lt;/LI&gt;
&lt;LI&gt;The target Hb of 13g/dl was higher than that aimed for in current clinical practice and no account was taken of the different normal ranges of Hb in men and women. &lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;These are issues that arise from other studies too.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Dialysis patients who achieve normal haemoglobin without an ESA are not disadvantaged.&lt;/LI&gt;
&lt;LI&gt;Secondary analysis of the CHOIR trial showed that patients achieving the target haemoglobin concentration than those that did not; and among subjects who achieved their randomised target, no increased risk associated with the higher haemoglobin goal was detected. (8). A similar finding was reported in&amp;nbsp; the Normal Hematocrit Study (3).&lt;/LI&gt;
&lt;LI&gt;Different ESAs were used in CHOIR, CREATE and TREAT and the doses used in the higher Haemoglobin target groups varied widely (~11,000 units/week in CHOIR; 5000 units/week in CREATE and ~8,800units/week in TREAT.&lt;/LI&gt;
&lt;LI&gt;The study populations had very different and rather specific characteristics. All the patients in TREAT had diabetes mellitus; 50% of those in CHOIR had diabetes and all the patients in the Normal Hematocrit Study had heart disease.&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;We have reached a more limited set of conclusions from this trial and those that preceded it.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;The benefits of ESA treatment in patients with mild to moderate anaemia (Hb ~10g/dl are modest so it should only be offered to patients with symptoms or blood transfusion requirement. If neither are relieved it should be stopped.&lt;/LI&gt;
&lt;LI&gt;ESAs cannot be regarded as cardio protective in patients with CKD but a benefit of amelioration of an anaemia (as opposed to complete reversal) has not been excluded&lt;/LI&gt;
&lt;LI&gt;There is a relative contraindication to the prescription of ESAs in patients suffering moderate anaemia with a history of stroke, previous thrombosis or cancer.&lt;/LI&gt;
&lt;LI&gt;Because aiming to reach normal haemoglobin with ESA treatment has been shown to confer a risk of adverse events it should be neither policy nor the objective in an individual patient.&amp;nbsp; The current recommendation of 12g/dL should stand until further evidence is obtained. We are agnostic on the question of what to do if a patient achieves a normal haemoglobin without an ESA or on a low dose.&lt;/LI&gt;
&lt;LI&gt;In individual patients the benefits should be balanced against the risks of an effect of ESAs on blood pressure and coagulation.&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;NICE CKD: Guideline (September 2008): Chronic kidney disease: early identification and management of chronic kidney disease in adults in primary and secondary care. [&lt;A href="nelh:294680:0" name=internalLink&gt;Link to NICE guideline&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Fort J et al on behalf of ANSWER investigators. Mortality in incident haemodialysis patients: time dependent haemoglobin levels and erythropoiesis-stimulating agent dose are independent predictive factors in the ANSWER study. Nephrol Dial Transplant 2010; e-published. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Mortality+in+incident+haemodialysis+patients%3A+time+dependent+haemoglobin+levels+and+erythropoiesis-stimulating+agent+dose+are+independent+predictive+factors+in+the+ANSWER+study&amp;amp;TransSchema=title&amp;amp;cmd=detailssearch" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kilpatrick RD, Critchlow CW, Fishbane S, Besarab A, Stehman-Breen C, et al. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol. 2008 Jul;3(4):1077-83. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/pubmed/18417744" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Singh AK, Szczech L, Tang KL, et al. Correction of anaemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-2098.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17108343" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Drüeke TB, Locatelli F, Clyne N, et al. Normalization of haemoglobin level in patients with chronic kidney disease and anaemia. N Engl J Med 2006;355:2071-2084.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17108342" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Pfeffer MA, Burdmann EA, Chen C-Y, et al. A trial of darbopoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361:2019-2032.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19880844" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Singh AK. Does TREAT give the boot to ESAs in the treatment of CKD anemia? JASN 2010;21:2-6.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20035034" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Szczech LA et al. Secondary analysis of the CHOIR trial epoetin-alfa dose and achieved haemoglobin outcomes. Kidney Int 2008;74:791-798.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18596733" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;*** The European ERBP has issued a position statement on the TREAT study:&lt;/P&gt;
&lt;P&gt;Locatelli F, Aljama P, Canaud B, Covic A, De Francisco A, Macdougal IC et al. Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) Study. Nephrology Dialysis Transplantation, doi: 10.1093/ndt/gfq336 [&lt;A href="http://ndt.oxfordjournals.org/cgi/content/abstract/gfq336v1" target="_blank"&gt;Link to NDT abstract&lt;/A&gt;] ***&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <expiryDate>23/06/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>381551</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=381551]]&gt;</url>
    <title>Mini Topic Review: Vasectomy and Vasectomy Reversal</title>
    <publicationDate>2010-08-02T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,FERTILITY,VASECTOMY,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Mini Topic Review: Vasectomy and Vasectomy Reversal&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Vasectomy and Vasectomy Reversal&lt;/STRONG&gt; &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;Mr T Evans &lt;BR&gt;Mr D Cranston&lt;BR&gt;Department of Urology Churchill Hospital Oxford OX3 7LJ&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Vasectomy began with a questionable history as a tool for eugenics, criminal punishment, and rejuvenation (1), but today it has become a common surgical procedure and one of the most reliable methods of birth control in the world used by an estimated 42 million men. Although traditionally viewed as a permanent procedure, vasectomy is neither irreversible nor without failure. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Vasectomy procedure&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Vasectomy is usually done under local anaesthesia. Single or bilateral 1cm incisions are made in the scrotum over the vas deferens which is then held with forceps and pulled into the wound forming an inverted ‘U’. The adventitia is stripped away, 1-2cm of the vas removed, and the lumen cauterised. The ends of the vas are separated into different tissue planes and dropped back under the skin. Sutures are often not used and it is not necessary to send the vas for histological examination, although the couple need to be advised to use contraception until negative semen samples are obtained.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;In many places the traditional scalpel method has been replaced by the ‘no scalpel’ vasectomy (NSV). This technique, also known as the ‘Li’ method, uses very pointed forceps which are capable of breaching the skin without the use of a scalpel.&amp;nbsp; Other variations include fascial interposition, vasal ligation, and the use of clips instead of, or in addition to, intraluminal cautery. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Follow-up&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;By convention in the UK, two specimens of semen are examined at 16 and 18 weeks after vasectomy to confirm the success of the operation. Most men will have no sperm in the samples (azoospermia) at these points. The risk of pregnancy following two negative results is about 1 in 2-3000 due to late recanalisation of the vas (2). There have been isolated cases of post-vasectomy fatherhood even after persistent negative semen analysis (3). This has been confirmed by DNA analysis of the father and child thus excluding the “milkman” factor. In this situation the odd sperm will have been getting though due to recanalisation but has not shown up on any of the tests. Successful clearance may also be given to men who have less than 10,000 sperm at 7 months (4), although a recent paper has suggested this could be extended 100,000 immotile sperm/ml in a sample at 3 months (5). This would allow 96% of men to be cleared by this time. Although it is not essential in the UK that wives or partners sign the operation consent form, many surgeons prefer that they do. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Complications&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The main complication following vasectomy is scrotal pain. One study found that 11.7% of previously asymptomatic patients had some degree of scrotal discomfort at seven months after the NSV operation (6) (with higher rates for the traditional scalpel method). Rarer complications include bleeding, infection and scrotal haematoma (7-8). Although there have been suggestions of a link between vasectomy and prostate cancer, the evidence does not show proof of any association (9-10). &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Reversal of vasectomy&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The most common reason for a reverse vasectomy is to regain fertility when entering a new relationship or following a marriage breakdown. Reported pregnancy rates following reversal vary widely from as low as 20% and up to 80%. This range is explained by the presence of several factors such as time since vasectomy, type of reversal operation, age, and a potential effect of circulating antisperm antibodies which are present in about 60% of men following bilateral vasectomy (11). The fertility potential of the partner is another confounding factor. The operation is also sometimes used in an attempt to relieve scrotal discomfort. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Vasovasostomy&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Incisions are made to provide access to the old vasectomy site and the scarred ends of the vas are excised. Fluid is then removed from the testicular end and examined microscopically for the presence of sperm. Depending on the motility of the sperm and the colour and consistency of the fluid, the surgeon can now decide which reverse vasectomy operation to use. If there is sperm present in the fluid a vasovasotomy is usually performed. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Vasovasostomy involves bypassing any scarred tissue and anastomosing the two ends of the vas back together. Two main variations are used; the modified one layer anastomosis or a two-layer anastomosis. Most surgeons today will use an operating microscope to assist during the operation. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Vasoepididymostomy&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;If there is no sperm present in the fluid then the more surgically demanding vasoepididymostomy should be performed. This involves connecting the abdominal end of the vas up to a much narrower epididymal tubule. This should be done using an operating microscope. Because the choice of procedure is best made during the operation (once the testicular vas fluid has been checked for sperm), reverse vasectomy should only be carried out when there is a surgeon present who is comfortable performing vasoepididymostomy. Both presence of sperm in semen and pregnancy rates are lower following vasoepididymostomy than vasovasostomy. Complications are rare for both procedures. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Conclusion&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Vasectomy remains a reliable method of birth control, but it is not free of complications. All patients and their partners must be made aware of the small possibility of vasectomy failure leading to pregnancy. Reversal of vasectomy may be possible but success and subsequent pregnancy cannot be guaranteed. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Drake MJ, Mills IW,&amp;nbsp; Cranston D. On the chequered history of vasectomy. BJU International. 1999; 84(4): 475-481&lt;/LI&gt;
&lt;LI&gt;Haldar N, Cranston D, Turner E, MacKenzie I, Guillebaud J. How reliable is a vasectomy? Long-term follow-up of vasectomised men. Lancet. 2000; 356(9223): 43-44. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/10892767" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Smith JC, Cranston D, O’Brien T, Guillebaud J, Hindmarsh J, Turner AG. Fatherhood without apparent spermatozoa after vasectomy. Lancet. 1994; 344(8914): 30 [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/7912302" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Davies, A.H., Sharp, R.J., Cranston, D., Mitchell, R.G. The long-term outcome following 'special clearance' after vasectomy. BJU. 1990; 66(2): 211-2. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/2390708" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Korthorst RA, Consten D, van Roijen JH. Clearance after vasectomy with a single semen sample containing &amp;lt; than 100 000 immotile sperm/mL: analysis of 1073 patients. BJU International. 2010; 105(11): 1572-5. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20002679" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Leslie TA, Illing RO, Cranston DW, Guillebaud J. The incidence of chronic scrotal pain after vasectomy: A prospective audit. BJU International. 2007; 100(6): 1330-1333. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17850378" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Philp T, Guillebaud J, Budd D. Complications of vasectomy: Review of 16,000 patients. BJU 1984; 56(6): 745-748. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/6534499" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Adams CE, Wald M. Risks and complications of vasectomy. Urol Clin North Am. 2009; 36(3): 331-6. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19643235" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Cox B, Sneyd MJ, Paul C, Delahunt B, Skegg DCG. Vasectomy and risk of prostate cancer. JAMA. 2002; 287(23): 3110-3115. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/12069674" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Holt SK, Salinas CA, Stanford JL. Vasectomy and the risk of prostate cancer. Journal of Urology. 2008; 180: 2565-2568. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18930503" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;The Practice Committee of the American Society for Reproductive Medicine. Vasectomy reversal. Fertility and Sterility. 2006; 86(4): S268-271. &lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <expiryDate>26/07/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>402372</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=402372]]&gt;</url>
    <title>Mini-Topic Review: Recent Clinical Trials in Adult Polycystic Kidney Disease</title>
    <publicationDate>2011-01-19T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,INHERITED KIDNEY DISEASE,POLYCYSTIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Mini-Topic Review: Recent Clinical Trials in Adult Polycystic Kidney Disease&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Mini-Topic Review: Recent Clinical Trials in Adult Polycystic Kidney Disease&lt;BR&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Edward Sharples, Consultant in Nephrology and Transplant Medicine, Churchill Hospital, Oxford, and specialist collection clinical lead.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Introduction&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Autosomal dominant polycystic kidney disease (ADPKD) is the most frequent hereditary kidney disease and the cause of end-stage renal disease in 7 to 10% of all patients undergoing dialysis. The disease is characterized by the growth of numerous kidney cysts, which leads to progressive destruction of the adjacent renal parenchyma and massive enlargement of the kidneys. Renal function is often preserved until the age of 40 years because functioning nephrons undergo compensatory hypertrophy. Subsequently, the glomerular filtration rate (GFR) decreases, and end-stage renal disease ensues in many patients by the fifth decade. As yet, no treatment is available to delay disease progression, but 2010 saw the publication of a number of randomised controlled trials and new developments in the management of APKD.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;AVP inhbitors&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;In the last 10 years, since the identification of the polycystin gene, it has been established that 3’5’ cyclic adenosine monophosphate (cAMP) stimulates mural epithelial cell proliferation and secretion of fluid into the cysts of patients with APKD, contributing to progressive increase in cyst burden and renal dysfunction. AVP promotes cAMP production in the distal tubule and collecting ducts via interaction with its AVP-V2 receptor. Experimental models of cyst development and growth have shown that blocking the effect of AVP slows cyst and kidney enlargement, and preserves renal function. A novel treatment for APKD that targets this AVP/ cAMP pathway is being evaluated in an ongoing large international clinical trial (TEMPO 3/4) utilizing an inhibitor of AVP (tolvaptan) (1, 2, 3, 4).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Barash et al (2) have assessed the changes in osmolality and urinary cAMP with water loading. In 13 patients and 10 normal controls, the effects of acute and sustained water loading was evaluated. Chronic water loading produced a 13% reduction in urinary cAMP although this was non significant. The authors suggested a large randomised trial to assess this strategy – which is effective in animal models of APKD.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;mTOR inhibitors&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The mammalian target of rapamycin (mTOR) is aberrantly activated in cystic epithelia in patients with ADPKD. Sirolimus, established in transplant immunosuppresion, inhibits mTOR, and in an orthologous mouse model of ADPKD and other rodent models of polycystic kidney disease, sirolimus significantly improved renal cystic disease. In 2010, two randomised controlled trials of mTOR inhibitors were published. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;In the first study by Serra et al (5), 100 patients were randomised to sirolimus or placebo in a open-label clinical trial. All patients had relatively well preserved kidney function at baseline, with eGFR &amp;gt;70 ml/min. Serial MR imaging to measure renal cyst volume was performed with the primary endpoint being change in cyst volume at 18 months. The median increase in cyst volume was 99 cm3 in the sirolimus group, compared to 97 cm3 in the placebo group (P=0.26). There was no difference between the groups in estimated GFR, but urinary protein excretion was higher in the sirolimus group. The results of this trial contrast with preclinical data, which showed significant benefits of mTOR inhibition in rodent models of polycystic kidney disease. However, the mTOR inhibitors were primarily used in rodent models of early-onset or rapidly progressive disease at early stages of cyst development. These models may not appropriately reflect the more complex and heterogeneous pathogenesis of ADPKD in humans, in whom the disease progresses slowly over several decades and the mechanism of cyst growth is not yet understood.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The SIRENA study (4) compared a six month treatment with sirolimus against conventional therapy in 21 patients with APKD. Compared with pre-treatment measurements, there was less increase in cyst volume on sirolimus therapy, although the difference was not significant. Sirolimus had no effect on GFR, but was associated with a small increase in proteinuria. This was a small, short term study which used pre-treatment changes in cyst volume to determine whether sirolimus therapy was associated with a benefit. These results contrast with the RCT by Serra, but this may be influenced by the lack of a separate control population, and the assumption that cyst volume change remains constant over time in order that pre-treatment data could be used for the comparison.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;A larger, two year double-blind trial (3) used everolimus, an mTOR inhibitor, and randomised 431 patients with ADPKD (mean baseline estimated GFR of approximately 55 mL/min per 1.73 m2) to either everolimus, or placebo. The increase in total kidney volume, as measured by MRI, was smaller in the everolimus group compared to placebo at one (102 versus 157 mL, p=0.02) and two (230 versus 301 mL, p=0.06) years. However, despite the difference in cyst volume demonstrated, there was no difference in the mean fall in eGFR (8.9 versus 7.7 mL/min per 1.73 m2), and the mean protein-to-creatinine ratio increased in the everolimus group. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;A suggested explanation for the lack of a functional benefit of mTOR inhibitors despite the reduction in kidney volume in these trials is that the drugs was started too late; patients had already sustained marked decline in estimated GFR, and fibrosis rather than increased cyst volume may have driven the decline in kidney function observed during the study. The lack of effect of mTOR inhibition on kidney volume at eighteen months is potentially attributable to the low target drug level, which was much lower than those associated with a beneficial effect in animal studies. However higher doses of mTOR inhibitors will almost certainly cause more adverse side effects.&amp;nbsp; Alternatively, mTOR inhibitors may inhibit compensatory hypertrophy, which usually preserves GFR [76]. The latter explanation suggests that mTOR inhibitors may exert a protective effect over the long term, but the duration of this study was too short to demonstrate such an effect. However, the known nephrotoxicity of the mTOR inhibitors as evidenced by increasing levels of proteinuria in all studies suggest that it will be difficult to establish the benefits of mTOR inhibition based on reduced changes in total kidney volume. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Somatostatin&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Somatostatin may reduce renal and liver cyst fluid accumulation among patients with APKD. In a pilot study comparing somatostatin to placebo in patients with APKD, active therapy was associated with a smaller increase in cyst size and total kidney volume after six months of treatment (6).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The benefit of somatostatin has also been shown in a randomized trial in which 34 patients with ADPKD and 8 with autosomal dominant polycystic liver disease received a long-acting somatostatin (octreotide) or placebo for one year (7). The mean kidney volume was stable on octreotide (1143 and 1129 mL at baseline and one year, respectively) but increased on placebo (803 and 874 mL at baseline and one year, respectively) with a significantly lower percentage change on octreotide compared to placebo (0.25 versus 8.60 percent, respectively).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;In summary, 2010 have been a breakthrough year for clinical trials of therapies in APKD. Although the results of the mTOR inhibitor trials is inconclusive with regard to long term benefit in renal function, it has been established that therapeutic interventions can alter the natural history of cyst development and growth. The results of currently ongoing trials, such as TEMPO 3/4, will be eagerly awaited in the clinic.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Torres WE, Bankir L, Grantham J. (2009) "A case for water in the treatment of polycystic kidney disease." Clin J Am Soc Nephrol 4(6):1040-1150. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19443627" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Barash I, Ponda MP, Goldfarb DS, Skolnik EY. (2010) "A pilot clinical trial to evaluate changes in urine osmolality and urine cAMP in response to acute and chronic water loading in autosomal dominant polycystic kidney disease." Clin J Am Nephrol; 5(4): 693-697.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20167686" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Walz G, Budde K Mannaa M et al. (2010) "Everolimus in patients with autosomal dominant polycystic kidney disease." N Engl J Med; 363(9): 830-840.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20581392" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;
&lt;P&gt;Perico N, Antiga L, Caroli A et al. (2010) "Sirolimus therapy to halt the progression of ADPKD." J Am Soc Nephrol; 21(6): 1031-1040.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20466742" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/P&gt;&lt;/LI&gt;
&lt;LI&gt;Serra A, Poster D, Kistler A et al. (2010) "Sirolimus and kidney growth in autosomal dominant polycystic kidney disease." N Engl J Med; 363(9): 820-829.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20581391" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Caroli A, Antiga L, Cafaro M et al. (2010) "Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide." Clin J Am Soc Nephrol; 5(5): 783-789.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20185596" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hogan MC, Masyuk TV, Page LJ. (2010) "Randomised clinical trial of long-action somatostatin for autosomal dominant polycystic kidney and liver disease." J Am Soc Nephrol; 21(6): 1052-1061.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20431041" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <expiryDate>19/01/2012 00:00:00</expiryDate>
  </document>
  <document>
    <id>266792</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.nelm.nhs.uk/en/NeLM-Area/News/491300/491554/491569/?query=mircera&amp;rank=4]]&gt;</url>
    <title>Mircera (methoxy polyethylene glycol-epoetin beta) approved in EU for treatment of anaemia associated with chronic kidney disease</title>
    <publicationDate>2007-07-27T00:00:00</publicationDate>
    <publisher>National electronic Library for Medicines</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ ANAEMIA,COMPLICATIONS OF KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Abstract from National Library for Medicines</description>
    <body>&lt;![CDATA[ &lt;P&gt;Extract&lt;/P&gt;
&lt;P&gt;Mircera™ (methoxy polyethylene glycol-epoetin beta) has been approved in the EU for the treatment of anaemia associated with chronic kidney disease. This continuous erythropoietin receptor activator is administered twice a month in previously untreated patients but monthly for patients who have previously been given an erythropoietin-stimulating agent (ESA). The approval was based on data comparing Mircera to three ESAs: epoetin alfa, epoetin beta and darbepoetin alfa&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>01/07/2010 15:00:51</lastReviewDate>
    <expiryDate>01/07/2011 15:00:51</expiryDate>
  </document>
  <document>
    <id>155006</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4115222]]&gt;</url>
    <title>Modernising services for renal patients</title>
    <publicationDate>2005-07-08T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ ACCESS,PERITONEAL DIALYSIS,ACCESS,HAEMODIALYSIS,NATIONAL SERVICE FRAMEWORK FOR RENAL SERVICES/POLICY DOCUMENTS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,DIALYSIS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Report on year long pilot looking at new and different ways of working to improve care to patients with CKD, focusing on roles within renal teams, improving access to vascular access surgery and reducing dealys and waste in the patient journey.</description>
    <body>&lt;![CDATA[ &lt;P&gt;Report covers redesigning the workforce and re-engineering elective dialysis access surgery, and is aimed at health professionals&lt;/P&gt;&lt;FONT face=Frutiger-Light color=#251b18&gt;
&lt;P align=left&gt;Identified 10 High Impact Changes which have been demonstrated to make significant, measurable improvements&lt;/P&gt;&lt;FONT face=Frutiger-Light color=#251b18&gt;
&lt;P align=left&gt;The 10 High Impact Changes are:&lt;/P&gt;
&lt;P align=left&gt;Change No 1 Treat day surgery (rather than inpatient surgery) as the norm for elective surgery&lt;/P&gt;
&lt;P align=left&gt;Change No 2 Improve patient flow across the whole NHS system by improving access to key diagnostic tests&lt;/P&gt;
&lt;P align=left&gt;Change No 3 Manage variation in patient discharge, thereby reducing length of stay&lt;/P&gt;
&lt;P align=left&gt;Change No 4 Manage variation in the patient admission process&lt;/P&gt;
&lt;P align=left&gt;Change No 5 Avoid unnecessary follow-ups for patients and provide necessary follow-ups in the right care setting&lt;/P&gt;
&lt;P align=left&gt;Change No 6 Increase the reliability of performing therapeutic interventions through a Care Bundle approach&lt;/P&gt;
&lt;P&gt;Change No 7 Apply a systematic approach to care for people with long-term conditions&lt;/P&gt;&lt;FONT face=Frutiger-Light color=#251b18&gt;
&lt;P align=left&gt;Change No 8 Improve patient access by reducing the number of queues&lt;/P&gt;
&lt;P align=left&gt;Change No 9 Optimise patient flow through service bottlenecks using process templates&lt;/P&gt;
&lt;P align=left&gt;Change No 10 Redesign and extend roles in line with efficient patient pathways to attract and retain an effective workforce&lt;/P&gt;&lt;/FONT&gt;
&lt;P&gt;&lt;/FONT&gt;&lt;/FONT&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>24/09/2010 10:26:10</lastReviewDate>
    <expiryDate>24/09/2011 10:26:10</expiryDate>
  </document>
  <document>
    <id>155679</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.uktransplant.org.uk/ukt/statistics/transplant_activity_report/current_activity_reports.jsp/ukt/tx_activity_report_2005_uk_complete-v2.pdf]]&gt;</url>
    <title>More transplants - new lives</title>
    <publicationDate></publicationDate>
    <publisher>UK Transplant</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ TRANSPLANTATION,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Report by UK Transplant on transplant activity in the UK from 2004-2005</description>
    <body>&lt;![CDATA[ The kidney transplant activity is explained in text, diagrams and tables at section 3.1 and 3.2 / or pages 11-18.]]&gt;</body>
    <lastReviewDate>24/09/2010 10:26:55</lastReviewDate>
    <expiryDate>24/09/2011 10:26:55</expiryDate>
  </document>
  <document>
    <id>177791</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.dopps.org/d_cdArchive/DoppsCD2006/ppt/Rayner_MortHosp_NDT2004_D21.ppt#258,3,Slide 3]]&gt;</url>
    <title>Mortality and hospitalization in hemodialysis patients in five European countries: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS)</title>
    <publicationDate>2004-10-04T00:00:00</publicationDate>
    <publisher>Nephrology Dialysis and Transplantation 2004</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ HAEMODIALYSIS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,DIALYSIS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Presentation from DOPPS</description>
    <body>&lt;![CDATA[ The study's conclusions highlight significant variations across countries.]]&gt;</body>
    <lastReviewDate>06/07/2010 11:26:21</lastReviewDate>
    <expiryDate>06/07/2011 11:26:21</expiryDate>
  </document>
  <document>
    <id>339088</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=339088]]&gt;</url>
    <title>Multicystic dysplastic kidney: Systematic reviews and meta-analyses</title>
    <publicationDate>2010-01-19T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ INHERITED KIDNEY DISEASE,POLYCYSTIC KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Multicystic dysplastic kidney: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Schreuder, M. F., R. Westland, et al. (2009). "Unilateral multicystic dysplastic kidney: a meta-analysis of observational studies on the incidence, associated urinary tract malformations and the contralateral kidney." Nephrol Dial Transplant 24(6): 1810-8. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19171687" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Cambio, A. J., C. P. Evans, et al. (2008). "Non-surgical management of multicystic dysplastic kidney." BJU Int 101(7): 804-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18190645" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2007-2006&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;No systematic reviews.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>21/12/2010 10:52:58</lastReviewDate>
    <expiryDate>21/12/2011 10:52:58</expiryDate>
  </document>
  <document>
    <id>396653</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.guardian.co.uk/lifeandstyle/2010/dec/07/my-week-peter-carey-consultant-genitourinary-medicine]]&gt;</url>
    <title>My week: Peter Carey, consultant in genitourinary medicine</title>
    <publicationDate>2010-12-07T00:00:00</publicationDate>
    <publisher>The Guardian</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE SEXUALLY TRANSMITTED INFECTIONS,BACTERIAL,GONORRHEA,HIV,VIRAL,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The impact of HIV since the 1980s has been huge, and no matter how great the leaps forward in treatment, it's still a difficult diagnosis for people to deal with</description>
    <body>&lt;![CDATA[ A week in the life of a genitourinary consultant.]]&gt;</body>
    <expiryDate>07/12/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>318046</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.ic.nhs.uk/services/national-clinical-audit-support-programme-ncasp/kidney-care]]&gt;</url>
    <title>National Kidney Care Audit</title>
    <publicationDate>2009-01-01T00:00:00</publicationDate>
    <publisher>NHS The Information Centre</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ ACUTE KIDNEY INJURY,COMPLICATIONS OF KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The National Kidney Care Audit is the latest clinical audit that the Healthcare Commission has commissioned The NHS Information Centre to provide. Delivered through our National Clinical Audit Support Programme (NCASP), the audit will help identify the best ways to improve renal services.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Extract from page:&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;About the audit&lt;/P&gt;
&lt;P&gt;The National Kidney Care Audit is the latest clinical audit that the Healthcare Commission has commissioned The NHS Information Centre to provide. Delivered through our National Clinical Audit Support Programme (NCASP), the audit will help identify the best ways to improve renal services.&lt;/P&gt;
&lt;P&gt;As well as all adults receiving haemodialysis, the audit also covers children and young people. The audit measures two distinct areas, both of which have a big impact on the quality of life for kidney patients:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;vascular access 
&lt;LI&gt;patient transport. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>01/07/2010 14:13:53</lastReviewDate>
    <expiryDate>01/07/2011 14:13:53</expiryDate>
  </document>
  <document>
    <id>156260</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/assetRoot/04/09/72/53/04097253.pdf]]&gt;</url>
    <title>National Service Framework for Renal Services Part 1: Dialysis and Transplantation - implementation toolkit for commissioners based on best practice</title>
    <publicationDate>2004-12-03T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ NATIONAL SERVICE FRAMEWORK FOR RENAL SERVICES/POLICY DOCUMENTS,TRANSPLANTATION,HAEMODIALYSIS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,DIALYSIS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A toolkit providing practical advice, guidance and support for commissioners implementing the Renal NSF Part 1 (dialysis and transplantation) and for those developing local service strategies</description>
    <body>&lt;![CDATA[ &lt;P&gt;Extract from document&lt;/P&gt;
&lt;P&gt;The toolkit covers the range of renal and transplant services for adults as outlined in the Renal NSF. It does not address in detail the needs of children and young people.&lt;/P&gt;
&lt;P&gt;The toolkit addresses:&lt;/P&gt;
&lt;P&gt;Stage 1 : Baseline Assessment - template provided in appendix&lt;/P&gt;
&lt;P&gt;Stage 2 : Early actions - steps to take by 2006&lt;/P&gt;
&lt;P&gt;Stage 3 : Implementation of the NSF Standards and Markers of Good Practice by 2014&lt;/P&gt;
&lt;P&gt;The toolkit framework is the five standards and thirty markers of good practice set out in the National Service Framework. &lt;BR&gt;&lt;/P&gt;]]&gt;</body>
    <expiryDate>01/09/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>304321</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.ndt-educational.org/case.asp]]&gt;</url>
    <title>NDT Educational - Case Studies CME</title>
    <publicationDate>2010-01-11T00:00:00</publicationDate>
    <publisher>NDT</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASE IN CHILDREN AND ADOLESCENTS,ACUTE KIDNEY INJURY,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Wide range of online case studies with multiple choice answers</description>
    <body>&lt;![CDATA[ &lt;P&gt;CME with multiple choice answers.&lt;/P&gt;
&lt;P&gt;A series of case studies is provided to help with CPD. &lt;/P&gt;]]&gt;</body>
    <lastReviewDate>13/12/2010 11:40:46</lastReviewDate>
    <expiryDate>13/12/2011 11:40:46</expiryDate>
  </document>
  <document>
    <id>288506</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.bestbets.org/bets/bet.php?id=777]]&gt;</url>
    <title>Nebulized levalbuterol or albuterol for lowering serum potassium</title>
    <publicationDate>2005-05-19T00:00:00</publicationDate>
    <publisher>Best Bets</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ ASSESSMENT OF RENAL FUNCTION,ASSESSMENT TESTS,POTASSIUM,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Critically appraised topic from Best Bets</description>
    <body>&lt;![CDATA[ &lt;P&gt;Extract&lt;/P&gt;
&lt;P&gt;Clinical Bottom Line&lt;/P&gt;
&lt;P&gt;Nebulized levalbuterol appears to be as effective as albuterol in lowering serum potassium in adults.&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>01/07/2010 15:01:00</lastReviewDate>
    <expiryDate>01/07/2011 15:01:00</expiryDate>
  </document>
  <document>
    <id>339131</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=339131]]&gt;</url>
    <title>Nephrectomy: Systematic reviews and meta-analyses</title>
    <publicationDate>2011-02-18T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,TRANSPLANTATION,TRANSPLANT OPERATION,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Nephrectomy: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2011&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Ahmed K, Wang TT, Patel VM, Nagpal K, Clark J, Ali M, et al. The role of single-incision laparoscopic surgery in abdominal and pelvic surgery: a systematic review. Surgical Endoscopy. 2011;25(2):378-96. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20623239" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Aboutaleb, E., P. Herbert, et al. (2010). "Mini-incision donor nephrectomy techniques: a systematic review." Experimental &amp;amp; Clinical Transplantation: Official Journal of the Middle East Society for Organ Transplantation 8(3): 189-95. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Mini-incision%20donor%20nephrectomy%20techniques%3A%20a%20systematic%20review" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Butt, Z., S. E. Jensen, et al. (2010). "What is the quality of life impact of living donor nephrectomy?" Clinical and Translational Science 3(2). [No PubMed abstract&amp;nbsp;available]&lt;/LI&gt;
&lt;LI&gt;Greco, F., M. R. Hoda, et al. (2010). "Laparoscopic living-donor nephrectomy: analysis of the existing literature." European Urology 58(4): 498-509. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20417024" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Antcliffe, D., T. G. Nanidis, et al. (2009). "A meta-analysis of mini-open versus standard open and laparoscopic living donor nephrectomy." Transpl Int 22(4): 463-74. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19175543" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Breda, A., A. Finelli, et al. (2009). "Complications of laparoscopic surgery for renal masses: prevention, management, and comparison with the open experience." Eur Urol 55(4): 836-50.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19168276" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kim, C., K. McKay, et al. (2009). "Laparoscopic Nephrectomy in Children: Systematic Review of Transperitoneal and Retroperitoneal Approaches." Urology 73(2): 280-284.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18952262" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;O'Malley, R. L., G. Godoy, et al. (2009). "The necessity of adrenalectomy at the time of radical nephrectomy: a systematic review." J Urol 181(5): 2009-17.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19286216" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Silberstein, J. and J. K. Parsons (2009). "Hand-assisted and total laparoscopic nephrectomy: a comparison." JSLS 13(1): 36-43.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19366539" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Touijer, K., D. Jacqmin, et al. (2009). "The Expanding Role of Partial Nephrectomy: A Critical Analysis of Indications, Results, and Complications." Eur Urol.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19853988" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Warren, J., V. da Silva, et al. (2009). "Robotic renal surgery: The future or a passing curiosity?"&amp;nbsp;Can Urol Assoc J 3(3): 231-240.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2692162/?tool=pubmed" target="_blank"&gt;Link to full text&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Nanidis T G, Antcliffe D, Kokkinos C, Borysiewicz C A, Darzi A W, Tekkis P P, Papalois V E. (2008) "Laparoscopic versus open live donor nephrectomy in renal transplantation: a meta-analysis." Annals of Surgery, 2008; 247(1): 58-70. [&lt;A href="nelh:319409:0" name=internalLink&gt;Link to DARE abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>21/12/2010 10:53:01</lastReviewDate>
    <expiryDate>21/12/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>339132</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=339132]]&gt;</url>
    <title>Nephritic Syndrome: Systematic reviews and meta-analyses</title>
    <publicationDate>2010-09-20T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ RENAL TRACT INFECTIONS,GLOMERULONEPHRITIS,UPPER URINARY TRACT INFECTION,PRIMARY GLOMERULAR DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Nephritic Syndrome: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Lee, Y. H., J. H. Woo, et al. (2010). "Induction and maintenance therapy for lupus nephritis: a systematic review and meta-analysis." Lupus 19(6): 703-10. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Induction%20and%20maintenance%20therapy%20for%20lupus%20nephritis%3A%20a%20systematic%20review%20and%20meta-analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Li, L. H., H. Yuan, et al. (2010). "Role of the Fcgamma receptor IIIA-V/F158 polymorphism in susceptibility to systemic lupus erythematosus and lupus nephritis: a meta-analysis." Scandinavian Journal of Rheumatology 39(2): 148-54.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Role%20of%20the%20Fcgamma%20receptor%20IIIA-V%2FF158%20polymorphism%20in%20susceptibility%20to%20systemic%20lupus%20erythematosus%20and%20lupus%20nephritis%3A%20a%20meta-analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mok, C. C., T. T. Cheung, et al. "Minimal mesangial lupus nephritis: a systematic review." Scandinavian Journal of Rheumatology 39(3): 181-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Minimal%20mesangial%20lupus%20nephritis%3A%20a%20systematic%20review" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Faust, W. C., M. Diaz, et al. (2009). "Incidence of post-pyelonephritic renal scarring: a meta-analysis of the dimercapto-succinic acid literature." J Urol 181(1): 290-7; discussion 297-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19013606" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mak, A., A. A. Cheak, et al. (2009). "Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression." Rheumatology (Oxford) 48(8): 944-52.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19494179" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Neumann, I., M. Fernanda Rojas, et al. (2008). "Pyelonephritis (acute) in non-pregnant women." Clin Evid (Online) 2008.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19450332" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Somani, B. K., G. Nabi, et al. (2008). "Is percutaneous drainage the new gold standard in the management of emphysematous pyelonephritis? Evidence from a systematic review." J Urol 179(5): 1844-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18353396" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Guan, F. J., Z. W. Yi, et al. (2007). "[Glucocorticoid administration in steroid sensitive nephritic syndrome: a meta-analysis]." Zhong Nan Da Xue Xue Bao Yi Xue Ban 32(6): 964-72.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18182711" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hodson, E. M., N. S. Willis, et al. (2007). "Antibiotics for acute pyelonephritis in children." Cochrane Database Syst Rev(4): CD003772.&amp;nbsp;[&lt;A href="nelh:238495:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Sierra, F., M. Suarez, et al. (2007). "Systematic review: Proton pump inhibitor-associated acute interstitial nephritis." Aliment Pharmacol Ther 26(4): 545-53.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17661758" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2006&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;No systematic reviews. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>21/12/2010 10:53:04</lastReviewDate>
    <expiryDate>21/12/2011 10:53:04</expiryDate>
  </document>
  <document>
    <id>310596</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.medi-smart.com/renal.htm]]&gt;</url>
    <title>Nephrology (Renal) Nursing Resources</title>
    <publicationDate>2009-03-27T00:00:00</publicationDate>
    <publisher>Medi-Smart Nursing Education Resources</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ HAEMODIALYSIS,ACUTE KIDNEY INJURY,ORGANISATIONS,TRANSPLANTATION,CHILDREN AND ADOLESCENTS ON HAEMODIALYSIS,RENAL TRACT INFECTIONS,PREVENTION OF INFECTIONS,LIVING WITH DIALYSIS,PERITONEAL DIALYSIS,ACCESS,COMPLICATIONS OF KIDNEY DISEASE,KIDNEY DISEASE IN CHILDREN AND ADOLESCENTS,OTHER CONDITIONS - ADULTS,GLOMERULONEPHRITIS,KIDNEY AND BLADDER STONES,END-OF-LIFE CARE,RENAL CANCER,PREVENTION OF INFECTIONS,STARTING HAEMODIALYSIS,STARTING PERITONEAL DIALYSIS,ACCESS,INHERITED KIDNEY DISEASE,RENOVASCULAR DISEASES,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES,HOME DIALYSIS,HOME HAEMODIALYSIS,DIALYSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Extract: Nephrology nursing is a specialized area of nursing that is directed towards individuals with End Stage Renal Disease and their families. Nephrology nurses practice in ambulatory care settings, such as clinics, and hospital-based dialysis centers, as well as free-standing dialysis facilities, home training programs, and transplant units. Nephrology nurses involved in the dialysis process may provide care for patients over a lenghty period of time, usually several years.</description>
    <body>&lt;![CDATA[ &lt;P&gt;This American webpage contains reading suggestions, links to articles of interest, printable pocket reference cards, as well as links to selected sites and resources. &lt;/P&gt;]]&gt;</body>
    <lastReviewDate>14/02/2011 11:40:11</lastReviewDate>
    <expiryDate>14/02/2012 11:40:11</expiryDate>
  </document>
  <document>
    <id>155717</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.renal.org/unit/index.pl?c=cardiff]]&gt;</url>
    <title>Nephrology and Transplant Directorate, Cardiff</title>
    <publicationDate></publicationDate>
    <publisher>Renal Association</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ TRANSPLANTATION,TRANSPLANT CENTRES,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Contact details and background information about the Directorate</description>
    <body>&lt;![CDATA[ &lt;P&gt;The Nephrology and Transplant Directorate offers a regional service covering South East, West and parts of Mid Wales serving a population of 2.2 million.&lt;/P&gt;
&lt;P&gt;Currently the Directorate is&amp;nbsp;introducing&amp;nbsp;specialist nurse roles: in the area of transplantation (live donor and recipient co-ordinators; and transplant nurse specialists&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>24/09/2010 10:27:15</lastReviewDate>
    <expiryDate>24/09/2011 10:27:15</expiryDate>
  </document>
  <document>
    <id>306468</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.kdigo.org/nephrology_guideline_database/compare_guideline_targets.php]]&gt;</url>
    <title>Nephrology Guideline Database</title>
    <publicationDate>2009-02-16T00:00:00</publicationDate>
    <publisher>Kidney Disease: Improving Global Outcomes  (KDIGO)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ END-OF-LIFE CARE,RENOVASCULAR DISEASES,INHERITED KIDNEY DISEASE,KIDNEY AND BLADDER STONES,GLOMERULONEPHRITIS,HAEMODIALYSIS,ACUTE KIDNEY INJURY,ORGANISATIONS,TRANSPLANTATION,RENAL TRACT INFECTIONS,PERITONEAL DIALYSIS,INTERNATIONAL,COMPLICATIONS OF KIDNEY DISEASE,OTHER CONDITIONS - ADULTS,KIDNEY DISEASE IN CHILDREN AND ADOLESCENTS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES,DIALYSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The Kidney Disease: Improving Global Outcomes has created summary tables listing the key features of the currently-available dialysis clinical practice guidelines in Europe, Canada, Australia, UK and US. The ultimate goal is to create an interactive and searchable database, available on the Internet, to facilitate comparison of the guidelines.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Extract&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Compare Guideline Targets&lt;/P&gt;
&lt;P&gt;The Kidney Disease: Improving Global Outcomes has created summary tables listing the key features of the currently-available dialysis clinical practice guidelines in Europe, Canada, Australia, UK and US. The ultimate goal is to create an interactive and searchable database, available on the Internet, to facilitate comparison of the guidelines.&lt;/P&gt;
&lt;P&gt;Choose from the list below for a guideline comparison table showing recommendations, evidence, and notes from the 5 international groups.&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;General Nephrology 
&lt;LI&gt;Hemodialysis 
&lt;LI&gt;Vascular Access for HD 
&lt;LI&gt;Peritoneal Dialysis 
&lt;LI&gt;Laboratory Determinations 
&lt;LI&gt;Guidelines 
&lt;LI&gt;Mode of Guideline Scoring, Depending on the Origin&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>11/01/2011 10:23:38</lastReviewDate>
    <expiryDate>11/01/2012 10:23:38</expiryDate>
  </document>
  <document>
    <id>339141</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=339141]]&gt;</url>
    <title>Nephropathies: Systematic reviews and meta-analyses</title>
    <publicationDate>2011-01-17T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,ACUTE KIDNEY INJURY,COMPLICATIONS OF KIDNEY DISEASE,OTHER CONDITIONS - ADULTS,DRUG-INDUCED RENAL PROBLEMS,GLOMERULONEPHRITIS,PRIMARY GLOMERULAR DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Nephropathies: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Crasto, W., L. J. Gray, et al. (2010). "Systematic review and meta-analysis examining the prevalence of diabetic nephropathy in South Asians and white Europeans with type 2 diabetes." Diabetic Medicine 27(2 SUPPL. 1). [No PubMed abstract available]&lt;/LI&gt;
&lt;LI&gt;Goergen, S. K., G. Rumbold, et al. (2010) "Systematic review of current guidelines, and their evidence base, on risk of lactic acidosis after administration of contrast medium for patients receiving metformin." Radiology 254(1): 261-9. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Systematic%20review%20of%20current%20guidelines%2C%20and%20their%20evidence%20base%2C%20on%20risk%20of%20lactic%20acidosis%20after%20administration%20of%20contrast%20medium%20for%20patients%20receiving%20metformin" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hills, C. E. and P. E. Squires (2010). "TGF-beta1-induced epithelial-to-mesenchymal transition and therapeutic intervention in diabetic nephropathy." American Journal of Nephrology 31(1): 68-74. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19887790" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kunadian, V., A. Zaman, et al. (2010). "Sodium bicarbonate for the prevention of contrast induced nephropathy: A meta-analysis of published clinical trials." Eur J Radiol.&amp;nbsp;2010 Jan 12 [Epub ahead of print] [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20074886" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Zeng, Z., L. Li, et al. (2010). "A meta-analysis of three polymorphisms in the endothelial nitric oxide synthase gene (NOS3) and their effect on the risk of diabetic nephropathy." Human Genetics 127(4): 373-81.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20049477" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Birnbaum, L. M., M. Lipman, et al. (2009). "Management of chronic allograft nephropathy: a systematic review." Clin J Am Soc Nephrol 4(4): 860-5.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Management%20of%20chronic%20allograft%20nephropathy%3A%20a%20systematic%20review" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Bomback, A. S., V. K. Derebail, et al. (2009). "Rituximab therapy for membranous nephropathy: a systematic review." Clin J Am Soc Nephrol 4(4): 734-44.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Rituximab%20therapy%20for%20membranous%20nephropathy%3A%20a%20systematic%20review" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Cheng, J., W. Zhang, et al. (2009). "ACEI/ARB therapy for IgA nephropathy: A meta analysis of randomised controlled trials." International Journal of Clinical Practice 63(6): 880-888.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=ACEI%2FARB%20therapy%20for%20IgA%20nephropathy%3A%20A%20meta%20analysis%20of%20randomised%20controlled%20trials" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Cheng, J., X. Zhang, et al. (2009). "Efficacy and safety of glucocorticoids therapy for IgA nephropathy: a meta-analysis of randomized controlled trials." Am J Nephrol 30(4): 315-22.&amp;nbsp;[&lt;A href="nelh:360824:0" name=internalLink&gt;Link to&amp;nbsp;DARE abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Heinrich, M. C., L. Haberle, et al. (2009). "Nephrotoxicity of iso-osmolar iodixanol compared with nonionic low-osmolar contrast media: meta-analysis of randomized controlled trials." Radiology 250(1): 68-86.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Nephrotoxicity%20of%20iso-osmolar%20iodixanol%20compared%20with%20nonionic%20low-osmolar%20contrast%20media%3A%20meta-analysis%20of%20randomized%20controlled%20trials" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kanbay, M., A. Covic, et al. (2009). "Sodium bicarbonate for the prevention of contrast-induced nephropathy: a meta-analysis of 17 randomized trials." Int Urol Nephrol 41(3): 617-27.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Sodium%20bicarbonate%20for%20the%20prevention%20of%20contrast-induced%20nephropathy%3A%20a%20meta-analysis%20of%2017%20randomized%20trials" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Meier, P., D. T. Ko, et al. (2009). "Sodium bicarbonate-based hydration prevents contrast-induced nephropathy: a meta-analysis." BMC Med 7: 23.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Sodium%20bicarbonate-based%20hydration%20prevents%20contrast-induced%20nephropathy%3A%20a%20meta-analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Navaneethan, S. D., S. Singh, et al. (2009). "Sodium bicarbonate therapy for prevention of contrast-induced nephropathy: a systematic review and meta-analysis." Am J Kidney Dis 53(4): 617-27.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Sodium%20bicarbonate%20therapy%20for%20prevention%20of%20contrast-induced%20nephropathy%3A%20a%20systematic%20review%20and%20meta-analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Reddan, D., M. Laville, et al. (2009). "Contrast-induced nephropathy and its prevention: what do we really know from evidence-based findings?" J Nephrol 22(3): 333-51.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Contrast-induced%20nephropathy%20and%20its%20prevention%3A%20what%20do%20we%20really%20know%20from%20evidence-based%20findings%3F" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Trivedi, H., S. Daram, et al. (2009). "High-dose N-acetylcysteine for the prevention of contrast-induced nephropathy." Am J Med 122(9): 874 e9-15.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=High-dose%20N-acetylcysteine%20for%20the%20prevention%20of%20contrast-induced%20nephropathy" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Wu, O., A. R. Levy, et al. (2009). "Acute rejection and chronic nephropathy: a systematic review of the literature." Transplantation 87(9): 1330-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Acute%20rejection%20and%20chronic%20nephropathy%3A%20a%20systematic%20review%20of%20the%20literature" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Xu, G., W. Tu, et al. (2009). "Mycophenolate mofetil treatment for IgA nephropathy: A meta-analysis." American Journal of Nephrology 29(5): 362-367.&amp;nbsp;[&lt;A href="nelh:342979:0" name=internalLink&gt;Link to&amp;nbsp;DARE abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Yahaya, I., A. O. Uthman, et al. (2009). "Interventions for HIV-associated nephropathy." Cochrane Database Syst Rev(4): CD007183.&amp;nbsp;[&lt;A href="nelh:327231:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Zoungas, S., T. Ninomiya, et al. (2009). "Systematic review: sodium bicarbonate treatment regimens for the prevention of contrast-induced nephropathy." Ann Intern Med 151(9): 631-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Systematic%20review%3A%20sodium%20bicarbonate%20treatment%20regimens%20for%20the%20prevention%20of%20contrast-induced%20nephropathy" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Boyden, T. F. and H. S. Gurm (2008). "Does gadolinium-based angiography protect against contrast-induced nephropathy?: a systematic review of the literature." Catheter Cardiovasc Interv 71(5): 687-93.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Does%20gadolinium-based%20angiography%20protect%20against%20contrast-induced%20nephropathy%3F%3A%20a%20systematic%20review%20of%20the%20literature" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Ho, K. M. and D. J. Morgan (2008). "Use of isotonic sodium bicarbonate to prevent radiocontrast nephropathy in patients with mild pre-existing renal impairment: a meta-analysis." Anaesth Intensive Care 36(5): 646-53.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Use%20of%20isotonic%20sodium%20bicarbonate%20to%20prevent%20radiocontrast%20nephropathy%20in%20patients%20with%20mild%20pre-existing%20renal%20impairment%3A%20a%20meta-analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Joannidis, M., M. Schmid, et al. (2008). "Prevention of contrast media-induced nephropathy by isotonic sodium bicarbonate: a meta-analysis." Wien Klin Wochenschr 120(23-24): 742-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Prevention%20of%20contrast%20media-induced%20nephropathy%20by%20isotonic%20sodium%20bicarbonate%3A%20a%20meta-analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kelly, A. M., B. Dwamena, et al. (2008). "Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy." Ann Intern Med 148(4): 284-94.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Meta-analysis%3A%20effectiveness%20of%20drugs%20for%20preventing%20contrast-induced%20nephropathy" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Wu, J. K. and M. T. Harris (2008). "Use of leflunomide in the treatment of polyomavirus BK-associated nephropathy." Ann Pharmacother 42(11): 1679-85.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18957628" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Gawenda, M., A. Moller, et al. (2007). "[Prophylaxis of contrast-induced nephropathy with N-acetylcysteine]." Zentralbl Chir 132(3): 227-31.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17610195" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Gonzales, D. A., K. J. Norsworthy, et al. (2007). "A meta-analysis of N-acetylcysteine in contrast-induced nephrotoxicity: unsupervised clustering to resolve heterogeneity." BMC Med 5: 32.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=A%20meta-analysis%20of%20N-acetylcysteine%20in%20contrast-induced%20nephrotoxicity%3A%20unsupervised%20clustering%20to%20resolve%20heterogeneity" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Passerini, P., A. Lupo, et al. (2007). "[Therapeutic strategies for membranous nephropathy: guideline from the Italian Society of Nephrology.]." G Ital Nefrol 24 Suppl 37: 13-29.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Therapeutic%20strategies%20for%20membranous%20nephropathy%3A%20guideline%20from%20the%20Italian%20Society%20of%20Nephrology" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Pozzi, C., C. Manno, et al. (2007). "[Immunosuppressive and non-immunosuppressive agents for patients with IgA nephropathy: guideline from the Italian Society of Nephrology.]." G Ital Nefrol 24 Suppl 37: 30-49.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Immunosuppressive%20and%20non-immunosuppressive%20agents%20for%20patients%20with%20IgA%20nephropathy%3A%20guideline%20from%20the%20Italian%20Society%20of%20Nephrology" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Sinert, R. and C. I. Doty (2007). "Evidence-based emergency medicine review. Prevention of contrast-induced nephropathy in the emergency department." Ann Emerg Med 50(3): 335-45, 345 e1-2.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Evidence-based%20emergency%20medicine%20review.%20Prevention%20of%20contrast-induced%20nephropathy%20in%20the%20emergency%20department" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Tejedor, A., A. M. Torres, et al. (2007). "Cilastatin protection against cyclosporin A-induced nephrotoxicity: clinical evidence." Curr Med Res Opin 23(3): 505-13.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Cilastatin%20protection%20against%20cyclosporin%20A-induced%20nephrotoxicity%3A%20clinical%20evidence" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2006&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Cruz, D. N., M. A. Perazella, et al. (2006) "Extracorporeal blood purification therapies for prevention of radiocontrast-induced nephropathy: a systematic review." Am J Kidney Dis 48(3): 361-71.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16931209" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;McCullough, P. A., M. E. Bertrand, et al. (2006). "A meta-analysis of the renal safety of isosmolar iodixanol compared with low-osmolar contrast media." J Am Coll Cardiol 48(4): 692-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16904536" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Meschi, M., S. Detrenis, et al. (2006). "Facts and fallacies concerning the prevention of contrast medium-induced nephropathy." Crit Care Med 34(8): 2060-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16763513" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Solomon, R. and W. Dumouchel (2006). "Contrast media and nephropathy: findings from systematic analysis and Food and Drug Administration reports of adverse effects." Invest Radiol 41(8): 651-60.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Contrast%20media%20and%20nephropathy%3A%20findings%20from%20systematic%20analysis%20and%20Food%20and%20Drug%20Administration%20reports%20of%20adverse%20effects" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Taji, Y., T. Kuwahara, et al. (2006). "Meta-analysis of antiplatelet therapy for IgA nephropathy." Clin Exp Nephrol 10(4): 268-73.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=2006[pdat]%20AND%20Meta-analysis%20of%20antiplatelet%20therapy%20for%20IgA%20nephropathy" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>21/12/2010 10:53:08</lastReviewDate>
    <expiryDate>21/12/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>301371</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://healthguides.mapofmedicine.com/choices/map/nephrotic_syndrome_in_children1.html]]&gt;</url>
    <title>Nephrotic syndrome - management in children</title>
    <publicationDate>2008-12-16T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASE IN CHILDREN AND ADOLESCENTS,NEPHROTIC SYNDROME,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Web pages from NHS Choices and the Map of Medicine.</description>
    <body>&lt;![CDATA[ This page provides a link to the Map of Medicine view on the management of nephrotic syndrome in children.]]&gt;</body>
    <lastReviewDate>26/11/2010 15:26:32</lastReviewDate>
    <expiryDate>26/11/2011 15:26:32</expiryDate>
  </document>
  <document>
    <id>288113</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.bmj.com/cgi/content/full/336/7654/1185]]&gt;</url>
    <title>Nephrotic syndrome in adults</title>
    <publicationDate>2008-05-24T00:00:00</publicationDate>
    <publisher>BMJ  2008;336:1185-1189</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEPHROTIC SYNDROME,OTHER CONDITIONS - ADULTS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Clinical review from BMJ</description>
    <body>&lt;![CDATA[ &lt;P&gt;This clinical review covers: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;What conditions can cause nephrotic syndrome?&lt;/LI&gt;
&lt;LI&gt;How do I assess patients who present with nephrotic syndrome?&lt;/LI&gt;
&lt;LI&gt;Which investigations should be performed? &lt;/LI&gt;
&lt;LI&gt;Complications of nephrotic syndrome&lt;/LI&gt;
&lt;LI&gt;How can nephrotic syndrome be treated?&lt;/LI&gt;
&lt;LI&gt;Who should be referred for targeted investigation and treatment?&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>24/09/2010 10:27:46</lastReviewDate>
    <expiryDate>24/09/2011 10:27:46</expiryDate>
  </document>
  <document>
    <id>388099</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=388099]]&gt;</url>
    <title>Nephrotic syndrome: Systematic reviews and meta-analyses</title>
    <publicationDate>2011-02-18T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,PRESENTATION OF CKD,HAEMATURIA/ PROTEINURIA,PROTEINURIA/ NEPHROTIC SYNDROME,GLOMERULONEPHRITIS,PRIMARY GLOMERULAR DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Nephrotic syndrome: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2011&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Shigidi MM. The treatment of relapse in adults with minimal change nephrotic syndrome: myths and facts. Saudi Journal of Kidney Diseases &amp;amp; Transplantation. 2011;22(1):10-7. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/21196608" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Hodson, E. M., N. S. Willis, et al. (2010). "Interventions for idiopathic steroid-resistant nephrotic syndrome in children." Cochrane Database Syst Rev 11: CD003594. [&lt;A href="nelh:238102:0" name=internalLink&gt;Link to Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Manrique-Rodriguez, S., C. M. Fernandez-Llamazares, et al. "Pharmacotherapeutic review and update of idiopathic nephrotic syndrome in children." Pharmacy World &amp;amp; Science 32(3): 314-21. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Pharmacotherapeutic%20review%20and%20update%20of%20idiopathic%20nephrotic%20syndrome%20in%20children" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Xu, G., W. Tu, et al. (2009). "Tripterygium wilfordii Hook F treatment for idiopathic refractory nephrotic syndrome in adults: A meta-analysis." Nephron - Clinical Practice 111(4): c223-c228.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Tripterygium%20wilfordii%20Hook%20F%20treatment%20for%20idiopathic%20refractory%20nephrotic%20syndrome%20in%20adults%3A%20A%20meta-analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Braun, N., F. Schmutzler, et al. (2008). "Immunosuppressive treatment for focal segmental glomerulosclerosis in adults." Cochrane Database Syst Rev(3): CD003233.&amp;nbsp;[&lt;A href="nelh:293690:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hodson, E. M., N. S. Willis, et al. (2008). "Non-corticosteroid treatment for nephrotic syndrome in children." Cochrane Database Syst Rev(1): CD002290.&amp;nbsp;[&lt;A href="nelh:237460:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Teeninga, N., M. F. Schreuder, et al. (2008). "Influence of low birth weight on minimal change nephrotic syndrome in children, including a meta-analysis." Nephrol Dial Transplant 23(5): 1615-20.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Influence%20of%20low%20birth%20weight%20on%20minimal%20change%20nephrotic%20syndrome%20in%20children%2C%20including%20a%20meta-analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Colquitt, J. L., J. Kirby, et al. (2007). "The clinical effectiveness and cost-effectiveness of treatments for children with idiopathic steroid-resistant nephrotic syndrome: a systematic review." Health Technol Assess 11(21): iii-iv, ix-xi, 1-93.&amp;nbsp;[&lt;A href="nelh:273049:0" name=internalLink&gt;Link to HTA abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hodson, E. M., N. S. Willis, et al. (2007). "Corticosteroid therapy for nephrotic syndrome in children." Cochrane Database Syst Rev(4): CD001533.&amp;nbsp;[&lt;A href="nelh:237181:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lupo, A., C. Pozzi, et al. (2007). "[Corticosteroid treatment for a first episode of steroid-sensitive nephrotic syndrome (SSNS) in children: guideline from the Italian Society of Nephrology.]." G Ital Nefrol 24 Suppl 37: 3-12.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Corticosteroid%20treatment%20for%20a%20first%20episode%20of%20steroid-sensitive%20nephrotic%20syndrome%20%28SSNS%29%20in%20children%3A%20guideline%20from%20the%20Italian%20Society%20of%20Nephrology" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <expiryDate>21/09/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>319056</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.bladderandbowelfoundation.org/bladder/neurogenic-bladder-management/]]&gt;</url>
    <title>Neurogenic Bladder Management</title>
    <publicationDate></publicationDate>
    <publisher>The Bladder and Bowel Foundation</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE BLADDER DISORDERS,MALE URINARY INCONTINENCE,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Information on Neurogenic Bladder Management</description>
    <body>&lt;![CDATA[ &lt;P&gt;Information on Neurogenic Bladder Management including links to:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;STRONG&gt;&lt;U&gt;&lt;FONT color=#0000ff&gt;&lt;A title="Alzheimer's disease and incontinence" style="FONT-SIZE: 14px" href="http://www.bladderandbowelfoundation.org/bladder/neurogenic-bladder-management/alzheimers-disease-and-incontinence/" target="_blank"&gt;&lt;STRONG&gt;Alzheimer's disease and incontinence&lt;/STRONG&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/U&gt;&lt;/STRONG&gt; 
&lt;LI&gt;&lt;STRONG&gt;&lt;U&gt;&lt;FONT color=#0000ff&gt;&lt;A title="Cauda Equina Syndrome" style="FONT-SIZE: 14px" href="http://www.bladderandbowelfoundation.org/bladder/neurogenic-bladder-management/cauda-equina-syndrome/" target="_blank"&gt;&lt;STRONG&gt;Cauda Equina Syndrome&lt;/STRONG&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/U&gt;&lt;/STRONG&gt; 
&lt;LI&gt;&lt;STRONG&gt;&lt;U&gt;&lt;FONT color=#0000ff&gt;&lt;A title="Multiple Sclerosis (MS) and Incontinence " style="FONT-SIZE: 14px" href="http://www.bladderandbowelfoundation.org/bladder/neurogenic-bladder-management/multiple-sclerosis-ms-and-incontinence-/" target="_blank"&gt;&lt;STRONG&gt;Multiple Sclerosis (MS) and Incontinence&lt;/STRONG&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/U&gt;&lt;/STRONG&gt;&lt;STRONG&gt;&lt;U&gt;&lt;FONT color=#0000ff&gt;&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/U&gt;&lt;/STRONG&gt; 
&lt;LI&gt;&lt;STRONG&gt;&lt;U&gt;&lt;FONT color=#0000ff&gt;&lt;A title="Parkinson's disease and bladder problems" style="FONT-SIZE: 14px" href="http://www.bladderandbowelfoundation.org/bladder/neurogenic-bladder-management/parkinsons-disease-and-bladder-problems/" target="_blank"&gt;&lt;STRONG&gt;Parkinson's disease and bladder problems&lt;/STRONG&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/U&gt;&lt;/STRONG&gt; 
&lt;LI&gt;&lt;STRONG&gt;&lt;U&gt;&lt;FONT color=#0000ff&gt;&lt;A title="Spina Bifida" style="FONT-SIZE: 14px" href="http://www.bladderandbowelfoundation.org/bladder/neurogenic-bladder-management/spina-bifida/" target="_blank"&gt;&lt;STRONG&gt;Spina Bifida&lt;/STRONG&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/U&gt;&lt;/STRONG&gt;&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
    <lastReviewDate>01/07/2010 14:14:26</lastReviewDate>
    <expiryDate>01/07/2011 14:14:26</expiryDate>
  </document>
  <document>
    <id>319195</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.pcc.nhs.uk/uploads/QOF/qof_bus_rules_v10/ckd_ruleset_r4_v10.0.pdf]]&gt;</url>
    <title>New GMS Contract QOF Implementation - Dataset And Business Rules - Chronic Kidney Disease (CKD)</title>
    <publicationDate>2009-07-01T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The business rules for the new CKD domain of the Quality and Outcomes Framework provide the definition and codes that map to individual components of the CKD QOF.</description>
    <body>&lt;![CDATA[ &lt;P&gt;The business rules for the new CKD domain of the Quality and Outcomes Framework provide the definition and codes that map to individual components of the CKD QOF. &lt;/P&gt;
&lt;P&gt;This is a 12-page PDF.&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>01/07/2010 14:14:37</lastReviewDate>
    <expiryDate>01/07/2011 14:14:37</expiryDate>
  </document>
  <document>
    <id>284626</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk/cancer/]]&gt;</url>
    <title>NHS Evidence - cancer</title>
    <publicationDate></publicationDate>
    <publisher>NHS Evidence</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RENAL CANCER,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Quality checked web resources on kidney cancer (Click on Urological Cancer and then on Kidney Cancer in the left hand topic tree)</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Extract&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 8pt; COLOR: black; FONT-FAMILY: Verdana"&gt;NHS Evidence - cancer&amp;nbsp;conducts comprehensive literature searches for systematic reviews relating to cancer and its management.&amp;nbsp; After rigorous sifting and quality checks, the results are 'mapped' to a clinical activities matrix.&amp;nbsp; This mapping exercise provides a simple method of demonstrating where secondary research has been published.&amp;nbsp; It also highlights the areas where little or no published secondary research has been found or is in the process of being quality checked by the specialist collection.&lt;BR&gt;&lt;/SPAN&gt;&lt;/P&gt;]]&gt;</body>
    <expiryDate>01/07/2011 00:00:00</expiryDate>
    <relatedLinks>&lt;a href="http://www.library.nhs.uk/cancer/" title="Link to website"/&gt;&lt;a href="http://www.library.nhs.uk/cancer/Page.aspx?pagename=KICAMAP" title="Link to 'map' indicating topic areas covered by systematic reviews"/&gt;</relatedLinks>
    <creator />
  </document>
  <document>
    <id>284630</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk/diabetes/]]&gt;</url>
    <title>NHS Evidence - diabetes</title>
    <publicationDate>2006-04-03T00:00:00</publicationDate>
    <publisher>NHS Evidence</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ PREDISPOSING FACTORS,DIABETES,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A collection of quality assessed websites including guidelines. In the left hand topic tree, click on Chronic Complicatons, then on Nephropathy.</description>
    <body>&lt;![CDATA[ &lt;P&gt;Web links on the following categories:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Diagnosis 
&lt;LI&gt;Condition Management 
&lt;LI&gt;Causes, Risk Factors and Screening 
&lt;LI&gt;Prevention &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
    <expiryDate>01/07/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>156032</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.corelearningunit.nhs.uk/SignIn.aspx]]&gt;</url>
    <title>NHS Infection Control Programme</title>
    <publicationDate>2009-04-23T00:00:00</publicationDate>
    <publisher>NHS</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ PERITONEAL DIALYSIS,COMPLICATIONS OF KIDNEY DISEASE,HAEMODIALYSIS,PREVENTION OF INFECTIONS,PREVENTION OF INFECTIONS,OTHER,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES,DIALYSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Online learning modules. Free Registration.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Extract from website&lt;/EM&gt; &lt;/P&gt;
&lt;P&gt;Infection prevention and control is everybody's business and this programme is aimed at all NHS staff, both clinical and non-clinical. The programme covers the critical aspects of infection prevention practice that everybody, regardless of their role, should follow.&lt;/P&gt;
&lt;P&gt;The modules are available for everybody in the NHS to use but you do have to register your name and details first. This registration process&amp;nbsp;is free.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
    <expiryDate>01/09/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>408067</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=408067]]&gt;</url>
    <title>NHS Kidney Care: Peer Support Literature Review</title>
    <publicationDate>2011-03-08T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,HAEMODIALYSIS,LIVING WITH DIALYSIS,COMPLICATIONS OF KIDNEY DISEASE,KIDNEY DISEASES,DIALYSIS,LIFESTYLE]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This review examines literature relating to peer support, to consider the effectiveness and potential relevance of peer support as a means of addressing the isolation sometimes experienced by people who dialyse at home and those who care for them.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;NHS Kidney Care: Peer Support Literature Review&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Introduction to Peer Support Literature Review for NHS Evidence &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This review examines literature relating to peer support, to consider the effectiveness and potential relevance of peer support as a means of addressing the isolation sometimes experienced by people who dialyse at home and those who care for them.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The review is based on an initial search of peer reviewed literature from the past ten years addressing peer support for adults in the context of long term conditions. It is not a systematic review. It does not include studies of peer education where the goal does not specifically include emotional support. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;There are many definitions of peer support. One that is commonly cited describes it as comprising emotional, appraisal and informational assistance. Other definitions emphasise the importance of only limited input from health professionals and the central role of shared experience. Approaches to delivering and evaluating peer support are wide-ranging and there is no meaningful generic peer support model. A distinction can be made between support provided by peers, or peer support with professional input. The former is likely to aim for emotional and informational support. Peer support with more professional input often incorporates a wider range of goals including educational, behavioural or physical outcomes.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Very few peer reviewed articles were found on peer support in the context of dialysis or kidney disease. The literature on peer support for long term conditions is dominated by peer support in the context of cancer, heavily weighted towards breast cancer. Very few studies have been conducted in England. The literature in peer support is generally acknowledged to be methodologically weak.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <expiryDate>08/03/2012 00:00:00</expiryDate>
  </document>
  <document>
    <id>394388</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.nelm.nhs.uk/en/Download/?file=MDs3NTU4MTQ7L3VwbG9hZC9kb2N1bWVudHMvSGVhbHRoIEluIEZvY3VzL05JQ0VCaXRlc05vdmVtYmVyMjAxMC5wZGY_.pdf]]&gt;</url>
    <title>NICE Bites – November 2010; Nocturnal enuresis</title>
    <publicationDate>2010-11-17T00:00:00</publicationDate>
    <publisher>NICE</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE URINARY INCONTINENCE,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>NICE Bites is a monthly bulletin which summarises key prescribing points from NICE guidance. This edition includes one topic; Nocturnal enuresis.</description>
    <body>&lt;![CDATA[ &lt;P&gt;This guideline covers the management of bedwetting in children and young people up to 19 years of age.&lt;/P&gt;
&lt;P&gt;2 page-document.&lt;/P&gt;]]&gt;</body>
    <expiryDate>18/11/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>408066</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.nice.org.uk/newsroom/podcasts/index.jsp?pid=13]]&gt;</url>
    <title>NICE podcast - CG114 Anaemia management in CKD (update) Podcast with Dr Paul Stevens</title>
    <publicationDate>2011-03-08T00:00:00</publicationDate>
    <publisher>NICE</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,COMPLICATIONS OF KIDNEY DISEASE,ANAEMIA,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Dr Paul Stevens, Consultant Nephrologist and Associate Medical Director from Kent and Canterbury Hospital and  clinical adviser for the Anaemia management in CKD guideline discusses implementation of the updated recommendations in clinical practice.</description>
    <body>&lt;![CDATA[ &lt;P&gt;Dr Paul Stevens, Consultant Nephrologist and Associate Medical Director from Kent and Canterbury Hospital and&amp;nbsp; clinical adviser for the Anaemia management in CKD guideline discusses implementation of the updated recommendations in clinical practice.&lt;/P&gt;
&lt;P&gt;The webpage includes the podcast, as well as facilities to download or read the transcript.&lt;/P&gt;]]&gt;</body>
    <expiryDate>08/03/2012 00:00:00</expiryDate>
  </document>
  <document>
    <id>182127</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.kidney.org.uk/campaigns/Renal-nsf/nkf-submissionon-palliative-doh-jul06.html]]&gt;</url>
    <title>NKF submission to the Department of Health on palliative care for adults in renal services</title>
    <publicationDate>2006-07-03T00:00:00</publicationDate>
    <publisher>National Kidney Federation</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ END-OF-LIFE CARE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Submission made in July 2006</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Extract from website&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;In March 2004 National Institute of Clinical Excellence (NICE) published its guidance on Cancer Services entitled Improving supportive and palliative care for adults with cancer. (NICE 2004). Although focused solely on services for adult patients with cancer and their families, it was envisaged that the document would inform the development of service models for other groups of patients. This submission on behalf of renal patients has used this guidance as a template for best practice to ensure equity of service provision for all groups of patients.&lt;/P&gt;
&lt;P&gt;In February 2005 part two of the Renal National Service Framework &lt;I&gt;Chronic Kidney Disease, Acute Renal Failure and End of Life Care&lt;/I&gt; was published. Quality requirement four of the document covers palliative care for renal patients and requires that: &lt;/P&gt;
&lt;P&gt;People with established renal failure receive timely evaluation of their prognosis, information about the choices available to them, and for those near the end of life a jointly agreed palliative care plan, built around their individual needs and preferences.&lt;/P&gt;
&lt;P&gt;Renal patient will enter Palliative Care and End of Life Care from four areas&lt;/P&gt;
&lt;UL type=disc&gt;
&lt;LI&gt;Pre-dialysis patients choosing not to commence dialytic treatment 
&lt;LI&gt;Dialysis patients withdrawing from dialysis 
&lt;LI&gt;Patients who come to the end of their lives while on dialysis 
&lt;LI&gt;Transplant patients &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Stopping dialysis presents health care professionals with important challenge in the care of their patients. Between 12% and 18% of patients may choose to stop dialysis as the burden of symptoms from co-morbidity, the presence of other life threatening illness or the burden of dialysis comes to outweigh its benefits.&lt;/P&gt;
&lt;P&gt;Gunda, et.al (2005) completed a national survey of palliative care in ESRD and Chambers (2005) surveyed renal departments to develop a picture of current practice and the areas that need particular attention. It was found that nearly all patients opting for conservative management of their renal failure are treated appropriately with erythropoietin and blood or iron support but only a minority of units had any palliative care guidelines.&lt;/P&gt;
&lt;P&gt;However by the summer of 2005 the majority of units questioned had been in discussion with their local palliative care teams and approximately half of units had designated pathways for patients who chose not to dialyse. Provision of written information remained poor.&lt;/P&gt;
&lt;P&gt;Between 2004 and 2005 there appears to have been an increase in the number of renal teams who refer a number of patients to their local palliative care service but there are still some who refer none. There is wide variation in practice with the number of patients referred varying from 0-50 per year. The provision of the types of intervention that may help teams improve their care of the dying remains patchy.&lt;/P&gt;
&lt;P&gt;Nearly all had access to spiritual support for patients and family, and most were discussing place of care with those who discontinue dialysis. There was however little provision for culturally appropriate care and use of the &lt;I&gt;preferred place of care document&lt;/I&gt; or &lt;I&gt;end of life guidelines.&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;No additional funding is available to support this module of the National Service Framework and it is apparent that current palliative care services are already stretched, particularly as so much community palliative and Hospice care relies heavily on voluntary funding and nearly 1/3 consultant palliative care posts are unfilled&lt;/P&gt;
&lt;P&gt;Imaginative use of existing resources with a revisiting of priorities within units will be necessary if the opportunity of this module is not to be lost. With the recognition that care of those at the end of life demands a change of emphasis but not of intensity comes the opportunity to reassess use of resources and make a difference to the care of renal patients&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:26:34</lastReviewDate>
    <expiryDate>06/07/2011 11:26:34</expiryDate>
  </document>
  <document>
    <id>311266</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://learning.bmj.com/learning/search-result.html?moduleId=6052441]]&gt;</url>
    <title>Nocturnal enuresis in childhood: diagnosis and management</title>
    <publicationDate>2009-04-06T00:00:00</publicationDate>
    <publisher>BMJ Learning</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE URINARY INCONTINENCE,OTHER INCONTINENCE,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Extract:&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Module type:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Just in time&lt;/STRONG&gt;&lt;/P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;P&gt;&lt;BR&gt;Want a fast, evidence based update? Here are the essentials on everyday conditions. Before you start a learning resource it is best to add it to your plan first.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;What's in this case:&lt;/STRONG&gt; &amp;nbsp;&lt;/P&gt;
&lt;P&gt;Nocturnal enuresis in childhood: diagnosis and management&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Target audience:&lt;/STRONG&gt; &amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Foundation programme&lt;/LI&gt;
&lt;LI&gt;International&lt;/LI&gt;
&lt;LI&gt;Practice nurse CPD&lt;/LI&gt;
&lt;LI&gt;Hospital doctor CPD&lt;/LI&gt;
&lt;LI&gt;GP CPD&lt;/LI&gt;
&lt;LI&gt;GP trainee&lt;/LI&gt;
&lt;LI&gt;Saudi Pediatric Association Channel&lt;/LI&gt;
&lt;LI&gt;Other healthcare professionals&lt;/LI&gt;
&lt;LI&gt;The Royal New Zealand College of General Practitioners&lt;/LI&gt;
&lt;LI&gt;Practice manager CPD&lt;/LI&gt;
&lt;LI&gt;Medical Students - international &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>08/03/2011 10:04:47</lastReviewDate>
    <expiryDate>08/03/2012 10:04:47</expiryDate>
  </document>
  <document>
    <id>224571</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://content.nejm.org/cgi/reprint/355/20/2071.pdf?andorexacttitleabs=and&amp;search_tab=articles&amp;tocsectionid=Original+Articles&amp;tocsectionid=Special+Reports&amp;tocsectionid=Special+Articles&amp;tocsectionid=Videos+in+Clinical+Medicine&amp;tocsectionid=Clinical+Practic]]&gt;</url>
    <title>Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia</title>
    <publicationDate>2006-11-16T00:00:00</publicationDate>
    <publisher>New England Journal of Medicine</publisher>
    <publicationType>RANDOMISED CONTROLLED TRIAL</publicationType>
    <topics>&lt;![CDATA[ ANAEMIA,COMPLICATIONS OF KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Article from CREATE Trial in New England Journal of Medicine, November 2006, 355, p2071-84
[CREATE- Cardiovascular risk reduction by early anemia treatment with epoetin Beta]</description>
    <body>&lt;![CDATA[ &lt;P&gt;BACKGROUND&lt;/P&gt;
&lt;P&gt;Whether correction of anemia in patients with stage 3 or 4 chronic kidney disease improves cardiovascular outcomes is not established.&lt;/P&gt;
&lt;P&gt;METHODS&lt;/P&gt;
&lt;P&gt;We randomly assigned 603 patients with an estimated glomerular f iltration rate (GFR) of 15.0 to 35.0 ml per minute per 1.73 m 2 of body-surface area and mild-to-moderate anemia (hemoglobin level,11.0 to 12.5 g per deciliter)to a target hemoglobin value in the normal range (13.0 to 15.0 g per deciliter,group 1)or the subnormal range (10.5 to 11.5 g per deciliter,group 2).Subcutaneous erythropoietin (epoetin beta)was initiated at randomization (group 1)or only after t he hemoglobin level fell below 10.5 g per deciliter (group 2).The primary end point was a composite of eight cardiovascular events;secondary end points included left ventricular mass index,quality-of-life scores, and the progression of chronic kidney disease.&lt;/P&gt;
&lt;P&gt;RESULTS&lt;/P&gt;
&lt;P&gt;During the 3-year study,complete correction of anemia did not affect the likelihood of a first cardiovascular event (58 events in group 1 vs.47 events in group 2;hazard ratio,0.78;95%confidence interval,0.53 to 1.14;P =0.20).Left ventricular mass index remained stable in both groups.The mean estimated GFR was 24.9 ml per minute in group 1 and 24.2 ml per minute in group 2 at baseline and decreased by 3.6 and 3.1 ml per minute per year,respectively (P =0.40).Dialysis was required in more patients in group 1 than in group 2 (127 vs.111,P =0.03).General health and physical function improved significantly (P =0.003 and P&amp;lt;0.001,respectively,in group 1,as compared with group 2).There was no significant difference in the combined incidence of adverse events between the two groups,but hypertensive episodes and headaches were more prevalent in group 1.&lt;/P&gt;
&lt;P&gt;CONCLUSIONS&lt;/P&gt;
&lt;P&gt;In patient s with chronic kidney di sease,early complete correction of anemia does not reduce the risk of cardiovascular events.&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>13/12/2010 11:40:53</lastReviewDate>
    <expiryDate>13/12/2011 11:40:53</expiryDate>
  </document>
  <document>
    <id>155744</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.renal.org/unit/index.pl?c=nottingham]]&gt;</url>
    <title>Nottingham Renal and Transplant Unit</title>
    <publicationDate></publicationDate>
    <publisher>Renal Association</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ TRANSPLANTATION,TRANSPLANT CENTRES,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Contact details and background information</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Extract from website&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Typically between 40-50 renal transplants are performed annually including paediatric and live donor transplants. &lt;/P&gt;
&lt;P&gt;We have an active living donor transplant programme. The work-up is very thorough and is led by a Nurse Specialist. The Nottingham Unit has produced a number of videos for National use, intended to inform patients and their families about kidney transplantation. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;In Nottingham all potential transplant candidates are initially assessed by a nephrologist and if medically suitable are invited to a Patient Information Evening. If they still wish to pursue transplantation as a treatment they are then assessed by a surgeon. Guidelines for the referral and selection of patients, and for the assessment and investigation of medically high risk patients have been developed. In addition, once patients are on the transplant list, they have a transplant focused review annually or bi-annually to ensure they remain suitable candidates. This process takes into account both equity of access and a risk benefit analysis. &lt;BR&gt;Post-transplantation care is provided by the multi-disciplinary team with the surgeon taking overall responsibility in the first six months and the nephrologist subsequently. Some patients from the Derby Renal Unit have their transplant follow-up here. &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;The alliance with the Transplant Units at Northern General Hospital, Sheffield and The Leicester General Hospital has been operating for a number of years and resulted in a common transplant waiting list. The Nottingham and Leicester transplant co-ordinators have a joint on-call rota.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>24/09/2010 10:29:49</lastReviewDate>
    <expiryDate>24/09/2011 10:29:49</expiryDate>
  </document>
  <document>
    <id>329628</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=329628]]&gt;</url>
    <title>November 2009 NHS Evidence - kidney diseases and male urogenital disorders newsletter</title>
    <publicationDate>2009-11-09T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;November 2009 NHS Evidence - kidney diseases and male urogenital disorders newsletter&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Welcome to the kidney diseases and male urogenital disorders specialist collection enewsletter for November 2009. &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;NHS Evidence - kidney diseases and male urogenital disorders is for busy health professionals, providing them with high quality information and keeping them up to date with the latest research and developments in this area.&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;Following the launch of the male urogenital disorder section at the British Association of Urological Nursing conference in Torquay (2-4 November 2009), we are now sending this newsletter out to as many professionals as possible. You can subscribe to this newsletter by joining our mailing group:&amp;nbsp;&amp;nbsp;&lt;A href="https://www.jiscmail.ac.uk/cgi-bin/webadmin?A0=NHSEVIDENCEKDMU" target="_blank"&gt;https://www.jiscmail.ac.uk/cgi-bin/webadmin?A0=NHSEVIDENCEKDMU&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=INTRO2009" target="_blank"&gt;Click here&lt;/A&gt; to read the introduction to the new male urogenital disorders content by Mr David Cranston (male urogenital disorders clinical lead).&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=center&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage0 style="WIDTH: 158px; HEIGHT: 182px" height=238 src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID329628/nelhImp_0000_BAUNpens_09nov09.jpg" width=245 name=nelh_tempImage0&gt;&amp;nbsp; &lt;IMG id=nelh_tempImage1 style="WIDTH: 211px; HEIGHT: 181px" height=234 src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID329628/nelhImp_0001_BAUNstand_09nov09.jpg" width=211 name=nelh_tempImage1&gt;&lt;/P&gt;
&lt;P align=center&gt;&lt;EM&gt;Images above are of the NHS Evidence - kidney diseases and male urogenital disorders stand at BAUN.&lt;/EM&gt; &lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Links to:&lt;/STRONG&gt;&lt;/P&gt;&lt;STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="#kidney"&gt;Kidney Diseases resources&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="#urogenital"&gt;Male Urogenital Disorders resources&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;&lt;/STRONG&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0005_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&amp;nbsp;RSS FEEDS&amp;nbsp; &lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0006_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;You can receive news from the kidney diseases specialist collection from the RSS feeds we provide:&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/RSS/CMS.aspx?feed=57" target="_blank"&gt;&lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0007_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk/kidney/RSS/CMS.aspx?feed=57" target="_blank"&gt;New Kidney Diseases Resources&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/RSS/CMS.aspx?feed=136" target="_blank"&gt;&lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0008_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk/kidney/RSS/CMS.aspx?feed=136" target="_blank"&gt;New Male Urogenital Disorders Resources&lt;/A&gt; &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/KIDNEY/RSS/News.aspx" target="_blank"&gt;&lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0008_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk//kidney/News.aspx" target="_blank"&gt;Kidney diseases and male urogenital disorders in the news&lt;/A&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/rss/Directory/MoreAboutRss.aspx" target="_blank"&gt;Click through this link to find out more about RSS feeds.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;JOURNALS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;You can link through to the latest Tables of Contents from all the major kidney, transplant and urology journals from &lt;A href="http://www.library.nhs.uk/KIDNEY/Page.aspx?pagename=EJOURNALS" target="_blank"&gt;this page&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=3&gt;&lt;STRONG&gt;&lt;BIG&gt;New resources added in&amp;nbsp;October 2009&lt;/BIG&gt;&lt;/STRONG&gt; &lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A name=kidney&gt;Chronic Kidney&amp;nbsp; Disease&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:327178:0" name=internalLink&gt;Vitamin D compounds for people with chronic kidney disease requiring dialysis&lt;/A&gt;. Cochrane systematic review (Issue 4, 2009). &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:327267:0" name=internalLink&gt;Vitamin D compounds for people with chronic kidney disease not requiring dialysis&lt;/A&gt;. Cochrane systematic review (Issue 4, 2009). &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2009---October/27/Review-Anaemia-and-renal-dysfunction-in-chronic-heart-failure/" target="_blank"&gt;Review: Anaemia and renal dysfunction in chronic heart failure&lt;/A&gt;. National electronic Library for Medicines summary(27/10/09). &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/Evidence/Medicines-Q--A/What-factors-need-to-be-considered-when-dosing-patients-with-renal-impairment/" target="_blank"&gt;What factors need to be considered when dosing patients with renal impairment?&lt;/A&gt; National electronic Library for Medicines summary (30/10/09). &lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Hypertension&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2009---October/27/Meta-analysis-Potency-of-pharmacist-and-nurse-led-care-interventions-for-hypertension-/" target="_blank"&gt;Meta-analysis: Potency of pharmacist and nurse led care interventions for hypertension&lt;/A&gt;. Analysis by the National electronic Library for Medicines. (27 Oct 2009).&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Acute kidney injury&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:326972:0" name=internalLink&gt;Meta-analysis of N-acetylcysteine to prevent acute renal failure after major surgery&lt;/A&gt;. DARE abstract (09 Sep 2009).&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:326981:0" name=internalLink&gt;Prevention of contrast media-induced nephropathy by isotonic sodium bicarbonate: a meta-analysis&lt;/A&gt;. DARE abstract (16 Sep 2009)&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:326948:0" name=internalLink&gt;Use of isotonic sodium bicarbonate to prevent radiocontrast nephropathy in patients with mild pre-existing renal impairment: a meta-analysis&lt;/A&gt;. DARE abstract (23 Sep 2009).&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:327177:0" name=internalLink&gt;Atrial natriuretic peptide for preventing and treating acute kidney injury.&lt;/A&gt; Cochrane systematic review (Issue 4, 2009). &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://renaltsar.blogspot.com/2009/10/acute-kidney-injury-on-agenda.html" target="_blank"&gt;Acute Kidney Injury - on the agenda&lt;/A&gt;. Renal Tsar's Blog entry (20 Oct 09)&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Diabetic nephropathy&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:326947:0" name=internalLink&gt;Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis&lt;/A&gt;. DARE abstract (09 Sep 2009).&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/Evidence/Guidelines/CKS-Topic-Review-Type-2-diabetes/" target="_blank"&gt;CKS Topic Review: Type 2 diabetes&lt;/A&gt;. Link to National electronic Library for Medicines abstract. (20/10/09)&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;IgA nephropathy&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:326955:0" name=internalLink&gt;Mycophenolate mofetil in the treatment of IgA nephropathy: a systematic review&lt;/A&gt;. DARE abstract (23 Sep 2009).&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;HIV - associated nephropathy&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:327231:0" name=internalLink&gt;Interventions for HIV-associated nephropathy&lt;/A&gt;. Cochrane systematic review (Issue 4 2009). &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Pyelonephritis&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/Evidence/Disease-Focused-Reviews/Antibiotic-treatment-for-acute-uncomplicated-or-primary-pyelonephritis-a-systematic-semantic-revision/" target="_blank"&gt;Antibiotic treatment for acute 'uncomplicated' or 'primary' pyelonephritis: a systematic, 'semantic revision'&lt;/A&gt;. Link to National electronic Library for Medicines abstract. (22/10/09)&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Kidney stones&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:327234:0" name=internalLink&gt;Extracorporeal shock wave lithotripsy (ESWL) versus percutaneous nephrolithotomy (PCNL) or retrograde intrarenal surgery (RIRS) for kidney stones&lt;/A&gt;. Cochrane systematic review (Issue 4 2009). &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Dialysis&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:326999:0" name=internalLink&gt;The ABCs of cardioprotection in dialysis patients: a systematic review&lt;/A&gt;. DARE abstract (09 Sep 2009). &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:327484:0" name=internalLink&gt;Competency Packages for Peritoneal Dialysis&lt;/A&gt;. Reference material from NHS Kidney Care. Published 12 Oct 2009.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:328425:0" name=internalLink&gt;Specification for the Commissioning of Peritoneal Dialysis Pathway&lt;/A&gt;. Published by NHS Kidney Care. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/Evidence/Medicines-Q--A/Can-oseltamivir-be-used-in-patients-with-renal-impairment-or-on-renal-replacement-therapies/" target="_blank"&gt;Can oseltamivir be used in patients with renal impairment or on renal replacement therapies?&lt;/A&gt; Abstract from the National electronic Library for Medicines (23/10/09)&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Transplantation&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:327344:0" name=internalLink&gt;Working together to save lives: the Organ Donation Taskforce Implementation Programme’s annual report, 2008/09&lt;/A&gt;. Report published by the Department for Health (08 Oct 2009). &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Kidney Cancer - Links to three new systematic reviews retrieved by the NHS Evidence - cancer team. &lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:124690:0" name=internalLink&gt;Kidney cancer: Causes, Risks and Prevention: Diet and Nutrition&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:124691:0" name=internalLink&gt;Kidney cancer: Causes, Risks and Prevention: Genetics&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:124694:0" name=internalLink&gt;Kidney cancer: Causes, Risks and Prevention: Miscellaneous topics&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:124711:0" name=internalLink&gt;Kidney cancer: Treatment and Disease management: Biological therapy&lt;/A&gt;. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A name=urogenital&gt;Male Urogenital Disorders&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Male Bladder Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Links to systematic reviews on bladder cancer retrieved by the cancer specialist collection team: &lt;A href="nelh:304644:0" name=internalLink&gt;Bladder cancer: Service Delivery and Standards: Survival&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:124789:0" name=internalLink&gt;Bladder cancer: Treatment and Disease Management: Surgery&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:155015:0" name=internalLink&gt;Bladder cancer: UK and International guidelines&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:327202:0" name=internalLink&gt;Alpha blockers prior to removal of a catheter for acute urinary retention in adult men&lt;/A&gt;. Cochrane systematic review (Issue 4 2009). &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Prostate Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=326971&amp;amp;tabID=289" target="_blank"&gt;Systematic review and economic modelling of effectiveness and cost utility of surgical treatments for men with benign prostatic enlargement&lt;/A&gt;. DARE abstract (16 Sep 2009). &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:327224:0" name=internalLink&gt;Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia&lt;/A&gt;. Cochrane systematic review (Issue 4 2009). &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:328471:0" name=internalLink&gt;Urology Informed Decision Making Project: Objectives&lt;/A&gt;. NHS Institute for Innovation and Improvement.&lt;/LI&gt;
&lt;LI&gt;Links to systematic reviews on prostate cancer retrieved by the cancer specialist collection team: &lt;A href="nelh:111445:0" name=internalLink&gt;Prostate cancer: Causes, Risks and Prevention: Genetics&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:155081:0" name=internalLink&gt;Prostate cancer: UK and International guidelines.&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:111448:0" name=internalLink&gt;Prostate cancer: Causes, Risks and Prevention: Carcinogens&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Penile Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2009---October/20/Hormonal-testing-and-pharmacological-management-in-erectile-dysfunction-US-guidelines/" target="_blank"&gt;Hormonal testing and pharmacological management in erectile dysfunction: US guidelines&lt;/A&gt;. Abstract from the National electronic Library for Medicines (20/10/09).&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Male Urethral Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:326894:0" name=internalLink&gt;Clinical Knowledge Summary on Urethritis in Men&lt;/A&gt; (Published 21 Sep 09).&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:326941:0" name=internalLink&gt;Fosfomycin: use beyond urinary tract and gastrointestinal infections&lt;/A&gt;. DARE abstract (16 Sep 2009). &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Testicular/Scrotal Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2009---October/27/SIGN-issues-draft-guideline-on-management-of-adult-testicular-germ-cell-tumours-for-consultation/" target="_blank"&gt;SIGN issues draft guideline on management of adult testicular germ cell tumours for consultation&lt;/A&gt;. National electronic Library for Medicines (27/10/09).&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Sexually Transmitted Infections&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:327065:0" name=internalLink&gt;Should asymptomatic men be included in chlamydia screening programs? Cost-effectiveness of chlamydia screening among male and female entrants to a national job training program&lt;/A&gt;. NHS Economic Evaluation Database (16 Sep 2009).&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2009---October/19/FDA-approves-use-of-HPV-vaccine-Gardasil-to-prevent-genital-warts-in-men-and-boys/" target="_blank"&gt;FDA approves use of HPV vaccine Gardasil® to prevent genital warts in men and boys&lt;/A&gt;. National electronic Library for Medicines. (19/10/09)&lt;BR&gt;&amp;nbsp;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Fertility&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:327210:0" name=internalLink&gt;Post-embryo transfer interventions for in vitro fertilization and intracytoplasmic sperm injection patients&lt;/A&gt;. Cochrane systematic review (Issue 4 2009). &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;**Subscribe to the NHS Evidence Eyes on Evidence Newsletter**&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;If you would like to receive Eyes on Evidence, the monthly e-bulletin from NHS Evidence, please sign up at &lt;A href="http://www.evidence.nhs.uk/NewsletterSignup.aspx" target="_blank"&gt;http://www.evidence.nhs.uk/NewsletterSignup.aspx&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The bulletin will keep you updated with new and important evidence and key developments on the NHS Evidence portal.&amp;nbsp; It comes out on the second Wednesday of the month and can be sent to any e-mail address that you provide.&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>11/10/2010 16:23:44</lastReviewDate>
    <expiryDate>11/10/2011 16:23:44</expiryDate>
  </document>
  <document>
    <id>392711</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=392711]]&gt;</url>
    <title>November 2010 NHS Evidence - kidney diseases and male urogenital disorders newsletter</title>
    <publicationDate>2010-11-01T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;November 2010 NHS Evidence - kidney diseases and male urogenital disorders newsletter&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Welcome to the kidney diseases and male urogenital disorders specialist collection enewsletter for&amp;nbsp;NOVEMBER 2010. &lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=left&gt;NHS Evidence - kidney diseases and male urogenital disorders is for busy health professionals, providing them with high quality information and keeping them up to date with the latest research and developments in this area. You can now join our mailing list to receive regular updates. &lt;A href="https://www.jiscmail.ac.uk/cgi-bin/webadmin?A0=NHSEVIDENCEKDMU" target="_blank"&gt;Click here for the link&lt;/A&gt;.&lt;/P&gt;
&lt;P align=center&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Links to:&lt;/STRONG&gt;&lt;/P&gt;&lt;STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="#kidney"&gt;New Kidney Diseases items&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="#mug"&gt;New Male Urogenital Disorders items&lt;/A&gt;&lt;/STRONG&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=center&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="3D male anatomy" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID392711/nelhImp_0000_3Dmaletorso_MUGXSmall_compressed.jpg" width=140 height=182&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H3&gt;STOP PRESS!: New mini topic review on Circumcision&amp;nbsp;by Dr J Manley and Mr D Cranston available. &lt;A href="nelh:392720:0" name=internalLink&gt;Link to Mini Topic Review on Circumcision&lt;/A&gt;.&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Recent Hotpicks in Kidney Disease &lt;/H2&gt;
&lt;H3&gt;- selected by the clinical lead, Dr Edward Sharples&lt;/H3&gt;
&lt;P&gt;&lt;BR&gt;The Lancet&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Dominic M Summers, Rachel J Johnson, Joanne Allen, Susan V Fuggle, David Collett, Christopher J Watson, J Andrew Bradley Analysis of factors that affect outcome after transplantation of kidneys donated after cardiac death in the UK: a cohort study. Lancet 376: 1303-1312 (Oct 16th 2010) [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Analysis%20of%20factors%20that%20affect%20outcome%20after%20transplantation%20of%20kidneys%20donated%20after%20cardiac%20death%20in%20the%20UK%3A%20a%20cohort%20study" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;The NHS Blood and Transfusion service used registry data from all 23 UK transplant centres to identify all renal transplantations from deceased donors from 2000 to end 2007. They analysed the outcome data according to controlled cardiac death donors, and excluded transplants of kidneys from uncontrolled cardiac-death donors (Maastricht categories 1, 2 and 4). Multivariate analysis was performed on donor- and recipient- variables. Survival was analysed by Kaplan-Meier curves. 9134 recipients of deceased donor renal tranplants were identified, with 845 transplants from cardiac-death donors. In recipients of a first kidney allografts, kidneys from cardiac-death donor had similar function and graft survival up to 5 years post transplant despite an increased rate of delayed graft function. Donor age of more than 60, and long cold-ischaemic times were both associated with an increased risk of graft failure. Renal transplantation from controlled cardiac-death donation is associated with similar long term outcomes to heart-beating donation.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Science&lt;/P&gt;
&lt;P&gt;Genovese G, Friedman DJ, Ross MD, Lecordier L, Uzureau P, Freedman BI, Bowden DW, Langefeld CD, Oleksyk TK, Uscinski Knob AL, Bernhardy AJ, Hicks PJ, Nelson GW, Vanhollebeke B, Winkler CA, Kopp JB, Pays E, Pollak MR. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science. 2010 Aug 13; 329(5993):841-5. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Association%20of%20trypanolytic%20ApoL1%20variants%20with%20kidney%20disease%20in%20African%20Americans" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Mapping by linkage disequilibrium has detected a strong association between nonmuscle myosin heavy chain 9 gene (MYH9) variants on chromosome 22 and non-diabetic nephropathy in African Americans. MYH9-related variants were posited to be the probable, but not necessarily the definitive, causal variants as a result of impressive statistical evidence of association, renal expression, and a role in autosomal dominant MYH9 disorders characterized by progressive glomerulosclerosis (Epstein and Fechtner syndromes). In this study, African Americans with&amp;nbsp; focal segmental glomerulosclerosis (FSGS) and hypertension-attributed end-stage kidney disease (H-ESKD) are associated with two independent sequence variants in the APOL1 gene on chromosome 22, which has strong linkage with MYH9. The two APOL1 variants are common in African chromosomes but absent from European chromosomes, and both reside within haplotypes that harbour signatures of positive selection. ApoL1 (apolipoprotein L-1) is a serum factor that lyses trypanosomes. In vitro assays revealed that only the kidney disease-associated ApoL1 variants lysed Trypanosoma brucei rhodesiense. We speculate that evolution of a critical survival factor in Africa may have contributed to the high rates of renal disease in African Americans&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;IMG id=nelh_tempImage0 alt=" name=nelh_tempImage0 border=" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0005_feed.gif" width=16 height=16 icon? RSS 0?&gt;&amp;nbsp;RSS FEEDS&amp;nbsp; &lt;IMG id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0006_feed.gif" width=16 height=16&gt;&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;You can receive news from the kidney diseases specialist collection from the RSS feeds we provide:&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/RSSFeed.aspx?feed=57" target="_blank"&gt;&lt;IMG id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0007_feed.gif" width=16 height=16&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk/kidney/RSSFeed.aspx?feed=57" target="_blank"&gt;New Kidney Diseases Resources&lt;/A&gt;&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/RSSFeed.aspx?feed=136" target="_blank"&gt;&lt;IMG id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0008_feed.gif" width=16 height=16&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk/kidney/RSSFeed.aspx?feed=136" target="_blank"&gt;New Male Urogenital Disorders Resources&lt;/A&gt; &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk//kidney/News.aspx" target="_blank"&gt;&lt;IMG id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0008_feed.gif" width=16 height=16&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk//kidney/News.aspx" target="_blank"&gt;Kidney diseases and male urogenital disorders in the news&lt;/A&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/rss/Directory/MoreAboutRss.aspx" target="_blank"&gt;Click through this link to find out more about RSS feeds.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;JOURNALS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;You can link through to the latest Tables of Contents from all the major kidney, transplant and urology journals from &lt;A href="http://www.library.nhs.uk/KIDNEY/Page.aspx?pagename=EJOURNALS" target="_blank"&gt;this page&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=3&gt;&lt;STRONG&gt;&lt;BIG&gt;Resources added in&amp;nbsp;October 2010&lt;/BIG&gt;&lt;/STRONG&gt; &lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A name=kidney&gt;Chronic Kidney&amp;nbsp;Disease&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.cochrane-renal.org/docs/Newsletter_October_2010.pdf" target="_blank"&gt;Cochrane Renal Group newsletter for October 2010&lt;/A&gt;. Link to full-text PDF. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2010---October/28/Using-allopurinol-above-dose-based-on-creatinine-clearance-in-patients-with-chronic-gout-including-those-with-renal-impairment2/" target="_blank"&gt;Using allopurinol above dose based on creatinine clearance in patients with chronic gout including those with renal impairment&lt;/A&gt;. Published 28/10/10 by the National electronic Library for Medicines. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2010---October/25/FDA-panel-votes-to-maintain-use-of-erythropoiesis-stimulating-agents-in-patients-with-chronic-kidney-failure-not-on-dialysis/" target="_blank"&gt;FDA panel votes to maintain use of erythropoiesis-stimulating agents in patients with chronic kidney failure not on dialysis&lt;/A&gt;. Published 25/10/10 by the National electronic Library for Medicines. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2010---October/15/FDA-to-review-safety-data-on-erythropoiesis-stimulating-agents-in-wake-of-data-from-TREAT-trial/" target="_blank"&gt;FDA to review safety data on erythropoiesis-stimulating agents in wake of data from TREAT trial&lt;/A&gt;. Published 15/10/10 by the National electronic Library for Medicines. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://renaltsar.blogspot.com/2010/10/q-our-son-has-kidney-disease-what.html" target="_blank"&gt;Renal Tsar Q and A - Our son has kidney disease - what should we do?&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_120988" target="_blank"&gt;Self Care Awareness Week 15-21 November 2010&lt;/A&gt;. From the Department of Health. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://renaltsar.blogspot.com/2010/10/growth-rate-slows-to-single-figures.html" target="_blank"&gt;Renal Tsar on the recorded prevalence of CKD in the UK&lt;/A&gt;. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://renaltsar.blogspot.com/2010/10/q-improving-choice.html" target="_blank"&gt;Renal Tsar on Improving Choice&lt;/A&gt;.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/Evidence/Drug-Specific-Reviews/SMC-does-not-recommend-lanthanum-carbonate-Fosrenol-for-hyperphosphataemia-in-adults-with-CKD-not-on-dialysis/" target="_blank"&gt;SMC does not recommend lanthanum carbonate -Fosrenol- for hyperphosphataemia in adults with CKD not on dialysis&lt;/A&gt;. Published 12/10/10 by the National electronic Library for Medicines. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:389328:0" name=internalLink&gt;Key Facts and Figures about Kidney Disease&lt;/A&gt;. Publication from NHS Kidney Care.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.kidneycarematters.nhs.uk/Default.aspx" target="_blank"&gt;October 2010 Kidney Care Matters&lt;/A&gt;. Monthly newsletter from NHS Kidney Care. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2010---October/04/NICE-consultation-on-clinical-guideline-for-the-management-of-anaemia-in-chronic-kidney-disease-/" target="_blank"&gt;NICE consultation on clinical guideline for the management of anaemia in chronic kidney disease&lt;/A&gt;. Published 04/10/10 by the National electronic Library for Medicines. &lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Diabetic nephropathy&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;No new resources this month. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Hypertension&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:391309:0" name=internalLink&gt;Nurse led interventions to improve control of blood pressure in people with hypertension- systematic review and meta-analysis&lt;/A&gt;. A new record from the Database of Abstracts of Reviews of Effects.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Acute kidney injury&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:382516:0" name=internalLink&gt;Sodium bicarbonate for prevention of contrast-induced acute kidney injury: a systematic review and meta-analysis&lt;/A&gt;. A new record from the Database of Abstracts of Reviews of Effects. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;End-Stage Renal Disease&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;No new resources this month. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Renovascular diseases&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:389663:0" name=internalLink&gt;Endovascular stents for the treatment of atherosclerotic renal artery stenosis&lt;/A&gt;. A new record from the CRD Health Technology Assessment Database.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Glomerulonephritis&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;No new resources this month. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Other renal conditions&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;No new resources this month. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Renal tract infections&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:359019:0" name=internalLink&gt;Early switch to oral versus intravenous antimicrobial treatment for hospitalized patients with acute pyelonephritis: a systematic review of randomized&amp;nbsp;controlled trials&lt;/A&gt;. A new record from the Database of Abstracts of Reviews of Effects.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Kidney stones&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;No new resources this month. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Renal vasculitis&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;No new resources this month. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Haemodialysis&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://renaltsar.blogspot.com/2010/10/listen-to-patients.html" target="_blank"&gt;Renal Tsar on the Manchester Conference on Home Dialysis&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:360905:0" name=internalLink&gt;Clinical outcomes of dialysis patients after implantation of DES: meta analysis and systematic review of literature&lt;/A&gt;. A new record from the Database of Abstracts of Reviews of Effects. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:389325:0" name=internalLink&gt;NHS Kidney Care Dialysis Capacity Survey&lt;/A&gt;. Publication from NHS Kidney Care. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Peritoneal Dialysis&lt;/STRONG&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;No new resources this month. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Transplantation&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:391505:0" name=internalLink&gt;The ANZICS statement on death and organ donation&lt;/A&gt;. Australian and New Zealand Intensive Care Society publication. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2010---October/20/Department-of-Health-issues-report-of-an-independent-review-of-the-NHS-Organ-Donor-Register/" target="_blank"&gt;Department of Health issues report of an independent review of the NHS Organ Donor Register.&lt;/A&gt; Published 20/10/10 by the National electronic Library for Medicines. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Kidney Cancer&lt;/STRONG&gt; &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;No new resources this month. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A name=mug&gt;Male Urogenital Disorders&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Male Ureteric Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;No new resources this month. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Male Bladder Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:392563:0" name=internalLink&gt;Percutaneous posterior tibial nerve stimulation for overactive bladder syndrome&lt;/A&gt;. A new NICE guideline.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:389407:0" name=internalLink&gt;Drugs for treatment of urinary retention after surgery in adults&lt;/A&gt;. New Cochrane systematic review. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.baus.org.uk/Updates/news/news-archive/2010/sept/Ketamin-pn" target="_blank"&gt;Surgeons warn clubbers about the dangers of Ketamine&lt;/A&gt;. News item from the British Association of Urological Surgeons.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Prostate Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:392568:0" name=internalLink&gt;Transperineal template biopsy and mapping of the prostate&lt;/A&gt;. A new interventional procedure guideline from NICE.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:389791:0" name=internalLink&gt;Molecular diagnostic test for prostate cancer&lt;/A&gt;. A new record from the CRD Health Technology Assessment Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:389754:0" name=internalLink&gt;Laser therapy for benign prostatic hyperplasia&lt;/A&gt;. A new record from the CRD Health Technology Assessment Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:391328:0" name=internalLink&gt;Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials&lt;/A&gt;. A new record from the Database of Abstracts of Reviews of Effects.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:374711:0" name=internalLink&gt;Is there a benefit from lycopene supplementation in men with prostate cancer? A systematic review&lt;/A&gt;. A new record from the Database of Abstracts of Reviews of Effects.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2010---October/07/10-year-results-of-EORTC-study-on-external-irradiation-with-or-without-long-term-androgen-suppression-for-prostate-cancer-with-high-metastatic-risk/" target="_blank"&gt;10 year results of EORTC study on external irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk&lt;/A&gt;. Published 07/10/10 by the National electronic Library for Medicines. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/Evidence/Drug-Specific-Reviews/DTB-reviews-OTC-tamsulosin-for-benign-prostatic-hyperplasia/" target="_blank"&gt;DTB reviews OTC tamsulosin for benign prostatic hyperplasia&lt;/A&gt;. Published 06/10/10 by the National electronic Library for Medicines.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:389383:0" name=internalLink&gt;Finasteride for benign prostatic hyperplasia&lt;/A&gt;. New Cochrane systematic review.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Penile Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:392720:0" name=internalLink&gt;Mini Topic Review: Circumcision&lt;/A&gt;. Published 01 November 2010, by Dr J Manley and Mr D Cranston. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:389695:0" name=internalLink&gt;Cialis (tadalafil) (Lilly USA LLC) for postprostatectomy erectile dysfunction&lt;/A&gt;. A new record from the CRD Health Technology Assessment Database.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Urethral disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;No new resources this month. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Urinary tract infections&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:360981:0" name=internalLink&gt;Bladder irrigation with amphotericin B and fungal urinary tract infection: systematic review with meta-analysis&lt;/A&gt;. A new record from the Database of Abstracts of Reviews of Effects.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Testicular/Scrotal Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;No new resources this month. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Male Urinary Incontinence&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:392424:0" name=internalLink&gt;Nocturnal enuresis - the management of bedwetting in children and young people&lt;/A&gt;. A new NICE guideline. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:369701:0" name=internalLink&gt;Absorbent products for urinary or faecal incontinence- a comparative evaluation of key product designs&lt;/A&gt;. A new record from the CRD NHS Economic Evaluation Database. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Sexually Transmitted Infections&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;No new resources this month. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Fertility&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;No new resources this month. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;/LI&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <expiryDate>01/11/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>318848</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.renal.org/pages/media/TsarFiles/NSFUpdateJune2009.doc]]&gt;</url>
    <title>NSF for Renal Services Update - June 2009</title>
    <publicationDate>2009-06-10T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ NATIONAL SERVICE FRAMEWORK FOR RENAL SERVICES/POLICY DOCUMENTS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This report contains an update on:&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;End of Life Care for Advanced Kidney Disease – Launch of Framework for Implementation&lt;/LI&gt;
&lt;LI&gt;NHS Health Checks (formerly Vascular Checks)&lt;/LI&gt;
&lt;LI&gt;Kidney Care Plans&lt;/LI&gt;
&lt;LI&gt;National Renal Dataset&lt;/LI&gt;
&lt;LI&gt;Developing SHA-wide local Kidney Care Networks&lt;/LI&gt;
&lt;LI&gt;CMO Intern in Kidney Care&lt;/LI&gt;
&lt;LI&gt;SpR in Green Nephrology&lt;/LI&gt;
&lt;LI&gt;Detecting and Managing Chronic Kidney Disease in England – Measuring Proteinuria using ACR&lt;/LI&gt;
&lt;LI&gt;NCEPOD Report on Acute Kidney Injury&lt;/LI&gt;
&lt;LI&gt;Use of Insulin in the treatment of Hyperkalaemia&lt;/LI&gt;
&lt;LI&gt;PbR for Kidney Dialysis – developing a Best Practice Tariff&lt;/LI&gt;
&lt;LI&gt;PbR for Kidney Transplantation – Developing robust Reference Costs&lt;/LI&gt;
&lt;LI&gt;Impact of Organ Donation Taskforce Report on Kidney Services&lt;/LI&gt;
&lt;LI&gt;The Year 2008/09 – David Nicholson’s Annual Report&lt;/LI&gt;
&lt;LI&gt;Personal Health Budgets – A pilot for Haemodialysis Transport&lt;/LI&gt;
&lt;LI&gt;Primary Care Journals&lt;/LI&gt;
&lt;LI&gt;Changes to the healthcare travel costs scheme&lt;BR&gt;&lt;/LI&gt;&lt;/OL&gt;]]&gt;</body>
    <lastReviewDate>01/07/2010 14:15:43</lastReviewDate>
    <expiryDate>01/07/2011 14:15:43</expiryDate>
  </document>
  <document>
    <id>388106</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=388106]]&gt;</url>
    <title>Obesity and kidney diseases: Systematic reviews and meta-analyses</title>
    <publicationDate>2010-09-21T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ PREDISPOSING FACTORS,DIETARY CHANGE,INTERVENTIONS,COMPLICATIONS OF KIDNEY DISEASE,OTHER,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,ACUTE KIDNEY INJURY,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Obesity and kidney diseases: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Afshinnia, F., T. J. Wilt, et al. (2010). "Weight loss and proteinuria: Systematic review of clinical trials and comparative cohorts." Nephrology Dialysis Transplantation 25(4): 1173-1183. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Weight%20loss%20and%20proteinuria%3A%20Systematic%20review%20of%20clinical%20trials%20and%20comparative%20cohorts" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Guh, D. P., W. Zhang, et al. (2009). "The incidence of co-morbidities related to obesity and overweight: A systematic review and meta-analysis." BMC Public Health 9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=The%20incidence%20of%20co-morbidities%20related%20to%20obesity%20and%20overweight%3A%20A%20systematic%20review%20and%20meta-analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Ildaphonse, G., P. S. George, et al. (2009). "Obesity and kidney cancer risk in men: a meta-analysis (1992-2008)." Asian Pac J Cancer Prev 10(2): 279-86.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Obesity%20and%20kidney%20cancer%20risk%20in%20men%3A%20a%20meta-analysis%20%281992-2008%29" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kaptein, E. M., E. Beale, et al. (2009). "Thyroid hormone therapy for obesity and nonthyroidal illnesses: a systematic review." J Clin Endocrinol Metab 94(10): 3663-75.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Thyroid%20hormone%20therapy%20for%20obesity%20and%20nonthyroidal%20illnesses%3A%20a%20systematic%20review" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mathew, A., P. S. George, et al. (2009). "Obesity and kidney cancer risk in women: a meta-analysis (1992-2008)." Asian Pac J Cancer Prev 10(3): 471-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Obesity%20and%20kidney%20cancer%20risk%20in%20women%3A%20a%20meta-analysis%20%281992-2008%29" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Navaneethan, S. D., H. Yehnert, et al. (2009). "Weight loss interventions in chronic kidney disease: a systematic review and meta-analysis." Clin J Am Soc Nephrol 4(10): 1565-74.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Weight%20loss%20interventions%20in%20chronic%20kidney%20disease%3A%20a%20systematic%20review%20and%20meta-analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Wang, Y., X. Chen, et al. (2008). "Association between obesity and kidney disease: a systematic review and meta-analysis." Kidney Int 73(1): 19-33.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Association%20between%20obesity%20and%20kidney%20disease%3A%20a%20systematic%20review%20and%20meta-analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <expiryDate>21/09/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>326265</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=326265]]&gt;</url>
    <title>October 2009 NHS Evidence - kidney diseases newsletter</title>
    <publicationDate>2009-10-01T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ INHERITED KIDNEY DISEASE,RENOVASCULAR DISEASES,RENAL CANCER,END-OF-LIFE CARE,GLOMERULONEPHRITIS,KIDNEY AND BLADDER STONES,PERITONEAL DIALYSIS,COMPLICATIONS OF KIDNEY DISEASE,KIDNEY DISEASE IN CHILDREN AND ADOLESCENTS,OTHER CONDITIONS - ADULTS,HAEMODIALYSIS,ORGANISATIONS,ACUTE KIDNEY INJURY,RENAL TRACT INFECTIONS,TRANSPLANTATION,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES,DIALYSIS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;October 2009 NHS Evidence - kidney diseases newsletter&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;NHS Evidence - kidney diseases is for busy health professionals, providing them with high quality information and keeping them up to date with the latest research and developments in this area.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=center&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=center&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage1 height=240 alt="Human kidneys" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID326265/nelhImp_0001_Humankidneys_istock_compressed.jpg" width=187 border=0 name=nelh_tempImage1&gt;&lt;/P&gt;
&lt;H2 align=left&gt;Coming soon: &lt;/H2&gt;
&lt;P align=left&gt;This specialist collection will be renamed&amp;nbsp;"NHS Evidence - kidney diseases and male urogenital disorders" from early October 2009 to&amp;nbsp;incorporate&amp;nbsp;evidence on disorders&amp;nbsp;affecting the male urogenital system and male sexual health, to complement the evidence on the female urogenital system and sexual health covered by the women's health specialist collection. This newsletter will therefore include the evidence on male urogenital disorders from November 2009 and will be disseminated to the urology community as well as to the renal community. &lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0005_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&amp;nbsp;RSS FEEDS&amp;nbsp; &lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0006_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;You can receive news from the kidney diseases specialist collection from the RSS feeds we provide:&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;&lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0007_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk/kidney/RSSFeed.aspx?feed=57" target="_blank"&gt;New Resources added to NHS Evidence - kidney diseases&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0008_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk//kidney/News.aspx" target="_blank"&gt;Kidney diseases in the news&lt;/A&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/rss/Directory/MoreAboutRss.aspx" target="_blank"&gt;Click through this link to find out more about RSS feeds.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;JOURNALS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;You can link through to the latest Tables of Contents from all the major kidney journals from &lt;A href="http://www.library.nhs.uk/KIDNEY/Page.aspx?pagename=EJOURNALS" target="_blank"&gt;this page&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=3&gt;&lt;STRONG&gt;&lt;BIG&gt;New resources added in&amp;nbsp;September 2009&lt;/BIG&gt;&lt;/STRONG&gt; &lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Chronic Kidney&amp;nbsp; Disease&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Free recipe book available from local dieticians. &lt;A href="http://www.kidneyresearchuk.org/news/kidney-research-news-articles.php?id=738" target="_blank"&gt;Click here for more&lt;/A&gt;. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:324157:0" name=internalLink&gt;How can we help employees with chronic diseases to stay at work: a review of interventions aimed at job retention and based on an empowerment perspective&lt;/A&gt;. Database of Abstracts of Reviews of Effects.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://renaltsar.blogspot.com/2009/09/q-could-you-explain-good-medium-and-low.html" target="_blank"&gt;Q&amp;amp;A on Renal Tsar's blog: Could you explain the good, medium and low eGFRs and what they mean?&lt;/A&gt;&amp;nbsp;10/09/09&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:325090:0" name=internalLink&gt;Patient information needs report “identifying chronic kidney disease patients’ priorities and preferences for information topics”&lt;/A&gt;. Published by the Salford Royal NHS Foundation Trust originally in April 2007. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://renaltsar.blogspot.com/2009/09/bnf-advice-on-drug-doses-adjustments-in.html" target="_blank"&gt;BNF advice on drug doses and CKD&lt;/A&gt; - link to Renal Tsar's blog report (23/09/09)&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk//en/NeLM-Area/News/2009---September/23/Evaluation-of-a-Medline-filter-for-nephrology-/" target="_blank"&gt;Evaluation of a Medline filter for nephrology&lt;/A&gt;. News item from the National electronic Library for Medicines. (23/09/09).&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2009---September/29/Patients-with-CKD-and-less-severe-renal-failure-have-a-low-risk-of-hyperkalaemia-on-ACE-inhibitors/" target="_blank"&gt;Patients with CKD and less severe renal failure have a low risk of hyperkalaemia on ACE-inhibitors. News item from the National electronic Library for Medicines&lt;/A&gt;. (29/09/09)&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://renaltsar.blogspot.com/2009/09/recorded-ckd-prevalence-continues-to.html" target="_blank"&gt;Renal Tsar's blog: Recorded CKD prevalence continues to rise&lt;/A&gt; (29/09/09)&lt;/LI&gt;
&lt;LI&gt;New BMJ Learning module on &lt;A href="nelh:326234:0" name=internalLink&gt;Chronic Kidney Disease: early identification and management in adults - in association with NICE&lt;/A&gt;. &lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Other conditions - adults&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2009---September/14/Meta-analysis-High-dose-N-acetylcysteine-reduces-contrast-nephropathy/" target="_blank"&gt;Meta-analysis: High-dose N-acetylcysteine reduces contrast nephropathy?&lt;/A&gt; News item from the National electronic Library for Medicines. (14/09/09)&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Haemodialysis&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:325077:0" name=internalLink&gt;Enhanced surveillance of Meticillin resistant Staphylococcus aureus (MRSA)&lt;/A&gt;. Briefing from the Renal Association. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://renaltsar.blogspot.com/2009/09/q-single-sex-areas-hospital-dialysis.html" target="_blank"&gt;Q&amp;amp;A on Renal Tsar's blog on Single sex areas and hospital dialysis&lt;/A&gt;. (15/09/09)&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://renaltsar.blogspot.com/2009/09/q-taking-frequency-length-of-hd.html" target="_blank"&gt;Q&amp;amp;A on Renal Tsar's blog on Taking frequency &amp;amp; length of HD sessions into account&lt;/A&gt; (28/09/09)&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:325518:0" name=internalLink&gt;Review of the Dialysis Services for the residents of Essex: a review by the Health Overview and Scrutiny Committee&lt;/A&gt;. A report published by the Renal Association. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Transplantation&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2009---September/09/Donor-pre-treatment-with-dopamine-may-improve-kidney-transplant-outcome/" target="_blank"&gt;Donor pre-treatment with dopamine may improve kidney transplant outcome&lt;/A&gt;. News item from the National electronic Library for Medicines. (09/09/09)&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;National Service Framework for Renal Services&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:325078:0" name=internalLink&gt;Renal NSF Update for September 2009&lt;/A&gt;. Published 17/09/09.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;**Subscribe to the NHS Evidence Eyes on Evidence Newsletter**&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;If you would like to receive Eyes on Evidence, the monthly e-bulletin from NHS Evidence, please sign up at &lt;A href="http://www.evidence.nhs.uk/NewsletterSignup.aspx" target="_blank"&gt;http://www.evidence.nhs.uk/NewsletterSignup.aspx&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The bulletin will keep you updated with new and important evidence and key developments on the NHS Evidence portal.&amp;nbsp; It comes out on the second Wednesday of the month and can be sent to any e-mail address that you provide.&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>23/09/2010 10:06:46</lastReviewDate>
    <expiryDate>23/09/2011 10:06:46</expiryDate>
  </document>
  <document>
    <id>388924</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=388924]]&gt;</url>
    <title>October 2010 NHS Evidence - kidney diseases and male urogenital disorders newsletter</title>
    <publicationDate>2010-10-01T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;October 2010 NHS Evidence - kidney diseases and male urogenital disorders newsletter&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Welcome to the kidney diseases and male urogenital disorders specialist collection enewsletter for&amp;nbsp;OCTOBER 2010. &lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=left&gt;NHS Evidence - kidney diseases and male urogenital disorders is for busy health professionals, providing them with high quality information and keeping them up to date with the latest research and developments in this area. You can now join our mailing list to receive regular updates. &lt;A href="https://www.jiscmail.ac.uk/cgi-bin/webadmin?A0=NHSEVIDENCEKDMU" target="_blank"&gt;Click here for the link&lt;/A&gt;.&lt;/P&gt;
&lt;P align=center&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Links to:&lt;/STRONG&gt;&lt;/P&gt;&lt;STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="#kidney"&gt;New Kidney Diseases items&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="#mug"&gt;New Male Urogenital Disorders items&lt;/A&gt;&lt;/STRONG&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=center&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage0 style="WIDTH: 269px; HEIGHT: 193px" height=213 alt="Laptop research" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID388924/nelhImp_0000_Research_Laptopnotepad.jpg" width=281 border=0 name=nelh_tempImage0&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;OCTOBER 2010: RENAL HOT TOPICS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;JAMA&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Genetic Variants of the Protein Kinase C-ß 1 Gene and Development of End-Stage Renal Disease in Patients With Type 2 Diabetes&lt;BR&gt;Ronald C. W. Ma; Claudia H. T. Tam; Ying Wang; Andrea O. Luk; Cheng Hu; Xilin Yang; et al. JAMA. 2010;304(8):881-889. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20736472" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;NEJM&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Erythropoietic Response and Outcomes in Kidney Disease and Type 2 Diabetes. Scott D. Solomon, M.D., Hajime Uno, Ph.D., Eldrin F. Lewis, M.D., M.P.H., Kai-Uwe Eckardt, M.D., Julie Lin, M.D., M.P.H., Emmanuel A. Burdmann,&amp;nbsp;et al. &amp;nbsp;N Engl J Med 2010; 363:1146-1155. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/%2020843249" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Intensive Blood-Pressure Control in Hypertensive Chronic Kidney Disease. Lawrence J. Appel, M.D., M.P.H., Jackson T. Wright, Jr., M.D., Ph.D., Tom Greene, Ph.D., Lawrence Y. Agodoa, M.D., Brad C. Astor, M.P.H., Ph.D., George L. Bakris, M.D.,&amp;nbsp;et al&amp;nbsp;for the AASK Collaborative Research Group. N Engl J Med 2010; 363:918-929 (September 2, 2010).&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20818902" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Sirolimus and Kidney Growth in Autosomal Dominant Polycystic Kidney Disease. Andreas L. Serra, M.D., Diane Poster, M.D., Andreas D. Kistler, M.D., Fabienne Krauer, B.S., Shagun Raina, M.S., James Young, Ph.D., Katharina M. Rentsch, Ph.D., Katharina S. Spanaus, M.D., Oliver Senn, M.D., M.P.H., Paulus Kristanto, Ph.D., Hans Scheffel, M.D., Dominik Weishaupt, M.D., and Rudolf P. Wüthrich, M.D. N Engl J Med 2010; 363:820-829 (August 26, 2010). [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20581391" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Everolimus in Patients with Autosomal Dominant Polycystic Kidney Disease. Gerd Walz, M.D., Klemens Budde, M.D., Marwan Mannaa, M.D., Jens Nürnberger, M.D., Christoph Wanner, M.D., Claudia Sommerer, M.D., et al.&amp;nbsp; N Engl J Med 2010; 363:830-840 (August 26, 2010). [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20581392" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Racial Variation in Medical Outcomes among Living Kidney Donors&lt;BR&gt;Krista L. Lentine, M.D., Mark A. Schnitzler, Ph.D., Huiling Xiao, M.S., Georges Saab, M.D., Paolo R. Salvalaggio, M.D., Ph.D., David Axelrod, M.D., et al.&amp;nbsp; N Engl J Med 2010; 363:724-732 (August 19, 2010). [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20818874" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;A Randomized, Controlled Trial of Early versus Late Initiation of Dialysis. Bruce A. Cooper, M.B., B.S., Ph.D., Pauline Branley, B.Med., Ph.D., Liliana Bulfone, B.Pharm., M.B.A., John F. Collins, M.B., Ch.B., Jonathan C. Craig, M.B., Ch.B., Ph.D., Margaret B. Fraenkel, B.M., et al. N Engl J Med 2010; 363:609-619 (August 12, 2010). [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20581422" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;BR&gt;The Lancet&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Daniel P Gale MRCP, Elena Goicoechea de Jorge PhD, Prof H Terence Cook FRCPath, Rubén Martinez-Barricarte PhD, Andreas Hadjisavvas PhD, Adam G McLean FRCP, et al. The Lancet, Volume 376, Issue 9743, Pages 794 - 801, (4 September 2010). [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20800271" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Faramarz Ismail-Beigi, Timothy Craven, Mary Ann Banerji, Jan Basile, Jorge Calles, Robert M Cohen,&amp;nbsp;et al.,&amp;nbsp;for the ACCORD trial group. The Lancet, volume 376, pages 419-430 (7th August 2010). [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20594588" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;IMG id=nelh_tempImage0 height=16 alt=" name=nelh_tempImage0 border=" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0005_feed.gif" width=16 icon? RSS 0?&gt;&amp;nbsp;RSS FEEDS&amp;nbsp; &lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0006_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;You can receive news from the kidney diseases specialist collection from the RSS feeds we provide:&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/RSSFeed.aspx?feed=57" target="_blank"&gt;&lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0007_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk/kidney/RSSFeed.aspx?feed=57" target="_blank"&gt;New Kidney Diseases Resources&lt;/A&gt;&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/RSSFeed.aspx?feed=136" target="_blank"&gt;&lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0008_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk/kidney/RSSFeed.aspx?feed=136" target="_blank"&gt;New Male Urogenital Disorders Resources&lt;/A&gt; &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk//kidney/News.aspx" target="_blank"&gt;&lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0008_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk//kidney/News.aspx" target="_blank"&gt;Kidney diseases and male urogenital disorders in the news&lt;/A&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/rss/Directory/MoreAboutRss.aspx" target="_blank"&gt;Click through this link to find out more about RSS feeds.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;JOURNALS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;You can link through to the latest Tables of Contents from all the major kidney, transplant and urology journals from &lt;A href="http://www.library.nhs.uk/KIDNEY/Page.aspx?pagename=EJOURNALS" target="_blank"&gt;this page&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=3&gt;&lt;STRONG&gt;&lt;BIG&gt;Resources added in&amp;nbsp;September 2010&lt;/BIG&gt;&lt;/STRONG&gt; &lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A name=kidney&gt;Chronic Kidney&amp;nbsp;Disease&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/Evidence/Medicines-Management/References/2010---September/07/Medication-adherence-behavior-and-priorities-among-older-adults-with-CKD-a-semistructured-interview-study/" target="_blank"&gt;Medication adherence behavior and priorities among older adults with CKD: a semistructured interview study&lt;/A&gt;. Published 07/09/10 by the National electronic Library for Medicines. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:333626:0" name=internalLink&gt;Chronic Kidney Disease - Systematic reviews and meta-analyses&lt;/A&gt;. The specialist collection team have updated this page with the latest evidence. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:388052:0" name=internalLink&gt;Exercise and kidney diseases- Systematic reviews and meta-analyses&lt;/A&gt;. The specialist collection team have updated this page with the latest evidence. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:388051:0" name=internalLink&gt;Diet nutrition and kidney diseases- Systematic reviews and meta-analyses&lt;/A&gt;. The specialist collection team have updated this page with the latest evidence. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:338797:0" name=internalLink&gt;Genetics of Kidney Diseases- Systematic Reviews and Meta-analyses.&lt;/A&gt; The specialist collection team have updated this page with the latest evidence. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:388011:0" name=internalLink&gt;Bone disease and kidney disorders-Systematic reviews and meta-analyses&lt;/A&gt;. The specialist collection team have updated this page with the latest evidence. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:333619:0" name=internalLink&gt;Anaemia- Systematic reviews and meta-analyses&lt;/A&gt;. The specialist collection team have updated this page with the latest evidence. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:388074:0" name=internalLink&gt;Immunosuppression and kidney diseases- Systematic reviews and meta-analyses&lt;/A&gt;. The specialist collection team have updated this page with the latest evidence. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:341852:0" name=internalLink&gt;Renal function- Systematic reviews and meta-analyses&lt;/A&gt;. The specialist collection team have updated this page with the latest evidence. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:341847:0" name=internalLink&gt;Proteinuria- Systematic reviews and meta-analyses.&lt;/A&gt; The specialist collection team have updated this page with the latest evidence. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:346856:0" name=internalLink&gt;Pregnancy and Kidney Diseases- Systematic reviews and meta-analyses&lt;/A&gt;. The specialist collection team have updated this page with the latest evidence. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:388106:0" name=internalLink&gt;Obesity and kidney diseases- Systematic reviews and meta-analyses.&lt;/A&gt; The specialist collection team have updated this page with the latest evidence.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.bmj.com/content/341/bmj.c4249.full" target="_blank"&gt;Low glomerular filtration rate and risk of stroke - meta-analysis&lt;/A&gt;. Open access meta analysis by Lee M et al. Published 01/10/10. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2010---September/30/Draft-NICE-quality-standard-for-consultation-Chronic-kidney-disease/" target="_blank"&gt;Draft NICE quality standard for consultation- Chronic kidney disease.&lt;/A&gt; Abstract from the National electronic Library for Medicines published 01/10/10&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.bmj.com/content/341/bmj.c4986.full" target="_blank"&gt;Chronic kidney disease and risk of major cardiovascular disease and non-vascular mortality - prospective population based cohort study&lt;/A&gt;. Open access article from the BMJ by Di Engelantonio E et al. Published 01/10/10. &lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Diabetic nephropathy&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:387485:0" name=internalLink&gt;Heparin and related substances for preventing diabetic kidney disease&lt;/A&gt;. New Cochrane systematic review.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nejm.org/doi/full/10.1056/NEJMoa1005109" target="_blank"&gt;Erythropoietic Response and Outcomes in Kidney Disease and Type 2 Diabetes&lt;/A&gt;. NEJM article by Solomon, S.D. et al. (Published 16/09/10)&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:333667:0" name=internalLink&gt;Diabetic Nephropathy- Systematic reviews and meta-analyses&lt;/A&gt;. The specialist collection team have updated this page with the latest evidence. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Hypertension&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://renaltsar.blogspot.com/2010/09/hypertension-kidney-disease-and.html" target="_blank"&gt;Renal Tsar on Hypertension kidney disease and pregnancy&lt;/A&gt;. Blog entry posted 16/09/10.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:385402:0" name=internalLink&gt;Hypertension in pregnancy- the management of hypertensive disorders during pregnancy&lt;/A&gt;. A new care guideline from NICE which offers evidence-based advice on the care and treatment of women who have or are at risk of developing hypertension. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Acute kidney injury&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:332400:0" name=internalLink&gt;Acute Kidney Injury- Systematic reviews and meta-analyses&lt;/A&gt;. The specialist collection team have updated this page with the latest evidence. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;End-Stage Renal Disease&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;End of Life Care Strategy: Second Annual Report. NHS Kidney Care have been involved in this DH report, published 25 August 2010. &lt;A href="http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_118810" target="_blank"&gt;Link to DH webpage to download the full-text document&lt;/A&gt;. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:338779:0" name=internalLink&gt;End-Stage Renal Disease- Systematic reviews and meta-analyses&lt;/A&gt;. The specialist collection team have updated this page with the latest evidence. &lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Renovascular diseases&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2010---September/17/Sub-group-analysis-Ticagrelor-versus-clopidogrel-in-acute-coronary-syndromes-in-relation-to-renal-function-results-from-the-PLATO-trial/" target="_blank"&gt;Sub-group analysis- Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function- results from the PLATO trial&lt;/A&gt;. Abstract from the National electronic Library for Medicines (20/09/10). &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:341905:0" name=internalLink&gt;Renovascular disease- Systematic reviews and meta-analyses&lt;/A&gt;. The specialist collection team have updated this page with the latest evidence. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.bmj.com/content/341/bmj.c4390.full" target="_blank"&gt;Glomerular filtration rate and the risk of stroke&lt;/A&gt;. BMJ editorial by Perkovic V and Cass A. Published 01/10/10. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.bmj.com/content/341/bmj.c4249.full" target="_blank"&gt;Low glomerular filtration rate and risk of stroke - meta-analysis&lt;/A&gt;. Open access meta analysis by Lee M et al. Published 01/10/10. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Glomerulonephritis&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.nejm.org/doi/full/10.1056/NEJMcibr1006936" target="_blank"&gt;Clinical Implications of Basic Research - Basophils and Nephritis in Lupus&lt;/A&gt;. NEJM article by Kaveri, S.V.,&amp;nbsp; Mouthon, L., and Beyry, J. (Published 09/09/10). &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:338800:0" name=internalLink&gt;Glomerulonephritis- Systematic reviews and meta-analyses&lt;/A&gt;. The specialist collection team have updated this page with the latest evidence. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:339132:0" name=internalLink&gt;Nephritic Syndrome- Systematic reviews and meta-analyses&lt;/A&gt;. The specialist collection team have updated this page with the latest evidence. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:388099:0" name=internalLink&gt;Nephrotic syndrome- Systematic reviews and meta-analyses&lt;/A&gt;. The specialist collection team have updated this page with the latest evidence. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2010---September/23/BMJ-Lesson-of-the-Week-Proton-pump-inhibitors-and-acute-interstitial-nephritis/" target="_blank"&gt;BMJ Lesson of the Week- Proton pump inhibitors and acute interstitial nephritis&lt;/A&gt;. Abstract from the National electronic Library for Medicines published 23/09/10&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Other renal conditions&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:341907:0" name=internalLink&gt;Systemic lupus erythematosus- Systematic reviews and meta-analyses&lt;/A&gt;. The specialist collection team have updated this page with the latest evidence. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Renal tract infections&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;EM&gt;No new resources this month. &lt;/EM&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Kidney stones&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:339010:0" name=internalLink&gt;Kidney and bladder stones- Systematic reviews and meta-analyses&lt;/A&gt;. The specialist collection team have updated this page with the latest evidence. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Renal vasculitis&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;EM&gt;No new resources this month. &lt;/EM&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Haemodialysis&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:333679:0" name=internalLink&gt;Dialysis- Systematic reviews and meta-analyses&lt;/A&gt;. The specialist collection team have updated this page with the latest evidence. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:333628:0" name=internalLink&gt;Continuous Renal Replacement Therapy- Systematic reviews and meta-analyses&lt;/A&gt;. The specialist collection team have updated this page with the latest evidence. &lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Peritoneal Dialysis&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:387490:0" name=internalLink&gt;Bicarbonate versus lactate solutions for acute peritoneal dialysis&lt;/A&gt;. New Cochrane systematic review. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Transplantation&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.newscientist.com/article/dn19496-blood-test-identifies-organ-transplant-rejection.html?DCMP=OTC-rss&amp;amp;nsref=online-news" target="_blank"&gt;Blood test identifies organ transplant rejection&lt;/A&gt;. New Scientist article published 24/09/10. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:339131:0" name=internalLink&gt;Nephrectomy- Systematic reviews and meta-analyses&lt;/A&gt;. The specialist collection team have updated this page with the latest evidence. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:339086:0" name=internalLink&gt;Living kidney donors- Systematic reviews and meta-analyses&lt;/A&gt;. The specialist collection team have updated this page with the latest evidence. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:338983:0" name=internalLink&gt;Immunosuppression and organ transplant- Systematic reviews and meta-analyses&lt;/A&gt;. The specialist collection team have updated this page with the latest evidence. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:341851:0" name=internalLink&gt;Renal transplant- Systematic reviews and meta-analyses&lt;/A&gt;. The specialist collection team have updated this page with the latest evidence. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:387716:0" name=internalLink&gt;Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients - BCSH and BTS Guidelines&lt;/A&gt;. Published by the British Committee for Standards in Haematology&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:387727:0" name=internalLink&gt;Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients- BCSH and BTS Guidelines&lt;/A&gt;. Published by the British Committee for Standards in Haematology&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Kidney Cancer&lt;/STRONG&gt; &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:155043:0" name=internalLink&gt;Kidney cancer- UK and International guidelines&lt;/A&gt;. The cancer specialist collection have added three new guidelines to this page.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A name=mug&gt;Male Urogenital Disorders&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Male Ureteric Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;EM&gt;No new resources this month.&lt;/EM&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Male Bladder Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;EM&gt;No new resources this month.&lt;/EM&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Prostate Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2010---September/06/Several-factors-increase-fracture-risk-with-androgen-deprivation-for-prostate-cancer-/" target="_blank"&gt;Several factors increase fracture risk with androgen deprivation for prostate cancer&lt;/A&gt;. Published 06/09/10 by the National electronic Library for Medicines. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2010---September/06/Study-suggests-use-of-some-common-medicines-may-alter-serum-PSA-levels/" target="_blank"&gt;Study suggests use of some common medicines may alter serum PSA levels&lt;/A&gt;. Published 06/09/10 by the National electronic Library for Medicines. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:111428:0" name=internalLink&gt;Prostate cancer: Causes, Risks and Prevention: Diet and nutrition&lt;/A&gt;. Three new systematic reviews have been added to this page by the cancer specialist collection team. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:111500:0" name=internalLink&gt;Prostate cancer: Treatment and Disease Management: Biological therapy&lt;/A&gt;. Two new systematic reviews have been added to this page by the cancer specialist collection team.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.bmj.com/content/341/bmj.c4543.full" target="_blank"&gt;Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials&lt;/A&gt;. An open access systematic review and meta-analysis published in the BMJ.&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.bmj.com/content/341/bmj.c4521.full" target="_blank"&gt;Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer- case-control study&lt;/A&gt;. An open access case-control study published in the BMJ. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2010---September/28/Pregabalin-seems-ineffective-for-symptom-relief-in-chronic-prostatitis-chronic-pelvic-pain-syndrome/" target="_blank"&gt;Pregabalin seems ineffective for symptom relief in chronic prostatitis /chronic pelvic pain syndrome&lt;/A&gt;. Published 28/09/10 by the National electronic Library for Medicines. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2010---September/28/Pfizer-discontinues-Phase-III-study-of-sunitinib-in-prostate-cancer--/" target="_blank"&gt;Pfizer discontinues Phase III study of sunitinib in prostate cancer&lt;/A&gt;. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2010---September/28/Zibotentan-fails-to-improve-survival-of-patients-with-prostate-cancer-in-Phase-III-trial/?id=754214" target="_blank"&gt;Zibotentan fails to improve survival of patients with prostate cancer in Phase III trial&lt;/A&gt;. Published 28/09/10 by the National electronic Library for Medicines. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Penile Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;EM&gt;No new resources this month.&lt;/EM&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Urethral disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;EM&gt;No new resources this month.&lt;/EM&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Urinary tract infections&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;EM&gt;&lt;EM&gt;No new resources this month.&lt;/EM&gt;&lt;/EM&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Testicular/Scrotal Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:331047:0" name=internalLink&gt;Testicular cancer: Causes, Risks and Prevention: Genetics&lt;/A&gt;. Three new systematic reviews have been added to this page by the cancer specialist collection team. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2010---September/27/Men-who-attend-primary-care-with-epididymo-orchitis-unlikely-to-receive-guideline-management/" target="_blank"&gt;Men who attend primary care with epididymo-orchitis unlikely to receive guideline management&lt;/A&gt;. Published 27/09/10 by the National electronic Library for Medicines. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Male Urinary Incontinence&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:387662:0" name=internalLink&gt;Management of continence - national audit of continence care (NACC) 2010 report&lt;/A&gt;. Published by the Royal College of Physicians, London. &lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Sexually Transmitted Infections&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:387486:0" name=internalLink&gt;Interactive computer-based interventions for sexual health promotion&lt;/A&gt;. New Cochrane systematic review. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Fertility&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;EM&gt;No new resources this month.&lt;/EM&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/LI&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <expiryDate>01/10/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>155535</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.cochrane-renal.org/trials_ongoing.php#]]&gt;</url>
    <title>On-going trials in Nephrology</title>
    <publicationDate></publicationDate>
    <publisher>Cochrane Renal Group</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ NEW RESEARCH,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>List of trials from website of Cochrane Renal Group</description>
    <body>&lt;![CDATA[ Overview of current trials collected by the Cochrane Renal Group, based in Australia]]&gt;</body>
    <lastReviewDate>24/09/2010 10:31:31</lastReviewDate>
    <expiryDate>24/09/2011 10:31:31</expiryDate>
  </document>
  <document>
    <id>155535</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.cochrane-renal.org/trials_ongoing.php#]]&gt;</url>
    <title>On-going trials in Nephrology</title>
    <publicationDate></publicationDate>
    <publisher>Cochrane Renal Group</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ NEW RESEARCH,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>List of trials from website of Cochrane Renal Group</description>
    <body>&lt;![CDATA[ Overview of current trials collected by the Cochrane Renal Group, based in Australia]]&gt;</body>
    <lastReviewDate>24/09/2010 10:31:31</lastReviewDate>
    <expiryDate>24/09/2011 10:31:31</expiryDate>
  </document>
  <document>
    <id>156174</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.cochrane-renal.org/trials_ongoing.php]]&gt;</url>
    <title>On-going trials in nephrology</title>
    <publicationDate>2009-07-15T00:00:00</publicationDate>
    <publisher>Cochrane Renal Group</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ NEW RESEARCH,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>List of ongoing trials</description>
    <body>&lt;![CDATA[ &lt;P&gt;List contains&amp;nbsp;a selection of ongoing studies from a variety of sources including:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Cochrane Renal Group's Prospective Trials Registration Database 
&lt;LI&gt;Cochrane Renal Group's Register of RCTs and CCTs [published annually as the Renal Health Library] 
&lt;LI&gt;Clinical Trials.Gov, National Institutes of Health US 
&lt;LI&gt;National Research Register UK 
&lt;LI&gt;ControlledTrials.com 
&lt;LI&gt;Various university, hospital and research web sites &lt;/LI&gt;&lt;/UL&gt;&lt;A href="http://www.cochrane-renal.org/trials_ongoing.php" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:29:41</lastReviewDate>
    <expiryDate>06/07/2011 11:29:41</expiryDate>
  </document>
  <document>
    <id>156174</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.cochrane-renal.org/trials_ongoing.php]]&gt;</url>
    <title>On-going trials in nephrology</title>
    <publicationDate>2009-07-15T00:00:00</publicationDate>
    <publisher>Cochrane Renal Group</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ NEW RESEARCH,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>List of ongoing trials</description>
    <body>&lt;![CDATA[ &lt;P&gt;List contains&amp;nbsp;a selection of ongoing studies from a variety of sources including:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Cochrane Renal Group's Prospective Trials Registration Database 
&lt;LI&gt;Cochrane Renal Group's Register of RCTs and CCTs [published annually as the Renal Health Library] 
&lt;LI&gt;Clinical Trials.Gov, National Institutes of Health US 
&lt;LI&gt;National Research Register UK 
&lt;LI&gt;ControlledTrials.com 
&lt;LI&gt;Various university, hospital and research web sites &lt;/LI&gt;&lt;/UL&gt;&lt;A href="http://www.cochrane-renal.org/trials_ongoing.php" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:29:41</lastReviewDate>
    <expiryDate>06/07/2011 11:29:41</expiryDate>
  </document>
  <document>
    <id>394688</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=394688]]&gt;</url>
    <title>Overactive bladder: Systematic reviews and meta-analyses</title>
    <publicationDate>2011-01-24T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE BLADDER DISORDERS,MALE UROGENITAL DISORDERS,OVERACTIVE BLADDER]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Overactive bladder: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2011&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Meek, P. D., S. D. Evang, et al. (2011). "Overactive bladder drugs and constipation: a meta-analysis of randomized, placebo-controlled trials." Digestive Diseases &amp;amp; Sciences 56(1): 7-18. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20596778" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Anger, J., A. Weinberg, et al. (2010). "Outcomes of intravesical botulinum toxin for idiopathic overactive bladder symptoms: A systematic review of the literature." Neurourology and Urodynamics 29(2). [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Outcomes%20of%20intravesical%20botulinum%20toxin%20for%20idiopathic%20overactive%20bladder%20symptoms%3A%20A%20systematic%20review%20of%20the%20literature" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Athanasopoulos, A. (2010). "Antimuscarinics and bladder outlet obstruction: From a contraindication to an indication?" Neurourology &amp;amp; Urodynamics 29 Suppl 1: S46-50.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Antimuscarinics%20and%20bladder%20outlet%20obstruction%3A%20From%20a%20contraindication%20to%20an%20indication%3F" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Bartoli, S., G. Aguzzi, et al. (2010). "Impact on Quality of Life of Urinary Incontinence and Overactive Bladder: A Systematic Literature Review." Urology 75(3): 491-500.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Impact%20on%20Quality%20of%20Life%20of%20Urinary%20Incontinence%20and%20Overactive%20Bladder%3A%20A%20Systematic%20Literature%20Review" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Irwin, D. E., I. Milsom, et al. (2010). "Dynamic progression of overactive bladder and urinary incontinence symptoms: A systematic review." European Urology 58(4): 532-543.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Dynamic%20progression%20of%20overactive%20bladder%20and%20urinary%20incontinence%20symptoms%3A%20A%20systematic%20review" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kessler, T. M., L. M. Bachmann, et al. (2010). "Adverse event assessment of antimuscarinics for treating overactive bladder: A network meta-analytic approach." European Urology, Supplements 9(2).&amp;nbsp;[No abstract available]&lt;/LI&gt;
&lt;LI&gt;Latthe, P. M., R. Champaneria, et al. (2010). "Systematic review of the accuracy of ultrasound as the method of measuring bladder wall thickness in the diagnosis of detrusor overactivity." International Urogynecology Journal and Pelvic Floor Dysfunction 21(8): 1019-1024.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Systematic%20review%20of%20the%20accuracy%20of%20ultrasound%20as%20the%20method%20of%20measuring%20bladder%20wall%20thickness%20in%20the%20diagnosis%20of%20detrusor%20overactivity" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Siddiqui, N. Y., J. M. Wu, et al. (2010). "Efficacy and adverse events of sacral nerve stimulation for overactive bladder: A systematic review." Neurourology &amp;amp; Urodynamics 29 Suppl 1: S18-23.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Efficacy%20and%20adverse%20events%20of%20sacral%20nerve%20stimulation%20for%20overactive%20bladder%3A%20A%20systematic%20review" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Biastre, K. and T. Burnakis (2009). "Trospium chloride treatment of overactive bladder." Ann Pharmacother 43(2): 283-95.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19193592" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Game, X., P. Mouracade, et al. (2009). "Botulinum toxin-A (Botox) intradetrusor injections in children with neurogenic detrusor overactivity/neurogenic overactive bladder: A systematic literature review." Journal of pediatric urology 5(3): 156-164.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Botulinum%20toxin-A%20%28Botox%29%20intradetrusor%20injections%20in%20children%20with%20neurogenic%20detrusor%20overactivity%2Fneurogenic%20overactive%20bladder%3A%20A%20systematic%20literature%20review" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Griebling, T. L., S. R. Kraus, et al. (2009). "Tolterodine extended release is well tolerated in older subjects." Int J Clin Pract 63(8): 1198-204.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Tolterodine%20extended%20release%20is%20well%20tolerated%20in%20older%20subjects" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Herbison, G. P. and E. P. Arnold (2009). "Sacral neuromodulation with implanted devices for urinary storage and voiding dysfunction in adults." Cochrane Database of Systematic Reviews(2).&amp;nbsp;[&lt;A href="nelh:312167:0" name=internalLink&gt;Link to Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lee, S., B. Malhotra, et al. (2009). "A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder." BMC Medical Research Methodology 9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=A%20meta-analysis%20of%20the%20placebo%20response%20in%20antimuscarinic%20drug%20trials%20for%20overactive%20bladder" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Tzefos, M., C. Dolder, et al. (2009). "Fesoterodine for the treatment of overactive bladder." Ann Pharmacother 43(12): 1992-2000.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19920160" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Chapple, C. R., V. Khullar, et al. (2008). "The Effects of Antimuscarinic Treatments in Overactive Bladder: An Update of a Systematic Review and Meta-Analysis." European Urology 54(3): 543-562.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18599186" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Drake, M. J. (2008). "Emerging drugs for treatment of overactive bladder and detrusor overactivity." Expert Opinion on Emerging Drugs 13(3): 431-46.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Emerging%20drugs%20for%20treatment%20of%20overactive%20bladder%20and%20detrusor%20overactivity" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Gallegos, P. J. and L. A. Frazee (2008). "Anticholinergic therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia." Pharmacotherapy 28(3): 356-365.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Anticholinergic%20therapy%20for%20lower%20urinary%20tract%20symptoms%20associated%20with%20benign%20prostatic%20hyperplasia" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Greco, K. A. and K. T. McVary (2008). "The role of combination medical therapy in benign prostatic hyperplasia." International Journal of Impotence Research 20 Suppl 3: S33-43.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=The%20role%20of%20combination%20medical%20therapy%20in%20benign%20prostatic%20hyperplasia" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Karsenty, G., P. Denys, et al. (2008). "Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review." Eur Urol 53(2): 275-87.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Botulinum%20toxin%20A%20%28Botox%29%20intradetrusor%20injections%20in%20adults%20with%20neurogenic%20detrusor%20overactivity%2Fneurogenic%20overactive%20bladder%3A%20a%20systematic%20literature%20review" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Michel, M. C. (2008). "Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome." Expert Opinion on Pharmacotherapy 9(10): 1787-96.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Fesoterodine%3A%20a%20novel%20muscarinic%20receptor%20antagonist%20for%20the%20treatment%20of%20overactive%20bladder%20syndrome" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Novara, G., A. Galfano, et al. (2008). "A Systematic Review and Meta-Analysis of Randomized Controlled Trials with Antimuscarinic Drugs for Overactive Bladder." European Urology 54(4): 740-764.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18632201" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Salvatore, S., M. Serati, et al. (2008). "Tolterodine for the treatment of overactive bladder." Expert Opinion on Pharmacotherapy 9(7): 1249-1255.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18422481" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Duthie, J., D. I. Wilson, et al. (2007). "Botulinum toxin injections for adults with overactive bladder syndrome." Cochrane Database Syst Rev(3): CD005493.&amp;nbsp;&amp;nbsp;[&lt;A href="nelh:266549:0" name=internalLink&gt;Link to Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Roxburgh, C., J. Cook, et al. (2007). "Anticholinergic drugs versus other medications for overactive bladder syndrome in adults." Cochrane Database Syst Rev(3): CD003190.&amp;nbsp;&amp;nbsp;[&lt;A href="nelh:266489:0" name=internalLink&gt;Link to Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2006&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Abrams, P., W. Artibani, et al. (2006). "Assessment of treatment outcomes in patients with overactive bladder: importance of objective and subjective measures." Urology 68(2 Suppl): 17-28.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Assessment%20of%20treatment%20outcomes%20in%20patients%20with%20overactive%20bladder%3A%20importance%20of%20objective%20and%20subjective%20measures" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Alhasso, A. A., J. McKinlay, et al. (2006). "Anticholinergic drugs versus non-drug active therapies for overactive bladder syndrome in adults." Cochrane Database Syst Rev(4): CD003193.&amp;nbsp;&amp;nbsp;[&lt;A href="nelh:237813:0" name=internalLink&gt;Link to Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Khullar, V., C. Chapple, et al. (2006). "The effects of antimuscarinics on health-related quality of life in overactive bladder: a systematic review and meta-analysis." Urology 68(2 Suppl): 38-48.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=The%20effects%20of%20antimuscarinics%20on%20health-related%20quality%20of%20life%20in%20overactive%20bladder%3A%20a%20systematic%20review%20and%20meta-analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Maniscalco, M., D. Singh-Franco, et al. (2006). "Solifenacin succinate for the treatment of symptoms of overactive bladder." Clin Ther 28(9): 1247-72.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Solifenacin%20succinate%20for%20the%20treatment%20of%20symptoms%20of%20overactive%20bladder" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Nabi, G., J. D. Cody, et al. (2006). "Anticholinergic drugs versus placebo for overactive bladder syndrome in adults." Cochrane Database Syst Rev(4): CD003781.&amp;nbsp;&amp;nbsp;[&lt;A href="nelh:238499:0" name=internalLink&gt;Link to Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Novara, G., A. Galfano, et al. (2006). "Anticholinergic drugs in patients with bladder outlet obstruction and lower urinary tract symptoms: A systematic review." Eur Urol 50(4): 675-83.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16930813" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Patel, A. K., J. M. Patterson, et al. (2006). "The emerging role of intravesical botulinum toxin therapy in idiopathic detrusor overactivity." Int J Clin Pract Suppl(151): 27-32.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=The%20emerging%20role%20of%20intravesical%20botulinum%20toxin%20therapy%20in%20idiopathic%20detrusor%20overactivity" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Tulikangas, P. K., A. Ayers, et al. (2006). "A meta-analysis comparing trials of antimuscarinic medications funded by industry or not." BJU Int 98(2): 377-80.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=A%20meta-analysis%20comparing%20trials%20of%20antimuscarinic%20medications%20funded%20by%20industry%20or%20not" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <expiryDate>22/11/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>325090</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.srht.nhs.uk/our-departments/renal-services/patient-news/patient-information/]]&gt;</url>
    <title>Patient information needs report “identifying chronic kidney disease patients’ priorities and preferences for information topics”</title>
    <publicationDate>2007-04-02T00:00:00</publicationDate>
    <publisher>Salford Royal NHS Foundation Trust</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ RENAL TRACT INFECTIONS,TRANSPLANTATION,HAEMODIALYSIS,ACUTE KIDNEY INJURY,PERITONEAL DIALYSIS,COMPLICATIONS OF KIDNEY DISEASE,KIDNEY DISEASE IN CHILDREN AND ADOLESCENTS,OTHER CONDITIONS - ADULTS,RENAL CANCER,RENOVASCULAR DISEASES,INHERITED KIDNEY DISEASE,END-OF-LIFE CARE,KIDNEY AND BLADDER STONES,GLOMERULONEPHRITIS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES,DIALYSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The study has now completed and the reports are available.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Background&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;An integral part of quality health care provision is that patients are given information that addresses their needs (DoH 2000). In a long-term condition such as chronic kidney disease (CKD) patients are encouraged to self manage their illness to a large extent and maintain their independence, whilst receiving appropriate education, information and support. Innovative studies to identify and measure the information needs of patients (cancer and asthma patients) highlight that patients have priorities and preferences with regard to what information they need and when (Degner et al 1998; Luker et al 1996; Caress et al 2002). The premise of this study was that CKD patients with end stage renal failure (ESRF) will share similar traits and have preferred key information topics, which are of a priority to them, at different times during progression of their disease, and when considering or undergoing different modalities of treatment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.srht.nhs.uk/EasysiteWeb/getresource.axd?AssetID=1631&amp;amp;type=full&amp;amp;servicetype=Attachment" target="_blank"&gt;Download the Executive Summary in PDF&amp;nbsp;[165kb]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.srht.nhs.uk/EasysiteWeb/getresource.axd?AssetID=1632&amp;amp;type=full&amp;amp;servicetype=Attachment" target="_blank"&gt;Download the Patient Summary in PDF [156kb]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.srht.nhs.uk/EasysiteWeb/getresource.axd?AssetID=1654&amp;amp;type=full&amp;amp;servicetype=Attachment" target="_blank"&gt;Download the Final Report in PDF&amp;nbsp; [1.44mb]&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
    <lastReviewDate>17/09/2010 16:39:36</lastReviewDate>
    <expiryDate>17/09/2011 16:39:36</expiryDate>
  </document>
  <document>
    <id>318034</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.ic.nhs.uk/services/national-clinical-audit-support-programme-ncasp/kidney-care/patient-transport/results-of-the-patient-transport-survey-2008]]&gt;</url>
    <title>Patient Transport Survey 2008</title>
    <publicationDate>2009-06-02T00:00:00</publicationDate>
    <publisher>NHS The Information Centre</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ COMPLICATIONS OF KIDNEY DISEASE,HAEMODIALYSIS,ACUTE KIDNEY INJURY,GLOMERULONEPHRITIS,INHERITED KIDNEY DISEASE,RENOVASCULAR DISEASES,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,DIALYSIS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>On the 15 and 16 October 2008 NHS The Information Centre carried out a patient transport survey of all renal and satellite units in England, Wales and Northern Ireland.

NHS The Information Centre asked all haemodialysis patients about their experience of travelling to their renal unit for treatment. This includes travelling by provided transport, or by private vehicle. They also carried out and organisational survey asked both renal units and commissioners of renal services about how they provide patient transport services.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Results of the Patient Transport Survey 2008: &lt;/STRONG&gt;&lt;STRONG&gt;National report&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.ic.nhs.uk/webfiles/Services/NCASP/Renal/NHSIC_Kidney%20Care_PT_Report_Lo.pdf" target="_blank"&gt;Patient Transport Survey 2008: National Report&lt;/A&gt; (Link to National Report in full-text PDF)&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Extract from press release:&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;New research highlights unacceptable transport service for some kidney patients receiving haemodialysis treatment&lt;/P&gt;
&lt;P&gt;The first major survey into kidney patient transport across England, Wales and Northern Ireland has found that a significant number of patients receive an unacceptable level of service.&lt;/P&gt;
&lt;P&gt;Kidney patients travelling to hospital for life-saving treatment receive a more punctual service from private and public transport than they do from hospital-provided transport, according to the National Kidney Care Audit Patient Transport Survey.&lt;/P&gt;
&lt;P&gt;Commissioned and funded by the Healthcare Quality Improvement Partnership as part of the National Clinical Audit and Patient Outcomes Programme, the survey was carried out by The NHS Information Centre.&lt;/P&gt;
&lt;P&gt;The survey asked all of the 19, 000 patients who have treatment in dialysis units (haemodialysis) about their views on patient transport, which can have a major impact on quality of life.&lt;/P&gt;
&lt;P&gt;Nearly two thirds (almost 12,000) of all haemodialysis patients, who typically have three or four hours of dialysis treatment three times a week, completed the survey. Patient responses were returned from 98 per cent of renal units.&lt;/P&gt;
&lt;P&gt;The survey concluded that just over 61 per cent of patients said the service met their needs.&lt;/P&gt;
&lt;P&gt;A large minority reported long waits and journey times when using hospital-provided transport. In all three countries, patients took less time to get to their dialysis unit and waited less time to start their journey home after treatment if they used public or private transport, rather than hospital-provided transport.&lt;/P&gt;
&lt;P&gt;Performance was measured against the standard that patients should not wait for longer than 30 minutes for their transport to arrive.&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>01/07/2010 14:26:45</lastReviewDate>
    <expiryDate>01/07/2011 14:26:45</expiryDate>
  </document>
  <document>
    <id>177798</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.dopps.org/show_Citation.aspx?id=142]]&gt;</url>
    <title>Patterns of hepatitis B prevalence and seroconversion in hemodialysis units from three continents: the DOPPS study</title>
    <publicationDate></publicationDate>
    <publisher>DOPPS</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ HAEMODIALYSIS,PREVENTION OF INFECTIONS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES,DIALYSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Presentation from DOPPS - Dialysis Outcomes and Practice Patterns Study</description>
    <body>&lt;![CDATA[ This presentation summarises the findings from a DOPPS study which examined Hepatitis B prevalence and seroconversion across 7 countries and investigated associations with facility level practice patterns.]]&gt;</body>
    <lastReviewDate>24/09/2010 10:31:48</lastReviewDate>
    <expiryDate>24/09/2011 10:31:48</expiryDate>
  </document>
  <document>
    <id>177794</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.dopps.org/show_Citation.aspx?id=142]]&gt;</url>
    <title>Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS</title>
    <publicationDate></publicationDate>
    <publisher>Kidney International</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ HAEMODIALYSIS,PREVENTION OF INFECTIONS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,DIALYSIS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Presentation from DOPPS</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Extract from website&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Hepatitis C virus (HCV) infection is a persistent public health concern in hemodialysis patients. Hemodialysis patients are vulnerable to HCV infection because of the risk for exposure to HCV associated with the dialysis procedure. In contrast with the hepatitis B virus, no vaccine is available for HCV. Accurate testing for HCV is complicated by regional variation in the HCV genome and by variation in screening tests. HCV persists within HD units despite infection control measures and it is likely that facility level practice patterns affect HCV transmission. This study examines HCV prevalence and seroconversion rates across 7 countries including the UK and investigages associations with facility level practice patterns.&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>24/09/2010 10:33:18</lastReviewDate>
    <expiryDate>24/09/2011 10:33:18</expiryDate>
  </document>
  <document>
    <id>293883</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_087652]]&gt;</url>
    <title>Payment by results for kidney dialysis project group: interim report June 2008</title>
    <publicationDate>2008-09-04T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ NATIONAL SERVICE FRAMEWORK FOR RENAL SERVICES/POLICY DOCUMENTS,HAEMODIALYSIS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES,DIALYSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Intermin report produced by the renal PbR project group</description>
    <body>&lt;![CDATA[ &lt;P&gt;Extract&lt;/P&gt;
&lt;P&gt;This interim report has been produced by the renal PbR project group which has been working on the development of tariffs for renal dialysis. Guidance has been developed to inform the 2008/09 reference cost exercise and the aim is to develop a mandatory tariff for dialysis for 2010/11.&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>24/09/2010 10:33:33</lastReviewDate>
    <expiryDate>24/09/2011 10:33:33</expiryDate>
  </document>
  <document>
    <id>321832</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=321832]]&gt;</url>
    <title>Penile disorders:  Systematic reviews and meta-analyses</title>
    <publicationDate>2010-09-09T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,PENILE DISORDERS,HAEMATOSPERMIA,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Penile disorders:  Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Fischer N, Hauser S, Brede O, Fisang C, Muller S. Implantation of Artificial Penile Nodules-A Review of Literature. J Sex Med.&amp;nbsp; Jan 19. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20102449" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Henning, J. and S. Waxman (2009). "Legal aspects of men's genitourinary health." International Journal of Impotence Research 21(3): 165-70.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19212325?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Leocadio DE, Stein BS. Hematospermia: etiological and management considerations. International Urology &amp;amp; Nephrology. 2009;41(1):77-83.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18563615" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Pestana IA, Greenfield JM, Walsh M, Donatucci CF, Erdmann D. Management of "buried" penis in adulthood: an overview. Plastic &amp;amp; Reconstructive Surgery. 2009;124(4):1186-95.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19935302" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Shindel, A. W. (2009). "2009 update on phosphodiesterase type 5 inhibitor therapy part 1: Recent studies on routine dosing for penile rehabilitation, lower urinary tract symptoms, and other indications (CME)." J Sex Med 6(7): 1794-808; quiz 1793, 1809-10.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19575771" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Schout, B. M. A., A. J. M. Hendrikx, et al. (2008). "Update on Training Models in Endourology: A Qualitative Systematic Review of the Literature between January 1980 and April 2008." European Urology 54(6): 1247-1261.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18597924?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Vardi, Y., Y. Harshai, et al. (2008). "A Critical Analysis of Penile Enhancement Procedures for Patients with Normal Penile Size: Surgical Techniques, Success, and Complications." European Urology 54(5): 1042-1050.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18760874" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Zang, Y. L., L. Y. Chung, et al. (2008). "A review of the psychosocial issues for nurses in male genitalia-related care." J Clin Nurs 17(8): 983-98.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18321268" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Pugliese, J. M., A. F. Morey, et al. (2007). "Lichen sclerosus: review of the literature and current recommendations for management." J Urol 178(6): 2268-76. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17936829?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:20:30</lastReviewDate>
    <expiryDate>06/07/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>321928</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=321928]]&gt;</url>
    <title>Penile pain:  Systematic reviews and meta-analyses</title>
    <publicationDate>2010-09-09T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,PENILE DISORDERS,PENILE PAIN,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Penile pain:  Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;van Driel, M. F., J. J. Beck, et al. (2008). "The treatment of sleep-related painful erections." J Sex Med 5(4): 909-18. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17971102?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:20:36</lastReviewDate>
    <expiryDate>06/07/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>321991</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=321991]]&gt;</url>
    <title>Penile surgery: Systematic reviews and meta-analyses</title>
    <publicationDate>2010-09-09T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,PENILE PAIN,PENILE DISORDERS,PHIMOSIS,BALANITIS,MALE UROGENITAL DISORDERS,CIRCUMCISION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Penile surgery: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Silberstein, J., T. Downs, et al. (2008). "Penile injection with silicone: case report and review of the literature." Journal of Sexual Medicine 5(9): 2231-7.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18657262?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Silberstein, J., J. Grabowski, et al. (2008). "Penile constriction devices: case report, review of the literature, and recommendations for extrication." Journal of Sexual Medicine 5(7): 1747-57.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18507720" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Babaei, A. R. and M. R. Safarinejad (2007). "Penile replantation, science or myth? A systematic review." Urol J 4(2): 62-5.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17701923?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Muula, A. S., H. W. Prozesky, et al. (2007). "Prevalence of complications of male circumcision in Anglophone Africa: a systematic review." BMC Urol 7: 4.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17335574" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>16/07/2010 14:33:35</lastReviewDate>
    <expiryDate>16/07/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>197286</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/index.htm]]&gt;</url>
    <title>Peritoneal Dialysis Adequacy Update 2006</title>
    <publicationDate>2006-01-31T00:00:00</publicationDate>
    <publisher>NKF-K/DOQI</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ PERITONEAL DIALYSIS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES,DIALYSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Guideline from National Kidney Federation (NKF) K/DOQI

</description>
    <body>&lt;![CDATA[ &lt;P&gt;Covers:&lt;/P&gt;
&lt;P&gt;I. Clinical Practice Guidelines for Peritoneal Dialysis Adequacy&lt;/P&gt;
&lt;LI&gt;&lt;A href="http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/pd_guide1.htm" target="_blank"&gt;Guideline 1.&lt;/A&gt;&amp;nbsp; Initiation of Dialysis 
&lt;LI&gt;&lt;A href="http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/pd_guide2.htm" target="_blank"&gt;Guideline 2.&lt;/A&gt; Peritoneal Dialysis Solute Clearance Targets and&amp;nbsp;&amp;nbsp; Measurements 
&lt;LI&gt;&lt;A href="http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/pd_guide3.htm" target="_blank"&gt;Guideline 3.&lt;/A&gt; Preservation of Residual Kidney Function 
&lt;LI&gt;&lt;A href="http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/pd_guide4.htm" target="_blank"&gt;Guideline 4.&lt;/A&gt; Maintenance of Euvolemia 
&lt;LI&gt;&lt;A href="http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/pd_guide5.htm" target="_blank"&gt;Guideline 5.&lt;/A&gt; Quality Improvement Programs 
&lt;LI&gt;&lt;A href="http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/pd_guide6.htm" target="_blank"&gt;Guideline 6.&lt;/A&gt; Pediatric Peritoneal Dialysis 
&lt;P&gt;II. Clinical Practice Recommendations for Peritoneal Dialysis Adequacy &lt;/P&gt;
&lt;LI&gt;&lt;A href="http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/pd_rec1.htm" target="_blank"&gt;Clinical Practice Recommendation for Guideline 1: &lt;/A&gt;Initiation of Dialysis 
&lt;LI&gt;&lt;A href="http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/pd_rec2.htm" target="_blank"&gt;Clinical Practice Recommendations for Guideline 2:&lt;/A&gt; Peritoneal Dialysis Prescription Targets and Measurements 
&lt;LI&gt;&lt;A href="http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/pd_rec3.htm" target="_blank"&gt;Clinical Practice Recommendations 3: &lt;/A&gt;Recommended Laboratory Measurements for Peritoneal Membrane Function and Ultrafiltration Volume 
&lt;LI&gt;&lt;A href="http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/pd_rec4.htm" target="_blank"&gt;Clinical Practice Recommendations 4:&lt;/A&gt; Writing the Peritoneal Dialysis Prescription 
&lt;LI&gt;&lt;A href="http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/pd_rec6.htm" target="_blank"&gt;Clinical Practice Recommendations for Guideline 6:&lt;/A&gt; Pediatric Peritoneal Dialysis 
&lt;P&gt;&lt;A href="http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/pd_rec.htm" target="_blank"&gt;III. Research Recommendations&lt;/A&gt; &lt;/P&gt;&lt;/LI&gt;]]&gt;</body>
    <lastReviewDate>04/10/2010 11:48:07</lastReviewDate>
    <expiryDate>04/10/2011 11:48:07</expiryDate>
  </document>
  <document>
    <id>339142</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=339142]]&gt;</url>
    <title>Peritoneal dialysis: Systematic reviews and meta-analyses</title>
    <publicationDate>2010-11-15T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ PERITONEAL DIALYSIS,STARTING PERITONEAL DIALYSIS,ACCESS,PREVENTION OF INFECTIONS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES,HOME DIALYSIS,DIALYSIS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Peritoneal dialysis: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Bai ZG, Yang K, Tian J, Ma B, Liu Y, Jiang L, Tan J, Liu TX, Chi I. Bicarbonate versus lactate solutions for acute peritoneal dialysis. Cochrane Database of Systematic Reviews 2010, Issue 9. Art. No.: CD007034. DOI: 10.1002/14651858.CD007034.pub2. [&lt;A href="nelh:387490:0" name=internalLink&gt;Link to Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Xu, G., W. Tu, et al. (2010). "Mupirocin for preventing exit-site infection and peritonitis in patients undergoing peritoneal dialysis." Nephrology Dialysis Transplantation 25(2): 587-592. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19679557" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Akbari, A., G. Knoll, et al. (2009). "Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in peritoneal dialysis: systematic review and meta-analysis of randomized controlled trials." Perit Dial Int 29(5): 554-61. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Angiotensin-converting%20enzyme%20inhibitors%20and%20angiotensin%20receptor%20blockers%20in%20peritoneal%20dialysis%3A%20systematic%20review%20and%20meta-analysis%20of%20randomized%20controlled%20trials" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Liem, Y. S., J. L. Bosch, et al. (2008). "Preference-based quality of life of patients on renal replacement therapy: a systematic review and meta-analysis." Value Health 11(4): 733-41.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Preference-based%20quality%20of%20life%20of%20patients%20on%20renal%20replacement%20therapy%3A%20a%20systematic%20review%20and%20meta-analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Wiggins, K. J., J. C. Craig, et al. (2008). "Treatment for peritoneal dialysis-associated peritonitis." Cochrane Database Syst Rev(1): CD005284.&amp;nbsp;[&lt;A href="nelh:279136:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Liem, Y. S., J. L. Bosch, et al. (2007). "Quality of life assessed with the Medical Outcomes Study Short Form 36-Item Health Survey of patients on renal replacement therapy: a systematic review and meta-analysis." Value Health 10(5): 390-7.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Quality%20of%20life%20assessed%20with%20the%20Medical%20Outcomes%20Study%20Short%20Form%2036-Item%20Health%20Survey%20of%20patients%20on%20renal%20replacement%20therapy%3A%20a%20systematic%20review%20and%20meta-analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;McCormack, K., K. Rabindranath, et al. (2007). "Systematic review of the effectiveness of preventing and treating Staphylococcus aureus carriage in reducing peritoneal catheter-related infections." Health Technol Assess 11(23): iii-iv, ix-x, 1-66.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Systematic%20review%20of%20the%20effectiveness%20of%20preventing%20and%20treating%20Staphylococcus%20aureus%20carriage%20in%20reducing%20peritoneal%20catheter-related%20infections" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Rabindranath, K. S., J. Adams, et al. (2007). "Automated vs continuous ambulatory peritoneal dialysis: a systematic review of randomized controlled trials." Nephrol Dial Transplant 22(10): 2991-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17875571" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Rabindranath, K. S., J. Adams, et al. (2007). "Continuous ambulatory peritoneal dialysis versus automated peritoneal dialysis for end-stage renal disease." Cochrane Database Syst Rev(2): CD006515.&amp;nbsp;[&lt;A href="nelh:260055:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Wiggins, K. J., D. W. Johnson, et al. (2007). "Treatment of peritoneal dialysis-associated peritonitis: a systematic review of randomized controlled trials." Am J Kidney Dis 50(6): 967-88.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Treatment%20of%20peritoneal%20dialysis-associated%20peritonitis%3A%20a%20systematic%20review%20of%20randomized%20controlled%20trials" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2006&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Brimble, K. S., M. Walker, et al. (2006). "Meta-analysis: peritoneal membrane transport, mortality, and technique failure in peritoneal dialysis." J Am Soc Nephrol 17(9): 2591-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Meta-analysis%3A%20peritoneal%20membrane%20transport%2C%20mortality%2C%20and%20technique%20failure%20in%20peritoneal%20dialysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>21/12/2010 10:53:16</lastReviewDate>
    <expiryDate>21/12/2011 10:53:16</expiryDate>
  </document>
  <document>
    <id>182661</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.ndt-educational.org/images/03Piraino4237ISPD.pdf]]&gt;</url>
    <title>Peritoneal Dialysis-related Infections</title>
    <publicationDate>2005-10-29T00:00:00</publicationDate>
    <publisher>Peritoneal Dialysis International</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ PERITONEAL DIALYSIS,PREVENTION OF INFECTIONS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES,DIALYSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>ISPD Guidelines/Recommendations 2005 Update</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Extract from Guideline&lt;/EM&gt;&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;Guidelines under the auspices of the International Society for Peritoneal Dialysis (ISPD) were f irst published in 1983 and revised in 1989, 1993, 1996, and 2000. The initial focus was on the treatment of peritonitis, but the more recent guidelines included sections on preventing peritonitis. In the present guidelines (published 2005), the Committee has expanded the section on prevention since prevention of peritonitis is one of the keys to success with PD.&lt;/P&gt;
&lt;P&gt;These guidelines are evidence based where such evidence exists. The bibliography is not intended to be comprehensive as there have been over 9000 references to peritonitis in PD patients published since 1966. The Com-mittee has chosen to include articles that are considered key references. Guidelines are not based solely on RCTs as such studies in PD patients are limited. &lt;/P&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:29:54</lastReviewDate>
    <expiryDate>06/07/2011 11:29:54</expiryDate>
  </document>
  <document>
    <id>321929</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=321929]]&gt;</url>
    <title>Peyronie's disease:  Systematic reviews and meta-analyses</title>
    <publicationDate>2010-09-09T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,PENILE DISORDERS,PEYRONIE'S DISEASE,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Peyronie's disease:  Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Abern MR, Levine LA. Peyronie's disease: evaluation and review of nonsurgical therapy. Thescientificworldjournal. 2009;9:665-75. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19649505" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Gonzalez-Cadavid NF. Mechanisms of penile fibrosis. Journal of Sexual Medicine. 2009;6 Suppl 3:353-62.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19267860" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Muller A, Mulhall JP. Peyronie's disease intervention trials: methodological challenges and issues. Journal of Sexual Medicine. 2009;6(3):848-61.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19138374" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Ryu JK, Suh JK. Peyronie's disease: Current medical treatment and future perspectives. Korean Journal of Urology. 2009;50(6):527-33.&amp;nbsp;[No abstract available]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Trussell, J. C. and J. C. Brien (2008). "Straightening out Peyronie's: a medical and surgical approach to the patient." Canadian Journal of Urology 15(3): 4047-55. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18570708" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Bella, A. J., M. A. Perelman, et al. (2007). "Peyronie's disease (CME)." J Sex Med 4(6): 1527-38.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17970969" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Russell, S., W. Steers, et al. (2007). "Systematic evidence-based analysis of plaque injection therapy for Peyronie's disease." Eur Urol 51(3): 640-7.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17092631" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:20:42</lastReviewDate>
    <expiryDate>06/07/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>319306</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.brook.org.uk/content/M1_policyandresearch.asp]]&gt;</url>
    <title>Policy and Research</title>
    <publicationDate></publicationDate>
    <publisher>Brook Advisory Centres</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Brook is committed to influencing public policy to ensure young people get the sexual health advice and services they deserve.</description>
    <body>&lt;![CDATA[ &lt;P&gt;Brook is committed to influencing public policy to ensure young people get the sexual health advice and services they deserve.&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>01/07/2010 15:02:21</lastReviewDate>
    <expiryDate>01/07/2011 15:02:21</expiryDate>
  </document>
  <document>
    <id>341848</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=341848]]&gt;</url>
    <title>Polycystic kidney disease: Systematic reviews and meta-analyses</title>
    <publicationDate>2010-01-22T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ INHERITED KIDNEY DISEASE,POLYCYSTIC KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Polycystic kidney disease: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;No systematic reviews.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Cambio, A. J., C. P. Evans, et al. (2008). "Non-surgical management of multicystic dysplastic kidney." BJU Int 101(7): 804-8. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18190645" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;No systematic reviews.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2006&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Dai, B. and C. L. Mei (2006). "Research on autosomal dominant polycystic kidney disease in China." Chin Med J (Engl) 119(22): 1915-24.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17134592" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Pereira, T. V., A. C. Nunes, et al. (2006). "Influence of ACE I/D gene polymorphism in the progression of renal failure in autosomal dominant polycystic kidney disease: a meta-analysis." Nephrol Dial Transplant 21(11): 3155-63.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16935894" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>11/01/2011 10:22:14</lastReviewDate>
    <expiryDate>11/01/2012 10:22:14</expiryDate>
  </document>
  <document>
    <id>182128</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.edren.co.uk/pages/handbooks/transplant-handbook/post-op-management.php]]&gt;</url>
    <title>Post-op management of a renal transplant</title>
    <publicationDate>2009-09-08T00:00:00</publicationDate>
    <publisher>EdRen Handbook</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ TRANSPLANT OPERATION,TRANSPLANTATION,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Abbreviated medical protocol from EdRen, Royal Infirmary of Edinburgh</description>
    <body>&lt;![CDATA[ Covers return to the Renal Unit, Day one and early days, early problems, allograft biopsy, discharge and follow-up, three months follow-up, six month follow-up, and long term follow-up.]]&gt;</body>
    <lastReviewDate>06/07/2010 11:30:04</lastReviewDate>
    <expiryDate>06/07/2011 11:30:04</expiryDate>
  </document>
  <document>
    <id>177608</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.gpnotebook.co.uk/simplepage.cfm?ID=1234829347&amp;linkID=29297&amp;cook=yes]]&gt;</url>
    <title>Postoperative renal failure</title>
    <publicationDate></publicationDate>
    <publisher>GPnotebook</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ CAUSES AND RISK FACTORS,MANAGEMENT,ACUTE KIDNEY INJURY,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Resource provided by GPnotebook</description>
    <body>&lt;![CDATA[ Resource provides links to sections on aetiology, management- early, management - continuing, management - further, management - later, and to section on acute renal failure.]]&gt;</body>
    <lastReviewDate>06/07/2010 11:30:15</lastReviewDate>
    <expiryDate>06/07/2011 11:30:15</expiryDate>
  </document>
  <document>
    <id>155614</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.hdcn.com/symp/05asn/05/05asn05.htm]]&gt;</url>
    <title>Post-transplant infections: updating the general Nephrologist</title>
    <publicationDate>2005-11-01T00:00:00</publicationDate>
    <publisher>Hypertension, Dialysis and Clinical Nephrology (HDCN)</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ PREVENTION OF COMPLICATIONS,TRANSPLANTATION,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Source of free CPD material for doctors, nurses and other medical professionals.</description>
    <body>&lt;![CDATA[ &lt;P&gt;The CPD resource comprises talks and slide presentations, for which some additional software (such as macromedia flash player) may be needed for access.&lt;/P&gt;
&lt;P&gt;Note : You need to register for a freezone&amp;nbsp;loginID and password to access the free resources&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;'Method of participation:&lt;/B&gt; Listen to the talk, read the PubMed abstracts linked to data slides and talk references, take the post-test, read the abstracts linked to post-test answer feedback material' (website extract)&lt;/P&gt;
&lt;P&gt;Click on&amp;nbsp;Free Zone Index to view the other free resources at a glance.&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:30:25</lastReviewDate>
    <expiryDate>06/07/2011 11:30:25</expiryDate>
  </document>
  <document>
    <id>346856</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=346856]]&gt;</url>
    <title>Pregnancy and Kidney Diseases: Systematic reviews and meta-analyses</title>
    <publicationDate>2011-01-17T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Pregnancy and Kidney Diseases: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;McDonald S.D., Han Z., Walsh M.W., Gerstein H.C., Devereaux P.J. (2010) Kidney Disease After Preeclampsia: A Systematic Review and Meta-analysis. American Journal of Kidney Disease. Published online 26 March 2010. [&lt;A href="http://cat.inist.fr/?aModele=afficheN&amp;amp;cpsidt=22891603" target="_blank"&gt;Link to abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Paulen, M. E., S. G. Folger, et al. (2010). "Contraceptive use among solid organ transplant patients: a systematic review." Contraception 82(1): 102-12.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Contraceptive%20use%20among%20solid%20organ%20transplant%20patients%3A%20a%20systematic%20review" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Piccoli, G. B., A. Conijn, et al. (2010). "Pregnancy in dialysis patients: is the evidence strong enough to lead us to change our counseling policy?" Clinical Journal of The American Society of Nephrology: CJASN 5(1): 62-71.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Pregnancy%20in%20dialysis%20patients%3A%20is%20the%20evidence%20strong%20enough%20to%20lead%20us%20to%20change%20our%20counseling%20policy%3F" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Sep, S., L. Smits, et al. (2010). "Prediction tests for recurrent hypertensive disease in pregnancy, a systematic review." Hypertension in Pregnancy 29(2): 206-230. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Prediction%20tests%20for%20recurrent%20hypertensive%20disease%20in%20pregnancy%2C%20a%20systematic%20review" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Smyth, A., G. H. Oliveira, et al. (2010). "A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis." Clinical Journal of The American Society of Nephrology: CJASN 5(11): 2060-8. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20688887" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Yinon, Y., D. Farine, et al. (2010). "." Journal of Obstetrics &amp;amp; Gynaecology Canada: JOGC 32(4): 348-54.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20500944" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Papanna, R., L. K. Mann, et al. (2008). "Protein/creatinine ratio in preeclampsia: a systematic review." Obstetrics &amp;amp; Gynecology 112(1): 135-44.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Protein%2Fcreatinine%20ratio%20in%20preeclampsia%3A%20a%20systematic%20review" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Skomsvoll, J. F., K. Aasarod, et al. (2007). "[Systemic lupus erythematosus and pregnancy]. [Norwegian] Systemisk lupus erythematosus og svangerskap." Tidsskrift for Den Norske Laegeforening 127(6): 725-9.&amp;nbsp;[No abstract available]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;2006&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Ramin, S. M., A. C. Vidaeff, et al. (2006). "Chronic renal disease in pregnancy." Obstetrics &amp;amp; Gynecology 108(6): 1531-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17138789" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>04/03/2011 11:16:28</lastReviewDate>
    <expiryDate>04/03/2012 11:16:28</expiryDate>
  </document>
  <document>
    <id>284005</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.institute.nhs.uk/option,com_joomcart/Itemid,26/main_page,document_product_info/products_id,367.html]]&gt;</url>
    <title>Preparing for end stage renal disease</title>
    <publicationDate>2008-01-01T00:00:00</publicationDate>
    <publisher>NHS Institute for Innovation and Improvement</publisher>
    <publicationType>CARE PATHWAY</publicationType>
    <topics>&lt;![CDATA[ END-OF-LIFE CARE,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A guide for an ideal pathway for management of a patient with end-stage renal disease.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Extract&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;The document&amp;nbsp;includes the approach, the idealised pathway, fundamental principles for delivering the pre-dialysis year idealised pathway, key characteristics of high quality, pre-dialysis care, measures for improvement, and case studies.&lt;/P&gt;]]&gt;</body>
    <expiryDate>30/05/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>182112</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=AbstractPlus&amp;list_uids=12500213&amp;query_hl=1&amp;itool=pubmed_docsum]]&gt;</url>
    <title>Prevalence of chronic kidney disease and decreased kidney function in the adult US population - 3rd National Health and Nutrition Examination Survey</title>
    <publicationDate>2003-01-01T00:00:00</publicationDate>
    <publisher>American Journal of Kidney Disease</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ SCREENING OPTIONS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Article from American Journal of Kidney Disease, 2003;41(1):1-12.</description>
    <body>&lt;![CDATA[ Background information on the NHANES III Study.]]&gt;</body>
    <lastReviewDate>06/07/2010 11:31:05</lastReviewDate>
    <expiryDate>06/07/2011 11:31:05</expiryDate>
  </document>
  <document>
    <id>287947</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.prevend.org/]]&gt;</url>
    <title>PREVEND Study (Prevention of Renal and Vascular End Stage Disease)</title>
    <publicationDate>2005-01-03T00:00:00</publicationDate>
    <publisher>PREVEND</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ NEW RESEARCH,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A population study aiming to assess the value of measuring urinary albumin loss to predict renal, cardiac and vascular disease.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Extract from website&lt;/EM&gt;&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;The PREVEND Study is a prospective, observational cohort study, focussed to assess the impact of elevated urinary albumin loss in non-diabetic subjects on future cardiovascular and renal disease. PREVEND is an acronym for Prevention of REnal and Vascular ENd-stage Disease. This study started with a population survey on the prevalence of micro-albuminuria and generation of a study cohort of the general population. The goal is to monitor this cohort for the long-term development of cardiac-, renal- and peripheral vascular end-stage disease. For that purpose the participants receive questionnaires on events and are seen every three/four years for a survey on cardiac-, renal- and peripheral vascular morbidity&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>24/09/2010 10:33:53</lastReviewDate>
    <expiryDate>24/09/2011 10:33:53</expiryDate>
  </document>
  <document>
    <id>321939</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=321939]]&gt;</url>
    <title>Priapism: Systematic reviews and meta-analyses</title>
    <publicationDate>2010-03-03T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,PRIAPISM,PENILE DISORDERS,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Priapism: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Jesus LE, Dekermacher S. Priapism in children: review of pathophysiology and treatment. Jornal de Pediatria. 2009;85(3):194-200. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19455267" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Muneer, A., S. Minhas, et al. (2008). "Stuttering priapism - A review of the therapeutic options." International Journal of Clinical Practice 62(8): 1265-1270. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18479367" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Sood, S., W. James, et al. (2008). "Priapism associated with atypical antipsychotic medications: a review." International Clinical Psychopharmacology 23(1): 9-17.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18090503" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:20:52</lastReviewDate>
    <expiryDate>06/07/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>197496</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=AbstractPlus&amp;list_uids=17058050&amp;query_hl=1&amp;itool=pubmed_docsum]]&gt;</url>
    <title>Primary focal segmental glomerular sclerosis in children: clinical course and prognosis</title>
    <publicationDate>2007-03-01T00:00:00</publicationDate>
    <publisher>Pediatric Nephrology 2006 October 21</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ GLOMERULONEPHRITIS,PRIMARY GLOMERULAR DISEASE,KIDNEY DISEASE IN CHILDREN AND ADOLESCENTS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Article from Pediatric Nephrology</description>
    <body>&lt;![CDATA[ A retrospective&amp;nbsp;analysis of &amp;nbsp;92 children with steroid-resistant primary focal segmental glomerulosclerosis.]]&gt;</body>
    <lastReviewDate>04/10/2010 11:48:15</lastReviewDate>
    <expiryDate>04/10/2011 11:48:15</expiryDate>
  </document>
  <document>
    <id>282597</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.medscape.com/viewarticle/571848]]&gt;</url>
    <title>Primer: Strategies for Identifying Genes Involved in Renal Disease</title>
    <publicationDate>2008-03-25T00:00:00</publicationDate>
    <publisher>Nature Clinical Practice Nephrology advance online version 25 March 2008</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEW RESEARCH,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Introduction to the identification of the molecular pathways involved in renal pathophysiology which can yield targets for intervention and aid tailored therapy.</description>
    <body>&lt;![CDATA[ &lt;P&gt;Extract&lt;/P&gt;
&lt;P&gt;This Review will address the technologies that can be used to identify potential genetic risk factors (candidate genes) for renal disease and the tools available for determining whether these genes actually contribute to disease. An overview of the most important candidate genes in renal disease will be provided. The potential role of epigenetic modification in renal disease will also be considered.&lt;/P&gt;]]&gt;</body>
    <expiryDate>30/05/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>156489</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.kidney.org/professionals/CRN/sub_resources.cfm]]&gt;</url>
    <title>Professional Education and Resources for Dietitians</title>
    <publicationDate>2009-12-07T00:00:00</publicationDate>
    <publisher>Council on Renal Nutrition, National Kidney Foundation</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ INTERVENTIONS,DIETARY CHANGE,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>List of resources of interest to renal dietitians</description>
    <body>&lt;![CDATA[ &lt;P&gt;The National Kidney Foundation webpage provideds further information on the Pocket guide to nutritional&amp;nbsp;assessment of the patient with&amp;nbsp;chronic kidney disease 3rd edition.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is available to members of the National Kidney Foundation and non-members can register here: http://tinyurl.com/39jx85&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>24/09/2010 10:33:58</lastReviewDate>
    <expiryDate>24/09/2011 10:33:58</expiryDate>
  </document>
  <document>
    <id>305587</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://learning.bmj.com/learning/search-result.html?moduleId=5004440]]&gt;</url>
    <title>Prostate cancer risk management: in association with the NHS Cancer Screening Programmes</title>
    <publicationDate>2009-02-02T00:00:00</publicationDate>
    <publisher>BMJ Learning</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE URINARY INCONTINENCE,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>BMJ Learning module - for BMA members</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Module type:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Interactive case history&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Use these interactive modules to learn as we guide you through a real life consultation. Before you start a learning resource it is best to add it to your plan first.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;What's in this case:&lt;/STRONG&gt; &amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Prostate cancer risk management: in association with the NHS Cancer Screening Programmes&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Target audience:&lt;/STRONG&gt; &amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Foundation programme 
&lt;LI&gt;International 
&lt;LI&gt;Practice nurse CPD 
&lt;LI&gt;Hospital doctor CPD 
&lt;LI&gt;GP CPD 
&lt;LI&gt;GP trainee 
&lt;LI&gt;Saudi Pediatric Association Channel 
&lt;LI&gt;Other healthcare professionals 
&lt;LI&gt;The Royal New Zealand College of General Practitioners 
&lt;LI&gt;Practice manager CPD 
&lt;LI&gt;Medical Students - international&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Author:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;bmjlearning with the NHS Cancer Screening Programmes&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
    <lastReviewDate>11/01/2011 10:23:46</lastReviewDate>
    <expiryDate>11/01/2012 10:23:46</expiryDate>
  </document>
  <document>
    <id>321938</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=321938]]&gt;</url>
    <title>Prostate disorders and surgical procedures: Systematic reviews and meta-analyses</title>
    <publicationDate>2010-11-25T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,PROSTATE DISORDERS,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Prostate disorders and surgical procedures: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Bach, T., S. J. Xia, et al. (2010). "Thulium: YAG 2 mum cw laser prostatectomy: where do we stand?" World Journal of Urology 28(2): 163-8. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20204378" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Bader, M. J., D. Tilki, et al. (2010). "Ho:YAG-laser: treatment of vesicourethral strictures after radical prostatectomy." World Journal of Urology 28(2): 169-172. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/2018273" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Barocas, D. A., R. Mitchell, et al. (2010). "Impact of surgeon and hospital volume on outcomes of radical prostatectomy." Urologic Oncology 28(3): 243-250.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19395287" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Burke, N., J. P. Whelan, et al. (2010). "Systematic Review and Meta-analysis of Transurethral Resection of the Prostate Versus Minimally Invasive Procedures for the Treatment of Benign Prostatic Obstruction." Urology 75(5): 1015-1022.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19854492" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kang, D. C., M. J. Hardee, et al. (2010). "Low Quality of Evidence for Robot-Assisted Laparoscopic Prostatectomy: Results of a Systematic Review of the Published Literature." European Urology 57(6): 930-937.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20138423" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Loughlin, K. R. and M. M. Prasad (2010). "Post-prostatectomy urinary incontinence: a confluence of 3 factors." Journal of Urology 183(3): 871-877.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20083262" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lourenco, T., M. Shaw, et al. (2010). "The clinical effectiveness of transurethral incision of the prostate: a systematic review of randomised controlled trials." World Journal of Urology 28(1): 23-32.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20033744" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Martinez-Salamanca, J. I., C. Martinez-Ballesteros, et al. (2010). "[Penile morphometric changes after radical prostatectomy: Evidence-based]. [Spanish] Cambios morfometricos peneanos tras prostatectomia radical: revision de la evidencia." Actas Urologicas Espanolas 34(7): 579-585.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20540873" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Morgan, S. C., C. Walker-Dilks, et al. (2010). "Does the benefit of adjuvant radiotherapy following radical prostatectomy for pathologic T3 or margin-positive prostate cancer extend to all pathologic subgroups? A meta-analysis of the randomized trials." International Journal of Radiation Oncology Biology Physics 78(3 SUPPL. 1): S29-S30.&amp;nbsp;[No abstract available]&lt;/LI&gt;
&lt;LI&gt;Rieken, M., N. Ebinger Mundorff, et al. (2010). "Complications of laser prostatectomy: a review of recent data." World Journal of Urology 28(1): 53-62.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20052586" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Ruiz, A., x00F, et al. (2010). "[Erectile dysfunction in patients with prostate cancer who have undergone surgery: Systematic review of literature]. [Spanish] Actas Urologicas Espanolas 34(8): 677-85.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20800031" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Seki, N. and S. Naito (2010). "Laser prostatectomy as a treatment option for BPH: HoLEP versus PVP." International Journal of Urology 17: A49-A50.&amp;nbsp;[No abstract available]&lt;/LI&gt;
&lt;LI&gt;Walz, J., A. L. Burnett, et al. (2010). "A critical analysis of the current knowledge of surgical anatomy related to optimization of cancer control and preservation of continence and erection in candidates for radical prostatectomy." European Urology 57(2): 179-192.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19931974" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Wilson, A., N. E. Marlow, et al. (2010). "Radical prostatectomy: a systematic review of the impact of hospital and surgeon volume on patient outcome." ANZ Journal of Surgery 80(1-2): 24-29.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20575876" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Ficarra, V., G. Novara, et al. (2009). "Retropubic, Laparoscopic, and Robot-Assisted Radical Prostatectomy: A Systematic Review and Cumulative Analysis of Comparative Studies." Eur Urol.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19185977" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Galvin, D. J. and J. A. Eastham (2009). "Critical appraisal of outcomes following open radical prostatectomy." Curr Opin Urol 19(3): 297-302.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19365894" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hawary A, Mukhtar K, Sinclair A, Pearce I. Transurethral resection of the prostate syndrome: almost gone but not forgotten. Journal of Endourology. 2009;23(12):2013-20. [Link to PubMed abstract]&lt;/LI&gt;
&lt;LI&gt;Leocadio DE, Stein BS. Hematospermia: etiological and management considerations. International Urology &amp;amp; Nephrology. 2009;41(1):77-83.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18563615" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mamoulakis C, Ubbink DT, de la Rosette JJMCH. Bipolar versus Monopolar Transurethral Resection of the Prostate: A Systematic Review and Meta-analysis of Randomized Controlled Trials. European Urology. 2009;56(5):798-809.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19595501" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Minggen Y, Xiaokun Z, Zhiping W, Yi H, Ning X, Chen L. Meta-analysis of prophylaxis value of antibiotic in preventing infection complications after transrectal prostatic biopsy. Chinese Journal of Andrology. 2009;23(2):17-23.&amp;nbsp;[No abstract available]&lt;/LI&gt;
&lt;LI&gt;Monzo Gardiner JI, Herranz Amo F, Cabello Benavente R, Bun M, Gomez Munoz J, Gonzalez Enguita C. [Controversies in the prostate surgical anatomy. A literature review]. [Spanish] Controversias en la anatomia quirurgica prostatica. Revision de la literarura. Actas Urologicas Espanolas. 2009;33(3):228-34.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19537059" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mulhall, J. P. (2009). "Defining and reporting erectile function outcomes after radical prostatectomy: challenges and misconceptions." Journal of Urology 181(2): 462-71.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19084865" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Naspro R, Bachmann A, Gilling P, Kuntz R, Madersbacher S, Montorsi F, et al. A review of the recent evidence (2006-2008) for 532-nm photoselective laser vaporisation and holmium laser enucleation of the prostate. European Urology. 2009;55(6):1345-57.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19361906" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Yang, M., X. Zhao, et al. (2009). "Meta-analysis of antibiotic prophylaxis use in transrectal prostatic biopsy." Zhong Nan Da Xue Xue Bao Yi Xue Ban 34(2): 115-23.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19552843?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Kaye, J. D., A. D. Smith, et al. (2008). "High-energy transurethral thermotherapy with CoreTherm approaches transurethral prostate resection in outcome efficacy: A meta-analysis." Journal of Endourology 22(4): 713-718.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18419216" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Nargund, V. H. and A. D. Grey (2008). "Tamsulosin MR and OCAS (modified release and oral controlled absorption system): current therapeutic uses." Expert Opinion on Pharmacotherapy 9(5): 813-24.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18345957" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Parsons, J. K. and J. L. Bennett (2008). "Outcomes of Retropubic, Laparoscopic, and Robotic-Assisted Prostatectomy." Urology 72(2): 412-416.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18267330?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Ramirez, M. L., E. C. Nelson, et al. (2008). "Current applications for prostate-specific antigen doubling time." European Urology 54(2): 291-300.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18439749?ordinalpos=4&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Saemi, A. M., J. B. Folsom, et al. (2008). "Injection therapy for prostatic disease: A renaissance concept." Indian J Urol 24(3): 329-35.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19468462" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Schout, B. M. A., A. J. M. Hendrikx, et al. (2008). "Update on Training Models in Endourology: A Qualitative Systematic Review of the Literature between January 1980 and April 2008." European Urology 54(6): 1247-1261.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18597924?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Schroder, F. and M. W. Kattan (2008). "The Comparability of Models for Predicting the Risk of a Positive Prostate Biopsy with Prostate-Specific Antigen Alone: A Systematic Review." European Urology 54(2): 274-290.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18511177" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Stock, C., M. Hruza, et al. (2008). "Transrectal ultrasound-guided biopsy of the prostate: development of the procedure, current clinical practice, and introduction of self-embedding as a new way of processing biopsy cores." Journal of Endourology 22(6): 1321-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18578661" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Wilt, T. J., T. A. Shamliyan, et al. (2008). "Association between hospital and surgeon radical prostatectomy volume and patient outcomes: a systematic review." J Urol 180(3): 820-8; discussion 828-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18635233" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Yang, Y. (2008). "Treatment of the positive surgical margin following radical prostatectomy." Chin Med J (Engl) 121(4): 375-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18304473?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Zhu, Y. C., L. Zhong, et al. (2008). "Meta-analysis of finasteride for perioperative bleeding in patients undergoing transurethral resection of prostate." Chinese Journal of Evidence-Based Medicine 8(6): 456-460.&amp;nbsp;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Briganti, A., A. Salonia, et al. (2007). "Management of erectile dysfunction after radical prostatectomy in 2007." World J Urol 25(2): 143-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17340159?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Ficarra, V., S. Cavalleri, et al. (2007). "Evidence from robot-assisted laparoscopic radical prostatectomy: a systematic review." Eur Urol 51(1): 45-55; discussion 56.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16854519?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kaufman, M. R., R. G. Baumgartner, et al. (2007). "The evidence-based pathway for peri-operative management of open and robotically assisted laparoscopic radical prostatectomy." BJU Int 99(5): 1103-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17309550" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;MacDonald, R., H. A. Fink, et al. (2007). "Pelvic floor muscle training to improve urinary incontinence after radical prostatectomy: a systematic review of effectiveness." BJU Int 100(1): 76-81.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17433028?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Martinez-Salamanca, J. I. and A. Allona Almagro (2007). "[Radical prostatectomy: open, laparoscopic and robotic. Looking for a new gold standard?]." Actas Urol Esp 31(4): 316-27.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17633916?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Martinez-Salamanca, J. I. and J. Romero Otero (2007). "[Critical comparative analysis between open, laparoscopic and robotic radical prostatectomy: perioperative morbidity and oncological results (Part I)]." Arch Esp Urol 60(7): 755-65.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17937335" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mochtar, C. A., P. C. Kauer, et al. (2007). "Urinary leakage after laparoscopic radical prostatectomy: a systematic review." J Endourol 21(11): 1371-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18042033?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Rodriguez, E., Jr., D. W. Skarecky, et al. (2007). "[Radical robot prostatectomy: oncological outcomes]." Arch Esp Urol 60(4): 421-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=2007[pdat]%20AND%20Rodriguez[author]%20AND%20Radical%20robot%20prostatectomy%3A%20oncological%20outcomes" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Romero Otero, J. and J. I. Martinez-Salamanca (2007). "[Critical comparative analysis between open, laparoscopic and robotic radical prostatectomy: urinary continence and sexual function (part II)]." Arch Esp Urol 60(7): 767-76.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17937336" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Seki, N. and S. Naito (2007). "Instrumental treatments for benign prostatic obstruction." Curr Opin Urol 17(1): 17-21.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17143106?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Tan, A., C. Liao, et al. (2007). "Meta-analysis of holmium laser enucleation versus transurethral resection of the prostate for symptomatic prostatic obstruction." Br J Surg 94(10): 1201-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17729384" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Tiong, H. Y., L. C. Liew, et al. (2007). "A meta-analysis of local anesthesia for transrectal ultrasound-guided biopsy of the prostate." Prostate Cancer Prostatic Dis 10(2): 127-36.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17211441" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Xu, Q. Q., X. B. Huang, et al. (2007). "[Prostatic abscess: a report of 2 cases and meta-analysis of domestic literature in recent 10 years]." Zhonghua Nan Ke Xue 13(10): 903-5.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17977322" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2006&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Kaminetsky, J. (2006). "Comorbid LUTS and erectile dysfunction: optimizing their management." Curr Med Res Opin 22(12): 2497-506.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17265598" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Nahon, I., G. Dorey, et al. (2006). "Systematic review of the treatment of post-prostatectomy incontinence." Urol Nurs 26(6): 461-75, 482.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17253081?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:20:56</lastReviewDate>
    <expiryDate>06/07/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>319318</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.prostate-cancer.org.uk/info/info.asp]]&gt;</url>
    <title>Prostate Information Pages</title>
    <publicationDate></publicationDate>
    <publisher>The Prostate Cancer Charity</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,PROSTATE DISORDERS,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Information pages containing in-depth information on the prostate gland and prostate problems, including prostate cancer.</description>
    <body>&lt;![CDATA[ Information pages containing in-depth information on the prostate gland and prostate problems, including prostate cancer.]]&gt;</body>
    <lastReviewDate>01/07/2010 15:02:29</lastReviewDate>
    <expiryDate>01/07/2011 15:02:29</expiryDate>
  </document>
  <document>
    <id>321940</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=321940]]&gt;</url>
    <title>Prostatitis: Systematic reviews and meta-analyses</title>
    <publicationDate>2011-01-05T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,PROSTATE DISORDERS,PROSTATITIS,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Prostatitis: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2011&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Anothaisintawee, T., Attia, J., Nickel, J.C., Thammakraisorn, S., Numthavaj, P., McEvoy, M., Thakkinstian, A. (2011). "Management of Chronic Prostatitis/ Chronic Pelvic Pain Syndrome: A systematic review and network meta-analysis". JAMA. 395(1):78-86. [&lt;A href="http://jama.ama-assn.org/content/305/1/78.short?rss=1" target="_blank"&gt;Link to JAMA abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Qiu, M. X., G. B. Xiong, et al. (2010). "Traditional Chinese medicine for prostatitis: A systematic review of randomized controlled trials." Chinese Journal of Evidence-Based Medicine 10(1): 56-72. [No abstract available]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Erickson, B. A., A. J. Schaeffer, et al. (2008). "Chronic prostatitis." Clinical Evidence 2008.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19450305" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Vaidyanathan, R. and V. C. Mishra (2008). "Chronic prostatitis: Current concepts." Indian J Urol 24(1): 22-7.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19468353?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Wang, C. Y. and R. F. Han (2008). "[Acupuncture for chronic prostatitis: a meta-analysis]." Zhonghua Nan Ke Xue 14(9): 853-6.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18998473" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Yang, M., X. Zhao, et al. (2008). "Management of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): A systematic review and meta-analysis of randomized controlled trials (RCTs)." Chinese Journal of Andrology 22(4): 20-26.&amp;nbsp;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Mishra, V. C., J. Browne, et al. (2007). "Role of alpha-blockers in type III prostatitis: a systematic review of the literature." J Urol 177(1): 25-30.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17161995" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Qiu, M. X., G. B. Xiong, et al. (2007). "[Qingrelishi-category Chinese medicine for chronic prostatitis: a systematic review]." Zhonghua Nan Ke Xue 13(4): 370-7.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17491276" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;2006&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Chen, J. X. and L. S. Hu (2006). "Traditional chinese medicine for the treatment of chronic prostatitis in China: a systematic review and meta-analysis." J Altern Complement Med 12(8): 763-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17034282" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:21:00</lastReviewDate>
    <expiryDate>06/07/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>269297</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.renal.org/eGFR/proteinuria.html]]&gt;</url>
    <title>Proteinuria</title>
    <publicationDate>2005-12-15T00:00:00</publicationDate>
    <publisher>UK CKD eGuide</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ PRESENTATION OF CKD,PROTEINURIA/ NEPHROTIC SYNDROME,HAEMATURIA/ PROTEINURIA,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>From the UK CKD eGuide</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Extract from webpage&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Any abnormal proteinuria is a significant risk factor for both renal disease and for cardiovascular morbidity and mortality. Unlike haematuria, proteinuria almost always has a renal origin&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>24/09/2010 10:34:20</lastReviewDate>
    <expiryDate>24/09/2011 10:34:20</expiryDate>
  </document>
  <document>
    <id>301383</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://healthguides.mapofmedicine.com/choices/map/proteinuria_and_nephrotic_syndrome1.html]]&gt;</url>
    <title>Proteinuria in adults</title>
    <publicationDate>2008-12-16T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ PRESENTATION OF CKD,PROTEINURIA/ NEPHROTIC SYNDROME,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Web pages from NHS Choices and the Map of Medicine.</description>
    <body>&lt;![CDATA[ This page provides a link to the Map of Medicine view on proteinuria in adults.]]&gt;</body>
    <lastReviewDate>09/11/2010 14:23:23</lastReviewDate>
    <expiryDate>09/11/2011 14:23:23</expiryDate>
  </document>
  <document>
    <id>308755</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_096040]]&gt;</url>
    <title>Proteinuria: detection and quantitation in adults using ACR: information for GPs</title>
    <publicationDate>2009-03-12T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ CREATININE,CREATININE CLEARANCE,CREATININE,PRESENTATION OF CKD,SCREENING OPTIONS,SCREENING TESTS,ASSESSMENT TESTS,ASSESSMENT OF RENAL FUNCTION,HAEMATURIA/ PROTEINURIA,PROTEINURIA/ NEPHROTIC SYNDROME,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Proteinuria is an important indicator of kidney disease, and the risk of its progression; its measurement is part of the diagnosis, staging and monitoring of chronic kidney disease (CKD).</description>
    <body>&lt;![CDATA[ &lt;P&gt;Proteinuria is an important indicator of kidney disease, and the risk of its progression; its measurement is part of the diagnosis, staging and monitoring of chronic kidney disease (CKD).&lt;/P&gt;
&lt;P&gt;Information sheets have been produced for laboratories, and for GPs, which summarise the benefits of using ACR, and provide practical guidance on its use.&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>14/02/2011 11:40:22</lastReviewDate>
    <expiryDate>14/02/2012 11:40:22</expiryDate>
  </document>
  <document>
    <id>308754</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_096042]]&gt;</url>
    <title>Proteinuria: detection and quantitation in adults using ACR: information for laboratories</title>
    <publicationDate>2009-03-12T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ PROTEINURIA/ NEPHROTIC SYNDROME,HAEMATURIA/ PROTEINURIA,ASSESSMENT OF RENAL FUNCTION,ASSESSMENT TESTS,SCREENING TESTS,SCREENING OPTIONS,PRESENTATION OF CKD,CREATININE,CREATININE CLEARANCE,CREATININE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Proteinuria is an important indicator of kidney disease, and the risk of its progression; its measurement is part of the diagnosis, staging and monitoring of chronic kidney disease (CKD).</description>
    <body>&lt;![CDATA[ &lt;P&gt;Proteinuria is an important indicator of kidney disease, and the risk of its progression; its measurement is part of the diagnosis, staging and monitoring of chronic kidney disease (CKD).&lt;/P&gt;
&lt;P&gt;Information sheets have been produced for laboratories, and for GPs, which summarise the benefits of using ACR, and provide practical guidance on its use.&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>14/02/2011 11:40:28</lastReviewDate>
    <expiryDate>14/02/2012 11:40:28</expiryDate>
  </document>
  <document>
    <id>341847</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=341847]]&gt;</url>
    <title>Proteinuria: Systematic reviews and meta-analyses</title>
    <publicationDate>2010-09-21T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ PRESENTATION OF CKD,PROTEINURIA/ NEPHROTIC SYNDROME,HAEMATURIA/ PROTEINURIA,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Proteinuria: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Afshinnia, F., T. J. Wilt, et al. (2010). "Weight loss and proteinuria: Systematic review of clinical trials and comparative cohorts." Nephrology Dialysis Transplantation 25(4): 1173-1183. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Weight%20loss%20and%20proteinuria%3A%20Systematic%20review%20of%20clinical%20trials%20and%20comparative%20cohorts" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Wu, S., C. Kim, et al. (2010). "Bevacizumab increases risk for severe proteinuria in cancer patients." Journal of the American Society of Nephrology 21(8): 1381-1389.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Bevacizumab%20increases%20risk%20for%20severe%20proteinuria%20in%20cancer%20patients" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Gonzalez Rodriguez, J. D., D. Canalejo, et al. (2009). "[Proteinuria in urinary infection and acute pyelonephritis in paediatric patients: can it replace scintigraphic studies in diagnostic localisation?]." Nefrologia 29(2): 163-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19396323" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Justus Hofmeyr, G. and M. Belfort (2009). "Proteinuria as a predictor of complications of pre-eclampsia." BMC Medicine 7.&amp;nbsp;[&lt;A href="http://www.biomedcentral.com/1741-7015/7/11" target="_blank"&gt;Link to full text on BMC Medicine&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Ninomiya, T., V. Perkovic, et al. (2009). "Proteinuria and stroke: a meta-analysis of cohort studies." Am J Kidney Dis 5(3): 417-25.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19070947" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Regeniter, A., H. Freidank, et al. (2009). "Evaluation of proteinuria and GFR to diagnose and classify kidney disease: systematic review and proof of concept." Eur J Intern Med 20(6): 556-61.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19782913" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Balamuthusamy, S., L. Srinivasan, et al. (2008). "Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis." Am Heart J 155(5): 791-805.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18440325" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Bomback, A. S., A. V. Kshirsagar, et al. (2008). "Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review." Am J Kidney Dis 51(2): 199-211.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18215698" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kunz, R., C. Friedrich, et al. (2008). "Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease." Ann Intern Med 148(1): 30-48.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17984482" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;McCormick, B. B., A. Sydor, et al. (2008). "The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis." Am J Kidney Dis 52(3): 454-63.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18433957" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Perkovic, V., C. Verdon, et al. (2008). "The relationship between proteinuria and coronary risk: a systematic review and meta-analysis." PLoS Med 5(10): e207.&amp;nbsp;[&lt;A href="http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.0050207" target="_blank"&gt;Link to PLoS Med full text&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;No systematic reviews.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2006&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Garg, A. X., N. Muirhead, et al. (2006). "Proteinuria and reduced kidney function in living kidney donors: A systematic review, meta-analysis, and meta-regression." Kidney Int 70(10): 1801-10.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17003822" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>11/01/2011 10:22:18</lastReviewDate>
    <expiryDate>11/01/2012 10:22:18</expiryDate>
  </document>
  <document>
    <id>311223</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_097489]]&gt;</url>
    <title>Putting Prevention First: NHS Health Check - Vascular Risk Assessment and Management</title>
    <publicationDate>2009-04-06T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ RENOVASCULAR DISEASES,IN CHILDREN,IN ADULTS,DELIVERY OF CARE,CARDIOVASCULAR,DIABETES,TYPE 1,TYPE 2,RISK MANAGEMENT,QUALITY AND MONITORING,PATIENT SAFETY,ORGANISATION OF CARE / CARE PLANNING,KEY POLICIES / NSF,CHRONIC COMPLICATIONS,CAUSES,HEALTH MANAGEMENT,CAUSES,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,QUALITY IMPROVEMENT,KIDNEY DISEASES,CAUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Best practice guidance.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Extract:&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;In this document, we have collated and referred to the current guidance available for each component of the NHS Health Check. This document provides best practice advice and supporting references for each element of the check, including how to identify and test those at high risk of diabetes. It also covers when and how someone should be assessed for hypertension and chronic kidney disease.&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>08/03/2011 10:04:52</lastReviewDate>
    <expiryDate>08/03/2012 10:04:52</expiryDate>
  </document>
  <document>
    <id>267844</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.acr.org/SecondaryMainMenuCategories/quality_safety/app_criteria/pdf/ExpertPanelonUrologicImaging/renalfailureDoc15.aspx]]&gt;</url>
    <title>Radiologic investigation of causes of renal failure</title>
    <publicationDate>2008-10-06T00:00:00</publicationDate>
    <publisher>American College of Radiology</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ ACUTE KIDNEY INJURY,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Guidelines from the American College of Radiology</description>
    <body>&lt;![CDATA[ &lt;P&gt;Tables outlining the appropriateness of various radiologic procedures.&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:33:59</lastReviewDate>
    <expiryDate>06/07/2011 11:33:59</expiryDate>
  </document>
  <document>
    <id>372798</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.renal.org/whatwedo/news/10-04-26/Rare_Kidney_Diseases_An_Integrated_Strategy_for_Patients_in_the_U_K.aspx]]&gt;</url>
    <title>Rare Kidney Diseases: An Integrated Strategy for Patients in the U.K.</title>
    <publicationDate>2010-04-28T00:00:00</publicationDate>
    <publisher>Renal Association</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ OTHER CONDITIONS - ADULTS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>21-page report</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Contents &lt;/STRONG&gt;&lt;/P&gt;&lt;STRONG&gt;
&lt;OL&gt;
&lt;LI&gt;&lt;/STRONG&gt;Executive summary 
&lt;LI&gt;Introduction 
&lt;LI&gt;Integrated models of care 
&lt;OL&gt;
&lt;LI&gt;Background 
&lt;LI&gt;The chronic care model 
&lt;LI&gt;Care pathways 
&lt;LI&gt;Disease-specific working groups &lt;/LI&gt;&lt;/OL&gt;
&lt;LI&gt;Diagnosis 
&lt;OL&gt;
&lt;LI&gt;Monogenic disorders and genetic testing 
&lt;LI&gt;Non-genetic investigations &lt;/LI&gt;&lt;/OL&gt;
&lt;LI&gt;Proposal for Renal RaDaR: a UK Registry for rare kidney diseases 
&lt;OL&gt;
&lt;LI&gt;Background 
&lt;LI&gt;Current infrastructure – UK Renal Registry 
&lt;LI&gt;Renal RaDaR: development and content &lt;/LI&gt;&lt;/OL&gt;
&lt;LI&gt;Research 
&lt;LI&gt;Governance of Renal RaDaR 
&lt;LI&gt;Audit 
&lt;LI&gt;Empowering patients and families 
&lt;LI&gt;Costs and Efficiencies&amp;nbsp; 
&lt;LI&gt;Summary 
&lt;LI&gt;Appendices&lt;/LI&gt;&lt;/OL&gt;
&lt;UL&gt;
&lt;LI&gt;Good practice for disease-specific working groups 
&lt;LI&gt;Applicable rare diseases and UK diagnostic tests 
&lt;LI&gt;Organisational Structure 
&lt;LI&gt;Contributors and acknowledgements&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
    <expiryDate>28/04/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>182668</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.kidney.org/professionals/kdoqi/guidelines_anemia/index.htm]]&gt;</url>
    <title>Recommendations for Anaemia in Chronic Kidney Disease</title>
    <publicationDate>2006-10-18T00:00:00</publicationDate>
    <publisher>K/DOQI</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ COMPLICATIONS OF KIDNEY DISEASE,ANAEMIA,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>NKF K/DOQI guidelines 2006</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Extract from guideline introduction&lt;/EM&gt;&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;Anemia commonly contributes to poor quality of life (QOL) in patients with chronic kidney disease (CKD). Fortunately, among the disorders that may afflict patients with CKD, anemia is perhaps the most responsive to treatment. Anemia was the subject of one of the first efforts of the National Kidney Foundation (NKF) to improve patient outcomes through the development, dissemination, and implementation of Dialysis Outcomes Quality Initiative (DOQI) Clinical Practice Guidelines. &lt;/P&gt;
&lt;P&gt;The first update of these guidelines appeared in 2001 under the newly organized NKF-Kidney Disease Outcomes Quality Initiative (KDOQI). In 2004, the NKF-KDOQI Steering Committee appointed a Work Group and Evidence Review Team (ERT) to undertake the first comprehensive revision of the KDOQI Clinical Practice Guidelines for the Management of Anemia in CKD. &lt;/P&gt;
&lt;P&gt;This Executive Summary provides a brief background description of CKD and anemia, outlines the scope of the guidelines and the methods of evidence review and synthesis, and provides the complete text of the guideline statements.&lt;/P&gt;]]&gt;</body>
    <expiryDate>03/11/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>269220</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.kidney.org.uk/campaigns/Dialysis/PatientTransport/Renal-Transport-Cheshire-and-Merseyside.pdf]]&gt;</url>
    <title>Recommendations for the Provision of a Patient Centred Renal Transport Service</title>
    <publicationDate>2006-09-01T00:00:00</publicationDate>
    <publisher>Cheshire and Merseyside Renal Transport Action Learning Set</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ HAEMODIALYSIS,LIVING WITH DIALYSIS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES,DIALYSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Report from Cheshire and Merseyside Renal Transport Action Learning Set
</description>
    <body>&lt;![CDATA[ &lt;P&gt;Covers:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;National policy drivers &lt;/LI&gt;
&lt;LI&gt;Why transport is important&lt;/LI&gt;
&lt;LI&gt;The case for change &lt;/LI&gt;
&lt;LI&gt;Current transport provision and Commissioning arrangements&lt;/LI&gt;
&lt;LI&gt;Commissioning a patient led transport service &lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
    <lastReviewDate>24/09/2010 10:34:27</lastReviewDate>
    <expiryDate>24/09/2011 10:34:27</expiryDate>
  </document>
  <document>
    <id>156054</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.ispd.org/guidelines/ISPDCurric.pdf]]&gt;</url>
    <title>Recommended training plan on peritoneal dialysis for nephrology trainees</title>
    <publicationDate>2000-07-03T00:00:00</publicationDate>
    <publisher>International Society for Peritoneal Dialysis</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ PERITONEAL DIALYSIS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,DIALYSIS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Suggested curriculum devised by the International Society for Peritoneal Dialysis</description>
    <body>&lt;![CDATA[ &lt;P&gt;The recommended training plan covers the following:&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Anatomy and physiology of PD 
&lt;LI&gt;PD modalities, their indications and associated technology 
&lt;LI&gt;Clearances on PD 
&lt;LI&gt;Ultrafiltration and management of fluid overload 
&lt;LI&gt;Peritonitis and exit site infection 
&lt;LI&gt;Mechanical complications 
&lt;LI&gt;Management of nutritional status 
&lt;LI&gt;Peritoneal dialysis solutions and biocompatibility 
&lt;LI&gt;Hematologic, electrolytic and metabolic complications of PD 
&lt;LI&gt;Acute PD 
&lt;LI&gt;Cardiovascular disease in PD 
&lt;LI&gt;Transplantation in the PD patient 
&lt;LI&gt;Delivery of PD in pediatric and geriatric populations 
&lt;LI&gt;The economics of PD&lt;/LI&gt;&lt;/OL&gt;]]&gt;</body>
    <lastReviewDate>09/11/2010 14:23:19</lastReviewDate>
    <expiryDate>09/11/2011 14:23:19</expiryDate>
  </document>
  <document>
    <id>288511</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.bestbets.org/bets/bet.php?id=82]]&gt;</url>
    <title>Rectal or Intravenous non-steroidal anti-inflammatory drugs in acute renal colic</title>
    <publicationDate>2005-08-26T00:00:00</publicationDate>
    <publisher>Best Bets</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ KIDNEY AND BLADDER STONES,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Critically appraised topic from Best Bets</description>
    <body>&lt;![CDATA[ &lt;P&gt;Extract&lt;/P&gt;
&lt;P&gt;Clinical Bottom Line&lt;/P&gt;
&lt;P&gt;Rectal NSAIDs are an effective form of analgesia for patients with acute renal colic and have fewer side effects compared to intravenous NSAIDs.&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>01/07/2010 15:02:38</lastReviewDate>
    <expiryDate>01/07/2011 15:02:38</expiryDate>
  </document>
  <document>
    <id>251323</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publichealth/Healthprotection/Healthcareacquiredinfection/Healthcareacquiredgeneralinformation/DH_063144]]&gt;</url>
    <title>Reducing MRSA and other healthcare associated infections in renal medicine</title>
    <publicationDate>2007-03-21T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>CARE PATHWAY</publicationType>
    <topics>&lt;![CDATA[ PERITONEAL DIALYSIS,PREVENTION OF INFECTIONS,HAEMODIALYSIS,PREVENTION OF INFECTIONS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,SAFER CARE,INNOVATION AND IMPROVEMENT,KIDNEY DISEASES,DIALYSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Part of Saving Lives: a delivery programme to reduce Healthcare Associated Infection including MRSA</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Extract from website&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;The list of elements is not meant to replace existing guidelines but to act as a method for improving the reliability of the clinical process surrounding dialysis catheter insertion and management. Where local guidance and policies already exist, their use in clinical practice can be assessed by using this intervention, or by tailoring the review tool to meet local needs.&lt;/P&gt;
&lt;P&gt;The assessment of dialysis catheter care has been divided into two sections to reflect clinical practice and aid review. The first set of elements is appropriate for dialysis catheter insertion. The second set is appropriate for the continuing care of dialysis catheters.&lt;/P&gt;
&lt;P&gt;The use of antimicrobial agents in the locking solution may also help prevent catheter related infections. Vancomycin is appropriate for preventing MRSA infection; the choice of other antibiotics should be based on local microbiological surveillance data.&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>24/09/2010 10:34:32</lastReviewDate>
    <expiryDate>24/09/2011 10:34:32</expiryDate>
    <relatedLinks>&lt;a href="http://www.dh.gov.uk/en/Publichealth/Healthprotection/Healthcareacquiredinfection/Healthcareacquiredgeneralinformation/DH_063144" title="Link to Department of Health webpage"/&gt;&lt;a href="http://www.dh.gov.uk/en/Policyandguidance/Healthandsocialcaretopics/Healthcareacquiredinfection/Healthcareacquiredgeneralinformation/DH_063144" title="Renal dialysis catheter care review tool: continuing care"/&gt;&lt;a href="http://www.dh.gov.uk/en/Policyandguidance/Healthandsocialcaretopics/Healthcareacquiredinfection/Healthcareacquiredgeneralinformation/DH_063144" title="Renal dialysis catheter care review tool: insertion"/&gt;</relatedLinks>
    <creator>Department of Health</creator>
  </document>
  <document>
    <id>155741</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.renal.org/unit/index.pl?c=mri]]&gt;</url>
    <title>Regional Kidney/Pancreas Transplantation Unit, Manchester Royal Infirmary</title>
    <publicationDate>2009-09-18T00:00:00</publicationDate>
    <publisher>Renal Association</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ TRANSPLANT CENTRES,TRANSPLANTATION,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Contact details and background information</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Extract from webpage&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;The Regional Kidney/Pancreas Transplantation Unit based within Manchester Royal Infirmary performs&amp;nbsp;around 150 renal transplantations per year. &lt;/P&gt;
&lt;P&gt;Manchester Royal Infirmary provides nephrology services to North, South and Central Manchester, Tameside &amp;amp; Glossop, Stockport, South Trafford and South Cheshire PCTs (population 1.4 million), including North Manchester General, Wythenshawe, CMMC, Macclesfield, Stepping Hill, Tameside, Prestwich and The Christie Hospitals.&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:34:03</lastReviewDate>
    <expiryDate>06/07/2011 11:34:03</expiryDate>
    <relatedLinks>&lt;a href="http://www.renal.org/unit/index.pl?c=mri" title="Click for webpage"/&gt;&lt;a href="http://www.mint-research.org.uk/" title="Website of Manchester Institute of Nephrology and Transplantation"/&gt;</relatedLinks>
    <creator>Manchester Royal Infirmary</creator>
  </document>
  <document>
    <id>236190</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Healthcare/Renal/RenalInformation/DH_4069293]]&gt;</url>
    <title>Reimbursement of living donor expenses by the NHS</title>
    <publicationDate>2009-07-03T00:00:00</publicationDate>
    <publisher>Department of Health / Inland Revenue</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ TRANSPLANTATION,ASSESSMENT/SELECTION,DONOR,TRANSPLANT OPERATION,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The Department of Health with the help of the Inland Revenue has prepared the following explanation of the proper reimbursement of a living organ donor's expenses</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Extract from web page&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;The Human Organ Transplants (HOT) Act, 1989 forbids the offer or payment of any inducement for the supply of a human organ. However, it does not prohibit the payment of reasonable expenses to a donor for travel and accommodation and any loss of earnings incurred if directly attributable to his/her donation of an organ.&lt;/P&gt;
&lt;P&gt;NHS trusts and PCTs are permitted to make such payments and should do so if the live transplant is permitted under the HOT Act. The NHS is not legally obliged to make such payments. However, as a renal transplant is the most cost-effective treatment for end stage renal failure, and a live donor transplant may be the only option for a patient in liver failure, payment of the cost of the donor operation, and any associated donor expenses, is justified.&lt;/P&gt;
&lt;P&gt;Renal transplantation now comes under the specialised commissioning groups' arrangements. Whether the NHS Trust or a PCT actually refunds the donor is a matter for those commissioning arrangements but should be agreed beforehand and the method of making a claim and receiving payment explained to all concerned. The service agreement should be explicit about how any such payments are to be made, whether by the Trust or by an application to a PCT.&lt;/P&gt;
&lt;P&gt;Any payments to living donors should ensure that, within reason, the donor is no worse off as a result of the donation, but neither should they gain any financial advantage. Any payments in excess of the amount needed to reimburse losses would constitute a payment for the donation and breach the HOT Act, 1989.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;A href="http://www.dh.gov.uk/PolicyAndGuidance/HealthAndSocialCareTopics/Renal/RenalInformation/RenalInformationArticle/fs/en?CONTENT_ID=4069293&amp;amp;chk=l/xDlR" target="_blank"&gt;&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:34:07</lastReviewDate>
    <expiryDate>06/07/2011 11:34:07</expiryDate>
  </document>
  <document>
    <id>155637</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.uktransplant.org.uk/ukt/how_to_become_a_donor/religious_perspectives/religious_perspectives.jsp]]&gt;</url>
    <title>Religious perspectives on organ donation</title>
    <publicationDate></publicationDate>
    <publisher>UK Transplant</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ ETHNICITY AND HEALTH,DISEASES AND CONDITIONS,CULTURAL COMPETENCE,RELIGION,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,TRANSPLANTATION,KIDNEY DISEASES,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Webpage from UK Transplant on religious belief and organ donation</description>
    <body>&lt;![CDATA[ Background&amp;nbsp;information on the development of a series of leaflets&amp;nbsp;setting out the views of different religions on organ donation and transplantation]]&gt;</body>
    <lastReviewDate>24/09/2010 10:37:10</lastReviewDate>
    <expiryDate>24/09/2011 10:37:10</expiryDate>
    <relatedLinks>&lt;a href="http://www.uktransplant.org.uk/ukt/how_to_become_a_donor/religious_perspectives/religious_perspectives.jsp" title="Click here for webpage"/&gt;&lt;a href="http://www.uktransplant.org.uk/ukt/newsroom/fact_sheets/religious_leaflets/general_religious_lflet-2005.pdf" title="Click here for leaflet PDF"/&gt;</relatedLinks>
    <creator>UK Transplant</creator>
  </document>
  <document>
    <id>306785</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.bestbets.org/database/browse-by-topic.php?CategoryID=232]]&gt;</url>
    <title>Renal BestBETs</title>
    <publicationDate>2009-02-19T00:00:00</publicationDate>
    <publisher>BestBETs</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ COMPLICATIONS OF KIDNEY DISEASE,ACUTE KIDNEY INJURY,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>BestBETs are Best Evidence Topics.</description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of the BestBETs website contains Best Evidence Topic reports (BETs) for the following topic:&lt;/P&gt;
&lt;P&gt;Specialty&amp;nbsp;&amp;gt; Medicine &amp;gt; Renal&lt;/P&gt;
&lt;P&gt;BETs were developed in the Emergency Department of Manchester Royal Infirmary, UK, to provide rapid evidence-based answers to real-life clinical questions, using a systematic approach to reviewing the literature.&lt;/P&gt;
&lt;P&gt;Note the coloured symbols next to each BET, which indicate how complete they are.&lt;/P&gt;
&lt;P&gt;Warning: Due to technical reasons the Critical Appraisals (CAs) found under this topic may not be relevant.&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>11/01/2011 10:23:51</lastReviewDate>
    <expiryDate>11/01/2012 10:23:51</expiryDate>
  </document>
  <document>
    <id>291867</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.nice.org.uk/guidance/index.jsp?action=folder&amp;o=41474]]&gt;</url>
    <title>Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: evaluation report</title>
    <publicationDate>2008-08-07T00:00:00</publicationDate>
    <publisher>NICE</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ RENAL CANCER,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Evaluation reports from NICE</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Links to:&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Assessment report&lt;/LI&gt;
&lt;LI&gt;Overview &lt;/LI&gt;
&lt;LI&gt;Consultee and commentator comments on assessment report&lt;/LI&gt;
&lt;LI&gt;Non-manufacturer submission &lt;/LI&gt;
&lt;LI&gt;Manufacturer submission &lt;/LI&gt;
&lt;LI&gt;Expert written personal statements &lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:34:18</lastReviewDate>
    <expiryDate>06/07/2011 11:34:18</expiryDate>
  </document>
  <document>
    <id>156027</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.connectingforhealth.nhs.uk/engagement/clinical/doas]]&gt;</url>
    <title>Renal Do Once and Share (DOAS)</title>
    <publicationDate>2009-10-05T00:00:00</publicationDate>
    <publisher>NHS Connecting for Health</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ INTERVENTIONS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Introduction to aims and objectives of the DOAS project.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Extract from website&lt;/EM&gt;&lt;/STRONG&gt; &lt;/P&gt;
&lt;P class=Heading&gt;The DOAS programme is being delivered by 42 action teams, each with a project focusing on a specialty or care process. They are undertaking national consultation, gathering evidence and taking soundings to create their best practice model.&lt;/P&gt;
&lt;P class=Heading&gt;Each action team will make recommendations to the teams within NHS Connecting for Health responsible for the design, development and implementation of the new solutions to ensure they support the needs of each individual specialty.&lt;/P&gt;
&lt;P class=Heading&gt;At the same time they will also review the specification for each new IT system and service in the light of current thinking and clinical practice in their particular field.&lt;/P&gt;
&lt;P class=Heading&gt;These new standard approaches to care - which aim to make optimum use of the new IT systems - can then be &lt;EM&gt;shared&lt;/EM&gt; and implemented across the NHS&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:34:22</lastReviewDate>
    <expiryDate>06/07/2011 11:34:22</expiryDate>
  </document>
  <document>
    <id>328325</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://clinicalevidence.bmj.com/ceweb/conditions/knd/2004/2004.jsp?rss=true]]&gt;</url>
    <title>Renal failure (chronic)</title>
    <publicationDate>2009-10-30T00:00:00</publicationDate>
    <publisher>BMJ</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ ACUTE KIDNEY INJURY,CAUSES AND RISK FACTORS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A BMJ Clinical Evidence topic</description>
    <body>&lt;![CDATA[ &lt;P&gt;Here is a list of clinical questions we have addressed in this review.&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;What are the effects of drug treatments used to reduce progression rate of chronic renal failure?&lt;/LI&gt;
&lt;LI&gt;What are the effects of lifestyle changes used to reduce progression rate of chronic renal failure?&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;What are the effects of drug treatments used to reduce progression rate of chronic renal failure?&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Likely to be beneficial&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;ACE inhibitors&lt;/LI&gt;
&lt;LI&gt;ACE inhibitors plus angiotensin II receptor antagonists (more effective than either drug alone)&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Unknown effectiveness&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Angiotensin II receptor antagonists&lt;/LI&gt;
&lt;LI&gt;Nicotinates&lt;/LI&gt;
&lt;LI&gt;Statins&lt;/LI&gt;
&lt;LI&gt;Targeted lowering of albuminuria/proteinuria (compared with non-targeted lowering of albuminuria/proteinuria)&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Unlikely to be beneficial&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Lowering blood pressure below usual targets&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Likely to be ineffective or harmful&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Fibrates&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;What are the effects of lifestyle changes used to reduce progression rate of chronic renal failure?&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Likely to be beneficial&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Psychoeducational intervention&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Unknown effectiveness&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Exercise&lt;/LI&gt;
&lt;LI&gt;Smoking cessation&lt;/LI&gt;
&lt;LI&gt;Sodium (dietary)&lt;/LI&gt;
&lt;LI&gt;Structured programmes to achieve therapeutic goals&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>30/09/2010 13:11:49</lastReviewDate>
    <expiryDate>30/09/2011 13:11:49</expiryDate>
  </document>
  <document>
    <id>341852</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=341852]]&gt;</url>
    <title>Renal function: Systematic reviews and meta-analyses</title>
    <publicationDate>2011-01-17T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,ACUTE KIDNEY INJURY,CAUSES AND RISK FACTORS,ASSESSMENT OF RENAL FUNCTION,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Renal function: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2011&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Fabrizi F, Dixit V, Martin P, Messa P. Pre-transplant Kidney Function Predicts Chronic Kidney Disease After Liver Transplant: Meta-Analysis of Observational Studies. Dig Dis Sci. 2011 Jan 8. [Epub ahead of print] [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/21221799?dopt=Abstract" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&amp;nbsp;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Asrani, S. K., M. D. Leise, et al. (2010). "Use of sirolimus in liver transplant recipients with renal insufficiency: a systematic review and meta-analysis." Hepatology (Baltimore, Md.) 52(4): 1360-1370. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20815021" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Cavalcanti, A. B., A. R. Goncalves, et al. (2010). "Teicoplanin versus vancomycin for proven or suspected infection." Cochrane Database of Systematic Reviews 6. [&lt;A href="nelh:378127:0" name=internalLink&gt;Link to Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Dart, A. B., T. C. Mutter, et al. "Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function." Cochrane Database Syst Rev(1): CD007594. [&lt;A href="nelh:341786:0" name=internalLink&gt;Link to Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kagoma, Y.K., Weir, M.A., Iansavichus, A.V., Hemmelgarn, B.R., Akbari, A., Patel, U.D., et al. (2010) "Impact of Estimated GFR Reporting on Patients, Clinicians, and Health-Care Systems: A Systematic Review". American Journal of Kidney Diseases. Published online 13 December 2010. [&lt;A href="http://www.ajkd.org/article/PIIS027263861001396X/abstract" target="_blank"&gt;Link to journal abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lee, M., J. L. Saver, et al. (2010). "Impact of microalbuminuria on incident stroke: a meta-analysis." Stroke 41(11): 2625-31. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Impact%20of%20microalbuminuria%20on%20incident%20stroke%3A%20a%20meta-analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lee, M., J. L. Saver, et al. (2010). "Low glomerular filtration rate and risk of stroke: meta-analysis." BMJ 341: c4249. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Low%20glomerular%20filtration%20rate%20and%20risk%20of%20stroke%3A%20meta-analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Pattaro, C., A. De Grandi, et al. (2010) "A meta-analysis of genome-wide data from five European isolates reveals an association of COL22A1, SYT1, and GABRR2 with serum creatinine level." BMC Medical Genetics 11;11:41. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=%20meta-analysis%20of%20genome-wide%20data%20from%20five%20European%20isolates%20reveals%20an%20association%20of%20COL22A1%2C%20SYT1%2C%20and%20GABRR2%20with%20serum%20creatinine%20level" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Van Pottelbergh G, Van Heden L, Mathei C, et al. (2010) "Methods to evaluate renal function in elderly patients: a systematic literature review." Age Ageing. 2010 Sep;39(5):542-8. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20716584" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;White, C. A., D. Siegal, et al. (2010). "Use of kidney function end points in kidney transplant trials: A systematic review." American Journal of Kidney Diseases 56(6): 1140-1157.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/21036442" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Bagshaw, S. M., D. R. Townsend, et al. (2009). "Disorders of sodium and water balance in hospitalized patients." Can J Anaesth 56(2): 151-67.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=2009[pdat]%20AND%20Disorders%20of%20sodium%20and%20water%20balance%20in%20hospitalized%20patients" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Baker, W. L., M. W. Anglade, et al. (2009). "Use of N-acetylcysteine to reduce post-cardiothoracic surgery complications: a meta-analysis." Eur J Cardiothorac Surg 35(3): 521-7.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Use%20of%20N-acetylcysteine%20to%20reduce%20post-cardiothoracic%20surgery%20complications%3A%20a%20meta-analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Brienza, N., M. T. Giglio, et al. (2009). "Does perioperative hemodynamic optimization protect renal function in surgical patients? A meta-analytic study." Crit Care Med 37(6): 2079-90.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Does%20perioperative%20hemodynamic%20optimization%20protect%20renal%20function%20in%20surgical%20patients%3F%20A%20meta-analytic%20study" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Dusing, R. and F. Sellers (2009). "ACE inhibitors, angiotensin receptor blockers and direct renin inhibitors in combination: a review of their role after the ONTARGET trial." Curr Med Res Opin 25(9): 2287-301.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=ACE%20inhibitors%2C%20angiotensin%20receptor%20blockers%20and%20direct%20renin%20inhibitors%20in%20combination%3A%20a%20review%20of%20their%20role%20after%20the%20ONTARGET%20trial" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Faber, P. and A. A. Klein (2009). "Acute kidney injury and renal replacement therapy in the intensive care unit." Nurs Crit Care 14(4): 207-12.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19531039" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Gagne, J. J., D. E. Griesdale, et al. (2009). "Aprotinin and the risk of death and renal dysfunction in patients undergoing cardiac surgery: a meta-analysis of epidemiologic studies." Pharmacoepidemiol Drug Saf 18(4): 259-68.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Aprotinin%20and%20the%20risk%20of%20death%20and%20renal%20dysfunction%20in%20patients%20undergoing%20cardiac%20surgery%3A%20a%20meta-analysis%20of%20epidemiologic%20studies" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Joannidis, M., W. Druml, et al. (2009). "Prevention of acute kidney injury and protection of renal function in the intensive care unit : Expert opinion of the working group for nephrology, ESICM." Intensive Care Med.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Prevention%20of%20acute%20kidney%20injury%20and%20protection%20of%20renal%20function%20in%20the%20intensive%20care%20unit%20%3A%20Expert%20opinion%20of%20the%20working%20group%20for%20nephrology%2C%20ESICM" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lopez, R. M., D. J. Casa, et al. (2009). "Does creatine supplementation hinder exercise heat tolerance or hydration status? A systematic review with meta-analyses." J Athl Train 44(2): 215-23.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Does%20creatine%20supplementation%20hinder%20exercise%20heat%20tolerance%20or%20hydration%20status%3F%20A%20systematic%20review%20with%20meta-analyses" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Michael, M., E. J. Elliott, et al. (2009). "Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: a systematic review of randomized controlled trials." Am J Kidney Dis 53(2): 259-72.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Interventions%20for%20hemolytic%20uremic%20syndrome%20and%20thrombotic%20thrombocytopenic%20purpura%3A%20a%20systematic%20review%20of%20randomized%20controlled%20trials" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Michael, M., E. J. Elliott, et al. (2009). "Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura." Cochrane Database Syst Rev(1): CD003595.&amp;nbsp;[&lt;A href="nelh:304876:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Miller, E. R., 3rd, S. P. Juraschek, et al. (2009). "The effect of n-3 long-chain polyunsaturated fatty acid supplementation on urine protein excretion and kidney function: meta-analysis of clinical trials." Am J Clin Nutr 89(6): 1937-45.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=The%20effect%20of%20n-3%20long-chain%20polyunsaturated%20fatty%20acid%20supplementation%20on%20urine%20protein%20excretion%20and%20kidney%20function%3A%20meta-analysis%20of%20clinical%20trials" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Morris, R., G. Malin, et al. (2009). "Antenatal ultrasound to predict postnatal renal function in congenital lower urinary tract obstruction: systematic review of test accuracy." BJOG.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Antenatal%20ultrasound%20to%20predict%20postnatal%20renal%20function%20in%20congenital%20lower%20urinary%20tract%20obstruction%3A%20systematic%20review%20of%20test%20accuracy" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Nigwekar, S. U. and J. K. Hix (2009). "The role of natriuretic peptide administration in cardiovascular surgery-associated renal dysfunction: a systematic review and meta-analysis of randomized controlled trials." J Cardiothorac Vasc Anesth 23(2): 151-60.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=The%20role%20of%20natriuretic%20peptide%20administration%20in%20cardiovascular%20surgery-associated%20renal%20dysfunction%3A%20a%20systematic%20review%20and%20meta-analysis%20of%20randomized%20controlled%20trials" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Ninomiya, T., V. Perkovic, et al. (2009). "Proteinuria and stroke: a meta-analysis of cohort studies." Am J Kidney Dis 53(3): 417-25.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Proteinuria%20and%20stroke%3A%20a%20meta-analysis%20of%20cohort%20studies" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Nutescu, E. A., S. A. Spinler, et al. (2009). "Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings." Ann Pharmacother 43(6): 1064-83.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Low-molecular-weight%20heparins%20in%20renal%20impairment%20and%20obesity%3A%20available%20evidence%20and%20clinical%20practice%20recommendations%20across%20medical%20and%20surgical%20settings" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Paul, R., J. Minay, et al. (2009). "Meta-analysis of the effects of lithium usage on serum creatinine levels." J Psychopharmacol.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=2009[pdat]%20AND%20Meta-analysis%20of%20the%20effects%20of%20lithium%20usage%20on%20serum%20creatinine%20levels" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Zhu, X., K. Stergiopoulos, et al. (2009). "Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis." Acta Oncol 48(1): 9-17.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Risk%20of%20hypertension%20and%20renal%20dysfunction%20with%20an%20angiogenesis%20inhibitor%20sunitinib%3A%20systematic%20review%20and%20meta-analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Castagnetti, M., G. Novara, et al. (2008). "Scintigraphic renal function after unilateral pyeloplasty in children: a systematic review." BJU Int 102(7): 862-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Scintigraphic%20renal%20function%20after%20unilateral%20pyeloplasty%20in%20children%3A%20a%20systematic%20review" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hursting, M. J. and P. T. Murray (2008). "Argatroban anticoagulation in renal dysfunction: a literature analysis." Nephron Clin Pract 109(2): c80-94.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Argatroban%20anticoagulation%20in%20renal%20dysfunction%3A%20a%20literature%20analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kielstein, J. T., S. R. Salpeter, et al. (2008). "Two cardiovascular risk factors in one? Homocysteine and its relation to glomerular filtration rate. A meta-analysis of 41 studies with 27,000 participants." Kidney Blood Press Res 31(4): 259-67.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Two%20cardiovascular%20risk%20factors%20in%20one%3F%20Homocysteine%20and%20its%20relation%20to%20glomerular%20filtration%20rate.%20A%20meta-analysis%20of%2041%20studies%20with%2027%2C000%20participants" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Naughton, F., D. Wijeysundera, et al. (2008). "N-acetylcysteine to reduce renal failure after cardiac surgery: a systematic review and meta-analysis." Can J Anaesth 55(12): 827-35.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=N-acetylcysteine%20to%20reduce%20renal%20failure%20after%20cardiac%20surgery%3A%20a%20systematic%20review%20and%20meta-analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Papanna, R., L. K. Mann, et al. (2008). "Protein/creatinine ratio in preeclampsia: a systematic review." Obstet Gynecol 112(1): 135-44.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Protein%2Fcreatinine%20ratio%20in%20preeclampsia%3A%20a%20systematic%20review" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Perkovic, V., C. Verdon, et al. (2008). "The relationship between proteinuria and coronary risk: a systematic review and meta-analysis." PLoS Med 5(10): e207.&amp;nbsp;[&lt;A href="http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.0050207" target="_blank"&gt;Link to full text on PLoS Medicine&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Schmitt, R., S. Coca, et al. (2008). "Recovery of kidney function after acute kidney injury in the elderly: a systematic review and meta-analysis." Am J Kidney Dis 52(2): 262-71.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Recovery%20of%20kidney%20function%20after%20acute%20kidney%20injury%20in%20the%20elderly%3A%20a%20systematic%20review%20and%20meta-analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Walsh, S. R., J. R. Boyle, et al. (2008). "Suprarenal endograft fixation and medium-term renal function: systematic review and meta-analysis." J Vasc Surg 47(6): 1364-1370.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Suprarenal%20endograft%20fixation%20and%20medium-term%20renal%20function%3A%20systematic%20review%20and%20meta-analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Zacharias, M., N. P. Conlon, et al. (2008). "Interventions for protecting renal function in the perioperative period." Cochrane Database Syst Rev(4): CD003590.&amp;nbsp;[&lt;A href="nelh:238098:0" name=internalLink&gt;Link to Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Coca, S. G., A. J. Peixoto, et al. (2007). "The prognostic importance of a small acute decrement in kidney function in hospitalized patients: a systematic review and meta-analysis." Am J Kidney Dis 50(5): 712-20.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=The%20prognostic%20importance%20of%20a%20small%20acute%20decrement%20in%20kidney%20function%20in%20hospitalized%20patients%3A%20a%20systematic%20review%20and%20meta-analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Damman, K., G. Navis, et al. (2007). "Worsening renal function and prognosis in heart failure: systematic review and meta-analysis." J Card Fail 13(8): 599-608.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Worsening%20renal%20function%20and%20prognosis%20in%20heart%20failure%3A%20systematic%20review%20and%20meta-analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Demyttenaere, S., L. S. Feldman, et al. (2007). "Effect of pneumoperitoneum on renal perfusion and function: a systematic review." Surg Endosc 21(2): 152-60.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Effect%20of%20pneumoperitoneum%20on%20renal%20perfusion%20and%20function%3A%20a%20systematic%20review" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Di Angelantonio, E., J. Danesh, et al. (2007). "Renal function and risk of coronary heart disease in general populations: new prospective study and systematic review." PLoS Med 4(9): e270.&amp;nbsp;[&lt;A href="http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.0040270" target="_blank"&gt;Link to full text on PLoS Medicine&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Halimi, J. M., S. Hadjadj, et al. (2007). "[Microalbuminuria and urinary albumin excretion: clinical practice guidelines]." Nephrol Ther 3(6): 384-91.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17919641" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Knight, S. R. and P. J. Morris (2007). "The clinical benefits of cyclosporine C2-level monitoring: a systematic review." Transplantation 83(12): 1525-35.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=The%20clinical%20benefits%20of%20cyclosporine%20C2-level%20monitoring%3A%20a%20systematic%20review" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lee, A., M. G. Cooper, et al. (2007). "Effects of nonsteroidal anti-inflammatory drugs on postoperative renal function in adults with normal renal function." Cochrane Database Syst Rev(2): CD002765.&amp;nbsp;[&lt;A href="nelh:237503:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Morris, R. K., E. Quinlan-Jones, et al. (2007). "Systematic review of accuracy of fetal urine analysis to predict poor postnatal renal function in cases of congenital urinary tract obstruction." Prenat Diagn 27(10): 900-11.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Systematic%20review%20of%20accuracy%20of%20fetal%20urine%20analysis%20to%20predict%20poor%20postnatal%20renal%20function%20in%20cases%20of%20congenital%20urinary%20tract%20obstruction" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Roos, J. F., J. Doust, et al. (2007). "Diagnostic accuracy of cystatin C compared to serum creatinine for the estimation of renal dysfunction in adults and children--a meta-analysis." Clin Biochem 40(5-6): 383-91.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Diagnostic%20accuracy%20of%20cystatin%20C%20compared%20to%20serum%20creatinine%20for%20the%20estimation%20of%20renal%20dysfunction%20in%20adults%20and%20children--a%20meta-analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2006&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Kielstein, J. T., S. R. Salpeter, et al. (2006). "Symmetric dimethylarginine (SDMA) as endogenous marker of renal function--a meta-analysis." Nephrol Dial Transplant 21(9): 2446-51.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Symmetric%20dimethylarginine%20%28SDMA%29%20as%20endogenous%20marker%20of%20renal%20function--a%20meta-analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Zhang, J., E. L. Ding, et al. (2006). "Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials." JAMA 296(13): 1619-32. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Adverse%20effects%20of%20cyclooxygenase%202%20inhibitors%20on%20renal%20and%20arrhythmia%20events%3A%20meta-analysis%20of%20randomized%20trials" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>11/01/2011 10:22:23</lastReviewDate>
    <expiryDate>11/01/2012 00:00:00</expiryDate>
  </document>
  <document>
    <id>339078</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=339078]]&gt;</url>
    <title>Renal laparoscopy: Systematic reviews and meta-analyses</title>
    <publicationDate>2010-01-19T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ TRANSPLANTATION,TRANSPLANT OPERATION,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Renal laparoscopy: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Antcliffe, D., T. G. Nanidis, et al. (2009). "A meta-analysis of mini-open versus standard open and laparoscopic living donor nephrectomy." Transpl Int 22(4): 463-74. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19175543" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kim, C., K. McKay, et al. (2009). "Laparoscopic nephrectomy in children: systematic review of transperitoneal and retroperitoneal approaches." Urology 73(2): 280-4.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18952262" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Seixas-Mikelus, S. A., L. C. Jenkins, et al. (2009). "Pediatric pyeloplasty: comparison of literature meta-analysis of laparoscopic and open techniques with open surgery at a single institution." J Urol 182(5): 2428-32.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19765755" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Silberstein, J. and J. K. Parsons (2009). "Hand-assisted and total laparoscopic nephrectomy: a comparison." JSLS 13(1): 36-43.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19366539" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Eng, M. K., M. H. Katz, et al. (2008). "Laparoscopic port-site metastasis in urologic surgery." J Endourol 22(8): 1581-5.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18620507" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Rashid, P., J. Goad, et al. (2008). "Laparoscopic partial nephrectomy: integration of an advanced laparoscopic technique." ANZ J Surg 78(6): 471-5.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18522568" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Keeley, F. X., Jr., C. G. Eden, et al. (2007). "The British Association of Urological Surgeons: guidelines for training in laparoscopy." BJU Int 100(2): 379-81.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17617143" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2006&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;No systematic reviews. &lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>21/12/2010 10:53:12</lastReviewDate>
    <expiryDate>21/12/2011 10:53:12</expiryDate>
  </document>
  <document>
    <id>306509</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.renal.org/pages/media/TsarFiles/NSF_Update_Feb_2009.pdf]]&gt;</url>
    <title>Renal NSF Update for February 2009</title>
    <publicationDate>2009-02-16T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ NATIONAL SERVICE FRAMEWORK FOR RENAL SERVICES/POLICY DOCUMENTS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This report is to update on Renal NSF activity.</description>
    <body>&lt;![CDATA[ &lt;P&gt;This report contains an update on:&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;World Kidney Day 
&lt;LI&gt;Kidney Risk Assessment Tool 
&lt;LI&gt;Personal Health Budgets 
&lt;LI&gt;Health Profile of England 
&lt;LI&gt;National Renal Dataset 
&lt;LI&gt;Kidney Care Plans 
&lt;LI&gt;Supporting People with LTCs, Commissioning Personalised Care Planning - Guide for Commissioners 
&lt;LI&gt;Transitional Guide for Kidney Services 
&lt;LI&gt;NICE Machine Perfusion Systems and Cold Storage of donated Kidneys.&lt;/LI&gt;&lt;/OL&gt;]]&gt;</body>
    <lastReviewDate>11/01/2011 10:25:07</lastReviewDate>
    <expiryDate>11/01/2012 10:25:07</expiryDate>
  </document>
  <document>
    <id>325078</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.renal.org/pages/media/TsarFiles/NSFRenalServices_Update_Sept%202009.pdf]]&gt;</url>
    <title>Renal NSF Update for September 2009</title>
    <publicationDate>2009-09-17T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ NATIONAL SERVICE FRAMEWORK FOR RENAL SERVICES/POLICY DOCUMENTS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This report contains an update on:&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Supporting Young Adults with Kidney Disease 
&lt;LI&gt;End of Life Care for Advanced Kidney Disease – A Framework for Implementation 
&lt;LI&gt;Pandemic Flu 
&lt;LI&gt;National Renal Dataset 
&lt;LI&gt;Clinical Advisor to National Clinical Director for Kidney Care 
&lt;LI&gt;SpR in Green Nephrology 
&lt;LI&gt;Detecting and Managing Chronic Kidney Disease in England – Patient Leaflet now available 
&lt;LI&gt;NCEPOD Report on Acute Kidney Injury launched 
&lt;LI&gt;PbR for Kidney Dialysis – developing a Best Practice Tariff (moving to non-mandatory tariff in April 2010) 
&lt;LI&gt;Enhanced Surveillance of MRSA in Kidney Care 
&lt;LI&gt;Publication of Health Building Note 07-01: Satellite dialysis unit 
&lt;LI&gt;Primary Care QOF data is now available on NHS comparators 
&lt;LI&gt;MORRIS – A Capacity Modelling Tool for Kidney Services 
&lt;LI&gt;Specification for Peritoneal Dialysis&lt;/LI&gt;&lt;/OL&gt;]]&gt;</body>
    <lastReviewDate>17/09/2010 16:40:06</lastReviewDate>
    <expiryDate>17/09/2011 16:40:06</expiryDate>
  </document>
  <document>
    <id>156242</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.renalpharmacy.org.uk/reference_texts.php]]&gt;</url>
    <title>Renal Reference Texts</title>
    <publicationDate>2009-10-05T00:00:00</publicationDate>
    <publisher>UK Renal Pharmacy Group</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ HAEMODIALYSIS,TRANSPLANTATION,PREDISPOSING FACTORS,INTERVENTIONS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES,DIALYSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Synopses of relevant renal reference textbooks</description>
    <body>&lt;![CDATA[ &lt;P&gt;Synopses of:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Renal Drug Handbook (written by UK Renal Pharmacy Group)&lt;/LI&gt;
&lt;LI&gt;Advanced Renal Care by Thomas, N&lt;/LI&gt;
&lt;LI&gt;Handbook of Dialysis by Daugirdas, JT&lt;/LI&gt;
&lt;LI&gt;Handbook of Kidney Transplantation by Danovitch GM&lt;/LI&gt;
&lt;LI&gt;Drug Dosage in Renal Insufficiency by Seyffart&lt;/LI&gt;
&lt;LI&gt;Advanced Renal Medicine by Raine AEG&lt;/LI&gt;
&lt;LI&gt;Manual of clinical problems on Nephrology by Rose, BD and Black, RM&lt;/LI&gt;
&lt;LI&gt;Drug Prescribing in Renal Failure: Dosing Guidelines for Adults by Bennett WM&lt;/LI&gt;
&lt;LI&gt;Handbook of Drug Therapy in Liver and Kidney Disease by Schrier, RW&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:34:27</lastReviewDate>
    <expiryDate>06/07/2011 11:34:27</expiryDate>
  </document>
  <document>
    <id>301810</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://healthguides.mapofmedicine.com/choices/map/renal_replacement_therapy1.html]]&gt;</url>
    <title>Renal replacement therapy - assessment</title>
    <publicationDate>2008-12-22T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ PERITONEAL DIALYSIS,TRANSPLANTATION,HAEMODIALYSIS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES,DIALYSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Web pages from NHS Choices and the Map of Medicine.</description>
    <body>&lt;![CDATA[ This page provides a link to the Map of Medicine view on assessment for renal replacement therapy.]]&gt;</body>
    <lastReviewDate>09/11/2010 14:23:15</lastReviewDate>
    <expiryDate>09/11/2011 14:23:15</expiryDate>
  </document>
  <document>
    <id>156442</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/assetRoot/04/07/05/88/04070588.pdf]]&gt;</url>
    <title>Renal Services Information Strategy</title>
    <publicationDate>2004-01-14T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ NATIONAL SERVICE FRAMEWORK FOR RENAL SERVICES/POLICY DOCUMENTS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Document to support planning and identification of  local priorities in terms of implementing the National Service Framework for Renal Services.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Extract from Strategy Executive Summary&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;The Information Strategy consists of a series of tables containing National and related Local Actions developed to support Part 1 of the NSF which addresses kidney transplantation and dialysis for people with established renal failure. Each action, where appropriate, is linked to further information that explains the background to and the reasoning behind the action.&lt;/P&gt;
&lt;P&gt;The tables are divided into themed sections as follows:&lt;/P&gt;
&lt;P&gt;Section 1: Information for direct care of the patient &lt;/P&gt;
&lt;P&gt;Section 2: Information for seconary purposes such as audit and service planning&lt;/P&gt;
&lt;P&gt;Section 3&amp;nbsp; : Information for patients, carers and healthcare professionals providing renal services &lt;/P&gt;
&lt;P&gt;Section 4 : Information for training and development of renal information services&lt;/P&gt;
&lt;P&gt;The implementation of the Information Strategy relies very heavily on the National Programme for IT (NPfIT)&amp;nbsp; &lt;/P&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:34:31</lastReviewDate>
    <expiryDate>06/07/2011 11:34:31</expiryDate>
  </document>
  <document>
    <id>156573</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4082061]]&gt;</url>
    <title>Renal Specific Management of Medicines</title>
    <publicationDate>2004-04-01T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ HAEMODIALYSIS,PERITONEAL DIALYSIS,COMPLICATIONS OF KIDNEY DISEASE,END-OF-LIFE CARE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,HOME DIALYSIS,HOME HAEMODIALYSIS,DIALYSIS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A resource document for aspects specific to the National Service Framework for Renal Services</description>
    <body>&lt;![CDATA[ &lt;P&gt;Document covers:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Information needs of people with chronic kidney disease 
&lt;LI&gt;Management of renal anaemia 
&lt;LI&gt;Prevention of renal scarring: urinary tract infection treatment and prophylaxis 
&lt;LI&gt;Dose adjustment and nephrotoxicity 
&lt;LI&gt;Medicines for hypertension in chronic renal impairment 
&lt;LI&gt;Medicines for control of common uraemic symptoms 
&lt;LI&gt;Calcium and phospate management in renal impairment 
&lt;LI&gt;Use of immunosuppresants 
&lt;LI&gt;Use of growth hormone in children 
&lt;LI&gt;Vaccination and infection prophylaxis 
&lt;LI&gt;'Self medication' in hospital 
&lt;LI&gt;Supplementary prescribing and patient group directions 
&lt;LI&gt;Home delivery of medicines and dialysis fluids 
&lt;LI&gt;End of life care &lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:34:35</lastReviewDate>
    <expiryDate>06/07/2011 11:34:35</expiryDate>
  </document>
  <document>
    <id>394386</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2962039-9/abstract]]&gt;</url>
    <title>Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial</title>
    <publicationDate>2010-11-18T00:00:00</publicationDate>
    <publisher>The Lancet</publisher>
    <publicationType>RANDOMISED CONTROLLED TRIAL</publicationType>
    <topics>&lt;![CDATA[ BLOOD PRESSURE,INTERVENTIONS,BLOOD PRESSURE,PREDISPOSING FACTORS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>RCT</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Extract from abstract:&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Activation of renal sympathetic nerves is key to pathogenesis of essential hypertension. We aimed to assess effectiveness and safety of catheter-based renal denervation for reduction of blood pressure in patients with treatment-resistant hypertension.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Methods&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;In this multicentre, prospective, randomised trial, patients who had a baseline systolic blood pressure of 160 mm Hg or more (=150 mm Hg for patients with type 2 diabetes), despite taking three or more antihypertensive drugs, were randomly allocated in a one-to-one ratio to undergo renal denervation with previous treatment or to maintain previous treatment alone (control group) at 24 participating centres. Randomisation was done with sealed envelopes. Data analysers were not masked to treatment assignment. The primary effectiveness endpoint was change in seated office-based measurement of systolic blood pressure at 6 months. Primary analysis included all patients remaining in follow-up at 6 months. This trial is registered with ClinicalTrials.gov, number NCT00888433.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;[&lt;A href="http://clinicaltrials.gov/ct2/show/NCT00888433?term=NCT00888433&amp;amp;rank=1" target="_blank"&gt;Link to Trial - NCT00888433&lt;/A&gt;]&lt;/P&gt;]]&gt;</body>
    <expiryDate>18/11/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>339087</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=339087]]&gt;</url>
    <title>Renal systematic review methodology papers: Systematic reviews and meta-analyses</title>
    <publicationDate>2011-01-17T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Renal systematic review methodology papers: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Henderson, L.K., Craig, J.C., Willis, N.S., Tovey, D., Webster, A. (2010) 'Clinical research for nephrologists: How to write a Cochrane systematic review'. Nephrology. DOI: 10.1111/j.1440-1797.2010.01380.x [&lt;A href="http://onlinelibrary.wiley.com/doi/10.1111/j.1440-1797.2010.01380.x/abstract" target="_blank"&gt;Link to Nephrology abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hodson, E. M. and J. C. Craig (2010). "How to apply results from randomized trials and systematic reviews to individual patient care: Clinical Research for Nephrologists." Nephrology 15(3): 277-280.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20470294" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Iansavichus, A.V., Haynes, R.B., Shariff, S.Z., et al. (2010) "Optimal Search Filters for Renal Information in EMBASE". American Journal of Kidney Diseases. Published online 15 March 2010. [&lt;A href="http://www.ajkd.org/article/PIIS0272638610000041/abstract?rss=yes" target="_blank"&gt;Link to AJKD abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mohan, S. and J. Radhakrishnan (2010). "Do meta-analyses in nephrology change the way we treat patients?" Kidney International 78(11): 1080-7.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20827259" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Palmer, S. C., S. D. Navaneethan, et al. (2010) "How to read a nephrology systematic review." Nephrology 15(2): 158-164. [&lt;A href="http://www3.interscience.wiley.com/journal/123268341/abstract" target="_blank"&gt;Link to abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Shariff, S. Z., M. S. Cuerden, et al. (2010). "Evaluating the impact of MEDLINE filters on evidence retrieval: study protocol." Implementation Science 5. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20646295" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Di Micco, L., C. Manno, et al. (2009). "[The usefulness of Cochrane systematic reviews in nephrology]." G Ital Nefrol 26(1): 38-54. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19255963" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Garg, A. X., A. V. Iansavichus, et al. (2009). "Filtering Medline for a clinical discipline: diagnostic test assessment framework." BMJ 339: b3435.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19767336" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Greene, T. (2009). "Randomized and Observational Studies in Nephrology: How Strong Is the Evidence?" American Journal of Kidney Diseases 53(3): 377-388.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19185399" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Mrkobrada, M., H. Thiessen-Philbrook, et al. (2008). "Need for quality improvement in renal systematic reviews." Clin J Am Soc Nephrol 3(4): 1102-14.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18400967" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;BR&gt;&lt;STRONG&gt;2007-2006&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;No systematic reviews.&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>21/12/2010 10:53:21</lastReviewDate>
    <expiryDate>21/12/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>155713</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.renal.org/unit/index.pl?c=birmingham]]&gt;</url>
    <title>Renal Transplant Unit, Queen Elizabeth Hospital, Birmingham</title>
    <publicationDate></publicationDate>
    <publisher>Renal Association</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ TRANSPLANTATION,TRANSPLANT CENTRES,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Contact details and background information</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Extract from website&lt;/STRONG&gt;&lt;/EM&gt; &lt;/P&gt;
&lt;P&gt;The renal transplant&amp;nbsp;unit has performed over 2,500 renal transplants since 1980 and is currently performing around 110 grafts annually. There is an expanding live donor kidney program projected to implant 35 - 40 kidneys this year and a newly implemented ‘non-heart beating’ transplant donor service.&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:34:45</lastReviewDate>
    <expiryDate>06/07/2011 11:34:45</expiryDate>
  </document>
  <document>
    <id>341851</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=341851]]&gt;</url>
    <title>Renal transplant: Systematic reviews and meta-analyses</title>
    <publicationDate>2011-03-04T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,TRANSPLANTATION,ASSESSMENT/SELECTION,TRANSPLANT OPERATION,UK TRANSPLANT,TRANSPLANT CENTRES,IMMUNOSUPPRESSIVE DRUGS,PREVENTION OF COMPLICATIONS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Renal transplant: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2011&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Alhawsawi AM, Rocca J, Florman S. Should we routinely use ureteric stents in kidney transplant? A meta-analysis of the randomized controlled trialsa. American Journal of Transplantation. 2011;11. [No PubMed abstract available yet]&lt;/LI&gt;
&lt;LI&gt;Su VC, Greanya ED, Ensom MH. Impact of Mycophenolate Mofetil Dose Reduction on Allograft Outcomes in Kidney Transplant Recipients on Tacrolimus-Based Regimens: A Systematic Review. Ann Pharmacother. 2011 Feb 8. [Epub ahead of print] [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/21304036?dopt=Abstract" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Tong, A., M. Howell, et al. (2011). "The perspectives of kidney transplant recipients on medicine taking: a systematic review of qualitative studies." Nephrology Dialysis Transplantation 26(1): 344-54. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20584734" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Wang LW, Fahim MA, Hayen A, Mitchell RL, Lord SW, Baines LA, Craig JC, Webster AC. (2011) "Cardiac Testing for Coronary Artery Disease in Potential Kidney Transplant Recipients: A Systematic Review of Test Accuracy Studies." Am J Kidney Dis. 2011 Jan 21. [Epub ahead of print]&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/21257239?dopt=Abstract" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Wang X, Zhuang J, Xie L, Li M, Lu Y. Isoniazid preventive therapy for postrenal transplant tuberculosis: A systematic review. Reviews in Medical Microbiology. 2011;22(1):5-11.&amp;nbsp;[No abstract available]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Balaban, V. and C. Marano (2010). "Medical tourism research: A systematic review." International Journal of Infectious Diseases 14. [No abstract available yet]&lt;/LI&gt;
&lt;LI&gt;Barry, A., Levine, M. (2010) "A systematic review of the effect of the CYP3A5 genotype on the apparent oral clearance of tacrolimus in renal transplant recipients." Ther Drug Monit. 2010 Dec;32(6):708-14. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20864901?dopt=Abstract" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Brooks, R. J., G. Y. Higgins, et al. (2010). "Systematic review of randomized controlled trial quality in pediatric kidney transplantation." Pediatric Nephrology 25(12): 2383-92. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Systematic%20review%20of%20randomized%20controlled%20trial%20quality%20in%20pediatric%20kidney%20transplantation" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Currie, A. C., S. R. Knight, et al. (2010). "Tuberculosis in renal transplant recipients: the evidence for prophylaxis." Transplantation 90(7): 695-704.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20647975" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Dobbels, F., T. Ruppar, et al. (2010). "Adherence to the immunosuppressive regimen in pediatric kidney transplant recipients: A systematic review." Pediatric Transplantation 14(5): 603-613.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20214741" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Dunn, B. L., A. C. Teusink, et al. (2010). "Management of hypertension in renal transplant patients: a comprehensive review of nonpharmacologic and pharmacologic treatment strategies." Ann Pharmacother 44(7-8): 1259-70. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Management%20of%20hypertension%20in%20renal%20transplant%20patients%3A%20a%20comprehensive%20review%20of%20nonpharmacologic%20and%20pharmacologic%20treatment%20strategies" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Gijsen, V. M., S. N. De Wildt, et al. (2010). "Tacrolimus-induced nephrotoxicity and genetic variability: A systematic review." Clinical Pharmacology and Therapeutics 87. [No PubMed abstract available]&lt;/LI&gt;
&lt;LI&gt;Greco, F., M. R. Hoda, et al. (2010). "Laparoscopic living-donor nephrectomy: analysis of the existing literature." European Urology 58(4): 498-509.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20417024" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Han, S. S., H. K. Sun, et al. (2010). "Outcome of renal allograft in patients with henoch-schonlein nephritis: Single-center experience and systematic review." Transplantation 89(6): 721-726.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20010329" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Johnston, O., D. Jaswal, et al. "Treatment of Polyomavirus Infection in Kidney Transplant Recipients: A Systematic Review." Transplantation. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20090569" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Karamchandani, D., R. Arias-Amaya, et al. "Thyroid cancer and renal transplantation: A meta-analysis." Endocrine-Related Cancer 17(1): 159-167. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=cancer%20and%20renal%20transplantation%3A%20A%20meta-analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kasiske, B. L., M. G. Zeier, et al. "KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary." Kidney International 77(4): 299-312. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19847156" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Knight, S. R. and P. J. Morris "Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk. A meta-analysis." Transplantation 89(1): 1-14. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20061913" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Landin, L., Rodriguez-Perez, J.C., Garcia-Bello, M.A., et al. "Kidney transplants in HIV-positive recipients under HAART. A comprehensive review and meta-analysis of 12 series." Nephrol Dial Transplant. 2010 Mar 11 (Epub ahead of print) [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20228071" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Landreneau, K., K. Lee, et al. (2010). "Quality of life in patients undergoing hemodialysis and renal transplantation--a meta-analytic review." Nephrology Nursing Journal: Journal of the American Nephrology Nurses' Association 37(1): 37-44. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Quality%20of%20life%20in%20patients%20undergoing%20hemodialysis%20and%20renal%20transplantation--a%20meta-analytic%20review" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Liu, Y., P. Zhou, et al. (2010). "Basiliximab or Antithymocyte Globulin for Induction Therapy in Kidney Transplantation: A Meta-analysis." Transplantation Proceedings 42(5): 1667-1670. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20620496" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Louis, W., M. Petra, et al. (2010). "Detection of coronary artery disease in potential kidney transplant recipients: A systematic review of diagnostic test accuracy." Immunology and Cell Biology 88(6): A36-A37.&amp;nbsp;[No PubMed abstract available]&lt;/LI&gt;
&lt;LI&gt;Maharjan, N., U. Bedi, et al. (2010). "Impact of Statins on Cardiovascular Outcomes in Renal Transplant Recipients: A Systematic Review." Am J Ther. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Impact%20of%20Statins%20on%20Cardiovascular%20Outcomes%20in%20Renal%20Transplant%20Recipients%3A%20A%20Systematic%20Review" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Ontario Health Technology Advisory Committee (2010). "Kidney and liver organ transplantation in persons with human immunodeficiency virus: An evidence-based analysis." Ontario Health Technology Assessment Series 10(4). [&lt;A href="http://www.health.gov.on.ca/english/providers/program/ohtac/tech/recommend/rec_organ_transplant_20100322.pdf" target="_blank"&gt;Link to full-text PDF&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Pascual, J., C. Galeano, et al. (2010). "A systematic review on steroid withdrawal between 3 and 6 months after kidney transplantation." Transplantation 90(4): 343-349.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20574419" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Sandroni, C., C. Adrie, et al. (2010). "Are patients brain-dead after successful resuscitation from cardiac arrest suitable as organ donors? A systematic review." Resuscitation. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Are%20patients%20brain-dead%20after%20successful%20resuscitation%20from%20cardiac%20arrest%20suitable%20as%20organ%20donors%3F%20A%20systematic%20review" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Tang, H. L., L. L. Ma, et al. (2010). "Effects of the CYP3A5*3 variant on cyclosporine exposure and acute rejection rate in renal transplant patients: a meta-analysis." Pharmacogenetics &amp;amp; Genomics 20(9): 525-31. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Effects%20of%20the%20CYP3A5*3%20variant%20on%20cyclosporine%20exposure%20and%20acute%20rejection%20rate%20in%20renal%20transplant%20patients%3A%20a%20meta-analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Tong, A., K. Howard, et al. "Community Preferences for the Allocation of Solid Organs for Transplantation: A Systematic Review." Transplantation. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20090570" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Webster, A. C., L. P. Ruster, et al. "Interleukin 2 receptor antagonists for kidney transplant recipients." Cochrane Database Syst Rev(1): CD003897. [&lt;A href="nelh:238439:0" name=internalLink&gt;Link to Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;White, C.A., Siegal, D.,&amp;nbsp;Akbari, A., Knoll, G.A.&amp;nbsp;"Use of Kidney Function End Points in Kidney Transplant Trials: A Systematic Review." American Journal of Kidney Disease. Published online&amp;nbsp; 01 November 2010. [&lt;A href="http://www.ajkd.org/article/PIIS0272638610012643/abstract?rss=yes" target="_blank"&gt;Link to abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Wu, B., F. B. Wu, et al. (2010). "Effectiveness and safety of calcineurin inhibitor withdrawal from target-of-rapamycin-inhibitor-based immunosuppression in kidney transplantation: A meta analysis." Chinese Journal of Evidence-Based Medicine 10(1): 33-39. [No PubMed abstract available]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Birnbaum, L. M., M. Lipman, et al. (2009). "Management of chronic allograft nephropathy: a systematic review." Clin J Am Soc Nephrol 4(4): 860-5. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Management%20of%20chronic%20allograft%20nephropathy%3A%20a%20systematic%20review" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Bond, M., M. Pitt, et al. (2009). "The effectiveness and cost-effectiveness of methods of storing donated kidneys from deceased donors: a systematic review and economic model." Health Technol Assess 13(38): iii-iv, xi-xiv, 1-156.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=The%20effectiveness%20and%20cost-effectiveness%20of%20methods%20of%20storing%20donated%20kidneys%20from%20deceased%20donors%3A%20a%20systematic%20review%20and%20economic%20model" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Bruchet, N. K. and M. H. Ensom (2009). "Limited sampling strategies for mycophenolic acid in solid organ transplantation: a systematic review." Expert Opin Drug Metab Toxicol 5(9): 1079-97.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Limited%20sampling%20strategies%20for%20mycophenolic%20acid%20in%20solid%20organ%20transplantation%3A%20a%20systematic%20review" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Cross, N. B., A. C. Webster, et al. (2009). "Antihypertensive treatment for kidney transplant recipients." Cochrane Database of Systematic Reviews(3): CD003598-NaN.&amp;nbsp;[&lt;A href="nelh:320739:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Cross, N. B., A. C. Webster, et al. (2009). "Antihypertensives for kidney transplant recipients: Systematic review and meta-analysis of randomized controlled trials." Transplantation 88(1): 7-18.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Antihypertensives%20for%20kidney%20transplant%20recipients%3A%20Systematic%20review%20and%20meta-analysis%20of%20randomized%20controlled%20trials" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;De Bleser, L., M. Matteson, et al. (2009). "Interventions to improve medication-adherence after transplantation: a systematic review." Transpl Int.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Interventions%20to%20improve%20medication-adherence%20after%20transplantation%3A%20a%20systematic%20review" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Dew, M. A., A. D. Dabbs, et al. (2009). "Meta-analysis of medical regimen adherence outcomes in pediatric solid organ transplantation." Transplantation 88(5): 736-46.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Meta-analysis%20of%20medical%20regimen%20adherence%20outcomes%20in%20pediatric%20solid%20organ%20transplantation" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Fry, K., A. Patwardhan, et al. (2009). "Development of evidence-based guidelines for the nutritional management of adult kidney transplant recipients." J Ren Nutr 19(1): 101-4.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Development%20of%20evidence-based%20guidelines%20for%20the%20nutritional%20management%20of%20adult%20kidney%20transplant%20recipients" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Knight, S. R., N. K. Russell, et al. (2009). "Mycophenolate mofetil decreases acute rejection and may improve graft survival in renal transplant recipients when compared with azathioprine: a systematic review." Transplantation 87(6): 785-94.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Mycophenolate%20mofetil%20decreases%20acute%20rejection%20and%20may%20improve%20graft%20survival%20in%20renal%20transplant%20recipients%20when%20compared%20with%20azathioprine%3A%20a%20systematic%20review" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Macdonald, J. H., D. Kirkman, et al. (2009). "Kidney transplantation: a systematic review of interventional and observational studies of physical activity on intermediate outcomes." Adv Chronic Kidney Dis 16(6): 482-500.&amp;nbsp;[&lt;A href="nelh:360817:0" name=internalLink&gt;Link to&amp;nbsp;DARE abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Moore, J., L. Middleton, et al. (2009). "Calcineurin inhibitor sparing with mycophenolate in kidney transplantation: a systematic review and meta-analysis." Transplantation 87(4): 591-605.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Calcineurin%20inhibitor%20sparing%20with%20mycophenolate%20in%20kidney%20transplantation%3A%20a%20systematic%20review%20and%20meta-analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Navaneethan, S. D., V. Perkovic, et al. (2009). "HMG CoA reductase inhibitors (statins) for kidney transplant recipients." Cochrane Database Syst Rev(2): CD005019.&amp;nbsp;[&lt;A href="nelh:312179:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Pascual, J., J. Zamora, et al. (2009). "Steroid avoidance or withdrawal for kidney transplant recipients." Cochrane Database Syst Rev(1): CD005632.&amp;nbsp;[&lt;A href="nelh:304902:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Rithalia, A., C. McDaid, et al. (2009). "A systematic review of presumed consent systems for deceased organ donation." Health Technol Assess 13(26): iii, ix-xi, 1-95.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=A%20systematic%20review%20of%20presumed%20consent%20systems%20for%20deceased%20organ%20donation" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Rithalia, A., C. McDaid, et al. (2009). "A systematic review of presumed consent systems for deceased organ donation." Health Technol Assess 13(26): iii, ix-xi, 1-95.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=A%20systematic%20review%20of%20presumed%20consent%20systems%20for%20deceased%20organ%20donation" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Shou, Z. F., Q. Zhou, et al. (2009). "Efficacy and safety of induction therapy with alemtuzumab in kidney transplantation: a meta-analysis." Chin Med J (Engl) 122(14): 1692-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Efficacy%20and%20safety%20of%20induction%20therapy%20with%20alemtuzumab%20in%20kidney%20transplantation%3A%20a%20meta-analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Shou, Z. F., Q. Zhou, et al. (2009). "Efficacy and safety of induction therapy with alemtuzumab in kidney transplantation: a meta-analysis." Chin Med J (Engl) 122(14): 1692-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Efficacy%20and%20safety%20of%20induction%20therapy%20with%20alemtuzumab%20in%20kidney%20transplantation%3A%20a%20meta-analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Tian, J. H., X. Wang, et al. (2009). "Induction with and without antithymocyte globulin combined with cyclosporine/tacrolimus-based immunosuppression in renal transplantation: a meta-analysis of randomized controlled trials." Transplant Proc 41(9): 3671-6.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Induction%20with%20and%20without%20antithymocyte%20globulin%20combined%20with%20cyclosporine%2Ftacrolimus-based%20immunosuppression%20in%20renal%20transplantation%3A%20a%20meta-analysis%20of%20randomized%20controlled%20trials" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Tong, A., R. Morton, et al. (2009). "Adolescent Experiences Following Organ Transplantation: A Systematic Review of Qualitative Studies." J Pediatr.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Adolescent%20Experiences%20Following%20Organ%20Transplantation%3A%20A%20Systematic%20Review%20of%20Qualitative%20Studies" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Wu, O., A. R. Levy, et al. (2009). "Acute rejection and chronic nephropathy: a systematic review of the literature." Transplantation 87(9): 1330-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Acute%20rejection%20and%20chronic%20nephropathy%3A%20a%20systematic%20review%20of%20the%20literature" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Yarlagadda, S. G., S. G. Coca, et al. (2009). "Association between delayed graft function and allograft and patient survival: a systematic review and meta-analysis." Nephrol Dial Transplant 24(3): 1039-47.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Association%20between%20delayed%20graft%20function%20and%20allograft%20and%20patient%20survival%3A%20a%20systematic%20review%20and%20meta-analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Butt, Z., S. E. Yount, et al. (2008). "Quality of life assessment in renal transplant: review and future directions." Clin Transplant 22(3): 292-303.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Quality%20of%20life%20assessment%20in%20renal%20transplant%3A%20review%20and%20future%20directions" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Dew, M. A., A. F. DiMartini, et al. (2008). "Meta-analysis of risk for relapse to substance use after transplantation of the liver or other solid organs." Liver Transpl 14(2): 159-72.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18236389" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Fabrizi, F., P. Messa, et al. (2008). "Hepatitis C virus infection and post-transplant diabetes mellitus among renal transplant patients: a meta-analysis." Int J Artif Organs 31(8): 675-82.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Hepatitis%20C%20virus%20infection%20and%20post-transplant%20diabetes%20mellitus%20among%20renal%20transplant%20patients%3A%20a%20meta-analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Jennings, D. L. and D. J. Taber (2008). "Use of renin-angiotensin-aldosterone system inhibitors within the first eight to twelve weeks after renal transplantation." Ann Pharmacother 42(1): 116-20.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Use%20of%20renin-angiotensin-aldosterone%20system%20inhibitors%20within%20the%20first%20eight%20to%20twelve%20weeks%20after%20renal%20transplantation" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Liem, Y. S., J. L. Bosch, et al. (2008). "Preference-based quality of life of patients on renal replacement therapy: a systematic review and meta-analysis." Value Health 11(4): 733-41.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Preference-based%20quality%20of%20life%20of%20patients%20on%20renal%20replacement%20therapy%3A%20a%20systematic%20review%20and%20meta-analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Nanidis, T. G., D. Antcliffe, et al. (2008). "Laparoscopic versus open live donor nephrectomy in renal transplantation: a meta-analysis." Ann Surg 247(1): 58-70.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18156924" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Nigwekar, S. U., M. Wolf, et al. (2008). "Calciphylaxis from nonuremic causes: a systematic review." Clin J Am Soc Nephrol 3(4): 1139-43.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Calciphylaxis%20from%20nonuremic%20causes%3A%20a%20systematic%20review" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Nowack, R. (2008). "Review article: cytochrome P450 enzyme, and transport protein mediated herb-drug interactions in renal transplant patients: grapefruit juice, St John's Wort - and beyond!" Nephrology (Carlton) 13(4): 337-47.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Review%20article%3A%20cytochrome%20P450%20enzyme%2C%20and%20transport%20protein%20mediated%20herb-drug%20interactions%20in%20renal%20transplant%20patients%3A%20grapefruit%20juice%2C%20St%20John%27s%20Wort%20-%20and%20beyond!" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Oremus, M., J. Zeidler, et al. (2008). "Utility of monitoring mycophenolic acid in solid organ transplant patients." Evid Rep Technol Assess (Full Rep)(164): 1-131.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Utility%20of%20monitoring%20mycophenolic%20acid%20in%20solid%20organ%20transplant%20patients" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Pascual, J., J. Zamora, et al. (2008). "A systematic review of kidney transplantation from expanded criteria donors." Am J Kidney Dis 52(3): 553-86. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=A%20systematic%20review%20of%20kidney%20transplantation%20from%20expanded%20criteria%20donors" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Sajjad, I., L. S. Baines, et al. (2008). "Commercialization of kidney transplants: a systematic review of outcomes in recipients and donors." Am J Nephrol 28(5): 744-54. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Commercialization%20of%20kidney%20transplants%3A%20a%20systematic%20review%20of%20outcomes%20in%20recipients%20and%20donors" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Thakkinstian, A., S. Dmitrienko, et al. (2008). "Association between cytokine gene polymorphisms and outcomes in renal transplantation: a meta-analysis of individual patient data." Nephrol Dial Transplant 23(9): 3017-23.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Association%20between%20cytokine%20gene%20polymorphisms%20and%20outcomes%20in%20renal%20transplantation%3A%20a%20meta-analysis%20of%20individual%20patient%20data" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;White, C. A., D. Huang, et al. (2008). "Performance of creatinine-based estimates of GFR in kidney transplant recipients: a systematic review." Am J Kidney Dis 51(6): 1005-15.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Performance%20of%20creatinine-based%20estimates%20of%20GFR%20in%20kidney%20transplant%20recipients%3A%20a%20systematic%20review" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Yarlagadda, S. G., S. G. Coca, et al. (2008). "Marked variation in the definition and diagnosis of delayed graft function: a systematic review." Nephrol Dial Transplant 23(9): 2995-3003.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Marked%20variation%20in%20the%20definition%20and%20diagnosis%20of%20delayed%20graft%20function%3A%20a%20systematic%20review" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Hiremath, S., D. Fergusson, et al. (2007). "Renin angiotensin system blockade in kidney transplantation: a systematic review of the evidence." Am J Transplant 7(10): 2350-60.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Renin%20angiotensin%20system%20blockade%20in%20kidney%20transplantation%3A%20a%20systematic%20review%20of%20the%20evidence" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Knight, S. R. and P. J. Morris (2007). "The clinical benefits of cyclosporine C2-level monitoring: a systematic review." Transplantation 83(12): 1525-35.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=The%20clinical%20benefits%20of%20cyclosporine%20C2-level%20monitoring%3A%20a%20systematic%20review" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kokkinos, C., D. Antcliffe, et al. (2007). "Outcome of kidney transplantation from nonheart-beating versus heart-beating cadaveric donors." Transplantation 83(9): 1193-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17496535" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Liem, Y. S., J. L. Bosch, et al. (2007). "Quality of life assessed with the Medical Outcomes Study Short Form 36-Item Health Survey of patients on renal replacement therapy: a systematic review and meta-analysis." Value Health 10(5): 390-7.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Quality%20of%20life%20assessed%20with%20the%20Medical%20Outcomes%20Study%20Short%20Form%2036-Item%20Health%20Survey%20of%20patients%20on%20renal%20replacement%20therapy%3A%20a%20systematic%20review%20and%20meta-analysis" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lim, A. K., K. J. Manley, et al. (2007). "Fish oil for kidney transplant recipients." Cochrane Database Syst Rev(2): CD005282.&amp;nbsp;[&lt;A href="nelh:259985:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lim, A. K., K. J. Manley, et al. (2007). "Fish oil treatment for kidney transplant recipients: a meta-analysis of randomized controlled trials." Transplantation 83(7): 831-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Fish%20oil%20treatment%20for%20kidney%20transplant%20recipients%3A%20a%20meta-analysis%20of%20randomized%20controlled%20trials" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Miners, A. H., G. Yao, et al. (2007). "Economic evaluations of calcineurin inhibitors in renal transplantation: a literature review." Pharmacoeconomics 25(11): 935-47.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Economic%20evaluations%20of%20calcineurin%20inhibitors%20in%20renal%20transplantation%3A%20a%20literature%20review" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Palmer, S. C., D. O. McGregor, et al. (2007). "Interventions for preventing bone disease in kidney transplant recipients." Cochrane Database Syst Rev(3): CD005015.&amp;nbsp;[&lt;A href="nelh:239029:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Shilliday, I. R. and M. Sherif (2007). "Calcium channel blockers for preventing acute tubular necrosis in kidney transplant recipients." Cochrane Database Syst Rev(4): CD003421.&amp;nbsp;[&lt;A href="nelh:238116:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Shokeir, A. A. (2007). "Open versus laparoscopic live donor nephrectomy: a focus on the safety of donors and the need for a donor registry." J Urol 178(5): 1860-6.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Open%20versus%20laparoscopic%20live%20donor%20nephrectomy%3A%20a%20focus%20on%20the%20safety%20of%20donors%20and%20the%20need%20for%20a%20donor%20registry" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Tsilimparis, N., P. Alevizakos, et al. (2007). "[Endovascular therapy of an abdominal aortic aneurysm in a renal transplant recipient]." Zentralbl Chir 132(3): 220-5; discussion 225-6.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Endovascular%20therapy%20of%20an%20abdominal%20aortic%20aneurysm%20in%20a%20renal%20transplant%20recipient" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2006&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Fabrizi, F., G. Lunghi, et al. (2006). "Meta-analysis: anti-viral therapy of hepatitis C virus-related liver disease in renal transplant patients." Aliment Pharmacol Ther 24(10): 1413-22.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Meta-analysis%3A%20anti-viral%20therapy%20of%20hepatitis%20C%20virus-related%20liver%20disease%20in%20renal%20transplant%20patients" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Johnston, A., X. He, et al. (2006). "Bioequivalence of enteric-coated mycophenolate sodium and mycophenolate mofetil: a meta-analysis of three studies in stable renal transplant recipients." Transplantation 82(11): 1413-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Bioequivalence%20of%20enteric-coated%20mycophenolate%20sodium%20and%20mycophenolate%20mofetil%3A%20a%20meta-analysis%20of%20three%20studies%20in%20stable%20renal%20transplant%20recipients" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kaplan, B. (2006). "Mycophenolic acid trough level monitoring in solid organ transplant recipients treated with mycophenolate mofetil: association with clinical outcome." Curr Med Res Opin 22(12): 2355-64.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Mycophenolic%20acid%20trough%20level%20monitoring%20in%20solid%20organ%20transplant%20recipients%20treated%20with%20mycophenolate%20mofetil%3A%20association%20with%20clinical%20outcome" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mitterbauer, C., C. Schwarz, et al. (2006). "Effects of bisphosphonates on bone loss in the first year after renal transplantation--a meta-analysis of randomized controlled trials." Nephrol Dial Transplant 21(8): 2275-81.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Effects%20of%20bisphosphonates%20on%20bone%20loss%20in%20the%20first%20year%20after%20renal%20transplantation--a%20meta-analysis%20of%20randomized%20controlled%20trials" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mulay, A. V., S. Cockfield, et al. (2006). "Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: a systematic review of the evidence." Transplantation 82(9): 1153-62.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Conversion%20from%20calcineurin%20inhibitors%20to%20sirolimus%20for%20chronic%20renal%20allograft%20dysfunction%3A%20a%20systematic%20review%20of%20the%20evidence" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Navaneethan, S. D. and S. Singh (2006). "A systematic review of barriers in access to renal transplantation among African Americans in the United States." Clin Transplant 20(6): 769-75.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=A%20systematic%20review%20of%20barriers%20in%20access%20to%20renal%20transplantation%20among%20African%20Americans%20in%20the%20United%20States" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;van der Mei, S. F., B. Krol, et al. (2006). "Social participation and employment status after kidney transplantation: a systematic review." Qual Life Res 15(6): 979-94.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Social%20participation%20and%20employment%20status%20after%20kidney%20transplantation%3A%20a%20systematic%20review" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Yao, G., E. Albon, et al. (2006). "A systematic review and economic model of the clinical and cost-effectiveness of immunosuppressive therapy for renal transplantation in children." Health Technol Assess 10(49): iii-iv, ix-xi, 1-157.&amp;nbsp;[&lt;A href="nelh:258568:0" name=internalLink&gt;Link to abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>17/02/2011 10:29:43</lastReviewDate>
    <expiryDate>17/02/2012 00:00:00</expiryDate>
  </document>
  <document>
    <id>182121</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://renux.dmed.ed.ac.uk/EdREN/Handbookbits/TPHdbkbits/appendices/TPhdbkappendix8.pdf]]&gt;</url>
    <title>Renal transplantation: the operation</title>
    <publicationDate>2007-01-23T00:00:00</publicationDate>
    <publisher>EdRen Handbook</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ TRANSPLANTATION,TRANSPLANT OPERATION,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Abbreviated medical protocols from EdRen, the website of the Royal Infirmary of Edinburgh, Renal Unit</description>
    <body>&lt;![CDATA[ Protocols covering anaesthetic protocol, pre-op assessment, anaesthetic room, theatre, return to the Unit, and preimplantation allograft biopsy]]&gt;</body>
    <lastReviewDate>06/07/2010 11:34:54</lastReviewDate>
    <expiryDate>06/07/2011 11:34:54</expiryDate>
  </document>
  <document>
    <id>155736</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.renal.org/unit/index.pl?c=glaswestern]]&gt;</url>
    <title>Renal Unit, Glasgow Western Infirmary</title>
    <publicationDate>2009-10-20T00:00:00</publicationDate>
    <publisher>Renal Association</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ TRANSPLANTATION,TRANSPLANT CENTRES,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Contact details and background information</description>
    <body>&lt;![CDATA[ &lt;P&gt;Extract from website &lt;/P&gt;
&lt;P&gt;The unit is part of the NHS Greater Glasgow, Argyll and Forth Valley Renal Unit and provides renal services for west and south Glasgow, Argyll &amp;amp; Clyde and North Ayrshire The unit is integrated with the Glasgow Royal Infirmary Renal Unit. Renal transplant services are also provided for the West of Scotland (population approx 2.5 million). &lt;/P&gt;]]&gt;</body>
    <expiryDate>01/09/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>341905</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=341905]]&gt;</url>
    <title>Renovascular disease: Systematic reviews and meta-analyses</title>
    <publicationDate>2011-01-17T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,RENOVASCULAR DISEASES,IN CHILDREN,IN ADULTS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Renovascular disease: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Assimon, M. M., S. Mousa, et al. (2010). "The effect of sevelamer hydrochloride and calcium-based phosphate binders on mortality in hemodialysis patients: a need for more research." Consultant Pharmacist 25(1): 41-54. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=The%20effect%20of%20sevelamer%20hydrochloride%20and%20calcium-based%20phosphate%20binders%20on%20mortality%20in%20hemodialysis%20patients%3A%20a%20need%20for%20more%20research" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Bergqvist, D., Bj, et al. (2010). "Enteric fistulation after renal artery reconstruction: a systematic literature review." World Journal of Surgery 34(10): 2305-7. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Enteric%20fistulation%20after%20renal%20artery%20reconstruction%3A%20a%20systematic%20literature%20review" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Cardinal, H. and F. Madore "[Are cardioprotective drugs underused after a myocardial infarction in patients who suffer from chronic kidney disease?]. [French] La pharmacopee de prevention cardiovasculaire est-elle sous-utilisee chez les patients souffrant d'insuffisance renale chronique apres un infarctus du myocarde ?" Nephrologie et Therapeutique 6(3): 162-70.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Are%20cardioprotective%20drugs%20underused%20after%20a%20myocardial%20infarction%20in%20patients%20who%20suffer%20from%20chronic%20kidney%20disease%3F" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;El-Menyar, A. A., J. Al Suwaidi, et al. (2010) "Use of drug-eluting stents in patients with coronary artery disease and renal insufficiency." Mayo Clinic Proceedings 85(2): 165-71. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20118392" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lee, M., J. L. Saver, et al. (2010). "Impact of microalbuminuria on incident stroke: a meta-analysis." Stroke 41(11): 2625-31.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20930164" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lee, M., J. L. Saver, et al. (2010). "Low glomerular filtration rate and risk of stroke: meta-analysis." BMJ 341:c4249.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20884696" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Saba, L., R. Sanfilippo, et al. (2010). "A Meta-analysis of the literature about renal artery stenosis evaluation by using magnetic resonance." Journal of Hypertension 28.&amp;nbsp;[No PubMed abstract available]&lt;/LI&gt;
&lt;LI&gt;Steichen, O., L. Amar, et al. "Primary stenting for atherosclerotic renal artery stenosis." Journal of Vascular Surgery 51(6): 1574-1580.e1.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20488331" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Symonides, B. and Z. Gaciong (2010). "The effect of percutaneous revascularisation of atherosclerotic renal artery stenosis on blood pressure. meta-analysis of randomised trials." Journal of Hypertension 28. [No PubMed abstract available]&lt;/LI&gt;
&lt;LI&gt;Tai, D. J., T. W. Lim, et al. "Cardiovascular Effects of Angiotensin Converting Enzyme Inhibition or Angiotensin Receptor Blockade in Hemodialysis: A Meta-Analysis." Clin J Am Soc Nephrol.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20133488" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Trinquart, L., Mounier-Vehier, C., Sapoval, M., Ganon, N., Plouin, P.F. (2010) "Efficacy of Revascularization for Renal Artery Stenosis Caused by Fibromuscular Dysplasia. A Systematic Review and Meta-Analysis". Hypertension 2010 Jul&amp;nbsp; 12 [Epub ahead of print] [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20625080" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Walters, G. D., N. S. Willis, et al. (2010). "Interventions for renal vasculitis in adults. A systematic review." BMC Nephrology 11.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Interventions%20for%20renal%20vasculitis%20in%20adults.%20A%20systematic%20review" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Abela, R., S. Ivanova, et al. (2009). "An analysis comparing open surgical and endovascular treatment of atherosclerotic renal artery stenosis." Eur J Vasc Endovasc Surg 38(6): 666-75. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19726208" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;de Mast, Q. and J. J. Beutler (2009). "The prevalence of atherosclerotic renal artery stenosis in risk groups: a systematic literature review." J Hypertens 27(7): 1333-40.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19365285" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lambers Heerspink, H. J., V. Perkovic, et al. (2009). "Renal and cardio-protective effects of direct renin inhibition: a systematic literature review." J Hypertens 27(12): 2321-31.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19727007" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Paraskevas, K. I., A. D. Giannoukas, et al. (2009). "Renal function impairment in peripheral arterial disease: an important parameter that should not be neglected." Ann Vasc Surg 23(5): 690-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19747617" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Murad, M. H., A. N. Sidawy, et al. (2008). "Timing of referral for vascular access placement: a systematic review." J Vasc Surg 48(5 Suppl): 31S-3S.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19000591" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Williams, G. J., P. Macaskill, et al. (2007). "Comparative accuracy of renal duplex sonographic parameters in the diagnosis of renal artery stenosis: paired and unpaired analysis." AJR Am J Roentgenol 188(3): 798-811.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17312071" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2006&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Balk, E., G. Raman, et al. (2006). "Effectiveness of management strategies for renal artery stenosis: a systematic review." Ann Intern Med 145(12): 901-12.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17062633" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Charytan, D. and R. E. Kuntz (2006). "The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease." Kidney Int 70(11): 2021-30.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17051142" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Coca, S. G., H. M. Krumholz, et al. (2006). "Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease." JAMA 296(11): 1377-84.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16985230" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Douglas, K., P. G. O'Malley, et al. (2006). "Meta-analysis: the effect of statins on albuminuria." Ann Intern Med 145(2): 117-24.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16847294" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kashani, A., C. O. Phillips, et al. (2006). "Risks associated with statin therapy: a systematic overview of randomized clinical trials." Circulation 114(25): 2788-97.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17159064" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>11/01/2011 10:22:27</lastReviewDate>
    <expiryDate>11/01/2012 00:00:00</expiryDate>
  </document>
  <document>
    <id>284648</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.thelancet.com/journals/lancet/article/PIIS0140673608606261/abstract]]&gt;</url>
    <title>Renovascular hypertension in children</title>
    <publicationDate>2008-04-26T00:00:00</publicationDate>
    <publisher>Lancet 2008; 371: 1453-1463</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ RENOVASCULAR DISEASES,IN CHILDREN,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Seminar from Lancet</description>
    <body>&lt;![CDATA[ &lt;P&gt;Extract from National Library for Medicines &lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.nelm.nhs.uk/Record%20Viewing/vR.aspx?id=592507" target="_blank"&gt;http://www.nelm.nhs.uk/Record%20Viewing/vR.aspx?id=592507&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;In this Seminar, the authors review current knowledge of renovascular disease in children, an uncommon but important cause of childhood hypertension. The following topics are covered:&lt;BR&gt;&lt;BR&gt;• Prevalence&lt;BR&gt;• Causes of renovascular hypertension&lt;BR&gt;• Clinical spectrum&lt;BR&gt;• Diagnosis and when should renovascular hypertension be suspected?&lt;BR&gt;• Investigations, imaging and invasive tests&lt;BR&gt;• Treatment&lt;BR&gt;• Endovascular intervention&lt;BR&gt;• Surgical procedures&lt;BR&gt;• Outcome&lt;BR&gt;&lt;BR&gt;The article provides a suggested treatment pathway for renovascular hypertension; all children should be treated with antihypertensive drugs as they generally present with very high blood pressure, of which slow reduction is important. Drugs affecting the renin-angiotensin axis are generally contraindicated, as they cause dilation of the glomerular efferent arteriole, and thus reduce the glomerular filtration pressure. Treatment typically includes a calcium-channel blocker, a beta blocker, or both.&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>01/07/2010 14:29:06</lastReviewDate>
    <expiryDate>01/07/2011 14:29:06</expiryDate>
  </document>
  <document>
    <id>267787</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.guideline.gov/summary/summary.aspx?doc_id=6577&amp;nbr=4137&amp;ss=6&amp;xl=999]]&gt;</url>
    <title>Report on the management of staghorn calculi</title>
    <publicationDate></publicationDate>
    <publisher>American Urological Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ KIDNEY AND BLADDER STONES,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Clinical guideline from American Urological Association</description>
    <body>&lt;![CDATA[ &lt;P&gt;Guideline covers diagnosis and treatment recommendations, and detailed analyses of alternative treatments for patients with staghorn calculi.&lt;/P&gt;
&lt;P&gt;Published in 2005&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>24/09/2010 11:20:32</lastReviewDate>
    <expiryDate>24/09/2011 11:20:32</expiryDate>
  </document>
  <document>
    <id>155616</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.hdcn.com/symp/05asn/07/05asn07.htm]]&gt;</url>
    <title>Resistant hypertension: reducing cardiovascular events</title>
    <publicationDate>2005-11-01T00:00:00</publicationDate>
    <publisher>Hypertension, Dialysis and Nephrology (HDCN)</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASE,COMPLICATIONS OF KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Source of free CPD material for doctors, nurses and other medical professionals</description>
    <body>&lt;![CDATA[ &lt;P&gt;The CPD resource comprises talks and slide presentations, for which some additional software (such as macromedia flash player) may be needed for access.&lt;/P&gt;
&lt;P&gt;Note : You need to register for a freezone&amp;nbsp;loginID and password to access the free resources&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;'Method of participation:&lt;/B&gt; Listen to the talk, read the PubMed abstracts linked to data slides and talk references, take the post-test, read the abstracts linked to post-test answer feedback material' (website extract)&lt;/P&gt;
&lt;P&gt;Click on&amp;nbsp;Free Zone Index to view the other free resources at a glance.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:34:58</lastReviewDate>
    <expiryDate>06/07/2011 11:34:58</expiryDate>
  </document>
  <document>
    <id>325518</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.renal.org/pages/media/TsarFiles/RenalDialysisReport_Essex_ScrutinyCommittee_June09.pdf]]&gt;</url>
    <title>Review of the Dialysis Services for the residents of Essex: a review by the Health Overview and Scrutiny Committee</title>
    <publicationDate>2009-06-30T00:00:00</publicationDate>
    <publisher>Renal Association</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ ACCESS,STARTING PERITONEAL DIALYSIS,STARTING HAEMODIALYSIS,PREVENTION OF INFECTIONS,PERITONEAL DIALYSIS,ACCESS,HAEMODIALYSIS,CHILDREN AND ADOLESCENTS ON HAEMODIALYSIS,LIVING WITH DIALYSIS,PREVENTION OF INFECTIONS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,HOME DIALYSIS,HOME HAEMODIALYSIS,DIALYSIS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Better quality of life is the goal of Essex County Council. Its Health Overview and Scrutiny Committee is determined to ensure that includes people with kidney disease. Scrutiny’s hard hitting report on dialysis services in Essex lays out an ambitious agenda for improvement and identifies some key areas where action is needed – home haemodialysis, transport and parking, dialysis away from home and the importance of social care.]]&gt;</body>
    <lastReviewDate>23/09/2010 10:04:51</lastReviewDate>
    <expiryDate>23/09/2011 10:04:51</expiryDate>
  </document>
  <document>
    <id>295169</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.nelm.nhs.uk/en/NeLM-Area/News/2008---October/01/Review-drug-induced-nephrotoxicity-and-how-to-reduce-it/]]&gt;</url>
    <title>Review: drug-induced nephrotoxicity and how to reduce it</title>
    <publicationDate>2008-10-01T00:00:00</publicationDate>
    <publisher>American Family Physician</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ DRUG-INDUCED RENAL PROBLEMS,CAUSES AND RISK FACTORS,OTHER CONDITIONS - ADULTS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,ACUTE KIDNEY INJURY,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Summary produced by National Electronic Library for Medicines</description>
    <body>&lt;![CDATA[ &lt;P&gt;Extract&lt;/P&gt;
&lt;P&gt;Drug-induced nephrotoxicity is a fairly common source of acute kidney injury, according to a review in American Family Physician, however there are predictable high-risk clinical situations, and various straightforward measures that can be taken to reduce the risk. &lt;/P&gt;
&lt;P&gt;According to the author, drugs are responsible for about 20% of episodes of acute renal injury, increasing in older people: the review aims to summarise the main mechanisms involved, and recommend preventive strategies&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
    <expiryDate>01/12/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>224331</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.bmj.com/cgi/content/full/333/7574/896]]&gt;</url>
    <title>Review: Monitoring renal function in hypertension</title>
    <publicationDate>2006-10-27T00:00:00</publicationDate>
    <publisher>BMJ 2006; 333: 896-899</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASE,COMPLICATIONS OF KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The sixth article in the BMJ series ‘Cases in primary care laboratory medicine’ looks at the monitoring of renal function in hypertension.
</description>
    <body>&lt;![CDATA[ Provides guidance on how often&amp;nbsp;renal function should be measured in hypertensive patients on ACE inhibitors, angiotensin receptor blockers or potassium sparing diuretics and when to consider seeking further advice. It advises that the concomitant use of potassium sparing diuretics and angiotensin inhibitors should normally be reserved for clinicians experienced in their use along with increased monitoring.]]&gt;</body>
    <lastReviewDate>13/12/2010 11:40:58</lastReviewDate>
    <expiryDate>13/12/2011 11:40:58</expiryDate>
  </document>
  <document>
    <id>182520</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.ndt-educational.org/mallamaciebpgquiz.asp]]&gt;</url>
    <title>Revised EBPG Anaemia Part III</title>
    <publicationDate></publicationDate>
    <publisher>NDT</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ ANAEMIA,COMPLICATIONS OF KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>NDT-Educational Quiz</description>
    <body>&lt;![CDATA[ An MCQ quiz on the revised EBPG Anaemia Part III]]&gt;</body>
    <lastReviewDate>06/07/2010 11:35:01</lastReviewDate>
    <expiryDate>06/07/2011 11:35:01</expiryDate>
  </document>
  <document>
    <id>182521</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.ndt-educational.org/images/New%20EBPG%20Anaemia%20Part%20III.pdf]]&gt;</url>
    <title>Revised European Best Practice Guideline for the management of anaemia in patients with chronic renal failure - Part IV. Failure to respond to treatment</title>
    <publicationDate>2004-01-01T00:00:00</publicationDate>
    <publisher>Nephrology Dialysis and Transplantation</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ COMPLICATIONS OF KIDNEY DISEASE,ANAEMIA,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Revised European Best Practice Guideline (2004; 19(Suppl 2): ii32-ii36.)</description>
    <body>&lt;![CDATA[ &lt;P&gt;Guidelines on :&lt;/P&gt;
&lt;P&gt;IV.1 Failure to reach or maintain target haemoglobin levels &lt;/P&gt;
&lt;P&gt;IV.2 Antibody-mediated pure red cell aplasia &lt;/P&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:35:08</lastReviewDate>
    <expiryDate>06/07/2011 11:35:08</expiryDate>
  </document>
  <document>
    <id>182523</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.ndt-educational.org/images/New%20EBPG%20Anaemia%20Part%20II.pdf]]&gt;</url>
    <title>Revised European Best Practice Guideline for the management of Anaemia in patients with chronic renal failure Part II. Targets for anaemia treatment</title>
    <publicationDate>2004-01-01T00:00:00</publicationDate>
    <publisher>Nephrology Dialysis and Transplantation</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ ANAEMIA,COMPLICATIONS OF KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Revised European Best Practice Guideline (2004; 19(Suppl 2): ii6-ii15).</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Contains Guidelines:&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;II.1 What are the appropriate haemoglobin targets for anaemia treatment?&lt;/LI&gt;
&lt;LI&gt;II.2 What are the appropriate iron targets for anaemia treatment?&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
    <lastReviewDate>24/09/2010 11:24:09</lastReviewDate>
    <expiryDate>24/09/2011 11:24:09</expiryDate>
  </document>
  <document>
    <id>182549</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.ndt-educational.org/images/New%20EBPG%20Anaemia%20Part%20I.pdf]]&gt;</url>
    <title>Revised European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure, Part I: Anaemia Evaluation</title>
    <publicationDate>2004-05-31T00:00:00</publicationDate>
    <publisher>Nephrology Dialysis and Transplantation</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ COMPLICATIONS OF KIDNEY DISEASE,ANAEMIA,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Revised European Best Practice Guideline (2004; 19(Suppl 2): ii2-ii5).</description>
    <body>&lt;![CDATA[ &lt;P&gt;Contains:&lt;/P&gt;
&lt;P&gt;Guideline I.1 Which patients should be evaluated and when should work-up begin?&lt;/P&gt;
&lt;P&gt;Guideline I.2 What is the appropriate work-up to investigate anaemia in chronic kidney disease?&lt;/P&gt;
&lt;P&gt;Guideline I.3 Diagnosis of renal anaemia&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:35:11</lastReviewDate>
    <expiryDate>06/07/2011 11:35:11</expiryDate>
  </document>
  <document>
    <id>182557</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://ndt.oxfordjournals.org/cgi/reprint/19/suppl_2/ii16]]&gt;</url>
    <title>Revised European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure: Part III - treatment of renal anaemia</title>
    <publicationDate>2004-05-31T00:00:00</publicationDate>
    <publisher>Nephrology Dialysis and Transplantation</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ ANAEMIA,COMPLICATIONS OF KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Revised European Best Practice Guideline (2004; 19(Suppl 2): ii16-ii31).</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Contains:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Guideline III.1:Treatment of anaemia with erythropoiesis-stimulating agents&lt;/P&gt;
&lt;P&gt;Guideline III.2 Treatment of anaemia with iron&lt;/P&gt;
&lt;P&gt;Guideline III.3 Optimization of dialysis for the treatment of anaemia&lt;/P&gt;
&lt;P&gt;Guideline III.4 Treatment of anaemia with vitamins and adjuvant therapies other than iron&lt;/P&gt;
&lt;P&gt;Guideline III.5 Treatment of anaemia through improved nutrition&lt;/P&gt;
&lt;P&gt;Guideline III.6 Treatment of anaemia by transfusion&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:35:14</lastReviewDate>
    <expiryDate>06/07/2011 11:35:14</expiryDate>
  </document>
  <document>
    <id>155716</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.renal.org/unit/index.pl?c=bristol]]&gt;</url>
    <title>Richard Bright Renal Unit, Bristol Southmead</title>
    <publicationDate></publicationDate>
    <publisher>Renal Association</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ TRANSPLANT CENTRES,TRANSPLANTATION,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Contact details and background information</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Extract from website&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Patients are referred to the unit from Avon, Bath and West Wiltshire, North and East Somerset, South Gloucestershire and West Dorset. The unit also provides transplantation services for patients attending the Renal Unit at Royal Devon and Exeter Hospital, Exeter from the East Somerset and North and East Devon areas and for some patients from Dorset. &lt;/P&gt;
&lt;P&gt;A team of experienced transplant coordinators provide a 24 hr on call recipient and donor service and a growing programme for the donation of organs from related and non-related living donors is being actively pursued. This team works in collaboration with UKT based at Filton, Bristol. &lt;BR&gt;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>24/09/2010 11:42:49</lastReviewDate>
    <expiryDate>24/09/2011 11:42:49</expiryDate>
  </document>
  <document>
    <id>155928</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.royalfree.org.uk/default.aspx?top_nav_id=3&amp;sel_left_nav=40&amp;tab_id=120]]&gt;</url>
    <title>Royal Free Hospital, London Renal Transplantation Service</title>
    <publicationDate></publicationDate>
    <publisher>Royal Free Hospital</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ TRANSPLANTATION,TRANSPLANT CENTRES,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Background information and contact details</description>
    <body>&lt;![CDATA[ Royal Free's renal transplantation service serves the whole of North London.]]&gt;</body>
    <lastReviewDate>24/09/2010 11:25:18</lastReviewDate>
    <expiryDate>24/09/2011 11:25:18</expiryDate>
  </document>
  <document>
    <id>155880</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.renal.org/unit/?c=liverpool]]&gt;</url>
    <title>Royal Liverpool University Hospital Renal Transplant Directorate</title>
    <publicationDate>2007-03-25T00:00:00</publicationDate>
    <publisher>Renal Association</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ TRANSPLANTATION,TRANSPLANT CENTRES,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Basic background information</description>
    <body>&lt;![CDATA[ &lt;P&gt;The Royal Liverpool University Hospital (RLUH) is a tertiary referral centre for Nephrology and Renal Transplantation for the Merseyside region, covering some two million people. It provides care for all aspects of Nephrology including approximately 80 patients per year who are referred with acute Renal failure. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The main chronic Haemodialysis unit is situated on the 6th Floor of the Royal Liverpool Hospital. This is reached by taking the ‘ABC’ Lifts to the 6th Floor. The RLUH also provides care for the 3 satellite dialysis units (SDU’s) in the region, Broadgreen, Whiston and Warrington. &lt;/P&gt;
&lt;P&gt;The Renal Replacement therapy programme includes approximately 450 haemodialysis (HD) patients, 100 peritoneal (PD) patients and 1000 Renal transplant recipients. &lt;/P&gt;
&lt;P&gt;Approximately 77 Renal transplants are performed each year, meaning a constant steady increase in the numbers of our patients. There is also an active combined Pancreas and Renal transplant programme underway along with continuing series of trials, audits and research. &lt;BR&gt;&lt;/P&gt;&lt;FIRSTPAGE&gt;&lt;/PAGESEQUENCE&gt;&lt;PAGETITLE&gt;&lt;/PAGETITLE&gt;&lt;PAGEBODY&gt;&lt;/PAGEBODY&gt;&lt;/PAGE&gt;&lt;/ARTICLE&gt;]]&gt;</body>
    <expiryDate>01/09/2011 00:00:00</expiryDate>
    <relatedLinks>&lt;a href="http://www.renal.org/unit/?c=liverpool" title="Click for webpage"/&gt;&lt;a href="http://www.merseyrenalunits.nhs.uk/?sub=1131" title="Nephrology Directorate - The Royal Liverpool and Broadgreen Univeristy Hospitals NHS Trust"/&gt;</relatedLinks>
    <creator>Renal Association</creator>
  </document>
  <document>
    <id>312834</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://learning.bmj.com/learning/search-result.html?moduleId=5003328]]&gt;</url>
    <title>Scrotal swellings: diagnosis and management</title>
    <publicationDate>2009-04-21T00:00:00</publicationDate>
    <publisher>BMJ Learning</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,TESTICULAR/ SCROTAL DISORDERS,SWELLING,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Want a fast, evidence based update? Here are the essentials on everyday conditions. Before you start a learning resource it is best to add it to your plan first.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Target audience:&lt;/STRONG&gt;&amp;nbsp; &amp;nbsp; &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;International&lt;/LI&gt;
&lt;LI&gt;Practice nurse CPD&lt;/LI&gt;
&lt;LI&gt;Hospital doctor CPD&lt;/LI&gt;
&lt;LI&gt;GP CPD&lt;/LI&gt;
&lt;LI&gt;GP trainee&lt;/LI&gt;
&lt;LI&gt;Saudi Pediatric Association Channel&lt;/LI&gt;
&lt;LI&gt;Other healthcare professionals&lt;/LI&gt;
&lt;LI&gt;The Royal New Zealand College of General Practitioners&lt;/LI&gt;
&lt;LI&gt;BMJ Learning Harmoni&lt;/LI&gt;
&lt;LI&gt;Medical Students - international &lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
    <lastReviewDate>08/03/2011 10:05:40</lastReviewDate>
    <expiryDate>08/03/2012 10:05:40</expiryDate>
  </document>
  <document>
    <id>262151</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_074811]]&gt;</url>
    <title>Second progress report on Renal NSF</title>
    <publicationDate>2007-05-18T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ PREDISPOSING FACTORS,ETHNIC GROUP,PRESENTATION OF CKD,PERITONEAL DIALYSIS,TRANSPLANTATION,NATIONAL SERVICE FRAMEWORK FOR RENAL SERVICES/POLICY DOCUMENTS,HAEMODIALYSIS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES,DIALYSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Report on achievements from late 2005 to early 2007.</description>
    <body>&lt;![CDATA[ &lt;P class=introText&gt;Extract from webpage&lt;/P&gt;
&lt;P class=introText&gt;The Second Progress Report on the Renal NSF celebrates the achievements of the renal community and the Department over the period from late 2005 until early 2007, looking particularly at areas where radical change has been achieved, such as improved facilities and prevention and early detection of Chronic Kidney Disease.&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>01/07/2010 15:02:51</lastReviewDate>
    <expiryDate>01/07/2011 15:02:51</expiryDate>
  </document>
  <document>
    <id>323977</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=323977]]&gt;</url>
    <title>September 2009 NHS Evidence - kidney diseases newsletter</title>
    <publicationDate>2009-09-02T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ PERITONEAL DIALYSIS,OTHER CONDITIONS - ADULTS,KIDNEY DISEASE IN CHILDREN AND ADOLESCENTS,COMPLICATIONS OF KIDNEY DISEASE,HAEMODIALYSIS,ACUTE KIDNEY INJURY,RENAL TRACT INFECTIONS,TRANSPLANTATION,RENAL CANCER,INHERITED KIDNEY DISEASE,RENOVASCULAR DISEASES,END-OF-LIFE CARE,KIDNEY AND BLADDER STONES,GLOMERULONEPHRITIS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES,DIALYSIS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;September 2009 NHS Evidence - kidney diseases newsletter&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;NHS Evidence - kidney diseases is for busy health professionals, providing them with high quality information and keeping them up to date with the latest research and developments in this area.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=center&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage0 height=203 alt="Human torso with kidneys" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID323977/nelhImp_0000_Humantorsowithkidneys_XSmall.jpg" width=262 border=0 name=nelh_tempImage0&gt;&lt;/P&gt;
&lt;P align=center&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=center&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0005_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&amp;nbsp;RSS FEEDS&amp;nbsp; &lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0006_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;You can receive news from the kidney diseases specialist collection from the RSS feeds we provide:&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;&lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0007_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk/kidney/RSSFeed.aspx?feed=57" target="_blank"&gt;New Resources added to NHS Evidence - kidney diseases&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0008_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk//kidney/News.aspx" target="_blank"&gt;Kidney diseases in the news&lt;/A&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/rss/Directory/MoreAboutRss.aspx" target="_blank"&gt;Click through this link to find out more about RSS feeds.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;JOURNALS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;You can link through to the latest Tables of Contents from all the major kidney journals from &lt;A href="http://www.library.nhs.uk/KIDNEY/Page.aspx?pagename=EJOURNALS" target="_blank"&gt;this page&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=3&gt;&lt;STRONG&gt;&lt;BIG&gt;New resources added in&amp;nbsp;August 2009&lt;/BIG&gt;&lt;/STRONG&gt; &lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Chronic Kidney&amp;nbsp; Disease&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:323305:0" name=internalLink&gt;New guest editorial on Acidosis and CKD &lt;/A&gt;by Ione Ashurst and Muhammad M Yaqoob.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:323588:0" name=internalLink&gt;Identifying unhealthy kidneys&lt;/A&gt;. Patient information leaflet from the Department of Health. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Henoch-Schonlein Purpura (HSP)&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:322289:0" name=internalLink&gt;Effects of corticosteroid on Henoch Schonlein purpura: a systematic review&lt;/A&gt;. Database of Abstracts of Reviews of Effects. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Acute renal failure&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:322337:0" name=internalLink&gt;Timing of renal replacement therapy initiation in acute renal failure&lt;/A&gt;. Database of Abstracts of Reviews of Effects.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:322406:0" name=internalLink&gt;N-acetylcysteine in cardiovascular-surgery-associated renal failure&lt;/A&gt;. Database of Abstracts of Reviews of Effects. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;End of life&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:322576:0" name=internalLink&gt;End of life care in advanced kidney disease: a framework for implementation&lt;/A&gt;. NHS End of Life Care Programme&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Other conditions - adults: SLE-related&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:322334:0" name=internalLink&gt;Topical tacrolimus and pimecrolimus in the treatment of cutaneous lupus erythematosus&lt;/A&gt;. Database of Abstracts of Reviews of Effects.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Haemodialysis&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:322486:0" name=internalLink&gt;A new haemodialysis catheter locking agent reduces infections in haemodialysis patients&lt;/A&gt;. NHS Economic Evaluation Database.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Transplantation&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:322261:0" name=internalLink&gt;Social participation and employment status after kidney transplantation&lt;/A&gt;. Database of Abstracts of Reviews of Effects.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:322281:0" name=internalLink&gt;Renin angiotensin system blockade in kidney transplantation&lt;/A&gt;. Database of Abstracts of Reviews of Effects.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:322539:0" name=internalLink&gt;Guidelines for the prevention and management of cytomegalovirus disease after solid organ transplantation 2nd edition&lt;/A&gt;. British Transplantation Society. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:322511:0" name=internalLink&gt;Guidelines for the detection and characterisation of clinically relevant antibodies in solid organ transplantation&lt;/A&gt;. British Transplantation Society. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Renal tract cancer&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:322477:0" name=internalLink&gt;Radiofrequency ablation versus nephron-sparing surgery for small unilateral renal cell carcinoma: cost-effectiveness analysis&lt;/A&gt; NHS Economic Evaluation Database.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:322430:0" name=internalLink&gt;Metastatic renal cell cancer treatments: an indirect comparison meta-analysis&lt;/A&gt;. Database of Abstracts of Reviews of Effects.&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:124691:0" name=internalLink&gt;New systematic review on genetics and kidney cancer&lt;/A&gt;. NHS Evidence - cancer. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:124690:0" name=internalLink&gt;New systematic reviews published on kidney cancer and diet and nutrition&lt;/A&gt;. NHS Evidence - cancer.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:323783:0" name=internalLink&gt;Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma&lt;/A&gt;. NICE Technology Appraisal. &lt;/LI&gt;&lt;/UL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>23/08/2010 12:03:14</lastReviewDate>
    <expiryDate>23/08/2011 12:03:14</expiryDate>
  </document>
  <document>
    <id>386851</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=386851]]&gt;</url>
    <title>September 2010 NHS Evidence - kidney diseases and male urogenital disorders newsletter</title>
    <publicationDate>2010-09-02T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;September 2010 NHS Evidence - kidney diseases and male urogenital disorders newsletter&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Welcome to the kidney diseases and male urogenital disorders specialist collection enewsletter for&amp;nbsp;SEPTEMBER 2010. &lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=left&gt;NHS Evidence - kidney diseases and male urogenital disorders is for busy health professionals, providing them with high quality information and keeping them up to date with the latest research and developments in this area. You can now join our mailing list to receive regular updates. &lt;A href="https://www.jiscmail.ac.uk/cgi-bin/webadmin?A0=NHSEVIDENCEKDMU" target="_blank"&gt;Click here for the link&lt;/A&gt;.&lt;/P&gt;
&lt;P align=center&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Links to:&lt;/STRONG&gt;&lt;/P&gt;&lt;STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="#kidney"&gt;New Kidney Diseases items&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="#mug"&gt;New Male Urogenital Disorders items&lt;/A&gt;&lt;/STRONG&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=center&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage0 style="WIDTH: 231px; HEIGHT: 153px" height=188 alt="Reviewing medical charts" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID386851/nelhImp_0000_Reviewingmedicalcharts.jpg" width=291 border=0 name=nelh_tempImage0&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;IMG id=nelh_tempImage0 height=16 alt=" name=nelh_tempImage0 border=" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0005_feed.gif" width=16 0? RSS icon?&gt;&amp;nbsp;RSS FEEDS&amp;nbsp; &lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0006_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;You can receive news from the kidney diseases specialist collection from the RSS feeds we provide:&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/RSSFeed.aspx?feed=57" target="_blank"&gt;&lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0007_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk/kidney/RSSFeed.aspx?feed=57" target="_blank"&gt;New Kidney Diseases Resources&lt;/A&gt;&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/RSSFeed.aspx?feed=136" target="_blank"&gt;&lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0008_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk/kidney/RSSFeed.aspx?feed=136" target="_blank"&gt;New Male Urogenital Disorders Resources&lt;/A&gt; &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk//kidney/News.aspx" target="_blank"&gt;&lt;IMG id=nelh_tempImage0 height=16 alt="RSS icon" src="https://rmsadmin.library.nhs.uk/libraryImages/kidney/contentID316973/nelhImp_0008_feed.gif" width=16 border=0 name=nelh_tempImage0&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk//kidney/News.aspx" target="_blank"&gt;Kidney diseases and male urogenital disorders in the news&lt;/A&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/rss/Directory/MoreAboutRss.aspx" target="_blank"&gt;Click through this link to find out more about RSS feeds.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;JOURNALS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;You can link through to the latest Tables of Contents from all the major kidney, transplant and urology journals from &lt;A href="http://www.library.nhs.uk/KIDNEY/Page.aspx?pagename=EJOURNALS" target="_blank"&gt;this page&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=3&gt;&lt;STRONG&gt;&lt;BIG&gt;Resources added in&amp;nbsp;August 2010&lt;/BIG&gt;&lt;/STRONG&gt; &lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A name=kidney&gt;Chronic Kidney&amp;nbsp;Disease&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.kidneycarematters.nhs.uk/Default.aspx?sID=2&amp;amp;aID=319" target="_blank"&gt;The Renal Education Network&lt;/A&gt;. A new group has been set up to support the delivery of high quality education for patients with Chronic Kidney Disease, and for those caring for them.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.kidneycarematters.nhs.uk/?sID=2&amp;amp;aID=326" target="_blank"&gt;New features on Renal Patient View&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;RCT: Toussaint, ND et al. (2010) Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial. Am J Kidney Dis. 56(1):57-68. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/%2020347511" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;. &lt;/LI&gt;
&lt;LI&gt;Stoves, J et al. (2010) Electronic consultation as an alternative to hospital referral for patients with chronic kidney disease: a novel application for networked electronic health records to improve the accessibility and efficiency of healthcare. Qual Saf Health Care. 2010 Jun 16. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20554576" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:379080:0" name=internalLink&gt;Effect of vitamin D on blood pressure: a systematic review and meta-analysis&lt;/A&gt;. A new abstract from the Database of Abstracts of Reviews of Effects. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://renaltsar.blogspot.com/2010/09/white-paper-consultation-your.html" target="_blank"&gt;Renal Tsar's blog: The White Paper consultation - your participation is essential&lt;/A&gt; (06/09/10). &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Diabetic nephropathy&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:385304:0" name=internalLink&gt;Behind the Headlines - Healthy diet 'cuts diabetes risk'&lt;/A&gt;. 20/08/10.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Acute kidney injury&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;EM&gt;Nothing new this month.&lt;/EM&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Renovascular diseases&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;EM&gt;Nothing new this month.&lt;/EM&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Renal tract infections&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:321994:0" name=internalLink&gt;Urinary tract infections- Systematic reviews and meta-analyses&lt;/A&gt;. The specialist collection team have updated this page with the latest evidence.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Kidney stones&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:339010:0" name=internalLink&gt;Kidney and bladder stones- Systematic reviews and meta-analyses.&lt;/A&gt; The specialist collection team have updated this page with the latest evidence. &lt;/LI&gt;
&lt;LI&gt;Worcester, EM and Coe, FL. (2010)&amp;nbsp;Calcium kidney stones. NEJM 363;954-93. &lt;A href="http://www.nejm.org/doi/full/10.1056/NEJMcp1001011" target="_blank"&gt;Link to NEJM&amp;nbsp;Clinical Pratice webpage&lt;/A&gt;.&amp;nbsp;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Renal vasculitis&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;EM&gt;Nothing new this month.&lt;/EM&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Dialysis&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:381593:0" name=internalLink&gt;Transport service for dialysis patients&lt;/A&gt;. An initiative published by the QIPP specialist collection. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://renaltsar.blogspot.com/2010/08/better-transport-saves-nhs-money.html" target="_blank"&gt;Renal Tsar on Transport for Dialysis Patients&lt;/A&gt; (16/08/10). &lt;/LI&gt;
&lt;LI&gt;RCT: Cooper, A. et al. (2010) A randomized, controlled trial of early versus late initiation of dialysis. NEJM. 363(7):609-19. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20581422" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:386198:0" name=internalLink&gt;Continuous renal replacement therapy (CRRT) versus sustained low-efficiency daily dialysis (SLED) for adults with non-trauma-related acute renal failure&lt;/A&gt;. A new record from the CRD Health Technology Assessment Database.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Transplantation&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.kidneycarematters.nhs.uk/?sID=2&amp;amp;aID=322" target="_blank"&gt;Donation: Transplantation: Conversation - useful guide for transplant patients&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://renaltsar.blogspot.com/2010/08/waiting-game-some-people-wait-longer.html" target="_blank"&gt;Renal Tsar on the Waiting Game&lt;/A&gt; (17/08/10).&lt;/LI&gt;
&lt;LI&gt;Analysis of factors that affect outcome after transplantation of kidneys donated after cardiac death in the UK: a cohort study. &lt;A href="http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2960827-6/fulltext#" target="_blank"&gt;Link to abstract on Lancet website&lt;/A&gt;&amp;nbsp;/ &lt;A href="http://www.nhs.uk/news/2010/08August/Pages/kidneys-from-heart-deaths-good-for-transplant.aspx" target="_blank"&gt;Link to NHS Choices Behind the Headlines analysis of the research&lt;/A&gt;. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Kidney Cancer&lt;/STRONG&gt; &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:386206:0" name=internalLink&gt;Robotically assisted nephrectomy for renal malignancy using the da Vinci surgical system (Intuitive Surgical Inc.) for adult patients&lt;/A&gt;. A new record from the CRD Health Technology Assessment Database.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A name=mug&gt;Male Urogenital Disorders&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:386850:0" name=internalLink&gt;Urological chronic pelvic pain- Systematic reviews and meta-analyses&lt;/A&gt;. The specialist collection team have updated this page with the latest evidence. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:387221:0" name=internalLink&gt;Lower urinary tract symptoms in men: a guide to management - in association with NICE&lt;/A&gt;. A BMJ Learning module - log in with your NHS Athens account details or BMA membership&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Male Ureteric Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:321947:0" name=internalLink&gt;Ureteric stones- Systematic reviews and meta-analyses&lt;/A&gt;. The specialist collection team have updated this page with the latest evidence.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Male Bladder Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:321796:0" name=internalLink&gt;Catheter-related infections- Systematic reviews and meta-analyses.&lt;/A&gt; The specialist collection team have updated this page with the latest evidence. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:339010:0" name=internalLink&gt;Kidney and bladder stones- Systematic reviews and meta-analyses.&lt;/A&gt; The specialist collection team have updated this page with the latest evidence. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:321803:0" name=internalLink&gt;Cystitis- Systematic reviews and meta-analyses&lt;/A&gt;. The specialist collection team have updated this page with the latest evidence. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:321952:0" name=internalLink&gt;Vesico-ureter-reflux- Systematic reviews and meta-analyses&lt;/A&gt;. The specialist collection team have updated this page with the latest evidence. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Prostate Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/kidney/SearchResults.aspx?searchText=LUTS%20in%20men%2C%20age-related%20%28prostatism%29&amp;amp;tabID=288" target="_blank"&gt;LUTS in men, age-related (prostatism)&lt;/A&gt; - A series of new Clinical Knowledge Summaries on this subject. &lt;/LI&gt;
&lt;LI&gt;BMJ Patient Journey article on Prostate Cancer. &lt;A href="http://www.bmj.com/content/341/bmj.c3834.short?rss=1" target="_blank"&gt;Link to BMJ Article&lt;/A&gt;. &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:321706:0" name=internalLink&gt;Benign Prostate Enlargement: Systematic reviews and meta-analyses&lt;/A&gt;. The specialist collection team have updated this page with the latest evidence.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:321938:0" name=internalLink&gt;Prostate disorders and surgical procedures- Systematic reviews and meta-analyses&lt;/A&gt;. The specialist collection team have updated this page with the latest evidence.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Penile Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:321806:0" name=internalLink&gt;Erectile dysfunction- Systematic reviews and meta-analyses&lt;/A&gt;. The specialist collection team have updated this page with the latest evidence.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:344284:0" name=internalLink&gt;Circumcision- Systematic reviews and meta-analyses&lt;/A&gt;. The specialist collection team have updated this page with the latest evidence.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Urethral disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:321992:0" name=internalLink&gt;Urethroplasty- Systematic reviews and meta-analyses&lt;/A&gt;. The specialist collection team have updated this page with the latest evidence.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:386835:0" name=internalLink&gt;Urethral stricture- Systematic reviews and meta-analyses&lt;/A&gt;. The specialist collection team have updated this page with the latest evidence.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Urinary tract infections&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:321994:0" name=internalLink&gt;Urinary tract infections- Systematic reviews and meta-analyses&lt;/A&gt;. The specialist collection team have updated this page with the latest evidence.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Testicular/Scrotal Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:321814:0" name=internalLink&gt;Hypospadias- Systematic reviews and meta-analyses&lt;/A&gt;. The specialist collection team have updated this page with the latest evidence.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:321950:0" name=internalLink&gt;Varicocele- Systematic reviews and meta-analyses&lt;/A&gt;. The specialist collection team have updated this page with the latest evidence.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:321993:0" name=internalLink&gt;Testosterone- Systematic reviews and meta-analyses&lt;/A&gt;. The specialist collection team have updated this page with the latest evidence.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:321943:0" name=internalLink&gt;Testicular and scrotal disorders- Systematic reviews and meta-analyses&lt;/A&gt;. The specialist collection team have updated this page with the latest evidence.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Male Urinary Incontinence&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;BMJ Clinical Review on Managing urinary incontinence in older people. &lt;A href="http://www.bmj.com/content/341/bmj.c3835.short?rss=1" target="_blank"&gt;Link to BMJ Clinical Review&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:321830:0" name=internalLink&gt;Male urinary incontinence- Systematic reviews and meta-analyses&lt;/A&gt;. The specialist collection team have updated this page with the latest evidence.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:321941:0" name=internalLink&gt;Stress incontinence- Systematic reviews and meta-analyses&lt;/A&gt;. The specialist collection team have updated this page with the latest evidence.&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Sexually Transmitted Infections&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:321812:0" name=internalLink&gt;HIV and male urogenital disorders- Systematic reviews and meta-analyses&lt;/A&gt;. The specialist collection team have updated this page with the latest evidence.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:321810:0" name=internalLink&gt;Hepatitis B - Systematic reviews and meta-analyses&lt;/A&gt;. The specialist collection team have updated this page with the latest evidence.&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:321798:0" name=internalLink&gt;Chlamydia- Systematic reviews and meta-analyses&lt;/A&gt;. The specialist collection team have updated this page with the latest evidence.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Fertility&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:321815:0" name=internalLink&gt;Infertility- Systematic reviews and meta-analyses&lt;/A&gt;. The specialist collection team have updated this page with the latest evidence.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/LI&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <expiryDate>02/09/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>345050</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=345050]]&gt;</url>
    <title>Sex reassignment: Systematic review</title>
    <publicationDate>2010-03-03T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,PENILE DISORDERS,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Sex reassignment: Systematic review&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence -&amp;nbsp;kidney diseases and male urogenital disorders&amp;nbsp;has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development&amp;nbsp;strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us &lt;/A&gt;if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Sutcliffe PA, Dixon S, Akehurst RL, Wilkinson A, Shippam A, White S, et al. Evaluation of surgical procedures for sex reassignment: a systematic review. Journal of Plastic, Reconstructive and Aesthetic Surgery. 2009;62(3):294-306. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18222742" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <expiryDate>05/04/2012 00:00:00</expiryDate>
  </document>
  <document>
    <id>380657</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://learning.bmj.com/learning/search-result.html?moduleId=10015357&amp;utm_campaign=7674737&amp;utm_content=47579591950&amp;utm_medium=email&amp;utm_source=Emailvision]]&gt;</url>
    <title>Sexual health: erectile dysfunction in primary care</title>
    <publicationDate>2010-07-12T00:00:00</publicationDate>
    <publisher>BMJ Learning</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,PENILE DISORDERS,ERECTILE DYSFUNCTION,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>BMJ Learning Module - for BMA Members</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Module type&amp;nbsp; &amp;nbsp; &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Read, reflect, respond:&lt;/STRONG&gt;&lt;BR&gt;Read and reflect on current issues; see what others think; and have your say. Before you start a learning resource it is best to add it to your plan first.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;What's in this case:&lt;/STRONG&gt; &amp;nbsp;&lt;/P&gt;
&lt;P&gt;Sexual health: erectile dysfunction in primary care&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Target audience&lt;/STRONG&gt; &amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;GPs&lt;/LI&gt;
&lt;LI&gt;Foundation doctors&lt;/LI&gt;
&lt;LI&gt;Hospital doctors&lt;/LI&gt;
&lt;LI&gt;Medical Students&lt;/LI&gt;
&lt;LI&gt;GP trainees&lt;/LI&gt;
&lt;LI&gt;Practice nurses&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
    <expiryDate>13/07/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>318604</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://learning.bmj.com/learning/search-result.html?moduleId=10012061]]&gt;</url>
    <title>Sexually transmitted infections: diagnostic picture tests</title>
    <publicationDate>2009-04-01T00:00:00</publicationDate>
    <publisher>BMJ Learning</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE SEXUALLY TRANSMITTED INFECTIONS,VIRAL,BACTERIAL,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>BMJ Learning Module - for BMA Members</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Extract:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Module type&lt;/STRONG&gt;&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;Interactive case history:&lt;BR&gt;Use these interactive modules to learn as we guide you through a real life consultation. Before you start a learning resource it is best to add it to your plan first.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;What's in this case:&lt;/STRONG&gt; &amp;nbsp;&lt;/P&gt;
&lt;P&gt;Sexually transmitted infections: diagnostic picture tests&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Target audience:&lt;/STRONG&gt; &amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;NHS London - Foundation programme&lt;/LI&gt;
&lt;LI&gt;NHS London - GP and trainee CPD&lt;/LI&gt;
&lt;LI&gt;International&lt;/LI&gt;
&lt;LI&gt;GP CPD&lt;/LI&gt;
&lt;LI&gt;Hospital doctor CPD&lt;/LI&gt;
&lt;LI&gt;GP trainee&lt;/LI&gt;
&lt;LI&gt;NHS London - Allied health professionals&lt;/LI&gt;
&lt;LI&gt;Other healthcare professionals&lt;/LI&gt;
&lt;LI&gt;Saudi Pediatric Association Channel&lt;/LI&gt;
&lt;LI&gt;The Royal New Zealand College of General Practitioners&lt;/LI&gt;
&lt;LI&gt;NHS London - Acute and community nursing and midwifery&lt;/LI&gt;
&lt;LI&gt;Foundation programme&lt;/LI&gt;
&lt;LI&gt;NHS London - Hospital doctor CPD&lt;/LI&gt;
&lt;LI&gt;Practice nurse CPD&lt;/LI&gt;
&lt;LI&gt;Medical Students - international &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>01/07/2010 14:29:20</lastReviewDate>
    <expiryDate>01/07/2011 14:29:20</expiryDate>
  </document>
  <document>
    <id>289437</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.emrn.org.uk/documents/Anaemia%20Management.pdf]]&gt;</url>
    <title>Shared care policy for anaemia management in renal patients</title>
    <publicationDate>2003-09-01T00:00:00</publicationDate>
    <publisher>East Midlands Renal Network</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ COMPLICATIONS OF KIDNEY DISEASE,ANAEMIA,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Local guideline published by the East Midlands Renal Network</description>
    <body>&lt;![CDATA[ &lt;P&gt;Extract from document&lt;/P&gt;
&lt;P&gt;The nature and continuing care of patients with renal disease requires a collaborative approach between general practitioners and the Renal Unit. A system of shared care; encompassing primary and specialist care optimises care delivery and continuing management. This protocol outlines the principles of therapy with erythropoesis stimulating drugs and gives guidelines for the continuing management of patients undergoing treatment. &lt;/P&gt;
&lt;P&gt;Published March 2005&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
    <expiryDate>04/08/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>155525</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.sharpinfo.org/]]&gt;</url>
    <title>SHARP Trial</title>
    <publicationDate></publicationDate>
    <publisher>SHARP</publisher>
    <publicationType>RANDOMISED CONTROLLED TRIAL</publicationType>
    <topics>&lt;![CDATA[ NEW RESEARCH,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>International multi centre RCT of heart and renal protection - effects of lowering cholesterol on vascular disease in patients with kidney disease</description>
    <body>&lt;![CDATA[ Website contains information for both health professionals and for patient/carers, FAQs and contact details.]]&gt;</body>
    <lastReviewDate>06/07/2010 11:35:22</lastReviewDate>
    <expiryDate>06/07/2011 11:35:22</expiryDate>
  </document>
  <document>
    <id>155749</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.renal.org/unit/index.pl?c=sheffield]]&gt;</url>
    <title>Sheffield Kidney Institute</title>
    <publicationDate></publicationDate>
    <publisher>Renal Association</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ TRANSPLANT CENTRES,TRANSPLANTATION,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Contact details and background information</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Extract from website&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;The Sheffield Kidney Institute is on the Northern General Hospital campus of the Sheffield Teaching Hospitals Foundation Trust, and affiliated to the University of Sheffield. &lt;/P&gt;
&lt;P&gt;It is one of the largest renal units in the United Kingdom, serving a population of about 1.7 million. Its 38 bed renal unit provides treatment for transplantation patients.&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>24/09/2010 11:27:05</lastReviewDate>
    <expiryDate>24/09/2011 11:27:05</expiryDate>
  </document>
  <document>
    <id>155676</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.uktransplant.org.uk/ukt/how_to_become_a_donor/religious_perspectives/leaflets/sikhism_and_organ_donation.jsp]]&gt;</url>
    <title>Sikhism and organ donation</title>
    <publicationDate></publicationDate>
    <publisher>UK Transplant</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ TRANSPLANTATION,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A guide to organ donation and the Sikh religion</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Extract from website&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;The Sikh philosophy and teachings place great emphasis on the importance of giving and putting others before oneself. &lt;/P&gt;
&lt;P style="COLOR: black"&gt;The Sikh faith stresses the importance of performing noble deeds. There are many examples of selfless giving and sacrifice in Sikh teachings by the ten Gurus and other Sikhs.&lt;/P&gt;
&lt;P style="COLOR: black"&gt;Sikhs believe life after death is a continuous cycle of rebirth but the physical body is not needed in this cycle - a person's soul is their real essence.&lt;/P&gt;
&lt;P&gt;"The Sikh religion teaches that life continues after death in the soul, and not the physical body. The last act of giving and helping others through organ donation is both consistent with and in the spirit of Sikh teachings."&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>24/09/2010 11:27:10</lastReviewDate>
    <expiryDate>24/09/2011 11:27:10</expiryDate>
    <relatedLinks>&lt;a href="http://www.uktransplant.org.uk/ukt/how_to_become_a_donor/religious_perspectives/leaflets/sikhism_and_organ_donation.jsp" title="Click here for webpage"/&gt;&lt;a href="http://www.uktransplant.org.uk/ukt/newsroom/fact_sheets/religious_leaflets/sikhism_and_organ_donation/sikhism_and_organ_donation.pdf" title="Click here for leaflet PDF"/&gt;</relatedLinks>
    <creator>UK Transplant</creator>
  </document>
  <document>
    <id>379536</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;db=pubmed&amp;cmd=Search&amp;TransSchema=title&amp;term=Sirolimus%20and%20Kidney%20Growth%20in%20Autosomal%20Dominant%20Polycystic%20Kidney%20Disease]]&gt;</url>
    <title>Sirolimus and Kidney Growth in Autosomal Dominant Polycystic Kidney Disease</title>
    <publicationDate>2010-06-28T00:00:00</publicationDate>
    <publisher>New England Journal of Medicine</publisher>
    <publicationType>RANDOMISED CONTROLLED TRIAL</publicationType>
    <topics>&lt;![CDATA[ INHERITED KIDNEY DISEASE,POLYCYSTIC KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This 18-month&amp;nbsp;randomised controlled trial&amp;nbsp;(n=100) found that in "adults with ADPKD (Autosomal Dominant Polycystic Kidney Disease) and early chronic kidney disease, 18 months of treatment with sirolimus did not halt polycystic kidney growth".&lt;/P&gt;
&lt;P&gt;Serra AL, Poster D, Kistler AD, Krauer F, Raina S, Young J, et al. "Sirolimus and Kidney Growth in Autosomal Dominant Polycystic Kidney Disease". New England Journal of Medicine. Published online June 26, 2010 (10.1056/NEJMoa0907419). &lt;/P&gt;]]&gt;</body>
    <expiryDate>28/06/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>235413</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.nature.com/ki/journal/v70/n10/pdf/5001791a.pdf]]&gt;</url>
    <title>Sleep disorders in end-stage renal disease: 'Markers of inadequate dialysis?</title>
    <publicationDate>2006-09-13T00:00:00</publicationDate>
    <publisher>Kidney International</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ LIVING WITH DIALYSIS,HAEMODIALYSIS,CONDITIONS,PALLIATIVE AND SUPPORTIVE CARE,SYMPTOM MANAGEMENT,SLEEP,RENAL DISEASES,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES,DIALYSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Article in Kidney International 2006, Vol 70, p1687-1693</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Published abstract&lt;/EM&gt; &lt;/P&gt;
&lt;P&gt;Excessive daytime sleepiness and sleep disorders, including sleep apnea syndrome, restless legs syndrome, and periodic limb movement disorder, occur with increased frequency in patients with end-stage renal disease (ESRD). The detection and management of sleep disorders in ESRD patients is often challenging but may have significant clinical benefits. Some of the poor quality of life in ESRD may be attributed to the presence of concomitant sleep disorders, yet the classical symptoms of sleep disorders (poor concentration, daytime sleepiness, and insomnia) are often ascribed to the uremic syndrome itself. Conventional risk factors and screening tools used in the diagnosis of sleep disorders seem to have limited applicability in dialysis patients implicating the unique pathophysiology of sleep disorders in ESRD. Emerging evidence suggests that sleep apnea may contribute to the augmented cardiovascular event rates and to the accelerated development of atherosclerosis in ESRD. Whether treatment of sleep disorders in ESRD patients can affect the high morbidity and mortality of ESRD patients has yet to be elucidated. To date, conventional renal replacement therapies do not appear to have a significant impact on the treatment of sleep disorders in ESRD. The promising therapeutic effects of optimal uremia control in the forms of nocturnal hemodialysis and renal transplantation on sleep disorders require further mechanistic and clinical studies&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>13/12/2010 11:41:04</lastReviewDate>
    <expiryDate>13/12/2011 11:41:04</expiryDate>
  </document>
  <document>
    <id>331432</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.hdcn.com/anna_ce/365/365.pdf]]&gt;</url>
    <title>So Just What Can I Eat? Nutritional Care in Patients with Diabetes Mellitus and Chronic Kidney Disease</title>
    <publicationDate>2009-09-01T00:00:00</publicationDate>
    <publisher>Nephrology Nursing Journal</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,PREDISPOSING FACTORS,INTERVENTIONS,DIABETIC METABOLIC CONTROL,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A Continuing Nursing Education article.</description>
    <body>&lt;![CDATA[ &lt;P&gt;The balance of nutrition in patients with diabetes mellitus and chronic kidney disease is essential to optimum health outcomes. Multiple nutritional parameters need to be monitored, including energy balance, protein intake (type and amount), mineral control (sodium, potassium, calcium, phosphorus), fluid requirements, and coordination of carbohydrates, to achieve glycemic control in diabetes mellitus. The nephrology nurse benefits by understanding the multiple nutrition parameters required in diabetes mellitus and chronic kidney disease to participate and reinforce the complexities of the daily nutritional challenges in coordination with a registered dietitian. A comprehensive overview of the nutrition parameters in chronic kidney disease and diabetes mellitus is discussed so the question “So just what can I eat?” can be answered with greater confidence.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Copyright 2009 American Nephrology Nurses’ Association&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Beto, J.A., &amp;amp; Nicholas, M. (2009). So just what can I eat? Nutritional care in patients with diabetes mellitus and chronic kidney disease. Nephrology Nursing Journal, 36(5), 497- 505.&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>09/11/2010 14:22:21</lastReviewDate>
    <expiryDate>09/11/2011 14:22:21</expiryDate>
  </document>
  <document>
    <id>177168</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.renalreg.com/Report-Area/Report%202005/chap-12.pdf]]&gt;</url>
    <title>Some Measures of Care of Renal Transplant Patients</title>
    <publicationDate>2005-12-01T00:00:00</publicationDate>
    <publisher>UK Renal Registry Report and UK Transplant</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ TRANSPLANTATION,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Chapter 12 of the UK Renal Registry Report 2005</description>
    <body>&lt;![CDATA[ Chapter 12 examines post transplant follow-up and post transplant variables including transplant function, haemoglobin and serum cholesterol. This is the beginning of collaboration between the UK Renal Registry and UK Transplant.]]&gt;</body>
    <lastReviewDate>24/09/2010 11:27:17</lastReviewDate>
    <expiryDate>24/09/2011 11:27:17</expiryDate>
  </document>
  <document>
    <id>155700</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.renal.org/unit/index.pl?c=plymouth]]&gt;</url>
    <title>South West Transplant Centre</title>
    <publicationDate></publicationDate>
    <publisher>South West Transplant Centre</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ TRANSPLANT CENTRES,TRANSPLANTATION,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Description of facilities at Derriford Hospital</description>
    <body>&lt;![CDATA[ &lt;P&gt;Extract&lt;/P&gt;
&lt;P&gt;The Renal Unit has dedicated teams specialising in Transplantation, Haemodialysis, CAPD, Pre-dialysis, Arterio-Venous access, Renal dietary requirements and Staff Development on site.&lt;/P&gt;
&lt;P&gt;From &lt;A href="http://www.plymouthhospitals.nhs.uk/ourorganisation/newsandpublications/pressreleases/Pages/MorePatientsBenefitfromKidneyTransplants.aspx" target="_blank"&gt;http://www.plymouthhospitals.nhs.uk/ourorganisation/newsandpublications/pressreleases/Pages/MorePatientsBenefitfromKidneyTransplants.aspx&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;More patients than ever before benefited from kidney transplants at the South West Transplant Centre at Derriford Hospital in 2007, surgeons have announced today. &lt;/P&gt;
&lt;P&gt;A total of 57 transplants were performed in 2007. Kidneys transplanted from living donors accounted for 16 of these operations; the remainder were from deceased donors either heart beating or controlled non heart beating donor transplants. This is the fourth successive year&amp;nbsp; that there has been an increase in the number of patients benefiting from the work of the South West Transplant Centre. &lt;/P&gt;
&lt;P&gt;The year also saw the South West Transplant Centre perform the second altruistic non directed living donor transplant and the second paired exchange living donor renal transplantation in the UK. &lt;/P&gt;
&lt;P&gt;Consultant Surgeon and Director of the South West Transplant Centre Mr Jacob Akoh said: “We are proud of be able to help so many patients in the peninsula. &lt;/P&gt;
&lt;P&gt;“The quality of the service we are providing is excellent and we know this because our cumulative (2001-2006) five-year patient and graft survival of 88% and 90% are well above the national average. We have received considerable positive feedback from patients treated at the South West Transplant Centre. &lt;/P&gt;
&lt;P&gt;“Every year the South West Transplant Centre is increasing its activity which benefits more patients. This year we have had some great firsts and I would like to publicly thank everyone who has been involved in the work of the Centre and other services closely related to it in the far South West.” &lt;/P&gt;
&lt;P&gt;The year also saw a record number of organ donations enabling many life saving transplants to be performed both locally and nationally:&amp;nbsp; 61 kidney transplants, 20 liver transplants, five heart transplants, two lung transplants, seven pancreas transplants, 36 heart valve transplants, and 82 corneal transplants. This is thanks to the generosity and courage of donors and their families. &lt;/P&gt;
&lt;P&gt;In June 2006 the South West had the highest proportion of the population registered in the UK on the NHS Organ Donor Register at 29%. This has since increased to 30.7% in January 2008 and remains the highest in the UK compared to the national figure of 24.7%.* &lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.renal.org/unit/index.pl?c=plymouth" target="_blank"&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>24/09/2010 11:27:22</lastReviewDate>
    <expiryDate>24/09/2011 11:27:22</expiryDate>
  </document>
  <document>
    <id>155754</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.renal.org/unit/index.pl?c=stgeorges]]&gt;</url>
    <title>St Georges Renal Unit, London</title>
    <publicationDate></publicationDate>
    <publisher>Renal Association</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ TRANSPLANTATION,TRANSPLANT CENTRES,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Contact details and background information</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Extract from website&lt;/EM&gt;&lt;/P&gt;
&lt;P class=standard&gt;The renal unit at St Georges is part of one of countries largest NHS trusts and is co-located with its Medical School. Whilst is has a short history compared to some units it offers the full panoply of services and several new cutting edge therapies. We work closely with our sister unit at St Helier to provide care for a large section of South West London and extending into Surrey and Sussex. The surgical team for St Georges covers this area and also Brighton for complex access and transplants covering a total population of 3.5M. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>24/09/2010 11:27:28</lastReviewDate>
    <expiryDate>24/09/2011 11:27:28</expiryDate>
    <relatedLinks>&lt;a href="http://www.renal.org/unit/index.pl?c=stgeorges" title="Click for website"/&gt;&lt;a href="http://www.stgeorges.nhs.uk/services_renalindex.asp" title="Click for Unit's Website"/&gt;</relatedLinks>
    <creator>St Georges Renal Unit</creator>
  </document>
  <document>
    <id>155756</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.renal.org/unit/index.pl?c=sthelier]]&gt;</url>
    <title>St Helier's South West Thames Renal and Transplantation Unit</title>
    <publicationDate></publicationDate>
    <publisher>Renal Association</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ TRANSPLANT CENTRES,TRANSPLANTATION,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Contact details and background information</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Extract from website&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Currently&amp;nbsp;services are provided to the residents of South West London, Surrey and Surrey Borders and Farnham Hospital (total population covered approximately 2.5 million).&amp;nbsp; Approximately 40 transplants per annum (&amp;gt;95% success rate at 1 year).&lt;/P&gt;
&lt;P&gt;To further develop the research activities of the renal unit the South West Thames Kidney Fund was formed. The charity which comprises patients of the Renal Unit and their relatives is chaired by Dr. Michael Bending and has Lord Rogers of Riverside (son of the unit's founder Dr. Will Rogers) as its Patron. The primary aim of this charity was to raise funds to build a permanent base for a renal research laboratory on the St. Helier Hospital site in Carshalton. This ambition has been realised with the opening of the South West Thames Institute for Renal Research in March 1998. &lt;BR&gt;&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>24/09/2010 11:27:34</lastReviewDate>
    <expiryDate>24/09/2011 11:27:34</expiryDate>
    <relatedLinks>&lt;a href="http://www.renal.org/unit/index.pl?c=sthelier" title="Click for website"/&gt;&lt;a href="http://www.swtirr.org.uk/" title="Click for SWThames Institute for Renal Rearch website"/&gt;</relatedLinks>
    <creator>St Helier's SW Themes Renal and Transplantation Unit</creator>
  </document>
  <document>
    <id>155738</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.renal.org/unit/index.pl?c=leedsjim]]&gt;</url>
    <title>St. James Renal Department, Leeds</title>
    <publicationDate></publicationDate>
    <publisher>Renal Association</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ TRANSPLANT CENTRES,TRANSPLANTATION,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Contact details and background information</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Extract from website&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;The Renal Department at St James’s has&amp;nbsp;10 renal transplant beds.&lt;/P&gt;
&lt;P&gt;The live donor renal transplant programme is rapidly expanding including laparoscopic donor retrieval. There is a well established donation after cardiac death (DCD) organ retrieval programme. Both the live donor programme and DCD programmes have been awarded central funds from UK Transplant to pump prime these initiatives.&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>24/09/2010 11:27:40</lastReviewDate>
    <expiryDate>24/09/2011 11:27:40</expiryDate>
  </document>
  <document>
    <id>309490</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.newbornnetworks.org.uk/staffs/guidelines_list.htm]]&gt;</url>
    <title>Staffordshire, Shropshire and Black Country Newborn Network</title>
    <publicationDate>2009-03-20T00:00:00</publicationDate>
    <publisher>NHS Staffordshire, Shropshire and Black Country Newborn Network</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ NEPHROTIC SYNDROME,KIDNEY DISEASE IN CHILDREN AND ADOLESCENTS,COMPLICATIONS OF KIDNEY DISEASE,ACUTE KIDNEY INJURY,REFLUX,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>These guidelines have been compiled as an aide-memoire for all staff concerned with the management of neonates, towards a more uniform standard of care across the Staffordshire, Shropshire and Black Country Newborn Network, including the care of newborns with renal/kidney problems.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Guidelines&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;These guidelines have been compiled as an aide-memoire for all staff concerned with the management of neonates, towards a more uniform standard of care across the Staffordshire, Shropshire and Black Country Newborn Network. They have been drafted with reference to published medical literature and amended after extensive consultation. Wherever possible, the recommendations made are evidence based. Where no clear evidence has been identified from published literature the advice given represents a consensus of the expert authors and their peers and is based on their practical experience.&lt;/P&gt;
&lt;P&gt;No guideline will apply to every patient, even where the diagnosis is clear-cut; there will always be exceptions. These guidelines are not intended as a substitute for logical thought and must be tempered by clinical judgment in the individual patient and advice from senior colleagues. (These guidelines are advisory, NOT mandatory).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Renal guidelines:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.newbornnetworks.org.uk/staffs/documents/Renalantenatal2007.pdf" target="_blank"&gt;Renal abnormalities on antenatal scan (Link to full-text PDF)&lt;/A&gt; 
&lt;LI&gt;&lt;A href="http://www.newbornnetworks.org.uk/staffs/documents/Renalabnormalitiesonantenatalscan-evidence.pdf" target="_blank"&gt;Renal abnormalities on antenatal scan (supporting information) - (Link to full-text PDF)&lt;/A&gt; 
&lt;LI&gt;&lt;A href="http://www.newbornnetworks.org.uk/staffs/documents/Renalfailure2007.pdf" target="_blank"&gt;Renal failure (Link to full-text PDF)&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>14/02/2011 11:40:59</lastReviewDate>
    <expiryDate>14/02/2012 11:40:59</expiryDate>
  </document>
  <document>
    <id>321941</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=321941]]&gt;</url>
    <title>Stress incontinence: Systematic reviews and meta-analyses</title>
    <publicationDate>2010-09-02T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,STRESS INCONTINENCE,MALE URINARY INCONTINENCE,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Stress incontinence: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Ashok, K. and A. Wang (2010). "Recurrent urinary stress incontinence: an overview." Journal of Obstetrics &amp;amp; Gynaecology Research 36(3): 467-473. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20598022" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Herschorn, S., H. Bruschini, et al. (2010). "Surgical treatment of stress incontinence in men." Neurourology &amp;amp; Urodynamics 29(1): 179-190.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20025026" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Latthe, P. M., P. Singh, et al. (2010). "Two routes of transobturator tape procedures in stress urinary incontinence: a meta-analysis with direct and indirect comparison of randomized trials." BJU International 106(1): 68-76.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19912182" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Latthe, P. M., R. Foon, et al. (2008). "Nonsurgical treatment of stress urinary incontinence (SUI): Grading of evidence in systematic reviews." BJOG: An International Journal of Obstetrics and Gynaecology 115(4): 435-444.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18271880" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Tsakiris, P., J. J. de la Rosette, et al. (2008). "Pharmacologic Treatment of Male Stress Urinary Incontinence: Systematic Review of the Literature and Levels of Evidence." European Urology 53(1): 53-59.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17920183" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Tan, E., P. P. Tekkis, et al. (2007). "Laparoscopic versus open colposuspension for urodynamic stress incontinence." Neurourol Urodyn 26(2): 158-69.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17252603?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:21:04</lastReviewDate>
    <expiryDate>06/07/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>406725</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.kidneycare.nhs.uk/_Ourworkprogrammes-Renalreplacementtherapies-SupportingYoungAdults.aspx]]&gt;</url>
    <title>Supporting Young Adults with Kidney Disease</title>
    <publicationDate>2010-03-01T00:00:00</publicationDate>
    <publisher>NHS Kidney Care</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,ACUTE KIDNEY INJURY,COMPLICATIONS OF KIDNEY DISEASE,KIDNEY DISEASE IN CHILDREN AND ADOLESCENTS,INHERITED KIDNEY DISEASE,RENOVASCULAR DISEASES,GLOMERULONEPHRITIS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This project aims to enable services  to develop innovative approaches to supporting young adults who have kidney disease, including those who have had a kidney transplant and those currently receiving dialysis.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;What does this project aim to achieve?&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;This project aims to enable services&amp;nbsp; to develop innovative approaches to supporting young adults who have kidney disease, including those who have had a kidney transplant and those currently receiving dialysis.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;How will this be achieved?&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;&lt;/STRONG&gt;Five project groups have been appointed to develop innovative new approaches to supporting young adults who have kidney disease. These approaches will centre on the role of a key worker to work across adult and paediatric kidney services as well as primary care, social care and other settings.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The networks will complete this work over 18 months during 2010 and 2011.&lt;/P&gt;
&lt;P&gt;The groups carrying out the project work are:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;North East network&lt;/LI&gt;
&lt;LI&gt;South Central network&lt;/LI&gt;
&lt;LI&gt;London network&lt;/LI&gt;
&lt;LI&gt;South West network&lt;/LI&gt;
&lt;LI&gt;East Midlands network&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Resources&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Literature Review - Supporting young adults with kidney disease - Slide set. Download: &lt;A href="http://www.kidneycare.nhs.uk/Library/SYAwithKDslidepack.ppt" target="_blank"&gt;Literature review - Supporting young adults with kidney disease - Slide set&lt;/A&gt; (PPT 523MB)&lt;/LI&gt;
&lt;LI&gt;The National Study of New Models. Clinical abstract poster, presented at the BRS/RA Conference, 20 May 2010. Download: &lt;A href="http://www.kidneycare.nhs.uk/Library/Nationalstudyofnewmodelsposter.pdf" target="_blank"&gt;The poster&lt;/A&gt; (PDF 549KB)&lt;/LI&gt;
&lt;LI&gt;The first meeting of the Supporting Young Adults with Kidney Disease project board held on 12 January 2010. Download: &lt;A href="http://www.kidneycare.nhs.uk/SYAprojectboard12Jan10FINAL-ppt.cmsdoc" target="_blank"&gt;The slideset from the meeting&lt;/A&gt; (PowerPoint 2.7MB)&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
    <expiryDate>21/02/2012 00:00:00</expiryDate>
  </document>
  <document>
    <id>319264</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.bladderandbowelfoundation.org/bladder/surgical-procedures-for-bladder-problems/]]&gt;</url>
    <title>Surgical Procedures For Bladder Problems</title>
    <publicationDate></publicationDate>
    <publisher>The Bladder and Bowel Foundation</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE BLADDER DISORDERS,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>There are surgeries available that may help certain bladder problems</description>
    <body>&lt;![CDATA[ &lt;P&gt;Information on Surgical Procedures For Bladder Problems provided by the Bladder and Bowel Foundation.&lt;/P&gt;
&lt;P&gt;There are surgeries available that may help certain bladder problems.&lt;/P&gt;
&lt;P&gt;Find out about an Urostomy:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;SPAN class=Apple-style-span style="WORD-SPACING: 0px; FONT: 16px 'times new roman'; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BORDER-COLLAPSE: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"&gt;&lt;SPAN class=Apple-style-span style="FONT-SIZE: 13px; FONT-FAMILY: Tahoma; TEXT-ALIGN: left"&gt;&lt;A title=Urostomy style="FONT-SIZE: 14px; COLOR: rgb(104,104,168); TEXT-DECORATION: none" href="https://rmsadmin.library.nhs.uk/admin/wizards/cardex/urostomy/" target="_blank"&gt;Urostomy&lt;/A&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/LI&gt;&lt;/UL&gt;&lt;SPAN class=Apple-style-span style="WORD-SPACING: 0px; FONT: 16px 'times new roman'; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BORDER-COLLAPSE: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"&gt;&lt;SPAN class=Apple-style-span style="FONT-SIZE: 13px; FONT-FAMILY: Tahoma; TEXT-ALIGN: left"&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;
&lt;P&gt;&lt;BR&gt;Visit&amp;nbsp; &lt;SPAN class=Apple-style-span style="WORD-SPACING: 0px; FONT: 16px 'times new roman'; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BORDER-COLLAPSE: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"&gt;&lt;SPAN class=Apple-style-span style="FONT-SIZE: 13px; LINE-HEIGHT: 20px; FONT-FAMILY: Tahoma; TEXT-ALIGN: left"&gt;&lt;A class="" style="COLOR: rgb(32,47,132); TEXT-DECORATION: underline" href="https://rmsadmin.library.nhs.uk/bladder/bladder-problems/stress-urinary-incontinence/surgery.htm" target="_blank"&gt;Stress Urinary Incontinence&lt;/A&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&amp;nbsp;(SUI) to read about different SUI related surgeries and visit&amp;nbsp;&lt;SPAN class=Apple-style-span style="WORD-SPACING: 0px; FONT: 16px 'times new roman'; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BORDER-COLLAPSE: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"&gt;&lt;SPAN class=Apple-style-span style="FONT-SIZE: 13px; LINE-HEIGHT: 20px; FONT-FAMILY: Tahoma; TEXT-ALIGN: left"&gt;&lt;A class="" style="COLOR: rgb(104,104,168); TEXT-DECORATION: none" href="https://rmsadmin.library.nhs.uk/bladder/bladder-problems/overactive-bladder/surgery.htm" target="_blank"&gt;Overactive bladder&lt;/A&gt;&lt;/SPAN&gt;&lt;/SPAN&gt; (OAB) to read about different OAB related surgeries.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>01/07/2010 15:03:50</lastReviewDate>
    <expiryDate>01/07/2011 15:03:50</expiryDate>
  </document>
  <document>
    <id>156792</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.era-edta-reg.org/files/presentations/pdf/berlin-Verrier-PaediatricReport03.pdf]]&gt;</url>
    <title>Survivors of Renal Replacement Therapy in Childhood</title>
    <publicationDate>2003-01-01T00:00:00</publicationDate>
    <publisher>ERA-EDTA</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ CHILDREN AND ADOLESCENTS ON HAEMODIALYSIS,TRANSPLANTATION,HAEMODIALYSIS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,DIALYSIS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Presentation of statistics relating to treatment outcomes for paediatric population</description>
    <body>&lt;![CDATA[ &lt;P&gt;Presentation of statistics from 20 year period 1980-2000 and outcomes in early adult life of children receiving RRT. Registries included in data analysis were Austria, Belgium (Dutch and French speaking regions), Denmark, Finland, Greece, Iceland, Norway, Catalonia (Spain), Sweden, the Netherlands, and Scotland (UK).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:35:27</lastReviewDate>
    <expiryDate>06/07/2011 11:35:27</expiryDate>
  </document>
  <document>
    <id>341907</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=341907]]&gt;</url>
    <title>Systemic lupus erythematosus: Systematic reviews and meta-analyses</title>
    <publicationDate>2011-01-17T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,OTHER CONDITIONS - ADULTS,SLE-RELATED,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Systemic lupus erythematosus: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Baizabal-Carvallo, J. F. and Y. Samson (2010). "Microembolic signals in systemic lupus erythematosus and other cerebral small vessel diseases." Journal of Neurology 257(4): 503-508. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Microembolic%20signals%20in%20systemic%20lupus%20erythematosus%20and%20other%20cerebral%20small%20vessel%20diseases" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lee, Y., J. H. Woo, et al. (2010) "Induction and maintenance therapy for lupus nephritis: a systematic review and meta-analysis." Lupus. May; 19(6):703-710. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20064907" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lee, Y. H., J. H. Woo, et al. (2010). "Functional monocyte chemoattractant protein-1 promoter -2518 polymorphism and systemic lupus erythematosus: a meta-analysis." Molecular Biology Reports 37(7): 3421-6.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19941075" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Li, G., M. Zhao, et al. (2010). "Meta-analysis of the risk factors of avascular necrosis of bone in patients with systemic lupus erythematosus." International Journal of Rheumatic Diseases 13.&amp;nbsp;[No PubMed abstract available]&lt;/LI&gt;
&lt;LI&gt;Li, L. H., H. Yuan, et al. (2010) "Role of the Fcgamma receptor IIIA-V/F158 polymorphism in susceptibility to systemic lupus erythematosus and lupus nephritis: a meta-analysis." Scand J Rheumatol. Mar; 39(2):148-54.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20059375" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mok, C. C., T. T. Cheung, et al. (2010) "Minimal mesangial lupus nephritis: a systematic review." Scandinavian Journal of Rheumatology 39(3): 181-9. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Minimal%20mesangial%20lupus%20nephritis%3A%20a%20systematic%20review" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Smyth, A., Oliveira, G.H., Lahr, B.D., Bailey, K.R., Norby, S.M., Garovic, V.D. (2010) "A Systematic Review and Meta-Analysis of Pregnancy Outcomes in Patients with Systemic Lupus Erythematosus and Lupus Nephritis." Clin J Am Soc Nephrol. 2010 Aug 5 [Epub ahead of print]. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20688887" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Touma, Z., M. Urowitz, et al. (2010). "Systematic review and meta-analysis of randomized trials for mycophenolic acid and mycophenolate mofetil for induction treatment of lupus nephritis." Journal of Rheumatology 37(6 SUPPL. 2): 1310-1311.&amp;nbsp;[No PubMed abstract available]&lt;/LI&gt;
&lt;LI&gt;Touma, Z., D. D. Gladman, et al. (2011). "Mycophenolate mofetil for induction treatment of lupus nephritis: a systematic review and metaanalysis." Journal of Rheumatology 38(1): 69-78. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20952473" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Bates, J. S., C. J. Lessard, et al. (2009). "Meta-analysis and imputation identifies a 109 kb risk haplotype spanning TNFAIP3 associated with lupus nephritis and hematologic manifestations." Genes Immun.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19387456" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Bertsias, G. K., J. P. A. Ioannidis, et al. (2009). "EULAR points to consider for conducting clinical trials in systemic lupus erythematosus: literature based evidence for the selection of endpoints." Annals of the Rheumatic Diseases 68(4): 477-483.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18434449" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lee, Y. H., J. D. Ji, et al. (2009). "Fcgamma receptor IIB and IIIB polymorphisms and susceptibility to systemic lupus erythematosus and lupus nephritis: a meta-analysis." Lupus 18(8): 727-34.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19502269" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lee, Y. H., J. H. Woo, et al. (2009). "Association of programmed cell death 1 polymorphisms and systemic lupus erythematosus: a meta-analysis." Lupus 18(1): 9-15.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19074163" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lee, Y. H., J. H. Woo, et al. (2009). "Functional monocyte chemoattractant protein-1 promoter -2518 polymorphism and systemic lupus erythematosus: a meta-analysis." Mol Biol Rep.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19941075" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mak, A., A. A. Cheak, et al. (2009). "Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression." Rheumatology (Oxford).&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19494179" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Ramos-Casals, M., M. J. Soto, et al. (2009). "Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases." Lupus 18(9): 767-76.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19578100" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Yuan, H., H. F. Pan, et al. (2009). "Meta analysis on the association between FcgammaRIIa-R/H131 polymorphisms and systemic lupus erythematosus." Mol Biol Rep 36(5): 1053-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18535921" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;No systematic reviews.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Madhok, R. and O. Wu (2007). "Systemic lupus erythematosus." Clin Evid (Online) 2007.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19454065" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mok, C. C. (2007). "Mycophenolate mofetil for non-renal manifestations of systemic lupus erythematosus: a systematic review." Scand J Rheumatol 36(5): 329-37.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17963161" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Stratta, P., C. Canavese, et al. (2007). "[Treating lupus nephritis: guideline from the Italian Society of Nephrology.]." G Ital Nefrol 24 Suppl 37: 50-63.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17347955" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Walsh, M., M. James, et al. (2007). "Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis." Clin J Am Soc Nephrol 2(5): 968-75.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17702723" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Zhu, B., N. Chen, et al. (2007). "Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials." Nephrol Dial Transplant 22(7): 1933-42.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17405792" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2006&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;No systematic reviews. &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>11/01/2011 10:22:31</lastReviewDate>
    <expiryDate>11/01/2012 00:00:00</expiryDate>
  </document>
  <document>
    <id>224544</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.bmj.com/cgi/content/full/328/7441/0-f]]&gt;</url>
    <title>Tamsulosin (Flomax) is effective for renal colic</title>
    <publicationDate>2004-03-20T00:00:00</publicationDate>
    <publisher>BMJ  2004;328 (20 March)</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ KIDNEY AND BLADDER STONES,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>InfoPOEM - Patient oriented evidence that matters</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Extract from website &lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Even though this study is fraught with methodological shortcomings, it seems highly likely that tamsulosin (Flomax) is effective in hastening the passage of juxtavesical ureteral stones and decreasing both the severity and duration of renal colic. &lt;BR&gt;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>13/12/2010 11:41:29</lastReviewDate>
    <expiryDate>13/12/2011 11:41:29</expiryDate>
  </document>
  <document>
    <id>321943</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=321943]]&gt;</url>
    <title>Testicular/ scrotal disorders: Systematic reviews and meta-analyses</title>
    <publicationDate>2011-01-24T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,TESTICULAR/ SCROTAL DISORDERS,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Testicular/ scrotal disorders: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Elyas, R., L. A. Guerra, et al. (2010). "Is staging beneficial for Fowler-Stephens orchiopexy? A systematic review." Journal of Urology 183(5): 2012-2018. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20303527" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Fernandez-Balsells, M. M., M. H. Murad, et al. (2010). "Adverse effects of testosterone therapy in adult men: A systematic review and meta-analysis." Journal of Clinical Endocrinology and Metabolism 95(6): 2560-2575. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20525906" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Fernandez-Balsells, M. M., M. H. Murad, et al. (2010). "Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis." Journal of Clinical Endocrinology &amp;amp; Metabolism 95(6): 2560-75.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20525906" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Fullerton, G., A. Maheshwari, et al. (2010). "Should non-mosaic Klinefelter's patients still be labelled as infertile? A systematic review of the success of surgical sperm retrieval in Klinefelter's patients." Journal of Obstetrics and Gynaecology 30(1). [No PubMed abstract available]&lt;/LI&gt;
&lt;LI&gt;Kumar, P., V. Mehta, et al. (2010). "Clinical management of chronic testicular pain." Urologia Internationalis 84(2): 125-131.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20215814" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Yiee, J. H. and L. S. Baskin (2010). "Environmental factors in genitourinary development." Journal of Urology 184(1): 34-41.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20478588" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Bergholz R, Wenke K. Polyorchidism: a meta-analysis. Journal of Urology. 2009;182(5):2422-7. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19765760" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Cornwall, G. A. (2009). "New insights into epididymal biology and function." Human Reproduction Update 15(2): 213-27.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=2009[pdat]%20AND%20cornwall[author]%20AND%20New%20insights%20into%20epididymal%20biology%20and%20function" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Gonzalez Lopez R, Bueno Serrano G, Garcia Navas R, Diez Nicolas V, Vazquez Escuderos JJ, Mayor de Castro J. [Cystic displasia of the testis. Review of literature]. [Spanish] Displasia quistica de rete testis: revision de la literatura. Actas Urologicas Espanolas. 2009;33(4):386-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19579889" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Henning, J. and S. Waxman (2009). "Legal aspects of men's genitourinary health." International Journal of Impotence Research 21(3): 165-70.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19212325?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mathers MJ, Sperling H, Rubben H, Roth S. The undescended testis: diagnosis, treatment and long-term consequences. Deutsches Arzteblatt. 2009;106(33):527-32.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19738919" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Gapany, C., P. Frey, et al. (2008). "Management of cryptorchidism in children: guidelines." Swiss Med Wkly 138(33-34): 492-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18726735?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Martin, O. V., T. Shialis, et al. (2008). "Testicular dysgenesis syndrome and the estrogen hypothesis: A quantitative meta-analysis." Environmental Health Perspectives 116(2): 149-157.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18288311?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;McCabe, J. E. and S. E. Kenny (2008). "Orchidopexy for undescended testis in England: is it evidence based?" J Pediatr Surg 43(2): 353-7.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18280289?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Schout, B. M. A., A. J. M. Hendrikx, et al. (2008). "Update on Training Models in Endourology: A Qualitative Systematic Review of the Literature between January 1980 and April 2008." European Urology 54(6): 1247-1261.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18597924?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Sijstermans, K., W. W. M. Hack, et al. (2008). "The frequency of undescended testis from birth to adulthood: A review." International Journal of Andrology 31(1): 1-11.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17488243?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Zang, Y. L., L. Y. Chung, et al. (2008). "A review of the psychosocial issues for nurses in male genitalia-related care." J Clin Nurs 17(8): 983-98.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18321268" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Fernandez, M. F., B. Olmos, et al. (2007). "[Exposure to endocrine disruptors and male urogenital tract malformations [cryptorchidism and hypospadias]]." Gac Sanit 21(6): 500-14.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18001666?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Magoha, G. A. and O. B. Magoha (2007). "Aetiology, diagnosis and management of haemospermia: a review." East African Medical Journal 84(12): 589-94.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18402311" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Walsh, T. J., M. A. Dall'Era, et al. (2007). "Prepubertal orchiopexy for cryptorchidism may be associated with lower risk of testicular cancer." J Urol 178(4 Pt 1): 1440-6; discussion 1446.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17706709?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:21:08</lastReviewDate>
    <expiryDate>06/07/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>321993</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=321993]]&gt;</url>
    <title>Testosterone: Systematic reviews and meta-analyses</title>
    <publicationDate>2011-02-21T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,TESTICULAR/ SCROTAL DISORDERS,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Testosterone: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2011&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Cunningham GR, Toma SM. Why is androgen replacement in males controversial? Journal of Clinical Endocrinology and Metabolism. 2011;96(1):38-52. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20881265" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Fernandez-Balsells, M. M., M. H. Murad, et al. (2010). "Adverse effects of testosterone therapy in adult men: A systematic review and meta-analysis." Journal of Clinical Endocrinology and Metabolism 95(6): 2560-2575. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20525906" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;MacDonald, A. A., G. P. Herbison, et al. (2010). "The impact of body mass index on semen parameters and reproductive hormones in human males: a systematic review with meta-analysis." Human Reproduction Update 16(3): 293-311. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19889752" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Novara G, Galfano A, Secco S, Ficarra V, Artibani W. Impact of surgical and medical castration on serum testosterone level in prostate cancer patients. Urologia Internationalis. 2009;82(3):249-55. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19440008" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Shabsigh R, Crawford ED, Nehra A, Slawin KM. Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review. International Journal of Impotence Research. 2009;21(1):9-23.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18633357" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Mueller, A. and L. Gooren (2008). "Hormone-related tumors in transsexuals receiving treatment with cross-sex hormones." European Journal of Endocrinology 159(3): 197-202.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18567667" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;2006&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Beauchet, O. (2006). "Testosterone and cognitive function: current clinical evidence of a relationship." Eur J Endocrinol 155(6): 773-81.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17132744?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>16/07/2010 14:33:38</lastReviewDate>
    <expiryDate>02/08/2012 00:00:00</expiryDate>
  </document>
  <document>
    <id>177762</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.dopps.org/pdf/dopps_report_2005.pdf]]&gt;</url>
    <title>The DOPPS Report 2005</title>
    <publicationDate>2005-01-03T00:00:00</publicationDate>
    <publisher>DOPPS</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DOPPS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Newsletter of the Dialysis Outcomes and Practice Patterns Study</description>
    <body>&lt;![CDATA[ &lt;FONT face=TimesNewRomanPSMT&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Extract from website&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;The DOPPS Report is an annual update from staff and researchers with information on the status of data collection worldwide, recent research publications and presentations, and relevant issues for study coordinators&lt;/P&gt;
&lt;P&gt;Launched as a prospective, longitudinal,observational study of hemodialysis facilities and patients in 1996, DOPPS I collected data for five years in the US and two years in France, Germany, Italy, Japan, Spain, and the United Kingdom beginning in 1998/99. The success of DOPPS I resulted in the extension of the study into a new stage, DOPPS II (2002-2004), and the added participation of five new countries—Australia, Belgium, Canada, New Zealand, and Sweden. In 2005, the DOPPS&amp;nbsp;launched another stage—DOPPS III—that will collect data through the end of 2007.&lt;/P&gt;&lt;/FONT&gt;&lt;A href="http://www.dopps.org/pdfs/dopps_report_2005.pdf" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:35:40</lastReviewDate>
    <expiryDate>06/07/2011 11:35:40</expiryDate>
    <relatedLinks>&lt;a href="http://www.dopps.org/pdf/dopps_report_2005.pdf" title="Link to report"/&gt;&lt;a href="http://www.dopps.org/pdf/dopps_report_2003.pdf" title="The DOPPS Report 2003"/&gt;&lt;a href="http://www.dopps.org/pdf/dopps_report_2004.pdf" title="The DOPPS Report 2004"/&gt;&lt;a href="http://www.dopps.org/pdf/dopps_report_2002.pdf" title="The DOPPS Report 2002"/&gt;&lt;a href="http://www.dopps.org/pdf/dopps_report_2001.pdf" title="The DOPPS Report 2001"/&gt;&lt;a href="http://www.dopps.org/pdf/dopps_report_2000.pdf" title="The DOPPS Report 2000"/&gt;&lt;a href="http://www.dopps.org/pdf/dopps_report_1999.pdf" title="The DOPPS Report 1999 (October)"/&gt;&lt;a href="http://www.dopps.org/pdf/dopps_report_1999_f.pdf" title="The DOPPS Report 1999 (February)"/&gt;&lt;a href="http://www.dopps.org/pdf/dopps_report_1998.pdf" title="The DOPPS Report 1998"/&gt;</relatedLinks>
    <creator>DOPPS</creator>
  </document>
  <document>
    <id>156426</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/assetRoot/04/13/21/07/04132107.pdf]]&gt;</url>
    <title>The Evidence Base for the National Service Framework for Renal Services</title>
    <publicationDate>2004-01-05T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ HAEMODIALYSIS,TRANSPLANTATION,NATIONAL SERVICE FRAMEWORK FOR RENAL SERVICES/POLICY DOCUMENTS,PERITONEAL DIALYSIS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,DIALYSIS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Modules One and Two: Dialysis and Transplantation</description>
    <body>&lt;![CDATA[ &lt;P&gt;Extract from website&lt;/P&gt;
&lt;P&gt;This report is the result of reviewing the evidence for modules one and two of the National Service Framework for Renal Services, which cover dialysis and transplantation.&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>24/09/2010 11:29:22</lastReviewDate>
    <expiryDate>24/09/2011 11:29:22</expiryDate>
  </document>
  <document>
    <id>156427</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/assetRoot/04/13/21/20/04132120.pdf]]&gt;</url>
    <title>The Evidence Base for the National Service Framework for Renal Services Part Two: Chronic Kidney Disease, Acute Renal Failure and End of Life Care</title>
    <publicationDate>2004-01-01T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ END-OF-LIFE CARE,ACUTE KIDNEY INJURY,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Modules covering chronic kidney disease (CKD), acute renal failure (ARF) and end of life care.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Extract from website&lt;/EM&gt; &lt;/P&gt;
&lt;P&gt;This report is the result of reviewing the evidence for Part Two of the National Service Framework (NSF) for Renal Services. These modules cover chronic kidney disease (CKD), acute renal failure (ARF) and end of life care.&lt;/P&gt;]]&gt;</body>
    <expiryDate>01/09/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>319302</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.brook.org.uk/content/M2_1_Contraception.asp]]&gt;</url>
    <title>The Facts: Contraception</title>
    <publicationDate></publicationDate>
    <publisher>Brook Advisory Centres</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE SEXUALLY TRANSMITTED INFECTIONS,FERTILITY,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>There are 14 methods of contraception to choose from. Here you'll find information on each of them, how they work, and their advantages and disadvantages.</description>
    <body>&lt;![CDATA[ &lt;P&gt;There are 14 methods of contraception to choose from. Here you'll find information on each of them, how they work, and their advantages and disadvantages.&lt;SPAN class=Apple-style-span style="WORD-SPACING: 0px; FONT: 16px Verdana; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BORDER-COLLAPSE: separate; TEXT-ALIGN: center; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"&gt;&lt;/P&gt;
&lt;P&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>01/07/2010 15:03:59</lastReviewDate>
    <expiryDate>01/07/2011 15:03:59</expiryDate>
  </document>
  <document>
    <id>293896</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.goldstandardsframework.nhs.uk/index.php]]&gt;</url>
    <title>The gold standards framework</title>
    <publicationDate></publicationDate>
    <publisher>NHS End of Life Care Programme</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ END-OF-LIFE CARE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Website for the gold standards framework - a programme for community palliative care</description>
    <body>&lt;![CDATA[ &lt;P&gt;Extract&lt;/P&gt;
&lt;DIV align=justify&gt;&lt;SPAN class=copy&gt;&lt;/SPAN&gt;&lt;SPAN class=copyb&gt;&lt;SPAN class=copy&gt;
&lt;P class=copy&gt;The Gold Standards Framework (GSF) is a systematic evidence based approach to optimising the care for patients nearing the end of life in the community.&lt;BR&gt;&lt;BR&gt;It was originally developed from within primary care for primary care by Dr Keri Thomas (a GP with a Special Interest in Palliative Care and NHS National Clinical lead for Generalist Palliative Care, supported by a multidisciplinary reference group of specialists and generalists, to improve palliative care provided in the community by the patient's usual health care team. It was first piloted in Yorkshire in 2001 in Phase 1, followed by a national programme of 11 Phases over the last 7 years. &lt;/P&gt;
&lt;P class=copy&gt;GSF has for 3 years (April 2005 -&amp;nbsp;March 2008) been part&amp;nbsp;of the &lt;A href="http://www.endoflifecare.nhs.uk/" target="_blank"&gt;NHS End of life Care Programme&lt;/A&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/DIV&gt;
&lt;DIV align=justify&gt;&lt;SPAN class=copyb&gt;&lt;SPAN class=copy&gt;GSF is applicable to patients with ANY ADVANCED ILLNESS (heart failure, COPD, neurological disorders, renal failure etc)&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/DIV&gt;
&lt;DIV align=justify&gt;&lt;SPAN class=copyb&gt;&lt;SPAN class=copy&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/DIV&gt;
&lt;DIV align=justify&gt;&lt;SPAN class=copyb&gt;&lt;SPAN class=copy&gt;The focus of the GSF programme&amp;nbsp;are to improve care for the dying in the community by optimising the local primary care team's provision, so that more patients are enabled to live and die where they choose, and un-needed hospital admissions are avoided&lt;/DIV&gt;
&lt;P&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
    <expiryDate>30/10/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>155005</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/PublicationsAndStatistics/Publications/PublicationsPolicyAndGuidance/PublicationsPolicyAndGuidanceArticle/fs/en?CONTENT_ID=4136317&amp;chk=0bHKlG]]&gt;</url>
    <title>The National Service Framework for Renal Services: working for children and young people</title>
    <publicationDate>2006-06-26T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ CHILDREN AND ADOLESCENTS ON HAEMODIALYSIS,TRANSPLANTATION,HAEMODIALYSIS,KIDNEY DISEASE IN CHILDREN AND ADOLESCENTS,NEONATAL NEPHROTIC SYNDROME,IN CHILDREN,INHERITED KIDNEY DISEASE,RENOVASCULAR DISEASES,END-OF-LIFE CARE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES,DIALYSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The document is intended to be user-friendly and details how the recommendations of the NSF for Renal Services can be delivered in paediatric services, and draws together information that was previously found in two different NSFs. It is aimed at those commissioning, providing and using services for children and young people with kidney disease. It details the quality improvements in children's services that will be achieved by implementing the standard and quality requirements.</description>
    <body>&lt;![CDATA[ &lt;P&gt;This guide is a supplement to The National Service Framework (NSF) for Renal Services. The Renal NSF deals with services for renal patients of all ages: this document focuses specifically on services for children and young people, and describes in greater detail than the Renal NSF how the standards, quality requirements and markers of good practice apply to the care of children and young people with kidney disease and their families.&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>01/07/2010 15:04:13</lastReviewDate>
    <expiryDate>01/07/2011 15:04:13</expiryDate>
  </document>
  <document>
    <id>308786</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.jurology.com/article/S0022-5347(07)00742-2/abstract]]&gt;</url>
    <title>The Oral Mucosa Graft: A Systematic Review</title>
    <publicationDate>2007-08-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE URETHRAL DISORDERS,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>We provide the reader with a critical, nonbiased, systematic review of current and precedent literature regarding the use of oral mucosa in the reconstruction of urethral defects associated with stricture and hypospadias/epispadias.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Extract:&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Purpose&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;We provide the reader with a critical, nonbiased, systematic review of current and precedent literature regarding the use of oral mucosa in the reconstruction of urethral defects associated with stricture and hypospadias/epispadias.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Materials and Methods&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;We reviewed pertinent English literature from January 1966 through August 1, 2006 via the databases MEDLINE/PubMed, the Cochrane Library, and EMBASE Drugs and Pharmacology regarding the use of oral mucosa graft urethroplasty in the reconstruction of urethral defects associated with stricture and hypospadias/epispadias. Bibliographies of pertinent articles were explored for additional important literature.&lt;BR&gt;Results&lt;/P&gt;
&lt;P&gt;Data were stratified among studies that only used oral mucosa graft urethroplasty in the reconstruction of urethral defects associated with stricture, and those that used oral mucosa graft urethroplasty in the reconstruction of urethral defects associated with hypospadias/epispadias. Recipient site success in the reconstruction of defects associated with stricture was significantly associated with the location of graft placement (ventral vs dorsal, p &amp;lt;0.001) when an onlay graft was used. Hypospadias/epispadias recipient site success was significantly associated with the type of graft used (tube vs onlay, p &amp;lt;0.001), and by the site of oral mucosa harvest (labial vs buccal, p &amp;lt;0.001). Other perioperative and patient oriented variables were not significantly associated with success at the recipient site.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Conclusions&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;The oral mucosa is a viable source of donor tissue displaying many characteristics of the ideal urethral graft. There are numerous variations of the oral mucosa graft urethroplasty technique. Herein comparisons are made.&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>14/02/2011 11:41:16</lastReviewDate>
    <expiryDate>14/02/2012 11:41:16</expiryDate>
  </document>
  <document>
    <id>299465</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_090312]]&gt;</url>
    <title>The potential impact of an opt out system for organ donation in the UK: an independent report from the Organ Donation Taskforce</title>
    <publicationDate>2008-11-17T00:00:00</publicationDate>
    <publisher>Organ Donation Taskforce</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ TRANSPLANTATION,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This independent report from the Organ Donation Taskforce about the potential impact of changing to an opt out system of consent provides an in-depth examination of this complex question.</description>
    <body>&lt;![CDATA[ &lt;P&gt;Contents &lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;A finely balanced question &lt;/LI&gt;
&lt;LI&gt;Setting the scene&lt;/LI&gt;
&lt;LI&gt;Methodology &lt;/LI&gt;
&lt;LI&gt;The current situation – issues and limitations &lt;/LI&gt;
&lt;LI&gt;Different forms of consent &lt;/LI&gt;
&lt;LI&gt;Legal issues &lt;/LI&gt;
&lt;LI&gt;Ethical issues&lt;/LI&gt;
&lt;LI&gt;How an opt out system would operate in practice&lt;/LI&gt;
&lt;LI&gt;Legislative implications&lt;/LI&gt;
&lt;LI&gt;The practical issues that would need to be addressed in order to implement an opt out system&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;Impact of the introduction of an opt out system on the number of organ donors&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;Attitudes of the public to an opt out system &lt;/LI&gt;
&lt;LI&gt;Attitudes of different faith and belief groups to an opt out system &lt;/LI&gt;
&lt;LI&gt;Communications requirements were an opt out system to be introduced &lt;/LI&gt;
&lt;LI&gt;Conclusion&amp;nbsp; &lt;BR&gt;&lt;/LI&gt;&lt;/OL&gt;]]&gt;</body>
    <lastReviewDate>09/11/2010 14:22:13</lastReviewDate>
    <expiryDate>09/11/2011 14:22:13</expiryDate>
  </document>
  <document>
    <id>258732</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.britishrenal.org/Workforce-Planning.aspx]]&gt;</url>
    <title>The renal team - a multiprofessional renal workforce plan for adults and children with renal disease. Recommendations of the National Renal Workforce Planning Group</title>
    <publicationDate>2002-03-31T00:00:00</publicationDate>
    <publisher>British Renal Society</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ NATIONAL SERVICE FRAMEWORK FOR RENAL SERVICES/POLICY DOCUMENTS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Recommendations of the National Renal Workforce Planning Group</description>
    <body>&lt;![CDATA[ The purpose of this document is to provide a robust renal workforce plan to support the implementation of the Renal National Service Framework and renal plans for Scotland, Wales and Northern Ireland.]]&gt;</body>
    <lastReviewDate>04/03/2011 11:18:54</lastReviewDate>
    <expiryDate>04/03/2012 11:18:54</expiryDate>
  </document>
  <document>
    <id>155624</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.hdcn.com/symp/05asn/03/05asn03.htm]]&gt;</url>
    <title>The role of iron deficiency in anemia management: key controversies</title>
    <publicationDate></publicationDate>
    <publisher>Hypertension, Dialysis and Clinical Nephrology (HDCN)</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ COMPLICATIONS OF KIDNEY DISEASE,ANAEMIA,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Source of free CPD material for doctors, nurses and other medical professionals.
</description>
    <body>&lt;![CDATA[ &lt;P&gt;The CPD resource comprises talks and slide presentations, for which some additional software (such as macromedia flash player) may be needed for access.&lt;/P&gt;
&lt;P&gt;Note : You need to register for a freezone&amp;nbsp;loginID and password to access the free resources&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;'Method of participation:&lt;/B&gt; Listen to the talk, read the PubMed abstracts linked to data slides and talk references, take the post-test, read the abstracts linked to post-test answer feedback material' (website extract)&lt;/P&gt;
&lt;P&gt;Click on&amp;nbsp;Free Zone Index to view the other free resources at a glance.&lt;/P&gt;
&lt;P&gt;Created November 2005&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>24/09/2010 11:29:54</lastReviewDate>
    <expiryDate>24/09/2011 11:29:54</expiryDate>
  </document>
  <document>
    <id>155514</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.renal.org/CKDguide/ckd.html]]&gt;</url>
    <title>The UK CKD Guidelines (2005)</title>
    <publicationDate>2009-01-05T00:00:00</publicationDate>
    <publisher>Joint Specialty Committee of RCP and Renal Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ INTERVENTIONS,SCREENING OPTIONS,PREDISPOSING FACTORS,ASSESSMENT OF RENAL FUNCTION,PRESENTATION OF CKD,COMPLICATIONS OF KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>UK Guidelines for the management of chronic kidney disease</description>
    <body>&lt;![CDATA[ Comprehensive proposals for identification and management of kidney disease in primary care]]&gt;</body>
    <expiryDate>01/09/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>288498</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.bestbets.org/bets/bet.php?id=297]]&gt;</url>
    <title>The use of loop diuretics in acute renal failure in critically ill patients to reduce mortality, maintain renal function or avoid the requirements for renal support</title>
    <publicationDate>2006-02-10T00:00:00</publicationDate>
    <publisher>Best Bets</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ SURGERY,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,ACUTE KIDNEY INJURY,MANAGEMENT,CLINICAL TOPICS,CRITICAL CARE,RENAL,ORGAN SUPPORT,PROCEDURES AND INTERVENTIONS,RENAL AND UROLOGICAL,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Critically appraised topic from Best Bets</description>
    <body>&lt;![CDATA[ &lt;P&gt;Extract&lt;/P&gt;
&lt;H2 class=noSpacing&gt;Clinical Bottom Line&lt;/H2&gt;
&lt;P&gt;In critically ill patients with acute renal failure, there is no evidence to suggest that the use of loop diuretics reduces mortality, reduces length of ITU/hospital stay or increases the recovery of renal function. &lt;/P&gt;]]&gt;</body>
    <lastReviewDate>01/07/2010 15:04:21</lastReviewDate>
    <expiryDate>01/07/2011 15:04:21</expiryDate>
  </document>
  <document>
    <id>155710</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.renal.org/unit/index.pl?c=belfast]]&gt;</url>
    <title>Transplant Centre for Northern Ireland, Belfast City Hospital</title>
    <publicationDate>2009-07-21T00:00:00</publicationDate>
    <publisher>Renal Association</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ TRANSPLANTATION,TRANSPLANT CENTRES,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Web page from the Renal Association providing contact details and background information</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Extract from website&lt;/EM&gt;&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;About the unit&lt;BR&gt;&amp;nbsp;&lt;BR&gt;The Mary G McGeown Regional Nephrology Unit at the Belfast City Hospital provides regional renal services to all of N Ireland and has strong links with the Sub Regional Units in Antrim, Newry,Omagh and Dundonald. It is also the Transplant Centre for N.Ireland where over 1300 transplants have taken place at an annual average of 50. &lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
    <expiryDate>01/09/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>126410</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.uktransplant.org.uk/ukt/about_transplants/organ_allocation/kidney_(renal)/national_protocols_and_guidelines/protocols_and_guidelines/transplant_list_criteria.jsp]]&gt;</url>
    <title>Transplant criteria list for potential renal transplant patients</title>
    <publicationDate>2000-09-01T00:00:00</publicationDate>
    <publisher>UK Transplant NHS</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ TRANSPLANTATION,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Guidelines</description>
    <body>&lt;![CDATA[ List of criteria for potential renal tansplant patients]]&gt;</body>
    <lastReviewDate>01/07/2010 14:29:46</lastReviewDate>
    <expiryDate>01/07/2011 14:29:46</expiryDate>
  </document>
  <document>
    <id>182119</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://renux.dmed.ed.ac.uk/edren/EdRenHDBKhome.html#anchor340890]]&gt;</url>
    <title>Transplant protocols</title>
    <publicationDate>2009-08-10T00:00:00</publicationDate>
    <publisher>EdRen Handbook</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ PREVENTION OF COMPLICATIONS,IMMUNOSUPPRESSIVE DRUGS,TRANSPLANT OPERATION,ASSESSMENT/SELECTION,TRANSPLANTATION,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Abbreviated medical protocols from Royal Infirmary of Edinburgh Renal Unit (EdRen Handbook)</description>
    <body>&lt;![CDATA[ Webpage of links to abbreviated medical protocols (presented in approximate temporal order: pretransplant, the operation, post operative management, immunosuppressive drugs, infection and infection prophylaxis, drugs and prescribing).&lt;BR&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:36:00</lastReviewDate>
    <expiryDate>06/07/2011 11:36:00</expiryDate>
  </document>
  <document>
    <id>155618</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.hdcn.com/symp/05asn/04/05asn04.htm]]&gt;</url>
    <title>Transplantation: key issues for the General Nephrologist</title>
    <publicationDate>2005-11-01T00:00:00</publicationDate>
    <publisher>Hypertension, Dialysis and Clinical Nephrology (HDCN)</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ TRANSPLANTATION,IMMUNOSUPPRESSIVE DRUGS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Source of free CPD material for doctors, nurses and other medical professionals</description>
    <body>&lt;![CDATA[ &lt;P&gt;The CPD resource comprises talks and slide presentations, for which some additional software (such as macromedia flash player) may be needed for access.&lt;/P&gt;
&lt;P&gt;Note : You need to register for a freezone&amp;nbsp;loginID and password to access the free resources&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;'Method of participation:&lt;/B&gt; Listen to the talk, read the PubMed abstracts linked to data slides and talk references, take the post-test, read the abstracts linked to post-test answer feedback material' (website extract)&lt;/P&gt;
&lt;P&gt;Click on&amp;nbsp;Free Zone Index to view the other free resources at a glance.&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:36:07</lastReviewDate>
    <expiryDate>06/07/2011 11:36:07</expiryDate>
  </document>
  <document>
    <id>301793</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.renal.org/pages/media/Guidelines/EPS-Guideline-4.pdf]]&gt;</url>
    <title>UK Encapsulating Peritoneal Sclerosis Clinical Guidelines - draft (12/10/08)</title>
    <publicationDate>2008-12-22T00:00:00</publicationDate>
    <publisher>UK EPS Network</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ PERITONEAL DIALYSIS,PREVENTION OF INFECTIONS,STARTING PERITONEAL DIALYSIS,ACCESS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES,DIALYSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A draft guideline has been produced on behalf of the UK EPS Network to help clinicians caring for patients on PD.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Extract:&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Encapsulating Peritoneal Sclerosis (EPS) is an important complication of long-term PD. Although it is uncommon (thus comparable to serious modality-specific complications of HD), it is causing increasing concern amongst nephrologists and potentially having a negative effect on PD uptake and management. There is uncertainty about the approach to a variety of aspects of this condition.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;A draft guideline has been produced on behalf of the UK EPS Network to help clinicians caring for patients on PD. These guidelines cover important aspects that cause concern to clinicians including:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Diagnosis of EPS (including differentiation from more ‘benign’ changes of long term PD) 
&lt;LI&gt;Management, including the place of a variety of medical treatments, surgery (for which units in Manchester and Cambridge have been designated by NSCAG as national referral centres for EPS surgery), and parenteral nutrition 
&lt;LI&gt;EPS following renal transplantation (implications and management) 
&lt;LI&gt;Management of long-term PD patients (can we screen for EPS of prevent it occurring)&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
    <lastReviewDate>09/11/2010 14:22:08</lastReviewDate>
    <expiryDate>09/11/2011 14:22:08</expiryDate>
  </document>
  <document>
    <id>287930</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.renalreg.com/Reports/2007.html]]&gt;</url>
    <title>UK Renal Registry 10th Annual Report</title>
    <publicationDate>2007-06-01T00:00:00</publicationDate>
    <publisher>UK Renal Registry</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ DOPPS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The UK Renal Registry (UKRR) is part of the UK Renal Association and provides independent, professionally led, audit and analysis of renal replacement therapy (RRT) in the UK.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Report covers:&lt;/EM&gt;&lt;/STRONG&gt; &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;New Adult Patients Starting RRT in the UK in 2006 
&lt;LI&gt;All Patients Receiving Renal Replacement Therapy in the United Kingdom in 2006 
&lt;LI&gt;Co-morbidities in UK Patients at the Start of RRT 
&lt;LI&gt;Survival of Incident and Prevalent Patients 
&lt;LI&gt;Haemodialysis Dose 
&lt;LI&gt;Management of Anaemia in Dialysis Patients 
&lt;LI&gt;Management of Biochemical Variables 
&lt;LI&gt;Blood Pressure in Prevalent RRT Patients 
&lt;LI&gt;Measures of Care in Adult Renal Transplant Recipients in the UK 
&lt;LI&gt;Comparison of UK Registry Data with other National Renal Registries &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;It is now possible for any member of the healthcare community or general public to see centre-specific analyses on each audit measure, including survival.&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>24/09/2010 11:32:21</lastReviewDate>
    <expiryDate>24/09/2011 11:32:21</expiryDate>
  </document>
  <document>
    <id>308756</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.renalreg.com/Maps/maps.html]]&gt;</url>
    <title>UK Renal Registry Interactive Maps</title>
    <publicationDate>2009-03-12T00:00:00</publicationDate>
    <publisher>UK Renal Registry</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ PERITONEAL DIALYSIS,HAEMODIALYSIS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES,DIALYSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>To mark World Kidney day on March 12th 2009, the UK Renal Registry has launched the world’s first interactive maps showing details of achievement of quality measures in the care of dialysis patients in kidney units.</description>
    <body>&lt;![CDATA[ &lt;P&gt;To mark World Kidney day on March 12th, the UK Renal Registry has launched the world’s first interactive maps showing details of achievement of quality measures in the care of dialysis patients in kidney units.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;These maps have been developed by Dr A Chaudry for UK Renal Registry in close collaboration and support from the East Midlands Public Health Observatory. The work was supported by a grant from the Department of Health (England).&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The maps allow clinicians, commissioners and patients to obtain details about a selected topic; to see how their renal centre is performing and how well any&amp;nbsp; centre is achieving specified national targets. The maps currently cover England, Wales and Northern Ireland, with Scotland to be added later in the year, along with additional quality indicators and other general population data. &lt;/P&gt;]]&gt;</body>
    <lastReviewDate>14/02/2011 11:41:28</lastReviewDate>
    <expiryDate>14/02/2012 11:41:28</expiryDate>
  </document>
  <document>
    <id>155711</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.renal.org/unit/index.pl?qp=1&amp;res=3]]&gt;</url>
    <title>UK Renal Units undertaking transplantation</title>
    <publicationDate></publicationDate>
    <publisher>Renal Association</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ TRANSPLANT CENTRES,TRANSPLANTATION,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Summary list from Renal Association</description>
    <body>&lt;![CDATA[ List of Transplant Units in the UK]]&gt;</body>
    <lastReviewDate>06/07/2010 11:36:15</lastReviewDate>
    <expiryDate>06/07/2011 11:36:15</expiryDate>
  </document>
  <document>
    <id>321946</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=321946]]&gt;</url>
    <title>Ureteric obstruction: Systematic reviews and meta-analyses</title>
    <publicationDate>2011-01-24T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE URETERIC DISORDERS,URETERIC OBSTRUCTION,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Ureteric obstruction: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Braga LHP, Pace K, DeMaria J, Lorenzo AJ. Systematic Review and Meta-Analysis of Robotic-Assisted versus Conventional Laparoscopic Pyeloplasty for Patients with Ureteropelvic Junction Obstruction: Effect on Operative Time, Length of Hospital Stay, Postoperative Complications, and Success Rate. European Urology. 2009;56(5):848-58. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19359084" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lamb, A. D., S. L. Vowler, et al. (2010). "Meta-analysis demonstrating beneficial effect of alpha blockers on ureteric stent discomfort." Journal of Endourology 24. [No PubMed abstract available]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Kouba, E., E. M. Wallen, et al. (2008). "Management of ureteral obstruction due to advanced malignancy: optimizing therapeutic and palliative outcomes." Journal of Urology 180(2): 444-50. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18550089?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Eden CG. Minimally invasive treatment of ureteropelvic junction obstruction: a critical analysis of results. Eur Urol. 2007 Oct;52(4):983-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17629395" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:21:12</lastReviewDate>
    <expiryDate>06/07/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>321947</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=321947]]&gt;</url>
    <title>Ureteric stones: Systematic reviews and meta-analyses</title>
    <publicationDate>2010-09-02T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE URETERIC DISORDERS,URETERIC STONES,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Ureteric stones: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Castagnetti, M. and W. Rigamonti (2010). "Extracorporeal shock wave lithotripsy for the treatment of urinary stones in children." Archivio Italiano di Urologia, Andrologia 82(1): 49-50. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20593721" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Ramsey, S., A. Robertson, et al. (2010). "Evidence-based drainage of infected hydronephrosis secondary to ureteric calculi." Journal of Endourology 24(2): 185-189. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/%2020063999" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Skolarikos, A., M. P. Laguna, et al. (2010). "The role for active monitoring in urinary stones: A systematic review." Journal of Endourology 24(6): 923-930.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20482232" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Skolarikos, A., H. Mitsogiannis, et al. (2010). "Indications, prediction of success and methods to improve outcome of shock wave lithotripsy of renal and upper ureteral calculi." Archivio Italiano di Urologia, Andrologia 82(1): 56-63.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20593724" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Zhu, Y., D. Duijvesz, et al. (2010). "alpha-Blockers to assist stone clearance after extracorporeal shock wave lithotripsy: A meta-analysis." BJU International 106(2): 256-261.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19889063" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Schuler, T. D., R. Shahani, et al. (2009). "Medical expulsive therapy as an adjunct to improve shockwave lithotripsy outcomes: a systematic review and meta-analysis." Journal of Endourology 23(3): 387-93.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19245302?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Seitz, C., E. Liatsikos, et al. (2009). "Medical Therapy to Facilitate the Passage of Stones: What Is the Evidence?" Eur Urol.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19560860?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Basiri, A., S. Zare, et al. (2008). "Ureteral calculi in children: what is best as a minimally invasive modality?" Urology Journal 5(2): 67-73.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18592456" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Haleblian, G., K. Kijvikai, et al. (2008). "Ureteral stenting and urinary stone management: a systematic review." Journal of Urology 179(2): 424-30.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18076928?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Losek, R. L. and L. S. Mauro (2008). "Efficacy of tamsulosin with extracorporeal shock wave lithotripsy for passage of renal and ureteral calculi." Ann Pharmacother 42(5): 692-7.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18413683?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Tricia, K. L. C., T. Y. Swam, et al. (2008). "To assess if alpha-blocker therapy increases stone free rates, and reduces renal colic in urinary stones, following extracorporeal shockwave lithotripsy (ESWL) - A systematic review." Singapore General Hospital Proceedings 17(2): 106-110.&amp;nbsp;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Kijvikai, K., G. E. Haleblian, et al. (2007). "Shock wave lithotripsy or ureteroscopy for the management of proximal ureteral calculi: an old discussion revisited." J Urol 178(4 Pt 1): 1157-63.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17698126" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Nabi, G., P. Downey, et al. (2007). "Extra-corporeal shock wave lithotripsy (ESWL) versus ureteroscopic management for ureteric calculi." Cochrane Database Syst Rev(1): CD006029.&amp;nbsp;[&lt;A href="nelh:239274:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Parsons, J. K., L. A. Hergan, et al. (2007). "Efficacy of alpha-blockers for the treatment of ureteral stones." J Urol 177(3): 983-7; discussion 987.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17296392" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Singh, A., H. J. Alter, et al. (2007). "A systematic review of medical therapy to facilitate passage of ureteral calculi." Ann Emerg Med 50(5): 552-63.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17681643" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;2006&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Beach, M. A. and L. S. Mauro (2006). "Pharmacologic expulsive treatment of ureteral calculi." Ann Pharmacother 40(7-8): 1361-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16849614" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:21:16</lastReviewDate>
    <expiryDate>06/07/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>321948</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=321948]]&gt;</url>
    <title>Ureterocele: Systematic reviews and meta-analyses</title>
    <publicationDate>2010-09-09T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE URETERIC DISORDERS,URETEROCELE,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Ureterocele: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2006&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Byun, E. and P. A. Merguerian (2006). "A meta-analysis of surgical practice patterns in the endoscopic management of ureteroceles." J Urol 176(4 Pt 2): 1871-7; discussion 1877. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/16945677" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:21:20</lastReviewDate>
    <expiryDate>06/07/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>386835</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=386835]]&gt;</url>
    <title>Urethral stricture: Systematic reviews and meta-analyses</title>
    <publicationDate>2011-01-24T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE URETHRAL DISORDERS,URETHRAL STRICTURE,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Urethral stricture: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence -&amp;nbsp;kidney diseases and male urogenital disorders&amp;nbsp;has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development&amp;nbsp;strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us &lt;/A&gt;if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Bader, M. J., D. Tilki, et al. (2010). "Ho:YAG-laser: treatment of vesicourethral strictures after radical prostatectomy." World Journal of Urology 28(2): 169-172. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20182734" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Gong, B. S., G. B. Xiong, et al. (2010). "Surgical management for Chinese children urethral injury: A systematic review." Chinese Journal of Evidence-Based Medicine 10(9): 1063-1071. [No PubMed abstract available]&lt;/LI&gt;
&lt;LI&gt;Jin, T., H. Li, et al. (2010). "Safety and efficacy of laser and cold knife urethrotomy for urethral stricture." Chin Med J (Engl) 123(12): 1589-95. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20819517" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Wong, S. S., R. Narahari, et al. (2010). "Simple urethral dilatation, endoscopic urethrotomy, and urethroplasty for urethral stricture disease in adult men." Cochrane Database of Systematic Reviews 4. [&lt;A href="nelh:371984:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Meeks, J. J., B. A. Erickson, et al. (2009). "Stricture recurrence after urethroplasty: a systematic review." Journal of Urology 182(4): 1266-1270. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19683309" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Wang, K., X. Miao, et al. (2009). "Dorsal onlay versus ventral onlay urethroplasty for anterior urethral stricture: A meta-analysis." Urologia Internationalis 83(3): 342-348. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19829038" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <expiryDate>02/09/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>321992</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=321992]]&gt;</url>
    <title>Urethroplasty: Systematic reviews and meta-analyses</title>
    <publicationDate>2010-09-02T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE URETHRAL DISORDERS,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Urethroplasty: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Wong, S. S., R. Narahari, et al. (2010). "Simple urethral dilatation, endoscopic urethrotomy, and urethroplasty for urethral stricture disease in adult men." Cochrane Database of Systematic Reviews 4. [&lt;A href="nelh:371984:0" name=internalLink&gt;Link to Cochrane abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Meeks, J. J., B. A. Erickson, et al. (2009). "Stricture recurrence after urethroplasty: a systematic review." Journal of Urology 182(4): 1266-1270. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19683309" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Markiewicz, M. R., M. A. Lukose, et al. (2007). "The oral mucosa graft: a systematic review." J Urol 178(2): 387-94. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17561150?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>16/07/2010 14:33:42</lastReviewDate>
    <expiryDate>16/07/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>321949</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=321949]]&gt;</url>
    <title>Urinary retention: Systematic reviews and meta-analyses</title>
    <publicationDate>2010-11-25T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,URINARY RETENTION,MALE BLADDER DISORDERS,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Urinary retention: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Buckley, B. S. and M. C. Lapitan (2010). "Drugs for treatment of urinary retention after surgery in adults." Cochrane Database Syst Rev 10: CD008023. [&lt;A href="nelh:389407:0" name=internalLink&gt;Link to Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Kaplan, S. A., A. J. Wein, et al. (2008). "Urinary retention and post-void residual urine in men: separating truth from tradition." Journal of Urology 180(1): 47-54. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18485378" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:21:24</lastReviewDate>
    <expiryDate>06/07/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>177615</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.gpnotebook.co.uk/simplepage.cfm?ID=-1777991673&amp;linkID=29272&amp;cook=yes]]&gt;</url>
    <title>Urinary tract cancers</title>
    <publicationDate></publicationDate>
    <publisher>GPnotebook</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RENAL CANCER,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A resource from GPnotebook</description>
    <body>&lt;![CDATA[ Resource provides links to sections on kidney tumours, bladder tumours, urethral tumours, and penile&amp;nbsp;carcinoma.]]&gt;</body>
    <lastReviewDate>06/07/2010 11:36:33</lastReviewDate>
    <expiryDate>06/07/2011 11:36:33</expiryDate>
  </document>
  <document>
    <id>305077</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://learning.bmj.com/learning/search-result.html?moduleId=10011035]]&gt;</url>
    <title>Urinary tract infection in children: diagnosis, treatment, and long term management - in association with NICE</title>
    <publicationDate>2009-01-27T00:00:00</publicationDate>
    <publisher>BMJ Learning</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ RENAL TRACT INFECTIONS,LOWER URINARY TRACT INFECTION,UPPER URINARY TRACT INFECTION,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Use these interactive modules to learn as we guide you through a real life consultation. Before you start a learning resource it is best to add it to your plan first.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Extract&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;What's in this case:&lt;/STRONG&gt;&amp;nbsp; &amp;nbsp; &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Urinary tract infection in children: diagnosis, treatment, and long term management - in association with NICE&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Target audience:&lt;/STRONG&gt; &amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;International 
&lt;LI&gt;GP CPD 
&lt;LI&gt;Hospital doctor CPD 
&lt;LI&gt;GP trainee 
&lt;LI&gt;Saudi Pediatric Association Channel 
&lt;LI&gt;Other healthcare professionals 
&lt;LI&gt;NICE medical students' pilot project 
&lt;LI&gt;The Royal New Zealand College of General Practitioners 
&lt;LI&gt;Practice manager CPD 
&lt;LI&gt;BMJ Learning Pre-hospital Care 
&lt;LI&gt;Foundation programme 
&lt;LI&gt;Emergency Medicine CPD 
&lt;LI&gt;Practice nurse CPD 
&lt;LI&gt;Medical Students - international &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>13/12/2010 11:41:44</lastReviewDate>
    <expiryDate>13/12/2011 11:41:44</expiryDate>
  </document>
  <document>
    <id>321994</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=321994]]&gt;</url>
    <title>Urinary tract infections: Systematic reviews and meta-analyses</title>
    <publicationDate>2011-01-24T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,RENAL TRACT INFECTIONS,LOWER URINARY TRACT INFECTION,MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Urinary tract infections: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Dai, B., Y. Liu, et al. (2010). "Long-term antibiotics for the prevention of recurrent urinary tract infection in children: a systematic review and meta-analysis." Archives of Disease in Childhood 95(7): 499-508. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20457696" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mori, R., N. Yonemoto, et al. (2010). "Diagnostic performance of urine dipstick testing in children with suspected UTI: a systematic review of relationship with age and comparison with microscopy." Acta Paediatrica 99(4): 581-584.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20055779" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Opperman, E. A. (2010). "Cranberry is not effective for the prevention or treatment of urinary tract infections in individuals with spinal cord injury." Spinal Cord 48(6): 451-6. [&lt;A href="http://www.nature.com/sc/journal/v48/n6/abs/sc2009159a.html" target="_blank"&gt;Link to abstract from Publisher's website&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Palese, A., S. Buchini, et al. (2010). "The effectiveness of the ultrasound bladder scanner in reducing urinary tract infections: a meta-analysis." J Clin Nurs 19(21-22): 2970-9. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/21040003" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Penna, F. J., J. S. Elder, et al. (2010). "Antimicrobial resistance patterns of Escherichia coli in uncomplicated community-acquired urinary tract infections among adults: A meta-analysis." Journal of Urology 183(4 SUPPL. 1).&amp;nbsp;[No abstract available]&lt;/LI&gt;
&lt;LI&gt;Schmiemann, G., E. Kniehl, et al. (2010). "The diagnosis of urinary tract infection: a systematic review." Deutsches Arzteblatt International 107(21): 361-367.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20539810" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Shaikh, N., A. L. Ewing, et al. (2010). "Risk of renal scarring in children with a first urinary tract infection: a systematic review." Pediatrics 126(6): 1084-91. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/21059720" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Williams, G. J., P. Macaskill, et al. (2010). "Absolute and relative accuracy of rapid urine tests for urinary tract infection in children: a meta-analysis." The Lancet Infectious Diseases 10(4): 240-250.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/%2020334847" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Zaffanello, M., G. Malerba, et al. (2010). "Genetic risk for recurrent urinary tract infections in humans: A systematic review." Journal of Biomedicine and Biotechnology 2010.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20379347" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Zaffanello, M., Tardivo, S., Cataldi, L., Fanos, V., Biban, P., Malerba, G. (2010). "Genetic susceptibility to renal scar formation after urinary tract infection: a systematic review and meta-analysis of candidate gene polymorphisms." Pediatr. Nephrol. 2010 Nov 30 (Epub ahead of print). [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/21116828" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Abad, C. L. and N. Safdar (2009). "The role of lactobacillus probiotics in the treatment or prevention of urogenital infections--a systematic review." Journal of Chemotherapy 21(3): 243-52.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19567343" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Ali ASM, Townes CL, Hall J, Pickard RS. Maintaining a Sterile Urinary Tract: The Role of Antimicrobial Peptides. Journal of Urology. 2009;182(1):21-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Maintaining%20a%20Sterile%20Urinary%20Tract%3A%20The%20Role%20of%20Antimicrobial%20Peptides" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Christman MS, Chen JT, Holmes NM. Obstructive complications of lichen sclerosus. Journal of pediatric urology. 2009;5(3):165-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19186109" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Jiyong J, Tiancha H, Wei C, Huahao S. Diagnostic value of the soluble triggering receptor expressed on myeloid cells-1 in bacterial infection: A meta-analysis. Intensive Care Medicine. 2009;35(4):587-95.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18936908" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mantadakis E, Plessa E, Vouloumanou EK, Karageorgopoulos DE, Chatzimichael A, Falagas ME. Serum procalcitonin for prediction of renal parenchymal involvement in children with urinary tract infections: a meta-analysis of prospective clinical studies. The Journal of pediatrics. 2009;155(6):875-81.e1.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19850301" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Masson, P., S. Matheson, et al. (2009). "Meta-analyses in prevention and treatment of urinary tract infections." Infectious Disease Clinics of North America 23(2): 355-85; Table of Contents.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19393914" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mathers MJ, Von Rundstedt F, Brandt AS, Konig M, Lazica DA, Roth S. Myth or truth. Cranberry juice for prophylaxis and treatment of recurrent urinary tract infection. Urologe - Ausgabe A. 2009;48(10):1203-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19636526" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mori R, Fitzgerald A, Williams C, Tullus K, Verrier-Jones K, Lakhanpaul M. Antibiotic prophylaxis for children at risk of developing urinary tract infection: a systematic review. Acta Paediatrica. 2009;98(11):1781-6.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19627258" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Naber, K. G., Y. H. Cho, et al. (2009). "Immunoactive prophylaxis of recurrent urinary tract infections: a meta-analysis." International Journal of Antimicrobial Agents 33(2): 111-119.&amp;nbsp;[&lt;A href="nelh:358412:0" name=internalLink&gt;Link to&amp;nbsp;DARE abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Nanda N, Juthani-Mehta M. Novel biomarkers for the diagnosis of urinary tract infection-a systematic review. Biomark Insights. 2009;4:111-21.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19707519" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Nergard CS, Solhaug V. [Cranberries for prevention of recurrent urinary tract infections]. [Norwegian] Tranebaer til forebygging av residiverende urinveisinfeksjoner. Tidsskrift for Den Norske Laegeforening. 2009;129(4):303-4.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19219097" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Tuon FF, Amato VS, Penteado Filho SR. Bladder irrigation with amphotericin B and fungal urinary tract infection--systematic review with meta-analysis. International Journal of Infectious Diseases. 2009;13(6):701-6.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19155184" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Bukhary, Z. A. (2008). "Candiduria: a review of clinical significance and management." Saudi J Kidney Dis Transpl. 2008 May; 19(3):350-60. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18445893?ordinalpos=&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&amp;amp;log$=citationsensor" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Chapple, C. R., A. J. Wein, et al. (2008). "Lower urinary tract symptoms revisited: a broader clinical perspective." Eur Urol 54(3): 563-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18423969" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Danso-Appiah, A., J. Utzinger, et al. (2008). "Drugs for treating urinary schistosomiasis." Cochrane Database of Systematic Reviews(3).&amp;nbsp;[&lt;A href="nelh:236333:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Gales, B. J. and M. A. Gales (2008). "Phosphodiesterase-5 inhibitors for lower urinary tract symptoms in men." Annals of Pharmacotherapy 42(1): 111-5.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18094344" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Jepson, R. G. and J. C. Craig (2008). "Cranberries for preventing urinary tract infections." Cochrane Database of Systematic Reviews(1).&amp;nbsp;[&lt;A href="nelh:236968:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Latthe, P. M., R. Foon, et al. (2008). "Prophylactic antibiotics in urodynamics: A systematic review of effectiveness and safety." Neurourology and Urodynamics 27(3): 167-173.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/17849482" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Shaikh, N., N. E. Morone, et al. (2008). "Prevalence of urinary tract infection in childhood: a meta-analysis." Pediatric Infectious Disease Journal 27(4): 302-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18316994" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Larcombe, J. (2007). "Urinary tract infection in children." Clinical Evidence 2007.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19454098" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lee, B. B., J. M. Simpson, et al. (2007). "Methenamine hippurate for preventing urinary tract infections." Cochrane Database Syst Rev(4): CD003265.&amp;nbsp;[&lt;A href="nelh:237716:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;2006&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Williams, G. J., L. Wei, et al. (2006). "Long-term antibiotics for preventing recurrent urinary tract infection in children." Cochrane Database Syst Rev 3: CD001534.&amp;nbsp;[&lt;A href="nelh:237182:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>16/07/2010 14:33:46</lastReviewDate>
    <expiryDate>16/07/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>177614</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.gpnotebook.co.uk/simplepage.cfm?ID=-19922919&amp;linkID=38764&amp;cook=yes]]&gt;</url>
    <title>Urinary tract stones</title>
    <publicationDate></publicationDate>
    <publisher>GPnotebook</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ KIDNEY AND BLADDER STONES,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,URETERIC STONES,MALE URETERIC DISORDERS,URETHRAL OBSTRUCTION,MALE URETHRAL DISORDERS,MALE BLADDER DISORDERS,BLADDER STONES,KIDNEY DISEASES,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Resource from GPnotebook</description>
    <body>&lt;![CDATA[ Resource provides links to sections on epidemiology of urinary tract stones, aetiology, pathogenesis, sites of stone impaction, clinical features, investigations, management, and prevention of urinary tract stones.]]&gt;</body>
    <lastReviewDate>06/07/2010 11:36:43</lastReviewDate>
    <expiryDate>06/07/2011 11:36:43</expiryDate>
  </document>
  <document>
    <id>386850</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=386850]]&gt;</url>
    <title>Urological chronic pelvic pain: Systematic reviews and meta-analyses</title>
    <publicationDate>2011-01-24T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE URINARY INCONTINENCE,MALE BLADDER DISORDERS,PENILE DISORDERS,PROSTATE DISORDERS,TESTICULAR/ SCROTAL DISORDERS,MALE URETERIC DISORDERS,MALE URETHRAL DISORDERS,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Urological chronic pelvic pain: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2011&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Anothaisintawee, T., J. Attia, et al. (2011). "Management of chronic prostatitis/chronic pelvic pain syndrome: a systematic review and network meta-analysis." JAMA 305(1): 78-86. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/21205969" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Fall, M., A. P. Baranowski, et al. (2010). "EAU guidelines on chronic pelvic pain." European Urology 57(1): 35-48. [&lt;A href="nelh:283009:0" name=internalLink&gt;Link to abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Itza Santos, F., J. Salinas, et al. (2010). "[Update in pudendal nerve entrapment syndrome: an approach anatomic-surgical, diagnostic and therapeutic]. [Spanish] Actualizacion del sindrome de atrapamiento del nervio pudendo: enfoque anatomico-quirurgico, diagnostico y terapeutico." Actas Urologicas Espanolas 34(6): 500-509. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20510112" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Itza, F., D. Zarza, et al. (2010). "Myofascial pain syndrome in the pelvic floor: a common urological condition [Spanish] Sindrome de dolor miofascial del suelo pelvico: una patologia urologica muy frecuente." Actas Urologicas Espanolas 34(4): 318-326. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20470693" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Dimitrakov, J. and D. Guthrie (2009). "Genetics and phenotyping of urological chronic pelvic pain syndrome." J Urol 181(4): 1550-1557. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19230927" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <expiryDate>02/09/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>321950</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=321950]]&gt;</url>
    <title>Varicocele: Systematic reviews and meta-analyses</title>
    <publicationDate>2011-01-24T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,TESTICULAR/ SCROTAL DISORDERS,VARICOCELE,SWELLING,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Varicocele: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Borruto, F. A., P. Impellizzeri, et al. (2010). "Laparoscopic vs open varicocelectomy in children and adolescents: Review of the recent literature and meta-analysis." Journal of Pediatric Surgery 45(12): 2464-2469. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/21129568" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Weedin, J. W., M. Khera, et al. (2010). "Varicocele repair in patients with nonobstructive azoospermia: a meta-analysis." Journal of Urology 183(6): 2309-2315. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20400156" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Agarwal A, Sharma RK, Desai NR, Prabakaran S, Tavares A, Sabanegh E. Role of oxidative stress in pathogenesis of varicocele and infertility. Urology. 2009;73(3):461-9.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19167039" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Barroso U, Jr., Andrade DM, Novaes H, Netto JM, Andrade J. Surgical treatment of varicocele in children with open and laparoscopic Palomo technique: a systematic review of the literature. Journal of Urology. 2009;181(6):2724-8.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19375741" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Biyani, C. S., J. Cartledge, et al. (2009). "Varicocele." Clinical Evidence 2009.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19445764" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Cayan, S., S. Shavakhabov, et al. (2009). "Treatment of palpable varicocele review in infertile men: A meta-analysis to define the best technique." Journal of Andrology 30(1): 33-40.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18772487" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evers, J. H., J. Collins, et al. (2009). "Surgery or embolisation for varicoceles in subfertile men." Cochrane Database of Systematic Reviews(1).&amp;nbsp;[&lt;A href="nelh:236643:0" name=internalLink&gt;Link to&amp;nbsp;Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Jin P, Yang LY, Peng YG. Effectiveness and safety of microscopic varicocelectomy versus Palomo surgery for varicocele: A systematic review. Chinese Journal of Evidence-Based Medicine. 2009;9(6):674-80.&amp;nbsp;[No abstract available]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:21:27</lastReviewDate>
    <expiryDate>06/07/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>182724</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.kidney.org.uk/letters/vascular-access-report-2006.pdf]]&gt;</url>
    <title>Vascular Access Joint Working Party Report</title>
    <publicationDate>2006-08-31T00:00:00</publicationDate>
    <publisher>Vascular Society of GB and Ireland</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ PERITONEAL DIALYSIS,ACCESS,HAEMODIALYSIS,ACCESS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,DIALYSIS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A joint report of the Renal Association, British Society of Interventional Radiology, and the Vascular Society of GB and Ireland</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Extract from working party document&lt;/EM&gt;&lt;/STRONG&gt; &lt;/P&gt;&lt;FONT face=TimesNewRoman&gt;
&lt;P&gt;Vascular access is essential for haemodialysis and its quality determines patient outcomes. Problems with vascular access are the commonest causes of infections and hospital admissions. The provision of vascular services in units in the UK is, with a few exceptions, suboptimal. This is a consequence of both resource limitations and poor organisation of services. This document attempts to describe the volume of the workload, the resources needed and models of service organisation to improve and shorten the patient pathway.&lt;/P&gt;
&lt;P&gt;&lt;/FONT&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:36:52</lastReviewDate>
    <expiryDate>06/07/2011 11:36:52</expiryDate>
  </document>
  <document>
    <id>177781</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.dopps.org/show_Citation.aspx?id=352]]&gt;</url>
    <title>Vascular access use and outcomes: an international perspective: results from the Dialysis Outcomes and Practice Patterns Study</title>
    <publicationDate></publicationDate>
    <publisher>Nephrol Dial Transplant 2008 23(10) 3219-3226</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ HAEMODIALYSIS,ACCESS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,DIALYSIS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Powerpoint presentation using DOPPS data</description>
    <body>&lt;![CDATA[ &lt;P&gt;Extract&lt;/P&gt;
&lt;P&gt;A well-functioning vascular access (VA) is essential to efficient dialysis therapy. Guidelines have been implemented improving care, yet access use varies widely across countries and VA complications remain a problem. This study took advantage of the unique opportunity to utilize data from the Dialysis Outcomes and Practice Patterns Study (DOPPS) to examine international trends in VA use and trends in patient characteristics and practices associated with VA use from 1996 to 2007.&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>24/09/2010 11:42:55</lastReviewDate>
    <expiryDate>24/09/2011 11:42:55</expiryDate>
  </document>
  <document>
    <id>313649</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_098627]]&gt;</url>
    <title>Vascular Programme briefing packs</title>
    <publicationDate>2009-04-29T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RENOVASCULAR DISEASES,IN ADULTS,IN CHILDREN,CAUSES,CHRONIC COMPLICATIONS,RETINOPATHY,CARDIOVASCULAR,DIABETES,STATISTICS,EYE DISEASES,CAUSES,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES,DATA GATHERING AND AUDIT AND QOF]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This revised vascular programme briefing pack was prepared in 2009 to provide the ten strategic health authorities with an assessment of progress, opportunities and future challenges in key areas of vascular disease.</description>
    <body>&lt;![CDATA[ &lt;P&gt;This revised vascular programme briefing pack was prepared in 2009 to provide the ten strategic health authorities with an assessment of progress, opportunities and future challenges in key areas of vascular disease.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The pack covers coronary heart disease, stroke, diabetes and renal disease. It provides data about these four conditions from the various sources available (QOF and HES, for example).&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Policy contacts within the DH Vascular Programme are Elizabeth Lynam and Stephen Green.&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>08/03/2011 10:07:58</lastReviewDate>
    <expiryDate>08/03/2012 10:07:58</expiryDate>
  </document>
  <document>
    <id>321951</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=321951]]&gt;</url>
    <title>Vasectomy: Systematic reviews and meta-analyses</title>
    <publicationDate>2010-09-09T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,VASECTOMY,FERTILITY,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Vasectomy: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2007&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Cook, L. A., A. Pun, et al. (2007). "Scalpel versus no-scalpel incision for vasectomy." Cochrane Database Syst Rev(2): CD004112. [&lt;A href="nelh:238320:0" name=internalLink&gt;Link to Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Cook, L. A., H. Van Vliet, et al. (2007). "Vasectomy occlusion techniques for male sterilization." Cochrane Database Syst Rev(2): CD003991. [&lt;A href="nelh:238370:0" name=internalLink&gt;Link to Cochrane abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:21:31</lastReviewDate>
    <expiryDate>06/07/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>321952</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//kidney/ViewResource.aspx?resID=321952]]&gt;</url>
    <title>Vesico-ureter-reflux: Systematic reviews and meta-analyses</title>
    <publicationDate>2010-11-15T00:00:00</publicationDate>
    <publisher>NHS Evidence - kidney diseases and male urogenital disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,MALE BLADDER DISORDERS,VESICO-URETER-REFLUX,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Vesico-ureter-reflux: Systematic reviews and meta-analyses&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence - kidney diseases and male urogenital disorders has identified the following resources relevant to this topic area. We perform systematic searches to identify up-to-date, high quality evidence for a given topic. View our &lt;A href="http://www.library.nhs.uk/kidney/Page.aspx?pagename=CONTENT" target="_blank"&gt;content development strategy&lt;/A&gt; for more information.&lt;/P&gt;
&lt;P&gt;Users should note that we have not performed an in-depth appraisal for each reference but have applied rigorous methods to select them.&amp;nbsp; Where pre-appraisals exist, we link to them.&amp;nbsp;&amp;nbsp; We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&amp;nbsp; We welcome feedback about resources that we identify, do &lt;A href="http://www.library.nhs.uk/KIDNEY/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Aubert, D. (2010). "[Vesico-ureteric reflux treatment by implant of polydimethylsiloxane (Macroplastique): Review of the literature]. [French] Traitement endoscopique du reflux vesico-ureteral par implant de polydimethylsiloxane (Macroplastique) : revue de la litterature." Progres en Urologie 20(4): 251-259. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20380986" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hensle, T. W., E. A. Reiley, et al. (2010). "The clinical utility and safety of the endoscopic treatment of vesicoureteral reflux in patients with duplex ureters." Journal of pediatric urology 6(1): 15-22.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/%2019625219" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mattoo, T. K. (2010). "Evidence for and against urinary prophylaxis in 1`vesicoureteral reflux." Pediatric Nephrology 25(12): 2379-82. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20725842" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Peters, C. A., S. J. Skoog, et al. (2010). "Summary of the AUA Guideline on Management of Primary Vesicoureteral Reflux in Children." Journal of Urology 184(3): 1134-1144.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20650499" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Routh, J. C., B. A. Inman, et al. (2010). "Dextranomer/hyaluronic acid for pediatric vesicoureteral reflux: systematic review." Pediatrics 125(5): 1010-1019.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20368325" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Skoog, S. J., C. A. Peters, et al. (2010). "Pediatric Vesicoureteral Reflux Guidelines Panel Summary Report: Clinical Practice Guidelines for Screening Siblings of Children With Vesicoureteral Reflux and Neonates/Infants With Prenatal Hydronephrosis." Journal of Urology 184(3): 1145-1151.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/20650494" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Ansari M. Prophylactic antibiotics in vesicoureteric reflux: Evidence-based analysis. Indian Journal of Urology. 2009;25(2):276-7. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19672369" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Zaffanello M, Franchini M, Brugnara M, Fanos V. Evaluating kidney damage from vesico-ureteral reflux in children. Saudi Journal of Kidney Diseases &amp;amp; Transplantation. 2009;20(1):57-68.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19112220" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2008&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Alvarez Ardura, M., E. De la Pena Zarzuelo, et al. (2008). "[Updated analysis of the efficacy of therapeutic options in primary vesicoureteral reflux]." Arch Esp Urol 61(2): 147-59. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18491729" target="_blank"&gt;Link to PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
    <lastReviewDate>06/07/2010 11:21:35</lastReviewDate>
    <expiryDate>06/07/2011 00:00:00</expiryDate>
  </document>
  <document>
    <id>155901</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.renal.org/unit/index.pl?c=portsmouth]]&gt;</url>
    <title>Wessex Renal and Transplant Service, Queen Alexandra Hospital, Portsmouth.</title>
    <publicationDate></publicationDate>
    <publisher>Queen Alexandra Hospital Portsmouth</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ TRANSPLANT CENTRES,TRANSPLANTATION,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Background information</description>
    <body>&lt;![CDATA[ &lt;P&gt;Wessex Renal &amp;amp; Transplant Service&amp;nbsp;covers approximately 2 million population and is based in Portsmouth.&lt;/P&gt;
&lt;P&gt;It is&amp;nbsp;a purpose-built regional kidney unit on the top floor of Porstmouth's Queen Alexandra Hospital.&lt;/P&gt;
&lt;P&gt;WRTS manages patients with all nephrological illnesses including acute, chronic, and end stage renal failure in patients of age 16 years upwards. All modalities of Renal Replacement Therapy (RRT) are available – haemodialysis (HD), haemodiafiltration (HDF), peritoneal dialysis (PD), automated peritoneal dialysis (APD) and Renal Transplantation. A comprehensive range of investigative procedures for all renal diseases is provided. The transplantation service provides an organ retrieval service, which has strong links with intensive care units and multi-organ transplant centres nation-wide.&lt;/P&gt;]]&gt;</body>
    <lastReviewDate>24/09/2010 11:43:05</lastReviewDate>
    <expiryDate>24/09/2011 11:43:05</expiryDate>
  </document>
  <document>
    <id>260900</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.cancerhelp.org.uk/help/default.asp?page=5511]]&gt;</url>
    <title>What's new in kidney cancer</title>
    <publicationDate>2007-01-24T00:00:00</publicationDate>
    <publisher>Cancer Research UK</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RENAL CANCER,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Information from Cancer Research UK</description>
    <body>&lt;![CDATA[ Information provided on genetics, removing part of the kidney, freezing tumours, heat treatment, treatment with radiowaves, high intensity ultrasound treatment, biological therapy, chemotherapy and stem cell transplants.&lt;BR&gt;&lt;BR&gt;All treatments have to be fully researched before they can be adopted as standard treatment for everyone.&amp;nbsp;]]&gt;</body>
    <lastReviewDate>08/03/2011 10:08:05</lastReviewDate>
    <expiryDate>08/03/2012 10:08:05</expiryDate>
  </document>
  <document>
    <id>155506</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://renux.dmed.ed.ac.uk/edren/Unitbits/Whentorefer.html]]&gt;</url>
    <title>When to refer to a renal unit</title>
    <publicationDate>2006-02-15T00:00:00</publicationDate>
    <publisher>EdRen</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ PREDISPOSING FACTORS,ASSESSMENT OF RENAL FUNCTION,PRESENTATION OF CKD,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Guideline from EdREN Renal Unit, Royal Infirmary, Edinburgh</description>
    <body>&lt;![CDATA[ Guidelines based on evidence in UK CKD Management and Referral Guidelines. Guideline ordered by urgency of referral.]]&gt;</body>
    <lastReviewDate>06/07/2010 11:36:59</lastReviewDate>
    <expiryDate>06/07/2011 11:36:59</expiryDate>
  </document>
  <document>
    <id>319057</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.nelm.nhs.uk/en/NeLM-Area/Evidence/Medicines-Q--A/Which-bowel-cleansing-solutions-are-suitable-for-use-in-people-with-renal-impairment/]]&gt;</url>
    <title>Which bowel cleansing solutions are suitable for use in people with renal impairment?</title>
    <publicationDate>2009-06-04T00:00:00</publicationDate>
    <publisher>UK Medicines Information</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ ACUTE KIDNEY INJURY,COMPLICATIONS OF KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>There are very few data relating to use of bowel cleansing solutions in patients with renal impairment (RI) and further studies are needed.</description>
    <body>&lt;![CDATA[ &lt;UL&gt;
&lt;LI&gt;There are very few data relating to use of bowel cleansing solutions in patients with renal impairment (RI) and further studies are needed.&lt;/LI&gt;
&lt;LI&gt;The patient’s renal function should be considered when selecting a bowel cleansing solution.&lt;/LI&gt;
&lt;LI&gt;Until more data are available it may be prudent to avoid bowel cleansing solutions containing oral sodium phosphate (OSP)(i.e. Fleet Phospho-soda) in patients with any degree of RI due to the possible increased risk of acute phosphate nephropathy.&lt;/LI&gt;
&lt;LI&gt;Klean Prep is the only preparation currently available in the UK which is not stated to be either cautioned or contraindicated in RI in the summary of product characteristics&lt;/LI&gt;
&lt;LI&gt;The Society of American Gastrointestinal and Endoscopic Surgeons guidelines for bowel preparation prior to colonoscopy state macrogols are preferable to osmotic laxatives and OSP in patients with RI.&lt;/LI&gt;
&lt;LI&gt;However, serious complications related to electrolyte imbalances have been associated with administration of four litre preparations of macrogols with electrolytes, in patients with RI.&lt;/LI&gt;
&lt;LI&gt;Fluid balance and electrolytes should be monitored in all patients with RI given any bowel cleansing solution, as they may be at increased risk of dehydration and electrolyte imbalance&lt;/LI&gt;
&lt;LI&gt;Adequate hydration before, during, and after the administration of bowel cleansing solutions is crucial for preventing serious adverse events.&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
    <lastReviewDate>01/07/2010 14:33:41</lastReviewDate>
    <expiryDate>01/07/2011 14:33:41</expiryDate>
  </document>
  <document>
    <id>327344</id>
    <name>&lt;![CDATA[ Kidney Diseases and Male Urogenital Disorders]]&gt;</name>
    <rootDirectory>/kidney</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_106618.pdf]]&gt;</url>
    <title>Working together to save lives: the Organ Donation Taskforce Implementation Programme’s annual report, 2008/09</title>
    <publicationDate>2009-10-08T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ UK TRANSPLANT,TRANSPLANT OPERATION,DONOR,ASSESSMENT/SELECTION,TRANSPLANTATION,HEALTH MANAGEMENT,QUALITY AND MONITORING,SERVICE SECTORS,ACUTE SERVICES,PERFORMANCE MANAGEMENT,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This report highlights the progress that has been made in the first year of the Implementation Programme, particularly the changes in structures and arrangements in the NHS with the move to a centrally managed, and enlarged, network of Donor Transplant Coordinators and the appointment of Clinical Leads for Organ Donation within hospital trusts.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Contents:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Foreword&lt;/LI&gt;
&lt;LI&gt;Vision for organ donation and transplantation&lt;/LI&gt;
&lt;LI&gt;Boosting organ donation, saving lives&lt;/LI&gt;
&lt;LI&gt;Timeline 2008/09&lt;/LI&gt;
&lt;LI&gt;A year of progress&lt;/LI&gt;
&lt;LI&gt;Other work to improve donation and transplantation&lt;/LI&gt;
&lt;LI&gt;Statistics&lt;/LI&gt;
&lt;LI&gt;Programme Delivery Board members&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
    <lastReviewDate>24/09/2010 11:45:17</lastReviewDate>
    <expiryDate>24/09/2011 11:45:17</expiryDate>
  </document>
</documents>